<SEC-DOCUMENT>0000875045-21-000052.txt : 20211020
<SEC-HEADER>0000875045-21-000052.hdr.sgml : 20211020
<ACCEPTANCE-DATETIME>20211020161952
ACCESSION NUMBER:		0000875045-21-000052
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211020
DATE AS OF CHANGE:		20211020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		211334426

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:a903f54e-5284-4407-a747-e0b1f5468222,g:e7d07c56-2dfc-4728-a119-070b245a209e,d:8046a3e69c814e7f9967395f631661c6--><html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:biib="http://www.biogenidec.com/20210930" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl8xLTEtMS0xLTA_dfdcb4e9-0516-4b30-9836-f1c2f3e08045">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl8yLTEtMS0xLTA_cefa7440-b606-4368-a679-9a8468858e39">12/31</ix:nonNumeric><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl8zLTEtMS0xLTA_e134e30e-c973-46a5-8e56-db7ecbebb5d9">2021</ix:nonNumeric><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl80LTEtMS0xLTA_d26b3c84-c74e-4c93-ae03-0eec6e1b9096">Q3</ix:nonNumeric><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl81LTEtMS0xLTA_2f7a2d17-d9be-4638-8ebc-47ad8bcab1a7">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="ic2146328de3549768f889075bad51afb_I20211019" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl82LTItMS0xLTA_71709f06-13dd-4b88-9903-5584c147ef50">146,892,712</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yOC9mcmFnOmQzNzJjOWJmMTllZjRkYTU5MjY2MzkzOTNhMzhmNGM3L3RhYmxlOjRmZmM4MjExZmUzMzRkODdiZjc4ZmRmOTIzYmJiNDczL3RhYmxlcmFuZ2U6NGZmYzgyMTFmZTMzNGQ4N2JmNzhmZGY5MjNiYmI0NzNfMS0xLTEtMS0w_068d4f22-962f-4311-a79d-00686509e534">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yOC9mcmFnOmQzNzJjOWJmMTllZjRkYTU5MjY2MzkzOTNhMzhmNGM3L3RhYmxlOjRmZmM4MjExZmUzMzRkODdiZjc4ZmRmOTIzYmJiNDczL3RhYmxlcmFuZ2U6NGZmYzgyMTFmZTMzNGQ4N2JmNzhmZGY5MjNiYmI0NzNfMS0zLTEtMS0w_5773aef0-f7af-4a42-a3fb-afea3cf0fcc2">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yOC9mcmFnOmQzNzJjOWJmMTllZjRkYTU5MjY2MzkzOTNhMzhmNGM3L3RhYmxlOjRmZmM4MjExZmUzMzRkODdiZjc4ZmRmOTIzYmJiNDczL3RhYmxlcmFuZ2U6NGZmYzgyMTFmZTMzNGQ4N2JmNzhmZGY5MjNiYmI0NzNfMi0xLTEtMS0w_0409e8dc-2113-4473-9e9b-ac484b25ee01">0.0005</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yOC9mcmFnOmQzNzJjOWJmMTllZjRkYTU5MjY2MzkzOTNhMzhmNGM3L3RhYmxlOjRmZmM4MjExZmUzMzRkODdiZjc4ZmRmOTIzYmJiNDczL3RhYmxlcmFuZ2U6NGZmYzgyMTFmZTMzNGQ4N2JmNzhmZGY5MjNiYmI0NzNfMi0zLTEtMS0w_f85ec007-79a9-43bf-970e-561447008b36">0.0005</ix:nonFraction><ix:nonNumeric contextRef="i47e67b006b354cc88698e7fe5664efe2_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82NC9mcmFnOmVhN2M4YzFjYWFmMDRjMzU5MTY3NTRhM2U1MTQ2NzgwL3RhYmxlOjU5NDBjMDIwNTBlYjRkNWVhYTRiMTY2MmY1ZWQ1NzlmL3RhYmxlcmFuZ2U6NTk0MGMwMjA1MGViNGQ1ZWFhNGIxNjYyZjVlZDU3OWZfMS0xLTEtMS0w_6d0e814d-cf23-4bea-8f41-09ca4a65bb0b">4</ix:nonNumeric><ix:nonNumeric contextRef="i5e115d8322fc4129abe228330a35b1c0_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82NC9mcmFnOmVhN2M4YzFjYWFmMDRjMzU5MTY3NTRhM2U1MTQ2NzgwL3RhYmxlOjU5NDBjMDIwNTBlYjRkNWVhYTRiMTY2MmY1ZWQ1NzlmL3RhYmxlcmFuZ2U6NTk0MGMwMjA1MGViNGQ1ZWFhNGIxNjYyZjVlZDU3OWZfMi0xLTEtMS0w_9400bc68-9cbd-416e-8af3-7c2132ea18b8">28</ix:nonNumeric><ix:nonNumeric contextRef="i3cd19afbd26746dca41eab54ab3017ba_D20210101-20210930" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82NC9mcmFnOmVhN2M4YzFjYWFmMDRjMzU5MTY3NTRhM2U1MTQ2NzgwL3RhYmxlOjU5NDBjMDIwNTBlYjRkNWVhYTRiMTY2MmY1ZWQ1NzlmL3RhYmxlcmFuZ2U6NTk0MGMwMjA1MGViNGQ1ZWFhNGIxNjYyZjVlZDU3OWZfNy0xLTEtMS0w_2e55d9b4-d168-43a0-a161-17a2bf194cba">Indefinite until commercialization</ix:nonNumeric><ix:nonNumeric contextRef="i65c9878611a94c1e8dd4e4c8e3723f18_D20210101-20210930" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82NC9mcmFnOmVhN2M4YzFjYWFmMDRjMzU5MTY3NTRhM2U1MTQ2NzgwL3RhYmxlOjU5NDBjMDIwNTBlYjRkNWVhYTRiMTY2MmY1ZWQ1NzlmL3RhYmxlcmFuZ2U6NTk0MGMwMjA1MGViNGQ1ZWFhNGIxNjYyZjVlZDU3OWZfOC0xLTEtMS0w_c83cc597-0b07-421d-9993-c37c54630006">Indefinite</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iadac69438a134e4685f396b8c53251d4_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfNS0xLTEtMS0w_53a0a5ee-e1db-4ee8-ac2f-9eff41076fe3">2.900</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ica74fb523d614349a5924b06d1bb5822_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfNi0xLTEtMS0w_40d3f860-2140-4949-850d-cb49f18ec0d8">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9f2d4471ced94158a3b9461f37a5a9b4_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfNy0xLTEtMS0w_ad54a3a6-b9bb-487c-8c20-f3828836b6a6">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia82ded1ca1fa4ec881505e83910f2470_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfOC0xLTEtMS0w_cc251056-ac40-4074-a962-c15a2407931e">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7a9933a802b04b7d8c62324f5f41c52a_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfOS0xLTEtMS0w_0f53203d-831a-41a4-9c3a-94c8f1cd7f17">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i86e1f0ba26984bf396b6de85e0803baa_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfMTAtMS0xLTEtMA_b4b0f2ec-e3f0-4f6c-8c67-515527e3dcbb">3.150</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i53759aa6be6e42a1a94cf191019495cb_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfMTEtMS0xLTEtMA_b0bf98eb-d725-49f1-9c7f-3fea7ddb38c6">3.250</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="0" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RleHRyZWdpb246NjQ5NDZhZTIwZTJjNDZkNGI2ZmY4MTMyOGNlYjQxOGNfOQ_a3f97b09-1839-4f08-96cb-9c4a56458026">0</ix:nonFraction><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMzAvZnJhZzoxYjhiZTVjNTMyZjY0YjRiODBhNmUwMjVjZjJhMDg1Ny90ZXh0cmVnaW9uOjFiOGJlNWM1MzJmNjRiNGI4MGE2ZTAyNWNmMmEwODU3XzEzODc_f028f2e2-dc8e-458e-8788-509c4cfbfdf3" escape="true">Subsequent EventsIn October 2021</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic2146328de3549768f889075bad51afb_I20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i28c7f8faaddf4de59fb5368e32d5ae6d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3672251f76c4fb3ab491f7a64f2a7d1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6629e89c034a4d89883d31d567178ed6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie862c4e3d0454092bd193a5d58ea0c3a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc49896e8f7749f9aec4691dac20e8f7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b23d904c3ce4fde94a3a645d27461d5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf69f40f83ce4c9da70c57f9064c7b4a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76c2b9076741473bbd3bced37f71ef41_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib36a038f73ce4e7b8013d75c309b00de_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27692e0f487e42cfa48cfb9ec74d1c5b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40db7f82bc1346e0a6ae09a03625fc9d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2782acd53f4eca80ff87db16f55ee5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6475881e6d0430cbc6e4826b376d1ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b9cfb542bbc414db0a805fe7b60fb21_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2438439cc2bd49c2a02917dc67d626e5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdbdde9753524c0da660204088296886_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15b7f4db2c14ac8ab03363218c293d8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i378cd243ed9e40c2932d604d62dcff73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd54a75bdf44146a9c81439174f3e10_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd41961e6e04619a145d1ae0002b71b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2504032f7755457db1beea26920a583a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5058265a969a4b00953e4a5f69286304_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76f00f49e5bf479dae0717aa402863ba_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea0b81b62734c95b602b7181db99080_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c76067d2c0e4450b18d7428a607dec6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c29f466fd44e7fbf5526fc6d6a77b3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c41282f9554a79a2dea81cc7c66db8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3134099b795d4facb8cd5e5dc6129d07_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc5c637588f4bc8b93afe094f041d88_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9151bbf7e80c4955aa4b4abcce3d7ee5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fcbd0aab3104a71a4ebbceb7c93d675_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic85bc0b5a4e146cf9ca22eeb646ac2f5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c1f2813a84947359d5e759ac017f8f6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71a7f514fe345aa81befd7e9f359804_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbdfb0e2e84e4397a54b042efb9de0f0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fc83a08693474992b85d83b3ad03b7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c617883bc449228e61f30f99e937e2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f998449b3e429fb58bc7328de88319_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9035a5654857474b8da6be9ce64ca30c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6724df5e760b4f7ea87e959a62b322b1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b4efc5c06194773aea1dd08796cbd25_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35bb8cece69f42eb993bbe2ed7b30d9a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb94a68217db4665853c23a8d028b610_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f7e3e5cead4308bd4010bcf303d6fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia82889fd7f49428faa0d8b8a9fe4787c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i435fb50e71d246339ab717cb193e55b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id008781cb78d456099bf8e65186045c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfaf0c65c04d483ba21b7c25f4adaecf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fcb29f76ded42b1bdb5c06b5a612d27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f28a59afdff41658f03256c0a201a98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4891b33ee68b4d7abe803e2851cb7dbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9be762ec3a9f4b09864941280d00a916_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd71258dd6f04433b5f81b927d3b1104_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc180996f76c4531ba0c767a0cd57adc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a7ad3e5c3a4b8d9bedc1dcb4f9f208_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fb5362e7a744d9a5acd4825e9a5104_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d9c800cfcc42f5a8dd99abd463e2be_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782d9d918ca94e65a4169da4cd3a12f6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b408fb3fdc34b0396023e455c198a69_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c7f17033684d18aefb36c4a3d6c13f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e81dc8b9c744b3b947fb4da4f5918f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b36a2284f3b473798aab3ac6e245627_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe878f771a841b3a6c7f704897f75ee_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98aa79e9ae8d45b880df1e5404273f17_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ddcef7d3e24fdcb32788e2157a6ff6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb06b37c185452292925fd0417673c9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d7ff60d15254b42afe32f65710162c7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7028acddd6fe42b6965135b35f8ff2f6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13ff900cbf7e400ab0e7e04c7df214d5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6b13e615cb43759f9fdc6492935587_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aa45623b9a24e4881896a979258ce6e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c04a426b78946e7b3b65f4903d01c57_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f841eba5163473e9f41740f7bde1720_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if307471114bc439a91ad32639f89c9f8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i751ac7dc5ebd4605b6778c1a2449f919_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie428e1222ddf45bf8896a772e454dfa3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6422fd73db7423eb9f8020ab03bd577_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib45574fe33ee4aae9246e107a7a53587_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4928957245d3432999a97b44b5267981_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c55152400e4e4b94a99a817965d09a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9feca16144f34b3ea3e89a6754731228_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a8b077b45d46d1a2ba18c46f68e9b5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1490d7028c484bb7b887d3edf0bcef_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5244c955b7f04faa811cb546d3b19da1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256c872a0ec64e8588e40eae87e54228_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27afa92fb58444e9a9f1ab64284947bf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e79a463f4584fb2aee6e8cdc33e7007_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e7708356fae41b9a13302bb04211203_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70705f35adb5455faecf1b3d1d84198a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e7b1968e93347ae998112702bfaf368_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc9ba742bf504e22bd14593ecb2ffb74_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7e856aca6b47abb4f2a597838710d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide5fdd4520c74830933b03379f613edf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607b477716754fa49b426a79cce7cfc3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e94a3f2f5aa4b088b330695096badd8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i327682b6937246d39b49fa2fe086a9ee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if699e259873a4362befe72d106cb46a3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70699e64e56642c78269f5581e49fa63_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb259e3e655451594ddea75cacc3031_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibded2627ed6f476488944808f5be525e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ed39bd20ce49eb845fbd4b5a6e399f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfc2c0b58ff4cc1b94d1cdf49392372_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id860c4b0dd10477c99ccee1b9a0e61f6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3b6f7ebf2148fb8095a10e72b1c4b3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a4c5ca8b3b448168efbbcea6f070598_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a9211cf5d342868594c98f4cc8953d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820c4f6fd7d141ae849266e77bd5174d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i708a8258e90c451fae809ded20edc887_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc98aa5d5bb3491b844c904832b5e17a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1022bbcfbc3d402986b98be3c4a7bdd9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e21f10ab3f4997b59d6e47015ee1e6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i459ef874f9bb4653ad831f334286be02_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic401292eb9c341d5a7a48926df3393fc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76acd6989c7c4783b9802597d4de0c06_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23640bd50272420a8b057701d4f91e71_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd886b210f074d43acf27a1993bc9ccf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if48a1d2ec8b247058bcdad6c8fbc6524_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia21b2da1eba940d2b84efc2f236e2b03_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10bf3e3f7595414482ea7c8e4d6e9daa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f65789ed29a4729929922d2a49c2ec3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36476b37490e44bb9a8cd6098004a18e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a94855763b44929978fdfdb0d8035d7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a216b36a235433c9df3617fbc22b9a7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfa480df7914627bc60143003413b0a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7517010697de4c77b9e59ece300efd26_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5a4376778b04d80abf3b1d76aac940f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0542ec377c8a46ae89671dcde4b12555_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09cfdb27d6654e3eaea1f9fd048da603_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87aa8be7620b41a68374745f1299b587_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d1d4d88e5204d3bbd4f8c2df05bc123_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11880cd08681479db15c4cf4a0e6a1b1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc711043de854adeaaa2267f4bb46ccd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a53327538a04446a4de09425ac19e0e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf06a525bc964241a3f2d2a390fe4a4f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f4359c2057476ba70d1737083d2a2b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c6a43fee8d4ad3b6c10202da96a3a4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i946868256a5e4b78bc18b85fe7d36a88_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6050c9c73f574a1d9ac74d02d7f8833a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia423a211a0e94eb2b77637ce741d2bb7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e3d9cc76b44ab2ab715dbe9256ee43_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae132257ea54725a3d8996647c5f187_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ca5e27d04c34b1b85b921b3c5f8955a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6315b659cf6e4730aa408da11bed5410_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i217b972b9d864b7ea3af5c2ddafb37c1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcb4fc909b874f1cad730a3ec955d0b7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ef0e02b0074d14ac43f42983797d65_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68820eb5ed4b440b8283a709119c6a35_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634f1e6f45a54e05bd52b24e519c4436_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c177a7d8bd40c3ad390904b9d500d8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dd866074adc42c98b75fe2cc20acab6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f60b9625d5649a094bc0b536c722ec2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911336cfeca046fdb0594c9edf8d9d0d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9cde429795a43629320e02fae4dc1f5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie98b919eea9c49c0ae92d49eae5d7e4e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b7f7eef9ad4f298c8c291b3ecaab47_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7560cc8fc1a4480e89be78cc3735e0a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82c486a127442488b1833a2dc7b7cd6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5008e8c4fa47649cfe38e4b9ebfe94_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9e403b349e4ca69958c093e19f74e4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847c83d47690436dbf95bf269e8be2f2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0763a9aea2ed45ba8300cc34209c8819_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb3dce21712c4912bcec60f52a212be5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fd874439cb1425eb709f078c0dc49cb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6126c7bc669b47cab645fe573efe2379_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52490028f86c4b18ae595bb12a3b413e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfe93de388de42aea652b2d937d7b20e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff76d3e091a4417f87d3022f27f8c714_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3133bc8432354bdd87b447ab0b25da57_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fcfb0f1a5aa4f28a82dd0078a64e4cb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6016cc0326e45fb8c5ab31460efbed5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9b12c794124230bdfb5c764ae089a2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i851e3d422f964199aae5ec5f16c2ed5f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2258c8387d342deb1dcd335b185c9c6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac3a6cb79f144da8b8a7cbd1c451028_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec078f0e0134c10ab04094dc10dcbb3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddbd3b911c4e4a9b8d3b7b3370ba5be4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id95e5c1cfeff4eb999843b5ab142dea1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6147368b3e5448f387b2621a347ff81a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib43b7a7b6aff426e8b3aa44f10665331_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d8c0ed6a308478f8a953ae999c37402_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7dd6c4bbab7427d884ea754f842614b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3637540f0742e282ee41d72bd9661b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f499618557b4da7acceb5cafb578dbd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9ec1982c6d44839c60d73b502fb183_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc59dc95e0974b669bee2fa38de73766_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a391c9c52574153aecfbbfb7003c5dd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide45d117f94948c39924a1add89e7b6d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90067ffe05f4ea3bef552a9c2baaf11_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a69686d751b4d78856ab4a9b5568f7c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265533229a0044408626b8fb90354de5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b240004575a41088f63cfd2893796da_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc59a1b194f46d9aab6abc4dad371c8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94113634bd1c4fd19a9b3f8785b02ebe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04560d42c0e54986baa4ff75a03e96bf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b12493f4b214da88a80d6a1be15a5ec_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c7085ac1e94084911a32c8c5150032_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a516cca4e1641a3a52085e438a3c519_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7189d4590dbf410981d535efbb77dafd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aa621e0a5cf4731b69211ee0236dfa4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b298d90ef649be871440f8e5609a5a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i055192050a884b09af25bd948ce893be_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i819e179a871a47bc9b2742b59e816fd5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8870751b462a458697438c86f8eedbe0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3447ed88deef4013aef8152951e512bb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i955579c517df40abbdcbafae0a9be8e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie518ab0a6fb54b19acd0e5840d451a8d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbdc18d489a44d0492145df9a238420f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d5e1daf4b14aebaff40a7bfcdae045_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f797b3134f4dfeb7404b4045bf8dff_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78c7deeed40b495cbdd4163ba45d904f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa6a3fdbaa84285a4f2caf4e5f6c13f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba938bf7466644249a1784f67476b2d8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b6d6875e5849df84d386d1cbbadf8f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a8b4a619ef48838cb6f537675db04d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae3263ec5c084ebdbf45685ad846b557_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7894b472498148dbb05439dbe1d0de4e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de479d587354958b584fa532dfa50e7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd108b031c74d6293853d4b7f765be2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44e2681e4af04220bc5659c30f65dad7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i997d11776fa54ff88c622c8a39e451cf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4463689b8f13459fb262230c8eeaa642_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia53918b8ecd640bd9d91e12ad6779d47_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f69c1b12cf4aa48eb2f5495743e9b5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a344b1c3ded4c809b0bdc426f095761_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2961e6b3f8584e359cd5fac9d7ae1a87_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018ca53b38334c258546194db151794a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id41fab9ee02a43b197272a5b13c0ec9b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9872f8c2bb2488280b710de2bd86613_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21d50af206e442cacfbcc591b7db41c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db43726d8244d069205c2ae2092eecb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i358a97db687a4532b4896a6818c1c570_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia80f3feab17d487ea2b255ed4e7fa9d9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a7281dfb87f4c759ded27994b4bc48a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48de9837733f44a7b1ae4335196cab8a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6500c755b0d48dfb3cfc643bc8aa24c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80c2d0a9c88d4d4189622a44b28df36e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ef513a65ec4140a5e0fe08899b47c6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d8ed76345a4acfaa73ca03e26f404d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b8289bbaf4401ca50ee623561b21ae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0201097c2b0b4fd8b09bf1320302b0df_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfebde8455d24e9dabbc61af5ac34b17_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ad690c84e494203ad19621f8be2258f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i365b2ee8a85c4fd0b42ca8da39cce072_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec836555e23418e9418b4c438dfbde4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7441b05974ec4515a4d0318950fd8c07_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34eef8f55bd84011bdd58c92bc395b12_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2050c886f441471bbf874fbf99723b8c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b58455f915944c5a8b42b07b2d4f95f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102f99b657e24bda89929e63215714e7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f766dd011914fd7aac023f50c96726a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i390f7d8898fd40cbb7ae0d2c48fb5ed8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacdaa759bf824f8ca47514fea1b47ee2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66ceb4c3c8641618bd0571332ab70e7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59ec4787fd04a5585eb63429b7020aa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78748439d3e4bdc967aa5af911f7391_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64722cd85a514d76b846ff90832c2934_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f7c01250cb438abd665e9b9c94e743_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2eb565fb2ca4e59be0ae2c0d7f3db8b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bbef3e76d1f47a29e6f947d82b47f45_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad39afa89ed54171a76ada18b22e630b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95260bc99cf64ae8b8bcaf3a4e5e7812_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3a1ac1941449be84c85e628ce9d89d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50a8c5663be04e9faed2b5f0d97a0e68_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79795b771df34c8fbe099d241c96d9b2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="i0549e44337674a5ca08eba019050c369_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f1dc85a6d443f5addb0eda7c8dc35c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5d0635317e4c16906d390ed841b9b3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e281fbe905d4e3e9728f08aa41f030a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc6970c546c489b94382b832606b1ab_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b71a9f27e79480681fe58993506eb15_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d1e15250b64a13b47a432932d37658_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64007592035142748ac7599f7a664be7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9bb0d6c15842358b1c0ddfa1c21b68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e6d8ecb5194fa9b70da244b06c3872_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib378e0758d7a484581e59302e22742cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b4afb6819034ad8ae8cce9d2e54cf47_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f620d3630247a0b5778586f131544a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic91c47df08824717aead53a81a56dc20_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb75ba94b11d4a699b755fdc629e6cbd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d2a9c8b03648879414ce30d6e746af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa3c889df0142bf89536f957b8eaee7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b173db27f4480e98a38ea719ffce5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1bfcb48e77b46bba81990b5298288bb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b18ce9f4621437b922497d189f85e55_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i701a2e8982b64d678d5770b22075f8b7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b7ad7518d94ebca15cc87bd32825ca_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3408b069db1d42f7b345ec1b7498f89d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec55d2ad3dc4febb73612f72beaebdf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic99dc3ab809743fabf00ba08bbbca28b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf7ab8592bc4011a62dfd0ea076ded4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90843cdfc614862a52278ee45bfc131_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414a6de3330847a1ba08416250b5bb7a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bae232cfcf14b48ab44d669cfbf4ea9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1b9df4cbfa42c3ac411955189a9091_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f198b587194af1b052efd3339aa9ac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e025fdb4f53458a856e099d5f619c31_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i744aacd6ec9a4103922fccc0ecf5a575_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23bc77237cc245c6bb9b3fd9dcf68cee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28924f2261242259992e93451202d13_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62cbf5b25f7f44f6997f9587acdb152a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3202bb6f2a554b45af9aa83e6ecacbce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6ee34a915d43d3b004660946221bbe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19b8b42bc9547abaf105a4b71dbd351_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i790f18c0415849f9b387fb21e49c9fd5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4ecc275acaf4fe883a279d9a574b48c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753c69a029d04474a9bed4a6271dece8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i805587f470f344d680991d5995876af0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if310e2943b1e4ccbbda6ed73c324ade3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be3bc83cfa548609221fb923b77b012_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa487875e3b4688bd646e5ea13ab375_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1627155704354fc0a8a424c6c2790177_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i463cd8459c624bd3882e48393200fab1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4c548cc92f48a4ac8e14803f6f43b6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53f4f3120ef84eefa4d661c020812d93_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45e7b551c5dc43d5a333a321f352359d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d6d0dc9ec648d4bea25189aedec636_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8e4d78e60454a64b89e8a75ff8f0450_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21c7a6ec4ab4bd2a8bbfc0f4cd56f43_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80bd0b2b32ea4b5680c869f40cc11b5f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i326c80e9243f4bf493aa660e564a3122_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7e99afec554a029eb237f033b39037_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i994f124b7f3741b2a6d52b940a0759f6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111AndBIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47e67b006b354cc88698e7fe5664efe2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e115d8322fc4129abe228330a35b1c0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cd19afbd26746dca41eab54ab3017ba_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65c9878611a94c1e8dd4e4c8e3723f18_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a7a60146fc349eab4e74a420635d5c4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i842cb6f355fe4d479461afd4ef4e083c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876974683e3549eea5fc8f61aead1156_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2fdb402e2824ce4a9bc71b9229835d6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c87b4112217442caf7f93008b36ae14_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i913028ac08ed43abbe4437b3e87d4ff8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9850ad45354252a28687b05a4f7ba0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ac3585271c4421bccc4835e25238e5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79db083a3de94f4287a9add466386aa1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaacdf0756fe34b82bc7e195e28ba5cac_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cfaf234a7a04182b6f04ff79328e86e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2382fc36d44058840ae3e3e28251b2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1deebd059f4c45a7a55fb2f7fb75cc43_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c1474a542b94f95b31adc32082b10e2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida9264d01fca4283942cd3738537b883_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0fdbee67b92424c881435c78e569bbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378cfd98f0dd499089706915fc4d9abd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81740b779f254c85bdb56c3ede0940b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd88cfa056ee42b688c44148869a89bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b77bc2d5ca1423eb85a5b99d2103f23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669d0acaf9ba4c9faa1e50b3d5545924_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2b5503377e4d60a68343ae4a275eb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aac397904bc47ceb520bf0b28475c0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i973902141e63471a80c622f966bf9204_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ea1ef8967d4c89b99809a24bec5629_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bf4f35802694c1fbbae2718a8f12142_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3993b259dd8a435f9cde46b68b063c55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ab4f097e1a4677acea953affeccc39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3467f79adfbd4e57b9fa997886b38ba5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d75b9475054c6aa2f4631f5a8ef20c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaefea2e4aa4742fcaf12b2e1a663a4b0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0a301c1d504d4cb75e0dfdc175fba8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacb3b16cceff4a69b162f9088df8f83e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aedfb52da3b4ed3ae009c32d7af2f34_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica74fb523d614349a5924b06d1bb5822_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d11beb9b3fb491897b7a82b6680ddb2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f2d4471ced94158a3b9461f37a5a9b4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa563a8c541342878a6a7502812ce7c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9933a802b04b7d8c62324f5f41c52a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70a8801ef78b4c00a73f94dd2ce1a172_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia82ded1ca1fa4ec881505e83910f2470_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819bef58752546e1bbb77cf85e7873c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e1f0ba26984bf396b6de85e0803baa_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fe6316e93084bcdb4bab71201828487_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53759aa6be6e42a1a94cf191019495cb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec1430297504929aeba4396860a0195_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc42842da7bc45f38b433b05022616d6_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad055f43eed4c1abc91e33ba1c4c608_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333a0bfdd0ca4d5180e70ebdd613c08f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dab2decb1da48ad8d4b8e3c14967ebb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7814cf51367420694a7166e5ceff073_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadac69438a134e4685f396b8c53251d4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ffca47ad8954ffd92872504490dcf03_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77b83c10d6543c4999b42d941ff32fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if652d73e263246e5831dc57a670a53fd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d676501ffe4026b9c68ccd7f42aeb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13df0a9587724904b596ca62dcf43f6f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2186b976c0174d35bd3cbdf1c89882c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id82eeedaf25949b28400154944eb6b4e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife2f354a35fc496eba95703d7b607384_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52475161692a4e19be21e73c51c53526_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i049d807889c149e8a50eafa9f58bb8dc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if153048dd394454eb1fb423f72bda912_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a18efbacb6145cdb2a0021473063184_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if70a9c11bf614396a6522c901ecb08f1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if077767e3ef64c2484a2cc92234da011_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44917b25ade349a8a5f06df642623475_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i470da7200d18439f98b62a166787441a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3caddce2c0c4c20a79927c2312baf96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4bd7705008143a9ba46119d91dce67d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bfcb2b7a789408ab7429d172cf3b595_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7673265729c248e8b545dd7073d36204_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea3ebd667744c9381c73def31f719fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2c365225e34a9da8933f6b3cbf7de6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4655f3abc15413baad6a40cd42927c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if87653e954194d689bd182fc5b42da74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d19a6c1cce48f890b4ff8854eb063e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia67769f4d9c64b70b1ee25a453d4c188_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7c54edc6349456abaaa90d10aa21a29_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b5d9e350944ffdad686ff95dd1085f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f721455f7aa4586a968ec0031e919d8_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea2f828e08946f9bfe96108463cde78_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2139678da5ba44c692cbccf26f3f86ad_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c77f922da23412fad540d818c968248_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf82a6b484d49e69065707a4f3422d8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic165a79eab2e42c1a838d2b473206e5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d4b70e429084cd896ddee8ad6a86f58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55d56fb32ff46218a8edddf870dc788_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic059a695f5624475b5bce97e745827bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id661e83da0184b60b9078c3003d2d512_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f88181fe304ebb96cc0a68b0ae12ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03aec522673d41f1bcbf6cdcdf6cac4d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if46410444ba14e6092450fb22efffc1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i882caa9f1b214f12a34a044e78765486_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8af15663b9a4d8d94e49f9f51c463d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d2d53f1521473fb2e87b588a892372_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67cf121e430342109d49fea777e579bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac6c255d1f3477ab244bffeaf22cfc6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a88eef09354000953b0bed96387192_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ca240b4a8a434dbdfdea26e500aee9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b54841e3504571a9b44de5987e542d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35d98789f1244be9ad4952ccbcc7c4e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a80f6779864dd992819b8e00be88b8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71e595781d44f16ac699138752f0bc8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cac1f347b104a4ca1db20bec5c47875_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c37dca65684a5e9f14392ae29cbaaf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c3ff6d74036499d8a7471834819584b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica4d96484afd47e3875930a4f7e88de5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7805cce3a52041d3b30f7a27f60fda1e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic725003c511544d9beede7d62b22bf41_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i021468994763467d8c149cb0f1b5dc8c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05a13a77e61439a8dd0d989c1ff1052_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7069a9554d224968b39144be715d4ba2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954add7d31b64b3698c2961782705265_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i662080f3255e4599a8eb926798a5d4f1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1ad6684545445c81eaf1e55b9da3a0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04673d30367460fa2896b503cf49adc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c14487107748cf8adf0aa48b1089e7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4f3485174db4d7c876667900c74e5bf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa2615942dbc42b59096307ded3cc0c3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="icc31d40d106d4c9f992098cfdbc25314_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d14a7ea6f44f81ab85c9eb63555a65_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b619c6a194a48d79f50c3ece23badc4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ead7913c08409dbc2595365e9f3e52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c68d2f0c36b4aa0873859e893028f61_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie613980df7054b379c880bbe236bd443_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3d42fc3ea64bd198bebd63ceb7ccd7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44dd1a2f10914daa9af2e90f8b3c8807_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1200adb5dbe47c7ae6a9a4a6961c216_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c93a139bb224308a3c7a36175e4107a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic554f230362f471382f660791fcc865b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a7748b009f646c8b31119a5c17aae59_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61f3acadd75433c99101969cf66411c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6968467d8d7b4c5c8a741ebc7f01c64b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdd697e3d7934db0959c809bdc451568_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481db3700c604a1bb15870d0cef6b1ad_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e3b2b199db482c94d883952512475d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icffd2e05c3e949db9d2bb4ffb7775e8a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0fd194e4f7a43a08b6a326d74102423_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8a70ef8aa048c2a91453d9a5dc5e74_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69578acd699b413fbb7d39b34e455de0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icddb8a04e2884668aba19d51821c5e40_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10aaea33d60c4e62b5c5437eb9aeef95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib911d65ad5594eb4ac4bcf4afb56823b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a39e90d5a084a6a82c0789525824916_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d23192df14482d8fa3fe146523c99f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib101119d811b445ea7aebef90a37dad9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15bfdcd49c954e93ab09b4090c28ce32_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c6b9edb2b704d33991c8e9a2425f671_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i5f65716caa83413388dac812d8d3219e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a3fd2b017b41fbb6dbb92df1d7ee68_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7855fb28a23947d995189305bed5f12b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b2d0a2aca64df688f77a7ea041914b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237f7b94a47e4d618bf0d30b1872ccd4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i726364fc850f428980b41bc6bf6ead64_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic94894775dbe4be685e8410ac06fb197_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic351f5dbf270449286ad0664853e2842_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21dab209cac741b08e2660f13a98e869_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a580abd0df4408a90cb100e5c26f1f_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i889cfd06e76047c4b4d5833cd7016227_I20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb73b7afe9dc4434b6d819770e912b56_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5ca321d1584c1ca6bcd8f53d653612_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i274d98ffd7f54b12bbcbb430a7f6446b_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a02d5c86ee49cea24a7e5760768b86_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106acfed1b1d45288e2c252eaeee518d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4f828fb4a924f93bdde2fb608c2e829_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c2e8e8d01b426285c6bd058cbb4b5a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a59c92aa5cf4dffb7a826f5ebeb931f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i939d909bc5be42e6be0dc04dd1a39954_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a8fc959a0849088adcffcd36d82f66_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9d05f7c1a74459b89c4ececa72d31d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1948d85fab604db881323ed2ad598c59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ce415c72f84e7faa6119e5db9ec7f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica50ab9119b04010bd04bd7d82bce622_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3612de0f43644d784871ebe849c27ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id753ed956fca4c9697045d3b819e7684_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i516bbb796f934334a222a0fa68f96141_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61dcd7cc49f41c0936daa62cdcbb1c6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f19acba9b346f8805c6bdd01935668_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f0df97465f48e7b7873ed9e345c3b9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b0f729cc7834d838ef13e90b13032e8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea582ea5aa4f4a669db07ca5961b838f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife32845f8f56459b828af29f233cea3e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f6137620d443d38f5a57b1cc4509ac_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8488f37532d44598b640e3d982bd4d1a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7aa58f98c924adeb22065e220c2905c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5170241300904fbea34b8142ff2a821c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8165a95911864bcfb5491d08afc84e94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165acb4a2b0d43dd81d356c112615871_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28faac3c4e4b4accb6e60a468b175a53_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13ee975c61c5467f9516d04c8a1176f1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1921ce00c34a2eb95d9de3595c2be7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c516cacf404828b016eddc54887f05_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7179a8875e614260b2c6e1b4cf82c9d1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1f03f52650459fa99a8fe57031cfe6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c86dfc3e9ee4f10af73ad81268a63bc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3ea666a48f4ea79d28dc480c0ac8f1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d395dde98524fa2959805ab74ab926f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b817c4f2c748f4ad54ab609bcb7259_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e79c56dd794f2c98635556f462cf4d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b67fb3aa82d43ffbf26b48ff2d8f1c5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0fc8c7198a43d9b9d0c99f6121cd13_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa38f90595e4e8fbfab0ba144b401a0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf8e0d7f30d8409cbfc5630b9d2bc341_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idde20bc926894280b4ff61e91056fe72_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8175286262ae459f85852ea172fe0373_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia346a814aa4d4577b59b906128f24eec_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c2e8e85ac5a4488b1adc8af19f319e2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143c1628336040789355760a0e36cb04_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib270c515c868406785b1ede039e1e002_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibade6508c50c4f938133f3c022f3073f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6013739ca1f54a5290b712e2dc11f329_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6fcfcabe5d445a9761fb8678c669c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f010fdc6c5e44c2868aa793118a0276_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9679d28935fc4a48900189cabb13e5d9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39e962f11bcf4bd980fff4715c3da316_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id98346bd89964dedadb43377f44a0d31_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a105cc514f40d7bf0743359acd5400_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id274468946a6454ca8c80e958563c1d5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23430e509b1b4117915b80c09a42657d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379169127f2b4a9395ced61d3e36c9e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if014c19f237748bd8ee32127e024b863_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477a6cb8b52f4f929eda17ce6dce344c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i150f4a13b0a145e8bf65f5c84097ec47_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ee866dd4344c0aa14cebd1e0c79e89_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75aa8742f42b41689c3d73f6bb82b7dd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7000526ec07f428091319155849fd704_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6747564e0b4a938f03505b3f95f165_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699b74e5bbfd4779a582c698d788d790_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied525c1179a741bb82b1d583a76e51e5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff1924f4ee8f43ee840ee57aff81df9e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d39579533114f4aa354f18fd1f299b5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654d114f9573429998ad4856d6fefb38_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i677267ca7d7e48f68e24c2371a4dffd1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f1075481e74bb98a9b2a2d1b4673ae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd96e2849ae7466dae303c5a5b80c085_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f267df3ba84643b8bffb1e5ff56f47_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib258d211097b4e64aa9629510fd53154_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2f98bd41f384786a46e50b06a48f2d3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2953a813c0d9467d9ae9f1e794ec1fd2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e1e20ca1e74fe0b437961b9da435a4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if314461b1e5b4baea50b55cd17fd0538_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b90ed783cf34d47b1bd424e613386be_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaae1cc404f343c5bfb355c19f2dd60e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i266dc39128f9407d870c90b7e77122dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c913a6dc6e40f3a5994b325c0067d5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790bc65eb68c43b0a56d4a861411da6d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc3cf0a2cd74d61854096f0dc29d4bd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2401c248b54473d9de51f32724fa7d4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05dbc5642aa740e898a9288a14e80f49_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248e2c4fa3d34b269a285cb1c63488bd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09ba7df5db74e13ba503168413abdff_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444b41b2ae2d4e7cb1136b88ed82f8aa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e35f43cb26444f81cfaccaad8eb9cc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fa67b093a54744bc17319d4330b45a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebee12b1fdff4baab053967a2a218895_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2515997127460a88ce3b7721c7f899_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if816cbeb32834f9c892e3d50f230ae8b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3ef8424e944022bba6665e253acdec_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia410aa53688a4c78b85ff75528ef68ea_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f86bfff90443dfad344994aa697b38_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia721ab9e8edf4ed7a17168531a631cd0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id81620b24a824ca2a03f609c9a047932_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f850ed68f24c55bf0e191cf454be49_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e940795a93d480cba3bee92ea71cde2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38006411cd644bd9bb6a9f6aff3265f7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28adb3330230472e88334d479def96ab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a13aa4f4d447958145380700133524_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia13f165b3be34174b50cecb4c27778d9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee279a7d1aed471ba23a5d4e8f28794a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756f3f5bdda54726bce4b571b4493a2a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5dec6bf41c4a37a79d8a1cc7f4a7da_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ea2be25eae54408bbb6eef779a3bab9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e718401bed449ed8eea180efb806b04_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:context id="icccb66447d924c0594b928f60f204b02_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590aa7c867af425baa597d7a5149c44b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4078cb7710e54f01b41c9089dc314b3a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633b5b8dfba24438ad91750ffda4fddf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dff1fe5988e4116a7e201e084821a57_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f8f42a6a9c41ddae4efe85bc2204b8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i648337729b824015ae37af96e3c8ea6b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02128433756c4eaeb9a1cb904b8b0757_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad97210ae5d418ca006b46280264849_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ac80dac77b54f829d7ff2f034bca438_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i980538f09ea6402c88eeb6295f06a52e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i509664d8b5114111a796a1f9c9e4bf21_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478b04cc484548cca1dda224d468b2e6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc6f9feb2e14b0b92a0d13fa4fa7b20_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0983fe25984681bb8e932d698e54aa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if795d18582b54e3b9e469252f6bb23c1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a30db781c9c4e588e9c2f59f6c0abc3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabde71d9b5fa451e97f28d6436d5b553_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f562316d0a4a2788f90566852c367f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2747153b7ca44e2a5d47259de2db6c9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487108ca40f748dd9b0bece4b437028b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32e8ba2ceec42cc82a16e2cd05dab84_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c43205ec30542ee94946dc9109e90bb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i751d4a0241cf4502ab3497a8e9ec0dce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad78ebefcf14b34899f5ddcb848be14_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idabf552e851142fe99517e02399fdd3f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0eaf2019e44f0682994cffd26a0133_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1572a6af6d488d9ab80a00623a94ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15516b5b057f44e9944b4a39df3e5c9e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic776742915944b44af8f827099040080_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9d32af2650947b8b8a4b511bb7ba6ff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd0e08d01ac49639fc6727d3904fee7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c7f3a2f08a498b8785ed63ef47838c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d833d38eb9f4e898a5898ddbf6dce39_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efa6afcaf1645f6b58846b7cc88b340_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie06b3989f9a34f469041414b1f9de0db_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e7531c621947d4a9119f4864109e24_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb3160ab3ff42eaae7dd54fa3d456e5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i199def73fc1342d0a937f3d464cb4c69_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5281eb5b3f824e51b96dd0c15c3e9f04_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6944bfac8bea4cacac93ae484b0bd09d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86671ce6531e4825b8e7437bac23648c_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbfdae3fc3af4808b767547c978da623_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f17596163b74714978d0ca8bb7716a7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i920ace51c79b4fd9aaea95747910f622_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901cded39aad4bb796bd2e4ea0b84524_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af199bf8cdb4db88ac9960dd490f47a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b972473b78a41948835d5e6b4829ce2_I20181107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d3585ab7f49447c9095cb7b649c5a3f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c3147acf584e02bc9574e010f74b90_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1fbddcf67fa4255b76afc8be76c1ee0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f34187e7424286895df7d07271d853_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc423654295e47e497b4d7f2985f4754_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22878c92c12541f19e966187ae7b1e40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50c9b8ddef6484aa041e78de26b485f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i869e4d6d217b488e998a60c8e87948c6_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i395c6f6eef504574a55e4ae26a68fee0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ac8ae1aedd4701923500c02d371f31_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1864f4ab43443795b18bf4e5518559_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021e9d577199419a8902601c80f14ba1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22969c273ab1477cacb6c894c96e65ca_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bab21bf098a42d1b19d7bb69acd037c_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b2b5750c244cafbf99dc052af4f8a1_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id73a857cd2af440ebad3dee0301dca58_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3c03d9b6e5a437fa43cc01794b646a3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46019d81d2e4485da3b49f6b7279b384_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72ca0603ce78428694ea1e92d86ad2ae_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c76f0606c54d3c92d00b9c6239054d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36b8f43567e4ffc8902418be40bc1ef_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68d34303bce4a2db8b2455c5f1c3285_I20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-15</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8046a3e69c814e7f9967395f631661c6_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDE1_4d10d025-6448-4c3e-9937-d7f85cc47e04">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6Mjk0ODZmN2Q1MGRiNDFiMmI1Y2U0ZDY4MzcxZjQ5MDQvdGFibGVyYW5nZToyOTQ4NmY3ZDUwZGI0MWIyYjVjZTRkNjgzNzFmNDkwNF8wLTAtMS0xLTA_6d0e89cd-1d88-4537-9067-56763618d251">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18xMjM_e07a8951-464d-4d8d-92b4-fcafe29cebb0">September 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6YjBhNDc5ZGQxZDE4NDFhNDhjN2IwYzZjY2JiNjczMDQvdGFibGVyYW5nZTpiMGE0NzlkZDFkMTg0MWE0OGM3YjBjNmNjYmI2NzMwNF8wLTAtMS0xLTA_7ee18576-bc01-4a4c-a316-0ae167582e8f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDEw_9368d39d-5c62-45a8-86d4-870b664a2bce">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20210930_g1.jpg" alt="biib-20210930_g1.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDA2_46c7a831-7a70-4416-99c0-6ce9b609bf1e">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6ZTdkOTlhMDc0OGNkNGNmZDhkZGRmZmVmODkzODNkNWQvdGFibGVyYW5nZTplN2Q5OWEwNzQ4Y2Q0Y2ZkOGRkZGZmZWY4OTM4M2Q1ZF8wLTAtMS0xLTA_39630c78-2b59-46c3-9962-73c6ebe9c381">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6ZTdkOTlhMDc0OGNkNGNmZDhkZGRmZmVmODkzODNkNWQvdGFibGVyYW5nZTplN2Q5OWEwNzQ4Y2Q0Y2ZkOGRkZGZmZWY4OTM4M2Q1ZF8wLTItMS0xLTA_7c05ebd0-83fb-4a5a-b9f3-d196441c4c26">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDA3_ccd1a8c8-bf34-4845-86b9-c37ec6ca9207">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDEx_b6f842ef-c8f7-411c-b14b-0e12d4077897">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDA4_e2bcd27c-71f8-481d-9017-10e61d5e0910">MA</ix:nonNumeric> <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDEy_e7b6315b-7548-4220-941a-65d7cd5444e2">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDE0_ba603cfe-4bca-4bcb-80ca-5dc60d9e2c9e">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDE2_44aa5556-b23f-4978-b7a3-0f93000e72ad">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6N2QxZDlmNjdhNDUyNDZmY2EzMWI2ZmM3NWQ3ZmZlMDAvdGFibGVyYW5nZTo3ZDFkOWY2N2E0NTI0NmZjYTMxYjZmYzc1ZDdmZmUwMF8xLTAtMS0xLTA_648b9896-fc3a-430d-b752-7725046a3355">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6N2QxZDlmNjdhNDUyNDZmY2EzMWI2ZmM3NWQ3ZmZlMDAvdGFibGVyYW5nZTo3ZDFkOWY2N2E0NTI0NmZjYTMxYjZmYzc1ZDdmZmUwMF8xLTItMS0xLTA_51bbaf20-1cb6-43e5-a1b4-b26a61247cc6">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6N2QxZDlmNjdhNDUyNDZmY2EzMWI2ZmM3NWQ3ZmZlMDAvdGFibGVyYW5nZTo3ZDFkOWY2N2E0NTI0NmZjYTMxYjZmYzc1ZDdmZmUwMF8xLTQtMS0xLTA_ef5e273b-dd46-4984-9e0a-fe77045ec089">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDEz_75923865-abf4-44a0-923b-4d3c85266ae0">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDE3_e2879aff-83b2-4274-8257-82645b88a42a">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6Yjg3MGE2NWJkNDNkNGFkOWE0NDBkZWRiZTYwMjk3OTYvdGFibGVyYW5nZTpiODcwYTY1YmQ0M2Q0YWQ5YTQ0MGRlZGJlNjAyOTc5Nl8wLTAtMS0xLTA_de47abe0-4be6-417d-b8c5-db5933532870">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6Yjg3MGE2NWJkNDNkNGFkOWE0NDBkZWRiZTYwMjk3OTYvdGFibGVyYW5nZTpiODcwYTY1YmQ0M2Q0YWQ5YTQ0MGRlZGJlNjAyOTc5Nl8xLTQtMS0xLTA_e83c25ca-c1f2-48d3-aae5-f73328a65975">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6Yjg3MGE2NWJkNDNkNGFkOWE0NDBkZWRiZTYwMjk3OTYvdGFibGVyYW5nZTpiODcwYTY1YmQ0M2Q0YWQ5YTQ0MGRlZGJlNjAyOTc5Nl8yLTQtMS0xLTA_d103514f-dbf8-4991-8aeb-9e03f6f085a4">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDA5_fea98eba-35ed-4545-94b8-5f754f715ea2">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of October&#160;19, 2021, was <ix:nonFraction unitRef="shares" contextRef="ic2146328de3549768f889075bad51afb_I20211019" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18xOTk1_71709f06-13dd-4b88-9903-5584c147ef50">146,892,712</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended September 30, 2021 </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_19">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_19">Nine</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_19"> Months Ended </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_19">September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_19"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_19">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_22">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_22">Nine</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_22"> Months Ended </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_22">September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_22"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_25">Condensed Consolidated Balance Sheets&#160;&#8212; As of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_25">September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_25"> 30, 2021 and December&#160;31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_25">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_31">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_31">Nine</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_31"> Months Ended </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_31">September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_31"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_34">Condensed Consolidated Statements of Equity &#8212; For the Three and </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_34">Nine</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_34"> Months Ended </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_34">September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_34"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_37">13</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_133">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_133">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_214">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_214">73</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_217">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_217">75</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_220">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_223">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_223">76</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_226">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_226">76</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_229">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_229">91</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_232">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_232">92</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_238">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_238">93</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our core and emerging growth areas as well as implementation of our corporate strategy;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expenses, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park, North Carolina to be operational;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#8482;, BENEPALI&#8482;, BYOOVIZ&#8482;, FLIXABI&#8482;, FUMADERM&#8482; and IMRALDI&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ENBREL&#174;, EYLEA&#174;, FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="i8046a3e69c814e7f9967395f631661c6_16"></div><div style="text-align:center"><span><br/></span></div><div id="i8046a3e69c814e7f9967395f631661c6_19"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c7f8faaddf4de59fb5368e32d5ae6d_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMy0xLTEtMS0w_59e54912-11e6-4d3d-b2d5-b84231ab6ff6">2,205.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3672251f76c4fb3ab491f7a64f2a7d1_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMy0zLTEtMS0w_7769f1e6-7259-4daf-9d52-5ecbd82337bb">2,690.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6629e89c034a4d89883d31d567178ed6_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMy01LTEtMS0w_f5fe006e-4432-4073-974e-c68b53ec11b0">6,653.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie862c4e3d0454092bd193a5d58ea0c3a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMy03LTEtMS0w_6150ee23-0e1e-4a6b-b415-f1985e2a0350">8,390.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc49896e8f7749f9aec4691dac20e8f7_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNC0xLTEtMS0w_986148e2-6378-43d1-9bb2-2ff5312bcae3">415.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b23d904c3ce4fde94a3a645d27461d5_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNC0zLTEtMS0w_a3f605cd-cf93-49fa-8666-592042778f07">560.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf69f40f83ce4c9da70c57f9064c7b4a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNC01LTEtMS0w_e40b62bb-af72-4977-9dd3-95573b611003">1,244.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c2b9076741473bbd3bced37f71ef41_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNC03LTEtMS0w_ecf536dc-4e04-410f-a99d-2d00a68aae03">1,558.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36a038f73ce4e7b8013d75c309b00de_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNS0xLTEtMS0w_9ff0d77b-b259-4741-803c-678b022e05d9">157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27692e0f487e42cfa48cfb9ec74d1c5b_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNS0zLTEtMS0w_f21aeea6-9f57-4ac5-9a8e-30cbe876ae96">125.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40db7f82bc1346e0a6ae09a03625fc9d_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNS01LTEtMS0w_2010c586-ace6-4bb2-bdf2-47110f7d9e65">350.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2782acd53f4eca80ff87db16f55ee5_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNS03LTEtMS0w_dea79b38-34e0-46f1-8336-5e77a8d6d1ff">642.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNi0xLTEtMS0w_24098114-2381-41c0-8bbb-58f83358685f">2,778.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNi0zLTEtMS0w_04f70111-c20a-4c5e-a0b2-ccf14ecabb85">3,376.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNi01LTEtMS0w_dac691a4-f2b6-4da0-b7f6-d4610e88841a">8,247.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNi03LTEtMS0w_031934a0-e87d-4f67-9894-3a0f888c18b7">10,592.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOC0xLTEtMS0w_7a640ebe-9694-4877-ac3b-664db6b8491b">511.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOC0zLTEtMS0w_5e1bd94f-43bd-45b6-b2b1-b806d450b9f4">449.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOC01LTEtMS0w_be1610c8-bbd5-4720-a445-7b3552dc5e65">1,449.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOC03LTEtMS0w_2c413ee3-e6b5-479c-86c5-3fceb8455acb">1,314.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOS0xLTEtMS0w_50ebca44-1461-4f5f-b460-468de6ef643f">702.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOS0zLTEtMS0w_decdd01c-7546-4bd2-b4cd-1410f7031e5a">1,140.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOS01LTEtMS0w_f3c2f6e3-6016-44c0-9629-c4824a9e9ab3">1,801.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOS03LTEtMS0w_d485dbd0-5822-48b9-827b-d7bbe1e8bd95">2,264.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTAtMS0xLTEtMA_ac910653-c13b-4a88-b550-02d19f2332f6">654.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTAtMy0xLTEtMA_ac052197-5f7c-438e-bddb-5caa0db53c30">573.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTAtNS0xLTEtMA_bef1c4dd-1c0b-4690-879d-bfb1b6a924a4">1,886.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTAtNy0xLTEtMA_e0f8337b-2aaf-4874-ab30-b479b3d37eb7">1,698.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTEtMS0xLTEtMA_9e2b4371-cb66-4554-94d9-a51f1bbddf33">111.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTEtMy0xLTEtMA_00842875-29de-40c6-b379-64a9ccc60588">82.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTEtNS0xLTEtMA_5547110c-3dec-4393-a8a5-cfbcc75bc476">813.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTEtNy0xLTEtMA_53a020ee-35a3-402f-9ba9-9a5d81ec6533">215.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit sharing</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTItMS0xLTEtMA_76025576-7900-4019-b50f-f67fce5bb346">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTItMy0xLTEtMA_2f04e3ca-99b6-43ac-be66-856e6ffe018b">73.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTItNS0xLTEtMA_35f1edfd-1768-4498-8dbc-46da20517648">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTItNy0xLTEtMA_24d442dc-9f4f-4157-b0b4-0e68682dc469">166.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTQtMS0xLTEtMA_a0bc14ba-5cd2-4f94-a12a-c5bae9714b80">15.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTQtMy0xLTEtMA_3d7c555c-2eab-471a-beaa-97640b70f4d5">29.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTQtNS0xLTEtMA_f1730e18-7b8c-48da-9604-81b8ae4bbb61">49.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTQtNy0xLTEtMA_e0038e68-e541-4005-9596-717db6ffc5a1">23.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTYtMS0xLTEtMA_15996fdf-2ec5-4d11-b42e-0b271558375a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTYtMy0xLTEtMA_5871ec4e-7f14-45a4-ae66-6a47694dc04a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTYtNS0xLTEtMA_83fe2259-6855-4c30-b7fd-cdf08b5dc064">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTYtNy0xLTEtMA_177448e5-0948-4977-84e7-dff07df81dde">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTctMS0xLTEtMA_97fdc7aa-7512-4fd6-90bb-4c124de68918">1,984.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTctMy0xLTEtMA_3834b94b-764b-48ae-b633-a2d35983590a">2,289.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTctNS0xLTEtMA_66023d00-df59-4f35-b627-051d083dec5c">5,994.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTctNy0xLTEtMA_6feeff64-c27d-45d3-87ee-04694fb8d7a4">5,711.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTgtMS0xLTEtMA_3fc1eb5b-26a2-4558-a050-391b2de9776e">794.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTgtMy0xLTEtMA_ab66d0d3-9a40-4af2-895d-12e9c3cca9b3">1,086.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTgtNS0xLTEtMA_4f5b4ea2-2e72-4c9e-8bb0-1ede20950376">2,253.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTgtNy0xLTEtMA_52d95e33-8320-405e-8b6a-6470ab4de550">4,880.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTktMS0xLTEtMA_c6385783-ed00-4976-970a-4025413fea29">502.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTktMy0xLTEtMA_4af3b50b-ec75-4c97-b58c-cbfe177400a9">128.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTktNS0xLTEtMA_d02197cf-2ca9-4761-8e18-056bda60da18">913.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTktNy0xLTEtMA_45557ea9-90b4-4d9e-9ad3-0eaa5eab1715">186.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjAtMS0xLTEtMA_dcab81bb-8491-4b28-978f-6d9515c905dc">291.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjAtMy0xLTEtMA_9c17deb1-f9eb-44bb-abb0-6012a9df7889">957.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjAtNS0xLTEtMA_42e69a50-98e8-4e1c-a5a1-b56eec1471c8">1,340.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjAtNy0xLTEtMA_b01bd430-057b-4503-9ff6-250bd4f02b7a">4,694.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjEtMS0xLTEtMA_21f8f2e7-971e-45f5-bf00-271ce86688d8">25.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjEtMy0xLTEtMA_f57e949c-df61-4555-a7d2-f426a304fe24">240.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjEtNS0xLTEtMA_9ab446fa-056c-4c48-8d69-6c86960766ae">390.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjEtNy0xLTEtMA_e79d79b6-8305-4399-a81e-767e1037d5a3">979.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (income) loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjItMS0xLTEtMA_4c84cc16-b988-4486-945b-3281e72d056c">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjItMy0xLTEtMA_0901aabb-fb61-4ffb-933d-377433afcbe7">13.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjItNS0xLTEtMA_283ef742-9826-487c-bdc7-2e6b10ae2380">17.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjItNy0xLTEtMA_641a8784-5b87-4ed2-ba99-2bbbc6750d45">12.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjMtMS0xLTEtMA_ffd677eb-b5b2-43d9-9d1e-9695bff46bd1">318.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjMtMy0xLTEtMA_d8fe1f12-2696-47be-91c4-4cb2c63caf64">703.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjMtNS0xLTEtMA_984d33c1-a22e-4bb8-8ead-62873fe46f6c">1,748.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjMtNy0xLTEtMA_0e192b19-e1b1-4aca-aaab-2fcdf889ec3e">3,702.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjQtMS0xLTEtMA_934264e3-ffdf-4b3c-82d6-be44b6aa8ef7">11.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjQtMy0xLTEtMA_f97ab05a-ad64-47da-b8c1-d25abdad5712">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjQtNS0xLTEtMA_7e836608-afcd-49a2-a82e-ffcaddb8810d">560.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjQtNy0xLTEtMA_5302ebde-b82a-4a5b-85bb-faec6766a50f">60.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjUtMS0xLTEtMA_eb1219c2-aaff-48de-9820-8750f3709cd0">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjUtMy0xLTEtMA_5e844396-8c7a-4c36-bc2c-46d4eb61b3be">701.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjUtNS0xLTEtMA_18236b9f-eaf3-4caa-86cd-c51dcf10afc8">1,187.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjUtNy0xLTEtMA_7a774652-573f-40cb-81c4-d3065d13e3cf">3,642.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjgtMS0xLTEtMA_304d2923-5648-4da5-9a89-96500d043496">2.22</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjgtMy0xLTEtMA_ff6a4e5d-9855-4d66-970e-9e59baa4a68f">4.47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjgtNS0xLTEtMA_a7f9e696-35f1-4cf9-b069-9935c2b4e0e1">7.93</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjgtNy0xLTEtMA_71f923f8-6224-44cd-8975-042dc50c8da5">22.29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjktMS0xLTEtMA_727ba72c-4562-4699-a70e-105a6137e050">2.22</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjktMy0xLTEtMA_701e31ab-773d-4ebc-9c8b-09278020b07d">4.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjktNS0xLTEtMA_6f93aa30-58d7-4eab-9ec9-d5d98c793cf2">7.90</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjktNy0xLTEtMA_a7c4f986-cdda-48c5-b040-56e6815fcef2">22.25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzItMS0xLTEtMA_253d7685-d00d-4d52-b337-a038882da16a">148.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzItMy0xLTEtMA_84129242-b0bc-4b3a-9af1-ec873e073312">156.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzItNS0xLTEtMA_12998b78-b75a-4e68-b6c6-f24f83957ee5">149.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzItNy0xLTEtMA_4b48819c-bcb2-4609-b117-964d83ad7de1">163.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzMtMS0xLTEtMA_ad9d1ee9-03cb-493b-b317-426c91b8c75b">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzMtMy0xLTEtMA_4349f918-d4fe-48f7-bc16-8945c5fb8150">157.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzMtNS0xLTEtMA_ac8d46be-968b-4dd6-9d6e-cbda6a4b2d1d">150.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzMtNy0xLTEtMA_598cba8d-4cda-462a-8d96-a078bd70d76e">163.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMi0xLTEtMS0w_951815b4-67d4-4ec0-9a33-93558d0d70e1">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMi0zLTEtMS0w_604526dc-d973-4b19-8b13-6a7f12fbc42f">701.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMi01LTEtMS0w_4bdb5332-aac2-4525-8753-ca5ed0dc2acf">1,187.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMi03LTEtMS0w_c82ac091-daff-4c7e-8b6f-11ff7f2266de">3,642.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNC0xLTEtMS0w_f49aca70-f7f8-4647-a8c0-e643f0433a97">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNC0zLTEtMS0w_67a50225-e799-4841-8e21-02f202782a43">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNC01LTEtMS0w_42651841-e48e-4739-88c9-b0e02af66bdf">1.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNC03LTEtMS0w_2a79e634-8855-499b-aaf2-6e8b5b204f96">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNS0xLTEtMS0w_c65c6b73-ab2c-44f5-be3c-78988be05506">66.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNS0zLTEtMS0w_3fb3874c-4b60-4fca-9278-0a7e6145e308">83.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNS01LTEtMS0w_5f08cf87-e348-4578-a320-afdd1ab5b5cb">205.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNS03LTEtMS0w_0744c5bc-ee02-423f-ad6a-709c6975c688">101.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNi0xLTEtMS0w_4da4573d-97bd-44f7-ae18-ec2b20858cf7">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNi0zLTEtMS0w_e97cba6a-5a08-4389-8f61-505ec4615929">11.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNi01LTEtMS0w_d884ff8b-1b92-4df7-bee4-52fd8e663c92">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNi03LTEtMS0w_09671624-bdab-4efd-9ea9-d87114056ba8">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNy0xLTEtMS0w_caee6e58-334c-4203-b82c-fe3e4519008a">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNy0zLTEtMS0w_629a59d3-4406-41aa-b0b9-607476f31407">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNy01LTEtMS0w_88fff180-3bda-4dc6-a629-84f22af11135">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNy03LTEtMS0w_505ca38c-3443-4f4c-b95d-7ae61142f2b0">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOC0xLTEtMS0w_77e98250-cbc9-4298-999e-3f9544cf301c">47.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOC0zLTEtMS0w_6a23289f-bdcb-45c9-ae01-214decdab41e">50.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOC01LTEtMS0w_15e5e741-4d78-45fe-bed1-614df936633a">80.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOC03LTEtMS0w_ca3a4c11-0e57-4a62-bbc2-40e2cf548f29">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOS0xLTEtMS0w_19a52129-45f5-4a7a-8bad-881c24c74db1">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOS0zLTEtMS0w_68f94d2a-434e-4e9e-9ae8-9a546db2afd2">44.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOS01LTEtMS0w_bf1009d2-6dde-4331-9005-e169d58b5a0c">162.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOS03LTEtMS0w_604f16ca-f90b-4121-9d59-cd1e2a274dcc">90.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTAtMS0xLTEtMA_e3e24097-b933-46eb-86b2-491691cad7d2">364.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTAtMy0xLTEtMA_ae0804cf-2484-4465-b972-3b28b3f669ad">657.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTAtNS0xLTEtMA_cc134d54-609b-46d2-b124-fccb38ac8162">1,350.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTAtNy0xLTEtMA_a607bdf9-d588-4117-8e2d-c7aa94be4d9b">3,552.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTEtMS0xLTEtMA_e75818c2-33b6-47ec-950b-dea31923b8be">11.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTEtMy0xLTEtMA_95b52439-99db-4323-8151-476dcca7d2c5">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTEtNS0xLTEtMA_e34773e3-4226-4822-bdf1-730d9e5d61ce">560.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTEtNy0xLTEtMA_f7b1576b-568a-4ae5-9532-d063df62c1a3">61.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTItMS0xLTEtMA_9b1a55e8-82db-4b91-948b-58dfcb90e18e">353.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTItMy0xLTEtMA_e8e7a3ff-c0fc-4797-a472-236474abaf19">658.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTItNS0xLTEtMA_bab97ce7-ab68-463c-9cc4-91110cccdb8f">1,911.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTItNy0xLTEtMA_d1f69eb6-de72-4d01-9a22-82d88162ccd0">3,613.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMy0xLTEtMS0w_7be1fff4-2523-41ce-ab51-52c1fda9a385">1,541.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMy0zLTEtMS0w_d594ccbd-3afe-4bd2-90da-4757499a155b">1,331.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNC0xLTEtMS0w_1094ec77-d4f5-49ba-a073-0ea65b4bd1f2">1,413.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNC0zLTEtMS0w_62022514-f442-44cb-ad7b-6bd84bb9225a">1,278.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNS0xLTEtMS0w_cdc0c6f6-ef91-43ab-b7b1-057d0bc9a4e4">1,723.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNS0zLTEtMS0w_1b37d9ed-f89b-47b0-99c0-edf468a18cdc">1,913.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNi0xLTEtMS0w_8e7519cd-64db-4a07-8924-c3e9712fabda">400.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNi0zLTEtMS0w_e28a445b-9d80-4beb-b5fb-63d3b759c9ac">413.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNy0xLTEtMS0w_683e6f83-a3d1-451a-99ec-c967547e8707">1,347.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNy0zLTEtMS0w_f859c4c7-51f9-4d52-aef1-bc8238efa3d8">1,068.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfOC0xLTEtMS0w_76a3852b-be1f-4747-96da-9c492199b882">736.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfOC0zLTEtMS0w_082cb61a-db4b-4986-b9ef-2b21cfa233a6">881.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfOS0xLTEtMS0w_d2ef382d-f032-42f2-8c55-c321a3e2d9e9">7,162.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfOS0zLTEtMS0w_66548351-eb61-4e4a-89c9-0fab02ee98a9">6,887.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTAtMS0xLTEtMA_7b61c290-704c-45f7-b9cf-c8f1d6bc936b">968.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTAtMy0xLTEtMA_dadbef40-2b10-4073-935d-1ec65c8c30b9">772.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTEtMS0xLTEtMA_acd00561-69fc-4000-b638-15ceba8258d4">3,410.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTEtMy0xLTEtMA_0261c352-abcb-46c1-a351-e19dd5f1cfbc">3,411.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTItMS0xLTEtMA_0a86b2bc-f28a-414d-8245-42db4a3fe450">389.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTItMy0xLTEtMA_7313b194-347b-4439-9d45-3014854fc8e3">433.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTMtMS0xLTEtMA_0056c60f-9fd8-42c4-b608-0fc9e4a8b5dc">2,286.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTMtMy0xLTEtMA_8e5f508c-f48d-4ca8-a918-5a39543f527f">3,084.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTQtMS0xLTEtMA_484f78cf-6669-44a3-92fd-ee6809b8d75f">5,760.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTQtMy0xLTEtMA_4a44b03f-1095-4c69-8d63-6f66badcb11e">5,762.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTUtMS0xLTEtMA_035ce3a8-6b88-4b71-bc55-9b6499f50092">1,810.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTUtMy0xLTEtMA_edd87e43-90f3-4a6b-b482-8fa690252f32">1,369.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTYtMS0xLTEtMA_46c3a6b4-c0ad-4d3d-901e-3f813e769d2e">2,018.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTYtMy0xLTEtMA_07b09455-ec30-4f01-b904-49b3589af792">2,899.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTctMS0xLTEtMA_295aef1c-578e-45ea-ba81-f5947fa6c2ef">23,806.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTctMy0xLTEtMA_a33b634f-3340-40b3-b047-875bcd24ecb4">24,618.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjAtMS0xLTEtMA_88f77eee-afdd-41d5-9b8d-c0dd93801699">998.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjAtMy0xLTEtMA_44b1e6d2-7b79-4f5e-a240-de9fe8d30cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjEtMS0xLTEtMA_ad452827-fc10-4756-bd51-e1810a8a2456">234.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjEtMy0xLTEtMA_a9b57d3e-376c-4c76-be7c-97a0070ed34c">142.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjItMS0xLTEtMA_736d3cd6-13e5-432c-942b-184f445010b6">427.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjItMy0xLTEtMA_f9d2612f-0dc4-4d9e-b004-8d8a57d30c11">454.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjMtMS0xLTEtMA_b5549b49-6b94-4e46-bd59-dda928803b86">2,550.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjMtMy0xLTEtMA_3a756581-359e-4145-a540-42c08244bd31">3,145.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjQtMS0xLTEtMA_af4d8af3-2313-4286-ba6a-91fadf8f2170">4,211.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjQtMy0xLTEtMA_13a965dc-ef83-40d9-a86e-2e9b98a5e6ad">3,742.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjUtMS0xLTEtMA_7046a6a9-9756-4a2a-9026-72441a4e62c4">6,272.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjUtMy0xLTEtMA_51b6e798-b57c-4226-9da6-79d8731fa854">7,426.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjYtMS0xLTEtMA_cc066739-6c3a-4615-95c6-6cea54624b87">774.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjYtMy0xLTEtMA_45733728-48cd-44bb-af43-59926e5feb6e">1,032.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjctMS0xLTEtMA_c44345f8-69d1-4f91-91e9-c8ad63ac6e06">348.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjctMy0xLTEtMA_a8e5c614-2c54-4ba7-9cc6-e135555d1ffc">402.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjgtMS0xLTEtMA_71fde94b-8d8b-4d9f-b9cc-3385f87edfb7">1,318.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjgtMy0xLTEtMA_ccd343b0-d0dd-4442-a172-0272699f9e13">1,329.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjktMS0xLTEtMA_b844e1ca-f92a-4bf9-910a-c1afdcc3319b">12,925.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjktMy0xLTEtMA_24a4234b-5b21-4d32-8691-7b7737db0dde">13,932.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzAtMS0xLTEtMA_9b7a3ad5-f5ed-444d-b329-3b4636fac1da"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzAtMy0xLTEtMA_bd48107b-7725-4bbf-8ff6-a3a3ac34387e"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzMtMS0xLTEtMA_3907be1e-6820-4bfd-8ed6-2c98c42c4c9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzMtMy0xLTEtMA_39b05365-3a63-4d02-a2bf-4d49cc0311a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzQtMS0xLTEtMA_1305eec6-0253-4993-949e-53c5cfacd6fe">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzQtMy0xLTEtMA_65205512-450e-4e8b-93e8-72e47577c3ad">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzUtMS0xLTEtMA_f25e5c81-1c58-4b8c-9871-5f8c066baeea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzUtMy0xLTEtMA_0eed2744-e616-45c6-9471-0273e76fbe29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzYtMS0xLTEtMA_c53f7968-701b-4798-9744-f2b78cd43929">136.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzYtMy0xLTEtMA_8e3d3631-9535-47b8-9874-87f5468489a8">299.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzctMS0xLTEtMA_4ab774fe-0d86-490d-abb2-2b231e0e5948">13,543.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzctMy0xLTEtMA_5af5575e-3670-4929-bf81-fd65935731b4">13,976.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzgtMS0xLTEtMA_88c77dda-bdb7-47d0-891f-c56016297948">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzgtMy0xLTEtMA_39182230-4707-4773-bba0-6276ef19cecd">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzktMS0xLTEtMA_930a781f-8fb6-4564-aa95-2e85c28380e5">10,429.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzktMy0xLTEtMA_0213046e-906b-432f-8288-69bc91ac12c9">10,700.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDAtMS0xLTEtMA_bbf6258c-f2aa-4bcd-b06a-72eb3c167fda">451.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDAtMy0xLTEtMA_b930e3b1-d3a6-4aef-8a5a-b372cd9115d4">14.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDEtMS0xLTEtMA_ad636bba-22f1-4306-9a0a-6b3448036114">10,881.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDEtMy0xLTEtMA_62783c04-f9da-4197-9fb7-611e40abf1b0">10,686.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDItMS0xLTEtMA_788f4a2d-22a6-47b1-bd00-5a51b3e4231d">23,806.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDItMy0xLTEtMA_11e92ed6-f2bf-4edb-9b14-bba28d49b859">24,618.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMy0xLTEtMS0w_a3ad1479-eb18-4809-955f-9e81b065c1d9">1,748.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMy0zLTEtMS0w_204e854a-4fe1-4f91-9a3c-d67a68689c1d">3,702.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNS0xLTEtMS0w_4e55de6b-c9a9-445e-96ae-cacda14aa352">353.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNS0zLTEtMS0w_9e0f4e63-757c-4520-89a4-45a95275c134">347.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNi0xLTEtMS0w_06bf3003-458f-4dba-953a-4d04ea3e7576">629.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNi0zLTEtMS0w_4602636a-272e-461f-8796-ee0d813058ce">19.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNy0xLTEtMS0w_5b36ae5e-268c-4632-8c85-85f2a71aed31">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNy0zLTEtMS0w_385fabee-9c30-43a1-b05b-be72989960d6">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfOC0xLTEtMS0w_5a2bb312-7aeb-4976-b14e-a7c54901a0c6">179.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfOC0zLTEtMS0w_5ee50723-6ce1-4e6e-8109-043f32f17a5e">149.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTAtMS0xLTEtMA_95f0b773-5ac1-448f-a494-7aac4fe79f6b">49.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTAtMy0xLTEtMA_a91e34a1-3d86-46b9-87dd-2a4f4d17cd9e">23.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTEtMS0xLTEtMA_e18d25a1-71af-4733-9a5e-1f2f42f7e1e4">750.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTEtMy0xLTEtMA_45f688e5-e811-4382-8ca5-03a4f6b38fcd">211.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTItMS0xLTEtMA_814c89b4-be53-424c-930b-3b209f566b6e">710.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTItMy0xLTEtMA_5a06248f-c008-4e8f-9d26-d9da73a5b9ba">41.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(Gain) loss on equity method investment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTMtMS0xLTEtMA_f2b1638e-142a-4286-90c0-e20d179a5ec3">17.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTMtMy0xLTEtMA_9b073224-e663-4e96-88f8-bedc9700995f">14.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTQtMS0xLTEtMA_bd31c622-54ca-4d5f-8b0d-3563cfe84828">201.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTQtMy0xLTEtMA_389aa8d1-5752-459a-8d10-6e85d30488cc">110.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTYtMS0xLTEtMA_9cc70055-f7b4-4192-afc8-0f4b22742e63">157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTYtMy0xLTEtMA_c09d84bd-c353-4af3-9ad4-2b466f700264">135.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTctMS0xLTEtMA_9c46c4cc-141d-49fc-8059-649e28bc5e14">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTctMy0xLTEtMA_e0b3fea4-d2e9-442d-9217-93111ab3d194">63.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTgtMS0xLTEtMA_7282158f-42ea-43d1-bd4d-0f6d32e372ed">322.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTgtMy0xLTEtMA_43e28d8f-1f09-4786-a9c7-3950798fd14d">270.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTktMS0xLTEtMA_b5f585d9-3b83-446a-8d98-693080458502">243.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTktMy0xLTEtMA_bfc3f694-2632-47ee-aa9c-38b939424ca0">372.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjAtMS0xLTEtMA_d14de068-a498-4363-a52d-0dfd81611aa9">260.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjAtMy0xLTEtMA_dfec9af2-32a7-4dbf-a8c3-ea583dba2d52">15.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjEtMS0xLTEtMA_79e2239e-86ab-4831-bab8-2d0a12264587">87.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjEtMy0xLTEtMA_95939c4c-446d-459c-af55-792aa4dd6e64">97.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjItMS0xLTEtMA_3b7126a1-8382-45d7-95da-b885b0c6fd93">2,801.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjItMy0xLTEtMA_b8a34d17-5fbd-4161-b7d4-5a8ae8f6e0c0">4,596.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjQtMS0xLTEtMzE0NjE_088c364e-efd1-4663-bbd0-dc542ee4cd72">206.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjQtMy0xLTEtMzE0NjU_357466e0-ff82-4854-b857-a402bcba5666">338.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjQtMS0xLTEtMA_3dfb9350-914a-487d-8125-271d465973d7">2,028.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjQtMy0xLTEtMA_ebb2e748-00ff-4d55-9c13-8e171d912e06">5,240.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjUtMS0xLTEtMA_6226478d-2fec-48a7-b8f0-016126072439">2,372.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjUtMy0xLTEtMA_abb608c1-e07b-4934-b7ce-4c929490c49a">4,649.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchase of Sangamo Therapeutics, Inc. stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9cfb542bbc414db0a805fe7b60fb21_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjYtMS0xLTEtMA_c4fdc77f-2269-4ae2-9839-72cc9c06ffd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2438439cc2bd49c2a02917dc67d626e5_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjYtMy0xLTEtMA_f32c1345-4eec-47d2-b03c-596c9ead7b87">141.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchase of Denali Therapeutics Inc. stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbdde9753524c0da660204088296886_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjctMS0xLTEtMA_3df98a4d-a2e0-4770-959c-35c6814feb0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id15b7f4db2c14ac8ab03363218c293d8_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjctMy0xLTEtMA_76d8b1f9-4cc9-4bb0-9345-91f7348311bc">423.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjgtMS0xLTEtMA_2574b784-9c17-4cd6-8733-2cd6ded1323b">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjgtMy0xLTEtMA_6ddf5405-7a18-4feb-8a0b-2a8546bb9168">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzAtMS0xLTEtMA_09c4478b-e757-4210-bc54-b0ef9576bbde">18.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzAtMy0xLTEtMA_c52fb3f1-e435-4e3f-9ad9-6e80262b4093">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzEtMS0xLTEtMA_a223d236-3fe2-439d-a4c0-3c42362daa1f">1.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzEtMy0xLTEtMA_17c76f45-ae83-4547-b93b-761bcce2f32f">37.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzQtMS0xLTEtMA_a3e1482f-234f-498e-a7e5-13ee434feb0e">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzQtMy0xLTEtMA_dfda492a-b23d-4023-9ee7-eb9855a64c0c">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzUtMS0xLTEtMA_ec969a5f-2c19-4408-96fd-f3aecb3f8abd">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzUtMy0xLTEtMA_4bc4ed71-5f1f-4d4d-a02b-ec0dea3dbd14">18.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow used in investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzYtMS0xLTEtMA_e5f809c9-9414-4aaa-85aa-2c6f328f6fb8">451.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzYtMy0xLTEtMA_9ad44288-6073-4409-b32c-d5d997fcc22c">442.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzgtMS0xLTEtMA_84044153-e6ea-4080-8bf5-6bc5f37c0d5a">1,800.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzgtMy0xLTEtMA_4ee77fff-3045-43b6-9b39-8005e11b7612">6,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzktMS0xLTEtMA_8b2b403f-664f-4d50-ba40-9a12eab40ced">8.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzktMy0xLTEtMA_b132b98d-2ff7-402c-b906-2ea078dc0a50">11.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Repayment of borrowings and premiums paid on debt exchange</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDAtMS0xLTEtMA_21560bad-2845-4f0d-8e63-c56c990378f3">170.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDAtMy0xLTEtMA_8a9f14c0-6f4f-4f04-bb44-3935be8f6ed7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDEtMS0xLTEtMA_cb70f086-6b48-472b-a0c5-1d06f2ca147e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDEtMy0xLTEtMA_6fd57d7a-d68e-4695-9747-fbef2d3a1d06">2,967.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Repayment of borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDItMS0xLTEtMA_73b72f2d-649e-4062-bbec-9ef395457db5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDItMy0xLTEtMA_11b1ec2d-0ac6-493c-8c4c-52b1937453e3">1,500.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash proceeds from settlement of swap</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDMtMS0xLTEtMA_3ede83c6-daca-4d69-bd68-3a34e7086abe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDMtMy0xLTEtMA_4ebe4964-ec39-47d4-85dd-6ec4357a7aac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDQtMS0xLTEtMA_5277aa5c-bcaa-4f7a-b00e-b9f6e6f628d1">94.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDQtMy0xLTEtMA_54d3d81c-7783-4e35-bbba-59ba6f9151b1">70.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDUtMS0xLTEtMA_faeccc2a-e139-47ca-a00d-8645facecb3d">22.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDUtMy0xLTEtMA_da7189e5-a240-49c3-adf6-001f0e3b93d5">22.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow used in financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDYtMS0xLTEtMA_c8a1cfc6-0a7a-47ea-a76e-85c447197fec">2,096.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDYtMy0xLTEtMA_20195a5e-3992-4934-bf65-8e059e41cbf2">4,871.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDctMS0xLTEtMA_ac596de0-fd67-45c7-8463-63cb09e52607">254.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDctMy0xLTEtMA_cdb11698-3031-41e5-a656-d9abf9412691">716.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDgtMS0xLTEtMA_cfd892ba-deea-4a67-8b30-8a6f134f5bf9">44.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDgtMy0xLTEtMA_e63e36ce-b280-4ad1-bb51-b17add254957">28.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDktMS0xLTEtMA_96f59eda-c013-4b0c-beeb-082821707f82">1,331.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cd243ed9e40c2932d604d62dcff73_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDktMy0xLTEtMA_ff2aad8e-d892-4dfe-bf9f-3af39b16deb4">2,913.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNTAtMS0xLTEtMA_621c1129-18c3-48d3-8294-4c0328c7875e">1,541.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd54a75bdf44146a9c81439174f3e10_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNTAtMy0xLTEtMA_98757e6e-d30c-49a4-972f-278ab25aa319">2,224.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fd41961e6e04619a145d1ae0002b71b_I20210630" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xLTEtMS0w_edf97938-b073-4af7-9ef4-355da1e2f91b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd41961e6e04619a145d1ae0002b71b_I20210630" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0zLTEtMS0w_fe6b3f63-85bf-4677-905b-4f73a5ad844c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2504032f7755457db1beea26920a583a_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi01LTEtMS0w_7af7845c-40aa-41e1-93ed-df6296175c17">172.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2504032f7755457db1beea26920a583a_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi03LTEtMS0w_92444c74-4cce-4295-befd-e7a514231fdf">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5058265a969a4b00953e4a5f69286304_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xMS0xLTEtMA_4aa2850a-f30c-464d-ae5d-3d8fe6220909">171.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f00f49e5bf479dae0717aa402863ba_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xMy0xLTEtMA_fabc3a3b-8f02-428e-bcdf-d9d4d4922a5d">13,900.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6ea0b81b62734c95b602b7181db99080_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xNS0xLTEtMA_d3ce5042-012d-4664-a505-4ffde8bb1f26">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ea0b81b62734c95b602b7181db99080_I20210630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xNy0xLTEtMA_efeb7b79-b417-4aa4-b568-1d8c6e6e8977">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c76067d2c0e4450b18d7428a607dec6_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xOS0xLTEtMA_143a50fd-269f-4cc4-899e-7450839d073d">10,751.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c29f466fd44e7fbf5526fc6d6a77b3_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0yMS0xLTEtMA_a30bb6f7-40f9-4db9-82d6-7a12f1933aea">462.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0yMy0xLTEtMA_2c2fa57e-e6e7-41e4-8289-5dc6c2bba15a">11,214.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3134099b795d4facb8cd5e5dc6129d07_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMy0xMy0xLTEtMA_e1a49832-8e71-4179-ae6a-b515a741bd29">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMy0xOS0xLTEtMA_79411797-a88e-4935-89c8-f04782e425ff">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc5c637588f4bc8b93afe094f041d88_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMy0yMS0xLTEtMA_15bbb298-42ff-4870-b554-f14f7c78421f">11.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMy0yMy0xLTEtMA_1601f5ca-6b90-42a0-9cee-03b205817998">318.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9151bbf7e80c4955aa4b4abcce3d7ee5_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNC0xMS0xLTEtMA_328c30dd-e979-4c23-97c3-c1cb973dd70f">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNC0xOS0xLTEtMA_2d1189ef-cb47-4033-9650-1337760194c7">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNC0yMy0xLTEtMA_ba0cc9a8-9510-409d-9fde-426173ae7e39">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNS0yMy0xLTEtMA_cb63539b-cd82-4511-b29f-ccf205e0b8b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNi0yMy0xLTEtMA_184c5980-61af-4de6-8fef-425ce982406a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNy0xNS0xLTEtMA_cb8abf08-8130-4b72-b14f-b7ed5116978a">2.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNy0xNy0xLTEtMA_93b39c25-6cd1-4be8-b6c4-f940c7c67fdd">750.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fcbd0aab3104a71a4ebbceb7c93d675_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNy0xOS0xLTEtMA_e9178f1e-4f27-41f1-91f5-5beb79834df4">750.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85bc0b5a4e146cf9ca22eeb646ac2f5_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNy0yMy0xLTEtMA_4260e149-4a3e-43f9-990e-6bcab114fdb1">750.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c1f2813a84947359d5e759ac017f8f6_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC01LTEtMS0w_21d85b68-5816-4be6-805e-d82f6fd2d2ea">2.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic71a7f514fe345aa81befd7e9f359804_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC05LTEtMS0w_b9969a21-d927-43c9-9e5d-b000b2c7796e">68.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbdfb0e2e84e4397a54b042efb9de0f0_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC0xMy0xLTEtMA_2972b65c-f1cb-4c88-b104-d17a17a3db7c">681.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC0xNS0xLTEtMA_a0f91928-bac0-4723-8df0-8721db99b026">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC0xNy0xLTEtMA_16dee54c-530b-40f0-89ee-11391fc21add">750.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85bc0b5a4e146cf9ca22eeb646ac2f5_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC0yMy0xLTEtMA_ab707569-d442-40ba-addd-51b60f617ea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fc83a08693474992b85d83b3ad03b7_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOS05LTEtMS0w_df2489aa-8e05-466f-a5aa-8c0236adba49">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOS0xOS0xLTEtMA_47f26cc6-31b7-4581-884c-930bd4fc4940">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOS0yMy0xLTEtMA_acdd1cc8-2142-458d-8e13-a5e32aaea445">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3134099b795d4facb8cd5e5dc6129d07_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTAtMTMtMS0xLTA_ee636c30-3ab4-4a42-b461-f1286af55f79">5.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTAtMTktMS0xLTA_afcbb78d-687c-4dae-8110-180ec83b4ddb">5.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTAtMjMtMS0xLTA_42cf3561-b62b-4820-a77d-fa3b5f787b52">5.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fc83a08693474992b85d83b3ad03b7_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTEtOS0xLTEtMA_d58f5b02-9071-4ee9-99aa-bc898babe4e6">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTEtMTktMS0xLTA_b02f0d40-4029-4ffe-9a31-97d92cfd19c2">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTEtMjMtMS0xLTA_dec8ca6e-570d-45b8-bd65-bc7aaf420949">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTItMjMtMS0xLTA_3d35a0f4-a2b4-4f26-bb00-e8858ceeb3d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27c617883bc449228e61f30f99e937e2_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMS0xLTEtMA_e8756765-e21f-45c6-96de-2fb95276e337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c617883bc449228e61f30f99e937e2_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMy0xLTEtMA_0a4c0160-9540-4dbc-933c-39487641ef72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtNS0xLTEtMA_042b2f5c-4def-40aa-a800-88f4c4779278">170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtNy0xLTEtMA_87d1f159-9f99-4c89-9c7a-3eaec667f043">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f998449b3e429fb58bc7328de88319_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtOS0xLTEtMA_cd98dec6-3c44-4968-a8ba-fdc6b96fa98d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9035a5654857474b8da6be9ce64ca30c_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTEtMS0xLTA_3dd06dd4-69fc-43ef-bd5d-8418981abe83">136.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6724df5e760b4f7ea87e959a62b322b1_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTMtMS0xLTA_870e2d14-b1c4-42a5-b2e1-44fdd55a79e0">13,543.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b4efc5c06194773aea1dd08796cbd25_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTUtMS0xLTA_ea2ab345-596e-4990-8a3e-1a83e4727839">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b4efc5c06194773aea1dd08796cbd25_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTctMS0xLTA_fb92d228-bd86-49af-801f-c696166eabbc">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bb8cece69f42eb993bbe2ed7b30d9a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTktMS0xLTA_7b48e2ae-f306-4cb5-a81c-246766c437e8">10,429.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb94a68217db4665853c23a8d028b610_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMjEtMS0xLTA_251fa91b-b2bf-4de4-b878-2b67b2cba0a5">451.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMjMtMS0xLTA_78a141fa-9e70-4c76-b69c-ab9789dea2ee">10,881.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="padding-left:54pt;padding-right:54pt;text-align:center;text-indent:36pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3f7e3e5cead4308bd4010bcf303d6fb_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xLTEtMS0w_4d298f76-ec4c-4348-8e5c-1af2fe5d618f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f7e3e5cead4308bd4010bcf303d6fb_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0zLTEtMS0w_b2fa8efb-22fe-407e-9938-5ca31d7cea0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia82889fd7f49428faa0d8b8a9fe4787c_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi01LTEtMS0w_7bcadae4-aadd-4b37-b64e-8424427d2a71">176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82889fd7f49428faa0d8b8a9fe4787c_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi03LTEtMS0w_e370ac44-c438-4a8c-92fe-0a3e199d087b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435fb50e71d246339ab717cb193e55b8_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi05LTEtMS0w_cbbd27d6-4014-4608-a499-1002c2661563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id008781cb78d456099bf8e65186045c8_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xMS0xLTEtMA_aaa8473f-1c66-4abc-af72-75b3c02beb4b">299.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfaf0c65c04d483ba21b7c25f4adaecf_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xMy0xLTEtMA_79ee1b52-2614-4877-b34d-6a5b3b4cc3dd">13,976.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8fcb29f76ded42b1bdb5c06b5a612d27_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xNS0xLTEtMA_eafe8ac4-32e8-4a8b-a43f-21ef48790852">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fcb29f76ded42b1bdb5c06b5a612d27_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xNy0xLTEtMA_07dfe9a4-8345-403b-af46-6b0172c9380d">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f28a59afdff41658f03256c0a201a98_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xOS0xLTEtMA_028f39cc-2027-4dc5-a7cd-f78b02625712">10,700.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4891b33ee68b4d7abe803e2851cb7dbb_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0yMS0xLTEtMA_a6bd10ed-fe3a-4610-b5ec-9fb6168a537e">14.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0yMy0xLTEtMA_545f9c51-a50d-4002-9d40-04c2d3b0f466">10,686.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be762ec3a9f4b09864941280d00a916_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMy0xMy0xLTEtMA_9b85f0bd-8897-4e68-a629-160ae2a2c37e">1,187.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMy0xOS0xLTEtMA_c15b0f08-f430-41ed-9f5e-39df55aa5605">1,187.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMy0yMS0xLTEtMA_57ba2414-fdfb-4571-993e-3d0f3b5d587a">560.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMy0yMy0xLTEtMA_de15057e-bd65-4e55-a565-db3df7e7030b">1,748.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd71258dd6f04433b5f81b927d3b1104_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNC0xMS0xLTEtMA_00351b74-94cc-4a90-9cb2-9b16a494f86d">162.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNC0xOS0xLTEtMA_02452f4e-5bd6-4596-8162-170c9f7234db">162.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNC0yMS0xLTEtMA_6493cc6b-bb80-4edd-b295-48d6884c7a12">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNC0yMy0xLTEtMA_ba3a7060-f0eb-48b4-8819-81d1a6340499">163.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNS0yMS0xLTEtMA_9a0f4bca-107e-459d-b2d0-086bbf4bc360">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNS0yMy0xLTEtMA_db468786-297f-4fe6-a7f8-13cb322f5d4f">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNi0yMS0xLTEtMA_c0ba6dfb-8a19-4401-ba72-274a88a1d58f">100.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNi0yMy0xLTEtMA_8f2b9c67-e0c2-4003-aa0b-efdc00b477ac">100.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNy0xNS0xLTEtMA_248928d1-2c5a-4226-aa2c-fd5696d0dab2">6.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNy0xNy0xLTEtMA_a463e758-ea3e-47ad-be2b-2e2e192f7fb5">1,800.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc180996f76c4531ba0c767a0cd57adc_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNy0xOS0xLTEtMA_09c86f3b-e62e-493b-b143-c964df6bc9d1">1,800.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06a7ad3e5c3a4b8d9bedc1dcb4f9f208_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNy0yMy0xLTEtMA_77a43bb8-13f8-46b1-b206-31efccd3ede0">1,800.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i58fb5362e7a744d9a5acd4825e9a5104_D20210101-20210930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC01LTEtMS0w_979a065a-8aa0-4b89-8767-d2f6ff1370b7">6.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67d9c800cfcc42f5a8dd99abd463e2be_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC05LTEtMS0w_778a3272-2301-48c2-8e38-7bdb2dbb4835">231.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782d9d918ca94e65a4169da4cd3a12f6_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC0xMy0xLTEtMA_3c3bacde-140a-4695-a96b-090592bf9cdc">1,568.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC0xNS0xLTEtMA_c44f494a-36cd-427c-b29d-82275b0ee8e7">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC0xNy0xLTEtMA_57f5ebfb-baa3-48e2-b7ce-576fdac9bb56">1,800.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a7ad3e5c3a4b8d9bedc1dcb4f9f208_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC0yMy0xLTEtMA_cc40b2d8-25c9-4227-883c-5cc17b72be51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b408fb3fdc34b0396023e455c198a69_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOS01LTEtMS0w_110d4d50-815c-486e-9e99-4ddeacde011b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c7f17033684d18aefb36c4a3d6c13f_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOS05LTEtMS0w_95819e6b-628b-4eb1-96ba-437f2c44d2ac">44.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOS0xOS0xLTEtMA_9a780386-611a-4cc6-8d98-05bced8b9c08">44.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOS0yMy0xLTEtMA_5b7d0466-bdc7-481b-9909-6e309706079f">44.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b408fb3fdc34b0396023e455c198a69_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTAtNS0xLTEtMA_3cd8862d-c8da-48c1-9c7a-72f1b71f29a5">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9be762ec3a9f4b09864941280d00a916_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTAtMTMtMS0xLTA_76e335f7-9a5f-498a-94d6-b98d48951927">52.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTAtMTktMS0xLTA_8ea19015-9bbf-4a37-a724-86caa50c8477">52.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTAtMjMtMS0xLTA_d0b93225-4c9a-4fb3-86f2-d37c2d0513c2">52.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c7f17033684d18aefb36c4a3d6c13f_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTEtOS0xLTEtMA_4377e6ea-2528-4323-a4f3-8735e80ff84c">186.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTEtMTktMS0xLTA_c3b99734-dc87-476f-97bc-6005b3295172">186.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTEtMjMtMS0xLTA_faef131f-b8a9-4f1e-8da7-c8aa6f6d8120">186.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c7f17033684d18aefb36c4a3d6c13f_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTItOS0xLTEtMA_4ee7d1c8-6f51-4f6d-8266-a1d47f54b824">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTItMTktMS0xLTA_601086f9-cd62-4868-ac5a-afc5d9e3aca9">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTItMjMtMS0xLTA_a5a63282-ebf6-48ac-b72a-7a56dcfc94dd">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27c617883bc449228e61f30f99e937e2_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMS0xLTEtMA_5c3c26e8-916a-4452-a1cf-2f7053cd3b16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c617883bc449228e61f30f99e937e2_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMy0xLTEtMA_31b95ebe-5fed-4488-a8e9-ab44fbe4aa07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtNS0xLTEtMA_dad579f4-4e92-41d3-90ff-4715519f8484">170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtNy0xLTEtMA_a4da241f-89c2-4f59-851f-2af58fa6ddc7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f998449b3e429fb58bc7328de88319_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtOS0xLTEtMA_07ec5b12-4e6e-4d3b-bd6b-c9eb739a9c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9035a5654857474b8da6be9ce64ca30c_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTEtMS0xLTA_64b76966-4ff8-4c71-8cbd-822298a289fe">136.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6724df5e760b4f7ea87e959a62b322b1_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTMtMS0xLTA_d0997420-d52f-46f2-8972-b0a104c982be">13,543.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b4efc5c06194773aea1dd08796cbd25_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTUtMS0xLTA_fc776d01-907e-4b39-944d-c04d6eb78fca">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b4efc5c06194773aea1dd08796cbd25_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTctMS0xLTA_9397affb-3be1-4f48-85c8-c2b5e1374d8e">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bb8cece69f42eb993bbe2ed7b30d9a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTktMS0xLTA_274e08a6-6399-4d24-a335-16bb5854c5d2">10,429.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb94a68217db4665853c23a8d028b610_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMjEtMS0xLTA_002d7a4f-f2bf-43de-a33f-d1fa78f852db">451.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMjMtMS0xLTA_bc558146-02af-4e54-951f-9814ec372e92">10,881.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55e81dc8b9c744b3b947fb4da4f5918f_I20200630" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xLTEtMS0w_5233e584-c21b-429f-bff4-79ac3a2e5076">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e81dc8b9c744b3b947fb4da4f5918f_I20200630" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0zLTEtMS0w_d2ce54ba-c94a-46b5-b802-a299ea48b081">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b36a2284f3b473798aab3ac6e245627_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi01LTEtMS0w_0d851f15-3000-4b33-896c-b87119d8e1cb">182.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36a2284f3b473798aab3ac6e245627_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi03LTEtMS0w_9adcb463-4e36-4706-a5e4-9a3daff4f2b5">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe878f771a841b3a6c7f704897f75ee_I20200630" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi05LTEtMS0w_55b3767b-a5c7-4c83-b909-b99c480b9d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98aa79e9ae8d45b880df1e5404273f17_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xMS0xLTEtMA_381ca757-ed32-4e76-8da8-bfc842ddb967">181.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ddcef7d3e24fdcb32788e2157a6ff6_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xMy0xLTEtMA_80f1f215-87e8-4166-9925-ee120fe75f8b">14,466.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2cb06b37c185452292925fd0417673c9_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xNS0xLTEtMA_71e70ed2-d4fe-4370-9785-57ddb42e7cce">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cb06b37c185452292925fd0417673c9_I20200630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xNy0xLTEtMA_9f255346-18ed-4801-9799-8df23f0a83aa">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7ff60d15254b42afe32f65710162c7_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xOS0xLTEtMA_cde3c304-b062-4f04-b871-fa7ac1df210b">11,308.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7028acddd6fe42b6965135b35f8ff2f6_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0yMS0xLTEtMA_3c3b0427-7e8b-41f9-821a-8171a964d939">19.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13ff900cbf7e400ab0e7e04c7df214d5_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0yMy0xLTEtMA_01660047-a34f-4688-8ee2-fbd08b7f701a">11,289.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6b13e615cb43759f9fdc6492935587_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMy0xMy0xLTEtMA_845d251f-844b-4f34-abc8-1bbf748607f2">701.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMy0xOS0xLTEtMA_1cdb2331-051c-4a7b-ae69-80999fdb96a4">701.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa45623b9a24e4881896a979258ce6e_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMy0yMS0xLTEtMA_13cc4cd6-bf00-4871-a2d4-67da849f058e">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMy0yMy0xLTEtMA_63c8ea08-7432-4ef3-8752-26ab5530e750">703.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c04a426b78946e7b3b65f4903d01c57_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNC0xMS0xLTEtMA_3e9049b7-5195-4c87-9e52-fafacc36461f">44.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNC0xOS0xLTEtMA_a3309516-2a3f-4f1f-948f-e9932c8a7c6e">44.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa45623b9a24e4881896a979258ce6e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNC0yMS0xLTEtMA_08053ae7-6e40-4dbe-9ec8-3a96ccf0aa81">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNC0yMy0xLTEtMA_cfa41392-c81c-4321-a89a-076c2a958598">45.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa45623b9a24e4881896a979258ce6e_D20200701-20200930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNS0yMS0xLTEtMA_f90c0358-e2d4-4a39-b1bb-ec82316d6954">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNS0yMy0xLTEtMA_ef6bc9f8-e2cc-472f-bcce-6f9acee62607">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNi0yMy0xLTEtMA_5b3d6eb7-a226-4876-9949-c05a30022e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfOS0xNS0xLTEtMA_ed403456-b0ac-4793-9975-1d43dbaddb1b">4.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfOS0xNy0xLTEtMA_4e9845c6-9c9d-4170-b9a4-c73e0e99fee1">1,250.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f841eba5163473e9f41740f7bde1720_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfOS0xOS0xLTEtMA_db79dafd-5607-4595-a51c-7c76fbe5674f">1,250.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if307471114bc439a91ad32639f89c9f8_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfOS0yMy0xLTEtMA_eddae68b-c39d-41ce-984e-c1fa110708db">1,250.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i751ac7dc5ebd4605b6778c1a2449f919_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtNS0xLTEtMA_00a96d54-8bc0-4a17-ac0c-4350268f59bd">4.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie428e1222ddf45bf8896a772e454dfa3_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtOS0xLTEtMA_3c636f32-8f3e-40d3-ad36-a7b7de4c86ef">45.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6422fd73db7423eb9f8020ab03bd577_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtMTMtMS0xLTA_008b3187-0273-44c4-8477-40c091ba8005">1,204.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtMTUtMS0xLTA_c6e13fcd-c698-42cd-8bf9-d5eee0c0c48c">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtMTctMS0xLTA_bb0d301b-1e9e-45c3-b1d4-82cb63474367">1,250.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if307471114bc439a91ad32639f89c9f8_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtMjMtMS0xLTA_bb62fe7f-2cdd-426c-9f0b-ccb85424170d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib45574fe33ee4aae9246e107a7a53587_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTEtNS0xLTEtMA_5c48e9b8-3b38-48a4-aac3-23739cc70f96">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4928957245d3432999a97b44b5267981_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTEtOS0xLTEtMA_9d51a53e-4fed-43e0-b43e-49a4213c6b2c">9.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTEtMTktMS0xLTA_58d216ce-e120-4923-8c4d-b61c68a0f54d">9.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTEtMjMtMS0xLTA_37942a88-ec6e-471a-8584-587af99ab507">9.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae6b13e615cb43759f9fdc6492935587_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTItMTMtMS0xLTA_b49f077d-e610-4f51-80a1-62d80ba82f1a">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTItMTktMS0xLTA_fc021d37-9932-4bca-a6a5-05dbc3e68d6b">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTItMjMtMS0xLTA_0705b297-63be-4354-af24-cc3e7eb964b0">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4928957245d3432999a97b44b5267981_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTMtOS0xLTEtMA_cb0de498-4279-4fe4-aed2-954d3c14b033">35.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTMtMTktMS0xLTA_be4e6cec-2191-4fde-8eb5-11d10cab7a73">35.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTMtMjMtMS0xLTA_8e328090-410c-4f77-a92f-1b595e01dddd">35.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72c55152400e4e4b94a99a817965d09a_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMS0xLTEtMA_754ee483-dddf-403e-add9-6a47a4d7c6d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c55152400e4e4b94a99a817965d09a_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMy0xLTEtMA_2432cd84-f43b-4af1-a6e2-630f58cbefd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9feca16144f34b3ea3e89a6754731228_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtNS0xLTEtMA_8c228683-15ce-4d24-aaa6-ffd6e37d3e83">177.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9feca16144f34b3ea3e89a6754731228_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtNy0xLTEtMA_7e0a220f-b26d-4cd8-b9c3-f698dbeb6059">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a8b077b45d46d1a2ba18c46f68e9b5_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtOS0xLTEtMA_f69d7e8b-adcb-4952-829f-40753c8fee24">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f1490d7028c484bb7b887d3edf0bcef_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTEtMS0xLTA_5616365d-88da-4dcb-9533-860265595618">225.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5244c955b7f04faa811cb546d3b19da1_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTMtMS0xLTA_46a65e14-0bd6-4fce-b86d-a44c737f7096">13,961.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i256c872a0ec64e8588e40eae87e54228_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTUtMS0xLTA_9a37e21b-d4b5-4842-94b8-19bbc021a720">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i256c872a0ec64e8588e40eae87e54228_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTctMS0xLTA_ea1e9630-15b7-4a6b-af48-4787399c7d7e">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27afa92fb58444e9a9f1ab64284947bf_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTktMS0xLTA_b07ffe3d-aafb-4e61-9a8f-34daeeb92795">10,758.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e79a463f4584fb2aee6e8cdc33e7007_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMjEtMS0xLTA_75e62d14-a406-4ace-a96c-2530f72ec352">14.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd54a75bdf44146a9c81439174f3e10_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMjMtMS0xLTA_d0677851-9a23-4041-864e-aa2daaf63027">10,744.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e7708356fae41b9a13302bb04211203_I20191231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xLTEtMS0w_5ba895b3-c00d-4e0c-b2aa-d021e970c2e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7708356fae41b9a13302bb04211203_I20191231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0zLTEtMS0w_afe3f651-9b01-434f-8faf-7341b78ac5f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70705f35adb5455faecf1b3d1d84198a_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi01LTEtMS0w_799cd6bd-bdfb-428a-b64c-b1dff03be5f3">198.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70705f35adb5455faecf1b3d1d84198a_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi03LTEtMS0w_4c17658d-c148-4cc8-89c6-320a921c60bd">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7b1968e93347ae998112702bfaf368_I20191231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi05LTEtMS0w_2774ca1c-e883-4a53-99ff-37c183d2b618">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc9ba742bf504e22bd14593ecb2ffb74_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xMS0xLTEtMA_93244b4d-f795-47bb-9682-716262277451">135.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7e856aca6b47abb4f2a597838710d7_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xMy0xLTEtMA_009df290-1993-4fb2-8adf-7d76fbacc761">16,455.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide5fdd4520c74830933b03379f613edf_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xNS0xLTEtMA_6d3c2bdb-0e37-41ea-bfd2-aaf773495074">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide5fdd4520c74830933b03379f613edf_I20191231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xNy0xLTEtMA_c98b6e3f-5cca-45c3-88bc-b657500b024b">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607b477716754fa49b426a79cce7cfc3_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xOS0xLTEtMA_0069990e-a2e3-4f0e-b076-721a20e7802d">13,343.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e94a3f2f5aa4b088b330695096badd8_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0yMS0xLTEtMA_d855c5b5-31ee-4fab-a445-860efa2c1c6d">4.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cd243ed9e40c2932d604d62dcff73_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0yMy0xLTEtMA_eb1baeb9-de6c-4f53-89f2-49ca4dfe9bd2">13,339.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i327682b6937246d39b49fa2fe086a9ee_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMy0xMy0xLTEtMA_a40f9b78-6e59-4f5c-871a-e16d259b8612">3,642.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMy0xOS0xLTEtMA_9471f786-5f34-4e69-a095-a1b441e2c867">3,642.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70699e64e56642c78269f5581e49fa63_D20200101-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMy0yMS0xLTEtMA_d106b1b1-1c32-4cd2-a7c2-a0b66f6038c2">60.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMy0yMy0xLTEtMA_4e3bcfe9-6ee8-434e-b2d9-3787cb39f914">3,702.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cb259e3e655451594ddea75cacc3031_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNC0xMS0xLTEtMA_e5c51060-2873-4e4f-ab67-1e3d38cc6444">90.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNC0xOS0xLTEtMA_91f81b3b-2020-41b8-8b5e-1743080acf95">90.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70699e64e56642c78269f5581e49fa63_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNC0yMS0xLTEtMA_bf0c7611-b5ec-48fe-aeea-f8143a30f2fd">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNC0yMy0xLTEtMA_0f16b2ed-bb38-4bb7-ac6d-62d3f3d1f58e">89.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70699e64e56642c78269f5581e49fa63_D20200101-20200930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNS0yMS0xLTEtMA_3ba9d416-3940-4777-9b20-55f49a482518">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNS0yMy0xLTEtMA_46ec125b-4e9d-4325-859d-1d6fa5cd7608">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70699e64e56642c78269f5581e49fa63_D20200101-20200930" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNi0yMS0xLTEtMA_181d5a07-d588-4e00-af86-22f4fe0518eb">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNi0yMy0xLTEtMA_82be17c0-4fd7-40c0-a855-ecba4616c1a4">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibded2627ed6f476488944808f5be525e_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNy0xNS0xLTEtMA_48715fda-ea3f-4690-b9e0-b656a8c8dddd">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibded2627ed6f476488944808f5be525e_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNy0xNy0xLTEtMA_c35c7844-c13b-4734-b126-7654cb86f781">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94ed39bd20ce49eb845fbd4b5a6e399f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNy0xOS0xLTEtMA_d81eaff3-4973-4c47-8a2d-e72b10f3e9f5">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddfc2c0b58ff4cc1b94d1cdf49392372_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNy0yMy0xLTEtMA_9a5672d6-6dfc-48aa-b3d4-95d767ad71a3">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id860c4b0dd10477c99ccee1b9a0e61f6_D20200101-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC01LTEtMS0w_09c86d67-e3f5-4889-be01-5f25e3f3c8b7">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3b6f7ebf2148fb8095a10e72b1c4b3_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC05LTEtMS0w_4d4de963-ba08-4bfb-ae14-27da27f3935d">71.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a4c5ca8b3b448168efbbcea6f070598_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC0xMy0xLTEtMA_0acefa98-e189-4112-8578-f1db2bd193b9">1,208.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibded2627ed6f476488944808f5be525e_D20200101-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC0xNS0xLTEtMA_293a82e0-53aa-47f5-a9ce-29a983471128">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibded2627ed6f476488944808f5be525e_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC0xNy0xLTEtMA_7dd4081a-e8b6-44e6-b6e2-15d940ee96f2">1,279.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOS0xNS0xLTEtMA_35347c13-6085-48a2-b4e9-fda66c4ff6cd">16.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOS0xNy0xLTEtMA_ae1ea1aa-a9b4-4639-8aab-ff2c7c702647">5,000.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a9211cf5d342868594c98f4cc8953d_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOS0xOS0xLTEtMA_790ff456-6d1c-4a1d-92b2-a61046e041a7">5,000.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i820c4f6fd7d141ae849266e77bd5174d_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOS0yMy0xLTEtMA_1c99c8ae-8911-446d-bfe8-51aa5be1744a">5,000.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i708a8258e90c451fae809ded20edc887_D20200101-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtNS0xLTEtMA_39423c5e-3909-4428-8cec-3564e6ab7601">16.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc98aa5d5bb3491b844c904832b5e17a_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtOS0xLTEtMA_b412fa07-a203-44f0-a670-bf4231db3245">121.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1022bbcfbc3d402986b98be3c4a7bdd9_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtMTMtMS0xLTA_af257baf-418f-471c-a3c8-92df88daa20b">4,878.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtMTUtMS0xLTA_44da9d90-c38d-4e54-8e14-0824d2f6f052">16.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtMTctMS0xLTA_b009adc1-8692-42af-ab98-1ae11c39c06b">5,000.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820c4f6fd7d141ae849266e77bd5174d_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtMjMtMS0xLTA_c17e3ab1-71e2-4d20-9ef4-9055ed15ed9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73e21f10ab3f4997b59d6e47015ee1e6_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTEtNS0xLTEtMA_5ec4ef49-42a2-49ca-b7fb-8f911af50be2">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTEtOS0xLTEtMA_cc6c94d4-715d-48b6-bcd9-ea87b1a37aba">38.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTEtMTktMS0xLTA_c308072b-8858-470e-a2fc-0d73399cf3d0">38.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTEtMjMtMS0xLTA_d9428239-c1c7-4016-a069-8c992a57a79e">38.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73e21f10ab3f4997b59d6e47015ee1e6_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItNS0xLTEtMA_bfbfbefc-a613-4d23-9a38-5c43ff5ab86c">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItOS0xLTEtMA_f88938b8-83c5-44ed-b802-6a624f97c4ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i327682b6937246d39b49fa2fe086a9ee_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItMTMtMS0xLTA_90b19b03-e079-4444-b0bc-343d16f2c3b2">50.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItMTktMS0xLTA_f1dec7a1-fc73-4b2a-adc0-2a0bc07bc2c8">50.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItMjMtMS0xLTA_baa4b516-400c-44ba-9858-3559f1362ce7">50.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTMtOS0xLTEtMA_9fcb6278-ebd9-4b6c-897b-6ce33b418ec4">154.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTMtMTktMS0xLTA_312a8ae5-ad38-4771-9c9f-d5799c384e8d">154.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTMtMjMtMS0xLTA_013f3888-2f6a-48da-b6b5-053c5acec12c">154.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTQtOS0xLTEtMA_40c83aa9-759c-45bb-bd10-7f8251d75afc">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTQtMTktMS0xLTA_c6b24aae-975a-4f3a-89c7-18f0ed7638b4">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTQtMjMtMS0xLTA_7beaa488-ddf7-43f5-892b-50bc715e0239">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72c55152400e4e4b94a99a817965d09a_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMS0xLTEtMA_47c198f2-d999-4eda-a599-b93072a7e790">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c55152400e4e4b94a99a817965d09a_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMy0xLTEtMA_7ce4b7a9-b811-4a6e-87ae-34ddad922dc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9feca16144f34b3ea3e89a6754731228_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtNS0xLTEtMA_1cecab68-c930-4202-ac27-138fb197116b">177.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9feca16144f34b3ea3e89a6754731228_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtNy0xLTEtMA_47de0963-a2c5-4d9f-bf3d-28d60c424b94">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a8b077b45d46d1a2ba18c46f68e9b5_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtOS0xLTEtMA_e2100cdc-05c7-453e-86c0-d8e55582dd0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f1490d7028c484bb7b887d3edf0bcef_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTEtMS0xLTA_a69d07f7-8288-46c7-b4e4-a398f5d4ea42">225.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5244c955b7f04faa811cb546d3b19da1_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTMtMS0xLTA_6e464619-80b5-420d-b1fc-f547446001f8">13,961.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i256c872a0ec64e8588e40eae87e54228_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTUtMS0xLTA_cacce0b9-02dd-4405-896d-cc1d6501fc22">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i256c872a0ec64e8588e40eae87e54228_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTctMS0xLTA_66d48492-b1f6-4aa8-8beb-b5ac813d0c0e">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27afa92fb58444e9a9f1ab64284947bf_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTktMS0xLTA_068d4f72-6e1f-4aa7-84e0-7df4cafa4c3c">10,758.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e79a463f4584fb2aee6e8cdc33e7007_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMjEtMS0xLTA_6f19fdd2-b15e-4e2a-863b-ebda752bb24b">14.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd54a75bdf44146a9c81439174f3e10_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMjMtMS0xLTA_ca9fac26-2b2d-41bd-bdcd-7fb2aff7e350">10,744.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i8046a3e69c814e7f9967395f631661c6_40"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA1OQ_4440c393-d759-4ecf-9243-7e0281eb03d3" continuedAt="ia8d0389f5c3942c3aeb9afe18ed51f88" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:BusinessOverviewPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA4NA_25cda64f-aea3-45fb-a6f0-c5446b309a72" continuedAt="idc9c1a25573244358c1b49777be9e5b4" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="idc9c1a25573244358c1b49777be9e5b4" continuedAt="i71299b10f88e4ecf977c70edbda30ca8"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i71299b10f88e4ecf977c70edbda30ca8"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA5Mg_7eb8f49f-d8cb-4c91-a85d-8d8fa932b594" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfNDA0Ng_cb05ad96-72d7-41ed-bb49-d7b18e8bfd1e">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia8d0389f5c3942c3aeb9afe18ed51f88"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA5Ng_a89ecc4a-11b6-4b3e-9d98-38a53a7bd8e6" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfNDU1Ng_7666bc4a-892f-423c-aa54-0a9c8139f2a4">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA1Mg_d410ef8c-14b1-41c1-9351-097c95b9022d" continuedAt="i0ec8bb02142e4e7fb18ff90febbb34a0" escape="true">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0ec8bb02142e4e7fb18ff90febbb34a0">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA3MA_ce000d24-799b-4c8b-a63d-3bc8c89fc0b9" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_43"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Acquisitions </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80My9mcmFnOmY5NTgxMTk0YmQ0YzQxNTdiY2RlNGFjMWNjNzk5ZTI1L3RleHRyZWdpb246Zjk1ODExOTRiZDRjNDE1N2JjZGU0YWMxY2M3OTllMjVfOTM4_d8609602-7c1e-414d-8bd4-411b9a71ece5" continuedAt="i0bf63cb115ab4f50b2c3c5e181f1d6cc" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i459ef874f9bb4653ad831f334286be02_D20200301-20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80My9mcmFnOmY5NTgxMTk0YmQ0YzQxNTdiY2RlNGFjMWNjNzk5ZTI1L3RleHRyZWdpb246Zjk1ODExOTRiZDRjNDE1N2JjZGU0YWMxY2M3OTllMjVfNTIz_08f7be57-a16d-46a9-a2fa-d2df6add0629">75.0</ix:nonFraction> million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0bf63cb115ab4f50b2c3c5e181f1d6cc">condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $<ix:nonFraction unitRef="usd" contextRef="i459ef874f9bb4653ad831f334286be02_D20200301-20200331" decimals="-5" format="ixt:num-dot-decimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80My9mcmFnOmY5NTgxMTk0YmQ0YzQxNTdiY2RlNGFjMWNjNzk5ZTI1L3RleHRyZWdpb246Zjk1ODExOTRiZDRjNDE1N2JjZGU0YWMxY2M3OTllMjVfNzky_9a1ed2e7-a3f7-4042-9913-614b5896f46a">635.0</ix:nonFraction> million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</ix:continuation></span></div><div id="i8046a3e69c814e7f9967395f631661c6_52"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Revenue </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA0Ng_5cca0ed5-82d1-4394-a8a0-f1fe7e6d0921" continuedAt="ia9563c229eca4c2a9d7f47a149ed5685" escape="true"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA0MA_701ba6f7-130f-4f47-b0aa-6b551b2658cb" continuedAt="ida867edb93f3480db0e73fea67f50d49" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic401292eb9c341d5a7a48926df3393fc_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC0yLTEtMS0w_6488530d-fa8b-4f73-bc40-13431f846482">299.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76acd6989c7c4783b9802597d4de0c06_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC00LTEtMS0w_2a298d0a-04c3-438d-b39a-3eeacfe0e516">319.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23640bd50272420a8b057701d4f91e71_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC02LTEtMS0w_057b11e0-84ec-49c2-aedb-041812fe644a">619.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd886b210f074d43acf27a1993bc9ccf_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC04LTEtMS0w_26709de6-c930-4f65-ba73-e4fea650f1f3">684.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48a1d2ec8b247058bcdad6c8fbc6524_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC0xMC0xLTEtMA_12672c6e-a5fd-4a9a-8b48-fb60c251e87c">283.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21b2da1eba940d2b84efc2f236e2b03_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC0xMi0xLTEtMA_491e47a8-ba90-4c3a-9f99-8afbcd1bed19">967.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10bf3e3f7595414482ea7c8e4d6e9daa_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS0yLTEtMS0w_9a38ab73-b9d3-4542-a6de-c6bae50d2839">252.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f65789ed29a4729929922d2a49c2ec3_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS00LTEtMS0w_5237b65b-651f-4320-b425-aa03a9d71993">135.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36476b37490e44bb9a8cd6098004a18e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS02LTEtMS0w_35d67fc7-d0cb-4fd9-b266-634c2f0b1f93">387.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a94855763b44929978fdfdb0d8035d7_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS04LTEtMS0w_fd5e74f6-633f-42d0-9bd6-80fdce021be4">327.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a216b36a235433c9df3617fbc22b9a7_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS0xMC0xLTEtMA_18bfb484-4817-49ae-a77a-6049bdba3648">146.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfa480df7914627bc60143003413b0a_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS0xMi0xLTEtMA_8e72752b-4cc3-4978-9b03-92000366f832">474.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7517010697de4c77b9e59ece300efd26_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi0yLTEtMS0w_5e173314-8c35-4f41-86cc-facbfb5b1bc7">281.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a4376778b04d80abf3b1d76aac940f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi00LTEtMS0w_daf4c52f-8eec-4552-81fa-78f946cf2fd0">241.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0542ec377c8a46ae89671dcde4b12555_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi02LTEtMS0w_5828ab96-e9d4-47a2-8fd9-06bea3ed7331">522.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09cfdb27d6654e3eaea1f9fd048da603_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi04LTEtMS0w_77f68823-41ec-4e58-a0e3-73decc382c54">304.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87aa8be7620b41a68374745f1299b587_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi0xMC0xLTEtMA_5085d141-9fa0-4878-9dee-39cc9e4489e3">212.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d1d4d88e5204d3bbd4f8c2df05bc123_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi0xMi0xLTEtMA_c33d7aba-d175-4d7d-9e5a-c72105702904">516.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11880cd08681479db15c4cf4a0e6a1b1_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy0yLTEtMS0w_1a4840bf-8bc6-4b36-8e50-9402af80f467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc711043de854adeaaa2267f4bb46ccd_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy00LTEtMS0w_a3a9c86d-6ea6-4dee-b8bc-6206367be7bf">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a53327538a04446a4de09425ac19e0e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy02LTEtMS0w_8ca0629a-7ce7-4c91-802a-655ca90e2e02">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf06a525bc964241a3f2d2a390fe4a4f_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy04LTEtMS0w_5d0bae66-c444-49f0-a3b9-df23f98112f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f4359c2057476ba70d1737083d2a2b_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy0xMC0xLTEtMA_b64dc9e7-1e62-4094-90ce-001ae3b51bd2">26.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c6a43fee8d4ad3b6c10202da96a3a4_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy0xMi0xLTEtMA_d3f1852f-498e-4f27-999b-d809b08878dd">26.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946868256a5e4b78bc18b85fe7d36a88_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC0yLTEtMS0w_09f832c3-e62d-4307-93b9-1a59dbb0203d">833.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6050c9c73f574a1d9ac74d02d7f8833a_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC00LTEtMS0w_e0ab8e0a-48a8-484d-9167-36b546eaff6a">722.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia423a211a0e94eb2b77637ce741d2bb7_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC02LTEtMS0w_6f083532-bdcc-46fe-90f9-eb21fe83a00c">1,556.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e3d9cc76b44ab2ab715dbe9256ee43_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC04LTEtMS0w_95d3f54b-5c72-4546-a8c9-51d4b5da7ab5">1,315.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae132257ea54725a3d8996647c5f187_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC0xMC0xLTEtMA_e9c51745-eff3-4f77-838b-234fcbf46482">669.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca5e27d04c34b1b85b921b3c5f8955a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC0xMi0xLTEtMA_e0aea5cc-8b6b-4e27-93be-1e096ef86e69">1,984.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6315b659cf6e4730aa408da11bed5410_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtMi0xLTEtMA_2ea1db8f-e49a-4bd9-8a2c-b494e69b1a76">139.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i217b972b9d864b7ea3af5c2ddafb37c1_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtNC0xLTEtMA_5301ff00-4788-4b62-b08a-79792b4c9233">304.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb4fc909b874f1cad730a3ec955d0b7_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtNi0xLTEtMA_46d16ef6-cf57-4143-a6a2-ba7d3d35749e">444.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ef0e02b0074d14ac43f42983797d65_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtOC0xLTEtMA_d09b1d86-288d-4f2c-819b-df905c3b5a61">182.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68820eb5ed4b440b8283a709119c6a35_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtMTAtMS0xLTA_11840805-4e91-4168-bd6c-4b4f7e3921bc">311.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634f1e6f45a54e05bd52b24e519c4436_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtMTItMS0xLTA_660e6daf-3c95-4001-98e7-f7b1f09de156">494.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c177a7d8bd40c3ad390904b9d500d8_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtMi0xLTEtMA_74bd6385-ca86-4d82-8576-a011bcdcb082">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd866074adc42c98b75fe2cc20acab6_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtNC0xLTEtMA_1f032b4f-128e-4477-9f3c-946c50523b76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f60b9625d5649a094bc0b536c722ec2_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtNi0xLTEtMA_f0ef2778-3194-4df2-afa4-54cfef80a3b0">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911336cfeca046fdb0594c9edf8d9d0d_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtOC0xLTEtMA_0636a4a1-8c56-4b7b-901f-a282e425548c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cde429795a43629320e02fae4dc1f5_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtMTAtMS0xLTA_c3ab84c3-8407-4e0b-a3bf-e620e837509c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b919eea9c49c0ae92d49eae5d7e4e_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtMTItMS0xLTA_4f6629a1-5696-453c-afca-44ccc94a21c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b7f7eef9ad4f298c8c291b3ecaab47_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctMi0xLTEtMA_7856d4cf-e3e1-4f48-8916-b25ccde45561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7560cc8fc1a4480e89be78cc3735e0a0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctNC0xLTEtMA_a96ec46a-b04a-4c55-8013-f7f5156f78be">120.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82c486a127442488b1833a2dc7b7cd6_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctNi0xLTEtMA_a9dc1242-8b47-4137-a96f-7f8205e97637">120.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5008e8c4fa47649cfe38e4b9ebfe94_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctOC0xLTEtMA_943903d5-e330-4a46-bd6b-61b1abb7ac11">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9e403b349e4ca69958c093e19f74e4_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctMTAtMS0xLTA_161d4e4d-ed76-4506-9e4b-c20e2dbf57e3">124.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847c83d47690436dbf95bf269e8be2f2_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctMTItMS0xLTA_84b72a69-64bd-45b9-abf8-18bc6197be1a">124.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0763a9aea2ed45ba8300cc34209c8819_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtMi0xLTEtMA_7228130a-f552-4db7-8040-0cf5f1c079db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3dce21712c4912bcec60f52a212be5_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtNC0xLTEtMA_9487ce4d-9f95-4aab-9bee-ef05edf39122">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd874439cb1425eb709f078c0dc49cb_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtNi0xLTEtMA_50ed6bb2-7df9-4f24-97a8-d48a0e6591fd">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6126c7bc669b47cab645fe573efe2379_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtOC0xLTEtMA_c5bbb134-bc5e-4838-b3df-6a273938671a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52490028f86c4b18ae595bb12a3b413e_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtMTAtMS0xLTA_5bf19890-d5ef-4760-b6e7-d0b26733427f">56.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe93de388de42aea652b2d937d7b20e_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtMTItMS0xLTA_58932c05-4be4-465a-bd3d-20898ad1e800">56.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff76d3e091a4417f87d3022f27f8c714_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktMi0xLTEtMA_f9c48ad9-b466-4244-8aaa-2ae38c1ce5f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3133bc8432354bdd87b447ab0b25da57_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktNC0xLTEtMA_2e463a25-ac9c-4d04-9ac5-2ebb0f1d3fc0">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fcfb0f1a5aa4f28a82dd0078a64e4cb_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktNi0xLTEtMA_773d54d8-ee56-4da9-a1e4-d1e61bc01ad3">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6016cc0326e45fb8c5ab31460efbed5_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktOC0xLTEtMA_f8dbd83a-09c0-42a7-83a0-220e66edc30e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9b12c794124230bdfb5c764ae089a2_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktMTAtMS0xLTA_ebf35dd6-4503-4ea3-8c4a-b2162056a843">27.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851e3d422f964199aae5ec5f16c2ed5f_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktMTItMS0xLTA_d013402b-f340-46be-baf5-9448f799129c">27.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2258c8387d342deb1dcd335b185c9c6_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtMi0xLTEtMA_73b78d3f-8136-4e19-9704-193425f448dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac3a6cb79f144da8b8a7cbd1c451028_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtNC0xLTEtMA_90b4194e-90fa-48ae-a319-24f0822c6576">202.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec078f0e0134c10ab04094dc10dcbb3_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtNi0xLTEtMA_82eb90dc-8cc3-468c-aa4f-b7cbd5fecaff">202.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbd3b911c4e4a9b8d3b7b3370ba5be4_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtOC0xLTEtMA_165e1dc2-1901-4029-8c77-8e5d28b2f107">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95e5c1cfeff4eb999843b5ab142dea1_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtMTAtMS0xLTA_7499855c-b231-4cc7-b527-457c7322f755">207.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6147368b3e5448f387b2621a347ff81a_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtMTItMS0xLTA_f4e058a4-f83e-49ac-ba87-e7b7a8a2d406">207.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43b7a7b6aff426e8b3aa44f10665331_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtMi0xLTEtMA_08d7549a-5f56-48bc-8e58-e7bf718b1936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c0ed6a308478f8a953ae999c37402_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtNC0xLTEtMA_0f6116f8-bf83-4488-8fa3-df2572eafc6c">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7dd6c4bbab7427d884ea754f842614b_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtNi0xLTEtMA_d21dd47c-950f-4c7c-a652-2e653c1f06a6">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3637540f0742e282ee41d72bd9661b_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtOC0xLTEtMA_42f64dd2-5aff-4065-b34f-d7071a501b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f499618557b4da7acceb5cafb578dbd_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtMTAtMS0xLTA_4e7f11b9-f229-46c6-b4d4-85c8d766a1fb">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9ec1982c6d44839c60d73b502fb183_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtMTItMS0xLTA_f6486468-1662-4539-89a6-486d12b7fc5c">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc59dc95e0974b669bee2fa38de73766_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtMi0xLTEtMA_e7d54666-a163-476e-be58-e70f49d1c918">973.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a391c9c52574153aecfbbfb7003c5dd_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtNC0xLTEtMA_1a2d92cb-3cc2-4c53-80e3-bd755c30342e">1,232.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c7f8faaddf4de59fb5368e32d5ae6d_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtNi0xLTEtMA_ca9b896b-4324-4141-a773-de78a958ea03">2,205.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide45d117f94948c39924a1add89e7b6d_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtOC0xLTEtMA_83a02ae9-ecad-4f85-850e-1851f6b8f0e5">1,498.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90067ffe05f4ea3bef552a9c2baaf11_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtMTAtMS0xLTA_28d1f23d-95b2-4681-b71c-79ac8dcd5555">1,192.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3672251f76c4fb3ab491f7a64f2a7d1_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtMTItMS0xLTA_c438df5c-62ef-45a3-bb60-c96ffb0538d2">2,690.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia9563c229eca4c2a9d7f47a149ed5685" continuedAt="i59de8741c5cd498e8686a842318e3b52"><ix:continuation id="ida867edb93f3480db0e73fea67f50d49"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a69686d751b4d78856ab4a9b5568f7c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC0yLTEtMS0w_260995c8-cd69-46f0-b3bb-f78d869d32bd">805.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265533229a0044408626b8fb90354de5_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC00LTEtMS0w_6e35b264-609e-4db1-8e44-6bf5545a37d9">945.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b240004575a41088f63cfd2893796da_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC02LTEtMS0w_4b5d6a82-64ea-4051-9483-8c8717c79d0b">1,750.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc59a1b194f46d9aab6abc4dad371c8_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC04LTEtMS0w_bf5dd2ce-7079-41a4-aecf-5b2931821e0e">2,383.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94113634bd1c4fd19a9b3f8785b02ebe_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC0xMC0xLTEtMA_27d79d9f-138d-4ea6-b24f-f51d89fa9f16">875.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04560d42c0e54986baa4ff75a03e96bf_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC0xMi0xLTEtMA_fa9bcc6c-c12b-423c-b1db-22dd4020cb8f">3,258.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b12493f4b214da88a80d6a1be15a5ec_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS0yLTEtMS0w_e2e11f11-f84f-4512-880c-2a57b8aea224">751.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c7085ac1e94084911a32c8c5150032_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS00LTEtMS0w_5bc9f16c-1cb7-492c-b897-2165b6b0aa71">436.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a516cca4e1641a3a52085e438a3c519_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS02LTEtMS0w_e5be507e-0710-4fe5-9337-049172e2f210">1,188.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7189d4590dbf410981d535efbb77dafd_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS04LTEtMS0w_02fe2595-5517-4a6a-b113-06fc0d3de03f">965.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa621e0a5cf4731b69211ee0236dfa4_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS0xMC0xLTEtMA_9ef67cbf-7844-47c9-be66-fe90c2777efd">456.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b298d90ef649be871440f8e5609a5a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS0xMi0xLTEtMA_dd57206f-de46-4d18-8c2f-37e3d8163c6a">1,421.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i055192050a884b09af25bd948ce893be_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi0yLTEtMS0w_15253965-3d59-4b7e-b8e9-1b2847263a69">854.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819e179a871a47bc9b2742b59e816fd5_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi00LTEtMS0w_3e841f88-0553-4185-b7d9-b3b897a0df84">696.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8870751b462a458697438c86f8eedbe0_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi02LTEtMS0w_39c42ae5-52d5-480d-9236-3d1cc367bf3e">1,550.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3447ed88deef4013aef8152951e512bb_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi04LTEtMS0w_55b1191f-0efa-444b-a173-53afc43a4e3b">826.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955579c517df40abbdcbafae0a9be8e3_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi0xMC0xLTEtMA_5c18381c-4155-40f0-9d55-c68448d07c37">644.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie518ab0a6fb54b19acd0e5840d451a8d_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi0xMi0xLTEtMA_93bddb7a-a398-4cd0-9083-c2cf932f0981">1,470.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdc18d489a44d0492145df9a238420f_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy0yLTEtMS0w_2c7acfaa-8e19-4fe1-b4ee-4921f632445a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d5e1daf4b14aebaff40a7bfcdae045_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy00LTEtMS0w_020c776b-d5b0-4f2b-9bd8-dcad0e97d44c">78.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f797b3134f4dfeb7404b4045bf8dff_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy02LTEtMS0w_f05fbf93-dbf3-433f-b0b8-507bdc37916e">78.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c7deeed40b495cbdd4163ba45d904f_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy04LTEtMS0w_ef14c9b4-1609-4566-8dc7-bbac302fa418">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa6a3fdbaa84285a4f2caf4e5f6c13f_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy0xMC0xLTEtMA_c5830c00-6013-4ddb-a94a-083301685a3d">78.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba938bf7466644249a1784f67476b2d8_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy0xMi0xLTEtMA_82126703-d911-4a0f-a4ea-05d08e0d041f">78.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b6d6875e5849df84d386d1cbbadf8f_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC0yLTEtMS0w_ffd42591-9504-4757-ab14-dd8184d5e08a">2,410.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a8b4a619ef48838cb6f537675db04d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC00LTEtMS0w_dfd7dded-7b4d-425a-ba66-cf6299fa5103">2,157.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3263ec5c084ebdbf45685ad846b557_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC02LTEtMS0w_b33bc798-7219-432e-92fd-74e9bce9b2fa">4,568.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7894b472498148dbb05439dbe1d0de4e_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC04LTEtMS0w_15af686a-e865-400d-8f6b-e9a8c69bab7e">4,174.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de479d587354958b584fa532dfa50e7_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC0xMC0xLTEtMA_db9990d1-1358-4d77-97fa-2cc0b69e4726">2,054.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd108b031c74d6293853d4b7f765be2_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC0xMi0xLTEtMA_ea0c1c7a-0fd8-42f8-851b-e0e70536bf15">6,229.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e2681e4af04220bc5659c30f65dad7_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtMi0xLTEtMA_a421a46e-c4ba-4729-a2de-e75a99e5aa22">437.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997d11776fa54ff88c622c8a39e451cf_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtNC0xLTEtMA_a8188f63-4b2f-4ab8-be65-abdcd511101c">1,026.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4463689b8f13459fb262230c8eeaa642_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtNi0xLTEtMA_a597cb59-33fb-40c8-afbf-03850a9506d1">1,464.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53918b8ecd640bd9d91e12ad6779d47_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtOC0xLTEtMA_70c270fa-eb69-4100-b2a4-05baa4a44fbc">628.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f69c1b12cf4aa48eb2f5495743e9b5_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtMTAtMS0xLTA_2907dbd3-254e-429a-9c93-f6685464612b">925.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a344b1c3ded4c809b0bdc426f095761_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtMTItMS0xLTA_389f23c5-06ed-4516-af6f-4f8b2afb1668">1,554.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2961e6b3f8584e359cd5fac9d7ae1a87_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtMi0xLTEtMA_06f4c2ca-ca2e-4ee3-bfab-1350fab621b8">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018ca53b38334c258546194db151794a_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtNC0xLTEtMA_9a80218a-b754-4911-a7ea-80b0f1a0295b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41fab9ee02a43b197272a5b13c0ec9b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtNi0xLTEtMA_8385574c-353a-4687-a84d-827a164ce57b">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9872f8c2bb2488280b710de2bd86613_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtOC0xLTEtMA_fca501ce-2e7f-4e82-97eb-c239d19a4f9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21d50af206e442cacfbcc591b7db41c_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtMTAtMS0xLTA_252b54e6-8f9d-40ab-bcb7-f5e8ea98412c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db43726d8244d069205c2ae2092eecb_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtMTItMS0xLTA_6f350810-8869-4f4e-8feb-6c6da5c10424">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358a97db687a4532b4896a6818c1c570_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctMi0xLTEtMA_ec1714cf-1717-4089-9100-a601b9e4af6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f3feab17d487ea2b255ed4e7fa9d9_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctNC0xLTEtMA_bd9d97e8-3488-4d93-ac92-f7bf9b17315a">363.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7281dfb87f4c759ded27994b4bc48a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctNi0xLTEtMA_969bdb31-24a0-4002-94cd-c905ab3f7cb2">363.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48de9837733f44a7b1ae4335196cab8a_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctOC0xLTEtMA_22e5a2ab-c7d6-459b-8752-38ca99e0484e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6500c755b0d48dfb3cfc643bc8aa24c_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctMTAtMS0xLTA_3d66c290-d48a-4fed-b763-a6aff0a8fa16">363.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c2d0a9c88d4d4189622a44b28df36e_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctMTItMS0xLTA_974e837f-d02a-4620-8bf4-c79a5a154f9d">363.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ef513a65ec4140a5e0fe08899b47c6_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtMi0xLTEtMA_f2aa1b70-ded1-431f-a415-57ee8c0ecafb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d8ed76345a4acfaa73ca03e26f404d_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtNC0xLTEtMA_08047ccb-7373-47f8-97ea-1a98184bf9f1">170.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b8289bbaf4401ca50ee623561b21ae_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtNi0xLTEtMA_4603adf7-1c74-4d4c-871e-7496f2ebf54d">170.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0201097c2b0b4fd8b09bf1320302b0df_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtOC0xLTEtMA_59856c94-f7a2-4326-89b0-3a31ae57aa0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfebde8455d24e9dabbc61af5ac34b17_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtMTAtMS0xLTA_da59ac67-81ee-41aa-8f4c-4d553933ea44">162.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad690c84e494203ad19621f8be2258f_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtMTItMS0xLTA_71b96635-9737-4677-a66e-2d97658bbd1c">162.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i365b2ee8a85c4fd0b42ca8da39cce072_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktMi0xLTEtMA_fdd0934d-df53-4393-ad4a-e3afcbd87f28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec836555e23418e9418b4c438dfbde4_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktNC0xLTEtMA_27b87ef5-e163-4448-be44-7507ea5d8e44">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7441b05974ec4515a4d0318950fd8c07_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktNi0xLTEtMA_a6d6d5cb-cf08-4ac3-95ce-ecda26da6cdd">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34eef8f55bd84011bdd58c92bc395b12_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktOC0xLTEtMA_d6123fe6-2cac-4436-ac65-c8f3dcb5adca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2050c886f441471bbf874fbf99723b8c_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktMTAtMS0xLTA_0f10e8cf-8056-4500-8044-1c84d4dcee80">71.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b58455f915944c5a8b42b07b2d4f95f_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktMTItMS0xLTA_4fa33ddc-3b92-4e30-81c1-927faa4b8275">71.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i102f99b657e24bda89929e63215714e7_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtMi0xLTEtMA_b420e5d1-9cc3-420d-885b-8405f3a816fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f766dd011914fd7aac023f50c96726a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtNC0xLTEtMA_c9a2bf6f-8971-416e-8587-057b4928f23b">610.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390f7d8898fd40cbb7ae0d2c48fb5ed8_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtNi0xLTEtMA_6b37c632-d38c-4cd9-9994-dce4671e0298">610.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacdaa759bf824f8ca47514fea1b47ee2_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtOC0xLTEtMA_3c0c6433-be11-40a5-b293-216429bd5521">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66ceb4c3c8641618bd0571332ab70e7_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtMTAtMS0xLTA_cc90fbcf-34eb-43b8-b5e6-e05d5951b416">598.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59ec4787fd04a5585eb63429b7020aa_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtMTItMS0xLTA_d90619d7-96be-404a-825d-1b2f7f90d7b3">598.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78748439d3e4bdc967aa5af911f7391_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtMi0xLTEtMA_29e4cc1f-83ab-4385-bf34-ba149e313b9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64722cd85a514d76b846ff90832c2934_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtNC0xLTEtMA_8b17412d-7454-4ab9-a266-7351f7f6f59c">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f7c01250cb438abd665e9b9c94e743_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtNi0xLTEtMA_6a8b2615-0ea9-495c-8dda-bada6328f432">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2eb565fb2ca4e59be0ae2c0d7f3db8b_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtOC0xLTEtMA_bca1ed8b-6c29-4600-adcb-5987cc6796e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbef3e76d1f47a29e6f947d82b47f45_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtMTAtMS0xLTA_083239e8-228f-4cec-88d6-e3a11bf82c5a">9.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad39afa89ed54171a76ada18b22e630b_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtMTItMS0xLTA_799cfec6-af23-47d1-bdbd-8c887237487a">9.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95260bc99cf64ae8b8bcaf3a4e5e7812_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtMi0xLTEtMA_944258f5-f778-44a9-8c5d-d02e685c80f5">2,850.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3a1ac1941449be84c85e628ce9d89d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtNC0xLTEtMA_66250261-85b3-4943-bec4-24c73d87c241">3,802.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6629e89c034a4d89883d31d567178ed6_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtNi0xLTEtMA_5a7044e0-629c-4fe7-a402-d4da71672b33">6,653.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a8c5663be04e9faed2b5f0d97a0e68_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtOC0xLTEtMA_014eb700-7048-4b2d-abad-c692e16e0eb9">4,803.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79795b771df34c8fbe099d241c96d9b2_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtMTAtMS0xLTA_c46660b7-1331-414e-9946-f0fbab1dd72a">3,587.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie862c4e3d0454092bd193a5d58ea0c3a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtMTItMS0xLTA_b0e942fd-8b21-4d4f-b176-9db380592161">8,390.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfNzkw_aa79abe0-c036-4933-bf1e-caeb03c8401e"><ix:nonFraction unitRef="wholesaler" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfNzkw_b84d1df3-08ea-4277-ae56-36c5d8a36c07">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="i0549e44337674a5ca08eba019050c369_D20210701-20210930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfODIw_6f83ce95-312b-473e-a38a-d4ce332507a0">26.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i35f1dc85a6d443f5addb0eda7c8dc35c_D20210701-20210930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfODI3_cd404361-9918-4584-8c9a-9c3474fcbd43">10.8</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2021, and <ix:nonFraction unitRef="number" contextRef="i1e5d0635317e4c16906d390ed841b9b3_D20210101-20210930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfODg3_846f0096-e0eb-404d-9bcb-ae3c19e18453">29.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3e281fbe905d4e3e9728f08aa41f030a_D20210101-20210930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfODk0_25fad52d-8428-4329-aba0-3703165ceded">10.0</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfOTc3_aa79abe0-c036-4933-bf1e-caeb03c8401e"><ix:nonFraction unitRef="wholesaler" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfOTc3_b84d1df3-08ea-4277-ae56-36c5d8a36c07">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="i2bc6970c546c489b94382b832606b1ab_D20200701-20200930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMTAwNw_342f1996-9d4b-4cd2-b303-19d908672194">31.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9b71a9f27e79480681fe58993506eb15_D20200701-20200930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMTAxNA_3a93e8b6-e10c-4959-8dd6-980dc95aba06">15.6</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2020, and <ix:nonFraction unitRef="number" contextRef="ib7d1e15250b64a13b47a432932d37658_D20200101-20200930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMTA3NA_0a15b55f-9149-496e-b692-cf5bdfb5344a">30.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i64007592035142748ac7599f7a664be7_D20200101-20200930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMTA4MQ_c12840d7-bff0-4324-ad44-e8985df40ac8">16.0</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2020.</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA2OA_9b79c545-76cb-441e-b9a6-a5e5b9419855" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9bb0d6c15842358b1c0ddfa1c21b68_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMS0yLTEtMS0w_af1ed51b-1fc4-4d6a-9fb1-b07a2560b00f">141.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e6d8ecb5194fa9b70da244b06c3872_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMS00LTEtMS0w_feab3fd8-bba4-4e64-91b1-ac3d8d59a16b">1,093.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib378e0758d7a484581e59302e22742cc_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMS02LTEtMS0w_b7176146-5ef1-4784-afbd-96604ad27424">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMS04LTEtMS0w_a6ce4061-d4aa-4b48-bad6-9bb1d799953a">1,276.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMi0yLTEtMS0w_33f4e260-9b29-4903-bce7-6921c3204b2f">556.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMi00LTEtMS0w_62fd1b07-ab0e-4794-a1e9-f2fd5497e007">2,255.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMi02LTEtMS0w_38ecc293-abd0-4915-9739-e22c7b2ac45d">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMi04LTEtMS0w_b0831b27-9780-4cd9-aba1-b7e09bcbe8e6">2,823.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMy0yLTEtMS0w_beddb70a-5036-457a-8448-e59732faad54">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMy00LTEtMS0w_fa10de0a-3486-4262-935a-7a4c248869e0">71.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMy02LTEtMS0w_873a216c-7bf4-4024-b312-d4692f12ed34">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMy04LTEtMS0w_94d89cd9-9ae7-4790-8916-466857a53dfc">70.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNC0yLTEtMS0w_f9080325-9b1a-461e-ad58-02b01faa7239">422.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNC00LTEtMS0w_4c65bae9-3e57-4ffa-8700-cb4459f68127">1,598.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNC02LTEtMS0w_cbd7a8a2-2b3e-4768-9091-9286970f784f">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNC04LTEtMS0w_9fa3ffc3-e240-42fc-96d6-66c4278bcf75">2,021.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNS0yLTEtMS0w_b4b6eba3-afee-4444-b798-2b8b76177b5b">136.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNS00LTEtMS0w_0f8d224b-7e0e-4500-913a-a528776af5ab">732.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNS02LTEtMS0w_49d8fc59-79a9-49c8-ae01-2c0696c5d80b">9.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNS04LTEtMS0w_27329378-db2a-40c0-87c2-75ac52baf8cd">878.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4afb6819034ad8ae8cce9d2e54cf47_I20210930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNi0yLTEtMS0w_8de3b17e-fe7a-4f0e-95ee-43183602a1cd">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f620d3630247a0b5778586f131544a_I20210930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNi00LTEtMS0w_708fcfb7-484d-4b6d-831a-4e187f5b36db">946.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91c47df08824717aead53a81a56dc20_I20210930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNi02LTEtMS0w_9d091d08-5c48-4bea-bb65-e2aebcce0678">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNi04LTEtMS0w_cfae2537-5fbe-4fba-883d-9022d31d187a">1,128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i59de8741c5cd498e8686a842318e3b52"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA3Mg_cae92f67-5ee5-4fc4-8a73-2c82eb4629b6" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb75ba94b11d4a699b755fdc629e6cbd_I20210930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMS0yLTEtMS0w_bf3c276a-68bd-422b-82ee-f24eac8efc9b">146.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d2a9c8b03648879414ce30d6e746af_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMS00LTEtMS0w_1b784ff1-3d86-4da0-aafd-d4da2c6265c1">195.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa3c889df0142bf89536f957b8eaee7_I20210930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMi0yLTEtMS0w_738237b7-a9cd-486e-90e5-dff5cd44469a">982.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b173db27f4480e98a38ea719ffce5f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMi00LTEtMS0w_51da0c1d-4ddc-4890-9e02-568dce80764b">1,080.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMy0yLTEtMS0w_72a7282f-927c-44b8-93ab-280f8d9b9643">1,128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMy00LTEtMS0w_95a0a4e1-9711-4512-9211-5d8c36d74e63">1,276.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA0MQ_cae03863-3234-4f16-85a1-a7e7b0015884" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1bfcb48e77b46bba81990b5298288bb_D20210701-20210930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMi0yLTEtMS0w_4929654f-6db6-4b0a-8c34-f815df6f66e7">145.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b18ce9f4621437b922497d189f85e55_D20200701-20200930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMi00LTEtMS0w_035ad6a8-4d4c-4fb6-ac8b-e2a06781377c">275.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701a2e8982b64d678d5770b22075f8b7_D20210101-20210930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMi02LTEtMS0w_619a320c-1e01-451b-8bab-1407d3fcd14a">498.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7ad7518d94ebca15cc87bd32825ca_D20200101-20200930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMi04LTEtMS0w_11b19c04-9bc1-4e5a-9612-68ce3b45d43d">873.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1bfcb48e77b46bba81990b5298288bb_D20210701-20210930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMy0yLTEtMS0w_396c68b2-107e-444e-a9c4-007db46168e9">269.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b18ce9f4621437b922497d189f85e55_D20200701-20200930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMy00LTEtMS0w_2e417cc3-10e6-4280-a909-3f9968d3d1ab">285.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701a2e8982b64d678d5770b22075f8b7_D20210101-20210930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMy02LTEtMS0w_0b463833-29cf-48c1-9fcf-b5cfb918586c">745.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7ad7518d94ebca15cc87bd32825ca_D20200101-20200930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMy04LTEtMS0w_b716370b-6874-4ec9-9910-ab8c28588d48">685.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc49896e8f7749f9aec4691dac20e8f7_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfNC0yLTEtMS0w_7e2fa574-1d03-4333-9952-f24577d33597">415.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b23d904c3ce4fde94a3a645d27461d5_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfNC00LTEtMS0w_1b7b9236-225d-4770-8abd-9d26fe166cd5">560.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf69f40f83ce4c9da70c57f9064c7b4a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfNC02LTEtMS0w_352aa871-acab-43a7-a896-88bcba580650">1,244.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c2b9076741473bbd3bced37f71ef41_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfNC04LTEtMS0w_d7209529-4b6d-4766-9812-3b1830631031">1,558.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:OtherrevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA0Mg_80bb80ff-891d-4e66-8b3e-fd8523d381f7" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3408b069db1d42f7b345ec1b7498f89d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfMy0yLTEtMS0w_9b5d52b1-cf8a-4d71-a7c5-ddd2c879e452">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec55d2ad3dc4febb73612f72beaebdf_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfMy00LTEtMS0w_d047d693-dd37-4470-bd97-ce10b8697662">5.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99dc3ab809743fabf00ba08bbbca28b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfMy02LTEtMS0w_73f14210-8714-4958-90e8-15775a82c09e">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf7ab8592bc4011a62dfd0ea076ded4_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfMy04LTEtMS0w_f4f365be-e627-4abd-9527-32f28f2aafee">13.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90843cdfc614862a52278ee45bfc131_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNC0yLTEtMS0w_b659add3-3b7d-4f9e-99f2-5f7f654a5978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414a6de3330847a1ba08416250b5bb7a_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNC00LTEtMS0w_4cbd1cf5-65fa-4eec-8c17-552573b99930">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bae232cfcf14b48ab44d669cfbf4ea9_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNC02LTEtMS0w_a66ada24-a3b4-4173-bc00-3760aaf36067">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1b9df4cbfa42c3ac411955189a9091_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNC04LTEtMS0w_5c2ca5b5-1693-4ad0-a293-8ff4e99da6d3">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f198b587194af1b052efd3339aa9ac_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNi0yLTEtMS0w_9fb4a99d-b4c9-436e-b0e8-63c5300356ee">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e025fdb4f53458a856e099d5f619c31_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNi00LTEtMS0w_f6786af0-78bb-447b-b9fc-fae670e5fa1b">10.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744aacd6ec9a4103922fccc0ecf5a575_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNi02LTEtMS0w_87a20236-189d-4aca-879d-0e496fb6a8be">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bc77237cc245c6bb9b3fd9dcf68cee_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNi04LTEtMS0w_8fcfda96-1f59-43b0-936d-59ecc8065ed2">28.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28924f2261242259992e93451202d13_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNy0yLTEtMS0w_9e0a40eb-ebfe-42ab-b8b7-24511d021e0d">143.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62cbf5b25f7f44f6997f9587acdb152a_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNy00LTEtMS0w_286683d2-7364-4073-8755-d0d22f2d2067">110.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3202bb6f2a554b45af9aa83e6ecacbce_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNy02LTEtMS0w_4098c5b5-1fc5-486b-a61f-2c97d77e949e">314.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6ee34a915d43d3b004660946221bbe_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNy04LTEtMS0w_cfa2377e-849e-4a4f-abcb-0c4321ba6ebf">599.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36a038f73ce4e7b8013d75c309b00de_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfOC0yLTEtMS0w_84788728-70f2-483d-baa2-a2ec16773655">157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27692e0f487e42cfa48cfb9ec74d1c5b_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfOC00LTEtMS0w_96a54613-94db-4e81-876e-0da894bbd689">125.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40db7f82bc1346e0a6ae09a03625fc9d_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfOC02LTEtMS0w_7d17b478-4f12-42b5-a44f-3c70d6b3e33b">350.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2782acd53f4eca80ff87db16f55ee5_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfOC04LTEtMS0w_94ad9896-c263-4d4b-bef0-4dd30b9ef761">642.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_58"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Inventory </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RleHRyZWdpb246MjNmMDVkNzE0ZjI1NGQ4MTk1NGE1YzFhMWRjN2NlM2RfNzM_bd8fd2c6-c47f-4106-9411-c44ee354a9c3" escape="true"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RleHRyZWdpb246MjNmMDVkNzE0ZjI1NGQ4MTk1NGE1YzFhMWRjN2NlM2RfNzY_c746cbba-f0ca-4ba5-acf9-1d8e4c0347f0" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:58.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMS0yLTEtMS0w_a833a2c4-ba29-430f-a0e5-3f256164bda3">366.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMS00LTEtMS0w_b5be6e66-81bc-4c69-b1fc-b6f30c28d647">314.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMi0yLTEtMS0w_fe3735e6-e9e1-4b82-adc9-e4274ef9a874">780.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMi00LTEtMS0w_d82705ef-eaf7-48bb-a545-6dfcdb51422e">544.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMy0yLTEtMS0w_d3d56124-4b84-4711-b71b-179ebae979b6">201.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMy00LTEtMS0w_de43588b-7a81-497b-87bc-80487a3720b9">209.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfNC0yLTEtMS0w_5705666c-c5c7-4b12-a587-6aba7b70a8d5">1,347.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfNC00LTEtMS0w_087a5611-f054-491f-b368-53afb82771c0">1,068.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_61"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTkzNQ_af1440a4-2c66-49e2-90f8-d74a68ca3547" continuedAt="icfdd4044ff5d4dbb89e158a7281b7d92" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTk1Mg_d2dc6f8b-5eab-4ee0-9468-daffb0aa804a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19b8b42bc9547abaf105a4b71dbd351_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi00LTEtMS0w_f183ec71-69c5-487e-b37f-f3584400c1e9">7,411.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie19b8b42bc9547abaf105a4b71dbd351_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi02LTEtMS0w_d538dc00-a08b-43d6-9b05-648aecde8208">5,320.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19b8b42bc9547abaf105a4b71dbd351_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi04LTEtMS0w_d7b03afb-7377-4b3e-ab29-85aa24e4e1db">2,090.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f18c0415849f9b387fb21e49c9fd5_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi0xMC0xLTEtMA_853e459d-a1a7-4b98-aba4-e47978b95c8b">7,394.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i790f18c0415849f9b387fb21e49c9fd5_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi0xMi0xLTEtMA_5760844f-0a2d-44c5-88fa-e3a63e7e7d20">5,136.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f18c0415849f9b387fb21e49c9fd5_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi0xNC0xLTEtMA_dd581e89-d60b-46f1-9767-d5720ab96cd3">2,257.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecc275acaf4fe883a279d9a574b48c_I20210930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy00LTEtMS0w_98204bcb-b2b2-4d6b-948a-03774cb544db">132.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecc275acaf4fe883a279d9a574b48c_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy02LTEtMS0w_2976e963-206e-4000-a328-e262a767a97a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ecc275acaf4fe883a279d9a574b48c_I20210930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy04LTEtMS0w_d7f045d6-d203-4cc9-a204-8ecefe8ae8c2">132.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753c69a029d04474a9bed4a6271dece8_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy0xMC0xLTEtMA_7992ba30-754e-4f30-9003-5ef70782b517">762.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753c69a029d04474a9bed4a6271dece8_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy0xMi0xLTEtMA_c1913541-3e5b-49f4-9296-81a7b4e4ff00">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753c69a029d04474a9bed4a6271dece8_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy0xNC0xLTEtMA_b43e90ca-33f7-48c1-b2ae-fa526ea76e51">762.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805587f470f344d680991d5995876af0_I20210930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC00LTEtMS0w_a7ec1c3a-074a-44e0-8939-df0f288c78f4">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805587f470f344d680991d5995876af0_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC02LTEtMS0w_c76cf99e-78dd-43c8-a38c-fa400aa9e577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805587f470f344d680991d5995876af0_I20210930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC04LTEtMS0w_4bd7951e-3236-43a9-8725-19b344ec37f4">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if310e2943b1e4ccbbda6ed73c324ade3_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC0xMC0xLTEtMA_cc8b66dd-7608-4f83-be1f-af54bf088229">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if310e2943b1e4ccbbda6ed73c324ade3_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC0xMi0xLTEtMA_146b54e0-eb33-4a8f-9a05-16e4d7562862">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if310e2943b1e4ccbbda6ed73c324ade3_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC0xNC0xLTEtMA_4cbf0087-14c3-4ea7-9ff7-8ced4e148fe9">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS00LTEtMS0w_3e31386f-06a7-4267-9f63-5d965495ec4c">7,607.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS02LTEtMS0w_6f0ed23f-a746-4b65-b08e-a82c9b0cbc38">5,320.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS04LTEtMS0w_579287c2-71ac-4ccf-9bdf-6d9ec50851be">2,286.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS0xMC0xLTEtMA_bee716de-e562-48f0-b388-9f5c361a8c87">8,220.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS0xMi0xLTEtMA_eee974c6-696d-4b3c-b807-9762f0599ae1">5,136.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS0xNC0xLTEtMA_8e5f508c-f48d-4ca8-a918-5a39543f527f">3,084.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, amortization and impairment of acquired intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjQ4_9e2b4371-cb66-4554-94d9-a51f1bbddf33">111.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjU1_5547110c-3dec-4393-a8a5-cfbcc75bc476">813.2</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjg1_00842875-29de-40c6-b379-64a9ccc60588">82.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjky_53a020ee-35a3-402f-9ba9-9a5d81ec6533">215.6</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, amortization and impairment of acquired intangible assets reflects impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i3be3bc83cfa548609221fb923b77b012_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcwODc2NA_9800c2f7-c5c9-44b6-bf7d-6501584115aa">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3aa487875e3b4688bd646e5ea13ab375_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNDUz_bab970f8-fd06-4928-a69e-3c0d6a34d2ca">365.0</ix:nonFraction>&#160;million, respectively, related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia, and impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i1627155704354fc0a8a424c6c2790177_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcwODgzNw_7db50372-ff19-46d5-8f1c-cf237fd41901">28.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i463cd8459c624bd3882e48393200fab1_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTY5_32246ee0-2b85-427e-9237-6713a9c94101">220.0</ix:nonFraction>&#160;million, respectively, related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, amortization and impairment of acquired intangible assets also reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="icd4c548cc92f48a4ac8e14803f6f43b6_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfODAx_26e21b27-55b7-449e-8423-96e6636a8243">44.3</ix:nonFraction>&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="i53f4f3120ef84eefa4d661c020812d93_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjE5OTAyMzI2MTczOA_624617af-1bc6-492d-af56-e36cb99fd285"><ix:nonFraction unitRef="usd" contextRef="i45e7b551c5dc43d5a333a321f352359d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjE5OTAyMzI2MTczOA_e08fbff0-59b4-4117-8c0c-c2cc01d10567">19.3</ix:nonFraction></ix:nonFraction>&#160;million impairment charge related to one of our IPR&amp;D intangible assets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of September 30, 2021, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="icd4c548cc92f48a4ac8e14803f6f43b6_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjg4MQ_26e21b27-55b7-449e-8423-96e6636a8243">44.3</ix:nonFraction>&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of September 30, 2021, the carrying value associated with the remaining vixotrigine IPR&amp;D asset for DPN was $<ix:nonFraction unitRef="usd" contextRef="i92d6d0dc9ec648d4bea25189aedec636_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzA2NA_b9faacc8-5f4e-4b66-8ad1-6e72cb6d2b3e">132.0</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="icfdd4044ff5d4dbb89e158a7281b7d92" continuedAt="ied87cddf330a4fd3ace4c63ade8e4f38"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ic8e4d78e60454a64b89e8a75ff8f0450_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzE5Mg_4ffb8969-784d-4a9e-b062-9b0592b7b1c7">115.0</ix:nonFraction>&#160;million related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and o</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ur Phase 2/3 XIRIUS study of BIIB112 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the three and nine months ended September 30, 2021, we recorded impairment charges of $<ix:nonFraction unitRef="usd" contextRef="ic21c7a6ec4ab4bd2a8bbfc0f4cd56f43_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcxMzUwMg_214a8c01-fdd6-4f9d-9eb8-766d8c7223de">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i80bd0b2b32ea4b5680c869f40cc11b5f_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcxMzUyMQ_15e4cf61-215d-457e-b8cc-5c44b01296ea">365.0</ix:nonFraction>&#160;million, respectively, related to BIIB111, and impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i326c80e9243f4bf493aa660e564a3122_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcxMzU0MA_c153b180-fbe7-4b39-aff2-83086a44dd7f">28.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5b7e99afec554a029eb237f033b39037_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcxMzU1OQ_362367a8-2827-4547-a40d-ccf03bd17d98">220.0</ix:nonFraction>&#160;million, respectively, related to BIIB112. As a result, the remaining book values associated with these programs were reduced to zero.  </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, for the three months ended September 30, 2021, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i994f124b7f3741b2a6d52b940a0759f6_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:ManufacturingAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcwNzY0MQ_eb4eb5f5-afc7-466f-9a0e-b752567030ca">39.1</ix:nonFraction> million related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span><span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTkzMA_e84ff91e-ecb7-446d-898b-817692440fad" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfMS0yLTEtMS0w_1410f747-0008-4917-872f-9181cb1ee05c">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfMi0yLTEtMS0w_6faf9fce-ffbf-4982-b648-529713539f69">255.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfMy0yLTEtMS0w_88ec512c-a7b7-40c9-abda-5feaa8f25b49">210.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfNC0yLTEtMS0w_b91128e4-a1d7-450f-a56a-e33add689f99">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfNS0yLTEtMS0w_8e96e084-4e61-4c68-8384-604cabb1c78f">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfNi0yLTEtMS0w_b655b811-1b0e-4078-bdf6-c5a56770329a">180.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTk1NQ_0c660259-5a0e-480c-9258-e5c5b86ffb45" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjFhYjkzOTMyOWNkMzQwMjdiNTczOTc1Mzk2NGMxNzQ2L3RhYmxlcmFuZ2U6MWFiOTM5MzI5Y2QzNDAyN2I1NzM5NzUzOTY0YzE3NDZfMS0yLTEtMS0w_4a44b03f-1095-4c69-8d63-6f66badcb11e">5,762.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjFhYjkzOTMyOWNkMzQwMjdiNTczOTc1Mzk2NGMxNzQ2L3RhYmxlcmFuZ2U6MWFiOTM5MzI5Y2QzNDAyN2I1NzM5NzUzOTY0YzE3NDZfMy0yLTEtMS0w_56f771eb-cde5-4d39-98d9-5c0d0cb96ada">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjFhYjkzOTMyOWNkMzQwMjdiNTczOTc1Mzk2NGMxNzQ2L3RhYmxlcmFuZ2U6MWFiOTM5MzI5Y2QzNDAyN2I1NzM5NzUzOTY0YzE3NDZfNC0yLTEtMS0w_34d986aa-2eb8-445f-90e8-b7a5fb0ab535">5,760.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><ix:continuation id="ied87cddf330a4fd3ace4c63ade8e4f38" continuedAt="ib653659f37f94df1a2bc4807610d6f3a"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTc3Mw_4b67f7db-1551-4ad2-b5e6-c837b335015e">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib653659f37f94df1a2bc4807610d6f3a">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_67"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Fair Value Measurements </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNTEwNg_0db4e4d0-70be-4094-8f8f-b7b1c616bd40" continuedAt="if8272d3f0f95406aac9662cbce65dd82" escape="true"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNTEwOA_a8ae26c9-718b-4ab4-b680-2be0646d0d84" escape="true"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMy0yLTEtMS0w_22cdfa84-e26f-4273-88ff-310018a6f07e">978.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMy00LTEtMS0w_ec39d90c-3c8f-4b5c-8ea3-ca50a568d46d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMy02LTEtMS0w_ec482989-16f2-4a6f-b085-63d2ecd0e099">978.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876974683e3549eea5fc8f61aead1156_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMy04LTEtMS0w_6684119f-b318-4fc0-98b1-9df3b3a3fe6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fdb402e2824ce4a9bc71b9229835d6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNS0yLTEtMS0w_9a6957ae-bc55-4d7b-8980-7e511e91fe73">1,486.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c87b4112217442caf7f93008b36ae14_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNS00LTEtMS0w_4d846c46-893f-4044-9b2f-26dfbbf8e640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913028ac08ed43abbe4437b3e87d4ff8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNS02LTEtMS0w_b80d077b-f991-4e49-b84b-6b0ddf11001d">1,486.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9850ad45354252a28687b05a4f7ba0_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNS04LTEtMS0w_5988da83-cb63-464d-8aaa-a29032d25e75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ac3585271c4421bccc4835e25238e5_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNi0yLTEtMS0w_a715f648-615e-4194-9799-83b9f812aa76">712.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79db083a3de94f4287a9add466386aa1_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNi00LTEtMS0w_450fb5e8-0485-4835-8bc2-f150d7094b3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf0756fe34b82bc7e195e28ba5cac_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNi02LTEtMS0w_e810d83a-4c6d-4cd0-8a90-402770802610">712.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cfaf234a7a04182b6f04ff79328e86e_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNi04LTEtMS0w_e30c330f-93d4-4714-84b7-3286d39a0c15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2382fc36d44058840ae3e3e28251b2_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNy0yLTEtMS0w_71fbef04-3dde-4b8f-add4-cabf1611ed52">181.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1deebd059f4c45a7a55fb2f7fb75cc43_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNy00LTEtMS0w_4d281889-9d86-4f1b-b4b2-5a397cb4e425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1474a542b94f95b31adc32082b10e2_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNy02LTEtMS0w_8de3d595-e5dc-4d60-a8d2-b6462f4b7ee8">181.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida9264d01fca4283942cd3738537b883_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNy04LTEtMS0w_4a450b3c-f331-444b-88d6-232ca3c67a41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOC0yLTEtMS0w_3c7879e0-521b-41dc-ab72-5df7a53ee4c9">1,166.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOC00LTEtMS0w_5433474f-3c22-4220-a872-937f586f25b4">215.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOC02LTEtMS0w_29eae691-d592-4cc2-a1ad-b84347ccf02c">950.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876974683e3549eea5fc8f61aead1156_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOC04LTEtMS0w_dd7d3184-e15d-4f5e-8cf5-680c9159be70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOS0yLTEtMS0w_21690525-13ce-4830-8a51-e77304aee21a">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOS00LTEtMS0w_0307380b-1690-4193-8d58-007316d4a3aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOS02LTEtMS0w_40d3430a-9553-4c7a-8319-0af589c9d51a">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876974683e3549eea5fc8f61aead1156_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOS04LTEtMS0w_823ad3f8-3217-403e-9aa5-614b32a9fd9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTAtMi0xLTEtMA_9cc1e299-8025-4547-bfd9-188662ee8c56">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930" decimals="-5" format="ixt:fixed-zero" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTAtNC0xLTEtMA_39329ec8-1d98-4570-971e-09cffff72762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTAtNi0xLTEtMA_4e34ce57-b394-49c3-b6e8-77fcf984f944">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876974683e3549eea5fc8f61aead1156_I20210930" decimals="-5" format="ixt:fixed-zero" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTAtOC0xLTEtMA_7bca7b40-2c0a-4be3-900e-0ed0e841610c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTEtMi0xLTEtMA_c9181b5b-290a-4499-8862-474be350b5ff">4,640.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTEtNC0xLTEtMA_6484f6fe-ac10-444d-93ed-77766771a2d6">215.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTEtNi0xLTEtMA_446e75be-064e-41e4-a731-d2d505718833">4,424.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876974683e3549eea5fc8f61aead1156_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTEtOC0xLTEtMA_cbe6470f-8ccf-41c1-905b-5342f58bb88d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTMtMi0xLTEtMA_931209d5-098e-469d-b796-931ab1522606">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTMtNC0xLTEtMA_d792cb1b-982e-4c80-bbc9-131b4afbce0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTMtNi0xLTEtMA_bec3e2c3-1bc6-4248-8301-0d8f2dc198d4">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876974683e3549eea5fc8f61aead1156_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTMtOC0xLTEtMA_cc0b91cc-d9b7-4839-8070-93203d5a218a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTQtMi0xLTEtMA_b4fdbdd0-2e65-41d2-b695-9b13a407bfea">210.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTQtNC0xLTEtMA_80b304e9-d066-4d38-bc30-0fffe310150f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTQtNi0xLTEtMA_8bd30e3c-1430-4c8a-a85c-c8f167624805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876974683e3549eea5fc8f61aead1156_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTQtOC0xLTEtMA_896fb00b-f1e4-4f5a-8f2f-cd02e6ce78aa">210.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTUtMi0xLTEtMA_33b4e33e-ab51-478b-9875-608a102eebb4">238.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTUtNC0xLTEtMA_e5ed0c7a-3a84-4b93-ac3e-ea5e9369c4ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTUtNi0xLTEtMA_205f1205-2cbf-4509-b4bd-d4c528b2207f">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876974683e3549eea5fc8f61aead1156_I20210930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTUtOC0xLTEtMA_296eaa72-7a37-4023-a706-5b782a682147">210.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMy0yLTEtMS0w_86cc229e-197d-4a23-84af-0dff2ec8bed4">626.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMy00LTEtMS0w_2ebfe4bc-67c7-4033-aa22-ace5976af836">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMy02LTEtMS0w_f412b351-ac8b-439c-a532-9f892ca4b45c">626.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMy04LTEtMS0w_dde50aa9-fb03-4002-8af2-71fcd1eacd48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81740b779f254c85bdb56c3ede0940b1_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNS0yLTEtMS0w_59ce4d4f-0f2b-4986-8867-29270e973b45">1,301.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd88cfa056ee42b688c44148869a89bf_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNS00LTEtMS0w_f9e6655a-3156-4f5d-b882-a03e9d2f2f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b77bc2d5ca1423eb85a5b99d2103f23_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNS02LTEtMS0w_a1ca30e5-e646-407a-b72f-18fcdfa1e54b">1,301.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669d0acaf9ba4c9faa1e50b3d5545924_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNS04LTEtMS0w_d9658b57-5cc2-4e35-a30a-d8d66f0f1afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2b5503377e4d60a68343ae4a275eb1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNi0yLTEtMS0w_5e72ad02-a4b3-48a2-bd16-8f2e72f5f2a2">627.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aac397904bc47ceb520bf0b28475c0f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNi00LTEtMS0w_06c9fa69-501d-42bd-9520-58769248d788">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973902141e63471a80c622f966bf9204_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNi02LTEtMS0w_d5fe7623-2a84-4e3a-aa0b-c29f0b17ca3a">627.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ea1ef8967d4c89b99809a24bec5629_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNi04LTEtMS0w_5ea1af95-dbe8-4e7c-8fc2-e878dfc33e7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf4f35802694c1fbbae2718a8f12142_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNy0yLTEtMS0w_51bc0a4e-44df-48d9-b067-461c71030e0e">122.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3993b259dd8a435f9cde46b68b063c55_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNy00LTEtMS0w_87020555-fcb5-48fa-b6c4-e5441184f20e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ab4f097e1a4677acea953affeccc39_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNy02LTEtMS0w_27189036-09b4-4cf0-a1f9-0f472d62d235">122.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467f79adfbd4e57b9fa997886b38ba5_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNy04LTEtMS0w_f7ac01db-4445-4956-8e99-60a7ed6b9937">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOC0yLTEtMS0w_2f90ce99-0512-43d3-ba97-33635de24a4a">1,974.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOC00LTEtMS0w_ecf3d167-4b12-49ae-8172-384252f90ec7">271.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOC02LTEtMS0w_3e449c66-088b-4b34-9dfc-13fa3cf492dd">1,703.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOC04LTEtMS0w_58a23497-90de-4a98-bb98-8787862d404f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOS0yLTEtMS0w_b980877e-5b59-46b3-975c-f32a665da419">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOS00LTEtMS0w_34593147-0330-4e33-9325-6236a0f00a4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOS02LTEtMS0w_7531f916-01f9-4030-bed8-3c3812a9669d">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOS04LTEtMS0w_66f513a8-fc05-4ea3-8d46-4ddf5cec5581">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTAtMi0xLTEtMA_1f1e152f-f75a-4f6e-970c-4282e2f07d61">28.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231" decimals="-5" format="ixt:fixed-zero" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTAtNC0xLTEtMA_801b9334-bd17-404d-a739-cb491b20a527">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTAtNi0xLTEtMA_703661db-4e52-429c-bb75-952b626f2ed9">28.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231" decimals="-5" format="ixt:fixed-zero" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTAtOC0xLTEtMA_c484217f-6da5-4611-b231-c0bf777457e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTEtMi0xLTEtMA_22ef57df-98ec-4621-8a10-a701b60aaee8">4,700.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTEtNC0xLTEtMA_8bf3e0aa-4153-4bdc-90a2-4e05d3585c16">271.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTEtNi0xLTEtMA_a55ecb6f-0d9c-4d23-ac86-7fc20a6d04b1">4,429.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTEtOC0xLTEtMA_17b07289-997e-454d-8d63-a82211e27041">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTMtMi0xLTEtMA_04c18240-866c-4242-b6ac-45ed10df351a">217.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTMtNC0xLTEtMA_e53da5f8-be24-49ab-913f-b4ae07ea2ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTMtNi0xLTEtMA_aa0797cd-600b-42a4-b419-f9ecf2d1bc5b">217.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTMtOC0xLTEtMA_06753261-eb90-4429-9f9e-399e85cf7960">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTQtMi0xLTEtMA_f59d1ead-72b2-4741-8c71-328a51bd4d62">259.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTQtNC0xLTEtMA_a4eef917-14ed-4fb3-ad71-0ee3f7ba221b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTQtNi0xLTEtMA_a3349dcb-836a-4de2-a536-d2d90b36ea29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTQtOC0xLTEtMA_45955683-95d1-4075-a2f0-7cd17ceb671a">259.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTUtMi0xLTEtMA_17823c2e-826d-4923-ad56-a3ea03105a0d">477.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTUtNC0xLTEtMA_5790e71c-ec27-4702-a1ef-f5f166c9d642">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTUtNi0xLTEtMA_af2d8ab4-a0d7-4adb-8f1e-14f92df13044">217.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTUtOC0xLTEtMA_51fedc0a-df6c-4143-8a5a-6e3e2c64b718">259.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjgy_ab9a4cf3-3289-4527-9812-bd96885777e1"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjgy_dfc9fbfe-9892-4008-ba01-c32f8fad93db">no</ix:nonFraction></ix:nonFraction> material impairments of our assets measured and carried at fair value during the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021. In addition, there have been no changes in valuation techniques during the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for a portion of our Sangamo investment expired during the second </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="if8272d3f0f95406aac9662cbce65dd82" continuedAt="i4b8a3af5d85e472e9e7f6f3030fc4639"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter of 2021. The fair value of this portion of our Sangamo investment was a Level 1 measurement as of September 30, 2021. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Financial Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of September 30, 2021 and December 31, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfMy0yLTEtMS0w_b4fdbdd0-2e65-41d2-b695-9b13a407bfea">210.7</ix:nonFraction>&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8d75b9475054c6aa2f4631f5a8ef20c_I20210930" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfMy04LTEtMS0w_243dcb53-ae76-4f8a-97ed-c0c30413ae73">0.83</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaefea2e4aa4742fcaf12b2e1a663a4b0_I20210930" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfMy0xMC0xLTEtMA_5e5c4762-8424-419c-81fb-083fcd2c9208">0.83</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 to 2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfOS0yLTEtMS0w_f59d1ead-72b2-4741-8c71-328a51bd4d62">259.8</ix:nonFraction>&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f0a301c1d504d4cb75e0dfdc175fba8_I20201231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfOS04LTEtMS0w_3f917d5e-5518-4afd-b6e3-c87c83969bcb">0.60</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacb3b16cceff4a69b162f9088df8f83e_I20201231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfOS0xMC0xLTEtMA_32bd9a7f-0c22-40a4-924e-cebb8b7a1df9">0.60</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from <ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" name="biib:TechnologicalAndRegulatorySuccessProbability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjA5Mg_0c094c3d-68be-4513-9447-60f079c65c54">10.8</ix:nonFraction>% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, we recorded impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i80bd0b2b32ea4b5680c869f40cc11b5f_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjE5OTAyMzI2MzcwMA_b6e80e1f-f447-4b67-bbe7-e8e72ab37c60">365.0</ix:nonFraction>&#160;million related to BIIB111 and $<ix:nonFraction unitRef="usd" contextRef="i7aedfb52da3b4ed3ae009c32d7af2f34_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjE5OTAyMzI2MzcxNg_44b226d7-fad6-47e0-89e4-c47128e3d01b">220.0</ix:nonFraction>&#160;million related to BIIB112. As a result, the remaining book value associated with these programs was reduced to zero.  For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNTExNw_1f18c0ea-ccc8-4103-82c7-35580ad1c582" continuedAt="i7e52aeda05d44d439b7a19d4334bad1d" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica74fb523d614349a5924b06d1bb5822_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfMy0yLTEtMS0w_5da47ab1-d7eb-4654-a4e1-7899838ca6f2">1,031.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica74fb523d614349a5924b06d1bb5822_I20210930" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfMy00LTEtMS0w_033902dc-c32d-4ff0-981d-478c5ee4569b">998.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d11beb9b3fb491897b7a82b6680ddb2_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfMy02LTEtMS0w_95e27bb9-3c53-44a6-8d27-56abea351c5e">1,054.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d11beb9b3fb491897b7a82b6680ddb2_I20201231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfMy04LTEtMS0w_30b1b04d-748d-4a11-8df0-18f93a8125c3">997.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2d4471ced94158a3b9461f37a5a9b4_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNC0yLTEtMS0w_5dc5c718-1c5a-4226-b6d9-fb0c99b1995a">1,927.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2d4471ced94158a3b9461f37a5a9b4_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNC00LTEtMS0w_23e3f44f-957a-4c4e-b4ee-c017cf8514fc">1,742.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa563a8c541342878a6a7502812ce7c1_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNC02LTEtMS0w_683288f7-932f-41b7-8993-3069427e17e1">2,003.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa563a8c541342878a6a7502812ce7c1_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNC04LTEtMS0w_81490900-61e0-4df0-a57a-1e6d6556adc9">1,741.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9933a802b04b7d8c62324f5f41c52a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNS0yLTEtMS0w_2a8fe049-33d0-4918-b453-474245db6ff6">1,491.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9933a802b04b7d8c62324f5f41c52a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNS00LTEtMS0w_4adb4419-7c6f-4654-a3fb-6dce47ef3f2d">1,491.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a8801ef78b4c00a73f94dd2ce1a172_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNS02LTEtMS0w_83209318-f171-4aa9-9113-cd1900523b8e">1,557.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a8801ef78b4c00a73f94dd2ce1a172_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNS04LTEtMS0w_3a035bc5-a6de-4aad-a976-dc36a3a73465">1,491.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82ded1ca1fa4ec881505e83910f2470_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNi0yLTEtMS0w_6d5daa40-901e-44a0-b249-6fa3dafd54fe">1,468.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82ded1ca1fa4ec881505e83910f2470_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNi00LTEtMS0w_e660f6a3-83e8-406a-aaf4-02a7fb292988">1,099.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819bef58752546e1bbb77cf85e7873c8_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNi02LTEtMS0w_5ed777e0-e012-48d7-8baa-6ae34617a6d5">2,365.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819bef58752546e1bbb77cf85e7873c8_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNi04LTEtMS0w_0c0c8a83-678e-4fd3-8aec-a0f8eb89b3b2">1,723.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e1f0ba26984bf396b6de85e0803baa_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNy0yLTEtMS0w_725378c3-26f1-44e8-9d2e-cad5d734e78a">1,443.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e1f0ba26984bf396b6de85e0803baa_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNy00LTEtMS0w_03149509-cc36-4b59-9e55-2950239f8159">1,473.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe6316e93084bcdb4bab71201828487_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNy02LTEtMS0w_95048d9f-22f9-4af8-a865-64577906f358">1,536.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe6316e93084bcdb4bab71201828487_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNy04LTEtMS0w_b6738bf5-f338-4002-a152-b4038adc5b00">1,472.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53759aa6be6e42a1a94cf191019495cb_I20210930" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOC0yLTEtMS0w_ba54acf0-16c2-4a93-ad0f-85a9109a6619">684.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53759aa6be6e42a1a94cf191019495cb_I20210930" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOC00LTEtMS0w_41fed5e3-9e7f-42af-a642-9f120ac4784e">465.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec1430297504929aeba4396860a0195_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOC02LTEtMS0w_5e952d36-c038-45c7-83ed-207f8dbc3a4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec1430297504929aeba4396860a0195_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOC04LTEtMS0w_5ea52fdd-6a4d-441d-922a-84426fb8b23a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOS0yLTEtMS0w_6f7fd7a4-e9b4-44ba-a253-08e977ce4225">8,046.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOS00LTEtMS0w_7ba650c5-91c4-495b-8351-d0d2acd534ae">7,271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOS02LTEtMS0w_192de73e-3784-41c1-95e2-4e4e449ea13f">8,515.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOS04LTEtMS0w_cfade741-d1e1-423d-923d-666a0562264f">7,426.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i4b8a3af5d85e472e9e7f6f3030fc4639"><div><ix:continuation id="i7e52aeda05d44d439b7a19d4334bad1d"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered <ix:nonFraction unitRef="number" contextRef="ia82ded1ca1fa4ec881505e83910f2470_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMzEwNw_abf5e201-92ff-4f09-8594-00da0b87a171">5.200</ix:nonFraction>% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $<ix:nonFraction unitRef="usd" contextRef="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMzE4OQ_11a6dd8c-f06e-49cb-88a4-31ff7592709f">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes were exchanged for approximately $<ix:nonFraction unitRef="usd" contextRef="icc42842da7bc45f38b433b05022616d6_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMzI1MA_fc7f37b8-28c5-47ad-9620-38568f4de3d5">700.7</ix:nonFraction>&#160;million of a new series of <ix:nonFraction unitRef="number" contextRef="i53759aa6be6e42a1a94cf191019495cb_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMzI3Mg_c93c44ed-027c-4ea4-8d16-c7b24e4b9b4d">3.250</ix:nonFraction>% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></ix:continuation></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNTA4Mg_22c817f7-2eca-47e0-8681-0c2a5caa9a1c" continuedAt="i75b0fa311c904d58847889a78b46975d" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><ix:continuation id="i75b0fa311c904d58847889a78b46975d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad055f43eed4c1abc91e33ba1c4c608_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMi0yLTEtMS0w_633e5a02-5df3-4332-a23f-ef751971b344">226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333a0bfdd0ca4d5180e70ebdd613c08f_I20200630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMi00LTEtMS0w_6512a013-ec7e-416a-a426-0595fafccd03">351.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMi02LTEtMS0w_339519a6-f454-4733-9ba0-7df5547809a8">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dab2decb1da48ad8d4b8e3c14967ebb_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMi04LTEtMS0w_f108c6a7-55a2-4b13-b5c3-876d91b3ce1f">346.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMy0yLTEtMS0w_a0bc14ba-5cd2-4f94-a12a-c5bae9714b80">15.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMy00LTEtMS0w_3d7c555c-2eab-471a-beaa-97640b70f4d5">29.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMy02LTEtMS0w_f1730e18-7b8c-48da-9604-81b8ae4bbb61">49.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMy04LTEtMS0w_e0038e68-e541-4005-9596-717db6ffc5a1">23.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfNS0yLTEtMS0w_089df3e8-0fa2-45ad-89af-abbd62cd1267">210.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7814cf51367420694a7166e5ceff073_I20200930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfNS00LTEtMS0w_0d7a6a17-dd78-4d17-a5b0-e6a0f9a583f5">322.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfNS02LTEtMS0w_c686b7be-7992-4ebf-8550-6d7138699a05">210.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7814cf51367420694a7166e5ceff073_I20200930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfNS04LTEtMS0w_7b74e523-3482-47d5-b057-839457323fca">322.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, approximately $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNDE4OA_8e33c92e-4202-40df-b212-7999ece935e3">210.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNDE5NQ_ba64dc68-4f6f-4a6b-bba7-9b213c73478f">110.3</ix:nonFraction> million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued expense and other.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, the decrease in the fair value of our contingent consideration obligations was primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2020, the decrease in the fair value of our contingent consideration obligations was primarily due to changes in the probability </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of technical and regulatory success</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the expected timing of the achievement of certain remaining developmental milestones as well as changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_73"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Financial Instruments </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTIxMQ_a9071640-e8c8-4c9a-b089-69473b8ec8b9" continuedAt="ib1370454c4f547c4ae5a07486a89c527" escape="true"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTIwMg_75b0f357-5260-474c-a358-e13a845c04a1" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffca47ad8954ffd92872504490dcf03_I20210930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMS0yLTEtMS0w_e9e3bc2e-b9fa-4ca1-ab69-b675b48334cb">167.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77b83c10d6543c4999b42d941ff32fe_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMS00LTEtMS0w_294884ba-d5cc-4150-bac1-33472868a874">61.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if652d73e263246e5831dc57a670a53fd_I20210930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMi0yLTEtMS0w_fe293f3c-ffe2-456f-b7ea-c7f057beb6bc">213.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d676501ffe4026b9c68ccd7f42aeb4_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMi00LTEtMS0w_5d0dd715-b9e0-44f3-b5a4-5d1678d83b6e">37.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df0a9587724904b596ca62dcf43f6f_I20210930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMy0yLTEtMS0w_64ac94ca-e1fa-49de-ba64-b47983778e74">485.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2186b976c0174d35bd3cbdf1c89882c8_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMy00LTEtMS0w_4013bcb2-c547-4d0b-985a-de8434dfb2f2">505.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82eeedaf25949b28400154944eb6b4e_I20210930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfNC0yLTEtMS0w_c4281cd2-6494-4709-bb3a-72f6d4ecbf23">112.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife2f354a35fc496eba95703d7b607384_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfNC00LTEtMS0w_ad5b5a4f-2218-4124-8974-08648fca2375">23.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfNS0yLTEtMS0w_81416ab0-b4d4-4384-82f1-a30fe54f4458">978.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfNS00LTEtMS0w_6432f33f-855c-4a7e-b757-ebd4405e7796">626.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ib1370454c4f547c4ae5a07486a89c527" continuedAt="i560a1f73ef6445ad9b9cce95e121bb4c"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTE5MA_373986ba-93c9-4198-835e-c90e33f2bc06" continuedAt="id4ddbb9e67004c09be07b4cbea853c5c" escape="true">The following tables summarize our marketable debt and equity securities, classified as available for sale:</ix:nonNumeric></span></div><ix:continuation id="id4ddbb9e67004c09be07b4cbea853c5c"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52475161692a4e19be21e73c51c53526_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNC0yLTEtMS0w_f0b0baa7-a30e-4f85-a5dd-184bc4533c07">1,135.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52475161692a4e19be21e73c51c53526_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNC00LTEtMS0w_c93c7de3-a5ef-414d-9201-40df5752e6a9">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52475161692a4e19be21e73c51c53526_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNC02LTEtMS0w_52a5b956-7620-46c9-9a92-9865814b67df">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52475161692a4e19be21e73c51c53526_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNC04LTEtMS0w_d3c7eab4-5a31-466a-b78c-a2a8fdf488fa">1,135.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049d807889c149e8a50eafa9f58bb8dc_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNS0yLTEtMS0w_bff6eabe-4f59-4948-8962-f4235c9e5fe5">350.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049d807889c149e8a50eafa9f58bb8dc_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNS00LTEtMS0w_be99eba6-e16c-4745-a8d7-261570a5b8d0">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i049d807889c149e8a50eafa9f58bb8dc_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNS02LTEtMS0w_6a3aa706-dbee-4f6a-a9f1-b849abb82c19">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049d807889c149e8a50eafa9f58bb8dc_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNS04LTEtMS0w_54d9956d-a679-4fbf-8230-fb0ab446d855">351.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if153048dd394454eb1fb423f72bda912_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNy0yLTEtMS0w_82f84ec3-ae3e-41ae-9ab3-9f837bf41730">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if153048dd394454eb1fb423f72bda912_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNy00LTEtMS0w_89aedec8-05df-4f3f-988a-14e50dbbf746">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if153048dd394454eb1fb423f72bda912_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNy02LTEtMS0w_eb6bf91a-2374-4317-8d37-dbb76a4ae1e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if153048dd394454eb1fb423f72bda912_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNy04LTEtMS0w_05ead992-6f81-4d54-a7fc-456f856250ea">277.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a18efbacb6145cdb2a0021473063184_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfOC0yLTEtMS0w_1c28fa5f-e52a-4e54-94db-bb4bb2537539">435.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a18efbacb6145cdb2a0021473063184_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfOC00LTEtMS0w_93c89ca0-5654-4df4-b618-d218dd71b539">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a18efbacb6145cdb2a0021473063184_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfOC02LTEtMS0w_1eea8df7-e18e-4bc0-9c6e-63e1c71ce5e3">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a18efbacb6145cdb2a0021473063184_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfOC04LTEtMS0w_22059eed-9eb0-4720-99f7-6288681ea642">435.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if70a9c11bf614396a6522c901ecb08f1_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTAtMi0xLTEtMA_41def94d-d716-4b3f-ab2c-2404e1e4f47d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if70a9c11bf614396a6522c901ecb08f1_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTAtNC0xLTEtMA_e4f4fff9-c5f0-4905-a7ee-4bd2d5dffe4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if70a9c11bf614396a6522c901ecb08f1_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTAtNi0xLTEtMA_3a022fd9-8d91-4253-a0e7-ed3b0428d8c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if70a9c11bf614396a6522c901ecb08f1_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTAtOC0xLTEtMA_ba43206a-905d-49a6-b530-5d71c2e2c7f9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if077767e3ef64c2484a2cc92234da011_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTEtMi0xLTEtMA_203574df-0865-48da-9b1a-add42773762d">182.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if077767e3ef64c2484a2cc92234da011_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTEtNC0xLTEtMA_76bdcb17-171d-4fba-889b-36a758a79834">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if077767e3ef64c2484a2cc92234da011_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTEtNi0xLTEtMA_2fa00ab4-baec-4838-91f4-50d4f057e80b">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if077767e3ef64c2484a2cc92234da011_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTEtOC0xLTEtMA_514ef904-fb1d-4083-aac3-fd7c75d0b5a4">181.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTItMi0xLTEtMA_f248895e-185d-4bf0-9266-61f9ee31efab">2,381.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTItNC0xLTEtMA_46794737-fddc-4aae-b6a9-fd6ea004d1aa">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTItNi0xLTEtMA_eeb3477a-efaa-48a3-abac-dcbc30a04b38">1.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTItOC0xLTEtMA_266d35be-f8c5-4c52-92a9-70a892204c7b">2,381.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44917b25ade349a8a5f06df642623475_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTUtMi0xLTEtMA_f1b66c5e-1e96-46b2-b905-1d577e384310">35.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44917b25ade349a8a5f06df642623475_I20210930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTUtNC0xLTEtMA_4cebc78c-071d-4b1a-b354-db95445d0ceb">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44917b25ade349a8a5f06df642623475_I20210930" decimals="-5" format="ixt:fixed-zero" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTUtNi0xLTEtMA_0a02f62e-3483-461f-8e6f-02c347dc8890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44917b25ade349a8a5f06df642623475_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTUtOC0xLTEtMzAyODI_a8836105-6b69-499d-b329-cb0f7fc83d35">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTYtMi0xLTEtMA_03156602-76a9-4ea0-9cbc-63dbc12d67a5">1,133.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTYtNC0xLTEtMA_41b2b79e-069a-433c-ab4b-97133b0d8958">238.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTYtNi0xLTEtMA_1a686ead-7096-4e3e-a43e-a080d6741f63">260.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTYtOC0xLTEtMA_26f53c7d-98d2-48a3-b5db-a9c20afc4ca8">1,111.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTctMi0xLTEtMA_e745a4d1-1c55-40f2-8592-34736373ae4d">1,168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTctNC0xLTEtMA_99cec9da-4e8e-4ee0-84d8-7d52d0391e32">257.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTctNi0xLTEtMA_15865413-ba38-4bd8-9a19-45991714dc4d">260.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTctOC0xLTEtMA_32daf9cc-e42c-47d4-b89a-8c7630546843">1,166.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470da7200d18439f98b62a166787441a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNC0yLTEtMS0w_7c7a4ebe-30a7-453d-a89c-ee893493a416">897.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470da7200d18439f98b62a166787441a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNC00LTEtMS0w_68a50595-20b0-46b6-8266-1e738f536caa">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i470da7200d18439f98b62a166787441a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNC02LTEtMS0w_3825b000-0191-43d3-9aa9-99ceb9a68b81">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470da7200d18439f98b62a166787441a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNC04LTEtMS0w_c6bd7dc7-f6eb-4247-84c9-580b760aef74">898.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3caddce2c0c4c20a79927c2312baf96_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNS0yLTEtMS0w_6fdb2d16-5d54-4b37-9de4-51abee022070">402.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3caddce2c0c4c20a79927c2312baf96_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNS00LTEtMS0w_62ef4e90-6862-47e3-aa07-184815be73e7">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3caddce2c0c4c20a79927c2312baf96_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNS02LTEtMS0w_747a4972-7bf2-490a-890b-79a2f47ab2c1">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3caddce2c0c4c20a79927c2312baf96_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNS04LTEtMS0w_5dc3f539-8a3e-48d0-a530-53207d02dd19">403.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bd7705008143a9ba46119d91dce67d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNy0yLTEtMS0w_7ff7d727-242e-4f70-82c9-078d974f53da">380.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bd7705008143a9ba46119d91dce67d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNy00LTEtMS0w_ecbc6bad-b9fd-4a26-a594-dac3b1b545df">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bd7705008143a9ba46119d91dce67d_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNy02LTEtMS0w_873f3cb5-4af9-4653-b99e-a4503e6a613b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bd7705008143a9ba46119d91dce67d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNy04LTEtMS0w_e7a519ad-7f86-4caa-b078-9aa6be27843f">380.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfcb2b7a789408ab7429d172cf3b595_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfOC0yLTEtMS0w_fe98623e-f1a2-4dcc-ac24-3b5ebf69a309">245.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfcb2b7a789408ab7429d172cf3b595_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfOC00LTEtMS0w_d4cf15cf-c97b-4d2f-8209-f8d6f708aaaf">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfcb2b7a789408ab7429d172cf3b595_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfOC02LTEtMS0w_94c2e014-d520-46c7-beac-98c8780301b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfcb2b7a789408ab7429d172cf3b595_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfOC04LTEtMS0w_3b5e112a-f83d-46c5-8055-f5c64108385d">246.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7673265729c248e8b545dd7073d36204_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTAtMi0xLTEtMA_9731bccd-338c-4b45-b6cd-0ff4df6db0c1">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7673265729c248e8b545dd7073d36204_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTAtNC0xLTEtMA_bfce90c3-6a62-430e-a209-88921ef8a3de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7673265729c248e8b545dd7073d36204_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTAtNi0xLTEtMA_ab6ff231-138b-4ba4-9577-29d8c0104ae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7673265729c248e8b545dd7073d36204_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTAtOC0xLTEtMA_6f6175eb-6164-41c7-ac7f-a7e74d4e71fb">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea3ebd667744c9381c73def31f719fe_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTEtMi0xLTEtMA_b11c6bd0-7f4e-44df-bb40-05c8b33635e9">122.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea3ebd667744c9381c73def31f719fe_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTEtNC0xLTEtMA_01c4b3f1-05c2-4a4e-8fe7-e1f39c7ff5ba">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idea3ebd667744c9381c73def31f719fe_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTEtNi0xLTEtMA_a7609db6-1c5f-4e19-aea3-3da022338e85">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea3ebd667744c9381c73def31f719fe_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTEtOC0xLTEtMA_a69ec626-7273-4f87-a226-e3631e79277c">122.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTItMi0xLTEtMA_4db7c4cf-94c1-47e8-a77b-4c234703f612">2,049.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTItNC0xLTEtMA_6a73760d-36c1-4f6c-a7fb-714c9f938406">2.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTItNi0xLTEtMA_6d6b5279-41d9-4823-8b3f-40b36c855f3f">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTItOC0xLTEtMA_134f7440-920b-470e-a575-e8a5d7f73761">2,051.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2c365225e34a9da8933f6b3cbf7de6_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTUtMi0xLTEtMA_e1c1a366-6fa8-48ce-a7e2-e2446c702b88">70.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2c365225e34a9da8933f6b3cbf7de6_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTUtNC0xLTEtMA_03adcbde-8334-4092-ba0f-d0976044f296">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2c365225e34a9da8933f6b3cbf7de6_I20201231" decimals="-5" format="ixt:fixed-zero" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTUtNi0xLTEtMA_9d61462e-35d0-49a6-a437-14460c9ef52b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2c365225e34a9da8933f6b3cbf7de6_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTUtOC0xLTEtMA_bebd9ac4-e55c-4033-9ab8-1f134dd276e2">86.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4655f3abc15413baad6a40cd42927c5_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTYtMi0xLTEtMA_6d240362-4d0f-4852-bb4c-5eba266cc30f">1,168.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4655f3abc15413baad6a40cd42927c5_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTYtNC0xLTEtMA_48c7b8bd-35d9-4830-b9fa-6c907f0b0cae">733.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4655f3abc15413baad6a40cd42927c5_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTYtNi0xLTEtMA_a2175604-e726-4f6e-8a57-05ff5b124fbd">14.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4655f3abc15413baad6a40cd42927c5_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTYtOC0xLTEtMA_99ff0a04-8ea5-4b4d-847b-e17d441bb02b">1,887.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTctMi0xLTEtMA_b49285e8-77b3-4a92-96f5-a956d5ee629b">1,239.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTctNC0xLTEtMA_abcf3c68-9928-4d6e-906a-2b3f90f8fb93">749.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTctNi0xLTEtMA_dbf0381f-fc63-4a86-833b-c22623971307">14.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTctOC0xLTEtMA_8305a51f-5cea-41c8-bac5-d6eee533115b">1,974.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i560a1f73ef6445ad9b9cce95e121bb4c" continuedAt="i98c8bbe736fb4aaeba6b96c51d483eac"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTE5MQ_54ed28f0-dbc9-44da-bba4-519b2be451f2" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMi0yLTEtMS0w_d97f743c-e119-4338-999b-4ce1962438f7">1,413.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMi00LTEtMS0w_62aff1f5-f85d-4dda-9916-c636086e710a">1,413.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMi02LTEtMS0w_f981478b-ad3a-4957-8b34-c7727c2de157">1,278.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMi04LTEtMS0w_aeadf1b7-77a0-42b7-8d6d-9b584ebb4f75">1,278.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMy0yLTEtMS0w_cdc4f9d3-0778-4119-bf07-558c3a2d5090">925.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMy00LTEtMS0w_7c899fb3-a9b9-46b9-bb2d-f33186824662">925.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMy02LTEtMS0w_9dccf430-c221-4456-9dd2-58f3000b6064">722.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMy04LTEtMS0w_238b749b-208f-4898-b078-aa53674409ee">721.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNC0yLTEtMS0w_8d265078-d43d-479c-a6cf-c06aaba2dba8">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNC00LTEtMS0w_8c0cd720-6326-4d9e-9231-8f58c2aeece6">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNC02LTEtMS0w_05644fe5-dd81-4bbf-9df6-49d704a0e481">49.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNC04LTEtMS0w_568e127c-34c2-461d-aecf-f01722596801">49.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNS0yLTEtMS0w_6d4b2633-e385-4f06-9f11-c9a855adbb05">2,381.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNS00LTEtMS0w_e037bef4-6c46-404d-968f-3688ae36fe66">2,381.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNS02LTEtMS0w_651e41a7-aec1-4a6d-80f3-94ff6ce86917">2,051.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNS04LTEtMS0w_9619ae7f-6b36-498e-9dbe-12c93ebe948e">2,049.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of September 30, 2021 and December 31, 2020, was approximately <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMTAyMw_31dbc7c9-3aa2-4c48-80a7-382d0653f886">12</ix:nonNumeric> months and <ix:nonNumeric contextRef="if87653e954194d689bd182fc5b42da74_D20200101-20201231" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMTAzNw_e0b82f91-7754-4159-8389-b01a1790a43b">11</ix:nonNumeric> months, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTE5NQ_424b02fb-09f8-4ce7-ba30-1bfc7c5b7fee" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:43.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMi0yLTEtMS0w_9cb2fa8d-e923-40da-8dfd-151d894b1392">575.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMi00LTEtMS0w_7243fe40-a47a-4d4f-85e9-1deec71c90db">1,360.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMi02LTEtMS0w_29b6d45e-a8c0-43f5-a24a-0ac7958dc030">2,028.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMi04LTEtMS0w_d52db38b-0442-4b38-a5b8-976af777d086">5,240.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMy0yLTEtMS0w_d13b8c59-47f7-4462-a62a-c548bd526ac6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMy00LTEtMS0w_3c83702a-292d-4424-8705-450e13794bfc">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMy02LTEtMS0w_08759dba-c444-466f-906d-4dc2eac3b2bc">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMy04LTEtMS0w_686a9c57-3905-47b4-bd12-27474cecb367">12.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfNC0yLTEtMS0w_ebd7078b-18c6-49b9-b7d6-b4f09ca696d6">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfNC00LTEtMS0w_c031f0ae-d132-443d-80b0-1ec0dc072db8">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfNC02LTEtMS0w_10e1089b-4b5f-4f6c-b54a-cc7bbc1c91fc">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfNC04LTEtMS0w_a2ab5158-5305-4c58-9fec-345f22046186">25.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="i34d19a6c1cce48f890b4ff8854eb063e_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMTM1Mw_ca857933-7eaa-47b0-9dc3-29b04b09de48">1,222.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia67769f4d9c64b70b1ee25a453d4c188_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMTM2MA_1d3870e2-ef84-44ae-b898-d56d6f4c0143">2,024.6</ix:nonFraction> million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio for the three and nine months ended September 30, 2021, was primarily due to decreases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the fair value of our investments in Denali, Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMjQ2Ng_888c760d-b56b-4f3c-a845-e6175728d0ed">650.0</ix:nonFraction>&#160;million of Sage common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMjQ3MA_fc3f42df-4272-473c-973e-c57e8f141cab">6.2</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="INF" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMjQ3NA_2d81b58e-e068-49e7-a1f5-f14808704a17">104.14</ix:nonFraction> per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="if7c54edc6349456abaaa90d10aa21a29_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="biib:DividendYieldPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzEyOQ_243fe287-d894-4637-8854-7045fa9399c4">zero</ix:nonFraction> based upon the fact that Sage and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i98c8bbe736fb4aaeba6b96c51d483eac"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately $<ix:nonFraction unitRef="usd" contextRef="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzUzNw_6e20d8e5-d23e-4ffc-9078-d9ca338a5278">465.0</ix:nonFraction>&#160;million of Denali common stock in September 2020, or approximately <ix:nonFraction unitRef="shares" contextRef="if8b5d9e350944ffdad686ff95dd1085f_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzU0NQ_96dfe927-f8bf-4032-a8f5-9f38a647d366">13</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzU0OQ_1346b44b-01ee-4e49-bffb-63c454ffc772">34.94</ix:nonFraction> per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i2f721455f7aa4586a968ec0031e919d8_D20200901-20200930" decimals="INF" format="ixt:fixed-zero" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzgzNg_ff79a3c7-b93e-4ff0-ba91-383d8dc7ee90">zero</ix:nonFraction> based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDE5NQ_8b76c249-5726-4861-a144-6e5f1c2ea28d">225.0</ix:nonFraction> million of Sangamo common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-6" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDE5OQ_96b27272-81b8-4f50-8394-25e5b1a99ae2">24</ix:nonFraction> million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDIwMw_594b7d56-d232-4ec1-8da5-ebbf70f9cdc1">9.21</ix:nonFraction> per share, of which approximately <ix:nonFraction unitRef="shares" contextRef="i8ea2f828e08946f9bfe96108463cde78_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDI0MA_f736b3cc-d8fc-499b-bd25-5c9a22c3dec1">12</ix:nonFraction>&#160;million shares remain subject to transfer restrictions as of September 30, 2021.&#160;This equity method investment is remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i2139678da5ba44c692cbccf26f3f86ad_D20200201-20200229" decimals="INF" format="ixt:fixed-zero" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDkxOA_ea45ab58-c519-40a2-8299-e6999cad5bcb">zero</ix:nonFraction> based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_79"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Derivative Instruments </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk2OA_455b93d5-8d99-491d-80ba-7d8887a72fed" continuedAt="i4694fa45fb73457287bc830621219f13" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of September 30, 2021 and December 31, 2020, had durations of <ix:nonNumeric contextRef="i2c77f922da23412fad540d818c968248_D20210101-20210930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjIz_035ad2f6-3216-4d19-8788-cb281c15b8f7">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i6cf82a6b484d49e69065707a4f3422d8_D20210101-20210930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjI5_6008b8fd-1f37-4bd0-821b-be169dd5e779">18</ix:nonNumeric> months and <ix:nonNumeric contextRef="ic165a79eab2e42c1a838d2b473206e5a_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjM2_2f86d7ca-3b27-4fae-beea-49fd1654f41d">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i1d4b70e429084cd896ddee8ad6a86f58_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjQy_56fb7550-4a8a-4e65-9a53-bada8ecc1413">24</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i4694fa45fb73457287bc830621219f13" continuedAt="ieba67a6e5fe44f93979ba857ae786afe"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk4OQ_23eea25f-4af2-4d4e-8a90-d24a10bce64a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55d56fb32ff46218a8edddf870dc788_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfMi0yLTEtMS0w_16bfff56-709d-4684-9319-0ad3b8b79b35">1,901.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic059a695f5624475b5bce97e745827bd_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfMi00LTEtMS0w_13d3fef5-1085-42e1-a472-4fe3abd05416">2,979.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id661e83da0184b60b9078c3003d2d512_I20210930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfMy0yLTEtMS0w_10376261-379e-4e54-8752-e9467a506e67">63.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f88181fe304ebb96cc0a68b0ae12ba_I20201231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfMy00LTEtMS0w_1f792083-7a45-4ec6-8392-25d0019ba159">250.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03aec522673d41f1bcbf6cdcdf6cac4d_I20210930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNC0yLTEtMS0w_c11cb641-37bd-4eaa-9adf-295d344af250">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if46410444ba14e6092450fb22efffc1a_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNC00LTEtMS0w_3d6e459e-b6b9-4bce-a41e-eafa2fb0ec8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882caa9f1b214f12a34a044e78765486_I20210930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNS0yLTEtMS0w_ce2d9f78-ed82-4e53-a274-0f3bfc94a725">30.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8af15663b9a4d8d94e49f9f51c463d6_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNS00LTEtMS0w_d5833593-5bb9-4ccc-bd3e-98b890a10dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d2d53f1521473fb2e87b588a892372_I20210930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNi0yLTEtMS0w_ef9a5de1-c0e3-43a8-b089-028e4c328e32">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cf121e430342109d49fea777e579bf_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNi00LTEtMS0w_f27ca7f4-7be6-47fb-ac17-9850367811cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac6c255d1f3477ab244bffeaf22cfc6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNy0yLTEtMS0w_08a6476b-8466-4950-817a-01819a5f9ea2">2,080.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a88eef09354000953b0bed96387192_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNy00LTEtMS0w_071a8a98-2370-4e7d-9f98-c7b2a1dad672">3,229.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of September 30, 2021, reflected aggregate net unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMTgxOQ_f60a37ca-8980-44e0-a8c1-c5b77a9f4f4d">21.9</ix:nonFraction> million, composed of gross unrealized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMTg3Ng_0ff6741a-84f0-465f-b501-29acb96de9a0">38.4</ix:nonFraction>&#160;million and gross unrealized losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMTkyMw_586ff4be-c85d-46ac-9583-24db9fe34a0d">16.5</ix:nonFraction>&#160;million, compared to aggregate net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMTk3NA_609ebd86-8569-42f3-b793-52d4f5bbed1a">212.5</ix:nonFraction> million as of December 31, 2020. We expect the net unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMjAyNg_f60a37ca-8980-44e0-a8c1-c5b77a9f4f4d">21.9</ix:nonFraction> million to be settled over the next <ix:nonNumeric contextRef="i6cf82a6b484d49e69065707a4f3422d8_D20210101-20210930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMjA1Nw_380c7109-0ae1-4472-8a89-2f7055526838">18</ix:nonNumeric> months, of which $<ix:nonFraction unitRef="usd" contextRef="i70ca240b4a8a434dbdfdea26e500aee9_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMjA3MA_af9a35d0-d09d-4b25-8c4f-afc72435559e">9.6</ix:nonFraction> million of unrealized gains are expected to be settled over the next <ix:nonNumeric contextRef="i01b54841e3504571a9b44de5987e542d_D20210101-20210930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMjEzNQ_6f567fc2-1609-4491-a065-cec9fd455fe2">12</ix:nonNumeric> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk2NA_2482d18e-8899-4072-ad8a-621821d815f6" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie35d98789f1244be9ad4952ccbcc7c4e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfMy0yLTEtMS0w_394d65f4-655a-48b3-849d-9c9b99c073c8">14.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06a80f6779864dd992819b8e00be88b8_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfMy00LTEtMS0w_6114d87b-eea0-4c90-98b8-19d3fe42e4e8">9.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib71e595781d44f16ac699138752f0bc8_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfMy04LTEtMS0w_121ccfcc-53d5-4f2d-a806-0e89d2234951">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cac1f347b104a4ca1db20bec5c47875_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfMy0xMC0xLTEtMA_f96a8b83-9849-46c1-be05-5a2485c430d3">8.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7c37dca65684a5e9f14392ae29cbaaf_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfNC0yLTEtMS0w_69bb84b6-a48a-446c-b9f0-5ee2e743d36e">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3ff6d74036499d8a7471834819584b_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfNC00LTEtMS0w_a9ac3f84-93f8-44d2-ba87-f13d203c9545">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica4d96484afd47e3875930a4f7e88de5_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfNC04LTEtMS0w_67f8d827-1ffe-4d84-bc91-6fe4a31a9cab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7805cce3a52041d3b30f7a27f60fda1e_D20200701-20200930" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfNC0xMC0xLTEtMA_058bd27f-c032-4a4f-a657-9baef9037eb4">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic725003c511544d9beede7d62b22bf41_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfMy0yLTEtMS0w_6d75584b-f8e8-4ea8-a8cb-88fcfe23b1cc">68.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021468994763467d8c149cb0f1b5dc8c_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfMy00LTEtMS0w_4c362ece-5730-487c-a02b-da4a147b8c7b">41.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05a13a77e61439a8dd0d989c1ff1052_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfMy04LTEtMS0w_286cf95c-34cf-470b-91f9-e2e019ae2bea">4.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7069a9554d224968b39144be715d4ba2_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfMy0xMC0xLTEtMA_3d85cbe7-59da-4c0b-9be3-a8e97b940201">1.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i954add7d31b64b3698c2961782705265_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfNC0yLTEtMS0w_27d45d7b-1498-42f0-8f4c-0d06b1cb19c1">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i662080f3255e4599a8eb926798a5d4f1_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfNC00LTEtMS0w_a4ef4cb1-e37a-4a15-8b37-488acbe06e07">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d1ad6684545445c81eaf1e55b9da3a0_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfNC04LTEtMS0w_bb598dbd-d342-463c-820f-85531d9fc82e">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if04673d30367460fa2896b503cf49adc_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfNC0xMC0xLTEtMA_9ce7802b-a1c1-480b-9618-63b0ce2a20b3">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Contracts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of our <ix:nonFraction unitRef="number" contextRef="iadac69438a134e4685f396b8c53251d4_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzA1NQ_78d51bac-1fac-42e3-98c0-54d3b1f3ab0b">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i25c14487107748cf8adf0aa48b1089e7_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzE2OA_7d552f0c-1026-4e9b-9d95-35a8f3019368">675.0</ix:nonFraction> million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our <ix:nonFraction unitRef="number" contextRef="iadac69438a134e4685f396b8c53251d4_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzMyMw_78d51bac-1fac-42e3-98c0-54d3b1f3ab0b">2.90</ix:nonFraction>% Senior Notes attributable to changes in interest rates. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our <ix:nonFraction unitRef="number" contextRef="iadac69438a134e4685f396b8c53251d4_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzQ4MQ_78d51bac-1fac-42e3-98c0-54d3b1f3ab0b">2.90</ix:nonFraction>% Senior Notes, resulting in a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="ib4f3485174db4d7c876667900c74e5bf_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzUzNQ_3314b152-054a-4418-bd6f-4945ac76c5bc">3.3</ix:nonFraction> million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ieba67a6e5fe44f93979ba857ae786afe" continuedAt="i6cca6d2d32704bb48af27c5f555f6b46"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="ifa2615942dbc42b59096307ded3cc0c3_I20200930" decimals="2" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDA0OA_7ab0906b-cc1c-4313-b171-a2e493889692">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDA2OA_9cf11c30-fbbc-4cab-af2a-eea0fe4cf3f3">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="icc31d40d106d4c9f992098cfdbc25314_D20181101-20181130" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDE2MQ_22b20347-bf26-4484-9885-4f1310055d04">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="icc31d40d106d4c9f992098cfdbc25314_D20181101-20181130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDE4Mg_68f31942-cfe6-4e09-9f78-97336e227413">676.6</ix:nonFraction> million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of September 30, 2021, had a remaining duration of <ix:nonNumeric contextRef="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDU1NQ_26b9dafd-213b-401d-94e2-ba6bbf6739da">one month</ix:nonNumeric>. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $<ix:nonFraction unitRef="usd" contextRef="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDkwOA_304cbb65-1865-4846-a904-63d257065131">25.0</ix:nonFraction> million and net losses of $<ix:nonFraction unitRef="usd" contextRef="i32d14a7ea6f44f81ab85c9eb63555a65_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDkyOQ_f25713ec-1554-43d7-b93a-f6f435d86569">21.2</ix:nonFraction> million as of September 30, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $<ix:nonFraction unitRef="usd" contextRef="i8b619c6a194a48d79f50c3ece23badc4_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNTM2NA_a4d7b5ce-061d-4042-b4b0-3078da66d91a">0.0 million</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i71ead7913c08409dbc2595365e9f3e52_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNTM3MQ_a8bd2028-b31b-40ba-9cdc-68b0b8adc58a">0.2</ix:nonFraction> million as of September 30, 2021 and December 31, 2020, respectively.</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk2OQ_2bba5fa9-99ca-473a-9533-a809a2647392" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c68d2f0c36b4aa0873859e893028f61_D20210701-20210930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy0yLTEtMS0w_1540f903-5a53-4258-907a-54c8d6622d1b">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie613980df7054b379c880bbe236bd443_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy00LTEtMS0w_77571e65-e225-4cb3-ae8d-ef8c1f945cbf">10.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c68d2f0c36b4aa0873859e893028f61_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy04LTEtMS0w_8aec8e6e-d61a-4ad5-951d-673e177c1e69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie613980df7054b379c880bbe236bd443_D20200701-20200930" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy0xMC0xLTEtMA_e146a426-cdfe-4ca9-924e-92b76fc30408">0.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3d42fc3ea64bd198bebd63ceb7ccd7_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy0xNC0xLTEtMA_d26ac8e2-13b1-49f4-9a11-2b6f86afb614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dd1a2f10914daa9af2e90f8b3c8807_D20200701-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy0xNi0xLTEtMA_3c60dffd-088b-405a-99cd-74c2b70c47bb">0.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy0yLTEtMS0w_6f4f8c80-bd98-4270-bfb2-fd4aa5b85d8f">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1200adb5dbe47c7ae6a9a4a6961c216_D20200101-20200930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy00LTEtMS0w_a3d2b41c-8869-4592-8cff-2205a856a584">5.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy04LTEtMS0w_372eac42-bed4-4e5b-a36b-a8bf6fc3859d">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1200adb5dbe47c7ae6a9a4a6961c216_D20200101-20200930" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy0xMC0xLTEtMA_38214b85-8758-462a-ab8f-8ac9383891e9">3.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c93a139bb224308a3c7a36175e4107a_D20210101-20210930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy0xNC0xLTEtMA_327e45cd-a5ea-42c9-a87f-b3c06074538f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic554f230362f471382f660791fcc865b_D20200101-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy0xNi0xLTEtMA_e192674b-1601-4176-be0d-c4a8d31f514a">2.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="i0a7748b009f646c8b31119a5c17aae59_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjA5MA_cf5fdc4c-89cc-4be9-8324-8055609ea305">1,400.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib61f3acadd75433c99101969cf66411c_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjA5Nw_e3959888-ffe2-45f0-9d73-17422f293db6">1,158.0</ix:nonFraction> million as of September 30, 2021 and December 31, 2020, respectively. Net losses of $<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjE0NA_0e796297-c3c1-464b-9a4b-03cfd82da11d">13.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjE2NQ_18f7292b-d8fd-4361-9732-6575376721ec">26.1</ix:nonFraction> million related to these contracts were recorded as a component of other income (expense), net for the three and nine months ended September 30, 2021, respectively, compared to net gains of $<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjMyOQ_df99a7a2-c8e4-4e0d-8712-0ce3c735c6a1">7.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjMzNg_9763b831-62a8-4587-ad24-d6248de238db">13.7</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i6cca6d2d32704bb48af27c5f555f6b46"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk2Ng_c37eb5dd-98c9-441b-af04-3da212675678" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6968467d8d7b4c5c8a741ebc7f01c64b_I20210930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMi00LTEtMS0w_ec4b39fb-ed99-4ded-b77a-439c99627a1d">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd697e3d7934db0959c809bdc451568_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMi02LTEtMS0w_fb568790-e6ca-4362-a531-33a3ea61fa7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481db3700c604a1bb15870d0cef6b1ad_I20210930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMy00LTEtMS0w_1214f71d-3e63-4718-9a8c-e17e6f17c0d3">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e3b2b199db482c94d883952512475d_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMy02LTEtMS0w_875af8cf-7aea-4a3a-b759-87cf2dc34ead">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icffd2e05c3e949db9d2bb4ffb7775e8a_I20210930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfNC00LTEtMS0w_f737580e-7817-492e-9baa-cd6e5c7244ae">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fd194e4f7a43a08b6a326d74102423_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfNC02LTEtMS0w_c37c9133-e51c-4334-b50c-bb0a55c6c054">157.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8a70ef8aa048c2a91453d9a5dc5e74_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfNS00LTEtMS0w_d3edea73-5573-4ecd-8988-2d8a43b9807a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69578acd699b413fbb7d39b34e455de0_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfNS02LTEtMS0w_886e9b5e-484b-468c-aad5-a2615bffec89">35.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb8a04e2884668aba19d51821c5e40_I20210930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfOC00LTEtMS0w_c9a91e99-2fa9-4b6c-99cf-69dfbe08d5ad">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10aaea33d60c4e62b5c5437eb9aeef95_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfOC02LTEtMS0w_a48c6150-3344-4797-824d-8b19acfda3ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib911d65ad5594eb4ac4bcf4afb56823b_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfOS00LTEtMS0w_fe5abcf2-321b-46db-a4f8-0188d4ea6a82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a39e90d5a084a6a82c0789525824916_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfOS02LTEtMS0w_6ed949c8-f314-44c0-96b9-92b0e2ccdf71">19.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d23192df14482d8fa3fe146523c99f_I20210930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMTYtNC0xLTEtMA_a0bfe09d-3359-46ad-876c-0698eb03ca45">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib101119d811b445ea7aebef90a37dad9_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMTYtNi0xLTEtMA_ed14edc2-8ddc-4348-9706-c5c871f1461c">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15bfdcd49c954e93ab09b4090c28ce32_I20210930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMTctNC0xLTEtMA_f63f9e8a-034f-4cfe-97cd-48b653e12ca1">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6b9edb2b704d33991c8e9a2425f671_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMTctNi0xLTEtMA_9857a2ae-3aba-48c6-a33f-5fe7b41bb703">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_85"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Property, Plant and Equipment </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMTIwMQ_13e52fc7-086c-46f1-bb2b-03b81f764bab" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMTcx_3dcbe556-764a-4dd6-b042-067ab578eb0c">1,944.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMTc4_ebf2de70-70d0-4de3-ace0-1e4fbe5acb34">1,782.3</ix:nonFraction> million as of September 30, 2021 and December 31, 2020, respectively. For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMjc2_c1308655-ed47-4d0e-bee8-c47c2a9932f2">65.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMjgz_e64bb7a1-9772-425c-8321-11dd0dc2536c">168.7</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMzEz_e89816f4-e817-4226-9620-a070325f80f5">51.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMzIw_936a7685-7b6f-46fb-97cb-b3bfebac8fae">151.2</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include <ix:nonFraction unitRef="sqft" contextRef="i5f65716caa83413388dac812d8d3219e_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfNjI2_0055d5cb-db46-4a38-b6d3-dae9541ccbb1">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="ib7a3fd2b017b41fbb6dbb92df1d7ee68_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfNzAw_3d4b5708-de6f-4a81-9fd8-e80c5b057e01">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="i7855fb28a23947d995189305bed5f12b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfNzYx_8e230958-e017-4b2a-a2b8-89702189a61d">51,000</ix:nonFraction> square feet of administrative space. As of September 30, 2021 and December 31, 2020, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i16b2d0a2aca64df688f77a7ea041914b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfODM5_b43bea80-6957-4251-8327-58e95e27a416">661.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i237f7b94a47e4d618bf0d30b1872ccd4_I20201231" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfODQ2_d2ae910d-8b2c-415e-9ebf-94b7ee5a504a">1.8</ix:nonFraction> billion, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="i16b2d0a2aca64df688f77a7ea041914b_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMTEyMw_c0b54e97-6e25-4e55-8d91-359fb88b4b99">1.2</ix:nonFraction>&#160;billion of fixed assets being placed in service during the second quarter of 2021.</span></div></ix:nonNumeric><div id="i8046a3e69c814e7f9967395f631661c6_88"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMzU2Ng_abfb09d2-d930-443d-ba91-f5e04a306bbf" continuedAt="ic0005ec7b25844ba80644ba94085ecf8" escape="true"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indebtedness</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:nonNumeric></div><ix:continuation id="ic0005ec7b25844ba80644ba94085ecf8" continuedAt="i3fd96fb161c149feb42e3ee0f537b0df"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjYx_059dfa3d-16a9-4876-b0d8-dbcc89221336">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="icc42842da7bc45f38b433b05022616d6_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMzU0_a15eee32-63c4-4df6-b34c-63e312086ddd">700.7</ix:nonFraction>&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i726364fc850f428980b41bc6bf6ead64_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfNDI3_83b78f97-8f17-4119-bdf1-5edbca6fbe2f">151.8</ix:nonFraction>&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="biib:DebtInstrumentRedemptionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfNzM4_5706b248-86f1-446a-bf7b-04b65126c7f2">8.9</ix:nonFraction>&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfODEx_f3fb8a56-de35-47dd-a76b-8cc14d1183ca">12.1</ix:nonFraction>&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ic94894775dbe4be685e8410ac06fb197_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfOTYx_80c162ad-0c58-4d0c-ae35-4165757cc940">3.2</ix:nonFraction>&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i3fd96fb161c149feb42e3ee0f537b0df"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="ic94894775dbe4be685e8410ac06fb197_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTQyNw_0f608d33-4bb9-4c44-aaf9-764c287c5372">13.8</ix:nonFraction>&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ic94894775dbe4be685e8410ac06fb197_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTU5Mg_1e33569f-ebf7-4567-a2b3-4fded7d81366">6.1</ix:nonFraction>&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Senior Notes </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ic351f5dbf270449286ad0664853e2842_I20200430" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTg4MA_7e4c2fa2-485e-476c-b50d-57f9158de2ab">3.0</ix:nonFraction> billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$<ix:nonFraction unitRef="usd" contextRef="i21dab209cac741b08e2660f13a98e869_I20200430" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTkzNA_274eec0e-09fa-4c89-890d-241a95102037">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i21dab209cac741b08e2660f13a98e869_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTk2Nw_e38beae6-9e21-4ba9-8025-5a7af9e0d872">2.25</ix:nonFraction>% Senior Notes due May 1, 2030, valued at <ix:nonFraction unitRef="number" contextRef="i21dab209cac741b08e2660f13a98e869_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjAwMQ_f99c942e-f132-4b81-afa8-25a167d63fd1">99.973</ix:nonFraction>% of par; and</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$<ix:nonFraction unitRef="usd" contextRef="i75a580abd0df4408a90cb100e5c26f1f_I20200430" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjAxNg_dd425f43-2472-4c91-ac41-19cf15bcccd5">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i75a580abd0df4408a90cb100e5c26f1f_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjA0OQ_49becfa3-dda2-4dab-ac6c-2ef9f2d89dac">3.15</ix:nonFraction>% Senior Notes due May 1, 2050, valued at <ix:nonFraction unitRef="number" contextRef="i75a580abd0df4408a90cb100e5c26f1f_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjA4Mw_543de700-4eba-470a-a4a5-bc66242992ef">99.174</ix:nonFraction>% of par.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjEyMA_e96d2b2a-5f5b-4712-bbc9-048175539799">24.4</ix:nonFraction> million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.90% Senior Notes due September 15, 2020</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjUxNw_592e0268-9095-44ab-9ce3-b13faa3bc26b">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjU1MA_296fbf94-84ad-4538-ab2b-c25b9d6ea547">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, at <ix:nonFraction unitRef="number" contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjU5Mw_a9438c05-864d-49f6-b0d6-652d202d7cd4">99.792</ix:nonFraction>% of par. Our <ix:nonFraction unitRef="number" contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjYwOA_293362bb-8a03-4901-81a7-d4b9ab06856a">2.90</ix:nonFraction>% Senior Notes were senior unsecured obligations. In connection with our <ix:nonFraction unitRef="number" contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjY4Mg_296fbf94-84ad-4538-ab2b-c25b9d6ea547">2.90</ix:nonFraction>% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our <ix:nonFraction unitRef="number" contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjg5MQ_ad872204-c77b-413c-8993-d0fc88d44971">2.90</ix:nonFraction>% Senior Notes prior to their maturity and recognized a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ibb73b7afe9dc4434b6d819770e912b56_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjk3MA_4b22d4ed-ad7f-42dd-8eb1-9f69a610d699">9.4</ix:nonFraction> million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $<ix:nonFraction unitRef="usd" contextRef="ieb5ca321d1584c1ca6bcd8f53d653612_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMzIxMw_b3129ec1-5be4-442b-860c-0d1777f26579">12.7</ix:nonFraction> million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $<ix:nonFraction unitRef="usd" contextRef="ib4f3485174db4d7c876667900c74e5bf_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMzM1Mg_3314b152-054a-4418-bd6f-4945ac76c5bc">3.3</ix:nonFraction> million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_97"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Equity </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTgwMA_8910d6a1-7270-4d17-a2ec-0c6126576fa9" continuedAt="i14b15a8c02b446d489d67ead87b3019c" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i274d98ffd7f54b12bbcbb430a7f6446b_I20201031" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTEx_7462722c-61e1-4e50-9fd9-f94aa45b2610">5.0</ix:nonFraction> billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="ib3a02d5c86ee49cea24a7e5760768b86_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMzk2_36d6c5ac-20e6-4921-9822-740807781116">2.2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i106acfed1b1d45288e2c252eaeee518d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNDAz_1e084d7b-1d62-4d3f-9f31-dd9d61ce8533">6.0</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="ib3a02d5c86ee49cea24a7e5760768b86_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNDYw_872f64d4-a937-46f4-8d9e-a28c4d849362">750.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i106acfed1b1d45288e2c252eaeee518d_D20210101-20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNDY3_02de5e30-0402-4e1a-bfb5-396755131aa5">1.8</ix:nonFraction> billion during the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, respectively. Approximately $<ix:nonFraction unitRef="usd" contextRef="ic4f828fb4a924f93bdde2fb608c2e829_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNTM2_10ac2939-1a3b-46e8-a9cd-6173c0edbcf9">2.8</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="if5c2e8e8d01b426285c6bd058cbb4b5a_I20191231" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNjc4_18cf3bd1-f9d7-45b4-95c3-ed9f7ca988bf">5.0</ix:nonFraction> billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i1a59c92aa5cf4dffb7a826f5ebeb931f_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfOTUx_f7fdd6b1-ee2a-4654-a2f1-e9cc860b83cf">4.5</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i939d909bc5be42e6be0dc04dd1a39954_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMjE5OTAyMzI1NzM5Nw_76e4292b-2a91-4403-b022-90bc28cdf0dc">16.7</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i1a59c92aa5cf4dffb7a826f5ebeb931f_D20200701-20200930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTAxNQ_6b295904-3093-4a6f-81d8-1aaca9105dfd">1.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i939d909bc5be42e6be0dc04dd1a39954_D20200101-20200930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMjE5OTAyMzI1NzQzNw_e69340e6-0aac-4da2-bf6a-fe37c0c42395">5.0</ix:nonFraction> billion during the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i34a8fc959a0849088adcffcd36d82f66_I20190331" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTE0OA_5aecfcb8-8c36-434c-af39-9f7574bfa00d">5.0</ix:nonFraction> billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="iddfc2c0b58ff4cc1b94d1cdf49392372_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMjE5OTAyMzI1NzQ3MQ_00b125bb-7eba-41ad-83a4-ccec148dc966">4.1</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="iddfc2c0b58ff4cc1b94d1cdf49392372_D20200101-20200930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMjE5OTAyMzI1NzUxNA_05da2d07-6b1c-4fda-84c0-b743cb88904d">1.3</ix:nonFraction> billion during the nine months ended September 30, 2020. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i14b15a8c02b446d489d67ead87b3019c"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTgwOA_ff9507f4-26ce-46c9-91d8-b865a51e6ad9" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9d05f7c1a74459b89c4ececa72d31d_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS0yLTEtMS0w_4d0578cd-f210-4f28-811e-d1d2803eaff5">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1948d85fab604db881323ed2ad598c59_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS00LTEtMS0w_06a9eaab-aa56-47df-9e07-6252181a92ed">179.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73ce415c72f84e7faa6119e5db9ec7f1_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS02LTEtMS0w_3a75cbc5-7689-4e9b-b1d9-d1e7a726f774">8.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica50ab9119b04010bd04bd7d82bce622_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS04LTEtMS0w_6b7b4e08-f477-4cd3-b899-302a3c7a9134">66.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3612de0f43644d784871ebe849c27ea_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS0xMC0xLTEtMA_7f514187-682f-453a-95c0-3aa0560ce5fc">46.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS0xMi0xLTEtMA_8e3d3631-9535-47b8-9874-87f5468489a8">299.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id753ed956fca4c9697045d3b819e7684_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi0yLTEtMS0w_569cb6f8-63d0-40ba-aebf-4cf5d823e016">2.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516bbb796f934334a222a0fa68f96141_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi00LTEtMS0w_a4cd7321-e44e-4366-846e-b1df32f23fe0">143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61dcd7cc49f41c0936daa62cdcbb1c6_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi02LTEtMS0w_e0347495-8a68-46a6-ba6d-7bd568545d54">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f19acba9b346f8805c6bdd01935668_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi04LTEtMS0w_9fc98fa2-a3cc-49be-9f67-be514807e73c">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62f0df97465f48e7b7873ed9e345c3b9_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi0xMC0xLTEtMA_fc20f917-1d29-4e53-b6a8-fd7e5ccd32d1">80.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi0xMi0xLTEtMA_a2a61c17-2e3c-4741-8eb7-a1f6025eb2e9">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id753ed956fca4c9697045d3b819e7684_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy0yLTEtMS0w_d2ac4c86-c7fa-4c97-bd73-5ddf411efacb">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516bbb796f934334a222a0fa68f96141_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy00LTEtMS0w_3ab96fc0-4d13-4285-b842-3db3c21d05e4">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia61dcd7cc49f41c0936daa62cdcbb1c6_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy02LTEtMS0w_29b13df0-2d4e-48b4-afa1-82e716ca4d22">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f19acba9b346f8805c6bdd01935668_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy04LTEtMS0w_b0bebb11-b8b4-4fbc-b722-4172c9e7fc31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f0df97465f48e7b7873ed9e345c3b9_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy0xMC0xLTEtMA_82ab282b-eb8e-4bfc-8fec-29d4e83cc488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy0xMi0xLTEtMA_b4cf8664-e6b4-4186-a7bc-7b1fd4cac61c">63.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id753ed956fca4c9697045d3b819e7684_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC0yLTEtMS0w_62b0ebd1-28fc-40a1-bab2-b59a5696dd0d">1.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516bbb796f934334a222a0fa68f96141_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC00LTEtMS0w_b1b89331-b827-4788-b0e4-e06b6d86b713">205.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61dcd7cc49f41c0936daa62cdcbb1c6_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC02LTEtMS0w_35d06516-e754-4713-a13c-98736ee43424">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f19acba9b346f8805c6bdd01935668_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC04LTEtMS0w_86dc8ab4-e131-4ea9-933c-a910027b2b6d">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62f0df97465f48e7b7873ed9e345c3b9_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC0xMC0xLTEtMA_1cc71c2b-fdaf-4846-832a-f2c79cab2b2e">80.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC0xMi0xLTEtMA_13dd0d4d-c98b-4f82-aeab-de09eb386c55">162.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0f729cc7834d838ef13e90b13032e8_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS0yLTEtMS0w_091b882d-5f85-45b4-aa02-32bb6dafe508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea582ea5aa4f4a669db07ca5961b838f_I20210930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS00LTEtMS0w_e5994f11-71d2-4a0a-9c73-d7faffa05ca5">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife32845f8f56459b828af29f233cea3e_I20210930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS02LTEtMS0w_d6fb8af4-823f-4c98-ae90-9d6c668f54e2">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3f6137620d443d38f5a57b1cc4509ac_I20210930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS04LTEtMS0w_8d5a0d16-7761-4955-beb2-748ebfd47ae6">62.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8488f37532d44598b640e3d982bd4d1a_I20210930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS0xMC0xLTEtMA_ce9f0315-0acd-43e3-9abd-dfd05c0abe64">126.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS0xMi0xLTEtMA_3c9a04bd-b9c4-4594-bf21-b8634e7b5665">136.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7aa58f98c924adeb22065e220c2905c_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS0yLTEtMS0w_951f4529-d040-40fe-8bc4-e0c3a2f4de55">4.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5170241300904fbea34b8142ff2a821c_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS00LTEtMS0w_01b1217d-e9d2-4cf3-a457-954cb70a0a85">7.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8165a95911864bcfb5491d08afc84e94_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS02LTEtMS0w_e683e92a-be07-4c15-9c09-559deede1036">25.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i165acb4a2b0d43dd81d356c112615871_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS04LTEtMS0w_f5b03e62-bd76-472c-ba71-977af5c6b4fb">32.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28faac3c4e4b4accb6e60a468b175a53_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS0xMC0xLTEtMA_085dce68-fc19-44c9-88ab-c8c9de55aa71">139.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i378cd243ed9e40c2932d604d62dcff73_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS0xMi0xLTEtMA_7ca05fde-31a4-4a58-abc9-4ea1ca5f2843">135.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13ee975c61c5467f9516d04c8a1176f1_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi0yLTEtMS0w_6629d72d-8037-43b5-baaf-4f6f29f820dc">8.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife1921ce00c34a2eb95d9de3595c2be7_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi00LTEtMS0w_a9e73b3d-40ad-47d2-a541-0db97a9afa02">58.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c516cacf404828b016eddc54887f05_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi02LTEtMS0w_429ebdba-c388-43e6-921a-77eda4fb3d61">8.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7179a8875e614260b2c6e1b4cf82c9d1_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi04LTEtMS0w_b8e8aa66-6745-40d6-9794-2cb0e6dbdc17">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1f03f52650459fa99a8fe57031cfe6_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi0xMC0xLTEtMA_a2508e67-cf6e-4e21-bd46-12d5fc1dfed0">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi0xMi0xLTEtMA_acddcb30-2a6f-4427-b3e1-f85818de2e40">54.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13ee975c61c5467f9516d04c8a1176f1_D20200101-20200930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy0yLTEtMS0w_a976e7e7-0ac7-4398-b6eb-48edb1a1e3a6">9.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife1921ce00c34a2eb95d9de3595c2be7_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy00LTEtMS0w_cdd6a715-0c00-4c68-93c3-2d624f3352bd">43.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3c516cacf404828b016eddc54887f05_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy02LTEtMS0w_c271fd5c-c776-4197-82b6-633404620777">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7179a8875e614260b2c6e1b4cf82c9d1_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy04LTEtMS0w_4e60f310-5023-4ff4-9bda-9b0d6958543a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1f03f52650459fa99a8fe57031cfe6_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy0xMC0xLTEtMA_3563a14c-c901-4954-9313-53d6bdc8f193">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy0xMi0xLTEtMA_e4fb042b-3f70-43fb-bb7f-a7eb1223c82c">35.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13ee975c61c5467f9516d04c8a1176f1_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC0yLTEtMS0w_d12936cb-093d-4377-a706-616b8071e877">1.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife1921ce00c34a2eb95d9de3595c2be7_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC00LTEtMS0w_51c0fe21-0441-4940-a077-3d6e6ee92eb9">101.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c516cacf404828b016eddc54887f05_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC02LTEtMS0w_92452e49-8313-482d-a112-e83c9f44c98f">5.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7179a8875e614260b2c6e1b4cf82c9d1_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC04LTEtMS0w_f9709c26-1de3-4153-95fb-8a97df9a1bec">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1f03f52650459fa99a8fe57031cfe6_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC0xMC0xLTEtMA_a1fe6fc2-9b54-4fd4-acc4-521d9e8d9a2b">3.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC0xMi0xLTEtMA_159f0888-7308-43d2-a5c5-709c5dc4c0b1">90.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c86dfc3e9ee4f10af73ad81268a63bc_I20200930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS0yLTEtMS0w_6d852207-971a-497a-b14f-324ace6a3774">5.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b3ea666a48f4ea79d28dc480c0ac8f1_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS00LTEtMS0w_a36e8bbc-e554-455c-aff1-577c1bbd731b">93.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d395dde98524fa2959805ab74ab926f_I20200930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS02LTEtMS0w_b4282685-b17a-433e-a432-98b7e6e649ce">30.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b817c4f2c748f4ad54ab609bcb7259_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS04LTEtMS0w_ebf28916-8be0-47df-8e48-e1e3885edcc9">32.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4e79c56dd794f2c98635556f462cf4d_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS0xMC0xLTEtMA_a7a6b799-3a41-4c4c-9649-13dfd474ec9b">135.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd54a75bdf44146a9c81439174f3e10_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS0xMi0xLTEtMA_754b410b-46e0-4c04-b973-9925d3ed6500">225.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTgxNQ_891cca8d-9e0d-4196-a939-db85bf31962e" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.006%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b67fb3aa82d43ffbf26b48ff2d8f1c5_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMy0zLTEtMS0w_a1a2e98a-e73b-4500-abb8-7d71df91a317">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0fc8c7198a43d9b9d0c99f6121cd13_D20200701-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMy01LTEtMS0w_ef1a27a4-f9e1-4348-b02d-d4e2b6ec7f56">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fa38f90595e4e8fbfab0ba144b401a0_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMy03LTEtMS0w_63191598-d210-4ea9-bff9-08f918d7a012">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf8e0d7f30d8409cbfc5630b9d2bc341_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMy05LTEtMS0w_a8957ee7-b297-47db-91c7-52a6a2eab303">12.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b67fb3aa82d43ffbf26b48ff2d8f1c5_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNC0zLTEtMS0w_5f095204-8e73-48d5-81ff-971a17ea7b5b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0fc8c7198a43d9b9d0c99f6121cd13_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNC01LTEtMS0w_97e24f8d-bcd3-414e-a3a9-224597b2b237">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa38f90595e4e8fbfab0ba144b401a0_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNC03LTEtMS0w_73439122-f12a-4423-b1cb-45408ac6366c">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8e0d7f30d8409cbfc5630b9d2bc341_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNC05LTEtMS0w_1106b558-6ed5-4bcf-b56e-8933d518ceb8">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNi0zLTEtMS0w_a78f49b5-5762-4b20-8afb-2ca61bcaebf8">14.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNi01LTEtMS0w_97edba0c-b25f-4024-89e2-97e77d9b5ed7">9.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idde20bc926894280b4ff61e91056fe72_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNi03LTEtMS0w_6684dccf-14a8-487e-a5c0-84793c55fb88">68.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8175286262ae459f85852ea172fe0373_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNi05LTEtMS0w_8dd9019d-b990-41d0-b7f3-8fad55b15ed9">41.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNy0zLTEtMS0w_cac58eb1-507c-461a-afad-6e210962e082">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNy01LTEtMS0w_35840408-3059-455d-8b02-923b365c86bc">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idde20bc926894280b4ff61e91056fe72_D20210101-20210930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNy03LTEtMS0w_e6be18ad-a26d-4666-baed-f100766b15c4">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8175286262ae459f85852ea172fe0373_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNy05LTEtMS0w_eaa56c46-5acc-4984-ace0-527cbcad1b44">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOC0zLTEtMS0w_c3129ebd-644d-4ade-8f1c-f011fed8b8c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOC01LTEtMS0w_6bb491bc-8b18-4303-b8f3-9c0b1f584db5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde20bc926894280b4ff61e91056fe72_D20210101-20210930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOC03LTEtMS0w_aee613da-301d-40c3-bd12-b9ba0c716d12">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8175286262ae459f85852ea172fe0373_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOC05LTEtMS0w_1985d420-9305-41ea-818a-414b9c35b760">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOS0zLTEtMS0w_4d8eaf8c-6529-499b-af66-09246f4d54ce">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOS01LTEtMS0w_a53e1848-11d5-4cc6-8c61-e4cf5cfc0504">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde20bc926894280b4ff61e91056fe72_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOS03LTEtMS0w_e320fb06-348e-46c2-ba21-c4ca0621986a">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8175286262ae459f85852ea172fe0373_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOS05LTEtMS0w_edb094fc-8662-48a2-952f-2113fcbaf276">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia346a814aa4d4577b59b906128f24eec_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTEtMy0xLTEtMA_8597a4d7-4af0-4f84-9e7b-5f8e60b64bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2e8e85ac5a4488b1adc8af19f319e2_D20200701-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTEtNS0xLTEtMA_e4a83212-a8f6-425c-9c51-b4c7cdf934d7">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143c1628336040789355760a0e36cb04_D20210101-20210930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTEtNy0xLTEtMA_a5d7add0-f15e-4bb2-9967-5c3ff0c6f256">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib270c515c868406785b1ede039e1e002_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTEtOS0xLTEtMA_992074f6-4d04-40d1-b11a-3684e84672c9">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibade6508c50c4f938133f3c022f3073f_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTQtMy0xLTEtMA_e871d765-bbcb-47c1-938d-226cf1d58d29">14.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6013739ca1f54a5290b712e2dc11f329_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTQtNS0xLTEtMA_f5230586-8d63-4225-8840-e2bbdcb592b9">6.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a6fcfcabe5d445a9761fb8678c669c8_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTQtNy0xLTEtMA_370eb868-10cd-4511-ba4b-131d9ec8d58f">63.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f010fdc6c5e44c2868aa793118a0276_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTQtOS0xLTEtMA_d8960e54-c288-49ad-ac8e-b0008eb562d8">35.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_100"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Earnings per Share </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90ZXh0cmVnaW9uOjVjZjI3NDJhNWQ2NDQ1Mjg5ZjhkMWRjNDgzNzUyYmYyXzI2MQ_53264f4b-dde6-4a1e-8489-95482034b179" escape="true"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90ZXh0cmVnaW9uOjVjZjI3NDJhNWQ2NDQ1Mjg5ZjhkMWRjNDgzNzUyYmYyXzI1OA_2d49e6d2-9a19-49eb-bb4c-0d59b80cd943" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzMtMi0xLTEtMA_eb1219c2-aaff-48de-9820-8750f3709cd0">329.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzMtNC0xLTEtMA_5e844396-8c7a-4c36-bc2c-46d4eb61b3be">701.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzMtNi0xLTEtMA_18236b9f-eaf3-4caa-86cd-c51dcf10afc8">1,187.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzMtOC0xLTEtMA_7a774652-573f-40cb-81c4-d3065d13e3cf">3,642.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzUtMi0xLTEtMA_253d7685-d00d-4d52-b337-a038882da16a">148.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzUtNC0xLTEtMA_84129242-b0bc-4b3a-9af1-ec873e073312">156.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzUtNi0xLTEtMA_12998b78-b75a-4e68-b6c6-f24f83957ee5">149.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzUtOC0xLTEtMA_4b48819c-bcb2-4609-b117-964d83ad7de1">163.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9679d28935fc4a48900189cabb13e5d9_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzgtMi0xLTEtMA_b2f36d70-ef0a-41b8-8d4d-dddff69350cf">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39e962f11bcf4bd980fff4715c3da316_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzgtNC0xLTEtMA_653b1807-f7aa-4310-8726-57fc42240179">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id98346bd89964dedadb43377f44a0d31_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzgtNi0xLTEtMA_a0ea4f3b-9cad-4325-bd16-0c21c3f578ca">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39a105cc514f40d7bf0743359acd5400_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzgtOC0xLTEtMA_2f80d8be-d6b4-4ac1-bcf8-4935c3b41b3f">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id274468946a6454ca8c80e958563c1d5_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzktMi0xLTEtMA_bf62fc7a-e036-47b9-b83c-1d3167f0ed0d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23430e509b1b4117915b80c09a42657d_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzktNC0xLTEtMA_ecc3b83c-9977-4fa3-b4ca-35333c555183">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i379169127f2b4a9395ced61d3e36c9e6_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzktNi0xLTEtMA_b6992d55-a01a-4d80-9d04-d3d4c261bbaa">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if014c19f237748bd8ee32127e024b863_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzktOC0xLTEtMA_48d2213c-d1ac-4e5f-b57f-f10d23951f4f">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i477a6cb8b52f4f929eda17ce6dce344c_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEwLTItMS0xLTA_d8c22e21-f33b-4774-b427-01fbe26938f5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i150f4a13b0a145e8bf65f5c84097ec47_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEwLTQtMS0xLTA_5038a19e-df23-4084-b437-5f6859a1e5a5">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5ee866dd4344c0aa14cebd1e0c79e89_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEwLTYtMS0xLTA_634654d3-24d4-49c8-abc4-139423a0b342">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75aa8742f42b41689c3d73f6bb82b7dd_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEwLTgtMS0xLTA_d30fec87-ae70-4255-bb86-cda79b4b088c">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzExLTItMS0xLTA_b43aa29b-fa8e-4957-a241-e5186b4be754">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzExLTQtMS0xLTA_5ee0606b-6895-4fa8-9080-86ff345f208f">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzExLTYtMS0xLTA_558ff2c7-d244-417d-9f23-ac588351f940">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzExLTgtMS0xLTA_6c4758d2-ee6a-4739-b288-074d6228639b">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEyLTItMS0xLTA_ad9d1ee9-03cb-493b-b317-426c91b8c75b">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEyLTQtMS0xLTA_4349f918-d4fe-48f7-bc16-8945c5fb8150">157.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEyLTYtMS0xLTA_ac8d46be-968b-4dd6-9d6e-cbda6a4b2d1d">150.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEyLTgtMS0xLTA_598cba8d-4cda-462a-8d96-a078bd70d76e">163.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div id="i8046a3e69c814e7f9967395f631661c6_103"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;Share-based Payments </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90ZXh0cmVnaW9uOjNiNzY2ZmQyYWQxMDQwMzliNmNlZDRkODMxMmMxNzIyXzY1Nw_9c2663dc-c661-4aab-ad73-34525c7772de" continuedAt="i1a90e77c394543f5bb623cd62ddd5f5a" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90ZXh0cmVnaW9uOjNiNzY2ZmQyYWQxMDQwMzliNmNlZDRkODMxMmMxNzIyXzY0NA_5f5c1d86-ccfe-443e-9713-71146e363c41" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7000526ec07f428091319155849fd704_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzItMi0xLTEtMA_20e10872-1163-4e4c-a722-3a6073dc1254">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6747564e0b4a938f03505b3f95f165_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzItNC0xLTEtMA_3451de84-a21e-47b2-837f-d64e8e34b5e8">14.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699b74e5bbfd4779a582c698d788d790_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzItNi0xLTEtMA_4d356af3-e8bc-40b2-9e4c-98d3bd961ff0">72.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied525c1179a741bb82b1d583a76e51e5_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzItOC0xLTEtMA_baae39d6-2754-455b-abc5-834a95d0cb83">63.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1924f4ee8f43ee840ee57aff81df9e_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzMtMi0xLTEtMA_3926228c-fca7-419c-8f2d-aecd3c6496d6">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d39579533114f4aa354f18fd1f299b5_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzMtNC0xLTEtMA_e81e2c51-9225-45d7-a5ff-26d7873e22b7">25.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654d114f9573429998ad4856d6fefb38_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzMtNi0xLTEtMA_e0edbba0-a661-4186-901b-ea24990bc915">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i677267ca7d7e48f68e24c2371a4dffd1_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzMtOC0xLTEtMA_9aebb04f-7ad2-4f3c-8fa7-3a456ab0936c">98.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzQtMi0xLTEtMA_cfdc47e0-1ddd-454c-a524-c9b2f99ae3be">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzQtNC0xLTEtMA_c36a9427-4abd-4c2b-8fb9-e3a312a86338">39.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzQtNi0xLTEtMA_381ddcc9-a745-4d03-95e0-22aaf7eba64f">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzQtOC0xLTEtMA_cde51b46-ca96-44b1-8525-ed6a59645211">161.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzUtMi0xLTEtMA_c15a27b0-bade-4196-87f5-1ce113c69e95">1.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzUtNC0xLTEtMA_51d9ba0a-54f6-4d14-b43f-c34176767b9c">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzUtNi0xLTEtMA_f6c9944c-70a8-4183-adbb-4cf16ba6198b">6.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzUtOC0xLTEtMA_0c5a5aa4-b826-4775-a599-7e69118101ac">4.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzYtMi0xLTEtMA_c2ad3c0b-9609-4a1a-93f0-bec5428143ed">60.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzYtNC0xLTEtMA_df0accd3-1acc-4490-82c2-eb0508891ab3">37.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzYtNi0xLTEtMA_8f0efe8a-8f49-495c-85df-02665aec18cb">193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzYtOC0xLTEtMA_6f645c0b-8ff3-4f39-ad7d-ab73e728b2b3">156.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzctMi0xLTEtMA_37884d48-76b7-4721-8e3c-7fab1afa4a2d">10.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzctNC0xLTEtMA_b8aa2839-d3ab-4c66-b285-cb3e268be6aa">5.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzctNi0xLTEtMA_3e32a11b-c509-4512-9d77-f7fb685e2b90">35.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzctOC0xLTEtMA_4a447cca-0bc4-403c-a987-90da3d89ba00">25.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f1075481e74bb98a9b2a2d1b4673ae_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzgtMi0xLTEtMA_5034b2ed-f92c-480e-abc6-70759b4affe4">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd96e2849ae7466dae303c5a5b80c085_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzgtNC0xLTEtMA_9350fac8-04d9-42a1-a343-80499f178115">32.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f267df3ba84643b8bffb1e5ff56f47_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzgtNi0xLTEtMA_8c127faa-5591-47fc-aecf-22825e23ccc6">157.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib258d211097b4e64aa9629510fd53154_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzgtOC0xLTEtMA_2a27de54-57ce-4b99-94f1-2f739e5dc369">130.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i1a90e77c394543f5bb623cd62ddd5f5a"><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90ZXh0cmVnaW9uOjNiNzY2ZmQyYWQxMDQwMzliNmNlZDRkODMxMmMxNzIyXzY0OQ_b53b5fab-f69d-4a23-bc91-f34106d2d523" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f98bd41f384786a46e50b06a48f2d3_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzItMi0xLTEtMA_dd780476-6c40-44ef-9202-5d4fa7d12a44">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2953a813c0d9467d9ae9f1e794ec1fd2_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzItNC0xLTEtMA_3e126013-95ac-4d8b-99f0-408f6d145671">5.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e1e20ca1e74fe0b437961b9da435a4_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzItNi0xLTEtMA_b3b88653-a279-4cd5-9f2d-9419fb90e360">35.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if314461b1e5b4baea50b55cd17fd0538_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzItOC0xLTEtMA_76f6c218-f5af-44f3-8fd5-fceebbf165ff">32.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b90ed783cf34d47b1bd424e613386be_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzMtMi0xLTEtMA_45342586-dee1-4618-b787-df4701eefb2a">38.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaae1cc404f343c5bfb355c19f2dd60e_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzMtNC0xLTEtMA_aaabad11-c32a-40d1-bd0f-57c3d15c8003">35.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i266dc39128f9407d870c90b7e77122dd_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzMtNi0xLTEtMA_42cd0b3b-11e9-4a39-a5c1-15e49d2a737d">121.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c913a6dc6e40f3a5994b325c0067d5_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzMtOC0xLTEtMA_4a8eb34e-26e1-40c8-b326-66ef4b505e47">107.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790bc65eb68c43b0a56d4a861411da6d_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzQtMi0xLTEtMA_b5a7fc7b-7f46-4509-9e41-740d90184837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc3cf0a2cd74d61854096f0dc29d4bd_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzQtNC0xLTEtMA_c1dbebac-8f9e-4d54-be76-d9558bff802e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2401c248b54473d9de51f32724fa7d4_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzQtNi0xLTEtMA_3fa51e7b-05e6-41a2-aa73-046b73cf8031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05dbc5642aa740e898a9288a14e80f49_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzQtOC0xLTEtMA_503b3860-1567-4d18-9c07-884eca3ee13f">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248e2c4fa3d34b269a285cb1c63488bd_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzUtMi0xLTEtMA_39f0fe6f-067a-4dd3-a712-1d72a5a08203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09ba7df5db74e13ba503168413abdff_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzUtNC0xLTEtMA_fe3f5667-206b-43c6-bcac-7090f1b0fdf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444b41b2ae2d4e7cb1136b88ed82f8aa_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzUtNi0xLTEtMA_0afa5adb-e4b1-442d-8a0d-425f4550b4de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0e35f43cb26444f81cfaccaad8eb9cc_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzUtOC0xLTEtMA_c907b1c4-8aa0-40df-9066-8145161a78ce">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fa67b093a54744bc17319d4330b45a_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzYtMi0xLTEtMA_a4b7e68f-72ca-4830-9cbd-8f589d862e17">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebee12b1fdff4baab053967a2a218895_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzYtNC0xLTEtMA_3a58ff6e-03c8-457a-96a2-f52b171b8d27">8.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2515997127460a88ce3b7721c7f899_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzYtNi0xLTEtMA_878cc984-bc66-4c69-9374-93c22a6ffa38">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if816cbeb32834f9c892e3d50f230ae8b_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzYtOC0xLTEtMA_37f9acb4-4258-4226-a4fe-6644343cb552">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3ef8424e944022bba6665e253acdec_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzctMi0xLTEtMA_30f2bd3f-6122-4308-b80f-9bc7f15b46e4">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410aa53688a4c78b85ff75528ef68ea_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzctNC0xLTEtMA_26f61322-4190-47a9-afb4-8a04d432c007">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f86bfff90443dfad344994aa697b38_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzctNi0xLTEtMA_63c8fe69-8cfe-4765-8cf1-85120bcdb6ea">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia721ab9e8edf4ed7a17168531a631cd0_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzctOC0xLTEtMA_26190a28-f5fc-4811-8957-04638e0cf0f2">9.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81620b24a824ca2a03f609c9a047932_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzgtMi0xLTEtMA_bf75e1b5-5400-43c0-be1b-7d8d8db232d3">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f850ed68f24c55bf0e191cf454be49_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzgtNC0xLTEtMA_0494928f-6d32-4e50-9d4b-50e434e28e15">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e940795a93d480cba3bee92ea71cde2_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzgtNi0xLTEtMA_d8320362-e820-4c8b-b26f-6a24762e048e">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38006411cd644bd9bb6a9f6aff3265f7_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzgtOC0xLTEtMA_cbfab432-f159-43d4-9b35-7da1b270223e">11.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEwLTItMS0xLTA_200a3b31-b739-478e-a004-dc39b855387e">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEwLTQtMS0xLTA_92dc5898-db89-4dc4-bf62-808990c9d45d">39.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEwLTYtMS0xLTA_54aae79a-ddf5-4a91-84e6-b7cee998e4d0">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEwLTgtMS0xLTA_b5355a51-43f5-4195-8ed8-f83d04273ed8">161.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzExLTItMS0xLTA_e2251072-7c63-4f23-8cbe-3ac085c08912">1.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzExLTQtMS0xLTA_f2283b8b-c310-427e-bb77-df3098d52e2c">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzExLTYtMS0xLTA_7613591b-a29d-4bef-a0c3-69bc668d3476">6.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzExLTgtMS0xLTA_014c7fb6-e703-4279-8fcd-d2e967be4ecb">4.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEyLTItMS0xLTA_2514bc16-b15b-4438-ad60-b37650c7c00f">60.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEyLTQtMS0xLTA_86732372-525b-46ed-9a67-7f1549fd1748">37.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEyLTYtMS0xLTA_47aee989-33e8-4bf1-8885-642ecb74de7d">193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEyLTgtMS0xLTA_aa2ba233-518b-4dde-ac9f-1a19d0a08235">156.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_106"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;Income Taxes</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzUyNTE_b165067f-f5e2-4b98-92a9-27c1ff9e2be6" continuedAt="i093fa897aada4f439091d79796bcfe78" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $<ix:nonFraction unitRef="usd" contextRef="i28adb3330230472e88334d479def96ab_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:DeferredTaxAssetsValueReductioninValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzEwNDA_8c151713-0721-4fe2-8ee2-6934799896af">1.7</ix:nonFraction> billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $<ix:nonFraction unitRef="usd" contextRef="i28adb3330230472e88334d479def96ab_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:DeferredTaxLiabilitiesValueReductioninValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzExODU_5f6d1ec9-218b-40b3-9b78-5f5260f1e101">1.6</ix:nonFraction> billion. We continue to assess the realizability of these deferred tax assets and have recorded no changes for the three months ended September 30, 2021. We have recorded an increase in these deferred tax assets of approximately $<ix:nonFraction unitRef="usd" contextRef="i92a13aa4f4d447958145380700133524_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:DeferredTaxAssetIncreaseDecreaseInValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzEzMzQ_13079c19-8475-41e4-b65a-35b31d3f69b0"><ix:nonFraction unitRef="usd" contextRef="ia13f165b3be34174b50cecb4c27778d9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:DeferredTaxAssetIncreaseDecreaseInValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzEzMzQ_3ee62982-fbc5-4f89-9e94-e7d2fd083fd7">92.6</ix:nonFraction></ix:nonFraction>&#160;million and an increase in these deferred tax liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="iee279a7d1aed471ba23a5d4e8f28794a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzE0MDQ_01911dc1-71c6-4fec-8d08-626461578761"><ix:nonFraction unitRef="usd" contextRef="i756f3f5bdda54726bce4b571b4493a2a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzE0MDQ_2851c16d-af1b-4686-b4f9-e0ec5092503f">88.7</ix:nonFraction></ix:nonFraction>&#160;million for the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i093fa897aada4f439091d79796bcfe78" continuedAt="i4883e683ca29460bbe0893eba5a89566"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzUyNjY_43c8e483-118c-4511-b496-24cc70825865" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzItMS0xLTEtMA_626c8a53-2266-4d11-9757-60c6fbcc0970">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzItMy0xLTEtMA_23364fbf-3230-483e-8d62-9f40f92bd552">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzItNS0xLTEtMA_02d64532-764e-4d18-a67f-6ef3a8e8f4ae">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzItNy0xLTEtMA_4b414697-aa06-4c80-b9fe-21f2648ad993">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzMtMS0xLTEtMA_8eae01df-da10-4605-ba9a-329114d81f8f">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzMtMy0xLTEtMA_fda0f282-3ccd-4d9b-8d6c-bc8d4354964c">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzMtNS0xLTEtMA_5d84b2de-a6b0-41e2-942f-46348258cd5c">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzMtNy0xLTEtMA_de5e9e28-1c9f-4873-956d-26e22529105c">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzQtMS0xLTEtMA_b89942fa-1959-4159-ae8d-8aa616c3b514">20.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzQtMy0xLTEtMA_ba11843c-0401-4de3-a39c-6724ad3f729f">3.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzQtNS0xLTEtMA_46e13a53-017b-4822-a082-8f93840a3b92">11.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzQtNy0xLTEtMA_d5b1d962-9421-4f79-8b16-dea9771dd51f">3.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzUtMS0xLTEtMA_f7d35dd3-430b-4ecd-a0b9-2bd9c07d7e78">7.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzUtMy0xLTEtMA_dbb3a288-5a65-4cca-a86e-a14d3a44f886">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzUtNS0xLTEtMA_4788defc-32f3-4f67-bd1c-c2f633201f2a">4.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzUtNy0xLTEtMA_a480d8c4-967f-4889-b650-0767613c678f">1.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzYtMS0xLTEtMA_cb5bb650-cea3-4175-bc2e-4d94c092b489">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzYtMy0xLTEtMA_f7211c22-9e82-4fe0-a023-0b8e309722a0">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzYtNS0xLTEtMA_86ba3594-9824-4718-999c-d4c177c4f25a">1.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzYtNy0xLTEtMA_8f8bf1ec-3ad6-41e4-815f-0551ccec6506">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzktMS0xLTEtMA_e34e18b9-85be-45d5-9bc3-d0e4988eb0c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzktMy0xLTEtMA_4480f7c5-d769-4bdf-ac40-2331e1e9ae27">3.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzktNS0xLTEtMA_165fe3b5-b751-46a6-a0ed-97d15e402a0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzktNy0xLTEtMA_fa6797d9-64df-46af-b5e2-b042a1461c49">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEwLTEtMS0xLTA_fa93226f-06e2-4e14-9ecc-3bbe70d53b45">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEwLTMtMS0xLTA_b3fd660a-aba3-41a6-b9b0-714fb5446dd0">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEwLTUtMS0xLTA_8d670715-e726-45bb-a1dd-9d9c0c903b74">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEwLTctMS0xLTA_3a85319e-e306-47e3-85f4-f0a18d7e5672">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEzLTEtMS0xLTA_b87d7cfb-80f8-4ab9-a3fe-56b9f639ebd5">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEzLTMtMS0xLTA_2356b83e-6631-4687-8a4f-7bfe31a63aa7">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEzLTUtMS0xLTA_886a71b6-aefe-459f-9206-9130c4c57324">36.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEzLTctMS0xLTA_89ca36b0-7380-4f45-a451-0e63d2ddf2c3">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE1LTEtMS0xLTA_a57c2bde-9c66-4bfe-9dac-fd0a0e61dc72">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE1LTMtMS0xLTA_abef6015-177f-46e5-b6e4-7c889e4f89d3">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE1LTUtMS0xLTA_b4e6ad70-6a42-43eb-9cae-a59f707f3b70">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE1LTctMS0xLTA_14c2ef1a-f2eb-4815-afd1-5cc1f7f9fa9e">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE2LTEtMS0xLTA_7df0488c-5f74-4831-938b-063b88774e6d">8.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE2LTMtMS0xLTA_b414b1b1-3ac5-4541-98bf-d27f8e486450">25.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE2LTUtMS0xLTA_5b77f7e6-18d2-4b68-96e4-326f9758e7eb">29.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE2LTctMS0xLTA_655083da-0661-4b8d-af6a-36a7ab4928f4">20.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset discussed below, were primarily due to the change in the territorial mix of our profitability, which included the adverse effect of generic competition for TECFIDERA in the U.S. market; the tax impacts of the BIIB111 and BIIB112 impairment charges; and the impact of the non-cash tax effects of changes in the value of our equity investments, where we recorded unrealized losses in 2021.  The tax effects of this change in value of our equity investments were recorded in the current period, as the changes in value of equity investments cannot be reliably forecasted. Our 2020 effective tax rate also reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for the nine months ended September 30, 2021, compared to the same period in 2020, the decrease in our effective tax rate was primarily due to a current year deferred tax benefit in Switzerland resulting from the accelerated approval of ADUHELM by the FDA in the U.S. recognized during the second quarter of 2021. We recorded a net deferred tax asset of approximately $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzE4OTk_ec1fedeb-27ac-40ee-b0e5-ecc368d9f485">500.0</ix:nonFraction>&#160;million. The net deferred tax asset is comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzE5NjA_74a68c4c-18d0-4903-9c72-c3b14fc3c937">875.0</ix:nonFraction>&#160;million of gross deferred tax asset, reduced by approximately $<ix:nonFraction unitRef="usd" contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzIwMTc_c80857f1-89f9-42ae-990c-0a69830f3359">375.0</ix:nonFraction>&#160;million of unrecognized tax benefit discussed below. The deferred tax benefit relates to Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc. For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we increased our gross unrecognized tax benefits by approximately $<ix:nonFraction unitRef="usd" contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzQzNTA_c80857f1-89f9-42ae-990c-0a69830f3359">375.0</ix:nonFraction>&#160;million, related to a deferred tax asset for Swiss tax purposes for Neurimmune's tax basis in ADUHELM, as discussed above. This unrecognized tax benefit was recorded as a reduction to the gross deferred tax asset, resulting in the net deferred tax asset discussed above, and not as a separate liability on our condensed consolidated balance sheet.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i4883e683ca29460bbe0893eba5a89566"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i5a5dec6bf41c4a37a79d8a1cc7f4a7da_I20220930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzUxMjY_c33bc4d0-2383-4391-8061-5672c4e8bab4">20.0</ix:nonFraction> million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_112"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE4MjM_ff2912f2-72e5-47e1-aece-7e555d2e0c07" continuedAt="ic45a1fd974a747beb8b38dc98a4d94c2" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE4MDc_b4c99085-5964-4944-a079-40fa64e32433" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzItMi0xLTEtMA_d315d35f-0c95-4a56-9dda-3ea90c9a6e15">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzItNC0xLTEtMA_87bd4248-90aa-479b-ab44-499e40458d6e">6.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzItNi0xLTEtMA_7f967946-a94f-4e30-a739-c54b7aff4372">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzItOC0xLTEtMA_4e934778-1036-49a1-8a5c-a0a093d6d7ca">38.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzMtMi0xLTEtMA_bb9892d0-410b-4339-bd23-7ad1dd85e9f8">66.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzMtNC0xLTEtMA_7eab7181-5f37-40f9-b4e2-20b77ec7e1f7">56.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzMtNi0xLTEtMA_98f8368c-e8ed-4373-9f33-383d64569f9f">187.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzMtOC0xLTEtMA_ce188f0e-7d73-4744-abf2-a97bbe14e3f2">166.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzQtMi0xLTEtMA_bdbcd833-8fd0-4cd1-9a3a-53e99f2d9632">424.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzQtNC0xLTEtMA_f628e7ba-9d32-4ace-909f-3314c9b63128">82.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzQtNi0xLTEtMA_6c26d267-6b6a-4290-8537-e82266fc0900">707.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzQtOC0xLTEtMA_c4dea341-b5a4-4655-b40c-43fa542b0cab">52.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzUtMi0xLTEtMA_b7ba488f-cc3f-4d5f-ac1a-3f0a9d296f20">13.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzUtNC0xLTEtMA_7003b595-921b-46c1-9412-876f772286ca">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzUtNi0xLTEtMA_eb46987c-7d36-4587-b24a-8b766e979278">23.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzUtOC0xLTEtMA_0681fab8-5b81-4ee0-b293-b71a1c16b297">5.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzYtMi0xLTEtMA_ed0f0e54-5a3f-4073-a1ed-2e7e4b602427">1.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzYtNC0xLTEtMA_d644e50b-5300-41a8-abb2-06ea023ebd6c">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzYtNi0xLTEtMA_031b32fa-7de4-4be4-b1a8-eac8b1c23cc2">4.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzYtOC0xLTEtMA_6e810b63-a7e6-45bb-a181-a3de6cfa1fde">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzctMi0xLTEtMA_ca9bc43e-d621-4df3-bfe7-b94a2e7a3ebf">502.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzctNC0xLTEtMA_9576f080-14df-4e19-b7cd-486a66c768a3">128.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzctNi0xLTEtMA_268ea3bb-6537-453e-ba63-45250c3badcc">913.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzctOC0xLTEtMA_bb1072db-96ae-418a-9210-6b973855f481">186.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzUzNw_8b5ec894-b134-4458-b177-f8bf57ca75fe">426.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzU0NA_18309bfc-bb47-4a09-bab2-451a50803cba">2.7</ix:nonFraction> million, respectively, compared to net unrealized losses and realized gains (losses) of $<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzYyNg_70b7d39c-78ef-46c6-a372-0ac54ed28074">82.3</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzYzMw_ef916116-15dc-437b-ba0a-77ca19d12d27">zero</ix:nonFraction>, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended September 30, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Ionis, Sage and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i5ea2be25eae54408bbb6eef779a3bab9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4Xzg0NA_96cc864c-5369-40d0-9dfb-80fd5a77c508">424.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzEwODI_67f5794e-e6d0-4012-a00e-02edb429f14e">715.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzEwODk_9301f35b-8034-45a7-90cf-59b94c52d036">9.3</ix:nonFraction> million, respectively, compared to net unrealized losses and realized gains (losses) of $<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzExNzE_df5112d8-501b-47d3-b3d6-28c6c6cd10db">40.3</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzExNzg_68d9f3aa-5e40-439b-b010-e5c28b43747b">zero</ix:nonFraction>, respectively, in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Ionis, Sage and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i4e718401bed449ed8eea180efb806b04_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE0MTM_3256ef12-7ce0-4c46-80cc-c0848b4b3f06">709.1</ix:nonFraction>&#160;million. </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE4MTk_21dd7f67-61c2-436b-9b91-0033548fd0c7" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzItMi0xLTEtMA_fe48c328-ac56-4b89-afd4-3124cebf9813">424.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzItNC0xLTEtMA_eab787ad-f879-42ea-8e16-649ce7c4f7d0">82.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzItNi0xLTEtMA_2accd7d9-5d4d-4719-b5c7-aea0ca467d4b">705.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzItOC0xLTEtMA_fae1108e-4426-41b2-b8d3-8511675ce27a">40.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzMtMi0xLTEtMA_18309bfc-bb47-4a09-bab2-451a50803cba">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzMtNC0xLTEtMA_ef916116-15dc-437b-ba0a-77ca19d12d27">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzMtNi0xLTEtMA_9301f35b-8034-45a7-90cf-59b94c52d036">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzMtOC0xLTEtMA_68d9f3aa-5e40-439b-b010-e5c28b43747b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzQtMi0xLTEtMA_8b5ec894-b134-4458-b177-f8bf57ca75fe">426.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzQtNC0xLTEtMA_70b7d39c-78ef-46c6-a372-0ac54ed28074">82.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzQtNi0xLTEtMA_67f5794e-e6d0-4012-a00e-02edb429f14e">715.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzQtOC0xLTEtMA_df5112d8-501b-47d3-b3d6-28c6c6cd10db">40.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ic45a1fd974a747beb8b38dc98a4d94c2"><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE4MTE_83d727ed-5d61-4d0e-bb7c-b3c0738a4c6c" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa3c889df0142bf89536f957b8eaee7_I20210930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzEtMi0xLTEtMA_c6a1027d-5fbe-4581-b788-d1a19103a22f">982.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b173db27f4480e98a38ea719ffce5f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzEtNC0xLTEtMA_b68b9f78-8ddb-4653-a36f-4dba663e72e7">1,080.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzItMi0xLTEtMA_45fd60ef-dfe4-4914-a6ef-1ce4d5774018">289.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzItNC0xLTEtMA_42959d93-7fa9-469c-a49b-ef0a330ff6aa">389.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzMtMi0xLTEtMA_dfd28e1b-b657-4f0d-9899-f5abc259dd7e">299.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzMtNC0xLTEtMA_ae1c8add-e118-4710-a981-c1e7a5814989">333.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzQtMi0xLTEtMA_f7ae1638-0142-4bdb-9e69-6094fc6d8bab">238.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzQtNC0xLTEtMA_29a8259c-1e9c-455e-a5a5-bc918ccbf06d">218.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzUtMi0xLTEtMA_4ef1f127-c400-4563-8636-41d6b0d184f7">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzUtNC0xLTEtMA_08e42ea3-9c3d-4b76-ba15-571cd0d014aa">181.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzYtMi0xLTEtMA_528cbba4-fc1e-4837-aa00-dfad27a33323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzYtNC0xLTEtMA_52ca13ed-14ef-4884-95d7-2c993b284f41">149.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzctMi0xLTEtMA_89f603b9-2d3e-40c9-9dba-8dba2fe2f1bc">713.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzctNC0xLTEtMA_8a99ff5c-cb58-4787-bec9-ad5be1f3a817">791.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzgtMi0xLTEtMA_3ca36418-8464-425e-a150-95457fc45da1">2,550.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzgtNC0xLTEtMA_3a756581-359e-4145-a540-42c08244bd31">3,145.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE2ODk_71fde94b-8d8b-4d9f-b9cc-3385f87edfb7">1,318.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE2OTY_ccd343b0-d0dd-4442-a172-0272699f9e13">1,329.6</ix:nonFraction> million as of September 30, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE3NzM_7e63272d-cc5e-4ff3-8920-da52c310a0f2">657.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE3ODA_4c2cb91f-4c6f-4538-ade7-6e4f6875be69">709.9</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_115"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;Collaborative and Other Relationships </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NTk4_9b374421-7945-4021-8cf4-c39a81008e75" continuedAt="i2e49b3d25f264a38a407b2ed0bdb8af6" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, <ix:nonFraction unitRef="product" contextRef="icccb66447d924c0594b928f60f204b02_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfProductCandidates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzI3NA_686d4ce4-8939-40da-83c4-20a89e028438">two</ix:nonFraction> Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the global operational and regulatory lead for lecanemab and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In addition, the Lecanemab Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i2e49b3d25f264a38a407b2ed0bdb8af6" continuedAt="id9d32704e1cc43d89c7e4a6f101451f5"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NjEy_d93c47c4-35cb-4d1a-bf1b-4ee35394e595" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590aa7c867af425baa597d7a5149c44b_D20210701-20210930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzItMi0xLTEtMA_9e186ee0-c28a-4cf1-8d3f-c9040b2d719e">118.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4078cb7710e54f01b41c9089dc314b3a_D20200701-20200930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzItNC0xLTEtMA_5982bd03-e73a-4ccc-a7f4-f67a241a5a5f">75.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633b5b8dfba24438ad91750ffda4fddf_D20210101-20210930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzItNi0xLTEtMA_da563502-fbef-45cf-a9d1-2ec3523202d3">236.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dff1fe5988e4116a7e201e084821a57_D20200101-20200930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzItOC0xLTEtMA_391f94cd-1ab8-4966-bc57-c8233ddd7e5f">153.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590aa7c867af425baa597d7a5149c44b_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzMtMi0xLTEtMA_cd33d76f-96c0-4fc1-8df9-b36867871b04">59.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4078cb7710e54f01b41c9089dc314b3a_D20200701-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzMtNC0xLTEtMA_face0b29-6f4c-4701-be2d-813706f6856d">37.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633b5b8dfba24438ad91750ffda4fddf_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzMtNi0xLTEtMA_d4b3fcb9-7ef8-471c-b9f5-655bdb37693a">118.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dff1fe5988e4116a7e201e084821a57_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzMtOC0xLTEtMA_cc07400b-4439-408f-8ca4-01ce53a649e2">76.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f8f42a6a9c41ddae4efe85bc2204b8_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzQtMi0xLTEtMA_222323bf-728d-4b82-a954-af10047bab44">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648337729b824015ae37af96e3c8ea6b_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzQtNi0xLTEtMA_a671104c-dffa-43a2-8d84-cd12e275edbd">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02128433756c4eaeb9a1cb904b8b0757_D20200101-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzQtOC0xLTEtMA_cc26873f-a35a-472a-a472-bf9d4e6d2071">6.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f8f42a6a9c41ddae4efe85bc2204b8_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzUtMi0xLTEtMA_c49b7e8e-aca4-41a0-afe7-b2cf522ba655">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648337729b824015ae37af96e3c8ea6b_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzUtNi0xLTEtMA_1cc91169-5621-4e48-839d-8e4162ca8ff5">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02128433756c4eaeb9a1cb904b8b0757_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzUtOC0xLTEtMA_ad0457ed-08c5-4156-b595-45fc94f16468">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> - For the three months ended September 30, 2020, sales and marketing expense related to lecanemab and elenbecestat was immaterial.</span></div><div style="margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ADUHELM Collaboration Agreement, we lead the ongoing development of ADUHELM, and we and Eisai will co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;<ix:nonFraction unitRef="number" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzIzMTA_c3804989-841c-4931-a463-a02badf20462">45.0</ix:nonFraction>%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of ADUHELM in patients with early Alzheimer's disease. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $<ix:nonFraction unitRef="usd" contextRef="i9ad97210ae5d418ca006b46280264849_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzI4Mzg_2e3f39da-c01b-45cd-91f0-2012e224ea1e">45.0</ix:nonFraction> million related to the termination of various clinical trials and research and development contracts net of the expected <ix:nonFraction unitRef="number" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzI5NTQ_c3804989-841c-4931-a463-a02badf20462">45.0</ix:nonFraction>% Eisai reimbursement of development costs incurred under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we and Eisai announced that we planned to pursue regulatory approval for ADUHELM in the U.S. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In July 2020 we completed the submission of a Biologics License Application (BLA) for the approval of ADUHELM to the FDA and made a $<ix:nonFraction unitRef="usd" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM0ODk_df2de88d-1e15-462b-ae43-3f77fb1ea8ea">75.0</ix:nonFraction> million milestone payment to Neurimmune. We recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM1Njg_cf90149b-536d-400f-a857-02b83ef86513">33.8</ix:nonFraction> million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM1OTA_c3804989-841c-4931-a463-a02badf20462">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM2MDY_df2de88d-1e15-462b-ae43-3f77fb1ea8ea">75.0</ix:nonFraction> million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $<ix:nonFraction unitRef="usd" contextRef="i1ac80dac77b54f829d7ff2f034bca438_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM4Mjk_2e32b0ff-0937-463c-a7ec-62b4fb34f282">100.0</ix:nonFraction>&#160;million milestone payment to Neurimmune. For the nine months ended September 30, 2021, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i980538f09ea6402c88eeb6295f06a52e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM5NDM_3b7fea9e-f9f9-4e9f-86df-ddf25f425cd4"><ix:nonFraction unitRef="usd" contextRef="i509664d8b5114111a796a1f9c9e4bf21_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM5NDM_b0e9c8f4-9495-4b3c-80cd-69d956ed149f">45.0</ix:nonFraction></ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM5NjU_c3804989-841c-4931-a463-a02badf20462">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i1ac80dac77b54f829d7ff2f034bca438_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM5ODE_2e32b0ff-0937-463c-a7ec-62b4fb34f282">100.0</ix:nonFraction>&#160;million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense are shared in proportion to the same region-based profit split that is utilized to co-promote ADUHELM. <ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NTg0_fb5ba1fc-5980-40a2-ac62-848d66f33c51" continuedAt="id8f8d29ed76943b1adb4cd54af3c579c" escape="true">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="id9d32704e1cc43d89c7e4a6f101451f5" continuedAt="ic31469814dbd493890cc12605b9494e5"><div><ix:continuation id="id8f8d29ed76943b1adb4cd54af3c579c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478b04cc484548cca1dda224d468b2e6_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzItMi0xLTEtMA_cfaecbc7-b27c-48de-9d2d-35714d33bc47">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc6f9feb2e14b0b92a0d13fa4fa7b20_D20200701-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzItNC0xLTEtMA_7495c9a1-cef8-4aba-8f36-5523026fb35b">37.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0983fe25984681bb8e932d698e54aa_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzItNi0xLTEtMA_159d498a-4d5e-4369-86d0-231e3efeb186">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if795d18582b54e3b9e469252f6bb23c1_D20200101-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzItOC0xLTEtMA_3591dc29-ade4-464e-bb48-4a35894683c2">92.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478b04cc484548cca1dda224d468b2e6_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzMtMi0xLTEtMA_9b2bfd63-b2c2-49fa-99b1-15148383c24e">24.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc6f9feb2e14b0b92a0d13fa4fa7b20_D20200701-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzMtNC0xLTEtMA_f259a2dd-92c7-4854-a419-faaef604574d">20.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0983fe25984681bb8e932d698e54aa_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzMtNi0xLTEtMA_ff7b313e-9b8b-42f2-9933-3edfa5cd9a7e">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if795d18582b54e3b9e469252f6bb23c1_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzMtOC0xLTEtMA_d5bd7ef6-05b7-470a-8b15-b4e1289eb811">50.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a30db781c9c4e588e9c2f59f6c0abc3_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzQtMi0xLTEtMA_37c0ad68-fea8-4e49-ac7d-4a9633dc5923">154.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabde71d9b5fa451e97f28d6436d5b553_D20200701-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzQtNC0xLTEtMA_62246d6e-9e97-4ca5-af8d-3d770839084a">90.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f562316d0a4a2788f90566852c367f_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzQtNi0xLTEtMA_508de187-4ba7-4e8a-96a9-05a231c071ad">391.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2747153b7ca44e2a5d47259de2db6c9_D20200101-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzQtOC0xLTEtMA_080d0dba-05bb-4007-af23-08b651c85b49">158.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a30db781c9c4e588e9c2f59f6c0abc3_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzUtMi0xLTEtMA_97da5629-040f-467a-8859-433727c34b71">83.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabde71d9b5fa451e97f28d6436d5b553_D20200701-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzUtNC0xLTEtMA_74334533-6684-40e6-8225-2a79dfe1b147">51.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f562316d0a4a2788f90566852c367f_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzUtNi0xLTEtMA_8b4e310a-8f3d-44a5-8336-7fd8b959e1a4">211.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2747153b7ca44e2a5d47259de2db6c9_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzUtOC0xLTEtMA_e9dd9be6-57bb-46fa-8044-7d0892bcd660">88.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509664d8b5114111a796a1f9c9e4bf21_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzYtMi0xLTEtMA_4fb33188-2696-43b8-8b2d-b03367fb0c9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487108ca40f748dd9b0bece4b437028b_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzYtNC0xLTEtMA_87c57730-be8b-48dc-9087-17ceb27d3b61">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980538f09ea6402c88eeb6295f06a52e_D20210101-20210930" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzYtNi0xLTEtMA_ef724865-40ac-4523-85a2-96f9ca17286d">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32e8ba2ceec42cc82a16e2cd05dab84_D20200101-20200930" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzYtOC0xLTEtMA_29fcd137-1562-4001-81e8-69b8cb1e4cef">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509664d8b5114111a796a1f9c9e4bf21_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzctMi0xLTEtMA_744c58f9-8571-4eda-a83e-5724a35e4fcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487108ca40f748dd9b0bece4b437028b_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzctNC0xLTEtMA_ab3952ed-dadb-4489-bcc6-1b9df36adf53">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980538f09ea6402c88eeb6295f06a52e_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzctNi0xLTEtMA_5e5a5eeb-e699-43b9-8397-d5a0a2a184db">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32e8ba2ceec42cc82a16e2cd05dab84_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzctOC0xLTEtMA_9c089bc6-3c6a-4041-af80-2e9d73093869">33.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its <ix:nonFraction unitRef="number" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzQ2Njk_c3804989-841c-4931-a463-a02badf20462">45.0</ix:nonFraction>% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2021, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i9c43205ec30542ee94946dc9109e90bb_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzIxOTkwMjMyNzQ0MDQ_06819da8-b466-4621-bcf6-f24a1104525f">50.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icccb66447d924c0594b928f60f204b02_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzQ5MDU_27629030-6a7b-47ad-9637-21cc8de7f9ff"><ix:nonFraction unitRef="usd" contextRef="icccb66447d924c0594b928f60f204b02_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzQ5MDU_f8661ed2-d36b-480c-bd4f-c8fbb42acd40">90.7</ix:nonFraction></ix:nonFraction>&#160;million, respectively, to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzgyNDYzMzcyNDIwNTA_37b9aa06-d344-4ae8-82cc-a5d7df2aa0b3">45.0</ix:nonFraction>% sharing of the net collaboration losses in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i751d4a0241cf4502ab3497a8e9ec0dce_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzItMi0xLTEtMA_4a27b06c-1e35-481d-b769-099d5d65ab23">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icad78ebefcf14b34899f5ddcb848be14_D20200701-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzItNC0xLTEtMA_63a89669-2841-4e91-be55-eb71f7817b3f">10.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabf552e851142fe99517e02399fdd3f_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzItNi0xLTEtMA_e489a023-6360-48ec-8999-567c4869bb06">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0eaf2019e44f0682994cffd26a0133_D20200101-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzItOC0xLTEtMA_0017d040-b5ef-434c-bbf9-622b856c014a">35.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i751d4a0241cf4502ab3497a8e9ec0dce_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzMtMi0xLTEtMA_1abbd240-17e9-4495-ab61-bc23c59b9b51">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icad78ebefcf14b34899f5ddcb848be14_D20200701-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzMtNC0xLTEtMA_6d929202-a3b1-46b5-b1d1-f9e5b58c5d58">5.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabf552e851142fe99517e02399fdd3f_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzMtNi0xLTEtMA_16370e1b-d923-4b4c-8b33-033a3136c880">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0eaf2019e44f0682994cffd26a0133_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzMtOC0xLTEtMA_0e80f0ba-ffa6-4b66-a029-02ce8b7eb7ef">17.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the closing of this transaction in December 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzY4MjM_888c760d-b56b-4f3c-a845-e6175728d0ed">650.0</ix:nonFraction>&#160;million of Sage common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzY4NjU_fc3f42df-4272-473c-973e-c57e8f141cab">6.2</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="INF" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzY4OTI_2d81b58e-e068-49e7-a1f5-f14808704a17">104.14</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzcxNDY_8394026a-32ba-405b-96bc-606c6ec94d10">209.0</ix:nonFraction>&#160;million to research and development expense in our condensed consolidated statements of income to reflect </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ic31469814dbd493890cc12605b9494e5" continuedAt="if803bb735ea14344813cca723a223e5b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the premium paid for the Sage common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="-5" format="ixt:num-dot-decimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzczMjY_4d6297a5-3162-4c15-9955-b8dfdb9703b6">875.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also pay Sage development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130" decimals="-8" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzc0ODg_710790b2-c11c-4d35-8d3f-036888d4416d">1.6</ix:nonFraction>&#160;billion if all the specified milestones set forth in this collaboration are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1572a6af6d488d9ab80a00623a94ad_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzItMi0xLTEtMA_7d439ae1-3673-49dc-ad1b-ac30ee092968">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15516b5b057f44e9944b4a39df3e5c9e_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzItNC0xLTEtMA_ec6a2506-1886-4a8a-b585-aec641dd306a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic776742915944b44af8f827099040080_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzItNi0xLTEtMA_8a4cd644-c033-4202-84b4-957ead631589">134.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d32af2650947b8b8a4b511bb7ba6ff_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzItOC0xLTEtMA_f6fd6b9d-fcde-4576-933a-2cced5009fb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1572a6af6d488d9ab80a00623a94ad_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzMtMi0xLTEtMA_8bc9c68b-3af9-4f65-8b02-68c04d6522f3">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15516b5b057f44e9944b4a39df3e5c9e_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzMtNC0xLTEtMA_1772717f-78d2-4edd-b772-41fafaf0424f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic776742915944b44af8f827099040080_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzMtNi0xLTEtMA_161ff9c6-c67f-4be3-8c37-225ce02de812">67.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d32af2650947b8b8a4b511bb7ba6ff_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzMtOC0xLTEtMA_779eae88-85cd-43b5-b970-cf341a839311">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd0e08d01ac49639fc6727d3904fee7_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzQtMi0xLTEtMA_3d207131-c388-4462-bedd-7cdab8f98747">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c7f3a2f08a498b8785ed63ef47838c_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzQtNC0xLTEtMA_9e52e280-aeab-43f4-aafd-472816741397">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d833d38eb9f4e898a5898ddbf6dce39_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzQtNi0xLTEtMA_8167ffcc-1779-4810-9b36-1a1af55f1d2a">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efa6afcaf1645f6b58846b7cc88b340_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzQtOC0xLTEtMA_d93b87f8-f8fd-4a13-8e84-c49a09aac5e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd0e08d01ac49639fc6727d3904fee7_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzUtMi0xLTEtMA_02ff0152-ffb0-4c81-b7cd-6d82a48e4ff2">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c7f3a2f08a498b8785ed63ef47838c_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzUtNC0xLTEtMA_a47619ef-8290-43d9-8d5d-57602952176c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d833d38eb9f4e898a5898ddbf6dce39_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzUtNi0xLTEtMA_f783502c-4125-4284-ad30-36e91425abf2">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efa6afcaf1645f6b58846b7cc88b340_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzUtOC0xLTEtMA_cabaeb62-42cc-4f17-a6fc-f8937b0b5245">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $<ix:nonFraction unitRef="usd" contextRef="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzg3OTE_6e20d8e5-d23e-4ffc-9078-d9ca338a5278">465.0</ix:nonFraction>&#160;million of Denali common stock in September 2020, or approximately <ix:nonFraction unitRef="shares" contextRef="if8b5d9e350944ffdad686ff95dd1085f_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzg4NDE_96dfe927-f8bf-4032-a8f5-9f38a647d366">13</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzg4Njg_1346b44b-01ee-4e49-bffb-63c454ffc772">34.94</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="ie06b3989f9a34f469041414b1f9de0db_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzkxMjQ_28e54ab9-9438-474d-b2bd-5437285537be">41.3</ix:nonFraction>&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie06b3989f9a34f469041414b1f9de0db_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzkzMDY_d2fe1820-ed17-41af-ae5d-987e5d19fca4">560.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Denali development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="ie06b3989f9a34f469041414b1f9de0db_D20210101-20210930" decimals="-8" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzk0NzA_ec9cba16-7411-448b-8804-ee2fcbab6892">1.1</ix:nonFraction>&#160;billion if the milestones related to the LRRK2 program are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NjA0_b9dc81ce-8800-4362-a98f-71bf0025210e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e7531c621947d4a9119f4864109e24_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzItMi0xLTEtMA_5e0426cc-2f77-4bfd-9a0c-b3808ca1637b">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb3160ab3ff42eaae7dd54fa3d456e5_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzItNC0xLTEtMA_c9906217-3351-4a7d-a1ab-21d72389393b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199def73fc1342d0a937f3d464cb4c69_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzItNi0xLTEtMA_710ec523-3c5a-4f8a-a3a3-6159a1a1b4d5">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5281eb5b3f824e51b96dd0c15c3e9f04_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzItOC0xLTEtMA_d44432d8-0eca-4fad-b85f-481db23352a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e7531c621947d4a9119f4864109e24_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzMtMi0xLTEtMA_10f3ec0d-2681-4057-81c1-5c798d1d15b3">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb3160ab3ff42eaae7dd54fa3d456e5_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzMtNC0xLTEtMA_e1a510e7-4db4-4b39-9c9f-0b8a1d664665">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199def73fc1342d0a937f3d464cb4c69_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzMtNi0xLTEtMA_9858f4cf-7187-4800-b03d-45b54bf88813">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5281eb5b3f824e51b96dd0c15c3e9f04_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzMtOC0xLTEtMA_03725c73-6baa-4203-86dd-2e2270b23c76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a <ix:nonNumeric contextRef="i6944bfac8bea4cacac93ae484b0bd09d_D20210101-20210930" format="ixt-sec:durwordsen" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NTky_dbb177b6-b9c5-4263-848d-615452c9c6fc">five-year</ix:nonNumeric> period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="if803bb735ea14344813cca723a223e5b" continuedAt="i0520820a4619432892d24c4b06851528"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction in April 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwNTIw_8b76c249-5726-4861-a144-6e5f1c2ea28d">225.0</ix:nonFraction> million of Sangamo common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-6" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwNTY1_96b27272-81b8-4f50-8394-25e5b1a99ae2">24</ix:nonFraction> million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwNTky_594b7d56-d232-4ec1-8da5-ebbf70f9cdc1">9.21</ix:nonFraction> per share, of which approximately <ix:nonFraction unitRef="shares" contextRef="i8ea2f828e08946f9bfe96108463cde78_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwNjI5_f736b3cc-d8fc-499b-bd25-5c9a22c3dec1">12</ix:nonFraction>&#160;million shares remain subject to transfer restrictions as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $<ix:nonFraction unitRef="usd" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwODg4_b79e36d8-f45d-489e-a822-58053b476da3">83.0</ix:nonFraction> million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-5" format="ixt:num-dot-decimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExMDcx_3aab01cc-34a1-4cb6-8ab2-9f8bb3fe046a">125.0</ix:nonFraction> million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-8" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExMjU4_c7ff9111-51fd-42e8-9a93-d27afa50f291">2.4</ix:nonFraction> billion if we select all of the targets allowed under this collaboration and all the specified milestones set forth in this collaboration are achieved. Of this amount, up to $<ix:nonFraction unitRef="usd" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExNDI3_6af5162e-3b9a-4d2d-809c-f02a48832822">80.0</ix:nonFraction> million relates to the selection of targets, $<ix:nonFraction unitRef="usd" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-8" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExNDY3_add32537-c667-46ef-bfac-4839a76c692e">1.9</ix:nonFraction> billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $<ix:nonFraction unitRef="usd" contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229" decimals="-5" format="ixt:num-dot-decimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExNTk0_1b1b1143-2538-4921-a08a-6682760f027e">380.0</ix:nonFraction> million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a license and collaboration agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of this transaction in August 2021, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i86671ce6531e4825b8e7437bac23648c_D20210801-20210831" decimals="-5" format="ixt:num-dot-decimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzIxOTkwMjMyNzYwODI_e63d4b02-7d68-43da-9458-eb0f3ccad757">125.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that was recorded as research and development expense. </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also pay InnoCare up to approximately $<ix:nonFraction unitRef="usd" contextRef="i86671ce6531e4825b8e7437bac23648c_D20210801-20210831" decimals="-5" format="ixt:num-dot-decimal" name="biib:ContingentMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzIxOTkwMjMyODQyNzI_e9e51a1d-3f18-4f58-b235-3d026d68c8ff">812.5</ix:nonFraction>&#160;million in potential development milestones and potential commercial payments should the collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties in the low to high teens on potential future net sales of any product developed under this collaboration.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="icbfdae3fc3af4808b767547c978da623_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyMjE0_6ab4b16b-20e0-42e2-9b2e-d559440a78ea">7.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6f17596163b74714978d0ca8bb7716a7_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM4NDgyOTA3MzA2MDE_9e1346f6-cfc9-4f5e-99aa-9395eee22dce">84.9</ix:nonFraction> million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to $<ix:nonFraction unitRef="usd" contextRef="i920ace51c79b4fd9aaea95747910f622_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyMzc4_e3098bb9-ec9a-4039-90ea-b2fbadd2689d">38.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i901cded39aad4bb796bd2e4ea0b84524_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM4NDgyOTA3MzA2MjA_2793330f-c3c8-425e-b90c-41c05ecb4f97">47.6</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="ifa2615942dbc42b59096307ded3cc0c3_I20200930" decimals="2" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyNzk1_7ab0906b-cc1c-4313-b171-a2e493889692">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyODE1_9cf11c30-fbbc-4cab-af2a-eea0fe4cf3f3">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="icc31d40d106d4c9f992098cfdbc25314_D20181101-20181130" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyOTA4_22b20347-bf26-4484-9885-4f1310055d04">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i0af199bf8cdb4db88ac9960dd490f47a_D20200101-20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyOTI5_0762254f-ebef-4a62-afad-c167cecf1b70">676.6</ix:nonFraction> million) to Samsung BioLogics. As of September 30, 2021, our ownership percentage remained at approximately <ix:nonFraction unitRef="number" contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEzMDE2_9cf11c30-fbbc-4cab-af2a-eea0fe4cf3f3">49.9</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i0520820a4619432892d24c4b06851528" continuedAt="i486cfb36821a4b81b2d20671da9bcfe3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $<ix:nonFraction unitRef="usd" contextRef="i7b972473b78a41948835d5e6b4829ce2_I20181107" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0MDMx_8a63df33-e224-459a-8889-6d1a18f9195d">675.0</ix:nonFraction> million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i6d3585ab7f49447c9095cb7b649c5a3f_D20210101-20210930" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0MjIz_bb046de5-3a0a-4073-8a12-929fde84a4f7">1.5</ix:nonNumeric> years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="if2c3147acf584e02bc9574e010f74b90_D20210101-20210930" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0Mzkx_71a7a36a-0961-4bfa-baa3-f899af55c6ce">15</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, we recognized net income on our investment of $<ix:nonFraction unitRef="usd" contextRef="ie1fbddcf67fa4255b76afc8be76c1ee0_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0ODk4_26e9924b-5f43-475a-8326-632330caec4a">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0OTA1_c0440fdf-f6cd-4491-b4e0-99b19fdc932c">17.2</ix:nonFraction> million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax, compared to net losses on our investment of $<ix:nonFraction unitRef="usd" contextRef="i45f34187e7424286895df7d07271d853_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MDc3_d850651e-3a9f-4efe-8cb0-decea3007e6e">13.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc423654295e47e497b4d7f2985f4754_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MDg0_fb13a59b-9223-46f7-ab24-bf70f2a540f5">12.7</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income on our investment for the nine months ended September 30, 2021, reflects a $<ix:nonFraction unitRef="usd" contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MjE2_a0e46982-14fc-4519-881c-4e3af02d5e04"><ix:nonFraction unitRef="usd" contextRef="ie1fbddcf67fa4255b76afc8be76c1ee0_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MjE2_c8df83a8-90c7-4d63-9f8d-cc87d9951c18">31.2</ix:nonFraction></ix:nonFraction>&#160;million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the second quarter of 2021 based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MzAz_d7d06e85-80d4-41f9-bf2a-80c4cdc9032a">692.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MzI0_9453be79-8d14-4a24-bc01-06148dff6ae6">586.1</ix:nonFraction> million) and <ix:nonFraction unitRef="krw" contextRef="i22878c92c12541f19e966187ae7b1e40_I20201231" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MzMy_87a4bf20-76be-4a02-93c7-ba60b8f2938a">673.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i22878c92c12541f19e966187ae7b1e40_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MzUz_22612427-f550-4610-b11d-4c52416297a2">620.2</ix:nonFraction> million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if50c9b8ddef6484aa041e78de26b485f_D20200101-20200331" decimals="-5" format="ixt:num-dot-decimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2MDYz_e4c35a5c-f976-461b-a5ae-adcb1a987be4">100.0</ix:nonFraction> million to Samsung Bioepis in January 2020, of which $<ix:nonFraction unitRef="usd" contextRef="if50c9b8ddef6484aa041e78de26b485f_D20200101-20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2MTEx_aa1b72fb-5157-435d-83dc-48383e14a160">63.0</ix:nonFraction> million was recorded as research and development expense in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i869e4d6d217b488e998a60c8e87948c6_I20200131" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2MTc1_5511da13-a028-453f-9c7d-954ca45439a0">37.0</ix:nonFraction> million was recorded as an intangible asset in 2019. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we paid Samsung Bioepis a $<ix:nonFraction unitRef="usd" contextRef="i395c6f6eef504574a55e4ae26a68fee0_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2Mjk3_1969b8a2-4dee-4e48-800e-cc1129d84fb9">15.0</ix:nonFraction>&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. During the third quarter of 2021, we accrued $<ix:nonFraction unitRef="usd" contextRef="i395c6f6eef504574a55e4ae26a68fee0_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:AccruedMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM4NDgyOTA3MzAxODM_12de3de5-47df-4b44-8b08-1a08f46f6939">15.0</ix:nonFraction>&#160;million in</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> milestones related to the approval of BYOOVIZ in the U.S. and E.U. that were capitalized within intangible assets. We may pay Samsung Bioepis up to $<ix:nonFraction unitRef="usd" contextRef="i22ac8ae1aedd4701923500c02d371f31_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2NDYz_baa102a2-36e4-46ac-bcba-e58f0774d596">180.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="i22ac8ae1aedd4701923500c02d371f31_D20210101-20210930" format="ixt-sec:durwordsen" name="biib:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2NjYy_200217af-f455-4217-b39e-ee8033ebaa93">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i22ac8ae1aedd4701923500c02d371f31_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:ContractOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2NzE0_1c5c6f0d-3299-4135-91d9-82053ffe5b11">60.0</ix:nonFraction> million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930" decimals="2" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3MTg0_2746480b-eb4d-4379-b0f0-1189c6b9c1c7">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i486cfb36821a4b81b2d20671da9bcfe3" continuedAt="i44544aa009244289a63f474b37709f92"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021, we recognized net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="ie1fbddcf67fa4255b76afc8be76c1ee0_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NDUw_4e1e3e8d-6428-46fa-b75f-f62d7bdb95ff">71.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NDU3_5c344063-095f-4b0e-b3e5-ea8cff4e91cf">210.2</ix:nonFraction> million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930" decimals="2" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NTAz_2746480b-eb4d-4379-b0f0-1189c6b9c1c7">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to a net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="i45f34187e7424286895df7d07271d853_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NTky_59c0beca-bf41-4213-bb41-663d3583ea41">72.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc423654295e47e497b4d7f2985f4754_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NTk5_086d2b21-9865-4824-bfff-6c547fda00cb">200.1</ix:nonFraction> million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts payable to Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="iac1864f4ab43443795b18bf4e5518559_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4Mjc2_3c272947-7800-44ee-b869-3dda61ea7f02">125.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i021e9d577199419a8902601c80f14ba1_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4Mjgz_80a7d7a7-b756-4de1-848b-7f5fcef2b607">99.0</ix:nonFraction>&#160;million as of September 30, 2021 and December 31, 2020, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i44544aa009244289a63f474b37709f92" continuedAt="i7f669db76e0a47f69f7bfc85a3d5ed45"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f669db76e0a47f69f7bfc85a3d5ed45"> to our consolidated financial statements included in our 2020 Form 10-K.</ix:continuation> </span></div><div id="i8046a3e69c814e7f9967395f631661c6_121"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzY1NzI_bd4d4702-520e-45e7-af48-3013c37a282d" continuedAt="i38e5c40a98a74830974902de3b7143fc" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="i22969c273ab1477cacb6c894c96e65ca_D20210101-20210930" format="ixt-sec:duryear" name="biib:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzc0Mg_e2356dd0-5f41-4f71-9381-3961c78ef6b2">12</ix:nonNumeric> years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="i22969c273ab1477cacb6c894c96e65ca_D20210101-20210930" decimals="INF" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzEwODU_d586a60e-34c3-4981-b65f-66464c12cec5">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017 we amended the terms of the Neurimmune Agreement and made a $<ix:nonFraction unitRef="usd" contextRef="i4bab21bf098a42d1b19d7bb69acd037c_D20171001-20171031" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzEyNDU_11e4cdf9-e66a-42b0-9f1e-7a9693140161">150.0</ix:nonFraction> million payment to Neurimmune in exchange for a <ix:nonFraction unitRef="number" contextRef="i4bab21bf098a42d1b19d7bb69acd037c_D20171001-20171031" decimals="2" name="biib:Reductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzEyODg_28e44950-4699-4179-a2fa-2c364745db45">15.0</ix:nonFraction>% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM. In May 2018 we made an additional $<ix:nonFraction unitRef="usd" contextRef="ia0b2b5750c244cafbf99dc052af4f8a1_D20180501-20180531" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzE1MDA_7e28cca1-1937-42ab-8682-ff88137b2ad8">50.0</ix:nonFraction> million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM, by an additional <ix:nonFraction unitRef="number" contextRef="ia0b2b5750c244cafbf99dc052af4f8a1_D20180501-20180531" decimals="2" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzE3MjI_9cb234a8-a150-4904-879d-7497cc40aae3">5.0</ix:nonFraction>%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$<ix:nonFraction unitRef="usd" contextRef="id73a857cd2af440ebad3dee0301dca58_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzIyNDk_635c36bd-aa71-4519-a464-1164571a4fdf">75.0</ix:nonFraction> million&#160;upon the regulatory filing with the FDA for the approval of ADUHELM. During the second quarter of 2020 we paid Neurimmune $<ix:nonFraction unitRef="usd" contextRef="id73a857cd2af440ebad3dee0301dca58_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzIzNzQ_635c36bd-aa71-4519-a464-1164571a4fdf">75.0</ix:nonFraction> million upon the completed submission of the BLA for the approval of ADUHELM to the FDA, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2020 we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i9ad97210ae5d418ca006b46280264849_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzI3MDc_fdce66e0-7af5-4e87-89e8-99aa67de78d2">33.8</ix:nonFraction> million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="if3c03d9b6e5a437fa43cc01794b646a3_D20210401-20210630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzI3Mjk_de3fd3c9-7670-42bc-97f4-ec5309f30d10"><ix:nonFraction unitRef="number" contextRef="i9ad97210ae5d418ca006b46280264849_D20200401-20200630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzI3Mjk_ed2e4cab-e492-4c61-913d-c0ac4dfd0022">45.0</ix:nonFraction></ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="id73a857cd2af440ebad3dee0301dca58_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzI3NDU_635c36bd-aa71-4519-a464-1164571a4fdf">75.0</ix:nonFraction> million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i46019d81d2e4485da3b49f6b7279b384_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzMwNDE_204ca9d8-6e43-4fba-9b3d-d961d2672716">100.0</ix:nonFraction>&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $<ix:nonFraction unitRef="usd" contextRef="i46019d81d2e4485da3b49f6b7279b384_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzMxMzY_204ca9d8-6e43-4fba-9b3d-d961d2672716">100.0</ix:nonFraction>&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i38e5c40a98a74830974902de3b7143fc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i72ca0603ce78428694ea1e92d86ad2ae_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzMzOTc_bc887d2a-5a1d-4ad7-8b56-a57ee2c4b8c9">45.0</ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="if3c03d9b6e5a437fa43cc01794b646a3_D20210401-20210630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM0MTk_de3fd3c9-7670-42bc-97f4-ec5309f30d10"><ix:nonFraction unitRef="number" contextRef="i9ad97210ae5d418ca006b46280264849_D20200401-20200630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM0MTk_ed2e4cab-e492-4c61-913d-c0ac4dfd0022">45.0</ix:nonFraction></ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i46019d81d2e4485da3b49f6b7279b384_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM0MzU_204ca9d8-6e43-4fba-9b3d-d961d2672716">100.0</ix:nonFraction>&#160;million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $<ix:nonFraction unitRef="usd" contextRef="i1ac80dac77b54f829d7ff2f034bca438_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM2OTA_fd9b7565-649f-48c8-8562-a1964c200385">100.0</ix:nonFraction>&#160;million in additional milestones to Neurimmune, which includes $<ix:nonFraction unitRef="usd" contextRef="i70c76f0606c54d3c92d00b9c6239054d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM3NDg_8c86543e-afce-4a5d-90a6-79b86a1f6884">50.0</ix:nonFraction>&#160;million if launched in three or more countries in the European Union (E.U.) and $<ix:nonFraction unitRef="usd" contextRef="ie36b8f43567e4ffc8902418be40bc1ef_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM4MjM_16de583c-6767-4e16-9cc4-324dea942e02">50.0</ix:nonFraction>&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021 and 2020, amounts reimbursed were immaterial.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, we recorded a net deferred tax asset of approximately $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzQyNjI_ec1fedeb-27ac-40ee-b0e5-ecc368d9f485">500.0</ix:nonFraction>&#160;million. The net deferred tax asset is comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzQyNjk_74a68c4c-18d0-4903-9c72-c3b14fc3c937">875.0</ix:nonFraction>&#160;million of gross deferred tax asset, reduced by approximately $<ix:nonFraction unitRef="usd" contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzQyNzU_c80857f1-89f9-42ae-990c-0a69830f3359">375.0</ix:nonFraction>&#160;million of unrecognized tax benefit. The deferred tax benefit relates to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ADUHELM Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on commercial sales of ADUHELM to be shared with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzU3NDU_570eb012-7121-4c7b-a0a2-cb7972814033">17.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzU3NTI_f5110a93-2d79-4542-83f2-a910698ce103">12.8</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div></ix:continuation><div id="i8046a3e69c814e7f9967395f631661c6_127"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;Litigation </span></div><ix:nonNumeric contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjcvZnJhZzphNGEwOTFhNzMzZDU0NTk1OGE2NWU4MDA1ZDRlNzk5My90ZXh0cmVnaW9uOmE0YTA5MWE3MzNkNTQ1OTU4YTY1ZTgwMDVkNGU3OTkzXzEyMzQ3_b9da27ec-fb7d-422d-9adb-79b2ed0d8de7" continuedAt="ie3724ee1e1d845d9898ef2c33c881bee" escape="true"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ie3724ee1e1d845d9898ef2c33c881bee" continuedAt="i93425e5295694fa782b9c9fd4aa30f40"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020 and now pending in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and monetary relief. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. We have filed a motion to dismiss, which is pending.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#252;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the '510 Patent, expiring in May 2035). In May 2020 the European Patent Office (EPO) revoked the &#8216;510 Patent. Fresenius Kabi has appealed to the EPO&#8217;s Technical Boards of Appeal, a hearing has been set for June 2022, and the German and French proceedings have been stayed pending the decision on appeal. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 the Danish Patent Board of Appeal revoked certain Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled in the appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced proceedings in Denmark&#8217;s Maritime and Commercial High Court alleging that IMRALDI infringes of the Danish counterpart of European Patent No. 3 145 488 and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid. Fresenius Kabi has appealed to the High Court of Eastern Denmark.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed during proceedings in the EPO seeking to invalidate that patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of a German utility model. A hearing has been set for November 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks damages of $<ix:nonFraction unitRef="usd" contextRef="id68d34303bce4a2db8b2455c5f1c3285_I20210715" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjcvZnJhZzphNGEwOTFhNzMzZDU0NTk1OGE2NWU4MDA1ZDRlNzk5My90ZXh0cmVnaW9uOmE0YTA5MWE3MzNkNTQ1OTU4YTY1ZTgwMDVkNGU3OTkzXzQ5NDc4MDIzOTAwMDU_a69a17e9-ea34-4e1a-8f20-599e6cc5c866">981.1</ix:nonFraction>&#160;million plus statutory trebling of damages, civil penalties, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss cannot be made at this time.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i93425e5295694fa782b9c9fd4aa30f40" continuedAt="ib4120422ed9f41ddab6a7ea99980e512"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $<ix:nonFraction unitRef="usd" contextRef="i378cd243ed9e40c2932d604d62dcff73_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjcvZnJhZzphNGEwOTFhNzMzZDU0NTk1OGE2NWU4MDA1ZDRlNzk5My90ZXh0cmVnaW9uOmE0YTA5MWE3MzNkNTQ1OTU4YTY1ZTgwMDVkNGU3OTkzXzUzMTE_d10cb317-d230-4dcb-a745-31cf0a63d97d">200.0</ix:nonFraction> million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung BioLogics Arbitration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. We expect a hearing in the fourth quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA.  Plaintiffs seek a declaration of the action as a class action and monetary and other relief. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys&#8217; fees and costs. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Petition for Inter Partes Review</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ib4120422ed9f41ddab6a7ea99980e512"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc. On October 8, 2021, the case was dismissed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Office Oppositions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 the EPO revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018 the EPO revoked Forward Pharma A/S's European Patent No. 2 801 355. In September 2021 the EPO&#8217;s Technical Boards of Appeal announced its affirmance of the revocation.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of our European Patent No. 1 485 127 (the E.U. '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for June 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the E.U. '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul decisions of the European Medicines Agency (EMA) refusing to validate their applications to market generic versions of TECFIDERA. The EMA&#8217;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021 the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;</span><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><div id="i8046a3e69c814e7f9967395f631661c6_136"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of our medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. In the second quarter of 2021 a portion of the facility received a Good Manufacturing Practice (GMP) multi-product license from the Swiss Agency for Therapeutic Products (SWISSMEDIC). We believe that the Solothurn facility will support our anticipated near-term needs for the manufacturing of ADUHELM and other biologic assets. In addition, we believe that the Solothurn site may provide us with the ability to further expand if we need additional large scale manufacturing capacity to support future clinical and commercial manufacturing requirements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Environment</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk and Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM (aducanumab)</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which we are developing in collaboration with Eisai Co., Ltd. (Eisai), based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. As part of the accelerated approval, we will conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer&#8217;s disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. ADUHELM product label states that treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population which was studied in clinical trials. We expect patient uptake will be gradual and we do not expect all eligible patients will be treated with ADUHELM for a variety of reasons, including appropriate patient selection criteria, a complex diagnostic and care pathway, the lack of readiness of healthcare providers and institutions to initiate treatment, concern regarding the accelerated approval of ADUHELM and its data and the ability to obtain and maintain adequate reimbursement for ADUHELM. We expect a Medicare National Coverage Determination by the second quarter of 2022, which should clarify Medicare reimbursement for the class of antibodies directed against amyloid.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement with Eisai (ADUHELM Collaboration Agreement), we and Eisai will co-promote ADUHELM with a region-based profit split, with Eisai reimbursing us for 45.0% of development and commercialization costs incurred by the collaboration for the advancement of ADUHELM in the U.S. Shipments of ADUHELM commenced during the second quarter of 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made, and will continue to make, commercial, medical and infrastructure investments in support of activities associated with the launch of ADUHELM in the U.S., including the adding of </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">headcount and the manufacture of pre-launch inventory.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for aducanumab and in December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application (NDA) for aducanumab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not receive regulatory approval or are unable to successfully commercialize aducanumab in other jurisdictions, our financial condition, business and operations may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the European Union (E.U.). This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face TECFIDERA generic competition in the E.U. if regulatory data protection is not upheld and we expect that this would have an adverse impact on our TECFIDERA sales and our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report and the discussion under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations - Product Revenue - Multiple Sclerosis (MS) - Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Update Regarding COVID-19</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future. For example, our Phase 3 study of BIIB093 (glibenclamide IV) for large hemispheric infarction (LHI), a severe form of ischemic stroke, has been delayed as this study involves administration of BIIB093 in an acute hospital setting. To help mitigate the impact of the COVID-19 pandemic to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions. These alternative measures have resulted in an immaterial increase to the cost of the clinical trials underway.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors such as the COVID-19 pandemic, adverse weather events, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays in manufacturing our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share attributable to Biogen Inc. was $2.22 for the three months ended September 30, 2021, representing a decrease of 50.2% compared to $4.46 in the same period in 2020.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended September 30, 2021, compared to the three months ended September 30, 2020, reflects the following:</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total revenue was $2,778.9 million for the third quarter of 2021, representing a $597.2 million, or 17.7%, decrease compared to $3,376.1 million in the same period in 2020.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Product revenue, net totaled $2,205.7 million for the third quarter of 2021, representing a $484.6 million, or 18.0%, decrease compared to $2,690.3 million in the same period in 2020. This decrease was primarily due to a $428.9 million, or 21.6%, decrease in MS product revenue as well as a $50.3 million, or 10.2%, decrease in SPINRAZA product revenue.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in MS product revenue was primarily due to a decrease in U.S. TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in SPINRAZA revenue was primarily due to a decrease in demand as a result of increased competition in the U.S.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Revenue from anti-CD20 therapeutic programs totaled $415.4 million for the third quarter of 2021, representing a $144.7 million, or 25.8%, decrease compared to $560.1 million in the same period in 2020. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">his decrease was primarily due to a $136.2&#160;million, or 51.7%, decrease in RITUXAN revenue. Sales of RITUXAN have been a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dversely affected by the onset of biosimilars competition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other revenue totaled $157.8 million for the third quarter of 2021, representing a 25.5% increase from $125.7 million in the same period in 2020.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total cost and expense was $1,984.9 million for the third quarter of 2021, representing a $304.8 million, or 13.3%, decrease compared to $2,289.7 million in the same period in </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020. This decrease was primarily due to a $438.5&#160;million decrease in research and development expense.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in research development expense for the third quarter of 2021 was primarily due to $601.3&#160;million in upfront payments recognized in connection with our collaboration with Denali Therapeutics Inc. (Denali) in the third quarter of 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition, Liquidity and Capital Resources:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We generated $2,801.6 million of net cash flows from operations for the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Cash, cash equivalents and marketable securities totaled approximately $3,923.4 million as of September 30, 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We repurchased and retired approximately 2.2 million shares of our common stock at a cost of approximately $750.0 million during the third quarter of 2021 under a program authorized by our Board of Directors in October 2020 to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of September 30, 2021.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions and Collaborative and Other Relationships</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 we entered into a license and collaboration agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton's tyrosine kinase inhibitor for the potential treatment of MS. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our proposed collaboration with InnoCare, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Key Developments</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes) for a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes) and cash, and an offer to purchase our tendered 2045 Senior Notes for cash.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">North Carolina Gene Therapy Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 we announced our plans to build a new gene therapy manufacturing facility in Research Triangle Park, North Carolina to support our growing gene therapy pipeline across multiple therapeutic areas. The new facility will be 175,000 square feet and is expected to be operational by 2023, with an estimated total investment of approximately $200.0&#160;million.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021 we announced that a portion of our Solothurn manufacturing facility received a GMP multi-product license from SWISSMEDIC.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Solothurn manufacturing facility, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB125 (zuranolone)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 we and Sage Therapeutics, Inc. (Sage) announced positive Phase 3 results for BIIB125 (zuranolone) for the potential treatment of major depressive disorder (MDD) and postpartum depression (PPD). In October 2021 we and Sage announced our plan to submit an NDA to the FDA for zuranolone in the second half of 2022, with rolling </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submission expected to start in early 2022. The planned initial submission package will seek approval of zuranolone for MDD, and an additional filing for PPD is anticipated in the first half of 2023. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab (BAN2401)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the FDA granted Breakthrough Therapy designation for lecanemab, an anti-amyloid antibody for the potential treatment of Alzheimer's disease, which we are developing in collaboration with Eisai. In September 2021 Eisai initiated a rolling submission to the FDA of a Biologics License Application (BLA) for lecanemab. The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early Alzheimer's disease and confirmed amyloid pathology. </span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BYOOVIZ (ranibizumab-nuna)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 we and Samsung Bioepis announced that the FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. In addition to the U.S. approval, BYOOVIZ was approved in Europe in August 2021.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB067 (tofersen)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 we announced topline results from our pivotal Phase 3 VALOR study of BIIB067 (tofersen), an investigational antisense drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), indicating that the primary endpoint was not met. We are engaging with regulators and other key stakeholders to determine potential next steps.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,498.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(524.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,690.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(484.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,778.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,376.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(597.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,850.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,803.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,952.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,802.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,587.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,390.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,737.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,244.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,558.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(292.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,247.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,592.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,344.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i8046a3e69c814e7f9967395f631661c6_145"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Revenue</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">967.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(348.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,556.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,984.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(428.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,690.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(484.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,258.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,507.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,470.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,568.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,229.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,660.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,554.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(89.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,390.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,737.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis (MS)</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumarate</span></div><div><img src="biib-20210930_g2.jpg" alt="biib-20210930_g2.jpg" style="height:525px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fumarate revenue includes sales from TECFIDERA and VUMERITY. In October 2019 the FDA approved VUMERITY for the treatment of RMS and VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, compared to the same periods in 2020, the decreases of 56% and 66%, respectively, in U.S. Fumarate revenue were primarily due to a decrease in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market. The decrease was partially offset by an increase in VUMERITY sales volume.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the increases of 13% and 8%, respectively, in rest of world Fumarate revenue were primarily due to increases in TECFIDERA sales volumes of 10% and 7%, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Hatch-Waxman Act in West Virginia and Delaware. We have appealed the judgments in both actions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate an increase in TECFIDERA sales volume in rest of world in 2021, compared to 2020, notwithstanding the increasing competition from additional treatments for MS and potential disruptions due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the E.U. This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face TECFIDERA generic competition in the E.U. if regulatory data protection is not upheld and we expect that this would have an adverse impact on our TECFIDERA sales and our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect an increase in VUMERITY sales volume driven by demand growth.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interferon</span></div><div><img src="biib-20210930_g3.jpg" alt="biib-20210930_g3.jpg" style="height:525px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases of 23% and 22%, respectively, in U.S. Interferon revenue were primarily due to decreases in Interferon sales volumes of 19% and 19%, respectively. The net declines in sales volumes reflect the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases of 8% and 4%, respectively, in rest of world Interferon revenue were primarily due to decreases in Interferon sales volumes of 11% and 5%, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that Interferon revenue will continue to decline in both the U.S. and rest of world markets in 2021, compared to 2020, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div><img src="biib-20210930_g4.jpg" alt="biib-20210930_g4.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, compared to the same period in 2020, the decrease of 8% in U.S. TYSABRI revenue was primarily due to a decrease in sales volume of 13%, partially offset by an increase in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the increase of 3% in U.S. TYSABRI revenue was primarily due to an increase in pricing, partially offset by a decrease in sales volume.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the increases of 14% and 8%, respectively, in rest of world TYSABRI revenue were primarily due to favorable volume impacts, partially offset by decreases in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate TYSABRI sales volume to modestly increase on a global basis in 2021, compared to 2020, despite increasing competition from additional treatments for MS, including OCREVUS. We expect to continue to face price reductions in certain European markets.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spinal Muscular Atrophy</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div><img src="biib-20210930_g5.jpg" alt="biib-20210930_g5.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases of 23% and 30%, respectively, in U.S. SPINRAZA revenue were primarily due to decreases in sales volumes resulting from increased competition.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, compared to the same period in 2020, the decrease of 2% in rest of world SPINRAZA revenue was primarily due to a decrease in sales volume resulting from increased competition as well as a decrease in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the increase of 11% in rest of world SPINRAZA revenue was primarily due to an increase in sales volume of 10% due in part to the timing of shipments in developing markets and increases in patients. The increase was also due to the favorable impact of foreign currency exchange of 4%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect that SPINRAZA revenue will be subject to increased competition resulting in higher discontinuations and a lower rate of new patient starts combined with the impact of loading dose dynamics, as patients transition to dosing once every four months, and lower prices in certain rest of world countries. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from a gene therapy product and an oral product. We expect that we will experience competition from both products in additional jurisdictions in the future, which may adversely affect our sales of SPINRAZA.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alzheimer's Disease</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For the three and nine months ended September 30, 2021, U.S. ADUHELM revenue was approximately $0.3 million and $2.0 million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2021 we expect minimal sales of ADUHELM in the U.S.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BENEPALI, IMRALDI and FLIXABI</span></div><div><img src="biib-20210930_g6.jpg" alt="biib-20210930_g6.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, compared to the same period in 2020, the decrease of 2% in biosimilar revenue was primarily due to decreases in pricing, partially offset by the favorable impact of higher volumes.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the increase of 2% in biosimilar revenue was primarily due to the favorable impact of higher volumes and foreign currency exchange, partially offset by decreases in pricing.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect revenue for our biosimilars business to be flat as compared to 2020. We expect to continue to face price reductions in certain European countries.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_148"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech (Roche Group)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><img src="biib-20210930_g7.jpg" alt="biib-20210930_g7.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:52.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:52.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,700.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,339.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,350.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in U.S.&#160;product revenue, net were primarily due to decreases in sales volumes of RITUXAN in the U.S. of 43.3% and 41.0%, respectively, primarily due to the onset of competition from multiple biosimilar products.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, product revenue, net also reflected increases in GAZYVA sales volume of 5.1% and 10.5%, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in collaboration costs and expense were primarily due to lower cost of sales on RITUXAN.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several other anti-CD20 molecules, including biosimilar products, that have recently been approved and are competing with RITUXAN and GAZYVA in the oncology and other markets. In November 2019, January 2020 and January 2021 biosimilar products referencing RITUXAN were launched in the U.S. and are being offered at lower prices. This competition has had a significant adverse impact on the pre-tax profits of our collaboration arrangements with Genentech, as the sales of RITUXAN have decreased substantially compared to prior periods. We expect that biosimilar competition will continue to increase as these products capture additional market share and that this will have a significant adverse impact on our co-promotion profits in the U.S. in future years.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consists of royalty revenue on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, compared to the same period in 2020, the increase in other revenue from anti-CD20 therapeutic programs was primarily due to sales growth of OCREVUS. Royalty revenue recognized on sales of OCREVUS for the three and nine months ended September 30, 2021, totaled $264.2 million and $730.5&#160;million, respectively, compared to $272.5 </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and $643.0&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note&#160;18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_151"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(293.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(292.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Collaborative and Other Relationships</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other relationships primarily includes royalty revenue on biosimilar products from Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Royalty and Corporate Revenue</span></div><div><img src="biib-20210930_g8.jpg" alt="biib-20210930_g8.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, compared to the same period in 2020, the increase in other corporate revenue was primarily due to higher revenue related to contract manufacturing agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the decrease in other corporate revenue was primarily due to higher contract manufacturing revenue during the second quarter of 2020, resulting from $329.4&#160;million in revenue related to the delivery of a license for certain of our manufacturing-related intellectual property to a contract manufacturing customer.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_154"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><img src="biib-20210930_g9.jpg" alt="biib-20210930_g9.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, reserves for discounts and allowances as a percentage of gross product revenue were 26.5% and 27.9%, respectively, compared to 27.3% and 26.3%, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discounts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in discounts were primarily driven by a decrease in gross sales.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Adjustments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, Veterans Administration, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in contractual adjustments were primarily caused by lower TECFIDERA sales in the U.S., resulting in lower Medicaid and managed care rebates, partially offset by pharmacy rebates.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Returns</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, return reserves were relatively consistent.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_157"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cost and Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">511.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,140.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(438.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,984.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,289.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(304.8)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,314.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,801.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,264.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(463.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,698.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,994.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,711.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20210930_g10.jpg" alt="biib-20210930_g10.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the increases in product cost of sales were primarily due to product mix and higher cost of sales associated with contract manufacturing agreements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the increases in royalty cost of sales were primarily due to higher royalties payable on higher sales of TYSABRI and VUMERITY.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="i8046a3e69c814e7f9967395f631661c6_163"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div><img src="biib-20210930_g11.jpg" alt="biib-20210930_g11.jpg" style="height:366px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20210930_g12.jpg" alt="biib-20210930_g12.jpg" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our research and development costs consists of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in research and development expense were primarily due to $601.3&#160;million in upfront payments recognized upon the closing of our collaboration with Denali in the third quarter of 2020, partially offset by a $125.0&#160;million upfront payment recognized upon closing of our collaboration with InnoCare in the third quarter of 2021, the development of zuranolone for the potential treatment of MDD and PPD, the development of BIIB124 (SAGE-324) for the potential treatment of essential tremor, which we are developing in collaboration with Sage, and closeout costs associated with BIIB111 (timrepigene emparvovec) and BIIB112 (cotoretigene toliparvovec).</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in spending related to our early stage programs were primarily due to decreases in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of opicinumab (anti-LINGO) in MS;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB054 (cinpanemab) in Parkinson's disease and the discontinuation of gosuranemab (BIIB092) in Alzheimer's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of dapirolizumab pego, an anti-CD40L pegylated Fab that we are developing in collaboration with UCB, for the </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential treatment of systemic lupus erytheatosus (SLE) into late stage; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 (anti-BDCA2) for the potential treatment of SLE into late stage.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by increases in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB124 for the potential treatment of essential tremor;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB122 (DNL151) for the potential treatment of Parkinson's disease, which we are developing in collaboration with Denali;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">close out costs related to the discontinuation of gosuranemab (BIIB092) in Alzheimer's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB135 (Orelabrutinib) for the potential treatment of MS; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">closeout costs related to BIIB112.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the increases in spending associated with our late stage programs were primarily due to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of zuranolone for the potential treatment of MDD and PPD;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of dapirolizumab pegol for the potential treatment of SLE into late stage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 for the potential treatment of SLE into late stage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to lecanemab; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">closeout costs related to BIIB111.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 Eisai initiated a global Phase 3 trial for the development of lecanemab in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for lecanemab and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="i8046a3e69c814e7f9967395f631661c6_166"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div><img src="biib-20210930_g13.jpg" alt="biib-20210930_g13.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, selling, general and administrative expense increased 14.1% and 11.1%, respectively, primarily due to increases in personnel in support of the launch of ADUHELM in the U.S. Beginning in the second quarter of 2021, reimbursement from Eisai for its share of U.S. ADUHELM selling, general and administrative expense is reflected within collaboration profit sharing.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i8046a3e69c814e7f9967395f631661c6_169"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20210930_g14.jpg" alt="biib-20210930_g14.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and other programs acquired through business combinations. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, amortization and impairment of acquired intangible assets reflects charges of $15.0&#160;million and $365.0&#160;million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to BIIB111</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the potential treatment of choroideremia, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and charges of $28.4&#160;million and $220.0&#160;million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to BIIB112</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the potential treatment of X-linked retinitis pigmentosa.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, amortization and impairment of acquired intangible assets reflects the impact of a $44.3&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $19.3&#160;million impairment charge related to one of our in-process research and development (IPR&amp;D) intangible assets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenue of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenue and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of September 30, 2021, the carrying value associated with the remaining vixotrigine IPR&amp;D asset for DPN was $132.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112 did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the three and nine months ended September 30, 2021, we recorded impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111, and charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112. As a result, the remaining book values associated with these programs were reduced to zero. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, for the three months ended September 30, 2021, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> $39.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> related to our manufacturing arrangements and </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">other costs that we expect to incur as a result of suspending these programs.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_172"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Profit Sharing</span></div><div><img src="biib-20210930_g15.jpg" alt="biib-20210930_g15.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit sharing primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and, beginning in the second quarter of 2021, Eisai's 45.0% share of income and expenses in the U.S. related to the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, we recognized net profit-sharing expense of $71.8 million and $210.2 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits compared to a net profit sharing expense of $72.9 million and $200.1 million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, we recognized net profit-sharing income of $50.6&#160;million and $90.7&#160;million, respectively, to reflect Eisai's 45.0% share of loss related to the ADUHELM Collaboration Agreement. For the nine months ended September 30, 2021, we also recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment made to Neurimmune related to the launch of ADUHELM in the U.S.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, we also recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment made to Neurimmune related to the submission of the BLA for the approval of ADUHELM to the FDA.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our condensed consolidated financial statements included in this report. </span></div><div id="i8046a3e69c814e7f9967395f631661c6_178"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div><img src="biib-20210930_g16.jpg" alt="biib-20210930_g16.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, the decrease</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the fair value of our contingent consideration obligations was primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development</span></div><div><img src="biib-20210930_g17.jpg" alt="biib-20210930_g17.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of BIIB118, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_184"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div><img src="biib-20210930_g18.jpg" alt="biib-20210930_g18.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, compared to the same period in 2020, the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change in other income (expense), net primarily reflects net unrealized losses on our holdings in equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the change in other income (expense), net primarily reflects net unrealized losses on our holdings in equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $426.9 million and $2.7 million, respectively, compared to net unrealized losses and realized gains (losses) of $82.3 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended September 30, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Ionis, Sage and Sangamo common stock of approximately $424.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $715.2 million and $9.3 million, respectively, compared to net unrealized losses and realized gains (losses) of $40.3 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Ionis, Sage and Sangamo common stock of approximately $709.1&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect a moderate increase in interest expense for 2021, compared to 2020, primarily due to lower interest being capitalized as a result of assets being placed into service during 2021.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income Tax (Benefit) Provision</span></div><div><img src="biib-20210930_g19.jpg" alt="biib-20210930_g19.jpg" style="height:425px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset discussed below, were primarily due to the change in the territorial mix of our profitability, which included the adverse effect of generic competition for TECFIDERA in the U.S. market; the tax impacts of the BIIB111 and BIIB112 impairment charges; and the impact of the non-cash tax effects of changes in the value of our equity investments, where we recorded unrealized losses in 2021.  The tax effects of this change in value of our equity investments were recorded in the current period, as the changes in value of equity investments cannot be reliably forecasted. Our 2020 effective tax rate also reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for the nine months ended September 30, 2021, compared to the same period in 2020, the decrease in our effective tax rate was primarily due to a current year deferred tax benefit in Switzerland resulting from the accelerated approval of ADUHELM by the FDA in the U.S. recognized during the second quarter of 2021. We recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit discussed below. The deferred tax benefit relates to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_190"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity in (Income) Loss of Investee, Net of Tax</span></div><div><img src="biib-20210930_g20.jpg" alt="biib-20210930_g20.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 we exercised our option under our joint venture agreement to increase our ownership </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018. As of September 30, 2021, our ownership percentage remained at approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. We recognize amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, we recognized net income on our investment of $1.1 million and $17.2 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax, compared to net losses on our investment of $13.1 million and $12.7 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income on our investment for the nine months ended September 30, 2021, reflects a $31.2&#160;million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the second quarter of 2021 based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_193"></div><div style="margin-top:14pt"><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div><img src="biib-20210930_g21.jpg" alt="biib-20210930_g21.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the increase is due to the recognition of a current year deferred tax benefit associated with the accelerated approval of ADUHELM by the FDA in the U.S. During the second quarter of 2021, we recorded a net deferred tax asset of approximately $500.0&#160;million related to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the change in net income (loss) attributable to noncontrolling interests, net of tax was also due to the $100.0&#160;million milestone payment to Neurimmune related to the launch of ADUHELM in the U.S. during the second quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, net income (loss) attributable to noncontrolling interests, net of tax was primarily related to the $75.0 million milestone payment to Neurimmune related to the submission of the BLA for the approval of ADUHELM to the FDA.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><div id="i8046a3e69c814e7f9967395f631661c6_196"></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change&#160;%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,413.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">968.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,923.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,382.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,272.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,271.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,162.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,887.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,211.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,742.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,950.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,144.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i8046a3e69c814e7f9967395f631661c6_199"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, certain significant cash flows were as follows:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$2,801.6 million in net cash flow provided by operating activities, which reflected an upfront payment of $125.0&#160;million made in connection with entering into our collaboration with InnoCare and recognized as research and development expense;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1,800.0 million used for share repurchases;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$170.0&#160;million used in connection with our Exchange Offer; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$206.5 million used for purchases of property, plant and equipment; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$100.1&#160;million in total net payments of income taxes; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$100.0&#160;million milestone payment to Neurimmune.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed our operating and capital expenditures primarily through cash flow earned through our operations. We expect our operating expenditures, particularly those related to research and development, clinical trials, commercialization of new products and international expansion to continue to grow. However, we expect to continue funding our current and planned operating requirements primarily through our cash flow earned from our operations as well as our existing cash resources. We believe generic competition for TECFIDERA in the U.S. will continue to reduce our cash flow from operations in 2021 and will have a </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">significant adverse impact on our future cash flow from operations. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had cash, cash equivalents and marketable securities totaling approximately $3.9 billion compared to approximately $3.4 billion as of December 31, 2020. The change in cash, cash equivalents and marketable securities at September 30, 2021, from December 31, 2020, was primarily due to net cash flow provided by operating activities, partially offset by cash used for share repurchases and capital expenditures, cash payments made in connection with our Exchange Offer and a milestone payment made to Neurimmune.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and other assets in our condensed consolidated balance sheets as of September 30, 2021 and December 31, 2020, include the carrying value of our investment in Samsung Bioepis of $586.1 million and $620.2 million, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment may be limited and we may realize significantly less than the value of such investment. This investment is also subject to foreign currency exchange fluctuations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Sangamo, we purchased approximately 24 million shares of Sangamo common stock in April 2020. As of September 30, 2021 and December 31, 2020, the fair value of this investment was $210.5 million and $333.7&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Denali, we purchased approximately 13&#160;million shares of Denali common stock in September 2020. As of September 30, 2021 and December 31, 2020, the fair value of this investment was $612.9&#160;million and $935.7&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Sage, we purchased approximately 6.2&#160;million shares of Sage common stock in December 2020. As of September 30, 2021 and December 31, 2020, the fair value of this investment was $236.9&#160;million and $433.9&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in Ionis common stock had a fair value of $96.4&#160;million and $249.1&#160;million as of September 30, 2021 and December 31, 2020, respectively. The decrease was partially due to the sale of a portion of our investment in Ionis common stock during the first quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, Sangamo, Denali and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer, consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$624.6&#160;million aggregate principal amount of our 2045 Senior Notes was exchanged for $700.7&#160;million aggregate principal amount of our 2051 Senior Notes and approximately $151.8&#160;million of aggregate cash payments; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$8.9&#160;million aggregate principal amount of our 2045 Senior Notes was redeemed for approximately $12.1&#160;million of aggregate cash payments, excluding accrued and unpaid interest.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior unsecured notes issued in 2015 (2015 Senior Notes):</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.12 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes and our 2015 Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of September 30, 2021 and December 31, 2020, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of September 30, </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Total working capital decreased by $194.2&#160;million, or 6.2%, primarily driven by an increase in current liabilities, partially offset by an increase in current liabilities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in current liabilities was primarily due to the reclassification of our $1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022 from long-term to short-term, partially offset by a reduction in accounts payable as well as accrued expense and other, which was primarily related to decreases in the accrual of contingent payments, the accrual for employee compensation and benefits and the fair values of derivative liabilities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total current assets was primarily driven by an increase in net cash, cash equivalents and marketable securities, due to $2,801.6&#160;million of cash generated from operations, partially offset by cash used for share repurchases, capital expenditures and a Neurimmune milestone payment as well as cash payments made in conjunction with our Exchange Offer.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million and 6.0 million shares of our common stock at a cost of approximately $750.0 million and $1.8 billion during the three and nine months ended September 30, 2021, respectively. Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 4.5&#160;million and 16.7&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion and $5.0&#160;billion during the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the nine months ended September 30, 2020.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_202"></div></div></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,801.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,596.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow used in investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(451.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(442.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow used in financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,096.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,871.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the decrease in net cash flow provided by operating activities was primarily due to lower net income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the increase in net cash flow used in investing activities was primarily due to higher net proceeds received from the sale of marketable securities in 2020 as compared to the current year, partially offset by higher capital expenditures and acquisitions of IPR&amp;D and other intangible assets in 2020 as well as the upfront payments made to Sangamo and Denali.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, compared to the same period in 2020, the decrease in net cash flow used in financing activities was primarily due to the greater number of shares repurchased in 2020 as compared to the comparative period in 2021, partially offset by cash used in connection with our Exchange Offer and a milestone payment to Neurimmune in 2021.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_205"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our contractual obligations since December 31, 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make contingent payments of 18.0% on annual worldwide net sales of TYSABRI up to $2.0 billion and 25.0% on annual worldwide net sales of TYSABRI that exceed $2.0 billion. Royalty payments are recognized as cost of sales in our condensed consolidated statements of income.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make royalty payments on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net sales of VUMERITY that is manufactured by us or our designee. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd., we agreed to make additional payments based upon the achievement of certain milestone events.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the contingent consideration liabilities associated with this acquisition at its fair value on the acquisition date and revalue this obligation each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to this acquisition.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of September 30, 2021, we could trigger potential future milestone payments to third parties of up to approximately $10.9 billion, including approximately $2.1 billion in development milestones, approximately $1.2 billion in regulatory milestones and approximately $7.6 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of September 30, 2021, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to $20.5&#160;million in milestones in 2021 under our current agreements. In addition, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $100.0&#160;million in additional milestones to Neurimmune, which includes $50.0&#160;million if launched in three or more countries in the E.U. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $47.0 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of September 30, 2021. We have approximately $644.1 million in cancellable future commitments based on existing CRO contracts as of September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM Corporation (FUJIFILM), we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of September 30, 2021, we have approximately $102.4 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, we have accrued income tax liabilities of approximately $633.0&#160;million and $697.0&#160;million, respectively, under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of September 30, 2021, approximately $72.7&#160;million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_208"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_211"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K. There have been no material changes to our critical accounting estimates since our 2020 Form&#160;10-K.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_214"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and pricing pressures worldwide as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of September 30, 2021, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Expense Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 18 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Risk Management Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of September 30, 2021 and December 31, 2020, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $344.1 million and $458.2 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedge Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of our approximately 49.9% ownership interest in Samsung Bioepis. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next one month. As of September 30, 2021 and December 31, 2020, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $52.4 million and $56.9 million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of September 30, 2021 and December 31, 2020, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $15.0 million and $13.2 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing Pressure</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition in many markets from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the E.U. This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face TECFIDERA generic competition in the E.U. if regulatory data protection is not upheld and we expect that this would have an adverse impact on our TECFIDERA sales and our results of operations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions, including as a result of the COVID-19 pandemic, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of September 30, 2021 and December 31, 2020. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_217"></div><div style="margin-top:12pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:8pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="margin-top:8pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2021. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part&#160;II&#160;&#8212; OTHER INFORMATION</span></div><div id="i8046a3e69c814e7f9967395f631661c6_223"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of September 30, 2021, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_226"></div><div style="margin-top:6pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction or greater acceptance of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third parties;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, regulatory or legislative developments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="margin-top:5pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM is in the early stages of commercial launch in the U.S. In addition to risks associated with new product launches and the other factors described in these Risk Factors, our ability to successfully commercialize ADUHELM may be adversely affected due to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the lack of readiness of healthcare providers to initiate treatment as well as our ability to successfully identify eligible patients based on the information included in ADUHELM&#8217;s label;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">concern regarding the accelerated approval of ADUHELM and its data;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain adequate reimbursement for ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the lack of market acceptance of ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the effectiveness of our commercial strategy for marketing ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in the manufacturing, distribution and supply of ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the approval of other new products for the same or similar indications; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others in the Alzheimer&#8217;s disease community, which may be impacted by pricing and reimbursement decisions relating to ADUHELM.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the accelerated approval, we will conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products from our research and development activities or our licenses or acquisitions from third parties, including our commercialization agreements with Samsung Bioepis, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to pursue other opportunities in our pipeline. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may not meet investor expectations.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market in 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may also be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain appropriate pricing and reimbursement for our products compared to our competitors in key international markets; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators, joint venture partners and other third parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative, joint venture and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third parties. Reliance on third parties subjects us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators, joint venture partners or third parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue as well as involve us in possible legal proceedings; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators, joint venture partners or third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that may impact its operations and business or divert the attention of the Samsung Bioepis management team from its ongoing operations. In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment may be limited and we may realize significantly less than the value of such investment.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is increasing public attention on the costs of prescription drugs and we expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. For example, two committees of the U.S. House of Representatives are investigating the approval and price of ADUHELM. In addition, there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of Samsung Bioepis, collaboration partners and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If these third parties fail to perform successfully, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet higher than anticipated demand. We are dependent on a third-party for the manufacture of biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of patent and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements, requiring confirmatory trials and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML) in the label for certain of our products, may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. Further, the COVID-19 pandemic has caused us to modify our business practices, including changing the requirement that most of our office-based employees in the U.S. and our other key markets work from the office. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including our cloud technologies, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA), and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management and other personnel changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management, other personnel and our overall retention rate may disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract or retain them. We may face difficulty in attracting and retaining talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late-stage programs, recruitment by competitors or changes in the overall labor market favoring flexible working arrangements. In addition, additional changes in our flexible working arrangements could impact employees' productivity and morale as well as our ability to attract, retain, and motivate employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">additional complexity in manufacturing internationally;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the United Kingdom (U.K.), including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped. If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a portion of the Solothurn facility received a GMP multi-product license from SWISSMEDIC in May 2021, the manufacturing of a product or product candidate at the Solothurn facility must be approved by the applicable regulatory agencies, including the FDA. There can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of a product or a product candidate. If we do not receive the necessary regulatory approvals of the Solothurn facility or if our future growth and drug development plans increase, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:12.53pt">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. Furthermore, factors such as the COVID-19 pandemic, weather events, labor or raw material shortages and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results in operations or result in product shortages.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors. </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk Relating to Government Actions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act, which may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. Further, the current administration could introduce new tax laws or revise or issue new interpretations of the 2017 Tax Act.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) resulted in significant changes to the Swiss cantonal income tax system. Final interpretation of the transitional and new regimes of the TRAF may require further adjustments and changes in our estimates, which could have a significant adverse effect on our business, results of operations or financial condition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected, directly or indirectly, by the ongoing COVID-19 pandemic. National, state and local governments have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns and other measures. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including limiting travel and working from home. We have also suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings. This limits our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in flexible working arrangements could impact employee retention, employees&#8217; productivity and morale, strain our technology resources and introduce operational risks. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties we rely on. Furthermore, delays and disruptions experienced by our collaborators, joint venture partners or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue our existing clinical trials or to initiate new clinical trials may be adversely affected, directly or indirectly, by the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for LHI has been delayed as this study involves administration of BIIB093 in an acute hospital setting. Restrictions on travel and/or transport of clinical materials as well as diversion of hospital staff and resources to COVID-19 infected patients could disrupt trial operations and recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. We may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, legislation has been enacted aimed at providing emergency assistance and health care for individuals, families and businesses and broadly supporting the U.S. economy. Additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures and have a financial impact our business that we cannot predict.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business, operations, employees, customers, suppliers or collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, supply chain and distribution systems, results of operations and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stock</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, negative company specific news, biotechnology market sentiment, instability in the global financial markets that reduces the liquidity of securities in our portfolio, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_229"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the third quarter of 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,550.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,100,000&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.89&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,100,000&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,834.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,230&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344.06&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,230&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,800.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199,230&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.03&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million and 6.0 million shares of our common stock at a cost of approximately $750.0 million and $1.8 billion during the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, respectively. Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 4.5&#160;million and 16.7&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion and $5.0&#160;billion during the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately  4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the nine months ended September 30, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="i8046a3e69c814e7f9967395f631661c6_235"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:19pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021930xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021930xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021930xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2021, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline XBRL.</span></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i8046a3e69c814e7f9967395f631661c6_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8046a3e69c814e7f9967395f631661c6_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October&#160;20, 2021 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2021930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6f7c11731d0b447c8880b563d10a390b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michel Vounatsos, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 20, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2021930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ida328b3fca4948d3ae30046691fa8322_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 20, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2021930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5803693557a947a7b286985c8e08e421_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 20, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 20, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a903f54e-5284-4407-a747-e0b1f5468222,g:e7d07c56-2dfc-4728-a119-070b245a209e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2104102 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual">
        <link:definition>2405402 - Disclosure - Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2106103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2307301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyproductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails">
        <link:definition>2408403 - Disclosure - Revenues - Revenues by product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1">
        <link:definition>2409404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2">
        <link:definition>2410405 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>2411406 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>2412407 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>2413408 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2114104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2315302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2416409 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2117105 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2318303 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2419410 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1">
        <link:definition>2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2121106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2322304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2423412 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2424413 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNonrecurringAssetsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails">
        <link:definition>2426415 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2427416 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2428417 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2129107 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2330305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2431418 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2432419 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2433420 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2434421 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2435422 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2436423 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2137108 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2338306 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2439424 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>2140109 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>2441425 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2142110 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2443426 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2144111 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2345307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2446427 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2447428 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2448429 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>2149112 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>2350308 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>2451430 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>2152113 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2353309 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2454431 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2455432 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2156114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2357310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2458433 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2459434 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2160115 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2361311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2462435 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2463436 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>2164116 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>2365312 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails">
        <link:definition>2466437 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2467438 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>2168117 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>2469439 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2170118 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2471440 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEvents">
        <link:definition>2172119 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BIIB118Member" abstract="true" name="BIIB118Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DebtInstrumentRedemptionAmount" abstract="false" name="DebtInstrumentRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" abstract="false" name="EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredTaxAssetIncreaseDecreaseInValue" abstract="false" name="DeferredTaxAssetIncreaseDecreaseInValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ManufacturingAndOtherCosts" abstract="false" name="ManufacturingAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetDomain" abstract="true" name="ResearchanddevelopmentassetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" abstract="false" name="GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DividendYieldPercentage" abstract="false" name="DividendYieldPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" abstract="true" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_VixotrigineMember" abstract="true" name="VixotrigineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_DeferredTaxAssetsValueReductioninValue" abstract="false" name="DeferredTaxAssetsValueReductioninValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InnoCarePharmaLimitedInnoCareAgreementMember" abstract="true" name="InnoCarePharmaLimitedInnoCareAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB112Member" abstract="true" name="BIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A3250SeniorNotesDueFebruary152051Member" abstract="true" name="A3250SeniorNotesDueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_December2019ShareRepurchaseProgramMember" abstract="true" name="December2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NoncontrollingInterestCapitalContribution" abstract="false" name="NoncontrollingInterestCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OthercorporaterevenuesMember" abstract="true" name="OthercorporaterevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DuefromantiCD20therapeuticprograms" abstract="false" name="DuefromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SangamoTherapeuticsInc.AgreementMember" abstract="true" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementAmountSharesPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_LongTermDebtExchangedAmount" abstract="false" name="LongTermDebtExchangedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" abstract="false" name="DeferredTaxLiabilitiesIncreaseDecreaseInValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AcquisitionsAbstract" abstract="true" name="AcquisitionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Biogenshareofcopromotionprofitsorlosses" abstract="false" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" abstract="false" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NoncontrollingInterestIncreaseDecreaseOther" abstract="false" name="NoncontrollingInterestIncreaseDecreaseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_OutLicensedPatentsMember" abstract="true" name="OutLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TechnologicalAndRegulatorySuccessProbability" abstract="false" name="TechnologicalAndRegulatorySuccessProbability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Termofcollaborationagreement" abstract="false" name="Termofcollaborationagreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" abstract="false" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" abstract="false" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="us-types:durationStringItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Investmentincommonstocksharespurchased" abstract="false" name="Investmentincommonstocksharespurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_AccruedMilestonePayments" abstract="false" name="AccruedMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_SangamoCommonStockMember" abstract="true" name="SangamoCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB111Member" abstract="true" name="BIIB111Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ADUHELMMember" abstract="true" name="ADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageParValueOfSeniorNotes" abstract="false" name="PercentageParValueOfSeniorNotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NightstarMember" abstract="true" name="NightstarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" abstract="false" name="GlobalLicensingCollaborationAgreementPurchasePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashSettledPerformanceSharesMember" abstract="true" name="CashSettledPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FUMADERMMember" abstract="true" name="FUMADERMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" abstract="false" name="PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ContingentMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="ContingentMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2.90SeniorNotesDueSept152020Member" abstract="true" name="A2.90SeniorNotesDueSept152020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="biib_BIIB111AndBIIB112Member" abstract="true" name="BIIB111AndBIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_Reductioninroyaltyratepayableoncommercialsales" abstract="false" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_TGNMember" abstract="true" name="TGNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_March2019ShareRepurchaseProgramMember" abstract="true" name="March2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ZINBRYTAMember" abstract="true" name="ZINBRYTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" abstract="false" name="EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesValueReductioninValue" abstract="false" name="DeferredTaxLiabilitiesValueReductioninValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="biib_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Inventorynetcurrentandnoncurrent" abstract="false" name="Inventorynetcurrentandnoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_October2020ShareRepurchaseProgramMember" abstract="true" name="October2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A2018ShareRepurchaseProgramMember" abstract="true" name="A2018ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>biib-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a903f54e-5284-4407-a747-e0b1f5468222,g:e7d07c56-2dfc-4728-a119-070b245a209e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_02614e7c-7812-4e3a-8404-93924d481413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be777ed0-9d1f-44f5-89ce-4e1b70db7e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_02614e7c-7812-4e3a-8404-93924d481413" xlink:to="loc_us-gaap_OperatingIncomeLoss_be777ed0-9d1f-44f5-89ce-4e1b70db7e48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3eb73807-13b5-43dd-9ae4-0d55b4a518f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_02614e7c-7812-4e3a-8404-93924d481413" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3eb73807-13b5-43dd-9ae4-0d55b4a518f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_958cbc8f-9848-4868-8d2c-822b2bc26337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f7115835-f849-49f3-b972-061354255b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_958cbc8f-9848-4868-8d2c-822b2bc26337" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f7115835-f849-49f3-b972-061354255b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9fa8abdc-3b19-4010-a8d9-af9bfe9217f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_958cbc8f-9848-4868-8d2c-822b2bc26337" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9fa8abdc-3b19-4010-a8d9-af9bfe9217f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1a0b24ec-585f-48cc-9ba7-dafda47927c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_958cbc8f-9848-4868-8d2c-822b2bc26337" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1a0b24ec-585f-48cc-9ba7-dafda47927c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_e46946aa-92fe-4ce0-9f56-08e1f3013ce2" xlink:href="biib-20210930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_958cbc8f-9848-4868-8d2c-822b2bc26337" xlink:to="loc_biib_Collaborationprofitlosssharing_e46946aa-92fe-4ce0-9f56-08e1f3013ce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c0e89d0a-ef43-494f-bdc3-32b3cdc6d9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_958cbc8f-9848-4868-8d2c-822b2bc26337" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c0e89d0a-ef43-494f-bdc3-32b3cdc6d9d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0a11a73b-b98a-4da2-988e-1ceb1e83a06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_958cbc8f-9848-4868-8d2c-822b2bc26337" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0a11a73b-b98a-4da2-988e-1ceb1e83a06d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_cbc8a9b3-bcf9-4d8f-b606-3bc9541ceb05" xlink:href="biib-20210930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_958cbc8f-9848-4868-8d2c-822b2bc26337" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_cbc8a9b3-bcf9-4d8f-b606-3bc9541ceb05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f113acdc-5880-47b2-bb8a-85f46c5a079b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cf004e46-25e0-40d9-8d92-5885148b230e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f113acdc-5880-47b2-bb8a-85f46c5a079b" xlink:to="loc_us-gaap_Revenues_cf004e46-25e0-40d9-8d92-5885148b230e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d9c53b41-1588-4e6f-952a-417d935803a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f113acdc-5880-47b2-bb8a-85f46c5a079b" xlink:to="loc_us-gaap_CostsAndExpenses_d9c53b41-1588-4e6f-952a-417d935803a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_208c77b3-2867-4375-8bce-9a23a8d36a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c20fa43b-29d2-4a9d-b4f3-e88e3d85b4fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_208c77b3-2867-4375-8bce-9a23a8d36a2b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c20fa43b-29d2-4a9d-b4f3-e88e3d85b4fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_069c2e3e-49bf-47ff-91f6-04ce0a8af248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_208c77b3-2867-4375-8bce-9a23a8d36a2b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_069c2e3e-49bf-47ff-91f6-04ce0a8af248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_983c9148-1590-4ad9-949b-ef378e034c01" xlink:href="biib-20210930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_208c77b3-2867-4375-8bce-9a23a8d36a2b" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_983c9148-1590-4ad9-949b-ef378e034c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_debf15dd-84f0-4c24-9da5-6e8bcc2812f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8e15df94-0e19-4da9-b457-5dc67a988d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_debf15dd-84f0-4c24-9da5-6e8bcc2812f3" xlink:to="loc_us-gaap_ProfitLoss_8e15df94-0e19-4da9-b457-5dc67a988d71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2615e5a6-4dcf-46fb-bac0-574ed64a9cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_debf15dd-84f0-4c24-9da5-6e8bcc2812f3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2615e5a6-4dcf-46fb-bac0-574ed64a9cd1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e705f444-01ed-4615-b1c6-00cc601a809e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a69bb06b-672e-44cf-a84c-962fc7f76b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e705f444-01ed-4615-b1c6-00cc601a809e" xlink:to="loc_us-gaap_NetIncomeLoss_a69bb06b-672e-44cf-a84c-962fc7f76b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ca662b83-efaa-457e-aab5-51fac763b85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e705f444-01ed-4615-b1c6-00cc601a809e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ca662b83-efaa-457e-aab5-51fac763b85f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b049315d-d753-4296-8af3-36f3110fe6a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bd9b36e0-5668-4085-9e67-4fc2bd4142d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b049315d-d753-4296-8af3-36f3110fe6a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bd9b36e0-5668-4085-9e67-4fc2bd4142d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a115ba9d-de32-4835-8a1b-0d999bcb1def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b049315d-d753-4296-8af3-36f3110fe6a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a115ba9d-de32-4835-8a1b-0d999bcb1def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_aad9ce7f-4222-4709-b397-6e7c388c7dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b049315d-d753-4296-8af3-36f3110fe6a4" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_aad9ce7f-4222-4709-b397-6e7c388c7dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8e81627a-fde2-4f27-8470-eb6398a17c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b049315d-d753-4296-8af3-36f3110fe6a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8e81627a-fde2-4f27-8470-eb6398a17c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3c78655a-1ac7-4da6-8625-30fb6e45039b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b049315d-d753-4296-8af3-36f3110fe6a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3c78655a-1ac7-4da6-8625-30fb6e45039b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c77c3495-984b-41e6-a27a-01d07b5902d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_fbed9093-337a-4da1-8a12-e28b9ea39a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c77c3495-984b-41e6-a27a-01d07b5902d1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_fbed9093-337a-4da1-8a12-e28b9ea39a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c6d87afd-181a-40e1-8473-b9b442d1973e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c77c3495-984b-41e6-a27a-01d07b5902d1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c6d87afd-181a-40e1-8473-b9b442d1973e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b82efa6-f3ba-40e2-8a58-f802e4c73a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2ed745a2-bfee-4358-b640-a31f4a39e219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b82efa6-f3ba-40e2-8a58-f802e4c73a21" xlink:to="loc_us-gaap_StockholdersEquity_2ed745a2-bfee-4358-b640-a31f4a39e219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6fdecf70-b314-4f05-b5e8-d36fbee1a04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b82efa6-f3ba-40e2-8a58-f802e4c73a21" xlink:to="loc_us-gaap_MinorityInterest_6fdecf70-b314-4f05-b5e8-d36fbee1a04b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36aa9ad0-6a63-4cb6-a570-19537c5affbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f920e795-eeaa-47ee-bf55-201fabe27a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36aa9ad0-6a63-4cb6-a570-19537c5affbd" xlink:to="loc_us-gaap_PreferredStockValue_f920e795-eeaa-47ee-bf55-201fabe27a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b264dda4-0fa2-4480-8181-97e72ca61fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36aa9ad0-6a63-4cb6-a570-19537c5affbd" xlink:to="loc_us-gaap_CommonStockValue_b264dda4-0fa2-4480-8181-97e72ca61fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a9ae94a3-9a24-4dc8-a2f2-dec846d5489e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36aa9ad0-6a63-4cb6-a570-19537c5affbd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a9ae94a3-9a24-4dc8-a2f2-dec846d5489e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3a9d464e-b707-457a-911b-f4138e0ecdc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36aa9ad0-6a63-4cb6-a570-19537c5affbd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3a9d464e-b707-457a-911b-f4138e0ecdc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_08128df5-d6fc-4125-8435-6333cc17a06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36aa9ad0-6a63-4cb6-a570-19537c5affbd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_08128df5-d6fc-4125-8435-6333cc17a06d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_021741a1-8dae-43b7-a565-14f651dee51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_36aa9ad0-6a63-4cb6-a570-19537c5affbd" xlink:to="loc_us-gaap_TreasuryStockValue_021741a1-8dae-43b7-a565-14f651dee51f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_97b99eb1-dcb1-4d4b-ab62-f304958706e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:to="loc_us-gaap_AssetsCurrent_97b99eb1-dcb1-4d4b-ab62-f304958706e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_87d43881-1807-4762-8242-f636e0405734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_87d43881-1807-4762-8242-f636e0405734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_483d1a5b-36de-4e90-a7e2-db2517c9fb84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_483d1a5b-36de-4e90-a7e2-db2517c9fb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_41e3874f-4aec-49c2-a786-eb9300b288f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_41e3874f-4aec-49c2-a786-eb9300b288f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1646f33d-0b7f-41b9-9a65-d5e7ce72eb84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1646f33d-0b7f-41b9-9a65-d5e7ce72eb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cbfc0a6b-0997-44a9-995b-7258e4da2905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:to="loc_us-gaap_Goodwill_cbfc0a6b-0997-44a9-995b-7258e4da2905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2e0fdf7f-df7e-4230-84a7-ff8678522f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2e0fdf7f-df7e-4230-84a7-ff8678522f7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b603ae43-42ca-4010-88ef-4eca4b6d3b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36cc13f4-a011-414d-b210-be847e27db3d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b603ae43-42ca-4010-88ef-4eca4b6d3b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_622782c1-d2d9-4e97-afa6-61b25d44a04d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ed937bff-f617-402d-a41a-a6cc474c7024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_622782c1-d2d9-4e97-afa6-61b25d44a04d" xlink:to="loc_us-gaap_AccountsPayableCurrent_ed937bff-f617-402d-a41a-a6cc474c7024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_a5354a80-3d03-4798-bd81-ee7bfb89ce43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_622782c1-d2d9-4e97-afa6-61b25d44a04d" xlink:to="loc_us-gaap_TaxesPayableCurrent_a5354a80-3d03-4798-bd81-ee7bfb89ce43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_09bc2c48-b254-4049-b3a3-98fabf798441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_622782c1-d2d9-4e97-afa6-61b25d44a04d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_09bc2c48-b254-4049-b3a3-98fabf798441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_2513cbd2-4878-4844-923b-0d56bb70a2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_622782c1-d2d9-4e97-afa6-61b25d44a04d" xlink:to="loc_us-gaap_NotesPayableCurrent_2513cbd2-4878-4844-923b-0d56bb70a2e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e51f1de4-318d-4f1c-899b-6bee6f44e285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e64b92c1-81ae-4ab0-b183-b901f9ca8cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e51f1de4-318d-4f1c-899b-6bee6f44e285" xlink:to="loc_us-gaap_LiabilitiesCurrent_e64b92c1-81ae-4ab0-b183-b901f9ca8cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_17a0f046-5580-4614-b791-c702eaeb953c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e51f1de4-318d-4f1c-899b-6bee6f44e285" xlink:to="loc_us-gaap_LongTermDebt_17a0f046-5580-4614-b791-c702eaeb953c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2d8aa44f-23ef-4b57-8ec9-81e63ef507a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e51f1de4-318d-4f1c-899b-6bee6f44e285" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2d8aa44f-23ef-4b57-8ec9-81e63ef507a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e2f50b8-461d-4501-afc1-4990a3f27f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e51f1de4-318d-4f1c-899b-6bee6f44e285" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e2f50b8-461d-4501-afc1-4990a3f27f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_042fa154-4024-4a7b-8706-59b6196a2283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e51f1de4-318d-4f1c-899b-6bee6f44e285" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_042fa154-4024-4a7b-8706-59b6196a2283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_859bb0b6-6b96-4ccc-9659-22d72a0335b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e43fbc2f-684c-4c14-9868-e005ff9dc40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_859bb0b6-6b96-4ccc-9659-22d72a0335b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e43fbc2f-684c-4c14-9868-e005ff9dc40b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cc59d39e-99f5-4fd7-8c82-2da84843f76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_859bb0b6-6b96-4ccc-9659-22d72a0335b4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cc59d39e-99f5-4fd7-8c82-2da84843f76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a1242206-891a-445d-8610-e0098dcc02af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_859bb0b6-6b96-4ccc-9659-22d72a0335b4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a1242206-891a-445d-8610-e0098dcc02af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_58a41d39-7503-4003-99bf-ff98c140c0fb" xlink:href="biib-20210930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_859bb0b6-6b96-4ccc-9659-22d72a0335b4" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_58a41d39-7503-4003-99bf-ff98c140c0fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_82e6fbe2-460b-480f-8cda-ba6d4852c67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_859bb0b6-6b96-4ccc-9659-22d72a0335b4" xlink:to="loc_us-gaap_InventoryNet_82e6fbe2-460b-480f-8cda-ba6d4852c67c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6d26e5f6-1809-49bd-baeb-67b664a0e488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_859bb0b6-6b96-4ccc-9659-22d72a0335b4" xlink:to="loc_us-gaap_OtherAssetsCurrent_6d26e5f6-1809-49bd-baeb-67b664a0e488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ce2b732-8979-4e0e-8c84-2b22eaedcc33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_858a827e-56f9-48c7-be8b-aa28b6f36eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ce2b732-8979-4e0e-8c84-2b22eaedcc33" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_858a827e-56f9-48c7-be8b-aa28b6f36eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f0f3dcef-3346-475a-bc3e-1f6a47c8edae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ce2b732-8979-4e0e-8c84-2b22eaedcc33" xlink:to="loc_us-gaap_Liabilities_f0f3dcef-3346-475a-bc3e-1f6a47c8edae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6edfcbbc-6af9-41af-8fed-7803fdf6d377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ce2b732-8979-4e0e-8c84-2b22eaedcc33" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6edfcbbc-6af9-41af-8fed-7803fdf6d377" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_1ef9e4b6-4ef4-42cf-8035-004fe834a831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_1ef9e4b6-4ef4-42cf-8035-004fe834a831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31e3a156-4c29-4914-a560-f303f3523406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31e3a156-4c29-4914-a560-f303f3523406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f4d31c04-ae60-437c-9448-9f7317e2dd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f4d31c04-ae60-437c-9448-9f7317e2dd5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ce117a77-78f7-4068-82f4-2496cbc22c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ce117a77-78f7-4068-82f4-2496cbc22c5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d205ea90-8a22-4a5f-8e68-f65dc145a461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d205ea90-8a22-4a5f-8e68-f65dc145a461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f964559a-39bd-4c75-9486-43f0e2e80bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f964559a-39bd-4c75-9486-43f0e2e80bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5a8265e1-4fe9-4692-8ebe-2073ee7986ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_ShareBasedCompensation_5a8265e1-4fe9-4692-8ebe-2073ee7986ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3066dd0a-fc64-48cf-a4da-0a3a5b037e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3066dd0a-fc64-48cf-a4da-0a3a5b037e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dd1eb17c-8a58-4243-8cb7-50bdd452555f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dd1eb17c-8a58-4243-8cb7-50bdd452555f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e9eb3dbc-aad3-4484-8d49-de6fbab44afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e9eb3dbc-aad3-4484-8d49-de6fbab44afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c0bebdc2-ad3f-43dd-93df-02c589fc3143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c0bebdc2-ad3f-43dd-93df-02c589fc3143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1e0cf8a0-5cd6-45d6-b180-991a53a8f8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1e0cf8a0-5cd6-45d6-b180-991a53a8f8f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c8050c1e-e4b3-4dc6-a7b7-cf86a691aaeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_ProfitLoss_c8050c1e-e4b3-4dc6-a7b7-cf86a691aaeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3f9282b8-b01b-4b57-9064-93863d4acb2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3f9282b8-b01b-4b57-9064-93863d4acb2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e8eb89b9-f5ec-4979-83d3-b26dee221914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e8eb89b9-f5ec-4979-83d3-b26dee221914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7fd068d0-17e7-47e9-9cbe-b09324088cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c38dc208-89a9-4e69-99e7-7c9e098c3b39" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7fd068d0-17e7-47e9-9cbe-b09324088cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3534eaab-745f-48b4-a5c1-cdfa86fafd26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ee678ab4-a21e-4639-809b-fbee34d47549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3534eaab-745f-48b4-a5c1-cdfa86fafd26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ee678ab4-a21e-4639-809b-fbee34d47549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41fd1c61-ec39-4342-bce5-173639d06a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3534eaab-745f-48b4-a5c1-cdfa86fafd26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41fd1c61-ec39-4342-bce5-173639d06a0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc66274f-41b6-4969-a068-9d432bba2526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3534eaab-745f-48b4-a5c1-cdfa86fafd26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc66274f-41b6-4969-a068-9d432bba2526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_69b43e8f-c896-44dc-b6a8-7c83d27ba451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_69b43e8f-c896-44dc-b6a8-7c83d27ba451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_52199bcd-b751-4a7b-95d3-013208f89f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_52199bcd-b751-4a7b-95d3-013208f89f6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_aae8522f-ccbf-48f3-b8c3-cfda640a7e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_aae8522f-ccbf-48f3-b8c3-cfda640a7e9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8aa349bc-c220-4054-baa6-f5a0e78cd446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8aa349bc-c220-4054-baa6-f5a0e78cd446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9a509cb7-434c-4525-b206-a486ecfceb60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9a509cb7-434c-4525-b206-a486ecfceb60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_0c28d642-fd07-40b7-b2fe-319fbdcdaff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_0c28d642-fd07-40b7-b2fe-319fbdcdaff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f83b2dd3-d3ba-41ba-93e7-97dd96e4baba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f83b2dd3-d3ba-41ba-93e7-97dd96e4baba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2b86c3d4-82bc-418e-b5ce-c16baeddaaa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2b86c3d4-82bc-418e-b5ce-c16baeddaaa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1a8d13e1-55da-4068-8a1d-0209583fa868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1466c431-d36e-4815-a064-8c3690a3c87a" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1a8d13e1-55da-4068-8a1d-0209583fa868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_01eb05b7-f301-4d6d-9c58-e7b3cfc94749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_01eb05b7-f301-4d6d-9c58-e7b3cfc94749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_73e2cff0-1cb6-43b4-8ff5-9d319b3c05f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_73e2cff0-1cb6-43b4-8ff5-9d319b3c05f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_aced1e55-5f26-4a7b-86b8-83b1d6953027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_aced1e55-5f26-4a7b-86b8-83b1d6953027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e589d1fb-4417-48e2-8ae4-14741b609b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e589d1fb-4417-48e2-8ae4-14741b609b72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a92767d4-f293-40b2-8b3c-838ea782da77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a92767d4-f293-40b2-8b3c-838ea782da77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5179b7a0-854e-417a-87d4-ebb37b6e7f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5179b7a0-854e-417a-87d4-ebb37b6e7f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_df344233-a374-435a-8020-e62d4b0a6eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_df344233-a374-435a-8020-e62d4b0a6eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0ed63986-b377-449c-952d-00df3cf26a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f33f5f7-2a7d-490a-95d4-eaf582b3b3f2" xlink:to="loc_us-gaap_RepaymentsOfDebt_0ed63986-b377-449c-952d-00df3cf26a85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ce36fa47-1f2f-4654-891d-796dba5e101f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_3d70c585-3822-4f53-aae5-58d56815c099" xlink:href="biib-20210930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ce36fa47-1f2f-4654-891d-796dba5e101f" xlink:to="loc_biib_ShareOfCoPromotionProfits_3d70c585-3822-4f53-aae5-58d56815c099" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_8a0cc8d2-a3ff-4ed8-b519-cc9983103b27" xlink:href="biib-20210930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_fdf1482b-76e7-4c2c-9314-1d7962d2096c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8a0cc8d2-a3ff-4ed8-b519-cc9983103b27" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_fdf1482b-76e7-4c2c-9314-1d7962d2096c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6384a597-c136-4071-b287-b367093e74b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8a0cc8d2-a3ff-4ed8-b519-cc9983103b27" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6384a597-c136-4071-b287-b367093e74b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7d4d4e6b-0f7f-4e9f-b91c-a13c55873898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8a0cc8d2-a3ff-4ed8-b519-cc9983103b27" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7d4d4e6b-0f7f-4e9f-b91c-a13c55873898" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d5d96752-ca9d-4d03-931b-93dfc4d558cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_158c3e01-b440-420f-8cce-5e41ec589e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d5d96752-ca9d-4d03-931b-93dfc4d558cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_158c3e01-b440-420f-8cce-5e41ec589e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_55c120e0-56af-49e3-af88-52ec14ba1d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d5d96752-ca9d-4d03-931b-93dfc4d558cc" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_55c120e0-56af-49e3-af88-52ec14ba1d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42f533e8-5ec6-4fd7-aebd-b9cb68b30c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4e6dcc3e-b37c-4daa-9ab8-45195eb314b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42f533e8-5ec6-4fd7-aebd-b9cb68b30c96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4e6dcc3e-b37c-4daa-9ab8-45195eb314b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_023d75b6-6c73-44fd-9120-84260b3b64b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42f533e8-5ec6-4fd7-aebd-b9cb68b30c96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_023d75b6-6c73-44fd-9120-84260b3b64b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6ddba492-dca8-416e-88c5-4492d05f9de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3c6456c5-6975-4a1d-821b-38c6c69efcd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6ddba492-dca8-416e-88c5-4492d05f9de8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3c6456c5-6975-4a1d-821b-38c6c69efcd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e335fb0c-bef8-47c0-90c8-3ae4d97a315a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6ddba492-dca8-416e-88c5-4492d05f9de8" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e335fb0c-bef8-47c0-90c8-3ae4d97a315a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0898c4d4-3367-450e-90e0-e7e6f2db1852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8c686df-af63-4dea-bc24-1e5d8ab9b3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0898c4d4-3367-450e-90e0-e7e6f2db1852" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8c686df-af63-4dea-bc24-1e5d8ab9b3a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bc0cadd6-8c84-4b50-8aaf-5c5fc82e0215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0898c4d4-3367-450e-90e0-e7e6f2db1852" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bc0cadd6-8c84-4b50-8aaf-5c5fc82e0215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed825d22-f15a-41e3-accb-a9134d0c3186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0898c4d4-3367-450e-90e0-e7e6f2db1852" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed825d22-f15a-41e3-accb-a9134d0c3186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_7c5437a9-32f7-44af-ba09-a99f5f3d431f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_56609d45-d253-4a8d-9f87-a79f72c3ad80" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_7c5437a9-32f7-44af-ba09-a99f5f3d431f" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_56609d45-d253-4a8d-9f87-a79f72c3ad80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_9f722e3a-ad9b-4685-ab26-45d1034cb82a" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_7c5437a9-32f7-44af-ba09-a99f5f3d431f" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_9f722e3a-ad9b-4685-ab26-45d1034cb82a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_79b40308-ba96-4121-8a2d-3d3808ef6b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_7c5437a9-32f7-44af-ba09-a99f5f3d431f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_79b40308-ba96-4121-8a2d-3d3808ef6b5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46a3145e-babf-4ceb-bda5-2832234de296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_fb36469b-2f20-4ed1-abae-d4ab24ee2d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46a3145e-babf-4ceb-bda5-2832234de296" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_fb36469b-2f20-4ed1-abae-d4ab24ee2d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_c365bb03-79a9-4ffa-ae81-673416eaab56" xlink:href="biib-20210930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46a3145e-babf-4ceb-bda5-2832234de296" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_c365bb03-79a9-4ffa-ae81-673416eaab56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec422cb2-1b4c-419d-b89a-067c5fd7c77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46a3145e-babf-4ceb-bda5-2832234de296" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec422cb2-1b4c-419d-b89a-067c5fd7c77d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e6480ea-0b16-4a5a-8acd-c0e68f86650d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8a9386f1-4fe6-4fae-9f5c-4cefe56f0531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e6480ea-0b16-4a5a-8acd-c0e68f86650d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8a9386f1-4fe6-4fae-9f5c-4cefe56f0531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a3f6c4cd-fb98-46ec-8210-d13f660606f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e6480ea-0b16-4a5a-8acd-c0e68f86650d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a3f6c4cd-fb98-46ec-8210-d13f660606f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_5741351b-9373-4e47-b0aa-f64cfc127f28" xlink:href="biib-20210930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e6480ea-0b16-4a5a-8acd-c0e68f86650d" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_5741351b-9373-4e47-b0aa-f64cfc127f28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7d0c6c40-32f2-43c4-bc55-0aeb3418e83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d5ac9f90-998e-4bae-b1a8-3e9f4a004857" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7d0c6c40-32f2-43c4-bc55-0aeb3418e83f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d5ac9f90-998e-4bae-b1a8-3e9f4a004857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_903d152e-8037-44a6-9a53-4f31c2568973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7d0c6c40-32f2-43c4-bc55-0aeb3418e83f" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_903d152e-8037-44a6-9a53-4f31c2568973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fd43a6e7-bf64-4648-8fbe-64e34907ab99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c31d096e-788b-4610-a624-9514dc6f14c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fd43a6e7-bf64-4648-8fbe-64e34907ab99" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c31d096e-788b-4610-a624-9514dc6f14c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_bd2fe0d2-c426-423e-8f9b-420142c31cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8423b726-dbaf-4cf5-a85e-b56900f169e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_bd2fe0d2-c426-423e-8f9b-420142c31cc3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8423b726-dbaf-4cf5-a85e-b56900f169e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_46b67a4e-b4ee-4eb5-9c34-3c3e41f0be27" xlink:href="biib-20210930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_bd2fe0d2-c426-423e-8f9b-420142c31cc3" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_46b67a4e-b4ee-4eb5-9c34-3c3e41f0be27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d5b63979-7012-4743-87d3-fe8280633c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a791d544-0203-423a-9ab2-0b5a55274737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d5b63979-7012-4743-87d3-fe8280633c9e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a791d544-0203-423a-9ab2-0b5a55274737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2fcc1254-b606-466a-986d-5b7fd9c4485f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d5b63979-7012-4743-87d3-fe8280633c9e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2fcc1254-b606-466a-986d-5b7fd9c4485f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b9d00fde-94c1-4e20-9ccf-1fdd2e42e480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b9d00fde-94c1-4e20-9ccf-1fdd2e42e480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f0d1119f-4060-4002-82df-676ec6b4936c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f0d1119f-4060-4002-82df-676ec6b4936c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_bc701784-7ff9-4173-ae0a-984b1d482a77" xlink:href="biib-20210930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_bc701784-7ff9-4173-ae0a-984b1d482a77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_c5aed0e0-efd0-40ad-b2c0-3a63beff1d97" xlink:href="biib-20210930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_c5aed0e0-efd0-40ad-b2c0-3a63beff1d97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_2fa63180-c108-4bf9-acea-0b1064eac7f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_2fa63180-c108-4bf9-acea-0b1064eac7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f9c75e6d-909a-4aad-94b9-b9464dc90c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f9c75e6d-909a-4aad-94b9-b9464dc90c92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_cbceb55a-69c9-480e-86db-627269030be9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_cbceb55a-69c9-480e-86db-627269030be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_c163cd7d-a23e-423f-84b1-99bdf7c1c273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_c163cd7d-a23e-423f-84b1-99bdf7c1c273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8347a357-0d05-41c6-8f35-b859213246d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3380ee46-7cd5-4946-a213-9c4096d9cb9c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8347a357-0d05-41c6-8f35-b859213246d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_979982f3-a58f-4c62-ab03-6ff7c1328542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4833b8ad-ac07-44dd-96f6-bef805d7a70b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_979982f3-a58f-4c62-ab03-6ff7c1328542" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4833b8ad-ac07-44dd-96f6-bef805d7a70b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7739ca5e-3070-44cf-bc0b-024d941f5949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_979982f3-a58f-4c62-ab03-6ff7c1328542" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7739ca5e-3070-44cf-bc0b-024d941f5949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_76fbb69f-9e88-4202-91f3-f398a27d398d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c1493a4a-af67-46a1-a10c-837da6ad2b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_76fbb69f-9e88-4202-91f3-f398a27d398d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c1493a4a-af67-46a1-a10c-837da6ad2b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b662f80f-45a2-43ca-ba86-528b01671af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_76fbb69f-9e88-4202-91f3-f398a27d398d" xlink:to="loc_us-gaap_InterestExpense_b662f80f-45a2-43ca-ba86-528b01671af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_f491127c-5cd9-49a1-8f2b-29946a9e2ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_76fbb69f-9e88-4202-91f3-f398a27d398d" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_f491127c-5cd9-49a1-8f2b-29946a9e2ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5e17afd5-94cc-4fa1-a803-6fc0768d3559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_76fbb69f-9e88-4202-91f3-f398a27d398d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5e17afd5-94cc-4fa1-a803-6fc0768d3559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0e081150-b23c-44de-a399-4bb28f6c7bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_76fbb69f-9e88-4202-91f3-f398a27d398d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0e081150-b23c-44de-a399-4bb28f6c7bd0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>biib-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a903f54e-5284-4407-a747-e0b1f5468222,g:e7d07c56-2dfc-4728-a119-070b245a209e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended" id="i05e6f64094564f5e96ed8d3a364ee58a_CondensedConsolidatedStatementsofIncomeUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_efd4cfa0-81c7-4013-b6bb-75c9e1074a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_Revenues_efd4cfa0-81c7-4013-b6bb-75c9e1074a1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5d4d2424-4cf1-470e-8c2d-bb08ed56e8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5d4d2424-4cf1-470e-8c2d-bb08ed56e8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_391aaaf3-2ea6-454b-a0d3-8091d255bb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_391aaaf3-2ea6-454b-a0d3-8091d255bb4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2bb94b63-5365-43c4-996d-3e1b7d85cfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2bb94b63-5365-43c4-996d-3e1b7d85cfc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_6843481a-eace-42ec-aef0-2587dfc80924" xlink:href="biib-20210930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_6843481a-eace-42ec-aef0-2587dfc80924" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_23d2bac1-57e0-4b24-89c7-65171efea11f" xlink:href="biib-20210930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_biib_Collaborationprofitlosssharing_23d2bac1-57e0-4b24-89c7-65171efea11f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3d0a71d3-354a-4f7b-af36-1445412f24d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3d0a71d3-354a-4f7b-af36-1445412f24d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_794f9370-1764-4fcf-b086-70eb9bf3bcf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_794f9370-1764-4fcf-b086-70eb9bf3bcf8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ed682e4b-d697-4ba0-b18a-9ba58903da53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_CostsAndExpenses_ed682e4b-d697-4ba0-b18a-9ba58903da53" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab6461e2-e379-4f96-8f01-de6440b4dbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_OperatingIncomeLoss_ab6461e2-e379-4f96-8f01-de6440b4dbe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6e26a712-440d-455e-895a-799a96449851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6e26a712-440d-455e-895a-799a96449851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9ba2b909-73ac-4efc-98e1-997ee4b8e1cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9ba2b909-73ac-4efc-98e1-997ee4b8e1cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_76c341a9-4ad0-468d-84f6-d4a66636afb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_76c341a9-4ad0-468d-84f6-d4a66636afb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0824b5fc-97de-4b48-905c-96d4d27a4183" xlink:href="biib-20210930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0824b5fc-97de-4b48-905c-96d4d27a4183" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ddf3588b-8e3e-4ea9-a68d-ea9025e12f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_ProfitLoss_ddf3588b-8e3e-4ea9-a68d-ea9025e12f07" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_29ca1acb-5b83-41f7-a096-a5c51ec589da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_29ca1acb-5b83-41f7-a096-a5c51ec589da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1705ddc0-ecfe-49ea-9338-773cf8bc3c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_NetIncomeLoss_1705ddc0-ecfe-49ea-9338-773cf8bc3c8d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a0eb6453-79d8-45ac-965b-4b176e7e21a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a0eb6453-79d8-45ac-965b-4b176e7e21a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3afb8691-c412-44f3-95be-1171b6fdc733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0eb6453-79d8-45ac-965b-4b176e7e21a8" xlink:to="loc_us-gaap_EarningsPerShareBasic_3afb8691-c412-44f3-95be-1171b6fdc733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ef0f0a15-cbde-48f5-865f-c0a754bd82c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0eb6453-79d8-45ac-965b-4b176e7e21a8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ef0f0a15-cbde-48f5-865f-c0a754bd82c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bd69e9c6-0e51-43b8-942a-561a32d2c4eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bd69e9c6-0e51-43b8-942a-561a32d2c4eb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e736bac-070a-486f-94ed-2e9ae2ffe910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bd69e9c6-0e51-43b8-942a-561a32d2c4eb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e736bac-070a-486f-94ed-2e9ae2ffe910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5cd36e96-4a6a-4dd8-93a9-b7a6c190f0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bd69e9c6-0e51-43b8-942a-561a32d2c4eb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5cd36e96-4a6a-4dd8-93a9-b7a6c190f0fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee10e022-d2e3-4c4e-b8e1-97b86711b349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_StatementTable_ee10e022-d2e3-4c4e-b8e1-97b86711b349" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ee10e022-d2e3-4c4e-b8e1-97b86711b349" xlink:to="loc_srt_ProductOrServiceAxis_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5" xlink:to="loc_srt_ProductsAndServicesDomain_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5" xlink:to="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3c630743-5d9b-4aee-a42a-74bd125b2985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:to="loc_us-gaap_ProductMember_3c630743-5d9b-4aee-a42a-74bd125b2985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_a2873d76-e986-450c-810e-19a4c15f2980" xlink:href="biib-20210930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_a2873d76-e986-450c-810e-19a4c15f2980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_dfd0f841-42e6-444c-b2d7-ba06bad3ec17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_dfd0f841-42e6-444c-b2d7-ba06bad3ec17" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="if8966187a63c4db3b10e1c83c0f0b236_CondensedConsolidatedStatementsofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5529ad0f-ec78-4d5d-8a86-82929fcefefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5529ad0f-ec78-4d5d-8a86-82929fcefefa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69fd0c81-67da-4119-9b41-444b5b4e10f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5529ad0f-ec78-4d5d-8a86-82929fcefefa" xlink:to="loc_us-gaap_ProfitLoss_69fd0c81-67da-4119-9b41-444b5b4e10f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5529ad0f-ec78-4d5d-8a86-82929fcefefa" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1a79f2e5-0fd3-4772-844e-4d4b79179b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1a79f2e5-0fd3-4772-844e-4d4b79179b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_aa229c4f-76f2-4e54-8b2c-0201001433ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_aa229c4f-76f2-4e54-8b2c-0201001433ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a41f31f5-38b8-4448-a730-eb4a9c1fe0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a41f31f5-38b8-4448-a730-eb4a9c1fe0e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d3b3a0b9-58be-4739-afde-b79e8d4b2d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_ShareBasedCompensation_d3b3a0b9-58be-4739-afde-b79e8d4b2d22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5844a7bb-50b0-4fba-96fa-2c95ae0d13d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5844a7bb-50b0-4fba-96fa-2c95ae0d13d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be8f41f9-fa7e-432d-a201-26eedbd26234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be8f41f9-fa7e-432d-a201-26eedbd26234" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_443d9551-f8d2-4e05-8837-587d160fd17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_443d9551-f8d2-4e05-8837-587d160fd17e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5b7cdc50-cf1e-4e27-84a9-1fd25c013607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5b7cdc50-cf1e-4e27-84a9-1fd25c013607" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9f657f25-1d9c-468b-88e2-72b57c7e85f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9f657f25-1d9c-468b-88e2-72b57c7e85f7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09c18018-f044-4fd2-a370-47cc5677675b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09c18018-f044-4fd2-a370-47cc5677675b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_33b36566-1fcc-40b1-888a-4654d2ba36ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_33b36566-1fcc-40b1-888a-4654d2ba36ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e135381e-d7a1-4e81-b189-69200da55bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e135381e-d7a1-4e81-b189-69200da55bbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b9d6a18b-81e7-48d6-8f6c-51d2ec50a9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b9d6a18b-81e7-48d6-8f6c-51d2ec50a9de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46850ec8-247e-4573-a178-0f24f448a1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46850ec8-247e-4573-a178-0f24f448a1ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2462f0e6-0704-4c4b-ac46-02dbbe4ff051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2462f0e6-0704-4c4b-ac46-02dbbe4ff051" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b8c3176-0278-4438-91a4-4bd619104aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b8c3176-0278-4438-91a4-4bd619104aec" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_193b3e85-3635-4bda-9e37-7e741b7a4152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_193b3e85-3635-4bda-9e37-7e741b7a4152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a22a0918-ed6c-4b4d-96f2-6d0f0422ffe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a22a0918-ed6c-4b4d-96f2-6d0f0422ffe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4720e649-f7a8-4187-95bd-c72832e2b811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4720e649-f7a8-4187-95bd-c72832e2b811" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dd3341a5-2b8e-4d05-87a2-dac15db58e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dd3341a5-2b8e-4d05-87a2-dac15db58e2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_86181a40-79b8-4075-bd0e-8c8a42da1ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_86181a40-79b8-4075-bd0e-8c8a42da1ac5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_5f55c93f-672d-414b-8292-ba1e9e4713f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_5f55c93f-672d-414b-8292-ba1e9e4713f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_305b4b05-83c1-4cb0-b2d8-e20e1dcbd7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_305b4b05-83c1-4cb0-b2d8-e20e1dcbd7f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e7564e62-f5f9-4987-b32e-a803752612c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e7564e62-f5f9-4987-b32e-a803752612c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_34d779c1-69fc-4132-8c92-20eb8570414a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_34d779c1-69fc-4132-8c92-20eb8570414a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e6c6bc8-6d86-4189-9b60-abf9a1118d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e6c6bc8-6d86-4189-9b60-abf9a1118d71" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fa0ae695-3989-41d7-8dbe-9ded4fd1c397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fa0ae695-3989-41d7-8dbe-9ded4fd1c397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b9105a5c-3799-4d2a-be1e-17bd5454d9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b9105a5c-3799-4d2a-be1e-17bd5454d9cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_8fc9678e-7d62-4e20-aba0-026b5eba4ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_RepaymentsOfDebt_8fc9678e-7d62-4e20-aba0-026b5eba4ee4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_93097f6b-f87c-431f-8aee-b27b556f377c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_93097f6b-f87c-431f-8aee-b27b556f377c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5f5c22a5-29d2-4ed7-aaad-1f5862120f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5f5c22a5-29d2-4ed7-aaad-1f5862120f63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_a368b9fe-1da4-4468-bae7-705aa03d5df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_a368b9fe-1da4-4468-bae7-705aa03d5df6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_814b2d38-0ae5-49d4-8972-6d1fcad81a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_814b2d38-0ae5-49d4-8972-6d1fcad81a78" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5909aafa-6068-4025-80c4-0a0534ebb853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5909aafa-6068-4025-80c4-0a0534ebb853" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8856982-458d-4827-ae78-da2ba5788cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8856982-458d-4827-ae78-da2ba5788cfc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_55ecae40-50d2-40e7-8cdc-79dccc8219f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_55ecae40-50d2-40e7-8cdc-79dccc8219f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_c49ac258-1e19-46b5-9ac8-f2e8f4115d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_c49ac258-1e19-46b5-9ac8-f2e8f4115d7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b890a846-7d0b-4477-97c4-4aca1fe2bf66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b890a846-7d0b-4477-97c4-4aca1fe2bf66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e039949-7314-4a58-baa1-8ee8fe7d61d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bcd8b76-bb5d-4fb0-a366-02184cc4e710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_StatementTable_2bcd8b76-bb5d-4fb0-a366-02184cc4e710" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2bcd8b76-bb5d-4fb0-a366-02184cc4e710" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_10c29972-e80a-4150-abf7-6315e5c62fb1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_10c29972-e80a-4150-abf7-6315e5c62fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_7b90472a-91e3-4040-9207-78a29e4cfc38" xlink:href="biib-20210930.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_10c29972-e80a-4150-abf7-6315e5c62fb1" xlink:to="loc_biib_SangamoCommonStockMember_7b90472a-91e3-4040-9207-78a29e4cfc38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_cd085d1e-bee9-425a-9463-af1a9cef444e" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_10c29972-e80a-4150-abf7-6315e5c62fb1" xlink:to="loc_biib_DenaliTherapeuticsIncMember_cd085d1e-bee9-425a-9463-af1a9cef444e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended" id="i80886ef397484e0a9d1561f2b0483587_CondensedConsolidatedStatementofEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c6c4802a-7e88-4966-848a-b9ea70014b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c6c4802a-7e88-4966-848a-b9ea70014b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b59b20cc-4a47-40ad-9eb2-3fc4c9758e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b59b20cc-4a47-40ad-9eb2-3fc4c9758e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c0fa152f-4ec5-4c70-b974-a1cb131d3b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_ProfitLoss_c0fa152f-4ec5-4c70-b974-a1cb131d3b71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0bc27a43-146d-4341-ba3d-29abcd1f957c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0bc27a43-146d-4341-ba3d-29abcd1f957c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_44263271-8950-4ccd-afe9-a1db6139607a" xlink:href="biib-20210930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_44263271-8950-4ccd-afe9-a1db6139607a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_27cbc344-c9e3-495e-8077-bdd562ef3493" xlink:href="biib-20210930.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_27cbc344-c9e3-495e-8077-bdd562ef3493" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7c95b661-5a11-4e06-a37c-4e2ffd18db08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7c95b661-5a11-4e06-a37c-4e2ffd18db08" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0aa7898b-8ff1-473a-ae78-99c7ad369ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0aa7898b-8ff1-473a-ae78-99c7ad369ac8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_55259939-e02b-4e92-8685-3952d20a7c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_55259939-e02b-4e92-8685-3952d20a7c3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_6c371015-0afa-42cd-95aa-3666ad3d688b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_6c371015-0afa-42cd-95aa-3666ad3d688b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c0103ece-f708-4b7c-91f1-01de8ead5fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c0103ece-f708-4b7c-91f1-01de8ead5fbe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_062cb23d-d042-457a-ac88-8a638c02b97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_062cb23d-d042-457a-ac88-8a638c02b97c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8afa6124-b77a-478f-97b9-f86c0726960a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8afa6124-b77a-478f-97b9-f86c0726960a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3addf5a5-9d5e-47a7-b1cf-6633f3af97cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3addf5a5-9d5e-47a7-b1cf-6633f3af97cc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_075d4336-116c-4e8d-9575-e0c336e0cbbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_075d4336-116c-4e8d-9575-e0c336e0cbbf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_ae3599ca-b5c3-4311-b1d7-019c77dc18c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockholdersEquityOther_ae3599ca-b5c3-4311-b1d7-019c77dc18c7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ced9aae4-e353-45e9-8af5-205b252918ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_95d25430-e6dd-401c-9d13-1b36158761a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_04c1b75f-78b6-4238-944b-2b8bd3641736" xlink:href="biib-20210930.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_04c1b75f-78b6-4238-944b-2b8bd3641736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_b68356c7-028e-4261-896f-86e44e10b853" xlink:href="biib-20210930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_b68356c7-028e-4261-896f-86e44e10b853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_edb34fd3-bfd5-4fce-9423-7635f86bebd7" xlink:href="biib-20210930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_edb34fd3-bfd5-4fce-9423-7635f86bebd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a2c2c79-383b-4dd1-9da3-9d94448e8673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a2c2c79-383b-4dd1-9da3-9d94448e8673" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a2c2c79-383b-4dd1-9da3-9d94448e8673_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a2c2c79-383b-4dd1-9da3-9d94448e8673" xlink:to="loc_us-gaap_EquityComponentDomain_0a2c2c79-383b-4dd1-9da3-9d94448e8673_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a2c2c79-383b-4dd1-9da3-9d94448e8673" xlink:to="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_182ff80f-4fb3-4732-a364-cafa680a96d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_PreferredStockMember_182ff80f-4fb3-4732-a364-cafa680a96d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d870bfca-9306-4c4d-b0b2-905f33311914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_CommonStockMember_d870bfca-9306-4c4d-b0b2-905f33311914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1ac9772a-89e9-4797-b6c8-3551481d08a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1ac9772a-89e9-4797-b6c8-3551481d08a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_436158a4-cd9b-442e-9321-5667dae9ae1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_436158a4-cd9b-442e-9321-5667dae9ae1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_821ed60e-60c1-4837-9337-c49206227a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_RetainedEarningsMember_821ed60e-60c1-4837-9337-c49206227a50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_a43c701a-243b-41df-96f8-e069abc5ed62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_TreasuryStockMember_a43c701a-243b-41df-96f8-e069abc5ed62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_2c6265e6-45d8-47e6-8dd4-7912efb66eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_ParentMember_2c6265e6-45d8-47e6-8dd4-7912efb66eb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3eb43f15-db1b-4d7c-bb11-052d49438597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3eb43f15-db1b-4d7c-bb11-052d49438597" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended" id="i9472ee9d53f847dea942672466909641_BusinessAcquisitionDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_890d4f31-e718-4eff-b683-3842a55424e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7b38c598-fc42-4e1b-8103-1c9a155be7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_890d4f31-e718-4eff-b683-3842a55424e8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7b38c598-fc42-4e1b-8103-1c9a155be7e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_8cc71cd9-c06a-4a8c-9d4d-549a921eb26d" xlink:href="biib-20210930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_890d4f31-e718-4eff-b683-3842a55424e8" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_8cc71cd9-c06a-4a8c-9d4d-549a921eb26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98c5a634-256c-412a-bb07-710d1c88cd03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_890d4f31-e718-4eff-b683-3842a55424e8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98c5a634-256c-412a-bb07-710d1c88cd03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a66d52c6-3131-4c8d-bfcf-d63159249cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98c5a634-256c-412a-bb07-710d1c88cd03" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a66d52c6-3131-4c8d-bfcf-d63159249cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a66d52c6-3131-4c8d-bfcf-d63159249cf1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a66d52c6-3131-4c8d-bfcf-d63159249cf1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a66d52c6-3131-4c8d-bfcf-d63159249cf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53c7dcd3-bb52-4ab0-a23e-2569c755c1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a66d52c6-3131-4c8d-bfcf-d63159249cf1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53c7dcd3-bb52-4ab0-a23e-2569c755c1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_a828936d-9ac5-4641-b978-cb893dbee19d" xlink:href="biib-20210930.xsd#biib_BIIB118Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53c7dcd3-bb52-4ab0-a23e-2569c755c1df" xlink:to="loc_biib_BIIB118Member_a828936d-9ac5-4641-b978-cb893dbee19d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended" id="if7876b1be2f544f990866a807cd65094_RevenuesRevenuesbyproductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6de7b24d-8319-4c05-a101-227fa760384d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6ca893d0-d401-4c98-88ae-09da2c6b1012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6de7b24d-8319-4c05-a101-227fa760384d" xlink:to="loc_us-gaap_Revenues_6ca893d0-d401-4c98-88ae-09da2c6b1012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6de7b24d-8319-4c05-a101-227fa760384d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_213a5392-e8cd-4b65-982e-32007e129d9d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:to="loc_srt_ProductOrServiceAxis_213a5392-e8cd-4b65-982e-32007e129d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_213a5392-e8cd-4b65-982e-32007e129d9d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_213a5392-e8cd-4b65-982e-32007e129d9d" xlink:to="loc_srt_ProductsAndServicesDomain_213a5392-e8cd-4b65-982e-32007e129d9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_213a5392-e8cd-4b65-982e-32007e129d9d" xlink:to="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_d3b6f180-9b71-4b7d-9298-b48065b68220" xlink:href="biib-20210930.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_FumarateMember_d3b6f180-9b71-4b7d-9298-b48065b68220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_440a8454-c074-4adf-808e-f107c9cf1505" xlink:href="biib-20210930.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_InterferonMember_440a8454-c074-4adf-808e-f107c9cf1505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_dc9263f5-0e3d-4bff-a7b4-98c9ea30f837" xlink:href="biib-20210930.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_TysabriProductMember_dc9263f5-0e3d-4bff-a7b4-98c9ea30f837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_73f7bd0c-aadc-4fdf-aa47-1184101c70c4" xlink:href="biib-20210930.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_FAMPYRAMember_73f7bd0c-aadc-4fdf-aa47-1184101c70c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_aa275100-879b-4e0e-8616-96ee0c533dee" xlink:href="biib-20210930.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_ZINBRYTAMember_aa275100-879b-4e0e-8616-96ee0c533dee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_77cd084a-15c0-4d3b-ab14-652960b9b2ef" xlink:href="biib-20210930.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_MSProductRevenuesMember_77cd084a-15c0-4d3b-ab14-652960b9b2ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_f1514c18-91b6-4d0d-a618-c007b7b31091" xlink:href="biib-20210930.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_SPINRAZAMember_f1514c18-91b6-4d0d-a618-c007b7b31091" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_eabd7418-acdc-450d-a0f4-1a24a60c30de" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_ADUHELMMember_eabd7418-acdc-450d-a0f4-1a24a60c30de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_cbe00ffd-9cfb-4840-8d89-efad9474b773" xlink:href="biib-20210930.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_BENEPALIMember_cbe00ffd-9cfb-4840-8d89-efad9474b773" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_ecdf1ca5-5223-4147-bf5a-9fefc298ee9c" xlink:href="biib-20210930.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_IMRALDIMember_ecdf1ca5-5223-4147-bf5a-9fefc298ee9c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_be5ade32-a972-4326-8112-e7f471bc5a57" xlink:href="biib-20210930.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_FLIXABIMember_be5ade32-a972-4326-8112-e7f471bc5a57" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_e6f842c8-4e1a-4bcb-95fe-c2db9130e7a6" xlink:href="biib-20210930.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_BiosimilarsMember_e6f842c8-4e1a-4bcb-95fe-c2db9130e7a6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_af18cfa4-d702-49a0-a43e-59db2766d385" xlink:href="biib-20210930.xsd#biib_FUMADERMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_FUMADERMMember_af18cfa4-d702-49a0-a43e-59db2766d385" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_89cfd44d-e1f7-41f8-96aa-a4d3bf677a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_us-gaap_ProductMember_89cfd44d-e1f7-41f8-96aa-a4d3bf677a21" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f19259b4-0b96-48df-8af6-a179f287c0bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:to="loc_srt_StatementGeographicalAxis_f19259b4-0b96-48df-8af6-a179f287c0bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f19259b4-0b96-48df-8af6-a179f287c0bf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f19259b4-0b96-48df-8af6-a179f287c0bf" xlink:to="loc_srt_SegmentGeographicalDomain_f19259b4-0b96-48df-8af6-a179f287c0bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4914aeb9-b44d-4fc5-9a4e-9adc0e06ec7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f19259b4-0b96-48df-8af6-a179f287c0bf" xlink:to="loc_srt_SegmentGeographicalDomain_4914aeb9-b44d-4fc5-9a4e-9adc0e06ec7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_827cb269-fdcc-4ce5-92bc-97ee8e1a081f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4914aeb9-b44d-4fc5-9a4e-9adc0e06ec7b" xlink:to="loc_country_US_827cb269-fdcc-4ce5-92bc-97ee8e1a081f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_aaea63de-0c97-4583-b71a-cf824ead3db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4914aeb9-b44d-4fc5-9a4e-9adc0e06ec7b" xlink:to="loc_us-gaap_NonUsMember_aaea63de-0c97-4583-b71a-cf824ead3db3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended" id="i24824ae267b0468ba068bd66a1fc8d62_RevenuesReservesforDiscountsandAllowancesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_20ee28e2-4f23-439a-b176-3d439ff6dfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_20ee28e2-4f23-439a-b176-3d439ff6dfa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_88174bd1-e198-4a74-a23b-a7d98b67f0c5" xlink:href="biib-20210930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_88174bd1-e198-4a74-a23b-a7d98b67f0c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_118a730f-6d38-4aa6-881f-4d98e3e3e2cd" xlink:href="biib-20210930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_118a730f-6d38-4aa6-881f-4d98e3e3e2cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c0908b88-2ab9-4bee-8d8b-58ea3a1db312" xlink:href="biib-20210930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c0908b88-2ab9-4bee-8d8b-58ea3a1db312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_76ba3b3f-0439-4682-b361-c9b076a0d7dc" xlink:href="biib-20210930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_76ba3b3f-0439-4682-b361-c9b076a0d7dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_709df4be-cdd6-45b5-a083-ae20a9f849d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a16022cf-93dc-45d7-856c-e50b23212080" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a16022cf-93dc-45d7-856c-e50b23212080" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3238ed5a-771b-45a0-be18-959315f16c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a16022cf-93dc-45d7-856c-e50b23212080" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3238ed5a-771b-45a0-be18-959315f16c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3238ed5a-771b-45a0-be18-959315f16c1b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3238ed5a-771b-45a0-be18-959315f16c1b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3238ed5a-771b-45a0-be18-959315f16c1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3238ed5a-771b-45a0-be18-959315f16c1b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_4e604ba5-9b8e-48aa-836f-5da671d95bdf" xlink:href="biib-20210930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:to="loc_biib_ReserveforCashDiscountsMember_4e604ba5-9b8e-48aa-836f-5da671d95bdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_0ae76845-bac0-4936-b3f4-79bf992ec91c" xlink:href="biib-20210930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:to="loc_biib_ContractualAdjustmentsMember_0ae76845-bac0-4936-b3f4-79bf992ec91c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_6bd7d95f-4b95-45f8-80b2-31bd63302c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_6bd7d95f-4b95-45f8-80b2-31bd63302c65" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended" id="i04c8bd00004f404490b833e9db3208b8_RevenuesReservesforDiscountsandAllowancesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a30cd749-7796-4521-a983-3bc5820d008f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8147ba68-ffac-4d59-9c16-9066a543d81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a30cd749-7796-4521-a983-3bc5820d008f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8147ba68-ffac-4d59-9c16-9066a543d81d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e2c34685-280c-48b2-b698-290e170bd3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a30cd749-7796-4521-a983-3bc5820d008f" xlink:to="loc_us-gaap_StatementTable_e2c34685-280c-48b2-b698-290e170bd3a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4d425fa0-53b2-4e2c-8c0d-ead492001712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e2c34685-280c-48b2-b698-290e170bd3a7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4d425fa0-53b2-4e2c-8c0d-ead492001712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4d425fa0-53b2-4e2c-8c0d-ead492001712_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d425fa0-53b2-4e2c-8c0d-ead492001712" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4d425fa0-53b2-4e2c-8c0d-ead492001712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e4ba0718-2297-4155-bb95-990f9a5b3ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d425fa0-53b2-4e2c-8c0d-ead492001712" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e4ba0718-2297-4155-bb95-990f9a5b3ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_99e07e1c-f754-49e5-9968-57d0ea9e22c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e4ba0718-2297-4155-bb95-990f9a5b3ae1" xlink:to="loc_us-gaap_AccountsReceivableMember_99e07e1c-f754-49e5-9968-57d0ea9e22c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_72a52d57-4a74-4e35-ace6-774b5b628d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e4ba0718-2297-4155-bb95-990f9a5b3ae1" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_72a52d57-4a74-4e35-ace6-774b5b628d83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="i2ee56d7e51cb4ea4b25b7b4ebb49a3f1_RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_b200e477-c9c1-43e4-abb0-d31dcb1f5c03" xlink:href="biib-20210930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:to="loc_biib_ShareOfCoPromotionProfits_b200e477-c9c1-43e4-abb0-d31dcb1f5c03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_613c47ab-9f02-4db2-9fb0-a75accd7bca4" xlink:href="biib-20210930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_613c47ab-9f02-4db2-9fb0-a75accd7bca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2be16321-86f2-4b6f-9d75-b1b938424c02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:to="loc_us-gaap_Revenues_2be16321-86f2-4b6f-9d75-b1b938424c02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:to="loc_srt_ProductOrServiceAxis_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f" xlink:to="loc_srt_ProductsAndServicesDomain_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2058cfcc-0394-470e-b4a1-c2be48c55d1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f" xlink:to="loc_srt_ProductsAndServicesDomain_2058cfcc-0394-470e-b4a1-c2be48c55d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_94526fc8-abbd-4363-b7ba-6de93bc77351" xlink:href="biib-20210930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2058cfcc-0394-470e-b4a1-c2be48c55d1f" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_94526fc8-abbd-4363-b7ba-6de93bc77351" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f0e36684-b7fb-4738-90a4-6e5598f348d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:to="loc_srt_MajorCustomersAxis_f0e36684-b7fb-4738-90a4-6e5598f348d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f0e36684-b7fb-4738-90a4-6e5598f348d8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f0e36684-b7fb-4738-90a4-6e5598f348d8" xlink:to="loc_srt_NameOfMajorCustomerDomain_f0e36684-b7fb-4738-90a4-6e5598f348d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c08b3b9b-3d88-4b79-884d-83af22557669" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f0e36684-b7fb-4738-90a4-6e5598f348d8" xlink:to="loc_srt_NameOfMajorCustomerDomain_c08b3b9b-3d88-4b79-884d-83af22557669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_0d23b05d-246c-469d-a2f4-d2d19ec9af3b" xlink:href="biib-20210930.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c08b3b9b-3d88-4b79-884d-83af22557669" xlink:to="loc_biib_RocheGroupGenentechMember_0d23b05d-246c-469d-a2f4-d2d19ec9af3b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" id="i1daf97dd42c74d5d9b992b389f8c926d_RevenuesOtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_093f7b82-4ba3-4474-b48f-530bc83de91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_24cdee2a-76e4-40d8-b4e2-f23d44983ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_093f7b82-4ba3-4474-b48f-530bc83de91e" xlink:to="loc_us-gaap_Revenues_24cdee2a-76e4-40d8-b4e2-f23d44983ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_093f7b82-4ba3-4474-b48f-530bc83de91e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d1c92d16-769a-4d9c-98e9-fdc56a9167dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d1c92d16-769a-4d9c-98e9-fdc56a9167dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1c92d16-769a-4d9c-98e9-fdc56a9167dd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1c92d16-769a-4d9c-98e9-fdc56a9167dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1c92d16-769a-4d9c-98e9-fdc56a9167dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b42e3ee8-c8d7-46c9-9c28-07692d390a00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1c92d16-769a-4d9c-98e9-fdc56a9167dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b42e3ee8-c8d7-46c9-9c28-07692d390a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e2371778-8d6b-4786-9fca-6da19a9dff8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b42e3ee8-c8d7-46c9-9c28-07692d390a00" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e2371778-8d6b-4786-9fca-6da19a9dff8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3de390f-51ad-47cd-80f7-b5836d09d6a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:to="loc_srt_ProductOrServiceAxis_e3de390f-51ad-47cd-80f7-b5836d09d6a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e3de390f-51ad-47cd-80f7-b5836d09d6a4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e3de390f-51ad-47cd-80f7-b5836d09d6a4" xlink:to="loc_srt_ProductsAndServicesDomain_e3de390f-51ad-47cd-80f7-b5836d09d6a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e3de390f-51ad-47cd-80f7-b5836d09d6a4" xlink:to="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c305b1d8-fa24-4261-8c2d-2dd257e37555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:to="loc_us-gaap_RoyaltyMember_c305b1d8-fa24-4261-8c2d-2dd257e37555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_c941bb1d-625e-43aa-ae85-d92974d2171e" xlink:href="biib-20210930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:to="loc_biib_OthercorporaterevenuesMember_c941bb1d-625e-43aa-ae85-d92974d2171e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3d37519f-f394-45db-b6ac-5148bd143b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3d37519f-f394-45db-b6ac-5148bd143b8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d7c085cd-f11d-4446-8d78-2d346ee7f543" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:to="loc_srt_MajorCustomersAxis_d7c085cd-f11d-4446-8d78-2d346ee7f543" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d7c085cd-f11d-4446-8d78-2d346ee7f543_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d7c085cd-f11d-4446-8d78-2d346ee7f543" xlink:to="loc_srt_NameOfMajorCustomerDomain_d7c085cd-f11d-4446-8d78-2d346ee7f543_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cc0186bc-38b1-43a8-9f5a-928b98fb8a71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d7c085cd-f11d-4446-8d78-2d346ee7f543" xlink:to="loc_srt_NameOfMajorCustomerDomain_cc0186bc-38b1-43a8-9f5a-928b98fb8a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5aa5cdd5-487e-4d95-b8e2-009a23164a68" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc0186bc-38b1-43a8-9f5a-928b98fb8a71" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5aa5cdd5-487e-4d95-b8e2-009a23164a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_92ac74b9-4d8e-4752-a274-97840c98c618" xlink:href="biib-20210930.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc0186bc-38b1-43a8-9f5a-928b98fb8a71" xlink:to="loc_biib_ZINBRYTAMember_92ac74b9-4d8e-4752-a274-97840c98c618" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i1132e9f121e94b988321c96178148493_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_080f0008-3d00-48e4-8269-8b3a10502f69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:to="loc_us-gaap_Revenues_080f0008-3d00-48e4-8269-8b3a10502f69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_659bee2a-898a-4307-a5c5-30664749bd24" xlink:href="biib-20210930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_659bee2a-898a-4307-a5c5-30664749bd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_7d830646-ead0-4320-b466-90ae19ceb6f5" xlink:href="biib-20210930.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:to="loc_biib_NumberOfWholesalers_7d830646-ead0-4320-b466-90ae19ceb6f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3a78b838-96fb-4fc6-8857-f205deb31da1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:to="loc_srt_ProductOrServiceAxis_3a78b838-96fb-4fc6-8857-f205deb31da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3a78b838-96fb-4fc6-8857-f205deb31da1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3a78b838-96fb-4fc6-8857-f205deb31da1" xlink:to="loc_srt_ProductsAndServicesDomain_3a78b838-96fb-4fc6-8857-f205deb31da1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8317da98-81c3-4409-9929-e107e819773a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3a78b838-96fb-4fc6-8857-f205deb31da1" xlink:to="loc_srt_ProductsAndServicesDomain_8317da98-81c3-4409-9929-e107e819773a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_ad012783-f175-4ccc-a43f-1d5ec8340905" xlink:href="biib-20210930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8317da98-81c3-4409-9929-e107e819773a" xlink:to="loc_biib_OthercorporaterevenuesMember_ad012783-f175-4ccc-a43f-1d5ec8340905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_24ce07a3-fe8b-485f-93c0-af8727ce70ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8317da98-81c3-4409-9929-e107e819773a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_24ce07a3-fe8b-485f-93c0-af8727ce70ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:to="loc_srt_MajorCustomersAxis_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58" xlink:to="loc_srt_NameOfMajorCustomerDomain_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_579a1991-2aaf-432d-92f9-84280d74835d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58" xlink:to="loc_srt_NameOfMajorCustomerDomain_579a1991-2aaf-432d-92f9-84280d74835d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_248dced1-a66c-49df-9942-d732a8d3f6f4" xlink:href="biib-20210930.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_579a1991-2aaf-432d-92f9-84280d74835d" xlink:to="loc_biib_DistributorOneMember_248dced1-a66c-49df-9942-d732a8d3f6f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_cd52bafb-2887-4fd5-8701-4c7c8e228fd8" xlink:href="biib-20210930.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_579a1991-2aaf-432d-92f9-84280d74835d" xlink:to="loc_biib_DistributorTwoMember_cd52bafb-2887-4fd5-8701-4c7c8e228fd8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i8b8f1adb1d9447ef93dba0eb463bb614_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d96bfd04-cd15-47ad-888c-66c092b67984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d96bfd04-cd15-47ad-888c-66c092b67984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_7ff28ef1-e0da-42d2-bde6-6d82ff0b7442" xlink:href="biib-20210930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_7ff28ef1-e0da-42d2-bde6-6d82ff0b7442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5253889-debb-4c92-ab9f-d76c9c53e849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5253889-debb-4c92-ab9f-d76c9c53e849" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4635aff2-f2bc-493c-b513-b4da34737732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4635aff2-f2bc-493c-b513-b4da34737732" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4e8eb007-016b-4647-9fe0-40613209baf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4e8eb007-016b-4647-9fe0-40613209baf1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dd9f4fe4-049d-49c6-b0b6-4ec566e9d215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dd9f4fe4-049d-49c6-b0b6-4ec566e9d215" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0951ea5e-b9e0-4061-a707-449ce421fa01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0951ea5e-b9e0-4061-a707-449ce421fa01" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5bf67d61-95d6-4a60-9070-89f5d6e89d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5bf67d61-95d6-4a60-9070-89f5d6e89d16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2815f3f3-efab-4c41-b575-709267469e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2815f3f3-efab-4c41-b575-709267469e78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_b9a9fa6c-8815-4ffb-b573-3c928e1d1ed4" xlink:href="biib-20210930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_b9a9fa6c-8815-4ffb-b573-3c928e1d1ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5f6abf6d-ac35-4dba-b4ba-287127f63cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5f6abf6d-ac35-4dba-b4ba-287127f63cec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cf233881-afb6-4c34-8c8c-447d5cd01e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cf233881-afb6-4c34-8c8c-447d5cd01e20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a783582e-fdb8-46c0-8d94-3d20602e786e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a783582e-fdb8-46c0-8d94-3d20602e786e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b784943a-f104-4966-b28f-c106e0b5c055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b784943a-f104-4966-b28f-c106e0b5c055" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c781a0ed-f712-4b58-a117-4dc9bec4cf70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c781a0ed-f712-4b58-a117-4dc9bec4cf70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_71438491-6da3-46fd-b8b3-2122707ba187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_71438491-6da3-46fd-b8b3-2122707ba187" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0d34c48a-ba6d-4af8-a57e-1f10d46271e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0d34c48a-ba6d-4af8-a57e-1f10d46271e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ManufacturingAndOtherCosts_c03e677d-3d18-4620-8308-cb893b239680" xlink:href="biib-20210930.xsd#biib_ManufacturingAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_biib_ManufacturingAndOtherCosts_c03e677d-3d18-4620-8308-cb893b239680" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_e1a6a96a-62e8-4504-9eda-09216a87c572" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_e1a6a96a-62e8-4504-9eda-09216a87c572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_e1a6a96a-62e8-4504-9eda-09216a87c572_default" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e1a6a96a-62e8-4504-9eda-09216a87c572" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_e1a6a96a-62e8-4504-9eda-09216a87c572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e1a6a96a-62e8-4504-9eda-09216a87c572" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_e57331f7-248e-450a-b848-bfd337227044" xlink:href="biib-20210930.xsd#biib_VixotrigineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_VixotrigineMember_e57331f7-248e-450a-b848-bfd337227044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_ce73abcf-3a3b-44f5-a6b0-96d57d8f22e4" xlink:href="biib-20210930.xsd#biib_TGNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_TGNMember_ce73abcf-3a3b-44f5-a6b0-96d57d8f22e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_03569b50-aaf7-4cd1-ae23-52c98537a043" xlink:href="biib-20210930.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_BIIB111Member_03569b50-aaf7-4cd1-ae23-52c98537a043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_0a950503-7201-4979-bddb-aaa04e305e51" xlink:href="biib-20210930.xsd#biib_BIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_BIIB112Member_0a950503-7201-4979-bddb-aaa04e305e51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member_75d5d365-163f-406b-a053-4bdf118289a8" xlink:href="biib-20210930.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_BIIB111AndBIIB112Member_75d5d365-163f-406b-a053-4bdf118289a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_820b4aa3-a0a0-4dd8-942f-055217c857e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_820b4aa3-a0a0-4dd8-942f-055217c857e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_d107e04a-5ccc-400c-bd13-e2747568882a" xlink:href="biib-20210930.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_820b4aa3-a0a0-4dd8-942f-055217c857e0" xlink:to="loc_biib_NightstarMember_d107e04a-5ccc-400c-bd13-e2747568882a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_defbdb3b-df48-414e-bfde-c8523bea2314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_defbdb3b-df48-414e-bfde-c8523bea2314" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_defbdb3b-df48-414e-bfde-c8523bea2314_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_defbdb3b-df48-414e-bfde-c8523bea2314" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_defbdb3b-df48-414e-bfde-c8523bea2314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e1911be-6b90-47b8-b6ed-f6b0acf0e5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_defbdb3b-df48-414e-bfde-c8523bea2314" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e1911be-6b90-47b8-b6ed-f6b0acf0e5ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a83454ef-1cd7-4ff7-b25e-785fce4b386a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e1911be-6b90-47b8-b6ed-f6b0acf0e5ef" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a83454ef-1cd7-4ff7-b25e-785fce4b386a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_fd9302ae-de2d-43d0-8a78-5bdb0c04882b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e1911be-6b90-47b8-b6ed-f6b0acf0e5ef" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_fd9302ae-de2d-43d0-8a78-5bdb0c04882b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_610f5588-ba27-43ac-b187-8516513ad869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_610f5588-ba27-43ac-b187-8516513ad869" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_610f5588-ba27-43ac-b187-8516513ad869_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_610f5588-ba27-43ac-b187-8516513ad869" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_610f5588-ba27-43ac-b187-8516513ad869_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8c61132-7e47-4bb6-979a-f9ffae2adc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_610f5588-ba27-43ac-b187-8516513ad869" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8c61132-7e47-4bb6-979a-f9ffae2adc52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_29ac5cd1-6522-4797-bcb6-114b77449aa5" xlink:href="biib-20210930.xsd#biib_OutLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8c61132-7e47-4bb6-979a-f9ffae2adc52" xlink:to="loc_biib_OutLicensedPatentsMember_29ac5cd1-6522-4797-bcb6-114b77449aa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_36325c2f-dc76-4066-9ad5-4a09d3a5fbef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8c61132-7e47-4bb6-979a-f9ffae2adc52" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_36325c2f-dc76-4066-9ad5-4a09d3a5fbef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_52cf0624-6fa0-4476-97de-08705a267c12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_srt_ProductOrServiceAxis_52cf0624-6fa0-4476-97de-08705a267c12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52cf0624-6fa0-4476-97de-08705a267c12_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_52cf0624-6fa0-4476-97de-08705a267c12" xlink:to="loc_srt_ProductsAndServicesDomain_52cf0624-6fa0-4476-97de-08705a267c12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96ec1c29-a969-4231-92d6-1992080731bc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_52cf0624-6fa0-4476-97de-08705a267c12" xlink:to="loc_srt_ProductsAndServicesDomain_96ec1c29-a969-4231-92d6-1992080731bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_3a02cf95-984d-4ea4-a683-36290c8e97eb" xlink:href="biib-20210930.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96ec1c29-a969-4231-92d6-1992080731bc" xlink:to="loc_biib_TysabriProductMember_3a02cf95-984d-4ea4-a683-36290c8e97eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_2232f479-0bc8-48ca-b684-020b0bfd3e8a" xlink:href="biib-20210930.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96ec1c29-a969-4231-92d6-1992080731bc" xlink:to="loc_biib_FumarateMember_2232f479-0bc8-48ca-b684-020b0bfd3e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87500b65-1ca6-4137-9714-a34a767074e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_srt_RangeAxis_87500b65-1ca6-4137-9714-a34a767074e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87500b65-1ca6-4137-9714-a34a767074e0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_87500b65-1ca6-4137-9714-a34a767074e0" xlink:to="loc_srt_RangeMember_87500b65-1ca6-4137-9714-a34a767074e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_55b00412-c41f-4269-8a60-4fd039f58ed5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_87500b65-1ca6-4137-9714-a34a767074e0" xlink:to="loc_srt_RangeMember_55b00412-c41f-4269-8a60-4fd039f58ed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_822ad528-3a6f-4c1e-be5a-7db1a2efab38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_55b00412-c41f-4269-8a60-4fd039f58ed5" xlink:to="loc_srt_MinimumMember_822ad528-3a6f-4c1e-be5a-7db1a2efab38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b475b98d-f78e-4ade-af12-c9b34e4b7418" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_55b00412-c41f-4269-8a60-4fd039f58ed5" xlink:to="loc_srt_MaximumMember_b475b98d-f78e-4ade-af12-c9b34e4b7418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ab8da1f1-e856-4152-8b0f-42b03e8c2516" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_srt_StatementScenarioAxis_ab8da1f1-e856-4152-8b0f-42b03e8c2516" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ab8da1f1-e856-4152-8b0f-42b03e8c2516_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ab8da1f1-e856-4152-8b0f-42b03e8c2516" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ab8da1f1-e856-4152-8b0f-42b03e8c2516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_597409aa-34a6-4bbc-bc7e-ebc4e9c9e0ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ab8da1f1-e856-4152-8b0f-42b03e8c2516" xlink:to="loc_srt_ScenarioUnspecifiedDomain_597409aa-34a6-4bbc-bc7e-ebc4e9c9e0ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a1ebe1ec-ecae-4588-b35e-86eec8582359" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_597409aa-34a6-4bbc-bc7e-ebc4e9c9e0ae" xlink:to="loc_srt_ScenarioForecastMember_a1ebe1ec-ecae-4588-b35e-86eec8582359" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i72a542cfcfc343b7904a92ad800bf282_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6188215a-f364-4a49-9969-8292e834761f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a6e6923f-f753-425a-8859-ef818feff533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6188215a-f364-4a49-9969-8292e834761f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a6e6923f-f753-425a-8859-ef818feff533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a6e6923f-f753-425a-8859-ef818feff533" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59de40ea-10a9-4b87-9abe-94847d7da1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59de40ea-10a9-4b87-9abe-94847d7da1b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bbc307a-601b-4dce-9959-036912b2d3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bbc307a-601b-4dce-9959-036912b2d3dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_809c8379-4457-4780-bdae-f33beb578359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_809c8379-4457-4780-bdae-f33beb578359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_b0e41e10-b85d-4608-aae7-f2ceecdb889d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_b0e41e10-b85d-4608-aae7-f2ceecdb889d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_86396f1b-793d-4c65-94cf-cb1fa3830646" xlink:href="biib-20210930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_86396f1b-793d-4c65-94cf-cb1fa3830646" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e4bbb3a5-4cad-4b24-b17a-9b6592ef9e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e4bbb3a5-4cad-4b24-b17a-9b6592ef9e04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a6e6923f-f753-425a-8859-ef818feff533" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_c3cc8e1e-727f-4642-b66c-b4d3102489e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_c3cc8e1e-727f-4642-b66c-b4d3102489e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_faedf59b-0011-449d-acc1-9b8854357120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_faedf59b-0011-449d-acc1-9b8854357120" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d17b9f1a-0349-4dfe-81c1-87f8de472c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d17b9f1a-0349-4dfe-81c1-87f8de472c08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6188215a-f364-4a49-9969-8292e834761f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_afb4446f-0d86-4a43-a6ec-88dc5b5c29e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_afb4446f-0d86-4a43-a6ec-88dc5b5c29e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3922e426-6c4c-435b-bbd3-984c3cb5b539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3922e426-6c4c-435b-bbd3-984c3cb5b539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c9a0a90c-6de1-431a-93cd-9b9309b4d884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c9a0a90c-6de1-431a-93cd-9b9309b4d884" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d4641cb-743b-445f-a563-401ad4f3745f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d4641cb-743b-445f-a563-401ad4f3745f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d4641cb-743b-445f-a563-401ad4f3745f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d4641cb-743b-445f-a563-401ad4f3745f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d4641cb-743b-445f-a563-401ad4f3745f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0c1a167-339a-40bd-a1ca-7fd6e04654c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d4641cb-743b-445f-a563-401ad4f3745f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0c1a167-339a-40bd-a1ca-7fd6e04654c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0bb3ca6f-0591-4001-86ee-4b968b51b611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0c1a167-339a-40bd-a1ca-7fd6e04654c2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0bb3ca6f-0591-4001-86ee-4b968b51b611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d32c93b7-1dde-4426-9efd-d5897cdb46a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d32c93b7-1dde-4426-9efd-d5897cdb46a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d32c93b7-1dde-4426-9efd-d5897cdb46a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d32c93b7-1dde-4426-9efd-d5897cdb46a5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d32c93b7-1dde-4426-9efd-d5897cdb46a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d32c93b7-1dde-4426-9efd-d5897cdb46a5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_bf2cfe38-5348-4aff-abff-b4a2ef1fc3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_bf2cfe38-5348-4aff-abff-b4a2ef1fc3b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_4a706496-6d46-453c-be2b-08408ff45c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_4a706496-6d46-453c-be2b-08408ff45c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_0bbe29d8-7b49-47dc-9df4-6c9b1a29c3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_0bbe29d8-7b49-47dc-9df4-6c9b1a29c3a7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" id="i1e354aa4eb7f4a779e6f71f384cb74d8_FairValueMeasurementsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_bcffc2bf-ba89-434c-9760-18686d1f358d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_us-gaap_AssetImpairmentCharges_bcffc2bf-ba89-434c-9760-18686d1f358d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25aa66a6-6324-473b-8b18-850b4b01b0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25aa66a6-6324-473b-8b18-850b4b01b0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ea1ffd31-1c35-4fa2-83bf-339c9970935a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ea1ffd31-1c35-4fa2-83bf-339c9970935a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_abc3385d-2f72-4faa-9cbf-faf84f6384fe" xlink:href="biib-20210930.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_abc3385d-2f72-4faa-9cbf-faf84f6384fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0c472cac-4255-4cd4-af93-c963fc75d8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0c472cac-4255-4cd4-af93-c963fc75d8f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_577e6b60-10cb-4009-b236-3e9ad0a079d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0c472cac-4255-4cd4-af93-c963fc75d8f6" xlink:to="loc_us-gaap_DebtInstrumentAxis_577e6b60-10cb-4009-b236-3e9ad0a079d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_577e6b60-10cb-4009-b236-3e9ad0a079d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_577e6b60-10cb-4009-b236-3e9ad0a079d7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_577e6b60-10cb-4009-b236-3e9ad0a079d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_577e6b60-10cb-4009-b236-3e9ad0a079d7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_f6aa7024-6b3f-4f47-a40b-95d665bf0ada" xlink:href="biib-20210930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_f6aa7024-6b3f-4f47-a40b-95d665bf0ada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_f0256b50-5e29-45bf-b934-e99c58421b7d" xlink:href="biib-20210930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_f0256b50-5e29-45bf-b934-e99c58421b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ab7539dd-b12f-442f-b43a-5d0a3101a638" xlink:href="biib-20210930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ab7539dd-b12f-442f-b43a-5d0a3101a638" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" id="i4f09b1dd234b46f08c576d223445e4e5_FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ff35153-c344-4f7c-82fd-e369ea763924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b6bc364e-6dc1-4891-926e-77259b5c9460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ff35153-c344-4f7c-82fd-e369ea763924" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b6bc364e-6dc1-4891-926e-77259b5c9460" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_54078bc0-82b9-41c7-9295-85584d70c40c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ff35153-c344-4f7c-82fd-e369ea763924" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_54078bc0-82b9-41c7-9295-85584d70c40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ff35153-c344-4f7c-82fd-e369ea763924" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_19b00100-d880-4278-9e15-8f1fbb4a98a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:to="loc_srt_RangeAxis_19b00100-d880-4278-9e15-8f1fbb4a98a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19b00100-d880-4278-9e15-8f1fbb4a98a9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_19b00100-d880-4278-9e15-8f1fbb4a98a9" xlink:to="loc_srt_RangeMember_19b00100-d880-4278-9e15-8f1fbb4a98a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c853bb6-7b25-4906-9b57-19a6d2171345" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_19b00100-d880-4278-9e15-8f1fbb4a98a9" xlink:to="loc_srt_RangeMember_0c853bb6-7b25-4906-9b57-19a6d2171345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_14de37f8-d5e3-4037-8a36-33896a1432b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c853bb6-7b25-4906-9b57-19a6d2171345" xlink:to="loc_srt_WeightedAverageMember_14de37f8-d5e3-4037-8a36-33896a1432b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9d9f4870-ef30-4b00-a348-63ef57f8895f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9d9f4870-ef30-4b00-a348-63ef57f8895f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9d9f4870-ef30-4b00-a348-63ef57f8895f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9d9f4870-ef30-4b00-a348-63ef57f8895f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9d9f4870-ef30-4b00-a348-63ef57f8895f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_37879041-d5d1-4922-be94-cb43b3b98e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9d9f4870-ef30-4b00-a348-63ef57f8895f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_37879041-d5d1-4922-be94-cb43b3b98e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3f4e11f8-a06a-491e-8faa-b104b3233eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_37879041-d5d1-4922-be94-cb43b3b98e08" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3f4e11f8-a06a-491e-8faa-b104b3233eac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsNonrecurringAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="extended" id="ifad1c671e70c49a28b4e45b2e5fc7209_FairValueMeasurementsNonrecurringAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0a2a47d5-638f-435b-9829-f9f76e674061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_77d47433-2feb-48e6-b88c-306771df2516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0a2a47d5-638f-435b-9829-f9f76e674061" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_77d47433-2feb-48e6-b88c-306771df2516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3612f193-b486-4d17-8303-427f47da523f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0a2a47d5-638f-435b-9829-f9f76e674061" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3612f193-b486-4d17-8303-427f47da523f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_bd5e26ff-7291-46a9-acad-a9c748a3b8fa" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3612f193-b486-4d17-8303-427f47da523f" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_bd5e26ff-7291-46a9-acad-a9c748a3b8fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_bd5e26ff-7291-46a9-acad-a9c748a3b8fa_default" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_bd5e26ff-7291-46a9-acad-a9c748a3b8fa" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_bd5e26ff-7291-46a9-acad-a9c748a3b8fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_291a47bf-4257-492d-81f8-ba4a6cdddd8f" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_bd5e26ff-7291-46a9-acad-a9c748a3b8fa" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_291a47bf-4257-492d-81f8-ba4a6cdddd8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_32a83862-2af8-4acf-9ff1-62a6ac8d8809" xlink:href="biib-20210930.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_291a47bf-4257-492d-81f8-ba4a6cdddd8f" xlink:to="loc_biib_BIIB111Member_32a83862-2af8-4acf-9ff1-62a6ac8d8809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_8bdf663d-20d0-452b-b88d-9b2159da6e9a" xlink:href="biib-20210930.xsd#biib_BIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_291a47bf-4257-492d-81f8-ba4a6cdddd8f" xlink:to="loc_biib_BIIB112Member_8bdf663d-20d0-452b-b88d-9b2159da6e9a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i7a7488d62df845fbbbeb6fc80bad7cc5_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_e05aede0-5b87-4efd-81ba-bb29109559d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_e05aede0-5b87-4efd-81ba-bb29109559d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_0aab6aec-d04d-4ec7-99bf-33d6c057910c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_NotesPayable_0aab6aec-d04d-4ec7-99bf-33d6c057910c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_91b872cc-5950-4675-a031-d8666add1e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_DebtInstrumentFairValue_91b872cc-5950-4675-a031-d8666add1e79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dadc62ab-ab26-4a0d-8d0b-606347a825d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dadc62ab-ab26-4a0d-8d0b-606347a825d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_c7075513-f00f-45a6-a897-323268556263" xlink:href="biib-20210930.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_biib_LongTermDebtExchangedAmount_c7075513-f00f-45a6-a897-323268556263" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f8fa3633-2a5c-42e1-884f-c6fefde88109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_DebtInstrumentTable_f8fa3633-2a5c-42e1-884f-c6fefde88109" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f8fa3633-2a5c-42e1-884f-c6fefde88109" xlink:to="loc_us-gaap_DebtInstrumentAxis_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_23bb35c5-b3e4-4818-8c4e-cf0aa2674b99" xlink:href="biib-20210930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_23bb35c5-b3e4-4818-8c4e-cf0aa2674b99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_bdf9fe0a-2b50-4b24-a521-f9cacd526328" xlink:href="biib-20210930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_bdf9fe0a-2b50-4b24-a521-f9cacd526328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_a7231e2c-164e-40cd-bda5-ee646d3bbe7a" xlink:href="biib-20210930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_a7231e2c-164e-40cd-bda5-ee646d3bbe7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_fb91334b-c3b0-4aed-879d-4253333c726c" xlink:href="biib-20210930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_fb91334b-c3b0-4aed-879d-4253333c726c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_066c2e01-ec25-44c9-8318-4111d16f309c" xlink:href="biib-20210930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_066c2e01-ec25-44c9-8318-4111d16f309c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_309d5354-8f91-4c10-b2ca-1a6743ef2d82" xlink:href="biib-20210930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_309d5354-8f91-4c10-b2ca-1a6743ef2d82" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="ic0ded26ae2ca46e98e350e83c25e1dcb_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c7a5650d-c92a-4b06-8b68-5aa9a64d7d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c7a5650d-c92a-4b06-8b68-5aa9a64d7d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3aa4139f-3a00-4f10-b2c6-fabc716dbc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3aa4139f-3a00-4f10-b2c6-fabc716dbc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_23cb1e34-ebcc-41ed-9ea2-fa0db5a598a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ee350e6b-5091-4495-b909-7db0a12025bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ee350e6b-5091-4495-b909-7db0a12025bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d8b88e54-52b5-4e2d-ac45-ba714b829f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ee350e6b-5091-4495-b909-7db0a12025bd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d8b88e54-52b5-4e2d-ac45-ba714b829f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d8b88e54-52b5-4e2d-ac45-ba714b829f76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d8b88e54-52b5-4e2d-ac45-ba714b829f76" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d8b88e54-52b5-4e2d-ac45-ba714b829f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21c4b0c5-963f-4cb4-892c-c8345ef96b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d8b88e54-52b5-4e2d-ac45-ba714b829f76" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21c4b0c5-963f-4cb4-892c-c8345ef96b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9cc72a99-87fc-45de-ade8-d60af2503f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_21c4b0c5-963f-4cb4-892c-c8345ef96b11" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9cc72a99-87fc-45de-ade8-d60af2503f7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" id="id773d9f9bc9d43c1a0465d35db632c4b_FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_4aebb826-d7ed-4de9-90d5-fa2e7391019b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_a90cc8d2-651d-49b7-b816-0b9e09ea67ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4aebb826-d7ed-4de9-90d5-fa2e7391019b" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_a90cc8d2-651d-49b7-b816-0b9e09ea67ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c936394f-dbb4-43b7-a89b-369eddfe2011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_a90cc8d2-651d-49b7-b816-0b9e09ea67ec" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c936394f-dbb4-43b7-a89b-369eddfe2011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9968b946-a1da-40fa-a0f2-e8d7c0909818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4aebb826-d7ed-4de9-90d5-fa2e7391019b" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9968b946-a1da-40fa-a0f2-e8d7c0909818" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e7d70c1c-8fad-4c2e-aa01-5951164592c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9968b946-a1da-40fa-a0f2-e8d7c0909818" xlink:to="loc_us-gaap_InvestmentTypeAxis_e7d70c1c-8fad-4c2e-aa01-5951164592c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e7d70c1c-8fad-4c2e-aa01-5951164592c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_e7d70c1c-8fad-4c2e-aa01-5951164592c1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e7d70c1c-8fad-4c2e-aa01-5951164592c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_e7d70c1c-8fad-4c2e-aa01-5951164592c1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2ae2501b-5996-4811-b9d5-256eeb2d90dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:to="loc_us-gaap_CommercialPaperMember_2ae2501b-5996-4811-b9d5-256eeb2d90dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_e40e6210-ea78-408f-bda7-fa97b72f1b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_e40e6210-ea78-408f-bda7-fa97b72f1b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_231ec2c8-06e9-4704-a0cb-ecceb1d14e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_231ec2c8-06e9-4704-a0cb-ecceb1d14e95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_65040527-4e3f-4fcb-8db1-1517c20cf543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:to="loc_us-gaap_DebtSecuritiesMember_65040527-4e3f-4fcb-8db1-1517c20cf543" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" id="ifadde246b7e74e10bbab4e6e7239cc87_FinancialInstrumentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5515a322-724d-4c08-9cef-231711dd33f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5515a322-724d-4c08-9cef-231711dd33f1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c57b6a9a-9561-4ed8-88c9-0f91e47b136b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c57b6a9a-9561-4ed8-88c9-0f91e47b136b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4dcbe1b-cbb2-4c12-8ace-15769c706939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4dcbe1b-cbb2-4c12-8ace-15769c706939" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0a55358d-4bac-4ba9-8578-319ff8882399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0a55358d-4bac-4ba9-8578-319ff8882399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccc6ae4f-7b79-4f2a-8dcf-930596f05176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccc6ae4f-7b79-4f2a-8dcf-930596f05176" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5515a322-724d-4c08-9cef-231711dd33f1" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_d965504f-2643-4411-924d-94f3ed1840a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_d965504f-2643-4411-924d-94f3ed1840a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_46db5169-83c0-4e83-9d4e-eb600936f6c2" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_46db5169-83c0-4e83-9d4e-eb600936f6c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_3e4c6c68-8110-4d61-af4d-36d92fac6ed6" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_3e4c6c68-8110-4d61-af4d-36d92fac6ed6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_2f1d5e91-e84d-4ea7-97ee-68b7c9002428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_2f1d5e91-e84d-4ea7-97ee-68b7c9002428" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3d96336d-1cb5-4c2f-98e2-a4ae8455af0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5515a322-724d-4c08-9cef-231711dd33f1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3d96336d-1cb5-4c2f-98e2-a4ae8455af0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b2000a0f-65d9-41ae-89c5-f24d40c56e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3d96336d-1cb5-4c2f-98e2-a4ae8455af0e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b2000a0f-65d9-41ae-89c5-f24d40c56e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2000a0f-65d9-41ae-89c5-f24d40c56e6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2000a0f-65d9-41ae-89c5-f24d40c56e6e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2000a0f-65d9-41ae-89c5-f24d40c56e6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2000a0f-65d9-41ae-89c5-f24d40c56e6e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_4057261b-c51f-42ea-a205-0b1cd0651e31" xlink:href="biib-20210930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_4057261b-c51f-42ea-a205-0b1cd0651e31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_f636b7f9-0ae5-4fbf-9f30-d511f1f3d3fa" xlink:href="biib-20210930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_f636b7f9-0ae5-4fbf-9f30-d511f1f3d3fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_b459fed1-a839-459a-a840-886301b67042" xlink:href="biib-20210930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_b459fed1-a839-459a-a840-886301b67042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_58c268aa-69cd-4755-8292-1726862f7c87" xlink:href="biib-20210930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_58c268aa-69cd-4755-8292-1726862f7c87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_47e8a9a9-f1dd-40bb-88ea-d7a6a42b1df2" xlink:href="biib-20210930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_47e8a9a9-f1dd-40bb-88ea-d7a6a42b1df2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_10efcfd3-e1a0-4531-ae3a-f6a15bcefec4" xlink:href="biib-20210930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_10efcfd3-e1a0-4531-ae3a-f6a15bcefec4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_d1343687-8453-47ae-a4b4-c2f335a655bb" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_EquitySecuritiesCurrentMember_d1343687-8453-47ae-a4b4-c2f335a655bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_fb8c7aeb-c10b-4223-af4c-f913a1cff019" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_fb8c7aeb-c10b-4223-af4c-f913a1cff019" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" id="i25de475fe9e44836a9a3a70024e29251_FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_86e3abbb-e25a-4e17-9c50-d1e51676199e" xlink:href="biib-20210930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_StrategicInvestmentPortfolio_86e3abbb-e25a-4e17-9c50-d1e51676199e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased_227948fe-afc7-4ca0-95fa-dcd340f9a09d" xlink:href="biib-20210930.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_Investmentincommonstocksharespurchased_227948fe-afc7-4ca0-95fa-dcd340f9a09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_8ab41885-d26e-40ca-81ab-50ab99db3271" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_8ab41885-d26e-40ca-81ab-50ab99db3271" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_8ea1edbe-108c-40f6-bf9e-2b8235720a54" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_8ea1edbe-108c-40f6-bf9e-2b8235720a54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_69c64cf4-2ed4-4c97-be65-73f802220c0c" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_69c64cf4-2ed4-4c97-be65-73f802220c0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_2b4a8913-e8a0-4a22-8cfb-6b6bf68061e6" xlink:href="biib-20210930.xsd#biib_DividendYieldPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_DividendYieldPercentage_2b4a8913-e8a0-4a22-8cfb-6b6bf68061e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_13586940-3aad-43b5-8987-479d0547e0ba" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_13586940-3aad-43b5-8987-479d0547e0ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7a6bd894-6213-4c39-a9b2-6a26a2a3666d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_dei_LegalEntityAxis_7a6bd894-6213-4c39-a9b2-6a26a2a3666d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a6bd894-6213-4c39-a9b2-6a26a2a3666d_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7a6bd894-6213-4c39-a9b2-6a26a2a3666d" xlink:to="loc_dei_EntityDomain_7a6bd894-6213-4c39-a9b2-6a26a2a3666d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e3c63d5e-2340-426e-9d69-6c9b6c6ba6e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7a6bd894-6213-4c39-a9b2-6a26a2a3666d" xlink:to="loc_dei_EntityDomain_e3c63d5e-2340-426e-9d69-6c9b6c6ba6e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_9063a3ea-acc5-4917-b349-b5f7851ad741" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e3c63d5e-2340-426e-9d69-6c9b6c6ba6e7" xlink:to="loc_biib_DenaliTherapeuticsIncMember_9063a3ea-acc5-4917-b349-b5f7851ad741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_fc73e8f0-444d-475a-a5f6-2f77874730f9" xlink:href="biib-20210930.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e3c63d5e-2340-426e-9d69-6c9b6c6ba6e7" xlink:to="loc_biib_SangamoCommonStockMember_fc73e8f0-444d-475a-a5f6-2f77874730f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_997772f5-9b11-4be2-9cc2-bc56dfbe747c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_997772f5-9b11-4be2-9cc2-bc56dfbe747c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_997772f5-9b11-4be2-9cc2-bc56dfbe747c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_997772f5-9b11-4be2-9cc2-bc56dfbe747c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_997772f5-9b11-4be2-9cc2-bc56dfbe747c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_76ecdb1c-7653-4fcf-adc6-1cd44fa02e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_997772f5-9b11-4be2-9cc2-bc56dfbe747c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_76ecdb1c-7653-4fcf-adc6-1cd44fa02e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_a296e22d-c5bc-4b41-8a0e-8839e0780a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_76ecdb1c-7653-4fcf-adc6-1cd44fa02e0b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_a296e22d-c5bc-4b41-8a0e-8839e0780a31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8da60c96-168b-4a52-b5b0-69793e19483a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8da60c96-168b-4a52-b5b0-69793e19483a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8da60c96-168b-4a52-b5b0-69793e19483a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8da60c96-168b-4a52-b5b0-69793e19483a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8da60c96-168b-4a52-b5b0-69793e19483a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f48c727-4a68-453f-861b-f54f750607d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8da60c96-168b-4a52-b5b0-69793e19483a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f48c727-4a68-453f-861b-f54f750607d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_e95b04e3-b5e9-449b-be94-23796f039ae3" xlink:href="biib-20210930.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f48c727-4a68-453f-861b-f54f750607d0" xlink:to="loc_biib_StrategicInvestmentsMember_e95b04e3-b5e9-449b-be94-23796f039ae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_35ac9f9a-32d9-447c-8b28-61edad3477f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_35ac9f9a-32d9-447c-8b28-61edad3477f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35ac9f9a-32d9-447c-8b28-61edad3477f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_35ac9f9a-32d9-447c-8b28-61edad3477f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35ac9f9a-32d9-447c-8b28-61edad3477f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_35ac9f9a-32d9-447c-8b28-61edad3477f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_a922cf73-c7a1-4dde-8628-f25ffced9258" xlink:href="biib-20210930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:to="loc_biib_SageTherapeuticsIncMember_a922cf73-c7a1-4dde-8628-f25ffced9258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_97a85334-45c8-4cca-9a65-5cf9e2c3b717" xlink:href="biib-20210930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_97a85334-45c8-4cca-9a65-5cf9e2c3b717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_7039ba20-1ef9-4e0e-be6a-9469a3261156" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:to="loc_biib_DenaliTherapeuticsIncMember_7039ba20-1ef9-4e0e-be6a-9469a3261156" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" id="i64e095da6c8c4befad77a3448f6aaf65_DerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_5bbd3e1b-0da7-4098-80f3-c2b2d0550a04" xlink:href="biib-20210930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_5bbd3e1b-0da7-4098-80f3-c2b2d0550a04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_cb0bc8a1-4ef8-49b0-bda4-8e570f63b675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_cb0bc8a1-4ef8-49b0-bda4-8e570f63b675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b93d03d8-2ad3-428d-98b8-be6d7a2189e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b93d03d8-2ad3-428d-98b8-be6d7a2189e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_77d87a15-e906-464c-ae11-97ce8e78a407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_77d87a15-e906-464c-ae11-97ce8e78a407" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2152f52e-933d-43dd-93d2-0951c65a2395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2152f52e-933d-43dd-93d2-0951c65a2395" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7e08176b-dc8b-4332-9f7e-95c249c7e39a" xlink:href="biib-20210930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7e08176b-dc8b-4332-9f7e-95c249c7e39a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d445603f-bdbc-42ec-b6c4-71ecf5beb39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d445603f-bdbc-42ec-b6c4-71ecf5beb39b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fd8ed164-5f72-4be3-8065-3b11a279b50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fd8ed164-5f72-4be3-8065-3b11a279b50b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_87756336-237f-40d8-bfef-2bb708603180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeTermOfContract_87756336-237f-40d8-bfef-2bb708603180" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_c035f01f-d89c-4a92-bcec-cf1d5142fe0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_c035f01f-d89c-4a92-bcec-cf1d5142fe0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_80ddf094-925b-4b3e-a072-10e2b8c43243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_80ddf094-925b-4b3e-a072-10e2b8c43243" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f34e34de-82eb-41aa-ac40-0af58387af42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f34e34de-82eb-41aa-ac40-0af58387af42" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_f8b0b474-f016-4f51-8b3b-8d0eba074921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_f8b0b474-f016-4f51-8b3b-8d0eba074921" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bfd7cc1a-1d07-4693-8b3f-de702bd453d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bfd7cc1a-1d07-4693-8b3f-de702bd453d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_015ee594-bb34-42c4-8dfe-21881daa2f4c" xlink:href="biib-20210930.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_015ee594-bb34-42c4-8dfe-21881daa2f4c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_1c93bfa5-8e0f-43d9-84d0-e94ee84c67b4" xlink:href="biib-20210930.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_1c93bfa5-8e0f-43d9-84d0-e94ee84c67b4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c950f1b9-778d-4431-a9e1-342cbb9bd77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c950f1b9-778d-4431-a9e1-342cbb9bd77a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_1e82ab4c-c68b-4680-a8bd-b670899341d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_1e82ab4c-c68b-4680-a8bd-b670899341d9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_87e8787b-74c8-41df-89aa-222388488217" xlink:href="biib-20210930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_87e8787b-74c8-41df-89aa-222388488217" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_2b03b456-66e0-4d66-9913-0c43e145daf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_2b03b456-66e0-4d66-9913-0c43e145daf8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_60ba0e6d-ee5f-4f13-abff-06d277c25943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_60ba0e6d-ee5f-4f13-abff-06d277c25943" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561" xlink:href="biib-20210930.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_biib_DerivativeMaturityAxis_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561_default" xlink:href="biib-20210930.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561" xlink:to="loc_biib_DerivativeMaturityDomain_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_b8f7ba2e-9e5f-4909-89ee-890446e79f40" xlink:href="biib-20210930.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561" xlink:to="loc_biib_DerivativeMaturityDomain_b8f7ba2e-9e5f-4909-89ee-890446e79f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_7a321a32-ff50-432c-bb2b-9e17bb23fe12" xlink:href="biib-20210930.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_b8f7ba2e-9e5f-4909-89ee-890446e79f40" xlink:to="loc_biib_ShorttermderivativeMember_7a321a32-ff50-432c-bb2b-9e17bb23fe12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20e12521-8cf0-4427-b6af-24407514e89e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20e12521-8cf0-4427-b6af-24407514e89e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_20e12521-8cf0-4427-b6af-24407514e89e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20e12521-8cf0-4427-b6af-24407514e89e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_20e12521-8cf0-4427-b6af-24407514e89e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e2c7008a-42ec-4dd4-9222-d918fc5e0701" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20e12521-8cf0-4427-b6af-24407514e89e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e2c7008a-42ec-4dd4-9222-d918fc5e0701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_76bced71-87a0-4b1d-ad79-296139cc0f1e" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e2c7008a-42ec-4dd4-9222-d918fc5e0701" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_76bced71-87a0-4b1d-ad79-296139cc0f1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4d8903b2-b675-47d9-bf0b-cdd39a7b3196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_DebtInstrumentAxis_4d8903b2-b675-47d9-bf0b-cdd39a7b3196" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4d8903b2-b675-47d9-bf0b-cdd39a7b3196_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d8903b2-b675-47d9-bf0b-cdd39a7b3196" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4d8903b2-b675-47d9-bf0b-cdd39a7b3196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_965c9be3-6950-4899-80b2-efbdc895d3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d8903b2-b675-47d9-bf0b-cdd39a7b3196" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_965c9be3-6950-4899-80b2-efbdc895d3c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_e46ee0ab-829d-4c6a-9263-f11a2c516a8c" xlink:href="biib-20210930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_965c9be3-6950-4899-80b2-efbdc895d3c6" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_e46ee0ab-829d-4c6a-9263-f11a2c516a8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_13e1e932-6e14-4c71-bc8f-899b090e0f7c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_srt_CurrencyAxis_13e1e932-6e14-4c71-bc8f-899b090e0f7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_13e1e932-6e14-4c71-bc8f-899b090e0f7c_default" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_13e1e932-6e14-4c71-bc8f-899b090e0f7c" xlink:to="loc_currency_AllCurrenciesDomain_13e1e932-6e14-4c71-bc8f-899b090e0f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_13e1e932-6e14-4c71-bc8f-899b090e0f7c" xlink:to="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_478225b1-65e7-47f7-b184-8408ee01a0cb" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_EUR_478225b1-65e7-47f7-b184-8408ee01a0cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_1080a2bd-2767-473a-9133-b65650d3b007" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_GBP_1080a2bd-2767-473a-9133-b65650d3b007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_ba1d8994-c634-4dcd-b301-98476696f429" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_CHF_ba1d8994-c634-4dcd-b301-98476696f429" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_5edbec70-536d-42a7-961a-064fad2ce043" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_JPY_5edbec70-536d-42a7-961a-064fad2ce043" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_eadf036a-7cab-4f80-a3ed-4191b8a2ca8b" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_CAD_eadf036a-7cab-4f80-a3ed-4191b8a2ca8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0d38c344-44e5-4d5e-98d2-4a42efce3890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0d38c344-44e5-4d5e-98d2-4a42efce3890" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0d38c344-44e5-4d5e-98d2-4a42efce3890_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d38c344-44e5-4d5e-98d2-4a42efce3890" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0d38c344-44e5-4d5e-98d2-4a42efce3890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d38c344-44e5-4d5e-98d2-4a42efce3890" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_cf9d7ed4-4978-4fad-8623-e774929fc4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:to="loc_us-gaap_InterestExpenseMember_cf9d7ed4-4978-4fad-8623-e774929fc4ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_4b063bda-76db-47de-bee8-c7136c18aed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:to="loc_us-gaap_SalesMember_4b063bda-76db-47de-bee8-c7136c18aed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_df2171e3-e9d7-415e-b9e1-b89f9f8f0b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:to="loc_us-gaap_OperatingExpenseMember_df2171e3-e9d7-415e-b9e1-b89f9f8f0b41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_eca9ea8b-933a-4e44-b051-a71a5e2f00cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_eca9ea8b-933a-4e44-b051-a71a5e2f00cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_02c5b893-6adc-4262-82ac-4481497f779b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:to="loc_us-gaap_CashFlowHedgingMember_02c5b893-6adc-4262-82ac-4481497f779b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_f04b52c2-9ded-4654-89f0-d497678e5faa" xlink:href="biib-20210930.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:to="loc_biib_CashflowsrevenueMember_f04b52c2-9ded-4654-89f0-d497678e5faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_093755e6-fe78-4759-8dc4-b9c42d8a50a6" xlink:href="biib-20210930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:to="loc_biib_CashflowsoperatingexpensesMember_093755e6-fe78-4759-8dc4-b9c42d8a50a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5015c523-9a9c-43aa-a63b-44513990a407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5015c523-9a9c-43aa-a63b-44513990a407" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_db573d45-ea35-4795-93a6-4b75286fe830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_db573d45-ea35-4795-93a6-4b75286fe830" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_db573d45-ea35-4795-93a6-4b75286fe830_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_db573d45-ea35-4795-93a6-4b75286fe830" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_db573d45-ea35-4795-93a6-4b75286fe830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0cbece4c-7b26-4e7a-b6be-92a12ebe10ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_db573d45-ea35-4795-93a6-4b75286fe830" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0cbece4c-7b26-4e7a-b6be-92a12ebe10ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f1f68188-3b2b-4a01-8a40-deaa6c011096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0cbece4c-7b26-4e7a-b6be-92a12ebe10ae" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f1f68188-3b2b-4a01-8a40-deaa6c011096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2dfb6ada-c694-4a01-bae4-0a3b20907fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0cbece4c-7b26-4e7a-b6be-92a12ebe10ae" xlink:to="loc_us-gaap_InterestRateSwapMember_2dfb6ada-c694-4a01-bae4-0a3b20907fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_f61840d1-905c-4fde-9f2b-4cfae2268f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_f61840d1-905c-4fde-9f2b-4cfae2268f01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e06c0e2d-239a-467b-b3f0-230898ab5b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e06c0e2d-239a-467b-b3f0-230898ab5b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_67efc4d8-e6bc-4a57-bd5c-7d3bd18e9e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_67efc4d8-e6bc-4a57-bd5c-7d3bd18e9e17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7d41b861-0cee-40d1-98b5-d7d41bf05867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7d41b861-0cee-40d1-98b5-d7d41bf05867" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_HedgingDesignationAxis_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640" xlink:to="loc_us-gaap_HedgingDesignationDomain_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a04e20e7-3d9f-4740-a9cd-20c14c152d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640" xlink:to="loc_us-gaap_HedgingDesignationDomain_a04e20e7-3d9f-4740-a9cd-20c14c152d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1d0cf044-1cb3-47b2-9584-99d223acd5c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a04e20e7-3d9f-4740-a9cd-20c14c152d24" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1d0cf044-1cb3-47b2-9584-99d223acd5c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_64d16f5b-2221-48e0-bf05-b9dd99c80f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a04e20e7-3d9f-4740-a9cd-20c14c152d24" xlink:to="loc_us-gaap_NondesignatedMember_64d16f5b-2221-48e0-bf05-b9dd99c80f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0626ba27-4b36-44ce-b389-179d110480f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_srt_RangeAxis_0626ba27-4b36-44ce-b389-179d110480f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0626ba27-4b36-44ce-b389-179d110480f1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0626ba27-4b36-44ce-b389-179d110480f1" xlink:to="loc_srt_RangeMember_0626ba27-4b36-44ce-b389-179d110480f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_205b907d-02e1-4613-902c-469ecfbadf14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0626ba27-4b36-44ce-b389-179d110480f1" xlink:to="loc_srt_RangeMember_205b907d-02e1-4613-902c-469ecfbadf14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ba0bd242-dc36-413d-ba6f-af2351a6e9f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_205b907d-02e1-4613-902c-469ecfbadf14" xlink:to="loc_srt_MinimumMember_ba0bd242-dc36-413d-ba6f-af2351a6e9f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b31cc70f-7128-4fb4-b958-799519f4f5b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_205b907d-02e1-4613-902c-469ecfbadf14" xlink:to="loc_srt_MaximumMember_b31cc70f-7128-4fb4-b958-799519f4f5b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3b78a5d1-ae9b-4780-9760-ba8465de362b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_dei_LegalEntityAxis_3b78a5d1-ae9b-4780-9760-ba8465de362b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3b78a5d1-ae9b-4780-9760-ba8465de362b_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3b78a5d1-ae9b-4780-9760-ba8465de362b" xlink:to="loc_dei_EntityDomain_3b78a5d1-ae9b-4780-9760-ba8465de362b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0969c6ec-0d46-45bd-8986-d968fbabe5f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3b78a5d1-ae9b-4780-9760-ba8465de362b" xlink:to="loc_dei_EntityDomain_0969c6ec-0d46-45bd-8986-d968fbabe5f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_cfc1f5e4-6888-4d3e-a61b-62bb825c3cdd" xlink:href="biib-20210930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0969c6ec-0d46-45bd-8986-d968fbabe5f5" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_cfc1f5e4-6888-4d3e-a61b-62bb825c3cdd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="i7775305e6d6f4349bda1df4d53622ad2_PropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae01b9db-2b5c-4897-b62b-f36f1e7d93b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae01b9db-2b5c-4897-b62b-f36f1e7d93b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_dd8fee2d-9270-47aa-9d5d-b662e23f1295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_Depreciation_dd8fee2d-9270-47aa-9d5d-b662e23f1295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_18afcc56-0e24-4620-b376-808aa3499fcd" xlink:href="biib-20210930.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_biib_NumberOfSquareFeet_18afcc56-0e24-4620-b376-808aa3499fcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_b11efb76-1c35-4509-ab25-f64f854c8589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_ConstructionInProgressGross_b11efb76-1c35-4509-ab25-f64f854c8589" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_43dc5d73-0629-4c4a-aa55-f3a3f70ca347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_43dc5d73-0629-4c4a-aa55-f3a3f70ca347" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_fe902949-4ee2-4e76-9538-a01e1f4fb32f" xlink:href="biib-20210930.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:to="loc_biib_FacilityLocationAxis_fe902949-4ee2-4e76-9538-a01e1f4fb32f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_fe902949-4ee2-4e76-9538-a01e1f4fb32f_default" xlink:href="biib-20210930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_fe902949-4ee2-4e76-9538-a01e1f4fb32f" xlink:to="loc_biib_FacilityLocationDomain_fe902949-4ee2-4e76-9538-a01e1f4fb32f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_43f5369e-50da-4a0a-859d-6e768d539310" xlink:href="biib-20210930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_fe902949-4ee2-4e76-9538-a01e1f4fb32f" xlink:to="loc_biib_FacilityLocationDomain_43f5369e-50da-4a0a-859d-6e768d539310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_86694dbb-e777-4063-9c88-b17fecca7eb3" xlink:href="biib-20210930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_43f5369e-50da-4a0a-859d-6e768d539310" xlink:to="loc_biib_SolothurnSwitzerlandMember_86694dbb-e777-4063-9c88-b17fecca7eb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_bcae1223-7427-473b-9729-84d66a60ab6e" xlink:href="biib-20210930.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:to="loc_biib_FacilityTypeAxis_bcae1223-7427-473b-9729-84d66a60ab6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_bcae1223-7427-473b-9729-84d66a60ab6e_default" xlink:href="biib-20210930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_bcae1223-7427-473b-9729-84d66a60ab6e" xlink:to="loc_biib_FacilityTypeDomain_bcae1223-7427-473b-9729-84d66a60ab6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:href="biib-20210930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_bcae1223-7427-473b-9729-84d66a60ab6e" xlink:to="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_7dfec408-cc51-4f43-a1a0-5d13d5218e9f" xlink:href="biib-20210930.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:to="loc_biib_BiologicsManufacturingMember_7dfec408-cc51-4f43-a1a0-5d13d5218e9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_b4ea6f04-be87-40d7-90f3-e18c91663f19" xlink:href="biib-20210930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_b4ea6f04-be87-40d7-90f3-e18c91663f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_ff215c50-1354-4415-846f-ac2975ba0c4a" xlink:href="biib-20210930.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:to="loc_biib_AdministrativeSpaceMember_ff215c50-1354-4415-846f-ac2975ba0c4a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" id="i8c5ca94ea9b744f4bcd6a0109a3791b1_IndebtednessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a5c1b268-7abb-4a5b-bfd0-a05c8e7496ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a5c1b268-7abb-4a5b-bfd0-a05c8e7496ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb7319de-3681-4dd8-a0a4-3458eba4c9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb7319de-3681-4dd8-a0a4-3458eba4c9a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_4e92154f-ba2f-4640-979d-c4f98c0bb0dd" xlink:href="biib-20210930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_4e92154f-ba2f-4640-979d-c4f98c0bb0dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_9997396a-f7b8-455d-b29c-11c183b8da69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_9997396a-f7b8-455d-b29c-11c183b8da69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_388e27b2-ca57-4efe-bc82-8441954524e7" xlink:href="biib-20210930.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_388e27b2-ca57-4efe-bc82-8441954524e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_dec01d9f-be2b-4974-a3b9-d5699fb8bd73" xlink:href="biib-20210930.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_dec01d9f-be2b-4974-a3b9-d5699fb8bd73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_5803dfab-995f-463c-a2ff-4f0fd3f81a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_5803dfab-995f-463c-a2ff-4f0fd3f81a53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_1354c116-09f4-4035-b9cb-624a3ff7e184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_1354c116-09f4-4035-b9cb-624a3ff7e184" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_70b928d4-c4c4-4153-9edb-6f67d1d02235" xlink:href="biib-20210930.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_70b928d4-c4c4-4153-9edb-6f67d1d02235" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_40d998ba-0aed-49e1-8032-c5ec01fb9c8b" xlink:href="biib-20210930.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_LongTermDebtExchangedAmount_40d998ba-0aed-49e1-8032-c5ec01fb9c8b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96772550-5240-4192-be65-ffd205700fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96772550-5240-4192-be65-ffd205700fb8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_714aed0e-a13a-44cc-8baa-49f90abe878b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_RepaymentsOfDebt_714aed0e-a13a-44cc-8baa-49f90abe878b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_98a328eb-b799-4307-8d46-aee1b37f1875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_InterestExpense_98a328eb-b799-4307-8d46-aee1b37f1875" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_25c07c5c-df1c-49c9-87ba-3de1cca13356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_25c07c5c-df1c-49c9-87ba-3de1cca13356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_25c07c5c-df1c-49c9-87ba-3de1cca13356_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_25c07c5c-df1c-49c9-87ba-3de1cca13356" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_25c07c5c-df1c-49c9-87ba-3de1cca13356_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_218dc9ce-3443-45f4-9fef-a15650915076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_25c07c5c-df1c-49c9-87ba-3de1cca13356" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_218dc9ce-3443-45f4-9fef-a15650915076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_67463979-a861-4964-9218-7cdb9c2bacad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_218dc9ce-3443-45f4-9fef-a15650915076" xlink:to="loc_us-gaap_InterestExpenseMember_67463979-a861-4964-9218-7cdb9c2bacad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b110dc9e-4b20-46f9-aff5-4d3810aea7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b110dc9e-4b20-46f9-aff5-4d3810aea7a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b110dc9e-4b20-46f9-aff5-4d3810aea7a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b110dc9e-4b20-46f9-aff5-4d3810aea7a7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b110dc9e-4b20-46f9-aff5-4d3810aea7a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_66af777c-7b65-48ae-a22e-7c8d0161f520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b110dc9e-4b20-46f9-aff5-4d3810aea7a7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_66af777c-7b65-48ae-a22e-7c8d0161f520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_54eaa45d-dbef-4da4-8e1f-e482e0870915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_66af777c-7b65-48ae-a22e-7c8d0161f520" xlink:to="loc_us-gaap_InterestRateSwapMember_54eaa45d-dbef-4da4-8e1f-e482e0870915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_51bc6b11-0d33-4a10-8777-4a188b103e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_51bc6b11-0d33-4a10-8777-4a188b103e12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_51bc6b11-0d33-4a10-8777-4a188b103e12_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_51bc6b11-0d33-4a10-8777-4a188b103e12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_51bc6b11-0d33-4a10-8777-4a188b103e12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_933efd65-63c3-4c23-8a02-06d7849f02d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_51bc6b11-0d33-4a10-8777-4a188b103e12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_933efd65-63c3-4c23-8a02-06d7849f02d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_98dc0050-648f-4436-87f3-894dadcc75b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_933efd65-63c3-4c23-8a02-06d7849f02d9" xlink:to="loc_us-gaap_SeniorNotesMember_98dc0050-648f-4436-87f3-894dadcc75b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c93e822c-224d-4fd2-ae1b-d5d15c4cca08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_DebtInstrumentAxis_c93e822c-224d-4fd2-ae1b-d5d15c4cca08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c93e822c-224d-4fd2-ae1b-d5d15c4cca08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c93e822c-224d-4fd2-ae1b-d5d15c4cca08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c93e822c-224d-4fd2-ae1b-d5d15c4cca08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c93e822c-224d-4fd2-ae1b-d5d15c4cca08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_5828e4f5-b413-4861-8b0d-b418dd45ff96" xlink:href="biib-20210930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_5828e4f5-b413-4861-8b0d-b418dd45ff96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_9cad9199-8aa4-438d-acf6-e84b3c57a812" xlink:href="biib-20210930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_9cad9199-8aa4-438d-acf6-e84b3c57a812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_832c8fd7-209e-454b-94c9-b7c3c2b4475e" xlink:href="biib-20210930.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_832c8fd7-209e-454b-94c9-b7c3c2b4475e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_0f45bd7c-939e-4755-bf1b-9a0bb02b9bb1" xlink:href="biib-20210930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_0f45bd7c-939e-4755-bf1b-9a0bb02b9bb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_445bd495-1cf7-40fb-8aa2-cbeb0089d924" xlink:href="biib-20210930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_445bd495-1cf7-40fb-8aa2-cbeb0089d924" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" id="i07de1b91f005449a9414146f7524777a_ShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3cccbcc3-8350-4066-a331-ecc813939990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3cccbcc3-8350-4066-a331-ecc813939990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3df3eff0-1d8a-49d6-94a5-c89336bf5e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3df3eff0-1d8a-49d6-94a5-c89336bf5e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3ad6685d-c887-4738-9b4d-d7ac15ebe054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3ad6685d-c887-4738-9b4d-d7ac15ebe054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4bcf488e-6e5b-402e-8335-b3f265778efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4bcf488e-6e5b-402e-8335-b3f265778efd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d9956fb6-cc38-4fb2-ade7-1327869bcd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d9956fb6-cc38-4fb2-ade7-1327869bcd78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_c99fa822-30f5-4090-a189-d20fc779e2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d9956fb6-cc38-4fb2-ade7-1327869bcd78" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_c99fa822-30f5-4090-a189-d20fc779e2d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_c99fa822-30f5-4090-a189-d20fc779e2d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_c99fa822-30f5-4090-a189-d20fc779e2d0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_c99fa822-30f5-4090-a189-d20fc779e2d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_c99fa822-30f5-4090-a189-d20fc779e2d0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_c1d2c9a8-c1f6-4f32-b92b-c0b000510ccb" xlink:href="biib-20210930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_c1d2c9a8-c1f6-4f32-b92b-c0b000510ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_9f9f8598-4cb6-40b2-b5c9-c01aae6d14e9" xlink:href="biib-20210930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_9f9f8598-4cb6-40b2-b5c9-c01aae6d14e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember_64e3d6ef-00ea-4aa2-bc0d-0a4f768c8fb7" xlink:href="biib-20210930.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:to="loc_biib_October2020ShareRepurchaseProgramMember_64e3d6ef-00ea-4aa2-bc0d-0a4f768c8fb7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="if637828c28ce495cb9fd62a0c1115bd9_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_699384c3-30fc-4174-9950-733c782d66d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_699384c3-30fc-4174-9950-733c782d66d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8648e3f4-eeb3-4000-befc-cb3735986d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_43cba1eb-3893-44aa-8b9e-667b6f324e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_43cba1eb-3893-44aa-8b9e-667b6f324e69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a2c56711-3672-487e-8907-04b299f0981a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a2c56711-3672-487e-8907-04b299f0981a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ff92f9c6-44d0-4338-8220-f7b41e8847d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ff92f9c6-44d0-4338-8220-f7b41e8847d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_015d2acd-79ac-4f9e-9438-d9193ceb4fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0b24a58b-18b7-4299-9270-37f471fa5a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0b24a58b-18b7-4299-9270-37f471fa5a7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecc7c3a5-62e4-417c-910f-df0378ac63e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecc7c3a5-62e4-417c-910f-df0378ac63e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecc7c3a5-62e4-417c-910f-df0378ac63e1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6" xlink:to="loc_us-gaap_EquityComponentDomain_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6" xlink:to="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ef9e6a6c-c831-48e8-8941-50e49012da4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ef9e6a6c-c831-48e8-8941-50e49012da4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_cd0a1da6-49d7-44b8-88d0-cc1c1a3485a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_cd0a1da6-49d7-44b8-88d0-cc1c1a3485a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_6fe198c3-2919-4781-9a35-9934f8c4c9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_6fe198c3-2919-4781-9a35-9934f8c4c9e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b78ac67d-83dd-47ea-8b9c-9dd923a3b418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b78ac67d-83dd-47ea-8b9c-9dd923a3b418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f8ee1daa-ddbc-422e-9ed7-2b49388ddf0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f8ee1daa-ddbc-422e-9ed7-2b49388ddf0f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="ic34475629ea5447cb0fb426e7c6a2721_ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_baa5a323-a656-4428-9189-abdbcf23a999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_baa5a323-a656-4428-9189-abdbcf23a999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_83ca8820-3956-4ec9-a049-5c306235b29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_83ca8820-3956-4ec9-a049-5c306235b29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e59d545b-c4e6-4525-a6a7-eccd34dc6696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_Revenues_e59d545b-c4e6-4525-a6a7-eccd34dc6696" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7b731c25-2575-41f4-99c1-d45f15a08eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_OperatingExpenses_7b731c25-2575-41f4-99c1-d45f15a08eca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62e313f7-84d0-46fc-9f9d-46ac345f940f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_NetIncomeLoss_62e313f7-84d0-46fc-9f9d-46ac345f940f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8aa10084-31ef-4874-a5cb-6e2ef3294025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8aa10084-31ef-4874-a5cb-6e2ef3294025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8aa10084-31ef-4874-a5cb-6e2ef3294025_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8aa10084-31ef-4874-a5cb-6e2ef3294025" xlink:to="loc_us-gaap_EquityComponentDomain_8aa10084-31ef-4874-a5cb-6e2ef3294025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8aa10084-31ef-4874-a5cb-6e2ef3294025" xlink:to="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ee87b33c-0145-4faa-879c-b2ed2d6bb440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ee87b33c-0145-4faa-879c-b2ed2d6bb440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bb81a61b-1055-4f12-835d-0fde6ea14dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bb81a61b-1055-4f12-835d-0fde6ea14dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_5f47b0a5-58a2-4beb-89e2-b133e3dd4fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_5f47b0a5-58a2-4beb-89e2-b133e3dd4fd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a58e5788-9ba7-40bf-8953-b7d68450755c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a58e5788-9ba7-40bf-8953-b7d68450755c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a58e5788-9ba7-40bf-8953-b7d68450755c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a58e5788-9ba7-40bf-8953-b7d68450755c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a58e5788-9ba7-40bf-8953-b7d68450755c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08fd05ad-d723-465c-ab7c-5a35f1ed8d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a58e5788-9ba7-40bf-8953-b7d68450755c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08fd05ad-d723-465c-ab7c-5a35f1ed8d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_65cb87db-bfa3-445f-9300-1db1d14ab49a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08fd05ad-d723-465c-ab7c-5a35f1ed8d0c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_65cb87db-bfa3-445f-9300-1db1d14ab49a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended" id="i4c73e523199c4d739b353b44d632fced_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f190cbbb-0087-4b6c-9a5a-7b21f515ec69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_84ecaccd-7c34-4b39-9f25-367f1561acc9" xlink:href="biib-20210930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f190cbbb-0087-4b6c-9a5a-7b21f515ec69" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_84ecaccd-7c34-4b39-9f25-367f1561acc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3d6698d6-0923-4b9a-b31e-94af2e3cceea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_84ecaccd-7c34-4b39-9f25-367f1561acc9" xlink:to="loc_us-gaap_NetIncomeLossAbstract_3d6698d6-0923-4b9a-b31e-94af2e3cceea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc352e21-91c5-4e64-a582-4eb142ed57c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3d6698d6-0923-4b9a-b31e-94af2e3cceea" xlink:to="loc_us-gaap_NetIncomeLoss_dc352e21-91c5-4e64-a582-4eb142ed57c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_84ecaccd-7c34-4b39-9f25-367f1561acc9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7728c49c-5ba1-4667-8f7a-71789ba07d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7728c49c-5ba1-4667-8f7a-71789ba07d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_37cc1c54-1e0d-4224-9c41-29fa70829a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_37cc1c54-1e0d-4224-9c41-29fa70829a77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77e604ff-9cd0-4c91-a217-6d926b620b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_37cc1c54-1e0d-4224-9c41-29fa70829a77" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77e604ff-9cd0-4c91-a217-6d926b620b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e8f18205-1fae-4ee2-b4ce-cf511dbfb933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_37cc1c54-1e0d-4224-9c41-29fa70829a77" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e8f18205-1fae-4ee2-b4ce-cf511dbfb933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c10e1103-f146-4eb4-9d90-18e0269ef9d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c10e1103-f146-4eb4-9d90-18e0269ef9d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5b1954e-726f-4f45-89a6-83dad5bd9abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f190cbbb-0087-4b6c-9a5a-7b21f515ec69" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5b1954e-726f-4f45-89a6-83dad5bd9abb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01d1bd5f-c19b-4c53-aa83-cd60682a72bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5b1954e-726f-4f45-89a6-83dad5bd9abb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01d1bd5f-c19b-4c53-aa83-cd60682a72bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_01d1bd5f-c19b-4c53-aa83-cd60682a72bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01d1bd5f-c19b-4c53-aa83-cd60682a72bc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_01d1bd5f-c19b-4c53-aa83-cd60682a72bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01d1bd5f-c19b-4c53-aa83-cd60682a72bc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_4f48ef09-f61a-4813-8b21-07d7f01403dd" xlink:href="biib-20210930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_4f48ef09-f61a-4813-8b21-07d7f01403dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_f9ac335f-d09a-4c12-a021-cabe7ae68528" xlink:href="biib-20210930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:to="loc_biib_MarketStockUnitsMember_f9ac335f-d09a-4c12-a021-cabe7ae68528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_853ee609-ba8f-461f-9d2d-a625fd5a44f6" xlink:href="biib-20210930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_853ee609-ba8f-461f-9d2d-a625fd5a44f6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="ibd1320bc627b40419a761d713f18a412_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5688d8f-1840-41f1-aa66-55396410aeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5688d8f-1840-41f1-aa66-55396410aeb8" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_be4396f2-350f-4e80-8b9c-cf09657d5f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_be4396f2-350f-4e80-8b9c-cf09657d5f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e3b90769-5183-4c5b-a3d4-6fb6bd2e6856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e3b90769-5183-4c5b-a3d4-6fb6bd2e6856" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_22a558a4-a6cc-4abf-bf03-ea03ef780859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_22a558a4-a6cc-4abf-bf03-ea03ef780859" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_dd98b22b-6e66-4304-81af-68564f6a1db4" xlink:href="biib-20210930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_dd98b22b-6e66-4304-81af-68564f6a1db4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_985119c9-7106-46b1-9e94-7bb774ef5c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_985119c9-7106-46b1-9e94-7bb774ef5c7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837e16cd-ac15-4a6a-9ce4-bfc4eab0c358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5688d8f-1840-41f1-aa66-55396410aeb8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837e16cd-ac15-4a6a-9ce4-bfc4eab0c358" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_00f18fde-2881-476f-a56b-36e464214e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837e16cd-ac15-4a6a-9ce4-bfc4eab0c358" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_00f18fde-2881-476f-a56b-36e464214e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_00f18fde-2881-476f-a56b-36e464214e5d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_00f18fde-2881-476f-a56b-36e464214e5d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_00f18fde-2881-476f-a56b-36e464214e5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_00f18fde-2881-476f-a56b-36e464214e5d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8b46474f-c1c1-4569-8116-ef67df16b1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8b46474f-c1c1-4569-8116-ef67df16b1fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_168c08a0-c403-4222-bf4d-46fe35ccbd08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_168c08a0-c403-4222-bf4d-46fe35ccbd08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_7720d648-9ce1-40f2-88ef-a104498f6af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:to="loc_us-gaap_ParentMember_7720d648-9ce1-40f2-88ef-a104498f6af5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#ShareBasedPaymentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" id="i9b6c547c70f445968df1f2c554757b9b_ShareBasedPaymentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bba46df0-ad1b-477d-98b6-5016081184fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:href="biib-20210930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bba46df0-ad1b-477d-98b6-5016081184fa" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_97f56a59-23c3-45e4-ad6e-766cb9f4793f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_97f56a59-23c3-45e4-ad6e-766cb9f4793f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7193715d-48c5-4026-8e88-b60e48aa4099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7193715d-48c5-4026-8e88-b60e48aa4099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e580e009-7c48-499e-81a4-b2349dc8225f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e580e009-7c48-499e-81a4-b2349dc8225f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1f7c3733-2903-4822-aae1-237bf7b94659" xlink:href="biib-20210930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1f7c3733-2903-4822-aae1-237bf7b94659" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bba46df0-ad1b-477d-98b6-5016081184fa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63e7f2e2-9703-41b1-aabe-b549a0bf3e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63e7f2e2-9703-41b1-aabe-b549a0bf3e20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63e7f2e2-9703-41b1-aabe-b549a0bf3e20_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63e7f2e2-9703-41b1-aabe-b549a0bf3e20" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63e7f2e2-9703-41b1-aabe-b549a0bf3e20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e6d1b97-21c4-40a3-a817-2e01886bb247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63e7f2e2-9703-41b1-aabe-b549a0bf3e20" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e6d1b97-21c4-40a3-a817-2e01886bb247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_61a2f8de-7caf-46cc-94b8-9f88df06992d" xlink:href="biib-20210930.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e6d1b97-21c4-40a3-a817-2e01886bb247" xlink:to="loc_biib_NightstarMember_61a2f8de-7caf-46cc-94b8-9f88df06992d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a190c9c-1f79-48d3-8474-616c0834db04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:to="loc_us-gaap_AwardTypeAxis_3a190c9c-1f79-48d3-8474-616c0834db04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a190c9c-1f79-48d3-8474-616c0834db04_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3a190c9c-1f79-48d3-8474-616c0834db04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a190c9c-1f79-48d3-8474-616c0834db04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3a190c9c-1f79-48d3-8474-616c0834db04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_4cf1e2d3-ca91-4916-8f99-6b7cc7328354" xlink:href="biib-20210930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_MarketStockUnitsMember_4cf1e2d3-ca91-4916-8f99-6b7cc7328354" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_05165afd-4e17-4a81-888b-c71fd23f4283" xlink:href="biib-20210930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_05165afd-4e17-4a81-888b-c71fd23f4283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7283aa08-850e-4f0e-b1ab-166d7b41a939" xlink:href="biib-20210930.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_CashSettledPerformanceSharesMember_7283aa08-850e-4f0e-b1ab-166d7b41a939" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e733ea58-a46c-4371-8794-46e0b11934f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_us-gaap_PerformanceSharesMember_e733ea58-a46c-4371-8794-46e0b11934f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_d02558e8-0253-45e9-a6d1-41102a8526d2" xlink:href="biib-20210930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_d02558e8-0253-45e9-a6d1-41102a8526d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_d6d0abce-cb17-4d3d-b531-03a4f2e4a998" xlink:href="biib-20210930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_d6d0abce-cb17-4d3d-b531-03a4f2e4a998" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_fa4a1732-614f-4e33-8241-5804a7e40452" xlink:href="biib-20210930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_fa4a1732-614f-4e33-8241-5804a7e40452" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="ia7d167c548504fdba77e643e2bbc063e_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_a3c81cae-a7c8-444c-9c7c-d4fcee66b023" xlink:href="biib-20210930.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_a3c81cae-a7c8-444c-9c7c-d4fcee66b023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_9b8ba42f-e5f1-4b44-9768-78c9568888f4" xlink:href="biib-20210930.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_9b8ba42f-e5f1-4b44-9768-78c9568888f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue_b9a76e89-0657-4f3a-8c31-8fd762b25932" xlink:href="biib-20210930.xsd#biib_DeferredTaxAssetIncreaseDecreaseInValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue_b9a76e89-0657-4f3a-8c31-8fd762b25932" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_968013df-f619-4dd8-9838-8355e7b7992c" xlink:href="biib-20210930.xsd#biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_968013df-f619-4dd8-9838-8355e7b7992c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_feb38c06-da73-491b-a236-8a7372410977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_feb38c06-da73-491b-a236-8a7372410977" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4967b4ff-4458-4597-a11b-a9b72513925a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4967b4ff-4458-4597-a11b-a9b72513925a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_023b6289-3aba-4a30-b7d7-c9ac3aa9bfa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_023b6289-3aba-4a30-b7d7-c9ac3aa9bfa9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_c60bad99-5b98-4f7d-be24-447e568080c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_c60bad99-5b98-4f7d-be24-447e568080c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c732d7a-01d0-469b-805d-609e0dba7c1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:to="loc_srt_ProductOrServiceAxis_3c732d7a-01d0-469b-805d-609e0dba7c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c732d7a-01d0-469b-805d-609e0dba7c1f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3c732d7a-01d0-469b-805d-609e0dba7c1f" xlink:to="loc_srt_ProductsAndServicesDomain_3c732d7a-01d0-469b-805d-609e0dba7c1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f00a1b08-8e97-46c6-a440-c52d59d6b207" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3c732d7a-01d0-469b-805d-609e0dba7c1f" xlink:to="loc_srt_ProductsAndServicesDomain_f00a1b08-8e97-46c6-a440-c52d59d6b207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_6169dcfa-bc8b-430d-a73d-2c9d1f18d49d" xlink:href="biib-20210930.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f00a1b08-8e97-46c6-a440-c52d59d6b207" xlink:to="loc_biib_TECFIDERAMember_6169dcfa-bc8b-430d-a73d-2c9d1f18d49d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_57151813-6e95-403c-8713-8363bb344497" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:to="loc_srt_StatementScenarioAxis_57151813-6e95-403c-8713-8363bb344497" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_57151813-6e95-403c-8713-8363bb344497_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_57151813-6e95-403c-8713-8363bb344497" xlink:to="loc_srt_ScenarioUnspecifiedDomain_57151813-6e95-403c-8713-8363bb344497_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8e84cc2c-1779-4ea4-92fc-a14cfb457571" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_57151813-6e95-403c-8713-8363bb344497" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8e84cc2c-1779-4ea4-92fc-a14cfb457571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_38a0aa1a-01fc-444f-b04c-24bbb3c234e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8e84cc2c-1779-4ea4-92fc-a14cfb457571" xlink:to="loc_srt_ScenarioForecastMember_38a0aa1a-01fc-444f-b04c-24bbb3c234e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended" id="i16cf573a613f49498c763b47421d2c81_OtherConsolidatedFinancialStatementDetailDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_dc6090f5-18f2-4965-8dc4-32cd2cd0c2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_InvestmentIncomeInterest_dc6090f5-18f2-4965-8dc4-32cd2cd0c2ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4267f3a4-8f27-48b5-8c92-24fd8bac1491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_InterestExpense_4267f3a4-8f27-48b5-8c92-24fd8bac1491" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_a0e2220a-9893-438a-974b-01b9ff868dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_a0e2220a-9893-438a-974b-01b9ff868dcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04cae6f7-0be3-4481-b431-0904f5fd1378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04cae6f7-0be3-4481-b431-0904f5fd1378" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_42f6db1b-30a3-4048-a06a-08a01707a593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_42f6db1b-30a3-4048-a06a-08a01707a593" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b983218-b20e-4cbf-bcb8-e8f95683e66a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b983218-b20e-4cbf-bcb8-e8f95683e66a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_30d528c7-354c-41ca-8c86-50df5e955253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_30d528c7-354c-41ca-8c86-50df5e955253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_87e2431b-ca11-450c-ac6f-63d1f7ef8cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_87e2431b-ca11-450c-ac6f-63d1f7ef8cbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d9735a58-bf4a-430f-bf3e-da6316008a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d9735a58-bf4a-430f-bf3e-da6316008a5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e55676f8-2b53-4c25-bd6b-ce2d705009c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e55676f8-2b53-4c25-bd6b-ce2d705009c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_692d8f6c-2739-4608-abd9-89a663aaea88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_692d8f6c-2739-4608-abd9-89a663aaea88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_a119f9e8-4e47-4e99-9f99-90534fd38907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_a119f9e8-4e47-4e99-9f99-90534fd38907" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_98d772d6-9108-466d-9624-6965e1297195" xlink:href="biib-20210930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_biib_Collaborationexpensesaccrual_98d772d6-9108-466d-9624-6965e1297195" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0fb78a3c-eecb-4ac1-9edc-14c589ebc228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0fb78a3c-eecb-4ac1-9edc-14c589ebc228" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_ab4774e6-590e-41f8-83d7-1132dfe74890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_ab4774e6-590e-41f8-83d7-1132dfe74890" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1ec5879e-4917-428d-9451-722a13a3af8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1ec5879e-4917-428d-9451-722a13a3af8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_98a0b397-c961-46ab-9957-7d988476efea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_98a0b397-c961-46ab-9957-7d988476efea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:to="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c805ea5-06df-4362-9666-aef15e73c460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c805ea5-06df-4362-9666-aef15e73c460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6c805ea5-06df-4362-9666-aef15e73c460_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c805ea5-06df-4362-9666-aef15e73c460" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6c805ea5-06df-4362-9666-aef15e73c460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_027c73e0-164f-480a-b9a9-a833d431f855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c805ea5-06df-4362-9666-aef15e73c460" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_027c73e0-164f-480a-b9a9-a833d431f855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5ad8034e-d6fd-4a7c-968e-563072fdb46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_027c73e0-164f-480a-b9a9-a833d431f855" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5ad8034e-d6fd-4a7c-968e-563072fdb46b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2cc4ece6-3bfd-459c-b44f-75e66dd5e715" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:to="loc_dei_LegalEntityAxis_2cc4ece6-3bfd-459c-b44f-75e66dd5e715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2cc4ece6-3bfd-459c-b44f-75e66dd5e715_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2cc4ece6-3bfd-459c-b44f-75e66dd5e715" xlink:to="loc_dei_EntityDomain_2cc4ece6-3bfd-459c-b44f-75e66dd5e715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f37360f-cb3d-4862-8e82-2e5f7203f956" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2cc4ece6-3bfd-459c-b44f-75e66dd5e715" xlink:to="loc_dei_EntityDomain_2f37360f-cb3d-4862-8e82-2e5f7203f956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_c2f2a511-50a0-4085-90ef-8bb880f22685" xlink:href="biib-20210930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2f37360f-cb3d-4862-8e82-2e5f7203f956" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_c2f2a511-50a0-4085-90ef-8bb880f22685" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" id="i9bfd73e9fa594d2a9f4fbbe810de45df_OtherConsolidatedFinancialStatementDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_396fedd7-d77b-4759-aaf2-55842fa2e6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_396fedd7-d77b-4759-aaf2-55842fa2e6fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cbc1b01f-a2db-4d3a-9137-5534103e7b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cbc1b01f-a2db-4d3a-9137-5534103e7b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_51fa70db-70b2-483e-afca-908bf8c26b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_51fa70db-70b2-483e-afca-908bf8c26b2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fd6e9a11-f240-426e-b5b3-f1d3a2d5dd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fd6e9a11-f240-426e-b5b3-f1d3a2d5dd4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_ca326b5a-9b3b-4c28-89be-0d7b4f2c2a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_ca326b5a-9b3b-4c28-89be-0d7b4f2c2a60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0351ae33-84c3-45bd-b5d2-033f5189fa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_StatementTable_0351ae33-84c3-45bd-b5d2-033f5189fa5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d40b8247-54b0-40c2-91c9-1ae7445792bb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0351ae33-84c3-45bd-b5d2-033f5189fa5e" xlink:to="loc_dei_LegalEntityAxis_d40b8247-54b0-40c2-91c9-1ae7445792bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d40b8247-54b0-40c2-91c9-1ae7445792bb_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d40b8247-54b0-40c2-91c9-1ae7445792bb" xlink:to="loc_dei_EntityDomain_d40b8247-54b0-40c2-91c9-1ae7445792bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a6b143e4-e333-4301-b509-dd0ed2a18c11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d40b8247-54b0-40c2-91c9-1ae7445792bb" xlink:to="loc_dei_EntityDomain_a6b143e4-e333-4301-b509-dd0ed2a18c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_939f0012-0eba-4f78-8dcd-d047092c14ac" xlink:href="biib-20210930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a6b143e4-e333-4301-b509-dd0ed2a18c11" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_939f0012-0eba-4f78-8dcd-d047092c14ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended" id="i70e82833404d44e3b6ee016e47ef8b05_CollaborativeandOtherRelationshipsCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_c2d750ef-ff7f-471b-a44b-537b1cbb36bc" xlink:href="biib-20210930.xsd#biib_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_NumberOfProductCandidates_c2d750ef-ff7f-471b-a44b-537b1cbb36bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_1a5dac5d-18a1-4dba-b6df-bb19a2b10718" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_1a5dac5d-18a1-4dba-b6df-bb19a2b10718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_7fbff20a-3e29-42df-af02-b1bdab09a33b" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_7fbff20a-3e29-42df-af02-b1bdab09a33b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_f5b4f8bb-1934-4891-ac74-e4839fd8354d" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_f5b4f8bb-1934-4891-ac74-e4839fd8354d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_402e9dfd-2914-4bb0-9789-76fec5d8a6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_402e9dfd-2914-4bb0-9789-76fec5d8a6b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_f3205ce9-2957-41e3-a084-984ff231ae9b" xlink:href="biib-20210930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_ExpenseIncurredByCollaboration_f3205ce9-2957-41e3-a084-984ff231ae9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_b19d4fba-dd8d-412b-b7ab-43a802860b7a" xlink:href="biib-20210930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_Expenseincurredbythecollaboration_b19d4fba-dd8d-412b-b7ab-43a802860b7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_e0e12583-c558-48e5-8fb3-6112279f8181" xlink:href="biib-20210930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_e0e12583-c558-48e5-8fb3-6112279f8181" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_afdc62d6-21b0-46a8-a43f-78db18ce2aec" xlink:href="biib-20210930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_afdc62d6-21b0-46a8-a43f-78db18ce2aec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_56ab6cb1-eeb2-4fcf-abe8-fbdccd4d4850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_LossOnContractTermination_56ab6cb1-eeb2-4fcf-abe8-fbdccd4d4850" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_d0c0be61-a5b0-4ca1-bc1f-4127795d6d90" xlink:href="biib-20210930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_d0c0be61-a5b0-4ca1-bc1f-4127795d6d90" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_75ff8bc9-4984-4650-8bdd-a8cf23e4e881" xlink:href="biib-20210930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_CollaborationAgreementTerm_75ff8bc9-4984-4650-8bdd-a8cf23e4e881" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_ead04fa3-74af-463d-b6a0-657aca24081b" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_ead04fa3-74af-463d-b6a0-657aca24081b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_cc1d0693-4608-4a29-abf8-53d06d2cdbae" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_cc1d0693-4608-4a29-abf8-53d06d2cdbae" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_695f3f89-f179-4fba-8306-b9772158bf93" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_695f3f89-f179-4fba-8306-b9772158bf93" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_fdecda34-6d05-4b9e-8808-c97eb97523f8" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_fdecda34-6d05-4b9e-8808-c97eb97523f8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_18d75ec8-633c-4902-a25e-7e753e7e625a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_18d75ec8-633c-4902-a25e-7e753e7e625a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_fc163bd3-0f6b-43a4-ad1f-6df1279342f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_fc163bd3-0f6b-43a4-ad1f-6df1279342f8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_cafcd40c-7b48-494b-9d03-6b2d9da10361" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_cafcd40c-7b48-494b-9d03-6b2d9da10361" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_b53c540b-1987-4676-9a78-0f76b67b886d" xlink:href="biib-20210930.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_Termofcollaborationagreement_b53c540b-1987-4676-9a78-0f76b67b886d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_898d32c7-1051-4f5a-8611-8bc7110c881a" xlink:href="biib-20210930.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_898d32c7-1051-4f5a-8611-8bc7110c881a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_9c76b24d-6b53-48c2-a635-0b22721b73ca" xlink:href="biib-20210930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_AdditionalMilestonePayment_9c76b24d-6b53-48c2-a635-0b22721b73ca" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5fc6f5b8-b13f-4150-a42c-d6907d30c672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5fc6f5b8-b13f-4150-a42c-d6907d30c672" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d92ae14-081f-4211-b1ba-9afe04b68ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d92ae14-081f-4211-b1ba-9afe04b68ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d92ae14-081f-4211-b1ba-9afe04b68ba8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d92ae14-081f-4211-b1ba-9afe04b68ba8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d92ae14-081f-4211-b1ba-9afe04b68ba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f552c969-3027-4664-a791-dfa4a5e1a528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d92ae14-081f-4211-b1ba-9afe04b68ba8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f552c969-3027-4664-a791-dfa4a5e1a528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ceb1651a-ae35-494e-b131-7e15dfb9750c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f552c969-3027-4664-a791-dfa4a5e1a528" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ceb1651a-ae35-494e-b131-7e15dfb9750c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_32edf905-e788-404d-ac47-2162b98bf7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f552c969-3027-4664-a791-dfa4a5e1a528" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_32edf905-e788-404d-ac47-2162b98bf7fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d0b2009a-61f3-4a44-9b52-fe55caac5d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d0b2009a-61f3-4a44-9b52-fe55caac5d72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0b2009a-61f3-4a44-9b52-fe55caac5d72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0b2009a-61f3-4a44-9b52-fe55caac5d72" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0b2009a-61f3-4a44-9b52-fe55caac5d72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0b2009a-61f3-4a44-9b52-fe55caac5d72" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_312def0a-595b-45e3-82c2-6554c4d7d9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_312def0a-595b-45e3-82c2-6554c4d7d9dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_a1ee1cd0-0626-4e03-a3b4-2d265b9b98a6" xlink:href="biib-20210930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_EisaiMember_a1ee1cd0-0626-4e03-a3b4-2d265b9b98a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_bdc373a0-757d-4c35-ab34-3dfa5c20edeb" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_DenaliTherapeuticsIncMember_bdc373a0-757d-4c35-ab34-3dfa5c20edeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_dd88e2aa-36f4-4136-84d8-c6c57b344b32" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_8320a20c-b029-4bba-81f7-c1a7e3c4021f" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_8320a20c-b029-4bba-81f7-c1a7e3c4021f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_86de68c0-f97f-4a32-a67e-a1e9522e22b6" xlink:href="biib-20210930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_SageTherapeuticsIncMember_86de68c0-f97f-4a32-a67e-a1e9522e22b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_3a8285de-b7e7-45bf-a6a3-2a9ff801c06f" xlink:href="biib-20210930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_UCBPharmaS.A.Member_3a8285de-b7e7-45bf-a6a3-2a9ff801c06f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_45044f85-ac68-40df-bc56-3f3592cd816b" xlink:href="biib-20210930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_45044f85-ac68-40df-bc56-3f3592cd816b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_e7658a0a-fe1d-4f5d-bfed-9f8bc98ce85a" xlink:href="biib-20210930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_OtherresearchanddiscoveryMember_e7658a0a-fe1d-4f5d-bfed-9f8bc98ce85a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_0bae8f65-2b1c-4ac4-89f3-b1f66ed963c3" xlink:href="biib-20210930.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_0bae8f65-2b1c-4ac4-89f3-b1f66ed963c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da932b46-d7b6-48d3-b3a7-6788b8c12e85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_srt_ProductOrServiceAxis_da932b46-d7b6-48d3-b3a7-6788b8c12e85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da932b46-d7b6-48d3-b3a7-6788b8c12e85_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_da932b46-d7b6-48d3-b3a7-6788b8c12e85" xlink:to="loc_srt_ProductsAndServicesDomain_da932b46-d7b6-48d3-b3a7-6788b8c12e85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65835da9-a391-4096-924c-92c87ec83c33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_da932b46-d7b6-48d3-b3a7-6788b8c12e85" xlink:to="loc_srt_ProductsAndServicesDomain_65835da9-a391-4096-924c-92c87ec83c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_5b6293d3-2231-405f-a38e-3fb09ab112cf" xlink:href="biib-20210930.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_65835da9-a391-4096-924c-92c87ec83c33" xlink:to="loc_biib_E2609andBAN2401Member_5b6293d3-2231-405f-a38e-3fb09ab112cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_68f9caa0-8dd1-4ba1-b7f9-f8832e29ffd9" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_65835da9-a391-4096-924c-92c87ec83c33" xlink:to="loc_biib_ADUHELMMember_68f9caa0-8dd1-4ba1-b7f9-f8832e29ffd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fa9ca056-c670-4a09-b73c-20d6d7c05e65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_dei_LegalEntityAxis_fa9ca056-c670-4a09-b73c-20d6d7c05e65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fa9ca056-c670-4a09-b73c-20d6d7c05e65_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fa9ca056-c670-4a09-b73c-20d6d7c05e65" xlink:to="loc_dei_EntityDomain_fa9ca056-c670-4a09-b73c-20d6d7c05e65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce04ffec-b656-4b31-bff0-983cee9e6a76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fa9ca056-c670-4a09-b73c-20d6d7c05e65" xlink:to="loc_dei_EntityDomain_ce04ffec-b656-4b31-bff0-983cee9e6a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_20ce6c9e-14e9-432c-a8ff-73e90c6d5e20" xlink:href="biib-20210930.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ce04ffec-b656-4b31-bff0-983cee9e6a76" xlink:to="loc_biib_SangamoCommonStockMember_20ce6c9e-14e9-432c-a8ff-73e90c6d5e20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e7762cd2-2eca-4698-8912-69695ed1991a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e7762cd2-2eca-4698-8912-69695ed1991a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e7762cd2-2eca-4698-8912-69695ed1991a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e7762cd2-2eca-4698-8912-69695ed1991a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e7762cd2-2eca-4698-8912-69695ed1991a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9de68a12-1953-4faa-9c88-bb24fdd97736" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e7762cd2-2eca-4698-8912-69695ed1991a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9de68a12-1953-4faa-9c88-bb24fdd97736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_2a9a98b7-e43f-4dd7-9526-fbb28791b228" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9de68a12-1953-4faa-9c88-bb24fdd97736" xlink:to="loc_biib_DenaliTherapeuticsIncMember_2a9a98b7-e43f-4dd7-9526-fbb28791b228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_154a8194-2e02-4cbc-8657-f1a9e79a8e8c" xlink:href="biib-20210930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9de68a12-1953-4faa-9c88-bb24fdd97736" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_154a8194-2e02-4cbc-8657-f1a9e79a8e8c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" id="i996ff18c80514632bbb5dd5b0e544c14_CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_a6bcbf65-b478-444b-be1d-4974b67d7986" xlink:href="biib-20210930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_a6bcbf65-b478-444b-be1d-4974b67d7986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_7107badf-e751-4961-9c37-0912454e4d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_LossOnContractTermination_7107badf-e751-4961-9c37-0912454e4d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_79625643-31c0-427a-8dde-cd320f91a02c" xlink:href="biib-20210930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_79625643-31c0-427a-8dde-cd320f91a02c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_01a51f65-ee87-4b1d-b469-cbd5a6f671d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_01a51f65-ee87-4b1d-b469-cbd5a6f671d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e5ecae8f-08ef-4cfa-83a3-8304d881706e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e5ecae8f-08ef-4cfa-83a3-8304d881706e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_e8feb174-d77e-4bde-b02d-a7faf80a96e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_e8feb174-d77e-4bde-b02d-a7faf80a96e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_c4e98fff-b07a-45e4-83ba-32577dd6b0b6" xlink:href="biib-20210930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_c4e98fff-b07a-45e4-83ba-32577dd6b0b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_343cc298-3607-409f-84cc-1d3137f79485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_343cc298-3607-409f-84cc-1d3137f79485" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1bc69dc3-9b67-4fb4-9e88-827c27c83607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1bc69dc3-9b67-4fb4-9e88-827c27c83607" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ff09a20b-d5ae-42b8-b6cf-e684b1833ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_EquityMethodInvestments_ff09a20b-d5ae-42b8-b6cf-e684b1833ff6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_4a1d7cb5-45b3-4c06-b8aa-ef4896d98e1d" xlink:href="biib-20210930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_4a1d7cb5-45b3-4c06-b8aa-ef4896d98e1d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3f47750-152d-4719-adc6-c24081040eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f3f47750-152d-4719-adc6-c24081040eee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a15d6002-5d4e-4300-b824-86d791d22a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a15d6002-5d4e-4300-b824-86d791d22a72" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1b77fa33-0192-4f5b-bed3-8f079bbdef2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1b77fa33-0192-4f5b-bed3-8f079bbdef2d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_762d13a3-105b-4617-9679-f014a6dbccb2" xlink:href="biib-20210930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_AdditionalMilestonePayment_762d13a3-105b-4617-9679-f014a6dbccb2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_b822bf5c-2bdf-4ce8-aa92-428c54624b25" xlink:href="biib-20210930.xsd#biib_AccruedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_AccruedMilestonePayments_b822bf5c-2bdf-4ce8-aa92-428c54624b25" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_b244e007-86ba-4f17-bd93-90cbf9d28947" xlink:href="biib-20210930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_b244e007-86ba-4f17-bd93-90cbf9d28947" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_f4222e6f-7c19-4fda-bd23-450cb3c805f6" xlink:href="biib-20210930.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_ContractOptionExerciseFee_f4222e6f-7c19-4fda-bd23-450cb3c805f6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_55cba908-6446-4e5c-8466-fc6277bd7e6d" xlink:href="biib-20210930.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_55cba908-6446-4e5c-8466-fc6277bd7e6d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_678d7224-83af-42bc-b256-c57f2bffd723" xlink:href="biib-20210930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_Collaborationprofitlosssharing_678d7224-83af-42bc-b256-c57f2bffd723" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bce5f3ea-e6f7-48b4-be62-bb3872049f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_Revenues_bce5f3ea-e6f7-48b4-be62-bb3872049f66" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1b8c4f4e-baa5-47dc-acef-a1be2b0a312c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1b8c4f4e-baa5-47dc-acef-a1be2b0a312c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_6dd92ed2-6f6b-4b2e-bca3-a2b9620ba0a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_6dd92ed2-6f6b-4b2e-bca3-a2b9620ba0a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_2a27cf29-8bce-4fa5-9a79-006012e195c0" xlink:href="biib-20210930.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_6dd92ed2-6f6b-4b2e-bca3-a2b9620ba0a2" xlink:to="loc_biib_NeurimmuneMember_2a27cf29-8bce-4fa5-9a79-006012e195c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568_default" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_f49664a0-b1c4-4414-8cbc-402767aca581" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_f49664a0-b1c4-4414-8cbc-402767aca581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_89df9b28-a2fa-4fc1-a5e1-25cac9f801ca" xlink:href="biib-20210930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_f49664a0-b1c4-4414-8cbc-402767aca581" xlink:to="loc_biib_RegulatoryMilestonesMember_89df9b28-a2fa-4fc1-a5e1-25cac9f801ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f9c608b7-1c01-45ed-9dc3-326a8c6742b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f9c608b7-1c01-45ed-9dc3-326a8c6742b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f9c608b7-1c01-45ed-9dc3-326a8c6742b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f9c608b7-1c01-45ed-9dc3-326a8c6742b3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f9c608b7-1c01-45ed-9dc3-326a8c6742b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f9c608b7-1c01-45ed-9dc3-326a8c6742b3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_f18dfb5d-2649-42be-ae22-b7f2287551fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:to="loc_us-gaap_InventoriesMember_f18dfb5d-2649-42be-ae22-b7f2287551fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_26b177b7-5132-4f43-a48c-d40ea845b47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_26b177b7-5132-4f43-a48c-d40ea845b47a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_578fa83a-e27d-4a2f-b13f-762ac2d2ee17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_578fa83a-e27d-4a2f-b13f-762ac2d2ee17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a60ce193-1ca2-46c2-b969-81fb6f526d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a60ce193-1ca2-46c2-b969-81fb6f526d8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a60ce193-1ca2-46c2-b969-81fb6f526d8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a60ce193-1ca2-46c2-b969-81fb6f526d8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a60ce193-1ca2-46c2-b969-81fb6f526d8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a60ce193-1ca2-46c2-b969-81fb6f526d8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_6e747fe1-cd06-4c1b-8aa6-146e1358ec8c" xlink:href="biib-20210930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:to="loc_biib_EisaiMember_6e747fe1-cd06-4c1b-8aa6-146e1358ec8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_aaee540e-05b5-488a-8172-f3ee1eee74da" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_aaee540e-05b5-488a-8172-f3ee1eee74da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_0a989d3b-969e-4d51-bf94-52a824dee0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:to="loc_us-gaap_CollaborativeArrangementMember_0a989d3b-969e-4d51-bf94-52a824dee0d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3d05e3b6-581d-4e5d-9848-a33e575f9c0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3d05e3b6-581d-4e5d-9848-a33e575f9c0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3d05e3b6-581d-4e5d-9848-a33e575f9c0c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3d05e3b6-581d-4e5d-9848-a33e575f9c0c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3d05e3b6-581d-4e5d-9848-a33e575f9c0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cc908998-c044-4473-a40e-47e4358d31e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3d05e3b6-581d-4e5d-9848-a33e575f9c0c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cc908998-c044-4473-a40e-47e4358d31e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_ee291281-8feb-4e57-8b97-e29356416ea9" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cc908998-c044-4473-a40e-47e4358d31e0" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_ee291281-8feb-4e57-8b97-e29356416ea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90d2177a-397d-4add-9671-e3ffcde1b79e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_srt_ProductOrServiceAxis_90d2177a-397d-4add-9671-e3ffcde1b79e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90d2177a-397d-4add-9671-e3ffcde1b79e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_90d2177a-397d-4add-9671-e3ffcde1b79e" xlink:to="loc_srt_ProductsAndServicesDomain_90d2177a-397d-4add-9671-e3ffcde1b79e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_344c5d34-70f6-4342-9eb0-8063c790e136" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_90d2177a-397d-4add-9671-e3ffcde1b79e" xlink:to="loc_srt_ProductsAndServicesDomain_344c5d34-70f6-4342-9eb0-8063c790e136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_959bc60a-807b-45bb-963e-83b2df16337b" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_344c5d34-70f6-4342-9eb0-8063c790e136" xlink:to="loc_biib_ADUHELMMember_959bc60a-807b-45bb-963e-83b2df16337b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended" id="ia37c592421f34609bd52b18e861eb0e3_InvestmentsinVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_b8f918f5-8c45-44b7-8e1a-65ab52a7f229" xlink:href="biib-20210930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_CollaborationAgreementTerm_b8f918f5-8c45-44b7-8e1a-65ab52a7f229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_b61e2981-254f-497f-a0b5-ad3760ba1b6c" xlink:href="biib-20210930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_b61e2981-254f-497f-a0b5-ad3760ba1b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_32cd105b-31cd-4c1c-b2c4-f2791839741a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_32cd105b-31cd-4c1c-b2c4-f2791839741a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_02c641f9-c330-4eea-a430-97b1b7aa6dfa" xlink:href="biib-20210930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_02c641f9-c330-4eea-a430-97b1b7aa6dfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_7359ea82-5a3a-41c8-8ac4-fa82bc914d7e" xlink:href="biib-20210930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_7359ea82-5a3a-41c8-8ac4-fa82bc914d7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0a31a7ce-ff3b-436f-a6ec-ab357676e187" xlink:href="biib-20210930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0a31a7ce-ff3b-436f-a6ec-ab357676e187" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_da4b2239-01ed-4c83-97e3-64dd4e1232e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_da4b2239-01ed-4c83-97e3-64dd4e1232e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e602f2e4-b5c9-490d-8770-35eebd56f175" xlink:href="biib-20210930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e602f2e4-b5c9-490d-8770-35eebd56f175" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_50645db2-75f2-4a88-9b2b-2997b6b08287" xlink:href="biib-20210930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_AdditionalMilestonePayment_50645db2-75f2-4a88-9b2b-2997b6b08287" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c3dc1621-202b-41a4-ab25-9e4f79194d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c3dc1621-202b-41a4-ab25-9e4f79194d54" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0b863536-20dc-472f-a4e5-f6faea019ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0b863536-20dc-472f-a4e5-f6faea019ab8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d1e6308e-cda0-4a81-915f-c3732964ee90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d1e6308e-cda0-4a81-915f-c3732964ee90" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_6ea75a99-5dbe-4e4e-9ea6-c6eee73d4282" xlink:href="biib-20210930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_6ea75a99-5dbe-4e4e-9ea6-c6eee73d4282" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_827ece8f-cade-4501-83e4-599613113274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_us-gaap_TypeOfArrangementAxis_827ece8f-cade-4501-83e4-599613113274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_827ece8f-cade-4501-83e4-599613113274_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_827ece8f-cade-4501-83e4-599613113274" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_827ece8f-cade-4501-83e4-599613113274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d2c414c-9709-446f-a86d-37a87f34da98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_827ece8f-cade-4501-83e4-599613113274" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d2c414c-9709-446f-a86d-37a87f34da98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_414cdf9c-2e66-433c-8677-1d65b25ef4c4" xlink:href="biib-20210930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d2c414c-9709-446f-a86d-37a87f34da98" xlink:to="loc_biib_EisaiMember_414cdf9c-2e66-433c-8677-1d65b25ef4c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_4741b770-5bef-4fdb-9d05-da92d476bf87" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_4741b770-5bef-4fdb-9d05-da92d476bf87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_4741b770-5bef-4fdb-9d05-da92d476bf87_default" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_4741b770-5bef-4fdb-9d05-da92d476bf87" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_4741b770-5bef-4fdb-9d05-da92d476bf87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_268b4d88-a724-4b80-812b-71f8dcbe9f6f" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_4741b770-5bef-4fdb-9d05-da92d476bf87" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_268b4d88-a724-4b80-812b-71f8dcbe9f6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_76db6dd5-abbe-4f5c-b8fd-333c40101664" xlink:href="biib-20210930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_268b4d88-a724-4b80-812b-71f8dcbe9f6f" xlink:to="loc_biib_RegulatoryMilestonesMember_76db6dd5-abbe-4f5c-b8fd-333c40101664" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_srt_StatementGeographicalAxis_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a" xlink:to="loc_srt_SegmentGeographicalDomain_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d2a8088-8d80-43bf-ae03-070e3ae102a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a" xlink:to="loc_srt_SegmentGeographicalDomain_6d2a8088-8d80-43bf-ae03-070e3ae102a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_6c460893-e4dd-4272-a184-f8a9bac4b418" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6d2a8088-8d80-43bf-ae03-070e3ae102a4" xlink:to="loc_country_JP_6c460893-e4dd-4272-a184-f8a9bac4b418" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6f078012-6341-4a53-a382-d6959df045c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6d2a8088-8d80-43bf-ae03-070e3ae102a4" xlink:to="loc_srt_EuropeMember_6f078012-6341-4a53-a382-d6959df045c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_98c8be5a-c160-4eb7-9c90-c9cf7948a340" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_srt_ConsolidatedEntitiesAxis_98c8be5a-c160-4eb7-9c90-c9cf7948a340" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_98c8be5a-c160-4eb7-9c90-c9cf7948a340_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_98c8be5a-c160-4eb7-9c90-c9cf7948a340" xlink:to="loc_srt_ConsolidatedEntitiesDomain_98c8be5a-c160-4eb7-9c90-c9cf7948a340_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_36c61a0a-2a8c-4eaa-b6cf-a87b1e94f746" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_98c8be5a-c160-4eb7-9c90-c9cf7948a340" xlink:to="loc_srt_ConsolidatedEntitiesDomain_36c61a0a-2a8c-4eaa-b6cf-a87b1e94f746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_46998555-d801-4736-8bb4-a02b643a04dc" xlink:href="biib-20210930.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_36c61a0a-2a8c-4eaa-b6cf-a87b1e94f746" xlink:to="loc_biib_NeurimmuneMember_46998555-d801-4736-8bb4-a02b643a04dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_srt_ProductOrServiceAxis_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a" xlink:to="loc_srt_ProductsAndServicesDomain_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8865e37b-ca6a-4fae-b7e0-039c8c127674" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a" xlink:to="loc_srt_ProductsAndServicesDomain_8865e37b-ca6a-4fae-b7e0-039c8c127674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_2b8292a9-2f21-4dda-aa9f-f291873b453d" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8865e37b-ca6a-4fae-b7e0-039c8c127674" xlink:to="loc_biib_ADUHELMMember_2b8292a9-2f21-4dda-aa9f-f291873b453d" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>biib-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a903f54e-5284-4407-a747-e0b1f5468222,g:e7d07c56-2dfc-4728-a119-070b245a209e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_Expenseincurredbythecollaboration_e9d367a2-c87c-460f-9183-c973d2d77700_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20210930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b6857a4b-6bd3-4cdb-8bd9-0fd10532542f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_cf0a1d82-09d6-488c-bc48-9e5450f51f88_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ef36d898-cdad-4765-8d82-1be0de5c37fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_26077396-a106-4a16-b29e-28fd0f61d3a7_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20210930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_c6e6a647-5ab4-496b-ac9d-e2fb63cef328_terseLabel_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_label_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_documentation_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:href="biib-20210930.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:to="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_4e8e6fda-7c2f-44cb-ace4-200334671781_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_01fcad28-37b7-478b-b94f-460805a48351_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9b889cc7-5527-465d-bc75-27b996d22686_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_a01a1880-6fde-4918-b84e-ff695efb2335_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZINBRYTAMember_75c3f7f4-5475-4797-bf40-35362c0ffc8e_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_label_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember" xlink:href="biib-20210930.xsd#biib_ZINBRYTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember" xlink:to="lab_biib_ZINBRYTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f9cd0393-ad73-4206-a89a-bd108e67ba5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_45bdc95f-4693-4988-a1a6-b26efa4c1096_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_65fb84e0-b661-46d9-a796-1a92434dc41b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e8f8e615-d8f7-4298-a90f-71ad75e5a10b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_61691dcc-8728-4fa0-a1c0-a818af4feefb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_7d965f6f-4d78-487e-a195-a7982a47ef3c_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20210930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_1fd105ad-1373-4937-8dd9-aa87dd62a330_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:href="biib-20210930.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:to="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_f574c96a-c832-49e4-be76-f3ba3a2bac52_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210930.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_86b9d283-d272-4d64-8eb2-581c4ace8df6_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bfa9fec3-2cc8-4f89-9144-97a71d608e3d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dcf43fe2-8503-44ef-924d-29dae7380a76_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_f9647da9-6670-49d3-afc2-d4c86bf9cb5b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments subsidiary and affiliates stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_4cc682ae-1c3d-456b-8fff-d5862e05f060_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_6abb9873-9e19-4ca4-8b2c-dfb1efa0ae16_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_cf0c6202-794b-44e1-9188-4d07e87dd459_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_12700f0c-2557-44f7-b902-61aa17e08a0b_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ed0feeaf-5640-4349-b3b5-8ddc2f46a88a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ca8b45fc-655d-4a14-92fe-bdcc1f74eaa8_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e5f80fb1-7388-413a-a55f-077d672dc1c3_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_547b03c8-eb39-45f1-af56-fdb7b2bc026d_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_label_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) Other</link:label>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:href="biib-20210930.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:to="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_14b76afb-89af-4cb2-99a9-f8beadb0dae8_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_6e19cc6f-48e1-48ca-903a-dc763e64b529_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20210930.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fed5b8db-f04e-4d1d-8bbb-7cc5619b74ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_977ddb62-0879-4ff6-ba4c-dd5f1ac9f356_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_40c63e3c-0814-42f9-81e9-48ce1deb8a31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_cf47f02a-d8eb-4d61-b0c1-034aefe32394_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20210930.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0a1f2ce2-d455-4e43-aa87-a7f4e4b991a7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_ea6845e6-3c4c-49c7-8aea-b01074c2a5c8_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_13d07429-e58a-4a9a-a0f0-55a52c577d14_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_fca52635-c770-4a8d-a846-583623001e91_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20210930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_fa2121ff-be89-4da0-b5b1-b05273140f66_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:to="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_f7453345-2dc6-4365-aa12-32a8b09dd48c_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6fce0525-401a-4c09-9c6c-21df09e81a13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e1f86dd8-40d5-4a09-8ebe-82a79eef6298_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_058590b2-459e-4fcf-bd52-f8d9f58ebfcd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_bb3dc208-6a8d-450f-bb59-a997a2fdb4a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_230179d2-ed44-4fee-bcb3-4cab46611390_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_9c1bb58f-6e02-45d7-9663-c78d23c9afaa_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bc0f069b-da21-4b6d-8ef3-81d543221bfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3c1b097a-eede-46f1-8f6a-f3b21eedc8e9_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_28254755-4805-4aec-8cce-1c57bdfefd23_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_f8dfae94-6c1d-4fdb-90b5-4424e958a354_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_c91d9a9c-b3ca-465e-8783-ae56152b7af8_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_03fe806c-894e-4d08-9800-2bb643d2cac2_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain" xlink:to="lab_biib_ResearchanddevelopmentassetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b4c9039d-8f37-4511-bdcc-601a92529e10_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_3775aff0-f18d-40f6-ba33-ba1258c46e5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_436cda07-44aa-46d6-8fdf-a16b91a335fa_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1311610e-0fd0-48c8-92b4-f4a795fc433f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_57b1a784-7996-4fab-b588-5441f42fa449_terseLabel_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_label_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement [Member]</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_documentation_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:href="biib-20210930.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:to="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b21fb5e7-bf0e-4b6d-a0eb-9a4e80be4114_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_ea24d725-e6f2-48a3-b044-0fa1f3119421_terseLabel_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112</link:label>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_label_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member" xlink:href="biib-20210930.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111AndBIIB112Member" xlink:to="lab_biib_BIIB111AndBIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ff68d0c6-1ca4-4797-bb4c-ef0e497602af_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_03747e6e-e7ee-44fe-9488-4e46fc312f21_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_bcd71bf2-d3ca-4756-9663-bb2cf0238bfb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_3b2e0bec-9ae4-48c6-897f-0adb9751e8de_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_6157f6ca-a62e-4700-b044-44e0ed12742e_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_67e9212e-4ca2-4775-b061-b5d1b5c16488_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_06c4cc85-2ffd-4640-b813-2f62f0bed614_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fcb89a78-bdbb-4efa-9f06-4869fc94148a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_ae0c2c36-c944-4aa9-aa2b-ca2a76f67b98_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20210930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_afda19b6-c22d-40d5-8fbf-2628a2e3ee0b_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_05951609-66fc-41e8-8214-32730b8befeb_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OutLicensedPatentsMember_7985ab3b-0390-4ecc-9886-9d1e5750beba_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember" xlink:href="biib-20210930.xsd#biib_OutLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember" xlink:to="lab_biib_OutLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_dd7e8ba6-bbd1-4bef-8266-2c396b27ddd3_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_49ecba13-a927-4d2f-819a-f7ba7a2059d6_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20210930.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_f4fb14f3-ccce-43ce-8115-b4e396e3f967_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20210930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_df12f237-c850-4eb8-a348-da15bfb91467_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20210930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_7b87afcb-2efc-4a90-a21e-a6e0f5fe55f2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_da623338-6c3c-497e-aa0d-7114bc5754e5_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e1de6278-d84c-438d-94f7-120523a36452_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_0aaded1e-c699-4928-93f7-b4bc0e8a70d2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_fb7fa29c-fe8d-4c26-af4d-d540f24ec23c_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration agreement, shares purchased per share (in usd per share)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7aa583fe-19e8-4ec7-8b70-8c1cd67d7ed4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_71c52ae9-eacd-4028-9962-36c8d5be8fec_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9bf301f3-7abd-41d1-8965-7c5cb59b4234_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_6dc5d39f-dc72-4884-a059-cd1ad04a74ab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_552463b3-7d7e-41d6-b654-83549cffe16e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06c031de-9d48-4804-9e37-fe21d400ea26_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_0b2c7b1b-bb96-4225-bed5-cbef6d8e36ec_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20210930.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_096f78ff-b2e0-4564-a21a-ea5309bc3f0d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_79c87de8-cf64-49ff-bed6-6d871d044bdb_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20210930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_20fee59f-9486-48c1-aa08-492bd7795105_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_fe83cb44-b274-41e4-b2fc-7517b52bdcf4_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_4d9e764b-4477-4f3f-838f-31ecfa92c0d3_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20210930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_d5d904c9-732a-4b2a-bdc4-94609e920470_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ab0c23b6-dec8-4280-9241-c764757bf17a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_dd57de2b-7970-4f59-8a5b-37694becf245_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_c57d02c4-3275-4749-9043-17e4872275e7_terseLabel_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_label_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_documentation_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member" xlink:href="biib-20210930.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.90SeniorNotesDueSept152020Member" xlink:to="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_64d336da-9e58-4a2e-9391-49289d04a7c9_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune tax impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:href="biib-20210930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:to="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_8c21c543-03df-4112-adc3-8cdb17cb09e1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_241affa0-909d-4c23-b4e8-05c9e3b41890_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_06e29069-526d-49ed-bab2-864b9f888ca9_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20210930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8ce75c69-db9f-4de1-957f-1497e26501b7_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6735966d-68bd-4e6b-ab0f-f2202ced0319_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9055a128-742f-4fa1-986d-ddd324546610_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_27ff34b5-86be-4002-9685-481f34d1ab6f_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20210930.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_22f9d51b-e139-4de1-989a-237c5dd50b69_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e64c515e-5905-4452-822f-68eb253baa9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_069e0c07-088a-4def-9740-d67a38a76a24_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20210930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_46b1e31a-dd24-47b3-8299-b2aab2ad80f8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f698b5c0-f1ca-4edd-a149-c2ec85bf5484_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_08ead683-44f9-4996-b639-2e2bad161a81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2c6bd3fb-68c3-48d5-b61f-840f03d2ea46_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_5ced3f50-a66d-4a4d-8056-99bab1ffaf49_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_3d24aa5f-ea62-4cd7-a1b2-0ac57e9cad1d_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_7ab45bd0-777e-4724-9740-ac8b7455e27a_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20210930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_843715f7-ed7b-4c4d-ba94-3c237dabd54e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_16d6fa51-e40a-4c5b-b797-5f783247551a_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_ea0f2bf2-6627-409e-b460-1ef57fb4a39c_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20210930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_9a2402e2-2a60-44e0-9a77-71ee9225c49b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_3019c8f4-6da9-445e-b27d-002983439d63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3312628d-ea59-4f8b-879c-db8d526e6a3b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8b2eebc9-1b73-4777-bc02-bd3cc46393b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_f0fe9c67-2bbf-4cd0-bf13-c2179992c686_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20210930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_95b2d6d8-ea3e-4f63-9ba7-bbf67b390791_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:href="biib-20210930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_9686b450-fef6-4af7-8078-56f2033226d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fad42736-2ea1-415f-b9d2-cc89556def9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_10b79f67-fdcb-410d-b849-b0952e53e171_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_c7af6fbb-9eda-47b2-aea6-8ee48609212b_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20210930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3cc1bdc4-e4ab-4989-bc11-3fa38134d2fd_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_3af84abb-31bf-4d09-9bb9-0a1a4c5cc464_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20210930.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_1daef818-0a3e-4482-92cc-e1aed5cae874_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_303c8a40-3a14-41f9-b169-e89cfe8746e1_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8df8c24a-798c-47a2-8101-72c98e85ab97_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e58183da-f73f-413f-ad79-7ed65d0fc318_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e50e8601-9a85-4e31-bfbe-6ba2d227f981_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e15e676d-1279-4107-9f6a-9658f7c08faa_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f37ed1a-ee6c-4e80-a008-599218c08987_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_f7a5ab3b-da29-46e5-a97c-733387d37ffb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_dbe02103-076e-4165-87b3-9013b27ecddd_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_fbacac34-8483-4721-ac09-6fff4bc82f9f_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20210930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ae9ee9fe-0a4c-4c71-8790-a485ec6fb3cc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_b802aee2-1c8b-40e9-b8cb-3e831e96fbe8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_21fda433-f797-4d15-86e8-65f508fde134_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_1b03c022-8862-47e3-97b8-b57175ad5df0_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20210930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_3291c58e-dd3f-42b8-856e-e9e4990fbc47_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20210930.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7cb1355-bbd0-4f6a-9f0c-bd9aa48c4d40_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_20b05f2f-a867-4549-b2cd-813ec52d0d36_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20210930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7c518ace-b693-4af5-97b5-51e2e5857d86_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_3b1288b4-54b5-4ef3-a76f-5b09a5f10241_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9940a501-8b84-4322-99ee-38762e5cf740_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_17da275b-1403-4c6e-a0e3-1cb510c8d0e0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_9e76e7e3-ca33-44e1-ab8a-b77ebc4974dd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_a55a51df-965a-4caf-9e8b-4d9e45224db6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858614b3-5bfc-44c9-895c-7eb5cf51001e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_24533ae1-7236-4788-a2a4-0caea1a1b223_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_5ee633ec-8d10-44bb-ba71-092f8f243dfc_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember" xlink:href="biib-20210930.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57ca424a-b4e6-45d6-9b74-c502609cfe2c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_72ef1bcc-c450-42f4-91ae-4d9f2f17ff8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_04260ce0-15f3-4fba-bbc8-fcde144ff56b_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20210930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_4edeb6da-ec39-4f69-b143-ffa21518abaf_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_3013966c-8f05-4dc4-b0d6-567f432110ce_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f6382988-b740-4f0e-844c-2da6685a1d99_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3de5be5b-00ed-4b84-90f3-7559c45b28b8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9abdf924-e24d-4412-bf77-5881c66330b1_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20210930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_0a2b83da-a813-4918-a2ae-15e266d8756d_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20210930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_507fcec2-def7-48fe-9e3c-5bedf280e38e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_954595ea-b9e6-4233-99c0-5ff53bb1de86_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_491f0249-d3e6-4596-bbf6-bd77bed9f1b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_33376496-f108-45d8-ba54-d3b901edcbf1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_a64b2b52-c671-4bc3-8d88-4bfca0818d11_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0f5788e3-3b94-4c3d-ac1f-1c316111ddeb_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0ae2136f-5a0b-436f-a561-1e5c4ed5c32d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ed55570d-2bca-42db-8cf4-13fed68dc649_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_97d1a40f-858c-49f1-9cae-43dc853ca544_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_c8399eac-e28f-47e2-b8d9-b8d70e412d14_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_bde9f834-99e3-4bb1-8bcf-6882e5ce513d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9caed225-5066-43e2-839f-9ceb0b6b6651_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_c9099292-9da5-434f-acd8-78cd52ae5de1_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7684ad12-19ea-450e-8ade-82d9fd994d64_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5d921f64-41b7-42aa-8da9-7215bf7fd759_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_33a1f733-be97-4328-8e5c-1db685d6202d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_20ce229d-26b7-4fb0-8e68-aa708e30f801_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5c983b8-54c4-4b9b-890b-cc03fa8671ca_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f73e5ffb-9cd3-4d40-b91b-ec2339e68d06_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_451fe350-ab76-430c-aaed-a29e93c7448e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMMember_9bf874fa-d014-4ed4-81bb-e1a19640a073_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_label_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember" xlink:href="biib-20210930.xsd#biib_FUMADERMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember" xlink:to="lab_biib_FUMADERMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_3568a005-aabc-478c-b8fb-c3663959b027_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue_0432c7e6-2bb7-499d-888c-95bc4cbf6e9b_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset, increase (decrease) in value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue_label_en-US" xlink:label="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Increase (Decrease) In Value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Increase (Decrease) In Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:href="biib-20210930.xsd#biib_DeferredTaxAssetIncreaseDecreaseInValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:to="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_f81ebc72-50df-460a-ad49-1faf8d7241b3_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20210930.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_d33dc235-f35e-4d10-beaa-fef7c7cfaa65_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20210930.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_cffb21c4-40f3-4d5d-bc3e-448cd5b4817a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7f70e045-0770-45a9-8ff0-acf3c4e044cb_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97437fe9-41f7-4337-8dd6-c5bf0c0d0b6e_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfProductCandidates_47d176b0-9039-4ba4-9186-f52038d69378_terseLabel_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_label_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates" xlink:href="biib-20210930.xsd#biib_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfProductCandidates" xlink:to="lab_biib_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cd2e4023-2b7e-49be-8ab5-5c5d71295b6b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_b195f11b-a616-417b-bd1c-8026f4dad905_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_ecc3516f-02a2-47e2-94ca-5187b60c8355_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bf88fd08-5de8-493f-a340-8a18c10eb571_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2ce9bf26-c495-4ec3-8ef6-d8e3641fa234_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_ce108934-0fcb-4a14-ab50-afd7c6de7aa5_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f1900723-60fd-4837-941e-070aa30d143a_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b5ff0592-5fb7-4ea3-b329-d3ff2c15eba1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_323fec69-847f-4094-b8ef-c6e5b6902fd9_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes" xlink:href="biib-20210930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes" xlink:to="lab_biib_PercentageParValueOfSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97985b6d-89f4-4a20-a57f-4dc1f20cac8e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_558adf20-5ec7-48e9-a320-941f8fa57f71_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f84f88b6-bed5-4ddb-8c6d-691bc8cd8e2b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_b9e1ca38-2618-497e-827c-ecfab78c8039_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20210930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_89e8af94-8739-4f72-a957-8fcd7775129c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_450e3341-c215-4b95-a734-52ced485db46_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_aa87dc24-9a56-4703-a481-982c099a5027_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_43b4ad48-6f25-4503-b8ee-c275a538e0d2_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_a50606d1-17bc-49c4-8f39-16c959e1359e_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20210930.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_1fd08cba-1de8-46ae-b813-318ff16a4238_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b63b0985-d90f-4379-ab51-9d05b4c2b5f0_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_f8afeda4-b8bb-45c2-b592-619e2c52e19c_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20210930.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5e0ab7e1-c242-46d8-9b0e-1cc029f3412c_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_861be957-3b0f-47f2-825d-a39194a8fa46_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB118Member_0883a7f4-ac24-4b3b-b665-99725cfef65f_terseLabel_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118</link:label>
    <link:label id="lab_biib_BIIB118Member_label_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:label id="lab_biib_BIIB118Member_documentation_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member" xlink:href="biib-20210930.xsd#biib_BIIB118Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB118Member" xlink:to="lab_biib_BIIB118Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9fb8ebc0-8266-441a-a2dd-82e8fc2c2a02_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1705f0da-abbf-46cf-bdfc-235bbec49975_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_99d0032b-6007-4293-b029-f6a0be7b349b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_4058f8fd-dd02-4cfe-a8ce-ab689e9cdb0d_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_5f75ffee-a010-44d1-b670-bb569c927f4d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_1171b288-4ace-4528-b851-8c43f6eca995_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_42a2392b-8d08-4b30-9150-e4adc17582ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_29536716-f55a-4df3-8070-395ee44b7125_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent" xlink:href="biib-20210930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_45c52a7b-7419-43a8-8372-95be1b3e63ef_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_ad669221-bdd4-43c6-8562-e19cd5a8ce52_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_1ffb9581-ada8-48eb-adbd-d296ecc5967a_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_08567036-c023-4e93-bcee-251dc8de942b_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20210930.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_c9b78a13-4c33-435b-a404-1fb9bd3956fb_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20210930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_3567f216-9a2c-4a53-a76e-9909abcda761_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c69f6f3c-6305-465d-b4fd-2ce3bf53ad2e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_9d867da5-ae81-4dca-b2ce-325320a34c2e_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4d036b0c-46a3-4bcd-8ba5-20c49e96d48b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fcf0fcaf-c11b-4c7f-9777-62d69b6ee694_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_d8135c9c-80e1-47e9-a0fc-dfae9c93d2b5_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20210930.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_af651573-1204-46de-9e66-d68d9f26f568_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:href="biib-20210930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_e11723f1-7e24-4f84-9175-f369e2de5f72_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1dc7fef8-dd12-4946-a433-2d3f22f614fa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_4eddfce3-7aa3-4dda-8ed1-b9aac6c4c34e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0c2ce7fb-a6c0-4dd1-afae-a9cad7d0c388_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5ed71ccf-a5a5-40c6-bf66-1d3fa292d3f1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_4fc0f603-6bd2-4737-8a5c-740fb4ea9cd8_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20210930.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_8e7722e3-b105-4e8e-9224-e29f2e692175_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ae5858f0-2487-42d6-9deb-3bae54435b75_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_901d487d-9539-4a66-a4c0-69cc89dd98fd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_2ed2f287-875c-4260-a686-bcba915bc20b_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d2eca5c6-9811-4b0d-8aed-f10539c90975_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_75f19bf0-ccf9-4546-ae6c-a619716b4e66_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_55a73942-c883-4b8b-88b8-fc02fa2746a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_abed31a6-59c0-44de-90e2-08047fa4188b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_350ade79-517e-47b0-94e5-a6eb5b80b0b2_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19930aa9-c95f-48c4-b88f-64f25fa77e60_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_cabcec4c-b0b2-4d02-8180-07f8adb703cf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_203e07f6-2adc-4cd7-a4c0-eb7d79ceb27f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_9049f20d-1c64-4fc9-ab1a-ccaf3837fa44_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_9a6f649a-6218-4d7b-8345-af6c17488cb7_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_09ed1bd6-3294-438b-8ed0-9b8165049028_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8e534ac1-75e3-43df-b352-ab1d8008e8ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_effbbaca-0527-4aab-8746-65d437db9cda_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_ae52b796-b2d3-4e1b-ac76-ce967495a8e1_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:href="biib-20210930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_c5e5ce57-cabd-492d-9c70-80cb823e98cf_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_ab30f3ca-a395-460b-a9c0-b0d5f699b25c_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20210930.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c42a0d4d-f515-4d1e-9b8e-873c21358a45_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_cea94e7c-fe7e-4e9b-addf-8f9609df037c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from settlement of swap</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_545f6e39-7f59-48ec-ad1e-3c5ffea7e389_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_98513672-0060-4716-abb7-56b168bff3ad_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_c5cc5bc2-7238-44f9-8c6b-ed759b3bd334_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20210930.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_4e8c4512-dd29-457e-a859-948d301a56bb_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e380e38-d6f7-4b78-922b-5387ccd68ede_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ee6610c7-f6dd-46de-a0d0-03a8dc876223_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets placed into service</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_ddd7dc60-22b8-428d-85e8-3d3bc16c8328_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_20ac2487-f7f5-445c-9d4a-94ee2a7cdb47_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration agreement, amount, shares purchased (in shares)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_ef47f1ff-5a51-41b0-83b2-ad51ec0e11f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_2764dd75-df5d-4b99-8312-50ec355dad5b_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20210930.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_913901fc-6225-4e7c-9bc5-a6686b0e9d65_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses recognized on the decrease in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0a77af13-9793-407d-b5f6-52efd68b68de_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_397a28e6-eff1-4db7-9ada-f4ccc29a0f62_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20210930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_7648e708-6216-43c5-9976-67f7840d5cb8_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20210930.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4da7390d-200e-4a64-a7a8-14b8b9d10ac1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_21f4a4d0-a24c-4793-a17a-4372153fd7f5_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_091f63eb-16ab-4def-ac01-93d902ea3081_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7971a561-bb08-4bd3-9812-2b61d64de3bf_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20210930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7f9a1835-6455-4929-a5ee-9fb8aa4b6093_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0c6744d4-26d1-4920-94c7-908679ae90e2_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_0594d03f-909f-4ced-91ae-2c761db78009_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_caba2242-2476-4a69-9e1e-cdcde74fc0b4_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e686a8f9-a71c-4b6f-8b8f-0e2f397d8a25_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c76e6eb4-41e3-4bac-97c9-c1b81dbb4b9b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_41dff556-75f8-481f-9e27-2a213133a820_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_85af80fe-ea76-4e92-96a9-ec1dc051d4cd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_819396d1-4ca4-4e79-b7cb-ad477c3e6717_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20210930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_b4c59fcf-4010-457a-9e03-d933cc921df0_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20210930.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_544e9a15-2f71-47a5-a965-1307b9fa108e_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9be10e96-1ca6-4749-8001-35b318c15843_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_bcd2b3ea-ec67-4c91-8100-35a151711ae3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8d6568b4-b616-4464-aebd-c9cfd30ee290_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_24a83bcc-bed3-4347-8315-c86ddb15428f_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount" xlink:href="biib-20210930.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionAmount" xlink:to="lab_biib_DebtInstrumentRedemptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_8344835d-78cf-461b-ad21-d9b153030d65_terseLabel_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent additional milestone payment</link:label>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Made To Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20210930.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_bafc39c7-d213-4a69-99e8-ab7b70da3e13_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_e93d34f3-ef28-4a74-b0ae-bc9f1fb421a3_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c09773b2-234e-4dd5-b9f1-94a426d73c2e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5a99c19e-af79-4b5a-8468-2e40635188b9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5d05f02a-175a-450a-b851-b52745cca67d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9efb1521-2875-4471-ab1c-41653301ebd0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_6ea39587-c266-44c1-a3d0-6a48d48488aa_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_c5042d80-fde0-43fa-8371-9de93bbb6376_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f6e8459d-7667-40a1-ae30-80daf9e03f3f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5fd46946-d21e-4601-aa07-b42b9d8adf26_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_48539e51-59a7-4f18-99dc-e7e716ab1c52_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8b4d0b6a-80c9-485f-8764-298b03de3828_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b9d2322f-eaa4-4dd7-8169-91cc3c4cb363_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6aabf3b9-dde2-488f-9573-1d47a6a8bf70_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0bb50b55-7a1f-4f0f-954c-364334338e30_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30c93599-808b-4605-926c-7eb2ceb1f713_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1c939e95-8825-47f5-a00d-9bd9212fa66d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_d48f1fa3-9a21-4096-98a6-914ee377028c_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20210930.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_bc86d2c1-92b7-4d7f-a2e7-1a5617b004a0_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcquisitionsAbstract_3bac412f-f345-45f7-b9a1-fadef9fb145b_terseLabel_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract" xlink:href="biib-20210930.xsd#biib_AcquisitionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract" xlink:to="lab_biib_AcquisitionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_136e0d55-f618-48d6-a4a1-aafbdf2bead7_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20210930.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_a757b480-f213-4f74-8a77-efbbb1944021_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8542a3b9-d0e7-4cac-be8a-7d4a9e3b77fa_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_a1120341-b3e6-4b23-a92f-ef774c12a2b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_021ae4cf-261f-4a9b-975f-9758503e7456_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_fa9b8a3d-6440-412a-a157-ff56ed56bb1e_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_971b2f90-e01a-4af6-a445-8990861af9ad_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, gain on derivative</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_b557fe3e-7cc1-4ac0-b11b-38b6fe54c211_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7b4d3a4a-fc9b-434a-92d2-2a315ee69ec8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c9288301-4ee4-4216-93df-6c2ef5c05ba7_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_0400332c-9825-488c-ae20-9d49ce04b366_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20210930.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0cd8b9c4-837d-4353-b92d-47a07cf47543_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1277a384-7f0f-4a0d-af5b-fcefe238c944_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_faff225d-237d-460e-9860-a081d6fe72e5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_07483f8c-0751-455f-93a5-e0fa811e2ed9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_1dffbd9c-185a-4b16-bc3c-77c77e5b8306_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20210930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3559d3a5-e833-457b-9661-c1f4861009c6_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_8e45044d-4ec2-45b6-a1d4-7e2a05493612_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration agreement, purchase price per share (in usd per share)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e727e499-c8b3-4ba1-99be-dc8fb011417b_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c151e51a-5780-4830-bdde-bd494aa784a6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ce012164-75bd-4102-811b-0f4f12af0271_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7a3aee34-6be8-408e-8dc7-b559f5a17be4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_db893fd7-dd71-4c53-9aa7-aee3e1b79e31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3fd2672b-fc19-49c3-8239-9490c6e45308_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7e62ef9c-2aed-44dc-8677-3db6ad890635_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e5216fa1-da95-4924-a6b7-e346a3862ef5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_ef57153b-9245-4a49-9a29-21d28ed71f51_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_a917a6b7-369b-4d7c-8b2a-8ac3582d90de_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_26b9bdeb-7c05-4f38-b9d9-40d8d91b8898_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_59bbefb8-6546-4769-94d6-397be3f4b127_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_92e5b320-9b77-4e86-be67-fe8e0fd6d921_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b2bdcc4b-7c9c-4503-8207-e65e31faccc2_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c69382b0-6559-40d5-96e1-27ce8633557e_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b074bf6f-23e2-45ce-a289-87436643ab82_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_86440100-2137-4e9f-94fb-14a6634d699b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_737d4269-836b-4666-be33-3bbb4221d735_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_716465f8-724d-465d-ae0f-cfd060254275_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20210930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3c883695-bf18-4c10-bbab-ade8ad96e4f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1eb67175-d588-404d-84ee-3c24bbdfcb2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_7732c1e9-63ea-4d0a-b68c-451dcc7f601b_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20210930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_da0aeb32-c31b-4467-8e60-676a80dd148e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_11a83cfe-f86a-47d1-8dd5-dd213bc60d8a_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20210930.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_4c099dbf-e387-4ab4-9a51-b4bc41c22626_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution by noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_label_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution" xlink:href="biib-20210930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestCapitalContribution" xlink:to="lab_biib_NoncontrollingInterestCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_78f59af4-b0fb-4a7f-95be-e32d12e47c45_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_69625dbd-0e51-4ca0-b6b7-804dc3c8e6b8_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20210930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ce0ec86d-a9f5-4671-9660-dd3189fda8dc_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d61c7a84-ce95-4245-9c1a-9535c1eec4c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_f1f73c14-3e7c-4988-9822-d75d2242550a_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210930.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_02ea8e9a-7de4-4e97-9a57-4d31ea3139ad_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_e2263c58-c985-44a5-b5d5-062c879277ec_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_9a03e8b5-9a3a-41fa-998b-05d688f5dbc3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_eabc80e4-d68f-47f6-8cbe-0868ae974b20_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20210930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_99ed7b3a-3d4b-48aa-abc7-f6ab590ece9d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f372cb72-d338-4635-9b0c-a90254bfe2c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2587afeb-e090-40d0-8f42-8371688ca606_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cb2c8a5e-30b3-49f8-ab30-54abbb159857_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5868fd1-13c1-4130-8a3b-8a83a9c23d38_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_c36e5455-9258-41b7-838c-7bb959ffe39c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a9fad645-26e9-450c-948d-675a218b6ad5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_73a1a41f-f96a-464b-b939-b41786f5865d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_4310b928-bdab-4c41-af08-4ff48782e2e1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_1b7b099f-e510-40e1-959e-85c59b705ff0_negatedTerseLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20210930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe6cc19f-da59-4817-b255-6ead778076a6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4da9f7a7-2009-4a09-8943-f65c901b3ddd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_81f9599f-1aee-42c5-8743-1120e1b13b3a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c49c1c24-d0f3-48b9-86d0-27d5d4c97a19_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_3e4efd0a-7ef6-45c5-b8bf-2b57e5f59959_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c6fc104f-7eaa-444d-98bd-975974055664_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_f091b406-34bd-4386-9575-ac78374a0ef4_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20210930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_66c846ff-7036-4ddc-9bcb-9a022fbc5683_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_941a6f07-a078-4c1a-9498-3e841dfed313_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Termofcollaborationagreement_74b3a0c3-f541-4739-ac1f-34c3fd019444_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement" xlink:href="biib-20210930.xsd#biib_Termofcollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement" xlink:to="lab_biib_Termofcollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_83b1e248-a959-4b48-b0f4-515aae859078_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_1dae82b3-7bf3-4e40-b4fd-f0789c6ee322_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20210930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5ddffcbb-40f5-4fc0-bd0e-e1a581738c48_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f4299e00-cbc7-4d39-a204-5560de90ad34_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_ae7da3e0-5493-4ef5-9322-af906333a0e3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2e8a2e56-5b36-4db8-b78f-aff7cc2c2a8a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_027270a2-22b4-4674-acd2-b1fc190d83ef_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_081cb005-16df-46ce-9b4b-45938899a37b_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1febf191-48da-4256-b33c-d22fd2f97cb7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_677caaba-44e6-4854-92b8-3f2ab3053efe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2a31729c-ba49-491d-b616-19e42a9e8583_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_0a02334b-062d-4ba0-80dc-7722bfe05c1e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_e3f65b87-7190-4b0a-997e-dc165905c04e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_f3beab73-0e10-499c-80ca-b6e2b26611ca_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_16c2de40-fdb4-47ac-9fa3-6bf56046734e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_dce46182-8958-4413-9bc1-0fdf17001d56_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_2473650e-5846-4474-a214-d32108aa8d23_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_3d153efc-2f7c-43bb-8e31-b24455f24d07_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20210930.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5a8a337f-6ee6-461e-8c88-9a428209f9bf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_11cd84c5-2be9-434e-a055-546a41bd41b9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d4e56377-a6d5-45b9-922f-3cf1b28bc47c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_6f075f36-f70d-494c-9ac8-9c42bd000577_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2f3726d7-d5fa-41fa-bf3e-fc830143bdfa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_b0ebe3ac-8025-40d7-8c63-6a3710251271_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_8c9a7884-4220-4f65-8a23-7bfe54f572a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0933c078-279d-4cd8-88ce-2a1268bec285_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_099a6673-d7a8-400b-824d-34c8c2ba7576_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_0ff7bcc5-2883-4ab8-a9aa-bc8a325f5996_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_953ea637-df88-4823-a4b1-cc27158a9ad0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_46915d59-1139-42e9-8ca9-8e261cecde65_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_2110d195-11f7-4299-916e-de78eebd0a89_terseLabel_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_label_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_documentation_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount" xlink:href="biib-20210930.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongTermDebtExchangedAmount" xlink:to="lab_biib_LongTermDebtExchangedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a2eb9ae9-24f0-4d9c-ab3a-438eea20afbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9d91c8ef-4705-46fb-a658-8df8d944a6d7_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a0d125c6-2c69-4a03-b7b6-8dbd2da7a78a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NightstarMember_049ff75a-5548-4bce-af9a-7340a2215cfa_terseLabel_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_label_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_documentation_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember" xlink:href="biib-20210930.xsd#biib_NightstarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember" xlink:to="lab_biib_NightstarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_e8a29be0-49d8-4100-b5c4-24c625cff94c_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_81ecb462-ccd1-4f25-bdb7-366e9e7e34e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_330e1ed8-a5d5-46fc-8a4a-01cd866667aa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_386d85fe-8ce2-4bb0-bbfb-1f1bd092fee8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_dd4a6321-7c84-4e29-8444-d8abbd62a907_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20210930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_45fb613c-df29-4ff3-9038-fa57cd193e19_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_c923d7b7-c07d-493a-959a-3faf352290bb_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20210930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_1d983994-f0b1-48e7-a6e7-5399624cc45b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationAgreementTerm_01a5c06e-8845-4f5c-8fc5-be31e93b6cc5_terseLabel_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_label_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm" xlink:href="biib-20210930.xsd#biib_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationAgreementTerm" xlink:to="lab_biib_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_03e655cc-a90b-408c-8afd-f248d5ac7df9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_bbfc8a4a-ca47-4840-a9d1-8ad2dfc05661_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20210930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c069a00f-6186-402f-b394-ce633a4005e4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_da89afb9-fb4d-4d9f-89e0-39d6ae5896b8_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20210930.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3ed64a41-ff38-4ddf-b575-3df135ecd763_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20210930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6efc2ad7-0b78-4fc2-a0d8-8992e7936b5a_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20210930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50ac0099-4a1d-472e-891f-89b2526ae755_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_df6559eb-5d6c-42f3-b1bd-f8ed21ccc98e_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_d935f9d4-427f-4893-91f4-e38f2c967b54_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_3066a10b-4327-47d3-8454-d020285588b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c22e15df-64f4-4c70-a6ce-3b539e9fa72c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_bdb15534-e7c6-4369-84ba-f9b65fe74ec9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a08a9fd1-12c8-4064-9f4e-e28821d6b5b2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6f31e599-402c-4060-9993-b7e2e801168b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cb7832fd-a739-40e0-943b-460d6108b487_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_74a6a163-b62d-4f0c-bd23-12e0dd074350_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_262780cb-70c1-4bdc-ac7e-7c668fa7d998_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20210930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d148715-9c15-45d2-9883-58e421f88782_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a60700a0-bc4a-413b-b787-f3d31094e84e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_b8e1087c-1dbf-4371-a1e7-9b6d7963dc9b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_88b951ff-b762-4859-8cfd-d0cba23cab37_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20210930.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_84eb5473-b634-4652-acd2-90e4e9a11f87_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c66af40a-0a3c-446e-a931-04a66fa215e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_2efb4607-c35c-47e2-ab88-8126e873e228_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_bab1baee-f9a7-41ed-9b76-74424ca0dcb4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_99f30660-c4f6-480c-93e0-62c10cf9efb3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_27fced15-ab49-4b97-a312-950814233d4c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_37354e84-d5a6-491e-88db-3c2ba65091e0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f2d3e971-6ba4-4f8d-9916-3defc4b8ee75_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_33cd90c1-a80b-4fea-9524-279e8fd61f70_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20210930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e6b11241-612d-4b00-a05c-14f734455a5a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2764db9d-739f-455d-bbf3-5a577ef62795_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_fbac6368-6f98-4667-a92c-9f3cf62b6838_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20210930.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_226af1e2-56f9-4e3a-9cc1-13f2d73c106a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fd93fbae-637b-4597-ab82-aa12e6abf280_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_506460d2-2761-4c0a-bd6b-c550afb3e9de_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_804c45a1-91cc-45ee-8b28-d8bbf2a89d58_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_71cec530-3f09-4036-8686-cf0aabf13d25_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VixotrigineMember_e817774d-9bc8-47d5-a89c-97001686508c_terseLabel_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:label id="lab_biib_VixotrigineMember_label_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine [Member]</link:label>
    <link:label id="lab_biib_VixotrigineMember_documentation_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember" xlink:href="biib-20210930.xsd#biib_VixotrigineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VixotrigineMember" xlink:to="lab_biib_VixotrigineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5fca0ad-85aa-4d81-ba5b-23c27c5291bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_dc3352a8-5564-4223-9981-67e5017c24ef_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_dacbe932-d8a9-4fe9-aba7-465d0baf7dd6_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:href="biib-20210930.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_57285e43-15a8-437b-b584-c6000248748f_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_label_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_documentation_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased" xlink:href="biib-20210930.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstocksharespurchased" xlink:to="lab_biib_Investmentincommonstocksharespurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_bd704236-fb80-40c2-af54-102f8e58c341_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_c31b8802-f386-43a7-ba8f-6eecf124adf9_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20210930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_1eaad057-8ca6-4ef1-9cce-fefeacd784c7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ef487880-a913-4e7f-bdf4-403ef9ed0cef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73e682ea-fd2d-45ca-bbb9-293f87c83e2a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73b5e513-3b60-4964-b85c-ae9a96656161_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_95a66ac2-7a16-47b2-b810-46aceabd4def_terseLabel_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember" xlink:href="biib-20210930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_March2019ShareRepurchaseProgramMember" xlink:to="lab_biib_March2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6e7c71e5-4ea5-4199-a6a2-a54aae4f5253_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_01cb30e9-5282-431c-9b11-bca442714b9d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_47c1c2ec-b84f-4614-9064-78c1e17e9e9e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_3e1db592-f5b7-4f49-84bd-2616b753d31d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_78ad5d58-f0a4-46a2-9eb8-c3df663380de_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_f548383a-d0b5-46bd-9169-61faf23dbfd8_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20210930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoCommonStockMember_13a7feed-9d93-4e29-b647-0008a2a12dad_terseLabel_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_label_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_documentation_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember" xlink:href="biib-20210930.xsd#biib_SangamoCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoCommonStockMember" xlink:to="lab_biib_SangamoCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9b3fe5b-658e-4f5f-9a6a-6cada21cd71f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_bc38a6d8-396c-47ad-b602-e26a10986973_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ManufacturingAndOtherCosts_b17d9b10-c885-4fa3-bdc6-ff2373dc11db_terseLabel_en-US" xlink:label="lab_biib_ManufacturingAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and other costs</link:label>
    <link:label id="lab_biib_ManufacturingAndOtherCosts_label_en-US" xlink:label="lab_biib_ManufacturingAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Other Costs</link:label>
    <link:label id="lab_biib_ManufacturingAndOtherCosts_documentation_en-US" xlink:label="lab_biib_ManufacturingAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Other Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ManufacturingAndOtherCosts" xlink:href="biib-20210930.xsd#biib_ManufacturingAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ManufacturingAndOtherCosts" xlink:to="lab_biib_ManufacturingAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_32b7383f-fc4c-46b4-a90c-45882b423e1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_161b8273-df1c-4267-9242-8b55a0891c3a_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a47b8244-9979-4e5c-9f9d-2e178f91cf47_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_9314ffa9-f285-47cf-846d-94433de1f722_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_d056730c-b5b2-49c5-879a-f2206c62f286_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_label_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:to="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9786e583-2c03-4369-9ff5-280b9a523f52_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0cd57fbc-d718-48c0-9367-0b905c2ed324_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OthercorporaterevenuesMember_cd0d2a77-51b0-4d62-90e0-ecdc2a6c78cd_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember" xlink:href="biib-20210930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember" xlink:to="lab_biib_OthercorporaterevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e30acda-b019-4421-97c1-7ccc6c393e9b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_47bf18de-c97a-436d-aef4-63c86ae6eb1d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_e77920cd-5234-4166-946f-889145034093_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20210930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_96b1dd41-6344-4d96-9711-140ffa32c821_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_17df34d4-c2ff-48e7-8a35-e08091a1c8eb_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20210930.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_dffebf3e-a62b-4285-a9ab-081716e5d5ab_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_1c4c609b-3b0c-42e0-b6f7-f9e16b89cec3_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20210930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6cae36f2-94ea-46f3-abe2-dd3e0fc4ebf2_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_900e7f62-d83e-4536-91ce-1879823d1c57_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20210930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_76981a62-bc28-479a-820a-c853cda7c0c1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_51e78527-3a0f-43b3-9ffb-63d10d215aac_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_c92c9a91-9888-47c6-954c-ca8fccc09e8a_terseLabel_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_label_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_documentation_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:href="biib-20210930.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:to="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_bd034adb-b6f2-4e18-90ed-947c536d67d1_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_be5af354-9fca-4893-9cf3-04816c5fd994_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4230681d-5523-4ac3-a5cf-880775f31c1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_6a011eff-435e-48d5-83aa-f408eb11c010_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_37193789-face-4289-aa5d-d9e36a4c3b70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_574b44b3-53eb-4812-975b-39e5b3c4aab0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5b962996-6975-456f-980e-33d055ce2b60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_0d5b61cd-25cf-4ac1-bc4a-9d3066a75602_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_f4263c52-1989-4822-816a-727a7cd0a798_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_b6a836d4-130e-44ad-acaa-be828e5bbdfa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_25c44755-32f4-4586-9e40-6cf12f76abe4_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3c8205bd-cadf-4b35-8ea2-a8e6041631e9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_800112a2-38be-409e-8d0e-b130f29deb1d_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20210930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_fb6448e9-a9c2-43a5-9203-030e05f46de1_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20210930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_962abdfc-4bfb-48c3-80b1-6dfe4472d6e5_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:href="biib-20210930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_b2e23503-0dc7-4234-8c6b-fccbfeae35a8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_3b5a038a-5302-4583-966e-c60fe9837f99_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9dec1986-05f8-48da-9966-52147da598b8_verboseLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_aaefe471-5edb-40ac-976c-bb87f094c567_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20210930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_be6cd7ed-f758-49ca-bf38-eed416ae3c37_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_77ac12d0-4692-4e26-a54e-e1f8e4aeb876_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1087fbf0-75e4-43c3-89c7-0fe372deb96d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b03c7900-ae2c-422f-a68a-dfa392ce0d84_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_da028a99-1df1-4ce4-a251-c4a8257fca5b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bc223727-1cf1-41b7-ab64-ce8a09a2add1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_8c839cd0-d71a-4756-8b65-2635f6d14acb_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20210930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_7b151f49-194b-4e30-8e7a-799e01b7a070_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember" xlink:href="biib-20210930.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember" xlink:to="lab_biib_CashSettledPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_de1a372d-43ea-4e69-b04b-d11359b80c6c_terseLabel_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_label_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:href="biib-20210930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:to="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6a4f5041-0aec-40d2-81da-03aafac2b3b7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_69ac2b4b-cf5f-49b4-afad-eb3617d06ede_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e015500f-8b89-446b-a890-6be92907e2f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b2d9ede-0b53-4435-bd89-9a4d1a718746_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_305d97ed-8e1a-487c-b93e-3e10cf05ead0_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2f83fb31-e3a3-4981-97af-a6d0821b1895_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c0cffb46-a416-4299-81e4-0bc926ae0a50_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_cc443429-b883-4955-a1b7-725999e98b47_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_390f30fc-3d40-41e1-95bd-59c3079b01af_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0862a166-372e-440c-b534-9e027c8b01ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_4cf58d8f-445c-4ccd-9409-75a1eb99304d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_6aa57b17-cc45-45ef-b59d-756b11eb1640_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_24b6be6c-e9df-4bc8-9e44-63b13cb05d61_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20210930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_77b7bbee-2976-48f4-92f9-21b15153c872_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_c47357a9-b5b2-466f-83a5-df4902b3e13d_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c1b681ea-6699-4cf5-bb60-b4ad576e2bed_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2af7e598-46a2-4304-b77e-ba8f4e50a346_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e7947c1e-20c6-428d-bac0-312c6600b6c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_beaa2c17-aae6-47b1-98b3-2732904f108e_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, increase (decrease) in value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax Liabilities, Increase (Decrease) In Value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax Liabilities, Increase (Decrease) In Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:href="biib-20210930.xsd#biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:to="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_f1b314d7-eff6-40dd-95f0-1e66ebdd2277_terseLabel_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember" xlink:href="biib-20210930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_December2019ShareRepurchaseProgramMember" xlink:to="lab_biib_December2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ac7a9f44-0021-4a49-a633-4186fa458fce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_96d50ad0-e251-48ae-9579-7a7799e59903_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0ab34d3-5038-4cf7-86e0-aacbf5318b9b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_2b660b12-ef89-4f07-b611-379e8f219b73_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20210930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_05c0b0f6-77bd-4c82-a14a-22391cee02bf_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c0f60419-901e-457e-87db-6fd99cbb5c78_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_9f4ea9db-8abd-443d-bf15-efa15cb448e9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c32e2c3c-9f99-441c-9c66-1b111d3894a8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_85fa51b6-c649-4f4b-b606-67a352d3c81c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_020f0494-f1d1-4e45-a7d2-133acdf2286a_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20210930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f902daf7-7a27-4957-b3cd-21736ba62209_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_89a647d9-7078-4c18-a473-6147aa9a7075_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20210930.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_94090253-eeba-4e01-b3af-50eecdc4d2d9_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a44d8402-17c5-4eec-aec6-29930ca793bc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_47cd2f3a-ac77-456e-80da-038302586264_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_cf239724-7548-4b75-a1b1-fce3264bbe32_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_f1831efb-2fb2-4847-902c-f90686753e52_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20210930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5bcfdb5b-bdee-44b6-b296-4089c99d488a_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d285340e-8910-42d0-9818-c5d1dec07c27_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e7b58187-4f37-4412-ae93-8702e07c744b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_2aaabe4d-9204-47ae-8375-41bc921524c0_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03890939-48f8-421a-96aa-090f40a4b20b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_69ecf5fb-689a-498d-b6f1-f7b505ea82ee_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_78057e87-29ba-41ba-8e3c-5755602888d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_9f12ff04-651f-4aed-971c-12f2bc72b4de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_6d9dad2d-2518-445e-b31d-424ef46fdcf9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_6cd3a628-e548-4dc1-8bd2-255a69645f07_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_37042ee5-42ca-411a-8eb4-85de7f34d6d1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_45d63e8c-3eed-491a-9644-6be99f2b8919_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20210930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0d964c50-fbc7-462d-8b06-c8204595061f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_120be879-8cc3-4e3a-af82-d8b51a957d4e_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_b95f495d-6289-4ea5-a1a4-a5cef193523e_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20210930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_34ae81f0-3cb4-4833-b162-4c3eeddc2909_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_63a877f9-4307-48e9-bf2f-63bbcfe92758_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_5207ce60-4682-43fc-b0d5-77f82a443b26_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_15baef71-caca-4722-b9d9-6fdf3dcbed96_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8f479efd-f582-4d38-bce6-658fec6cb59a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_7f1e6522-d342-4cf1-98d0-4ce4b967d60c_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20210930.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_963788e9-88c7-4c81-b92f-291098ca396b_terseLabel_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember" xlink:href="biib-20210930.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_October2020ShareRepurchaseProgramMember" xlink:to="lab_biib_October2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8c41290b-aaa0-4068-bbd5-013bbadb2aad_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1959faf8-e99e-45f2-b7fb-803dfb750135_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a7ebd021-bd69-41db-b9e2-538073b795e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ADUHELMMember_4dd07177-c9e9-4983-9d4e-aa21c8e6070c_terseLabel_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:label id="lab_biib_ADUHELMMember_label_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM [Member]</link:label>
    <link:label id="lab_biib_ADUHELMMember_documentation_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ADUHELMMember" xlink:to="lab_biib_ADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9ce7e87-b1ef-42ef-9e6e-3bac67570433_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b136484f-0f4a-47f3-9ee7-f3cab17ae531_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_02ba9fa5-7a48-44d3-afb5-2494cd93751a_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20210930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TGNMember_50f20fe8-381c-4ef6-ae8b-69a2f968cd82_terseLabel_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:label id="lab_biib_TGNMember_label_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_documentation_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember" xlink:href="biib-20210930.xsd#biib_TGNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember" xlink:to="lab_biib_TGNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedMilestonePayments_d732dcf7-e77e-4d5d-b066-b14d214f82a3_terseLabel_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued milestone payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_label_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_documentation_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments" xlink:href="biib-20210930.xsd#biib_AccruedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedMilestonePayments" xlink:to="lab_biib_AccruedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_65e7635c-7ab3-4413-9c2d-4dbe694024f5_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20210930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryMilestonesMember_7fe54ebe-ea97-42fa-8c39-99fe1070a9b9_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember" xlink:href="biib-20210930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember" xlink:to="lab_biib_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_93bbb6c9-0d3c-4c9c-ae17-9910b8945abf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DividendYieldPercentage_a78c307e-6db1-435b-b742-87dc82107f78_terseLabel_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_label_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_documentation_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage" xlink:href="biib-20210930.xsd#biib_DividendYieldPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DividendYieldPercentage" xlink:to="lab_biib_DividendYieldPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_d4dc5873-e18e-4e09-8d37-e5be72260127_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5f01ffa6-a82a-45ec-824b-e05c52377eda_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_c6335ada-7a0e-4e80-8e14-c9064e6fd4de_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5d214f45-a890-4626-8053-f9b4a8bba88f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e0b1b1cc-edea-4688-bb9e-fd4a2518c67b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_75106f5d-3fa6-4be2-be38-4903f28b5669_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_827c06af-2254-4746-8883-8583a107fbe3_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_ceb56f62-d70c-4c00-83f8-5c5f0ea8bbb7_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_15272845-0007-46aa-9273-67a9f50bec9d_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_43eed9ac-cb83-4907-b655-1273042d0176_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8b487ed7-934c-47a2-8324-304b0ebd9029_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_dbe3ef08-6849-4d6d-80eb-a6e1026738bd_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:href="biib-20210930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_5d64c312-7721-425b-84d8-ac3a3d1e81be_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_733549f1-e794-4c03-a7b1-040245a37072_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a71c601a-7f6f-4838-9db7-16c18abe3504_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0bf29a52-4a95-48d9-b7b3-86b17e1161a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_76c29021-8383-4f4e-b6ea-3fa3da1d2c50_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_dcfc0ba8-c2b0-4dd1-a96f-66ebeddd517e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_7e8d6b7a-0b45-4c6b-a4b9-e67bab54bca3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7aadfad6-182a-430a-be94-e5d74627054c_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_921a8a20-6939-469a-8be2-4179c8af4b54_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_310d2291-0067-4bb0-9703-51e7214d5fbf_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111Member_4a4c1170-b54d-40a8-8417-d4848b730620_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_label_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_documentation_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member" xlink:href="biib-20210930.xsd#biib_BIIB111Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member" xlink:to="lab_biib_BIIB111Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_879b4d26-2bc8-4c32-b56d-c5d1cd555704_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20210930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_dc92528a-054e-4c85-ab4c-8f47dcbd8b44_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_label_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue" xlink:href="biib-20210930.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetsValueReductioninValue" xlink:to="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_11ca20e9-ba23-4288-a5cf-76dea0bd90c5_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20210930.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB112Member_ac8f0bb8-3d02-49b8-bff3-8b87dabea5f1_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_label_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member" xlink:href="biib-20210930.xsd#biib_BIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member" xlink:to="lab_biib_BIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_5ef6fe3e-cff5-499c-a2fc-4b5392b1662d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_45d41378-8305-4841-85a4-654bd60d5a23_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms" xlink:href="biib-20210930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_fd90e8c1-ac2a-4af0-8072-874c0bfe11e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_e29e9152-c727-43ec-b7fc-5354ca896bbb_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_81fc8ea9-40f9-4342-9fa4-61d634dbd534_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_dea7bf5b-f2b8-4387-b767-1d04b9c481e1_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_73534c4e-2146-4e6c-a6b5-2cd78d6c6733_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_55928690-dca9-4926-903e-f4e7716c471f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ac6b56cd-bca8-4feb-aa7f-237914f7e0a0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ea912bcd-43ab-4dbd-806b-ab9933bff186_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_78612e22-f48e-4c9f-8304-046dbe1f320f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_7c3f4f0d-514e-4676-b378-d0a66ce8317a_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20210930.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_d3c97e03-af63-45a6-8491-54dc073200af_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_f2c7dafc-deb4-4c60-88b1-ae8bce03ed91_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a49f9b32-27fd-445f-82ca-80bc2146e1c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_a99a36af-e0ec-4e8d-8096-b45ca9e461d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a8961574-f712-4502-8039-66ba5db1f530_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_571c8d9d-e6b3-418f-a551-6a51c6cf3f70_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0b7f0653-7012-4d42-9850-4b95e33413b0_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_43af17c4-a606-4526-a900-36ca2c0190bb_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b473ea4d-55a5-4a56-8350-8cf10683437e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_94b2dbfc-02d9-45ac-b3ed-f040c3ea2ac1_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e1f8ad8-f4b3-45dd-a095-d028c2f45f4b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_705216c8-9af5-4917-9cf6-439782f3b13f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_711e3c52-105b-4f24-a183-73cf788c6781_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_9213cd9f-020e-4695-a7c0-f36989dae5ef_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1a36fd13-3334-40ba-b2e1-99c541ba843f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_2ac63ab1-9ea3-457f-a7d9-37bde5a75c29_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_d5a0682e-af3a-4587-9886-f17ee12fb8b2_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20210930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_c4d9c3ed-8020-45cd-a63e-8e9d428181f5_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20210930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1c614be5-0628-4d42-8596-4592c9cb99c8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f4882bd-8f3e-40e6-9c36-8dfb724703f5_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_8152749b-df73-4740-af37-89543d8ed77e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19a1a7ba-0e6a-4a73-88d5-b16dee6b4c9d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02be2477-b201-475e-a4da-d46612d91d23_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c9f56ce8-d2ab-48b4-bbec-56664e1eb59e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_f60b668f-228a-48b8-a6b9-5a0ef63da150_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20210930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_3b91988c-4862-446a-afb4-6ee562c259f5_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20210930.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9f24bdaa-8bb4-4389-8b4a-741d34b26422_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_217e56f0-7580-4095-9e7c-d2ee22c20de6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_6ca9ed80-df23-43a7-bc4d-2cdf1a227f01_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_65cc02fb-6f36-4a17-a4a4-9ce53e68db52_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_253b3694-7a0b-4a6a-a3a8-bd05787f59e0_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_fa98bd1c-a46e-443a-ac5c-fd9586e6061f_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cce4a39d-62a4-49f8-830b-29a6aa61f982_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_74d513ae-e956-4db1-8f19-32b835c0ce44_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_799a3686-d7e1-4fbc-b8f2-f8765f900e80_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_153c3630-19d0-4cb4-a2c4-43b218a8fd23_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef7abde4-1082-419e-a517-a244f6b1eab8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5d5cd11-bb05-4f00-b646-b0ac01913aa2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecedb8a8-0189-4680-bb47-0c3c3c8d27d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_1f3414fc-baa4-4c94-b59d-d71f812335cc_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_93b378d3-8db2-4da1-9b78-694f1bea4a7a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a830da5d-05de-4bbc-a0f1-794a1258d54b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1be25f19-b79f-4cae-b2b9-c92ed49553bc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_970f2095-f034-4e47-85aa-e2ca00199c9b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_90a817ad-6b6f-44df-a518-72856c4a572d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6777f1af-3f40-43cb-853b-f5f84adc5af2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_50dbfd07-67f0-4655-b0ac-d78ee4b975a4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4efee410-cc80-4ac5-83cd-3a4dff5e9aae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_9f9db259-1f6a-4003-83ce-345051b55ff1_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_eb109030-0ef1-4ebf-b187-906dde4d5eff_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_76dc7d75-1e8a-4f1a-99cf-22845d382f86_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b50195e9-1c6e-41ff-add2-ec3947651cb7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_3e86f647-3cda-448a-acf1-00589b70af0f_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20210930.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_d7907598-bafb-4f2c-a2e8-a70a320b09bb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a5e27cdc-b1b5-4211-b502-0f0a9b5efec6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_947627fd-a9ba-4ed5-8818-2a92ddf0db23_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0457406d-7251-4ade-b468-426f1da8e305_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_767c0ccf-9928-4193-b6bd-778c91a574b7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_efc025ec-8162-4886-9d3f-bef669d7fd27_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ad9b27a1-8671-49d2-9bed-713b4de8d2e1_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3fbd2924-e0fa-4aa5-a393-5032dcc23559_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7189eae0-746d-4688-b788-c3be4ae4948a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_df8ab649-9b36-4289-ac84-fe85593c2d08_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_987bc6f0-361e-4ffc-9416-c2ee83215dc8_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20210930.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_18cdbe7f-1a2d-41ed-9af3-f1c530180307_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_81780311-5e85-45ba-9aa9-a9382053ffb1_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration agreement, shares, purchased (in shares)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_e48edda0-8fbe-45e6-a9d5-1b592dd7c695_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c5197922-55a1-4bd3-b89b-637ce7c4d952_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_97ddb8d2-de48-47b1-9df3-80dd4358f5ef_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_4b4d646a-6b28-44ff-be7b-b8b0f2957b1d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_f0919594-7eaf-4abc-b535-50ca2a08acf3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_3ca07fd7-2236-4c06-8c4e-696db61500e1_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20210930.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c1288c23-945f-4567-bf90-e381e64cd35d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1c0a9b38-93fe-4334-8861-efbc594c9b35_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1387f8b5-7a3b-41f9-a5be-f4a8a9268a60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_33610a05-24e7-4458-aa93-a39e8c54f302_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c136b6e-d791-4a74-b9f8-fb876c6a6128_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dd5a2e0-ce97-4cf2-a7ca-a32c3e36477c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_c5b7c815-6087-4271-ace5-f3188eb58047_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20210930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_cc77e43f-3372-4d5d-afea-1b53b37a14f4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_93d5aa63-ea88-47a5-9d58-5d642e6ce639_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20210930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_bd0ecbdd-5d23-4eaf-9e19-8397eec2abe5_terseLabel_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of early call premium and write off of remaining unamortized debt issuance costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_label_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_documentation_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:href="biib-20210930.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:to="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_28db7bc2-590a-408d-aa16-8d5834932e73_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ec98ec27-06f4-4ed0-a3b2-ec175e2962af_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_1d2dba8b-0382-46d8-9fdd-30ecf8e41f58_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0cb89194-dd04-4777-84de-f8dd6aa6efdc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_67277788-15db-4c3c-b32b-481997759759_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_495401e4-2a83-461d-9819-e425d124616f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_e114fc10-a480-48ed-8288-75b799299cd2_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_bd5a17c1-9734-42f5-9f37-7f21ee582a62_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1cdbfa0e-8ad8-43b1-8221-b4fe00e51fcc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_75a1b6a2-abc8-47f3-8c18-612483ca47e0_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bcc754f6-aeee-4d6d-90e1-048ffd1aca18_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_17efd30f-8f00-47de-b1fb-627067814b32_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_e21090cc-ed14-4543-badc-64d48ec57ea4_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20210930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_780dcdce-7f27-4176-a573-4f97bc95e5d1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_dc07910f-3cce-458b-81e3-333dd4679cfb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_92f4fa9f-dcef-45c5-9581-7d65aa55f3a3_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_38226f1c-f95f-48e5-bb7c-41c37371a6dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b783f539-157d-4909-a8f1-388ca0b55932_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_7e6d587c-fffa-4e93-8d2d-fe3ca1f2aa8a_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20210930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_bec8add8-cd70-45a0-9899-8c1651fb240f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8016b0b6-6bea-41b3-9568-8e237b8b8463_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_786307ba-6c5f-41e0-9684-73ecf3c1e5b7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6d84e2e9-b95e-4cc6-a6a3-2dcd8b79c63e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_8c788221-8ca2-49aa-a01a-71abd9920bd4_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20210930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>biib-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a903f54e-5284-4407-a747-e0b1f5468222,g:e7d07c56-2dfc-4728-a119-070b245a209e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8c56cdeb-71f6-4ddf-b1fa-170ba12fea9a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_DocumentType_8c56cdeb-71f6-4ddf-b1fa-170ba12fea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b171adc4-258d-4d03-b9a8-c22ef0a2c86d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_DocumentQuarterlyReport_b171adc4-258d-4d03-b9a8-c22ef0a2c86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_81149aa7-0e12-4b6c-a1c4-13b906852f1b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_DocumentPeriodEndDate_81149aa7-0e12-4b6c-a1c4-13b906852f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f759fba7-7f0b-4a4a-a583-9039dabb7644" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_DocumentTransitionReport_f759fba7-7f0b-4a4a-a583-9039dabb7644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b4936a3d-647f-4e21-95ff-3ceacb50246c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityFileNumber_b4936a3d-647f-4e21-95ff-3ceacb50246c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0af76ad1-6cbe-4e13-957e-22c84e4ca398" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityRegistrantName_0af76ad1-6cbe-4e13-957e-22c84e4ca398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4af2f325-745c-4aaf-b00f-c7ac06c8a3de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityCentralIndexKey_4af2f325-745c-4aaf-b00f-c7ac06c8a3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2e3cb13c-53fe-41b7-b889-c3b09aa1eea0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_CurrentFiscalYearEndDate_2e3cb13c-53fe-41b7-b889-c3b09aa1eea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c992ce13-5839-402a-accd-9d53c0c23999" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_DocumentFiscalYearFocus_c992ce13-5839-402a-accd-9d53c0c23999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_79b8d502-ff55-485e-805e-ff908c51a014" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_DocumentFiscalPeriodFocus_79b8d502-ff55-485e-805e-ff908c51a014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6939d9b5-3f72-4c6f-b436-fc9d1790793d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_AmendmentFlag_6939d9b5-3f72-4c6f-b436-fc9d1790793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fe4067e9-4c57-47c6-b4a3-f40977a31de2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fe4067e9-4c57-47c6-b4a3-f40977a31de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_20d9d143-5821-435d-8f82-904f44c6d2d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityTaxIdentificationNumber_20d9d143-5821-435d-8f82-904f44c6d2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8cd3f736-3e32-460b-992a-91821febb927" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityAddressAddressLine1_8cd3f736-3e32-460b-992a-91821febb927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2f8ca0d1-4812-4262-8ad8-eab12a5ce561" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityAddressCityOrTown_2f8ca0d1-4812-4262-8ad8-eab12a5ce561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7764aec1-5e05-4234-80f3-289712ccf80f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityAddressStateOrProvince_7764aec1-5e05-4234-80f3-289712ccf80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6b3f1e02-0a0f-4a93-bdf1-b1a0cadd568b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityAddressPostalZipCode_6b3f1e02-0a0f-4a93-bdf1-b1a0cadd568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_64f86d17-e51b-48e6-bfcf-6aac26094cd5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_CityAreaCode_64f86d17-e51b-48e6-bfcf-6aac26094cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0d0057bf-c4c3-47c1-954b-83c529d0c6bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_LocalPhoneNumber_0d0057bf-c4c3-47c1-954b-83c529d0c6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_589592a7-aaa8-4d25-adee-4ffea7c9414a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_Security12bTitle_589592a7-aaa8-4d25-adee-4ffea7c9414a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3b8b703a-2a8f-4a12-9a2a-bd547e688f1b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_TradingSymbol_3b8b703a-2a8f-4a12-9a2a-bd547e688f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c8accc92-6a08-4dba-bc1d-dec142f1a1ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_SecurityExchangeName_c8accc92-6a08-4dba-bc1d-dec142f1a1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_512bf830-c8b4-4b7b-9d16-f8ea7fa09cfc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityCurrentReportingStatus_512bf830-c8b4-4b7b-9d16-f8ea7fa09cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_639d8e40-fa00-4e2d-a305-df36466eaa61" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityInteractiveDataCurrent_639d8e40-fa00-4e2d-a305-df36466eaa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f28a73f5-c765-473e-90b1-63398817edc5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityFilerCategory_f28a73f5-c765-473e-90b1-63398817edc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f2f2c44e-ae9e-412b-8889-347f8df4efd5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntitySmallBusiness_f2f2c44e-ae9e-412b-8889-347f8df4efd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c0706992-a044-4bdf-8006-eb0aa5476c21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityEmergingGrowthCompany_c0706992-a044-4bdf-8006-eb0aa5476c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_893cd924-f6f9-4b12-b401-79ea25d196a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityShellCompany_893cd924-f6f9-4b12-b401-79ea25d196a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a671b837-04b5-4827-8f39-1054cf177832" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f933ff2d-9ae3-4971-9c77-10b7e5898c32" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a671b837-04b5-4827-8f39-1054cf177832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_440872bf-a649-47f4-992b-37d35c242bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee10e022-d2e3-4c4e-b8e1-97b86711b349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_440872bf-a649-47f4-992b-37d35c242bd9" xlink:to="loc_us-gaap_StatementTable_ee10e022-d2e3-4c4e-b8e1-97b86711b349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee10e022-d2e3-4c4e-b8e1-97b86711b349" xlink:to="loc_srt_ProductOrServiceAxis_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ec2f4640-498c-43aa-afb3-8b8ef85aa6b5" xlink:to="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3c630743-5d9b-4aee-a42a-74bd125b2985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:to="loc_us-gaap_ProductMember_3c630743-5d9b-4aee-a42a-74bd125b2985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_a2873d76-e986-450c-810e-19a4c15f2980" xlink:href="biib-20210930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_a2873d76-e986-450c-810e-19a4c15f2980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_dfd0f841-42e6-444c-b2d7-ba06bad3ec17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cc60a14-cfea-4bd1-8e0f-9e69c64bebeb" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_dfd0f841-42e6-444c-b2d7-ba06bad3ec17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee10e022-d2e3-4c4e-b8e1-97b86711b349" xlink:to="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_efd4cfa0-81c7-4013-b6bb-75c9e1074a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_Revenues_efd4cfa0-81c7-4013-b6bb-75c9e1074a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5d4d2424-4cf1-470e-8c2d-bb08ed56e8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5d4d2424-4cf1-470e-8c2d-bb08ed56e8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_391aaaf3-2ea6-454b-a0d3-8091d255bb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_391aaaf3-2ea6-454b-a0d3-8091d255bb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2bb94b63-5365-43c4-996d-3e1b7d85cfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2bb94b63-5365-43c4-996d-3e1b7d85cfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_6843481a-eace-42ec-aef0-2587dfc80924" xlink:href="biib-20210930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_6843481a-eace-42ec-aef0-2587dfc80924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_23d2bac1-57e0-4b24-89c7-65171efea11f" xlink:href="biib-20210930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_biib_Collaborationprofitlosssharing_23d2bac1-57e0-4b24-89c7-65171efea11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3d0a71d3-354a-4f7b-af36-1445412f24d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3d0a71d3-354a-4f7b-af36-1445412f24d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_794f9370-1764-4fcf-b086-70eb9bf3bcf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_794f9370-1764-4fcf-b086-70eb9bf3bcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ed682e4b-d697-4ba0-b18a-9ba58903da53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b97ad55f-7698-4477-9ae5-7ab362c19fa2" xlink:to="loc_us-gaap_CostsAndExpenses_ed682e4b-d697-4ba0-b18a-9ba58903da53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab6461e2-e379-4f96-8f01-de6440b4dbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_OperatingIncomeLoss_ab6461e2-e379-4f96-8f01-de6440b4dbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6e26a712-440d-455e-895a-799a96449851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6e26a712-440d-455e-895a-799a96449851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9ba2b909-73ac-4efc-98e1-997ee4b8e1cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9ba2b909-73ac-4efc-98e1-997ee4b8e1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_76c341a9-4ad0-468d-84f6-d4a66636afb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_76c341a9-4ad0-468d-84f6-d4a66636afb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0824b5fc-97de-4b48-905c-96d4d27a4183" xlink:href="biib-20210930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0824b5fc-97de-4b48-905c-96d4d27a4183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ddf3588b-8e3e-4ea9-a68d-ea9025e12f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_ProfitLoss_ddf3588b-8e3e-4ea9-a68d-ea9025e12f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_29ca1acb-5b83-41f7-a096-a5c51ec589da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_29ca1acb-5b83-41f7-a096-a5c51ec589da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1705ddc0-ecfe-49ea-9338-773cf8bc3c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_NetIncomeLoss_1705ddc0-ecfe-49ea-9338-773cf8bc3c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a0eb6453-79d8-45ac-965b-4b176e7e21a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a0eb6453-79d8-45ac-965b-4b176e7e21a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3afb8691-c412-44f3-95be-1171b6fdc733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0eb6453-79d8-45ac-965b-4b176e7e21a8" xlink:to="loc_us-gaap_EarningsPerShareBasic_3afb8691-c412-44f3-95be-1171b6fdc733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ef0f0a15-cbde-48f5-865f-c0a754bd82c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0eb6453-79d8-45ac-965b-4b176e7e21a8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ef0f0a15-cbde-48f5-865f-c0a754bd82c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bd69e9c6-0e51-43b8-942a-561a32d2c4eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e0d46c-c9b1-46a4-b81b-a810ca972094" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bd69e9c6-0e51-43b8-942a-561a32d2c4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e736bac-070a-486f-94ed-2e9ae2ffe910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bd69e9c6-0e51-43b8-942a-561a32d2c4eb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e736bac-070a-486f-94ed-2e9ae2ffe910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5cd36e96-4a6a-4dd8-93a9-b7a6c190f0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bd69e9c6-0e51-43b8-942a-561a32d2c4eb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5cd36e96-4a6a-4dd8-93a9-b7a6c190f0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75e84420-a51b-498a-b2fd-9673ea24d1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8feb459a-862e-4cfd-ac6c-2610e6588372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75e84420-a51b-498a-b2fd-9673ea24d1e5" xlink:to="loc_us-gaap_NetIncomeLoss_8feb459a-862e-4cfd-ac6c-2610e6588372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_75e84420-a51b-498a-b2fd-9673ea24d1e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f2a60faa-f7d8-461f-a6a6-57b475de3d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f2a60faa-f7d8-461f-a6a6-57b475de3d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_60a6681e-67ef-45ac-b045-e7585b022b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_60a6681e-67ef-45ac-b045-e7585b022b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_84174249-c750-430a-bf98-d265d1aa7ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_84174249-c750-430a-bf98-d265d1aa7ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1fb05acb-0cd5-4294-ae07-2d7436757849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1fb05acb-0cd5-4294-ae07-2d7436757849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a9145176-f3cf-4358-813b-9b01b1298fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a9145176-f3cf-4358-813b-9b01b1298fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_323c0b2a-236c-44d7-b1e2-4cd6af99678f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_323c0b2a-236c-44d7-b1e2-4cd6af99678f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e6e53f83-d422-4193-ad6c-ba48eea153bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e6e53f83-d422-4193-ad6c-ba48eea153bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7b8cf278-ac96-4a28-82aa-81dbe7a0182a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7b8cf278-ac96-4a28-82aa-81dbe7a0182a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_42196891-dd17-445e-8b67-2f49655da1a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c23c209d-1756-44ab-8489-57383017625d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_42196891-dd17-445e-8b67-2f49655da1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49cb5777-5857-4f31-bc00-52218ead56ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49cb5777-5857-4f31-bc00-52218ead56ad" xlink:to="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d3d60fc-0a6a-40ee-a805-bc7152cc0757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d3d60fc-0a6a-40ee-a805-bc7152cc0757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b59e2de3-264f-482e-8ef3-cd3c02625224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b59e2de3-264f-482e-8ef3-cd3c02625224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c99dd6d7-6d25-4ddb-a183-755d1be8aa2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c99dd6d7-6d25-4ddb-a183-755d1be8aa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_4af5ec2a-bd71-4cb4-b1dc-ab5186e7eb11" xlink:href="biib-20210930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_4af5ec2a-bd71-4cb4-b1dc-ab5186e7eb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_01366d5a-f661-4dfd-8e3e-baa267b20587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:to="loc_us-gaap_InventoryNet_01366d5a-f661-4dfd-8e3e-baa267b20587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_afd2a485-816e-42b3-9acb-8cffbaca0c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:to="loc_us-gaap_OtherAssetsCurrent_afd2a485-816e-42b3-9acb-8cffbaca0c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dd7ec89a-2ec4-49b5-bf61-e86f21a82636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5707ce52-52d9-482d-9625-54755f0b3c23" xlink:to="loc_us-gaap_AssetsCurrent_dd7ec89a-2ec4-49b5-bf61-e86f21a82636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c084c9e4-80ce-43a8-857a-551238605b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c084c9e4-80ce-43a8-857a-551238605b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b1eb2eef-da95-4257-a9f7-178b71416b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b1eb2eef-da95-4257-a9f7-178b71416b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_56fdd7a5-3f48-4dd7-9c3c-721c1b99014c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_56fdd7a5-3f48-4dd7-9c3c-721c1b99014c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcac7df8-31b8-4231-b16a-f061328ea2a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcac7df8-31b8-4231-b16a-f061328ea2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_49d545f0-2bd1-49ac-82d0-512d20a7aa7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_Goodwill_49d545f0-2bd1-49ac-82d0-512d20a7aa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_fcff0b76-0294-44e3-8600-d8e39417df93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_fcff0b76-0294-44e3-8600-d8e39417df93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9288d15a-40be-4e41-ad81-a9c1131eae46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9288d15a-40be-4e41-ad81-a9c1131eae46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0fd8e1b3-d033-4e7d-9b61-10b15f895865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4bc9a49-cc3c-493a-a310-0c6ea1bea790" xlink:to="loc_us-gaap_Assets_0fd8e1b3-d033-4e7d-9b61-10b15f895865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49cb5777-5857-4f31-bc00-52218ead56ad" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f59aca43-6d93-4da3-a42e-e784644d826f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f59aca43-6d93-4da3-a42e-e784644d826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_99fc3e4d-8a73-4356-845e-db7281ea3229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f59aca43-6d93-4da3-a42e-e784644d826f" xlink:to="loc_us-gaap_NotesPayableCurrent_99fc3e4d-8a73-4356-845e-db7281ea3229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_47cd2b93-141d-46c0-9e6c-d0e039bc7725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f59aca43-6d93-4da3-a42e-e784644d826f" xlink:to="loc_us-gaap_TaxesPayableCurrent_47cd2b93-141d-46c0-9e6c-d0e039bc7725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ecc97ee4-06bc-42f3-ae23-e769110d66f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f59aca43-6d93-4da3-a42e-e784644d826f" xlink:to="loc_us-gaap_AccountsPayableCurrent_ecc97ee4-06bc-42f3-ae23-e769110d66f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_624bf3d4-d8ba-44b8-9f19-318d21936064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f59aca43-6d93-4da3-a42e-e784644d826f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_624bf3d4-d8ba-44b8-9f19-318d21936064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9c3c0476-c5b0-4c25-b967-3fe04f302669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f59aca43-6d93-4da3-a42e-e784644d826f" xlink:to="loc_us-gaap_LiabilitiesCurrent_9c3c0476-c5b0-4c25-b967-3fe04f302669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_064fb544-1136-4f4e-a4f7-d8d551f71ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_LongTermDebt_064fb544-1136-4f4e-a4f7-d8d551f71ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c1695c9b-0186-428b-b97e-64a183791945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c1695c9b-0186-428b-b97e-64a183791945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e1f1886a-d22b-426d-88d3-36b386eabd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e1f1886a-d22b-426d-88d3-36b386eabd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ebd38db4-ffa3-4964-a16d-47b9ebc10013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ebd38db4-ffa3-4964-a16d-47b9ebc10013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fcd18a65-cca0-4f58-8c78-c0af4391c56a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_Liabilities_fcd18a65-cca0-4f58-8c78-c0af4391c56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9b1e8596-183a-4124-8d68-ef50e4dbd485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9b1e8596-183a-4124-8d68-ef50e4dbd485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ef5ef82-08a2-4df5-b784-b990beffde20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ef5ef82-08a2-4df5-b784-b990beffde20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ef5ef82-08a2-4df5-b784-b990beffde20" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5c392282-1556-43db-9623-bd2caca21378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:to="loc_us-gaap_PreferredStockValue_5c392282-1556-43db-9623-bd2caca21378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_69f1aec8-b3b0-4068-b521-8cd917285e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:to="loc_us-gaap_CommonStockValue_69f1aec8-b3b0-4068-b521-8cd917285e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_28ae50d8-cb45-4f00-81c6-b94d8407e58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:to="loc_us-gaap_AdditionalPaidInCapital_28ae50d8-cb45-4f00-81c6-b94d8407e58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_811ff500-1fd0-4ce3-89c9-d905e2dad305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_811ff500-1fd0-4ce3-89c9-d905e2dad305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffe16b02-92b3-47b7-9f03-655d0c53afc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffe16b02-92b3-47b7-9f03-655d0c53afc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_12b11df7-aa64-4a4a-b083-f5f481538345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:to="loc_us-gaap_TreasuryStockValue_12b11df7-aa64-4a4a-b083-f5f481538345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c2ae1954-40f5-4537-856c-76edf94251a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4b5b9854-3e4f-45be-9a0e-ef8548a1d445" xlink:to="loc_us-gaap_StockholdersEquity_c2ae1954-40f5-4537-856c-76edf94251a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8952c892-85f1-448c-8475-947de27f5390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ef5ef82-08a2-4df5-b784-b990beffde20" xlink:to="loc_us-gaap_MinorityInterest_8952c892-85f1-448c-8475-947de27f5390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c568ad4f-3f1e-4b00-b443-abb99aacb787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7ef5ef82-08a2-4df5-b784-b990beffde20" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c568ad4f-3f1e-4b00-b443-abb99aacb787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5d3cd04d-c429-4fa4-af27-c91423b85215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34ace9ed-2b53-4cf2-9409-66598efef898" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5d3cd04d-c429-4fa4-af27-c91423b85215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_80e6449b-8917-484d-8861-f5ce6ac159ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b19bf189-ea74-4cfb-abc1-d1e9bc42228b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80e6449b-8917-484d-8861-f5ce6ac159ba" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b19bf189-ea74-4cfb-abc1-d1e9bc42228b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f96feb0d-be07-447d-b88f-6fb5bb5aeb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80e6449b-8917-484d-8861-f5ce6ac159ba" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f96feb0d-be07-447d-b88f-6fb5bb5aeb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7fd4a983-f19d-4368-a5e9-88ee5c8dfeda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bcd8b76-bb5d-4fb0-a366-02184cc4e710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7fd4a983-f19d-4368-a5e9-88ee5c8dfeda" xlink:to="loc_us-gaap_StatementTable_2bcd8b76-bb5d-4fb0-a366-02184cc4e710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bcd8b76-bb5d-4fb0-a366-02184cc4e710" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_10c29972-e80a-4150-abf7-6315e5c62fb1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_86f0bcba-a6d1-4bf8-a2c9-86031e5b40fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_10c29972-e80a-4150-abf7-6315e5c62fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_7b90472a-91e3-4040-9207-78a29e4cfc38" xlink:href="biib-20210930.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_10c29972-e80a-4150-abf7-6315e5c62fb1" xlink:to="loc_biib_SangamoCommonStockMember_7b90472a-91e3-4040-9207-78a29e4cfc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_cd085d1e-bee9-425a-9463-af1a9cef444e" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_10c29972-e80a-4150-abf7-6315e5c62fb1" xlink:to="loc_biib_DenaliTherapeuticsIncMember_cd085d1e-bee9-425a-9463-af1a9cef444e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bcd8b76-bb5d-4fb0-a366-02184cc4e710" xlink:to="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5529ad0f-ec78-4d5d-8a86-82929fcefefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5529ad0f-ec78-4d5d-8a86-82929fcefefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69fd0c81-67da-4119-9b41-444b5b4e10f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5529ad0f-ec78-4d5d-8a86-82929fcefefa" xlink:to="loc_us-gaap_ProfitLoss_69fd0c81-67da-4119-9b41-444b5b4e10f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5529ad0f-ec78-4d5d-8a86-82929fcefefa" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1a79f2e5-0fd3-4772-844e-4d4b79179b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1a79f2e5-0fd3-4772-844e-4d4b79179b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_aa229c4f-76f2-4e54-8b2c-0201001433ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_aa229c4f-76f2-4e54-8b2c-0201001433ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a41f31f5-38b8-4448-a730-eb4a9c1fe0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a41f31f5-38b8-4448-a730-eb4a9c1fe0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d3b3a0b9-58be-4739-afde-b79e8d4b2d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_ShareBasedCompensation_d3b3a0b9-58be-4739-afde-b79e8d4b2d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5844a7bb-50b0-4fba-96fa-2c95ae0d13d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5844a7bb-50b0-4fba-96fa-2c95ae0d13d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be8f41f9-fa7e-432d-a201-26eedbd26234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be8f41f9-fa7e-432d-a201-26eedbd26234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_443d9551-f8d2-4e05-8837-587d160fd17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_443d9551-f8d2-4e05-8837-587d160fd17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5b7cdc50-cf1e-4e27-84a9-1fd25c013607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5b7cdc50-cf1e-4e27-84a9-1fd25c013607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9f657f25-1d9c-468b-88e2-72b57c7e85f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9f657f25-1d9c-468b-88e2-72b57c7e85f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09c18018-f044-4fd2-a370-47cc5677675b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09c18018-f044-4fd2-a370-47cc5677675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_33b36566-1fcc-40b1-888a-4654d2ba36ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_33b36566-1fcc-40b1-888a-4654d2ba36ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e135381e-d7a1-4e81-b189-69200da55bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e135381e-d7a1-4e81-b189-69200da55bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b9d6a18b-81e7-48d6-8f6c-51d2ec50a9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b9d6a18b-81e7-48d6-8f6c-51d2ec50a9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46850ec8-247e-4573-a178-0f24f448a1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46850ec8-247e-4573-a178-0f24f448a1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2462f0e6-0704-4c4b-ac46-02dbbe4ff051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d5fc2558-a536-405e-b705-7508d83d1952" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2462f0e6-0704-4c4b-ac46-02dbbe4ff051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b8c3176-0278-4438-91a4-4bd619104aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c41217db-c142-49ed-8ef7-16b74638836a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b8c3176-0278-4438-91a4-4bd619104aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_193b3e85-3635-4bda-9e37-7e741b7a4152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_193b3e85-3635-4bda-9e37-7e741b7a4152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a22a0918-ed6c-4b4d-96f2-6d0f0422ffe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a22a0918-ed6c-4b4d-96f2-6d0f0422ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4720e649-f7a8-4187-95bd-c72832e2b811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4720e649-f7a8-4187-95bd-c72832e2b811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dd3341a5-2b8e-4d05-87a2-dac15db58e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dd3341a5-2b8e-4d05-87a2-dac15db58e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_86181a40-79b8-4075-bd0e-8c8a42da1ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_86181a40-79b8-4075-bd0e-8c8a42da1ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_5f55c93f-672d-414b-8292-ba1e9e4713f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_5f55c93f-672d-414b-8292-ba1e9e4713f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_305b4b05-83c1-4cb0-b2d8-e20e1dcbd7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_305b4b05-83c1-4cb0-b2d8-e20e1dcbd7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e7564e62-f5f9-4987-b32e-a803752612c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e7564e62-f5f9-4987-b32e-a803752612c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_34d779c1-69fc-4132-8c92-20eb8570414a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_34d779c1-69fc-4132-8c92-20eb8570414a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e6c6bc8-6d86-4189-9b60-abf9a1118d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_add86307-9a1f-4093-bd87-c55b1233e3c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e6c6bc8-6d86-4189-9b60-abf9a1118d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fa0ae695-3989-41d7-8dbe-9ded4fd1c397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fa0ae695-3989-41d7-8dbe-9ded4fd1c397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b9105a5c-3799-4d2a-be1e-17bd5454d9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b9105a5c-3799-4d2a-be1e-17bd5454d9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_8fc9678e-7d62-4e20-aba0-026b5eba4ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_RepaymentsOfDebt_8fc9678e-7d62-4e20-aba0-026b5eba4ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_93097f6b-f87c-431f-8aee-b27b556f377c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_93097f6b-f87c-431f-8aee-b27b556f377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5f5c22a5-29d2-4ed7-aaad-1f5862120f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5f5c22a5-29d2-4ed7-aaad-1f5862120f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_a368b9fe-1da4-4468-bae7-705aa03d5df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_a368b9fe-1da4-4468-bae7-705aa03d5df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_814b2d38-0ae5-49d4-8972-6d1fcad81a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_814b2d38-0ae5-49d4-8972-6d1fcad81a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5909aafa-6068-4025-80c4-0a0534ebb853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5909aafa-6068-4025-80c4-0a0534ebb853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8856982-458d-4827-ae78-da2ba5788cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c77bd70f-a4a0-4a47-bd4e-dbb9abc6aeb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8856982-458d-4827-ae78-da2ba5788cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_55ecae40-50d2-40e7-8cdc-79dccc8219f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_55ecae40-50d2-40e7-8cdc-79dccc8219f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_c49ac258-1e19-46b5-9ac8-f2e8f4115d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_c49ac258-1e19-46b5-9ac8-f2e8f4115d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b890a846-7d0b-4477-97c4-4aca1fe2bf66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b890a846-7d0b-4477-97c4-4aca1fe2bf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e039949-7314-4a58-baa1-8ee8fe7d61d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b5ed1cb-3665-4448-a3e1-a8323bc6f1c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e039949-7314-4a58-baa1-8ee8fe7d61d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20210930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0b42062c-295b-4168-8d87-01bf1e0be2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0b42062c-295b-4168-8d87-01bf1e0be2be" xlink:to="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_e95df5e7-8f5e-4f24-8edd-e0e53c3b663d" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_04c1b75f-78b6-4238-944b-2b8bd3641736" xlink:href="biib-20210930.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_04c1b75f-78b6-4238-944b-2b8bd3641736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_b68356c7-028e-4261-896f-86e44e10b853" xlink:href="biib-20210930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_b68356c7-028e-4261-896f-86e44e10b853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_edb34fd3-bfd5-4fce-9423-7635f86bebd7" xlink:href="biib-20210930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_92ce51d2-8388-4575-9397-44bef7f34e40" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_edb34fd3-bfd5-4fce-9423-7635f86bebd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a2c2c79-383b-4dd1-9da3-9d94448e8673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a2c2c79-383b-4dd1-9da3-9d94448e8673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a2c2c79-383b-4dd1-9da3-9d94448e8673" xlink:to="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_182ff80f-4fb3-4732-a364-cafa680a96d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_PreferredStockMember_182ff80f-4fb3-4732-a364-cafa680a96d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d870bfca-9306-4c4d-b0b2-905f33311914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_CommonStockMember_d870bfca-9306-4c4d-b0b2-905f33311914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1ac9772a-89e9-4797-b6c8-3551481d08a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1ac9772a-89e9-4797-b6c8-3551481d08a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_436158a4-cd9b-442e-9321-5667dae9ae1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_436158a4-cd9b-442e-9321-5667dae9ae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_821ed60e-60c1-4837-9337-c49206227a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_RetainedEarningsMember_821ed60e-60c1-4837-9337-c49206227a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_a43c701a-243b-41df-96f8-e069abc5ed62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_TreasuryStockMember_a43c701a-243b-41df-96f8-e069abc5ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_2c6265e6-45d8-47e6-8dd4-7912efb66eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_ParentMember_2c6265e6-45d8-47e6-8dd4-7912efb66eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3eb43f15-db1b-4d7c-bb11-052d49438597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8693dc6-2f95-4cbf-9adc-91d5e536ab71" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3eb43f15-db1b-4d7c-bb11-052d49438597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca017f31-327d-4e26-abc4-86a588cb0396" xlink:to="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c6c4802a-7e88-4966-848a-b9ea70014b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c6c4802a-7e88-4966-848a-b9ea70014b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b59b20cc-4a47-40ad-9eb2-3fc4c9758e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b59b20cc-4a47-40ad-9eb2-3fc4c9758e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c0fa152f-4ec5-4c70-b974-a1cb131d3b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_ProfitLoss_c0fa152f-4ec5-4c70-b974-a1cb131d3b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0bc27a43-146d-4341-ba3d-29abcd1f957c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0bc27a43-146d-4341-ba3d-29abcd1f957c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_44263271-8950-4ccd-afe9-a1db6139607a" xlink:href="biib-20210930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_44263271-8950-4ccd-afe9-a1db6139607a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_27cbc344-c9e3-495e-8077-bdd562ef3493" xlink:href="biib-20210930.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_27cbc344-c9e3-495e-8077-bdd562ef3493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7c95b661-5a11-4e06-a37c-4e2ffd18db08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7c95b661-5a11-4e06-a37c-4e2ffd18db08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0aa7898b-8ff1-473a-ae78-99c7ad369ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0aa7898b-8ff1-473a-ae78-99c7ad369ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_55259939-e02b-4e92-8685-3952d20a7c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_55259939-e02b-4e92-8685-3952d20a7c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_6c371015-0afa-42cd-95aa-3666ad3d688b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_6c371015-0afa-42cd-95aa-3666ad3d688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c0103ece-f708-4b7c-91f1-01de8ead5fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c0103ece-f708-4b7c-91f1-01de8ead5fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_062cb23d-d042-457a-ac88-8a638c02b97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_062cb23d-d042-457a-ac88-8a638c02b97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8afa6124-b77a-478f-97b9-f86c0726960a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8afa6124-b77a-478f-97b9-f86c0726960a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3addf5a5-9d5e-47a7-b1cf-6633f3af97cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3addf5a5-9d5e-47a7-b1cf-6633f3af97cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_075d4336-116c-4e8d-9575-e0c336e0cbbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_075d4336-116c-4e8d-9575-e0c336e0cbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_ae3599ca-b5c3-4311-b1d7-019c77dc18c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockholdersEquityOther_ae3599ca-b5c3-4311-b1d7-019c77dc18c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ced9aae4-e353-45e9-8af5-205b252918ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ced9aae4-e353-45e9-8af5-205b252918ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_95d25430-e6dd-401c-9d13-1b36158761a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23801aca-06af-4644-959a-b77b1b660fbe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_95d25430-e6dd-401c-9d13-1b36158761a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7418ded5-f6b4-4ba0-a6e9-7dce68a58336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_502d274e-8ca1-47bf-b043-941b98a5678b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7418ded5-f6b4-4ba0-a6e9-7dce68a58336" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_502d274e-8ca1-47bf-b043-941b98a5678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20210930.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_031c5291-605e-42b4-888c-4432e9956376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_ff1e5252-7301-495c-8481-d75c99613286" xlink:href="biib-20210930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_031c5291-605e-42b4-888c-4432e9956376" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_ff1e5252-7301-495c-8481-d75c99613286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_65a8f328-cdd3-4995-80cb-25a5d9e3b7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_031c5291-605e-42b4-888c-4432e9956376" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_65a8f328-cdd3-4995-80cb-25a5d9e3b7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0230c643-fb23-4f4d-8c70-5d49eb99f54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_031c5291-605e-42b4-888c-4432e9956376" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0230c643-fb23-4f4d-8c70-5d49eb99f54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_eb501db6-8e57-476a-a673-7f1a365976de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_031c5291-605e-42b4-888c-4432e9956376" xlink:to="loc_us-gaap_UseOfEstimates_eb501db6-8e57-476a-a673-7f1a365976de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_28e36702-18d8-48e8-9020-234d6fd175a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_031c5291-605e-42b4-888c-4432e9956376" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_28e36702-18d8-48e8-9020-234d6fd175a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_713f53f5-6f9b-4914-92e7-08ead7e2fb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_f7b27d58-7d22-445c-ab8b-2ec93433129e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_713f53f5-6f9b-4914-92e7-08ead7e2fb2d" xlink:to="loc_us-gaap_NumberOfReportableSegments_f7b27d58-7d22-445c-ab8b-2ec93433129e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_0cff2eca-7448-40f2-b1b2-da95a5fad386" xlink:href="biib-20210930.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_713f53f5-6f9b-4914-92e7-08ead7e2fb2d" xlink:to="loc_biib_InterestInSubsidiary_0cff2eca-7448-40f2-b1b2-da95a5fad386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20210930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_54677e0a-6a65-442c-b913-39bb434c8862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_960d1921-73e4-44cd-b4d9-e5db33ea0210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_54677e0a-6a65-442c-b913-39bb434c8862" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_960d1921-73e4-44cd-b4d9-e5db33ea0210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract_b4d8042a-e5d5-4680-ae26-2f1db68a139a" xlink:href="biib-20210930.xsd#biib_AcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98c5a634-256c-412a-bb07-710d1c88cd03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_b4d8042a-e5d5-4680-ae26-2f1db68a139a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98c5a634-256c-412a-bb07-710d1c88cd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a66d52c6-3131-4c8d-bfcf-d63159249cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98c5a634-256c-412a-bb07-710d1c88cd03" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a66d52c6-3131-4c8d-bfcf-d63159249cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53c7dcd3-bb52-4ab0-a23e-2569c755c1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a66d52c6-3131-4c8d-bfcf-d63159249cf1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53c7dcd3-bb52-4ab0-a23e-2569c755c1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_a828936d-9ac5-4641-b978-cb893dbee19d" xlink:href="biib-20210930.xsd#biib_BIIB118Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53c7dcd3-bb52-4ab0-a23e-2569c755c1df" xlink:to="loc_biib_BIIB118Member_a828936d-9ac5-4641-b978-cb893dbee19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_890d4f31-e718-4eff-b683-3842a55424e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98c5a634-256c-412a-bb07-710d1c88cd03" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_890d4f31-e718-4eff-b683-3842a55424e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7b38c598-fc42-4e1b-8103-1c9a155be7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_890d4f31-e718-4eff-b683-3842a55424e8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7b38c598-fc42-4e1b-8103-1c9a155be7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_8cc71cd9-c06a-4a8c-9d4d-549a921eb26d" xlink:href="biib-20210930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_890d4f31-e718-4eff-b683-3842a55424e8" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_8cc71cd9-c06a-4a8c-9d4d-549a921eb26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20210930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bbe0659d-4aa4-4a4a-8df8-8366d6c2ac8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_e34ba7a2-bce8-48f9-81bb-431aede17d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bbe0659d-4aa4-4a4a-8df8-8366d6c2ac8b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_e34ba7a2-bce8-48f9-81bb-431aede17d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2dc3d143-f918-4c5f-ba54-44828893f4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0e148c08-6be2-49d6-ba55-32b63e96b1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2dc3d143-f918-4c5f-ba54-44828893f4f9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0e148c08-6be2-49d6-ba55-32b63e96b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_8932d30f-7435-485e-bb06-5b67f8ddd0a3" xlink:href="biib-20210930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2dc3d143-f918-4c5f-ba54-44828893f4f9" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_8932d30f-7435-485e-bb06-5b67f8ddd0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_9446844e-4202-4af6-8eb6-f0c8e4c4a0ba" xlink:href="biib-20210930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2dc3d143-f918-4c5f-ba54-44828893f4f9" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_9446844e-4202-4af6-8eb6-f0c8e4c4a0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_19591e8e-26bf-4551-bf01-aa2559fa7da7" xlink:href="biib-20210930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2dc3d143-f918-4c5f-ba54-44828893f4f9" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_19591e8e-26bf-4551-bf01-aa2559fa7da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_7a1a346c-238a-47fc-80ea-372d612c4c0f" xlink:href="biib-20210930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2dc3d143-f918-4c5f-ba54-44828893f4f9" xlink:to="loc_biib_OtherrevenuesTableTextBlock_7a1a346c-238a-47fc-80ea-372d612c4c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_b6653644-f50e-4d86-9a58-b64c3d1ef29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_b6653644-f50e-4d86-9a58-b64c3d1ef29c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_213a5392-e8cd-4b65-982e-32007e129d9d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:to="loc_srt_ProductOrServiceAxis_213a5392-e8cd-4b65-982e-32007e129d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_213a5392-e8cd-4b65-982e-32007e129d9d" xlink:to="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_d3b6f180-9b71-4b7d-9298-b48065b68220" xlink:href="biib-20210930.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_FumarateMember_d3b6f180-9b71-4b7d-9298-b48065b68220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_440a8454-c074-4adf-808e-f107c9cf1505" xlink:href="biib-20210930.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_InterferonMember_440a8454-c074-4adf-808e-f107c9cf1505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_dc9263f5-0e3d-4bff-a7b4-98c9ea30f837" xlink:href="biib-20210930.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_TysabriProductMember_dc9263f5-0e3d-4bff-a7b4-98c9ea30f837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_73f7bd0c-aadc-4fdf-aa47-1184101c70c4" xlink:href="biib-20210930.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_FAMPYRAMember_73f7bd0c-aadc-4fdf-aa47-1184101c70c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_aa275100-879b-4e0e-8616-96ee0c533dee" xlink:href="biib-20210930.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_ZINBRYTAMember_aa275100-879b-4e0e-8616-96ee0c533dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_77cd084a-15c0-4d3b-ab14-652960b9b2ef" xlink:href="biib-20210930.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_MSProductRevenuesMember_77cd084a-15c0-4d3b-ab14-652960b9b2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_f1514c18-91b6-4d0d-a618-c007b7b31091" xlink:href="biib-20210930.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_SPINRAZAMember_f1514c18-91b6-4d0d-a618-c007b7b31091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_eabd7418-acdc-450d-a0f4-1a24a60c30de" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_ADUHELMMember_eabd7418-acdc-450d-a0f4-1a24a60c30de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_cbe00ffd-9cfb-4840-8d89-efad9474b773" xlink:href="biib-20210930.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_BENEPALIMember_cbe00ffd-9cfb-4840-8d89-efad9474b773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_ecdf1ca5-5223-4147-bf5a-9fefc298ee9c" xlink:href="biib-20210930.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_IMRALDIMember_ecdf1ca5-5223-4147-bf5a-9fefc298ee9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_be5ade32-a972-4326-8112-e7f471bc5a57" xlink:href="biib-20210930.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_FLIXABIMember_be5ade32-a972-4326-8112-e7f471bc5a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_e6f842c8-4e1a-4bcb-95fe-c2db9130e7a6" xlink:href="biib-20210930.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_BiosimilarsMember_e6f842c8-4e1a-4bcb-95fe-c2db9130e7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_af18cfa4-d702-49a0-a43e-59db2766d385" xlink:href="biib-20210930.xsd#biib_FUMADERMMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_biib_FUMADERMMember_af18cfa4-d702-49a0-a43e-59db2766d385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_89cfd44d-e1f7-41f8-96aa-a4d3bf677a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d005745d-5ce7-43ce-b5f7-a67787d94082" xlink:to="loc_us-gaap_ProductMember_89cfd44d-e1f7-41f8-96aa-a4d3bf677a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f19259b4-0b96-48df-8af6-a179f287c0bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:to="loc_srt_StatementGeographicalAxis_f19259b4-0b96-48df-8af6-a179f287c0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4914aeb9-b44d-4fc5-9a4e-9adc0e06ec7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f19259b4-0b96-48df-8af6-a179f287c0bf" xlink:to="loc_srt_SegmentGeographicalDomain_4914aeb9-b44d-4fc5-9a4e-9adc0e06ec7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_827cb269-fdcc-4ce5-92bc-97ee8e1a081f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4914aeb9-b44d-4fc5-9a4e-9adc0e06ec7b" xlink:to="loc_country_US_827cb269-fdcc-4ce5-92bc-97ee8e1a081f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_aaea63de-0c97-4583-b71a-cf824ead3db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4914aeb9-b44d-4fc5-9a4e-9adc0e06ec7b" xlink:to="loc_us-gaap_NonUsMember_aaea63de-0c97-4583-b71a-cf824ead3db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6de7b24d-8319-4c05-a101-227fa760384d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_824b7bdb-7b81-4ecc-8e77-48bbd5ac5f08" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6de7b24d-8319-4c05-a101-227fa760384d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6ca893d0-d401-4c98-88ae-09da2c6b1012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6de7b24d-8319-4c05-a101-227fa760384d" xlink:to="loc_us-gaap_Revenues_6ca893d0-d401-4c98-88ae-09da2c6b1012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_d03f3928-e0c7-4aaf-be9c-327833b06851" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a16022cf-93dc-45d7-856c-e50b23212080" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_d03f3928-e0c7-4aaf-be9c-327833b06851" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a16022cf-93dc-45d7-856c-e50b23212080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3238ed5a-771b-45a0-be18-959315f16c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a16022cf-93dc-45d7-856c-e50b23212080" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3238ed5a-771b-45a0-be18-959315f16c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3238ed5a-771b-45a0-be18-959315f16c1b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_4e604ba5-9b8e-48aa-836f-5da671d95bdf" xlink:href="biib-20210930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:to="loc_biib_ReserveforCashDiscountsMember_4e604ba5-9b8e-48aa-836f-5da671d95bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_0ae76845-bac0-4936-b3f4-79bf992ec91c" xlink:href="biib-20210930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:to="loc_biib_ContractualAdjustmentsMember_0ae76845-bac0-4936-b3f4-79bf992ec91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_6bd7d95f-4b95-45f8-80b2-31bd63302c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b9067670-ec40-424a-8526-6d4925e9d376" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_6bd7d95f-4b95-45f8-80b2-31bd63302c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a16022cf-93dc-45d7-856c-e50b23212080" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_20ee28e2-4f23-439a-b176-3d439ff6dfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_20ee28e2-4f23-439a-b176-3d439ff6dfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_88174bd1-e198-4a74-a23b-a7d98b67f0c5" xlink:href="biib-20210930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_88174bd1-e198-4a74-a23b-a7d98b67f0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_118a730f-6d38-4aa6-881f-4d98e3e3e2cd" xlink:href="biib-20210930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_118a730f-6d38-4aa6-881f-4d98e3e3e2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c0908b88-2ab9-4bee-8d8b-58ea3a1db312" xlink:href="biib-20210930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_c0908b88-2ab9-4bee-8d8b-58ea3a1db312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_76ba3b3f-0439-4682-b361-c9b076a0d7dc" xlink:href="biib-20210930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_76ba3b3f-0439-4682-b361-c9b076a0d7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_709df4be-cdd6-45b5-a083-ae20a9f849d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6e5c5f76-9a1a-4f7b-9832-f50f03004071" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_709df4be-cdd6-45b5-a083-ae20a9f849d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_908d7d93-d029-44aa-bc75-247ddc0f8e15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e2c34685-280c-48b2-b698-290e170bd3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_908d7d93-d029-44aa-bc75-247ddc0f8e15" xlink:to="loc_us-gaap_StatementTable_e2c34685-280c-48b2-b698-290e170bd3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4d425fa0-53b2-4e2c-8c0d-ead492001712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e2c34685-280c-48b2-b698-290e170bd3a7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4d425fa0-53b2-4e2c-8c0d-ead492001712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e4ba0718-2297-4155-bb95-990f9a5b3ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d425fa0-53b2-4e2c-8c0d-ead492001712" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e4ba0718-2297-4155-bb95-990f9a5b3ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_99e07e1c-f754-49e5-9968-57d0ea9e22c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e4ba0718-2297-4155-bb95-990f9a5b3ae1" xlink:to="loc_us-gaap_AccountsReceivableMember_99e07e1c-f754-49e5-9968-57d0ea9e22c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_72a52d57-4a74-4e35-ace6-774b5b628d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e4ba0718-2297-4155-bb95-990f9a5b3ae1" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_72a52d57-4a74-4e35-ace6-774b5b628d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a30cd749-7796-4521-a983-3bc5820d008f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e2c34685-280c-48b2-b698-290e170bd3a7" xlink:to="loc_us-gaap_StatementLineItems_a30cd749-7796-4521-a983-3bc5820d008f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8147ba68-ffac-4d59-9c16-9066a543d81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a30cd749-7796-4521-a983-3bc5820d008f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8147ba68-ffac-4d59-9c16-9066a543d81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_613bcb11-ba54-409e-9068-e6cc5b79face" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_613bcb11-ba54-409e-9068-e6cc5b79face" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:to="loc_srt_ProductOrServiceAxis_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2058cfcc-0394-470e-b4a1-c2be48c55d1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_616c275f-ba47-4dd4-bc9f-bbd0e3622c3f" xlink:to="loc_srt_ProductsAndServicesDomain_2058cfcc-0394-470e-b4a1-c2be48c55d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_94526fc8-abbd-4363-b7ba-6de93bc77351" xlink:href="biib-20210930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2058cfcc-0394-470e-b4a1-c2be48c55d1f" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_94526fc8-abbd-4363-b7ba-6de93bc77351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f0e36684-b7fb-4738-90a4-6e5598f348d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:to="loc_srt_MajorCustomersAxis_f0e36684-b7fb-4738-90a4-6e5598f348d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c08b3b9b-3d88-4b79-884d-83af22557669" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f0e36684-b7fb-4738-90a4-6e5598f348d8" xlink:to="loc_srt_NameOfMajorCustomerDomain_c08b3b9b-3d88-4b79-884d-83af22557669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_0d23b05d-246c-469d-a2f4-d2d19ec9af3b" xlink:href="biib-20210930.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c08b3b9b-3d88-4b79-884d-83af22557669" xlink:to="loc_biib_RocheGroupGenentechMember_0d23b05d-246c-469d-a2f4-d2d19ec9af3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4c4ef31b-3c55-4b5e-90ca-5d404b5a3ad2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_b200e477-c9c1-43e4-abb0-d31dcb1f5c03" xlink:href="biib-20210930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:to="loc_biib_ShareOfCoPromotionProfits_b200e477-c9c1-43e4-abb0-d31dcb1f5c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_613c47ab-9f02-4db2-9fb0-a75accd7bca4" xlink:href="biib-20210930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_613c47ab-9f02-4db2-9fb0-a75accd7bca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2be16321-86f2-4b6f-9d75-b1b938424c02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9198c533-15dc-4638-aed8-d7d604e7e8b1" xlink:to="loc_us-gaap_Revenues_2be16321-86f2-4b6f-9d75-b1b938424c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_75d47ebd-5004-4ed6-9099-813d1c14a008" xlink:href="biib-20210930.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_75d47ebd-5004-4ed6-9099-813d1c14a008" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d1c92d16-769a-4d9c-98e9-fdc56a9167dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d1c92d16-769a-4d9c-98e9-fdc56a9167dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b42e3ee8-c8d7-46c9-9c28-07692d390a00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1c92d16-769a-4d9c-98e9-fdc56a9167dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b42e3ee8-c8d7-46c9-9c28-07692d390a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e2371778-8d6b-4786-9fca-6da19a9dff8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b42e3ee8-c8d7-46c9-9c28-07692d390a00" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e2371778-8d6b-4786-9fca-6da19a9dff8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3de390f-51ad-47cd-80f7-b5836d09d6a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:to="loc_srt_ProductOrServiceAxis_e3de390f-51ad-47cd-80f7-b5836d09d6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e3de390f-51ad-47cd-80f7-b5836d09d6a4" xlink:to="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c305b1d8-fa24-4261-8c2d-2dd257e37555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:to="loc_us-gaap_RoyaltyMember_c305b1d8-fa24-4261-8c2d-2dd257e37555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_c941bb1d-625e-43aa-ae85-d92974d2171e" xlink:href="biib-20210930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:to="loc_biib_OthercorporaterevenuesMember_c941bb1d-625e-43aa-ae85-d92974d2171e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3d37519f-f394-45db-b6ac-5148bd143b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b4ddb606-afb5-4976-b234-8070e36f97f3" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3d37519f-f394-45db-b6ac-5148bd143b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d7c085cd-f11d-4446-8d78-2d346ee7f543" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:to="loc_srt_MajorCustomersAxis_d7c085cd-f11d-4446-8d78-2d346ee7f543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cc0186bc-38b1-43a8-9f5a-928b98fb8a71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d7c085cd-f11d-4446-8d78-2d346ee7f543" xlink:to="loc_srt_NameOfMajorCustomerDomain_cc0186bc-38b1-43a8-9f5a-928b98fb8a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5aa5cdd5-487e-4d95-b8e2-009a23164a68" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc0186bc-38b1-43a8-9f5a-928b98fb8a71" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5aa5cdd5-487e-4d95-b8e2-009a23164a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_92ac74b9-4d8e-4752-a274-97840c98c618" xlink:href="biib-20210930.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc0186bc-38b1-43a8-9f5a-928b98fb8a71" xlink:to="loc_biib_ZINBRYTAMember_92ac74b9-4d8e-4752-a274-97840c98c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_093f7b82-4ba3-4474-b48f-530bc83de91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6a5a04a-ba6b-4c72-a672-d4d188186a71" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_093f7b82-4ba3-4474-b48f-530bc83de91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_24cdee2a-76e4-40d8-b4e2-f23d44983ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_093f7b82-4ba3-4474-b48f-530bc83de91e" xlink:to="loc_us-gaap_Revenues_24cdee2a-76e4-40d8-b4e2-f23d44983ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d35b5efb-a5e9-4a78-aea2-0b28a0d2d7d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d35b5efb-a5e9-4a78-aea2-0b28a0d2d7d4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3a78b838-96fb-4fc6-8857-f205deb31da1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:to="loc_srt_ProductOrServiceAxis_3a78b838-96fb-4fc6-8857-f205deb31da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8317da98-81c3-4409-9929-e107e819773a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3a78b838-96fb-4fc6-8857-f205deb31da1" xlink:to="loc_srt_ProductsAndServicesDomain_8317da98-81c3-4409-9929-e107e819773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_ad012783-f175-4ccc-a43f-1d5ec8340905" xlink:href="biib-20210930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8317da98-81c3-4409-9929-e107e819773a" xlink:to="loc_biib_OthercorporaterevenuesMember_ad012783-f175-4ccc-a43f-1d5ec8340905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_24ce07a3-fe8b-485f-93c0-af8727ce70ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8317da98-81c3-4409-9929-e107e819773a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_24ce07a3-fe8b-485f-93c0-af8727ce70ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:to="loc_srt_MajorCustomersAxis_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_579a1991-2aaf-432d-92f9-84280d74835d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6f8ae6ae-751a-42e4-bf3e-833c2e5bec58" xlink:to="loc_srt_NameOfMajorCustomerDomain_579a1991-2aaf-432d-92f9-84280d74835d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_248dced1-a66c-49df-9942-d732a8d3f6f4" xlink:href="biib-20210930.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_579a1991-2aaf-432d-92f9-84280d74835d" xlink:to="loc_biib_DistributorOneMember_248dced1-a66c-49df-9942-d732a8d3f6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_cd52bafb-2887-4fd5-8701-4c7c8e228fd8" xlink:href="biib-20210930.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_579a1991-2aaf-432d-92f9-84280d74835d" xlink:to="loc_biib_DistributorTwoMember_cd52bafb-2887-4fd5-8701-4c7c8e228fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1319b94d-f233-4c27-817d-ee8084267149" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_080f0008-3d00-48e4-8269-8b3a10502f69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:to="loc_us-gaap_Revenues_080f0008-3d00-48e4-8269-8b3a10502f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_659bee2a-898a-4307-a5c5-30664749bd24" xlink:href="biib-20210930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_659bee2a-898a-4307-a5c5-30664749bd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_7d830646-ead0-4320-b466-90ae19ceb6f5" xlink:href="biib-20210930.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ffd2c11e-0faf-4b6e-8903-ea4b6525932e" xlink:to="loc_biib_NumberOfWholesalers_7d830646-ead0-4320-b466-90ae19ceb6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20210930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7324e324-dfbd-4bc7-bd1b-74bc9209a4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7b880332-474c-4fa7-a5cc-70c633da414c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7324e324-dfbd-4bc7-bd1b-74bc9209a4dc" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_7b880332-474c-4fa7-a5cc-70c633da414c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20210930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5d92ff6d-bfbc-4923-b726-f36c2fca195f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fbd91873-ea12-4b9c-9af8-f51b59d5fe9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5d92ff6d-bfbc-4923-b726-f36c2fca195f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fbd91873-ea12-4b9c-9af8-f51b59d5fe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f8ad8f2f-c9c5-467d-bfcd-159cac6da04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_363dcff7-dd82-4e1b-b75c-5223d264527e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f8ad8f2f-c9c5-467d-bfcd-159cac6da04b" xlink:to="loc_us-gaap_InventoryNetAbstract_363dcff7-dd82-4e1b-b75c-5223d264527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2972c663-cffb-4581-a1a3-ab87fc4ae2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_363dcff7-dd82-4e1b-b75c-5223d264527e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2972c663-cffb-4581-a1a3-ab87fc4ae2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8929ad7b-6f1c-4d6f-bd5d-189d3d32479f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_363dcff7-dd82-4e1b-b75c-5223d264527e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8929ad7b-6f1c-4d6f-bd5d-189d3d32479f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f166d545-1b85-48b8-9868-175aa127a93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_363dcff7-dd82-4e1b-b75c-5223d264527e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f166d545-1b85-48b8-9868-175aa127a93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_a975f417-c361-44ba-a98c-95fb10df35c8" xlink:href="biib-20210930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_363dcff7-dd82-4e1b-b75c-5223d264527e" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_a975f417-c361-44ba-a98c-95fb10df35c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20210930.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a38aecbb-5bef-4fd1-916f-b36b6b8d088f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_befa067f-9962-43e1-8934-421e4a9744b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a38aecbb-5bef-4fd1-916f-b36b6b8d088f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_befa067f-9962-43e1-8934-421e4a9744b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20210930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_734702c9-0347-4fcc-b8df-ef404b577510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_f3cca853-dd4c-4714-934e-ed4e83cf473e" xlink:href="biib-20210930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_734702c9-0347-4fcc-b8df-ef404b577510" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_f3cca853-dd4c-4714-934e-ed4e83cf473e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_02b98b88-fb08-42da-afa7-e766badd54a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_734702c9-0347-4fcc-b8df-ef404b577510" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_02b98b88-fb08-42da-afa7-e766badd54a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_47b94dbb-12a7-45e3-9098-215fcc423efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_734702c9-0347-4fcc-b8df-ef404b577510" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_47b94dbb-12a7-45e3-9098-215fcc423efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f3e9d-5d3b-4df8-919d-72b2a2d26b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f3e9d-5d3b-4df8-919d-72b2a2d26b1c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_e1a6a96a-62e8-4504-9eda-09216a87c572" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_e1a6a96a-62e8-4504-9eda-09216a87c572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e1a6a96a-62e8-4504-9eda-09216a87c572" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_e57331f7-248e-450a-b848-bfd337227044" xlink:href="biib-20210930.xsd#biib_VixotrigineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_VixotrigineMember_e57331f7-248e-450a-b848-bfd337227044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_ce73abcf-3a3b-44f5-a6b0-96d57d8f22e4" xlink:href="biib-20210930.xsd#biib_TGNMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_TGNMember_ce73abcf-3a3b-44f5-a6b0-96d57d8f22e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_03569b50-aaf7-4cd1-ae23-52c98537a043" xlink:href="biib-20210930.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_BIIB111Member_03569b50-aaf7-4cd1-ae23-52c98537a043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_0a950503-7201-4979-bddb-aaa04e305e51" xlink:href="biib-20210930.xsd#biib_BIIB112Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_BIIB112Member_0a950503-7201-4979-bddb-aaa04e305e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member_75d5d365-163f-406b-a053-4bdf118289a8" xlink:href="biib-20210930.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_316251b4-3c66-4cf8-8a30-1926d974f72b" xlink:to="loc_biib_BIIB111AndBIIB112Member_75d5d365-163f-406b-a053-4bdf118289a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_820b4aa3-a0a0-4dd8-942f-055217c857e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42143d7e-afe5-42b0-9bf8-31a9ea9e32e3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_820b4aa3-a0a0-4dd8-942f-055217c857e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_d107e04a-5ccc-400c-bd13-e2747568882a" xlink:href="biib-20210930.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_820b4aa3-a0a0-4dd8-942f-055217c857e0" xlink:to="loc_biib_NightstarMember_d107e04a-5ccc-400c-bd13-e2747568882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_defbdb3b-df48-414e-bfde-c8523bea2314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_defbdb3b-df48-414e-bfde-c8523bea2314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e1911be-6b90-47b8-b6ed-f6b0acf0e5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_defbdb3b-df48-414e-bfde-c8523bea2314" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e1911be-6b90-47b8-b6ed-f6b0acf0e5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a83454ef-1cd7-4ff7-b25e-785fce4b386a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e1911be-6b90-47b8-b6ed-f6b0acf0e5ef" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a83454ef-1cd7-4ff7-b25e-785fce4b386a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_fd9302ae-de2d-43d0-8a78-5bdb0c04882b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e1911be-6b90-47b8-b6ed-f6b0acf0e5ef" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_fd9302ae-de2d-43d0-8a78-5bdb0c04882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_610f5588-ba27-43ac-b187-8516513ad869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_610f5588-ba27-43ac-b187-8516513ad869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8c61132-7e47-4bb6-979a-f9ffae2adc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_610f5588-ba27-43ac-b187-8516513ad869" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8c61132-7e47-4bb6-979a-f9ffae2adc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_29ac5cd1-6522-4797-bcb6-114b77449aa5" xlink:href="biib-20210930.xsd#biib_OutLicensedPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8c61132-7e47-4bb6-979a-f9ffae2adc52" xlink:to="loc_biib_OutLicensedPatentsMember_29ac5cd1-6522-4797-bcb6-114b77449aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_36325c2f-dc76-4066-9ad5-4a09d3a5fbef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d8c61132-7e47-4bb6-979a-f9ffae2adc52" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_36325c2f-dc76-4066-9ad5-4a09d3a5fbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_52cf0624-6fa0-4476-97de-08705a267c12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_srt_ProductOrServiceAxis_52cf0624-6fa0-4476-97de-08705a267c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96ec1c29-a969-4231-92d6-1992080731bc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_52cf0624-6fa0-4476-97de-08705a267c12" xlink:to="loc_srt_ProductsAndServicesDomain_96ec1c29-a969-4231-92d6-1992080731bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_3a02cf95-984d-4ea4-a683-36290c8e97eb" xlink:href="biib-20210930.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96ec1c29-a969-4231-92d6-1992080731bc" xlink:to="loc_biib_TysabriProductMember_3a02cf95-984d-4ea4-a683-36290c8e97eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_2232f479-0bc8-48ca-b684-020b0bfd3e8a" xlink:href="biib-20210930.xsd#biib_FumarateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96ec1c29-a969-4231-92d6-1992080731bc" xlink:to="loc_biib_FumarateMember_2232f479-0bc8-48ca-b684-020b0bfd3e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87500b65-1ca6-4137-9714-a34a767074e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_srt_RangeAxis_87500b65-1ca6-4137-9714-a34a767074e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_55b00412-c41f-4269-8a60-4fd039f58ed5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_87500b65-1ca6-4137-9714-a34a767074e0" xlink:to="loc_srt_RangeMember_55b00412-c41f-4269-8a60-4fd039f58ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_822ad528-3a6f-4c1e-be5a-7db1a2efab38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_55b00412-c41f-4269-8a60-4fd039f58ed5" xlink:to="loc_srt_MinimumMember_822ad528-3a6f-4c1e-be5a-7db1a2efab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b475b98d-f78e-4ade-af12-c9b34e4b7418" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_55b00412-c41f-4269-8a60-4fd039f58ed5" xlink:to="loc_srt_MaximumMember_b475b98d-f78e-4ade-af12-c9b34e4b7418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ab8da1f1-e856-4152-8b0f-42b03e8c2516" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_srt_StatementScenarioAxis_ab8da1f1-e856-4152-8b0f-42b03e8c2516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_597409aa-34a6-4bbc-bc7e-ebc4e9c9e0ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ab8da1f1-e856-4152-8b0f-42b03e8c2516" xlink:to="loc_srt_ScenarioUnspecifiedDomain_597409aa-34a6-4bbc-bc7e-ebc4e9c9e0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a1ebe1ec-ecae-4588-b35e-86eec8582359" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_597409aa-34a6-4bbc-bc7e-ebc4e9c9e0ae" xlink:to="loc_srt_ScenarioForecastMember_a1ebe1ec-ecae-4588-b35e-86eec8582359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ec920724-4eff-4cda-a033-625c6127afb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d96bfd04-cd15-47ad-888c-66c092b67984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d96bfd04-cd15-47ad-888c-66c092b67984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_7ff28ef1-e0da-42d2-bde6-6d82ff0b7442" xlink:href="biib-20210930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_7ff28ef1-e0da-42d2-bde6-6d82ff0b7442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5253889-debb-4c92-ab9f-d76c9c53e849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5253889-debb-4c92-ab9f-d76c9c53e849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4635aff2-f2bc-493c-b513-b4da34737732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4635aff2-f2bc-493c-b513-b4da34737732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4e8eb007-016b-4647-9fe0-40613209baf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4e8eb007-016b-4647-9fe0-40613209baf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dd9f4fe4-049d-49c6-b0b6-4ec566e9d215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dd9f4fe4-049d-49c6-b0b6-4ec566e9d215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0951ea5e-b9e0-4061-a707-449ce421fa01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0951ea5e-b9e0-4061-a707-449ce421fa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5bf67d61-95d6-4a60-9070-89f5d6e89d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5bf67d61-95d6-4a60-9070-89f5d6e89d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2815f3f3-efab-4c41-b575-709267469e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e911d058-b421-4b43-966b-02499ed7f8f6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2815f3f3-efab-4c41-b575-709267469e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_b9a9fa6c-8815-4ffb-b573-3c928e1d1ed4" xlink:href="biib-20210930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_b9a9fa6c-8815-4ffb-b573-3c928e1d1ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5f6abf6d-ac35-4dba-b4ba-287127f63cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5f6abf6d-ac35-4dba-b4ba-287127f63cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cf233881-afb6-4c34-8c8c-447d5cd01e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cf233881-afb6-4c34-8c8c-447d5cd01e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a783582e-fdb8-46c0-8d94-3d20602e786e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a783582e-fdb8-46c0-8d94-3d20602e786e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b784943a-f104-4966-b28f-c106e0b5c055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b784943a-f104-4966-b28f-c106e0b5c055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c781a0ed-f712-4b58-a117-4dc9bec4cf70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c781a0ed-f712-4b58-a117-4dc9bec4cf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_71438491-6da3-46fd-b8b3-2122707ba187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_71438491-6da3-46fd-b8b3-2122707ba187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0d34c48a-ba6d-4af8-a57e-1f10d46271e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0d34c48a-ba6d-4af8-a57e-1f10d46271e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ManufacturingAndOtherCosts_c03e677d-3d18-4620-8308-cb893b239680" xlink:href="biib-20210930.xsd#biib_ManufacturingAndOtherCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f409e15a-27da-4773-9270-e698a5c2907b" xlink:to="loc_biib_ManufacturingAndOtherCosts_c03e677d-3d18-4620-8308-cb893b239680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c81f322-9f40-4c1f-a237-6af78eb3161b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_10a7b638-00f9-4a01-9f3c-721a50295fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c81f322-9f40-4c1f-a237-6af78eb3161b" xlink:to="loc_us-gaap_GoodwillRollForward_10a7b638-00f9-4a01-9f3c-721a50295fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ca2788cd-a588-494a-9a13-187205644ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_10a7b638-00f9-4a01-9f3c-721a50295fdc" xlink:to="loc_us-gaap_Goodwill_ca2788cd-a588-494a-9a13-187205644ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_c5aa4264-145f-492a-8da5-4bcbc2a6d6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_10a7b638-00f9-4a01-9f3c-721a50295fdc" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_c5aa4264-145f-492a-8da5-4bcbc2a6d6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_91bdb3be-d76d-4db2-b746-5cb7c88b708a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_10a7b638-00f9-4a01-9f3c-721a50295fdc" xlink:to="loc_us-gaap_Goodwill_91bdb3be-d76d-4db2-b746-5cb7c88b708a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_4a61570d-e268-4925-b4b5-3c1586306b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c81f322-9f40-4c1f-a237-6af78eb3161b" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_4a61570d-e268-4925-b4b5-3c1586306b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_fe43a74d-5bb8-4c95-a6d5-c2f7292512bc" xlink:href="biib-20210930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c81f322-9f40-4c1f-a237-6af78eb3161b" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_fe43a74d-5bb8-4c95-a6d5-c2f7292512bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e70da320-dcaa-4420-b797-41189691d748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c81f322-9f40-4c1f-a237-6af78eb3161b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e70da320-dcaa-4420-b797-41189691d748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2e6208ff-b849-451f-92f2-05bca891bead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c81f322-9f40-4c1f-a237-6af78eb3161b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2e6208ff-b849-451f-92f2-05bca891bead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_43c0a54a-4483-4f3f-9eb4-9b14d9b08b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7f5f3af3-7479-4ea5-843e-06b22916cf6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_43c0a54a-4483-4f3f-9eb4-9b14d9b08b30" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7f5f3af3-7479-4ea5-843e-06b22916cf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dfdb12ca-f495-42d0-9b9a-17ce8455450e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7275d92a-1f7d-40c1-b076-214f82d93bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dfdb12ca-f495-42d0-9b9a-17ce8455450e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7275d92a-1f7d-40c1-b076-214f82d93bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e97a1914-9c5c-40c5-b610-be9b2ea3d66a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dfdb12ca-f495-42d0-9b9a-17ce8455450e" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e97a1914-9c5c-40c5-b610-be9b2ea3d66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_601db0da-5885-4dc7-ab6f-483181acf4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dfdb12ca-f495-42d0-9b9a-17ce8455450e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_601db0da-5885-4dc7-ab6f-483181acf4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_869179d3-b60f-48ff-85cb-a82ed0050513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_869179d3-b60f-48ff-85cb-a82ed0050513" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5bb6b56f-aaf7-4c38-99fa-52a6ea0757e0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_afb4446f-0d86-4a43-a6ec-88dc5b5c29e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_afb4446f-0d86-4a43-a6ec-88dc5b5c29e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3922e426-6c4c-435b-bbd3-984c3cb5b539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3922e426-6c4c-435b-bbd3-984c3cb5b539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c9a0a90c-6de1-431a-93cd-9b9309b4d884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69ec1ca5-5f52-4a8c-b88d-a1d272260be4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c9a0a90c-6de1-431a-93cd-9b9309b4d884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d4641cb-743b-445f-a563-401ad4f3745f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d4641cb-743b-445f-a563-401ad4f3745f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0c1a167-339a-40bd-a1ca-7fd6e04654c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3d4641cb-743b-445f-a563-401ad4f3745f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0c1a167-339a-40bd-a1ca-7fd6e04654c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0bb3ca6f-0591-4001-86ee-4b968b51b611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0c1a167-339a-40bd-a1ca-7fd6e04654c2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0bb3ca6f-0591-4001-86ee-4b968b51b611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d32c93b7-1dde-4426-9efd-d5897cdb46a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d32c93b7-1dde-4426-9efd-d5897cdb46a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d32c93b7-1dde-4426-9efd-d5897cdb46a5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_bf2cfe38-5348-4aff-abff-b4a2ef1fc3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_bf2cfe38-5348-4aff-abff-b4a2ef1fc3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_4a706496-6d46-453c-be2b-08408ff45c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_4a706496-6d46-453c-be2b-08408ff45c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_0bbe29d8-7b49-47dc-9df4-6c9b1a29c3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_64e0955d-b573-447e-be37-33beaf576670" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_0bbe29d8-7b49-47dc-9df4-6c9b1a29c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6188215a-f364-4a49-9969-8292e834761f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7beb55b0-3961-48c4-a2c3-4957f16ba309" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6188215a-f364-4a49-9969-8292e834761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a6e6923f-f753-425a-8859-ef818feff533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6188215a-f364-4a49-9969-8292e834761f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a6e6923f-f753-425a-8859-ef818feff533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a6e6923f-f753-425a-8859-ef818feff533" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59de40ea-10a9-4b87-9abe-94847d7da1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59de40ea-10a9-4b87-9abe-94847d7da1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bbc307a-601b-4dce-9959-036912b2d3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bbc307a-601b-4dce-9959-036912b2d3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_809c8379-4457-4780-bdae-f33beb578359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_809c8379-4457-4780-bdae-f33beb578359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_b0e41e10-b85d-4608-aae7-f2ceecdb889d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_b0e41e10-b85d-4608-aae7-f2ceecdb889d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_86396f1b-793d-4c65-94cf-cb1fa3830646" xlink:href="biib-20210930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_86396f1b-793d-4c65-94cf-cb1fa3830646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e4bbb3a5-4cad-4b24-b17a-9b6592ef9e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_475ea30b-bf2a-4e09-978d-c7e0dd2b8f32" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e4bbb3a5-4cad-4b24-b17a-9b6592ef9e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_a6e6923f-f753-425a-8859-ef818feff533" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_c3cc8e1e-727f-4642-b66c-b4d3102489e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_c3cc8e1e-727f-4642-b66c-b4d3102489e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_faedf59b-0011-449d-acc1-9b8854357120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_faedf59b-0011-449d-acc1-9b8854357120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d17b9f1a-0349-4dfe-81c1-87f8de472c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_721af896-bc94-4a8b-a1cf-7f1fe667753c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d17b9f1a-0349-4dfe-81c1-87f8de472c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3d836b18-a41a-4b32-bd48-b6512ad2f6da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0c472cac-4255-4cd4-af93-c963fc75d8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3d836b18-a41a-4b32-bd48-b6512ad2f6da" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0c472cac-4255-4cd4-af93-c963fc75d8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_577e6b60-10cb-4009-b236-3e9ad0a079d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0c472cac-4255-4cd4-af93-c963fc75d8f6" xlink:to="loc_us-gaap_DebtInstrumentAxis_577e6b60-10cb-4009-b236-3e9ad0a079d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_577e6b60-10cb-4009-b236-3e9ad0a079d7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_f6aa7024-6b3f-4f47-a40b-95d665bf0ada" xlink:href="biib-20210930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_f6aa7024-6b3f-4f47-a40b-95d665bf0ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_f0256b50-5e29-45bf-b934-e99c58421b7d" xlink:href="biib-20210930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_f0256b50-5e29-45bf-b934-e99c58421b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ab7539dd-b12f-442f-b43a-5d0a3101a638" xlink:href="biib-20210930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62f343db-9701-40d5-834b-667954ae8144" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ab7539dd-b12f-442f-b43a-5d0a3101a638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0c472cac-4255-4cd4-af93-c963fc75d8f6" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_bcffc2bf-ba89-434c-9760-18686d1f358d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_us-gaap_AssetImpairmentCharges_bcffc2bf-ba89-434c-9760-18686d1f358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25aa66a6-6324-473b-8b18-850b4b01b0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25aa66a6-6324-473b-8b18-850b4b01b0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ea1ffd31-1c35-4fa2-83bf-339c9970935a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ea1ffd31-1c35-4fa2-83bf-339c9970935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_abc3385d-2f72-4faa-9cbf-faf84f6384fe" xlink:href="biib-20210930.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_08f680e9-4fbd-4200-b240-be3da86a8e71" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_abc3385d-2f72-4faa-9cbf-faf84f6384fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bbc60d4b-8114-4702-9567-7812cf1a1d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bbc60d4b-8114-4702-9567-7812cf1a1d55" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_19b00100-d880-4278-9e15-8f1fbb4a98a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:to="loc_srt_RangeAxis_19b00100-d880-4278-9e15-8f1fbb4a98a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c853bb6-7b25-4906-9b57-19a6d2171345" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_19b00100-d880-4278-9e15-8f1fbb4a98a9" xlink:to="loc_srt_RangeMember_0c853bb6-7b25-4906-9b57-19a6d2171345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_14de37f8-d5e3-4037-8a36-33896a1432b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c853bb6-7b25-4906-9b57-19a6d2171345" xlink:to="loc_srt_WeightedAverageMember_14de37f8-d5e3-4037-8a36-33896a1432b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9d9f4870-ef30-4b00-a348-63ef57f8895f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9d9f4870-ef30-4b00-a348-63ef57f8895f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_37879041-d5d1-4922-be94-cb43b3b98e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9d9f4870-ef30-4b00-a348-63ef57f8895f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_37879041-d5d1-4922-be94-cb43b3b98e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3f4e11f8-a06a-491e-8faa-b104b3233eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_37879041-d5d1-4922-be94-cb43b3b98e08" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3f4e11f8-a06a-491e-8faa-b104b3233eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ff35153-c344-4f7c-82fd-e369ea763924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8141fa13-96d7-472e-a748-b8cf3b3811a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ff35153-c344-4f7c-82fd-e369ea763924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b6bc364e-6dc1-4891-926e-77259b5c9460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ff35153-c344-4f7c-82fd-e369ea763924" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b6bc364e-6dc1-4891-926e-77259b5c9460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_54078bc0-82b9-41c7-9295-85584d70c40c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ff35153-c344-4f7c-82fd-e369ea763924" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_54078bc0-82b9-41c7-9295-85584d70c40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsNonrecurringAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_91cb179e-1175-4602-9cd8-c058170b3f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3612f193-b486-4d17-8303-427f47da523f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_91cb179e-1175-4602-9cd8-c058170b3f24" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3612f193-b486-4d17-8303-427f47da523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_bd5e26ff-7291-46a9-acad-a9c748a3b8fa" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3612f193-b486-4d17-8303-427f47da523f" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_bd5e26ff-7291-46a9-acad-a9c748a3b8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_291a47bf-4257-492d-81f8-ba4a6cdddd8f" xlink:href="biib-20210930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_bd5e26ff-7291-46a9-acad-a9c748a3b8fa" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_291a47bf-4257-492d-81f8-ba4a6cdddd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_32a83862-2af8-4acf-9ff1-62a6ac8d8809" xlink:href="biib-20210930.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_291a47bf-4257-492d-81f8-ba4a6cdddd8f" xlink:to="loc_biib_BIIB111Member_32a83862-2af8-4acf-9ff1-62a6ac8d8809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_8bdf663d-20d0-452b-b88d-9b2159da6e9a" xlink:href="biib-20210930.xsd#biib_BIIB112Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_291a47bf-4257-492d-81f8-ba4a6cdddd8f" xlink:to="loc_biib_BIIB112Member_8bdf663d-20d0-452b-b88d-9b2159da6e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0a2a47d5-638f-435b-9829-f9f76e674061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3612f193-b486-4d17-8303-427f47da523f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0a2a47d5-638f-435b-9829-f9f76e674061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_77d47433-2feb-48e6-b88c-306771df2516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0a2a47d5-638f-435b-9829-f9f76e674061" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_77d47433-2feb-48e6-b88c-306771df2516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7ab3fa43-253e-4326-b51d-11c7624b33c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f8fa3633-2a5c-42e1-884f-c6fefde88109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7ab3fa43-253e-4326-b51d-11c7624b33c0" xlink:to="loc_us-gaap_DebtInstrumentTable_f8fa3633-2a5c-42e1-884f-c6fefde88109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f8fa3633-2a5c-42e1-884f-c6fefde88109" xlink:to="loc_us-gaap_DebtInstrumentAxis_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_792a83d5-f9f3-470a-bee0-4ff24b5c2e5e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_23bb35c5-b3e4-4818-8c4e-cf0aa2674b99" xlink:href="biib-20210930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_23bb35c5-b3e4-4818-8c4e-cf0aa2674b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_bdf9fe0a-2b50-4b24-a521-f9cacd526328" xlink:href="biib-20210930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_bdf9fe0a-2b50-4b24-a521-f9cacd526328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_a7231e2c-164e-40cd-bda5-ee646d3bbe7a" xlink:href="biib-20210930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_a7231e2c-164e-40cd-bda5-ee646d3bbe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_fb91334b-c3b0-4aed-879d-4253333c726c" xlink:href="biib-20210930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_fb91334b-c3b0-4aed-879d-4253333c726c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_066c2e01-ec25-44c9-8318-4111d16f309c" xlink:href="biib-20210930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_066c2e01-ec25-44c9-8318-4111d16f309c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_309d5354-8f91-4c10-b2ca-1a6743ef2d82" xlink:href="biib-20210930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8e6b613-0b1a-4ec3-93ab-83330e022006" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_309d5354-8f91-4c10-b2ca-1a6743ef2d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f8fa3633-2a5c-42e1-884f-c6fefde88109" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_e05aede0-5b87-4efd-81ba-bb29109559d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_e05aede0-5b87-4efd-81ba-bb29109559d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_0aab6aec-d04d-4ec7-99bf-33d6c057910c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_NotesPayable_0aab6aec-d04d-4ec7-99bf-33d6c057910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_91b872cc-5950-4675-a031-d8666add1e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_DebtInstrumentFairValue_91b872cc-5950-4675-a031-d8666add1e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dadc62ab-ab26-4a0d-8d0b-606347a825d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dadc62ab-ab26-4a0d-8d0b-606347a825d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_c7075513-f00f-45a6-a897-323268556263" xlink:href="biib-20210930.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6fd0ad2-1f3f-4eea-8083-99cad1cddd09" xlink:to="loc_biib_LongTermDebtExchangedAmount_c7075513-f00f-45a6-a897-323268556263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20210930.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_22c9f8bc-3509-4925-a309-fb44b7cef62d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ee350e6b-5091-4495-b909-7db0a12025bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_22c9f8bc-3509-4925-a309-fb44b7cef62d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ee350e6b-5091-4495-b909-7db0a12025bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d8b88e54-52b5-4e2d-ac45-ba714b829f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ee350e6b-5091-4495-b909-7db0a12025bd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d8b88e54-52b5-4e2d-ac45-ba714b829f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21c4b0c5-963f-4cb4-892c-c8345ef96b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d8b88e54-52b5-4e2d-ac45-ba714b829f76" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21c4b0c5-963f-4cb4-892c-c8345ef96b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9cc72a99-87fc-45de-ade8-d60af2503f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_21c4b0c5-963f-4cb4-892c-c8345ef96b11" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9cc72a99-87fc-45de-ade8-d60af2503f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ee350e6b-5091-4495-b909-7db0a12025bd" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c7a5650d-c92a-4b06-8b68-5aa9a64d7d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c7a5650d-c92a-4b06-8b68-5aa9a64d7d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3aa4139f-3a00-4f10-b2c6-fabc716dbc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3aa4139f-3a00-4f10-b2c6-fabc716dbc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_23cb1e34-ebcc-41ed-9ea2-fa0db5a598a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_18827629-fb59-49a4-9750-574f2cf35d97" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_23cb1e34-ebcc-41ed-9ea2-fa0db5a598a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e6cea598-35e8-4b51-bcc7-d779782a1a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_915411c2-526d-48c6-af61-4b37ac12fc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e6cea598-35e8-4b51-bcc7-d779782a1a39" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_915411c2-526d-48c6-af61-4b37ac12fc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bca0cbbe-352b-42cf-82bf-eab695fc54df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6ca4a726-8ef0-430c-baac-c5f29a8732c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bca0cbbe-352b-42cf-82bf-eab695fc54df" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6ca4a726-8ef0-430c-baac-c5f29a8732c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_620bec02-637c-4331-8fd9-2992a687239d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bca0cbbe-352b-42cf-82bf-eab695fc54df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_620bec02-637c-4331-8fd9-2992a687239d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_82382fa8-c793-48aa-969f-d53a0644771b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bca0cbbe-352b-42cf-82bf-eab695fc54df" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_82382fa8-c793-48aa-969f-d53a0644771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_4a5c8fc1-e240-4ae3-95a0-3e9a5ceddffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bca0cbbe-352b-42cf-82bf-eab695fc54df" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_4a5c8fc1-e240-4ae3-95a0-3e9a5ceddffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ee38e0a4-76cb-4086-8fc0-edf272a74459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9968b946-a1da-40fa-a0f2-e8d7c0909818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ee38e0a4-76cb-4086-8fc0-edf272a74459" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9968b946-a1da-40fa-a0f2-e8d7c0909818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e7d70c1c-8fad-4c2e-aa01-5951164592c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9968b946-a1da-40fa-a0f2-e8d7c0909818" xlink:to="loc_us-gaap_InvestmentTypeAxis_e7d70c1c-8fad-4c2e-aa01-5951164592c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_e7d70c1c-8fad-4c2e-aa01-5951164592c1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2ae2501b-5996-4811-b9d5-256eeb2d90dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:to="loc_us-gaap_CommercialPaperMember_2ae2501b-5996-4811-b9d5-256eeb2d90dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_e40e6210-ea78-408f-bda7-fa97b72f1b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_e40e6210-ea78-408f-bda7-fa97b72f1b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_231ec2c8-06e9-4704-a0cb-ecceb1d14e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_231ec2c8-06e9-4704-a0cb-ecceb1d14e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_65040527-4e3f-4fcb-8db1-1517c20cf543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6f4f6864-b5c4-4321-bac3-f5637df571fc" xlink:to="loc_us-gaap_DebtSecuritiesMember_65040527-4e3f-4fcb-8db1-1517c20cf543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_4aebb826-d7ed-4de9-90d5-fa2e7391019b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9968b946-a1da-40fa-a0f2-e8d7c0909818" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_4aebb826-d7ed-4de9-90d5-fa2e7391019b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_a90cc8d2-651d-49b7-b816-0b9e09ea67ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4aebb826-d7ed-4de9-90d5-fa2e7391019b" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_a90cc8d2-651d-49b7-b816-0b9e09ea67ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c936394f-dbb4-43b7-a89b-369eddfe2011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_a90cc8d2-651d-49b7-b816-0b9e09ea67ec" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c936394f-dbb4-43b7-a89b-369eddfe2011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bb0d7bf9-21db-45fb-bd0d-fe712bdcc196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3d96336d-1cb5-4c2f-98e2-a4ae8455af0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bb0d7bf9-21db-45fb-bd0d-fe712bdcc196" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3d96336d-1cb5-4c2f-98e2-a4ae8455af0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b2000a0f-65d9-41ae-89c5-f24d40c56e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3d96336d-1cb5-4c2f-98e2-a4ae8455af0e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b2000a0f-65d9-41ae-89c5-f24d40c56e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2000a0f-65d9-41ae-89c5-f24d40c56e6e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_4057261b-c51f-42ea-a205-0b1cd0651e31" xlink:href="biib-20210930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_4057261b-c51f-42ea-a205-0b1cd0651e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_f636b7f9-0ae5-4fbf-9f30-d511f1f3d3fa" xlink:href="biib-20210930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_f636b7f9-0ae5-4fbf-9f30-d511f1f3d3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_b459fed1-a839-459a-a840-886301b67042" xlink:href="biib-20210930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_b459fed1-a839-459a-a840-886301b67042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_58c268aa-69cd-4755-8292-1726862f7c87" xlink:href="biib-20210930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_58c268aa-69cd-4755-8292-1726862f7c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_47e8a9a9-f1dd-40bb-88ea-d7a6a42b1df2" xlink:href="biib-20210930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_47e8a9a9-f1dd-40bb-88ea-d7a6a42b1df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_10efcfd3-e1a0-4531-ae3a-f6a15bcefec4" xlink:href="biib-20210930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_10efcfd3-e1a0-4531-ae3a-f6a15bcefec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_d1343687-8453-47ae-a4b4-c2f335a655bb" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_EquitySecuritiesCurrentMember_d1343687-8453-47ae-a4b4-c2f335a655bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_fb8c7aeb-c10b-4223-af4c-f913a1cff019" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24aea6b8-53e5-4781-8a0d-570ef8f391f2" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_fb8c7aeb-c10b-4223-af4c-f913a1cff019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5515a322-724d-4c08-9cef-231711dd33f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3d96336d-1cb5-4c2f-98e2-a4ae8455af0e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5515a322-724d-4c08-9cef-231711dd33f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5515a322-724d-4c08-9cef-231711dd33f1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c57b6a9a-9561-4ed8-88c9-0f91e47b136b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c57b6a9a-9561-4ed8-88c9-0f91e47b136b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4dcbe1b-cbb2-4c12-8ace-15769c706939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4dcbe1b-cbb2-4c12-8ace-15769c706939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0a55358d-4bac-4ba9-8578-319ff8882399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0a55358d-4bac-4ba9-8578-319ff8882399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccc6ae4f-7b79-4f2a-8dcf-930596f05176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_853a1de8-1b4b-444e-91f7-8ed85df517b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccc6ae4f-7b79-4f2a-8dcf-930596f05176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5515a322-724d-4c08-9cef-231711dd33f1" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_d965504f-2643-4411-924d-94f3ed1840a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_d965504f-2643-4411-924d-94f3ed1840a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_46db5169-83c0-4e83-9d4e-eb600936f6c2" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_46db5169-83c0-4e83-9d4e-eb600936f6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_3e4c6c68-8110-4d61-af4d-36d92fac6ed6" xlink:href="biib-20210930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_3e4c6c68-8110-4d61-af4d-36d92fac6ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_2f1d5e91-e84d-4ea7-97ee-68b7c9002428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c5b799a7-3331-4820-bab3-245476a2c98e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_2f1d5e91-e84d-4ea7-97ee-68b7c9002428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd367098-1696-4845-8733-110b3e199742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd367098-1696-4845-8733-110b3e199742" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1222a69b-044b-484e-ad78-9b9615a3e759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1222a69b-044b-484e-ad78-9b9615a3e759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd4ab614-10c0-4cda-8e67-67505f2cc901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd4ab614-10c0-4cda-8e67-67505f2cc901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0a01415c-9845-4c6e-929a-0aca4886b0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0a01415c-9845-4c6e-929a-0aca4886b0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9848eda4-217a-461a-a24a-006fbbf80541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9848eda4-217a-461a-a24a-006fbbf80541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_fba72255-f4d1-4440-a27f-9ce796c0f4ca" xlink:href="biib-20210930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_fba72255-f4d1-4440-a27f-9ce796c0f4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_71972957-256f-4984-8fb7-3632af16d156" xlink:href="biib-20210930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_71972957-256f-4984-8fb7-3632af16d156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_05e04772-e592-4358-b606-c8a4da2e3153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_05e04772-e592-4358-b606-c8a4da2e3153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c5e17b60-1251-4092-a669-ccd1a61b1c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_d4edeb31-0f7e-4120-941d-4deafcfa64c4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c5e17b60-1251-4092-a669-ccd1a61b1c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ac4ac094-b337-4c7c-b331-7cbbdcaf5561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_dbdaea69-47f8-454b-abb1-2966beb95936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ac4ac094-b337-4c7c-b331-7cbbdcaf5561" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_dbdaea69-47f8-454b-abb1-2966beb95936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9f2e4008-b5cf-4004-b1ff-4f50db25b6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ac4ac094-b337-4c7c-b331-7cbbdcaf5561" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9f2e4008-b5cf-4004-b1ff-4f50db25b6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_85adadd7-f9c9-444b-b419-6043c7f75cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ac4ac094-b337-4c7c-b331-7cbbdcaf5561" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_85adadd7-f9c9-444b-b419-6043c7f75cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fe46f41e-1b91-44e0-8690-99d77e3f8942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_f3417d19-d8b3-430b-8dec-636f35d8082b" xlink:href="biib-20210930.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fe46f41e-1b91-44e0-8690-99d77e3f8942" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_f3417d19-d8b3-430b-8dec-636f35d8082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20210930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_76bc5809-e5e2-4cac-a892-0055f0cfc95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_76bc5809-e5e2-4cac-a892-0055f0cfc95c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7a6bd894-6213-4c39-a9b2-6a26a2a3666d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_dei_LegalEntityAxis_7a6bd894-6213-4c39-a9b2-6a26a2a3666d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e3c63d5e-2340-426e-9d69-6c9b6c6ba6e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7a6bd894-6213-4c39-a9b2-6a26a2a3666d" xlink:to="loc_dei_EntityDomain_e3c63d5e-2340-426e-9d69-6c9b6c6ba6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_9063a3ea-acc5-4917-b349-b5f7851ad741" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e3c63d5e-2340-426e-9d69-6c9b6c6ba6e7" xlink:to="loc_biib_DenaliTherapeuticsIncMember_9063a3ea-acc5-4917-b349-b5f7851ad741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_fc73e8f0-444d-475a-a5f6-2f77874730f9" xlink:href="biib-20210930.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e3c63d5e-2340-426e-9d69-6c9b6c6ba6e7" xlink:to="loc_biib_SangamoCommonStockMember_fc73e8f0-444d-475a-a5f6-2f77874730f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_997772f5-9b11-4be2-9cc2-bc56dfbe747c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_997772f5-9b11-4be2-9cc2-bc56dfbe747c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_76ecdb1c-7653-4fcf-adc6-1cd44fa02e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_997772f5-9b11-4be2-9cc2-bc56dfbe747c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_76ecdb1c-7653-4fcf-adc6-1cd44fa02e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_a296e22d-c5bc-4b41-8a0e-8839e0780a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_76ecdb1c-7653-4fcf-adc6-1cd44fa02e0b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_a296e22d-c5bc-4b41-8a0e-8839e0780a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8da60c96-168b-4a52-b5b0-69793e19483a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8da60c96-168b-4a52-b5b0-69793e19483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f48c727-4a68-453f-861b-f54f750607d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8da60c96-168b-4a52-b5b0-69793e19483a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f48c727-4a68-453f-861b-f54f750607d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_e95b04e3-b5e9-449b-be94-23796f039ae3" xlink:href="biib-20210930.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f48c727-4a68-453f-861b-f54f750607d0" xlink:to="loc_biib_StrategicInvestmentsMember_e95b04e3-b5e9-449b-be94-23796f039ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_35ac9f9a-32d9-447c-8b28-61edad3477f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_35ac9f9a-32d9-447c-8b28-61edad3477f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_35ac9f9a-32d9-447c-8b28-61edad3477f4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_a922cf73-c7a1-4dde-8628-f25ffced9258" xlink:href="biib-20210930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:to="loc_biib_SageTherapeuticsIncMember_a922cf73-c7a1-4dde-8628-f25ffced9258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_97a85334-45c8-4cca-9a65-5cf9e2c3b717" xlink:href="biib-20210930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_97a85334-45c8-4cca-9a65-5cf9e2c3b717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_7039ba20-1ef9-4e0e-be6a-9469a3261156" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_857431c4-1bab-4a40-9e5e-f5d80a777a65" xlink:to="loc_biib_DenaliTherapeuticsIncMember_7039ba20-1ef9-4e0e-be6a-9469a3261156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8ca7354-3f75-485a-bfd1-55f3cb5adcfc" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_86e3abbb-e25a-4e17-9c50-d1e51676199e" xlink:href="biib-20210930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_StrategicInvestmentPortfolio_86e3abbb-e25a-4e17-9c50-d1e51676199e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased_227948fe-afc7-4ca0-95fa-dcd340f9a09d" xlink:href="biib-20210930.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_Investmentincommonstocksharespurchased_227948fe-afc7-4ca0-95fa-dcd340f9a09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_8ab41885-d26e-40ca-81ab-50ab99db3271" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_8ab41885-d26e-40ca-81ab-50ab99db3271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_8ea1edbe-108c-40f6-bf9e-2b8235720a54" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_8ea1edbe-108c-40f6-bf9e-2b8235720a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_69c64cf4-2ed4-4c97-be65-73f802220c0c" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_69c64cf4-2ed4-4c97-be65-73f802220c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_2b4a8913-e8a0-4a22-8cfb-6b6bf68061e6" xlink:href="biib-20210930.xsd#biib_DividendYieldPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_DividendYieldPercentage_2b4a8913-e8a0-4a22-8cfb-6b6bf68061e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_13586940-3aad-43b5-8987-479d0547e0ba" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bebfe869-d3a7-413b-877b-1140a8e98484" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_13586940-3aad-43b5-8987-479d0547e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20210930.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dff8d3cb-7f4b-4d97-92ea-998580b96367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_94bb57f2-c60a-4f53-9e26-8db49b57223b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dff8d3cb-7f4b-4d97-92ea-998580b96367" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_94bb57f2-c60a-4f53-9e26-8db49b57223b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20210930.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_911776b2-059f-47b9-9e68-2ad02bccc42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_ed531461-3009-4770-bcb0-da9a544dc887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_911776b2-059f-47b9-9e68-2ad02bccc42a" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_ed531461-3009-4770-bcb0-da9a544dc887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_8791ac5d-6f3f-443f-ab56-5b84b17d6b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_911776b2-059f-47b9-9e68-2ad02bccc42a" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_8791ac5d-6f3f-443f-ab56-5b84b17d6b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b6666b5c-99a8-4e05-b489-97c95ba03be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_911776b2-059f-47b9-9e68-2ad02bccc42a" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b6666b5c-99a8-4e05-b489-97c95ba03be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8e520ca3-40f9-407f-be7b-0555d81d876d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_911776b2-059f-47b9-9e68-2ad02bccc42a" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8e520ca3-40f9-407f-be7b-0555d81d876d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b963ab1a-631d-4308-a61a-46149e298c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b963ab1a-631d-4308-a61a-46149e298c1a" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561" xlink:href="biib-20210930.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_biib_DerivativeMaturityAxis_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_b8f7ba2e-9e5f-4909-89ee-890446e79f40" xlink:href="biib-20210930.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_3b3eb7da-3a66-4ed4-b7bf-02a65dc6b561" xlink:to="loc_biib_DerivativeMaturityDomain_b8f7ba2e-9e5f-4909-89ee-890446e79f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_7a321a32-ff50-432c-bb2b-9e17bb23fe12" xlink:href="biib-20210930.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_b8f7ba2e-9e5f-4909-89ee-890446e79f40" xlink:to="loc_biib_ShorttermderivativeMember_7a321a32-ff50-432c-bb2b-9e17bb23fe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20e12521-8cf0-4427-b6af-24407514e89e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20e12521-8cf0-4427-b6af-24407514e89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e2c7008a-42ec-4dd4-9222-d918fc5e0701" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20e12521-8cf0-4427-b6af-24407514e89e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e2c7008a-42ec-4dd4-9222-d918fc5e0701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_76bced71-87a0-4b1d-ad79-296139cc0f1e" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e2c7008a-42ec-4dd4-9222-d918fc5e0701" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_76bced71-87a0-4b1d-ad79-296139cc0f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4d8903b2-b675-47d9-bf0b-cdd39a7b3196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_DebtInstrumentAxis_4d8903b2-b675-47d9-bf0b-cdd39a7b3196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_965c9be3-6950-4899-80b2-efbdc895d3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d8903b2-b675-47d9-bf0b-cdd39a7b3196" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_965c9be3-6950-4899-80b2-efbdc895d3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_e46ee0ab-829d-4c6a-9263-f11a2c516a8c" xlink:href="biib-20210930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_965c9be3-6950-4899-80b2-efbdc895d3c6" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_e46ee0ab-829d-4c6a-9263-f11a2c516a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_13e1e932-6e14-4c71-bc8f-899b090e0f7c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_srt_CurrencyAxis_13e1e932-6e14-4c71-bc8f-899b090e0f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_13e1e932-6e14-4c71-bc8f-899b090e0f7c" xlink:to="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_478225b1-65e7-47f7-b184-8408ee01a0cb" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_EUR_478225b1-65e7-47f7-b184-8408ee01a0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_1080a2bd-2767-473a-9133-b65650d3b007" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_GBP_1080a2bd-2767-473a-9133-b65650d3b007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_ba1d8994-c634-4dcd-b301-98476696f429" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_CHF_ba1d8994-c634-4dcd-b301-98476696f429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_5edbec70-536d-42a7-961a-064fad2ce043" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_JPY_5edbec70-536d-42a7-961a-064fad2ce043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_eadf036a-7cab-4f80-a3ed-4191b8a2ca8b" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_a888ab88-fe69-49d6-ab8c-dc2407e93e9e" xlink:to="loc_currency_CAD_eadf036a-7cab-4f80-a3ed-4191b8a2ca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0d38c344-44e5-4d5e-98d2-4a42efce3890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0d38c344-44e5-4d5e-98d2-4a42efce3890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d38c344-44e5-4d5e-98d2-4a42efce3890" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_cf9d7ed4-4978-4fad-8623-e774929fc4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:to="loc_us-gaap_InterestExpenseMember_cf9d7ed4-4978-4fad-8623-e774929fc4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_4b063bda-76db-47de-bee8-c7136c18aed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:to="loc_us-gaap_SalesMember_4b063bda-76db-47de-bee8-c7136c18aed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_df2171e3-e9d7-415e-b9e1-b89f9f8f0b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:to="loc_us-gaap_OperatingExpenseMember_df2171e3-e9d7-415e-b9e1-b89f9f8f0b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_eca9ea8b-933a-4e44-b051-a71a5e2f00cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_665c2c36-eb2d-481a-aeda-46433caf7485" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_eca9ea8b-933a-4e44-b051-a71a5e2f00cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e20fd09c-ee9c-43d4-a60a-6e9eb25e71b3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_02c5b893-6adc-4262-82ac-4481497f779b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:to="loc_us-gaap_CashFlowHedgingMember_02c5b893-6adc-4262-82ac-4481497f779b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_f04b52c2-9ded-4654-89f0-d497678e5faa" xlink:href="biib-20210930.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:to="loc_biib_CashflowsrevenueMember_f04b52c2-9ded-4654-89f0-d497678e5faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_093755e6-fe78-4759-8dc4-b9c42d8a50a6" xlink:href="biib-20210930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:to="loc_biib_CashflowsoperatingexpensesMember_093755e6-fe78-4759-8dc4-b9c42d8a50a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5015c523-9a9c-43aa-a63b-44513990a407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e8790608-3307-4535-8c15-613ce9dc6b30" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5015c523-9a9c-43aa-a63b-44513990a407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_db573d45-ea35-4795-93a6-4b75286fe830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_db573d45-ea35-4795-93a6-4b75286fe830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0cbece4c-7b26-4e7a-b6be-92a12ebe10ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_db573d45-ea35-4795-93a6-4b75286fe830" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0cbece4c-7b26-4e7a-b6be-92a12ebe10ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f1f68188-3b2b-4a01-8a40-deaa6c011096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0cbece4c-7b26-4e7a-b6be-92a12ebe10ae" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f1f68188-3b2b-4a01-8a40-deaa6c011096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2dfb6ada-c694-4a01-bae4-0a3b20907fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0cbece4c-7b26-4e7a-b6be-92a12ebe10ae" xlink:to="loc_us-gaap_InterestRateSwapMember_2dfb6ada-c694-4a01-bae4-0a3b20907fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a80e64a1-246c-4f25-8f7d-0b1c56ab0da2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_f61840d1-905c-4fde-9f2b-4cfae2268f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_f61840d1-905c-4fde-9f2b-4cfae2268f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e06c0e2d-239a-467b-b3f0-230898ab5b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e06c0e2d-239a-467b-b3f0-230898ab5b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_67efc4d8-e6bc-4a57-bd5c-7d3bd18e9e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_67efc4d8-e6bc-4a57-bd5c-7d3bd18e9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7d41b861-0cee-40d1-98b5-d7d41bf05867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_168e117d-3e01-4d4b-8d3f-20ea3baf8706" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7d41b861-0cee-40d1-98b5-d7d41bf05867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_HedgingDesignationAxis_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a04e20e7-3d9f-4740-a9cd-20c14c152d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a1a2c9fa-d8a3-4ccb-8a52-8820c31a0640" xlink:to="loc_us-gaap_HedgingDesignationDomain_a04e20e7-3d9f-4740-a9cd-20c14c152d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1d0cf044-1cb3-47b2-9584-99d223acd5c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a04e20e7-3d9f-4740-a9cd-20c14c152d24" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1d0cf044-1cb3-47b2-9584-99d223acd5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_64d16f5b-2221-48e0-bf05-b9dd99c80f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a04e20e7-3d9f-4740-a9cd-20c14c152d24" xlink:to="loc_us-gaap_NondesignatedMember_64d16f5b-2221-48e0-bf05-b9dd99c80f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0626ba27-4b36-44ce-b389-179d110480f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_srt_RangeAxis_0626ba27-4b36-44ce-b389-179d110480f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_205b907d-02e1-4613-902c-469ecfbadf14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0626ba27-4b36-44ce-b389-179d110480f1" xlink:to="loc_srt_RangeMember_205b907d-02e1-4613-902c-469ecfbadf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ba0bd242-dc36-413d-ba6f-af2351a6e9f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_205b907d-02e1-4613-902c-469ecfbadf14" xlink:to="loc_srt_MinimumMember_ba0bd242-dc36-413d-ba6f-af2351a6e9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b31cc70f-7128-4fb4-b958-799519f4f5b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_205b907d-02e1-4613-902c-469ecfbadf14" xlink:to="loc_srt_MaximumMember_b31cc70f-7128-4fb4-b958-799519f4f5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3b78a5d1-ae9b-4780-9760-ba8465de362b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_dei_LegalEntityAxis_3b78a5d1-ae9b-4780-9760-ba8465de362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0969c6ec-0d46-45bd-8986-d968fbabe5f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3b78a5d1-ae9b-4780-9760-ba8465de362b" xlink:to="loc_dei_EntityDomain_0969c6ec-0d46-45bd-8986-d968fbabe5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_cfc1f5e4-6888-4d3e-a61b-62bb825c3cdd" xlink:href="biib-20210930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0969c6ec-0d46-45bd-8986-d968fbabe5f5" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_cfc1f5e4-6888-4d3e-a61b-62bb825c3cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_500b15a5-8bdd-44e4-b6d7-eea55a9db4fc" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_5bbd3e1b-0da7-4098-80f3-c2b2d0550a04" xlink:href="biib-20210930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_5bbd3e1b-0da7-4098-80f3-c2b2d0550a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_cb0bc8a1-4ef8-49b0-bda4-8e570f63b675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_cb0bc8a1-4ef8-49b0-bda4-8e570f63b675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b93d03d8-2ad3-428d-98b8-be6d7a2189e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b93d03d8-2ad3-428d-98b8-be6d7a2189e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_77d87a15-e906-464c-ae11-97ce8e78a407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_77d87a15-e906-464c-ae11-97ce8e78a407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2152f52e-933d-43dd-93d2-0951c65a2395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2152f52e-933d-43dd-93d2-0951c65a2395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7e08176b-dc8b-4332-9f7e-95c249c7e39a" xlink:href="biib-20210930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7e08176b-dc8b-4332-9f7e-95c249c7e39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d445603f-bdbc-42ec-b6c4-71ecf5beb39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d445603f-bdbc-42ec-b6c4-71ecf5beb39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fd8ed164-5f72-4be3-8065-3b11a279b50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fd8ed164-5f72-4be3-8065-3b11a279b50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_87756336-237f-40d8-bfef-2bb708603180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeTermOfContract_87756336-237f-40d8-bfef-2bb708603180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_c035f01f-d89c-4a92-bcec-cf1d5142fe0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_c035f01f-d89c-4a92-bcec-cf1d5142fe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_80ddf094-925b-4b3e-a072-10e2b8c43243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_80ddf094-925b-4b3e-a072-10e2b8c43243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f34e34de-82eb-41aa-ac40-0af58387af42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f34e34de-82eb-41aa-ac40-0af58387af42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_f8b0b474-f016-4f51-8b3b-8d0eba074921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_f8b0b474-f016-4f51-8b3b-8d0eba074921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bfd7cc1a-1d07-4693-8b3f-de702bd453d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bfd7cc1a-1d07-4693-8b3f-de702bd453d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_015ee594-bb34-42c4-8dfe-21881daa2f4c" xlink:href="biib-20210930.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_015ee594-bb34-42c4-8dfe-21881daa2f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_1c93bfa5-8e0f-43d9-84d0-e94ee84c67b4" xlink:href="biib-20210930.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_1c93bfa5-8e0f-43d9-84d0-e94ee84c67b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c950f1b9-778d-4431-a9e1-342cbb9bd77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c950f1b9-778d-4431-a9e1-342cbb9bd77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_1e82ab4c-c68b-4680-a8bd-b670899341d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_1e82ab4c-c68b-4680-a8bd-b670899341d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_87e8787b-74c8-41df-89aa-222388488217" xlink:href="biib-20210930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_87e8787b-74c8-41df-89aa-222388488217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_2b03b456-66e0-4d66-9913-0c43e145daf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_2b03b456-66e0-4d66-9913-0c43e145daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_60ba0e6d-ee5f-4f13-abff-06d277c25943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_334a0f73-d50a-4cfd-9719-8e213d854f86" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_60ba0e6d-ee5f-4f13-abff-06d277c25943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20210930.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_555894fb-da44-4ef8-af53-3406db13ef34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_28220d21-1ea6-4421-b517-df5644e411ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_555894fb-da44-4ef8-af53-3406db13ef34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_28220d21-1ea6-4421-b517-df5644e411ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3d75e67-1199-4fa5-a447-5e183126da75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3d75e67-1199-4fa5-a447-5e183126da75" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_fe902949-4ee2-4e76-9538-a01e1f4fb32f" xlink:href="biib-20210930.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:to="loc_biib_FacilityLocationAxis_fe902949-4ee2-4e76-9538-a01e1f4fb32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_43f5369e-50da-4a0a-859d-6e768d539310" xlink:href="biib-20210930.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_fe902949-4ee2-4e76-9538-a01e1f4fb32f" xlink:to="loc_biib_FacilityLocationDomain_43f5369e-50da-4a0a-859d-6e768d539310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_86694dbb-e777-4063-9c88-b17fecca7eb3" xlink:href="biib-20210930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_43f5369e-50da-4a0a-859d-6e768d539310" xlink:to="loc_biib_SolothurnSwitzerlandMember_86694dbb-e777-4063-9c88-b17fecca7eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_bcae1223-7427-473b-9729-84d66a60ab6e" xlink:href="biib-20210930.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:to="loc_biib_FacilityTypeAxis_bcae1223-7427-473b-9729-84d66a60ab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:href="biib-20210930.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_bcae1223-7427-473b-9729-84d66a60ab6e" xlink:to="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_7dfec408-cc51-4f43-a1a0-5d13d5218e9f" xlink:href="biib-20210930.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:to="loc_biib_BiologicsManufacturingMember_7dfec408-cc51-4f43-a1a0-5d13d5218e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_b4ea6f04-be87-40d7-90f3-e18c91663f19" xlink:href="biib-20210930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_b4ea6f04-be87-40d7-90f3-e18c91663f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_ff215c50-1354-4415-846f-ac2975ba0c4a" xlink:href="biib-20210930.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_4fe0f718-0f53-4927-ac0f-28887445c600" xlink:to="loc_biib_AdministrativeSpaceMember_ff215c50-1354-4415-846f-ac2975ba0c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e1c678f-c0fa-44de-8a73-cf32ee89a963" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae01b9db-2b5c-4897-b62b-f36f1e7d93b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae01b9db-2b5c-4897-b62b-f36f1e7d93b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_dd8fee2d-9270-47aa-9d5d-b662e23f1295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_Depreciation_dd8fee2d-9270-47aa-9d5d-b662e23f1295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_18afcc56-0e24-4620-b376-808aa3499fcd" xlink:href="biib-20210930.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_biib_NumberOfSquareFeet_18afcc56-0e24-4620-b376-808aa3499fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_b11efb76-1c35-4509-ab25-f64f854c8589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_ConstructionInProgressGross_b11efb76-1c35-4509-ab25-f64f854c8589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_43dc5d73-0629-4c4a-aa55-f3a3f70ca347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0eea55b4-c03a-484b-99dd-3d2843c743f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_43dc5d73-0629-4c4a-aa55-f3a3f70ca347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20210930.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ddf5c967-101e-433a-8535-8cf707208afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a75788ca-8ea0-41ee-b853-5de03031e59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ddf5c967-101e-433a-8535-8cf707208afc" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a75788ca-8ea0-41ee-b853-5de03031e59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_de1f5049-76b0-4d6c-9f16-b71a88457a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_de1f5049-76b0-4d6c-9f16-b71a88457a47" xlink:to="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_25c07c5c-df1c-49c9-87ba-3de1cca13356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_25c07c5c-df1c-49c9-87ba-3de1cca13356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_218dc9ce-3443-45f4-9fef-a15650915076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_25c07c5c-df1c-49c9-87ba-3de1cca13356" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_218dc9ce-3443-45f4-9fef-a15650915076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_67463979-a861-4964-9218-7cdb9c2bacad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_218dc9ce-3443-45f4-9fef-a15650915076" xlink:to="loc_us-gaap_InterestExpenseMember_67463979-a861-4964-9218-7cdb9c2bacad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b110dc9e-4b20-46f9-aff5-4d3810aea7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b110dc9e-4b20-46f9-aff5-4d3810aea7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_66af777c-7b65-48ae-a22e-7c8d0161f520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b110dc9e-4b20-46f9-aff5-4d3810aea7a7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_66af777c-7b65-48ae-a22e-7c8d0161f520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_54eaa45d-dbef-4da4-8e1f-e482e0870915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_66af777c-7b65-48ae-a22e-7c8d0161f520" xlink:to="loc_us-gaap_InterestRateSwapMember_54eaa45d-dbef-4da4-8e1f-e482e0870915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_51bc6b11-0d33-4a10-8777-4a188b103e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_51bc6b11-0d33-4a10-8777-4a188b103e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_933efd65-63c3-4c23-8a02-06d7849f02d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_51bc6b11-0d33-4a10-8777-4a188b103e12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_933efd65-63c3-4c23-8a02-06d7849f02d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_98dc0050-648f-4436-87f3-894dadcc75b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_933efd65-63c3-4c23-8a02-06d7849f02d9" xlink:to="loc_us-gaap_SeniorNotesMember_98dc0050-648f-4436-87f3-894dadcc75b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c93e822c-224d-4fd2-ae1b-d5d15c4cca08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_DebtInstrumentAxis_c93e822c-224d-4fd2-ae1b-d5d15c4cca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c93e822c-224d-4fd2-ae1b-d5d15c4cca08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_5828e4f5-b413-4861-8b0d-b418dd45ff96" xlink:href="biib-20210930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_5828e4f5-b413-4861-8b0d-b418dd45ff96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_9cad9199-8aa4-438d-acf6-e84b3c57a812" xlink:href="biib-20210930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_9cad9199-8aa4-438d-acf6-e84b3c57a812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_832c8fd7-209e-454b-94c9-b7c3c2b4475e" xlink:href="biib-20210930.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_832c8fd7-209e-454b-94c9-b7c3c2b4475e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_0f45bd7c-939e-4755-bf1b-9a0bb02b9bb1" xlink:href="biib-20210930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_0f45bd7c-939e-4755-bf1b-9a0bb02b9bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_445bd495-1cf7-40fb-8aa2-cbeb0089d924" xlink:href="biib-20210930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7622e01-69ef-4c9c-917c-b64853404cfd" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_445bd495-1cf7-40fb-8aa2-cbeb0089d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_175aff47-e1e9-4fc9-b997-130138de4b82" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a5c1b268-7abb-4a5b-bfd0-a05c8e7496ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a5c1b268-7abb-4a5b-bfd0-a05c8e7496ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb7319de-3681-4dd8-a0a4-3458eba4c9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb7319de-3681-4dd8-a0a4-3458eba4c9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_4e92154f-ba2f-4640-979d-c4f98c0bb0dd" xlink:href="biib-20210930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_4e92154f-ba2f-4640-979d-c4f98c0bb0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_9997396a-f7b8-455d-b29c-11c183b8da69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_9997396a-f7b8-455d-b29c-11c183b8da69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_388e27b2-ca57-4efe-bc82-8441954524e7" xlink:href="biib-20210930.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_388e27b2-ca57-4efe-bc82-8441954524e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_dec01d9f-be2b-4974-a3b9-d5699fb8bd73" xlink:href="biib-20210930.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_dec01d9f-be2b-4974-a3b9-d5699fb8bd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_5803dfab-995f-463c-a2ff-4f0fd3f81a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_5803dfab-995f-463c-a2ff-4f0fd3f81a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_1354c116-09f4-4035-b9cb-624a3ff7e184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_1354c116-09f4-4035-b9cb-624a3ff7e184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_70b928d4-c4c4-4153-9edb-6f67d1d02235" xlink:href="biib-20210930.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_70b928d4-c4c4-4153-9edb-6f67d1d02235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_40d998ba-0aed-49e1-8032-c5ec01fb9c8b" xlink:href="biib-20210930.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_biib_LongTermDebtExchangedAmount_40d998ba-0aed-49e1-8032-c5ec01fb9c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96772550-5240-4192-be65-ffd205700fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96772550-5240-4192-be65-ffd205700fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_714aed0e-a13a-44cc-8baa-49f90abe878b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_RepaymentsOfDebt_714aed0e-a13a-44cc-8baa-49f90abe878b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_98a328eb-b799-4307-8d46-aee1b37f1875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3fe84c0-9d01-4ea2-bcf1-9ddd20cbc5ea" xlink:to="loc_us-gaap_InterestExpense_98a328eb-b799-4307-8d46-aee1b37f1875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20210930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0843089d-cce6-4113-a633-dbcd6a906bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_73f8c73b-1454-4961-93e7-7021a890f409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0843089d-cce6-4113-a633-dbcd6a906bdb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_73f8c73b-1454-4961-93e7-7021a890f409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20210930.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f9228026-d035-48be-a7c6-ac5d727a219c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6407be6b-c9f3-46b5-b3e8-97471e1ecad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f9228026-d035-48be-a7c6-ac5d727a219c" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6407be6b-c9f3-46b5-b3e8-97471e1ecad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_f8624d57-ba4b-45a8-beb6-c39e9c6a8648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f9228026-d035-48be-a7c6-ac5d727a219c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_f8624d57-ba4b-45a8-beb6-c39e9c6a8648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5b29baaa-f591-41f9-91b5-6a0affebf648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d9956fb6-cc38-4fb2-ade7-1327869bcd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b29baaa-f591-41f9-91b5-6a0affebf648" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d9956fb6-cc38-4fb2-ade7-1327869bcd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_c99fa822-30f5-4090-a189-d20fc779e2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d9956fb6-cc38-4fb2-ade7-1327869bcd78" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_c99fa822-30f5-4090-a189-d20fc779e2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_c99fa822-30f5-4090-a189-d20fc779e2d0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_c1d2c9a8-c1f6-4f32-b92b-c0b000510ccb" xlink:href="biib-20210930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_c1d2c9a8-c1f6-4f32-b92b-c0b000510ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_9f9f8598-4cb6-40b2-b5c9-c01aae6d14e9" xlink:href="biib-20210930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_9f9f8598-4cb6-40b2-b5c9-c01aae6d14e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember_64e3d6ef-00ea-4aa2-bc0d-0a4f768c8fb7" xlink:href="biib-20210930.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dbdb0137-32bb-4570-aa12-cc7686efc6be" xlink:to="loc_biib_October2020ShareRepurchaseProgramMember_64e3d6ef-00ea-4aa2-bc0d-0a4f768c8fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d9956fb6-cc38-4fb2-ade7-1327869bcd78" xlink:to="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3cccbcc3-8350-4066-a331-ecc813939990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3cccbcc3-8350-4066-a331-ecc813939990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3df3eff0-1d8a-49d6-94a5-c89336bf5e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3df3eff0-1d8a-49d6-94a5-c89336bf5e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3ad6685d-c887-4738-9b4d-d7ac15ebe054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3ad6685d-c887-4738-9b4d-d7ac15ebe054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4bcf488e-6e5b-402e-8335-b3f265778efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_106ea6b2-1573-485a-8094-0959afb31f58" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4bcf488e-6e5b-402e-8335-b3f265778efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e9396a17-6684-40b7-95fb-e3e482acc3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecc7c3a5-62e4-417c-910f-df0378ac63e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9396a17-6684-40b7-95fb-e3e482acc3ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecc7c3a5-62e4-417c-910f-df0378ac63e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecc7c3a5-62e4-417c-910f-df0378ac63e1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa0b1253-0bd0-4e0b-b812-6f6c74aa66b6" xlink:to="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ef9e6a6c-c831-48e8-8941-50e49012da4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ef9e6a6c-c831-48e8-8941-50e49012da4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_cd0a1da6-49d7-44b8-88d0-cc1c1a3485a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_cd0a1da6-49d7-44b8-88d0-cc1c1a3485a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_6fe198c3-2919-4781-9a35-9934f8c4c9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_6fe198c3-2919-4781-9a35-9934f8c4c9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b78ac67d-83dd-47ea-8b9c-9dd923a3b418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b78ac67d-83dd-47ea-8b9c-9dd923a3b418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f8ee1daa-ddbc-422e-9ed7-2b49388ddf0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2db7d314-f52d-4ead-bdb5-1f77d924aa7a" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f8ee1daa-ddbc-422e-9ed7-2b49388ddf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecc7c3a5-62e4-417c-910f-df0378ac63e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_699384c3-30fc-4174-9950-733c782d66d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_699384c3-30fc-4174-9950-733c782d66d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8648e3f4-eeb3-4000-befc-cb3735986d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8648e3f4-eeb3-4000-befc-cb3735986d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_43cba1eb-3893-44aa-8b9e-667b6f324e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_43cba1eb-3893-44aa-8b9e-667b6f324e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a2c56711-3672-487e-8907-04b299f0981a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a2c56711-3672-487e-8907-04b299f0981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ff92f9c6-44d0-4338-8220-f7b41e8847d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ff92f9c6-44d0-4338-8220-f7b41e8847d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_015d2acd-79ac-4f9e-9438-d9193ceb4fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_015d2acd-79ac-4f9e-9438-d9193ceb4fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0b24a58b-18b7-4299-9270-37f471fa5a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_21266c34-209a-40d5-98e9-7a9db6b8dfcd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0b24a58b-18b7-4299-9270-37f471fa5a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_0ad8b1a4-1766-4542-baa3-85588aaa7ee2" xlink:href="biib-20210930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_0ad8b1a4-1766-4542-baa3-85588aaa7ee2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8aa10084-31ef-4874-a5cb-6e2ef3294025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8aa10084-31ef-4874-a5cb-6e2ef3294025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8aa10084-31ef-4874-a5cb-6e2ef3294025" xlink:to="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ee87b33c-0145-4faa-879c-b2ed2d6bb440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ee87b33c-0145-4faa-879c-b2ed2d6bb440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bb81a61b-1055-4f12-835d-0fde6ea14dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bb81a61b-1055-4f12-835d-0fde6ea14dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_5f47b0a5-58a2-4beb-89e2-b133e3dd4fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_524435e2-f1f8-4482-a625-8baea9f9446b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_5f47b0a5-58a2-4beb-89e2-b133e3dd4fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a58e5788-9ba7-40bf-8953-b7d68450755c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a58e5788-9ba7-40bf-8953-b7d68450755c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08fd05ad-d723-465c-ab7c-5a35f1ed8d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_a58e5788-9ba7-40bf-8953-b7d68450755c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08fd05ad-d723-465c-ab7c-5a35f1ed8d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_65cb87db-bfa3-445f-9300-1db1d14ab49a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08fd05ad-d723-465c-ab7c-5a35f1ed8d0c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_65cb87db-bfa3-445f-9300-1db1d14ab49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f6e770f0-7056-45a8-88ce-74d161b12f9d" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_baa5a323-a656-4428-9189-abdbcf23a999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_baa5a323-a656-4428-9189-abdbcf23a999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_83ca8820-3956-4ec9-a049-5c306235b29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_83ca8820-3956-4ec9-a049-5c306235b29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e59d545b-c4e6-4525-a6a7-eccd34dc6696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_Revenues_e59d545b-c4e6-4525-a6a7-eccd34dc6696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7b731c25-2575-41f4-99c1-d45f15a08eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_OperatingExpenses_7b731c25-2575-41f4-99c1-d45f15a08eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62e313f7-84d0-46fc-9f9d-46ac345f940f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c2057e46-5ffb-492c-8325-a89015bda65c" xlink:to="loc_us-gaap_NetIncomeLoss_62e313f7-84d0-46fc-9f9d-46ac345f940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20210930.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9f348c93-5b63-435b-bc73-3e2eb1167cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ca538a9b-8e1c-4882-bffa-3f447af785d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9f348c93-5b63-435b-bc73-3e2eb1167cf0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ca538a9b-8e1c-4882-bffa-3f447af785d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20210930.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b3f8faf7-6421-4e03-a511-2ae51c320f56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_112da3c6-01ee-476f-aefe-bfea867f63af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b3f8faf7-6421-4e03-a511-2ae51c320f56" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_112da3c6-01ee-476f-aefe-bfea867f63af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f5e1c66a-8361-476d-9883-716203b7df0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5b1954e-726f-4f45-89a6-83dad5bd9abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f5e1c66a-8361-476d-9883-716203b7df0b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5b1954e-726f-4f45-89a6-83dad5bd9abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01d1bd5f-c19b-4c53-aa83-cd60682a72bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5b1954e-726f-4f45-89a6-83dad5bd9abb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01d1bd5f-c19b-4c53-aa83-cd60682a72bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01d1bd5f-c19b-4c53-aa83-cd60682a72bc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_4f48ef09-f61a-4813-8b21-07d7f01403dd" xlink:href="biib-20210930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_4f48ef09-f61a-4813-8b21-07d7f01403dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_f9ac335f-d09a-4c12-a021-cabe7ae68528" xlink:href="biib-20210930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:to="loc_biib_MarketStockUnitsMember_f9ac335f-d09a-4c12-a021-cabe7ae68528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_853ee609-ba8f-461f-9d2d-a625fd5a44f6" xlink:href="biib-20210930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8f99e614-1e11-4fe1-9416-e4fabcc87e79" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_853ee609-ba8f-461f-9d2d-a625fd5a44f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f190cbbb-0087-4b6c-9a5a-7b21f515ec69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5b1954e-726f-4f45-89a6-83dad5bd9abb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f190cbbb-0087-4b6c-9a5a-7b21f515ec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_84ecaccd-7c34-4b39-9f25-367f1561acc9" xlink:href="biib-20210930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f190cbbb-0087-4b6c-9a5a-7b21f515ec69" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_84ecaccd-7c34-4b39-9f25-367f1561acc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3d6698d6-0923-4b9a-b31e-94af2e3cceea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_84ecaccd-7c34-4b39-9f25-367f1561acc9" xlink:to="loc_us-gaap_NetIncomeLossAbstract_3d6698d6-0923-4b9a-b31e-94af2e3cceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc352e21-91c5-4e64-a582-4eb142ed57c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3d6698d6-0923-4b9a-b31e-94af2e3cceea" xlink:to="loc_us-gaap_NetIncomeLoss_dc352e21-91c5-4e64-a582-4eb142ed57c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_84ecaccd-7c34-4b39-9f25-367f1561acc9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7728c49c-5ba1-4667-8f7a-71789ba07d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7728c49c-5ba1-4667-8f7a-71789ba07d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_37cc1c54-1e0d-4224-9c41-29fa70829a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_37cc1c54-1e0d-4224-9c41-29fa70829a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77e604ff-9cd0-4c91-a217-6d926b620b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_37cc1c54-1e0d-4224-9c41-29fa70829a77" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77e604ff-9cd0-4c91-a217-6d926b620b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e8f18205-1fae-4ee2-b4ce-cf511dbfb933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_37cc1c54-1e0d-4224-9c41-29fa70829a77" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e8f18205-1fae-4ee2-b4ce-cf511dbfb933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c10e1103-f146-4eb4-9d90-18e0269ef9d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_78337e09-b368-48ed-bf39-bfc842fffd96" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c10e1103-f146-4eb4-9d90-18e0269ef9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20210930.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1df36648-ea42-4254-aca7-a69a55a16401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_83f586b1-f3f2-4d69-84b9-470a5cec48bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1df36648-ea42-4254-aca7-a69a55a16401" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_83f586b1-f3f2-4d69-84b9-470a5cec48bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20210930.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e63a79e4-8382-4da8-bb24-d6619ea437ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ec525e40-a0cb-4315-b2c6-6e81c1e88762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e63a79e4-8382-4da8-bb24-d6619ea437ab" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ec525e40-a0cb-4315-b2c6-6e81c1e88762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_4655f388-8fd4-4882-ba1f-4c62654afb32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e63a79e4-8382-4da8-bb24-d6619ea437ab" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_4655f388-8fd4-4882-ba1f-4c62654afb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6002cb75-41d0-4389-8b56-34756e04b728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837e16cd-ac15-4a6a-9ce4-bfc4eab0c358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6002cb75-41d0-4389-8b56-34756e04b728" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837e16cd-ac15-4a6a-9ce4-bfc4eab0c358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_00f18fde-2881-476f-a56b-36e464214e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837e16cd-ac15-4a6a-9ce4-bfc4eab0c358" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_00f18fde-2881-476f-a56b-36e464214e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_00f18fde-2881-476f-a56b-36e464214e5d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8b46474f-c1c1-4569-8116-ef67df16b1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8b46474f-c1c1-4569-8116-ef67df16b1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_168c08a0-c403-4222-bf4d-46fe35ccbd08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_168c08a0-c403-4222-bf4d-46fe35ccbd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_7720d648-9ce1-40f2-88ef-a104498f6af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4ba452ce-158f-4a8d-a2fb-7b49d70465ac" xlink:to="loc_us-gaap_ParentMember_7720d648-9ce1-40f2-88ef-a104498f6af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5688d8f-1840-41f1-aa66-55396410aeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_837e16cd-ac15-4a6a-9ce4-bfc4eab0c358" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5688d8f-1840-41f1-aa66-55396410aeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5688d8f-1840-41f1-aa66-55396410aeb8" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_be4396f2-350f-4e80-8b9c-cf09657d5f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_be4396f2-350f-4e80-8b9c-cf09657d5f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e3b90769-5183-4c5b-a3d4-6fb6bd2e6856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e3b90769-5183-4c5b-a3d4-6fb6bd2e6856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_22a558a4-a6cc-4abf-bf03-ea03ef780859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_22a558a4-a6cc-4abf-bf03-ea03ef780859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_dd98b22b-6e66-4304-81af-68564f6a1db4" xlink:href="biib-20210930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_dd98b22b-6e66-4304-81af-68564f6a1db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_985119c9-7106-46b1-9e94-7bb774ef5c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_7d593979-adb0-48ed-a9f2-fb9f82e5c224" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_985119c9-7106-46b1-9e94-7bb774ef5c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20210930.xsd#ShareBasedPaymentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49128b25-3c80-4057-9275-7f6bf940e09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49128b25-3c80-4057-9275-7f6bf940e09a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63e7f2e2-9703-41b1-aabe-b549a0bf3e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63e7f2e2-9703-41b1-aabe-b549a0bf3e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e6d1b97-21c4-40a3-a817-2e01886bb247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63e7f2e2-9703-41b1-aabe-b549a0bf3e20" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e6d1b97-21c4-40a3-a817-2e01886bb247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_61a2f8de-7caf-46cc-94b8-9f88df06992d" xlink:href="biib-20210930.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e6d1b97-21c4-40a3-a817-2e01886bb247" xlink:to="loc_biib_NightstarMember_61a2f8de-7caf-46cc-94b8-9f88df06992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a190c9c-1f79-48d3-8474-616c0834db04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:to="loc_us-gaap_AwardTypeAxis_3a190c9c-1f79-48d3-8474-616c0834db04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3a190c9c-1f79-48d3-8474-616c0834db04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_4cf1e2d3-ca91-4916-8f99-6b7cc7328354" xlink:href="biib-20210930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_MarketStockUnitsMember_4cf1e2d3-ca91-4916-8f99-6b7cc7328354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_05165afd-4e17-4a81-888b-c71fd23f4283" xlink:href="biib-20210930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_05165afd-4e17-4a81-888b-c71fd23f4283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7283aa08-850e-4f0e-b1ab-166d7b41a939" xlink:href="biib-20210930.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_CashSettledPerformanceSharesMember_7283aa08-850e-4f0e-b1ab-166d7b41a939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e733ea58-a46c-4371-8794-46e0b11934f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_us-gaap_PerformanceSharesMember_e733ea58-a46c-4371-8794-46e0b11934f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_d02558e8-0253-45e9-a6d1-41102a8526d2" xlink:href="biib-20210930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_d02558e8-0253-45e9-a6d1-41102a8526d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_d6d0abce-cb17-4d3d-b531-03a4f2e4a998" xlink:href="biib-20210930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_d6d0abce-cb17-4d3d-b531-03a4f2e4a998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_fa4a1732-614f-4e33-8241-5804a7e40452" xlink:href="biib-20210930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93d54c11-10e6-4b4f-8e10-03a7ef99bc4f" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_fa4a1732-614f-4e33-8241-5804a7e40452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bba46df0-ad1b-477d-98b6-5016081184fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3c7a0594-e9ef-4248-a8bf-ab429f9cc861" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bba46df0-ad1b-477d-98b6-5016081184fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:href="biib-20210930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bba46df0-ad1b-477d-98b6-5016081184fa" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_97f56a59-23c3-45e4-ad6e-766cb9f4793f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_97f56a59-23c3-45e4-ad6e-766cb9f4793f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7193715d-48c5-4026-8e88-b60e48aa4099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7193715d-48c5-4026-8e88-b60e48aa4099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e580e009-7c48-499e-81a4-b2349dc8225f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e580e009-7c48-499e-81a4-b2349dc8225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1f7c3733-2903-4822-aae1-237bf7b94659" xlink:href="biib-20210930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_88e96a7f-2c10-42b3-b4d1-8e82c6194662" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1f7c3733-2903-4822-aae1-237bf7b94659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9657b5d6-e9cc-43b2-84fd-174955518780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_227542fd-3f9b-49ee-abb2-652c693bc735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9657b5d6-e9cc-43b2-84fd-174955518780" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_227542fd-3f9b-49ee-abb2-652c693bc735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20210930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b6b7db9-14f0-4550-b9c4-839763b2ea42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_048e92b4-b5cf-4ff3-ab80-4882ed8e2df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b6b7db9-14f0-4550-b9c4-839763b2ea42" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_048e92b4-b5cf-4ff3-ab80-4882ed8e2df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5a840fca-f079-4526-a2ce-9cddc82e5a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5a840fca-f079-4526-a2ce-9cddc82e5a92" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c732d7a-01d0-469b-805d-609e0dba7c1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:to="loc_srt_ProductOrServiceAxis_3c732d7a-01d0-469b-805d-609e0dba7c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f00a1b08-8e97-46c6-a440-c52d59d6b207" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3c732d7a-01d0-469b-805d-609e0dba7c1f" xlink:to="loc_srt_ProductsAndServicesDomain_f00a1b08-8e97-46c6-a440-c52d59d6b207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_6169dcfa-bc8b-430d-a73d-2c9d1f18d49d" xlink:href="biib-20210930.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f00a1b08-8e97-46c6-a440-c52d59d6b207" xlink:to="loc_biib_TECFIDERAMember_6169dcfa-bc8b-430d-a73d-2c9d1f18d49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_57151813-6e95-403c-8713-8363bb344497" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:to="loc_srt_StatementScenarioAxis_57151813-6e95-403c-8713-8363bb344497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8e84cc2c-1779-4ea4-92fc-a14cfb457571" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_57151813-6e95-403c-8713-8363bb344497" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8e84cc2c-1779-4ea4-92fc-a14cfb457571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_38a0aa1a-01fc-444f-b04c-24bbb3c234e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8e84cc2c-1779-4ea4-92fc-a14cfb457571" xlink:to="loc_srt_ScenarioForecastMember_38a0aa1a-01fc-444f-b04c-24bbb3c234e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_69b8e2bb-ddea-45c2-b2b8-d1b36c3ba303" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_a3c81cae-a7c8-444c-9c7c-d4fcee66b023" xlink:href="biib-20210930.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_a3c81cae-a7c8-444c-9c7c-d4fcee66b023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_9b8ba42f-e5f1-4b44-9768-78c9568888f4" xlink:href="biib-20210930.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_9b8ba42f-e5f1-4b44-9768-78c9568888f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue_b9a76e89-0657-4f3a-8c31-8fd762b25932" xlink:href="biib-20210930.xsd#biib_DeferredTaxAssetIncreaseDecreaseInValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue_b9a76e89-0657-4f3a-8c31-8fd762b25932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_968013df-f619-4dd8-9838-8355e7b7992c" xlink:href="biib-20210930.xsd#biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_968013df-f619-4dd8-9838-8355e7b7992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_feb38c06-da73-491b-a236-8a7372410977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_feb38c06-da73-491b-a236-8a7372410977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4967b4ff-4458-4597-a11b-a9b72513925a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4967b4ff-4458-4597-a11b-a9b72513925a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_023b6289-3aba-4a30-b7d7-c9ac3aa9bfa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_023b6289-3aba-4a30-b7d7-c9ac3aa9bfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_c60bad99-5b98-4f7d-be24-447e568080c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_fbdd6089-ef1a-42da-8c5e-623a4f44afde" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_c60bad99-5b98-4f7d-be24-447e568080c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bb66ec30-85e6-4b02-b623-30846598f767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb66ec30-85e6-4b02-b623-30846598f767" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b3fb83aa-524d-43d6-8206-4bf5cb2da1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b3fb83aa-524d-43d6-8206-4bf5cb2da1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ddfc1768-e24a-45f3-8463-6dea6edb6951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ddfc1768-e24a-45f3-8463-6dea6edb6951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c3712f00-cae9-4e0b-bba9-41ea202d7ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c3712f00-cae9-4e0b-bba9-41ea202d7ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_e25ff54a-cd8d-4c41-b821-f7c1d393f0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_e25ff54a-cd8d-4c41-b821-f7c1d393f0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7694d57f-c4d6-47d7-9b26-f160adb24036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7694d57f-c4d6-47d7-9b26-f160adb24036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_e6e23104-218f-43b4-b4ea-24b98ce74090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_e6e23104-218f-43b4-b4ea-24b98ce74090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_503f981c-ebcf-4cc8-9d91-64b5dafd3f1c" xlink:href="biib-20210930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_503f981c-ebcf-4cc8-9d91-64b5dafd3f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_43c21806-35b9-442d-8191-81473d021013" xlink:href="biib-20210930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_43c21806-35b9-442d-8191-81473d021013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ba966aff-7a88-402d-ae4d-bbc03391f217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ba966aff-7a88-402d-ae4d-bbc03391f217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_89949bbb-ba9f-47ba-bd4e-39182f7f4b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b3fafa9b-c8e9-4860-bebb-43094c82719d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_89949bbb-ba9f-47ba-bd4e-39182f7f4b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20210930.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30fc20ed-b1cc-4c18-8aec-945de6c8365b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e63b48eb-8195-43c2-ae3d-95697be9f48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30fc20ed-b1cc-4c18-8aec-945de6c8365b" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e63b48eb-8195-43c2-ae3d-95697be9f48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20210930.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a2bdc01-72f4-4e17-a0fd-25f5a6ad3eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_daf62cbb-bc96-4ef1-913a-14d27afd048a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a2bdc01-72f4-4e17-a0fd-25f5a6ad3eba" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_daf62cbb-bc96-4ef1-913a-14d27afd048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_a56b83b5-c812-4368-bc93-93b7b6b2ceb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a2bdc01-72f4-4e17-a0fd-25f5a6ad3eba" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_a56b83b5-c812-4368-bc93-93b7b6b2ceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_80b20f9f-560d-4414-a042-d7ff386fd864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a2bdc01-72f4-4e17-a0fd-25f5a6ad3eba" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_80b20f9f-560d-4414-a042-d7ff386fd864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68a2e132-aa48-423a-ad5e-11577366fbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68a2e132-aa48-423a-ad5e-11577366fbd3" xlink:to="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c805ea5-06df-4362-9666-aef15e73c460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c805ea5-06df-4362-9666-aef15e73c460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_027c73e0-164f-480a-b9a9-a833d431f855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c805ea5-06df-4362-9666-aef15e73c460" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_027c73e0-164f-480a-b9a9-a833d431f855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5ad8034e-d6fd-4a7c-968e-563072fdb46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_027c73e0-164f-480a-b9a9-a833d431f855" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5ad8034e-d6fd-4a7c-968e-563072fdb46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2cc4ece6-3bfd-459c-b44f-75e66dd5e715" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:to="loc_dei_LegalEntityAxis_2cc4ece6-3bfd-459c-b44f-75e66dd5e715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f37360f-cb3d-4862-8e82-2e5f7203f956" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2cc4ece6-3bfd-459c-b44f-75e66dd5e715" xlink:to="loc_dei_EntityDomain_2f37360f-cb3d-4862-8e82-2e5f7203f956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_c2f2a511-50a0-4085-90ef-8bb880f22685" xlink:href="biib-20210930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2f37360f-cb3d-4862-8e82-2e5f7203f956" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_c2f2a511-50a0-4085-90ef-8bb880f22685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e796e9db-c08e-4e7e-940e-aa6cb7a85dcd" xlink:to="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_dc6090f5-18f2-4965-8dc4-32cd2cd0c2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_InvestmentIncomeInterest_dc6090f5-18f2-4965-8dc4-32cd2cd0c2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4267f3a4-8f27-48b5-8c92-24fd8bac1491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_InterestExpense_4267f3a4-8f27-48b5-8c92-24fd8bac1491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_a0e2220a-9893-438a-974b-01b9ff868dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_a0e2220a-9893-438a-974b-01b9ff868dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04cae6f7-0be3-4481-b431-0904f5fd1378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04cae6f7-0be3-4481-b431-0904f5fd1378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_42f6db1b-30a3-4048-a06a-08a01707a593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_42f6db1b-30a3-4048-a06a-08a01707a593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b983218-b20e-4cbf-bcb8-e8f95683e66a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_9148775d-f8bc-4b26-bbf3-07e33aac2e01" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b983218-b20e-4cbf-bcb8-e8f95683e66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_30d528c7-354c-41ca-8c86-50df5e955253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_30d528c7-354c-41ca-8c86-50df5e955253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_87e2431b-ca11-450c-ac6f-63d1f7ef8cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_87e2431b-ca11-450c-ac6f-63d1f7ef8cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d9735a58-bf4a-430f-bf3e-da6316008a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_68513895-24c9-405b-9651-9309ce487a10" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d9735a58-bf4a-430f-bf3e-da6316008a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b973b2e4-bbcc-48f9-af65-bed51a0c20f8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e55676f8-2b53-4c25-bd6b-ce2d705009c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e55676f8-2b53-4c25-bd6b-ce2d705009c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_692d8f6c-2739-4608-abd9-89a663aaea88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_692d8f6c-2739-4608-abd9-89a663aaea88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_a119f9e8-4e47-4e99-9f99-90534fd38907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_a119f9e8-4e47-4e99-9f99-90534fd38907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_98d772d6-9108-466d-9624-6965e1297195" xlink:href="biib-20210930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_biib_Collaborationexpensesaccrual_98d772d6-9108-466d-9624-6965e1297195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0fb78a3c-eecb-4ac1-9edc-14c589ebc228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0fb78a3c-eecb-4ac1-9edc-14c589ebc228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_ab4774e6-590e-41f8-83d7-1132dfe74890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_ab4774e6-590e-41f8-83d7-1132dfe74890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1ec5879e-4917-428d-9451-722a13a3af8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1ec5879e-4917-428d-9451-722a13a3af8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_98a0b397-c961-46ab-9957-7d988476efea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_63796c67-a9ca-4280-be51-e5e0c5167d19" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_98a0b397-c961-46ab-9957-7d988476efea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20210930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eacffa73-cbdf-45fb-ac89-4ef028cee0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0351ae33-84c3-45bd-b5d2-033f5189fa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eacffa73-cbdf-45fb-ac89-4ef028cee0a8" xlink:to="loc_us-gaap_StatementTable_0351ae33-84c3-45bd-b5d2-033f5189fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d40b8247-54b0-40c2-91c9-1ae7445792bb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0351ae33-84c3-45bd-b5d2-033f5189fa5e" xlink:to="loc_dei_LegalEntityAxis_d40b8247-54b0-40c2-91c9-1ae7445792bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a6b143e4-e333-4301-b509-dd0ed2a18c11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d40b8247-54b0-40c2-91c9-1ae7445792bb" xlink:to="loc_dei_EntityDomain_a6b143e4-e333-4301-b509-dd0ed2a18c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_939f0012-0eba-4f78-8dcd-d047092c14ac" xlink:href="biib-20210930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a6b143e4-e333-4301-b509-dd0ed2a18c11" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_939f0012-0eba-4f78-8dcd-d047092c14ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0351ae33-84c3-45bd-b5d2-033f5189fa5e" xlink:to="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_396fedd7-d77b-4759-aaf2-55842fa2e6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_396fedd7-d77b-4759-aaf2-55842fa2e6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cbc1b01f-a2db-4d3a-9137-5534103e7b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cbc1b01f-a2db-4d3a-9137-5534103e7b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_51fa70db-70b2-483e-afca-908bf8c26b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_51fa70db-70b2-483e-afca-908bf8c26b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fd6e9a11-f240-426e-b5b3-f1d3a2d5dd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fd6e9a11-f240-426e-b5b3-f1d3a2d5dd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_ca326b5a-9b3b-4c28-89be-0d7b4f2c2a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12e01c87-db2f-435e-8b68-3380534037a8" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_ca326b5a-9b3b-4c28-89be-0d7b4f2c2a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20210930.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ddc3d21-b59e-4030-9246-435ee364ca6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c19add17-4996-4e44-bc97-f83b0a2cd520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ddc3d21-b59e-4030-9246-435ee364ca6d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c19add17-4996-4e44-bc97-f83b0a2cd520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20210930.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_153df380-3244-439d-bd0f-301b4725be91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_c0c62dab-e85e-47a4-87b1-b3a8f98ec4ce" xlink:href="biib-20210930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_153df380-3244-439d-bd0f-301b4725be91" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_c0c62dab-e85e-47a4-87b1-b3a8f98ec4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_d83319ae-3381-418d-aef6-d00ec6f1c222" xlink:href="biib-20210930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_153df380-3244-439d-bd0f-301b4725be91" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_d83319ae-3381-418d-aef6-d00ec6f1c222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_4172ff0c-bca4-4bf2-92e2-b82d07e082d5" xlink:href="biib-20210930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_153df380-3244-439d-bd0f-301b4725be91" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_4172ff0c-bca4-4bf2-92e2-b82d07e082d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9153bd2b-145b-4e8c-b6d3-fa97fa05a5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9153bd2b-145b-4e8c-b6d3-fa97fa05a5f1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d92ae14-081f-4211-b1ba-9afe04b68ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d92ae14-081f-4211-b1ba-9afe04b68ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f552c969-3027-4664-a791-dfa4a5e1a528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d92ae14-081f-4211-b1ba-9afe04b68ba8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f552c969-3027-4664-a791-dfa4a5e1a528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ceb1651a-ae35-494e-b131-7e15dfb9750c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f552c969-3027-4664-a791-dfa4a5e1a528" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ceb1651a-ae35-494e-b131-7e15dfb9750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_32edf905-e788-404d-ac47-2162b98bf7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f552c969-3027-4664-a791-dfa4a5e1a528" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_32edf905-e788-404d-ac47-2162b98bf7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d0b2009a-61f3-4a44-9b52-fe55caac5d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d0b2009a-61f3-4a44-9b52-fe55caac5d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0b2009a-61f3-4a44-9b52-fe55caac5d72" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_312def0a-595b-45e3-82c2-6554c4d7d9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_312def0a-595b-45e3-82c2-6554c4d7d9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_a1ee1cd0-0626-4e03-a3b4-2d265b9b98a6" xlink:href="biib-20210930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_EisaiMember_a1ee1cd0-0626-4e03-a3b4-2d265b9b98a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_bdc373a0-757d-4c35-ab34-3dfa5c20edeb" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_DenaliTherapeuticsIncMember_bdc373a0-757d-4c35-ab34-3dfa5c20edeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_dd88e2aa-36f4-4136-84d8-c6c57b344b32" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_8320a20c-b029-4bba-81f7-c1a7e3c4021f" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_8320a20c-b029-4bba-81f7-c1a7e3c4021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_86de68c0-f97f-4a32-a67e-a1e9522e22b6" xlink:href="biib-20210930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_SageTherapeuticsIncMember_86de68c0-f97f-4a32-a67e-a1e9522e22b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_3a8285de-b7e7-45bf-a6a3-2a9ff801c06f" xlink:href="biib-20210930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_UCBPharmaS.A.Member_3a8285de-b7e7-45bf-a6a3-2a9ff801c06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_45044f85-ac68-40df-bc56-3f3592cd816b" xlink:href="biib-20210930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_45044f85-ac68-40df-bc56-3f3592cd816b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_e7658a0a-fe1d-4f5d-bfed-9f8bc98ce85a" xlink:href="biib-20210930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_OtherresearchanddiscoveryMember_e7658a0a-fe1d-4f5d-bfed-9f8bc98ce85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_0bae8f65-2b1c-4ac4-89f3-b1f66ed963c3" xlink:href="biib-20210930.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af47a740-a3bd-4f38-96d7-73406b0faff3" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_0bae8f65-2b1c-4ac4-89f3-b1f66ed963c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da932b46-d7b6-48d3-b3a7-6788b8c12e85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_srt_ProductOrServiceAxis_da932b46-d7b6-48d3-b3a7-6788b8c12e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65835da9-a391-4096-924c-92c87ec83c33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_da932b46-d7b6-48d3-b3a7-6788b8c12e85" xlink:to="loc_srt_ProductsAndServicesDomain_65835da9-a391-4096-924c-92c87ec83c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_5b6293d3-2231-405f-a38e-3fb09ab112cf" xlink:href="biib-20210930.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_65835da9-a391-4096-924c-92c87ec83c33" xlink:to="loc_biib_E2609andBAN2401Member_5b6293d3-2231-405f-a38e-3fb09ab112cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_68f9caa0-8dd1-4ba1-b7f9-f8832e29ffd9" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_65835da9-a391-4096-924c-92c87ec83c33" xlink:to="loc_biib_ADUHELMMember_68f9caa0-8dd1-4ba1-b7f9-f8832e29ffd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fa9ca056-c670-4a09-b73c-20d6d7c05e65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_dei_LegalEntityAxis_fa9ca056-c670-4a09-b73c-20d6d7c05e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce04ffec-b656-4b31-bff0-983cee9e6a76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fa9ca056-c670-4a09-b73c-20d6d7c05e65" xlink:to="loc_dei_EntityDomain_ce04ffec-b656-4b31-bff0-983cee9e6a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_20ce6c9e-14e9-432c-a8ff-73e90c6d5e20" xlink:href="biib-20210930.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ce04ffec-b656-4b31-bff0-983cee9e6a76" xlink:to="loc_biib_SangamoCommonStockMember_20ce6c9e-14e9-432c-a8ff-73e90c6d5e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e7762cd2-2eca-4698-8912-69695ed1991a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e7762cd2-2eca-4698-8912-69695ed1991a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9de68a12-1953-4faa-9c88-bb24fdd97736" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e7762cd2-2eca-4698-8912-69695ed1991a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9de68a12-1953-4faa-9c88-bb24fdd97736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_2a9a98b7-e43f-4dd7-9526-fbb28791b228" xlink:href="biib-20210930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9de68a12-1953-4faa-9c88-bb24fdd97736" xlink:to="loc_biib_DenaliTherapeuticsIncMember_2a9a98b7-e43f-4dd7-9526-fbb28791b228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_154a8194-2e02-4cbc-8657-f1a9e79a8e8c" xlink:href="biib-20210930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9de68a12-1953-4faa-9c88-bb24fdd97736" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_154a8194-2e02-4cbc-8657-f1a9e79a8e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b2b98243-a001-49f3-be24-a835665a289c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_c2d750ef-ff7f-471b-a44b-537b1cbb36bc" xlink:href="biib-20210930.xsd#biib_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_NumberOfProductCandidates_c2d750ef-ff7f-471b-a44b-537b1cbb36bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_1a5dac5d-18a1-4dba-b6df-bb19a2b10718" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_1a5dac5d-18a1-4dba-b6df-bb19a2b10718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_7fbff20a-3e29-42df-af02-b1bdab09a33b" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_7fbff20a-3e29-42df-af02-b1bdab09a33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_f5b4f8bb-1934-4891-ac74-e4839fd8354d" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_f5b4f8bb-1934-4891-ac74-e4839fd8354d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_402e9dfd-2914-4bb0-9789-76fec5d8a6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_402e9dfd-2914-4bb0-9789-76fec5d8a6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_f3205ce9-2957-41e3-a084-984ff231ae9b" xlink:href="biib-20210930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_ExpenseIncurredByCollaboration_f3205ce9-2957-41e3-a084-984ff231ae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_b19d4fba-dd8d-412b-b7ab-43a802860b7a" xlink:href="biib-20210930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_Expenseincurredbythecollaboration_b19d4fba-dd8d-412b-b7ab-43a802860b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_e0e12583-c558-48e5-8fb3-6112279f8181" xlink:href="biib-20210930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_e0e12583-c558-48e5-8fb3-6112279f8181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_afdc62d6-21b0-46a8-a43f-78db18ce2aec" xlink:href="biib-20210930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_afdc62d6-21b0-46a8-a43f-78db18ce2aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_56ab6cb1-eeb2-4fcf-abe8-fbdccd4d4850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_LossOnContractTermination_56ab6cb1-eeb2-4fcf-abe8-fbdccd4d4850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_d0c0be61-a5b0-4ca1-bc1f-4127795d6d90" xlink:href="biib-20210930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_d0c0be61-a5b0-4ca1-bc1f-4127795d6d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_75ff8bc9-4984-4650-8bdd-a8cf23e4e881" xlink:href="biib-20210930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_CollaborationAgreementTerm_75ff8bc9-4984-4650-8bdd-a8cf23e4e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_ead04fa3-74af-463d-b6a0-657aca24081b" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_ead04fa3-74af-463d-b6a0-657aca24081b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_cc1d0693-4608-4a29-abf8-53d06d2cdbae" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_cc1d0693-4608-4a29-abf8-53d06d2cdbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_695f3f89-f179-4fba-8306-b9772158bf93" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_695f3f89-f179-4fba-8306-b9772158bf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_fdecda34-6d05-4b9e-8808-c97eb97523f8" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_fdecda34-6d05-4b9e-8808-c97eb97523f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_18d75ec8-633c-4902-a25e-7e753e7e625a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_18d75ec8-633c-4902-a25e-7e753e7e625a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_fc163bd3-0f6b-43a4-ad1f-6df1279342f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_fc163bd3-0f6b-43a4-ad1f-6df1279342f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_cafcd40c-7b48-494b-9d03-6b2d9da10361" xlink:href="biib-20210930.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_cafcd40c-7b48-494b-9d03-6b2d9da10361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_b53c540b-1987-4676-9a78-0f76b67b886d" xlink:href="biib-20210930.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_Termofcollaborationagreement_b53c540b-1987-4676-9a78-0f76b67b886d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_898d32c7-1051-4f5a-8611-8bc7110c881a" xlink:href="biib-20210930.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_898d32c7-1051-4f5a-8611-8bc7110c881a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_9c76b24d-6b53-48c2-a635-0b22721b73ca" xlink:href="biib-20210930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_biib_AdditionalMilestonePayment_9c76b24d-6b53-48c2-a635-0b22721b73ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5fc6f5b8-b13f-4150-a42c-d6907d30c672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6bb0284a-c83f-409c-9311-db004c8ed8f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5fc6f5b8-b13f-4150-a42c-d6907d30c672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4417595d-3db5-4d72-a1c4-36774032b96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4417595d-3db5-4d72-a1c4-36774032b96a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_6dd92ed2-6f6b-4b2e-bca3-a2b9620ba0a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_8d06c668-5fe4-4c2a-8387-0b6ab77b1ebb" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_6dd92ed2-6f6b-4b2e-bca3-a2b9620ba0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_2a27cf29-8bce-4fa5-9a79-006012e195c0" xlink:href="biib-20210930.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_6dd92ed2-6f6b-4b2e-bca3-a2b9620ba0a2" xlink:to="loc_biib_NeurimmuneMember_2a27cf29-8bce-4fa5-9a79-006012e195c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_f49664a0-b1c4-4414-8cbc-402767aca581" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_2ffd2cd0-9d0c-4889-8b8d-d90bebf78568" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_f49664a0-b1c4-4414-8cbc-402767aca581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_89df9b28-a2fa-4fc1-a5e1-25cac9f801ca" xlink:href="biib-20210930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_f49664a0-b1c4-4414-8cbc-402767aca581" xlink:to="loc_biib_RegulatoryMilestonesMember_89df9b28-a2fa-4fc1-a5e1-25cac9f801ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f9c608b7-1c01-45ed-9dc3-326a8c6742b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f9c608b7-1c01-45ed-9dc3-326a8c6742b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f9c608b7-1c01-45ed-9dc3-326a8c6742b3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_f18dfb5d-2649-42be-ae22-b7f2287551fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:to="loc_us-gaap_InventoriesMember_f18dfb5d-2649-42be-ae22-b7f2287551fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_26b177b7-5132-4f43-a48c-d40ea845b47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_26b177b7-5132-4f43-a48c-d40ea845b47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_578fa83a-e27d-4a2f-b13f-762ac2d2ee17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_77afc001-384d-4119-848f-636091226734" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_578fa83a-e27d-4a2f-b13f-762ac2d2ee17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a60ce193-1ca2-46c2-b969-81fb6f526d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a60ce193-1ca2-46c2-b969-81fb6f526d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a60ce193-1ca2-46c2-b969-81fb6f526d8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_6e747fe1-cd06-4c1b-8aa6-146e1358ec8c" xlink:href="biib-20210930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:to="loc_biib_EisaiMember_6e747fe1-cd06-4c1b-8aa6-146e1358ec8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_aaee540e-05b5-488a-8172-f3ee1eee74da" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_aaee540e-05b5-488a-8172-f3ee1eee74da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_0a989d3b-969e-4d51-bf94-52a824dee0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81fcbd0e-b3e9-41ec-8ba8-b4e8cc02eefb" xlink:to="loc_us-gaap_CollaborativeArrangementMember_0a989d3b-969e-4d51-bf94-52a824dee0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3d05e3b6-581d-4e5d-9848-a33e575f9c0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3d05e3b6-581d-4e5d-9848-a33e575f9c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cc908998-c044-4473-a40e-47e4358d31e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3d05e3b6-581d-4e5d-9848-a33e575f9c0c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cc908998-c044-4473-a40e-47e4358d31e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_ee291281-8feb-4e57-8b97-e29356416ea9" xlink:href="biib-20210930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cc908998-c044-4473-a40e-47e4358d31e0" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_ee291281-8feb-4e57-8b97-e29356416ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90d2177a-397d-4add-9671-e3ffcde1b79e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_srt_ProductOrServiceAxis_90d2177a-397d-4add-9671-e3ffcde1b79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_344c5d34-70f6-4342-9eb0-8063c790e136" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_90d2177a-397d-4add-9671-e3ffcde1b79e" xlink:to="loc_srt_ProductsAndServicesDomain_344c5d34-70f6-4342-9eb0-8063c790e136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_959bc60a-807b-45bb-963e-83b2df16337b" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_344c5d34-70f6-4342-9eb0-8063c790e136" xlink:to="loc_biib_ADUHELMMember_959bc60a-807b-45bb-963e-83b2df16337b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5670232d-8c29-4363-8be5-e5719979b939" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_a6bcbf65-b478-444b-be1d-4974b67d7986" xlink:href="biib-20210930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_a6bcbf65-b478-444b-be1d-4974b67d7986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_7107badf-e751-4961-9c37-0912454e4d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_LossOnContractTermination_7107badf-e751-4961-9c37-0912454e4d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_79625643-31c0-427a-8dde-cd320f91a02c" xlink:href="biib-20210930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_79625643-31c0-427a-8dde-cd320f91a02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_01a51f65-ee87-4b1d-b469-cbd5a6f671d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_01a51f65-ee87-4b1d-b469-cbd5a6f671d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e5ecae8f-08ef-4cfa-83a3-8304d881706e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e5ecae8f-08ef-4cfa-83a3-8304d881706e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_e8feb174-d77e-4bde-b02d-a7faf80a96e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_e8feb174-d77e-4bde-b02d-a7faf80a96e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_c4e98fff-b07a-45e4-83ba-32577dd6b0b6" xlink:href="biib-20210930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_c4e98fff-b07a-45e4-83ba-32577dd6b0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_343cc298-3607-409f-84cc-1d3137f79485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_343cc298-3607-409f-84cc-1d3137f79485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1bc69dc3-9b67-4fb4-9e88-827c27c83607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1bc69dc3-9b67-4fb4-9e88-827c27c83607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ff09a20b-d5ae-42b8-b6cf-e684b1833ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_EquityMethodInvestments_ff09a20b-d5ae-42b8-b6cf-e684b1833ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_4a1d7cb5-45b3-4c06-b8aa-ef4896d98e1d" xlink:href="biib-20210930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_4a1d7cb5-45b3-4c06-b8aa-ef4896d98e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3f47750-152d-4719-adc6-c24081040eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f3f47750-152d-4719-adc6-c24081040eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a15d6002-5d4e-4300-b824-86d791d22a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a15d6002-5d4e-4300-b824-86d791d22a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1b77fa33-0192-4f5b-bed3-8f079bbdef2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1b77fa33-0192-4f5b-bed3-8f079bbdef2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_762d13a3-105b-4617-9679-f014a6dbccb2" xlink:href="biib-20210930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_AdditionalMilestonePayment_762d13a3-105b-4617-9679-f014a6dbccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_b822bf5c-2bdf-4ce8-aa92-428c54624b25" xlink:href="biib-20210930.xsd#biib_AccruedMilestonePayments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_AccruedMilestonePayments_b822bf5c-2bdf-4ce8-aa92-428c54624b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_b244e007-86ba-4f17-bd93-90cbf9d28947" xlink:href="biib-20210930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_b244e007-86ba-4f17-bd93-90cbf9d28947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_f4222e6f-7c19-4fda-bd23-450cb3c805f6" xlink:href="biib-20210930.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_ContractOptionExerciseFee_f4222e6f-7c19-4fda-bd23-450cb3c805f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_55cba908-6446-4e5c-8466-fc6277bd7e6d" xlink:href="biib-20210930.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_55cba908-6446-4e5c-8466-fc6277bd7e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_678d7224-83af-42bc-b256-c57f2bffd723" xlink:href="biib-20210930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_biib_Collaborationprofitlosssharing_678d7224-83af-42bc-b256-c57f2bffd723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bce5f3ea-e6f7-48b4-be62-bb3872049f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_Revenues_bce5f3ea-e6f7-48b4-be62-bb3872049f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1b8c4f4e-baa5-47dc-acef-a1be2b0a312c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bccbd326-c4e4-4905-889d-e093a871007e" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1b8c4f4e-baa5-47dc-acef-a1be2b0a312c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20210930.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_561462cb-2101-487b-ad82-db5c96305a68" xlink:href="biib-20210930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_0a409af5-7028-4986-a0c1-2145243efc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_561462cb-2101-487b-ad82-db5c96305a68" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_0a409af5-7028-4986-a0c1-2145243efc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_b1d37392-22fb-426e-a8dc-0847ef692d27" xlink:href="biib-20210930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_b1d37392-22fb-426e-a8dc-0847ef692d27" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_827ece8f-cade-4501-83e4-599613113274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_us-gaap_TypeOfArrangementAxis_827ece8f-cade-4501-83e4-599613113274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d2c414c-9709-446f-a86d-37a87f34da98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_827ece8f-cade-4501-83e4-599613113274" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d2c414c-9709-446f-a86d-37a87f34da98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_414cdf9c-2e66-433c-8677-1d65b25ef4c4" xlink:href="biib-20210930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d2c414c-9709-446f-a86d-37a87f34da98" xlink:to="loc_biib_EisaiMember_414cdf9c-2e66-433c-8677-1d65b25ef4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_4741b770-5bef-4fdb-9d05-da92d476bf87" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_4741b770-5bef-4fdb-9d05-da92d476bf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_268b4d88-a724-4b80-812b-71f8dcbe9f6f" xlink:href="biib-20210930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_4741b770-5bef-4fdb-9d05-da92d476bf87" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_268b4d88-a724-4b80-812b-71f8dcbe9f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_76db6dd5-abbe-4f5c-b8fd-333c40101664" xlink:href="biib-20210930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_268b4d88-a724-4b80-812b-71f8dcbe9f6f" xlink:to="loc_biib_RegulatoryMilestonesMember_76db6dd5-abbe-4f5c-b8fd-333c40101664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_srt_StatementGeographicalAxis_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d2a8088-8d80-43bf-ae03-070e3ae102a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_55c472d9-9aad-421b-b0cf-d3ba27d0ed3a" xlink:to="loc_srt_SegmentGeographicalDomain_6d2a8088-8d80-43bf-ae03-070e3ae102a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_6c460893-e4dd-4272-a184-f8a9bac4b418" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6d2a8088-8d80-43bf-ae03-070e3ae102a4" xlink:to="loc_country_JP_6c460893-e4dd-4272-a184-f8a9bac4b418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6f078012-6341-4a53-a382-d6959df045c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6d2a8088-8d80-43bf-ae03-070e3ae102a4" xlink:to="loc_srt_EuropeMember_6f078012-6341-4a53-a382-d6959df045c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_98c8be5a-c160-4eb7-9c90-c9cf7948a340" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_srt_ConsolidatedEntitiesAxis_98c8be5a-c160-4eb7-9c90-c9cf7948a340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_36c61a0a-2a8c-4eaa-b6cf-a87b1e94f746" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_98c8be5a-c160-4eb7-9c90-c9cf7948a340" xlink:to="loc_srt_ConsolidatedEntitiesDomain_36c61a0a-2a8c-4eaa-b6cf-a87b1e94f746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_46998555-d801-4736-8bb4-a02b643a04dc" xlink:href="biib-20210930.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_36c61a0a-2a8c-4eaa-b6cf-a87b1e94f746" xlink:to="loc_biib_NeurimmuneMember_46998555-d801-4736-8bb4-a02b643a04dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_srt_ProductOrServiceAxis_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8865e37b-ca6a-4fae-b7e0-039c8c127674" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e8ad3c9d-e245-4e08-ad53-9b4aeb95ff0a" xlink:to="loc_srt_ProductsAndServicesDomain_8865e37b-ca6a-4fae-b7e0-039c8c127674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_2b8292a9-2f21-4dda-aa9f-f291873b453d" xlink:href="biib-20210930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8865e37b-ca6a-4fae-b7e0-039c8c127674" xlink:to="loc_biib_ADUHELMMember_2b8292a9-2f21-4dda-aa9f-f291873b453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf8c451f-6876-4397-a3e7-3fece3f23828" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_b8f918f5-8c45-44b7-8e1a-65ab52a7f229" xlink:href="biib-20210930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_CollaborationAgreementTerm_b8f918f5-8c45-44b7-8e1a-65ab52a7f229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_b61e2981-254f-497f-a0b5-ad3760ba1b6c" xlink:href="biib-20210930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_b61e2981-254f-497f-a0b5-ad3760ba1b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_32cd105b-31cd-4c1c-b2c4-f2791839741a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_32cd105b-31cd-4c1c-b2c4-f2791839741a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_02c641f9-c330-4eea-a430-97b1b7aa6dfa" xlink:href="biib-20210930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_02c641f9-c330-4eea-a430-97b1b7aa6dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_7359ea82-5a3a-41c8-8ac4-fa82bc914d7e" xlink:href="biib-20210930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_7359ea82-5a3a-41c8-8ac4-fa82bc914d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0a31a7ce-ff3b-436f-a6ec-ab357676e187" xlink:href="biib-20210930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0a31a7ce-ff3b-436f-a6ec-ab357676e187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_da4b2239-01ed-4c83-97e3-64dd4e1232e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_da4b2239-01ed-4c83-97e3-64dd4e1232e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e602f2e4-b5c9-490d-8770-35eebd56f175" xlink:href="biib-20210930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e602f2e4-b5c9-490d-8770-35eebd56f175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_50645db2-75f2-4a88-9b2b-2997b6b08287" xlink:href="biib-20210930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_AdditionalMilestonePayment_50645db2-75f2-4a88-9b2b-2997b6b08287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c3dc1621-202b-41a4-ab25-9e4f79194d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c3dc1621-202b-41a4-ab25-9e4f79194d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0b863536-20dc-472f-a4e5-f6faea019ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0b863536-20dc-472f-a4e5-f6faea019ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d1e6308e-cda0-4a81-915f-c3732964ee90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d1e6308e-cda0-4a81-915f-c3732964ee90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_6ea75a99-5dbe-4e4e-9ea6-c6eee73d4282" xlink:href="biib-20210930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_f44f1418-122a-44fa-9e7d-7bf6ff44a7fb" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_6ea75a99-5dbe-4e4e-9ea6-c6eee73d4282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20210930.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_be1e2908-cc18-49fe-aae9-4f2cdb95c8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_84b69808-c50f-42e2-9e2c-bea34841de93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_be1e2908-cc18-49fe-aae9-4f2cdb95c8dd" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_84b69808-c50f-42e2-9e2c-bea34841de93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20210930.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_d6be3a40-cb6c-4b76-8542-cd3e9e5e82b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4cbec3d2-65f4-41b4-a713-f56275092887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_d6be3a40-cb6c-4b76-8542-cd3e9e5e82b7" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4cbec3d2-65f4-41b4-a713-f56275092887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="simple" xlink:href="biib-20210930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_bb908a56-351b-4783-a20f-8cc54ffab713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4c2492f1-8de7-44de-b9fd-691b413f4e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bb908a56-351b-4783-a20f-8cc54ffab713" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4c2492f1-8de7-44de-b9fd-691b413f4e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>biib-20210930_g1.jpg
<TEXT>
begin 644 biib-20210930_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  E@    $  0"6     0 !_^%2)&AT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX-"@D\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B/@T*"0D)/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^#0H)
M"0D\9&,Z=&ET;&4^#0H)"0D)/')D9CI!;'0^#0H)"0D)"3QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^0FEO9V5N7TQO9V]?,3(P,S$T/"]R9&8Z;&D^
M#0H)"0D)/"]R9&8Z06QT/@T*"0D)/"]D8SIT:71L93X-"@D)/"]R9&8Z1&5S
M8W)I<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^
M#0H)"0D\>&UP.DUE=&%D871A1&%T93XR,#$T+3$R+3 U5#$P.C0Y.C(P+3 U
M.C P/"]X;7 Z365T861A=&%$871E/@T*"0D)/'AM<#I-;V1I9GE$871E/C(P
M,30M,3(M,#54,34Z-#DZ,C=:/"]X;7 Z36]D:69Y1&%T93X-"@D)"3QX;7 Z
M0W)E871E1&%T93XR,#$T+3$R+3 U5#$P.C0Y.C(P+3 U.C P/"]X;7 Z0W)E
M871E1&%T93X-"@D)"3QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T
M;W(@0U,V("A-86-I;G1O<V@I/"]X;7 Z0W)E871O<E1O;VP^#0H)"0D\>&UP
M.E1H=6UB;F%I;',^#0H)"0D)/')D9CI!;'0^#0H)"0D)"3QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@T*"0D)"0D)/'AM<$=);6<Z:&5I9VAT/C@X
M/"]X;7!'26UG.FAE:6=H=#X-"@D)"0D)"3QX;7!'26UG.F9O<FUA=#Y*4$5'
M/"]X;7!'26UG.F9O<FUA=#X-"@D)"0D)"3QX;7!'26UG.FEM86=E/B\Y:B\T
M04%14VM:2E)G04)!9T5"3$%%<T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!
M0311:VQ.02LP04%!04%!0D%"3$%!04%!14$-"D%117-!04%!05%!0B\K24U7
M16Q$43$Y455K.4=357A&04%%0D%!04U317AP8FTX0T5!04%B5S4P8VQ*2%%I
M0EE75F]G0C@T04%G04H-"D%!64%-44%!65=.>F-%,512;%%!04%!05-55D1)
M2$Y34C!)04%!04%!04%!04%!04%!04%!4&)704%%04%!04$P>3%)54-!9T%!
M04$-"D%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!4EDS0GED04%!059!04%!07H-"EI'5GI9=T%!
M05E104%!0G-D,U)W9$%!04%F04%!04%566UT=V1!04%!9U%!04%!56-L:%I7
M9T%!06AG04%!055:,6A:5V=!04%I=T$-"D%!0559;&A:5V=!04%K04%!04%5
M6D<Q=5I!04%!;%%!04%"=UI',6M:04%!07-104%!0TED;E9L6D%!04$P=T%!
M04-'9&UL;&1W04$-"D$Y44%!04%K8DA6=&%104%!+V=!04%!56)75FAC=T%!
M0D%W04%!06MD1U9J84%!04)$04%!04%-8VQ24U%W04%"1'=!04%G35HQ4E,-
M"E%W04%"1'=!04%G35EL4E-1=T%!0D1W04%!9TUD1U8T9$%!04%!0D1B,T(U
M8VUL;F%(46=+1TUP241%-4]49V=31U8S8D=6,&1#,5$-"EE73G)96$IK245.
M=F)80FAB;FM!04=2;&,R34%!04%!04%!045N3E-2,$EG4U561$YJ135.:EET
M36DT>$%!04%!04%!04%!04%!05,-"F,Q2DA1:4)*4E5-,DU4:S).:3!Y3&I%
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04$-"D%!04%!04%!04%!04%&:%I7:4%!04%!04%!1'I544%"04%!
M04%28DU71FQA24%!04%!04%!04%!04%!04%!04%!04)95U9O9T%!04$-"D%!
M04%B-DE!041J,4%!041K1FA:5VE!04%!04%!04)I;5%!070T54%!0FIA5T9L
M84E!04%!04%!04-39T%!05!H04%!=',Y:UI83FH-"D%!04%!04%!04):2E)5
M36=A2%(P8T1O=DPS9#-D>35P6E=-=5DR9T%!04%!04%!04%!04%!0EI*4E5-
M9V%(4C!C1&]V3#-D,V1Y-7 -"EI73759,F=!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!6D=6
M>EEW04$-"D%!04%!04%U4U561$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&
M2DA1:4)J8C)X=F1826=C,T)H63)59TQ30GI5:V1#04%!04%!04$-"D%!04%!
M04%U4U561$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F18
M26=C,T)H63)59TQ30GI5:V1#04%!04%!04$-"D%!04%!04%!04%!04%!04%!
M04%!04=2;&,R34%!04%!04%!04Q&2FQ:;59Y6E<U:EI30E=A5U8S85<U;DE%
M3G9B;5)P9$=L=F)I0G -"F)I0DI254TR351K,DYI,'E,:D5!04%!04%!04%!
M04%!04-X4UI76FQC;59U63)59U9M;&QD,FQU6GE"1&(R-6MA6%)P8C(T9V%7
M-&<-"E-55D1.:D4U3FI9=$UI-'A!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!0C)A5U8S04%!04%!051P4#1!1D8X=4%"1% -"D9!040W8W=!
M0D)-3$%!3F-N9T%!04%&65=6;V=!04%!04%"34-664%504%!049C9C4R,6Q9
M6$U!04%!04%!04%!44%!04%!04%!04$-"D%!04%!04%!04%!04%!2U!!04%!
M06Y.<%IY04%!04%!43%*54E'3C%C;EE!04%!04%!045!04%!04%504-G05!!
M0E%!1U%!94%#34$-"DM!071!1$E!3G=!-T%%04%244)+044X059!0EI!1C1!
M67=";T%',$%C9T(S04AW06=10T=!27-!:T%#5D%*;T%N=T-K04MK07)G0WD-
M"D%,8T%V041"04U907EW1%%!3E5!,G=$9T%/54$V=T1W05!902MW14)!46-"
M1%%%5$%2:T)(=T5L05-S0DUG131!5#1"4E%&34%624(-"E=11F=!5V-"8F=&
M,4%8=T)G=T=,05I)0FUG1VA!86M"<U%'-4%C14)Y44A2061K0C112'!!9DE"
M*V=)1$%G=T-&04ED06E90TQW230-"D%K14-3=TI506PP0UIW2GA!;F]#:$%+
M3T%P9T-O9TMS07)90W=13$Q!=%5#-$%,<D%V541!04U,07A91$E1371!>F=$
M47=.4$$Q;T0-"EIG3GE!,S1$:6=/5T$V241R9T\V03AC1#!W4&=!*W=$*U%1
M1T)"345)05%T0D1S15-!4E9"1TU%8U%2*T))=T5M9U-O0DQ917A!5%0-"D)/
M144X050K0E$P1DA!57)"5&]&4U%664)78T9D=U='0EI91G!G5S%"8U5&,5%8
M;$)F64="9UE70FEC1TYW6DE";&M'86=:-T)O=T<-"FY1879"<T%',%%B:D)V
M54A"=V-:0GES2%!19%!",D5(9$%E1T(U:TAR064O0CE)2#519C1#07-)2'=G
M>4-%64E79VAU0TE)26QG:7$-"D-,-$DP9VIN0U!S2D5!:VQ#5&]*5'=L:T-8
M:TIJ=VUK0V)O2GIW;FQ#9G-+15%O;D-J,$M607!Q0V]%2VU!<75#<U5+,T%R
M>D-W<TP-"DEG<S5#,45,85%U04,U9TQS079)0RM%3"M1=U-$0V]-47=X8T1(
M54UJ9WEN1$U!33)1>GI$43!.2F<Q0416;TYD03)/1&%K3G=W,V4-"D1F9T]%
M=S1U1&MK3UI!-2]$<'-/=&<W4T1U-%!#43AL1#!%4%AG.39$-5E0<W<O4$0K
M=U%#4D%M145-45E20BM%2G-1=5)$6$5055(-"D5X17A%53A28E)'345A;U)Y
M4DAO16=C4TIH2D9%;5%3:$)+:D5S35,T>$U$17E-5%%X3FI%-$U4<$)01D4K
M555":%%N1D5K56%H4TP-"D9+,%5Z:%1W1E))5DY"5E=&6&=6;7A7.49E05=!
M>%EM1FMK5V)"85!&<DE7,6AB-D9X,%A14F1L1C1K6')H9E-&+V-91WAH04='
M55D-"FEH:79'3E59*VAK9T=555IA>&U21V)C6C-2;T5':6]A55)P,T=P-&%X
M4G)S1WA18D]X=&I'-&]B<VAV84A!26-+:'A32$AS8V]X>DT-"DA0561(:#%(
M2%A!9&U2,T1(97=E1F@U04AM;V5L0C8K2'5K9D5X."M(,FMF;$(K+T@K;V=&
M4T)"24=W9VU#1$5)4$%H2$-&24E856@-"F]32$])9G-I2GE*5DEO26ER>4QD
M27=O:D]#3FU)-5%J=VE0=TI".&M44U(X2DMS:S)I54I*5&=L84-76$IC8VPY
M>5EN2FQC;6AY83,-"DIU9VY'0V1*2C-O;G%Y9F-+03!O4'EH>$M+26\Q0VM'
M2U1G<&%Y;61+9$%Q06EO,4MM9W%M>7)02W=)<DYI='!+-3!R,%-W1DQ$:W,-
M"F)I>6E,3F-T1$,Q0DQ8671Q>3-H3&A9=51#-D-,<F-U-VDX:TPQ;W9K4R](
M3"\T=TY40G--2U%W,GI%4TU5;WAG:D<V369)>4MJ2FH-"DUP<WDQ1$U.33!9
M>F9Z3S1-+T4P2WI2;$Y*-# R1%543E4P,6AZ6$-.9C R3GI:>4YQ-#(V5&-K
M3C)!,VY$9EA/0E$T541I34]-9S4-"D)4;$-/6#@U=D1N-4]J639D1'%Y3W4X
M-TQ4=')/-F\W-D1W;E!'53AP1'IJ4%-).5E4,FA094$K240U9U!Q02LT1#AH
M4#)%+V]J+VD-"E%#3D%:14-M44]D0DM51G%187A"-VM)=U%N2D-T54PS47IP
M1&954$%204Y%4C!32U)--49%:U964EIP1C-K66E2;61'<3!B=U)Z5D@-"F4P
M9D%3059)4S!I4E-.9$I(56QJ4V%L2CA%;S-3;C%+>$5S35,Q3DQM:W9I5$-P
M36-K>39444I.4VLR5%1D>$]*535U5')D4$%%.4H-"E0U3E S5D%N54A&474Q
M14=55D)2;3%(;55J1E-F1DQ(57A.5%@Q3W%5+UI546Q34%9.=%9+1E8Q5F-*
M5T0Q6F-6<6Q7.3%D158U2E@-"C1&9W972#%9>3%K85=7;%IU1F](5VQ:87!L
M<C%7,%9B;%9V;%A$5F-H;'I76%-D9&5&,TI8:'!E8D8V.5AW.6995BMZ64%6
M9U8R0W$-"EE0>&A4,D=I6696:5-72V-9=D)J43)/6%DK=&M11U-56D]L;%!7
M5U-:961M4%=A4UIU:&Y05V546BML;U R:5=A3WAP43)M86%F1G$-"E-'<69A
M=F1R5#)U;F$O.7-6,GEV8E%H=%E',C5B:$IU83(W16)X-79E1R]28T-T=VAN
M1&=C5'!X;%A(=V-K='EP;DU"8S$Q>G5(454-"F1(0C!Z2%5O9%E6,31862MD
M<'0R*TAD5V0W3C1%6&AU94UX-4MN;4IE960V4FYQ;&5W4C=9,W9#9D-&.&=8
M>FAF548Y;U@T0F9M2BL-"G=N.&IF-%(O-5E"2&=+:4)#;T9R9V,R0TU)2U-G
M=E-$5C1/-FA",D5G251J:%5E1G$T64]H;DM',31C-V@U*TE"26AP:4TV2DTT
M;5H-"FEF-DM:27)+:7I#3&QO=CAJ1T]->6\P>&I::4XO-#5M:G,V4$YO*V5K
M06%18G!$5VM4*U)Q2DE2:VYQ4S0U3DYK-V%524I32VQ04U8-"E@U6$IL:E-7
M;C5C2VPS5U@T2FA-;4QI6DI*;5%M9GEA84IR5FTP2V)R-7=C;DEM8SDU,6MN
M9$ME44HV=6YX,F9I-2\V;T=M9S)+1D@-"F]B86E*<4M7;W=A:F1Q4&UP1F%K
M>#95-'!A;6U'<6%,<'8R;F)Q9F=Q1DMO>$MK,W%A;7%(2W%0<7=+<F1A=G!R
M1GES,$LQ17)B:74-"DQA-FAR>&%V:3=!07-(5W<V<D9G<V1A>5,W3$-S>FEZ
M<G)1;'1*>3%%-U=+=&=',F5B8G=T,FDS-$QH6G5.1S53<FY#=6IU-G1B<W4-
M"G4V93A)8GEB=E)7.6HW-$MV;U,K+S<Y-G8O6$%C341S=U=F0C0X2F9W='9$
M5TU057A&2$5Z<U9,>&-J1U)S8D1X,$A(=CAG.7E,>DH-"D]S;35Y:FI+=#AS
M,GDW8DU.8WDQ>E183G1C-#)Z<F)03C@K-#!$;E%U=$4X,&(W4U Y3$(P,%14
M>'122C%-=E94=%A2,6Q85S).9&,-"C$K1%E:3FIO,E=Z6CAD<#(R=G9B9TYW
M1C-)<F1%3C)7,VAZ96]T.' S-B]G3G5#.3155&AZ3TI4-'1V:EDK4'(U2%!K
M+T]7135G,VT-"FQU8V8U-FYO375I.#958G P3W!B-G58<F-/=C<W26)T164R
M8S=I:G5T3SE!-SAZ=U=01&PX6$QX+R]+33AX;GIP+U$P.4U,,5506&4-"CEM
M,S(K+V5+*T)N-'%0:S0K8V8V5B]R;BLS9CA"+WE9+U-N.75V-4PO='HO8F8O
M+R\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44$-"D)G445"055%0F=51D)G
M:T="45E*0W=G1T)G9TQ$06]+0W=O2T1"04U$07=-1$%W441!-%!%03A/1$)-
M5$9"451%>'=B1WAS8TAX.&8-"DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H
M55)&4F]F2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&8-"DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%7045!07=%4D%!
M25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!448-"D%W24=!
M44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!04%104-!=U%&0F=C24-1
M;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34(-"D%G35)"04%&25))>%%614=%
M,D5I8UE%54UP1VA">%=X46E00E5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS
M4$-.55%N:S9/>DYH9%4-"EI(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+
M0G)Y-"]013%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T
M95@-"G W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6G%B;DHR
M96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1544-"D)1645#04U$
M8E%%04%H141"0T53355%1E523FA)9UIX9UI%>6]B2'=&34A2-%-.0T962FEC
M=D5Z2D121&=H85-5>5=I63=,0T(S4%,-"DYE2D5G>&15:W=G2D-H9UI*:EI&
M1VED:V1&53,X<4]Z=WEG<# K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2
M;%IM9&]A5W!R8D<-"C%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT
M>4YJ;RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V$-
M"D%!=T1!44%#15%-4D%$.$$Y43,Y+V)71G$Y>F-T>&I4=S-*2C9!1'54:V]2
M36I167EK26EY.# Q+W=!-#8W8S-+>3(X<E=C151";V\-"EEZ,4E0-UHO82M8
M5$YL:3 X04XY,UA:33AI9'1M3BM99E!V;4<O;6%/-'579V=04S-G2FI3;G91
M.&TK:S5D2%,T=TMQ,G%E;VY,<7@-"FAY1UES1TQC=#9N<CE/8W!R.4=C138O
M:%!*67ET3TY%.#)E63E+;%9R3SEK15DV=U-%=D52-&-'<5!U>D=H;6Q(:U<R
M1U-1-48W0C4-"E X-U<R=E)E:DUG='12459E1W9W=4(Q84UN9C5J=&UX=V%K
M5#(V=61J>6-8=EI.;5,R=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W4-"GA6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9G*W588C9R<D0R
M-FUT=F%S63!8<UA'>G0Y*S):,DM00D<K<&-,2DP-"FEL6%%-9C%U>45)27!M
M4FIL8E)K:E1!9&9H3%%/-F9B:7%W.7=/;WI+-D].,5-+>'9W>$%9+T-E=5EE
M<G=$3FI-9794,W-X<WE+,'0-"BM63G,T<61G,%A):D9K96I1>G=8354X1$=/
M5TIG>4]/>$=5.%I"<T]40TPR8E1R=UAL;$1C:6=-:3%91'-W,EEF9FY266-N
M2$%38VP-"D5:87)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)Z1%$W,$DO<75A<W@-"C5%*S4S
M>F%:675T>'E54$U&-'-P62M/2$9';4]75$-B=&=Z;DTR3&E&9S%O2U1/1C-1
M35%P.7$W6E-','92=DQ&<71X64Q+-2MW>%$-"F=$=T%0-FIN2#ET=T5-*S,X
M478Y2#9(33 T=4Q+8E=*5F]&1D)M;T1L9TTX.'%%+V\U:U!26D14-45!-79/
M>GHV2S@R861:;G$W1E@-"EEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3AB=F5E;39L9%=B8D=#5FQ(
M*W(-"E@T5#E),WIC>#E545A54SE*25-V54PX1E-786=(56Y,27AA-5-9:G%U
M;WE3:&]B96]$8DY*-V4R5$HW;4E#;&]0;#8O,4,V5S)S-%<-"FQK4%=N4E(T
M<V5G2'IY;DIK:FIJ>%-.0G-J17E.0C90<#)L2%1,9&).9V9546MY16EL5U!8
M3T8W43%2>C5426EU9SEZ<W-74&=&2G0-"F%X-VI-5TEB9WIZ>2]!671/56M5
M36I&+V\V1#E78B]247)(-S!V0B]Z6C$W6$Q8.'=.5F=T9%)U;TE%*W(X26]P
M<$515G1O>6%+<$$-"D93834Q*V=X44]'2DE(6#=Y.#ER<W-H;4E"4%0W;4MP
M<C-M-E)E4V%J<41Q96I,3DU2*T1:;&Y&:C=O+TE/2TUU5'9L.7)N,3=Z9$<-
M"G9*.5(Q0D9(5FUM;4$O1G-2:7@Y,&9K1D]82C-Y*S%.=$4O3E!Z=G!--D].
M4VQV6590>#(Y-'AN5F@T8VYQ-"\R3$1+8W5H>%1(2W8-"F,R-#EB;&=E9"LY
M.4-E55!.3F@U;C!/2%9,449/4DM4=T4Q84M69G1)5#,V,4(W:D]D,4=!-' X
M2F5G=UIX;&IX0C1F*V)/=F$U82\-"FU"<7-&<G%.,4)!;C%F:$9&3DEI0W1T
M1U125DE!<5183C=O355$:&E30C$K.'5K,3)747I%06YP.7HQ8CAN-W4W=2])
M;&Q09%136$4-"GI35&AP6E=,<V%3<T)6;4I/86IT0TE'66=B8VYA-D-23TE%
M*V).37=N361I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G,-"E9D
M:7)S5F1I<DAD83AJ-EAQ*W%#+W5*2DEZ=T-Y>'A52$UR,$I*0C=B6FM9.51+
M16%$:C5.4$=5<DQ"+T]0-6-8,&5O<3)K=VUE=VT-"D=Y1F@K-EEB14U84%$Y
M46-Y.%=U9TDK<S T;6)3>31V5'E59$TO2W%/;VLQ4S0R-BMH0C$K;'E0,41-
M3% R=T]50CA3,EDY168T:7H-"D=X,#=4=$UT>&(R34-14D1Q1D<U23=S5'5X
M*V5A4$YN;FM.>4YU9$-!:4M#;&5145A(.31T5TA2:#%(,#5I5$%,26AD<%=H
M=%!/04,-"F9253%D<61"-&902C9F5$=C=DI&57I&5E9&0W%+2V]O04]W1V(P
M0VA3=FUJ.#1V+T%#62MR+SA!4G8X03E1<U=D5#)D+V-2*U S;#4-"G)T1"LK
M;#A0=40Q+SAL=B]!0U@Q:B]X:VXO-5!.;6TW4R]V:CA(8CEN9C-)*TQ/1U98
M56\T1$MW25I32V=G.5%2;4$U>C4S+T%$<C@-"G5A6&\S;6%#5%1O:W0T<BM$
M,7!,9$)25FM$1E-Y<4YL1&)B1'983VLW37I3;D$X6%%V4&1O-%EW;G0Q6D@O
M>FIV8U1(.4]7*S5G2#$-"F5194-U9E5"+W=#0T$O1$U8=&=$,&XS=5(R4U0V
M:#=K,3@V96-0>7<P+WI.95=E=#9#.3=Q8UAP+U=,;&)E0U%.>6E2:RM*-499
M,%$-"F=B:DMT3G X.&]!=VQ59F57,U5A:D)'6D5O,TPS0FUF:V95=$(Q3'DU
M0F0V1F%'># Q,FM%5G-Y2D=62W51>#1O>G)U,B]834Q646X-"D=:17IC;DXP
M,#139T1!545X,6I7.4LP87AE*S%/-5,Q=%4R3'5E<#=+<6EP62MW1F-R>#1P
M5$Y21FQS>5I)=T9Y3D(U,V4O.#5!95<-"EEP:6QP65A6>D=#4C9P-%)G*S9G
M;&I4-3!Z67@W2FU2=5%(6%,W5F=$<T-56&]V-39E56(K9%E,>$HY3EIJ4EI:
M9TAI<5115EI#4U -"G!7;G9K379:95-)<U9*;FHW5'AY3DA:-DI&3$9,1VMS
M5')*1DE!>4]P1$MY;F-%16)%2$YC4E1S06)5-S(Y=$Q',&QU-WE:24QA1F4-
M"E5S,&@T<6](:51H:D5Y3D1M:55H15=E5'IJ5E!Z.#AQ,C!R4C).<F,S+T@O
M04AA07-56BM833@O=E5:<V]D;%I$>DE$<G Y<5EX>4(-"DM#9R\U>4<P;&TO
M,&I2-VE.9D=/5DA0,T5*:WHR4DQP24U",G)(<D5P9')V+T]15GDO2U!1=$Y7
M269S,T8T951F.&EK24%0*WI/5S0-"G5Y4B]'9FLQ-64Q5"]!4&UZ<CAQ9DTK
M;V59+TMX=F12;$4Q-4AC>7=Y=4960G12,4%#9T1:6$%Z03$K0T]02E5E5D]D
M;V-X>5DW4$\-"C!8-7$O35AY=#5:8C!R*S5-;#53;W-R8V5P3%-L4GE&47$Q
M+WEI36AG,&543'5"=#-S."MR>#0K6C,W;4=N+VY)6%)/5D)P5GIX<G,-"F5C
M9&%F3"LS33,K4THO>F<T9CA!2W-F-7!:8C55+TTS>7(U;&Q&=&%43F(S>"MZ
M6C-)0U-.459006=S<F9)1W9T;4AN,%=41G5D>#,-"FAY.$=S>#5.:'I:6&U)
M-51Z:38O4&IY:&)833%U.6YQ0F5&,FI9<DA$4W%':'!7665'8D]06E=1:3=J
M.78V;EA3-U1X9S%5=G,O5WD-"F)Z9C4W.'8K5EE%9E5P5V$T;$)-1G!#03!R
M9V)6;U-!1CDR3UEU;C!S.' Y4$IY8RMP:&E(<5E:8F8X04]16&PQ-6Q7-# R
M-FAI2F\-"EI&36)K9357<35M>3=*;E=X1&AJ=%=&-V=V4CE',7)3.6$P*U!5
M3DUU1G5B5U0W36DQ1D-/<7-P;U9).$1M='E9<%%.4T9&,D]02D<-"EEU2G-)
M,TLR8G-68U%#2T560C9J16A51F-A5VML5$<S02M",T=9=5139SAT:S)G6#!3
M.$HR94]N>F(K;5EX,%4K.$QA*T1Y*V])864-"E1L+VMR="M*>6-.0U T:71P
M=$9&2$5G4TY1<41O0FUD1TEI2T-&,E-6.'HO04IX9BM42#%F+V\S+W=#;U=,
M3V\W3R]U22](-WDX,3(-"F@O9E,K2#-":V9K1#@S=$4X="M73&938G%Y=5IP
M;UAK6G!)=E0T;FTU654U340S>D8Q9EHX<W51>4)$:S986'AX=T530WE#6"]N
M250-"GDK23)-5VU88GE!9D-R;4Y62CDR1$Y4-W-X>#)24'%1,VYT5TAC6&PR
M=6%R-6HX*RM:1W59<E(U-VQW23=E,&=5=4EO;$HT<EAW<7@-"DQ-9G=Z831S
M8TY00W(R9%IL;E!03S8S93<O;&HU26)Y<&]*:'53<F%L94U*<GAL,T-K0VEX
M9SEW;2LO:51M9S%U<#A79&HV4GED-V\-"CE.-%5+4$UV1G9Z:2]W1$IJ-G8O
M04Y'+R]53$9M.#=/+W5)+T@W>398=$0K*VPX4'5$,3,X;5I%:B],<7IK9&=Q
M23EW>DUE9T%L66L-"FY.3C)K3'I(-$\S-U!0-VMF1C1R-2\X04]L-35P,3)7
M-5IY3E!H67!95R]13$=$<WA(.'HY5RLW;TTS;6LP=WA1<G(Q9$QQ=%%C<W(-
M"C9D1V$K5"]Y3"]33VMW-FAR9#5*871C;TI)<E-&5C5Q:F)Q6%IU5S5'+T=M
M,EE/;S=5-%IC34)D3V)P*WI/2TYY3E=K4#5J9FQ:8V4-"E9)63<K,75$96%8
M22]P<S=+1FMI8VEQ:#9B14Y4-U@P6FMA4%A$2V%)<512<3E%8U%S1S1P-2M2
M+VYE-6<Q16578C)5=F%825IT4#4-"D=V<'EQ0WI)2R]S=4MM;FHX.&\W5#!W
M369%2$UC,B]S,U5K2&=023AL,S4O-B]D='%L;&]58FQB4T]%6%5Y1%E023=-
M<3AV2&EQ8F8-"E!",E1I2$-:.653.7%:5'A#2%1M;&XU469L-7!V;5=3-C%(
M5F<P;&A:<W-59'-R1F95:TDU2&UY,&)I;W P3SEF=G0W43%K<U92:GH-"DQ6
M;TY*2$I:;'E$,%AZ1BM49FLK+W="36QJ,#)Z1FAF<6@K<E1X=3E/64=W9%=9
M9V<Y*RMA,T0R:FMJ3#%'=S=(3#)F:FQ(,&EI*V4-"DQ+-49T95$S0FE38U)/
M<FU'5E%Y3T9.4W)!.5%E;61(2TYI;FYO;6IB-DXX,V599$HX;F535W8Y1G,T
M3$MF54]!<V]);VMJ6#%:57(-"C9J2V=!2E)"6#=H;DXV9D1,3FQQ4DIR;3E&
M;GEX=S1R:4%,-5!$+TM(;&Y5=D]F;5@V<3 W8W!/5GAF,VML6%E*56-M3F9T
M37AA9SD-"C@S=6]Z>'=W=79C2%,V9D1,3D]R.35E>F8X<4TX:F95+U$T,U!R
M8V%F5R]74'%6.&5.4%0O=T-&>E-F>7!L=3EN8V9Y8FEQ=#-I+VT-"B]W07-A
M:C50.'AM>6%9;&\K33EL94I60WE6*T9X43%69WEK9&5O>F0V9E!(3D,O;4A4
M86I#8TTV*U0V0B],6'I7+VUB>71"951K1RL-"F=*=#<R;3%:14%03"]:<5$S
M>GIN=&)G.$Q)44]834\O,&5F>$U92C4Y6'I4<E@O2%IV.$$O;4EL+W=#2FY/
M;7AF4U!C.#-K*V\K.38-"D9O9FMB6"]Z23%#-SAY-FQD9E5B1S1K6EE82VU2
M;4-'9U-*4U9(0E!S.'$Y9D4Q>E@U9%9$5%)%26EY-T1(<' V9VUC:E%3;CAX
M9GD-"G9U+TM+43-K5GHY9# R9"]4.55R=V5/4VA)5F=#=TE)0F]C=#!E=4=B
M87%K,6%V4DA&=F1H3F9Y1S%Q93(X,%1A5UA0,6$O9UIV5#<-"F5R1#A3="]W
M2$E:5C)R:D)X.%A51G,W37E%5#1E:&4O6GIZ=C-9<3=&6%EQ-T9867$W1EA9
M<2M:+W=!-'8O2FHV=CA!.4<O+T%&0W@-"EHQ2%HS.7A(-"]E6&UU,% W-EAW
M*S1*,35(+THR,CAY*UA)3EAF5DAT;6UA4E1#<TEC1# S2R]A3'(Q<&Q'<3=2
M3TM::E9T*VTW4$<-"E-!;&1*-B\O041J=F$X5'<Q>'<S66TS0D@O2G=::B]Y
M=V8U=C)T+SAK:BMD.6IZ>GI:-5$X=V539%9H17-X55-697DQ0S-::T1C858-
M"F]24FQ:86EO>EIA9E51>G@K.$]U>C9E94=8,T8V>BM4,S5I6&9M0TMB4CE7
M9C%.4W1%.5='-#9'5T5%2V58*U5P23,W9RMX>E5D;S8-"DU9+U9(-E,W8G,O
M5FY*-EIF54AM6#5X9BM42#%F+V\S+W=#;U=,3G R9"]C4BM0,VPQ;F%(.3E,
M-&9C1V4K5V)I4S,O04-'=EI)>E(-"B]2=3!R-U!+>4@X1WI8-7AE<DAV1&XT
M5%=K4'AE4#A!;#9Z4SDQ+U1,2C$U2F,S8T5,3#1I4U)622](3GIM;'=W2C=G
M6%59;SA5=T\-"CAH.61G04-G,D$V1$]/9719>BM:;'!(9&51.6%J:S9*8FU5
M8E8K2TEI4F9X6$UR4E-R3D@S=4YR23-I;#=N>F0U5W5M=%!-,FLS2VL-"F=W
M,VM$-V5!:U=O*VM:,#)E3C0U1'E,>FU#5E1I9DU06"]Z>#AK,V5O=WAE67)&
M9E5E>&A-5CE&*S$V2W-85C%(9FE78FPW9DQ.3C(-"EAQ4D4X0C8X;F(Y<&%9
M>4A'3VY.9T@U8F9M3DPU475B:4]A,TXQ<'0S>$TP845+-D]T44A3=7@R3D-$
M-V(U<TYB;R]'06\Q24]";SD-"E@T4DYI=U=C95EF>CDP>5142F]D1'-R;&(R
M5D-I5#-):E)9>3(S24)(:TQ%9'5M64](<VU1;&-Y2SAN3GDY<5)-86E$9FTX
M,#AK*U0-"DY4.# V=DAA,C!B3%IO=TXW9# K0TM/=2LO5&M2.6QF-%9Z6C9N
M57AX4G,X*VIR9$YP-5I:54]85FYN+T%$:T9.-F,K:&%F1T]&=D0-"D9+-F]/
M;3521BLT2FUV-TI&:5(V=60R<60T:#4O=T-69D]M="M6-4QI6%-J17-L,$97
M5G!%1#=)4U%"6' Q>EDU.4Y(3%A&,&-$0G$-"DI9<C1E<DEV*U8T*V90.$%F
M='8O04UI4B]836(K4SA0;C@S22]L3$PU36,X,65C=&$X,%1W5#9Q63)K=&Q:
M23)J44HX3$=T1%1R;50-"F<P,&-126HQ8V90<4I:4T1,;SE*+W=#8V0W;5-U
M=5=P,VHO,&569EDO=D90,S=F9&UT-UAJ.4HY-W-E>50Y43EZ>6)7=BM/>F8O
M.$$-"DU23"]!351/8F)&.4DY>G%S;C%(,W9Q:GEH6E(R4&QB4TQ61C1I2S!H
M1$0O04-I9TQ(-E=*3V-P<4IC5U-2.'DY4G T.$]/23AM3"\-"D%*-"\X;TA,
M+W=!>$U0-GIM5C):+V9F075.,FPO9&9&-5HK4S,O:W=B2"]J2% X03AM5WIB
M9'!F,THK2#-U<C=/+W9H.%@P;&Y-=E(-"G5X5C)+=7A6,DMU>%8R2W5X5CAZ
M+VY&+S5-9E8O=T1O,R\V:%ES-FIS-RLT:CAF=DQZ6&%(.3E,-&9C2'(O-4QF
M*U,K<V8X06I*4"\-"D%-;FUZ5&1P9C-X*T1T*WIV-VMF1FY/641N4$AV*V-G
M=%<P.7)85&1+5C%E+U-6<FE24E%T2$AX-&IL-&-Y9'9L;34W27AM>DQO-FH-
M"G1824M%97)%=GE25UDK9G)9>#$T3$)/6F%F>3A+8B\W26I->G1/=D)0=D1I
M9&TS-&\K2T8O3TPO04UM4'$O.$$P8B\Y47-75#=/+W4-"DDO2#=Y=S=1+W9P
M9D0W9SE).&DV6DIQ;C5+>C9F14]5,7A&94Q#;S=Y8S-+1"]G9TTQ;7%N=V%O
M2'5P,E=M:'AA879E.$XP-C=A>#$-"DLQ=D].5W1:;S5U4&E9,D15+T1.-T]0
M1D5J=F1(0UA$24AU9EAL;&57,3=A43-L<S1K=#=H1FQH:TA2:V-60BLW3U!L
M17A.2&U(<F\-"GE%:%DU350O041C,65$5'9)=6]+-VA:<C%287=*,UEY16-Q
M9DI!>'I,-U!X;5=595<W:6$O24DT:C4W4$)F24]M4S9L-7HP93%J6&P-"B]P
M56-S;B]'3T9V568O:%5/9$)Q-3A/2U(X;E$V5TA&:VE03FPS-35E84Y2=69-
M:C9#<VI2-F99<$=Z46EO5U-74D)*>F(K8FE'04@-"FAV;4@R6&=I26-F575:
M,FQM2FYW9$%Y;CAV4$MV-6$V=C5.<S)N=')E-'9+2#8X,'-N1V1:<3!917%Y
M<W$O>6IW>D4Q;6901$MA2D$-"C9D>FQA5$)H;FI&9U@Q6D)"*U=0-5AW4T-2
M3E!G3$1T2F-3>4PO=TQY378T6FIN5S5Z,5!Y+UDS:E)90C K,6QU;C)M;C)T
M;VM';G<-"GA15VDO=T(S2$%Q<D=01V=88DU/8VE48W5B;'AI04M(2C5(+T%-
M-41A835J,&95,5@Y,G!L='!7.$-W5C1X+W=R-75/>4HO5D@T=7 -"C=7:#E-
M:W8O04]C9F159V<Q;E4Y3FMC3$IE=WAY46<W8VI!5W%"-SA:0V9O>7IT94)-
M4DQU+U,Q.6Q406M9.2\V2'5M848S:D=F3F8-"C5H*U<O2SDQ8C)U<'E3971C
M;UI!<TMH>7%!,$1/2V=G36$P*U)Z2W=A3V5517@V3TYN,6--4D%L,5(O;'9Z
M6&]F;5,Q:W5D26YA94L-"D8O5&Q,4GE2,&%L869'<3$R,S)Y=DYG;FE.4T10
M1&YJ:T9X9DLK=&8X9&TO+W=#66E8+VE:>G$X6#!J,U!,-5!Q4'9F5V5I9CAC
M87<-"B]W0UEA3"]I07IK8W8Q2#-V5C0O<$AU65HK95 O2T)Y+W=$351$*W,U
M;3EM9C,S=TQH.7!F,UAX95=F:W0O-4U'>"\T>'HO.&U7>F(-"F1P9C-**T@S
M=7(W3R]V:#A8,&QN3792=7A6,DMU>%8R2W5X5C)+=7A6.'HO04IX9BM42#%F
M+V\S+W=#;U=,3V\W3R]U22](-WDX,3(-"F@O9E,K2#-"2710.#-E84Y.=%9T
M3$163&TQ=&M*2U%X4TUQ9W-A;6="-VY,-39F2$DR66=L;VAN;D550U%%43-N
M-WIS>6Q4<FPW43<-"F)4=40Y-$]2+TM9=C5O*U1,.#%L+VY(-7!61$)Q5W%8
M=D-'3V$Y=EIJ6&EO85=2>64K,5=/5VMX:4XY9S%!4VMD='DK9U!Y:R],>68-
M"GDQ6GIA:'%903%A.55)66=19E)H0C5C2VHY<&I1=#AH;E!D;V%W6E1W>"MK
M3R\P1VM/35A,-FDX<"]/3"]W06U0<2\O045B+T%054P-"D9M,S=/+W5)+T@W
M>39R=$0K*VPX4'5$,2]W1$IB+WE8,6HO>&MN+S503FUM-U,O=FHX2&(Y;F8S
M22M,>GHX,B]Y,79D3S%+-#$S4V\-"D1,<&0P>&QU631W4V)E4G0S2E5F-W)9
M-V<Y=6YH;7@W4#%O;$51:V954'1D9G(Y1UEY330O4V9S670U82]-9GIB-61T
M5&%A9&1J-G -"E5L8F5:0DEI:S=K<%AD82M!3DUY.#)J>#5$8VAU-'5(5C5-
M66](6D-A>C5G.#!E8G13:"MU>7DS.3$Y:3)T;VLR5W954GAO2V(P,S(-"G%C
M;FIW-#A-9'1G>'E:6C5:8C=L-U@K52]W0U<P;FQU,V)63E559G!I-E1I26A1
M*VA'9'ET4C%D=C)Q9DQ.2'(Y8C1P-%DO4U!T9'H-"F]D2#19-'!F569S65 K
M971X-6)N.'=21WEL6CE::5%286EQ04=)2TXP1$Y8*SA7=$-!3VY7:$=:+UI9
M;4EB+U0P8TQT37=-.79Q-G,-"D%U3D$Q,C)53F,V9&11<7=$0G!)6D9"0G!1
M,4DY.#)!>7=026AW1&EM3UE+1RMP6&XK*TI0*T%B*VU3-&@S<T]%.7ET<#)Q
M-G)P5C$-"C8Y:&145V1W:#-A2FU1,4A:9T]V>4]#94]->%)&:&Q#8V]'=V%E
M-RM79%1T+W=!>F9);#-P,G)!4C9H0U)(3DUI.4I!3U5--G(R<BL-"C!V>C9!
M-6]-.$1P8V]L2&PK3$1V8TUX<6-2:DQN*TXS:D]U95@O369L1%=64S574S%U
M65@U,FPW2%5)+T4W4$4O9CA!5T\K8G)&;&@-"FUJ='5/-3 R5$901$QF63DW
M230O>GDX.7)B0T5Y5WIU0E0V=S!)-3$X9&E%<B]S8WAJ,EAH=3DS24AA5U=U
M:D@Y4#!V>E8U,S$Q,FH-"D5L.694<T1C,V-M,&-9-F-N641I:6=D05!K0FU2
M4$IJ=U$W9S!1:&MZ5#=Y*VMF2B]L97HX<S9$8C968DAM639V8U15;UI*5RLR
M-4@-"C1$=T9--7)56GIL;5I&-E!4-%)J9TEH.'1A,2]X,F(O05 U:4IF.$%I
M6GIQ<U@P:C-03#50<5!V9E=E:68X8V%W+S5H;W8X06E!>FL-"F-V,4@S=E8T
M+W!(=5E:*V50+TM">2\X04U41"MS-6TY;68S,W=,:#EP9C-8>&579FMT+S5-
M1W@O-'AZ+T%02FQS,C-A6#EY9F@Y-W$-"BMZ=C<T9D8W6C5G+TU$4G1"=35,
M9E5)8FQ22'<O9F]I3VI'4DAD1D%$.#9T-F)+2W(Q*R].2&@P:W-G=4Y/-GDV
M<4]-,&):3FU+-4P-"G-69&ER<U9D:7)S5F1I<4=M,'942C5$3$YA47EY=%1K
M-WAO>D=G;TMK:7942D-C:'E,17=I95E79F]44G8K5T,R+S5&2B]41#1S=3@-
M"F\X3U!C2&9O5%)V*U=#,B\U1DHO5$AX6F0U6'<T.7=6-V4P=&):4W1V0VM+
M;G%),4-G+V-":U1);FUY15%/4W)G4VAP=$PP>651>7H-"E=K37-R535/.&%-
M>&]+0W!)<C!Y46Y)8VEX34EN;49A0T-#0TU245)R1D=/:4EO5E)8,D=!:VYM
M:T%$:W9W2E-7-CAL955,=55Z6$<-"FI78VMR9F%C=U(X:69C9V(U9DA5-4)S
M2D@U=$UT4&I/-6E0:VI.33!(4DY,0D=M,D9V6CAV=$=#2DEY9FU604HK;DE4
M>7IN.5)*6G<-"GA2:CE)05(R5G,S>4YQ13DU6BM:3&UE-5AN95<Y-#AK>7EI
M=DM22E-71$1V5FAV;EE104U!0GE)95-M4TIK;FYB-E$X="]M6#53,3(-"C!J
M:U,K:71,<&=057,W;#%J:U9U-$A,:4A(=75C,6TP5U1'959J=D0P94A7635J
M;E(W:RMF5TY*4TU3=F4R-GA'<$1T2V=88G)U5%0-"DUC635D>&)Z:VHS:#1:
M*V0R=CA!;&969%)S53!H-')M.'1X24PR.&=O5EE(:G=4,4)S.4M%.39:=G5Z
M35=3151X8D1O2%(Y<%I94TD-"C1D>C%:4#A!.#0K-E)D5RMK86YQ8W%L66(K
M4TM/,W)T>49U2#5-4&)L2E0V37AE,7-G36A(=2]3-5A:5TUI2FPS+V]E<%A6
M;F%88TP-"E%88T5D>$$S,F]P5E8P4'I69U)M<&I)9S).;F%3:4-+2U1F-$(X
M:SAU6#9#<V$Q<B]C2E0W<55Y+W=$3C5F-7@K8E0K5GAF>E(X:S4-"G1,3S!S
M-%)"85%2,CA#+UII:595469*5D%'57EK4V)*='5J14%51EA)<%%B84YP1$U7
M87AT>7A.4U1%:$I**VI**TI,=DQ$=S0Y=U(-"FEQ<7%&54%+0E%!8D%!6D)M
M<'HR.79C4BMN4$5K,&1A.$I&1$Q597AW9VMC:T5!.#%+1%1.3F=K17-&<$1&
M24]J<$=Q<TLK-$=%>FL-"F5:44E22$E+:W1P851%;5='3U%M;%-Y:'$P-F12
M,G)G16E%;4E+<F=3-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$-"C=&6%EQ-T970BME4'EJ,%1Z3F-T<45-<F%D<6(O=T(W36EH-#5+0V=,
M>#%89F)Q0U!E=6)$4SEO4WA#:G9&=V14;TDU1%DR:S@X=68-"GE".#-X=E-#
M-G-P,#=(;DEJ9E-$1U(K3V)'4&$R4'%#-C0Y;#5/:$-K;C5#*V1M64%Y,DM!
M+W1'5U-G*S9-;D0O2W5,>E(O2F58>5H-"E(U9"])0WAG;5-F6'(T,UE5,4YP
M8F=X;V8Y85%N;5(X9W9Z>D9Z9')%:6]#;DMX9&QG1S5M,W)&=&)7.71B>#(Y
M=D=S5453:$EO:T$-"E965E)104%D<S%"2DIS=3%!049"57=*9&ER<U9D:7)S
M5F1I<G-69&ER<U9F+SEK/3PO>&UP1TEM9SII;6%G93X-"@D)"0D)/"]R9&8Z
M;&D^#0H)"0D)/"]R9&8Z06QT/@T*"0D)/"]X;7 Z5&AU;6)N86EL<SX-"@D)
M/"]R9&8Z1&5S8W)I<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL;G,Z<W1%=G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^#0H)
M"0D\>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C X.# Q,3<T,#<R,#8X,3$X
M,C)!.4,U-3 Q,$,Q,#)&/"]X;7!-33I);G-T86YC94E$/@T*"0D)/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#HP.#@P,3$W-# W,C V.#$Q.#(R03E#-34P
M,3!#,3 R1CPO>&UP34TZ1&]C=6UE;G1)1#X-"@D)"3QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U
M,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@T*"0D)/'AM<$U-.E)E
M;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N0VQA<W,^
M#0H)"0D\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@T*"0D)"3QS=%)E9CII;G-T86YC94E$/G5U:60Z-F$V9F0Y,F0M9#0Y
M,2TU-C0W+6(U8F(M8F,P968Y.#1D,V8P/"]S=%)E9CII;G-T86YC94E$/@T*
M"0D)"3QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,#,X,#$Q-S0P-S(P-C@Q
M,3@P.#-%144Q040S0T1$034\+W-T4F5F.F1O8W5M96YT240^#0H)"0D)/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y
M,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^#0H)
M"0D)/'-T4F5F.G)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO<W12968Z<F5N
M9&ET:6]N0VQA<W,^#0H)"0D\+WAM<$U-.D1E<FEV961&<F]M/@T*"0D)/'AM
M<$U-.DAI<W1O<GD^#0H)"0D)/')D9CI397$^#0H)"0D)"3QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#I&13=&,3$W-# W,C V.#$Q.#(R048Q,T)%-$-".#DV-3PO<W1%
M=G0Z:6YS=&%N8V5)1#X-"@D)"0D)"3QS=$5V=#IW:&5N/C(P,30M,3(M,#)4
M,30Z,S Z,3$M,#4Z,# \+W-T179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*$UA8VEN=&]S:"D\
M+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)"0D\<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)"0D)"0D\<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C X.# Q,3<T,#<R,#8X,3$X,C)!.4,U-3 Q,$,Q,#)&
M/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T.G=H96X^,C Q-"TQ
M,BTP-50Q,#HT.3HR,"TP-3HP,#PO<W1%=G0Z=VAE;CX-"@D)"0D)"3QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H36%C:6YT
M;W-H*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X-"@D)"0D)"3QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"3PO
M<F1F.E-E<3X-"@D)"3PO>&UP34TZ2&ES=&]R>3X-"@D)/"]R9&8Z1&5S8W)I
M<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS
M.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R
M+S$N,"\B/@T*"0D)/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT
M/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X-"@D)/"]R9&8Z1&5S8W)I
M<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS
M.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^#0H)"0D\<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C
M97(^#0H)"3PO<F1F.D1E<V-R:7!T:6]N/@T*"3PO<F1F.E)$1CX-"CPO>#IX
M;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
M?X4!X1?15  QP!7-T5_1F2\-X'*Z:CAH>]UD]9/Y_HK(_G_..(<;F53FQ$_=
MZ17PKY?J[L***ZKX3? KQE\=M:;3_!OAC6O$EU'CS%L+1I5@!Z&1@-J#W8@5
M[52K"G%SJ-)+=MV1X].G.I)0IIMOHM6<K17UEX<_X(G_ +0.NV"SS>&](TEF
M (BO-9M_,Q_VS9P/H3GGZ@4_&7_!&3]H'PC9M<1^$K/68U4%QIVJVTCKUZ(S
MJS'I]T'K]<>.N)LI<N18F%_\2_S/6?#N:*/,\/.W^%_Y'RS16QXZ^'>O_"_Q
M#+I/B31=5T#5(>7M-0M7MIE'8[7 .#V/0UCU[4)QDN:+NF>/*,HOEDK,****
MHD**^QOV$/\ @E/I/[</PM?Q'8_%2WT>ZL9S:ZGI0T,W%Q8R9)3),Z HZ?,K
M@8)W+U5@/I;0?^#>+P7;C_B9_$3Q/><'_CULH+;Z?>\S_/I7R>.XVRC!U94*
MU1\\79KEE_E;\3ZC \&YKBZ4:]&FN62NGS1_SN?5'_!.SQY_PL;]AWX7ZGY@
MD9=!@L7?.2SVP-LQ/ONB.??->T5YW^R[^SAH_P"R;\&M.\#Z!J&LZEI.ERS2
MP2:G+').OFR-(RYC1%V[V8CY<\]37HE?SIF52E4Q=6I0^!RDUZ-MK\#^@,NI
MU:>$I0K?&HI/U25_Q"OFG]N?_@ISX&_8LLY--D;_ (27QM)'N@T.TE ,&1E7
MN9.1"IR"!@NP((7'S#A/^"J'_!3N']D[1I/!?@Z:&Z^(NIV^Z2;B2/0(7'RR
M..AF8'*(1@ AVR-JO^-FM:W>>)-7NM0U"ZN+Z^O96GN+BXD,DL\C'+,S$DLQ
M)))/6OO^#N!'CXK&X^ZI=([.7GY1_%]++5_"\6\;+!2>#P-G4ZO=1\O-_@O-
MZ+VG]J+_ (**?%7]K.\N(_$7B*XL=#F)"Z'I;-:Z>J_W60',N/64N1VQTKPZ
MBBOV["8.AA::HX>"C%=$K'XSBL96Q-1U<1)RD^K=PHH1&E=552S,<  9)-;,
MGPW\11Z>+QM!UI;1CM$YL91&3Z;MN.Q_*NB52,?B9C&$I?"C&HHHJB3T3]GO
M]K+XA?LM^(5U#P3XFU#25\P23V6_S+*[Z9$L#91L@8SC<!T(/-?J[^P#_P %
M?/#'[5=W9^%_%L-KX1\=382%!(?[/U=_2!F.4D/_ #R<DGC:SG('XO4L4K02
MK)&S(Z$,K*<%2.A!KY?B#A/ YK!^UCRU.DUO\^Z\G\FCZ3(N*,;EDU[.7-#K
M%[?+L_-?.Y_3717P-_P2(_X*;W'QYM8?AGX^OA)XPL8"=)U.9OFUJ%!S'(3U
MN$49SUD4$GYE);[YK^=\XRG$9;BI87$K5;/HUT:\G_P-S]^RG-:&8X:.)P[T
M?3JGU3\_^'V"BBBO+/2/P;_X*O\ _*0GXE_]?MO_ .DD%?.]?1'_  5?_P"4
MA/Q+_P"OVW_])(*^=Z_J[(?^19A_^O</_24?R_G?_(QK_P".?_I3"OV6_P""
M"W_)D%Y_V,]Y_P"B;>OQIK]EO^""W_)D%Y_V,]Y_Z)MZ^5\2_P#D3?\ ;\?U
M/I_#O_D;_P#;LOT/KKXC?$71/A'X&U+Q+XDU*WTG0]'A-Q=W<YPL2]/J6)(4
M* 2S$  D@5^-O_!0#_@K9XM_:IU&\\/^%)[[PG\/N8_LT;^7>:LO3=<.IR%/
M_/)3MP?FW$ B[_P5X_X*!3?M.?%*;P7X9OV_X0#PK<-&&A<[-9NU^5YVQPT:
M'*Q]1C+_ ,0 ^-*X."."J6&I1Q^.C>H]8I_9733^;KY>IV\9<85,14E@L%*U
M-:-K[3ZZ_P OY^@4445^GGYN%%%% 'TE^Q9_P5 ^(G['NH6MA'>2>)O!:';+
MH5_,66%.YMY.3"PYX&4.3E2>1^RG[,/[4GA']KCX86WBGPA??:+=B(KNUE^6
MZTZ; )AE3^%AG@C*L.02#FOYV:]J_8*_;"U7]C#X^Z;XBMI)I=!O'6TUVQ4_
M+>6A/) _YZ1YWH>N1CHS _G_ !=P3A\PI2Q.%BHUEKIHI>3\WT?WZ;?=<*\8
MU\#5CA\3+FHO37>/FO+NON/Z J*I^']>L_%>@V6J:?<1WFGZE;QW5K/&<I/$
MZAD<>Q4@CZU<K^?&FG9G[RFFKH****0PHHHH **** "BBB@ HHHH *CN;6.\
MA:.6-9$;JK#(-244FDU9@<GK7PLM[S<]G,UJY_@;YD_Q'ZUR6K_#[5]-)_T5
MIU_O0G?G\.OZ5ZS17A8OAW"5M8IQ?E_E_E8I2/ [Q)+21DD1XV'\+#!%4Y9:
M^A9K>.X3;)&DB^C+D50G\'Z3<_?TRP;/?R%S^>*\&MP=4;_=U5\U_P %E<YX
M#++5<L6;VKZ"7P'HJ-G^RM//U@4_S%7+/1+/3C_H]G:P8Z>7$JX_(5SQX*K-
M^_52^3?^0>T/ ]*\%:MK9'V73[J16_B*;5_[Z.!^M==X>^ %Y<LLFI74=K'U
M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
M-(WX]OH,"MBBBOJ:-&G2A[.E%)=EH2%%%%:@%%%% !1110!\H_\ !:S_ )1[
M>*O^OW3_ /TKBK\0:_;[_@M9_P H]O%7_7[I_P#Z5Q5^(-?OWA?_ ,BF?_7R
M7_I,3\+\2?\ D:Q_P+\Y!1117Z,?GY^\G_!)[_E'K\-/^O*X_P#2N>OHBOYO
M_#WQ^\>>$=&@TW2?&WB[2]/M05AM;36+B&&$$DD*BN .23P.I-7O^&H?B9_T
M43QU_P"#ZZ_^.5^/YAX9U\3BJF(5=+GE*5N5Z7=^_F?K& \1J.'PU/#NBWR1
M4;W6MDEV/Z,J*_G-_P"&H?B9_P!%$\=?^#ZZ_P#CE'_#4/Q,_P"BB>.O_!]=
M?_'*X_\ B%.(_P"@A?\ @+_S.K_B)]#_ )\/_P "7^1_1E6+XX^(>@?#+0I-
M4\2:UI.@Z;#]ZZU"[CMH5]MSD#/M7\\K?M0?$MEY^(GCH@\$'7KKG_R)7)Z[
MXCU#Q1??:M3O[W4;D@+YMU.TTF!T&YB36U'PIGS?OL0K>4=?Q?\ F9UO$^'+
M^ZP[OYRT_!'Z6?\ !0S_ (+7:?J/AS4/!OP;N+B:2]1K>]\3-&T*PH>&6T5@
M&+$9'FL!CJF20Z_F.S;CD\D\DGO117Z;DF0X3*J'L,*M]V]V_-_ILC\XSC/,
M5F=;VV*>VR6R7DOZ;"BK?A_P[J'BS6K;3=*L;S4]1O'$=O:VD+333N>BHB@L
MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
M@OQ\ F\9_ ;P[X^LX"]QX-OC:7K*.EI=;5#-[+,L0'_78U]^USOQ:^&.E_&C
MX9:]X3UN+SM*\0V4MC<J/O*KJ1N4]F4X8'L0#VK\>R+,WE^/I8Q;1>OH]&ON
M;/UK.\M6/P-3"/[2T]5JOQ2/YM:*ZSX[?!O5_P!GWXO>(/!FO1F/4O#]X]K(
MVTJLZCE)5!_@D0JZ_P"RPKDZ_JJE5C4@JE-W32:?=/8_F.I3E3FZ<U9IV:[-
M!7[C?\$B?VI;?]H[]DC1["ZNED\2>!XTT74HV;]XT:+BWF/<AX@!D]7CD]*_
M#FO6OV+_ -KOQ!^QA\:[/Q5HVZZLW'V;5=-:39'J5L2"R$X.U@0&5\':P[@D
M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20210930_g10.jpg
<TEXT>
begin 644 biib-20210930_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
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MD\R[>UMDC,S\G<Y4#<>3R?4U<KS'_ALC]F__ **-_P"4B\_^,T?\-D?LW_\
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MO5G]&X;_ ':'HOR-BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJR-S\U_\
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MR7=E&U[)9K-/;VGG.L9EC)WKN 1E8X&<?GI_P5U_:?\ ^"8W[>7P'TGX!?\
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MVHK73HKRZ\"^!M1U?3K.?/EW%W% QMXGQR$:;RU8CD FOQ=_9LUK_@A/XS^
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M&V5#W+$?B*U* "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
M2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /S4\2?\ (Q7_ /U^R_\ H9JE5WQ)_P C%?\ _7[+_P"AFJ5?M4/@1_-5
M3^(_4*^/?^"I?AGQ)JWC/X2:_P"/?AEXK\:?!32M6U*3XI^&/"$$UQ--(UN@
MT^>XMX662XMHI?,9U'RC^(-E5/V%7F?Q]\>?M.> =4T?4?@3\ M*^(&E2Q3K
MKVGOXKCTJ_MY,IY+P-.AAE0CS RLR'.T@]:Y\;3C5PSC*]M-E?9I[=5W7:YV
M9;5G0QD9Q2OKNU'=-:2=K-;I]'8^7?\ @D*?^"=&L:1I6L_ &31;'XK67AV>
MT\3Z;;O=65W) TX9C):RE4GV[8OWJHVS.-PW$'C/"/Q1^/\ XV_X*S_':Y^"
MGP3T;Q=XQ\.V.F:+H&L^,=8>TTKPKI$<&Z8!HXY)7EN;A]P2-0<"4EMN16]^
MPY\"?CO\=_B#\#/VC?&OPETKP+X:^%7A_68K#4?[;AO-5\4/>K)"L;K -L%M
M%N=@KNS%B<##DCTKQS\*OVA_V3_VU/&?[5OP!^!3_$GPQ\5-'T^'QAX?TK6K
M:RU'2]1LD,45S$+EE2:%XV(90P;>S,< <^)2A6EA*3Y>6,9)MQC9M<OQ<MF]
MW;9[<R/I:]7#T\QQ$>93G.#24YII/VB]WF32MRJZ5UOR/K?O/V2/VMO$/QY\
M;>.OV>_CS\(K?P=\1_ ;6R>(M&M]0%[8ZA97*%H+JVE*J7B8$Y1AE=Z@G+$"
MO_P4-^,?PN^!/[+&J_#.?PA;ZSJ_C;2Y_#/@3X?Z=9J\NL7D\1ACAB@4<11[
MU9V PJ@ ?,R \W^R-\%?VB6^//Q4_;I^/7PWMO#GB/QII5GIGA3X>P:S%<RV
M5A9QG8+FYCS%YTSA#\I(3G/7"^&?!#1_^"F?A/X\Z[^U5\?O^":EQX]^(.HE
M[30+[_A;^A6EEX9TLYQ9V-NTDOEDY;?,6+OD]-SE^J>)Q"PJA*,FY.2YN5NT
M;Z-I+=JUE9:ZNQPT\'A)8Z52$HJ,%%\O/%)SLKJ,I2^%2O=W=EHKZ,V_VMOV
M7OB_\+/^"*_AKX'7MA=^(M0\%0:+>>-M)TQC*]U9072SW5NF/]8D6X<]-D&[
MM7,?\%:OV[_V1/C!^P?#I'[.?Q,TOQ%XFCU/2M8\,6_AV,O<^'%MKB-S=S(J
MYL=B9A&_8=TRJ <G'W#;?$K]H*Y_9S/Q*D_9J^S?$ 63S#X:3>,+1B95F*B#
M^T$!@RT8#AL;06"GD&OESXF?"7]IO]O6&V^!'B+]BRS^"/P\U/6[2_\ B;KU
M_KFGW&H:[!;3"<6%O'99.7E5"9I#@8R.05;+&8>4:3A0O[\%%)QD]KVUT4=]
M>;;<Z,NQ<)5XU<7:U.I*;:G%;V<O=U<EIIRZ/:]M5]J^!=<N?$_@G1_$M["(
MYM0TJWN98P,;6DB5R/P)KXR_; \63_ 7_@J!X$^.OPY\)3?$OQ9JWPQN?#UY
M\,=&C=M4L+ 7C3C6(7*&&)-Y:%O.>+()"ELMM^F_C!XE_:(\+^//A]H?P/\
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ML99Q*$L1!1:TA%63NHM+9-7OWW>]KZ'Z/?#?_DG>@?\ 8%M?_1*UM5B_#?\
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M1^S?_P!%&_\ *1>?_&:/[,S+_GS/_P !?^0?VUDW_033_P# X_YGIU%>8_\
M#9'[-_\ T4;_ ,I%Y_\ &:[[PKXJT'QMX>M?%7AB_P#M5A>(7MI_*=-Z@D9V
MN PY!Z@5C6PF+P\>:K3E%>::_,WP^88#%S<:%6,VM;1DF[?)FA1117.=@444
M4 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\
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M#4W_ *%7U'"'^^5/\/ZH^&\0?^1?1_Q_HSBZ***^_/R<**1W2-2[L%51DDG
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M>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH ****
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M7+3CO=6<K<TG?;?W5WLK'S%\1OB'X"_9@_X+!7OQA_:>U:#0_#7C#X36^D^
MO&&LC;86=S#<A[FR,[#9 [?-)EBHPX&?GP>;^ ?[2/P^^*W_  6\US6/@%J
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M%_">BVVG:=9H4M;*SB"1Q*220JC@#))_&K]%*RO<=W:P4444Q!1110 4444
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M "BBB@ HHHH **** /T>^&__ "3O0/\ L"VO_HE:VJQ?AO\ \D[T#_L"VO\
MZ)6MJOQBM_&EZL_I'#?[M#T7Y!7Y]_M%_P#)=/%7_8:F_P#0J_02OS[_ &B_
M^2Z>*O\ L-3?^A5]1PA_OE3_  _JCX;Q!_Y%]'_'^C.+HHHK[\_)PHHHH **
M** "BBB@ HHHH **** "OO?]E;_DWWPQ_P!>3_\ HUZ^"*^]_P!E;_DWWPQ_
MUY/_ .C7KY7B[_<(?XOT9]YX??\ (UJ_X'_Z5$]!HHHK\]/UP**** "BBB@
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M)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /S4\2?\ (Q7_ /U^R_\ H9JE7;:_\%?B9-KU[-%X
M:RKW<C*?MD/(+'_;JI_PI'XH?]"Q_P"3L'_Q=?J$>).'5%)XRE_X,A_F?S[4
MR7.'-_[-4W_DE_D<I175_P#"D?BA_P!"Q_Y.P?\ Q='_  I'XH?]"Q_Y.P?_
M !=5_K+PY_T&4O\ P9#_ #(_L7.?^@:I_P" 2_R.4HKJ_P#A2/Q0_P"A8_\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M[AS_ )\?^33_ /DCRG_AF/\ ZG?_ ,IO_P!LH_X9C_ZG?_RF_P#VRO5J*/\
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MVD>,+W3+"^>:.-BUW':21M<%#;ILRV%W/_>- 'TM17P5_P &Q/\ R@S^!/\
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M%^/_ /D=-3_Z_'_G7S'%O^Z4_P#%^@&/1117P8!1110 4444 %%%% !1110
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M=9US5I_+@MH\A1D]69F945%!9V954%B ? OV9?\ @L__ ,$]?VL_BSIGP/\
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M_9O_ .BC?^4B\_\ C-'_  V1^S?_ -%&_P#*1>?_ !FOA6BC_5++?YY_>O\
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MBDDDXR3M9*]V[VU/GK]I+X%?$;]O;]@[5OAA\1_ J_#CQIKEFMU::3<:U%J
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MXM>"_&>O^(-8UJV%M^T?XXT;Q!;6'BGQ"'#&YAUB1D3#3(2I^6':!DL,L?V
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M8_\ J=__ "F__;*]6HH_XB)QC_T%?^24_P#Y /\ 4[AS_GQ_Y-/_ .2/*?\
MAF/_ *G?_P IO_VRC_AF/_J=_P#RF_\ VRO5J*/^(B<8_P#05_Y)3_\ D _U
M.X<_Y\?^33_^2/*?^&8_^IW_ /*;_P#;*/\ AF/_ *G?_P IO_VRO5J*/^(B
M<8_]!7_DE/\ ^0#_ %.X<_Y\?^33_P#DCRG_ (9C_P"IW_\ *;_]LH_X9C_Z
MG?\ \IO_ -LKU:BC_B(G&/\ T%?^24__ ) /]3N'/^?'_DT__DCRG_AF/_J=
M_P#RF_\ VRNF^#7[/O\ PCOQ4T#7?^$N\[[)J<4GE?8-N[!Z9\PX_*NPK8\
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M$_\ QI\88;C2)[RXN?"NHVL$-M,&;]Q(CAI79_O?NXW)ST)XKRW_ (($^%O
MN@?L%OK?@OXBZ5KD_B7Q_K6M>(M-T2RGM;;PUJ4\J>;HZ07")+%]G"QC#HN2
M^Y0596.]3#T7@O;136J7Q*5[WOHDG';2^X'V]IW_ "$(/^NR_P Q7T-7SSIW
M_(0@_P"NR_S%?0U?2\(_!6]8_J 4445]D!\\ZC_R$)_^NS?S-0U-J/\ R$)_
M^NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'T#X?_ .0#8_\
M7G%_Z *MU4\/_P#(!L?^O.+_ - %6Z_8Z/\ !CZ( KPOQ_\ \CIJ?_7X_P#.
MO=*\+\?_ /(Z:G_U^/\ SKYCBW_=*?\ B_0#'HHHKX, HHHH **** "BBB@
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M2&3[UU_XV_MDV_[)UC\8O#W[$J3?$]Y8VU'X/7/Q$L \,7VEHY%35%!MF?R
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M7A?C_P#Y'34_^OQ_YU[I7A?C_P#Y'34_^OQ_YU\QQ;_NE/\ Q?H!CT445\&
M4444 %%%% !1110 4444 %%%% !7M_PS_P"1%T[_ *XG_P!"->(5[?\ #/\
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M+]DW_HHWQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5'^J'_3_ /\ )?\
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MR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J/\ 5#_I_P#^2_\
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M17CQ= \'Z2]NE[JR:?<WA#SS)#"B0VL<DLC/)(B@(A)+#MS7@_P"_P""Y/\
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M'\0/'?C_ $R_O1:V4XG-II]G8L[F9V48F8A.-K;0Q( /U*KP[PS^Q=:^&_\
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M&/<OV;O'?[3/[7WP;\:>#OVZ?V#KCX*)J4$NCQZ#-\2M-\1G5["XMV2:42V
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M/^"?@_XEZO9K;W?B+PMI^IW5N@P(I)[:.5E /0 N1^%?GG^TM^S?_P %8/\
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MQ=T[P1J,]I^S[X7@^/WAC2]&\*6HD(_M/[--+*USJ,RK&_VB0(8SPJ*4B\H
M^LO^"#/[''Q._92_X)CZ#\)OVB_!MOI.K>*M5U;Q#J'@2>,20:!:ZE.TL>E,
MC#'R1,/,C(^5Y)$(."3YQXS\-^'?"/\ P<W_  G\/^%- LM+L+?]D755M['3
MK5((8A_;4O"H@"J/H*^P_P!F#XR?M2_%?X&W_C[]H_\ 8TF^$_C.WO+J.Q\
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MD\B.5IX=C@C,L:!NJEAS0!YW_P %7/\ E,5_P3K_ .QS\=_^FBSKVC_@M/\
MLF_!/]J__@F]\6](^+7A#3KJ^\,_#_5]>\*:[/;+]JT34K.SDN8+F";&^+YX
ME#A2-\9=#PQKRS_@L#\!/VT_%/[9/[)G[6G[(?[*L_Q:B^"^O>*;[Q1H%MXT
MTO1'VWUE:6\ $NH31@Y*RGY%?'EX.-RD\O\ M.Z?_P %O?\ @IU\)=6_9$N?
MV./"7[+O@;QG;MIGCWQQXE^*=GXHU>32)#MN;>QM-,7REDECW1GS9-I21QN0
MD, #Z3_X([?'#Q[^T?\ \$N_@;\9OBCJ4]]XAUCX>V0UC4;IBTM[/"IMVN9"
M>KR^5YC'N7)KH_CG^Q=:_&K]MCX$?MD2_$233I?@A:^*X8O#RZ6)5UC^V[&W
MM23/YJ^1Y/V?>/D??OQ\N,GT#]GKX&^ _P!F3X%>#_V=_A=9R0>'?!/ANST7
M1DG<-(;>VA6)6D8 ;I&"[F;'S,Q/>NQH X/XP?%']G_]D+X3^+?VA/BMK&A^
M#?#&EQ2:OXKUR2!(5D?"KYC[!NGG?"1J &DD8HB@D@5\#_\ !(CPC\5OA'^R
M;^U-_P %%[GX8W'@/3OC7XNU_P"(WPU^'][;"*73]+CLY7M+J>$?+%-=$"5D
M P5$; D, .'_ ."A/PJ_X*U?M&_\%'+?Q/\ $'_@EQ<?&?\ 9U^%]]'=?#'P
M#8_&GP]H>G:_JRHI&LZK%=RO+=;&:18K:2.-$ &0P:7S?O']DGXM_M8_M-^"
M_%FA_MM_\$^Y?@E"(X[+3]*NOB;IGB4:Y;3QR+.=VGX%N$ 5</RWF9'W30!\
M^_\ !OG\"/AKK'_!#KX=>%?%?AZVUBW^)VAZSJ7CYK]!(VN3ZC>72W#7+'F5
MC$4A);)VQJ.U1_\ !L=XO\2>(/\ @D5X-\)^)-7FO_\ A"_%'B'PYIU[<-N>
M2SMM3G\@9]$1Q&HZ!8U':O+?V:- _P""PO\ P2Y_9EUC_@FU\$?V$#\6[;P_
M?:I;?!'XR6OC[3++38=.O+B:>!]6MKEUGCEM7G9F1%*R!1&APHD;[/\ ^"5W
M[#Z?\$Z?V#/A]^R5=>((M7U7P[ITT_B35X-VR\U2ZN)+J[="P#-&)IG1"P#%
M$3(!R* /H2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+
MXD_"[X9_&7P?=?#SXO\ PZT+Q7X?OBAO=#\2:1#?6=P4<.A>&=61]KJK#(."
MH(Y%;M% $&E:5IFAZ9;:)HFG06=E9P)!:6EK"L<4$2*%1$10 JJ   !@  "I
MZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AXI\*^%_'/AJ_\&>-O
M#=AK&CZK:26NIZ3JMFEQ;7D#J5>*6*0%9$92058$$'!%0^!_ G@?X8^$['P#
M\-O!NE>'M"TN#R=,T70].BM+2TCR3LBAB54C7))PH YK5HH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"M_X$N4U"2ZL--TR;0FN;@VL8R8PS*6=%4-O4@KN!%?8WP5_:9^"/[1'[/\
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M=RMM#<8/- 'F?_!,MT@_X+%?\%"=/F<+./%7P^F,+'#>6_AZ0JV.N#V-??\
M7SC^TE_P23_X)\_M:_&$?M _''X &\\:FSAM9_$NA^+-6T6ZNH8L"-)VTVZ@
M^T!0 H\W<0JJO0 #Z.H **** "BBB@ KQW]NC_D@L_\ V%;;^9KV*N.^.GPF
M_P"%T^ G\$?V_P#V9ONHYOM7V3SL;">-N]>N>N:[<NJTZ&/IU*CM%239YN<8
M>MBLJK4:2O*46DO-KST/SXHKZ<_X=R?]5C_\M[_[HH_X=R?]5C_\M[_[HK]$
M_P!8\F_Y^_\ DLO\C\?_ -3N(_\ GQ_Y-#_Y(U?^">'_ ")'B'_L*Q_^BJ^A
MZ\\_9W^ O_"A-$U'1O\ A*_[6^WW:S>9]A\CR\+MQC>^?KQ7H=? 9OB*6*S&
MI5I.\6]'\EW/UGA_"8C Y/1H5U:<4[JZ?5OI=!1117FGLA7YC_\ !QGX"U3X
MI?$']B_X;Z'\0]:\)7FN?M/Z;8VOBCPY,D=_I3R0.HN;=G5E65"=RDJ1D#@U
M^G%>=?'7]D[]G_\ :5\2^ _&'QL\ _VUJ/PR\70^)_ ]Q_:MW;?V;JL(Q'<;
M8)46; /W)0\9[J: /RY_:9_92\3_ /!*_P#;X^ /[>'[8'[2/CC]HOX31^)3
MX3EUOXMZJ\US\+M6OP%M=;@6!DMFA=E,<KR0YC"HRLTGE%?=/CM_87_$3C\%
M&^,/D_V,?V8-:_X54=0QY7_"4?VJ_P!N^S[N//\ [-QG'S;,>U?</[1O[.7P
M5_:V^"NO_L[?M$^ [?Q-X-\3VR6^MZ)<W$L*W")(DJ$20NDD;+(B.KHRLK*"
M""*X7]HK_@G%^QS^U=\%O"_P&^._PE;7-$\$);CP;>R:[?1ZKHKP1I'%-;ZD
MDPO%EVQIN<REI"@,A<T ?*W[57]A'_@Y-_95_P"%4^5_PDX^$GC3_A;'V#'F
M_P#"/?9C_9?VK;SY?]H;]F[^+&.U>/?M)_M<1_\ !"#]K']J;1OL^SPS\<_!
M$GQ2^"-AY1:*7QVSQ:9J.G(@YDDGN9K.\=5'RQ*>M?H)^Q[_ ,$V/V//V%=6
MU_Q9^SW\,KBW\2>*@B^)/%_B'7[W6-8U%$QLCDO+Z6641C"_NU94RH)!(S7R
MK^TA\%/C%_P53_X*6?![1_B#^Q5XG\%?"#]FKQUJ_B'5_''C^VLXCXNU."1(
MM/@TJ..:21[&26".Z=W55DC10RHP0. ,;5_%O_!!'_@A-X=OM-\&Z;XD^)L;
MZ;_;3>);IA9S^+=<OXVN;N_G4AVA@GN&RP(9DMXUW)G<OSK_ ,%W? G_  4*
M^#?[('@[XB?M@_\ !1[X>^)99OB[X8E\.> /#7P5BTN1=6CO%E$ECJ4FH2W
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M,?B?]OKXT:2UMX__ &H?&EUX_P!6BFY>QTB4F/1K%6[PQ6822//(%R17)_\
M!8[X:_'[_@I7J^E_\$K_  -^Q]XNA\%:AXYT'4_B'\<-<AM(=$L=%@*7=P-,
MD,QGFOB?]&P(UP6D4G8Q8?H1X=\/:'X1\/V'A3PSI<-CINF6<5II]E;(%CMX
M(T"1QH!T554 #L!0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20210930_g11.jpg
<TEXT>
begin 644 biib-20210930_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
M?/7_  48_P""8WQT_;!_:>^#?[77[-G[;4?P9\:?!NQUZVT?4)?AI;^)%N!J
MD$=O,3'<74,:XA61,,DF?-R-I4&OKL>(O#YUK_A&QKMG_:(B\TV'VI//V?WM
MF=V/?&*M2RQ6\33SRJB(I9W=L!0.I)["@#Y*_9O_ &0_^"KGPU^-6A^-_P!H
MG_@L/9_$WP;8R3'6_ T7[.NCZ(VJ*T$B1J+VWNGD@V2M'+E5.[R]IX8FNX_9
M"_89_P"&5/CY\>_CA_PM'^WO^%W^/+?Q)_9?]B?9?[%\JT6W^S^9Y\GVG.W=
MOVQXSC:>M>Y:'XC\/>)[1K_PUKUEJ,"R%&FL;I)D##JI*$C(]*GU'4M.TBRE
MU/5K^&UMH5W37%Q*$2-?5F8@ ?6@#YN^"O\ P3:\'?#KXG?M-^+OB'XTB\7Z
M!^TOK$5QKGA:?13:II]F---A-9M*)W-R)(V8EPL1&[&#UKY\T/\ X(S?MO:-
M^SGJ'_!/I/\ @JC>']GM])N='TO2#\-;<^*(M%=66/1Y-4^TA6ME5O+9UA61
MX08E,2L-GZ*:?J%AJUE'J6EWT-S;S)NAN+>4.DB^H8<$?2IJ /CBY_X(X_"_
MQ7_P2Z^'_P#P3<^)'Q7U:ZNOAI:Z=<>$/B;X>LQINHZ5K5B[O:ZK;1&2412*
M792A=LH[@,"0RP^!_P!D7_@L8FM:)HGQ3_X*V>&+WPSI&H6\NIW/A[X"6EGK
M.OVT<BLT$TTEY)#:F55*M)#%N&X[<'!'V;10!\B?M=_\$WOB]X]_:STG]OC]
MA_\ :@@^$WQ5@\+?\(QXJ.K^$UUK1O%6CB7SHH;NU\Z%DFBD.Y)T?=@!.@R,
M;]C[_@D_\3_V?_\ @H5KW_!2+XX?MGWOQ+\:>,/A2WA+Q/8S^#8]-M1<?VC;
MW*3V0CN'6UM8X+6"W6UV.Q8/,T[-(RU]J44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'A__!2S5OVAM"_X)_\ QBUC]D^"_D^(UM\/M3?PD-)C+W@NA V&ME&2UPJ[
MFC !)D"  G K\MO^"<7P3_X->?VJOV;_  9\/_B5J'@C4OC!J^B6J^/'^)?B
M^_TOQ3=>(WC7[;^_N9X9'F^T^9M%NQ7@;<BOV(_: ^-OA7]F_P"#'B/XZ^.=
M)UB]T?POIK7VIVWA_3&O+PP*1O,<"?-(5!+%1SA3@'I7Y;_\%)?^"@/_  ;>
M?MH_LK^-=1\0:AX"^(7C_7/#=W;^$+;1? -ROB^36'A9;2.!_LJ74$OG^6#Y
MA5.,/E<@@'W/^UQ^UG\-/^"6_P"S/X&\+:!X!\0^.==U"^TOP)\)O &FWPDU
M3Q)J1A$5M UQ,<(HCB+S7,F0H!8[F95;R_1/^"FW[8GP*^-?P\^'G_!2/]A+
M2?AGX8^+'B6#PUX2\=>#OB5'X@M-/UVX5C:Z9J,?V:!HFF*LB3)OC+C'3++\
M2?M3?LD_M5:;_P $L_V$_CI^U7I'Q/N9/@9J"R_&:U\#:G=V_BK0]!OH?*CO
MHW@/VA9K*WCMUE53YB@N&P!(R]IX-T'_ ((!?'GXG?#/PAH'_!3WXU_%K7M2
M\=Z/>>"?!E[\8?$>O*=52ZC:VGN+.5'6V6-SN>2<1B-0^2.E 'U/\?O^"M/Q
MN\)_\%#O$'_!,[]F?]AZ7XB>.[#P/8>)-+U>X\=1Z9IJ6TS,)YK]GM7-K##^
MZ4,AF>:29$5%R7&]^RO_ ,%+?C?\7/B;\4/V.OCQ^R-;^!/VAOAYX/\ ^$ET
M;P*OC9+K2/&&FR!DMKNSU,6X\J%KGRX)6>%C"T@X=@Z)\P^-_P!L[X._L4?\
M'(?Q9\=?M$W,VA^"M:^ 7AS3+_QR]C++9:%=M<F2W6\DC5OLT$VR5!,V$$JQ
M*Q&\&NX_9(^*_A#_ (*,_P#!=/7_ -NC]F&>?6?A!\+/@!_PKY_B#%9R167B
M#7KG5OMSV]H\BK]HB@BSO=<A7V]5D1F .._X-_?VCO\ @HCXJ^$NJ>']<_9+
MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
M"@<#_1K&@"U\;/\ @L_^U!\#/A_IO[;/B_\ X)VSV_[+M[J=@LWQ G\>Q+XB
M@T>]GCAMM<?1OLY,=O(9HF6!IO.V2H7$1)5>3_X+9?&S4?@1_P %/OV!?BSX
M4^&>J^.=2@UGXA6V@^%M EB2?5[Z\T6SM+6%99"(X8VFN(M\SG;%'OD.0I%=
M%_P6L1$_X-MO',:( J_"GPN%4#@#[7IE>>_\%=?C?I7[.'[>?_!.3XX>(_"N
MJ:SI7AY_&EQK<&CZ;)>7%M8'0M/2ZO1#$K/(MM \ERP16;9 VT$X% 'T)\+?
M^"FW[3/@/]KSP5^R+_P46_8RTWX67/Q6BNQ\+_&'A3Q^NOZ5J-_;1^;+I=RY
MMH'MKCR\%&(*RDA5&>:O_&[_ (*4?M >(OVK/%/[&/\ P3M_9&L_BOXG^'=E
M9S_$[Q1XF\:IH.@^')[N,RVUCYH@GDN[IXQO9(T C!^9B0RK\\_M2_M;? /_
M (*S_M^?LI? K]@;QY!\1+?X6_%6+XF?$GQEX>MY7TWPYIME!(L-O-<%0OFW
M4CF-8E)8%1N S7A_CSX,?LS?LE_\%2_VA]+_ ."D_P"TS\:?@OX?^+7C"'Q?
M\)_B#X,^)&KZ!X=\00S0?Z58W$UD?*6\MG&P";!*#@A3'O /T2_9+_X*6ZM\
M=?#7Q@\%_&G]GJ\^''Q@^!, D\?_  XNM>COH7BEM)+JRN[.^CC"SVMS'&VU
M_+#(00RGY2WFG[ /_!5O]M/_ (*0>%OA[\=?@I_P3A@T'X4>(+Q;?Q7XP\3_
M !.A6:!EE:*Z;3;46J27T4#*4,SB'S)%D1$/E[FXW]A/P-_P3!OO#_[2/QC_
M &!/VD/B!\6/$#?#A=*\=^,_&/BK5-:@E06U\UK!#>WR!;AHQ')N$3N(U= <
M;@*]>_X-ZXHH?^",'[/R11A0?!;L0HQR;RX)/XDDT ?8NHV%OJNGSZ9=AC%<
MPM%*$<J=K @X(Y!P>HK\7/\ @I3^RC_P;6?LD?"GQ_\ LV^&_!FDZ#\?M'T0
MGP1I/A35-:O/%Z^(KBU6?2S%*)))))))9;=_WC%,/EL"OV3\?>--&^&_@36O
MB)XC6Y;3] TFYU&_6SMFFF,,$32OLC7YG;:IPHY)P!UK\T/VWO\ @K__ ,$!
M/VEOV7?&FCZUXQ\)_%/7O%?AVYL-(\'6/@&[G\0:GJ+P&.UABCDM%F@G$GEA
M)&*>4R@A@5% "?M__&G]N?\ 9[_X(1?!OX4?$;Q[J.A?';XLWW@_X:^(/%"7
M>[4--O-1XNI6E0\W7D0RQO*K9\QW=6R U<7_ ,%3O^"=W[,'_!&G]DKPO_P4
MA_X)\?#Z?P+XV^!GBO07U[5-/U:X:;QAHMU?06-[8ZGO<K=>>UQ&[.PW @[2
MHP WXZ_L=_MQ7_\ P;B? J#QMX-UKQ#\9O@1J_ASX@MX2N \NI7$.FW<SQV!
M7ES<0Z=<*ICP7W6Y0 M@%?\ @J5_P43_ &8?^"S/[)GA?_@F[_P3X\>W/CGQ
MM\<?%F@IX@TRPT>Y27P=HMK?07U[?:GOC"VOD-;QHR$DDD[=V!D _7>TNK>^
MM(KZUD#Q31J\;C^)2,@_E4E>,_'?]M7X)_LN_''X.?LQ>-=-UR77OC-JM]I/
M@F/2+!)H8WL8(I9FN&,BM'&L<B'<JOT.<=:]FH ^._BM_P $,O\ @EC\6?B)
MXW_: _:6^ B>-_$'BV\N;_7O$/C7Q3?2BQA;+&*V G2.R@B7(7RU5E Y8XS7
MSU_P1+^/WB[X)_\ !+[]HWXO6'BG6O%WP?\ A/\ $#QQ<?L_ZQXFNY)IM1\(
MZ7;F6W1)7^:6W#Q2HC=CYB@*$"KXY_P5,_X+'_LI_M/?MH>(/^"8/QK_ &K)
M_@O\"? FH-:?&WQ##I>HR:OX\NXI-LGAZQ-G;RM:V092MQ</M:4 HF4YD^]/
MV??B_P#\$_/^"E7[ 7Q _9L_X)V?$31[OP';^"K[P$(M(\/WFGVNC"ZTUX8X
MEBN8(F*K'*&RH.><G.: /CW]B+_@C-^SY^W5_P $K[+]K;]I33M0\1_M&_&7
MPY=>,_\ A<=QK-RFK:/JMP9)M,:R=) +:*W7[,!"@"'81C;M5?=?^"?VC>"_
M^"Y7_!%+X,ZM^VO=:YK46IQ?\5E;Z9KUQI[Z_=:5=W>GM]KDMF21XYS")Y$1
MDW.PY &*\(_8D_X+-_L__L*?\$LK+]D7]I2]U+PY^T=\&O#EUX,7X.3Z)=2:
MMK&J6YDATP62)&1<Q7"FV(F0E!N8YVA6;O?@I\;++_@W1_X-Y_AQKW[2/@>^
MOO%NDZ:\4/A&W.R2;Q!JUU=ZC'83R8*P+")7663G:+=]H=BJL >>_M]?L._L
MG_\ !.']LO\ 9(U#_@EMX#/P\^-'C'XTZ?I&I^%?"6JW1A\0^#%5VU>34+9Y
M'5X(5$9,Q (#NV245H_OC_@H-_P3@_9I_P""@_A[1H?VFX?%.HZ5X1M-2DMO
M#VB^,+W2['4&N$A+&\2TDC:XV?9UV98;=\G]\U^=?_!+'_@I9_P2:T3XQR_M
M6?M<_P#!0C1/B'^U3\7)K;2[J\M?!>NC3_"]K-*JVWAS1Q)9;8+9'=5>7(,S
MY=F(^8_I'^WK_P %$?V-O^"?G@73]5_:_P#C5!X-M_%JWEGX>DGT>^N_MD\4
M0+H!:02E,"1.6V@YX/6@#YW_ .#6W_E!7\$/]_Q-_P"I+JM?H%7Y)_\ !JU_
MP41_8VUG_@GS\(?^">NF_&J"7XQ:3:>)+S4/!@T>^#PPG6M0O _V@P?9S_H\
MT3X$I/S8QN! _6MRX0F-06Q\H)P": /C+XM?M@?\%@O"FK>)/%7PW_X)->&]
M;\(>'[^[6QM+OXYVT6O:_902,%NK>VCLI(H6EC7>D$DID^8*<,=HE^.'_!8[
MX8^!?^".\_\ P6!^#OPQN_&'A[^Q-.O[/PE?ZN-,N&DN-5@TV>VEG6*X6*2"
M:656VHZLT! .&##\WOV9/B7_ ,$WOCC\#]=\8_\ !7;XF?%3QY^UW_PEFLV7
MB#X)GQ]XHT_4H=46]G2QT?1]*TRX@C6%X?LX5E#(ID<LZ*IVT-*6=/\ @QRU
M:*XB,;I-.K1[B=A_X6,,KDD]\]Z /NOXS?\ !8_]K[]G3P7H_P"V!\<O^":T
M_A_]F_4]6T^&^\83_$2"3Q)HNFWLT<5MJMYI"P%8HV::+-N)S*GF .5;*U[;
M_P % /\ @HGX@_95\=?#G]FW]GGX"S_%?XS?%JZNU\&>"XM=CTVT@LK2,27>
MI7UXZ.+>WB5@1\I:0@JO()'EW_!R$B)_P0H^-T:( JZ!H@50.!C6M.K@?V\O
M'.E?L-?\%1OV<?\ @I+\<[:\@^#]Q\)M2^'7BWQ=#8RW%OX3O[B1+JSNKH1J
MS1Q3N3#YF,+M.XCC(!P/Q)_:,_:.^+/_  7J_86^%O[67[+B?#3QKX3M?B7>
M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
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MV]^R9XZ\$W/_  4S_P""<%C\-_ASX]\46OAZV\?^#/BC;^(4\/:A=$K;Q:C
ML$;"-B#NG1BJA3@,2%(!^A%%>!?\%!_^"@'@3]@/X::'KVH^!-9\;^-/&_B*
M'P]\-OAQX:V_VCXEU:7[D$9;Y88E'S23L"L:XX9F56Y;]E3]I+_@J3X\^+UC
MX2_:[_X)L^'OAYX3U.PGG_X2SP]\9+36GTJ=$W1VMS:K!&TA<Y7S8B44CG@B
M@#ZFHKR?]MG]KGP'^Q!^SGKGQ_\ '.FW6JR61BL_#GAG33F]\1:Q<.(;+3+5
M0"6FGF9$&%;:"SD;4:N#_P""4G_!074O^"F/[)L7[3&L_!+_ (5[>?\ "4:G
MHMUX9/B0:KY$EG-Y3-]H%O &R<\!,#'4]: /I2BN8^-?Q>\$?L_?!SQ7\=_B
M9J#VOAWP9X<O=<UVYBBWO':6L#SS,JCEFV(V%').!WK\^C_P6=_X*))^R\/^
M"BTG_!)F#_A09T@:^9A\7;<^*!X<QO\ [7^P_9?*V^3^_P#)\W=LYW;?GH _
M2RBN:^#/Q:\$_'SX0>%?CG\-=0>[\.^,O#EEKFA74D11I;.[@2>%F4\J2DBY
M4\@Y%=+0 4444 %%%% !1110 4444 %%%% !1110 45XE^P1JFIZO\&M5N=6
MU&>ZD7QOK"+)<3,[!1<D!<L3P!T':O;: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _-[_ (*]
M_L:?M>:#\;_%G_!2W]D6;P/XBW?LTZU\.OB#X*\<W,]K)%HQ>XOFO],N8E<+
M<J7(:*0*C+'C)+_+W_\ P2Q_X*3ZC\:O$>D?L,?M%?LM>(/A!\5_#OPFTOQ%
MI6EZIJ]MJECXB\/8BMEU"RO;?"N/,*!HF4,A8C+%) G1_P#!3C]E7]K[XF^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_=3_ &//^"_'Q_D/B7XH?\%9? /P5$QWKX.^#_P;@UJV@!Z*;_594N'8<9(
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MSX1_9WDLH_!?@^2S@@-N(O#D=_(S3(@FE:\NI@J;V8+M54 YSXE^QO\ $_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7A?C_\ Y'34_P#K\?\ G7NE>%^/_P#D=-3_ .OQ_P"=
M?)\6_P"Z4_\ %^@&/1117P8!1110 4444 %%%% !1110 4444 %>W_#/_D1=
M._ZXG_T(UXA7M_PS_P"1%T[_ *XG_P!"-?4\)_[]/_#^J W:***^_ **** "
MBBB@ HHHH _&/_@IO\9?#O\ P3P\0?M[^$?VH/!6NV&F?M3?#MKCX1_$^UT"
M>]L-1O4\,MI8T"[G@1_LDT=PN81)B,QSEV:,'GO?V:?VI?!G_!5S]J[]DW3O
MV.=!U[6O '[-^F7.N_$WXH7>@7-AIJ:D^@MIEOHUF]RB-<3&69VE 7:(X]RE
MQG'K'[1'[?7_  50UC]OCX@?L;?L1?L5_"SXD^&O!6GZ7<:UXD\0>-)[)=+^
MVV<<R6U\&0(+AV,KI##YK>3Y4CA!(,^>7/\ P4T_X+F_#/\ :"T_]F+QC_P2
MY^$46NZAH%UK/A/0K#XJ/:IXKL[3;]KATRZ>-K<7$(DC9H9MD@617",F6 !^
MI5%>/?L'?ME^!_V]OV9-"_:0\$>&-4T#^T)[JQUOPQKD86]T/5+2=[:[L9P/
MXXYHW .!N7:V!NP/8: /"_\ @GO_ ,D3U;_L>]9_]*37NE?/7[!?ANPU;X.:
MM=7,UPK#QQK*XBG*C'VENPKVW_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ M
MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -
MBBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/
M^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_
M .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](
M_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!]
M(_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GY
MO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_G
MYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\
M"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P
M+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@
M#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:
MJ6L:7X'\.M9IX@\4?83J%ZEG8"\U41&YN'#%88]Q&^0A6(09)"GCB@#I:*Q_
M^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:H[GPAH%
MG;O=W>HW,442%Y99+TJJ*!DDDG  '>@#<HKFM#TGP3XGLO[2\-^)O[0MMY3[
M18ZH)4W#J-R$C/M3M9T3P;X=L3J?B#Q$UA;*P5KB\U/RD!/0;F(&30!T=%8L
M7@S0YXEG@OKMT=0R.EXQ# ]"#W%._P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_G
MYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\
M"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BO"_'_\ R.FI_P#7
MX_\ .O7/^$'TC_GYO?\ P+:O'O&EM'9^*]0M8F8K'<LJEVR>O<]Z^3XM_P!T
MI_XOT S****^# **** "BBB@ HHHH **** "BBB@ KV_X9_\B+IW_7$_^A&O
M$*]<\ ^$]-O_  ?8WDUQ=!GB)(2Y91]X]!7U/"?^_3_P_J@.PHK+L_"6FV-T
MEW#<71:-LJ'N6(_$5J5]^ 4444 %%%% !1110!^?'Q5^&W_!3/\ 8!_;6^*O
M[2W[%7[+NA?M!?#CXW7VFZQXC\#OXZMO#NN>&]9M;&*Q>:"XNU:&XMI8H8F*
M<N&&T! NZ2W\ /A5_P %(_VV?V\OAQ^VO^W'^SEH/P&\'?!73=<'@/X<VGC2
M#Q!K&L:GJMI]AFN[VZM5$$<"6Y;9&N'#MR&'S#YW_P""K/[2_P#P4#^*47[7
M7Q,^ O[86M_"3P%^RM;Z1I>C^'_!NF0"_P#%&K7%K:W=W=7EW(IEA@B2Z")'
M%@.%W'!!W>@?#WX ?MA?L _\%1_@19_&O_@J1\6OB]\+?BG+K>DZ+HOB*^A5
M(M:BTBYN(8KZ-05NK>2(221R1>6T<\$0965MP /L3_@F_P#LF>//V0?@EXC\
M*_%3Q#H^H^)O&/Q3\3^--;?P^TIL8)=5U.:Z6"$RHCE4B:-22J_,&QQ@GZ H
MHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OQ?^*'[1G[5'_!17]JW5O"#_ +=\
M/PE7X;?MDIX"\'_"CPSX9TJ;5[&&SM[H1>)KI[^.6:<SGS!&@46P&\?.1D?M
M!7XV_P#!7GXW?\$*OVBOBUX5T[]J3X?6>@>/M#^,MMH_Q&N/$7@/5=%UZ?1;
M9+R&21+RWA26]MRR6[PO!+(2K1E<9(H _43X._!SXRZ1^SK/\&OVF/VBKKXA
M^(;RUO[+4/'FG>'X- NKBVG:01,(+4F*&>.)U7S(\ LF\*N=H_-3X)?L#_LZ
M?L ?\''GPM\!_L\Z7KJ1>(?V<M=U3Q!J7B3Q/>:K>:C>?;FB\Z26ZD<@[(U&
MU J\9QDDU]$?\$$KKXS>&/V+_'&I_%W5O'<GPYLOBKK\OP,N_B?'/_;O_""(
M(C8O<"8";9D3F,2 /LQ@!/+%?&'Q2_X+A_\ !+/Q!_P7C^%_[7VC_M76<WPY
M\/\ P"U;P]J_B4>%]6"V^I37TDL=N83:"9BR$'<J%1GE@: /W K\U?\ @X'\
M+VNN?$3]FK5OVHCKC_LEZ=XXU-_VAXM(DNA;+(UM$-$DU%;7]Z;$78D61ON+
MO&[YC'7U7^TI_P %*_V8_P!F+]C[P]^W-XFO];U[P!XL_L5O#5UX9TDRW6H1
MZJ$:RD2"=HG =9$8JV' /*Y!%?(/_!;[5?!OPS_X* _LH?'O]M;PO=:Q^R]X
M:O->3QD9](EU#1](\1RVP33+[4[=$<.@8@1LZL$*RD=2& /.?V0O"G[&-S_P
M6H^&/B3_ ((9M:I\,;+P/KB_M/R^!9KG_A%7C>V(T2,[SY#7QNMS;8OG")N/
M DSW?@?]GWX3_P#!7W_@KY^TG)^VCX8_X37X;_LZ'0_!_P -/ &J7<O]EPZA
M=6LD^I:E+ C*LEQYB>6KMG]VX!YC0CC]0^-G[)/[7?\ P6T_9K\7_P#!(>/2
M]6O/"-GKS_'_ ,<?#W0FM='_ .$=FM$%K8ZA.D:17+M,C>4IW&-V0C! V]?X
M*_:#^%'_  1__P""O7[20_;1\2GP5\-OVBSH?C#X:_$#4[.8Z7+J%K:R0:EI
MLL\:,L=QYC^8J-C]V@).9$! .Q_X)%PWG[(?_!0K]I[_ ()2>&=<U&Z^&G@,
M:#XP^$6F:E?RW+:!I^J6V^\TV-Y69_L\<Y01(6.!O8DL[&O#/VOO^"<'[-/[
M%7_!7W]B?XI_".'Q3?>*?'OQ<\0-XH\0^+/&%[JEQ=(EBLL<2K/(8X45II,"
M-%X."2 ,>Y_\$BYKW]KS_@H1^T]_P5;\-Z#J-K\-/'O]@^#_ (1:EJ>GRVKZ
M]I^EVVR[U*..55?[/+.$,3E1D;U(#(PKYL_X*N?\%B_^";GB3_@IC^R=K.B_
MM,VL]M\#OBSXD'Q3E'AS5%_L(_94M?F#6H,_[Z)T_<^9]W/0@T ?M77DW[7W
M["_[*'[>W@73?AI^UU\'++QKH>D:L-3TW3[Z]N8%@NQ%)$)0;>6-B=DKK@DC
MYNF<5ROB;_@I[^R)I/[ &H_\%,_"?C/4/%7PEL-.FO4UC0-'E6XNXHKXV,GE
M6]V('RMPKIA]N=A(R,$^J:9\<?AY?? 6W_:3O]5;3?"<WA!/$TU]J2",VNG&
MU%T9)0"0I6+)8 G&#R: /R)UG_@E-_P3YC_X+]?!7]FO]C3]FC2?"FF_!#PT
M_P 3_BWJ>GZA>7!FN_.C71+!C<32!'6=(KDH!EXI3V4X_:6OSS_X-\O!GB?X
MM?#/XK?\%4/BKI$MMXJ_:A^(MUKNFPW8_>V/ABR>2STBS.<G"1K,0<X:-HCV
M!K]#* "BBB@ KPOQ_P#\CIJ?_7X_\Z]TKPOQ_P#\CIJ?_7X_\Z^3XM_W2G_B
M_0#'HHHKX, HHHH **** "BBB@ HHHH **** "O;_AG_ ,B+IW_7$_\ H1KQ
M"O;_ (9_\B+IW_7$_P#H1KZGA/\ WZ?^']4!NT445]^ 4444 %%%% !117(_
M'KX<^*_BY\'/$7PT\#_%C5_ NKZSIKVUAXOT".-[S2I"1B>$2 J7&._'- 'S
M[X1^!/[$G[1?Q\_:]^$%KHWB"]U+QBFA>'/CMHU_+Y>G7,DOA^,VLUECYDE-
MA<PJ\BD'?$AQE Q\/^%'_!/OX,?L4?M\_L^VG[2?[;OQM^,OB6Y3Q!HW[.^@
M>.;BWGTWPT;;2))[R:=HE0RS_8(VB29QR?X<A"GG.E?\$@/VGOV:?B]\3/BU
M\7O^"^_C#P'9>/M<TVXL/$,M[IEK?:\;;3(+5GU#[5&D2RQF/RHQ"S@PI&6P
MQ('L'[%O[&/[/NE?M>>$OC[\4?\ @L#KO[2'Q!\*:?J=K\.=!U[QQI,D&E-=
MVQ2]N(+.S)>29K9'4OG CW$J< J ?H-1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*
M\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#
M_&KX%>'?C?=>#+OQ!J][:-X)\<6?B?3Q9E,3W%O%/&L4FY3^[(G8G&#D#FM>
M3XK> 8I&BDU[#*Q##[++P1_P&F_\+:^'W_0P?^2DO_Q%<7]I9<O^7T/_  )?
MY@='17.?\+:^'W_0P?\ DI+_ /$4?\+:^'W_ $,'_DI+_P#$4?VEEW_/Z'_@
M2_S Y[]H+]EKX/\ [3]QX'?XQZ-<:E;_  ^\=V?B_0;!;DI VJVD<R6TLZ#_
M %RQF9I%0_+O5&(.T5Z#<VUO>6[VEW DL4J%)8I%#*ZD8((/!!':N?\ ^%M?
M#[_H8/\ R4E_^(H_X6U\/O\ H8/_ "4E_P#B*/[2R[_G]#_P)?Y@;&BZ!H7A
MRS.G^'M%M+"W+ES!96RQ)N/4[5 &>!S2ZOHFC>(+(Z;KVD6M];,P9K>\MUE0
MD=#M8$<5C?\ "VOA]_T,'_DI+_\ $4?\+:^'W_0P?^2DO_Q%']I9=_S^A_X$
MO\P.ACCCAC6&&-41% 55&  .@ IU<Y_PMKX??]#!_P"2DO\ \11_PMKX??\
M0P?^2DO_ ,11_:67?\_H?^!+_,#HZ*YS_A;7P^_Z&#_R4E_^(H_X6U\/O^A@
M_P#)27_XBC^TLN_Y_0_\"7^8'1T5SG_"VOA]_P!#!_Y*2_\ Q%'_  MKX??]
M#!_Y*2__ !%']I9=_P _H?\ @2_S Z.BF6\\5U;I=0/N21 R-C&01D'FGUV)
MIJZ *\+\?_\ (Z:G_P!?C_SKW2O"_'__ ".FI_\ 7X_\Z^4XM_W2G_B_0#'H
MHHKX, HHHH **** "BBB@ HHHH **** "O;_ (9_\B+IW_7$_P#H1KQ"O;_A
MG_R(NG?]<3_Z$:^IX3_WZ?\ A_5 ;M%%%??@%%%% !1110 4444 ?E'J_P"S
MO_P3M^,'_!8_]HBR_P""KUUX*\0^)I(/#K_!33/B-XDC33H?#9TV,3PV,$LJ
MQ"X6\\UIHV'FCS$E50DQ=_JG]F;]B;_@C%\(OC=HGQ#_ &3_ (1?!/2_B!I_
MVG^P+[PC>6;ZC%YEM+%/Y0CD+'-N\P; ^X6SQFOEC_@KGXO_ ."+?PZ_:-\;
M:Y\9O^"9&L?M!?%K2?"T/B;XJW?@OPPUV/#>E0VBK!=:O>//'#:@VMNNQ/F<
MI&I*@,I;V+X)?LV?\$?/V0_VJ_V?M7^$/["^G>"?B!\7=%U6^^&GBW2M,!AL
M98M),]U9S2FX+1SO97$P4"-E<+( P(H ^^**** /"_\ @GO_ ,D3U;_L>]9_
M]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*0:-)>6]W#(?GC$$L(\S&599@#@X- 'T[1110!X7_P $]_\ DB>K?]CWK/\
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M/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\\ZC_P A"?\ Z[-_,U#4VH_\A"?_ *[-_,U#7XS/
MXV 4445(!1110 4444 %%%% !1110 4444 ?0/A__D V/_7G%_Z *MU4\/\
M_(!L?^O.+_T 5;K]CH_P8^B *\+\?_\ (Z:G_P!?C_SKW2O"_'__ ".FI_\
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M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
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MO.+_ - %6ZJ>'_\ D V/_7G%_P"@"K=?L='^#'T0!7A?C_\ Y'34_P#K\?\
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M>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH ****
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MZ1HNC>'[%=,T'2;:RME)*V]I L2 DY)"J .: +-%%% !1110!\\ZC_R$)_\
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M^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444
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MM5CT:TC3PI=N%MHP'5EPWRCFK7_"2ZO_ -"A>_\ ?2U^QT?X,?1 ;%>%^/\
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MCU_^Q5\8?#W@_P 5_L7_ !C\8^"-5TC[9KGQ+^'/@^;6;'P\YFDC\N[A@!E
M 0.S(&(5UPK$XK#\+?\ !1S7;3QK^V'XH^)V@:-:_#W]F>2WCTQ[%)4U*_,.
M@)JM^T[O(T9!:5(X0B*<*=Q<L,>!?L4_M^_\%3;+XN_L^>*_V]]/^&,_P\_:
MML[Q_!^C^#=-NK;4O!-W_9KZK807#RL1<I-:HR,.623&6 4AP#])?#?B'2?%
MOAVP\5Z!<M-8:G917=E,\+QEX9$#HQ1P&4E6!VL 1T(!J[110!X7_P $]_\
MDB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% '%_'7X\^
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M#7S]7T#X@_Y -]_UYR_^@&OGZOA^+OXM+T?Z %%%%?'@%%%% 'Q?_P />?\
MJWO_ ,NS_P"Y*/\ A[S_ -6]_P#EV?\ W)7Q?17^G'_$O7@__P!"S_RMB/\
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M&4X(-?4-% !1110 4444 5/$'_(!OO\ KSE_] -?/U?0/B#_ ) -]_UYR_\
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M_KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^'_ /D V/\
MUYQ?^@"K=5/#_P#R ;'_ *\XO_0!5NOV.C_!CZ( KPOQ_P#\CIJ?_7X_\Z]T
MKPOQ_P#\CIJ?_7X_\Z^8XM_W2G_B_0#'HHHKX, HHHH **** "BBB@ HHHH
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M7G-%'^L.<?\ /W_R6/\ D!Z-_P +_P#^I2_\G_\ [71_PO\ _P"I2_\ )_\
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M;=\:?#+7/#-S\*]1U'1?'W@.ZFCFO=/UVT:-&T])5 24O)/ JR84?O?F"E6
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M$>],K^=*B:J-/N?3IIJZ"BBBH&%%%% !1110 4444 %%%% !1110!] ^'_\
MD V/_7G%_P"@"K=5/#__ " ;'_KSB_\ 0!5NOV.C_!CZ( KPOQ__ ,CIJ?\
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M_P#^1TU/_K\?^=>Z5X7X_P#^1TU/_K\?^=?,<6_[I3_Q?H!CT445\& 4444
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M$]_^2)ZM_P!CWK/_ *4FO5_B9_R(NH_]<1_Z$*Y,?_N-7_#+\F!XA1117Y$
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MVV^K;/S;'>$7AYF6.JXS$X+FJ5)2G)^TK*\I-N3LJB2NVW9)+LCXO_X=#?\
M5PG_ ):?_P!UUVG[/7_!.3_A0WQ@TCXK_P#"X_[5_LK[1_H'_"/>1YOFV\D/
MW_M#[<>9N^Z<XQQG-?3E%&9>.OBIF^75L!B\PYJ5:$H3C[*@KQFG&2NJ2:NF
MU=--=&F&!\(O#S+<=2QF&P7+4IRC.+]I6=I1:<79U&G9I.S37=!1158:SI#:
MJ="75;8WRP^:UF)U\T1YQOV9SMSQG&*_)#])+-%5M3UC2-$A2XUG5;:TCEF2
M&)[J=8P\CG"H"Q&6)X ZDU9H *]O^&?_ "(NG?\ 7$_^A&O$*]O^&?\ R(NG
M?]<3_P"A&OJ>$_\ ?I_X?U0&[1117WX!1110 4444 %%%% ' _&W]JS]EW]F
MA+23]H[]I+P#\/UU $V#>-O&-EI0N<<'R_M4J;\>V:YWX6_\%"?V!?CCX[L?
MA;\%/VX?@_XP\3ZIYO\ 9GASPM\2]*U"_N_+B>:3RK>"X>239%')(VU3M5&8
MX )K\^KW1?\ @E5HG_!9K]I*U_X*MZ_\&-<\5ZZGANY^%TGQ?U'3+S3K#0ET
MJ))-/CBO6:"QNEN-TABD"2RI<131AED8U]9?LS>'O^"%=C\;M$NOV-]#_9,A
M^)"?:?\ A')/AE;>&%UP9MI1<?9C8CS_ /CV\_?L_P"67F;OEW4 ?6=%%% '
MA?\ P3W_ .2)ZM_V/>L_^E)KU?XF?\B+J/\ UQ'_ *$*\H_X)[_\D3U;_L>]
M9_\ 2DUZO\3/^1%U'_KB/_0A7)C_ /<:O^&7Y,#Q"BBBOR( HHHH *I:MX;\
M.Z\T;ZYH-E>M"<PF[M4D*'U&X''X5=HH3: **** *5EX:\.:9J$NK:;X?LK>
MZGSY]S!:(DDF3D[F R>?6K<L44\303QJZ.I5T<9# ]01W%.HHNP(--TS3=&L
M(M*T?3X+2UMT"06UM$L<<:CHJJH  ]A26VD:59WL^I6FF6\5S=;?M-Q'"JO-
M@8&Y@,M@=,]*L4478!6QX _Y'33/^OQ/YUCUL> /^1TTS_K\3^==."_WRG_B
M7YH#W2BBBOU\"IX@_P"0#??]><O_ * :^?J^@?$'_(!OO^O.7_T U\_5\/Q=
M_%I>C_0 HHHKX\ HHHH **** "BBB@ HHHH **** )M._P"0A!_UV7^8KZ&K
MYYT[_D(0?]=E_F*^AJ^VX1^"MZQ_4 HHHK[(#YYU'_D(3_\ 79OYFH:FU'_D
M(3_]=F_F:AK\9G\; *\__:;_ &:?AI^UO\([SX'?&!M6;PYJ5U;RZI:Z-K$M
MC)=I%*LGD/+"5D$3E0'"LI*Y&1FO0*\;_;Y_;3^'G_!/W]EOQ'^T_P#$K2;W
M4K314CBLM)T\8EO[R9Q'!!O((C5G(W2'(50QPQ 4W0565:*I?%=6MO?H!\'?
M\%(OV(OV5?V O$7P*\;_ /!.WP"/A_\ &_6/BSI6C^$],\+:I=%_$.G,_P#I
MT-Y"\C":U5"AED<<!E#-AJ^]/VO_ -AOX%_MR:#HOA#X_GQ'<Z+HUY+<'1]$
M\3W6FP7Y=0I2Y^S.CRH .!N&"2>]?G)^P1_P4H_X)I/\6)_VY?VY?VVM%\1?
M'SQ=;BSTO2[3PIK+Z;X!TR0G9H^G V94/\Y$UP"2[,P#,"\DOZ4?M8?ML_LO
M_L.>#M-\?_M4?%2'PGI&KZG_ &?IUY-IEW=":Y\MI/+VVT4C#Y$8Y( XZYKU
ML8L=3JTJ=I.:O[UG=OJH]6ET]6]F!\P?\&X6F6.B_P#!-6VT;3(/*MK3XB>)
M(;>/<6V(E^ZJ,DDG  Y/-?>=?EC_ ,&Z?[?W[(DOP(TG]C&/XQ0'XF:YXY\2
MZAI7A?\ LF]WSVQEGO!()O)\E?\ 1XWDPT@/RXQNP*^^?"'[8GPF\:_M=>+O
MV*M'MM7'C'P7X;L]<UB6:S1;)K6YV>6(Y Y9G^<9!0 <\FL,TH5UF%5N+W;V
MZ7M?TOU _-BQ\,?\$\M)_;"_:,N/^"XS:8WCN]\?WD_PXF^(<UW]@D\#E1_9
MW]DE#Y>5_>JXB_>JR@??WUT'P-T3]KCPM_P01^/4?PN;QJEC+K.OS_ 6/4WF
M.MQ> VEM_(VA_P!\C&U%Z\0.'VLA3@I5;]BW]H+]AO\ 93^*W[0W@W_@JK)H
M&A?&+5?BQJ^H7NM?$?PZUR=>\.R;!8?89I(7$EH$5PD"= 1A>@'NO_!!33M<
M_P"%/_%OQAX2\+:OH/P?\1_&?5]2^!^B:O:26_D:#(5(DMH9/FAM7?)CCX (
MD('))]/$SG2I.33:BX-7^!V_D[?CI?8#S7]GWQS^P#\)/V\_"/Q%_P""=/B7
MPIIOPIT/]G[6-2^/&H^$)U.E6MG UM)I<VHF/*#4@PNRWF?Z5L\S<,9KZ'_X
M)^Z1>_$;QEK?_!0']H#R=(\;_&2VC@^'OA;5KA$N_#_@R!B]A9)&QW":?<;V
MX"_\M)D4@>4!65^TEX?T#]L;]JFP_P""?7@/0[.W^'WA*>S\8_M#SZ?;+%%J
M+EQ+I7A^0H,.US)&+JX!Y^SP(N[][BOCK]K=?V6;>X_;.T[]KNPT]OVB9_%A
M_P"% ?;;<MKQT_\ L^U'AL>'R!YH O1+YOV3^+=YO>L%!8M<NJDTK_:ERN6E
M]M[W?:*CW8'[&T5SGP?7QROPD\++\3R#XE'ARQ'B$C'-]]G3S_N\?ZS?TXKH
MZ\!JSL!] ^'_ /D V/\ UYQ?^@"K=5/#_P#R ;'_ *\XO_0!5NOV*C_!CZ(
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M R <' JS10!7U/2M+UJS;3]8TVWN[=R"\%S"LB,0<C*L"#@\U.JJJA5   P
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M#7S]7T#X@_Y -]_UYR_^@&OGZOA^+OXM+T?Z %%%%?'@%%%% !1110 4444
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M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO5_B9_R(NH_]<1_Z$*\H_X)[_\
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M#X?_ .0#8_\ 7G%_Z *MU4\/_P#(!L?^O.+_ - %6Z_8Z/\ !CZ( KPOQ_\
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M9-%..79?&2:HQ37]U?Y ?*?_  J3_@K[_P!'<?"S_P (62C_ (5)_P %??\
MH[CX6?\ A"R5]645V ?*%Q\'/^"O%U;O:S_M:_"QDD0JZ_\ "#2C((P1P:Y_
M_ADK_@I[_P!',?"S_P )"Z_^+K[/HK"MA<-B&G5@I6[I/\P/C#_ADK_@I[_T
M<Q\+/_"0NO\ XNC_ (9*_P""GO\ T<Q\+/\ PD+K_P"+K[/HK'^S<N_Y\P_\
M!7^0'QA_PR5_P4]_Z.8^%G_A(77_ ,71_P ,E?\ !3W_ *.8^%G_ (2%U_\
M%U]GT4?V;EW_ #YA_P" K_(#XP_X9*_X*>_]',?"S_PD+K_XNN7^-7P2_P""
MF'P@^%6N?$S4?VC?AI<0:-8FXEAM/"4XD< @84NQ7//<5][UYQ^UWX4\1^.?
MV:?&/A'PCI$M_J5_H[16=G  7E?<IVC/?BC^S<N_Y\P_\!7^0'S5X:_9B_X*
M<>(?#FGZ_#^TK\+T2^LHKA$D\(7.Y0Z!@#A\9Y[5=_X9*_X*>_\ 1S'PL_\
M"0NO_BZ^M_A]8W>E^ =#TS4+=HI[?1[:*>)^J.L2AE/N""*V*/[-R[_GS#_P
M%?Y ?&'_  R5_P %/?\ HYCX6?\ A(77_P 71_PR5_P4]_Z.8^%G_A(77_Q=
M?9]%']FY=_SYA_X"O\@/C#_ADK_@I[_T<Q\+/_"0NO\ XNC_ (9*_P""GO\
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MO]I7X!GQ_P")_%<OF7^H^+_$=]-%I\*Q+&(+2%9DBM8U"9!10^226Z8^=_\
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M1110 4444 %%%% !1110 4444 %%%% !1110!^>7_!9WX7?&/X-_M,_LZ?\
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M\5M7MY,K<:A]CMI!!I4,BY2U9@\K!6=0<"+]>_V;_P!MO]D#]HK]F&;]I_\
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MR6/BJTT>YU3Q%83<26=UJ%[/?-;2#M)$MPL3#^]&>O6OK:BB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ-H$]CHT\-]%-)&2CI%);S8E4E710XX85W/A;_@K'_P4)^/GPPN_VN?V1_\
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MF?$_2OA3KSZ!X[^(7C+XA)H&DC7(E5I]*LE%O/)=31!E620A$C?@Y#(S>O\
M_!/G]N_2OVY_AYXDO=9^%>I_#[Q[\/\ Q9<>%_B7\/-9O([F?0=6A56*)/&
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MI HW']J>^!..2!8V^/YG\Z/^"%:(OC_]MQP@!/[;GC$$@<G]S9?XG\Z^_J*
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MM]<27MFEPMM^Y-O ZRS-,ZQI;J3-(3\B-UJO^Q]_P4W_ &.?VY?%FO\ PY^
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MK8I?:IX4\#^#M2U^]TRU8!EFNTT^"46JE2K 2E6*LK!2"#7K?[-?[3OP%_;
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M+XBZUH.G:M.Q^>2:TL+N*'<W.XHJELDG).: /F[X]?\ !,#XW? ;_@WZ\/\
MP+TCXGZ?XP^+7[,>I/\ $#X=>*M&ADV"]TG5+J_CMXE<ER4LI)K14S]Y5';%
M3_"?]H?P;_P6@_X*L? WQU\/'%W\,?V?O@]:_$G7K82>9''XP\06ZII]A.!Q
MYUI;B2=3P5D208K]'?@K\"OA+^SM\(=%^ OP8\$6NA^$/#UA]BTC0X'>2*"
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M\:?A9>0^-M)L_L=AXW\(^);_ $+5UMLD^0]U831/-'R<)(6"[CMQDU'\)O\
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M96NG/IVBZ]XN\9:IKL^C6;@AK>R.H7$WV5"K,F4PQ1F7=M8@[_[7_P#P3/\
MV,OVY]>T3QM^T'\*9+GQ1X:C,?A[QEX>UV\T?6=/C)),27MC+%*8\LY\MF9
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MZGI?CUK-;2Z\:>!O%VI>']2O;=5"K%<2Z?/%]I 554&4,RJBJ"%&*[[]D?\
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M^,^N_ OPRFM>!?CAX,M[(0>(].O-/N)X#<0VQ>V%W:SP&*7: CDK\IPS,O\
MP2/G_P""GG[:?[-/PA_X*!_M7?\ !0J?2-'N+$7\_P ./#G@+2X;;6[&&22-
M[C4KI8E?S;C890MN(HX4\L!2V\D _2>BOS*_8MUO_@I1_P %A_A?=_MYZ'_P
M4 UKX"_#CQ)KNI0_"'P!X&\#Z3>S+IMI=RVBWVIW.H0RO/-+)!)F%=L8"Y4@
M/@=1_P %0/V^/CM^P;\._P!G_P#9!NOVM/!'A_XH?%Z_N=-\0_M!>.=%M+#2
MM#L=-MXY=0U@V,D@MEN9#-"L-N[^49)"G/RT ?H;17Y(> _^"DNH_LH_M?\
MP4\#>%?^"S7@[]K/P1\7_'UKX(\3^%I)-!.N>'-1O@RV6JVKZ2%8VIG"12QR
MJR()$"G=("OI&J?%/_@I5^U?_P %>OVC/V%_A%^V*OPT^%OP]\.^$=2CUC3O
M!>FWVKZ9)>Z<)'M+)YX=O^DR-+))-<>>8A;*D2IYA90#])ZX_P"!/Q]^#?[3
M?PUL_C%\ _B%I_BGPQJ$]Q!9:UI;EH9I()G@F4$@'*2QNAXZJ:^+OV#?BO\
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M+2"-I996"@L=J*3A02>@!) K\W/V0O$G_!3?_@L3\+/$7[=_PM_X*':A\"?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20210930_g12.jpg
<TEXT>
begin 644 biib-20210930_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2
M N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLW@?Q%N_9IUKX=?$'P5XYN9[62+1B]Q?-?Z9<Q*X6Y4N0T4@5&6/&27^7O\
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M*^O^&;>/XA?$R6R;6+YC/.US>:<Q-S"TB!)#9F195)CCZ%6*UQ7[/7_!)O\
MX*O?LO?#/PU\$?@Q_P %M=!T+P7X6MHK73/#NF_LEZ%%&L"MEEW_ &TL7<EF
M>5BSL[L[%F))_16B@#YU_P""AW_!/S3OVY?#G@WQ!X2^+FH_#?XG?"_Q,OB#
MX8_$?2=/CO)=&O=NR6.6VE*I=6TR866!F4/L3)P"#YA\&/\ @E]^T7XL_:\\
M&_MI_P#!1O\ ;+M/BSK_ ,+[&\A^&'A;PSX%CT#1M$N;J,17.H21^?,]U<N@
M"@L56/:I )"[?MFB@##O/AE\-]0NY;_4/A]H<\\TA>::;286>1B<EF)7))/.
M37@__!+G_@G3HG_!-3]GFZ^!UKX_M?%UW=>+-6UE_$4?AI=-D\N]N/.%L4$T
MQ*Q\*#OPV,[5Z5]*44 ?-7PG_P""??B1_P!BWQ]^QG^VA^TUX@^-=E\0+K68
M]1\1:O:O9W=MIM\-L=G%ON+@K]G',<F[ ;!"#&*^<3_P1_\ ^"FTG[-O_#!$
MO_!8*(_!;^Q/^$>+CX/6W_"4'P]Y?D_V9]O^U[/]1^X\_P O?LYQ_#7Z1T4
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M_:9_Z*7_ .4:R_\ C-'_  VK^TS_ -%+_P#*-9?_ !FO+** /4_^&U?VF?\
MHI?_ )1K+_XS1_PVK^TS_P!%+_\ *-9?_&:\LHH ]3_X;5_:9_Z*7_Y1K+_X
MS1_PVK^TS_T4O_RC67_QFO+** /4_P#AM7]IG_HI?_E&LO\ XS1_PVK^TS_T
M4O\ \HUE_P#&:\LHH ]3_P"&U?VF?^BE_P#E&LO_ (S1_P -J_M,_P#12_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?G5^TG_R7OQ;_P!AR?\ ]"K]%:_.K]I/_DO?BW_L.3_^A4 <
M11110 4444 %%%% !1110 4444 %%%% !7Z#_LE?\FZ>%O\ KQ?_ -'25^?%
M?H/^R5_R;IX6_P"O%_\ T=)0!Z+1110 4444 %%%% !1110 4444 %%%% 'A
M?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5^=7[2?\ R7OQ;_V')_\ T*OT5K\ZOVD_^2]^+?\ L.3_ /H5 '$4444
M%%%% !1110 4444 %%%% !1110 5^@_[)7_)NGA;_KQ?_P!'25^?%?H/^R5_
MR;IX6_Z\7_\ 1TE 'HM%%% !1110 4444 %%%% !1110 4444 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?FZ&@#C**** "BBB@ HHHH **** "BBB@ HHHH *_0?]DK_DW3PM_P!>+_\
MHZ2OSXK[S_97UW4K7]G[PS;P^&;J=5LG E1EPW[U^E 'K-%9=GKVI7-TD$WA
MFZA5FPTKLN%]S6I0 4444 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V
M/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^=7[2?_
M "7OQ;_V')__ $*OT5K\ZOVD_P#DO?BW_L.3_P#H5 '$4444 %%%% !1110
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M)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G5^TG_R7OQ;
M_P!AR?\ ]"K]%:_.K]I/_DO?BW_L.3_^A4 <11110 4444 %%%% !1110 44
M44 %%%% !7Z#_LE?\FZ>%O\ KQ?_ -'25^?%?H/^R5_R;IX6_P"O%_\ T=)0
M!Z+1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKP
MO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<
M5\9?CY\/_@3-X3A\?7,\9\9>+K;PYI#0JA O)XY70R%F7;'B%LL,D$KP<T =
MK15/Q#X@T3PGH%]XJ\2ZI#8Z=IEG+=ZA>W#[8[>"-"\DC'LJJ"2?05\V_LR_
M\%F/^":'[97Q[;]F3]F+]J2P\8>-%TZ>^_LS3- U,0M;P[?,=;N2V6V;&Y>!
M(2<\ T ?3U%%>3_M?_MP_LN?L&_#BV^*?[5'Q7M?#&EW^H)I^D1?9)[N\U.\
M<$K;VMK;I)-<2''1$.!RV!S0!ZQ17SC^R5_P5?\ V(/VT_B7?_!+X-_$O4K7
MQSING_;[GP5XQ\*ZAH6J-9Y ^T107T,1FCY&3'NVY!; (S>_;$_X*??L9_L+
M>*-$^'OQ]^)5ZOBOQ':O=:+X/\,>'+[6=6N;9"0]Q]EL8I9(X05<>8X5248*
M25( !] 45YM^RG^UW^SG^VY\(K;XY_LO_%"R\5^&KBYDM7N[:*2&6UN8\>9;
MW$$RI+;S+N4F.1%;#*<88$^/>#?^"W'_  2U^(G[36E_L>> /VN-*USXB:SJ
MLFF:=H6D:'J5S')=QAR\1NX[8VR,/+?.Z4#Y: /JJBBO)OVOOVXOV9/V#_ N
MF_$G]J7Q]>^'M&U?5AIFGW5CX6U+5FDNC%)*$,>GV\\B#9&YWLH7C&<D @'K
M-%?&7@+_ (."/^"2OQ,^)GACX.^#OVF=6G\2>,M>M=%\-:;<_"KQ/:_;KZXE
M6*&%9)]-1%R[J"S,%4'+$ $U]FT %%%% !7YU?M)_P#)>_%O_8<G_P#0J_16
MOSJ_:3_Y+WXM_P"PY/\ ^A4 <11110 4444 %%%% !1110 4444 %%%% !7Z
M#_LE?\FZ>%O^O%__ $=)7Y\5^@_[)7_)NGA;_KQ?_P!'24 >BT444 %%%% !
M1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$
M]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\_?[7FB?LZ?"
MC]LWQGX@_P""U?[//C&_U;5OVJ?M_A_XI>*?#FH:MX5E^&9@F%GIEE+;>9'
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M^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444
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M_P"'EO\ U17_ ,N/_P"YJ /J:BOEG_AY;_U17_RX_P#[FH_X>6_]45_\N/\
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M/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ1?\)QK.5EA+'/VEN<U[;]B\;_\ 0;LO_ 8_XUY'_P $]_\ DB>K?]CWK/\
MZ4FO=* ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_
MQH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,
M?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^
M@W9?^ Q_QK8HH Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#
M=E_X#'_&C[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_
MQK8HH Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&
MC[%XW_Z#=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_
ML7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#
M=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V
M7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&
MMBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH _,#Q&&'B&_#D$_;9<D
M>N\U2J]XF_Y&/4/^OZ7_ -#-4: "BBB@ HHHH **** "BBB@ HHHH **** /
MT:^&]GXR;X=Z"8-9M%0Z+:[%:V)('DKCO6U]B\;_ /0;LO\ P&/^-1_#'_DF
MWA[_ + =I_Z)2MR@#'^Q>-_^@W9?^ Q_QK\_OVB%N4^.7BI;R57E&M3>8Z+@
M$[NPK]&:_.K]I/\ Y+WXM_[#D_\ Z%0!Q%%%% !1110 4444 %%%% !1110
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MQ[;P)KWP\@\30>%UO7F@T'6%F"RQP*[,85E@82LF<99,   #[<H _3#X8_\
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M110 4444 %%%% !1110 4444 %?H/^R5_P FZ>%O^O%__1TE?GQ7Z#_LE?\
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M#CJ*['_A0/Q;_P"A3_\ )^W_ /CE'_"@?BW_ -"G_P"3]O\ _'* ..HKL?\
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M$N64?ZU^@H ]9HK+L_"6FV-TEW#<71:-LJ'N6(_$5J4 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\^W_\ Q_3_ /79OYFH:FO_
M /C^G_Z[-_,U#0 4444 %%%% !1110 4444 %%%% !1110![[X?_ .0#8_\
M7G%_Z *MU4\/_P#(!L?^O.+_ - %6Z "OSJ_:3_Y+WXM_P"PY/\ ^A5^BM?G
M5^TG_P E[\6_]AR?_P!"H XBBBB@ HHHH **** "BBB@ HHHH **** "OT'_
M &2O^3=/"W_7B_\ Z.DK\^*_0?\ 9*_Y-T\+?]>+_P#HZ2@#T6BBB@ HHHH
M**** "BBB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_
M &/>L_\ I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y]O_\ C^G_ .NS
M?S-0U-?_ /']/_UV;^9J&@ HHHH **** "BBB@ HHHH **** "BBB@#WWP__
M ,@&Q_Z\XO\ T 5;JIX?_P"0#8_]><7_ * *MT %?G5^TG_R7OQ;_P!AR?\
M]"K]%:_.K]I/_DO?BW_L.3_^A4 <11110 4444 %%%% !1110 4444 %%%%
M!7Z#_LE?\FZ>%O\ KQ?_ -'25^?%?H/^R5_R;IX6_P"O%_\ T=)0!Z+1110
M4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1
M/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/M__P ?T_\
MUV;^9J&IK_\ X_I_^NS?S-0T %%%% !1110 4444 %%%% !1110 4444 >^^
M'_\ D V/_7G%_P"@"K=5/#__ " ;'_KSB_\ 0!5N@ K\ZOVD_P#DO?BW_L.3
M_P#H5?HK7PG\??@M\3-<^-/B?5]+\->;;W.L320R?;(5W*6X."X(_&@#Q^BN
MQ_X4#\6_^A3_ /)^W_\ CE'_  H'XM_]"G_Y/V__ ,<H XZBNQ_X4#\6_P#H
M4_\ R?M__CE'_"@?BW_T*?\ Y/V__P <H XZBNQ_X4#\6_\ H4__ "?M_P#X
MY1_PH'XM_P#0I_\ D_;_ /QR@#CJ*['_ (4#\6_^A3_\G[?_ ..4?\*!^+?_
M $*?_D_;_P#QR@#CJ*['_A0/Q;_Z%/\ \G[?_P".4?\ "@?BW_T*?_D_;_\
MQR@#CJ*['_A0/Q;_ .A3_P#)^W_^.4?\*!^+?_0I_P#D_;__ !R@#CJ_0?\
M9*_Y-T\+?]>+_P#HZ2OBG_A0/Q;_ .A3_P#)^W_^.5]P?LRZ+J?AWX$^'-%U
MFV\FZM[-UFBWJVT^:YZJ2#P>QH [NBBB@ HHHH **** "BBB@ HHHH ****
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M_P#0C7B=>V?#7_D1M._ZXG_T(T ;E%%% !1110 4444 %%%% !1110 4444
M>%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(K2O#?Q#N!/INB_%_P 1?$#1KG3='A;=&FI*\2FZ?:C;Q;JN\$X(;!! +/\
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M@ HHHH *]L^&O_(C:=_UQ/\ Z$:\3KVSX:_\B-IW_7$_^A&@#<HHHH ****
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MW_\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
MPF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#
M4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4
M'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I4
M5F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/
MAC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z
M#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!
MI45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_P
MF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^
M&/\ H-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'
M_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!X??_ /']/_UV;^9J&I;U
ME>\F=3D&5B#^-14 %%%% !1110 4444 %%%% !1110 4444 >^^'_P#D V/_
M %YQ?^@"K=8>A^+?#<.BV<4NL0JRVL88$]"%%6O^$Q\,?]!J#_OJ@#2KP[QY
M_P CEJ?_ %^/_.O7_P#A,?#'_0:@_P"^J\<\:7$%WXLU"YMI \;W3E&'0C-
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MI/\ 8TE^ 'PH^!=[JFL:%HWB;Q);ZAX@\5ZU=V,EC&S1VX L[:&.:1R&Y=L
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MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
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MV)KN=>\$>"_%5_8:KXH\(:7J5UI4K2Z7<W^GQS26;L &>)G4F-B ,E<$X%?
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MZM]GU/P_!\1-.\-FPM?*=OM7GWXV2_.J)Y:_-\^[H#7Q%_P0:\&_\%2_V-/
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M44 %>V?#7_D1M._ZXG_T(UXG7MGPU_Y$;3O^N)_]"- &Y1110 4444 %%%%
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M9L0MMS@XSC&<&OF?_AY;_P!45_\ +C_^YJ^BOB=_R3;Q#_V [O\ ]$O7YGT
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M_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%%
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M<BYUBZ6XFN;S49AG$EQ<W#O-,1N; 9B%WMM R:]6HH *]L^&O_(C:=_UQ/\
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MU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'\3O^2;>(?\
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
MZ%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^
M^EK8HH Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** .-^)'B+59/AWK\
M;^%+M VBW0+LRX7]RW-?G+7Z8?$[_DFWB'_L!W?_ *)>OS/H **** "BBB@
MHHHH **** "BBB@ HHHH N^'&*^(;!@I)%[$0!W^<5^D_P#PDNK_ /0H7O\
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M_$FCWTO@+Q$NIPWVG:^+9I);A%>,!K>55R?+<$X R1N0-] ?M9_M8>!_V4/
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MVVHK2UVKZ79S4:3JSMVU9[1^P5^W!K'[:>F^,[G7_@?=^!+OPAKZ:;-IE_K
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M>*DM=-5)-/YH(R<7='Q_^PA^Q7XRALOAW^T%^T5\5]7\0:QX.T>^@\%>%IM
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MO#/_ ",>G_\ 7]%_Z&*_3ZOS!\,_\C'I_P#U_1?^ABOT^H **** /R]\3_\
M(RZC_P!?TW_H9JC5[Q/_ ,C+J/\ U_3?^AFJ-?P17_CR]7^9\8]PHHHK(044
M44 %%%% !1110 4444 %%%% 'Z:?#'_DFWA[_L!VG_HE*W*P_AC_ ,DV\/?]
M@.T_]$I6Y7]XX#_<:7^&/Y(^RA\""O#O'G_(Y:G_ -?C_P Z]QKP[QY_R.6I
M_P#7X_\ .NLHR**** "BBB@ HHHH **** "BBB@ HHHH *]L^&O_ "(VG?\
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MJ3<UB<-9Z_'5_P#E)^3RXIR]2:Y9?<O_ )(S:*TOL%I_SR_\>-'V"T_YY?\
MCQJ?^):.._\ H)PW_@=7_P"4D_ZU9?\ RS^Y?_)&;16E]@M/^>7_ (\:/L%I
M_P \O_'C1_Q+1QW_ -!.&_\  ZO_ ,I#_6K+_P"6?W+_ .2,VBM+[!:?\\O_
M !XT?8+3_GE_X\:/^):.._\ H)PW_@=7_P"4A_K5E_\ +/[E_P#)&;16E]@M
M/^>7_CQH^P6G_/+_ ,>-'_$M''?_ $$X;_P.K_\ *0_UJR_^6?W+_P"2,VBM
M+[!:?\\O_'C1]@M/^>7_ (\:/^):.._^@G#?^!U?_E(?ZU9?_+/[E_\ )&;1
M6E]@M/\ GE_X\:/L%I_SR_\ 'C1_Q+1QW_T$X;_P.K_\I#_6K+_Y9_<O_DC]
M(OAC_P DV\/?]@.T_P#1*5N5B_#4!?AUH"@<#1+7'_?E:VJ_<*%&6&HQI2WB
MDG;R5C]6I24Z49+JD%>'>//^1RU/_K\?^=>XUX=X\_Y'+4_^OQ_YUJ:&1111
M0 4444 %%%% !1110 4444 %%%% !7MGPU_Y$;3O^N)_]"->)U[9\-?^1&T[
M_KB?_0C0!N4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CW
MK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!A_$[_DFWB'_ + =W_Z)>OS/K],/B=_R3;Q#_P!@
M.[_]$O7YGT %%%% !1110 4444 %%%% !1110 4444 7O#/_ ",>G_\ 7]%_
MZ&*_3ZOS!\,_\C'I_P#U_1?^ABOT^H **** /S4\2?\ (Q7_ /U^R_\ H9JE
M5WQ)_P C%?\ _7[+_P"AFJ5?M4/@1_-53^(_4****H@**** "BBB@ HHHH *
M*** "BBB@#]'OAO_ ,D[T#_L"VO_ *)6MJL7X;_\D[T#_L"VO_HE:VJ_&*W\
M:7JS^D<-_NT/1?D%?"/Q_P#C7\3="^-7B?1]*\3>5;6VL31PQ_8H6VJ&X&2A
M)_&ONZOSG_:6_P"2^^+O^PY/_P"A5^/>+^99CEF3X>>#K3I2=2S<).+:Y7HV
MFM#CS2I4ITHN+:UZ$/\ PT!\7/\ H;?_ "0M_P#XW1_PT!\7/^AM_P#)"W_^
M-UQM%?S]_K9Q3_T'UO\ P;/_ .2/$^LXG^=_>SLO^&@/BY_T-O\ Y(6__P ;
MH_X: ^+G_0V_^2%O_P#&ZXVBC_6SBG_H/K?^#9__ "0?6<3_ #O[V=E_PT!\
M7/\ H;?_ "0M_P#XW1_PT!\7/^AM_P#)"W_^-UQM%'^MG%/_ $'UO_!L_P#Y
M(/K.)_G?WL[+_AH#XN?]#;_Y(6__ ,;H_P"&@/BY_P!#;_Y(6_\ \;KC:*/]
M;.*?^@^M_P"#9_\ R0?6<3_._O9V7_#0'Q<_Z&W_ ,D+?_XW1_PT!\7/^AM_
M\D+?_P"-UQM%'^MG%/\ T'UO_!L__D@^LXG^=_>SLO\ AH#XN?\ 0V_^2%O_
M /&Z/^&@/BY_T-O_ )(6_P#\;KC:*/\ 6SBG_H/K?^#9_P#R0?6<3_._O9V7
M_#0'Q<_Z&W_R0M__ (W7W%^S)K>I^(_@1X<UO6;GSKJXLW::78J[CYKCHH '
M ["OSKK]"OV2?^3<_"O_ %XO_P"CGK]8\(<ZSG,\^KT\9B:E2*I-I3G*23YX
MJ]FWKYGI995JU*S4I-Z=7YH]&HHHK^A3W HHHH **** "BBB@ HHHH ****
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M_-53^(_4****H@**** "BBB@ HHHH **** "BBB@#]'OAO\ \D[T#_L"VO\
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M^3<_"O\ UXO_ .CGK[OP4_Y*/$?]>G_Z7 [,I_CR]/U1Z-1117],GT 4444
M%%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2OGK]@NV\22_!
MS5FTG4K>*+_A.-9RLL)8Y^TMSFO;?L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9
M?^ Q_P :/L7C?_H-V7_@,?\ &@#Y1_X*#?\ !9O]EK]B/Q;9?!JW\=Q:]\1(
M_%?AFW\1^$=&\-ZGJ\^E:1?ZI:07,\_V"%Q!<?9)I)((9&$DTGE!(Y-ZJWMG
MP1_;'^$_[6GP!UGX[_L>W[>.8M.-]9V6EWMK=:++/JMO$'^P3"^@22U8LT:E
MWCPHD#8(%?FG^WA^R;_P40_86^+?C[X[_L_^$? 7Q5^'_P 9_P!I#X=^+KK1
M+W6FTCQ'9^(;?Q#I:VFG1SRHUL]I/<I#"LCL/($S,5PC%_N7_@GG^WS=?MX>
M'/&=I-\.=5^''C[X<^)SH/Q)^'WBFTC:[TB_\I71A-"QCN(9$YCF&-P0_*!M
M) /#_P!H7_@JW_P5?_98^"7B;]HCXX?\$5?#NC>$_"&DR:CKFHM^U5I<ABA3
MLJ)I9:1V8JJHH)9F  R:]I\3_P#!4+PQ\%O^"6VD?\%,/VH?A'?^#EU7PA8:
MPGP]T_4AJ-\US?E!8Z?%(T4/F3R^;#G,:>7N?<,1L:^>?^"WA\8_M;_&_P#9
M\_X([:/KD5Q#\7O&:^)_BC%:QE?(\(Z*PN94E(/RK<3(%C;O); =QF3_ (.*
M=+U[3?@3^S79ZK=V2^&HOVP? L>NPPVNR&*Q'VT8<=!$&$8QT^[0!U^C_P#!
M6C]L/X'?$7X;0_\ !2/_ ()X6_PC\!?%SQ%;:!X<\8Z+\2(=<;P_J]T";2QU
M> 6\7D&7!7SD8HC*0PZE?9_VROVH/V\?AC\3]*^$?[%?_!/9_BI)?:(NHZKX
MSU_Q];:!HFD%II(UMV>2.22YGQ'O,<2Y59$8]:^;_P#@Z)M?$T?_  2 \7.V
MJ6TFK?\ "9>&/^$:2"#;,=0_M>VV>6?[^SS.G;-?9W[37[1_@G]COX':]^T5
M^T7\5M'\.^%?#EF9]1U"YMR2S=$AB0'=+-(Q")&H+.S  4 >+_L-_P#!3CXB
M?'7]J#Q9^P5^V%^RO=?!SXT>%?#,7B6#18?$L6LZ7X@T-YE@^WV5Y'''N"RL
MJ-&RY4DC)9)%3Z^K\]/^":OP"_:@_:6_:R\4?\%F_P!J?PN?!.K^-/!$/A#X
M/_#O4[?_ $WP_P"#UN?M:S7RCA+NZFQ,8^3$LC*3\^U/N/Q5K&O^"_"^I>,?
M$/B.TAT_2;":]OI5LF<I#$A=V"KDG"J3@<F@#YY_X*R_\%3_  K_ ,$O?@M9
M^-;/X3W7Q&\:ZRMY<:!X T[5Q8RW&GV%NUUJ6H2SF&;R+:UMD+L_EMEWBC ^
M?<ON'[*GQP_X:;_9>^&W[27_  C']B?\+"\ Z/XE_L7[;]I^P?;[*&Z^S^=L
M3S=GF[-^Q-VW.U<X'X4_$+_@J!^Q+^U%^RG^U+^V/\=OVLO"T7QF^+GPMUSP
M=\+?AG/;W$EUX4\,)',MGIBLL9B6[O)L75PP<KN>)<J$*C]2/^"(O[1_PW_:
M._X)I_"#3O@3\8=&U]_ 7PS\->&?%D%K:2AM*U6VT:S$UG(75<NF0"5ROH30
M!]F45C_8O&__ $&[+_P&/^-'V+QO_P!!NR_\!C_C0!L45C_8O&__ $&[+_P&
M/^-'V+QO_P!!NR_\!C_C0!'\3O\ DFWB'_L!W?\ Z)>OS/K]&OB19^,E^'>O
MF?6;1D&BW6]5MB"1Y+9[U^<M !1110 4444 %%%% !1110 4444 %%%% %[P
MS_R,>G_]?T7_ *&*_3ZOS \.!CXAL A /VV+!/KO%?I/]B\;_P#0;LO_  &/
M^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ?G9XD_Y&*__P"O
MV7_T,U2JYXA##7[X.03]LER1Z[S5.OVJ'P(_FJI_$?J%>,_M3?M8ZG\!_%G@
MKX0?#;X4W'C?Q_\ $.ZO(_#/AY=6CL+<0VD2RW-S<7,BN(8XT93PC,Q.%&:]
MFKQG]JS]E3X:?M.ZUX5N+[XF:UX.\>>$I+J_\%>)?"NJQV^IV2R*D=SM1PPE
M@<>6LBE<$8&1N.<<5[?V+]E\6G;NKVOI>U[7TN=&!^K?65]85XZ]][.U[6=K
MVO;6U['%_P#!//XV_M:?$;X?>';'XZ? R&'1[K0Y[FV^(,'CF._>[F6?:L$]
ML\4<L;D%L."ZXCP2"0*U?BK^SA^VY\4OB5K6NZ+^WG<> _"_G*/#/AWPOX)L
MKB6)!&N9+FYN06D8ON/EJ NW'-?/G["/QF_:8_9_\?\ P._9X^(/Q2TCQYX-
M^+&AZU)HMN-$CL]6\,M8))-F1H3MN()""N]P&W$\C9A_=_VO?VM?'>G^.;7]
MCG]C^QMM:^,'B"T\VXNIAOL?!NGM@-J=\<$ @,#%"02[%200423S:%:C4P*]
MK*5XM*U[-NR:2Y;7O=-:^NVGM8G#8BEFLEAXP2DFT[7BHJ33D^=/ELTT]%Y;
MJ\'_  3P_:.^,WQ*3XH?!G]H[7],UKQ)\(_&3Z+>>,=,LUM8-8M]A=)WB7Y(
MI0%;>JX5<J,9!)\K^&OQ<_:4_;QMY_CQH_[;-G\$/A_J^M7=C\+_  ]8Z-I\
MVH:Y;VTS0F_N)+W))>1' AC& %P>FYOH;X!?L=>%?V;/V9]5^!W@G6;K4M5U
MRVOKGQ%XHU-LW6LZM=1D37LS9/+-@ 9.U5498@L?CW_@DM^PI^R#\8/V#)M9
M_:+^&>E>(?$R:EJND>*;KQ&VZZ\.+:SR(MI"['-B$CQ,=A0[IF8D\8B<<9>C
M0EJVI-^\ULU9.2U=D_GOT-:<\M:Q&*@K)2A%6A&6C4KM1EHKN-UV7NK?3[@O
M/AQ^T1+^SDOPVLOVCXH?B"+2.%OB2WA"V<&03JSS_P!GEO)W-""FS.T,=W;%
M?+?[3>H?MM_\$]= \._'Z?\ ;6OOBAIEQXNT_2-=\"^)_"5A;-JB74FP_8I+
M95DCF7DJ@R.K'<%*MWW_  1J^('BGQ;^P=X>F\;^*+C4[;3]?U/2/#.L:G+F
M74-.@NGCMCN;[^ &C7VB [5XQ_P48_9/^%/[#7@6W_;R^"_C/6?^$^\+>*[2
M?0M%\7ZJ=9L]7ENKM$FM88+L.T,GEL\BO 5=%B;!'#*8J;J8".)IW7NIWYW[
MJWO:]I/UW%@:2HYM/!5N5^^U;DC:3VM>UX+;;X=[*Q^BM>.?M$? C]I;XO>,
M;.[^%?[9>I_#?PY!I@BN]'T3PC8W=S=W?F.3.;JY#-&NPHHC5<94DGFO3+_Q
MWX3T*72-/\6>(].TB_UQQ%IFGZAJ$<4UU-M!,,2L097&1D*":YWX\_ _X>_M
M*^!IOA9X]U758K-+R&YG&@:Y+8W*.N2F9(&#A3D\9P:]:O%5:;BM7VNX_BM3
MP,-.5"M&;T7=Q4M.Z4M'_6IX3^QU\8?VCO#'[8GQ!_8@^._Q7MOB1!X7\,66
MO:/XW31H;&[@2=U3[#>1P?N_,PP=#PQ5"QSN 3ZOKX;_ &+/"&C_ +(/_!2'
MQQ^Q-\'=>;7?!>J_#Z+QEJ<VH)#/J6C:J;L0?9KB\5!).KQ.)%68LZK(FW W
M%ON2N?+93E0:DW=2DM7>VNU^MN[U.S.84XXM2@E:48NZ7+>Z6O*M(W?1:=K[
MGZ/?#?\ Y)WH'_8%M?\ T2M;5<?\/+/QDW@#0S!K-HJ'1[;8K6Q) \I<=ZV/
ML7C?_H-V7_@,?\:_)ZW\:7JS][PW^[0]%^1L5^<_[2W_ "7WQ=_V')__ $*O
MT ^Q>-_^@W9?^ Q_QK\^_P!HM;E/CIXJ6\E5Y1K4WF.BX!.[L*_$?&S_ )$F
M&_Z^?^VLX,V_@Q]3BZ***_FP\$\3_;*^*O[(_A/1],^'G[8_A".^\-:\)98;
MW5_"<VHZ9!-%L $LL<4@MI2)"49MO"OA@17Q;_P3;T[P5:_M"_">?]B&]\1G
M0Y=!UA_CS#"]ZV@*VQO[/(\_]T+LR[>(3PHZ >9G]/JYKX/?##2/@S\--)^&
M&@W]S=6>D0-%!<7>WS'!=GRVT =6/05]7EW$%#+\DK82,9.4]&G/]V[QG'FY
M.7>/,FO>^)1E]FSZ:=>,*+C9W?GIUZ6/DG_@M)^UO^SQX1_9;\??LN>(OB/%
M;>/-<\/VEQI7A\Z?<LT\9O(V#"58S$O$,APS@_+[C/L'[)_[6/P6_:F^!EYX
M=_9A^*%OK&N^%O"MG:WY_LZYA6PO);5U@W>?$@<;X9/N[A\ASU&?>Z*Y)YKE
MSR2G@HT)<\).?,ZD7%RDH*5X>S3Y;0T7/=-W;:T(=2G[)0MJM=_3I;R[GYI_
ML8_'_P#X)X?!C]D._P#A1^VEI&D:;\2+6ZU)?B?H?C/PX]QK&K7KW$K;RSQL
M]R7C:,(58XXY'4N;X>?M5C_@A(OAAM!\3_;Q=_:6\/;I/[5_X1;^T=_V7^__
M ,>W.WKY/RXQ\M?I#<Z+HU[>Q:E>:3;2W$&/)N)8%9X^<_*Q&1SZ59KV*W&%
M-XGZQ2H/F=:%:2G/FBG#F]V"Y8\L7S/=R:2BNEWJ\4N;F2ZIZO\ (_-/]L_X
M_?\ !/+XT?LCZ=\*/V*M(TC4OB5=7>FK\+]$\&>''M]7TB]2XB;?N2-7MBD:
MR!BS#/J?O#[;\<_M)>%O@-K'PQ^%_P 6VO[GQ'\0KU-(L)]-M4>$WR1(96D)
M9=B$MD$ _2O2+;1=&LKV74K/2;:*XGSYUQ% JO)SGYF R>?6K->7C<YP6*H4
ML.J4W3@ZDO?J<TW*:2^+D5HQ<4[6]YWNU?3.=6$DHV=E?=ZZ_(^(_P!I.#P;
M^RA_P5)\,?ML_&6SDMO ?B+X=S>&IO%)LGF@T+6%FW1O.45C$LL'[I7QU9\X
M )$GPF\>^$?VM_\ @JO:_M"?LX2OJG@OP5\+I]#\3^,[:U>.SU*^FN3)%91R
M,H\\QAA(2,@;>OW<_:MS;6]Y;O:7=NDL4BE9(Y$#*P/4$'@BFV=E9Z=;)9:?
M:100QC"10QA57OP!P*U7$=-X-*5)NLJ3HJ7-[O([Z\G+?F2=E[UMI6ON_;KE
MVUM;Y>G_  26OT*_9)_Y-S\*_P#7B_\ Z.>OSUK[W_96M?%<G[/OAA[#5;6.
M$V3[$> D@>:_4U]UX*?\E'B/^O3_ /2X'9E/\>7I^J/6:*R[.T\6I=(]]JUJ
M\0;]XB6Y!(]C6I7],GT 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]
MCWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110!^>7_!2C]BS_@H#J$$
M/B/X'?\ !0WQ'/X9UWX[^"M2L_ >N?"NQUUO#4S>*-.D6[MKM&AG^QV<@6Z,
M$V]/*MV0NBDN/H_]@?\ 8(T#]B'0O&6L:I\6==^(?Q ^)GBAO$/Q'^(/B."&
M"XUB^\M8D6.WMU6*UMXT7;'"F0@9ADC 'OU% 'S?\*_^"?7_  AW_!2CXE_\
M%(OB!\7/^$GUCQ=X,TSPEX)T#^P/LR>$='MR);BW68SR&Y:XN56<MLBV$N &
M#<=G^W7^Q?\ "?\ X*!?LN^)_P!E;XRO>6^D^(H(VM]5TN0)>:7>0R+-;7D#
M$$+)'*BL,\,-RG*L17KM% 'P)HW_  24_; ^-WQ&^&UQ_P %(O\ @HE%\7O
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M'X*?\E'B/^O3_P#2X'J93_'EZ?JCT:BBBOZ9/H HHHH **** "BBB@ HHHH
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MBB@#PO\ X)[_ /)$]6_['O6?_2DUU_[6O_)NGBG_ *\4_P#1T=<A_P $]_\
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M@_90B_9^UOQ;\2?%WQ.U/QOX[\>W=M/XL\5ZG:16OGK;1F*W@AMX1L@AC1F
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MC_R=@_\ BZ/^%(_%#_H6/_)V#_XNOH&BC_B+/$?_ #ZI?^ S_P#E@?\ $/\
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M $9Q=%%%??GY.%%%% !1110 4444 %%%% !1110 5][_ +*W_)OOAC_KR?\
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M?[1?_)=/%7_8:F_]"K]!*_/O]HO_ )+IXJ_[#4W_ *%7V7"'^^5/\/ZH_/\
MQ!_Y%]'_ !_HSBZ***^_/R<**** "BBB@ HHHH **** "BBB@ K[W_96_P"3
M??#'_7D__HUZ^"*^]_V5O^3??#'_ %Y/_P"C7KY7B[_<(?XOT9]YX??\C6K_
M ('_ .E1/0:***_/3]<"BBB@ HHHH **** "BBB@ HHHH \+_P"">_\ R1/5
MO^Q[UG_TI->L?$K_ )$;4?\ KB/_ $(5Y/\ \$]_^2)ZM_V/>L_^E)KUCXE?
M\B-J/_7$?^A"@#Q.BBB@ HHHH **** "BBB@ HHHH **** "M?P'_P CEIG_
M %^)_.LBM?P'_P CEIG_ %^)_.@#W&BBB@##^)W_ "3;Q#_V [O_ -$O7YGU
M^F'Q._Y)MXA_[ =W_P"B7K\SZ "BBB@ HHHH **** "BBB@ HHHH **** +W
MAG_D8]/_ .OZ+_T,5^GU?F#X9_Y&/3_^OZ+_ -#%?I]0 4444 ?/.H_\A"?_
M *[-_,U#4VH_\A"?_KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !11
M10!] ^'_ /D V/\ UYQ?^@"K=5/#_P#R ;'_ *\XO_0!5NOV.C_!CZ( K\^_
MVB_^2Z>*O^PU-_Z%7Z"5^??[1?\ R73Q5_V&IO\ T*OLN$/]\J?X?U1^?^(/
M_(OH_P"/]&<71117WY^3A167XV\;>$/AOX2U#QYX^\26>CZ-I-JUSJ6IZA.(
MX;>)1DLS'@#^9P!R:^;?A7_P5D_9C^(?Q>U?P'/XLO+;2I]6TRP\%:S+X-U:
M*'5)+J),*\TEN(XRTS[8R^P.I!!8$&L*N)P]":C4DDWM=G50P6+Q-.4Z4')1
MWLF_Z_RU/J:BO,?VD?B5^TKX!BT:R_9N_9LM?B!=ZE).-2N-1\80:1;:2B"/
M8[F1'>8N68!8QD;"3VKSKX'_ +<'Q7OOVCK/]DS]K/\ 9R'P_P#%VMZ+/JGA
M._TKQ''JNFZU#!DS(DBHC0RH S;&!X4DE<H&4\51IU53E=-Z7L[7>RO:WX[Z
M;E4\!B*M!U86:2;MS1YK+=\M^;3TVUVU/I.BOG3XU?MI?%"U_:'NOV5/V3O@
M)!X_\7:'HT.J>,;S5?$:Z7INAPS<P122F.1I)Y%PPC51A6#9(#;>G_8__:XB
M_:=T_P 3^&_%7P[N_!?COP'K(TKQOX.O;U+DV$[*7BEBG0!9H)5#%) !NVMP
M0 S*.+P\ZWLT]=5L[76Z3M9M=5?OV8YY?BZ>']M*/NV3W5TGLVKW2?1M6U7=
M'LE%?'7P?_X*%_MK?M">%[GQ_P#!3_@G'I^L:!'K-[IUOJ-Q\:;2T:9[:=H7
M/E2V(9?F4_XFOK3PAJ/B'5_"6EZMXN\-KHVK76G03:II"7RW*V-PT:M) )E"
MB4(Y9=X #;<@#.*=#%4<2KT[V[N,DODVE?Y$XK XC!/EJV3VLI1;7JHMM?,T
M:*X;]H3XI^.?@_\ #QO%GPY^".M?$'5FO8K>W\.Z%<10ROOSF1I)2%CC7'+'
MID<5Y]^PS^V7XP_:WB\>:;\0/@0WP^UOP!XK;0=4T9_$T>J$SK&'8F6*&- 0
M3MPI<<9#4Y8BE&NJ3?O/;1V^^UOQ%'!XB>&EB(I<L=]5?MM>]KO>UCWJOO?]
ME;_DWWPQ_P!>3_\ HUZ^"*^]_P!E;_DWWPQ_UY/_ .C7KYSB[_<(?XOT9]EX
M??\ (UJ_X'_Z5$]!HHHK\]/UP**** "BBB@ HHHH **** "BBB@#PO\ X)[_
M /)$]6_['O6?_2DUZQ\2O^1&U'_KB/\ T(5XU^P-X@T73/@UJUMJ&HQQ2?\
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M /4F%J_."@ HHHH **** "BBB@ HHHH **** "BBB@"]X9_Y&/3_ /K^B_\
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M + O[2FI?M>_LA>"?VAM<T>&PU#7]/F74[:V!$0NK>XEM9FC!)(1I(69022
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M,,L8!'S"O+/^">__ "1/5O\ L>]9_P#2DUZQ\2O^1&U'_KB/_0A0!XG1110
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M+"[\,ZAJ.E3N=1U&/3]46&Z:)Q\[W,FG*P+#]X[EBOSL*\)^/'A/_@E3K?P
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MVY8KNW610?7# C-6J* &P006L*6UM"D<<:A8XT4!54#   Z"G444 ?0/A_\
MY -C_P!><7_H JW53P__ ,@&Q_Z\XO\ T 5;K]CH_P &/H@"OS[_ &B_^2Z>
M*O\ L-3?^A5^@E?,_P 4OA'\/=8^(FLZIJ7A_P R>XOY'ED^US#<Q/)P' 'X
M5Z.#XEP/#,W6Q4924M%RI-WWUNXGR_%.28K.\+3I4)13C*_O-KI;HF?+]%?0
M/_"D?A?_ -"Q_P"3L_\ \71_PI'X7_\ 0L?^3L__ ,77H_\ $6>'/^?57_P&
M'_RP^(_XA_G/_/RG]\O_ ) ^?J*^@?\ A2/PO_Z%C_R=G_\ BZ/^%(_"_P#Z
M%C_R=G_^+H_XBSPY_P ^JO\ X##_ .6!_P 0_P Y_P"?E/[Y?_('S]17T#_P
MI'X7_P#0L?\ D[/_ /%T?\*1^%__ $+'_D[/_P#%T?\ $6>'/^?57_P&'_RP
M/^(?YS_S\I_?+_Y ^?J*^@?^%(_"_P#Z%C_R=G_^+H_X4C\+_P#H6/\ R=G_
M /BZ/^(L\.?\^JO_ (##_P"6!_Q#_.?^?E/[Y?\ R!\_45] _P#"D?A?_P!"
MQ_Y.S_\ Q='_  I'X7_]"Q_Y.S__ !='_$6>'/\ GU5_\!A_\L#_ (A_G/\
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MPOQ__P CIJ?_ %^/_.OF.+?]TI_XOT QZ***^# **** "BBB@ HHHH ****
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M#L/GG4?^0A/_ -=F_F:AJ;4?^0A/_P!=F_F:AK\9G\; ****D HHHH ****
M"BBB@ HHHH **** /H'P_P#\@&Q_Z\XO_0!5NJGA_P#Y -C_ -><7_H JW7[
M'1_@Q]$ 5X7X_P#^1TU/_K\?^=>Z5X7X_P#^1TU/_K\?^=?,<6_[I3_Q?H!C
MT445\& 4444 %%%% !1110 4444 %%%% !7M_P ,_P#D1=._ZXG_ -"->(5[
M?\,_^1%T[_KB?_0C7U/"?^_3_P /ZH#=HHHK[\ HHHH **** "BBB@ HHHH
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M_P#(0G_Z[-_,U#7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/A_\
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MCI7Z4ZEX&\%:S>OJ.K^#]+N[B3'F3W.GQR.V  ,LRDG  'X5XA^QS^P-X?\
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M=/O?C1LF@NY(Y4_X1S4CM96((R+?!Y%5/^'FG[$/_1;/_+;U+_Y&K\L/B/\
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MB+IW_7$_^A&OJ>$_]^G_ (?U0&[1117WX!1110 4444 %%%% !1110 4444
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MJ)_RD7_8;_[*9K__ *;X:VH4*2Q<J-2GT;5W>UHMIIJR=]/*P'TW^V=^U?\
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M!GA/P+\++SXA_$CXFZ\='^'/@33M1CM#J<ZH'FGEN9 RV]M"C*TDI5MN]<@
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M'4O",?[,W[#?Q&@U<>'M.;4=2B_LN\BN;DLZ)+>W$MQ!&)I7D=-QSGD  *H
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M%'_$6>(_^?5+_P !G_\ + _XA_DW_/RI]\?_ ) ^?O\ A2/Q0_Z%C_R=@_\
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M^'FG[;W_ $6S_P MO3?_ )&H_P"'FG[;W_1;/_+;TW_Y&H_X@#QC_P _\/\
M^!5/_E0?\1+R+_GW5^Z/_P F?K117Y+_ /#S3]M[_HMG_EMZ;_\ (U'_  \T
M_;>_Z+9_Y;>F_P#R-1_Q 'C'_G_A_P#P*I_\J#_B)>1?\^ZOW1_^3/UHHK\E
M_P#AYI^V]_T6S_RV]-_^1J/^'FG[;W_1;/\ RV]-_P#D:C_B /&/_/\ P_\
MX%4_^5!_Q$O(O^?=7[H__)GZT45^2_\ P\T_;>_Z+9_Y;>F__(U'_#S3]M[_
M *+9_P"6WIO_ ,C4?\0!XQ_Y_P"'_P# JG_RH/\ B)>1?\^ZOW1_^3/UHHK\
ME_\ AYI^V]_T6S_RV]-_^1J/^'FG[;W_ $6S_P MO3?_ )&H_P"( \8_\_\
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MJ_\ @_\ ;D?GGB;_ ,BNA_C_ /;6>,4445^Y'XL%%%% !1110 4444 %%%%
M!1110 5^]?\ P2N_Y1^?#+_L"S?^E4]?@I7[U_\ !*[_ )1^?#+_ + LW_I5
M/7YEXI_\B2C_ -?%_P"DR/T?PS_Y'-;_ *]O_P!*B?0-%%%?A!^VA1110 44
M44 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KI?VSOBW_P *(_9@
M\7_%O_A'_P"U?[$T])O[/^U^1YV9HTQYFQ]OWLYVGI7-?\$]_P#DB>K?]CWK
M/_I2:I?\%4?^4?GQ-_[ L/\ Z505VY;A:&.S&CAJZO"<XQDM5=2:35U9JZ?1
MW.',ZU3#Y;7JTW:482:?FHMH^!/^'V?_ %;-_P"7G_\ <='_  ^S_P"K9O\
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M^7G_ /<='_#[/_JV;_R\_P#[CKX/HH_X@_X=?] /_E6M_P#+ _UZXJ_Z"/\
MR2'_ ,B?>'_#[/\ ZMF_\O/_ .XZ/^'V?_5LW_EY_P#W'7P?11_Q!_PZ_P"@
M'_RK6_\ E@?Z]<5?]!'_ ))#_P"1/O#_ (?9_P#5LW_EY_\ W'7?_LK?\%:_
M^%P?M&^"_A=_PH#^SO[>\06]G]N_X2OSO(WMC?L^RKNQZ;A]:_-"O9_^"=G_
M "?-\*_^QTLO_0ZY<=X3^'^$P56O2P=IPC*2?M*KLTFT]:EM^YUY?QKQ-7Q]
M*G.O>,I13]V&S:3^R?T"T445^('[X5/$'_(!OO\ KSE_] -?/U?0/B#_ ) -
M]_UYR_\ H!KY^KX?B[^+2]'^@!1117QX$=[<BRLY;PP22^5$S^5"FYWP,X4=
MR>PK\<_VU/BC_P $-/VC_P!H_P $?$+QGX7N_#6L7NG^()O&\6B^#=6T'Q9'
MJOD6YLB\4$$<LUX)O-"L1(C-]YF6OV0KC_%WP:T+QC\8/!WQEOM4NXK_ ,%V
MVJ06%K$5\J<7T<*2&3()RHA4K@CJ<YKMP.)AA:CD[[/9VZ/R?_  ^5OV4;Z_
MT?\ X(J:->?\%>=.U"^L%\)W(\?P^,=-N+J^_LEKZ06;7L42M.9UMC;,S ><
MC+N)$BDU\*?M&_ G_@FO^UGX-T7]B[_@F#XR\:?%WQSXFO[*QTF\UCQ-K.KZ
M'\+="%Q')>7ZB](@M?W,9@4?-+ARJX9@'_<0@$8(JII6A:'H221:'HUI9K*^
M^5;2W6,.W]X[0,GWK>AF3HU)5$FFVY))VC?S5M;>JNM /%/CY^W7^QE^P%<^
M$/A1^T3\68_!L.JZ2T?AJZU+3KF2UECM1'&8VGBB9(W 9#ARN1DC.#7R5X5^
M-GPR_P""B_\ P6K^$7Q]_8GM[K7O!_P=\%>(+7XF_$NUTJ:WT_4#>VSPV6E)
M-*B?:'BFD,P49&'=ESL8C])-1TS3=8M&T_5M/@NH'^_!<Q*Z-]0P(-+I^G:?
MI-FFGZ78PVUO$,1P6\01$&<\*.!S6%'$T:,&U%\[35[Z:Z/2U]O/?4#S#PA^
MV)\)O&W[7/B[]BO1K;5QXQ\%>&[/7-8EFLT6R:VN=GEB.0.69_G&04 '/)KX
M/_86^,_[,_\ P2 _:"_:/_9^_;+\4V_P^O/%GQ5O/&7@CQ1K.GS"U\2>'[E
MT$<%PB,LDENWF*\6=P>9@H)W8_46JNJZ'HFNQ)!K>CVMXD4@>-+NW60(W]X!
M@<'GK2I8FE3C*FXOEDE?76ZUO>WX6 ^'?^"('AW7M<M_V@/VH-,\&ZCX=\!?
M%_XUZAXA^'&F:G8M:R76G%0IU(0, 8UN&P0" 3Y>>1M)^[***RQ-;ZQ6=2UK
M_HK(";3O^0A!_P!=E_F*^AJ^>=._Y"$'_79?YBOH:OK^$?@K>L?U ****^R
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MY:M[71\K5[/_ ,$[/^3YOA7_ -CI9?\ H=>,5[/_ ,$[/^3YOA7_ -CI9?\
MH=?19M_R*L1_@G_Z2SP,J_Y&E#_''_TI'] M%%%?R6?U*<_\6/$O_"&?"SQ+
MXP^Q?:?[)\/WEY]G\S9YOE0.^S=@[<[<9P<9Z&ORC_X?9_\ 5LW_ )>?_P!Q
MU^I'[2'_ ";OX]_[$O5/_226OYQZ_0N"N"^&>*J%:IFE#VC@TH^].-DT[_!*
M-]NI^;<>9_F^2UZ$<'4Y%)2OI%WLU_,F?>'_  ^S_P"K9O\ R\__ +CH_P"'
MV?\ U;-_Y>?_ -QU\'T5]O\ \0?\.O\ H!_\JUO_ )8? _Z]<5?]!'_DD/\
MY$^\/^'V?_5LW_EY_P#W'1_P^S_ZMF_\O/\ ^XZ^$8HY)I%AB0L[L JJ,DD]
M!7V1=_L0_LW? [X<>-_ /[1?[0QL_&>EG0FUZ31/ [Z@GAB6Y\R1(%E,\9N"
MZ,OF>6 %"@?,>!Y^.\,O##+W%5,"VY;)3KR=KI-V4WHN9?-I+5I'?@N*>,L?
MS.GB$E'=M4HK9M*[BM7RO[FWHFSIO^'V?_5LW_EY_P#W'1_P^S_ZMF_\O/\
M^XZ\!_9 ^"WPE^)'[=_A?X(^(-0C\8>#K[Q)-:->1+<6*ZI;+'*4E #)-#NV
MJVW(8=#WKIOCSXS_ &9_">DZYX8M/^"9TOA:ZN%NK/0O$]YX[UQA%*-Z1W*1
MSGRYMI ?8<J<8/%95?#3PWAC(X:&6RE)Q4M*LU92;2NIUHN^CNDFT:4^)N+)
MX1XB>-C%*3CK!.[23=G&G)6U5FVDSUC_ (?9_P#5LW_EY_\ W'1_P^S_ .K9
MO_+S_P#N.OE/]GGQ?^S;X+U74M5_:+^#^L^-8?LZ#1])TSQ"=-B\W<=YFE12
M^TC &WGK7??\%,_@U\*?@3^U%/X&^#'@[^P="?P[IM[#IO\ :$]UY<DT D?]
MY.[N>3W./0"M7X7^&\<Q6#EETDVG)2]I4Y7R\MTOWO-=<R^S;S,EQ7Q9++WB
MUBXM)I./)'F5[V?\.UGROK?R/;O^'V?_ %;-_P"7G_\ <='_  ^S_P"K9O\
MR\__ +CKX/K['_8B\$_L+_'OPWK/PMUC]F[6;WQ;I'PTU/6[WQ;J7C&XCB6\
MMHQ@0VMN479N<$;V/W<$'-&9>%_AOEF']M/+I2BM^6I4T7=WJK3TN_(>7<5\
M69CB/8QQ<8M[<T(ZOLK4WKZV7F=3_P /L_\ JV;_ ,O/_P"XZ/\ A]G_ -6S
M?^7G_P#<=?!]%>A_Q!_PZ_Z ?_*M;_Y8<'^O7%7_ $$?^20_^1/T \)_\%H?
M[9\4Z9I'_#-GE_:M0AA\S_A,<[=SA<X^QC.,]*_6ROYK/AQ_R4/0?^PU:_\
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M&\XRBK[7::U/QYHK]"_^'!/[1_\ T/GPL_/6/_BJ/^'!/[1__0^?"S\]8_\
MBJ_;O^(I</\ _/JK_P" P_\ DS\:_P"(:9[_ ,_*7WR_^0/STIT4LL$JS0R,
MCHP9'4X*D="#7Z$_\."?VC_^A\^%GYZQ_P#%4?\ #@G]H_\ Z'SX6?GK'_Q5
M+_B*7#__ #ZJ_P#@,/\ Y,?_ !#3/O\ GY3^^7_R!XAX0_X*D_M2Z3\+?$FB
MZW\9M1N?$MR^GKX>UF;1K*:X@CC:7S]]R\1E+%2FUB6((."O)/@>F?%CXF:/
M\28_C%IWCO58_%4>HF_7Q!]M<W9N223*9"268Y.<YR"0<@U]U_\ #@G]H_\
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M!Q7.ZQ\</BCK_P (-'^ NK>)_-\)Z#J<VH:3I7V*!?(N9<^8_FJ@E;.X\,Q
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M;X5_]CI9?^AU]2?\."?VC_\ H?/A9^>L?_%5M?#K_@B7^U_\)_'6E?$KX?\
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M_P#Y]5?_  &'_P F'_$-,]_Y^4OOE_\ ('YZ45^A?_#@G]H__H?/A9^>L?\
MQ5'_  X)_:/_ .A\^%GYZQ_\51_Q%+A__GU5_P# 8?\ R8?\0TSW_GY2^^7_
M ,@?GI17VU\$?^"-7QS^-OA*Y\6Z!XM^'-O#;:Q=Z>Z7XU4.7@D*,PV.1M)'
M'?UKL?\ AP3^T?\ ]#Y\+/SUC_XJC_B*7#__ #ZJ_P#@,/\ Y,/^(:9[_P _
M*7WR_P#D#\]**_0O_AP3^T?_ -#Y\+/SUC_XJC_AP3^T?_T/GPL_/6/_ (JC
M_B*7#_\ SZJ_^ P_^3#_ (AIGO\ S\I??+_Y _/2BOT+_P"'!/[1_P#T/GPL
M_/6/_BJ/^'!/[1__ $/GPL_/6/\ XJC_ (BEP_\ \^JO_@,/_DP_XAIGO_/R
ME]\O_D#\]*_>O_@E=_RC\^&7_8%F_P#2J>OA_P#X<$_M'_\ 0^?"S\]8_P#B
MJ][^%?[(G_!7+X)_#[3/A9\,?VJOA9IF@Z-"8M-L/^$;EF\E"[.1OE@9V^9F
M/S,>M?'<:<999Q'EU.AAH33C/F?,HI6LUTD]=3ZW@_A',N'\PG7Q$X-2CR^Z
MVW>Z?6*['W-17RW\)?A1_P %9-'^)>B:I\8?VIOAUJWA>#4$?7=,TWPP8KBY
MM@?G2-_(7:Q'0Y&*^I*_-3]$"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHJA8>*O#&JZK<:'I?B.PN;VTS]JL[>\1Y8<'!WH#E>>.1UH OT4C,J*7=
M@ !DDG@"J&A^+?"GB=ID\->)M/U$VS!;@6-[',8CZ-L)VGZT >8?M'^!?%WB
MSXL?"36_#F@SW=IH?C"2ZU:>$ K:PF!E#MSTSQ7K]%% !15"^\4^&=,U6WT'
M4O$5A;WUW_QZV4]XB2S<X^1"<MSZ"K] !1110 4444 %%%% !1110 4444 %
M%4/^$J\,?V[_ ,(M_P )'8?VGMW?V=]L3S\8W9\O.[&.>G3FK] !7G'[7?A3
MQ'XY_9I\8^$?".D2W^I7^CM%9V< !>5]RG:,]^*[;3O%_A+5]5GT+2?%&G75
M]; FYL[>]C>6+!Q\R*25YXY%:- &/\/K&[TOP#H>F:A;M%/;Z/;13Q/U1UB4
M,I]P016Q15#6O%/AGPV85\1>(K"P-R^RW%[>)%YK>B[B-Q]A0!?HHJG<>(O#
M]GK$'AZ[UVSBO[E"]M8R72+-*HSEE0G<P&#R!V- %RBBB@ HHHH **** "BB
MB@ HHHH **** /./VN_"GB/QS^S3XQ\(^$=(EO\ 4K_1VBL[.  O*^Y3M&>_
M%=?\/K&[TOP#H>F:A;M%/;Z/;13Q/U1UB4,I]P016Q10 4450U+Q3X9T?4;;
M2-7\1V%K=WAQ:6MS>(DDYZ816(+?A0!?HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \@_8I\"^+OA]\)]2T3QIH,^G7<WC#5+J."X #-#).61^#T(Y%>O
MT44 %%4=<\4>&O#$<4OB7Q%8Z>L\FR%KZ[2(2-_=4N1D\]!5X$, RG(/0B@
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MP#KOP"T3PSIFLC48"TNIV^J7-Q+#Y ?S5 CD1MY0(<X!)!%?5=% 'Y_?&_\
MX(.?\$6O _P=\>_%C]H_X0M-OL+[6O&'Q4\5>,=0FU:T(5Y7O$N6FQ"T?5%C
M0)\JKL;)!O\ _!#2W^.O[3/_  1#\$^&_P!K'Q9XJDO?%OAC6=*LO$5Q?R6^
MMS:!-/<V]C=>?DNDWV5D:*;);:(I,L3N/PI^T3_P6>_X)X_\%+_VQ-2^%?[:
M_P"U/'\.OV8/A7XA7[/\/)M!U6:_^*VKV\F5N-0^QVT@@TJ&1<I:LP>5@K.H
M.!%^O?[-_P"VW^R!^T5^S#-^T_\ LX?$RRU7X8Z':W:/K-EHMU:06L-BA,ZK
M;RPQRA8T7@+'T&%S0!^>7[''[#W[/G[ O_!RW+\(/V<]%U>UTS5?V,9M;UBX
MUWQ%=ZI=W^H2^)XX)+B2:ZD=LF.WA7:NU!LR%!))_6^OP^G_ ."X7_!+-_\
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M2QWLP';%?MQ7YT_L1_\ *Q?^VY_V(GP]_P#34E 'C'_!4C_@GC^QGHW[8O\
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M._:'TF^>=+CQ+X6MM2L-5A@M3%$RBX#Q7,1=V3]W,$W;2RG4^&%I:V'_  =
M>/K&QMHX8(?V-=,CAAB0*L:#7X@%4#@  8 % 'JGQG_:G_X*[Z#XV\32? O_
M ():>%/$'A+P]JES!I5SKOQSMK'5/$]M$[*MQ;6Z6<D=J)0N42>7=@C<%S@-
MU7_@KW\/-0_X)(ZY_P %6?AK\)]1U2ST'P_<WE]X"UG41I]Y;W]K=_8[K3YI
MA%+Y3QS+(-_EMN558* PQ^=OP?\ BC_P3B^,.H?%C6?^"V?QJ^)FL?M"Z3\4
MM:L(O@X?&_B;3YK2U6X9=,L-!TO29X%N8Y8C&(V7?O:0LS -O-']FR":T_X-
M'_VAK.?PW/HS0Z]XMC.C75T\TE@1J\6;=I'+,[(<J68DD@DDDYH ^\O"W[;/
M[:?[8G[/_B?XGZA^P?;^ _@EXI^#VLZEHGBW7_'\,VMW2OIDDEO,=,CA!A@F
MS\F^3S-A1V1-VQ?)O^">O_!1/P'^QK_P1O\ V7/AEX5\"ZC\2OC%XY\!Q0?#
MGX/^&+E%U'6I!-,&N)I&#+8V,>&:6\E&Q%1B Y4K7V;=110?\$OY((8PB)\!
M2J*HP !HO %?DW_P2I^%7Q6_X)4_LJ_"W_@K?\._ M[\4_AC\1OA?IUG\==&
M-FMYXE\%6EM)(J:II$Q'F2Z<B@-<6(.%""1?E7,(!^G'[7/_  45\<?LH>%/
MA=\.6_9I/C3X_P#Q?N);/P?\'O"?BU'MVN+>$37TTNJW%O$L=E;(RE[AH ?F
M&(\;F7F?@W_P4B_:9\(_M5^#?V0_^"BG['>F_"_5OB=;WK?#+Q=X2\=KKVC:
MO>6D7G3Z;,QMX)+2Y$7SIN!27E5.1@_*G_!8K3?A!\8OV@_V7O\ @JDOQ/\
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M\&R:9H>I>3>VWVJ"YF\^WB,,GVN7-OL2W)B#M(/WJ8Y\Q_X-C/\ E!I\"?\
MKSU[_P!2'4ZXG_@Y.\<7_P ,?!G[)?Q+TSP/J/B:?P[^V3X2U2/P[I%MYUYJ
M1M[>_F^SP1C[\SA-J*.2Q44 =[/_ ,%4/VO?V>?C5\//#/\ P43_ & [#X8>
M ?BOXG@\-^&/'/ASXF0Z\-$UFY!-I8ZK$MM$(C*05\Z-GC5E/++EAI_M5_\
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M3X;^*O&%MI\MS;>$K^2]^V6EU=B)6:**=F\@28P-K;B!C.#>?M ?#'_@JO\
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MVKOV@O\ @G!X ^*O[9L%X_C745OA_:FI:*-.NM7TY+N5+*_FM0%$+S6ZQO@
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M8%5 /TU\0:Y!H'AR]\2/&9HK*REN2D;#+JB%L ].0*\I_P""?_[8OAK]O_\
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MQ-'9W$+*L9<A=Z3$+G]Z2 ?LKJ6IZ;HMA+JFL:C!:6L"[IKFYF6..,>K,Q
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M5='TG7K%],US2[:]MI,>9;W<"R(V#D95@0>>: /Q5_8 M/V%;7_@X3\%S?\
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MID\0?%[Q#XQLY;6S9XK>+4+GS8HR)E_UJ#() QSP:^G: /EWQ-\#_$G[1?\
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M ZBJE[KNAZ;?6NEZCK-I;W-ZQ6SMY[A4DG(&2$4G+$#KC-6Z "BBB@ HHHH
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M_P %&O"OAOPAKOV8V7@+QK\'(=6307CM889'MKR*[@ED$KQM,4E#!6D8 XH
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M(Y8$L$CN6%G;0JC#RF65Y9)996ER^T 'R]_P3U_X)K_LO?MP?MK_ +;'C/\
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MA%=!KA%>"1_,DG#L9SR JK7H/[57[$O_  TU_P $\?$?[!?_  LW^Q/^$@\
MP^&O^$K_ +%^T^1Y<<:?:/LOG)NSY>=GFC&?O<4 >G? GQEJGQ&^"'@WXA:X
M$%[KWA33M1O!&N%\V>VCE? [#<QXKX>_X*KZA^Q'\7/VM?!?[.'C?_@G7XA_
M:C^,]EX+N-;T?P-IVI0VVF:!HLESY+7U]+>W4-E"99D\M&=7D^3'R!EW_=7P
MD\"?\*M^%/ACX8_VK]N_X1SP]9:7]N\CROM'V>!(O,V;FV;MF=NXXSC)ZU\O
M_M:?\$Y?V@?&?[:&F?\ !0']A_\ :QL/AC\0O^$$_P"$.\66'B;P6NNZ1KVE
M+<M=0[HO/A>":.5B?,1CN4*OR@-O /E;_@C=/X]_9U_X*[_%G]C33OV1M9_9
M_P# WB#X+6/CRW^#NH>/[+Q#::9J2:HMB]]9O9S316L=PDAWPA@=T() 3RP,
M;_@D=_P3#_9%_;5N_P!J?XC_ +7_ ,.A\0[>T_:]\?:7X<\-Z]J%P=,T5?M$
M+3W,%O'(J+=3&15><@R!+>%5*X.?K+]CC_@D]\1OV<_V_O$G_!1/XR_MGZG\
M3O&7C7X8#PMXHMK[PA%IT!N1?PW"7%H(KADM;9(+>&!+0(QRK2M,[2,*]2_X
M)]?L,_\ #"?ASXI>'_\ A:/_  E/_"ROC;XA^(7G?V)]A_L[^U'B;[#CSY?.
M\KRL>=E-^[_5KCD _-/X9_M2?&O]B3_@@#^V5I?PD\=ZQ)=?L^?'OQ7\,OAC
MJUW>/->Z3I U73[*W996);?;KJ,KQL3\GEH!@* .U_X*'?\ !$7]A[]F?_@C
M3\0_B)\%/#$NA?$OPI\*;K4;_P"*MEK%Q_:GB21K;.HQWTID(NH;U&G1HG!0
M><I0*43'V!\&O^"2GPQ\'_L[?M'_ +,/QE\=2>-?#'[1GQ<\5>-=8CATC^SY
M=)CUGR"+2-O.F\R6W:!72YPF7"GREVX/A_C_ /X(N_M]_'3]DW4?V!?CS_P5
MF?5?A3%X?.EZ(VG?"B&#7+N.%,:>FI7?VS_28;=T@9TC$3W/D@/*H9L@'V)_
MP3O_ .4?_P #/^R.^&/_ $U6U?'W[>/PX\._M_?\%N/A?_P3I_:)-SJ/P>\(
M_ >]^*>J>"OMLD-EXHU<ZO\ V9;Q7:QLIG2W \Y4)QDL""K,#]Y?L[_";_A0
MG[/_ (%^!?\ ;_\ :W_"%^#M,T'^U/LOD?;/L=I%;^=Y6]_+W^7NV;FVYQN.
M,UX3^WK_ ,$ZO&'[2GQ@^'_[7/[,?[0LGPG^-/PTAN[+1/%;^'TU6PU32KH#
M[1IE_9O)'YT+$;D8.#&S,P!8J5 /C_4OV(?@?^Q+_P '$G[,.@?LUZ8_AOP=
MXB^'?C:]B\ VE[(^G:1?K8[+BYM(79A;"X3[.'1,(7MBP 9F)[[]D#PW\1O&
M7[?G_!3KPA\'O%":'XNU6Y\+6?A;6I&*KI^HR^%9TMK@D D!)61\@$_+7H'P
MC_X))?'V+_@H1\/O^"EO[4O[=;>/?'/@_P /ZMHUWH.G^ 4TS2/L5U;M%!!9
M(MV[6HA>6XE=Y//>=I1DQA% ]-^&W_!//Q3\)_C3^U/\<_ _[1USINM_M')I
MSZ/=V?AF,3>"[JSTB33XKE&DG=+Y@[K. R1*"@0A@2: /S$_9U^'?_!,?]CW
MX=^!_A?_ ,%@?^"1/CSX7^/]-OK.#Q#^T-KNG7&K:)JNOB53_:+>(;&Y:2!Y
M[C][M8!(PV"VQ2:^I_VFOAAX:_X*8?\ !<0_L.?M/75YJOP8^$?P0M?&<7PX
MCU*6WL?$VNWE^(4N[U8F4W,,$14)&255Q_=DD5NI^-G_  2O_P""C_[9OPS?
M]EO]N'_@IYX=\3?"74;VS?Q?9>$/@I!HVM>)+:VN8[A+=[G[9+%9[I(HV9X8
ML_+@#!(KU3]L_P#X)F^)?C-\=O!W[9?['_[1EQ\&?C-X(\.2>'+;Q&GAZ+5]
M-US07?S?[+U"RD=/-B63+HZN&C9BV&98R@!SW[0?[.G[-_\ P1]_83_:-_:>
M_8$^!>E>!/$;_#6YU"2#1FF-DU[8VUS]CN?LKNT*&-[AF<HBF15 <L%7'S5X
M*_X(B_L4>+?^"0%E^T+X@TJ_N?CGK7PCC^(4_P ?9?$-V?$,?B6731J*WRWG
MF[A$DQ51&"%,:\_.2]?;WP*_97_:IUOP#\1? '_!1G]J30/C#HWQ T0:,/"V
M@?#N+0-.TNQ>*YBNXPRSS3W#7"3H&:1QL$*A "6)^:8?^",?[>ND_L\2_P#!
M/KP[_P %9+RW_9ZDLWT>+3I?AC;2>++?PZV5;15U7[0(S'Y1,(F,&X1G8$V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !115?6+_P#LK2;K5/*\S[-;/+Y>[&[:I.,]NE %BBO._P#A??\ U*G_
M )/?_:Z/^%]_]2I_Y/?_ &N@#T2BN5\#?$W_ (335I-+_L3[-Y=L9?,^T[\X
M91C&T?WOTKJJ "BBB@ HHHH **H77BKPQ8ZS#X<O?$=A#J-PNZWL);Q%FE'J
MJ$[F'!Z"K] !12,RHI=V  &22>E9/@3X@> _BEX4M/'GPQ\;:1XCT._#FQUG
M0=2BO+2Y".T;^7-$S(^UT93@G#*0>0: ->BBB@ HHHH **** "BBB@ HHHH
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MR[M-(6Z0X\J>47+;D..%1OX@  =K_P $+/CK^W3\0OV%_@]H'QC_ &6=)L_
M9^%<,EC\59?B\-3U+5G6(>4\VFM8H\32Y)8FX<IC^+-?+O\ P0V_;1_X*!>
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M'Q!)X4O[QQ':1ZK MK"!$\A"-<0NR1GJ#N4'XW_:*\-?MY?MU_\ !#[]G?\
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M:G917%O,A6:">,.CJ>H*G@CV-,TO2=*T.Q33-%TRWL[://EV]K"L:+DY.%4
M#FK%% %,>'?#XUH^(QH5F-1,?EF_^RIYQ3^[OQNQ[9J74]*TS6K)]-UC3H+N
MVE&)+>YA61'[\JP(-3T4 0:9I6EZ)8QZ9HVFV]I;1#$5O:PK&B#.>%4 "IZ*
M* *!\+>&&UL>)F\.6!U(+@:@;-// QC'F8W=..M7Z** "BBB@ HHHH ****
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MXE^/OVL-2N[7X<6W@^]@\8-I\\T=S-97$9MV@@>!DE6:4RB*,HRL'D7#*>0
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MY^R]_P %'O"GAWPAKK0-8>!?&OP:AU4: R6T44C6UY%>02RB1XWFV2A@K2,
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M@O\ PM#[-_PA'PXU7PI_PB/]B;_MOVV=)?M/VKSQY>S;CR_*;=G.X=*]^HH
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M[$=*MKJR6TELQ)YTGGG8&/F[8_O?<XS7/_\ !.[_ ()_?M9_L'6NB?"#6O\
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MTK  %SCC)ZGZU/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20210930_g13.jpg
<TEXT>
begin 644 biib-20210930_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=%'^M_\ TX_\F_\ M0/HRBOG.BC_ %O_ .G'_DW_ -J!]&454\/_ /(!L?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;6VN!:_X)>^#?VC/!'[%/@G3?VFOC1I/CG6;C1+*YTG4]'\,KI4=IICV5O\
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M/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GG4?^0A/_ -=F_F:A
MJ;4?^0A/_P!=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH **** /H'P
M_P#\@&Q_Z\XO_0!5NJGA_P#Y -C_ -><7_H JW7['1_@Q]$ 5X7X_P#^1TU/
M_K\?^=>Z5X7X_P#^1TU/_K\?^=?,<6_[I3_Q?H!CUY!^TY\2_P!L+X8ZQH6J
M_LV?LQZ-\3]%FAN$\2Z9)XVBT74[67,9@DMVN4-O,A'FAT=XV!V$'&17K]%?
M#0DH2NTGY._Z-/\ $#\OO^"<O[-G[2G[2GQ1_9P_:O\ B%\#M%^&_A'X*^&-
M?ATW5?\ A(H+[6O&4FHK+;K$ZVR[;:T@W2,%D=F+%L*!(2OJ_P#P6@TG]OS]
MH7X$^-?V+OV9/V"IO&N@^,O#MHO_  L5?B=H^G)97*W:3/ ;&[=)9-H@7YPX
M4^;Q]TBOMCP?X.\*_#_PU:>#O!'AZTTK2K",I9:?8P".&%22Q"J. ,DG\:TJ
M[IYC)XM5N1>[\*=[+5OH[WN[[V^0'@/[ OQ)_:W\5_#V7P;^U9^Q9-\(#X4T
MC3++1+B;XB:;KHUS;%(D[@66?LWE^5$<.3N\_@_(U</^RG\1?&G_  5B_P""
M??CR3X_^"].\/^'OB-=^(O#OA:YT2.4?;/#Y#6EOJ.V9V(E9Q,XZ*=B,!@@G
MZTDCCFC:&:-71U(96&00>H(J'2-(TGP_I=OHF@Z7;V5E:1+%:V=I L<4* 8"
MHB@!0!T &*YWB(7E*,$I-IJU]+;VNV]7;=@?F[X8;_@K5\)_V'?^':.D?L$6
MNM^(=.\'R>"-!^+UMX^T^+PX^EF%K2'4I(9&%TCQVY!,!C+,Z9Q\P2OI/P7\
M,/C)_P $\_\ @GOX#^!_[/\ \"S\:-9\%Z/9:3JV@P^(;;2&U",JQO+F&2[!
MCXD9F6%CEE;;G-?2]%:5<:ZNC@DK\S6NK\]?RMN!^>V@?LW?M._MW_M!_#77
M?C/^QAI7[/OP9^$_C&/QDGA5M8L+O5/%WB*!"MG))'8#RK>" LY.\EI 2!D-
MF/I/VC_@M^UY^S9_P4OD_P""B'[-W[/R_%[P[XM^&D/A'QGX1L?$-KIVK:4\
M%R)HKNU:[98YHV"HK1!MV=Q.."/N6BJ^OU.?X5RV:Y=;6>KZWO?6]_PT ^'/
MV:O@K^UY^T=_P4M;_@HI^TI\ $^$7A_PO\,I/!_@OP?>^(;;4=6U,S71GEO+
MIK5FCBC&YU6(MNSM/J3]"?!CQW^V+XA\7_%FP^-'P1T/0=(T37G@^$=[9ZK'
M(WB*P$;E9[D)/(8&+A 0RQ'#$[>*]?HK&KBG6>L5:R2WT2[:_?>^X'Q-XB_;
M?_X*Q:KX6NO!?AG_ ((Z:CI_C*X@:WMM3U+XMZ+/H-M*RX%R\JLLDL2D[S$%
M5V VY!-?8O\ P1G_ &,M8_8 _P"";?PU_9;\3>)[?6-8T*SO+G6K^SW?9VO+
MN^GNY4AW $QHTQC5B%+!-Q52Q U*]O\ AG_R(NG?]<3_ .A&OJN&,2IXJ=.,
M%%6N[7U::MNWM=@;M%%%?:@%%%% !1110 4444 %%%% !1110!\]?L%ZQ?V'
MP<U:"VT"XN5_X3C63YD1&,_:6XYKVW_A)=7_ .A0O?\ OI:\C_X)[_\ )$]6
M_P"Q[UG_ -*37NE &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!\\7S%KV9BI!,K$@]N:BJ;4?^
M0A/_ -=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH **** /:M%\1:K'
MHUI&GA2[<+;1@.K+AOE'-6O^$EU?_H4+W_OI:N^'_P#D V/_ %YQ?^@"K=?L
M='^#'T0&/_PDNK_]"A>_]]+7CWC2:2X\5ZA/+;M$SW+%HWZKST->\UX7X_\
M^1TU/_K\?^=?,<6_[I3_ ,7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110
M5ZYX!UW4K7P?8V\/AFZF58B!*C+AOF/2O(Z]O^&?_(BZ=_UQ/_H1KZGA/_?I
M_P"']4!9L]>U*YND@F\,W4*LV&E=EPON:U***^_ **** "BBB@ HHHH ****
M "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=*
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M* "BBB@#YYU'_D(3_P#79OYFH:FU'_D(3_\ 79OYFH:_&9_&P"BBBI ****
M"BBB@ HHHH **** "BBB@#Z!\/\ _(!L?^O.+_T 5;JIX?\ ^0#8_P#7G%_Z
M *MU^QT?X,?1 %>%^/\ _D=-3_Z_'_G7NE>%^/\ _D=-3_Z_'_G7S'%O^Z4_
M\7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110 5[?\ #/\ Y$73O^N)_P#0
MC7B%>W_#/_D1=._ZXG_T(U]3PG_OT_\ #^J W:***^_ **** "BBB@ HHHH
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
MZ%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^
M^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[
MZ6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@
M#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^
MEH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q
M_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (27
M5_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X2
M75_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_
M^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_
M .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W
M_OI: /$=1_Y"$_\ UV;^9J&I;YBU[,Q4@F5B0>W-15^,S^-@%%%%2 4444 %
M%%% !1110 4444 %%%% 'T#X?_Y -C_UYQ?^@"K=<[HOB+58]&M(T\*7;A;:
M,!U9<-\HYJU_PDNK_P#0H7O_ 'TM?L='^#'T0&Q7A?C_ /Y'34_^OQ_YUZY_
MPDNK_P#0H7O_ 'TM>/>-)I+CQ7J$\MNT3/<L6C?JO/0U\QQ;_NE/_%^@&911
M17P8!1110 4444 %%%% !1110 4444 %>W_#/_D1=._ZXG_T(UXA7KG@'7=2
MM?!]C;P^&;J95B($J,N&^8]*^IX3_P!^G_A_5 =A1679Z]J5S=)!-X9NH59L
M-*[+A?<UJ5]^ 4444 %%%% !117#_M$_M*_ ;]DKX5:A\;OVDOBII'@[PMIF
MT76KZS<[$,C9V11J 7FE;!"Q1JSN1A5)H [BBOS]U3_@MS\</B2YU/\ 8J_X
M([?M#?$SP^>;3Q9KVE1>%K#4DSQ-:&^S)-&1G#&-#D8Q6AX2_P""[G@GP'J]
MOH7_  4)_8E^-/[-R74ZPP^+?'/A9KWPP96;:D;:K9[XXF)(R9$1%!R7 YH
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M^&O#7AWP9X<T_P '^$-!LM*TG2K**STO2].M4@M[.VB0)'#%&@"QQHBJJJH
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MHKX, HHHH **** "BBB@ HHHH **** "O;_AG_R(NG?]<3_Z$:\0KV_X9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"N6MO/MHKF+,EO<R1MNAFB?Y6.-V#@@@=[_P3-E_X-:6_;=\$K_P3D\1^?\
M&;_B9?\ "&Q?VUXWFW?\2VZ^U_)JDAM#_H?VD_O1QC*_/MH _6:BBB@#YZ_8
M+UB_L/@YJT%MH%Q<K_PG&LGS(B,9^TMQS7MO_"2ZO_T*%[_WTM>1_P#!/?\
MY(GJW_8]ZS_Z4FO=* ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\
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M=)!-X9NH59L-*[+A?<UJ445]^ 4444 %%%% !45W8V6H1""_LXIT#!@DT88
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M"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@
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MWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVO/B3_P5O?2O&.H6\,$<OA/]H"/3X+"&.WA@\NU1,F!'$*NZJV&<LQY-=_\
M\$]O@_\ \$9_"W[7_A#7OV4?^"K7C#XE>/X/[0_L#P5JO[03ZY!J.[3[E9]U
MD3B?RX#-,/[AB#_PT ?IM1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P""
M>_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_R$
M)_\ KLW\S4-3:C_R$)_^NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444
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MI9C_ ,_I_P#@3_S Z/\ X6U\0?\ H8/_ "4B_P#B*/\ A;7Q!_Z&#_R4B_\
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M7C.]^'.G>-](N/$.G6J7.H:##J43WMK"^-DLD ;>B-D89@ <C!KXJ_X+_?\
M)MWPC_[.4\'_ /HV>N3+M,9&,HIJ7=)Z?/\ ,%N?=E:_@-$D\9::DBA@;M,@
MC(/-9%;'@#_D=-,_Z_$_G6&"_P!\I_XE^: ]N_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHK]? K7%MI5K;O=3V<*I&A9V\D'  R3P*Y_\ X63\+_\ H(P_^ $G
M_P 16]X@_P"0#??]><O_ * :^?J^<SW-\3EDX*DD^9/>_3T: ]C_ .%D_"__
M *",/_@!)_\ $4?\+)^%_P#T$8?_   D_P#B*\<HKP?];,Q_DA]S_P#D@/8_
M^%D_"_\ Z",/_@!)_P#$4?\ "R?A?_T$8?\ P D_^(KQRBC_ %LS'^2'W/\
M^2 ]C_X63\+_ /H(P_\ @!)_\11_PLGX7_\ 01A_\ )/_B*\<HH_ULS'^2'W
M/_Y(#V/_ (63\+_^@C#_ . $G_Q%'_"R?A?_ -!&'_P D_\ B*\<HH_ULS'^
M2'W/_P"2 ]C_ .%D_"__ *",/_@!)_\ $4?\+)^%_P#T$8?_   D_P#B*\<H
MH_ULS'^2'W/_ .2 ]C_X63\+_P#H(P_^ $G_ ,11_P +)^%__01A_P# "3_X
MBO'**/\ 6S,?Y(?<_P#Y(#V6/XB_#&618H]0A+,P"C[!)R3_ , KH?[.T_\
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M[^$_[,W@*7P[H%]K,FJW5C-KE]J!>[DBBB>3S+V::092"(;0P4;<@ DD^R>
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M6M(B*6=W^%/B<!0.I)_LW@5Z]I7_  4!_9&UG]D0_MWV'Q9)^%(A>7_A*IM
MU"+<JWALB1;/ +ELW \L 1$L<$9!!KQW_@N%\;O%_@#]BV3X!_".;/C_ ..O
MB&S^'G@^!'(;?J#^7<RG'*HMMYJEQ]QI4.:^DOV>_@9X,_9Q^ W@_P#9]\$6
MJ_V/X.\/V>EV)>, RBWC5?.8?WV93(QZEF)ZU-6G@XX:%51DFY;.2=TM_LJV
MKLM]GH!X7\)_^"T'_!/GXO?$_1_A!I?Q7U;0M;\27"P>&8_&7@S4]'AU>5B
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MC7U/"?\ OT_\/ZH#=HHHK[\ HHHH **** "BBB@ HHHH **** /"_P#@GO\
M\D3U;_L>]9_]*37J_P 3/^1%U'_KB/\ T(5Y1_P3W_Y(GJW_ &/>L_\ I2:]
M7^)G_(BZC_UQ'_H0KDQ_^XU?\,OR8'B%%%%?D0!1110 4444 %%%% !1110
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MJ<@RL0?QJ*IM0 %_. /^6S?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444
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M !1110!] ^'_ /D V/\ UYQ?^@"K=5/#_P#R ;'_ *\XO_0!5NOV.C_!CZ(
MKPOQ_P#\CIJ?_7X_\Z]TKPOQ_P#\CIJ?_7X_\Z^8XM_W2G_B_0#'HHHKX, H
MHHH **** "BBB@ HHHH **** "O;_AG_ ,B+IW_7$_\ H1KQ"O;_ (9_\B+I
MW_7$_P#H1KZGA/\ WZ?^']4!NT445]^ 4444 %%%% !1110 4444 %%%% 'A
M?_!/?_DB>K?]CWK/_I2:]7^)G_(BZC_UQ'_H0KRC_@GO_P D3U;_ +'O6?\
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MBB@ HHHH *]O^&?_ "(NG?\ 7$_^A&O$*]O^&?\ R(NG?]<3_P"A&OJ>$_\
M?I_X?U0&[1117WX!1110 4444 %%%% !1110 4444 >%_P#!/?\ Y(GJW_8]
MZS_Z4FO5_B9_R(NH_P#7$?\ H0KRC_@GO_R1/5O^Q[UG_P!*37J_Q,_Y$74?
M^N(_]"%<F/\ ]QJ_X9?DP/$****_(@"BBB@ HHHH **** "BBB@ HHHH *V/
M '_(Z:9_U^)_.L>MCP!_R.FF?]?B?SKIP7^^4_\ $OS0'NE%%%?KX%3Q!_R
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M!1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KU?XF?\
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M9_\ @+_R ]OT[_D(0?\ 79?YBOH:O@ZR_P""C'[$T5Y%+)^T+HH595+'RY^
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M_P#XW1_P\4_8H_Z.$T7_ +]S_P#QNC^S<Q_Y\S_\!?\ D![317BC_P#!1?\
M8GC0NW[0>CX']V&<G\A'2C_@HK^Q00"/VA-&Y]8I_P#XW1_9N8_\^9_^ O\
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M]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\
MHWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\ \:KN:* .&_X9?_9I_P"C>/ O
M_A)6?_QJC_AE_P#9I_Z-X\"_^$E9_P#QJNYHH ^7/VG_ -G_ . VC_&'X-6.
MD_!+PC:P7_C66*^AMO#=JB7$?V=CLD"Q@.N><'(KVK_AE_\ 9I_Z-X\"_P#A
M)6?_ ,:K5\;_  I\(_$'Q%X<\4>(X9VN_"VI-?:289RBK,4*$L/XA@]*Z2@#
MAO\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\
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M!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\
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M_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\
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M*M-\9_\ "6_VSN^T_:[Z:U^R?9?)&S9Y._S?-;=NQL&,GW2N)TS]G+X+Z/\
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M[O3UU&*QC$EI:V^VW+R--PTY=?(Y3#AJ^YJ_.VZ_Y6K[?_LQ,_\ J6M7Z)4
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M%_$WB:)M/\/V^N?L_P"G^('\+Z-N)CTVREO+_;"@!(=XHHFE)8ODNV?TAHH
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MG_P1;_;:\??\%%?$?_!1;X/_ /!5^W\)>(;_ $_^RO".G:Y\!;#Q%_PB>E[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20210930_g14.jpg
<TEXT>
begin 644 biib-20210930_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
M\$IM'^&?@V[6X.K>-;7]H/3M=DT\I;R/$!90V,3S>9*L<7#C8)-YR%(/T[JN
MKZ3H5A)JNN:G;V=K" 9;F[G6.- 3@99B .2!^-?,'[*?P:_X*X>"_C#:Z[^U
M[^VG\,?&W@E+.=;O0/"_PQ?2[N2<IB)UN#.X55;DC'(XKXV_8H_X)Y_LU?ML
M_P#!2_\ ;@UW]K#P>WC?0/#_ ,9K*'1/!.K7LPTB&\DTU3+?R6R.J3W'EB..
M-Y WE+YFS!D8T ?K;;7-O>6\=W:3I+%*@>*6-@RNI&001P01SFN.^-GQ9LOA
MI\+O&?BK0K_3;O6_"_A*_P!8BTF>Y!9C!;/*GF(K!PA*J">.#P:_+_\ 9*^*
M7BK_ ()S_LS_ /!1KX/_  !O[P^&_P!G77]3U3X0:3J5R]XGA\7>BF\2UC,Q
M9C;0S@.$8G/SDDEV8VO ?_!&;]CR]_X(UI^TS<:??/\ '37O@E)X^O\ X[OK
MUTVNRZ[=:2;^29[DR9DM6:0PO W[N2 L&!9BY /OW_@F_P#M.^+?VS_V%?A?
M^U1X[T#3M*UCQSX5@U34-.T@2?9K>1RP*Q^8S/MX_B8GWKV#3/$GAW6KNYL-
M&UZRNY[*39>0VUTDCP-S\KA22IX/!QTK\1_B?^T#\5/A?_P;S?L1_ SX7KXQ
M$7QH\2^&_"'BM?A],D6N7NC2"YFNM/T^222-8[JY$20J2Z@AG4G#&F_%+X#6
M_P +KOX?_%7_ ()4_P#!#']H?X)?%?P+XOTR>V\2-96$%EK.C"=%U#3=4,>K
M3O=Q30;LLZ.^]5^906- '[?:OK6C^'[!]5U[5K:RM8\>9<W<ZQ1KDX&68@#G
MBOG"R_;=\<7O_!7V7_@GA#X9T5_"B_LVQ_$>+7T,IOGOFUXZ;Y&=_E&#ROG^
M[NW?Q8XKYC^(?P*^&_\ P4\_X+H?$KX!_MB:*?%7PT_9Z^%^@7/A#X<:C<R#
M2[W5]75YIM5GA5@+B2.(>0 ^5 VG&1D\]^QM^R?\-/V-?^#EOQ=\(_@M<7=K
MX.E_8V&H^&_"\VH2W%OX:AE\46XDL+7S69HK<SI/<K%G:ANW"A5VJ #]5:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N._:)^$O_  OW]G[QU\"O^$@_LG_A-?!NIZ#_ &K]D\_[']LM);?S
MO*WIYFSS-VS<N[&-PSFNQHH \G_84_9?_P"&*OV/OAW^RA_PG'_"2_\ " ^&
M+?1_[?\ [,^Q?;O*!'F^1YLOE9S]W>V/4UYC^WE_P3D\3?M,?&'P%^UW^S5^
MT+<_"7XU_#6WNK'0O%ZZ#'JMCJ>EW/,^F:A92/&)X&.65@ZM&SLP!;:5^IJ*
M /D']E#_ ()J?%GP?^US=_M^_MS?M21_%SXIP^&'\.>#DTCPFFB:)X4TMY-\
MR6EJ)IF>>5L[IW?=M9DP1@UW_P"PS^PS_P ,7^)_C?XD_P"%H_\ "2_\+E^-
M6K?$#R?[$^Q_V/\ ;4A3[#GSY?M&SR<^=B/=N^XN.??Z* "OC'0O^"8G[2/P
M1_:X\=_M _L??M^?\(+X/^*7CFW\5?$'X;:Y\++37([R^"QI=-:WK7,,MIYZ
M1D'Y9-A;(!V@5]G5G2^,/"4&O+X6F\4Z<FIN,IIS7T8G88SQ'G<>.>E 'B/[
M,O[#/_#.?[8G[0O[6/\ PM'^V?\ A?&K>'KW^P/[$^S_ -A_V7I[6>SS_/?[
M3YN[?GRXMF-N&ZU4^"?_  3YT+X6_M;_ +2W[3'BCQW!XETS]HY/#D6H^#[K
M0!%%I<&EZ5)ITD+S&9Q=K<+(6/[N+8/E^?.ZOHJB@#X#^%/_  2[_P""B/[&
M_AB3X"_L&_\ !3?2M"^$MO=3-X3\,?$GX31^(-0\*02R-(;:VO5O(#<Q*SL4
M6=3M&%R>M?9GP"\!_$?X9?"#1/ WQ>^,UY\0_$UA;N-:\9WVD06$FJ3M([F3
M[-;CRH%&X(J)PJHHR>M=A10!'=P?:K26UW[?,C9=V,XR,9KY\_X)6?L%?\.S
M/V'/"'[&/_"UO^$V_P"$5N-2E_X23^PO[-^U?:[^XO,?9_/GV;//V?ZQMVW=
MQG ^AZ* / /V6_V&?^&:_P!J_P#:"_:>_P"%H_VU_P +V\0Z-JG]A_V)]F_L
M/[!8&T\OSO/?[3YF=^[9%MZ8;K69\'?^">__  J;]H_]IO\ :"_X6[_:'_#1
MK:,?[(_L#RO^$>^P:5)I_P#K?M#?:_,W^9]R';C;\V=U?25% 'BG_!.C]CW_
M (8"_8J\ ?L??\+$_P"$L_X0;2I;/_A(O[(^P?;=]S+/O^S^=-Y>/-VX\QON
MYSS@?/FB_P#!+']L#]D_Q_XOO?\ @F5^WAI/P^\ >-_$5SKU]\+O'OPV37]/
MT74KDAKB;39DNK>6WB=AN^S'=&IR0><5]W5CZW\0O /AKQ1HW@?Q'XXT?3]:
M\1M.OA[1[[4XHKK5# @DF%O$S!YS&A#OL!VJ<G H \"UC_@GUK?[1'[#7BW]
MC3_@H?\ M!WGQBE\;O*^L^*K7PU:Z UF=\4EL+*WMS(D'V:6&.2-F,A+KE]X
M)!\L\._L+_\ !9GPSX5MO@]I_P#P64T5O#5C"MK:>*[SX#6ESXH-HJ[422>6
M]-O),%PIN&A9F(WL"Q(K[HHH BL;>6TLH;6:Z>=XHE1YY,;I"!@L<=SUKXU^
M/'_!-G]J"Q_;<\3?MT_L#_ME:5\-->^(OAS3M'^)7AWQ=X 77].U8V"-'9WL
M6+F"2":*)C'M#%6!).,D'[/HH ^/?^"?O_!*OQ-^Q5^U7\6OVN/'O[6NL?%'
MQ+\8M)T>/Q-<ZYX;BLIA?68E\R=&AF:-8&\Q4BMDB18(HHTWR8W'T/\ X)G_
M +#/_#NO]E2R_9D_X6C_ ,)A]C\1ZQJO]M_V)_9^_P"W7TUWY?D^?-C9YNS=
MO^;;G"YP/?ZSO^$O\)_V]_PBW_"4:=_:>,_V=]MC\_&,Y\O.[ISTH ^//AK_
M ,$6?A1I7_!,CQA_P3+^-'Q-NO%FA>+O$.KZPWB73](&FW6GW-WJ3:A;RPH9
MIP)+:;RR&+$/Y?S*%8K7DW[2G_!%7_@H)^W-^R[>_LB?MC?\%:X];\+6D%N-
M$N=!^$,-G=:E=02H8+K6&%]F\V(K$0QM"K3%)79S$%;]+:IZ=XB\/ZO>W6FZ
M3KMG=7%C)LO8+>Z1WMVY^5U4DH>#P<=* #P[I/\ 8'A^QT+[1YOV*SB@\W9M
MW[$"[L9.,XSC)KP7QS^P9_PFG_!3/P-_P46_X6K]F_X0OX9:CX0_X0[^PM_V
MS[5<&;[5]K\\>7MSM\OR6SUWCI7T-10!\$_\%3?^"%7@C_@I#^TM\-/VJ/#W
MQXG^''B7P3-:Q>)#;>&O[0C\4V%K>Q7MK;3 74'EM%*DNV0^9Q+ROR+7O'Q>
M_8;_ .%K?\%!?@]^W;_PM#[!_P *G\,^(=(_X17^Q/-_M7^U(HX_-^T^<OD>
M5Y>=OE2;\XRN*]OUKQ3X9\./!'XA\1V%@UT^RV6]O$B,K>B[B-Q]A5^@#P#]
MEO\ 89_X9J_:O_:"_:?_ .%H_P!M?\+V\0Z-JG]A_P!B?9O[#^P6!M/+\[SW
M^T^9G?NV1;>F&ZU1^"/_  3R\/?"W]IS]I;X^^+O'$'BG2?VD)M$&J>$+K0?
M)BTRWL-+?3Y('F\]_M:SI(S']W%M!*X;[U?0-QXB\/VNL0^';K7;./4+F,O;
MV,ET@FE49RRH3N8<'D#L:N$@#). .I- 'P'\*/\ @E__ ,%&_P!COPF?@!^P
MS_P4_P!*T;X36D\O_"(^'OB1\)(O$&I^%;:21G^RV]ZMY!]JB0L=@G0[1A>0
M*^SO@1X%^(?PT^$6A^!_BS\8;SX@>)-/M"NM>,K_ $J"QEU6=G9VE-O;@10#
MYMJQIPJJ!SUKH-$\3^&O$RROX;\0V.H+ ^R<V-VDHC;^ZVTG!X/!]*O4 ?//
M[8?[!G_#6/[1/[/_ ,?/^%J_V!_PHOQQ=>(O[)_L+[5_;?G6PA\CS?/C^S8Q
MNW[9<]-HZU['9_!WX1:?\4+OXWV'PL\.0>-+_3!IM]XOAT.W75+BS#(PMI+H
M)YKQ QH1&6*Y13C@5T=% 'RI^RY_P2O\ _ WX3?M'?!#XJ>.4\>^&OVC?BWX
MJ\8Z[I[Z(=/^P6FMQ112Z:&$\IE,:QG%P/+)+ A$*BO"9?\ @C'^WK>_L[)_
MP3XU+_@K)>2?L\K9+HS:<GPQME\62>'!\HT4ZK]H\OR_* A\[R-QC&PIL)2O
MTAHH ^8?CY_P3+\#_%$_LT:)\,O&<?@KPY^S5XXTW7-!T&+13>+?V=E9M:0V
M D,\9@^0K^^(E/R\J2<UT'[;?[#?_#8_CKX'>-?^%H?\(Y_PICXP6'CK[-_8
MGVS^V/LT4T?V/=YT?V?=YN?-Q)C;C8<\>_44 ?(?[4O_  35^-GQ _;+B_;P
M_8V_;6E^#GCR\\ Q^#_%*:A\.[7Q+IVL:=%=-=0DV\T\#0S)(V/,5SE548'S
M;^KTO]@CQ+)_P4&\%?\ !0/QG\=H]5UCPQ\"G^'VK:-#X5%LFJW,EZEW+JBR
M"Y86X9U8"V$;@;O];Q@^\ZS\0O /ASQ9HO@+Q#XXT>PUWQ)]I_X1W1;W4XHK
MO5/L\8DN/LT+,'G\I"'?8#L4@M@5L4 > ^*OV&_^$F_X*5^$_P#@H?\ \+0\
MC_A%_A1?^"_^$/\ [$W?:?M-ZMU]K^U^<-FW;L\KRFSG.\=*\6^(O[!__!7[
MQUX7\1?!:7_@K?X8F\$^)H+NQN-2U#X"6K:]9Z=<!T:VCFCOD@D<1,8Q.\6_
M^(@L.?MC4O%/AG1M0MM)UCQ'86EU>-MM+:YO$CDG/HBL06/TJ_0!Y[^R=^S5
M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2
M N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,"VKR/_ ()[_P#)$]6_['O6?_2DU[I0!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_
M #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\
M_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!\\7RA+V9!G E8#/UJ*IM1_P"0A/\
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M!;4?\(/I'_/S>_\ @6U;%% &79^$M-L;I+N&XNBT;94/<L1^(K4HHH ****
M"BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\
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M-9QJX:>/E4=1)<MMI6;<.71)-I)[7M9;=@/OJORM_P""IG@']N?X5>#-)_:
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M@&Q_Z\XO_0!5NJGA_P#Y -C_ -><7_H JW7ZU1_@Q]$ 4445J 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?/.H_\A"?_ *[-_,U#4VH_\A"?_KLW\S4-
M?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^'_ /D V/\ UYQ?^@"K
M=5/#_P#R ;'_ *\XO_0!5NOV.C_!CZ( HHHK4 HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6
M_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /GG4?^0A/_P!=F_F:AJ;4?^0A/_UV;^9J&OQF?QL HHHJ
M0"BBB@ HHHH **** "BBB@ HHHH ^@?#_P#R ;'_ *\XO_0!5NJGA_\ Y -C
M_P!><7_H JW7['1_@Q]$ 4445J 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4F
MO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?/.H_\A"?_KLW\S4-3:C_ ,A"?_KLW\S4-?C,_C8!1114@%%%% !1110
M4444 %%%% !1110!] ^'_P#D V/_ %YQ?^@"K=5/#_\ R ;'_KSB_P#0!5NO
MV.C_  8^B ****U **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(
MGJW_ &/>L_\ I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YYU'_D(3_]
M=F_F:AJ;4?\ D(3_ /79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **** "B
MBB@#Z!\/_P#(!L?^O.+_ - %6ZJ>'_\ D V/_7G%_P"@"K=?L='^#'T0!111
M6H!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!\]?L%ZQ?V'P<U:"VT"XN5_X3C63YD1&,_:6XYKVW_A)=7_Z%
M"]_[Z6O(_P#@GO\ \D3U;_L>]9_]*37NE &/_P )+J__ $*%[_WTM'_"2ZO_
M -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )
M+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2Z
MO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#P
MDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_
M -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )
M+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2Z
MO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#P
MDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_
M -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )
M+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2Z
MO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 ?/%\Q
M:]F8J03*Q(/;FHJFU'_D(3_]=F_F:AK\9G\; ****D HHHH **** "BBB@ H
MHHH **** /:M%\1:K'HUI&GA2[<+;1@.K+AOE'-6O^$EU?\ Z%"]_P"^EJ[X
M?_Y -C_UYQ?^@"K=?L='^#'T0&/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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M'O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SSJ/_ "$)_P#KLW\S
M4-3:C_R$)_\ KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!]
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MK2YK:WT=[J6-/M;S7,B.D8W*FUW4_P"MV^Y?MF_'_P#X*BV/Q<\0?"?X.?\
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MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#YYU'_D(3_]=F_F:AJ;4?\ D(3_ /79OYFH:_&9_&P"BBBI ***
M* "BBB@ HHHH **** "BBB@#Z!\/_P#(!L?^O.+_ - %6ZJ>'_\ D V/_7G%
M_P"@"K=?L='^#'T0!1116H!1110 4444 %%%% !1110 4444 %%%% !1110
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M>Z5\]?L%^&[#5O@YJUU<S7"L/'&LKB*<J,?:6["O;?\ A!](_P"?F]_\"VH
MV**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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MU'_D(3_]=F_F:AJ6^4)>S(,X$K 9^M15^,S^-@%%%%2 4444 %%%% !1110
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MRK(S?PU]?T4 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\
ML>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SSJ/_(0G_Z[-_,U
M#4VH_P#(0G_Z[-_,U#7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/
MA_\ Y -C_P!><7_H JW53P__ ,@&Q_Z\XO\ T 5;K]CH_P &/H@"BBBM0"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKEOC1\;
MOA#^SI\-M1^,7QW^)&C^$?"ND&$:GX@U^^2VM+7S9DABWR.0J[I9(T&>K.!W
MH _/'Q%^R)J__!3C_@IQ^T/\-/VP/VH/BMX>\-?"N3P];?#7X6>!/&\VA64V
ME7FG+.^LS"##7C270GB$F?W;0R1DG:JI[Q^RY_P1/_9/_9&^.VA?M"_#3XD_
M&#4-;\/_ &K[%:>*?BE?ZE82>?:RVS^;;RL4DPDSE<_=8*PY45\D_M7>#?\
M@W3_ &POVH-2_:\^)/\ P5O?2O&.H6\,$<OA/]H"/3X+"&.WA@\NU1,F!'$*
MNZJV&<LQY-=__P $]O@__P $9_"W[7_A#7OV4?\ @JUXP^)7C^#^T/[ \%:K
M^T$^N0:CNT^Y6?=9$XG\N S3#^X8@_\ #0!^FU%%% 'A?_!/?_DB>K?]CWK/
M_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?/.H_P#(0G_Z[-_,U#4VH_\ (0G_ .NS?S-0U^,S^-@%%%%2 4444 %%
M%% !1110 4444 %%%% 'T#X?_P"0#8_]><7_ * *MU4\/_\ (!L?^O.+_P!
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M1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'SSJ/_ "$)_P#KLW\S4-3:C_R$)_\
MKLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^'_^0#8_]><7
M_H JW53P_P#\@&Q_Z\XO_0!5NOV.C_!CZ( HHHK4 HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\
MR1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
M-BBL?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q
M>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%X
MW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?
M^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%XW_Z#=E_X
M#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QH V
M**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: /$=1_P"0A/\ ]=F_F:AJ6^#"
M]F#D$^:V2/7-15^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'T#X?_Y
M-C_UYQ?^@"K=<[HMGXR;1K0P:S:*AMH]BM;$D#:,=ZM?8O&__0;LO_ 8_P"-
M?L='^#'T0&Q7"Z_\:O[#UJYT?_A&O-^S3%/,^V;=V.^-AQ71?8O&_P#T&[+_
M ,!C_C7CWC1;E/%>H+>2J\HN6\QT7 )SV%>'Q%CL5@</"5"5FW;9/IYI@=G_
M ,+_ /\ J4O_ "?_ /M='_"__P#J4O\ R?\ _M=><T5\E_K#G'_/W_R6/^0'
MHW_"_P#_ *E+_P G_P#[71_PO_\ ZE+_ ,G_ /[77G-%'^L.<?\ /W_R6/\
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M'34_^OQ_YU\QQ;_NE/\ Q?H!CT445\&!YQ^TM^UO^SQ^R!X1L_&O[0WQ)M]
MM-3OUL=(MQ:3W=WJ5TPR(+:UMDDGN'_V8T;'4X%>2_\ !/W_ (*C_ O]MW1=
M(\(0:S<:=\1;G0I]5U#PQ<^%=3L(_LT4XB::WENX5CGC!>($I(Y!?G%5?^"A
M/[)7[1_Q0^-?P<_;#_9,U+PE=^-_@Q=ZS]E\)>.WFCTW6;34[:.WG GA5FM[
MA%C_ ';[=N6^8@+AO&O^"47_  4%\1Z1HOPD_8M_:9_9DUCP#K'B[0-2F^&/
MBQ-8M]2TGQ0MHTDUTB21!7M9D3<?*D!.%&2-Z!O4IX6C/ .<%S2ZZI6^+I:[
M5DF[?A9@>U?&G]J?_@I!;?%SQ!X#_9B_X)O6OB+P[X>N%B3QIXR^)EMH\.LO
MY22,MI;>3)*5!8IYKD(64^AKJ?V ?V\-)_;@\&^*%UCX5ZKX!\=?#_Q++X?^
M(/@36+I+B72;]!D;)XP%N(7&=DH5=VQN, %M']N?]N+X<?L/?"^W\3^(=+N_
M$7BWQ%>#3/A[\/\ 11YFI>)]4? CMH$ )"AF4R2X(C4C@LR(W%_\$O/V/_BE
M^S=X!\8_%[]I/5+*[^+7QE\62>*_B#'I9S::9*ZX@TV @D,EO&2N[)RS, S*
M%8YN-&6"<Y047HHM-W;Z[MJWFDM;)=0.!_X>R?M!:)^U[\-_V<OBA_P3A\1^
M"O#GQ/\ %-[HGASQIXF\<VB3S-;1F229=.AADDV;=A&^2/(DX)((KZ$_;J_:
MC_X8K_9*\;_M2?\ "#?\)+_PANEI>?V%_:?V/[9NFCBV>=Y4OE_ZS.=C=,8Y
MS7S=_P %0_\ E(S^PW_V4O7_ /TW0U],?ML_LP:=^V?^RSXQ_9?U?Q?/H-KX
MPT^.TN-7MK03R6Z+/'*2J,R@DB/:,GC.><8-5(X52H3<>6,OBM?92:?5O9=
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M/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110
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M7SG6QX _Y'33/^OQ/YUI1XK]M6C3]C:[2^+O_P!N@>Z4445]@ 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_R$)_^NS?S-0U-J/\
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MDUZO\3/^1%U'_KB/_0A7E'_!/?\ Y(GJW_8]ZS_Z4FO5_B9_R(NH_P#7$?\
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MZ1:W?D2"2#[3;K)Y;C^)=P.#[BBEB*,(R@XOEDE?76ZZIV?GI;J!\9?\$4?
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MBU35?"T5W(L<,U[:?9HPXW.BL(WRI8#[V%+?V\/VU/V-?VH_^"*&M_M$>(O
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M'_X*,?L3HRJ?V@]'^8X&(;@_GB/BG?\ #Q3]BC_HX31?^_<__P ;H_LW,?\
MGS/_ ,!?^0'M-%>+?\/%/V*/^CA-%_[]S_\ QNC_ (>*?L4?]'":+_W[G_\
MC=']FYC_ ,^9_P#@+_R ]IHKQ;_AXI^Q1_T<)HO_ '[G_P#C='_#Q3]BC_HX
M31?^_<__ ,;H_LW,?^?,_P#P%_Y >TUL> /^1TTS_K\3^=?/W_#Q3]BC_HX3
M1?\ OW/_ /&ZT?"'_!2/]A[2_$]CJ-_^T3HL<,-RK2/Y-P< 'K@1YKHPF79A
M'%4VZ,DE)?9??T ^Y**^<_\ A[=_P3H_Z.DT7_P O/\ XS1_P]N_X)T?]'2:
M+_X 7G_QFOU,#Z!\0?\ (!OO^O.7_P! -?/U5M8_X*S?\$[;K2+JU@_:AT5G
MDMG5%^PW@R2I ',->/\ _#Q3]BC_ *.$T7_OW/\ _&Z^.XHPN)Q%6DZ4'*R>
MR;[=@/::*\6_X>*?L4?]'":+_P!^Y_\ XW1_P\4_8H_Z.$T7_OW/_P#&Z^5_
MLW,?^?,__ 7_ ) >RWML;RSEM!<21>;$R>;"V'3(QN4]B.H-?GS\5?V'O^"B
M%O\ M%_"OP=I'_!3#Q-J&EQZ5XCM[/QC??"?3I]4T*W:WM5:.6[C9(I9IEPJ
M321!U:,L-S$X^H?^'BG[%'_1PFB_]^Y__C='_#Q3]BC_ *.$T7_OW/\ _&ZZ
M,/ALTPS;C0EKWA?HUU3[_,#B?$__  2>_9KUW_@G)%_P33L+S6K+PG9V2_V=
MKRW2OJ<&HK=&\&HF3:%:9KEFD8 !2'9 %4@#RWXC?\$N_P!N[]J#P#8_LY?M
ME?\ !2R'Q3\+([JU;Q'IGAOX90Z5JWB>"WE22.&ZO!<R"(%D1F:-,L5YR>1]
M$?\ #Q3]BC_HX31?^_<__P ;IK_\%%_V)XT+M^T'H^!_=AG)_(1UI"&=TW=4
MI-WO=PNTWNTVM'Z >3?\%+/^"7?Q)_;TNOAQIOP__:SA^'7AGX=W(O8?!UU\
M/8=>TW4KV,H+::>WENH8I5A12JQ2I(F';@9(/7?LX?LR?\%&?AI\5].\5_M!
M_P#!3RT^)7A.VAG2^\'0_ [3-$-VS1,L3"[M[AWCV.5? 4[MFTX!KK!_P45_
M8H(!'[0FC<^L4_\ \;I?^'BG[%'_ $<)HO\ W[G_ /C=3['./8*DZ+<5>UZ=
MWKOKRW^=[@:GA#X#?%GP]^USXN_:#UG]I35]4\'>(/#=GIVC_"^:R=;+1;F'
M9YE['*9V5GEVG($2$;C\QKQ3QW_P3K_:.^'/Q_\ &_QY_P""?_[7]C\,H_B?
M=IJ'CSPEXC\"Q:YITVJ*FPZG:YFB:WF<<R+\RR,=S=%4>K_\/%/V*/\ HX31
M?^_<_P#\;H_X>*?L4?\ 1PFB_P#?N?\ ^-U,,/F\)75&6R7P:-+:ZM9[;[@5
M_P!@O]A_PS^PY\,-8\,1>/\ 4_&?BOQAXFNO$GC_ ,<ZU"D5SKNK7!'FSF-"
M5AC 4!(@2%&>268GW&O%O^'BG[%'_1PFB_\ ?N?_ .-T?\/%/V*/^CA-%_[]
MS_\ QNLJF!S2M4<YTIMO^Z_\@/;]._Y"$'_79?YBOH:O@ZR_X*,?L317D4LG
M[0NBA5E4L?+GX /_ %SKV7_A[=_P3H_Z.DT7_P  +S_XS7UO"V&Q&'A5]K!Q
MO;=-=^X'T917SG_P]N_X)T?]'2:+_P" %Y_\9H_X>W?\$Z/^CI-%_P# "\_^
M,U]6!-J/_(0G_P"NS?S-0UXU>_\ !1C]B:6\EEC_ &A=%*M*Q4^7/R"?^N=1
M_P##Q3]BC_HX31?^_<__ ,;K\FEEN8N3_<S_ / 7_D![317BW_#Q3]BC_HX3
M1?\ OW/_ /&Z/^'BG[%'_1PFB_\ ?N?_ .-U/]FYC_SYG_X"_P#(#VFBO%O^
M'BG[%'_1PFB_]^Y__C='_#Q3]BC_ *.$T7_OW/\ _&Z/[-S'_GS/_P !?^0'
MM-%>*/\ \%%_V)XT+M^T'H^!_=AG)_(1TH_X**_L4$ C]H31N?6*?_XW1_9N
M8_\ /F?_ ("_\@/:J*\6_P"'BG[%'_1PFB_]^Y__ (W1_P /%/V*/^CA-%_[
M]S__ !NC^S<Q_P"?,_\ P%_Y >TT5XM_P\4_8H_Z.$T7_OW/_P#&Z/\ AXI^
MQ1_T<)HO_?N?_P"-T?V;F/\ SYG_ . O_(#VFBO%O^'BG[%'_1PFB_\ ?N?_
M .-T?\/%/V*/^CA-%_[]S_\ QNC^S<Q_Y\S_ / 7_D!]U>'_ /D V/\ UYQ?
M^@"K=?-6C_\ !6;_ ()VVND6MK/^U#HJO';(KK]AO#@A0".(:L_\/;O^"='_
M $=)HO\ X 7G_P 9K]7I)JE%/L@/HRO"_'__ ".FI_\ 7X_\ZQ_^'MW_  3H
M_P"CI-%_\ +S_P",UY/XO_X*1_L/:IXGOM1L/VB=%DAFN6:-_)N!D$]<&/-?
M.\3X>OB,+!4H.3OT3?3R ]8HKQ;_ (>*?L4?]'":+_W[G_\ C='_  \4_8H_
MZ.$T7_OW/_\ &Z^*_LW,?^?,_P#P%_Y >TT5XM_P\4_8H_Z.$T7_ +]S_P#Q
MNC_AXI^Q1_T<)HO_ '[G_P#C=']FYC_SYG_X"_\ (#VFBO%O^'BG[%'_ $<)
MHO\ W[G_ /C='_#Q3]BC_HX31?\ OW/_ /&Z/[-S'_GS/_P%_P"0'M-%>*1_
M\%&/V)Y5W+^T'HXYQ\T-P/YQT[_AXI^Q1_T<)HO_ '[G_P#C=']FYC_SYG_X
M"_\ (#VFBO%O^'BG[%'_ $<)HO\ W[G_ /C='_#Q3]BC_HX31?\ OW/_ /&Z
M/[-S'_GS/_P%_P"0'M-%>+?\/%/V*/\ HX31?^_<_P#\;H_X>*?L4?\ 1PFB
M_P#?N?\ ^-T?V;F/_/F?_@+_ ,@/::]O^&?_ "(NG?\ 7$_^A&OB?_AXI^Q1
M_P!'":+_ -^Y_P#XW7J?@;_@JW_P3UT?PG9:9J/[3NBQSPQ$2)]CNS@[B>HA
M(KZ3AC"8K#XV<JM.45R]4UU7<#ZBHKPKP!_P4P_86^*7C73/AWX!_:)TG4M:
MUF[2UTRPBM+I6GF8X5 7B"@D^I%>ZU]N 4444 %%%% !1110 4444 %%%% '
M+^*O@A\%O'6KMX@\;?"'POK%^Z*CWVJ^'[:XF95&%!>1"Q '09XK._X9?_9I
M_P"C>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\ A)6?_P :H_X9?_9I_P"C
M>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\ A)6?_P :H_X9?_9I_P"C>/ O
M_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\ A)6?_P :H_X9?_9I_P"C>/ O_A)6
M?_QJNYHH ^7/VG_V?_@-H_QA^#5CI/P2\(VL%_XUEBOH;;PW:HEQ']G8[) L
M8#KGG!R*]J_X9?\ V:?^C>/ O_A)6?\ \:K5\;_"GPC\0?$7ASQ1XCAG:[\+
M:DU]I)AG**LQ0H2P_B&#TKI* .&_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]
MFG_HWCP+_P"$E9__ !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:
M?^C>/ O_ (25G_\ &J[FB@#AO^&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_
MZ-X\"_\ A)6?_P :KN:* .&_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_H
MWCP+_P"$E9__ !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>
M/ O_ (25G_\ &J[FB@#AO^&7_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\
M"_\ A)6?_P :KN:* .&_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+
M_P"$E9__ !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_ ,:KR_\ ;0_9W_9_T#]E
MCQOK.A? SP=97EOHCO;W5IX8M(Y(FW+RK+&"I]Q7T36)\2/A]X<^*O@74_AW
MXNBE?3=6MC!>+!*4<H2#PPZ'B@#AOAM^S/\ LX7?P[T"ZNOV?O!$LLNBVKR2
M2>%+-F=C"I)),>22>];?_#+_ .S3_P!&\>!?_"2L_P#XU78:-I5IH.CVFAZ>
MK""RMHX( [9(1%"KD]S@"K- '#?\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S
M3_T;QX%_\)*S_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]
M&\>!?_"2L_\ XU7<T4 <-_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'
M@7_PDK/_ .-5W-% '#?\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S3_T;QX%_
M\)*S_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2
ML_\ XU7<T4 <-_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'@7_PDK/_
M .-5W-% '#?\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S3_T;QX%_\)*S_P#C
M5=S10!\[?MH?L[_L_P"@?LL>-]9T+X&>#K*\M]$=[>ZM/#%I')$VY>598P5/
MN*[7X;?LS_LX7?P[T"ZNOV?O!$LLNBVKR22>%+-F=C"I)),>22>]=S\2/A]X
M<^*O@74_AWXNBE?3=6MC!>+!*4<H2#PPZ'BM+1M*M-!T>TT/3U8065M'! ';
M)"(H5<GN< 4 <?\ \,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/
M_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-
M5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-%
M '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?
M\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_
M +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/
M_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'
M@7_PDK/_ .-4?\,O_LT_]&\>!?\ PDK/_P"-5W-% 'RY^PC^S_\  ;Q'\'M4
MOO$/P2\(W\Z>-=7B2:]\-VLKK&MP0J M&2% X Z"O:O^&7_V:?\ HWCP+_X2
M5G_\:K5^%OPI\(_![P[/X7\%PSI:7&I7%](+B<R-YTS[W.3VST':NDH X;_A
ME_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\ &J[FB@#AO^&7
M_P!FG_HWCP+_ .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P :KN:* .&_X9?_
M &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH Y#1/V?/@
M'X9U:WU_PY\$/"&GWUI()+6]L?#5K%-"XZ,CK&"I]P:Z^BB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \%_P""A7_!0?X1?\$[/@[8_$CXB:%K/B37
M?$NNP:#X!\!^%[83ZKXGUB<XAL[:/WZLYX48 #,R(WSA\0?^"I'_  5(_9E\
M!R_M'_M>?\$@$TGX6Z?%]K\5W'@/XOVFN:]X9L.KW4]D+>-+E8UYD$4@" ,Y
M8*I-8/\ P4G^S#_@OQ^P(?B3M_X13[/XZ_L7[5_Q[_VW_9:^5G/'F;_LFSOO
MVX[U^A_Q!/@P> =</Q&^R_\ "/?V/<_V]]OQY'V+RF\_S,\;/+W9SVS0!YA\
M0/VI_%GBC]D&P_:B_80^$$/QPN?$>G6%]X,\/V?BJWT6+5;:ZDC!F>[NE*6Z
MQ1NTCJREQY;)MW\5\Q:W_P %9?VXOV4?B7X#T[_@I;_P3KTSP!X ^(GBZS\,
M:=\0_ OQ/AUZ'1M4NR1;0WUM]GB=8V(;,RG:H4X#' -/_@U>_P"$J_X<I?#,
M>(1<_8_[9\0_\(]]J^]]@_MB[V]>WF>;CVZ<8KP#_@I9X%_X* _L\Z]\(?VE
MO^"KGQP\*_&G]GKP7\6M(O->\(_#O11X;GT[4WG,6GZI=1O',VI6]N\AW6RS
M0AV=,AEW$ '['UX7X7_;3_X23_@HQXK_ & O^%:^3_PC'PJTWQG_ ,);_;.[
M[3]KOIK7[)]E\D;-GD[_ #?-;=NQL&,GW2N)TS]G+X+Z/^T'JG[5.F^"8XO'
MVM>%[?P[J?B$7DY:?3()GGBM_*+^4H621VW! YS@L1@4 ?(GBS_@H%_P6-FA
MUGXB?#'_ ((J+<>#M&FG:ULO$?QHLK+Q#KEK$S9F@L4MI/(=E4E89&,C<  E
M@*]T_99_X*"?#K]LS]@JV_;P_9]\">(-<LKSPWJ%_;^"HH4&K27]F)4ETL+N
MV&X,\+1(<[6+(P.U@:X#_@II_P %#?%7P#N=(_8W_8X\-1>-OVE?B;:21> _
M"D3!H-!MCE)->U1N1;V5O\S#?S*Z;%! =E]!_P""9'[#.@?\$Y?V)_!?[)VC
M^)7UR[T&VFN/$&O2*5.I:I=3/<7<X!Y5#+(P13R(U0$D@D@'BG[&?_!6_P#:
M#_:%_P""@=S^P1^T9_P3HU?X*ZF_PGF\?:/?:[\1+34[N[T]=1BL8Q):6MOM
MMR\C3<-.77R.4PX:ON:OSMNO^5J^W_[,3/\ ZEK5^B5 !1110 4444 %%%%
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M''P8^%D'CCQ3I&CS7>B>#Y]<_LT:Q/&NX6JW/DS"%W *H3&5+E0Q4$L.LHH
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MP>OC[]HWXG1R6OPP^']JP86^0ROK&HG.+?3[?#.SN5\PQLH("R/& =?^Q?\
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MV7_@EI4MGX7\%Z-'I^EI<2!YI0"6DFE8 !I99&>5V  +R,0!G%>@44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20210930_g15.jpg
<TEXT>
begin 644 biib-20210930_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
M_P#9,^'OAK_@F=_P7&U;]@7]GV.YTCX+_&/X*-XZT3P,+V66S\/>(K._:VN3
M9K*S&&*:!6D=5."Y0 !8U _2^OS0_9*^(?AO_@IE_P %Q-6_;]_9^>YU;X+?
M!WX*-X%T+QS]AEAL_$7B*[OVN;G[&TJJ9HH8&:-V P'"$$K(I/Z7T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %9\7A/PK!K;>)8/#.GIJ+YWZ@ED@G;
M(P<R8W'CCK6A10 51TOPOX9T2\N-1T7P[86=Q=MNNI[6T2-YCG.790"W))Y]
M:O44 ?-/@']AGQ3X8_X*@?$_]NG6_%&CWOAOQ]\+M'\*V_ATP.US%+9S.\DD
MNY?+:-P^  2?45]'Z=ING:/91Z9I&GP6MM"N(K>VB"(@ZX"J !4]% !5/6_#
MGA[Q+;+9>(]"LM0A1]Z17UJDJJW3(# @'D\^]7** &PPQ6\2P01*B(H5$1<!
M0.  !T%.HHH **** *FE:#H>@I+'H>C6EDL\IEG6TMUC$DAZNVT#+'U/-.U;
M1M(UZQ?2]=TJVO;:0@R6]W LD;8.1E6!!P>:LT4 0V&GV&E6<>G:78PVUO"N
MV&"WB"(@] HX ^E3444 %9\/A/PM;:V_B6W\-:?'J,@(DU!+-!.V1@Y<#<>.
M.M:%% !533] T+2;RYU#2]$M+:XO7WWD]O;*CSMSR[ 98\GDYZFK=% 'G7B?
M]EKX/^-/VFO"O[6_BC1KB]\8^"/#>HZ+X5FGN2;?38;YXFNIHXN@GD6%(S)U
M\O<O1C7HM%% !1110!4GT#0KK5X=?N=$M)+^W0I;WLELIFB4YRJN1N4<G@'N
M:MT44 %%%% !1110!3_X1_0?[9_X2/\ L2S_ +0\KR_M_P!F3SMG]W?C=CVS
MBKE%% !4=Y9V>HVDEAJ%K'/!,A2:&:,,CJ1@J0>"".QJ2B@"'3].T_2+*/3=
M*L(;6WA7;#;V\01$'H%& !]*FHHH **** *G]@:"-9_X2(:):?V@8O+-]]F7
MSMG]W?C=CVSBK=%% !4-_I]AJME)IVJ6,-S;S+MF@N(@Z.OH5/!'UJ:B@"*P
ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2
M N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\+\?\
M_(Z:G_U^/_.O=*\+\?\ _(Z:G_U^/_.OD^+?]TI_XOT QZ***^# **** "BB
MB@ HHHH **** "BBB@ KV_X9_P#(BZ=_UQ/_ *$:\0KV_P"&?_(BZ=_UQ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7A?C_ /Y'34_^OQ_YU[I7A?C_ /Y'34_^OQ_YU\GQ;_NE
M/_%^@&/1117P8!1110 4444 %%%% !1110 4444 %>W_  S_ .1%T[_KB?\
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M/1J*\Y_X7_\ ]2E_Y/\ _P!KH_X7_P#]2E_Y/_\ VNC_ %AR?_G[_P"2R_R
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M  MKX??]#!_Y*2__ !%>+44?ZV9C_)#[G_\ ) >T_P#"VOA]_P!#!_Y*2_\
MQ%'_  MKX??]#!_Y*2__ !%>+44?ZV9C_)#[G_\ ) >T_P#"VOA]_P!#!_Y*
M2_\ Q%'_  MKX??]#!_Y*2__ !%>+44?ZV9C_)#[G_\ ) ?1-O/%=6Z74#[D
MD0,C8QD$9!YI]5/#_P#R ;'_ *\XO_0!5NOOJ<G.FI/J@"O"_'__ ".FI_\
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M_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\
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MV/O'WQAMK+XD>,XDE\.^%X],N[B2X1RX0O)#$\4&XQ28\UTSM)&17KU?D?\
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M:A0+M\ # '-?,<6_[I3_ ,7Z 9%%%%?!@%%%% !1110 4444 %%%% !1110
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M++*\\]Q,X #22322.V  "V    .*_8._8>_X8UL/B'K?B?XG_P#";^,/B?\
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MX7X__P"1TU/_ *_'_G7S'%O^Z4_\7Z 8]%%%?!@%%%% !1110 4444 %%%%
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M7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%%
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MP.\'>,+3Q3X<^U?V7<:K\1M6OX%^T6LMK)N@N+AXWS%/(!N4X)##! -?+?\
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M[_D(0?\ 79?YBOH:OGG3O^0A!_UV7^8KZ&K[;A'X*WK']0"BBBOL@/GG4?\
MD(3_ /79OYFH:FU'_D(3_P#79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **
M** "BBB@#Z!\/_\ (!L?^O.+_P! %6ZJ>'_^0#8_]><7_H JW7['1_@Q]$ 5
MX7X__P"1TU/_ *_'_G7NE>%^/_\ D=-3_P"OQ_YU\QQ;_NE/_%^@&/1117P8
M!1110 4444 %%%% !1110 4444 %>W_#/_D1=._ZXG_T(UXA7M_PS_Y$73O^
MN)_]"-?4\)_[]/\ P_J@-VBBBOOP"BBB@ HHHH ***\O_:T^)7[3?PK^&EIX
MC_90_9HM?BMXEEUZVMKOPW=^,[;0E@L7#^==_:+A61C'A/W0&YM_!XH ^"M/
M_:R_9>_X)@_\%?\ ]HKQ=_P4.+^#+GXR2:!J'PF^+FL:'/<:?J&C6VEP6T^C
MI=11O]D>"XB=GC.U7W(['_5;B]_:P_9?_P""GO\ P6"_9U\9?\$\3)XSN/@T
MWB"_^+7Q;T?0Y[?3[#1[K2YK:WT=[J6-/M;S7,B.D8W*FUW4_P"MV^Y?MF_'
M_P#X*BV/Q<\0?"?X.?\ !&;PI\9OAM:R6K:-XI\0?&S1M.35"UM%)*S:?=P.
MT1CG>6(;L[A%O'#"E_8P^/\ _P %1+_XNZ!\)OC+_P $:/"OP8^&UT]VVL>*
M?#_QKT?45TMEM99(BNGVD"-*99TAA.W&T2[SD*: /M*BBB@#PO\ X)[_ /)$
M]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"IX@_Y -]_UYR_^@&OGZOH'Q!_R ;[_KSE_P#0
M#7S]7P_%W\6EZ/\ 0 HHHKX\ HHHH **** "BBB@ HHHH **** )M._Y"$'_
M %V7^8KZ&KYYT[_D(0?]=E_F*^AJ^VX1^"MZQ_4 HHHK[(#YYU'_ )"$_P#U
MV;^9J&IM1_Y"$_\ UV;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB@ HHH
MH ^@?#__ " ;'_KSB_\ 0!5NJGA__D V/_7G%_Z *MU^QT?X,?1 %>%^/_\
MD=-3_P"OQ_YU[I7A?C__ )'34_\ K\?^=?,<6_[I3_Q?H!CT445\& 4444 %
M%%% !1110 4444 %%%% !7M_PS_Y$73O^N)_]"->(5[?\,_^1%T[_KB?_0C7
MU/"?^_3_ ,/ZH#=HHHK[\ HHHH **** "O+OVN_A-^TE\9OA0G@_]E?]K.7X
M,>)UU6&X;QA#X'L?$!:U57$EM]EOOW0WED/F?>7R\#[QKU&OF/\ X*QV/_!.
M#5/V8;+2O^"I%SY7PVNO&-A#9XO=8M]^KLDPMEWZ0RW'*F7J?+_O=J /+/\
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MW53P_P#\@&Q_Z\XO_0!5NOV.C_!CZ( KPOQ__P CIJ?_ %^/_.O=*\+\?_\
M(Z:G_P!?C_SKYCBW_=*?^+] ,>BBBO@P"BBB@ HHHH **** "BBB@ HHHH *
M]O\ AG_R(NG?]<3_ .A&O$*]O^&?_(BZ=_UQ/_H1KZGA/_?I_P"']4!NT445
M]^ 4444 %%%% !45W8V6H1""_LXIT#!@DT88 CH<'O4M% 'PS^TI_P %2?B-
M8?M3>+_V5?V'?^"9OB;]H7Q3\/([+_A8VL6WB+3M!TK1[BZ@6>"T%Y>JPN)_
M)*LR*!M!QDD,%V_V4?VO_P#@HM\4OC[H'@3X[_\ !$^\^$?A2^^U?VK\0I?C
M'H>JKI.RUFDBS:VL2RR^;*D<'RGY?.W'Y5-?//B[]I3]K'X+_P#!6KX\^&O^
M"47[$MY\;+2^BT2Z^/MEK_B>R\/:9I'B5=/C2U?3M0N)/WCR6(@%Q 8GQ)&K
M*RY?/TE^RY^UE_P5T^)GQVT+P1^T_P#\$E-'^&/@:]^U?VYXXM?CSI>M2:;L
MM99(<6<$2R3>9.D4/RD;1*7/"F@#Z_HHHH \+_X)[_\ )$]6_P"Q[UG_ -*3
M7NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** *GB#_ ) -]_UYR_\ H!KY^KZ!\0?\@&^_Z\Y?_0#7S]7P
M_%W\6EZ/] "BBBOCP"BBB@ HHHH **** "BBB@ HHHH FT[_ )"$'_79?YBO
MH:OGG3O^0A!_UV7^8KZ&K[;A'X*WK']0"BBBOL@/GG4?^0A/_P!=F_F:AJ;4
M?^0A/_UV;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB@ HHHH ^@?#_P#R
M ;'_ *\XO_0!5NJGA_\ Y -C_P!><7_H JW7['1_@Q]$ 5X7X_\ ^1TU/_K\
M?^=>Z5X7X_\ ^1TU/_K\?^=?,<6_[I3_ ,7Z 8]%%%?!@%%%% !1110 4444
M %%%% !1110 5[?\,_\ D1=._P"N)_\ 0C7B%>W_  S_ .1%T[_KB?\ T(U]
M3PG_ +]/_#^J W:***^_ **** "BBB@ HHHH _-WXI^!?^"Q7[,O_!2'XP_&
MS]@_]C'X>>+OAE\3$T:YU:'Q1\1XK&;4=5M=-AMVU"%,!K-B ;>2-A(LHMHY
M5V,S;O8_V7/C_P#\%F/&WQVT+PQ^U=_P3[^&_@CP!=?:O[?\4:!\5TU.[LMM
MK*\'EVPC!DWSK#&>?E61F_AKZ_HH **** /"_P#@GO\ \D3U;_L>]9_]*37N
ME>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *GB#_D WW_7G+_Z :^?J^@?$'_(!OO^O.7_ - -?/U?#\7?Q:7H
M_P! "BBBOCP"BBB@ HHHH **** "BBB@ HHHH FT[_D(0?\ 79?YBOH:OGG3
MO^0A!_UV7^8KZ&K[;A'X*WK']0"BBBOL@/GG4?\ D(3_ /79OYFH:FU'_D(3
M_P#79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/_\ (!L?
M^O.+_P! %6ZJ>'_^0#8_]><7_H JW7['1_@Q]$ 5X7X__P"1TU/_ *_'_G7N
ME>%^/_\ D=-3_P"OQ_YU\QQ;_NE/_%^@&/1117P8!1110 4444 %%%% !111
M0 4444 %>W_#/_D1=._ZXG_T(UXA7M_PS_Y$73O^N)_]"-?4\)_[]/\ P_J@
M-VBBBOOP"BBB@ HHHH ***Y;XT?&[X0_LZ?#;4?C%\=_B1H_A'PKI!A&I^(-
M?ODMK2U\V9(8M\CD*NZ62-!GJS@=Z /SQ\1?LB:O_P %./\ @IQ^T/\ #3]L
M#]J#XK>'O#7PKD\/6WPU^%G@3QO-H5E-I5YIRSOK,P@PUXTET)XA)G]VT,D9
M)VJJ>\?LN?\ !$_]D_\ 9&^.VA?M"_#3XD_&#4-;\/\ VK[%:>*?BE?ZE82>
M?:RVS^;;RL4DPDSE<_=8*PY45\D_M7>#?^#=/]L+]J#4OVO/B3_P5O?2O&.H
M6\,$<OA/]H"/3X+"&.WA@\NU1,F!'$*NZJV&<LQY-=__ ,$]O@__ ,$9_"W[
M7_A#7OV4?^"K7C#XE>/X/[0_L#P5JO[03ZY!J.[3[E9]UD3B?RX#-,/[AB#_
M ,- 'Z;4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_
M -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5/$'_ " ;
M[_KSE_\ 0#7S]7T#X@_Y -]_UYR_^@&OGZOA^+OXM+T?Z %%%%?'@%%%% !1
M110 4444 %%%% !1110!-IW_ "$(/^NR_P Q7T-7SSIW_(0@_P"NR_S%?0U?
M;<(_!6]8_J 4445]D!\\ZC_R$)_^NS?S-0U-J/\ R$)_^NS?S-0U^,S^-@%%
M%%2 4444 %%%% !1110 4444 %%%% 'T#X?_ .0#8_\ 7G%_Z *MU4\/_P#(
M!L?^O.+_ - %6Z_8Z/\ !CZ( KPOQ_\ \CIJ?_7X_P#.O=*\+\?_ /(Z:G_U
M^/\ SKYCBW_=*?\ B_0#'HHHKX, HHHH **** "BBB@ HHHH **** "O;_AG
M_P B+IW_ %Q/_H1KQ"O;_AG_ ,B+IW_7$_\ H1KZGA/_ 'Z?^']4!NT445]^
M 4444 %%%% !7BW[??Q=_9V^#'[.UYXG_:T^"E_XZ^'$^IVMOXLT^W\"_P#"
M1VNGVX8S+?WMD$D9K6&2*-FD6.0QML;;QD>TT4 ?%?P7\-?\&]G[1'AR'Q5\
M%/AW^R1XBM)HPY6Q\+^'//ASVE@:(2PM_LR*K#TJCX__ &A_^"!W[ /B^P\=
MZ'HWP"T7Q_;2/#X<TOX6>#-+O?%,T\T;0^3:V^E0O=!I5D:+.%5A(59@":]$
M^/?_  1=_P""5G[3?B:?QI\9OV%O .H:Q=R&2]U73]+.FW-TY.2\TEDT32L<
M?><D]LUV?[,'_!.']@_]B^Y;4OV7?V3O!'@S4'C,<FLZ5H<9U!T/5&NY T[)
M_LE\>U 'J7PZ\8-\0_A]H7C]_"FL:"VN:-:Z@=#\168M]0TXS1+)]FNH@S>5
M/'NV.F3M=6&3C-;-%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2OGK]@NV\22_!S5
MFTG4K>*+_A.-9RLL)8Y^TMSFO;?L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7
M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#
M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7
M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#
M'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7
M_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#
M'_&@"[X@_P"0#??]><O_ * :^?J]JUJS\9+HUV9]9M&06TF]5MB"1M.>]>*U
M\/Q=_%I>C_0 HHHKX\ HHHH **** "BBB@ HHHH **** )M._P"0A!_UV7^8
MKZ&KYXL0QO80A /FK@GUS7M_V+QO_P!!NR_\!C_C7VW"/P5O6/Z@;%%8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-?9 >(ZC_ ,A"?_KLW\S4-2WP87LP
M<@GS6R1ZYJ*OQF?QL HHHJ0"BBB@ HHHH **** "BBB@ HHHH ^@?#__ " ;
M'_KSB_\ 0!5NN=T6S\9-HUH8-9M%0VT>Q6MB2!M&.]6OL7C?_H-V7_@,?\:_
M8Z/\&/H@-BO"_'__ ".FI_\ 7X_\Z]<^Q>-_^@W9?^ Q_P :\>\:+<IXKU!;
MR57E%RWF.BX!.>PKYCBW_=*?^+] ,RBBBO@P"BBB@ HHHH **** "BBB@ HH
MHH *]O\ AG_R(NG?]<3_ .A&O$*]<\ VOBN3P?8O8:K:QPF([$> D@;CU-?4
M\)_[]/\ P_J@.PHK+L[3Q:ETCWVK6KQ!OWB);D$CV-:E??@%%%% !1110 44
M44 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[
MUG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4\0?\@&
M^_Z\Y?\ T U\_5] ^(/^0#??]><O_H!KY^KX?B[^+2]'^@!1117QX!1110 4
M444 %%%% !1110 4444 3:=_R$(/^NR_S%?0U?/.G?\ (0@_Z[+_ #%?0U?;
M<(_!6]8_J 4445]D!\\ZC_R$)_\ KLW\S4-3:C_R$)_^NS?S-0U^,S^-@%%%
M%2 4444 %%%% !1110 4444 %%%% 'T#X?\ ^0#8_P#7G%_Z *MU4\/_ /(!
ML?\ KSB_] %6Z_8Z/\&/H@"O"_'_ /R.FI_]?C_SKW2O"_'_ /R.FI_]?C_S
MKYCBW_=*?^+] ,>BBBO@P"BBB@ HHHH **** "BBB@ HHHH *]O^&?\ R(NG
M?]<3_P"A&O$*]O\ AG_R(NG?]<3_ .A&OJ>$_P#?I_X?U0&[1117WX!1110
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MO.+_ - %6ZJ>'_\ D V/_7G%_P"@"K=?L='^#'T0!7A?C_\ Y'34_P#K\?\
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MP"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/\ _(!L?^O.+_T 5;JIX?\
M^0#8_P#7G%_Z *MU^QT?X,?1 %>%^/\ _D=-3_Z_'_G7NE>%^/\ _D=-3_Z_
M'_G7S'%O^Z4_\7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110 5[?\ #/\
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M_P#D1=._ZXG_ -"-?4\)_P"_3_P_J@-VBBBOOP"BBB@ HHHH **** "BBB@
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M?_@+_P @/::*\6_X>*?L4?\ 1PFB_P#?N?\ ^-T?\/%/V*/^CA-%_P"_<_\
M\;J?[-S'_GS/_P !?^0'M-%>+?\ #Q3]BC_HX31?^_<__P ;H_X>*?L4?]'"
M:+_W[G_^-T?V;F/_ #YG_P" O_(#VFBO%'_X*+_L3QH7;]H/1\#^[#.3^0CI
M1_P45_8H(!'[0FC<^L4__P ;H_LW,?\ GS/_ ,!?^0'M5%>+?\/%/V*/^CA-
M%_[]S_\ QNC_ (>*?L4?]'":+_W[G_\ C=']FYC_ ,^9_P#@+_R ]IHKQ;_A
MXI^Q1_T<)HO_ '[G_P#C='_#Q3]BC_HX31?^_<__ ,;H_LW,?^?,_P#P%_Y
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M/_P%_P"0'M-%>+?\/%/V*/\ HX31?^_<_P#\;H_X>*?L4?\ 1PFB_P#?N?\
M^-T?V;F/_/F?_@+_ ,@/::*\4C_X*,?L3RKN7]H/1QSCYH;@?SCIW_#Q3]BC
M_HX31?\ OW/_ /&Z/[-S'_GS/_P%_P"0'M-%>+?\/%/V*/\ HX31?^_<_P#\
M;H_X>*?L4?\ 1PFB_P#?N?\ ^-T?V;F/_/F?_@+_ ,@/::*\6_X>*?L4?]'"
M:+_W[G_^-T?\/%/V*/\ HX31?^_<_P#\;H_LW,?^?,__  %_Y >TU[?\,_\
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M?\,O_LT_]&\>!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-5Y?\
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M12OINK6Q@O%@E*.4)!X8=#Q6EHVE6F@Z/::'IZL(+*VC@@#MDA$4*N3W. *
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M>(?@EX1OYT\:ZO$DU[X;M976-;@A4!:,D*!P!T%>U?\ #+_[-/\ T;QX%_\
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M/Q$^&/\ P146X\':--.UK9>(_C1967B'7+6)FS-!8I;2>0[*I*PR,9&X !+
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ML7_A!-O_  @'_#8OBW_A"S;_ /'MY>8=_D8X\K9Y&,<8]\T :7QI_P""L?\
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MX@>(]#G^.%KI4.@2&YDMKO3UN9-/DBN_(EC"B=63S0V1& .>;_X(/?\ )?\
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M5\._M7?![XC?L\?&36?AOJ?[5GB[3?@A\:YO#\*'^V]%NY8S'=$-P+J*&.6
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M-.TZTCM=/L+.%8X;:"-0B1HB@!550%"C@  "K=%% 'YS?'/_ ((M_MM>/O\
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20210930_g16.jpg
<TEXT>
begin 644 biib-20210930_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
M?[;G_!P-^P]<_LR:V?%/A+PM9_$F!O'^GV<@TO4M0F\-LTUC;7#JJW#6T<=N
M\ACW(IO47=NW ?K;0!\*_%__ ((/_P#!'1/#GQ ^,_[2_P %8]8N=8_M'7/&
M?Q$\:^,;][RR1C)/+.EP9U6TCA4G:(E155 "#SGPK_@GK^V/^T?^SW_P;7>-
M/VLO&_B76M;OO!NA^*)/A!KWBY3)?7ND1S20:-<7(D&Z11(1@-UA1 /EVFO#
M_P!L[_@LM^P=_P %"OVT=<_90_:Z_:I/PM_9C^%?B P^)/#7]CZK)JGQ8UBU
MG8&"9K*WD^RZ3#+'DQLRR3$*V 2IM_O_ .*GB+]F/_@L3_P2+^*_PM_X)Z^.
M=+U[P[JW@[4?"GA5[#2+C3+.VU.UM8Y+6S6*YAA,42L;9<A=BJW'W<4 ?)MS
M_P $5/V>+/\ X(S']KBW@UA?VGH?A-_PM#_A>8\0W?\ PD!\4#3_ .U#_I/F
M\PE\VVW&/+^;'F?/7U?\+O@K\"_^"W__  3<^ ?Q4_;-\/ZEK5CJGAK3?$>N
M^'-,UVYTZQU/53:&&<7"VKQO+ )C*ZQ;@N=N0P&*^3KG_@M9^SW>?\$:3^R%
M;R:TW[4$WPG_ .%7_P#"C!X<O/[?'B@Z?_99_P!'\K_4ALW.[./+^7/F?+7K
M?[07[9FE_P#!NW_P1?\ @[X$\9^'8=<^(MKX3T[PIX?TIV;^SSKWV3S;J>YF
MCY%I#)YKG9\\@"JN-Q= #SGXO?LE_LY?\$]O^"T'[*_@#_@EWX7D\$>*?'4V
MJ_\ "Y? 7AC4[A]-O?"$-OQ?7]L\C)$4D$HAD.W?*G&745WW[4GPY\+_ /!3
M?_@N9;?L*?M$0W&L_!?X)_!:+QEJG@-KV6*RU_Q)>WJPV\EXD;+Y\4-NRNB,
M2 ZMU61U/ _\$>?V\?\ @D'X#^)HO/$7_!0>Q^+W[5?QWUFUMO&7C:?P;K4)
MO[R5U6WT?3S-8HEII\+;(XT)C5MBLP4+&D?>_M3?$?PQ_P $QO\ @N5;?MW?
MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
M_P#9,^'OAK_@F=_P7&U;]@7]GV.YTCX+_&/X*-XZT3P,+V66S\/>(K._:VN3
M9K*S&&*:!6D=5."Y0 !8U _2^OS0_9*^(?AO_@IE_P %Q-6_;]_9^>YU;X+?
M!WX*-X%T+QS]AEAL_$7B*[OVN;G[&TJJ9HH8&:-V P'"$$K(I/Z7T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %9\7A/PK!K;>)8/#.GIJ+YWZ@ED@G;
M(P<R8W'CCK6A10 51TOPOX9T2\N-1T7P[86=Q=MNNI[6T2-YCG.790"W))Y]
M:O44 ?-/@']AGQ3X8_X*@?$_]NG6_%&CWOAOQ]\+M'\*V_ATP.US%+9S.\DD
MNY?+:-P^  2?45]'Z=ING:/91Z9I&GP6MM"N(K>VB"(@ZX"J !4]% !5/6_#
MGA[Q+;+9>(]"LM0A1]Z17UJDJJW3(# @'D\^]7** &PPQ6\2P01*B(H5$1<!
M0.  !T%.HHH **** *FE:#H>@I+'H>C6EDL\IEG6TMUC$DAZNVT#+'U/-.U;
M1M(UZQ?2]=TJVO;:0@R6]W LD;8.1E6!!P>:LT4 0V&GV&E6<>G:78PVUO"N
MV&"WB"(@] HX ^E3444 %9\/A/PM;:V_B6W\-:?'J,@(DU!+-!.V1@Y<#<>.
M.M:%% !533] T+2;RYU#2]$M+:XO7WWD]O;*CSMSR[ 98\GDYZFK=% 'G7B?
M]EKX/^-/VFO"O[6_BC1KB]\8^"/#>HZ+X5FGN2;?38;YXFNIHXN@GD6%(S)U
M\O<O1C7HM%% !1110!4GT#0KK5X=?N=$M)+^W0I;WLELIFB4YRJN1N4<G@'N
M:MT44 %%%% !1110!3_X1_0?[9_X2/\ L2S_ +0\KR_M_P!F3SMG]W?C=CVS
MBKE%% !4=Y9V>HVDEAJ%K'/!,A2:&:,,CJ1@J0>"".QJ2B@"'3].T_2+*/3=
M*L(;6WA7;#;V\01$'H%& !]*FHHH **** *G]@:"-9_X2(:):?V@8O+-]]F7
MSMG]W?C=CVSBK=%% !4-_I]AJME)IVJ6,-S;S+MF@N(@Z.OH5/!'UJ:B@"*P
ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_
M //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4 5K;Q1X?O)UM;758GD<X1%/)-7ZB2QLHV#QV<2L.A6
M, BI: "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5
MX7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">_
M_)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8
M]ZS_ .E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YZ_8+UB_L/@YJT%MH%Q
M<K_PG&LGS(B,9^TMQS7MO_"2ZO\ ]"A>_P#?2UY'_P $]_\ DB>K?]CWK/\
MZ4FO=* ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MB
MB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V
M** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#+
ML]>U*YND@F\,W4*LV&E=EPON:U*** "BBB@ HHHH **** "BBB@ HHHH \+_
M .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH
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M^TLQ_P"?T_\ P)_Y@>1_\,-?LX_] 3Q/_P"'&US_ .3:/^&&OV<?^@)XG_\
M#C:Y_P#)M>N44?VEF/\ S^G_ .!/_,#R/_AAK]G'_H">)_\ PXVN?_)M'_##
M7[./_0$\3_\ AQM<_P#DVO7**/[2S'_G]/\ \"?^8'D?_##7[./_ $!/$_\
MX<;7/_DVC_AAK]G'_H">)_\ PXVN?_)M>N44?VEF/_/Z?_@3_P P/(_^&&OV
M<?\ H">)_P#PXVN?_)M'_##7[./_ $!/$_\ X<;7/_DVO7**/[2S'_G]/_P)
M_P"8'D?_  PU^SC_ - 3Q/\ ^'&US_Y-H_X8:_9Q_P"@)XG_ /#C:Y_\FUZY
M11_:68_\_I_^!/\ S \C_P"&&OV<?^@)XG_\.-KG_P FU:T3_@G_ /LW^)-7
MM]!DL_%UJMW*(S<VOQ%UGS(\_P 2[[MES]5(]J]2K8\ ?\CIIG_7XG\ZZ,)F
M.82Q5-.M)IR7VGW]0.'_ .'/7[,/_10?BG_X<2[H_P"'/7[,/_10?BG_ .'$
MNZ^K**_4P/DZ^_X)$?LQ:;93:BOCGXGRFWB:012_$2\VOM&=IVD'!Q@X(/H1
M7$?\,-?LX_\ 0$\3_P#AQM<_^3:^W?$'_(!OO^O.7_T U\_5\=Q1BL3AZM)4
MIN-T]FUV[ >1_P###7[./_0$\3_^'&US_P"3:/\ AAK]G'_H">)__#C:Y_\
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M?_)M>Q:C_P A"?\ Z[-_,U#7Y-+,LQ4G^^G_ .!/_,#R/_AAK]G'_H">)_\
MPXVN?_)M'_##7[./_0$\3_\ AQM<_P#DVO7**G^TLQ_Y_3_\"?\ F!Y'_P ,
M-?LX_P#0$\3_ /AQM<_^3:/^&&OV<?\ H">)_P#PXVN?_)M>N44?VEF/_/Z?
M_@3_ ,P/(_\ AAK]G'_H">)__#C:Y_\ )M'_  PU^SC_ - 3Q/\ ^'&US_Y-
MKURBC^TLQ_Y_3_\  G_F!Y'_ ,,-?LX_] 3Q/_X<;7/_ )-H_P"&&OV<?^@)
MXG_\.-KG_P FUZY11_:68_\ /Z?_ ($_\P/(_P#AAK]G'_H">)__  XVN?\
MR;1_PPU^SC_T!/$__AQM<_\ DVO7**/[2S'_ )_3_P# G_F!Y'_PPU^SC_T!
M/$__ (<;7/\ Y-H_X8:_9Q_Z GB?_P .-KG_ ,FUZY11_:68_P#/Z?\ X$_\
MP.:L?^"1'[,6I64.HMXY^)\1N(ED,47Q$O-J;AG:-Q)P,X&23ZDU+_PYZ_9A
M_P"B@_%/_P .)=U]0^'_ /D V/\ UYQ?^@"K=?J])MTHM]D!\I_\.>OV8?\
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M$)U;Q/YEQ9:5K&HQ/<VUMY(.4M+5I88O)CP-L+8Y;-?'W[:'[2WQ1_X*$?\
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M HHHH **** )M._Y"$'_ %V7^8KZ&KYYT[_D(0?]=E_F*^AJ^VX1^"MZQ_4
MHHHK[(#YYU'_ )"$_P#UV;^9J&IM1_Y"$_\ UV;^9J&OQF?QL HHHJ0"BBB@
M HHHH **** "BBB@ HHHH ^@?#__ " ;'_KSB_\ 0!5NJGA__D V/_7G%_Z
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M%% !1110 4444 %%%% $VG?\A"#_ *[+_,5]#5\\6+%;V%@I)$JD =^:]O\
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M2G_B_0#'HHHKX, HHHH **** "BBB@ HHHH **** "O;_AG_ ,B+IW_7$_\
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MY/$?G_&;_B9?\(;%_;7C>;=_Q+;K[7\FJ2&T/^A_:3^]'&,K\^V@#]9J***
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M'_D(3_\ 79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/\
M_(!L?^O.+_T 5;JIX?\ ^0#8_P#7G%_Z *MU^QT?X,?1 %>%^/\ _D=-3_Z_
M'_G7NE>%^/\ _D=-3_Z_'_G7S'%O^Z4_\7Z 8]%%%?!@%%%% !1110 4444
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MG+_Z :^?J^'XN_BTO1_H 4445\> 4444 %%%% !1110 4444 %%%% $VG?\
M(0@_Z[+_ #%?0U?/.G?\A"#_ *[+_,5]#5]MPC\%;UC^H!1117V0'SSJ/_(0
MG_Z[-_,U#4VH_P#(0G_Z[-_,U#7XS/XV 4445(!1110 4444 %%%% !1110
M4444 ?0/A_\ Y -C_P!><7_H JW53P__ ,@&Q_Z\XO\ T 5;K]CH_P &/H@"
MO"_'_P#R.FI_]?C_ ,Z]TKPOQ_\ \CIJ?_7X_P#.OF.+?]TI_P"+] ,>BBBO
M@P"BBB@ HHHH **** "BBB@ HHHH *]O^&?_ "(NG?\ 7$_^A&O$*]O^&?\
MR(NG?]<3_P"A&OJ>$_\ ?I_X?U0&[1117WX!1110 4444 %%%% 'YN_%/P+_
M ,%BOV9?^"D/QA^-G[!_[&/P\\7?#+XF)HUSJT/BCXCQ6,VHZK:Z;#;MJ$*8
M#6;$ V\D;"191;1RKL9FW>Q_LN?'_P#X+,>-OCMH7AC]J[_@GW\-_!'@"Z^U
M?V_XHT#XKIJ=W9;;65X/+MA&#)OG6&,\_*LC-_#7U_10 4444 >%_P#!/?\
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M6K/QDNC79GUFT9!;2;U6V()&TY[UXK7P_%W\6EZ/] "BBBOCP"BBB@ HHHH
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M!:+X_MI'A\.:7\+/!FEWOBF:>:-H?)M;?2H7N@TJR-%G"JPD*LP!->B?'O\
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MW_7G+_Z :^?J^@?$'_(!OO\ KSE_] -?/U?#\7?Q:7H_T ****^/ ^7OV_\
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
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M_LW+O^?,/_ 5_D!R'_"+?!?_ )Y0?^!DW_Q5'_"+?!?_ )Y0?^!DW_Q5=?\
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M7_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%']FY=_SYA_X"O\@.1C\-?!J*198XX
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M/\&/H@*?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%%:@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_
M['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SSJ/_(0G_P"NS?S-
M0U-J/_(0G_Z[-_,U#7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/A
M_P#Y -C_ -><7_H JW53P_\ \@&Q_P"O.+_T 5;K]CH_P8^B ****U ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /GK]@NV\22_!S5FTG4K>*+_A.-9RLL)8Y^TMSFO;?L7C?_H-V7_@,?\
M&O(_^">__)$]6_['O6?_ $I->Z4 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%%
M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@Q]$ 4445J 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['
MO6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;> 7@BMQ%:[P-K.7VEMIKZSK/%27)2AUC'7YMR_)H#Z!\/\ _(!L?^O.+_T
M5;JIX?\ ^0#8_P#7G%_Z *MU^KT?X,?1 %%%%:@%%%% !1110 4444 %%%%
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MYKX3_;"_9F\<^([/PCX2^,6DWVI:A,(K.SA+[Y7/11E<9KTJ@ HHHH ****
M"BBB@ HHHH **** ,G6/ 7@7Q#>G4M?\%Z3?7!4*;B\TZ*5R!T&YE)P*J_\
M"IOA7_T33P__ .":#_XBN@HH Y__ (5-\*_^B:>'_P#P30?_ !%'_"IOA7_T
M33P__P"":#_XBN@HH Y__A4WPK_Z)IX?_P#!-!_\11_PJ;X5_P#1-/#_ /X)
MH/\ XBN@HH Y_P#X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\
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MT'_Q%'_"IOA7_P!$T\/_ /@F@_\ B*Z"B@#G_P#A4WPK_P"B:>'_ /P30?\
MQ%'_  J;X5_]$T\/_P#@F@_^(KH** .?_P"%3?"O_HFGA_\ \$T'_P 11_PJ
M;X5_]$T\/_\ @F@_^(KH** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P
M_P#^":#_ .(KH** .?\ ^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X
M)H/_ (BN@HH Y_\ X5-\*_\ HFGA_P#\$T'_ ,11_P *F^%?_1-/#_\ X)H/
M_B*Z"B@#G_\ A4WPK_Z)IX?_ /!-!_\ $4?\*F^%?_1-/#__ ()H/_B*Z"B@
M#G_^%3?"O_HFGA__ ,$T'_Q%'_"IOA7_ -$T\/\ _@F@_P#B*Z"B@#YS_8*^
M'G@#6?@WJMUK'@;1[N5?&^KQK)<Z9%(P1;DA5!92< =!VKVS_A4WPK_Z)IX?
M_P#!-!_\14?PM^%/A'X/>'9_"_@N&=+2XU*XOI!<3F1O.F?>YR>V>@[5TE '
M/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30?_$5T%% '/\ _"IO
MA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!10!S_P#PJ;X5_P#1
M-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%=!10!BZ?\-OAWI-['J.E^
M =%MKB%MT,]OI4*.A]0P7(/TK:HHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /!?\ @H5_P4'^$7_!.SX.V/Q(^(FA:SXDUWQ+KL&@^ ? ?A>V$^J^
M)]8G.(;.VC]^K.>%&  S,B-\X?$'_@J1_P %2/V9? <O[1_[7G_!(!-)^%NG
MQ?:_%=QX#^+]IKFO>&;#J]U/9"WC2Y6->9!%( @#.6"J36#_ ,%)_LP_X+\?
ML"'XD[?^$4^S^.O[%^U?\>_]M_V6OE9SQYF_[)L[[]N.]?H?\03X,'@'7#\1
MOLO_  CW]CW/]O?;\>1]B\IO/\S/&SR]V<]LT >8?$#]J?Q9XH_9!L/VHOV$
M/A!#\<+GQ'IUA?>#/#]GXJM]%BU6VNI(P9GN[I2ENL4;M(ZLI<>6R;=_%?,6
MM_\ !67]N+]E'XE^ ]._X*6_\$Z],\ > /B)XNL_#&G?$/P+\3X=>AT;5+LD
M6T-];?9XG6-B&S,IVJ%. QP#3_X-7O\ A*O^'*7PS'B$7/V/^V?$/_"/?:OO
M?8/[8N]O7MYGFX]NG&*\ _X*6>!?^"@/[/.O?"']I;_@JY\</"OQI_9Z\%_%
MK2+S7O"/P[T4>&Y].U-YS%I^J74;QS-J5O;O(=ULLT(=G3(9=Q !^Q]>%^%_
MVT_^$D_X*,>*_P!@+_A6OD_\(Q\*M-\9_P#"6_VSN^T_:[Z:U^R?9?)&S9Y.
M_P WS6W;L;!C)]TKB=,_9R^"^C_M!ZI^U3IO@F.+Q]K7A>W\.ZGXA%Y.6GTR
M"9YXK?RB_E*%DD=MP0.<X+$8% 'R)XL_X*!?\%C9H=9^(GPQ_P""*BW'@[1I
MIVM;+Q'\:+*R\0ZY:Q,V9H+%+:3R'95)6&1C(W  )8"O=/V6?^"@GPZ_;,_8
M*MOV\/V?? GB#7+*\\-ZA?V_@J*%!JTE_9B5)=+"[MAN#/"T2'.UBR,#M8&N
M _X*:?\ !0WQ5\ [G2/V-_V./#47C;]I7XFVDD7@/PI$P:#0;8Y237M4;D6]
ME;_,PW\RNFQ00'9?0?\ @F1^PSH'_!.7]B?P7^R=H_B5]<N]!MIKCQ!KTBE3
MJ6J74SW%W. >50RR,$4\B-4!)()(!XI^QG_P5O\ V@_VA?\ @H'<_L$?M&?\
M$Z-7^"NIO\)YO'VCWVN_$2TU.[N]/748K&,26EK;[;<O(TW#3EU\CE,.&K[F
MK\[;K_E:OM_^S$S_ .I:U?HE0 4444 %%%% !1110 5Y9^VA^V-\#OV"?V<?
M$7[4/[0VORV/AOP[ I>*SB$MU?7$C!(;2VC)'F32.0JKD 9+,5568>IU^;'_
M  <6?9AJ?[&I\>;?^$ '[8OA3_A,?M'_ ![;<S>5Y^>/+V?:,YXQGVH Z0_\
M%)?^"PB_#_\ X:+;_@B<_P#P@8M/[0/AP?&*U_X3#^SMN[S_ .SOLNWS]GS_
M &/?YN?W?WJ^C?@G^W?X(_:Y_8<'[:G[%?A*[^(:W_A^ZN_#W@UK^'3;V[U*
M$,ITJ>28F.TG$R^4S.2BY#@LA5C[M7YK_P#!N6;<R?MB_P#"";?^$ _X;%\6
M_P#"%FW_ ./;R\P[_(QQY6SR,8XQ[YH TOC3_P %8_\ @II^Q?X('[2'[<O_
M  2@TO0/A)97ENGBW6/ OQEM=<U7PU;S3)"MQ+:_9HENE#NBD1. -V2P%?H5
MX>U_1_%>@6/BCP]?I=:?J5G%=6-U'G;-#(@='&>Q4@_C7Y3_ /!;WX&_\%/1
M\!?B!\4/C;\>_"GQ _9ET7Q'_;OC?X->$M,'AS7M0\+07JSI9G5GCN/,:)5B
M:78(6E6)P'!8*?TY^!'CCP'\3?@?X-^)/PLM#;^&/$/A33M3\.0- (C'83VT
M<MNNP$A,1.@V]L8H \V^*G[:?_"L_P!OCX3?L/\ _"M?MO\ PM#PIXAUK_A)
M_P"V?+_LS^RUMV\K[-Y+>=YOG_>\Q-FWHV>/*/C+^V9_P5B;XL^*?"7[+'_!
M)NS\0>%/#&I36EIXO\=?%^ST1O$ACZM96GD22)&3]R64A'SD8 -?2OBC]G+X
M+^,_CIX5_:6\3>"8[KQOX)TO4-.\+ZZ;R=6L;6]$8NHQ&KB)]XB3ET8C;\I&
M37E/_!1G_@HCX&_8*^'.F0V'A:[\;?%+QQ>'2?A/\*]$.[4?$^J-@*H49,5M
M&65IKAAMC3U9D5@!?^"<G_!1;P1_P4%^".O_ !';X=ZK\/O$_@3Q5?>&/B7X
M&\2W"-<>&]8LPIG@>50JRQ@,")=J@X8%5*L!\TVW_!;#]L+XL?"[Q1^VE^R;
M_P $RI_'/[.OA2]OU3QC=_$6'3]<\2:?8R.E[J>FZ8UN^^&,QRE4>0/+Y1 V
MME5V_@/^PK\9/V*O^"3'[1NM?%CQ3;ZW\<?B[X>\9^//B+J&CC%M%K]]IDQ6
MTM /^64.U$4]WWL,*5 [[_@AV? 7_#D_X$E_LO\ 8G_"K(_[5W8\K/[W[7O_
M .VGF[O?- 'TI^SI\?OAG^U1\"?"?[1OP;UIM0\+^,]#M]5T:YD39)Y,J!MD
MBY.R1#E'3.5=67M7:5^?7_!K;_;O_#CWX._VUYOE_:/$7]G>=][[-_;^H;?P
MSNQ[8QQBOT%H **** "BBB@ KD_COXO^)WP_^#?B7QQ\&/A9!XX\4Z1H\UWH
MG@^?7/[-&L3QKN%JMSY,PA=P"J$QE2Y4,5!+#K** /GW]D;_ (*1?L]?M6?L
M.P_MUKK<?A3P[INDW<_CVQUR?$WA*\LD)U"SN\JI5X"K<E5+H4<* ZBO"/A/
M_P %1/\ @IC^TK\'-"_:*_9A_P"".-OXA\%>+9[RX\*W?B+]H"RT._N=*28I
M:7TUI<::WD_:4!E6-7D 0J0[!P:^8_\ @H5^P5X?U+_@M1\.OV.?"'Q-UCPY
M\'/VO[FZ\7_'/X>:4 EIK6H^'()+UBK AH5O2(5N-FTLR&0ECM"_L;I.DZ5H
M&E6NA:%IMO96-E;I!9V=I"L<4$2*%2-$4 *JJ   ,   4 ?FU^SQ_P %G/\
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M4^&-7MM0TW4K2*ZT^_LYEDAN8)%#QRHZDAD92&##@@@UXM\=OVT_^%*?MO\
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M:QX<USPWKD&O> O'GA>Y$&J^&-8@.8;RVD]NC(>&&""K*CK\ _\ !2#]D_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20210930_g17.jpg
<TEXT>
begin 644 biib-20210930_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
M\$IM'^&?@V[6X.K>-;7]H/3M=DT\I;R/$!90V,3S>9*L<7#C8)-YR%(/T[JN
MKZ3H5A)JNN:G;V=K" 9;F[G6.- 3@99B .2!^-?,'[*?P:_X*X>"_C#:Z[^U
M[^VG\,?&W@E+.=;O0/"_PQ?2[N2<IB)UN#.X55;DC'(XKXV_8H_X)Y_LU?ML
M_P#!2_\ ;@UW]K#P>WC?0/#_ ,9K*'1/!.K7LPTB&\DTU3+?R6R.J3W'EB..
M-Y WE+YFS!D8T ?K;;7-O>6\=W:3I+%*@>*6-@RNI&001P01SFN.^-GQ9LOA
MI\+O&?BK0K_3;O6_"_A*_P!8BTF>Y!9C!;/*GF(K!PA*J">.#P:_+_\ 9*^*
M7BK_ ()S_LS_ /!1KX/_  !O[P^&_P!G77]3U3X0:3J5R]XGA\7>BF\2UC,Q
M9C;0S@.$8G/SDDEV8VO ?_!&;]CR]_X(UI^TS<:??/\ '37O@E)X^O\ X[OK
MUTVNRZ[=:2;^29[DR9DM6:0PO W[N2 L&!9BY /OW_@F_P#M.^+?VS_V%?A?
M^U1X[T#3M*UCQSX5@U34-.T@2?9K>1RP*Q^8S/MX_B8GWKV#3/$GAW6KNYL-
M&UZRNY[*39>0VUTDCP-S\KA22IX/!QTK\1_B?^T#\5/A?_P;S?L1_ SX7KXQ
M$7QH\2^&_"'BM?A],D6N7NC2"YFNM/T^222-8[JY$20J2Z@AG4G#&F_%+X#6
M_P +KOX?_%7_ ()4_P#!#']H?X)?%?P+XOTR>V\2-96$%EK.C"=%U#3=4,>K
M3O=Q30;LLZ.^]5^906- '[?:OK6C^'[!]5U[5K:RM8\>9<W<ZQ1KDX&68@#G
MBOG"R_;=\<7O_!7V7_@GA#X9T5_"B_LVQ_$>+7T,IOGOFUXZ;Y&=_E&#ROG^
M[NW?Q8XKYC^(?P*^&_\ P4\_X+H?$KX!_MB:*?%7PT_9Z^%^@7/A#X<:C<R#
M2[W5]75YIM5GA5@+B2.(>0 ^5 VG&1D\]^QM^R?\-/V-?^#EOQ=\(_@M<7=K
MX.E_8V&H^&_"\VH2W%OX:AE\46XDL+7S69HK<SI/<K%G:ANW"A5VJ #]5:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N._:)^$O_  OW]G[QU\"O^$@_LG_A-?!NIZ#_ &K]D\_[']LM);?S
MO*WIYFSS-VS<N[&-PSFNQHH \G_84_9?_P"&*OV/OAW^RA_PG'_"2_\ " ^&
M+?1_[?\ [,^Q?;O*!'F^1YLOE9S]W>V/4UYC^WE_P3D\3?M,?&'P%^UW^S5^
MT+<_"7XU_#6WNK'0O%ZZ#'JMCJ>EW/,^F:A92/&)X&.65@ZM&SLP!;:5^IJ*
M /D']E#_ ()J?%GP?^US=_M^_MS?M21_%SXIP^&'\.>#DTCPFFB:)X4TMY-\
MR6EJ)IF>>5L[IW?=M9DP1@UW_P"PS^PS_P ,7^)_C?XD_P"%H_\ "2_\+E^-
M6K?$#R?[$^Q_V/\ ;4A3[#GSY?M&SR<^=B/=N^XN.??Z* "OC'0O^"8G[2/P
M1_:X\=_M _L??M^?\(+X/^*7CFW\5?$'X;:Y\++37([R^"QI=-:WK7,,MIYZ
M1D'Y9-A;(!V@5]G5G2^,/"4&O+X6F\4Z<FIN,IIS7T8G88SQ'G<>.>E 'B/[
M,O[#/_#.?[8G[0O[6/\ PM'^V?\ A?&K>'KW^P/[$^S_ -A_V7I[6>SS_/?[
M3YN[?GRXMF-N&ZU4^"?_  3YT+X6_M;_ +2W[3'BCQW!XETS]HY/#D6H^#[K
M0!%%I<&EZ5)ITD+S&9Q=K<+(6/[N+8/E^?.ZOHJB@#X#^%/_  2[_P""B/[&
M_AB3X"_L&_\ !3?2M"^$MO=3-X3\,?$GX31^(-0\*02R-(;:VO5O(#<Q*SL4
M6=3M&%R>M?9GP"\!_$?X9?"#1/ WQ>^,UY\0_$UA;N-:\9WVD06$FJ3M([F3
M[-;CRH%&X(J)PJHHR>M=A10!'=P?:K26UW[?,C9=V,XR,9KY\_X)6?L%?\.S
M/V'/"'[&/_"UO^$V_P"$5N-2E_X23^PO[-^U?:[^XO,?9_/GV;//V?ZQMVW=
MQG ^AZ* / /V6_V&?^&:_P!J_P#:"_:>_P"%H_VU_P +V\0Z-JG]A_V)]F_L
M/[!8&T\OSO/?[3YF=^[9%MZ8;K69\'?^">__  J;]H_]IO\ :"_X6[_:'_#1
MK:,?[(_L#RO^$>^P:5)I_P#K?M#?:_,W^9]R';C;\V=U?25% 'BG_!.C]CW_
M (8"_8J\ ?L??\+$_P"$L_X0;2I;/_A(O[(^P?;=]S+/O^S^=-Y>/-VX\QON
MYSS@?/FB_P#!+']L#]D_Q_XOO?\ @F5^WAI/P^\ >-_$5SKU]\+O'OPV37]/
MT74KDAKB;39DNK>6WB=AN^S'=&IR0><5]W5CZW\0O /AKQ1HW@?Q'XXT?3]:
M\1M.OA[1[[4XHKK5# @DF%O$S!YS&A#OL!VJ<G H \"UC_@GUK?[1'[#7BW]
MC3_@H?\ M!WGQBE\;O*^L^*K7PU:Z UF=\4EL+*WMS(D'V:6&.2-F,A+KE]X
M)!\L\._L+_\ !9GPSX5MO@]I_P#P64T5O#5C"MK:>*[SX#6ESXH-HJ[422>6
M]-O),%PIN&A9F(WL"Q(K[HHH BL;>6TLH;6:Z>=XHE1YY,;I"!@L<=SUKXU^
M/'_!-G]J"Q_;<\3?MT_L#_ME:5\-->^(OAS3M'^)7AWQ=X 77].U8V"-'9WL
M6+F"2":*)C'M#%6!).,D'[/HH ^/?^"?O_!*OQ-^Q5^U7\6OVN/'O[6NL?%'
MQ+\8M)T>/Q-<ZYX;BLIA?68E\R=&AF:-8&\Q4BMDB18(HHTWR8W'T/\ X)G_
M +#/_#NO]E2R_9D_X6C_ ,)A]C\1ZQJO]M_V)_9^_P"W7TUWY?D^?-C9YNS=
MO^;;G"YP/?ZSO^$O\)_V]_PBW_"4:=_:>,_V=]MC\_&,Y\O.[ISTH ^//AK_
M ,$6?A1I7_!,CQA_P3+^-'Q-NO%FA>+O$.KZPWB73](&FW6GW-WJ3:A;RPH9
MIP)+:;RR&+$/Y?S*%8K7DW[2G_!%7_@H)^W-^R[>_LB?MC?\%:X];\+6D%N-
M$N=!^$,-G=:E=02H8+K6&%]F\V(K$0QM"K3%)79S$%;]+:IZ=XB\/ZO>W6FZ
M3KMG=7%C)LO8+>Z1WMVY^5U4DH>#P<=* #P[I/\ 8'A^QT+[1YOV*SB@\W9M
MW[$"[L9.,XSC)KP7QS^P9_PFG_!3/P-_P46_X6K]F_X0OX9:CX0_X0[^PM_V
MS[5<&;[5]K\\>7MSM\OR6SUWCI7T-10!\$_\%3?^"%7@C_@I#^TM\-/VJ/#W
MQXG^''B7P3-:Q>)#;>&O[0C\4V%K>Q7MK;3 74'EM%*DNV0^9Q+ROR+7O'Q>
M_8;_ .%K?\%!?@]^W;_PM#[!_P *G\,^(=(_X17^Q/-_M7^U(HX_-^T^<OD>
M5Y>=OE2;\XRN*]OUKQ3X9\./!'XA\1V%@UT^RV6]O$B,K>B[B-Q]A5^@#P#]
MEO\ 89_X9J_:O_:"_:?_ .%H_P!M?\+V\0Z-JG]A_P!B?9O[#^P6!M/+\[SW
M^T^9G?NV1;>F&ZU1^"/_  3R\/?"W]IS]I;X^^+O'$'BG2?VD)M$&J>$+K0?
M)BTRWL-+?3Y('F\]_M:SI(S']W%M!*X;[U?0-QXB\/VNL0^';K7;./4+F,O;
MV,ET@FE49RRH3N8<'D#L:N$@#). .I- 'P'\*/\ @E__ ,%&_P!COPF?@!^P
MS_P4_P!*T;X36D\O_"(^'OB1\)(O$&I^%;:21G^RV]ZMY!]JB0L=@G0[1A>0
M*^SO@1X%^(?PT^$6A^!_BS\8;SX@>)-/M"NM>,K_ $J"QEU6=G9VE-O;@10#
MYMJQIPJJ!SUKH-$\3^&O$RROX;\0V.H+ ^R<V-VDHC;^ZVTG!X/!]*O4 ?//
M[8?[!G_#6/[1/[/_ ,?/^%J_V!_PHOQQ=>(O[)_L+[5_;?G6PA\CS?/C^S8Q
MNW[9<]-HZU['9_!WX1:?\4+OXWV'PL\.0>-+_3!IM]XOAT.W75+BS#(PMI+H
M)YKQ QH1&6*Y13C@5T=% 'RI^RY_P2O\ _ WX3?M'?!#XJ>.4\>^&OVC?BWX
MJ\8Z[I[Z(=/^P6FMQ112Z:&$\IE,:QG%P/+)+ A$*BO"9?\ @C'^WK>_L[)_
MP3XU+_@K)>2?L\K9+HS:<GPQME\62>'!\HT4ZK]H\OR_* A\[R-QC&PIL)2O
MTAHH ^8?CY_P3+\#_%$_LT:)\,O&<?@KPY^S5XXTW7-!T&+13>+?V=E9M:0V
M D,\9@^0K^^(E/R\J2<UT'[;?[#?_#8_CKX'>-?^%H?\(Y_PICXP6'CK[-_8
MGVS^V/LT4T?V/=YT?V?=YN?-Q)C;C8<\>_44 ?(?[4O_  35^-GQ _;+B_;P
M_8V_;6E^#GCR\\ Q^#_%*:A\.[7Q+IVL:=%=-=0DV\T\#0S)(V/,5SE548'S
M;^KTO]@CQ+)_P4&\%?\ !0/QG\=H]5UCPQ\"G^'VK:-#X5%LFJW,EZEW+JBR
M"Y86X9U8"V$;@;O];Q@^\ZS\0O /ASQ9HO@+Q#XXT>PUWQ)]I_X1W1;W4XHK
MO5/L\8DN/LT+,'G\I"'?8#L4@M@5L4 > ^*OV&_^$F_X*5^$_P#@H?\ \+0\
MC_A%_A1?^"_^$/\ [$W?:?M-ZMU]K^U^<-FW;L\KRFSG.\=*\6^(O[!__!7[
MQUX7\1?!:7_@K?X8F\$^)H+NQN-2U#X"6K:]9Z=<!T:VCFCOD@D<1,8Q.\6_
M^(@L.?MC4O%/AG1M0MM)UCQ'86EU>-MM+:YO$CDG/HBL06/TJ_0!Y[^R=^S5
M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2
M N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444
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M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44
M 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
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MO"_'_P#R.FI_]?C_ ,Z^>XBQV*P.'A*A*S;MLGT\TP-S_A=_B?\ Y]X/R_\
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M* "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O"_'__ ".FI_\ 7X_\Z]TKPOQ__P CIJ?_ %^/_.OD^+?]
MTI_XOT QZ***^# **** "BBB@ HHHH **** "BBB@ KV_P"&?_(BZ=_UQ/\
MZ$:\0KV_X9_\B+IW_7$_^A&OJ>$_]^G_ (?U0&[1117WX!1110 4444 %%%%
M !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_
M -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /R.FI_]?C_SKY/BW_=*?^+] ,>BBBO@P"BBB@ HHHH **** "BBB@ HHHH
M*]O^&?\ R(NG?]<3_P"A&O$*]O\ AG_R(NG?]<3_ .A&OJ>$_P#?I_X?U0&[
M1117WX!1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_
M^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7A?C__ )'34_\ K\?^=>Z5
MX7X__P"1TU/_ *_'_G7R?%O^Z4_\7Z 8]%%%?!@%%%% !1110 4444 %%%%
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M_P#^1TU/_K\?^=>Z5X7X_P#^1TU/_K\?^=?)\6_[I3_Q?H!CT445\& 4444
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MHI$)61&4AE9200002#5R@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\
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M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
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MW%QX)^(7C+7(KNVAGMI+22633]08+<1A+DC>F]8W>,DJQ7(!^J5%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO-+UG3X;[3;M 0L]O+&LD;@$ @%6!YYYKYP_X*"?\%%=8_9)\;_#O]G#X#?
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MK:XM]6\;Z7X,M/#<R1F5)K5HK2W>6))+>6..17.X,R#<I&0?G3QA_P $@O\
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M'_G7NE>%^/\ _D=-3_Z_'_G7R?%O^Z4_\7Z 8]%%%?!@%%%% !1110 4444
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M&OJ>$_\ ?I_X?U0&[1117WX!1110 4444 %%%% !1110 4444 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#X?_ .0#8_\ 7G%_Z *MU4\/_P#(!L?^O.+_ - %6Z_8Z/\ !CZ( KPOQ_\
M\CIJ?_7X_P#.O=*\+\?_ /(Z:G_U^/\ SKYCBW_=*?\ B_0#'HHHKX, HHHH
M **** "BBB@ HHHH **** "O;_AG_P B+IW_ %Q/_H1KQ"O;_AG_ ,B+IW_7
M$_\ H1KZGA/_ 'Z?^']4!NT445]^ 4444 %%%% !1110 4444 %%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
M)$]6_P"Q[UG_ -*37NE !1110 4444 >1_MU_MD?#3]@']E3Q;^UE\6M.U&^
MT?PK;0G^S-(B#W5_<W%Q';6UM$&(&Z2>:-,DX4,6/ -?(O[+O[:O_!6GQ1^U
MQ\1M.\?_ /!.ZRD\/-XC\+V^M>'(?CK:SW?@.UNM/A9YHXI+-(;S]VYN)HH9
M%;?N5/,."?L+]M3]G?\ 9W_:T_9J\2?LV?M3>1_PAGC%+?3[TRZFMG(MR;B-
M[5H921MG6X2%H^N751M8$J?R:^+NN_M[?\$8O%7Q]_:8^%O[=4_Q5\&_#;Q3
MX+L?%7@/XR:+;7&L>+[:\L[2&%8-6@$<WVR&*8(HV%76-I&#%2C '[<T5X+^
MTK<?\%-+OQ?IMU^Q=!\#8O#4NBQ/J,7Q6761J*7YDD+A!8?NQ$(_)'/S;_,[
M8KSK_C?G_P!6@?\ ETT ?7]%?+7PY_X?8?\ "P-#_P"%N?\ #+7_  BO]K6_
M_"2?\(Y_PDG]H?8?,7S_ +-YW[OSO+W;-_R[L9XS7U+0 4444 %%%% !1110
M 4444 %%%% !3+B>"U@>ZN95CCC0M([G 50,DD]ABGU'=/:QVLDEZ\:PK&3,
MTI 4+CDG/&,=<T ?EMIO_!6[]N_]KKXZ_"3XR_L-_L0C5/A7XA'C!/!T'BSX
MNQ:)+\0+>Q\B&2\>V6TF6R6*1'\@3LS.78D1C!/Z5_"3Q3XU\;?##0/%_P 2
M/AM/X.\0:EI,%QK7A2YU.&]DTBZ9 9+5KB#]W,4;*^8GRMC(X-?E+\3O^"8_
MQ _9(_:5^$0_X)6_\%$M4\!>%]8TOQIX@\&>'_&MK9>)/"?AZ/R+6ZN8+-I
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M?_ "\_\ C- 'T917SG_P]N_X)T?]'2:+_P" %Y_\9H_X>W?\$Z/^CI-%_P#
M"\_^,T >N?'GX ?!;]J#X5ZI\$/V@_AKI7BWPGK2QC4]"UFW\V"8QR+)&V.J
MLKHKJRD,K*"""*^1OV;/^"$/[#OP0_:O\8?':_\ V<-%U&PM=7TB]^%46M^(
M]3UC^Q7@L8TGD$%]/)&D@N5+QOAV0!=A3  ]=_X>W?\ !.C_ *.DT7_P O/_
M (S1_P /;O\ @G1_T=)HO_@!>?\ QF@#Z,HKYQ?_ (*Y?\$YD95/[4>C_,<#
M&G7I_/$'%._X>W?\$Z/^CI-%_P# "\_^,T ?1E%?.?\ P]N_X)T?]'2:+_X
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M_P# "\_^,T ?1E%?.?\ P]N_X)T?]'2:+_X 7G_QFC_A[=_P3H_Z.DT7_P
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M . VC_&'X-6.D_!+PC:P7_C66*^AMO#=JB7$?V=CLD"Q@.N><'(KVK_AE_\
M9I_Z-X\"_P#A)6?_ ,:K5\;_  I\(_$'Q%X<\4>(X9VN_"VI-?:289RBK,4*
M$L/XA@]*Z2@#AO\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9_
M_&J[FB@#AO\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[
MFB@#AO\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#
MAO\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\
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M2"XG,C>=,^]SD]L]!VKI* .&_P"&7_V:?^C>/ O_ (25G_\ &J/^&7_V:?\
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MRRO/#>H7]OX*BA0:M)?V8E272PN[8;@SPM$ASM8LC [6!K@/^"FG_!0WQ5\
M[G2/V-_V./#47C;]I7XFVDD7@/PI$P:#0;8Y237M4;D6]E;_ #,-_,KIL4$!
MV7T'_@F1^PSH'_!.7]B?P7^R=H_B5]<N]!MIKCQ!KTBE3J6J74SW%W. >50R
MR,$4\B-4!)()(!XI^QG_ ,%;_P!H/]H7_@H'<_L$?M&?\$Z-7^"NIO\ ">;Q
M]H]]KOQ$M-3N[O3UU&*QC$EI:V^VW+R--PTY=?(Y3#AJ^YJ_.VZ_Y6K[?_LQ
M,_\ J6M7Z)4 %%%% !1110 4444 %>6?MH?MC? []@G]G'Q%^U#^T-K\MCX;
M\.P*7BLXA+=7UQ(P2&TMHR1YDTCD*JY &2S%55F'J=?FQ_P<6?9AJ?[&I\>;
M?^$ '[8OA3_A,?M'_'MMS-Y7GYX\O9]HSGC&?:@#I#_P4E_X+"+\/_\ AHMO
M^")S_P#"!BT_M ^'!\8K7_A,/[.V[O/_ +.^R[?/V?/]CW^;G]W]ZOHWX)_M
MW^"/VN?V'!^VI^Q7X2N_B&M_X?NKOP]X-:_ATV]N]2A#*=*GDF)CM)Q,OE,S
MDHN0X+(58^[5^:__  ;EFW,G[8O_  @FW_A /^&Q?%O_  A9M_\ CV\O,._R
M,<>5L\C&.,>^: -+XT_\%8_^"FG[%_@@?M(?MR_\$H-+T#X265Y;IXMUCP+\
M9;77-5\-6\TR0K<2VOV:);I0[HI$3@#=DL!7Z%>'M?T?Q7H%CXH\/7Z76GZE
M9Q75C=1YVS0R('1QGL5(/XU^4_\ P6]^!O\ P4]'P%^('Q0^-OQ[\*?$#]F7
M1?$?]N^-_@UX2TP>'->U#PM!>K.EF=6>.X\QHE6)I=@A:58G <%@I_3GX$>.
M/ ?Q-^!_@WXD_"RT-OX8\0^%-.U/PY T B,=A/;1RVZ[ 2$Q$Z#;VQB@#S;X
MJ?MI_P#"L_V^/A-^P_\ \*U^V_\ "T/"GB'6O^$G_MGR_P"S/[+6W;ROLWDM
MYWF^?][S$V;>C9X\H^,O[9G_  5B;XL^*?"7[+'_  2;L_$'A3PQJ4UI:>+_
M !U\7[/1&\2&/JUE:>1)(D9/W)92$?.1@ U]*^*/V<O@OXS^.GA7]I;Q-X)C
MNO&_@G2]0T[POKIO)U:QM;T1BZC$:N(GWB).71B-ORD9->4_\%&?^"B/@;]@
MKX<Z9#8>%KOQM\4O'%X=)^$_PKT0[M1\3ZHV JA1DQ6T996FN&&V-/5F16 %
M_P""<G_!1;P1_P %!?@CK_Q';X=ZK\/O$_@3Q5?>&/B7X&\2W"-<>&]8LPIG
M@>50JRQ@,")=J@X8%5*L!\TVW_!;#]L+XL?"[Q1^VE^R;_P3*G\<_LZ^%+V_
M5/&-W\18=/USQ)I]C(Z7NIZ;IC6[[X8S'*51Y \OE$#:V57;^ _["OQD_8J_
MX),?M&ZU\6/%-OK?QQ^+OA[QGX\^(NH:.,6T6OWVF3%;2T _Y90[413W?>PP
MI4#OO^"'9\!?\.3_ ($E_LO]B?\ "K(_[5W8\K/[W[7O_P"VGF[O?- 'TI^S
MI\?OAG^U1\"?"?[1OP;UIM0\+^,]#M]5T:YD39)Y,J!MDBY.R1#E'3.5=67M
M7:5^?7_!K;_;O_#CWX._VUYOE_:/$7]G>=][[-_;^H;?PSNQ[8QQBOT%H **
M** "BBB@ KD_COXO^)WP_P#@WXE\<?!CX60>./%.D:/-=Z)X/GUS^S1K$\:[
MA:K<^3,(7< JA,94N5#%02PZRB@#Y]_9&_X*1?L]?M6?L.P_MUKK<?A3P[IN
MDW<_CVQUR?$WA*\LD)U"SN\JI5X"K<E5+H4<* ZBO"/A/_P5$_X*8_M*_!S0
MOVBOV8?^".-OXA\%>+9[RX\*W?B+]H"RT._N=*28I:7TUI<::WD_:4!E6-7D
M 0J0[!P:^8_^"A7[!7A_4O\ @M1\.OV.?"'Q-UCPY\'/VO[FZ\7_ !S^'FE
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MM<)X(C'Q$E\$)X0D\2?;)]QT5+QKU;3RM_DX%P[2;]GF<XW;>*\'_P""E_\
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MX[2_ (^%8-/_ .$3U)/!$>J)!I\,+(+&YL+XHS!U<%S(5F#KN)WYKYY\2?\
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MG_@JCXS^,/@"TU"*\NOAKX3\!:?X,TK5GBD$B1WQLGEFNH0RJ=AD4AE#*RD
MU^@%% %30="T3PMH=EX9\-:3;6&G:=:1VNGV%G"L<-M!&H1(T10 JJH"A1P
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MGZ6EQ('FE ):2:5@ &EED9Y78  O(Q &<5Z!10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20210930_g18.jpg
<TEXT>
begin 644 biib-20210930_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
M!3S]KC]H#XP^/?A]_P $S_V&M+^)OAKX7^(Y_#OBOXB>-/B-'X?TZ]UNW -S
MIVG(+:>2Y:(LJM.VR,,<#*E6;Q3_ ((E?MF?LW?LIS^.?^"<?[1GQ%_X0[XS
M7?[1WBL:/X*US2;N&?5(KR^,MK/;2&+RI8I4R5</@@9Z,I/S%^R_\&_V+/V,
M?B7\5_V4/^"GO[:7QU^ _C*Q^)^M:QX3O-*^+FM^'O#?C#0;N?SK?4K)K8BV
M:8[BLJY#A@H.6#J@!^CWA[_@L)X=\1_\$Y?B[^V[_P *!U72O%_P.;5].^(_
MPBUS6HX;K3-;TY5::Q-Y'%(CQLKHT=RL;*ZN#M!#*/)?&_\ P6Y_;#\!?LY:
M!_P4,\2_\$P+FQ_9SO;32[W6O$,WQ)@;Q';:;>-$G]J1:6+8;[8/,IC5I$EE
MC*2LL*N=GF?C3P%_P3[TG_@AS^V=\3O^">WQ9\:^/-$\4:-JP\5^,O&NJZC?
M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_
M //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4 5K;Q1X?O)UM;758GD<X1%/)-7ZB2QLHV#QV<2L.A6
M, BI: "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5
MX7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">_
M_)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:[2^+O\ ]N@,_P"'I_\ P3V_Z.K\,?\ ?R7_ .(H_P"'I_\ P3V_Z.K\,?\
M?R7_ .(KU/\ X4'\"_\ HBWA+_PG+7_XW1_PH/X%_P#1%O"7_A.6O_QNOL /
M+/\ AZ?_ ,$]O^CJ_#'_ '\E_P#B*/\ AZ?_ ,$]O^CJ_#'_ '\E_P#B*]+U
M;X'?!2QTNYOK'X/^%H9H;=WAFB\/VRLC!20P(3((/((KR>O#S?.?[*G"/L^;
MFOUMM\F!=_X>G_\ !/;_ *.K\,?]_)?_ (BC_AZ?_P $]O\ HZOPQ_W\E_\
MB*I45X_^M_\ TX_\F_\ M0+O_#T__@GM_P!'5^&/^_DO_P 11_P]/_X)[?\
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M))Y)-6/^%!_ O_HBWA+_ ,)RU_\ C=?90ESP4NX'EG_#T_\ X)[?]'5^&/\
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M'I__  3V_P"CJ_#'_?R7_P"(H_X>G_\ !/;_ *.K\,?]_)?_ (BJ5%'^M_\
MTX_\F_\ M0+O_#T__@GM_P!'5^&/^_DO_P 11_P]/_X)[?\ 1U?AC_OY+_\
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MS6]PBQ_NWV[<M\Q 7#?+8:%*I64:CLM?+IHKZVN]+]-P+7_!/W_@J/\  O\
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M:#I_BWX<:EI_F*-;T&5Q;W'FJ[,!<6]XK1MM(#))&P5>:^_J_)?]MB:;PO\
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M[>$_V=I<0>YO;B>>.WM[>,$@;GFEC7).%!+'@&O3Z\W_ &M_@5\"OVF_V?\
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M44 %%%% !1110 5L> /^1TTS_K\3^=8];'@#_D=-,_Z_$_G73@O]\I_XE^:
M]THHHK]? **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>=
M1_Y"$_\ UV;^9J&IM1_Y"$__ %V;^9J&OQF?QL HHHJ0"BBB@ HHHH ****
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M *4FO5_B9_R(NH_]<1_Z$*\H_P"">_\ R1/5O^Q[UG_TI->K_$S_ )$74?\
MKB/_ $(5R8__ '&K_AE^3 \0HHHK\B **** "BBB@ HHHH **** "BBB@ K8
M\ ?\CIIG_7XG\ZQZV/ '_(Z:9_U^)_.NG!?[Y3_Q+\T![I1117Z^ 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_R$)_\ KLW\S4-3
M:C_R$)_^NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'T#X?\
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M.FF?]?B?SK'K8\ ?\CIIG_7XG\ZZ<%_OE/\ Q+\T![I1117Z^ 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_R$)_^NS?S-0U-J/\
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M!K+[5_;G@>U^ VEZ+)J6^UECAQ>02M)#Y<[Q3?*#N$10\,:^<?B#^PY\ _\
M@H!_P56^.OP]_P""HWCSQ/?6OA^+0YO@/\.)O'=YHNDS>'Y-/0W6I64=M-"U
MW-]M6>*=PS&-E4,-K18^@OV4?^"(G_!*O]D+X^Z!^T1^S=\+;S3?&GA[[5_8
MM[+\2=7U!8_/M9K:;-O<7DD<F89I1\R'&=PP0" #[+HHHH ^>OV"_#=AJWP<
MU:ZN9KA6'CC65Q%.5&/M+=A7JOC[PGIMAX/OKR&XNBR1 @/<LP^\.HKSO_@G
MO_R1/5O^Q[UG_P!*37J_Q,_Y$74?^N(_]"%<F/\ ]QJ_X9?DP/$****_(@/@
MG_@H;_P4;^-UOKOQ)_9L_8R^"UUJ^K?#)O#;_$'Q[=^+TTBVT6XU&[MY+6R@
M4122W<DT1VR%=BQH[9)(VGZM_9G^)/[1/Q(\*ZE=?M+?LW6_PUURPU0VUM86
M/C*#7+;4;?RT87<,\4<152S.GER1JX,9."""?CS_ (*H_L'>!O$6G_$/]L#]
MG3]I'Q+X#\<:C>>'=+^(6G>'+ZWO-+UJ:&^LHK-]0L958?:($DB=#N3Y0 1A
MV)]/_P""</[37[3OCGXX?'+]B_\ :@\;>'?&GB'X+:AH\5M\2O#&D"QAUB'4
M;66=8[BU5FC@NH?+PZ(=N6*X^3<_KU:5"> 4J*6F][\WV4_)J[^YK3<"]_P3
MN^,_Q$_:Z^,?QJ_:FU'QKJ+> ;;QI+X'^&'AM+IA9?8]*.V[U7RQ\KRW5U(X
M$C#<L<"IP.OSI^SO\4OV[?VNOBK\:8F_X+$6?PLC\*?M">*/!GA'P1)\-?"]
MY-)I]C<1_9V1KF-)I?EF$>2')\K)9B37K7_!NRATO_@E7X-\%:E&8];\-^)O
M$NF>)87.7BODUJ\=U?\ V@DD?Z5W'Q:_X)*_\$J_B7X9\7^-_B/^S-X+*>*9
MK_6_$?C62<QW2RW#R7%Q>K?&3=#\SO)E6"*.P48JYU,/AL95IR6S44^6,K):
M7M+35:^8'9_'OXY>)/V ?V!/$GQS^-WCZ7XA:YX \(R7%]K=QI<&FMKU_G9
M&AMQY5N))GBC.P84'(!KY%^(6I?\%<OV=?V+[?\ X*9>*?VS8?%&N:;HMKXK
M\:?!&Y\$6%OH8TB7RY9]/MYXT^TPS6\#D^>78LT3 [LY;R30+SXU_M0_\&N?
MQ,T75?$&J^*7T"2_A\+:_J =[G5= TC6H+E)F)Y<)!;31@]EA [5]=?MW_M)
M?"K4_P#@A?XV^-UEXCLWT3QC\#6L]$E692)KC4K$6L$*CO()9PI7JI5@0-IQ
MI"C]7FH<JDW4<7HMM-%II>[VL]/(#TSXS:;^TY^V)\(OAUXW_8J_:JM/A3X>
M\4:1'K6L>(9/"%OJ^I7%C<V\,UK%;1W!\F(E7??(V2OR[0>:\(\+?%#]MG]A
M/_@HE\(/V3/CG^U0_P ;? GQRL=;CTF[UKPS::?K7AR^TVU6X=RUHJK<6\@9
M!EQD98C;L_>>F>#_ -H7X>_\$QO^"6?PEU;]I&>[AU/P_P##3P[H5KX8LH?-
MU/6-:73X8ETVT@^]+.TBE0.BA2S$*I(S/V%OV2OC9XV^-=W_ ,%*/V]+.&#X
MJ:]I#:?X)\"6\OF6?P[T)R6%DA_Y:7L@.9YN.69%P"P//#EI4I\Z7L_>2T5Y
M/6UG:^FC;O:VG4#["K\_O 7CS]MS_@I?^TA\;+3X0_M@WWP4^&_P=\?W7@;1
MK/POX5L+_4-:U>S ^UWEU->(^V)790D484.K '#(6;[J;X@^ D\<K\,'\;Z0
M/$K:;_:*^'CJ47VXV>_R_M @W>9Y6\%?,V[=PQG-?(NM_L _M8? 7]HWXC_'
M7_@GU^U'X0\+Z-\5-5_M?QUX+^(/A*74[.RU<I^]U&TD@N(GCDD#;WC?Y2QR
M2R[%3GP;IPY^:RDU[KDKK?7H^FSL!T'_  3._:J^+'[1FA?%C]F7]IO7;._^
M)'P8\:W'A7Q-XD\.PFQCUNT=6-IJ:1QD?999463<B$!&CRNW.U=S_@C_ /&S
MXB>._P#A-?V3_C[XPO==\=_ [XD7'A;5=?OI<W>M:6_[_2]2E8?\M);9PK'J
M6A9CRU?-/_! 'X6:KI'QJ_:Q^.=O\5+WQ[H?BOXEV&F6GC^\MHX5\2:CI\=V
M^HWT"1_(+=[F^/EA"R*@50S;2:]@_P"":44NM?\ !;[]LCQGH7_(&%_X TR:
M9/N3W\&C.)0/]J/.UO=AZUZL:-&.83A&UE[.6UM;P37E\3T\O(#]/_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJV**_10,?_ (0?2/\ GYO?_ MJ/^$'TC_G
MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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M_P!"A>_]]+1_PDNK_P#0H7O_ 'TM:@;%%8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+0!L45EV>O:E<W203>&;J%6;#2NRX7W-:E !1110 4444 %%%% !
M1110 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI
M->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_P A"?\ Z[-_,U#4VH_\
MA"?_ *[-_,U#7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/A__D V
M/_7G%_Z *MU4\/\ _(!L?^O.+_T 5;K]CH_P8^B ****U **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_\
M@GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^>=1_Y"$_\ UV;^9J&IM1_Y"$__ %V;^9J&OQF?
MQL HHHJ0"BBB@ HHHH **** "BBB@ HHHH ^@?#_ /R ;'_KSB_] %6ZJ>'_
M /D V/\ UYQ?^@"K=?L='^#'T0!1116H!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CW
MK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!\\ZC_R$)_\ KLW\S4-3:C_R$)_^NS?S-0U^,S^-@%%%%2 4444
M%%%% !1110 4444 %%%% 'T#X?\ ^0#8_P#7G%_Z *MU4\/_ /(!L?\ KSB_
M] %6Z_8Z/\&/H@"BBBM0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5\]
M?L%VWB27X.:LVDZE;Q1?\)QK.5EA+'/VEN<U[;]B\;_]!NR_\!C_ (T ;%%8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q1
M6/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!XCJ/_ "$)_P#KLW\S4-2W
MP87LP<@GS6R1ZYJ*OQF?QL HHJIH6OZ%XHTF'7_#.M6FHV-RI:WO;&Y6:&4
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M-EO= \2:9-I^L6D%Y+;O-;2J5D02PLLD>5)&Y&##/!%?D+_P4 ^#_P#P2&\
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MSE%='_PJ7X@_]"__ .3<7_Q='_"I?B#_ -"__P"3<7_Q=']FYC_SYG_X"_\
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M4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\
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M  30?_$4 <+_ ,-W?LA_]%XT3_OJ3_XBC_AN[]D/_HO&B?\ ?4G_ ,17=?\
M"IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30?_$4 <+_ ,-W?LA_]%XT
M3_OJ3_XBC_AN[]D/_HO&B?\ ?4G_ ,17=?\ "IOA7_T33P__ .":#_XBC_A4
MWPK_ .B:>'__  30?_$4 <+_ ,-W?LA_]%XT3_OJ3_XBC_AN[]D/_HO&B?\
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MPW=^R'_T7C1/^^I/_B*[K_A4WPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\
M^":#_P"(H X7_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?
M"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B
M?]]2?_$4?\-W?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7
M_P!$T\/_ /@F@_\ B* .%_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T7C1/^^I/
M_B*[K_A4WPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(H X7_AN[
M]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\ Z)IX?_\ !-!_
M\11_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B?]]2?_$4?\-W?LA_
M]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\
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M?VAM?EL?#?AV!2\5G$);J^N)&"0VEM&2/,FD<A57( R68JJLP /4Z*_/P_\
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M'\+_  )\,K?P_9ZY?VS;H&O[GSY9980W6  *V205(! !^@E<3IG[.7P7T?\
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MPM?+VO;M#:RRK<!FRVYB".F,5\DV_P#P1,_:]^%/PO\ %'[%_P"R=_P4XNO
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MF_\ "F-%\1:?_P (G_8/G?VQ_:MF;;?]J\]?L_E9W8\J3?TRO6OHN@#\Z?\
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ML?\ PC%[Y^S&SS_[3O/M&>V?.\S/OFN*_P"#6[S?^'17AS['G^Q?^$]\4_\
M"-8^Y]@_M>XV[/\ 9\SS?QS4$?\ P1>_:^^"OA?QK^S1^PW_ ,%*W^&?P(\=
M:K?7C^";SX;P:GJ?A:.^9FO;72-0-Q&889-[[-R%H2Q927W.WVQ^RK^S-\*O
MV-OV=?"'[+_P2TJ6S\+^"]&CT_2TN) \TH!+232L  TLLC/*[  %Y&( SB@#
MT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20210930_g19.jpg
<TEXT>
begin 644 biib-20210930_g19.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@#
M4@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH R?!WCKPC\0=+DUOP7KT&HVD-W+:R3VY)59HVVNG
M/<'@UK5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#G=&P&2JD,"M>DT4 ?E[\"O^"3W[2/[2?QP^*FF?MZ?MGZ]XJ\!>'OVB=/\
M$=WX.TCX:6OAZT\=ZE9^'- >VU"><22R-9ILCMVMH2(VELI'+ASMC^ROVT_@
MG^W5\5+SPSKG[$W[:^E?"B?1TO$U_2M?^&]OX@L]>64P&%F:26*2V>'RY<&,
MD/Y[!A\JD>\44 ?*G[#'_!-;7_V=/C5XI_;&_:D_:/U'XS_'+QEH\.C7_CB^
MT*'2[/2-'B?S4TO3;&%F6U@\P!W.XF1U#D*2V[;_ &SO^"?7_#:?[1GP%^*G
MCCXN?8_!?P3\9S>++CX?KH'G#Q%K"0A=/N)+HSJ(!:R;G"^3)O\ ,=25R"/I
M"B@!LZ/)"\<<I1F4A7 R5..M?GS\0/\ @EA_P4[_ &E?"$W[.O[8'_!81_$?
MPEU("W\6:?X.^#UAH.N^);#(WV4]['.ZVZ2 %9&BC^=2RE=KD#]"** /"/VI
M?V./%WQ*_8D?]CW]CO\ : U'X!7%AI^E:=X3\7>$]/>>;0;*RF@(MXHDN(&*
MO!"8#^]&%<D[NAS_ /@H3_P3Y\._M[_!CP[X-G^*6J^"O''@/Q-9>)OAQ\2=
M%M4FN] UNUSY=SY3D+/&P+"2%F <$<@JK#Z'HH ^*?@A_P $P_VC_$?[6W@[
M]LO_ (*-_MFV?Q=U_P"&&GWEO\+_  UX=\!QZ!I&C7-U&(KG4I8Q/,US=/&
MJDE5CP"H)"[?M:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)
M[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\H\7_ !+\;:7XGOM.L-:\N&&Y98T^S1G !Z9*YKU>O"_'_P#R.FI_
M]?C_ ,Z^9XGQ%?#X6#I3<7?HVNGD!;_X6U\0?^A@_P#)2+_XBC_A;7Q!_P"A
M@_\ )2+_ .(KG**^*_M+,?\ G]/_ ,"?^8'1_P#"VOB#_P!#!_Y*1?\ Q%'_
M  MKX@_]#!_Y*1?_ !%<Y11_:68_\_I_^!/_ # Z/_A;7Q!_Z&#_ ,E(O_B*
M/^%M?$'_ *&#_P E(O\ XBN<HH_M+,?^?T__  )_Y@='_P +:^(/_0P?^2D7
M_P 11_PMKX@_]#!_Y*1?_$5SE%']I9C_ ,_I_P#@3_S Z/\ X6U\0?\ H8/_
M "4B_P#B*/\ A;7Q!_Z&#_R4B_\ B*YRBC^TLQ_Y_3_\"?\ F!T?_"VOB#_T
M,'_DI%_\11_PMKX@_P#0P?\ DI%_\17.44?VEF/_ #^G_P"!/_,#H_\ A;7Q
M!_Z&#_R4B_\ B*]3\#:G>ZQX3LM3U&?S)YHB9'V@9.XCH !7A->W_#/_ )$7
M3O\ KB?_ $(U])PQB\5B,;.-6I*2Y>K;ZKN!NT445]N 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%%
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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M6U>/>-+:.S\5ZA:Q,Q6.Y95+MD]>Y[U[S7A?C_\ Y'34_P#K\?\ G7R?%O\
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M444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE
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MER,O$VX?>&YOCO\ ;$_9_P#^"E/_  5F_9G\,?L'^,X?'\7P1U+Q%XG^)GQ
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M_P#D1=._ZXG_ -"->(5[?\,_^1%T[_KB?_0C7O\ "?\ OT_\/ZH#=HHHK[\
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M>-_^@W9?^ Q_QK8HKA/3,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
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M 4444 %%%% !1110 4444 %%%% !1110 5X7X_\ ^1TU/_K\?^=>Z5X7X_\
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M445]^ 4444 %%%% !117(_'KPU\7O&/P<\1>&/@'\2[/P;XRO=->+P[XHO\
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M87.!VKU*@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\
MZ4FO=* "BBB@ HHHH **** "BBB@ HHHH ***\X^.?CG7I+JR^#/PXN-OB3Q
M"I#W*]-,LNDERV.AQD+WSG'( .V'H2Q%50CIW?1+JWY(YL7B882@ZDM>B2W;
M>B2\V]#'U8G]H[XGMX:A._P5X3O VJ./N:KJ"\B#/\4<?5NQ/U4CU\ * JC
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M ,B+IW_7$_\ H1KQ"O;_ (9_\B+IW_7$_P#H1KZGA/\ WZ?^']4!NT445]^
M4444 %%%% !1110!^+__  4B^-OPV_8,\<_\% O 7[6&EWVAW_[3?PQ:X^"O
MQ!GT:>>S\0^5X8;3O[ -S$C+;SP7*,4BD*J5G#DKN7=Z'\"OVK/A9_P4]_;$
M_9"\#_L73W_BK0/V=-*N?$/Q;^(=MI-Q!IFDW$GAYM.M](BGF1!<7$LLQ+HF
M0(XRP+[7"?9'[/G[1.L_M=?M1_M(_L[_ !(^'WA.[\"?"3Q1H>@:):W>FM/=
MZA<SZ5%?7<UVLSM$8P\\:1!8U.$<DMD89^T%^T7J_P"R%^U1^S;^SG\-OAUX
M4M/ ?Q=\3:[H.MV]GIK07>G74&E27UI-:K"ZQ",O!(DH:-CAU(92"& /IBBB
MB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB
M@ HHHH **** "BBB@ HHILTT-M"]Q<2K''&I9W=L!0.223T% ;&#\3_B+HOP
ML\&W7B_6@7$0"6MK&?GN9VX2)!W)/Y $]JP/@9\.M:T"UO?B'\0,2^*O$CB?
M4VQQ:1?\L[5/14&,^XZG -8/@F";]H+XD+\6-4B;_A%?#T[P^$K61<"\N </
M>L#U (PGH1G@@Y]=KT:_^QT?8+XW\?EVC\MY>>G0\C#?\*.(^M2_AQO[-=^C
MG\]H_P!V[^T%%%%><>N%%%% !1110 5X7^V!_P $X?V./VW[FR\3?M#? VPU
M[Q'HFG36OA_Q%#J5WIVH62/N/EI=V4L4PCW,6V;MN23CDU[I10!\M?\ !+7_
M ()@?L^?\$[O@'X4M/"_P8\/Z7\3[GP%H^F_$KQ;97,]]<ZG?P6D*W*I=7):
M46QG1F2)-D0 3$:[0!R/Q4_X-Y/^"0'QJ^*_B?XW_$C]DZYOO%'C+7+G6/$N
MIP?$GQ':_;;VXE:664QP:BD:;G=CM1549P !Q7VG10!XY^QE^P)^R=_P3Z\$
M:M\.?V1_AA/X6T;7-5_M+4[2?Q+J6IF:Y\I(M^^_N)W3Y$4;58+QG&236]^U
M7^R=\ /VV_@CJG[.7[3W@'_A)O!FM36TNI:-_:MW9><]O.D\)\ZTEBE7;+&C
M?*XSC!R"17HM% &)\2/AOX!^,/@'6/A9\4_!^G^(/#FOZ?)8ZUHNJVRS6]Y;
MR+M>.1&X8$'^HYKYM_9J_P"")_\ P3B_9/\ BWI/QO\ A)\#[U_$/AN"2#PA
M/XE\8:IK,/AR*0$,EA#?7$L=KE3MW*N\#@, 3GZMHH \W^)7[(W[/7Q?^/WP
M\_:A^(GP^_M'QU\*AJ0\ ZY_:UW#_9?V^ 07?[F*589_,C 7]\C[>J[3S7!?
MM@?\$LOV(_VY?&VC?%3X]_"BY?QEX?M3:Z-XU\,^([[1=7MK<ECY'VJQFB>2
M/+OA)"RJ78J 6)/T+10!XK^QG_P3Q_9"_8!T+6=&_9:^$<6@S^)+M;KQ-K=Y
MJ5SJ&IZQ,N[:]S>7<DDTN"[E5+;%+L54;CGVJBB@ KC_ ([?#^?XC_#6^T73
M&*:E;;;S1YE.&CNXCNC(/8GE<^C&NPHK2C5G0JQJ1W3N8XBA3Q-"5*>TDT_F
M<U\(/'\'Q.^'6E^,D4)-<V^V]A QY5PAVR)CMA@<>V*Z6O*O!'_%JOC]K/P[
MD_=Z5XN1M9T,=%2Z7BYB'N0 ^.@ %>JUOC:4*=>\/AEJO1]/D[KU1S9;7J5L
M-:K\<&XR]5U_[>5I+R:"BBBN0[PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH X;]H/QWJ/@OP"UCX:RVNZ[<)IFAQ(?F,\OR[QZ;5RV>F0,]:\JA\&6?P
M]C'@NQ?>FG#RFEQCS''WG_%LG\:[CPM_Q=[]H#4/&TG[S1/!"OIFC]TEOW'^
MD2CUVC"?]\D5@^/_ /D=-3_Z_'_G7A\;-X?+*.'6[ES2]6G9?)/[VSRL%_M6
M*J8M[?!#T3]Y_P#;TE\U&+,>BBBOS,]4**** "BBB@ HHHH **** "BBB@ K
MV_X9_P#(BZ=_UQ/_ *$:\0KV_P"&?_(BZ=_UQ/\ Z$:^IX3_ -^G_A_5 ;M%
M%%??@%%%% !1110 4444 ?"W[3'[ /[0NN_M<^,/VQO^"6/[=.B?#7XBZU;6
M&C?&3P;K^APZWHFN7%K:HUC+=PAO-L;Q+66'# %GA>,@*&8R0_LW_L(_'/PU
M^V-X'_:U_P""JO[>6@_$GXG6%MJ6C?!/P/H.BPZ)HVCSSV<DFH36<!;S;^[:
MTAFW.R@I"KD[@J&/P3_@JYJ]E\)_^"B^C^+/^"1OBOQ+>_MJ>(CIZ^//AWX8
MB%]X<US0HHXD2;Q6DLJ06"QV_EB&X#I,%:/  >.5+?\ P1ED^&GQO_;%\0?%
MK_@I!X\\2WG[<_AC[9;R> ?B%:+IUOX,TF02)CPQ:)(\$]G) Q#WD3/(ZLQ;
M:LI>8 _5^BBB@#YZ_8+UB_L/@YJT%MH%Q<K_ ,)QK)\R(C&?M+<<U[;_ ,)+
MJ_\ T*%[_P!]+7D?_!/?_DB>K?\ 8]ZS_P"E)KW2@#'_ .$EU?\ Z%"]_P"^
MEH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q
M_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (27
M5_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6O,/BYXR\1_%CQ$/@+X2TJ\@B
MPDWC"[@8%X+0\BW!Z!Y/?^'L03CMOC5\3Y/AOX:CCT2S^VZ_JTPL_#^FKR9[
MAN Q']Q<@L>G09&:?\&OAA'\,?"IM+^\^VZSJ,QN]>U-^6NKEN6.3SM&< >G
M.,DUZ&&2PM+ZS+?:"\_YO2/3N_1GDXR4L=7^I0?N[U'Y=(^LNO:-^Z+FC7LG
MA_2;;0]%\!W-O:6D*Q6T$94*B*, #GTJU_PDNK_]"A>_]]+6Q17 VY.[/5C&
M,4DE9(Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V**0S'_ .$EU?\ Z%"]_P"^
MEH_X275_^A0O?^^EK8HH YW6O$6JR:-=QOX4NT#6T@+LRX7Y3S7BM?0/B#_D
M WW_ %YR_P#H!KY^KX?B[^+2]'^@!1117QX!1110 4444 %%%% !1110 444
M4 2V+%;V%@I)$JD =^:]O_X275_^A0O?^^EKQ'3O^0A!_P!=E_F*^AJ^VX1^
M"MZQ_4#R?]H>W\2:QX2MO&GA_P *7<6K^%+U=4L)3@Y5/];&<<E63.1WV@5V
M/A?XD/XO\.V7BC1?"]W+:W]LDT+JZGAAG'U'0^XKIG1)$,<BAE8892,@BO+/
M@0[?#KQKXC^ 5XQ6"PF.J>&]Q^]83MED'M'(2/<L:_08?[1@7'[5/5?X7O\
M<[/YL\JI_LF9QG]FK[K_ ,<5>+^<;KY11WG_  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+6Q17 >J8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\
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M%C21I>K^+?$,FD'3(8;6Q+-)%:PB2:8S,<2 A<(>* /T_HHHH \+_P"">_\
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MW#'+2W<IW2$GOCA<]PHKL***PK59UZLJD]V[G3AZ%/"T(TJ>T59?(*\+\?\
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M45\& 4444 %%%% !1110 4444 %%%% !7M_PS_Y$73O^N)_]"->(5[?\,_\
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M?]DC_@X-\4ZOKJF#P[^UG\);"31]1<827Q/X:3R7L<] QTV3SE_O;' !VDT
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MFF#1X?#DWB:/76O983<"]_M) IMA;B @L%<2[!D@'ZY4444 %%%% %3Q!_R
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M_G7NE>%^/_\ D=-3_P"OQ_YU\GQ;_NE/_%^@&/1117P8!1110 4444 %%%%
M!1110 4444 %>W_#/_D1=._ZXG_T(UXA7M_PS_Y$73O^N)_]"-?4\)_[]/\
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M:$?WS*$_BH _3:BBB@#XU_9:_;@_9._9^\!ZMX!^,WQRT7P]K/\ PF&K7/\
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M_P )RU_^-UX_^J'_ $__ /)?_M@/'Z*]@_X4'\"_^B+>$O\ PG+7_P"-T?\
M"@_@7_T1;PE_X3EK_P#&Z/\ 5#_I_P#^2_\ VP'C]%>P?\*#^!?_ $1;PE_X
M3EK_ /&Z/^%!_ O_ *(MX2_\)RU_^-T?ZH?]/_\ R7_[8#Q^BO8/^%!_ O\
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MWUZVOIO$OAW2[>[GGMHP_F692?Y0DFY<L.1L&* /E'_AH?\ X../^D=7[/\
M_P"'=N/_ (W7?_LN?&7_ (+5>*_CMH6@?M;?L7_!_P )_#VX^U?\)!X@\+?$
M::_O[7;:RM!Y4#( ^ZX$*-D\*[-VK+_;)_8H_:K\<_&K6?C!X6_X+5>-?@QX
M6UF2V32?!=KX?TAK'3VCM8HI%BFNB'<R/&\Q!Z&5@. *H?L>_LK_ +0'PW_:
M,\.^-/&__!<[Q)\8]+LOM?VKX<7^F:+'#J^^SFC7<ULQE'E,RSC:.L SQF@#
M[BHHHH \+_X)[_\ )$]6_P"Q[UG_ -*37MNIZ99:Q82:9J,'F03+B1-Q&1G/
M4$&O$O\ @GO_ ,D3U;_L>]9_]*37NE*48SBXR5TP.<_X5+\/O^A?_P#)N7_X
MNC_A4OP^_P"A?_\ )N7_ .+KHZ*X_P"S<N_Y\P_\!7^0'.?\*E^'W_0O_P#D
MW+_\71_PJ7X??]"__P"3<O\ \77QG\8O^#@+]A;X;?M/Z%\&_#WQ0E\2>&[9
M-=M_B%XF\+^!=;UB#1[VS%KY445Q8VTD,X!EF\XQ>:(MJ;BFX9^LI/VF_@>/
MV9Y/VPK?QW;S?#I/!;>+%\2)&ZQOI M3=?:0KA6 ,(W!2 W; /%']FY=_P ^
M8?\ @*_R VO^%2_#[_H7_P#R;E_^+H_X5+\/O^A?_P#)N7_XNOGOX#_MK_M/
M?$'_ ()JV7[=&N?LHW&O^+/%-D-;\%?";PA<>5>W&E7EVJZ9%-/<,R"8VLL-
MQ/+A8T!?"@)SXC\4O^"OG_!0#]BW2M)^-_\ P4<_X)<VG@/X0:AK5KI^O^,/
M!GQ:M?$-WX1^TRK%#+?6T=N@EB\QE5GB? ) &YF1'/[-R[_GS#_P%?Y ?>7_
M  J7X??]"_\ ^3<O_P 71_PJ7X??]"__ .3<O_Q=>!?\%.O^"A7CC]@GP3\+
M]4^$?[.4'Q6\1?%?XJZ;X&\.^'W\;1Z'&;J]@N)(93=/;7";2T"I@JHQ)N+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\I_B9^R5^P=\5/\
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MMOVC^VO.^T;?.\K]QL\C.WGS/X:\J_:8_94_X*O>/_C%XBU[]F;_ (*G:+X
M\#>(3 ++PUJGP3L=6O/#86WBBE-I=M<(9R[I),!,IV-*5!( P ?+W_!NM/\
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M6Y;\$^(T\5^&+36P LDD>VX3^Y*O##';D'\,5I75S!96TEY=2A(HD+R.W15
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ML7EU.5*7,I*_-9KF;=W*S2>KN_3R"BBBO&/2"BBB@#Z!\/\ _(!L?^O.+_T
M5;JIX?\ ^0#8_P#7G%_Z *MU^QT?X,?1 %%%%:@%%%% !1110 4444 %%%%
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MIE[$'"2*X!26,AW5X95:.16(9>A'IM% 'Y^ZE\-/^#DKX$2GP_\ "?\ :/\
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (T >(ZC_P A"?\ Z[-_,U#4M\&%[,'()\ULD>N:BK\9G\;
M****D HHHH J:YH]GX@T>YT74$S#<Q%']1GH1[@\CW%&AZ/9^']'MM%T],0V
MT01/4XZD^Y/)]S5NBM_K-?ZM]7YGR7YK=+VM?UMH9>QI>V]KR^]:U^MKWM]X
M4445@:A1110 4444 ?0/A_\ Y -C_P!><7_H JW7.Z+9^,FT:T,&LVBH;:/8
MK6Q) VC'>K7V+QO_ -!NR_\  8_XU^QT?X,?1 ;%%8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C6H&Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C0!L45EV=IXM2Z1[[5K5X@W[Q$MR"1[&M2@ HHHH **** "BBB@
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M/\+O#OP<^%FF:_=>(]#T_3YM3\9>)]6GNY;C5[^2^@G\VW$D3-)"FTL\Q!D
M5 OT_P#\$R_VDO''[7G[!_PU_:)^)=E;P>(/$6A,=8-G%LAGN()Y;9YT7^%)
M3#YH4< 2 #C%<6,PZA!3@URJR\]4VF].NKW=MN@'WOX?_P"0#8_]><7_ * *
MMU4\/_\ (!L?^O.+_P! %6Z_4Z/\&/H@"BBBM0"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$
M]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_KSB_P#0!5NBBOLH1Y(*/8 HHHJ@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\
MTI->Z5\]?L%ZQ?V'P<U:"VT"XN5_X3C63YD1&,_:6XYKVW_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8KX7_P""J'_!
M2SXG_!K6?&7[%_[(GP.O_&/Q-@^!NL>./$>O_P#"51Z+9>"]$1)[>/4?/:.1
MY[H3(3';1J&)56+J#D?:'_"2ZO\ ]"A>_P#?2U\$?\%@OV&_AI^T1X>^('[6
M'P^^+'C7X<?%_P "_!+6--UB_P#!.NVP_MCP\UO<W(TW5;.17$MK(ZS%6PC9
MR0S>6H4 ^AO^">_QQ_;0^+G@46'[7G[)UGX!>Q\.:3<:'XITOXC0:_;>)Q-"
MYE?:((9K65-D;.LJ$,9QM=MK8\]_9O\ CO\ $_\ :Z_X*O\ QEDT+Q]JEG\)
M_P!GG2;3P59Z#8WC1VFO^*KU1=ZC=W"J1YILXEAMD1\A6ED=>3D>0_\ !+O]
MKS]M[X?_ +8LO_!,_P#:K\?Z%\6K:T^ NE_$#PKXZT+PY#I&H:9:R7$-F-+U
M*V@=H?,PZO&Z[69%#G=YF(]#_@@_J^K^%/%'[9W@'7_#=U)XBM_VTO&&J:DI
M91(;:]CLY+60@]%=$=E[8H ]>_: _89_X*+_ !F^+OB+QQX'_P""P7BCX<^&
MKFX#>$?!?A;X5:++%I""-5Q/<W(>6^+.&<[B@ ;:.F3YA_P3R_X*<?'B[_85
M_:5^*?[8EYI7C?7?V6/%_BS0]1\;>%K%+*T\:P:+:?:OM"1H#'#,X!1EC&Q=
MR'')KVW]MW]@[X!?\%'M-T2W^-,'C^*'PTNI6EB_@?Q[<Z4I:X,4=PLPMG"S
MLK6ZJ%D#!"'&/F8'Y6_X(CR:=XR^!W[3'_!+_7-'M/'/P>^%OCK4O ?AGQ%I
MNFV=F=4T:]MI!=6-T]FD<-Q<Q;V66X50\C3;FYQ0!E> H?\ @M%\5_\ @GI'
M_P %8;7_ (*1VNE>*]2\#2?$'0O@I;_#C3'\*#2/L[7L.DR2NOVQWEM@H-P9
M0Z/)C)V^97KG[1W_  64U?3?^"-O@3_@H!^SOX'L[CQY\9!HOA_X>^'-2<R6
MUOXEU&4V[PR$8,B6\D5T>WF>0 =H8D?/OQ[_ &2_V\OV"_\ @FQXX_9_\:?\
M%'/#]E^S%X6\'7]M#J]]X#5/&7]A/&XCT&"]^U?92\RN+2.<0M)^\7RT'RH/
M'/B7\(OB5^RY_P &[7[$?BOXI^"]2LK/X/?'WPE\1?&AN82#9Z5<ZIJ5POFK
MU0J-4ME(894G! /% 'U)^T7XU_X*8?\ !'S3_AS^UU^T+_P4!N/CI\/-4\:Z
M7X>^-WAC7/ >FZ9'I$6H2>4-5TJ6SC22)()B%\B0L'#KG!Y3]0*_-'_@YC\;
M0?%#_@E]#^SIX7L#<>(?C5\1?"WAWP%!;W"2OJ-U)J4%TIA"$F1?+A)W+Q\Z
M\_,,_?6M?&_P?X7\7:+\//$FHV.GZ_XB$_\ PCVB7^L6\5YJGDIOF^SPNX>?
M8I#/L!V@Y.!0!XI^TY^R7_P44^+/Q>OO&O[._P#P5GU?X3^%KBW@2S\%6GP6
M\/:TEK(D862075[&9G\QP7PQPN[ X%>#_P#!$/XW_MX_M ?'[]HZZ_:!_;1O
M/B]\+?AMXW'@7P%K5UX!T;1?[4U6U&[4[H#3[="8T9HHX_WCHZREN"*]Q_X*
MT_MTZM^PK_P3[^)'[06F:#=0>(;?13IG@M<JSRZW>D6UD%0<R%9I%E*CDI$_
MIFG?\$F_V5M2_8$_X)]?#7]FB\\&7;:YIFAB]\7W1=6:XUJ[8W-Z[/G+XFE>
M-6/.R-!VQ0!S'_!/SX[_ !.\'_MM?M"_\$XOCEX]U3Q)>>"=7MO&OPQUW7;Q
MKB[N_"NL9D%HTCDO(+&[$EL'<Y*-&.0E?9=?G-I&K:OXD_X.>]8\2^%_#=T8
M/#?[%MMI?BA8V4[;FX\3M<6\;]@QB <=\+7Z _\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5EV>O:E<W203>&;J%6;#2NRX7W-:E !1110 4444 %%%% !1110 4444 >%_
M\$]_^2)ZM_V/>L_^E)KW2OF7]FKXR?"_]FCP3JGPW^//C:R\+ZZ_BK4K]=,U
M-RLIMIIV:*7"@\,O(KT/_AN?]D?_ *+UH/\ W^?_ .)H ]7HKRC_ (;G_9'_
M .B]:#_W^?\ ^)H_X;G_ &1_^B]:#_W^?_XF@#U>BO*/^&Y_V1_^B]:#_P!_
MG_\ B:/^&Y_V1_\ HO6@_P#?Y_\ XF@#U>BO*/\ AN?]D?\ Z+UH/_?Y_P#X
MFC_AN?\ 9'_Z+UH/_?Y__B: /5Z*\DF_;O\ V0X'CC?X\:*3(V%*&1@#[D)A
M1[G%2?\ #<_[(_\ T7K0?^_S_P#Q- 'J]%>4?\-S_LC_ /1>M!_[_/\ _$T?
M\-S_ +(__1>M!_[_ #__ !- 'J]%>4?\-S_LC_\ 1>M!_P"_S_\ Q-'_  W/
M^R/_ -%ZT'_O\_\ \30!ZO17E'_#<_[(_P#T7K0?^_S_ /Q-'_#<_P"R/_T7
MK0?^_P __P 30!ZO17E'_#<_[(__ $7K0?\ O\__ ,31_P -S_LC_P#1>M!_
M[_/_ /$T >KT5Y1_PW/^R/\ ]%ZT'_O\_P#\31_PW/\ LC_]%ZT'_O\ /_\
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M:A8VC<-:226\R,R'Y(W!<Y4=S_PW/^R/_P!%ZT'_ +_/_P#$T?\ #<_[(_\
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MKN^SW,D4$J)<A-[XCF$D9W'*G->D5Y1_PW/^R/\ ]%ZT'_O\_P#\31_PW/\
MLC_]%ZT'_O\ /_\ $T </^PU^QCXX^ _Q;^-G[47QZ\0:/J_Q'^-'C@7M]-H
M4DLEKI>@6,?V71],C>:.-W,5N"\C[%#2S/@$*&/T?7E'_#<_[(__ $7K0?\
MO\__ ,31_P -S_LC_P#1>M!_[_/_ /$T >KT5Y1_PW/^R/\ ]%ZT'_O\_P#\
M31_PW/\ LC_]%ZT'_O\ /_\ $T >KT5Y1_PW/^R/_P!%ZT'_ +_/_P#$T?\
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M]$[T+_P40_\ Q-;M% &%_P *N^&?_1.]"_\ !1#_ /$T?\*N^&?_ $3O0O\
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MO#GQ5\"ZG\._%T4KZ;JUL8+Q8)2CE"0>&'0\5I:-I5IH.CVFAZ>K""RMHX(
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M2"SL[2%8XH(D4*D:(H 554   8   H _-K]GC_@LY_P4^_:F\2?$/PG\&/\
M@BII&HWWPL\;W7A+QG'<?M/:?;BTU6WQYL2&32@)5&1\Z94]C7=_M ?\%8OV
MS/AE^UG\/?V'?A#_ ,$SK#QO\3/%OP1MOB!XCT.?XX6NE0Z!(;F2VN]/6YDT
M^2*[\B6,*)U9/-#9$8 YYO\ X(/?\E__ &[_ /L\3Q%_):=\0?\ E:<\!?\
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MZ'X-TC1?&?BD:[K%GIEO!JNMK8+:C4+E(U66X\E"5A\QPS^6I(7=@$@5IT4
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MXKT"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(TVL_!2T\"^'(X-!N!*P?2_[*O(Q>W"QA?+,WF;F^\'SS0!^OE%?G)_P5/\
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MYND>%M3EU.VA\3:_K_BWPG_9&CP^:HGN89;<23WNQ=S(B1(SD 97)(_0JB@
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MWP%_X*2W_P '/!/PJ\,^%=1T;3;'X3^']=,KZAI\<DP,E]!YH_>!WY=OOX
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M?#OXY?$/6S96GQB;1/A"FE_!KQ%NDTAXXEA^V-%8-]FE,KL#]J\EU'+*J\T
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MF'#\6M,^$DO[0TRMK&NKHFF^*W\)ZFOAV?4BVT6BZL;<69?=E21+L4@@L""
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M+X/\<W>BZ->?$G3)KSP]::U:Z7;0Z";V*"2)GE.R[\H[U(E.XY 8'U+XW_L
M_P#!63]J#XM?!7X@?M._M+?L[VEE\(OB]I'B_3[[P5X$U>PU240R[)[!)[B]
MF417,3F-X]N'819^[BON']HK]FSX$?M:_"74_@7^TC\+]*\7^$]751?:-J\)
M9"RG*2(RD/%(IY61&5U/*L#7@GP9_P"")'_!/;X'_$SP[\6_#G@#Q=JVL>#K
MY+SP>/%OQ/UW5[;1)T^Y);VUW>/"K*.%+*Q7'!% 'UG7P!_P1@=(OVK?V[-.
ME<+<)^U#=S/"3\RQR6$!1B.N&P<'O@U]_P!?./Q9_P""2G_!/KXV?M$_\-8^
M//@ 1\0GNK2YN_$FA>+-6TB2^FM=GD/<QV%U#%=%!&@_?(^54*<CB@#P;PU^
MT/\ \%%O^"@W[6'QT^%'[(G[1'P]^!W@CX)>-T\)W.HZK\.#XGUW7M26W22:
MYDBEO+>&WMN0D1 9F",2>,+Q/_!N'XAU$>(/VQ=%U;XTZ1XXM]-_:3OY[GQ;
MH>B1:5IVIWC6L2W=[!:Q2R1P)(\.[Y'93MW!B#FOIG]H+_@C1_P3Z_:7^.&J
M?M$?$;X3ZQ:^*O$5K%;>+;WPIXXU;18_$4,2A$COHK"YB2Y 0;"6&XK@$D 8
MZCP+_P $P?V&/A;\)?B+\"OA?\#$\,^$_BL1_P )UHOAWQ%J5C'?*+=+;RXF
M@N5>SC,"+&8[8Q(5R"#N;(!^,6C3? 6X_P""AEG\=KOPSXJ@_P""<=]^T=*^
MC"2[A_X11_B"MLL0U9K<KN71&OA(J'/V;S%))";H1_0PK*RAE(((R".]>8ZG
M^QA^RWK'[*+?L.:C\%M'D^%#>&ET#_A"PKK;"P50%0.&$BN" XF#^:) ) ^_
MYJ[#X5_#'P=\%OAMH7PD^'MI>6^A>&]+AT[1[>_U:YOYH;:) D:-<74DDTNU
M0 &D=FP!S0!\$_M-^!/"7C7_ (.4?V<;[Q3H=O?/X?\ @'XEU32?M,0<6]VM
MT85F /&Y5F?!Z@D$<@&O3_\ @I+^V)^TC\-OVEO@-^PI^R)-X.T/QU\<[K7W
MC\>^.].EO;+0+#2;2.YN/)M8I(C<W4HD4(A<(-GS##!E^A]<_9=^!7B3]I'0
MOVNM:\#>=\0_#7AJZ\/Z)XA_M.Z7[-IUQ())H/(640/N< [VC+C& P'%<W^V
M3^P1^RQ^WOX2T?PC^TW\-VU@>'-4&I>&M6T_5KG3M1T>[P 9;:[M)(YHB0%W
M -M;:NX$JN #\YO$WAW]IOX1?\'$_P"Q_P""/VE_VY?#/Q;\4ZGX0\=_;+7P
M_P#"RW\,7&E:4VC3R01W'DWERUU%+<6\CQA]HC:VD(W&0X]]_P"">SI;_P#!
M=C_@H=;3N$DN(_A--!&QP9(U\-7"LRCN Q )[$XKV?X'?\$@/^"?'[//Q1\(
M_'7X<? R<>._!%WJEUHGC75_%FJ7^J23:A9K97;W4]Q<N;W=;H(T6?S%A&3$
M(RS$V_VHO^"2_P#P3\_;*^*4?QM_:!^ )U'Q>FG)8/XDT/Q7JVB7EQ;(3LBF
METRZMVG5<X'F;L  #@# !\(:#IO[=^K_ /!PQ^U99_LZ_$WX/>'/%W_"$^#C
MX63XO>%M0U*>Y\,BP7SO[)-I=0&.!;W/VD'<&E:/&-K9^G/V*_V$OVUOAE_P
M4>\9_MT?M9_&[X3ZC>^-OA7;^&M3\.?"[PU?:8E]<6E[%+;:E<)=W$QEDCA:
M:WW[ONM&H P<^U?M??\ !-?]C7]N:\T+7_VA_A.U[X@\+*R^&O%VB:U>:3K&
MF*<Y2*]LI8IO+.2?+9BF6)VY.:3]D3_@FU^R/^P_XBUSQO\  3P/J\?B/Q+:
MQ6NO^)O$OB_4M:U"]@B8M'$TU_<2E45F)"IM&>2": .(_P""YH^(1_X)"?M"
MCX7_ &K^U?\ A6E_O^QY\S[%@?;,8YQ]E\_/MFO,OC8?V01_P;::R8/[!_X5
M=_PRZ/[&V^7Y'G_V2/LFSM]J^V^5M_C^TXS\^:^]KVRL]2LY=.U&TBN+>XB:
M.>":,.DB,,,K*>"""00>"#7QO8?\&_G_  2DT[QE!XFA_9LN'TNUULZQ:^!9
M_&6JR>&8;XMN\Y=(:Y-GC))\LQ^7SC9C H ^-/BIX*UKX@_LU?\ !)/PE^T7
MH1U*\G\;>&Y-6L=9BWM+Y6B++")U?[S82(NK\D@AN]?3'_!9:SM;+]L3]A#Q
M?:VZ1ZI;_M*QV$%\JXE2UN=/F%Q"&ZA)!&FX=#M&>E?7_P 8/V6?@/\ 'OQA
MX"\>_%?P&-4U;X8>(_[>\#72ZE<VXTS4/*,7G;()42;Y&(V2ATYSMSS3OC1^
MR]\"_P!H7Q1X%\:?&#P-_:^I_#3Q4GB3P3<_VG=6_P#9VII&T:W&V"5%FPKL
M-DH=.<[<XH [^OS/_P"".Q^$G_#V_P#X*!!?L'_"=_\ "S=)W^9M^U?V1]FD
MV^7GYO+\_=OV\;O*W?P5^F%?F+^SW_P2*^'O[0W[7_[6'Q!_;!^!'B72?[5^
M-*ZC\,O&NE:Y?:'J$^GR:=#'<&UO+&:*5[=VC"O&S&-B@)7*@@ Q?V?_ .QC
M^W9_P5)/P@\K_A!?^$6T7[?]@Q]C_P"$F_X1V]_M/R\?+YWF;OM&.?,QNYQ7
MO'_! /P)I7P__P"")?P4M/ACH5G97NI>!I=4;;$JBYU&XEFE:64_Q$NP&3T5
M5'10![_^SY^PC^RA^RQ^SM>_LJ? CX0VF@>"-4ANTUG38+R=YM2>ZC\NXFN+
MIY#/--(F%,K2%P%4 @*H'7_ 3X$?"G]F+X.>'O@!\#O"O]A^$?"FG+8:!I/V
MZ>Y^RVZDE4\VX=Y7QD\N['WH _(;_@@/X;_X*MZ]_P $\;%_V8/CE^SGIBCQ
MGKZ^/=+\>^ =9O/$D'B ZC-]J&K2P7\2O<,OE%244B$P@Y()KZM_8X_8D_X*
M2_L"_L0ZW\$_V:OB7\!?$7CV_P#C-JGB%+?Q+I^KVGAC1-'OU\^;3K2"U=[B
M)X[HEHT9B@CE;)+8)]/^.7_!%K_@GO\ 'OXP:Q\>]<^%FN>&_%OB0Y\4:Q\/
MO'6K>'FUL_WKN/3[F*.=R229&7>Q8EF->U_LR?LM? ?]CGX26?P-_9P\!)X<
M\,65S/<PZ>M_<73O/,YDEEDFN9))97=B6+.[$GO0!^>O_!<B#]MNX_X-X_C_
M !_MT1?"]_&8U30FLA\(1J1TW^S5U_1F0R?VA^]\\.+@MCY-@CQSNK[!_P""
MH?[;A_8 _P"">'Q _;-T+P=:^*9_"^CV;Z1I<\Q%M=7-Y>6]G;O*R\^2LES'
M(^""45@""01[1\5_A1\-_CI\-M:^#_Q@\%V'B+PQXBT^2RUO1-4@$D%W XPR
M,/R((P00""" :\0^#'_!(_\ X)[_  "^&'CCX*_#;X ,OA+XCZ5#IOC#PYKO
MBW5]7L[RUA\WRHHXK^[F6U"^=(08/+(.TYRB%0#\VO\ @OWX%_X*/>!/^"4'
MB7XM?MC?\%(?AAJ5K?ZCH4FF?#CP?\&([59]5.H6\T2:;J\VH/<!H466?S1%
MN>*"0$ .QK[$_P""_P!KGP#U'_@F_)X2^+>A:IK/C_Q1J^GVWP(TGPK+Y>NR
M^.&(.FS:>X!:)HY"6D<=(?,3DNJMNZ;_ ,&]O_!**'P9?_#WQ/\ L^:QXFT>
M\TQ=.M;/Q5\1M=O_ .R;-98I1!8-+>EK ;H8P6@*.R*49BC,I^A_%/['/[.'
MC?\ :*\(_M7^,/AS_:?COP#HUQI?@S5K[5[R2'1X)QB9H+1IOLR3.ORM<"+S
MBH"[]H  !\,?\&\T/_"->(?CIX'_ &O1J9_;(A\9BX^.M[XFGADNM3T\KC2;
MC3VB 0Z6+<JJ+&-J.6R%1H17Z:5YKXF_9!_9V\7?M.>'?VR=9^'FWXE^%M"N
M-%TGQ58ZM=VDK:=.2TEI<1P2I%>0[B75+A)!&YWH%;FO2J /P@\/?\J87Q _
M["&M?^IT:^S_ /@N'\,/A_X4_P"#=OXA_#[P[X2L;31O#?PXT!="T^"W58[+
M[/>6'DF, ?*5VC!'/7U-?3%O_P $S/V(K3]C#4/^">UO\$]OP?U229[_ ,(?
M\))J1\UIK[[?(?M1N?M2YNOWG$HQ]T87Y:[SX\_LR? _]IOX!ZQ^R_\ '#P3
M_;?@77M.BL=6T/\ M*YMO/MXW1T3SK>1)EPT:'*N"=O).3D ^ _VHK_2M4_X
M+3?L'ZM^T-<QS>%;GX:>(9?!DVL$&T?Q@UI 0Q+_ "?:3&8C%GYO-V;/GQ7Z
M)_&#_A*?^%7>)1\/O^1E_P"$:O\ _A']F/,^U>0WE;<_]-/+_'%<?^TK^Q%^
MRO\ M@?!.W_9X_:/^#NG^*/"=DT#Z;8W<TT<UA+"FR*:WN8G6>WE525$L;J^
M&8$D,0>/_9(_X)=_L@_L4_$*_P#BY\%?#7B>;Q5J6B'1[CQ!XM\?:MK=PFGF
M6*4VL?VZYE6*,R0Q,=B@DHN20 * /GG_ (-V?^&?!_P0Q\"?:O[%_LH:;KW_
M  M3^V/+V_;_ +9=?VC_ &EYO?R\;O-_Y8^7_!MKX!ET>[\0?\&DUGH&LP7L
MGA*^^.$%OX,COF<.V@/XQ580"WS!23-CVQCC%?J7\7O^"$G_  3&^-GQ*\0?
M$_Q?\!M0M+CQ?J OO&>C^'/&^KZ5I7B"YW;C->6-G=1P2NS99CL!<DEMQ))]
MJ^,'[$O[+/QV_9ZL/V4?B3\'K"?X=Z6^G-IGA32[F?3;:T^P2QRVBQ?8Y(F1
M(WBC(16"D+@@C(H ^-O^#E/X4?#G6_\ @G+X%\ WW@W3_P"QK'XX^"[*PTZ*
MV5(K2W:[^RF.)5 $:^1(\8"XPK$=*UO^#@C1M(T+X$_LX:KHNEV]I<>'?VN?
M #:');0K&;'%S-&!%M V#9\N!@8 ]!7V1^T?^R[\"OVM_ MG\-/VA/ W_"0:
M)I_B"QUNTLO[3NK3R[^SE$MM-OMI8W.QP#M)*MT8$<4?M#_LN_ K]JWP[H7A
M3X^^!O[>T_PSXML/$^B6_P#:=U:_9M5LG+VMQNMI8V?8S$['+(V?F5J /S1_
M:!L?VR]4_P"#D_7[+X"?$/X5^'?%#_LY:>/AO-\7_#E]J,%QIGVQSJ"::MK<
MP%+CSQ(9""S&)7X"AJ]^_9X_8-_;[L/^"F^B_M]?M;?'CX-7=[;?#"_\'WVC
M_#'PIJ.F3:Q9-<QW,33_ &NYF\WR9]I!R-H<#N*^B?VP_P#@GY^R1^WGH6D:
M-^T_\)(-=G\.W37/AK7+/4+G3]4T>9L;GM;VTDCGAR50LJOM8HNY6VC&!^R?
M_P $N/V-OV,?B3??&CX,^"]?G\9ZEHSZ1>>+/%OCG5=<OFL&EBE:V5[^YE$<
M9DAB8A N2BY)Q0!]"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20210930_g2.jpg
<TEXT>
begin 644 biib-20210930_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#\_%_X*Y?MV_%/]JKXS_LW_L??\$J].^(]G\%_%D6A:YXDOOC[9Z&;B66
M(RQN+>XTYBN0K<*[XV\GFOK?]E'XE_M*?%;X6OXH_:J_9AM/A)XH&J30+X4L
MO'EOXB1K550QW'VN"&% 7+./+VY79G)W<?EK^R)\,?\ @H[\0/\ @I[^W/<?
ML+_M1^ _AY8VWQAT]?$-OXQ\!OK+WLQLI#$\3+-'Y050X(YR6'I7NG_!7;XA
M?MN_L_\ _!)_PI\(OB1^T58R_$_XG_%/1O /BCXG>!](;28[.QU/4IBTUM%O
M8V["T1+=FW9RSL"I(( /T5T[Q)X=U>_N=+TG7K*ZNK)]MY;6]TCR0-Z.H)*G
M@\'%720!DG '4FOR*_X*Y?\ !,_]DC_@E/\ L#G_ (* _P#!/?P GPP^*/P*
MU;1+_2/$^E:I<>?X@MYM3M;.YL=39Y"+V.=;@LXD!+%0N0K,IZ'_ (*#?LZ>
M"_VVO^"[7[.7PM^*-QJ]OX0UC]GW7[_Q7H&GZG-9MK%FMRLG]G3RPLL@@>4P
MF5%(\Q(V0_*Y% 'ZE:/KFB>(K+^T?#^L6M];EV03V=PLJ;@<$;E)&0>HKQKQ
M]^V[X5\ _M[> /V"KSP/J%QJ_C_P5JOB.SU^.X06UI%8NJO$Z'YF9MW!' QS
M79?LW_LO? #]D+X:I\'?V:?A=IO@_P ,1WTUY'HNDAQ D\I!D<!F;!8@$@<9
M^M?G#^WA^P1^QS^T%_P</?!S1OC1^S[H'B*U\>_!KQ#J7C"#4879=5N[$6]O
M:32X89:*%%1<8X4=: /L3]J[]MGQ]\ OV^OV7_V2_#?A/1[W1?CGJ'BVW\0Z
ME?"7[58+I6E1WL)M]KA,N[E7WJWRCC!YKZ,TKQ!H.O>?_8>MVE[]FF,5S]DN
M5D\J0=4;:3M;V/-?EA_P5,_8O^#5W^WK_P $[_V+OAQI]WX(\!#5/B%8C2_"
M.H36+QZ8NCVL]S8QS1L)8H[B(30.R,'"3OM93@C2^(W['W[/'_!,K_@LO^R)
MJ'[#GP[@^'>E_&*'QAX7^)/AS0;F9+#6[6RTE;NRDEA9ROFQ3G?YF-S8&3UR
M ?I]K.NZ)X=L6U3Q!K%K86R$!KB\N%BC!/0%F(%3V]Q!=0)=6LR212('CDC8
M%64C(((Z@CO7XD^-?'WA?]M/_@J+^T9KG[8/_!.+XR?M+^'?A+XOA\%_#7PC
MX0M;.Y\/^%HH8,W-S+:W-_;"2\NI#YGFLCX0!0V H7Z=_P""(?@GXZ?!OX^?
M'#X7:1^R9\5/A)^SU??V5K?PE\(?%%H6DT"_D21-4L[0QW5SMMI)!',L7F83
M)P 6;(!]=_MA?&#]K[X/^&='U/\ 9!_8UL?C+J=Y?O%K&EWWQ-M?#(TZ )E9
MA+<6\PF+-\NP $=<U\9^!_\ @LY_P4^^(O[4/CC]CGPI_P $5-(G\>_#K2=.
MU+Q7I;_M/:>D=M;WT8DMV69M*$<A92"0K$KWQ7Z6U^=/[&__ "L>_MC_ /9,
M? G_ *0QT >BW_\ P43_ &L/"?[5_P"R-^S7\;OV6O#_ ,/M5_: E\?+XW\/
M-XM&NSZ -#T\7=D;6^MUAAE\]61WW1':'V##*6/V-I/B#0=?69]"UNTO1;S&
M*<VERL@CD'5&VDX8>AYK\U/^"T'P,T7]I3_@K7^P#\$?$_B+5],TG7KGXGQZ
MU)H>I2V=Q<V,>AV,MS9^="RR1QW$,<EM(496\N=]K*<$9_C+]D3]GS_@F9_P
M6P_9)B_8>^'L'P\T7XV:1XV\.?$KPSH-Q*FGZQ!INDQWMC,\+.5$T<[9,F-S
M #)Y)(!^H&H:CI^D64FI:K?PVMM"NZ:XN)0B(/4L< #ZU&^N:)%HX\0R:Q:K
MIY@$POFN%$)C(!#[\[=I!!!SCFOR<^$'[ ?P _;H_P""\O[=4/[46@7'BGPA
MX7;X;R1^!+K49X]+O]0G\-XBO;J&)U%Q);QQ3)$'W*OVN1MNX*1P_P"V'/X#
M\?\ _!6"?]A'Q_\ L*?%+XS? K]G+X.^'[?P/\%/ACY#Z9#>7$2>5J.H17-]
M;_:4AMU2UA5FD52A) )8L ?L]INIZ;K5A%JFCZC!=VTR[H;FVF62.0>JLI((
M^E0ZIXD\.Z'<VUGK6O65G->2>79Q75TD;3OQ\J!B"QY' SUK\N?^"9?@WXI_
ML_\ _!1;Q3J'[.'_  3Q^,?P-_9S\5?"VXO?$G@CQW#;)IUIXMM;A6BN].B@
MO;E;?S[4M$\:[ S*"1\JX^4?V$'^#O[=_P"S_??MC?MV_P#!''X^?M+^/_BQ
MJ^JW5]\0]-MK&YTFQLEO9[>WT[1C+JT#V<%LD>S*1QN)1(-Q54- '] ->8?M
MI?M5_#_]B#]E7QU^U=\3P[Z/X)T"6_DM(G"R7L^1';VJ$\"2:=XH5)XW2#->
M!_\ !"NR_:P\-?L2W7PU_:S\#>.-"N?"/C_5])\ 1?$EXWUNX\*JT<NFO=O'
M)(KR)',T!(=@/L^ 2 ">$_X.*IYM1^ G[/GPWO\ )T#QI^U_X"T3Q;&WW)-.
M>>YF97'=?-@A/U H ^A[W]LBX_9>_P"">EG^V=_P45?1_!U_I7@ZVU?QUIV@
M6\IBLKR<+LTZW25V>6?S)8[< M\\O/RJ>/GG1/\ @I9_P5\\<_#V/]I#X??\
M$56F^'US:?VAINA:O\8K6U\6WVG%=ZW"Z?\ 966*9D.\6K.9#]T9)&>=_P"#
MG;[-_P ,K? L^+=O_"$C]JWP=_PL/S?]3_8^+WS//SQY6_RLY[[*_2>@#P7]
ME_\ ;_\ AK^V[^Q;<?M@_LE^&-1\42+I5_Y'@:]ECL-236;6-BVC7!D)2VN#
M*$CW,2@$B2 LC!C\S?&?_@J?_P %5_V2?AY=_M,_M:_\$AM*TKX6Z-LG\7R>
M#?C=9ZQK>@63.%:Y:W%M''=!-PW+&Z@#+%E4%AE?\$&C;G]K3]O8^! O_"$?
M\-.W?]CFV_X]O[3V2_VCY>/ESO\ (SCC&WMBL#_@MM\ _P#@JQKWP!^*_CW4
M?VC?"/B;]GC2HY]<\9?"+P]I(T+Q!J/A2T'VB[LEUAXKD!_+B9F*QH7160-\
MVU@#ZO\ VY_V[M?_ &;_ -BO1/V^?@KX:L/%_@.TN]$UOQE')!-]K?PA>-&+
MB^LE5E_TB&.>*XVR J8XY 0#@CZ-T#7M&\4Z%9>)_#FIPWNG:E:1W5A>VT@>
M.XAD4.DB,."K*00>X-?.'B+7?@/^T;_P1WU/7_AKX>_LWX;>,?V<KE]$TBZC
MVFQTBXT)O*MW7)P8X6"'DX*<$]:Q?^"$?BSQ/XU_X(]_L]:WXNED>\3X;V=F
MCRG+&WMBUO;_ /D&*/\ "@#ZPN[NUL+:2]OKF.&&)"\LTKA511U))X ]Z@T7
M7M"\26(U3P[K5I?VS$A;BRN5EC)'4;E)%?&__!9'Q?\ L6W.B_"WX"_M0?LK
M^)/CMXJ\:>++F7X7?!_PQ,RR:S?6EJS7%S<!KB"#[-;PS;G:=F1/,5]AV[E^
M,?V8='\:?L:_\%N/V??!OPZ_X)LZM^RKX8^.&@>+])\7^$(_B7I>LZ7XI_LS
M2_M]M>)9Z=<RI9W%O(J*TC!2Z7&U<XEW '[-ZAJ.GZ192ZGJM]#:VT*%IKBX
ME")&OJS'  ]S2V-_8ZI9QZCIMY%<6\R!X9X) Z2*>A##@CW%?E!\)OV$_@'^
MVY_P7R_;FM/VFO#\WBGPGX9MOAE,/ M[?2KI.HWTWAPB&\NH(V5;E[=(IUB6
M3<B_:Y&VE@I74_87O;3_ ()Q_M&_\%$?V:OV?-/N(_AQ\&?#>@>//AUX*N;R
M6XM](O+[P]=W]Y;P^8Q989)[>,A <*!@<DD@'ZA77B30[;4CH1UJS&HFV:>.
MP:Y7SF09^8)G<5XZXQ7SU_P2&_;3\>?\%#_^"=GPZ_;&^)WA72-$USQE%J;7
MVEZ")1:0&VU6\LT\OS7=^4MU8Y8_,QQ@8%?&_P#P3E_X)&?LK_M,_P#!-#PM
M^V-\95OM8^/_ ,4O#+^-M0^/,VMW"Z_I6MW(>>WN+:X60"W6U_=((E C80D.
MK!F!]D_X-A/^4&'P*_Z]_$/_ *D>J4 >C?\ !8K_ (*<ZK_P2E_9H\/?'_0O
MV=Y_B??>(OB%8>%+/PQ:^(CIDK2W5M=S)(DBVMR9&W6H01B/+&7.X8P>ST#_
M (*!_#/XB?\ !-:]_P""E/P@TK_A(/#\/PJU#QG9Z*U^('E>SLIIYM/DF".(
MI4EADMW8(^QT8[6Q@_./_!Q1_P DO_9:_P"SVO /\[ZO _B[_P :OO$7[77_
M  36U?\ T/X4?'7X)>.?B+^SVS_+!IVIC1[IM<T"+L IQ=11KA4B]6D- 'W7
MX;_:X_:I_:1_8'^$G[6_[(7[/^@77B/XBQ>'M6U7PEXC\0;H-)TB\VO>LESF
MW\Z6&)B4^5=Y'W.U?3I( R37XS_M%_\ *M_^QE_V-7PH_P#1\->J_P#!27]F
MKP7^UG_P7M_9U^"_Q/U+5!X3O?@CXHF\4:1I>IS69UNSCN$;[!-+"RR"WDD\
MHRHK#S$1HV^5V! /TXT;7]"\1VAO_#VM6E_ LAC:>RN5E0..JY4D9&>E)K?B
M+P_X:MEO?$>NV>GPO((TEO;I(E9ST4%B 2?2OS2^'/[,WP7_ ."</_!>WX;_
M  H_8U\&Q^!O!/QG^".NR>-?!6D7$HTRXOM,GCDMKY(&8K'.%8Q[EP-I;C+N
M6^8?A3XR\ _MV_M0_M!_M#?MM?\ !*_XV_M.W&B_&77/!7@-- L[&[\.^#]$
MTYTBCL8+>YU&W$=ZY/G3R>5DET96!9\@'[K*RLH92"",@CO6'\4/B3X,^#7P
MU\0_%WXC:S'IWA_PMHEUJVN:A+]VVM+:)III#_NHC'\*^'_^"#_A7]HOX5Z'
M\8_@OX[_ &?_ (E_#SX2Z-XVM[WX#Z!\598Y=2TS2+N!FN-,1TN)\V]M/&?+
M!D8A9QDDD@7?^#F;Q7XF\'?\$0?CEJ7A6:2*>YL-&L+F:,\K:W.N6%O.#ZAH
MI'0^SF@"T_\ P5'_ &GO G_!+?0?^"GGC[]CJ#7=+UB_7Q!K/@_P[KDEKJ/A
MWP-<3L;?4RLD4PO[J.S,-S-$IMTVR.0R",D^R_M5?\%)/V<OV8?V%I_V]V\1
M1>*/"M_HEK=^![;19LS>*;J\4&PLK7Y2QDG9E'W247>[+A&Q[)X3\$>#='^&
M6F?#?2]*M9_#]KH4.FV]C+"KP26:PB)8RC9#(8P!@\$<5^0W[!'[ WAS2O\
M@M=X_P#V+?%'Q*U?7O@K^R=<V_CSX)?#;4E5[/1M5\0Q17*DL26ECLF,_P!G
M#Y*/+Y@*DOO /K#QC^WY_P %B/"?A=_&X_X(F:'<:5;^'(-6OIV_:?T^"6UW
M6:7$\#PR:4'$D#-)"W&&:)BI92I/)_L8_P#!6W_@IO\ MP?"?P9^T/\ ";_@
MC7I'_"OO&4^;7Q%/^TMIZRPVJ73VT\YM9-,21BC12D(=I;;P>0:^XOVA?^2
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M7?[+O_!.KXQ_ ;]GSQI\.KK_ (3?P=XZM[6/2;;Q-;S*]KJ%A#!>W(@>6#=
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M:-I%U([W&D6>LM<82-O,D5;AH&EB60[ "JM7TA_P3"_8?_X=O_L,>!/V+?\
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MO%/BZSM;#3_#EM*&64:;IEHHAM&=7=68%N';&TLQ;[#HH ^,/VAO@?\ $O\
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M,*R"3:K,A0[6W%0* /ES]A[]D7_@W0^-7Q5\*?&;_@G>/AJWCCP3=QZKI#^
M/&MQ;ZI"J8S]JL3<"26%@=K">(@Y/(/->R?M7_\ !1SXJ^"_VHK7]A3]A[]F
M!?B[\5H_#2>(O%:ZGXJCT31/">ER2>7!+>W;12LTTK [+:-"Y7Y\A>OYU?M]
M>-?^"7_[7'[3O[/D?_!%/PWX:U7]HRR^-&D:I?>*?@[X5DL8=-\/QL_V^XU:
M>"&.%X<&//F;GVJZY",ROU_[=/P6^"G[.?\ P6I^)/Q^_;Y^-OQ@^%WPI^./
M@_P\?!?Q0^&_C?5=$TNTU;3;1;*;2=3GT_[CNJ>?$9L( S8;+/@ ^]?V*/\
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MF<B.-B%')(P*_#[X&?\ !9?_ ()F?MT?M76W[=W_  5#_:QTWPWHO@+6)?\
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M=3:K_P +E\!>&-3N'TV]\(0V_%]?VSR,D1202B&0[=\J<9=17??M2?#GPO\
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M/%\WJ0.] 'Z!4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !39H8KB)K>XB5XW4JZ.N0P/!!!ZBG44 4=#\,>&O#$,EOX:\/6
M.G1RMNE2QM$A#MZD(!DU8O\ 3[#5;.33M4L8;FWF7;-!<1!T<>A4\$?6IJ*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ+]@C5-
M3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7[?F@^)_VC_&MLMCI&CV?@W79-*^&^E2DB/1-+!LBH?#D3W(),C,X#,&DDF
M/;/^#CSPA\'O%_QH_9&MOVB_@KXC^('P]M?B#K\_C+PQX6T*]U&[NK0:;&%"
MPV6)C^],7W2/<XS7:_\ !&VW_P""%R_'+Q8/^"<GP3G^&OQ:T[PZ;+Q?X/\
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M$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@
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MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
MO[0W_)</%/\ V&9O_0J^^J^!?VAO^2X>*?\ L,S?^A5\UQ-_NT/7]#]8\)/^
M1QB/^O?_ +<CC:***^,/WP**** "BBB@ HHHH **** "BBB@ K[N_9<_Y(%X
M:_Z\G_\ 1KU\(U]W?LN?\D"\-?\ 7D__ *->OHN&O]\G_A_5'Y7XM?\ (BH?
M]?%_Z3([ZBBBOMC^?PHHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M[U6*.1+-@R,>1^]>OB"ONG]E^RLY?@)X:DDM(F8V;Y9HP2?WKU]%PU_OD_\
M#^J/ROQ:_P"1%0_Z^+_TF1VEMXH\/WDZVMKJL3R.<(BGDFK]1)8V4;!X[.)6
M'0K& 14M?;'\_A1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_
M *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\"_M#?\EP
M\4_]AF;_ -"K[ZKX%_:&_P"2X>*?^PS-_P"A5\UQ-_NT/7]#]8\)/^1QB/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:]>IPU_OD_\ #^J/C?%K_D14/^OB_P#29'?4445]L?S^%%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O@7]H;_ )+AXI_[#,W_ *%7WU7P+^T-_P EP\4_]AF;_P!"KYKB;_=H
M>OZ'ZQX2?\CC$?\ 7O\ ]N1QM%%%?&'[X%%%% !1110 4444 %%%% !1110
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M1J\WF.BX!.>PKYKB;_=H>OZ'ZQX2?\CC$?\ 7O\ ]N1R-%%%?&'[X%%%=O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0KXD_P"&P/VB_P#HHG_E(M/_ (U1_P -@?M%_P#11/\ RD6G_P :H_UEP/\
M++[E_F'_ !";B/\ Y^TO_ I__*S[;_L[3_\ GQA_[]"C^SM/_P"?&'_OT*^)
M/^&P/VB_^BB?^4BT_P#C5'_#8'[1?_11/_*1:?\ QJC_ %EP/\LON7^8?\0F
MXC_Y^TO_  *?_P K/MO^SM/_ .?&'_OT*/[.T_\ Y\8?^_0KXD_X; _:+_Z*
M)_Y2+3_XU1_PV!^T7_T43_RD6G_QJC_67 _RR^Y?YA_Q";B/_G[2_P# I_\
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MV7_T,U2J[XC_ .1AO_\ K]E_]#-4J_*)?$S^T*/\&/H@HHHI&@4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'YP>(_^1AO_ /K]E_\ 0S5*KOB/_D8;_P#Z_9?_ $,U2K\HE\3/
M[0H_P8^B"BBBD:!1110 4444 %%%% !1110 4444 ?HG\.O^2?:%_P!@:U_]
M%+6S6-\.O^2?:%_V!K7_ -%+6S7ZI1_A1]$?QIC/][J?XG^85_/U_P %$_\
MD^;XJ?\ 8Z7O_H=?T"U_/U_P43_Y/F^*G_8Z7O\ Z'7ZMX5_\C:O_@_]N1^5
M^)O_ "*Z'^/_ -M9XQ1117[D?BP4444 %%%% !1110 4444 %%%% !7[U_\
M!*[_ )1^?#+_ + LW_I5/7X*5^]?_!*[_E'Y\,O^P+-_Z53U^9>*?_(DH_\
M7Q?^DR/T?PS_ .1S6_Z]O_TJ)] T445^$'[:%%%% !1110 4444 %%%% !11
M10!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!^<'B/_ )&&_P#^OV7_ -#-4JN^(_\
MD8;_ /Z_9?\ T,U2K\HE\3/[0H_P8^B"BBBD:!1110 4444 %%%% !1110 4
M444 ?HG\.O\ DGVA?]@:U_\ 12ULUC?#K_DGVA?]@:U_]%+6S7ZI1_A1]$?Q
MIC/][J?XG^85_/U_P43_ .3YOBI_V.E[_P"AU_0+7\_7_!1/_D^;XJ?]CI>_
M^AU^K>%?_(VK_P"#_P!N1^5^)O\ R*Z'^/\ ]M9XQ1117[D?BP4444 %%%%
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M.FZDN56^;2_,Z\3B:>%I>TFFU_=C*3^Z*;_"RZG*T5VWQ)^$NF^%/#.G>/\
MP9XP37- U.=X(KHVK02PSJ,F.2-B<' )!!YQVXSQ-.K2G1GRSW^_\43A,9A\
M=1]K1=U=K5---.S332::>Z:/T3^'7_)/M"_[ UK_ .BEK9K&^'7_ "3[0O\
ML#6O_HI:V:_4*/\ "CZ(_CW&?[W4_P 3_,*_GZ_X*)_\GS?%3_L=+W_T.OZ!
M:_GZ_P""B?\ R?-\5/\ L=+W_P!#K]6\*_\ D;5_\'_MR/ROQ-_Y%=#_ !_^
MVL\8HHHK]R/Q8**** "BBB@ HHHH **** "BBB@ K]Z_^"5W_*/SX9?]@6;_
M -*IZ_!2OWK_ ."5W_*/SX9?]@6;_P!*IZ_,O%/_ )$E'_KXO_29'Z/X9_\
M(YK?]>W_ .E1/H&BBBOP@_;0HHHH **** "BBB@ HHHH **** /"_P#@GO\
M\D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /S@\1_\C#?_ /7[+_Z&:I5=\1_\C#?_ /7[+_Z&:I5^42^)
MG]H4?X,?1!7=_"3Q]X.T3PUXB^'GCV&_CTSQ'';;[_2PIFMI(7+K\K$!T)/(
MZ\<=>.$KH?!7BKPEH-M=6'B[X>6VN0W#(T;F]DMIX"N?N2)G@YY!!' K;#S=
M.JG=+??5:JVMM==CCS3#QQ."<'"4M8M*+2E>,E)-.32O%I/5V=K:['>?'?X3
M6=Q<Z_\ $CP5XUM]5M["[A76[ V[PSV)D"JA(;(D4G^(>OL<13WO@/XQ?"_P
MUH6H^/K+P]K7AF"6TDCU6.3R+J!F#*Z.BMA@!@J1DG/;%1_&GXNZ2TVO>!?
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M*** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\
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M;0!DG  XKI-0\.>'M6OK?4]5T&RN;FS;=:7%Q:H[P'.<HQ&5.0.GI0!^6O\
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MT$<:!54850, #TI: "BBB@ HHHH _.#Q'_R,-_\ ]?LO_H9JE5WQ'_R,-_\
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MZ_,O%/\ Y$E'_KXO_29'Z/X9_P#(YK?]>W_Z5$^@:***_"#]M"BBB@ HHHH
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M !1110 4444 %?O7_P $KO\ E'Y\,O\ L"S?^E4]?@I7[U_\$KO^4?GPR_[
MLW_I5/7YEXI_\B2C_P!?%_Z3(_1_#/\ Y'-;_KV__2HGT#1117X0?MH4444
M%%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/
M5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?[_R$O\ A1_Q![B;_G]1_P# I_\ RL/^)CN!_P#H'Q/_ (!2_P#EQV%%<?\
M\)3KW_/]_P"0E_PH_P"$IU[_ )_O_(2_X4?\0>XF_P"?U'_P*?\ \K#_ (F.
MX'_Z!\3_ . 4O_EQ^H?PZ_Y)]H7_ &!K7_T4M;-87PND>7X9^'99#EFT*T+'
MU/DI6[3]G*C^[ENM/N/RVK6CB*DJL=I-M?/4*_GZ_P""B?\ R?-\5/\ L=+W
M_P!#K^@6OY^O^"B?_)\WQ4_['2]_]#K]2\*_^1M7_P '_MR/S'Q-_P"170_Q
M_P#MK/&****_<C\6"BBB@ HHHH **** "BBB@ HHHH *_>O_ ()7?\H_/AE_
MV!9O_2J>OP4K]Z_^"5W_ "C\^&7_ &!9O_2J>OS+Q3_Y$E'_ *^+_P!)D?H_
MAG_R.:W_ %[?_I43Z!HHHK\(/VT**** "BBB@ HHHH **** "BBB@#PO_@GO
M_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "BBB@#XY_
MX*#?\%F_V6OV(_%ME\&K?QW%KWQ$C\5^&;?Q'X1T;PWJ>KSZ5I%_JEI!<SS_
M &"%Q!<?9)I)((9&$DTGE!(Y-ZJWOW[,'[7'[/O[9/POE^,?[.WCM];T"WU*
M?3KRYN]'N].EM;N$*TL$L%Y%%-$ZAU)#(/O"OS-_;V_94_;W_84^,OQ!^//[
M/'@+P-\5_AQ\:/VD_ASXOGT'4?$#Z/XFL?$%OXBTH6VF)<2QO;26EQ<QQ0K(
MY'V<3EBN$8O](+_P4/C_ &Y/^";O[4A\)?"#Q-\-?BQ\-? OB?1/&?P_\1>6
MU]H^LC1IY+=HYH24N8GPICF7&[8?E VD@&1X;_X*S?MM_M<:IK?C?_@F'_P3
MAL_B9\*="UFYTRS^)7C/XH6_AV'Q5<6\ABG.EP/!*SP*ZLJW+D(Q!&%966OI
M_P")/[1?QQ^''['5K^T*/V._$^O^/Y-%TRXO?@WX;UBUNM0M[ZZ>".>S%WE8
M)!;M*Y>8?*4A9E'05^8?_!)G]BK_ (*#_&G_ ((^_#KX\_"C_@IEXM^&.L6/
M@VX/PK\!>$="TT>&[2*UFG2/^TXYX));^6ZFC>:61I $-P0$(0*?T)_X(_\
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M4UI,T<5S+.S3E\E%#SLR@8"U[W10!^:_[/?_  1C_P""EW[/7[3'C?\ :?\
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MG*[CHOCA*V[VL?I!_P )U_U"_P#R/_\ 8T?\)U_U"_\ R/\ _8U^;]%?9_\
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MJ#QA]A_:!\66G]G;O+U9QN\[&>![5P7_  G7_4+_ /(__P!C7SS_ ,%9M?\
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MWT?0YGXJ?!K3/"'A32_B7X#\8CQ!X9U>=[:*^:S-O-;7*#+031DG:V,D$'D
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M_P!?%_Z3(_1_#/\ Y'-;_KV__2HGT#1117X0?MH4444 %%%% !1110 4444
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M +:SQBBBBOW(_%@HHHH **** "BBB@ HHHH **** "OWK_X)7?\ */SX9?\
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MVNG9/HVM4TTT]GW.3&8.>#E'WE*,ES1DKV:NUU2>C33NMT%%?7_Q(T/]E?\
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M% !1110 4444 %%%% !1110!_1Q^S?\ \F[^ O\ L2]+_P#22*NTKB_V;_\
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M9"<[5'7!P,BO,/!O[./Q$\2_&N+X%ZK9QZ5JZL&OQ<2HXMHO+$I?Y&(<[&!
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M>D__ &T_7O"[^%BO6'_MP4445^0GZL?S6?$?_DH>O?\ 8:NO_1S5C5L_$?\
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M@/C)\9OB8OQA^*/CZ]UKQ$DD3PZA>!"(?+;<BQQA1'&BMDA%4+DGCDU['/\
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M(*_GZ_X*)_\ )\WQ4_['2]_]#K^@6OY^O^"B?_)\WQ4_['2]_P#0Z_2O"O\
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M%&^*?_A;'_XU1_PY"_9-_P"BC?%/_P +8_\ QJK_ .(L_P#4'_Y4_P#N9/\
MQ"W_ *B__*?_ -N?BS17ZL?';_@DU^SE\/?B1\-/"VA^/?B,]MXJ\3O8:DUU
MXO9W2(0EP8R(QM;(ZD&O3O\ AR%^R;_T4;XI_P#A;'_XU1_Q%G_J#_\ *G_W
M,/\ B%O_ %%_^4__ +<_%VTO+S3[A;NPNI()4.4EAD*LOT(Y%)<W-S>3O=7=
MP\LLC;GDD<LS'U)/6OVC_P"'(7[)O_11OBG_ .%L?_C5'_#D+]DW_HHWQ3_\
M+8__ !JE_P 185[_ %+_ ,J?_<Q_\0N=K?7/_*?_ -N?BS17[3?\.0OV3?\
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M2-<O?B)\4%FO=,MYY5B\:$*&>-6.!Y7 R:/^(L_]0?\ Y4_^YA_Q"W_J+_\
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MM-?$FT^#WPG_ &P=$/BC4)4BT[0O$VD:AH-S>2.<)'"FJ6]N9G8\*B99NP-
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MS=VFI7WB#PI=()[?3(M2NY[DZ8RON5@D<X21#E=[2#+#D_&N@>$?^"UFL_\
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M/\+:781"7Q!J-SO*:?:VR@":XN)"WRXQR[N0JNP]OK\==?\ !/\ P6?\9?\
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M !:B^"^O>*;[Q1H%MXTTO1'VWUE:6\ $NH31@Y*RGY%?'EX.-RD\O^T[I_\
MP6]_X*=?"75OV1+G]CCPE^R[X&\9V[:9X]\<>)?BG9^*-7DTB0[;FWL;33%\
MI9)8]T9\V3:4D<;D)#  ^D_^".WQP\>_M'_\$N_@;\9OBCJ4]]XAUCX>V0UC
M4;IBTM[/"IMVN9">KR^5YC'N7)KH_CG^Q=:_&K]MCX$?MD2_$233I?@A:^*X
M8O#RZ6)5UC^V[&WM23/YJ^1Y/V?>/D??OQ\N,GT#]GKX&^ _V9/@5X/_ &=_
MA=9R0>'?!/ANST71DG<-(;>VA6)6D8 ;I&"[F;'S,Q/>NQH X/XP?%']G_\
M9"^$_BW]H3XK:QH?@WPQI<4FK^*]<D@2%9'PJ^8^P;IYWPD:@!I)&*(H)(%?
M _\ P2(\(_%;X1_LF_M3?\%%[GX8W'@/3OC7XNU_XC?#7X?WML(I=/TN.SE>
MTNIX1\L4UT0)60#!41L"0P X?_@H3\*O^"M7[1O_  4<M_$_Q!_X)<7'QG_9
MU^%]]'=?#'P#8_&GP]H>G:_JRHI&LZK%=RO+=;&:18K:2.-$ &0P:7S?O']D
MGXM_M8_M-^"_%FA_MM_\$^Y?@E"(X[+3]*NOB;IGB4:Y;3QR+.=VGX%N$ 5<
M/RWF9'W30!\^_P#!OG\"/AKK'_!#KX=>%?%?AZVUBW^)VAZSJ7CYK]!(VN3Z
MC>72W#7+'F5C$4A);)VQJ.U1_P#!L=XO\2>(/^"17@WPGXDU>:__ .$+\4>(
M?#FG7MPVYY+.VU.?R!GT1'$:CH%C4=J\M_9HT#_@L+_P2Y_9EUC_ ()M?!']
MA _%NV\/WVJ6WP1^,EKX^TRRTV'3KRXFG@?5K:Y=9XY;5YV9D12L@41H<*)&
M^S_^"5W[#Z?\$Z?V#/A]^R5=>((M7U7P[ITT_B35X-VR\U2ZN)+J[="P#-&)
MIG1"P#%$3(!R* /H2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L+XD_"[X9_&7P?=?#SXO_#K0O%?A^^*&]T/Q)I$-]9W!1PZ%X9U9'VN
MJL,@X*@CD5NT4 0:5I6F:'IEMHFB:=!9V5G D%I:6L*QQ01(H5$1% "JH
M&   *GHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *'BGPKX7\<^&K
M_P &>-O#=AK&CZK:26NIZ3JMFEQ;7D#J5>*6*0%9$92058$$'!%0^!_ G@?X
M8^$['P#\-O!NE>'M"TN#R=,T70].BM+2TCR3LBAB54C7))PH YK5HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[6'Q7^,^A:3\.;;2H=2/BXW?G6D]M,%,#PM%N-QYN]/+6(,TA=0@8D5^=_\
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M ,DU^X_ZS93_ -//_!-;_P"0/Q?_ %;S7M#_ ,&TO_DS]1/V*/\ DS3X2?\
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M-I%U<:=;:%JEAN^R3I':21B0)O8^7+OC<L2ZL:]BH _.O_@CM_RDL_X*#_\
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M,7VJ61HD9R6\I"L:EB549.?1Z ,?X=_\+ _X5_H7_"V?[&_X2K^QK7_A)O\
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MFXN=)CN19S$L S(T1C8CYD.3GV#X3_L+?LG?!']F[4_V0OAU\&-/M_AKK/\
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MX$U+PEXQU31;K1; )&GV:*6QN(BT>V&,;7W?<'?FM_\ 8_\ ^">'[)/["O\
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MH'_!5K]N_P#:5_X)0_\ !*FQ\7^-OCEIWBSXY-?V&G6'BZ+X=S+I^LO_ &I
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M5TC2?!>JS6WA6\^"WAW1D^V+:NT%S]HLX_,S&ZAMARK=&!%?,_\ P3)\%?\
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MPKXXN/'7A:?2Q?>'-5\.7FKZ/+J]M#<3637D$/VNW9)0K^46(5QN !!/ZPT
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M /@DI<ZA<BT_9^URPT.^NFN;WP9I7Q*UZUT2>1CELV45XL04GGRU 3C&W'%
M'C/_  <00_"K]JKX6_L<Z#H?C./6?"/C;]LSPEI4FM^%M:V^=;3?;;:9[:Z@
M;*L,N%EC;*L RG@&OJ;]DK_@D9^RK^Q=\6U^-/P?\2?$NZUA=-FL1%XJ^)NI
MZM:>5+MW'R+F5DW?*,-C(YQUKO\ QM^P!^QY\0/!'PQ^&OB#X&Z;%X?^#7BS
M3?$WPST;2+JXTZVT+5+#=]DG2.TDC$@3>Q\N7?&Y8EU8U[%0!^=?_!';_E)9
M_P %!_\ LLVB_P#IOGIG_!JK-%;_ /!#SX77%Q*J1IJOB1G=VP% UN])))Z"
MOM+X._LG?L__  !^)?Q"^,'PD\ _V3XC^*FLP:MX]U'^U;N?^U+R&-HXY?+F
ME>.#",PVPJBG.2">:^6],_X-J_\ @BOI-G%I=I^QS<FRA<NFG7'Q0\3S6N22
M3F"34C&V22<%2#F@#RGX1^/_  G^W!_P<P:K\;?V>-:M_$'@GX$?L\'PEXM\
M7Z3*)[";7;O4IIEL(YTRDC+',Y."0KVTRGD5XO\ \$N?^"5_[,O[=/Q:_;&^
M)_QK\0?$2TU+2_VS_'&EVT?A#XC:CH]N8%GBE!>*UE1'DW3/\Y&X@*,X45^N
M7P"_9P^ G[*_PZMOA)^SA\(?#_@GPW:R&2+1_#FF1VL+2, &E<( 9)&P-TCD
MLV!DFOEWXC?\&[7_  1Y^+'Q*\2_%_QY^R7=7?B'Q?X@O-;\17\'Q+\2VPO+
M^ZF:>>;RH-12-"TCLVU%51G    H H_MJ?LA?"C]B;_@B/\ M*_!SX.:EXFN
MM(E^%/BK46E\6>)[K5KKSI=+=6 GN79PF(UPF< Y(ZFOA?6O^"1?[5'Q._X(
M@_#3XS_#C]NWXM_$6Q@^#7A;Q;>?LZ^+-<=?#?B#3HM-M;R308Q8&WN4C$8*
M0KYC$F.->&(D7]1O@M_P2G_8+_9Z_9N\<_LC?"/X'SZ9\/?B3#<Q>-- G\8:
MO>'44N+86LP^T7-W)/#NA 7]U(F.HPW->S_"7X6> _@9\*_#7P4^%FA?V7X8
M\'Z!9Z)X<TS[5+/]DL+6!(+>'S)F>23;'&B[G9F.,L2230!\"?M=_P#!3[X9
M6G_! W3/VF_V*M(CTZ[^*/A/3_ _P?\ "VE%%ETW6K\?V<NG0A<*);+9<X
M7-EQP17RE^T)^SU_P5.L/^"/7A;]A+P?_P $;;CPG<?!BPTGQ#X5^(]A\?=
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MZ*=(^)%WXE\6ZGJU[X@LC%/#Y$]S=W$DJIY=S.H$;(!YC$8/-<%X)_X(*_\
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20210930_g20.jpg
<TEXT>
begin 644 biib-20210930_g20.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
M'[,5\V_\%3/VXM:_8<_8!^*7[6/P@L_#WB3Q#\/K.SD31]3N&DM_-FO[>V9)
MQ ZNI"RN0-P.5';(K\U/#G[6?[2?@O\ X-CM/\.>&_C'K%OXHN/BG)\);'Q_
M-=L;_3M)?Q')9";S<@JZ68^SJX(*+M*D,H-=)_P78_X(T?L+?L<_\$<O'_Q.
M_9/^'+> O$G@[2])MK_7=-U6X$_BBRFU.SMY[75"SE;T.\B3@NI*SPQE-HR"
M ?L7X7U6;7?#.G:W<1JDEY80SNB=%+H&(&>W-?#/_!3+_@N?X/\ ^"97[9OP
MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_
M //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4 5K;Q1X?O)UM;758GD<X1%/)-7ZB2QLHV#QV<2L.A6
M, BI: "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5
MX7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **9<3Q6MN]U.^U(T+.V,X &2>*Y__A;7P^_Z&#_R4E_^(K"MBL-A
MVE5FHW[M+\P.CHKG/^%M?#[_ *&#_P E)?\ XBC_ (6U\/O^A@_\E)?_ (BL
M?[2R[_G]#_P)?Y@='17.?\+:^'W_ $,'_DI+_P#$4?\ "VOA]_T,'_DI+_\
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M_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM
M&Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]
M+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q
M7A?C_P#Y'34_^OQ_YUZY_P )+J__ $*%[_WTM>/>-)I+CQ7J$\MNT3/<L6C?
MJO/0U\GQ;_NE/_%^@&91117P8!1110 4444 %%%% !1110 4444 %>W_  S_
M .1%T[_KB?\ T(UXA7KG@'7=2M?!]C;P^&;J95B($J,N&^8]*^IX3_WZ?^']
M4!V%%9=GKVI7-TD$WAFZA5FPTKLN%]S6I7WX!1110 4444 %%%% !1110 44
M44 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 5/$'_(!OO^O.7_ - -
M?/U?0/B#_D WW_7G+_Z :^?J^'XN_BTO1_H 4445\> 5FZEX.\*ZQXETSQCJ
MGAZTN-5T:.=-)U"6 --:+.%681L>5#A%#8Z[16E133:V ****0!1110 4444
M %%%% $VG?\ (0@_Z[+_ #%?0U?/.G?\A"#_ *[+_,5]#5]MPC\%;UC^H!11
M17V0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%^/_P#D=-3_
M .OQ_P"=>Z5X7X__ .1TU/\ Z_'_ )U\GQ;_ +I3_P 7Z 8]%%%?!@%%%% !
M1110 4444 %%%% !1110 5[?\,_^1%T[_KB?_0C7B%>W_#/_ )$73O\ KB?_
M $(U]3PG_OT_\/ZH#=HHHK[\ HHHH **** "BBB@ HHHH **** /"_\ @GO_
M ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH J>(/^0#??\ 7G+_ .@&OGZOH'Q!_P @
M&^_Z\Y?_ $ U\_5\/Q=_%I>C_0 HHHKX\ HHHH **** "BBB@ HHHH ****
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M2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444
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M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!SNM6?C)=&NS/K-HR"VDWJML02-ISWKQ6OH'Q!_P @
M&^_Z\Y?_ $ U\_5\/Q=_%I>C_0 HHHKX\ HHHH **** "BBB@ HHHH ****
M);$,;V$(0#YJX)]<U[?]B\;_ /0;LO\ P&/^->(Z=_R$(/\ KLO\Q7T-7VW"
M/P5O6/Z@8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q17V0&/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?C_\ Y'34_P#K\?\
MG7NE>%^/_P#D=-3_ .OQ_P"=?)\6_P"Z4_\ %^@&/1117P8!117R]^W_ /\
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M*) \D+2RY\P[1"05R>/KZJKT*F'GR3WLGNGH]M4V@"O;_AG_ ,B+IW_7$_\
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M\Q+;5^8K0![;X$^/GP_^(OQ9\;_!?PY<SG6_A_<6,.O)*J!";NV6YB,9#$L
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M#'QVU?\ X*RVUE<?#[Q/J&K_  WLA\ M.D_L(7/R>4SB]07>V()'NE4YV[L
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M5M"=3L[9KJ73M1M+GF.1X$D:.2/"DJ%&\EC&WX^?LF_\%,_V7/VQO'O[8/\
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M=7X8_P"_DO\ \15*BC_6_P#Z<?\ DW_VH%W_ (>G_P#!/;_HZOPQ_P!_)?\
MXBC_ (>G_P#!/;_HZOPQ_P!_)?\ XBJ5%'^M_P#TX_\ )O\ [4"[_P /3_\
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M?_)#_P"V5Z-11_J]D_\ SZ_\FE_F!YS_ ,* _P"IM_\ )#_[91_PH#_J;?\
MR0_^V5Z-11_J]D__ #Z_\FE_F!YS_P * _ZFW_R0_P#ME'_"@/\ J;?_ "0_
M^V5Z-11_J]D__/K_ ,FE_F!YS_PH#_J;?_)#_P"V5<T#X*_V'K5MK'_"2^;]
MFF#^7]CV[L=L[SBNZHJH9#E-.:G&GJM=Y?Y@%%%%>P 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!\\ZC_ ,A"?_KLW\S4-3:C_P A"?\
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
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M7B'[5_9S:_\ #/4M/M!Y%K+=2>9<3Q+''^[A?&XC<VU1R10!]?T444 >%_\
M!/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?/.H_\A"?_ *[-_,U#4VH_\A"?_KLW\S4-?C,_
MC8!1114@%%%% !1110 4444 %%%% !1110!] ^'_ /D V/\ UYQ?^@"K=5/#
M_P#R ;'_ *\XO_0!5NOV.C_!CZ( HHHK4 HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\Z_:P\=?M$_#7X!Z[XT_91^!5G\2_'MF
M;7^P_!>H>)8=(BU /=1).6NYODB\N!I91G[QC"CEA7HM>9?M9^$?VJ?%WPH\
MO]C;XN^'/"'CC3]2AO;*7QAX?;4=*U6)%</I]VL;++#%*67,T)\U"@*A@2I
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MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
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MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%4+;Q1X?O)UM;758GD<X1%/)-7Z "BBB@ HHHH **** "BBB@
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M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@
M#YYU  7\X _Y;-_,U#4VH_\ (0G_ .NS?S-0U^,S^-@%%%%2 4444 %%%% !
M1110 4444 %%%% 'O>@6%BVA63-90DFTCR3&/[HJW_9VG_\ /C#_ -^A47A_
M_D V/_7G%_Z *MU^QT?X,?1 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%345J!#
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!$EC
M91L'CLXE8="L8!%2T44 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_
M &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!\\ZC_R$)_^NS?S-0U-J/\ R$)_^NS?S-0U^,S^-@%%%%2
M4444 %%%% !1110 4444 %%%% 'T#X?_ .0#8_\ 7G%_Z *MU4\/_P#(!L?^
MO.+_ - %6Z_8Z/\ !CZ( HHHK4 HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[
MI7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7\.+BR77=,U6V6(SVUW#YUM>VY5F$UNX#KOX*O&ZLJD#/H=9RA*#M)6_X.J
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M@#+L]>U*YND@F\,W4*LV&E=EPON:U*** "BBB@ HHHH **** "BBB@ HHHH
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M)I]SKR:?$+V6T1VD2W:<+O:)79F"$[0S$@9)KUO_ (4!_P!3;_Y(?_;*/^%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_
M &/>L_\ I2:]TKR3XE?L6_"#XH>*I?%NJZAXBTV:6-4>VT+7'L[?C^+RT&-Q
MSDGJ3S6!_P .ZO@?_P!#=X[_ /"OGH ]ZHKP7_AW5\#_ /H;O'?_ (5\]'_#
MNKX'_P#0W>.__"OGH ]ZHKP7_AW5\#_^AN\=_P#A7ST?\.ZO@?\ ]#=X[_\
M"OGH ]ZHKP7_ (=U? __ *&[QW_X5\]'_#NKX'_]#=X[_P#"OGH ]ZHKXR^/
MO[''PS\"?$SX8>&]#\5>+S;>)O%4EEJ1N?$TSN(A 7'ED_<;(ZBO4_\ AW5\
M#_\ H;O'?_A7ST >]45X+_P[J^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^%?/0
M![U17@O_  [J^!__ $-WCO\ \*^>C_AW5\#_ /H;O'?_ (5\] 'O5%>"_P##
MNKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\] 'O5%>"_\.ZO@?\ ]#=X[_\
M"OGH_P"'=7P/_P"AN\=_^%?/0![U17@O_#NKX'_]#=X[_P#"OGH_X=U? _\
MZ&[QW_X5\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\ A7ST
M >]45X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7ST >]45X+_P[J^!
M_P#T-WCO_P *^>N _:D_8E^%7PR_9\\5^/O#?BOQDU_I>E-/:B[\432QE@RC
MYE/WASTH ^N:*^</ W_!/[X,:WX)T?6;WQ;XX$UWI5O/*(_%LZKN>-6.!V&3
MTK5_X=U? _\ Z&[QW_X5\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\
M^AN\=_\ A7ST >]45X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7ST
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M['B>-,_$:+P*GC*3P[_9MSQHCWK62W7VCR_(YN$:/R_,\SC=LVX:OF7XF_\
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M-?Z?X7^*LNJ1> KP_#OQ!)/JCZ=.(+P?98[!KB'RY"!^^C3>#N3<O-+\ /\
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M>_OXI[G=$DK7,ID6%R1M?8&X#5\U_ME>%/\ @IQ_P69\*^&?V/?%G_!.R[^
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MMK6)I$1F8L65D1P7"F-OTOTW3;#1].M](TJSCM[6U@2&VMX4"I%&H"JJ@=
M  /:@#Q2']BZUB_X*3W'_!1'_A8DAFG^!T/PY_X1+^RQM58]8EU/[=]I\W.2
M9/*\KR^V[?SMIW[9?[4/[,'_  3G_98U[XP?%O3M.TWPW:K+!I_A;2["(2^(
M-1N=Y33[6V4 37%Q(6^7&.7=R%5V'M]?CKK_ ()_X+/^,O\ @I'K'[:?[37_
M  1TNOB[IW@C49[3]GWPO!\?O#&EZ-X4M1(1_:?V::65KG49E6-_M$@0QGA4
M4I%Y0!]9?\$&?V./B=^RE_P3'T'X3?M%^#;?2=6\5:KJWB'4/ D\8D@T"UU*
M=I8]*9&&/DB8>9&1\KR2(0<$GSCQGX;\.^$?^#F_X3^'_"F@66EV%O\ LBZJ
MMO8Z=:I!#$/[:EX5$ 51]!7V'^S!\9/VI?BO\#;_ ,??M'_L:3?"?QG;WEU'
M8^ )?B!I^N-=Q1QJT,OVVS'DQ^:Y9-K<ILR>"*_-_P 6:A_P6Y\3?\%3?"O_
M  4B7_@A]>0P>&OA!=^"&\(']H[PJSW#37SW7VO[3Y@"@;MOE^6<XSN'2@#]
M?**Q/AKKOC#Q3\.= \3?$/P(WA;7]1T2UNM<\,/J<5Z=(O)(5>:S-Q#^[G,4
MA:/S4^5]FY>"*VZ "BBB@ HHHH *_(+_ (*%1?M:?\$>/VJ]6O?^"=NC:3=^
M&_VU=>C\/Z+X:U*^6"V\&?$NZ>.%-:A5E*^3<0O)+)'@J9H 7(18T/Z^U\7_
M /!6W]DW]H#]ISXJ_LF^)?@?X _MNR^&?[3&A>*_&\W]JVEM_9ND6^[SKG%Q
M*AFVY'[N(/(>RF@#V+_@GC^P[\//^">O[+&@?LY>!+Z75+NV,FH>+O%%YDW7
MB+6[@A[S49V8EF>23IN+%8UC3)" U\K_ +$?_*Q?^VY_V(GP]_\ 34E?HM7Q
M?^RU^R;^T!\.?^"T?[4O[6?C/P!]C^'WQ&\)^#;+P9K_ /:MI)_:,]CIZPW2
M>1'*T\.QP1F6- W52PYH \[_ ."KG_*8K_@G7_V.?CO_ --%G7M'_!:?]DWX
M)_M7_P#!-[XMZ1\6O"&G75]X9^'^KZ]X4UV>V7[5HFI6=G)<P7,$V-\7SQ*'
M"D;XRZ'AC7EG_!8'X"?MI^*?VR?V3/VM/V0_V59_BU%\%]>\4WWBC0+;QII>
MB/MOK*TMX )=0FC!R5E/R*^/+P<;E)Y?]IW3_P#@M[_P4Z^$NK?LB7/[''A+
M]EWP-XSMVTSQ[XX\2_%.S\4:O)I$AVW-O8VFF+Y2R2Q[HSYLFTI(XW(2& !]
M)_\ !';XX>/?VC_^"7?P-^,WQ1U*>^\0ZQ\/;(:QJ-TQ:6]GA4V[7,A/5Y?*
M\QCW+DUT?QS_ &+K7XU?ML? C]LB7XB2:=+\$+7Q7#%X>72Q*NL?VW8V]J29
M_-7R/)^S[Q\C[]^/EQD^@?L]? WP'^S)\"O!_P"SO\+K.2#P[X)\-V>BZ,D[
MAI#;VT*Q*TC #=(P7<S8^9F)[UV- '!_&#XH_L__ +(7PG\6_M"?%;6-#\&^
M&-+BDU?Q7KDD"0K(^%7S'V#=/.^$C4 -)(Q1%!) KX'_ ."1'A'XK?"/]DW]
MJ;_@HO<_#&X\!Z=\:_%VO_$;X:_#^]MA%+I^EQV<KVEU/"/EBFNB!*R 8*B-
M@2& '#_\%"?A5_P5J_:-_P""CEOXG^(/_!+BX^,_[.OPOOH[KX8^ ;'XT^'M
M#T[7]65%(UG58KN5Y;K8S2+%;21QH@ R&#2^;]X_LD_%O]K']IOP7XLT/]MO
M_@GW+\$H1''9:?I5U\3=,\2C7+:>.19SNT_ MP@"KA^6\S(^Z: /GW_@WS^!
M'PUUC_@AU\.O"OBOP];:Q;_$[0]9U+Q\U^@D;7)]1O+I;AKECS*QB*0DMD[8
MU':H_P#@V.\7^)/$'_!(KP;X3\2:O-?_ /"%^*/$/AS3KVX;<\EG;:G/Y SZ
M(CB-1T"QJ.U>6_LT:!_P6%_X)<_LRZQ_P3:^"/["!^+=MX?OM4MO@C\9+7Q]
MIEEIL.G7EQ-/ ^K6URZSQRVKSLS(BE9 HC0X42-]G_\ !*[]A]/^"=/[!GP^
M_9*NO$$6KZKX=TZ:?Q)J\&[9>:I=7$EU=NA8!FC$TSHA8!BB)D Y% 'T)111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%\2?A=\,_C+X/N
MOAY\7_AUH7BOP_?%#>Z'XDTB&^L[@HX="\,ZLC[756&0<%01R*W:* (-*TK3
M-#TRVT31-.@L[*S@2"TM+6%8XH(D4*B(B@!54   #   %3T44 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %#Q3X5\+^.?#5_P"#/&WANPUC1]5M)+74
M])U6S2XMKR!U*O%+%("LB,I(*L""#@BH? _@3P/\,?"=CX!^&W@W2O#VA:7!
MY.F:+H>G16EI:1Y)V10Q*J1KDDX4 <UJT4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20210930_g21.jpg
<TEXT>
begin 644 biib-20210930_g21.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
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M;\8Z+\28=<;0-7N@3:6.KPK;Q>09<%?.1BB,I##&2OR+^V%^W5XQ_P""A_\
MP2#_ &(OVL/B9X,CT]?$/[67@]/B&EHNVSF^Q7FJ65RZJQ.R*2>W60*2=N]5
MR<9KZ1_X.B=;O[W_ () ^+K>V\.7-OK3>,O#'_",2EEWC4/[7MMGEXYW[/-Q
MCMF@#])*^3OVF/VM?^"E^@?'?5_@_P#L<?\ !,JW\;:%H<-L]S\1_&OQ/MM!
MTV]EE@29H+2 PRSS[=_EM*,(KHRGI7TPOB76-HW>$+S..<,O^->-_MR?\%"O
MA-^P'\$Y?C%\9M"U.::ZNTT[PIX7TM5FU/Q+JLO$&GV4"Y:6:1L#@$*,LV #
M0!S?_!.'_@I'+^W#J?Q&^#GQ6^ >J_"CXO\ P?UFVTWXD?#S5-5BU!;,W,;R
M6MU;7<2JES;S)&[*X5>F>59'?ZAKX;_X)-?LM?M%_"K7OBQ^W=^V/X--K\9O
MVBM<L=5\3>'=-E5[;POI=E T&F:0KY_>2PP.5DD_B(5>=F]OLS_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBLNSU[4KFZ2";PS=0JS8:5V7"^YK4H **** "BBB@ HHHH
M **** "OBS_@JS^QO\?_ (C_ !;^!?[?W['?@S2_%/Q0_9\\2W]S;^"-5U9-
M/3Q1HVHVPMK^RCNI/W<%R$4&)Y,(I:0GG /VG10!^<+?"?\ ;P_X*;?M^? S
MX]_M#_L=W?P&^%G[/VI7WB&"R\3>++#4M9\4:Y/ L4,<<=B\BV]M 5#EW(,@
M+ #)^31^(WP7_;7_ .">?_!27XI?MJ?LF_LKW/QL^&_Q_P!&TA_'7@_0/$]E
MINK^'M?TV%K>&\A6]=(Y[>:)VWA6W^8Y8X6-0_Z&T4 ?$/\ P3)_8T_:"B^+
M?Q\_;U_;O\ :;X<\??M"W]A:#X=6>KQZBGACPWI]JUK:6,MS%^[EGD1BTQCR
MA*(P(+,J^&?LQ>'/^"O7_!*C]G/6_P#@G'\"_P!@T_&#3=!U358_@;\7+7Q]
MIEEI\&G7MS+<0_VO;W4BSI):R3NSJ@*R "-" H=OU1HH ^=O^"4O[#LG_!.G
M]@WP'^RIJOB.'6=<T6TGO/%.LP%BE[JMW<275TZ%@&9%DE,:,P#%(T) )(KZ
M)HHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW
M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KYZ_;*_9F_:O^*VOP_$?]EW]O#7/A;<6?AZ:P
MU/PS/X)L?$&C:LNZ2196MK@QRQ3_ #E/,BF4E0H(.*^A:* /SY_X) ?\$SO&
M?@+P7\$OVTOVL?CKXD\:>/- ^ 6B^&_ 7A/5/#4&BV7@#39]/M6FL1;1YDFO
M%"B"2YG8.P1@47@)W'Q?_8__ ."Q&I?$;Q3?_ +_ (*XZ!H'A'Q#K%U=Z-H_
MB/X$V.I7OA>WFE+BVM[G[2GVI8P2$,ZYP .@&/LZB@#YW_X)W?\ !.7X:_\
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M;.#X/:?X7_LF1&<RR%[2>4W'F!D&UL!?+R,[C7T!110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]
M9_\ 2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !5#Q1>W.G>&[^_LY-DT-G(\3X!VL%)!P>#5
M^LSQK_R)^J?]@^;_ - -8XEN.'FUO9_D!Y3_ ,+:^(/_ $,'_DI%_P#$4?\
M"VOB#_T,'_DI%_\ $5SE%?E7]I9C_P _I_\ @3_S Z/_ (6U\0?^A@_\E(O_
M (BC_A;7Q!_Z&#_R4B_^(KG**/[2S'_G]/\ \"?^8'1_\+:^(/\ T,'_ )*1
M?_$4?\+:^(/_ $,'_DI%_P#$5SE%']I9C_S^G_X$_P#,#H_^%M?$'_H8/_)2
M+_XBC_A;7Q!_Z&#_ ,E(O_B*YRBC^TLQ_P"?T_\ P)_Y@='_ ,+:^(/_ $,'
M_DI%_P#$4?\ "VOB#_T,'_DI%_\ $5SE%']I9C_S^G_X$_\ ,#H_^%M?$'_H
M8/\ R4B_^(H_X6U\0?\ H8/_ "4B_P#B*YRBC^TLQ_Y_3_\  G_F![A\.=8U
M'7O"%KJFJW'FSR-)ODV!<X=@.  .@%;E<U\(O^1 LO\ >E_]&-72U^GY?*4\
M!2E)W;C&[^2 ****[ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_[
M'O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\:_\B?J
MG_8/F_\ 0#6G69XU_P"1/U3_ +!\W_H!K#%?[M/T?Y >#4445^/ %%%% !11
M10 4444 %%%% !1110![/\(O^1 LO]Z7_P!&-72US7PB_P"1 LO]Z7_T8U=+
M7ZUEG_(NH_X(_D@"BBBNX HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HKQ+]GW_@HQ^Q=^U5\>/'?[-'[/OQQM?$_
MC3X:3-%XUTNRTJ]2/3W68P,HN9(5MYR)59#Y,CX*G/2N(_:;_P""T7_!-K]C
MSXV:A^SI^T)\?[_1O&>E6-M>:AHMC\/M?U,P07";X7,MC8S1?,O. ^1T(!H
M^I**\N_9)_;-_9R_;G^&=U\8/V8?'%YX@\/6>LRZ5<7M[X:U'2G6[CBBE=/)
MU"W@E("31G>$*'<0&)5@/%OC?_P70_X)E_L^?%O7/@S\0_CW>/J7A2^2S\9:
MCH7@[5-3TSP[<.VT0WU[:6TD$#AOE92^4((?:00 #ZZHJAX6\4^&O''AG3O&
MG@S7[/5='U>QBO-*U33KE9K>\MY4#QS1R(2KHRL&# D$$$5?H **** /"_\
M@GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *%"]_[Z6L[Q9X@U2?POJ,,GA:[B5[*4-(S+A05/)KJ:S/&O_(GZI_V#YO\
MT UABO\ =I^C_(#P:BBBOQX HHHH **** "BBB@ HHHH **** /5?AEK>HV?
M@NTM[?PY<W"*TF)8V7#?O&]:W_\ A)=7_P"A0O?^^EJE\(O^1 LO]Z7_ -&-
M72U^M99_R+J/^"/Y(#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HKN Q_
M^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M:V** ,?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EK8HH R[/7M2N;I()O#-
MU"K-AI79<+[FM2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "LSQK_R)^J?]@^;_P! -:=9GC7_ )$_5/\
ML'S?^@&L,5_NT_1_D!X-1117X\ 4444 %%%% !1110 4444 %%%% 'L_PB_Y
M$"R_WI?_ $8U=+7-?"+_ )$"R_WI?_1C5TM?K66?\BZC_@C^2 ****[@"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X*_:"_:_\
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M?,0/D^E 'DO[&G_!5G]AS]O+Q?J_PS_9\^+<\OC#0+476L>"_$GA^]T?5K:
ME1YWV:]BC>2,%T!>/<JEU#$%AFU^V)_P4]_8S_86\4:)\/?C[\2KU?%?B.V>
MZT7P?X8\.7VLZM<VR$A[C[+8Q2R1P@JX\QPJDHP4DJ0/AGX"?&?Q-^V?_P %
M]_ /Q0_:A^ ^H?LX^+?AS\*-7M? ?@#Q>KS:S\0H[I9!<3K=Q1"S>VM$>1A
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M\<>)/#6E7=P^YWLK;4IFA&>X59=B]@J*!P!7Z"4 %%%% 'A?_!/?_DB>K?\
M8]ZS_P"E)KW2OGK]@O6+^P^#FK06V@7%RO\ PG&LGS(B,9^TMQS7MO\ PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
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MB@ HHHH **** "BBB@ HHHH ]G^$7_(@67^]+_Z,:NEKFOA%_P B!9?[TO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA\:]-U>;3MEK-)!MM(?GE\R=883C[HE+'A37$:G_ ,%1?^"I7P'<^&?VF?\
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M"2*^B: "BBB@#YZ_8+UB_L/@YJT%MH%Q<K_PG&LGS(B,9^TMQS7MO_"2ZO\
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M7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**[@,?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M:V** ,?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EK8HH Q_^$EU?_H4+W_O
MI:/^$EU?_H4+W_OI:V** ,NSU[4KFZ2";PS=0JS8:5V7"^YK4HHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[U
MG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/&O_(GZI_V
M#YO_ $ UIUF>-?\ D3]4_P"P?-_Z :PQ7^[3]'^0'@U%%%?CP!1110 4444
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M8,V6WR^VS?YF,=\U^AU[>V>FV<VHZC=Q6]O;Q-)///($2-%&69F/   ))/
MH ^"]&_X*Q?M@?L__M!?#;X-?\%-?^"?UG\+]!^+WB6'PWX*^(/@[XC0^(-/
M@UR?/V?3KV,01/ TG1902I.2 561D^^:_,RYUO6/^"[?[;/@/Q9\-+22#]E+
M]F[XBQ^)(/&DL97_ (63XSL=Z6ZZ?D?-IUHS2![C[LS.Z+N!#)^F= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_
M^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%4M=\2>'?"]I%?^)M>LM.@GO;>S
M@FOKI(4DN)Y5A@A4N0#))*Z1H@Y9W50"2!5V@ HJA'XI\,RZX_AB+Q'8-J4:
M;WTY;Q#.JXSDQYW 8[XJ_0 4444 %%%% !1110 5F>-?^1/U3_L'S?\ H!K3
MK,\:_P#(GZI_V#YO_0#6&*_W:?H_R \&HHHK\> **** "BBB@ HHHH ****
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M?^8'1_\ "VOB#_T,'_DI%_\ $4?\+:^(/_0P?^2D7_Q%<Y11_:68_P#/Z?\
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M%U\4_P#P.M*/^'@G[3W_ $BZ^*?_ ('6E 'U917RG_P\$_:>_P"D77Q3_P#
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M 6:*K?;]1_Z$?Q;_ .$9J7_QBC[?J/\ T(_BW_PC-2_^,4?V;F/_ #YG_P"
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M)ZM_V/>L_P#I2:]9\=^#O^$VTN+3?[1^S>5<"7?Y._.%(QC(]:\F_P"">_\
MR1/5O^Q[UG_TI->Z5E7H4L32=*HKQ>_](#SG_A0'_4V_^2'_ -LH_P"% ?\
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M\):WKG[7_P"P[-\"M1T^_2+2M*N?B3IGB/\ M*W,>YKCS; !(0K?+L?D]>E
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M: /8_"/@_P )?#_POI_@CP'X7T[1-%TFT2UTO2-(LH[:ULX$&U(HHHP$C10
M J@  <"M&O"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_ !H
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MIQ+!'?\ BF>:%FP1AT8X8<]#7K] !1110 4444 %%%% !1110 4444 %%%%
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M_LP>)_&GV7QSXYTK4=2\+:'_ &;<O]MM;$1FZD\Y(S#'L$L?RR.K-N^4-@X
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M;$;:JLQP%)$WPD^+7PW^/'PPT'XT?"'Q?::]X7\3Z5#J6A:S9,?*N[:5 Z.
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M?#WC/P[8>+_".NVFJ:5JME%>:9J6GW"S07=O(@>.6.1"5=&5@RL"00015V@
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MW2-<\8>%#H.KWFF6\^J:&UZER=.N7C5I;8S1_)+Y;EDWK\K;<C@UIT %%%%
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M9/*\KR^V[?SMKVO3=-L-'TZWTC2K..WM;6!(;:WA0*D4:@*JJ!T    ]JFH
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20210930_g3.jpg
<TEXT>
begin 644 biib-20210930_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@$
M&@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
M)P&^W/AW_P D_P!"_P"P-:_^BEK\V_V]/@5\./VG?^"^OPX_9Z^+VB+J/AGQ
ME^R1XJTG6;4X#&&:\="R$@[)%)#HXY5U5AR!0!]:?\%(OV^H/^"??P.\,?&J
MV^&">,X_$OQ&T/PK'9)KPL5B7493&+H2B";>$ W;-HWY^^O6NY\=^*?VJ=/_
M &H_ 7A3X?\ PQT"_P#A/J&CZK)\0?%%YJ&S4-+O8T4V$5O%YH\Q)7+ASL?:
M .5K\6OVE?CK\1](_P""=&D_\$R_VF];:Y^*W[,G[5'@7PW<WT^5?Q!X9>YD
M?1=60,<LLEJ%C/4CRD+G=)BOOG]KW_E8+_8]_P"R9_$+_P!)+>@#[TU/5=,T
M2PEU76=1@M+6%=TUS=3+''&,XRS,0!SZT^TN[2_M8[ZQN8YH9D#Q31.&5U(R
M""."".]?DQ^R]^P#^SK^VW_P6(_;GO/VJ?"LGC+PUX;\;>$O[+\#:C>S+I$E
M]+HGS7UQ;HZK<S)&GEQ&3<(Q+,0-SY%S]BGQQ>_\$W+#_@I)\#O@+#<R>"/V
M<XD\8?"WPMJ%W+=0Z3)>>&KC5)+*(R,S+;">!<)GC+'EF8D _5*Z\2>';'5X
M/#][KUE#?W2EK:QEND6:91GE4)W,.#T':KM?@5^RY\"?V=OC]^Q=HOQ$_:/_
M .",/[4?Q@^*?Q+\.0^(/$'[0=O'IT^H7FI7<8GBO],NGUB-[>&(O'Y"+'&-
MD2;X\EA7ZQ_\$A=6_:VU;_@G'\+E_;J\.:QI?Q4L-(N-.\4P>(,&^E^S7D]O
M;7$Y#-OEEM8K>5G))9I"Q))- 'G?_!9G_@K[JO\ P24\+?#_ ,1:/^R[<_%&
M3QOJ6IP2V-IXK_LN2P@L;474TX_T2X\[$6]MOR8"'DYX]_\ BO\ MD?!SX6?
ML5ZQ^W?-K*7W@C3?AZWB^SN8I AO[(VGVF!8R<_/,&C1!SEI%'-?'_\ P6ET
M'1O%/[>O[!OACQ'ID-[I^H_&76+6_L[A T<\,FEA'C8'JK*2"/0U\H> +OQ=
M\19/ W_!LQXK:^O)? /[0=V?'%Q=JS"^^%.DF+7M,,[=%^U?:;&S4#./L^#G
M.: /T0_X([_\%/M=_P""JGP%\9?&#Q1^S?-\+=3\&?$F]\'ZCX9N/$_]JR">
MUM;2>21I/LMML8-=&,Q[#@Q9W'=@?5(\2>'3K9\-#7K(ZD(_,.G_ &I//"==
MWEYW8]\5^//[*'[0GCW]E#_@FU_P4X_:!^%,OD>)/#'[67Q-GT&Z$8;[)=.M
MC%%<!2"#Y32"3!!!V<C&:ZK7/^"(G[%&D_\ !'Z?]H73]*OXOCG9?")OB$GQ
M^7Q%=_\ "0MXF33?[1-\;SS=WE-,"OEYP(SQ\X\R@#]::J:?X@T'5[NZL-)U
MNTNI[*3R[V&WN5=[=^?E< DH>#P<=*_&W]LSQMX]_P""A/['/_!,SQC\2_&6
MJZ'K_P 2_BOX?'BC7O#]P;.]\R72YH[N>VDCP;>24"5D=,&,R@K]T5Z/^V!^
MPU^R_P#\$P_VXOV._CM^PI\,(?ASJGB_XV0_#_QI;Z%?7'D>(='U"TF+I>))
M(PN'1X@ZR/EMY#,2R(5 /N?PK^V[X5\5?\%!/%?_  3\M_ ^H1:QX4^&]AXP
MN/$+W"&VG@NKIK=8%0?.'4KN)/&*Y;Q/^VYX\T'_ (*W>&_^"?,?A;1CX7UG
MX$WOCFYUR3S?MT5W#J@LQ"IW^7Y)0[CE=V[OCBOB?_AVC^P;\?O^#B?XU>!O
MC+^S!X9\0Z1=_ S2O%ES8:A [1R:U=ZK(MS?'#C][(.">GM6M^UO^Q;\&OV@
M_P#@O_\ "#]F3Q=87EK\.=(_9#NDU'P?I.HS6EMJVFVNLF*#3)VA=9&M0_D2
M-&& ?[.J/N1F4@'ZH:-KNB>(K(:EX?UFTO[8N5%Q9W"RH6'!&Y21D5!JOB[P
MGH6H0:3K?B?3K.[NL?9;:ZO8XY)LG VJQ!;GCBOS>_9[_9W^$G_!/'_@OY:_
ML]?LB>%E\&_#OXK_ +.%WX@\3>!=,N)/[,&LV.K)#%?Q0LQ$4GD,8B%PN&8X
MRQ-?-.H? 7]G[]D[XA_%[Q#_ ,%N_P#@DU\0?BO/K_Q%UC66_:6T71W\4Z4=
M!EE+6IG$-P)]'AMX,)Y:Q_(%&  %H _<BOCS_@H;_P %,_C?^R/^U+\&OV/_
M -G+]C&W^+_C+XS6.O7.D6EU\2H?#D=J-+MX[B53)-9SH^Z%I&R63!CP-Q88
M^A_V6M4^!>L_LU^ ;[]F'6;?4/AS_P (?IT?@:[M;J:='TI+9$M?GG)E8B)4
M!\T^9D'?\V:_.K_@LIX:_:&\7_\ !:G]A[P]^RK\3=#\'>/+C0?B)_8?B/Q)
MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2
M N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS
M_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?/W[ WB#1=,^#6K6VH:C'%)_PG.LMM
M<\X^TMS7M_\ PF/AC_H-0?\ ?5>,_P#!/RTM9_@KJSS6T;G_ (3K61ED!/\
MQ\FO<O[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\
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M#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\
M"8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU
M1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4
M'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#
M4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/A
MC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H
M I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_
M +]"@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_
M /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^
MSM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0
MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
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M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
MPF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
M *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU4U^- TJSDU'5!9VUO"NZ:>XV(B#
MU+'@#ZTS2+CPQK^GQZMH4]A>VLPS%<VC))&XZ<,N0: &?\)CX8_Z#4'_ 'U1
M_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"M;>*/#]
MY.MK:ZK$\CG"(IY)J_426-E&P>.SB5AT*Q@$5+0 4444 %%%% !1110 4444
M %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?E__ ,%EOVP?COJ/[4NL?\$[/"'[3&C_  5\)7'[,NN^
M.=1\1WNCV=S?^-KL/<6H\/63WP,,/[N-I7:-6G*EM@4#=7U)_P $R_@=^U%\
M'_@_H][\;/VT]0^*GAK5_!.B2>%-(UKP3IVG7?A\_9MTL?VJQ6/[9&RO$J^9
M&'3RCEFW<>,_\%N_C]_P3)7X7^+/V<_V^/AU:2Z]'\.-0U?X<^(/%WP]NKK3
MA?RP7$<:66J) \=M=++#'O0R1G#Q_>!X\(_X(,Z+X5T?]M34X?\ @GCJ?CN;
M]ET_ 33'\7QZ_)J3Z!%\06N8C(FCMJ'SD_9O-,WDDQ!FQG'D@ &;_P ' _\
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MVVGP0W#;_P"/,J.=W?K7IU !1110 4444 %%%% !1110 4444 %%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'<X10,GD]36]7S%_P^2_X)N_]'&_^6AK'_R)1_P^2_X)N_\ 1QO_ ):&L?\
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M2C_A\E_P3=_Z.-_\M#6/_D2C^V,H_P"@BG_X''_,/^(=>(/_ $)\5_X3U?\
MY ^G:*^8O^'R7_!-W_HXW_RT-8_^1*]\^%7Q4\!?&WX>Z9\5/AAKW]IZ#K,!
MFTV_^RRP^<@=D)V2JKK\RL/F4'BMZ&/P.*DXT:L9-:V4D_R9Y>:\*\3Y%0C6
MS/ UJ$).RE4I3@F[-V3E%)NR;MO9,Z&BBBNL\$**** "BBB@ HHHH **** "
MBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@
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M<-L5>1L1X.YU&6SVP?F;XB:58:%\0-=T32H/*M;/6+J"VBW%MD:2LJC)))P
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MQFIPLW>$HR3C)I76J3BTV45]*_L]_"GX(?"_]DS6/VT_V@?AT?&9N/%B>&?
M_A";4Y;2UGNA"9YKNX>$B1HT0$*H(!92#]X%4_:(^%'P1^)G[*&B?MJ?L_?#
ML^#1%XKD\,>./"$.IRW=M;WGD>?#=6[S$R+&Z<,I) 9@!]TEM?[-J^P]IS*_
M+S<NM^6]K[6\[7O;6QR?ZY8'^U?JGL:GL_:^P]M[OL_;<M^3X_:?W>;DY.?W
M>:Y\UU^^/_!*K_E'S\,?^P+-_P"E4]?@=7[X_P#!*K_E'S\,?^P+-_Z53U]-
MP)_R-*G^!_\ I43\0^E5_P D3@_^PA?^FJA]!T445^JG\&A1110 4444 %%%
M% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I-
M>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7\^?\ P47_ .3Z?BK_ -CK>_\ H=?T&5_/G_P47_Y/
MI^*O_8ZWO_H=?"<>?[A2_P 7Z,_J?Z*?_)68_P#Z\+_TY$\7HHHK\N/[I/6_
MV9OVF/B%^SII'B6"S^'>D>+/!7BB.VLO%_A[Q+IKSZ?=LC/);Y="IBF4^8R,
M&R#DX.T8^D/VT_A)^SQ\<O _QE^/'@;X;ZKX)\6?#'6=(CU:<ZP]WIGB);UD
MBP@E&Z"=,AMBDKM X._*_*'P4_:;^.W[.K:@OP;^(MUHT.K*@U2S$$5Q;7>S
M=L\R&='C<KN;!*DC<?6NV_;,_;:^*O[4/B^^TNY^(.IS>"H[];C1M >UAM((
MV\L+YCPP *[YW89MS $X(SBO;P^-PT,LE2JMR>RBXK1M2LU*]TDVI.RWTV;9
M^7YOPSG.)XVHX_ PC1CO.K&K43G&,J'-&I14%3E*<(RIQ<I/W;3NG3C$UO\
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M\EP\4_\ 89F_]"KYKB;_ ':'K^A^L>$G_(XQ'_7O_P!N1QM%%%?&'[X%%%%
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MOX@6W]J:3XKU=;5CIR6FF1QK*D]K KQ/<_:44CY1$?OR>Q?\$NO^"27[;/\
MP3;UC1O!LG_!4NW\:_">RU?5=4UGX;?\*,L--?4KJ]CF)D&I?;9YX-MS)'/M
M4$'RO+P%8XW/B[_P2V_:4\%?MC^-_P!M?_@G-^VM:?"O6?BG;62_$WP=XJ\!
MQZ_HVL75I$8H+Z)?/ADM9E0D':6#EW)(R00#RK_@CUXH'P$_:A_:X^%W[:RO
M=_M$Z7>:7XK^+OQ%M[Y;G2O%&@_87.FRV$,=O";."UMRT1M65W4O_K9,[8_!
M_P#@GG\#?^"K_P 6/V!/$WC/_@E9\9_"?PB^ _C;5=<OO@M\-O'T2ZIK^FV,
MMW.LRPZC';B/3EFG$[PI(EV8?,!,C??/WW^P7_P3#G_9A\6_%/X]?M*_'N[^
M,OQ9^-1MHO'_ (NU#08M-LS86\+0P:=:64;NL%ND;E3\Y+A4R!MQ7C'PN_X)
M#?\ !17]D?X:W_[+/["W_!5V#PA\'Y+N[;POI7BKX30:QK?A*WN97EE@L[XW
M48F :1V1I$!5FXP>2 >I_P#!!#QW^SKXV_X)7?#*R_9B^&^K>#_#WAV"]T6_
M\,:[J"WEY8:K!>3"_$UPB(L[27+23>8J(&$PQ''_ *M>,_X+W?\ !0+1OV3O
M@_X(_9GC^,L'PUU;X^ZW<Z#/\3+U7\GPEH-ND3:MJ"&-2S78AGCAMT !,MP'
M#+Y=>E_#W_@EY;_LY_\ !,*7_@G5^Q]^T9XD^'NJ#3)$LOBND!N=5AU&:[%U
M<Z@R1RP;GD8R+M$B[48*"0O/T%X1^%ME9?#CPWX-^)MS;^,=2T+1+:SNM>UG
M3T>6^GCA1);DK(7*-*R;V&YN3R3C- 'XL>#?^"@__!(SX-_\%G_V=]1_9O\
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M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%%
M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
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MZ1[[5K5X@W[Q$MR"1[&M2BBOMC^?PHHHH **** "BBB@ HHHH **** /"_\
M@GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M110 4444 %%%% !1110 4444 %?I!^QS_P FS^$O^O!__1TE?F_7Z0?L<_\
M)L_A+_KP?_T=)7PW'O\ R*Z?^/\ ]MD?9<$_\C*I_@_5'IE%%%?E!^G!1110
M 4444 %%%% !1110 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R
M1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH **** "BBB@ HHHH _.#Q'_ ,C#?_\ 7[+_ .AFJ57?$?\ R,-__P!?LO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.WPQ-MHR? R+3X/&,-OI(L=*TA;JR^W1112 +$0EOAW"<1[@&P3BOE[X1_\
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MI/\ A.=9;:YYQ]I;FO;_ /A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J
M -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,
M?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
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M_5(>&W!4HIO"_P#D]3_Y,^5?C7XFP?+''Z+_ *=4?_E9T'_"=?\ 4+_\C_\
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M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
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M[C_T*OMN ?\ D85?\/ZH^/XW_P!QI?XOT9P5%%%?JA^:A1110 4444 %%%%
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MJ7_7_-_Z&:H5_1M/^&O0_ :GQOU"BBBK)"BBB@ HHHH **** "BBB@ HHHH
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M_9V#_E_%_P"8?VCC/YOP7^1] ?\ #='_ %2[_P K?_VBOV%_X)Y^,?\ A/\
M]C+P%XP_L[[)]NTN1_LWG>9LQ<2KC=@9Z>@K^?JOWK_X)7?\H_/AE_V!9O\
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MPB2W7 ^=IUCZ/7,>+OVZ?#7_  3I_P""MWQZ^'_P*_9J^)G[0<OQ+@T/Q/\
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MN7.K7"7-\TR*Q> 1L$4#=@  Y((]Z\P^)'Q)U;XY_$>WU77/(TVT9H;'3;*
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MPW_V +/_ -$)6]7X7B/]XGZO\S]FP_\  AZ+\@K^?K_@HG_R?-\5/^QTO?\
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M)INF^5:RSKYQCE9AYC1K"N!]^5.U?7]% !1110!X7_P3W_Y(GJW_ &/>L_\
MI2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%)IPFTUM9O2^]O4W?B#\2O'/Q3UW_A)/'OB*;4;L1B.-I JK$@Z(B* J+[*
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M /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH ****
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M $F1^C^&?_(YK?\ 7M_^E1/H&BBBOP@_;0HHHH **** "BBB@ HHHH ****
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MZ7X5_P#(VK_X/_;D?G7B;_R*Z'^/_P!M9XQ1117[D?BP4444 %%%% !1110
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
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MB@ HHHH _FL^(_\ R4/7O^PU=?\ HYJQJV?B/_R4/7O^PU=?^CFK&K^P*/\
M"CZ(_DZK_%EZL****T("BBB@ HHHH **** "BBB@ HHHH _HX_9O_P"3=_ 7
M_8EZ7_Z215VE<7^S?_R;OX"_[$O2_P#TDBKM*_D/%_[W4_Q/\S^K,+_NM/\
MPK\@K^?K_@HG_P GS?%3_L=+W_T.OZ!:_GZ_X*)_\GS?%3_L=+W_ -#K]*\*
M_P#D;5_\'_MR/SSQ-_Y%=#_'_P"VL\8HHHK]R/Q8**** "BBB@ HHHH ****
M "BBB@ K]Z_^"5W_ "C\^&7_ &!9O_2J>OP4K]Z_^"5W_*/SX9?]@6;_ -*I
MZ_,O%/\ Y$E'_KXO_29'Z/X9_P#(YK?]>W_Z5$^@:***_"#]M"BBB@ HHHH
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ME<6L=S<0W?V*&1(Y9Q)*<M(&#!$4J0M 'Z+T5X7_ ,$O/^49W[.W_9"O"/\
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MZ!HHHK\(/VT**** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\
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M?^"P7_!.G5]1M])T[]HCS+BZG2&"/_A$M7&YV(51DV@ R2.O%?2U?S2_#?\
MY*)H'_8:M?\ T<M?TM5]5PQGF+SJ-5UXQ7+:W*FM[[W;['X1XX>%^0>&E? P
MRNK5FJZJ.7M)0=N1PM;EA#^9WO?IL%%%%?5'X.?S6?$?_DH>O?\ 8:NO_1S5
MC5L_$?\ Y*'KW_8:NO\ T<U8U?V!1_A1]$?R=5_BR]6%%%%:$!1110 4444
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M>7[:'[2?_#57Q\U+XHV&@_V3H\=O!IOAO22<M9Z=;IY<*,<G+D NW) 9R 2
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M_+0UC_Y$H_X?)?\ !-W_ *.-_P#+0UC_ .1*\_\ MC*/^@BG_P"!Q_S/K?\
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MXVY?:3E.U[WMS-VO97MO9!1117Q!]2?S6?$?_DH>O?\ 8:NO_1S5C5L_$?\
MY*'KW_8:NO\ T<U8U?V!1_A1]$?R=5_BR]6%%%%:$!1110 4444 %%%% !11
M10 4444 ?T<?LW_\F[^ O^Q+TO\ ])(J[2N+_9O_ .3=_ 7_ &)>E_\ I)%7
M:5_(>+_WNI_B?YG]687_ '6G_A7Y!7\_7_!1/_D^;XJ?]CI>_P#H=?T"U_/U
M_P %$_\ D^;XJ?\ 8Z7O_H=?I7A7_P C:O\ X/\ VY'YYXF_\BNA_C_]M9XQ
M1117[D?BP4444 %%%% !1110 4444 %%%% !7[U_\$KO^4?GPR_[ LW_ *53
MU^"E?O7_ ,$KO^4?GPR_[ LW_I5/7YEXI_\ (DH_]?%_Z3(_1_#/_D<UO^O;
M_P#2HGT#1117X0?MH4444 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V
M/>L_^E)K3_;\\ _\+1_8]\=> ?[6^P_VEID<?VOR/-\O%Q$V=NY<_=QU'6LS
M_@GO_P D3U;_ +'O6?\ TI-=M^U'_P D"\2_]>2?^C4KEQT5+ U8O9QE^3/;
MX:K5<-Q'@JU-VE&K3:?9J<6M]-S\;?\ AVM_U6C_ ,MS_P"Z*/\ AVM_U6C_
M ,MS_P"Z*^I**_)/[.P?\OXO_,_NC_7SBO\ Z"/_ "2G_P#(GRW_ ,.UO^JT
M?^6Y_P#=%/MO^";GV:YCN#\8TD\MPWER>&\JV#G!'VGD&OJ&EC4/(J%PH) W
M'H/>C^SL'_+^+_S$^/.*VM<1_P"24_\ Y$M>$/@3^RC'\.?%NH3?LWZ7')>W
MFF3ZGI=EK=]%IMU/')*T;"W:5WCC#%B8EEVD';P*\*^.7[+OQ*^/OQGUSXZ>
M+OCVMKK.NRJ9UTKPZT$4$2(D<<$8%T2$1(T4 DD[022<FONOQGH'@'X,:%X@
M\*'X2'5+&U73?-U34-0N$_M8N&8R(T9"HJDD +GG.<]*\8L/&5QX6\;'QEX!
MM_[+:&XD?3HI"MP;96!4+EUPY ;&2/>O9Q^#IJ$*-5I);J*MJG+7113M=VUZ
MNV]S\_X8XHS58C$8_!.;E)6A*K)5$XN%-\J<W5E!2Y8.5H[1BGK!17E/P6^!
M/C/X)?"7XE?#;5/B1J>IM\1="M].MM4N+62$Z88I6<RJIE;S<[L8#)C'4]*X
MGX"?L0:)\*?CAX:^+'B[QD_BFWT+6HM1DT1M,^SF^EC;?&K2F23 \P(Q!1MP
M!7OD??W@?5?C9)I>K:C^TB99?!DVD2M<'6(XOGE9?W/D #=YA)XQP.O!Q7&?
M!>YF\&?!;QC\4?#$$9U^RN+6TMKQH@[V,$C8>100<%L[<]L?6F\KH\U*[=HI
MM<RU2C[VUW>[VN_+9!3\0,Z5''\KBY5Y4X3=.47"<JD522YU!.#C%)2Y$FE:
M2O*1\7?'?]B?Q3\;?C)XE^+OC3XQ/#J7B/6)[Z>W?PZ3Y D8E(E)N =J)M1>
M.BBM'Q%^Q9\/]8_9[\/?"'31IUAXCTC6KF\U'QS%HJFYU."3=LMG3>"JID8)
MD;.WH*^SK:]\2?&W]G7Q-XC\>2F^O_"UY;R:3J\T8\THYQ- 7 &Y0I#8.>2/
M:O&*X\1E^'I2<TKJHKW>[N]>KL[K=?J>]EO&^?XRC'#2J<CPDU%1AR\J<8+E
MLU&/-'DG\,DTGNFXIF7X:^#?PJ\=?"3PG\//VJ/ EQ\0)OA_:_8O#GB#2KF;
M2IQIP;<ME<[&D$L:=%8%2J\#DL6\T_:C_9F\5?M3?%B;XF>)?BE9Z7!%8P:=
MH>A:=X;(MM*T^!=L-M'FXSM4$DGC+,Q  ( ^I-#_ &C?CH;K3-!\)^(# D'E
M6]AI=A8QB.0C"A2NTERQZY)))I?VJ;#P]IWQBO+?0;2VMY#:P/JEO9X\J.[*
M R*N.!S@GW)[UT8C#4*^"=G=)Q3NK-Z.VJ=Y62ZGD95Q'G>5\0J5E"<XU90M
M/VD8*4XNIRTY04*7/)IMTTDVFGY_"O\ P[6_ZK1_Y;G_ -T5Z;^QC^P/_P *
M]_:L\ >-_P#A:_VS^R_$]M<?9?["\OS=KYV[O/.WZX->KUV7[//_ "7#PM_V
M&8?_ $*N'!X#"1Q=-J/VEU??U/I<^XWXHKY'BJ<\1>,J<T_<ALXM/[)]]444
M5^NG\(F#\5?^27^)/^P!>?\ HAZ_+&OU.^*O_)+_ !)_V +S_P!$/7Y8U^G>
M'_\ N]?UC^3/SKCG^/0])?F@HHHK]"/A#T/X*_L[>-?BW/'JJ:5);Z%NECDU
M66ZA@0RK$S!$,K#>=P&=H.!DG&*YGQ]\-?&7PQU*#2O&>EQVTMU;BXM6AO(I
MXYHBQ4.KQ,RD94CKVKV7X"_$/X8>/-"\(_#/QI=:KI&K>%5U0:7>V=NLUI<Q
M7$<CR&5,AE=1G!7J%Z\\>9_%[X.3?#.ST?Q%I'B^S\0>']>AEDT;6+)'C$GE
ML%D1XW^:-U)&5.>O7(('AX?'8F69RHUWRK[,>5ZZRLU*]FVE=JU]U;W6SV*^
M#PZRZ-6BN;N^9::1NG&U[)NU[^=]4CIA^S9X)O/ACKWCKP]\=[#5K_P_IT5W
M?:3I^CRE%$C;0IG9E7.<]%/3WKSSX>^!-?\ B9XTT[P'X7A5[[4[@10^8<*O
M!+.Q[*J@L?8&O2?V>/\ DAGQ>_[%^R_]'M1^POC_ (7U'Y/_ !]?V'?_ &''
M7SO(;&/?&ZH>+Q6%P^,E*?.Z?PW27V(RZ):7?K;J6L+AL37PL8QY54WLW_.U
MU;ULO2_04?LW?#GQ1=:IX0^%'QI_MSQ1I%M+*VF2Z*T$-_Y0_>I;R[VW,,'
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M?\%8]2A\1:C\/_$OAO2=)T[39S/\&O#&I:3/=Z%I!4@0R:<H9LB-@".9,YP
M< <]?B*,*M.E&,8RE",VJD^2REM'X97E=.^R6EWJC:CD$ITJE63E*,92@G3C
MSW<=W\4;*S5MV]=-&?GC117LG[('P8\(^,M:UCXU?&B&1?AQ\.[5-2\4;6VM
MJ<Q;%KI<1_YZ7,H"?[*"1LC KWL5B:>$H2JSV71;MO1)>;=DEW9XF&P]3%UU
M2AN^KV26K;\DM7Y'C=%?8_\ P5E^(NJ_%WPM\!OB?KEE:VMUKWPR^VRVME$$
MA@\R<L(XU'1%!"@>@%?'%<^5XV>8X&->4.1NZ:O>S4G'>ROMV-\RP<<!C94(
MRYDK-.UKW2>UW;?N?T<?LW_\F[^ O^Q+TO\ ])(J[2N+_9O_ .3=_ 7_ &)>
ME_\ I)%7:5_*>+_WNI_B?YG]/87_ '6G_A7Y!7\_7_!1/_D^;XJ?]CI>_P#H
M=?T"U_/U_P %$_\ D^;XJ?\ 8Z7O_H=?I7A7_P C:O\ X/\ VY'YYXF_\BNA
M_C_]M9XQ1117[D?BP4444 %%%% !1110 4444 %%%% !7[U_\$KO^4?GPR_[
M LW_ *53U^"E?O7_ ,$KO^4?GPR_[ LW_I5/7YEXI_\ (DH_]?%_Z3(_1_#/
M_D<UO^O;_P#2HGT#1117X0?MH4444 %%%% !1110 4444 %%%% 'SU^P7K%_
M8?!S5H+;0+BY7_A.-9/F1$8S]I;CFNP_:>\37@^ OB0WWARZMX?L:;YG((0>
M:G) YK _X)[_ /)$]6_['O6?_2DUU'[8W_)L_BW_ *\$_P#1T=;8?"T\=B(8
M:HVHS:B[;VD[.V^NO8/K];*_]MI).=+WTGLW'WE>S3M=:V:]3X/_ .$IT'_G
M^_\ (3?X4?\ "4Z#_P _W_D)O\*X^BOL_P#B#W#/_/ZM_P"!0_\ E8O^)CN.
M/^@?#?\ @%7_ .7'8?\ "4Z#_P _W_D)O\*=%XET*658AJ*KN8#<T; #W)Q7
M&T4?\0>X9_Y_5O\ P*'_ ,K#_B8[CC_H'P__ (!5_P#EQ]B_#;3/VEO"/@W4
M]+TS4HKZUBEM%TV2XU&"[T\V^Y_,P[,56/;MR."!T ->:_$71_"WQ(_:#U?P
M?\#197*2N6M+:TE6.&21(E,PB9L(1O#[0#@_P\8KQC3/%5YI?A?5?"L-O$T.
MK26[S2-G<AA9BNWG'.XYS66"0<@U"\)LMJ4)4JV(FTOA?NZ:/>Z>EW9I6V6I
MRT_'?/L+F'US#X2C&4D^=6G:5^7M):KENF[V<Y::GUQ\$O"7Q0^%FOW/B[XR
MRW&C^#[6PGCUN+6KL>5=H8F58EC+'S&+8Q@=B!UP?.O@+K7Q/OM;U6Y^!D+7
MK1VX&I:<T:2+-;LQ #Q2\2#MP"1GMDUXC=7]]>[1>7LLVP?+YLA;'TS38)Y[
M:43VTSQNOW71B"/Q%$/"7+%AU%XFISQ;<6N56O:Z>C;VZ-;]1S\>L^GC*E5X
M*@X5(QC.+C)I\KDTU[Z5_>U;4ME:UCZQ^)?Q(\1_#?X*:KX9^+%YI^FZSXC:
M&#2?#&FV\48L+5'WRSO%",(9#\OS<G ]"!X[J?AFYTKX;:;\5;N]M_[*U6^E
MM+4J7,GF1YW97;P.#SFO+Y999Y&FGE9W8Y9W;))]S3:TJ>$N35X0]MB*CE%6
M;O'5:O2\79Z[MM6Z;6C!>/?$V6RJ_5<+0C&<N:W+/1V4;:36EET2=]7)N]_L
M?X?_  ,^(GPT^']MXX\#>#O[9\6:W:![.[\Z$0Z-;NH(91(PWS,IZX(7GWW>
M$_$[1?$GPU\4-HGQ-MY;/5+B(73I/()GD5V;YRR%@22&ZG->745C'PARJ4DJ
MN)FX+9148_.[4M>^GW+0Z:?T@^)</*=6EA:+J3>LI<\M%M%)2C:*Z)>;=VVW
MV'_"4Z#_ ,_W_D)O\*[']GWQ1I1^-GA<6<C3R_VQ#Y<*1L"YW=!D8KQZN]_9
M=_Y.'\'?]A^W_P#0J*_A-PYA*,J\*M6\$Y*\H6NE=7_=FG_$P7&>8_[+4P^'
M4:GNNT*E[2T=KU6KV>FC/T7_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HK
MXL#BOB?XBU63X:^(8W\*7:!M#NP79EPO[E^:_,BOU.^*O_)+_$G_ & +S_T0
M]?EC7Z=X?_[O7]8_DS\ZXY_CT/27YH****_0CX0]<^ /Q'^%ECK6DZ5XM^%%
MD;VSMKM!X@@UJ6T:13#*<2H0R.Q#; PVGE>N*Y7XJ_%UOB)8Z/X9T?PM:Z%H
M'A^&6/2-(M9GE\LRL'DD>1_FD=B!D\=.G7/&T5PPR_#PQ?UC5OI=MI/6[2;L
MMVM%IK;=G9+'5Y8;V&B76R2;6FC:5WLGOKI?9'M'@;]I'X+^!_!FH>#K7]FN
M25-;T^&UUZ;_ (32=?MGE\[@#$?*RV3A2,9QFN%M/BA;>#_BW!\4/A)X9'A^
M*QN8Y=/TN6_>[6(",)(C2,%9U?Y\],!R!T!KD:*5/+<)2E.23?/I*\I23Z:J
M3:V5MMM-AU,PQ52,(MI<GPVC%-==TD]]?77<]C_X:2^'?ABYU3Q=\*?@J-"\
M4:O;RQ-J<NM-/#8>;_K6MXMB[&.3@D_+T'&0>0^#GQ@?X73ZIIFK>&X=;T#7
M[(6NN:-/.8A<(#E'5U!*2*22K8.,GO@CBZ*(Y9@XTI4^5M2M>[DWIMJW=6Z6
M>CU6H2S#%RJ1G=)QO:R26N^B5G?K=:K1Z'H_CCXV>%Y_AW)\)_A+\/W\/:/>
MWJ7>L2W6I&ZN;^1/]6K.54*BGD*!U /'.>;U/QEX:OOAEIG@FU\!6MOJEE?R
MSW7B%)09;N-L[8F78" N1@[CTZ"N<HK2E@L/1BE%/1\V[;;M:[=[O3O=;=D9
MU,97JR;DUJN7962O>R5K+7M;KW9ZAHWQS\":[X*TCP;\:OAA-X@;P]$8=&U.
MQUAK2=;<G(MY/E8.@['@J.!W-<]\9?B[J'Q>\0VNH-HMOI6FZ7I\=AHND6CE
MH[.V3[J;CRQYY8@9]@ *Y"BII9?A:-;VL5KK;5M*^]DW97ZV153'8FK2]G)Z
M:7T5W;:[M=VZ79>\,,5\2Z>P4DB^A( [_.*_4;_A)=7_ .A0O?\ OI:_+KPK
M_P C/IO_ %_P_P#H8K]7:^!\0/XF'])?^VGW' W\.OZQ_4Q_^$EU?_H4+W_O
MI:/^$EU?_H4+W_OI:V**_.C[T_FK^(C%OB!KK%2"=9NB0>W[UJQZV?B/_P E
M#U[_ +#5U_Z.:L:O[ H_PH^B/Y.J_P 67JPKV+]DGX9?M3>*-6U'QY^R7XJ>
MR\0Z(8HYK32O%$-AJ,\,NXDQQR2(;B(&,!U7=RRY4YKQVBL\52G7H2IQ:N_Y
MH\R\TU=7NO,TPU6%&NIR3LOY7RORL[.WW'Z0?\%"-0\7W/P&^)\'[9-IX?&L
MQ:WI*?!&:5;1==9=Z_;@?(_>&U$>[F8?>/4GR\>::EH/Q+_;C_X)S?"_X;_
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MS\&^LX;^=?>CT"G12>5*LNQ6VL#M<9!]C[5Y[_PU)\"?^AZ_\IEU_P#&J/\
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MOD/_ $I'F9U_R)\3_P!>Y_\ I+/P4HHHK^KS^7@HHHH **** "BBB@ HHHH
M**** "O9_P#@G9_R?-\*_P#L=++_ -#KQBO9_P#@G9_R?-\*_P#L=++_ -#K
MS\V_Y%6(_P $_P#TEG?E7_(TH?XX_P#I2/Z!:***_DL_J4XO]I#_ )-W\>_]
MB7JG_I)+7\X]?T<?M(?\F[^/?^Q+U3_TDEK^<>OVOPH_W3%?XH_DS\=\4/\
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MH2AS*+:Y[1;5]4XIM63UBGL_*_BU%?<G[+J_L#_'K0OB#X\\6?\ !/VP\/\
MAOX>^$)=7U+4XOB;K<[2W).VVLU4S*-\S!P#G^#WKRC]DSX._!6S^ 7Q"_;$
M^/?@N?Q3I?@^]LM+T#P=!J,EI#J&H7+?>GEC/F+%&I5MJG+<@GC!P6?4TJJG
M1G&4'"-GR-N4_ABN6;5]5>[5DTWH;O)*C=-PK0E&:E*ZYTE&'Q-\T$[:.UD[
MM-+4^<J*^H?&?PV^!G[3?[(OBS]ICX*?!B/X?^(_AMJUC#XKT/2]5N+O3]1L
M+QC'%<1"X9GBE20890=NU2W)/'R]7H8+&PQL9VBXR@^647:Z=D^C:U3333V?
M<X,9@YX.4?>4HR7-&2O9J[75)Z--.ZW045]@_%_0/V3OV%+7P=\)/&_[,%M\
M2_%&K^%++6_&>MZUXEO+-8#= L+.S2W9538H_P!:P8G(X[#RO]N_]G+PI^SQ
M\5])D^&<][)X/\;>%+'Q/X3&HL&G@M+I2?(D8?>9&5AGKM*YR22>3!YS0QE:
M$%"45--PD[6FH[VLVUW7,E=:G5B\HK82E*;G&3@TIQ5[Q<MKW23[.S=GH>5_
M#C_DH>@_]AJU_P#1RU_2G7\UGPX_Y*'H/_8:M?\ T<M?TIU^8^+'\7">D_\
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MB/\ \E#U[_L-77_HYJQJ_L"C_"CZ(_DZK_%EZL****T("BBB@ HHHH ****
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MJE_P51_Y1^?$W_L"P_\ I5!7JY'_ ,CO"_\ 7R'_ *4CS,Z_Y$^)_P"O<_\
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M3K\9\6/XN$])_P#MI^O>%W\+%>L/_;@HHHK\A/U8_FL^(_\ R4/7O^PU=?\
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M6Q_^-5]C44 ?'/\ PY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\ 11OBG_X6Q_\
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M+8__ !JOL:B@#XY_X<A?LF_]%&^*?_A;'_XU1_PY"_9-_P"BC?%/_P +8_\
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M>)F# ?,HC!(Y]17Z 5QW[07PSOOC+\%_$7POTS4XK*XUO3FMHKJ="R1DD')
MY(XH ^5_!/\ P18_96U[P9I&N7OQ$^*"S7NF6\\JQ>-"%#/&K' \K@9-:?\
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MX&_"O5C)\%? EG\;O#NBZ7?7Z'"^(-2ANI9)+N?&3%#)'&L((&TG>9/UTHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%8%9(=ZD"4+^B_P8\*_$#P/\)_#OA'XK_%"X\;>)]/TB"'Q!XMNM-MK-]6O
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M\5?MV?LE>#_V1IOV\-5^-FFS_"2#2(]3?QII%O/?P&U>580ZQVL<DK$2L$9
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M3^!'PJ^(/P<\%?!ZZNM(^+&FK8?$J;Q%XKU/5+WQ%;K'-$J7%U=7$DP"I<3
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M+;?\%3/^"D_CC_@HU&5GTGP%^SUX-\"Z,ZK^Y35M3A76=91!T$L%QBV<]<#
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MX5_LL?L\:!/I_A;PM\<O"4=F+RX\ZYN99-0DEFN)Y,#?+)([NQ  RV%55"J
M#]8J_+SX?>+O^"I'[<?_  4H_:M^!?PC_P""H>H_"+P=\%?$^@6/AS1+'X/>
M'=:\R*_T]YG#37EN)?E>%B-SN3YA&0% K]0Z_&_]G/\ X)Q?L^?M[_\ !8?]
MN^]^..M^.K-_"_C;PFFFCP;X[O\ 10XN-*F,GFBUD3SC^Y3:6SMRV/O&@#]
M_@OX:_:&_8:^#/Q'^,O[>G_!0+4/C+HF@Z')KAU*]^&VDZ V@V-E;SS7>U-.
M51<&1 I^?E3$ OWC7RY^RKI__!6[_@K)\+K']M36_P!NBY_9M^'?C!GO?AK\
M,_ '@C3M1U'^R?,(M[S4=0OT<M+*B[_+C41E65L+G8/5?C1_P2F\"?!O_@F-
M^T/^R_\ LEWOC34]6^(WP_U9+"W\6>,KS69I]0^P2)!!%)=2,8ED;:A (&7R
M11_P1P^,?@S]L/\ X(R?#GP!\&_BK<>&O$?A[X2VO@+7[S2/*.J>$M;L=/&G
MO*T$JL(IT>(7$:RIA@48@J: /5?V)_A'_P %#?@GXG\3>"OVP?VKO#OQD\)_
M9+67P1XL3P;%HFNPS;I!<6U]#:G[-*@7R3'*@#L?,W@?+7P_^P-J'_!8_P#X
M*.^$?BW\8?"7_!8&Y^'\/A+XX>)O"/A_PN_P)\-:G:K;V$L9@\R=H(YF4K,$
M/)?"9W$FO1/^"?/BO]J_X2?\%FOBU^PM\9/VV/&GQ=\*^&O@MI?B'3)?&-K8
MQ36][<WD2L<6D,8X0D#/9J^6O^"5W_!.#X[?MA? C]HKQ7\(/^"FGQG^#4LW
M[2'C?3+30?!&IPQZ3]H$D)%U+&$6=G;S K%)D.V-<%2,T ??_P#P1A_;T^-?
M[=O[''B;QA^T+I.C6WQ ^&WQ$UOP+XKU#PY&R6&J7NG+"WVR!&SM5TGCR!\I
M=7("J0B_,_P5_P""EO[;/BW_ (-<-7_X*,>(?C5]H^,MKH&M7,'C'_A'--3;
M+!XBGLXF^R+;"U.V!%3!AP<;CELFO6?^#?GQMX#T#]B3Q5^Q6?A!I7@#XD_
M7Q5J'AGXK>&],N9IEO=2)=TUH23LTLL=ZJF17=B"8W5,1I&!\8_LX_\ *DMK
MW_8K>(__ %+;F@#["^&'[,G_  7&\8? ?PM\=OA]_P %I],UO6M<\*V.LP>$
M?''[/FA0Z7/)<6T<PMI;K3UCN(D!?:9$5CCG9GI:^ '[;G[;7_!2_P#8)^+7
M@SX,ZK9?!']J_P"#GBBY\.>)=)@LK34=+?6K,[UC47T<RBQO55XQ)DO$P9ED
M=4#2?5?[-'CCP7\-OV%?AOXY^(GB[3-!T33/A=HD^I:OK-]';6MK$NG0%GDE
MD(5% ZDD"OC#_@@'?/\ 'C]H']LG_@H#X.L+A/AY\7_C/#;_  ^U">W:)=7M
M-*CN('OXE8 F.5IUPV/O(ZGYD8  WKW_ (+R>$;S_@F1;_M,>'OAW))\=M0\
M0_\ "O+/X(,C?VA'\1-WD-I;0DA_)23]^6)!\C )$C!:^OOV+_!'[2_P^_9F
M\)^'/VQ/C./'OQ,&FB?QCXABTJSLH#>2$N]O!%9PPQ^3#N\I'*;G$>]N6P/@
M'PQ^S7\#5_X.U-<\3K\-].%Y#^RO_P )O$PC.Q/$+ZO;Z4^I!,[1.UDS1%L<
M[BQ^<[J_4^@ HKYK_:M_X?!_\+27_AAW_AFO_A"?[,AW?\+7_P"$@_M7[;N?
MS<?V?^Y\G'E[?XL[L]J^A_#7_"1_\(YI_P#PF/V'^U_L,7]J_P!F;_LWVG8/
M-\K?\WE[]VW=SC&>: /CSX-_M9?M >*_^"Z7QB_8XU_Q_P"?\-_"OP5T37M!
M\.?V5:)]EU"XGC2:;[0L0G?<K$;'D9!GA11_P54_:R_: _9N_:)_9&\"_!;Q
M_P#V+I7Q/^/MIX<\<VO]E6ES_:>F/&"T&Z>)VAR?XXBC_P"U7F/PSU.Q^''_
M  =#?$S0_&=TFGS?$3]F/2;KP?\ :F"#4_LE\D<\<)/WY%\J5R@YVQ.V, FC
M_@L]JEAXR_X*(_L#? [PU=)>>)S\=Y/$\FDV[!YHM+L+8/<7+J.5C"[\,< ^
M6^,[6P ?2_[1?_!5G]@O]E/XG:M\$_CA\<_[+\9:1HMGJDGA:V\.:C=WMY#=
M2/';I:);V[B\F=HW_<PEY%5&=E5%+#;_ &,/^"AW[)W[?FE>(+W]FGXBSZE>
M^$K]++Q7X?U?1+O2]3T>=PQC6XM+N..5 X1]K[2K%' .58#Y:^&G@OPKK?\
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M\1/VYOVWKOXP:'HD"7WAWQ#_ ,*O2TU/3+<(4:">VTF.0WQ\QHB)$CW8+;E
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MV0(V=JND\>0/E+JY 52$7YG^"O\ P4M_;9\6_P#!KAJ__!1CQ#\:OM'QEM=
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M\'7'B?\ M6[.[1!=K=BU^S&7[./WZ*_F"/S.,;]N17HU?GA>_P#!>3PC>?\
M!,BW_:8\/?#N23X[:AXA_P"%>6?P09&_M"/XB;O(;2VA)#^2DG[\L2#Y& 2)
M&"U]??L7^"/VE_A]^S-X3\.?MB?&<>/?B8--$_C'Q#%I5G90&\D)=[>"*SAA
MC\F'=Y2.4W.(][<M@ 'J-%%% 'BG[9?_  3O_8^_;\T71]*_:E^#\&O7/ARY
M:X\-:Y9ZC<Z?J>D2MMW-;7EI)'/$"50E ^QBBEE.T8YW]D+_ ()/_L+?L/\
MC[4/B[\"?A#<?\)IJMG]CO?&GBGQ'?:WJIML@^0EQ?32M#&<+E8]H;:-V<"O
MF;]HOXG_ /!1?]H#_@MIK_[ O[-7_!0.]^#'@[0OV?[+QKBQ^&.A:\T]ZVIB
MTD4F_@,BAEE4\2$#R^%^8FNF_8$_:O\ VWOA[_P4Z^(/_!*+]MOXS:'\6KG1
MOA?;>/\ P9\4-+\)P:)=S6+7<-I+:7UI;$P+())E*% .(V))\Q50 ^P='_9=
M^!6@?M*ZS^U]I/@;ROB+K_A:W\.:OXA_M.Z;S],@F,T4'D-*8%VR$MO6,.>A
M8CBC3OV7?@7I/[3&I?MAZ?X&\OXC:OX0A\+ZCXB_M.Z/FZ3%<&XCM_LYE\A<
M2DMYBQB0]"Q'%>:_M7_\%4_V)_V,_B+9?!GXO_$G4KOQM?V'V^'P7X-\*ZAK
MVJQV><?:9;>PAE:"+T:3;NYVYP:Z[X _MV?LD_M._L_7_P"U'\&/CAH^I>!M
M&2[/B#6[HO9#1FM4\RY2]BN5CDLWB3YW694(4AOND$@%[X/_ +&_[-'P'^&7
MBKX,_#'X56EIX6\;ZYJNK^+-#O[RXOX-3N]2)^W-(+N23Y)LD-$,1@$@* <5
MQG[)7_!+C]AK]A?QEJ7CK]E?X-W?A6]U;3'TZ[@'C+6+VR6V>5)FCBL[N[EM
MX!OC4YBC4@ @$ D'SOX<_P#!=W_@G%\5?&N@^$?!WC[QK+:^*=:MM)\,^*;C
MX3^((=%U.\N9U@@CBOGLA%B25E59&*H21\V.:\G^)/\ P7,^&OP3_P""Q'BO
M]DWXJ>.M5M?A=X;^#T=S<)IWPHUW4+Y/%@U7RI%!M+*666V^R8Q,B-;E^!*7
M^6@#U+Q-_P $"O\ @F%X@\3ZOK^E_!GQ#X:LO$-ZUWK_ (8\%?$G7-%T:_F8
MY9GL+*\C@0'@%8U1>.E>T_$K]@/]CWXO?LHV?[$'Q$^!6D:C\+M-TRUL-*\*
MN\J)816RA;<P3*XFADC PLJ.)!D_-R<^E^ ?''AOXF^!=%^)/@ZYGFTCQ#I-
MMJ>E375A-:RR6T\2RQ,\,Z)+"Q1U)CD174Y#*I! \5_:]_X*>_L9_L/^+]%^
M&?QU^)-Z?&'B*T>[T7P5X5\-WVMZO=6RE@UQ]DL899(XLHX$CA58HX4DJ0 #
MC?AO_P $0_\ @FW\-?$GAWQW:_!+5-:\3>$_%6G>(O#_ (J\4^/-9U+4[.^L
M?,^R!;B>[9S!'YLA%J<P,Q#/&S $?65>"_"?_@IM^Q-\<?V:=?\ VMOA5\8W
MUSP7X4F>#Q1)IWAS49M2TFX1E5[>?34MS>I,"R_N_)+$'< 5YKX+_P"")W[8
M]G_P4&^//_#0?QC_ &]?CG=_$&[\7^)9]%^#&G:#?:?X$M-$A>>WM896_LP6
M\\B0LLOSW?F^:B;E+JX8 ^M?CC_P0W_X)O\ Q[^+NN?'KQ#\)->T+QAXHNFN
M/$VN>"OB#K.C/JTAY+3QVETD3L3DEM@))Y)KUW]CS]A']DW]@;P!=_#7]DSX
M,Z?X2TW4KS[9J\L5Q-=7>I7&"/-N;JY>2>=ADXWN0NXA0 36[^TW^U#\"_V.
M/@_?_'W]I#QQ_P (WX0TN[M+;4=;;3+JZCMGN;B.VAWK;12.JM-+&F\KM7<"
MQ YK"_:2_;M_9/\ V0_'/P[^&W[1GQ?MO#.M?%?Q$-"\ 64^FW<_]J7QD@C\
MO?!$Z0*'N8 9)C'&/,&6'- '&_!?_@DG_P $^?V=/VA/^&H?@9\ #X5\8?;+
MR[$NC>+-6ATX3744D4[C3!=?80625QQ!A205P5!'(:;_ ,$)?^"8.D?$N[^(
M^G_L^7,<%]KQUNY\&CQAJG_"-2:CO#_:3H_VG[&2& 8(8C&"!A!@8]^U_P#:
MB^!?AC]H_P /_LD:SXY\OXA^*/#MWKVB^'8],NI6ETZV<)-<O,D1A@4.P4>:
MZ%VX4,:\)^/7_!<+_@FW^SG\5/$'P>\>?&G5;_5_!L@3QS-X3\$:MK5GX9/.
M1?W-C;2Q0,N&#(6+H58,JD8H ]5\ ?L#?LA?#/\ 9 3]@?PI\$M/_P"%1)IM
MU8#P5JEY<ZA UO<7$ES*C2W4LDS$S2O(&+ED8C:5VKC*_98_X)I_L5_L7>'/
M%?@W]GGX/3:9HWC:S@L_$VC:UXJU36[2[MH5G1(!!J=S<1Q1;+F96CC55=7
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MC]MZV\ ;?BA=>!1X.N/$_P#:MV=VB"[6[%K]F,OV<?OT5_,$?F<8W[<BO1J
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M%MG_ %#W-A-$\T8R<+(6"Y.W&33/A5_P2@_8.^#OP2\=_L^>%?@O/<^'/BA
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M\*EVY\C_ (1S_A+-*\CR,\>5YWVG&.-V[OFOU^_:Q\">$_A?_P $IOB=\-_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20210930_g4.jpg
<TEXT>
begin 644 biib-20210930_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
M!3S]KC]H#XP^/?A]_P $S_V&M+^)OAKX7^(Y_#OBOXB>-/B-'X?TZ]UNW -S
MIVG(+:>2Y:(LJM.VR,,<#*E6;Q3_ ((E?MF?LW?LIS^.?^"<?[1GQ%_X0[XS
M7?[1WBL:/X*US2;N&?5(KR^,MK/;2&+RI8I4R5</@@9Z,I/S%^R_\&_V+/V,
M?B7\5_V4/^"GO[:7QU^ _C*Q^)^M:QX3O-*^+FM^'O#?C#0;N?SK?4K)K8BV
M:8[BLJY#A@H.6#J@!^CWA[_@L)X=\1_\$Y?B[^V[_P *!U72O%_P.;5].^(_
MPBUS6HX;K3-;TY5::Q-Y'%(CQLKHT=RL;*ZN#M!#*/)?&_\ P6Y_;#\!?LY:
M!_P4,\2_\$P+FQ_9SO;32[W6O$,WQ)@;Q';:;>-$G]J1:6+8;[8/,IC5I$EE
MC*2LL*N=GF?C3P%_P3[TG_@AS^V=\3O^">WQ9\:^/-$\4:-JP\5^,O&NJZC?
M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
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M3X-ZMXLN-!\-_#/3]&L].N8;DP1QQSA7NI@-C-N:10=V"IQF@#]-:**^"/\
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M -N? 2XYY9-?5_\ R?\ ^U/ULHK\DZ*?_$/O^HG_ ,D_^W%_KU_U#_\ D_\
M]J?K917Y)T4?\0^_ZB?_ "3_ .W#_7K_ *A__)__ +4_6RBOR3HH_P"(??\
M43_Y)_\ ;A_KU_U#_P#D_P#]J?K917Y)T4?\0^_ZB?\ R3_[</\ 7K_J'_\
M)_\ [4_6RBOR3HH_XA]_U$_^2?\ VX?Z]?\ 4/\ ^3__ &I^ME%?DG11_P 0
M^_ZB?_)/_MP_UZ_ZA_\ R?\ ^U/ULHK!^%7_ "2_PW_V +/_ -$)6]7YU4A[
M.HX]G8^]ISYZ:EW5PHHHJ"S\A?\ @O\ ^"]57]JF/XF_M=_ 3Q_\1/V<[7]G
MC6;+PA#X2T^ZU#2O#7Q ::9H]3U6TMF!"?9O)2.>56C1L87*LP^A?^"&:_\
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M!;HZT =C^VY^UY\//V&OV:O$7[1GQ%MKB^CTF%(-$\/V W7FO:I.PBL]-MD
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MY_\ [FH_X>E?]4+_ /+G_P#N:C_5'B'_ )\_^30_^2#_ %IR'_G]_P"2R_\
MD3Z>^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:^8?^'I7_5"__+G_ /N:
MC_AZ5_U0O_RY_P#[FH_U1XA_Y\_^30_^2#_6G(?^?W_DLO\ Y$^GOL7C?_H-
MV7_@,?\ &C[%XW_Z#=E_X#'_ !KYA_X>E?\ 5"__ "Y__N:C_AZ5_P!4+_\
M+G_^YJ/]4>(?^?/_ )-#_P"2#_6G(?\ G]_Y++_Y$^GOL7C?_H-V7_@,?\:/
ML7C?_H-V7_@,?\:^8?\ AZ5_U0O_ ,N?_P"YJ/\ AZ5_U0O_ ,N?_P"YJ/\
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MQ'^\3]7^9^]8?^!#T7Y!7YH?M1?\G#^,?^P_<?\ H5?I?7YH?M1?\G#^,?\
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MFV\3_P!KQ_88+F.^^Q?9]RR+N V;VQ^=:O[.O[.=_P#'K5IXKKQ/'H6FPR)
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M $=)7QW'O_(KI_X__;9'U?!/_(RJ?X/U1Z91117Y0?IP4444 %%%% !1110
M4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?E%XJ_Y&?4O^O^;_ -#-4*O^*O\
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M\RC/W]$EH[2VYKR2YGT]#FJ8S!TYIR7/+ELY0]W5M[7COR^ZW9=?4]^_;/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%?T;3_AKT/P&I\;]0HI0"Q"J"23P!6CXO\*:MX(\17/A?6U07-JP63RR2IR
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M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
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MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R
MB\5?\C/J7_7_ #?^AFJ%7_%7_(SZE_U_S?\ H9JA7]&T_P"&O0_ :GQOU"K&
MJ:KJ6MW\NJZO?2W-S,<RSS.69SC&23UX%5Z*JRO<5W:P4444Q!1110 4444
M%%%% !1110!^IWPJ_P"27^&_^P!9_P#HA*WJP?A5_P DO\-_]@"S_P#1"5O5
M_.N(_P!XGZO\S]ZP_P# AZ+\@K\T/VHO^3A_&/\ V'[C_P!"K]+Z_-#]J+_D
MX?QC_P!A^X_]"K[;@'_D85?\/ZH^/XW_ -QI?XOT9P5%%%?JA^:A1110 444
M4 %%%% !1110 4444 %?I!^QS_R;/X2_Z\'_ /1TE?F_7Z0?L<_\FS^$O^O!
M_P#T=)7PW'O_ "*Z?^/_ -MD?9<$_P#(RJ?X/U1Z91117Y0?IP4444 %%%%
M!1110 45Q_Q._:$^ 7P3:)?C-\</!_A$SKN@'B?Q+:V'F#.,KY\BY&>.*UO
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M_P"TOXC^%,E]J4)UOQ/X/L[=]5DTX*XFM;2:=66SED)3%RJ,\84[1DY'IM%
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MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
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M>_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@
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M1\?QO_N-+_%^C."HHHK]4/S4**** "BBB@ HHHH **** "BBB@ K](/V.?\
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MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
M,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$
MEU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^
M$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\ OI:/^$EU
M?_H4+W_OI:V** /RA\3L6\2Z@Q4@F^F)![?.:HU?\5?\C/J7_7_-_P"AFJ%?
MT;3_ (:]#\!J?&_4****LD**** "BBB@ HHHH **** "BBB@#]-_AAXBU6/X
M:^'HT\*7;A=#M '#+AOW*<UN_P#"2ZO_ -"A>_\ ?2U#\*O^27^&_P#L 6?_
M *(2MZOYUQ'^\3]7^9^]8?\ @0]%^1C_ /"2ZO\ ]"A>_P#?2U^<?[2\TEQ\
M?O%T\MNT3/KDY:-^J_-T-?II7YH?M1?\G#^,?^P_<?\ H5?;< _\C"K_ (?U
M1\?QO_N-+_%^C."HHHK]4/S4**** "BBB@ HHHH **** "BBB@ K]#?V1M=U
M*U_9Q\*V\/AFZG5;%P)49<-^^DZ5^>5?I!^QS_R;/X2_Z\'_ /1TE?#<>_\
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MDZ]9:UNL;A'\RQMU$D_DHS7"[?N- KGA#7FOQ1^%O_!-7X7_ /!6KXX^+_\
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M)9)'(5$506+$@  DFOD#P!_P7X_X)=?%'XJZ/\*/ GQRUK49?$7B2#P_X?\
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M6@MM N+E?^$XUD^9$1C/VEN.:]M_X275_P#H4+W_ +Z6O(_^">__ "1/5O\
ML>]9_P#2DU[I0!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 ?CK^W-^
MS=_P4 _8?^,_Q!^._P  OA+X1^)WPY^-'[27PZ\83Z'JFNMI'B2R\06WB'2Q
M;:9'<R(]O):7%S'%"LCX\@3EBN$8O]T?L*_\%$M&_;V\&^.M ?X >*/AYX]\
M!Z\_A[XD>!/$9ADNM&OVA#(PEC.RYA=.4E&W>$/ &"?%/^"E'[%G_!0'4((?
M$?P._P""AOB.?PSKOQW\%:E9^ ]<^%=CKK>&IF\4:=(MW;7:-#/]CLY MT8)
MMZ>5;LA=%)<>Z?LH_P#!.0_LI_![XHZ1H_[1OB;7_BK\8;V\U7QI\8]7L+9;
MV35I;4V\%S!:1!8((K8;6BMQE5P1NP0  ?%-W_P2H_;N_P""8G[$5SKO[$/_
M  5!^)R77PC\,WVKZ9X*\6>'M+F\,:C#!YU[<VAM=A>#SF:;$AE=E+CD8#+]
MZ?L)?MHW?[8'[$?PZ_:XU7P"VC#Q?X.M]6U6W6X M[.?81<A7<Y\I9$DVLW.
MP GO7S;\4_\ @F!_P5N_:4^'M[^SC^TC_P %F;.\^&^MV[6/BV3P=\#K'2-=
MUW3G 66U:Y6Y>.U$B;E9HT(()4JRL5KU#]N?_@E7=_M'_P#!.'1O^";'[+/[
M1]]\$/"NE6^GZ7<7VGZ"=5>^T.UMWB;395^TV[E9F,+R2>9E_+96#"5Z /GG
M5/&?B?\ X+I_MF_#_P 7?#/PI>)^RO\ LY?$:/Q+'XN*@?\ "Q?&-CO2W6P)
MX;3[1FD#SC*S%W1<@AD^[_VF/VO?A1^Q_P#!/7?VAOVB+[_A&_"GAVU,VH:C
M>2KEB>$AB0?-+*[$(D:@L[, !7R[^SU_P34_X*O_ +/EMX.\#:#_ ,%H=!'@
M'PE+90)X(TG]E+0M/@FTV!UWV4<D5X6@#QJR>8H+*6W<GK<_X*E_\$B_V@?^
M"A_[17PT^-_P_P#V^XOAUI/POB6[T+P1J_PHMO$VFOK8EE;^UI(;F\BAEE6-
MXHT66*01F(LA!=J .=_X)M_"?]HG]HK]L+Q=_P %F?VJ_A%J?A+4O&G@F#P?
M\&OAU=A5N_#W@];G[6)K_/2\NIL3&/\ Y9"1U)._:GWI_P )+J__ $*%[_WT
MM?//[(O[+G_!2SX/_%AO%O[6/_!5&T^,?A4Z5- OA"'X#Z7X<*W3,ACN?M=K
M<R2'8%<>7MPV_)/RBN[^"W[.?QH^&O[5/Q=^._C?]JS6_%WA/XA'1SX.^&U]
M8/':>"?L=LT5S]GD-PZR_:782MMBBP5P=_6@#\M_^"?GA_\ X*4_'?X;_%[X
M[_\ !&WXF^%_A)\"/'_Q"US4/A[X=^).FKKEU)J7G-#>:A:.D*_V9:RSQY2W
ME^U^6T;G;@_-]9_\&^GQ ^%;?\$^5^&GPE^#'B/P_J_@#Q]K?AOXGV.NZY'J
M5V_BN&<2ZA/)=I'$MP9#/&X81H%5@@&$R<KX>_\ !(O]N[]C=/%/PM_X)M_\
M%+--^'_PJ\2Z]>:MI7@SQE\)H-?G\(SW3[YAI]R;F+?%N)*12H57'.YF=V^E
M/^"<G[ W@#_@G)^S='\!?!7C+5O%%_?Z[>>(/&'B_7B/MFOZS=LK7-[*JY"%
MMB*%!)"1J"SMEV /8?\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X
M275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6MBB@#'_X275_^A0O?^^EK\S?^"X.A>)=9_:?^$7Q$_:F_9G^(WQ(
M_9=T/PSK2^+O"W@JQN;^"S\2.%^Q:CJEE:,'N+5$&$+!DC?>2/FVO^I5?/'[
M9WQB_;O^$FMQW'[.7[&VB_%KP7=^')EUI+;XAV^AZUIMZ#)ET2]3[/<P&+9@
M>;&X8-U&* /C[_@W?UK_ ()1:G\%O"GBC]B#2M#C^,5K\'M"TSXPZ9HVH75K
M=37:6UK]JN9]/G94D/VM&!NXXB&+X$C!QFU)\(_^"Q?[,?\ P44_:>_:B_9)
M_9+^'/BWPM\8-6\,75C'XV\=O8W<\>E:,EJR0) CJC/+)*NZ9D \L'&&!K!_
MX(\_LD_M/?&WXH?LV?\ !0+XO?!'P[\+_"?PS_97TCP?X6^Q>(H=1UGQZEQI
MMHL6H7GV= EM:+"OF16\CO,CN-P&2$^COB_^WA_P5%^%WQ&\4^!/"_\ P1AU
M_P =Z?::Q=0^"/%GASXPZ)!9:W9B4BWFN([@B6P8H5WJZO@@D<'@ ZW_ ()P
M_P#!2:S_ ."@OPE\0:[>_ ;6O!'C;P)XJNO"OQ,\ :K=QSS:%J]OCS(1*%43
M1$,"LFU<X88RIKYI_:]T;P]X$_X+W_L':'X&^&%KH-A:>&OB2+;2=*LH;:+G
M1,'8D8"C'TKV[_@CK^Q3^T1^S'X4^*WQX_;#FT2#XJ_'GXE77C+Q5X?\-7'G
M6&@1NH2WTZ.7D3-&N_=("0=P4,^W>_RG^T?<?\%K/C#_ ,%)O@7^W-I/_!$Z
M[@L?@=9>*;%-"/[1/A=FUY-5LC:)*)C(OV;RQB3:8W+9V_+UH [S_@Z6^/VN
M?#;_ ()I:5X4U#P_KT'A[Q]\7?#_ (<\9Q:,X%W=Z.3<7MQ;0D$'?*+)8\9
M8.5)PQ%3>)?^"F?[=?\ P3R\"^"?B%^VC_P33\"_#_\ 9YNM1TW0<> ?&[7F
MH_#RWF98K,W]NUM'!)$AV(WV<A4.,$G:C^S_ /!0[]CSXW?\%4_^"8<7P_\
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MG_\ N:C_ %1XA_Y\_P#DT/\ Y(/]:<A_Y_?^2R_^1/K:BODG_AZ5_P!4+_\
M+G_^YJ/^'I7_ %0O_P N?_[FH_U1XA_Y\_\ DT/_ )(/]:<A_P"?W_DLO_D3
MZVHKY)_X>E?]4+_\N?\ ^YJ/^'I7_5"__+G_ /N:C_5'B'_GS_Y-#_Y(/]:<
MA_Y_?^2R_P#D3ZVHKY1TK_@IY_:>J6VF_P#"D-GVBX2+?_PDN=NY@,X^S<]:
M^KJ\S,,IS#*G%8J'+S7MJGMOLWW/1P.:8',E)X:?-RVOHUOZI!1117G'>?S6
M?$?_ )*'KW_8:NO_ $<U8U;/Q'_Y*'KW_8:NO_1S5C5_8%'^%'T1_)U7^++U
M84445H0%%%% !1110 4444 %%%% !1110!_1Q^S?_P F[^ O^Q+TO_TDBKM*
MXO\ 9O\ ^3=_ 7_8EZ7_ .DD5=I7\AXO_>ZG^)_F?U9A?]UI_P"%?D%?S]?\
M%$_^3YOBI_V.E[_Z'7] M?S]?\%$_P#D^;XJ?]CI>_\ H=?I7A7_ ,C:O_@_
M]N1^>>)O_(KH?X__ &UGC%%%%?N1^+!1110 4444 %%%% !1110 4444 %?O
M7_P2N_Y1^?#+_L"S?^E4]?@I7[U_\$KO^4?GPR_[ LW_ *53U^9>*?\ R)*/
M_7Q?^DR/T?PS_P"1S6_Z]O\ ]*B?0-%%%?A!^VA1110 4444 %%%% !1110
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M_29'Z/X9_P#(YK?]>W_Z5$^@:***_"#]M"BBB@ HHHH **** "BBB@ HHHH
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M;;-LRK4J^)4H.^B3LFE=*WNI[+LK+T1?\*_\C/IO_7_#_P"ABOU=K\HO"O\
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M=_Y6_P#[11_PW1_U2[_RM_\ VBOG^BC^SL'_ "_B_P#,/[1QG\WX+_(^@/\
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M7I?_ *215VE?R'B_][J?XG^9_5F%_P!UI_X5^05_/U_P43_Y/F^*G_8Z7O\
MZ'7] M?S]?\ !1/_ )/F^*G_ &.E[_Z'7Z5X5_\ (VK_ .#_ -N1^>>)O_(K
MH?X__;6>,4445^Y'XL%%%% !1110 4444 %%%% !1110 5^]?_!*[_E'Y\,O
M^P+-_P"E4]?@I7[U_P#!*[_E'Y\,O^P+-_Z53U^9>*?_ ")*/_7Q?^DR/T?P
MS_Y'-;_KV_\ TJ)] T445^$'[:%%%% !1110 4444 %%%% !1110!X7_ ,$]
M_P#DB>K?]CWK/_I2:I?\%4?^4?GQ-_[ L/\ Z505=_X)[_\ )$]6_P"Q[UG_
M -*35+_@JC_RC\^)O_8%A_\ 2J"O5R/_ )'>%_Z^0_\ 2D>9G7_(GQ/_ %[G
M_P"DL_!2BBBOZO/Y>+&EZ3JFMWJZ9HNFW%Y<N&*6]K"TCL%4LQ"J"3A02?0
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M ,C:O_@_]N1^>>)O_(KH?X__ &UGC%%%%?N1^+!1110 4444 %%%% !1110
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M_P#)0]>_[#5U_P"CFK&K^P*/\*/HC^3JO\67JPHHHK0@**** "BBB@ HHHH
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M?_(]'_#RG]K+_I$_\4__  +'_P CU]C45\D?4GP_\2/V^OVLOB#\.]?\ _\
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M+>#M NO$_B7]GKXDV%A91>9=7E[X.6.*)?[S,;C"CWK^@NO*/VY_^31_'O\
MV 7_ /0UH_U_XM_Z"?\ R2G_ /(!_J+PK_T#_P#D\_\ Y(_%6Q_8#_:IU&RA
MU"R_9K^*$L,\2R12Q>"@RNK#((/VCD$'.:E_X=[_ +67_1LGQ3_\(@?_ "17
M[O\ PN_Y)GX=_P"P%:?^B4K=H_U_XM_Z"?\ R2G_ /(!_J+PK_T#_P#D\_\
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M_P#%O_03_P"24_\ Y /]1>%?^@?_ ,GG_P#)'X0?\.]_VLO^C9/BG_X1 _\
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M  B!_P#)%'_#O?\ :R_Z-D^*?_A$#_Y(K]_**]W_ %_XM_Z"?_)*?_R!XO\
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MT;)\4_\ PB!_\D5^_E%'^O\ Q;_T$_\ DE/_ .0#_47A7_H'_P#)Y_\ R1^
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MF_?&H51M4X7<57PGX#:K_P %G?V^_P!C6_\ ^"HOPQ_;L'PYU/7X-1UWX3?
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M>_\ !M-_P14U#5+S69_V.KI;C4+R2ZO'A^*7BB,232-N=]J:F%!)/8"OH_X
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M;3?C?^U-\#+OQ%XJTC0%T33]8LO&^M:4\5@LTLXAVZ?>0(P\R:1MS*6.[!.
M  #YX_X.9_C_ /#_ $K_ ()O^)/V--#U*VUKXK?&K4]'\._#WP#83++J6I7#
MZG;2M*L )<1JD3?O"-OF-&N07%?=_P #O M_\+_@IX/^&>JWBW-UX=\+:?IE
MS<(21+);VT<3,,]B4)_&O&_V4?\ @D;_ ,$W_P!B+Q>?B)^S/^R=X=T'Q)Y;
M)'XFO);G5-3B5EVL([N_EFFCW+PVUQN'!S7T;0 5^?O[;?[6GQM_;J^..M_\
M$IO^":GBEM.OK.,6W[07QSM5,EIX T^3*R:;9N"!-K$RAT"J?W'S<JZN]O\
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M.SN=3G\@X]'1!(IZ%9%/>O1OC3_P0K_X)B_'WXN:W\9OB%^S[<C4?%.H)?\
MC#3-%\7ZIINE^(+I6WB>]L;6YCMYW+?,S%,NQ)?<2<_5WAOPWX>\&^';#PCX
M2T.TTO2M*LHK/3--T^W6&"TMXT"1Q1QH J(JJ%50    * +M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOSU_X.H/^4&GQC_Z_/#7_J0Z=7W]X<_Y%ZP_Z\HO_0!0!<HK\;_^"0G[;?\
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MB[6/$.M:C:>)+]+^$7$MA+J\\TDEM%^ZA\R,B)Y4E"[MFX^R_L7?MF?LW?\
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M]N/_ ()(C7/VB_V7/"^L>)/$/BKQ18W/C1-/6+68%749XXI(KM0)$>,!=G)
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M=V4UNCDCH T@.?:OS:_8!_X+3_L9?L2_\$P_#7[-_P"T]J]WX2^-?P:\*_\
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-20210930_g5.jpg
<TEXT>
begin 644 biib-20210930_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M2@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
M"@<#_1K&@"U\;/\ @L_^U!\#/A_IO[;/B_\ X)VSV_[+M[J=@LWQ G\>Q+XB
M@T>]GCAMM<?1OLY,=O(9HF6!IO.V2H7$1)5>3_X+9?&S4?@1_P %/OV!?BSX
M4^&>J^.=2@UGXA6V@^%M EB2?5[Z\T6SM+6%99"(X8VFN(M\SG;%'OD.0I%=
M%_P6L1$_X-MO',:( J_"GPN%4#@#[7IE>>_\%=?C?I7[.'[>?_!.3XX>(_"N
MJ:SI7AY_&EQK<&CZ;)>7%M8'0M/2ZO1#$K/(MM \ERP16;9 VT$X% 'T)\+?
M^"FW[3/@/]KSP5^R+_P46_8RTWX67/Q6BNQ\+_&'A3Q^NOZ5J-_;1^;+I=RY
MMH'MKCR\%&(*RDA5&>:O_&[_ (*4?M >(OVK/%/[&/\ P3M_9&L_BOXG^'=E
M9S_$[Q1XF\:IH.@^')[N,RVUCYH@GDN[IXQO9(T C!^9B0RK\\_M2_M;? /_
M (*S_M^?LI? K]@;QY!\1+?X6_%6+XF?$GQEX>MY7TWPYIME!(L-O-<%0OFW
M4CF-8E)8%1N S7A_CSX,?LS?LE_\%2_VA]+_ ."D_P"TS\:?@OX?^+7C"'Q?
M\)_B#X,^)&KZ!X=\00S0?Z58W$UD?*6\MG&P";!*#@A3'O /T2_9+_X*6ZM\
M=?#7Q@\%_&G]GJ\^''Q@^!, D\?_  XNM>COH7BEM)+JRN[.^CC"SVMS'&VU
M_+#(00RGY2WFG[ /_!5O]M/_ (*0>%OA[\=?@I_P3A@T'X4>(+Q;?Q7XP\3_
M !.A6:!EE:*Z;3;46J27T4#*4,SB'S)%D1$/E[FXW]A/P-_P3!OO#_[2/QC_
M &!/VD/B!\6/$#?#A=*\=^,_&/BK5-:@E06U\UK!#>WR!;AHQ')N$3N(U= <
M;@*]>_X-ZXHH?^",'[/R11A0?!;L0HQR;RX)/XDDT ?8NHV%OJNGSZ9=AC%<
MPM%*$<J=K @X(Y!P>HK\7/\ @I3^RC_P;6?LD?"GQ_\ LV^&_!FDZ#\?M'T0
MGP1I/A35-:O/%Z^(KBU6?2S%*)))))))9;=_WC%,/EL"OV3\?>--&^&_@36O
MB)XC6Y;3] TFYU&_6SMFFF,,$32OLC7YG;:IPHY)P!UK\T/VWO\ @K__ ,$!
M/VEOV7?&FCZUXQ\)_%/7O%?AVYL-(\'6/@&[G\0:GJ+P&.UABCDM%F@G$GEA
M)&*>4R@A@5% "?M__&G]N?\ 9[_X(1?!OX4?$;Q[J.A?';XLWW@_X:^(/%"7
M>[4--O-1XNI6E0\W7D0RQO*K9\QW=6R U<7_ ,%3O^"=W[,'_!&G]DKPO_P4
MA_X)\?#Z?P+XV^!GBO07U[5-/U:X:;QAHMU?06-[8ZGO<K=>>UQ&[.PW @[2
MHP WXZ_L=_MQ7_\ P;B? J#QMX-UKQ#\9O@1J_ASX@MX2N \NI7$.FW<SQV!
M7ES<0Z=<*ICP7W6Y0 M@%?\ @J5_P43_ &8?^"S/[)GA?_@F[_P3X\>W/CGQ
MM\<?%F@IX@TRPT>Y27P=HMK?07U[?:GOC"VOD-;QHR$DDD[=V!D _7>TNK>^
MM(KZUD#Q31J\;C^)2,@_E4E>,_'?]M7X)_LN_''X.?LQ>-=-UR77OC-JM]I/
M@F/2+!)H8WL8(I9FN&,BM'&L<B'<JOT.<=:]FH ^._BM_P $,O\ @EC\6?B)
MXW_: _:6^ B>-_$'BV\N;_7O$/C7Q3?2BQA;+&*V G2.R@B7(7RU5E Y8XS7
MSU_P1+^/WB[X)_\ !+[]HWXO6'BG6O%WP?\ A/\ $#QQ<?L_ZQXFNY)IM1\(
MZ7;F6W1)7^:6W#Q2HC=CYB@*$"KXY_P5,_X+'_LI_M/?MH>(/^"8/QK_ &K)
M_@O\"? FH-:?&WQ##I>HR:OX\NXI-LGAZQ-G;RM:V092MQ</M:4 HF4YD^]/
MV??B_P#\$_/^"E7[ 7Q _9L_X)V?$31[OP';^"K[P$(M(\/WFGVNC"ZTUX8X
MEBN8(F*K'*&RH.><G.: /CW]B+_@C-^SY^W5_P $K[+]K;]I33M0\1_M&_&7
MPY=>,_\ A<=QK-RFK:/JMP9)M,:R=) +:*W7[,!"@"'81C;M5?=?^"?VC>"_
M^"Y7_!%+X,ZM^VO=:YK46IQ?\5E;Z9KUQI[Z_=:5=W>GM]KDMF21XYS")Y$1
MDW.PY &*\(_8D_X+-_L__L*?\$LK+]D7]I2]U+PY^T=\&O#EUX,7X.3Z)=2:
MMK&J6YDATP62)&1<Q7"FV(F0E!N8YVA6;O?@I\;++_@W1_X-Y_AQKW[2/@>^
MOO%NDZ:\4/A&W.R2;Q!JUU=ZC'83R8*P+")7663G:+=]H=BJL >>_M]?L._L
MG_\ !.']LO\ 9(U#_@EMX#/P\^-'C'XTZ?I&I^%?"6JW1A\0^#%5VU>34+9Y
M'5X(5$9,Q (#NV245H_OC_@H-_P3@_9I_P""@_A[1H?VFX?%.HZ5X1M-2DMO
M#VB^,+W2['4&N$A+&\2TDC:XV?9UV98;=\G]\U^=?_!+'_@I9_P2:T3XQR_M
M6?M<_P#!0C1/B'^U3\7)K;2[J\M?!>NC3_"]K-*JVWAS1Q)9;8+9'=5>7(,S
MY=F(^8_I'^WK_P %$?V-O^"?G@73]5_:_P#C5!X-M_%JWEGX>DGT>^N_MD\4
M0+H!:02E,"1.6V@YX/6@#YW_ .#6W_E!7\$/]_Q-_P"I+JM?H%7Y)_\ !JU_
MP41_8VUG_@GS\(?^">NF_&J"7XQ:3:>)+S4/!@T>^#PPG6M0O _V@P?9S_H\
MT3X$I/S8QN! _6MRX0F-06Q\H)P": /C+XM?M@?\%@O"FK>)/%7PW_X)->&]
M;\(>'[^[6QM+OXYVT6O:_902,%NK>VCLI(H6EC7>D$DID^8*<,=HE^.'_!8[
MX8^!?^".\_\ P6!^#OPQN_&'A[^Q-.O[/PE?ZN-,N&DN-5@TV>VEG6*X6*2"
M:656VHZLT! .&##\WOV9/B7_ ,$WOCC\#]=\8_\ !7;XF?%3QY^UW_PEFLV7
MB#X)GQ]XHT_4H=46]G2QT?1]*TRX@C6%X?LX5E#(ID<LZ*IVT-*6=/\ @QRU
M:*XB,;I-.K1[B=A_X6,,KDD]\]Z /NOXS?\ !8_]K[]G3P7H_P"V!\<O^":T
M_A_]F_4]6T^&^\83_$2"3Q)HNFWLT<5MJMYI"P%8HV::+-N)S*GF .5;*U[;
M_P % /\ @HGX@_95\=?#G]FW]GGX"S_%?XS?%JZNU\&>"XM=CTVT@LK2,27>
MI7UXZ.+>WB5@1\I:0@JO()'EW_!R$B)_P0H^-T:( JZ!H@50.!C6M.K@?V\O
M'.E?L-?\%1OV<?\ @I+\<[:\@^#]Q\)M2^'7BWQ=#8RW%OX3O[B1+JSNKH1J
MS1Q3N3#YF,+M.XCC(!P/Q)_:,_:.^+/_  7J_86^%O[67[+B?#3QKX3M?B7>
M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2
M N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME00*^[* "BBB@ HHHH ^$O\ @KK_ ,$^O@_^T=I7C/\ :G\ _M!^*OAQ\9/
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MA]JRQ2>&=3BOEDN+-!<2VH:%F!EQ$5\O.[+ 8R:X>X_:L^#9_P"#<)OVC_\
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M !$G_J%_\G_^T#_6K_IS_P"3?_:GW917PG11_P 1)_ZA?_)__M _UJ_Z<_\
MDW_VI]V45\)T4?\ $2?^H7_R?_[0/]:O^G/_ )-_]J?=E%?"=%'_ !$G_J%_
M\G_^T#_6K_IS_P"3?_:GW917PG7UW^S_ /\ )'="_P"O5O\ T8U>_P .\6?V
M_BY4/8\G+'FOS7ZI6^%=STLKSG^TJSI^SY;*^]^OHCL:***^Q/<"BBB@ HHH
MH **** "BBB@ HHHH ^>OV"[;Q)+\'-6;2=2MXHO^$XUG*RPECG[2W.:]M^Q
M>-_^@W9?^ Q_QKR/_@GO_P D3U;_ +'O6?\ TI->Z4 8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (U\W:K^TC\:+;5+FWA\9[4CN'5%_LZV. &('_+.J_\ PTO\;?\ H=?_ "FV
MW_QNOA)>(62Q;7LZGW1_^3/G7Q-@$[<LON7_ ,D?3/V+QO\ ]!NR_P# 8_XT
M?8O&_P#T&[+_ ,!C_C7S-_PTO\;?^AU_\IMM_P#&Z/\ AI?XV_\ 0Z_^4VV_
M^-TO^(AY+_S[J?='_P"3%_K/@/Y9?<O_ )(^F?L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&OF;_AI?XV_]#K_ .4VV_\ C='_  TO\;?^AU_\IMM_\;H_
MXB'DO_/NI]T?_DP_UGP'\LON7_R1],_8O&__ $&[+_P&/^-'V+QO_P!!NR_\
M!C_C7S-_PTO\;?\ H=?_ "FVW_QNC_AI?XV_]#K_ .4VV_\ C='_ !$/)?\
MGW4^Z/\ \F'^L^ _EE]R_P#DCZ9^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
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M3?-/80R2O@#<S("3@<#DU?K[FG-5(*:V:N?0QDI1374Q_L7C?_H-V7_@,?\
M&OD[XOK<I\3]=6\E5Y1J,GF.BX!.>PK[)KX[^-/_ "5CQ!_V%)?YU^?^(O\
MR+J/^/\ 1GS7%'^ZT_\ %^AR]%%%?D1\4%%%% !1110 4444 %%%% !1110
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M?\AJ\_Z^I/\ T(U5JUKG_(:O/^OJ3_T(U5K^8JG\1^I^2S^-A1114$A1110
M4444 %%%% !1110 4444 ?;/@G_D3-(_[!=O_P"BUK3K,\$_\B9I'_8+M_\
MT6M:=?TSA?\ =H>B_(_6*/\ "CZ(*^._C3_R5CQ!_P!A27^=?8E?'?QI_P"2
ML>(/^PI+_.O@_$7_ )%U'_'^C/G.*/\ =:?^+]#EZ***_(CXH**** "BBB@
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ML4?X4?1!7QW\:?\ DK'B#_L*2_SK[$KX[^-/_)6/$'_84E_G7P?B+_R+J/\
MC_1GSG%'^ZT_\7Z'+T445^1'Q04444 %%%% !1110 4444 %%%% !7UW^S__
M ,D=T+_KU;_T8U?(E?7?[/\ _P D=T+_ *]6_P#1C5]_X=_\C:K_ ('_ .E1
M/I.&/]\G_A_5'8T445^PGW 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>
MK?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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MOAG?Z1H>AFYTZ3[8\S?:/(#RP0&!'DC9MSJBE=Y- 'W_ $444 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\2+?Q_'J+WDRW&U8)[5X8YHW*E\."Z8BP2"0*[K]K_\ 9"^%G[5NN^$;F_\
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M6/A4EU;0G4[.V:ZET[4;2YYCD>!)&CDCPI*A1O)8Q@'WK1110!X7_P $]_\
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M?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/
M^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK
M-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?
M]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S?^$Q\,?]!J#_
M +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH TJ*S
M?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\
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MCX8_Z#4'_?5?N=-6II7OH?H45:*1I5\=_&G_ )*QX@_["DO\Z^LO^$Q\,?\
M0:@_[ZKY)^,-Q!=_%'7;FVD#QOJ4A1AT(S7Y_P"(O_(NH_X_T9\UQ1_NM/\
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MACPS\'/^"#WQ@^#'B2Y^V_V=\2O%/[*%GX:L-'VV4[R>;J4?S6WFQJ]NN/\
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M_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\
MSXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344
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MM-- K/$?521E>@Z>E6:*$VM@/M/P586+>#=)9K*$DZ9!DF,?\\UK3_L[3_\
MGQA_[]"J7@G_ )$S2/\ L%V__HM:TZ_IG"_[M#T7Y'ZQ1_A1]$0_V=I__/C#
M_P!^A7R!\9T2/XK:^D:A5&IRX & .:^Q:^._C3_R5CQ!_P!A27^=?!^(O_(N
MH_X_T9\YQ1_NM/\ Q?H<O1117Y$?%!1110 4444 %%%% !1110 4444 %?6W
MP"LK.7X/Z%)):1,QM6RS1@D_O&KY)KZ[_9__ .2.Z%_UZM_Z,:OO_#O_ )&U
M7_ __2HGTG#'^^3_ ,/ZHZQ+&RC8/'9Q*PZ%8P"*EHHK]A/N HHHH **** "
MBBB@#\UO%7P?_:O_ ."E/_!1;X_?![Q=_P %"_BQ\$?!7P7O-!T_PAX*^#FJ
MPZ1?:E#?::EVVK7=VT;O/')*98T4#8IA9>&1MWM7[+G_  2=\6?LT?';0OC;
MJ?\ P5*_:G^(\&B?:M_@SXC_ !,CU#1=1\ZUEMQ]HMQ;(9/+,HE3YAMDBC;G
M&#\W>-OV&_$/_!4#_@KE\=+SX^?M8?$SX6M\$;+0]"^&FB_![6H- U2YT74+
M!+R6_N+\0/-=6\MT)T5 =B/#(N<JP/TC^RY_P1Y\)_LL_';0OCQIG_!0']J?
MQO/H7VK9X7^(_P 9)-5T6]\^UEMS]HM3;H)=@F,B?,-LD<;<[<4 ?7]%%% '
MA?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?#NN?\ (:O/^OJ3_P!"-5:M:Y_R&KS_ *^I
M/_0C56OYBJ?Q'ZGY+/XV%%%%02%%%% !1110 4444 %%%% !1110!]L^"?\
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M>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%% !1110 5]=_L__P#)'="_Z]6_]&-7R)7UW^S_ /\
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M[5G_  2F\-_#7P#>_:O[>\:V'QKTW5YM.V6LTD&VTA^>7S)UAA./NB4L>%-
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M)# >O5^:?_!N1=?\([\*OVI='T+P<\=I!^VMXZ2WMK-$CCMT6+3E6)5& H4
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MM)^US)_PC7[.O_!-?2_@-I5P=D_Q'^/WBJ.ZFM4/#&#1+ ":291\R>;(L3'
M8XS7WS10!C?#K0_%GAGX?:%X;\>^-V\3:[I^C6MMK7B1M.CLSJMW'$J379@B
M^2#S7#2>6GRIOVC@"MFBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM
M_P!CWK/_ *4FO=* "BBB@#\;/VT?VGOVEOVV?VK_ (F?LZI^VC:_"#2/A'^T
ME\-/#'A3X9:+X>TV;7-9>Y\0Z04\22RWZ22/'%+*L\$<*"(^5&)@ZD^9^I7[
M+/PQ_:"^$GPUE\'_ +2/[3#_ !9UQ-6FELO%L_A&TT6<V3*GEP306?[EY$82
M9E54WAA\HQ7YI_\ !;?XY?\ !%KXVZHGP^_:V^'6GZ5\3?"_Q>\)Z1K=_P"+
M? 6HZ;J=WX<7Q%8KJ4EIJ4,*FZLVT\W;*89F8(6*JKD5T_\ P2^^!_[0_P =
M?V%_VG_@%\"?C/\ $7PE\(O%?B2^T?\ 9>\9_$:UO)-5TW1IK01SSVZW9CNO
ML0D8BW+E' WL"K[C0!\P?\'#GCGQ1_P4>_8\^,'[6/A[7[J'X%? CQ+IOAKX
M6_99BL'C/Q3)J]K9ZMK>1Q-:6L3RV-NPW*[R7,BL.E?MW^T)\>_A;^RW\$?%
M'[0WQK\2QZ1X5\(:/-J6M7\G)6*,<(B_QR.Q5$0<N[JHR6%?B)_P6:_81_X*
M0_L9?\$3=:^%GQ"_;D^'OB/X/^#(_#NEV_@/PY\'8])G>-=3M8X&%V+EV#+*
M5E=B"TI#;CER:^^OVO?^":/_  4 _;&_95^&/PC^)'[>'A*;QKX(^(Z>*O$.
MO2?"\'1_$7V9Y'T^WGTU;D(R0NT;E'9HY'B5F0X& #XW^'?P\^/.N_\ !>O]
MBW]N/]JJ&^TOQ[\=++XAZG%X*N9B8_!OARV\-S+H^CA3C$Z0W$L]PV%)N+N4
M%05Y_2[_ (*5_MB>*_V6OA#I7@KX$:-;Z[\:/BIK(\+?!SPS-RMQJLJDO?3C
M!(L[.+==3N1M"QA25\P&OS*_;#_9]_X*WZ3_ ,%E?V._"/C_ /X*'^!=7^(.
MK:7X\;P!XPM?@[%;VN@)%HVZ]6>S%P1=F:']VI++Y9^;GI7V?^U7_P $T?\
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MXG@EL2F][G2-6M=3@B;>I'EO+:(CXYV,V"#@CN*X3_AI?X)?]#K_ .4VY_\
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M?\AJ\_Z^I/\ T(U5JUKG_(:O/^OJ3_T(U5K^8JG\1^I^2S^-A1114$A1110
M4444 %%%% !1110 4444 ?;/@G_D3-(_[!=O_P"BUK3K,\$_\B9I'_8+M_\
MT6M:=?TSA?\ =H>B_(_6*/\ "CZ(*_$?]NK_ )/$^)'_ &-MW_Z'7[<5^(_[
M=7_)XGQ(_P"QMN__ $.OG.*_]TI_XOT/+SC^#'U/)Z***^%/GPHHHH ****
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MV[_]#KYKBO\ W2G_ (OT/*SC^#'U/)Z***^%/GPHHHH **** "BBB@ HHHH
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MK/A3\6?"'_!,NXDTGX,^,]5OK*8_&+0E_P"$BMYHQ!&ZAW5K7*H),,KD;]I
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MD#[-'CO75_8O&_\ T&[+_P !C_C7Z_1_@Q]$?:T_@7H;%?B/^W5_R>)\2/\
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M88C(Y]*XZ-; PG><);+X9I._5W<7OT73NS"G/#QE>47TVE;7KT>_X>9\A?\
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MVZ[+6/?$[*"5)W '^%<\\#VBBLY8JK)U&]Y[OYW_ !?Y$NM-\S?VM_ON<?\
M$?7OC%I/BWPG8_#;P19:II%]JC1^+;VZNEC?3K7 Q+&K2*78G(P YXZ5Y?\
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M 4444 %%%% !7[1?\$W_ /DR+X??]@F7_P!*9J_%VOVB_P"";_\ R9%\/O\
ML$R_^E,U?3\*_P"_3_P_JCULG_WB7I^J/;J***^]/H@HHHH **** "BBB@ H
MHHH **** /"_^">__)$]6_['O6?_ $I-3?\ !2#_ ),B^(/_ &"8O_2F&H?^
M">__ "1/5O\ L>]9_P#2DU-_P4@_Y,B^(/\ V"8O_2F&N3'_ .XU?\,OR9CB
M/]WGZ/\ (_%VBBBOR8^-"L;Q]XYT+X;^%I_%_B1I!:6\L,<GDJ"V9)5B7 )
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ME&I>^MO.WXL^H/AU\2? OQ:\(VOCSX<>);;5M)O03;WEL3@D'!4A@&1@>"K
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M<T*;5X](BD6UTU[^6.T+N5)D>-&7S&&W W9 !/%?,O[2OQ;_ &/?B7^SU9^
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M6N/_ $:U9-?CL_C9\0]PHHHJ1!1110 4444 %%%% !1110 4444 ?O)\ _\
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M 9@8,A0V"&(W8(XK]]_^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\
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M>-"%#/&K' \K@9-:?_#D+]DW_HHWQ3_\+8__ !JC_5*__+__ ,E_^V#^QO\
MIY^'_!/RUHK]2O\ AR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :
MH_U2_P"GW_DO_P!L']C?]//P_P""?E=-I>F7%TE]<:= \\?^KF>%2Z_0D9%3
MU^I7_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU1_JD_\
MG_\ ^2__ &P?V-_T\_#_ ()^9?@/_D>-&_["UO\ ^C5K]^J^.?\ AR%^R;_T
M4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :KVLIRG^RU-<_-S6Z6VOYON=V
M"P?U12]Z]_*Q]C45\<_\.0OV3?\ HHWQ3_\ "V/_ ,:H_P"'(7[)O_11OBG_
M .%L?_C5>P=Q^9?CS_D>-9_["UQ_Z-:LFOU*_P"'(7[)O_11OBG_ .%L?_C5
M'_#D+]DW_HHWQ3_\+8__ !JOCGPG=W]M_P"2_P#VQX;R:[_B?A_P3\M:*_4K
M_AR%^R;_ -%&^*?_ (6Q_P#C5'_#D+]DW_HHWQ3_ /"V/_QJE_JE_P!/O_)?
M_M@_L;_IY^'_  3\M:*_4K_AR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__
M  MC_P#&J/\ 5+_I]_Y+_P#;!_8W_3S\/^"?EK17Z(?M-?\ !(3]FGX4? 3Q
M3\1?#7C_ .),E_I&EM/:I>^,6>)F# ?,HC!(Y]173^"?^"+'[*VO>#-(UR]^
M(GQ06:]TRWGE6+QH0H9XU8X'E<#)H_U2_P"GW_DO_P!L']C?]//P_P""?F11
M7ZE?\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\ T4;XI_\ A;'_ .-4?ZI?]/O_
M "7_ .V#^QO^GGX?\$_+6BOU*_X<A?LF_P#11OBG_P"%L?\ XU1_PY"_9-_Z
M*-\4_P#PMC_\:H_U2_Z??^2__;!_8W_3S\/^"?EK17ZE?\.0OV3?^BC?%/\
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MJ64:7E01TSUH ^Z**^4OB)_P6Y_X)E?"CX._#WX]_$#]H:_T_P +_%675(O
M5X?AWX@DGU1].G$%X/LL=@UQ#Y<A _?1IO!W)N7FE^ '_!;[_@E;^TU\2;3X
M/?"?]L'1#XHU"5(M.T+Q-I&H:#<WDCG"1PIJEO;F9V/"HF6;L#0![7^S7\&=
M3^!G@*]\(:KK4%_)=>(;[45FMXV556>4N$P>X!P:]!HKA?'?[2OP3^&?QP\
M_LX>-_&GV+QI\3XM6E\#:-_9MS)_::Z9!'/?'SHXVBA\N*:-OWKIOW83<00
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MK&C>#?">CK-JWB+4DMDB^T7#D9.U #/<S/M15&9)'95&217H]?D7^VE\,/\
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M7EI9& &^61RTDCGEW=F/)-?,_P"U7^R;^T!\2?\ @L_^RI^UCX*\ ?;?A_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-?2:?;2I;'&249MX R5&1GVCP5^U9^S?\1?V=8OVM_!GQI\/WWPTET275_\
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MZED^,JYAEE+$U$E*:N[;?*]_S/L,#7GB<)"K+=J^@4445Z1U!117P!_P5_\
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MB>2QA>21V/+,S,22>I)H ]"HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU+D  M@ 5Z1\$OV#_P!DO]GG]GC5/V4OA=\&+"#P!KIO#KWA[5KJ?4TU5KI
MERUU)>22R7!E4 ,9&;(% 'Q[_P '+I_9S_X<0>//MQT#^R#;>'_^%9_8O*\K
M[5]NM?LOV#9QC[+YV/+X\CS?X,U]]?!O_DD/A7_L6['_ -)TKY.TK_@WJ_X)
M.6/AR_\ !6K?LZ:IK>A75C+96&AZ_P#$37;RUT6WD</(FGI)>G["6VA3)"5D
MV93=M9U;[,T;2-.\/Z/::#I%OY-I8VT=O:Q;RVR-%"JN6))P !DDF@#YL_;K
M_P""9_[ _P#P4I\1:=H_[0OA]9O'?@RS6;1?$7A7Q(^G>(=#MYG8HPD@</Y3
M.LA02J\>X.5&[)KY'_9^LOV@_P#@F!_P6>^%G_!.GPM^VUX_^,WPI^,/@36]
M4N?#?Q4UE=7UCP5+86\TT-REV%5UMYFA,")M1"6?*LRJU?8G[7?_  28_82_
M;@^)%C\:/CY\)+V7QMIFFKIVG^,?#GBS4M'U&&T5G80^;8W$6] 9'.'#8WG&
M*M_L<_\ !+#]AK]@_P 5ZQ\1?V=?@T;3Q9X@M_L^M>,M?UV]UC5KN'*GRC=7
MTTLB1DHA*(55BB$@E0: /!?^"*+I#^T=^W/ITKA;A/VLM6F>$GYECDL[8HY'
M7#8.#WP:J^$?VAO^"C/_  4-_:C^.OPX_9(_:+^'OP-\#_!3Q^?!TU[JGPW/
MB?7==U**"-Y[J6*6\MH;>V.0L1 9F"MDG''O?Q1_X))_\$^?C%^T;_PUMXU^
M !3XAO?6=Y=>(]"\6:MI+7L]J4,$ES%8W4,-T5\M!^^1\A0K9'%8_P ?O^",
M?_!/?]I/XWZM^T/\1?A+J]KXH\2V\5OXON?"OCC5M%A\111J$1+^&QN8H[GY
M!M)8;F7AB0!@ ^(?^"06JZSJG[(7_!1+PN?BWIGCY;;XI^,V'B;P]H4>FV.L
M7DFBA+B[MK2*22.%)I(]P5'93P0QSFOI3_@F3=^/+K_@W=^'T_P5FEE\5K^S
MQ=)X8-@V9?[46RG6!4Q_&)PHQU##%?3/[,W[#W[*7['&G^*-'_9F^#.G>$;#
MQGJRZEXBTW3[B=[6>X6!+==D,LCQVZ"*-$$42I& /N]:XO\ 9K_X)-?L ?L>
M_%V;XX?LT? >3PAKTT5S%Y>F>+M7.G1I<$&41Z=)=M919(&-D*[?X<4 ? '_
M  1*\"_\%0?&?_!*WX;V'[(_QM_96C^']UH]U;7>B^(_AOK%Y?I=M/*+Z#4F
MBU!$EN#*S^9E%#*RG;M*UZYX)_X(H_%[3/\ @F=\(/V08/VP-!TOXF_ [XN3
M>.OAAXQTO0S>Z5;WT%[>S1V,EG<R;Y8(_M<L9&XM&47J%*-[I\4/^"&O_!-_
MXH_$W7/BTWPFU_POJWBJZ:Y\61_#_P"(.L^'[36IF.6DN+:PNHH6=B6+.%5F
M+,6))S76^/O^"37[ WQ&_9K\'_LDZU\#Y+3P-\/M0>_\$Z?HOBC4[&YT:[<S
M%[B&[@N4N#(S7$Q9GD;<9&+9S0!XY^SY^WC^W_\ "#]O7P/_ ,$[_P#@I/\
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M^&=O$'_"K?[1QY/_  E'V]OMGD;N//\ [/VYQ\VW;[4W]L3^PS_P<<_L?_\
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-20210930_g6.jpg
<TEXT>
begin 644 biib-20210930_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2
M N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C7[8W[>W[+
MG["OAC3=:_:*^*4&C7OB*6:W\*:';:;=:CJ.LW$:!F2VL[.*6XF"[DWLJ;4W
MKN9=PKSS_@F=_P %6?V?_P#@H?\ #CPUIV@>(9[/XFM\.]+\1>-?"%QX4U33
M8[)YX(?.>U>]A1+JU$\NQ)8I)592IW$')X7_ (*4_L9_M>:S^U9\/O\ @HS^
MQ+-X'UWQ5\/?!&L^&M:\ _$.YGMK74M,O<.TUG=0J_V:[4AAEEVNI +  J_
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M:XLY"(8I+658R"-P.XN@P-P)^XZ "BBB@ HHHH **** "BBB@ HHHH ****
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M;;XXVNH6]NF@V<'P>T_PO_9,B,YED+VD\IN/,#(-K8"^7D9W&OH"B@ HHHH
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M?_DB>K?]CWK/_I2:]TKYZ_8+\-V&K?!S5KJYFN%8>.-97$4Y48^TMV%>V_\
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M'_/S>_\ @6U 'SSJ?[0_QBM]2N+>'QAA$G=5']GV_ !('_+.H/\ AHWXS?\
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MJG_[]I_\31_PM_XD?]#5/_W[3_XFC_4O-/YX??+_ .1#_B(.2_\ /NI]T?\
MY,^MZ*^2/^%O_$C_ *&J?_OVG_Q-'_"W_B1_T-4__?M/_B:/]2\T_GA]\O\
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MA?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110
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MM_%'Q_\ \$JM#T_0_#NDW&I:Q?2?M$Z>1!;01M)(^!8$G"J3@ D] ":Z8?\
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M1/\ KV;_ -&-7RG&O_(NI_X_T9]MX>_\C:K_ ('_ .E1.NHHHK\T/U\****
M"BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\
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MODCXQ?\ )4M>_P"PG+_.OK>ODCXQ?\E2U[_L)R_SKZ_@K_?JO^']4?">(?\
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M'\2/I$=^--N&7"3FVD94GVGG8Q /3-?%7A7_ ()8_P#!0/P9\>?$W[2V@?\
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MZ-?$1=-IVC%-I-1NE]E-*R^2UO96"OJ[X#_\DCT3_KV;_P!&-7RC7U=\!_\
MDD>B?]>S?^C&KY[C7_D74_\ '^C/J?#W_D;5?\#_ /2HG74445^:'Z^%%%%
M!1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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M4O\ Z4RU\]Q)_ND/\7Z,^GX5_P!^G_A_5'M-%%%?&'WH4444 %%%% !1110
M4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?@YXY_Y';6/^PK<?^C&K*K5\<_\
M([:Q_P!A6X_]&-657ZE#X$?CL_C85Z1\"?@#9?%7P_XF^(GC/Q[#X8\)>$(+
M9];U=K![N8R7$AC@AA@0J9'=E(Y90O4FO-Z])^ OQZ\:_!#3->AM?!.F^(_"
MGB!(+3Q+HFO6#RV5R4+/#EE(,<JG>R$'(Y.#@8SQ'M?9/V>^GYZ[Z7MM?J:X
M;V/ME[7X=?RTO;6U][:V.E_:^^&7[/\ X-\7:Q=?"WXI22:C!JD4$WA&7PL]
MHMO&T63+%.LCQNH(7*D*V7X!P:Z#]A;1/V3_ (E^.O#?P9^*/P/U3Q!K^O7\
M\5QJTOB::TM;:-8WD39%!M9VPF#EAR<]L5UW[5/PV^"?Q;\)?%'XP>$? NH>
M%/$?@'5--34I?[3>YL-;6Z9(\()!F&5,@[5)& .N[*^8?\$Y/^3U_ 7_ &$9
M_P#TEFKSE-U<MF^:7-%=[-/ENM8]-4_S/4=-4LV@N6+C)KI=-.5GI+9Z-?D>
M4>+K'3M#\=:IIMK9_P"B6>K3Q1VYD;_5I*P"[LYZ#&<YKZ$^!GB7]ECXY_%[
MP]\)="_8*L(Y]<U)+=IQ\1=7;R(OO2RD;QD)&KN1W"U\_P#Q(_Y*)K__ &&K
MK_T<U>Z?L<C_ (4K\$_B3^UU=_N[S3]-_P"$:\&2'J=3O /,E0_WHHBK>ZLU
M=&+5\,I7?-HE9M:O1;-7U.7 O_:N6RY=6[Q3T6KM=.VGZ%'3_@1\*?C[^WI=
M_!?X/V1T'P2FL31>9#>23F.SM(B;B99)F=B9#$Y4L2 95XP,5TWPRT_]DC]J
MKXBWW[.?@;X#+X/N;^UNE\#>+(=>NIKA[B"-Y$%W'*Q1EE5&)  *GY5/.X<U
M_P $R]4L+?\ :ML-!O[Q('U[0]2TRUFE; $TELY09]25P/4D#O3?^">7@OQ!
M9?MMZ!;ZQ82V7_"+3WUWXA:X7:+"."WE60RY^Z Y5#GNPKGKJ4%47,[P@FM7
MOKJ^^RWO^)UX9QFZ;4%^\FU+1;>[HNV[VM^!X)=VES87<MC>0F.:&1HY8VZJ
MP."#^->^?#+P%\&_A)^RY#^TU\5_AV/&>I^(/$DFD>&M!NM1EMK.V2)"TMS,
M82'D;<"H3('0_3Q_Q#9:UX]\2^(_&/AGP[?75BE]/>W<UM:.Z6D,DK,K2%01
M&.>K8'%>B?"/]HOP)IWP6N?V>?CY\.+[Q#X5;6#JFC7FCZD+6^TN[V;',;.C
M(Z,IY1A@%B><C'9B?:3IKEONKI.SMVZ?GL<&%=*G5ESVV?*VKJ_1M6?GT>II
M?'3X8?##QA^SMH?[6'P:\$2>%[:?Q#+H'B?PVM_)=06]XL?G1S0/*2X1TZJQ
M(5BH'J?":^O_ ([>-O!.F?\ !-[1?"OA7X<R^%=.U_QV9O"VFZC>FXOK^S@A
M)FU"9RJABTK! %4*%V 9'-?(%3@9SG2E>^DFE?5V]?+8K,:<(5H\MKN*;LK*
M]NVEK[[+<_<[X$_\D0\&_P#8J:=_Z31UU5<K\"?^2(>#?^Q4T[_TFCKJJ_/*
MO\67JS]1H_PH^B"OQ;_;?_Y.[^(G_8UW?_H=?M)7XM_MO_\ )W?Q$_[&N[_]
M#KW^&_\ >9^GZGS/%?\ NE/_ !?HSRNBBBOL3X4559F"JI))P !UK8^(/@37
MOAIXOO?!/B9(Q>V+A9C"Q*'*A@5) )&#Z5[C^PGK>BZ?X:^(.D^%/&V@>&OB
M9?V%DG@37/$4L<,<2"9C=Q0S2@I%,Z;%4GD]B,$UO_\ !0T?MCZ;J-_IOQ:3
M4KKP%<ZQ%/H=[,L%S;I*(BH"3Q[FBSF3]V67=C.TXR.%XN7USV-DO5V;VVTU
MW[]'M8]!8*/U'V]VWY*Z6^C=]-D]NJWN>1_!_P#8V_:7^/6@CQ1\*/A5=ZII
MID>-;YKRWMXF93A@&GD0,0>.*\YU+3KS2-1N-)U&'R[BUG>&>/<#M=2589&0
M<$'IQ7N'_!.G6]9F_;#^'NAS:O=/90ZI<-#9M<,8HV-K.20F< GU KS'Q!I,
M>O\ QJO="FF,:7OBF6!I!_"'N2I/ZUI"K56)E3G:R2:LN[>^OEY&<Z-%X6%2
M%[MM.[5M$GIIIOYG5?#']C#]H;XM>$HO'OAGP=;V^C7,ACLM1UK5K:QCNV!(
M(B\]U,G((RH(R",Y%8%A^SO\9M4^,$OP$TSP//<>+8)WBETB&XB8JRIO8^8'
M\O:%YW;L8[U]6?MU^ OV9Q^T'%X'^,OQTUO1$LM*LK#POHGAW05N;+PY8+$B
MH;AGD4DNP>0K&I(4IDGBOESX\_"3QO\ LR?%[5?AEJGB$RSVL2B#4].F9$OK
M.:,,CC!SM9& *Y(!!7)QFN?"XNIB5>Z3DKI<K_.^MKZVL=.,P5+"NUFU%VDU
M)?E;W;VTO?SU-_Q_^PW^TG\./!][X[UKP5;7>F:8,ZM/HNM6M\U@.YF2"1F0
M 9);& !DD5Y'7TO^Q1:WWP)\ ^,OVJ/B'<M8^&+GPU>:#HVG3-@^)+^8 +"B
M'[\:%27?!"X.,[6Q\T5T8>K5G.<9M/EMJE;U6[V]3FQ5*C"G"<$US7T;OIT>
MRT?IT.H^$OP7^)_QT\3_ /"'_"OPC<:M?+"9IEB94C@B'!DDD<A(UY RQ R0
M.IK9^,G[+_QA^!&DV7B#X@:/8+I^H7#6]K?:;K5K>1M,J[FC)AD8JP'/( ]*
M]_\ @?X(\#:7_P $W-5\4^+?B+/X6TO7_'7E^*=0TRR^T7VHVL,6V#3H4W*#
MNE)D)9@H7>3D9KR3XP?LZ^ =-^#-K^T/\ ?B+?Z_X4DUG^RM7LM9T];:_P!*
MN]F]!(J,R.K*>'4X!8#G)QA#&.>(<;VBGR[/5^M[+R7^9T3P,:>%4K7DX\WQ
M+1?X;7?F[K\#QJOV/_X)V?\ )EG@'_L%2_\ I3+7XX5^Q_\ P3L_Y,L\ _\
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MKP[<^';NX9FVJL;W:K!(['A8TE+D\!:]M^$W[2'[-,OC7XC_ +.WPQ-MHR?
MR+3X/&,-OI(L=*TA;JR^W1112 +$0EOAW"<1[@&P3BOE[X1_\%0?^"8W_!7O
MQK;?L@?$']FGQ9J&C^,;'4;KX>7_ ,8?A@MOH?CF&S!^U3Z+/*SF5XD!D)VQ
M2(%)&"I  /ONBL;X=> /"?PG^'VA?"SP%I;6.A>&M&M=*T6R:YDF-O:6\2PP
MQF25F=]J(HW.S,<9)))-;- 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\
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M"A>_]]+7XW?MJ327'[67Q!GEMVB9_%%T6C?JOS]#7[4U^+?[;_\ R=W\1/\
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MAM_\D+C_ .-T>VI?S+[P]A7_ )7]S.RHKC?^&@/A'_T-O_DA<?\ QNC_ (:
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M[NN$_9;_ .39?AU_V(FD?^D45=W7QL_C9]S3^!>@5_-I_P %./\ E(+\8/\
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M#MW_ .CGK"K=^*/_ "4SQ%_V';O_ -'/6%7V<?A1\(]PHHHIB"BBB@ HHHH
M**** "BBB@ HHHH _J%_9;_Y-E^'7_8B:1_Z115W=<)^RW_R;+\.O^Q$TC_T
MBBKNZ^-G\;/N:?P+T"OYM/\ @IQ_RD%^,'_8]WW_ *,-?TEU_-I_P4X_Y2"_
M&#_L>[[_ -&&O4RG^-+T/)SK^!'U_0\*HHHKWCYP**** "BBB@ HHHH ****
M "BBB@ K^BW_ () ?\HV?A1_V IO_2R>OYTJ_HM_X) ?\HV?A1_V IO_ $LG
MKRLV_@1]?T/7R;_>9>GZH^DZ***\ ^E"BBB@ HHHH **** /RM\7?MT^&O\
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MTY\$OV._@=KW[17[1?CNT\.^%?#EF9]1U"Y.2S=$AB0?-+-(Q")&H+.S  4
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M;XBUI-3O'\5P3B34)Y+Q(XUN?,,\<@98T"JP0+A,D ^YJ*** "BBB@ HHHH
M*^5OV\O^"AOC3]GOXP^$?V/_ -FK]GFX^)WQ<\>^'M2UNRTB7Q-%HNG:-I%H
M LVH7=Y)'*5&]@J1QQNSLK#*G;N^J:^4?^"A'_!/KX/_ +8_CS0/BCX?_:#\
M4_"_XS_#KP]>R^&/%O@#6X(=233+G<DMO=6LJNMU92.C##*!N# ,,N" 8O\
MP1\_:1_;J^-O[-WPUA_:Q_9CBTK2KSX-Z!JVC?%JW^)4.LMXJDDLK4[[NU:"
M*XM+J5)#.^XRINWCS&(R:WQ:_8@_X*L_&7XH>*_&UC_P5_O/AKH4FL73> /!
M_@?X3Z5=0Z;9[S]F-[<7H,M[(4VF1/D0-D*V.:^;?^"-G[4?[9_P'^)O[-W[
M _QY^+_AGXH>!_BE^RYIGC/P-=Z=X;CTS6? ]M;Z?:F+3[Q8&,=S:B-A!'<N
M!+*Z98@A@??/V^_VZ/C;\5_C7+_P2U_X)D7UO<_&'4K%9/B1\1V0RZ9\*-'E
M&#=W#+Q)J,B$_9[4'=DAVP ,@!_P2N_X*/?%GXM?L9_&CQY^VY=Z3=^)OV;?
MB%XH\)>._%OABT$5CK\>B0K/)J,,8PJ,T;'*+A<J& 0.$7PCX1ZK_P %J?VO
M?V&;S_@JUX'_ &[8O!.NZQI%]XK^'/P"M? &G7>@'1H#*]MIUY<2I]JGFNH8
MP?M =2AF7&W&%^H?$'_!.'P%^S%_P1S^*/[ _P"R]I=]=SZI\(/%.G0W]X_F
MZAKVM7^F7*27EPXYDGFFD&>P&U%PJJ!Q7_!+C]JGX/:+_P &^_P\^/FI>)[&
M'0? /P.:S\22RSJHM;C2K1[:YAD!^[(9(" AY;>N =PR >A_"3XR_&C_ (*J
M_P#!-CX;?M&?LE_M)W/P-\0^-M.M=4OM=T_PC8>(#:21>;!?:>L&H*8F07*.
MHEP'Q".FXBOD/]JC4/\ @L'^S#^V;^SA^R5X0_X+'ZQ\0?$/QE\;RC6=&F^!
M/A6P73?#5@BSZE?-)';2,&$1(C'RABKX8%:^C?\ @W!^&7BKX2?\$3_@-X4\
M96,MM>W.@:AJZ0S*586VH:M>W]NV#V:"YB8>S5Y[_P $W_\ C/'_ (*Z?M&?
M\%*]0_TOPE\-&3X,?!^=OFB9;-Q<:Q=Q'H=]RR[)5^]'.ZYXY /T@K\\/B=\
M:?VVOV^_^"H7Q3_8+_9D_:FN/@?\/_@%X<T.?QSXF\/>&K+4=;\1:MJ]L;JW
MMXGO4>.VMHX0<LJ;R\; EED&S[TUSXE_#GPSXOT;X?>)/'^B:?K_ (C\_P#X
M1[0[[588KS5/)3?-]GA=@\_EJ0S; =H.3@5\A?M$?\$X?VE]#_;FUO\ X*"?
M\$Y_VFO#'@;QMXU\-66C?%#PAX^\+RZKHGB..U799WC"WGBGM[B*-!&"I(95
MQE?G#@%;_@FO^UG^TCI_[8OQF_X);_MF?%.Q^('C/X56&F>(/"7Q'M=%ATZ?
MQ'X?OHU(^UVT&(H[FWDDCB9D 63S <94L_W#7Y$_\$@_@K\3;[_@O1^TS^T#
MXT_:$'Q7O_#WPTT[PK\0O'>GZ4EEI,GB2YN+6X.FZ?"C.$ALK:QCMV0N[JZ,
M9"&DQ7Z[4 %%%% !1110!_*Y\4?^2F>(O^P[=_\ HYZPJW?BC_R4SQ%_V';O
M_P!'/6%7V<?A1\(]PHHHIB"BBB@ HHHH **** "BBB@ HHHH _J%_9;_ .39
M?AU_V(FD?^D45=W7"?LM_P#)LOPZ_P"Q$TC_ -(HJ[NOC9_&S[FG\"] K^;3
M_@IQ_P I!?C!_P!CW??^C#7])=?S:?\ !3C_ )2"_&#_ +'N^_\ 1AKU,I_C
M2]#R<Z_@1]?T/"J***]X^<"BBB@ HHHH **** "BBB@ HHHH *_HM_X) ?\
M*-GX4?\ 8"F_]+)Z_G2K^BW_ () ?\HV?A1_V IO_2R>O*S;^!'U_0]?)O\
M>9>GZH^DZ***\ ^E"BBB@ HHHH *S_%GA'PIX]\-7W@OQUX8T[6M'U.V:WU+
M2=6LH[FVNX6&&CEBD!21"."K @UH44 ?!?CG_@W#_P"";>K^(KSQ-\%[;XD?
M!R?493+J%M\(/B1?:1:3.<<BV+20Q# QMC1% [5UO[.G_!!C_@FG^SMX^M_B
M_)\'+_XA>-+1P]IXN^+/B&Y\17=NRG<C1I=LT$;J>5D2(.#R&K['HH ****
M/"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH **
M** /SR_X*4?L6?\ !0'4((?$?P._X*&^(Y_#.N_'?P5J5GX#USX5V.NMX:F;
MQ1ITBW=M=HT,_P!CLY MT8)MZ>5;LA=%)<>W_LP?\$X=0_97^!_Q8T3PE^TQ
MXAUCXO\ QCN+[5/%?QJUW2;9[H:U+:&WMKN*QB\N&."U^5HK4$+P5WX(V_3U
M% 'Y>_LG_P#!#C_@II^Q'X*U/P)^S?\ \%N]/T6VUS6[C6/$%_=_LNZ3?ZAJ
M^H3,6DN;N\N]1DGN9"3C=([8' P*^OOV@_V![#]LW]@6;]BG]LCXK77C#5-1
MT.UBU?XAZ1HL.D73ZM;NLL6JV]M&7CM9%F17$:EEQE#E6.?H2B@#X$T;_@DI
M^V!\;OB-\-KC_@I%_P %$HOB]X#^$GB*VU_PWX-T?X;0Z&=>U>U!6TOM7G6X
ME-P8LEO*551V8ECC(;1_X*E_\$B_V@?^"A_[17PT^-_P_P#V^XOAUI/POB6[
MT+P1J_PHMO$VFOK8EE;^UI(;F\BAEE6-XHT66*01F(LA!=J^ZJ* /F']D7]E
MS_@I9\'_ (L-XM_:Q_X*HVGQC\*G2IH%\(0_ ?2_#A6Z9D,=S]KM;F20[ KC
MR]N&WY)^45W?P6_9S^-'PU_:I^+OQW\;_M6:WXN\)_$(Z.?!WPVOK!X[3P3]
MCMFBN?L\AN'67[2["5ML46"N#OZU['10!^>7P]_X)%_MW?L;IXI^%O\ P3;_
M ."EFF_#_P"%7B77KS5M*\&>,OA-!K\_A&>Z??,-/N3<Q;XMQ)2*5"JXYW,S
MNWTI_P $Y/V!O '_  3D_9NC^ O@KQEJWBB_O]=O/$'C#Q?KQ'VS7]9NV5KF
M]E5<A"VQ%"@DA(U!9VR[>\T4 %%%% !1110 4444 %>%_M@?\$X?V./VW[FR
M\3?M#? VPU[Q'HFG36OA_P 10ZE=Z=J%DC[CY:7=E+%,(]S%MF[;DDXY->Z4
M4 ?+7_!+7_@F!^SY_P $[O@'X4M/"_P8\/Z7\3[GP%H^F_$KQ;97,]]<ZG?P
M6D*W*I=7):46QG1F2)-D0 3$:[0!R/Q4_P"#>3_@D!\:OBOXG^-_Q(_9.N;[
MQ1XRURYUCQ+J<'Q)\1VOVV]N)6EEE,<&HI&FYW8[455&<  <5]IT4 >.?L9?
ML"?LG?\ !/KP1JWPY_9'^&$_A;1M<U7^TM3M)_$NI:F9KGRDBW[[^XG=/D11
MM5@O&<9)->0>/O\ @@M_P2R^)7Q6U/XL>*/V;7,FNZX-9\0^&;+Q7J=KH.K:
MB&W_ &FYTN&X6TE<L S Q[7(RRMEL_85% %5-%TR'11X=LK06MDEK]FA@L6,
M AB"[0L9C*F/"\#;@K@8QBN%_99_91_9_P#V*?@MIW[/7[,?P\C\,>$=*N+F
M>STM=0N;MA+<3//-(\]U))-*S2.QW2.Q PHPJJ!Z)10!YO\ $K]D;]GKXO\
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M\;+\YS>>/I1EB*C3E&ZYY=UYGT_]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
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MUT%4I<D5)--/M?IZV"BOK/X)?"K]G/X ?L-V_P"VO\>O@^/B/K?BSQG-X?\
M!?A6]U>>STZSB@B+S7EP;=EDE;<&18]P7H>^5H_M1?!#X(?$3]C_ ,,?M[_L
MY?#*7P1977BZ?PIXV\&IJLU[:VFHK#]HBN;628F0121_>1B0K,JKT),^WCSV
MMI>U_/\ ,IX>2A>ZO:]NMOR/EJOZ&O\ @D;:^*Y/^"<?PK>PU6UCA.AS;$>
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MNQ:OJ'A/PYJ.KV&AH9=3U#3]/DEAM8=Q FE901$AP<%B!7NG[/W[8?PLT?\
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MT_MC^&/'/Q'OOBAJG@#6_$,FA)XABU[3#=Z=:W40>*(0RQ-O6%]N"S@;,$D
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M(FFEV,VT?:81T4$GD]A1_P $]_\ DB>K?]CWK/\ Z4FL#_@K_P#\HV?BO_V
MH?\ TL@K?#-QQ,&NC7YG/BHJ6%J)]8O\C\:/^&@/A'_T-O\ Y(7'_P ;H_X:
M ^$?_0V_^2%Q_P#&Z^::*^Y^NU>R_KYGYY_9U#N_P_R/I;_AH#X1_P#0V_\
MDA<?_&Z/^&@/A'_T-O\ Y(7'_P ;KYIHH^NU>R_KYA_9U#N_P_R/J"U_:<^'
M=CI5WH=G\0)HK.^:-KRV2TN DQC)*%ALYVECCTR:J_\ #0'PC_Z&W_R0N/\
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M* "BBB@ HHHH **** "BBB@ K^BW_@D!_P HV?A1_P!@*;_TLGK^=*OZ+?\
M@D!_RC9^%'_8"F_]+)Z\K-OX$?7]#U\F_P!YEZ?JCZ3HHHKP#Z4**** "BBB
M@ HHHH **** "BBB@#YZ_8+MO$DOP<U9M)U*WBB_X3C6<K+"6.?M+<YKGO\
M@KE:^*X_^"<?Q4>_U6UDA&AP[T2 @D?:X.AKLO\ @GO_ ,D3U;_L>]9_]*36
M!_P5_P#^4;/Q7_[ 4/\ Z605MA_X\/5?F8XC_=Y^C_(_G2HHHKZX^)"BBB@
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M\!C_ (USG[+?_)LOPZ_[$32/_2**N[KXV?QL^YI_ O0Q_L7C?_H-V7_@,?\
M&OYR/^"ERW*?M^?%Q;R57E'CF^\QT7 )\SL*_I/K^;3_ (*<?\I!?C!_V/=]
M_P"C#7J93_&EZ'DYU_ CZ_H>%4445[Q\X%%%% !1110 4444 %%%% !1110
M5_0U_P $C;7Q7)_P3C^%;V&JVL<)T.;8CP$D#[7/U-?SRU_1;_P2 _Y1L_"C
M_L!3?^ED]>5FW\"/K^AZ^3?[S+T_5'O]G:>+4ND>^U:U>(-^\1+<@D>QK4HH
MKP#Z4**** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU@?\
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MD3U;_L>]9_\ 2DU@?\%?_P#E&S\5_P#L!0_^ED%;8?\ CP]5^9CB/]WGZ/\
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M !JC_AR%^R;_ -%&^*?_ (6Q_P#C5?8U% 'QS_PY"_9-_P"BC?%/_P +8_\
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M_P#&J^QJ* /CG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\
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MQ_\ C5?8U% 'QS_PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\
MXU7V-10!\<_\.0OV3?\ HHWQ3_\ "V/_ ,:H_P"'(7[)O_11OBG_ .%L?_C5
M?8U% 'QS_P .0OV3?^BC?%/_ ,+8_P#QJC_AR%^R;_T4;XI_^%L?_C5?8U%
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M9_:,U;]DS3?&GF?$'0_"MMXDU30/[-N5\G2[B=X(;CSS&(&W21NNQ9"XQDJ
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MZGJ4*%8[O4)YI+J\F0'D(US/,R@\A2H/(KW*BB@ HHHH **** "BBB@#XO\
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MAA^D]% ''?L]? WP'^S)\"O!_P"SO\+K.2#P[X)\-V>BZ,D[AI#;VT*Q*TC
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MA]^R5=>((M7U7P[ITT_B35X-VR\U2ZN)+J[="P#-&)IG1"P#%$3(!R*^A**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BO$?VD_^"C7[&G[(7CJT^&O[1'Q
MC_X1[6[[28]3M;+_ (1[4;O?:O++$LF^VMY$&7AE&TD-\N<8()\]_P"'X?\
MP2Z_Z.>_\LK6_P#Y"K6-"O)74&UZ,QEB,/"5I32?JCZPHKY/_P"'X?\ P2Z_
MZ.>_\LK6_P#Y"KZ:\!>./"WQ.\"Z+\2O ^J?;M$\0Z3;:GH][Y#Q?:+6>)98
MI-DBJZ;D=3M8!AG! /%*=*K37O1:]45"M1JNT))^CN:U%%%9F@4444 %%%%
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MA7X._MP_\'"O[7>A?%_Q3XZTR'0/!/@6>R;P/XZOM#>1I=*B5A,UG(AE7"#
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M7G_*;_\ X*-_]A;X9?\ ICOZ /7O^"Z_[3GQQ_8V_P""4_Q8_:3_ &;O&_\
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M!^R=HO[-MW\ /'W]@2>/OVK_  CX-\6M_95I=?;]$O5O#<VG^DQ2>5O\J/\
M>1[9%V_*ZY.?L^ORB_X*R_M*>#_VQ?V-O^"?W[4?@-E&F>.OVP/AMJT<"R;C
M:R2P7YFMV/\ ?BE\R)O]J,U^KM 'Y7_LU:__ ,%8O^"@'[4?[4.B?#W_ (*P
MZA\+/#?PD^.6I>$_#'AVT^"GAO6$6SC^>+=-<0)*VT$+\S,Q R6R:](^"G[;
M'[>/[&W[?_@?_@G?_P %,?$OA+X@:1\7M/OI/@_\;?">@'1I+Z_LXQ)<:=J5
MB'>**4H4*-"=N98ER_F-Y5/_ ((9_P#)T7[>?_9V&J_^BQ7)?\%'/B+X._;!
M_P""UO['?[)_[/\ K]KXC\0?"'Q9JOCOXH7.CSK/'X9L(88!#%=21DB*29XS
M'Y;$,#)!D8E4T >Y?LO?M8_M ?$7_@M)^U#^R9XR\??;/A]\.O!_@Z^\&^'_
M .RK2/\ L^>^L5ENG\](EGEWN2<2R.%Z*%'%?9]?G7^Q3_RL8?MK_P#9/_A]
M_P"FQ:_12@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#X!_X*J_\ !,CX?_MH?M"Z-\4?%?[5
M?_"#7%AX,M]*32?^$&EU/SD2[NYA/YJ7,07)G*[-I(\O.?FP/F;_ (<'?!G_
M *2)?^8DN/\ Y.K]#OVN/^2D67_8#B_]'35Y97Z5E.14,3EM*JZDTVMERV_&
M+?XGY)GG$N)PF;5J,:4&HNUWSW^=II?@?(G_  X.^#/_ $D2_P#,27'_ ,G5
M^LG[.7@&R^%/[/7@/X7:;XB_MBW\->#-+TJWU;[(;?[:EO:10K/Y19C'O"!M
MA8E=V,G&:^5J^P?AG_R3?P__ -@.T_\ 1*5Y'%&5TL!0IRC.4KM[\O;RBCV^
M#LZKYIBJL)TXQLD_=YN_G)FW1117QA^@!1110!\J?M'_ /!$O_@F=^UK\=-:
M_:4^/7[/5_JWC;Q#!:PZSK=C\0_$&FFZ2W@2"%3%8W\,0VQQHO"#.,G)))[[
M]CK_ ()P_L1?L V.J6G[(O[/.C^#Y=;*_P!LZG%/<7E_?!3E5FO+N26XD4$D
MA6D*@DG&237QOXD\>_\ !3']K7_@L7^T+^Q]\!?^"DM_\'/!/PJ\,^%=1T;3
M;'X3^']=,KZAI\<DP,E]!YH_>!WY=OOX   %>S?'*U_;I_8/_P""8O[0/Q9^
M)/[>]]\5O'OAWP%K&N^"_%U]\-=&T=M$DM[!VC06MK$8+@"5/,S,C9SM((XH
M 7XO?\&^/_!(KX[_ !9\2_'+XH_LIW.H>*?%^LSZKXCU.#XD>([07EY,Q>24
MQ6^H)$F6).U%51V KTC]GC_@E3^P;^RG\&?'G[/GP'^",^C>$/B;82V7C?29
M_&&KWQU&"2WDMG037=W++!F&61<Q.A^;(.0".H_X)\_%'QU\</V"/@A\:OBC
MKG]J>)O%_P (/#6M^(M3^RQ0?:[^[TNVGN)O+A58X]TLCMM1549PH  %>'>*
M?VL?V@-._P""_7AG]B>R\?;/ACJ'[+T_BZ\\,_V5:'S-977)K5;K[08OM Q"
MJIY8D$?&=N>: /J#X3_ 7X1_!#X(:)^S?\-/!<-CX)\.Z!'HFDZ!<SRW<<=@
MD?E+ SW#2/*NSY29&8L.I->=_LF?\$V/V*?V&?A3XH^"'[*_P47PKX6\9WDM
MWXDTI/$&HW@NY98!;NP>[N)7B!B4+MC90,9 !YKPG6OVV_C?^PK_ ,%-[[X!
M?MT?%FVU#X)_&BUDU'X&^/M5T^RT^'POJ=LA>\\.7L\$42LK)^]MYIR9& 6,
MO*Q8IJ?\$P/VHOVI/^"A'Q;^(?[:]UXMN=#_ &<;FZ;P]\#/!,NA6L<WB".U
ME*7/B6XG>'[4JRR(T<,(D5 @?=&64.X!@VW_  ;*?\$2+*!;6S_8WO(HD^Y'
M%\5O%2JOT U3BO=+K_@EU^PO??LD>'_V%;WX)23?"SPMK$>JZ%X8E\5:JS6U
MVEY)>K(;LW7VJ3%Q-(^UY67YMN-H"CY _P""W_\ P4(_;\^%?QWT[]GO_@F9
MXJL[/7?AI\*=5^+7QC2YT2TOENM!M9XHH-.'VB&7RI)=MTQ$>R8J$*L!7W?X
M-_:)\-_'/]CJQ_:G^#NJ?\2WQ/\ #P>(_#]R0KM$LMEY\88$$;T) 92.&4@C
M@B@#T^O-_@/^R-^SU^S-XI\>^-_@I\/_ .R-7^)_BN7Q)XZU&;5KN\FU34I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?.W[7'_ "4BR_[ <7_HZ:O+*^E_BY\ O^%J>)(/
M$/\ PEGV#R;%;?R?L'FYP[MNSYB_W\8QVKEO^&./^JC?^4C_ .W5^F91Q!E&
M%RVE2JU;22LURR_1'Y!GO"V>XS-ZU>C1O&3NGS17YR3/$:^P?AG_ ,DW\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-20210930_g7.jpg
<TEXT>
begin 644 biib-20210930_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
M"@<#_1K&@"U\;/\ @L_^U!\#/A_IO[;/B_\ X)VSV_[+M[J=@LWQ G\>Q+XB
M@T>]GCAMM<?1OLY,=O(9HF6!IO.V2H7$1)5>3_X+9?&S4?@1_P %/OV!?BSX
M4^&>J^.=2@UGXA6V@^%M EB2?5[Z\T6SM+6%99"(X8VFN(M\SG;%'OD.0I%=
M%_P6L1$_X-MO',:( J_"GPN%4#@#[7IE>>_\%=?C?I7[.'[>?_!.3XX>(_"N
MJ:SI7AY_&EQK<&CZ;)>7%M8'0M/2ZO1#$K/(MM \ERP16;9 VT$X% 'T)\+?
M^"FW[3/@/]KSP5^R+_P46_8RTWX67/Q6BNQ\+_&'A3Q^NOZ5J-_;1^;+I=RY
MMH'MKCR\%&(*RDA5&>:O_&[_ (*4?M >(OVK/%/[&/\ P3M_9&L_BOXG^'=E
M9S_$[Q1XF\:IH.@^')[N,RVUCYH@GDN[IXQO9(T C!^9B0RK\\_M2_M;? /_
M (*S_M^?LI? K]@;QY!\1+?X6_%6+XF?$GQEX>MY7TWPYIME!(L-O-<%0OFW
M4CF-8E)8%1N S7A_CSX,?LS?LE_\%2_VA]+_ ."D_P"TS\:?@OX?^+7C"'Q?
M\)_B#X,^)&KZ!X=\00S0?Z58W$UD?*6\MG&P";!*#@A3'O /T2_9+_X*6ZM\
M=?#7Q@\%_&G]GJ\^''Q@^!, D\?_  XNM>COH7BEM)+JRN[.^CC"SVMS'&VU
M_+#(00RGY2WFG[ /_!5O]M/_ (*0>%OA[\=?@I_P3A@T'X4>(+Q;?Q7XP\3_
M !.A6:!EE:*Z;3;46J27T4#*4,SB'S)%D1$/E[FXW]A/P-_P3!OO#_[2/QC_
M &!/VD/B!\6/$#?#A=*\=^,_&/BK5-:@E06U\UK!#>WR!;AHQ')N$3N(U= <
M;@*]>_X-ZXHH?^",'[/R11A0?!;L0HQR;RX)/XDDT ?8NHV%OJNGSZ9=AC%<
MPM%*$<J=K @X(Y!P>HK\7/\ @I3^RC_P;6?LD?"GQ_\ LV^&_!FDZ#\?M'T0
MGP1I/A35-:O/%Z^(KBU6?2S%*)))))))9;=_WC%,/EL"OV3\?>--&^&_@36O
MB)XC6Y;3] TFYU&_6SMFFF,,$32OLC7YG;:IPHY)P!UK\T/VWO\ @K__ ,$!
M/VEOV7?&FCZUXQ\)_%/7O%?AVYL-(\'6/@&[G\0:GJ+P&.UABCDM%F@G$GEA
M)&*>4R@A@5% "?M__&G]N?\ 9[_X(1?!OX4?$;Q[J.A?';XLWW@_X:^(/%"7
M>[4--O-1XNI6E0\W7D0RQO*K9\QW=6R U<7_ ,%3O^"=W[,'_!&G]DKPO_P4
MA_X)\?#Z?P+XV^!GBO07U[5-/U:X:;QAHMU?06-[8ZGO<K=>>UQ&[.PW @[2
MHP WXZ_L=_MQ7_\ P;B? J#QMX-UKQ#\9O@1J_ASX@MX2N \NI7$.FW<SQV!
M7ES<0Z=<*ICP7W6Y0 M@%?\ @J5_P43_ &8?^"S/[)GA?_@F[_P3X\>W/CGQ
MM\<?%F@IX@TRPT>Y27P=HMK?07U[?:GOC"VOD-;QHR$DDD[=V!D _7>TNK>^
MM(KZUD#Q31J\;C^)2,@_E4E>,_'?]M7X)_LN_''X.?LQ>-=-UR77OC-JM]I/
M@F/2+!)H8WL8(I9FN&,BM'&L<B'<JOT.<=:]FH ^._BM_P $,O\ @EC\6?B)
MXW_: _:6^ B>-_$'BV\N;_7O$/C7Q3?2BQA;+&*V G2.R@B7(7RU5E Y8XS7
MSU_P1+^/WB[X)_\ !+[]HWXO6'BG6O%WP?\ A/\ $#QQ<?L_ZQXFNY)IM1\(
MZ7;F6W1)7^:6W#Q2HC=CYB@*$"KXY_P5,_X+'_LI_M/?MH>(/^"8/QK_ &K)
M_@O\"? FH-:?&WQ##I>HR:OX\NXI-LGAZQ-G;RM:V092MQ</M:4 HF4YD^]/
MV??B_P#\$_/^"E7[ 7Q _9L_X)V?$31[OP';^"K[P$(M(\/WFGVNC"ZTUX8X
MEBN8(F*K'*&RH.><G.: /CW]B+_@C-^SY^W5_P $K[+]K;]I33M0\1_M&_&7
MPY=>,_\ A<=QK-RFK:/JMP9)M,:R=) +:*W7[,!"@"'81C;M5?=?^"?VC>"_
M^"Y7_!%+X,ZM^VO=:YK46IQ?\5E;Z9KUQI[Z_=:5=W>GM]KDMF21XYS")Y$1
MDW.PY &*\(_8D_X+-_L__L*?\$LK+]D7]I2]U+PY^T=\&O#EUX,7X.3Z)=2:
MMK&J6YDATP62)&1<Q7"FV(F0E!N8YVA6;O?@I\;++_@W1_X-Y_AQKW[2/@>^
MOO%NDZ:\4/A&W.R2;Q!JUU=ZC'83R8*P+")7663G:+=]H=BJL >>_M]?L._L
MG_\ !.']LO\ 9(U#_@EMX#/P\^-'C'XTZ?I&I^%?"6JW1A\0^#%5VU>34+9Y
M'5X(5$9,Q (#NV245H_OC_@H-_P3@_9I_P""@_A[1H?VFX?%.HZ5X1M-2DMO
M#VB^,+W2['4&N$A+&\2TDC:XV?9UV98;=\G]\U^=?_!+'_@I9_P2:T3XQR_M
M6?M<_P#!0C1/B'^U3\7)K;2[J\M?!>NC3_"]K-*JVWAS1Q)9;8+9'=5>7(,S
MY=F(^8_I'^WK_P %$?V-O^"?G@73]5_:_P#C5!X-M_%JWEGX>DGT>^N_MD\4
M0+H!:02E,"1.6V@YX/6@#YW_ .#6W_E!7\$/]_Q-_P"I+JM?H%7Y)_\ !JU_
MP41_8VUG_@GS\(?^">NF_&J"7XQ:3:>)+S4/!@T>^#PPG6M0O _V@P?9S_H\
MT3X$I/S8QN! _6MRX0F-06Q\H)P": /C+XM?M@?\%@O"FK>)/%7PW_X)->&]
M;\(>'[^[6QM+OXYVT6O:_902,%NK>VCLI(H6EC7>D$DID^8*<,=HE^.'_!8[
MX8^!?^".\_\ P6!^#OPQN_&'A[^Q-.O[/PE?ZN-,N&DN-5@TV>VEG6*X6*2"
M:656VHZLT! .&##\WOV9/B7_ ,$WOCC\#]=\8_\ !7;XF?%3QY^UW_PEFLV7
MB#X)GQ]XHT_4H=46]G2QT?1]*TRX@C6%X?LX5E#(ID<LZ*IVT-*6=/\ @QRU
M:*XB,;I-.K1[B=A_X6,,KDD]\]Z /NOXS?\ !8_]K[]G3P7H_P"V!\<O^":T
M_A_]F_4]6T^&^\83_$2"3Q)HNFWLT<5MJMYI"P%8HV::+-N)S*GF .5;*U[;
M_P % /\ @HGX@_95\=?#G]FW]GGX"S_%?XS?%JZNU\&>"XM=CTVT@LK2,27>
MI7UXZ.+>WB5@1\I:0@JO()'EW_!R$B)_P0H^-T:( JZ!H@50.!C6M.K@?V\O
M'.E?L-?\%1OV<?\ @I+\<[:\@^#]Q\)M2^'7BWQ=#8RW%OX3O[B1+JSNKH1J
MS1Q3N3#YF,+M.XCC(!P/Q)_:,_:.^+/_  7J_86^%O[67[+B?#3QKX3M?B7>
M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2+XWUA%DN)F=@HN2
M N6)X Z#M7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!XHEL;8:K;7FK6YENK#4[NWC3[?.KCY9ILS!8F5V;:JI],?M8?\ !)']A/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^
MA0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_
M^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
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MKT**** "BBB@ HHHH **** "BBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\
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M>=+UU(O$/[.6NZIX@U+Q)XGO-5O-1O/MS1>=)+=2.0=D:C:@5>,XR2:^B/\
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M>_\ DJ\5_P!>'_Z<@>]4445_/A_7H4444 %%%% !1110 4444 %%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)KW2OGK]@NV\22_!S5FTG4K>*+_A.-9RLL)8Y^TMSF
MO;?L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@
M#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?
M\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@
M#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?
M\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@
M#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?
M\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@
M#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?
M\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@
M#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?
M\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@
M#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&@#8KA_C5\"O#OQONO!EWX
M@U>]M&\$^.+/Q/IXLRF)[BWBGC6*3<I_=D3L3C!R!S7B>H_\%6OV,]*U"?2[
M_P#:9LHY[:9HIX_^$,U8[74D$9%K@\@]*A_X>T_L4?\ 1SUE_P"$5J__ ,BU
M[2X:XC:NL'5_\%S_ ,CYE\:\&Q=GF6'_ /!U/_Y(^JJ*^5?^'M/[%'_1SUE_
MX16K_P#R+1_P]I_8H_Z.>LO_  BM7_\ D6G_ *M<1_\ 0%5_\%S_ ,A?Z[<&
M?]#+#_\ @ZG_ /)'LW[07[+7P?\ VG[CP._QCT:XU*W^'WCNS\7Z#8+<E(&U
M6TCF2VEG0?ZY8S,TBH?EWJC$':*]$KY5_P"'M/[%'_1SUE_X16K_ /R+1_P]
MI_8H_P"CGK+_ ,(K5_\ Y%H_U:XC_P"@*K_X+G_D'^NW!G_0RP__ (.I_P#R
M1]545\J_\/:?V*/^CGK+_P (K5__ )%H_P"'M/[%'_1SUE_X16K_ /R+1_JU
MQ'_T!5?_  7/_(/]=N#/^AEA_P#P=3_^2/JJBOE7_A[3^Q1_T<]9?^$5J_\
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MV<5<125J=U&"_EIP2C3C\H)(_H7_ &=_^3?_  +_ -B=IG_I)%78UQW[._\
MR;_X%_[$[3/_ $DBKL:_D'&_[Y4_Q/\ -G^B66_\BZC_ ((_D@K\&/\ @H'_
M ,GL_$__ +'&\_\ 0Z_>>OP8_P""@?\ R>S\3_\ L<;S_P!#K]1\(O\ D<8C
M_KW_ .W(_"OI#?\ ).X/_KZ__2)'CU%%%?OQ_)(5<\0>(=<\5ZS/XA\2ZM/?
M7UTP:XN[J0O)(< 9)/)X 'X53HI<L>:]M2N:2BXWT?3TV_-_>%%%%,D****
M"BBB@ HHHH *_<[_ ()@_P#)A?PW_P"P/+_Z535^&-?N=_P3!_Y,+^&__8'E
M_P#2J:ORKQ<_Y$5#_KZO_29'[W]'O_DJ\5_UX?\ Z<@>]4445_/A_7H4444
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M0 4444 %%%% !1110 4444 ?SG_$/_D?]<_[#%S_ .C6K'K8^(?_ "/^N?\
M88N?_1K5CU_:E'^#'T1_F;B?]YGZO\PHHHK0Q+GB#Q#KGBO69_$/B75I[Z^N
MF#7%W=2%Y)#@#))Y/  _"J=%%*,8Q225DBI2E.3E)W;W84444R0HHHH ****
M "BBB@#^A?\ 9W_Y-_\  O\ V)VF?^DD5=C7'?L[_P#)O_@7_L3M,_\ 22*N
MQK^,,;_OE3_$_P V?Z5Y;_R+J/\ @C^2"OP8_P""@?\ R>S\3_\ L<;S_P!#
MK]YZ_!C_ (*!_P#)[/Q/_P"QQO/_ $.OU'PB_P"1QB/^O?\ [<C\*^D-_P D
M[@_^OK_](D>/4445^_'\DA1110 4444 %%%% !1110 4444 %?N=_P $P?\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
MGYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^
M?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_
M ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W
M_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ
MV** /YSOB H3QYK:#.!J]R!G_KJU9%;'Q#_Y'_7/^PQ<_P#HUJQZ_M2C_!CZ
M(_S-Q/\ O,_5_F%%%%:&(4444 %%%% !1110 4444 %%%% '] /[/O@S2I_@
M)X(F>YNP7\(::Q"W3 <VL==?_P (/I'_ #\WO_@6U8W[._\ R;_X%_[$[3/_
M $DBKL:_C#&_[Y4_Q/\ -G^E>6_\BZC_ ((_DC'_ .$'TC_GYO?_  +:OPL_
M;XMH[/\ ;0^)EK$S%8_%]XJEVR?O]SWK]ZZ_!C_@H'_R>S\3_P#L<;S_ -#K
M]1\(O^1QB/\ KW_[<C\*^D-_R3N#_P"OK_\ 2)'CU%%%?OQ_)(4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?SG_$/_D?]<_[#%S_ .C6K'K8^(?_ "/^N?\ 88N?_1K5CU_:
ME'^#'T1_F;B?]YGZO\PHHHK0Q"BBB@ HHHH **** "BBB@ HHHH _H7_ &=_
M^3?_  +_ -B=IG_I)%78UQW[._\ R;_X%_[$[3/_ $DBKL:_C#&_[Y4_Q/\
M-G^E>6_\BZC_ ((_D@K\&/\ @H'_ ,GL_$__ +'&\_\ 0Z_>>OY_/^"B7Q)\
M%Z9^W+\5-/OM:V30^-+U9$^S2'!#],A<5^F>%&(H8?-L0ZLU%<G5I?:7<_$_
M'W!8S&\/X2.'IRFU5NU%-_8EV3/.J*YW_A:_@#_H/_\ DK+_ /$T?\+7\ ?]
M!_\ \E9?_B:_=O[2R[_G]#_P)?YG\K?V!GO_ $"U/_ )?Y'145SO_"U_ '_0
M?_\ )67_ .)H_P"%K^ /^@__ .2LO_Q-']I9=_S^A_X$O\P_L#/?^@6I_P"
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M^P,]_P"@6I_X!+_(Z*OW._X)@_\ )A?PW_[ \O\ Z535^!__  M?P!_T'_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_.?\0_\ D?\ 7/\
ML,7/_HUJQZV/B'_R/^N?]ABY_P#1K5CU_:E'^#'T1_F;B?\ >9^K_,****T,
M0HHHH **** "BBB@ HHHH **** /Z%_V=_\ DW_P+_V)VF?^DD5=C7'?L[_\
MF_\ @7_L3M,_])(J[&OXPQO^^5/\3_-G^E>6_P#(NH_X(_D@K^:;_@I__P I
M"_C%_P!C[?\ _HPU_2S7\TW_  4__P"4A?QB_P"Q]O\ _P!&&OIN#_\ ?*G^
M']4?)\=_[A2_Q?HSPBBBBOT$_, HHHH **** "BBB@ HHHH **** "OZ.O\
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M+;7/./M+<U[?_P )CX8_Z#4'_?5>,_\ !/RTM9_@KJSS6T;G_A.M9&60$_\
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M44 %%%% !1110 4444 %%%% !7]'7_!'?_E&E\)O^P#/_P"EEQ7\XM?T=?\
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MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH ****
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M  8^B/\ ,W$_[S/U?YA1116AB%%%% !1110 4444 %%%% !1110!_0O^SO\
M\F_^!?\ L3M,_P#22*NQKCOV=_\ DW_P+_V)VF?^DD5=C7\88W_?*G^)_FS_
M $KRW_D74?\ !'\D%?S3?\%/_P#E(7\8O^Q]O_\ T8:_I9K^:;_@I_\ \I"_
MC%_V/M__ .C#7TW!_P#OE3_#^J/D^._]PI?XOT9X11117Z"?F 4444 %%%%
M!1110 4444 %%%% !7]'7_!'?_E&E\)O^P#/_P"EEQ7\XM?T=?\ !'?_ )1I
M?";_ + ,_P#Z67%?)\8?[A3_ ,7Z,^VX%_Y&53_!_P"W(^EJ***_.S]2"BBB
M@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE?/W[ WB#1
M=,^#6K6VH:C'%)_PG.LMM<\X^TMS7M__  F/AC_H-0?]]4 :5%9O_"8^&/\
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M$KX/^)_ 7BCX$?:XOBA\,=96*74;2^AMQ)%'#-$3%<1S@*L<_P H."2 H#$
MR?\ @LC_ ,%OO"O_  2BT[3M+\,? "Z^*WBE]-76O$N@V7B0:7%X>T-[J.RB
MO[JX^S7&WSKR:*"*/R\N1*VY1'AOJO\ :E^,?COX!? W6?BI\,_@%XB^)^NZ
M<ULFG^"/"LL27NHO-<1PG8\Q"(L8D,KLQX2-CSTK^?']N/\ ;B_8<^+'_!&O
MXR^)/$7[6WA;QE^U)^T#XG\/>(_'&CZ5#=,=,M[?4[62TT&U>2((+;3K-63[
MQW2><^YMPK^@;]GO]K[]FO\ :M^%UE\:OV>OBWIOBCPMJ,TT-EK%BDJ1RO%(
MT<B@2(K?*ZLO([4 >#_\$R/^"G7Q;_;L^,?QL^ GQU_8QG^#'BOX*WFA0:MH
M]UX]M]=DN3J<%U<1[FM[>.*)EB@C8A7ER9L$J4(,_P#P4*_X*0?'7]DO]I3X
M-_LH_LV_L96WQ@\8?&.R\0W.F6=W\2H?#<=FNDP6\\H,DUI.C[HIG;EDQY6!
MN+<>-?\ !+GQ)H5O_P %F/\ @HA=3ZG$L<_B7X>F)R>&QHMX#BO7/^"@/_!.
M[2/VX_C]\*?VA?#7[:/B[X3ZY\*=-UZTTK4? EK;?;IO[4CMHIF6>X5UB B@
M=,",D^<2&7;R >D_L=_'G]O#XPZ[K=C^V!_P3_TWX,V-E:12:+?V/QAL_$YU
M.5F821&.WM83!L4*VXE@V[&!BO>J_-_]D3]H?]K+]C;_ (*CI_P3*_:@_:KF
M^-O@CQQ\-;CQ?\-O'>O:5!;:WI$MM<&*?3KUK=56Y0JKN)F&[.P# +*OW_XG
M^*G@+P?X:U'Q=KWB&**QTJQFO+V1%9RD42%W(4 DD*IX')H ^<O^"LO_  5/
M\*_\$O?@M9^-;/X3W7Q&\:ZRMY<:!X T[5Q8RW&GV%NUUJ6H2SF&;R+:UMD+
ML_EMEWBC ^?<ON'[*GQP_P"&F_V7OAM^TE_PC']B?\+"\ Z/XE_L7[;]I^P?
M;[*&Z^S^=L3S=GF[-^Q-VW.U<X'X;?$+_@J9^P#^U%^R?^U;^V)\=_VH?#\7
MQJ^+_P +]=\'?"3X9S17,EQX0\+I%,MEI@98C$+N\GQ=W#!RI9XERH0K7ZB_
M\$3/VN?V;_CS_P $T/@YHOPB^+&G:W=> _A?X9\,^+H;9)5.F:M;:-9K/:OO
M1<NAX)7*^A- 'V%16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\ "8^&
M/^@U!_WU1_PF/AC_ *#4'_?5 &9\9M?U?PG\'_%?BG0+O[/?Z;X:OKJRG\M7
M\N:.W=T;:P*G# '!!!QR*_&[_A[M_P %#O\ HX/_ ,M/2?\ Y$K]=/VA/%OA
MN;X!^.(HM8A9F\(:F% /4FUDK^?FOV;PLRO+,QPN*>*H0J-2C;FC&5M'M=.Q
M_-?CSGN>9/C\#' 8JI14HSNH3E"]G&U^5J]O,^DO^'NW_!0[_HX/_P M/2?_
M )$H_P"'NW_!0[_HX/\ \M/2?_D2OFVBOU?_ %:X<_Z J7_@N'^1^!?Z[<9_
M]#+$?^#JG_R1])?\/=O^"AW_ $<'_P"6GI/_ ,B4?\/=O^"AW_1P?_EIZ3_\
MB5\VT4?ZM<.?] 5+_P %P_R#_7;C/_H98C_P=4_^2/I+_A[M_P %#O\ HX/_
M ,M/2?\ Y$H_X>[?\%#O^C@__+3TG_Y$KYMHH_U:X<_Z J7_ (+A_D'^NW&?
M_0RQ'_@ZI_\ )'TE_P /=O\ @H=_T<'_ .6GI/\ \B4?\/=O^"AW_1P?_EIZ
M3_\ (E?-M%'^K7#G_0%2_P#!</\ (/\ 7;C/_H98C_P=4_\ DCZ2_P"'NW_!
M0[_HX/\ \M/2?_D2C_A[M_P4._Z.#_\ +3TG_P"1*^;:*/\ 5KAS_H"I?^"X
M?Y!_KMQG_P!#+$?^#JG_ ,D?27_#W;_@H=_T<'_Y:>D__(E'_#W;_@H=_P!'
M!_\ EIZ3_P#(E?-M%'^K7#G_ $!4O_!</\@_UVXS_P"AEB/_  =4_P#DCZD\
M&_\ !6?_ (*!ZKXOTK2[_P"/WF07.I013Q_\(KI0W(TB@C(M<C@GI7[25_.=
M\/V5/'NB.QP!J]L2?^VJU_0__P )CX8_Z#4'_?5?COBKEN79=5PBPE&%/F4[
M\L5&]N6U[)7L?T=X"YUG&<4,P>/Q-2MRNG;GG*=KJ=[<S=KV5[;V-*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZK\D/Z#/YX?B'_ ,C_ *Y_V&+G_P!&M6/6
MO\065_'NMNIR#J]R0?\ MJU9%?VI1_@Q]$?YFXG_ 'F?J_S"BBBM#$**** "
MBBB@ HHHH **** "BBB@#^A?]G?_ )-_\"_]B=IG_I)%78UY[^SWXM\-P_ /
MP/%+K$*LOA#3 P)Z$6L==A_PF/AC_H-0?]]5_&&-_P!\J?XG^;/]*\M_Y%U'
M_!'\D:5?S3?\%/\ _E(7\8O^Q]O_ /T8:_I'_P"$Q\,?]!J#_OJOYM?^"F]Q
M!=_\%!/B_<VT@>-_'=^48="/,-?3<'_[Y4_P_JCY/CO_ '"E_B_1GA=%%%?H
M)^8!1110 4444 %%%% !1110 4444 %?T=?\$=_^4:7PF_[ ,_\ Z67%?SBU
M_17_ ,$@?$^@67_!-KX46MWJL4<B:%,&1CR/],GKY/C#_<*?^+]&?;<"_P#(
MRJ?X/_;D?4M%4+;Q1X?O)UM;758GD<X1%/)-7Z_.S]2"BBB@ HHHH **** "
MBBB@ HHHH \'_P""?EI:S_!75GFMHW/_  G6LC+("?\ CY->Y?V=I_\ SXP_
M]^A7B/\ P3W_ .2)ZM_V/>L_^E)KW2@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0J:B@#\[?^"DW[#W[>=]!#XD^!?_  4!UZ;PUKOQV\%ZC9^!-;^$]AKC>&YG
M\4:<XNK:[C:&?['9R;;HP3;T\JW9"Z*2X^BOV&/^"=G@;]C?PKXUF\4_$+4_
MB;XW^)_B5M>^)?CGQ786T<FM7AC6-$2VA00VUM&B[8X%!"!F&2, ?1%% 'RU
M_P %/O\ @EW\.O\ @HI^QEXE_9-\/ZSHGPZNO$-YIT\?BRS\&PWLEH+6]AN2
MHA66W+;Q$4_UBXWYYQ@^Q?'3X0>/O%/P+UOX<?LQ?$[3?A5XHO(4&@^+X?!E
MKJT6DR><CN_V"5HXI]R!TPS#!DW=5%>AT4 ?FG^S[_P17_X*1?L^_M*^-?VG
M-!_X+06%SK/Q0UK1[[XFQ-^S-I2KKJ:<C0PPKNOW6S_<O)'NA1?O[B&(%?2W
M[8?[,_[?WQ'^)NF?$7]BW]O/1?AEI]MHB6.K^"O$OPJM=>L-1G6:607@F::*
M:WDV2",JA*L$7/(%?2U% 'QQ^Q'_ ,$KO&/P2_:;U[]N[]LS]J6\^-GQGUOP
MVOAVPUI_#$&C:5X=T<2B4V=A8Q.ZIND&6E+;F^8[5,DA?USX-?LO?%3X=_M2
M?%_XX^/?VFM3\8>$/B)_8X\(_#34=**67@L6EL\-R+>1KB191=.PE?$46"N#
MOZU[710!XI^U_P#L/_"[]J;]ECXA?LW:9H^@>%;CQUX/O]#@\20>%H+A],:Y
M@:(7"Q Q&0INW;1(F<8W#K6_^R-^S1X;_91_9B^'W[.6FSV.IOX(\$Z3H%UK
MD&CI9G5I;*RAM6NWB#/L:3RMY4NY&[&YL9/IE% $/]G:?_SXP_\ ?H4?V=I_
M_/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% '$_M#V%BOP \<
MLME""/!VIX(C'_/I)7\]M?T+_M$?\F_^.O\ L3M3_P#226OYZ*_=?"#_ '/%
M_P"*/Y,_E;Z17_(QR_\ P5/SB%%%%?L9_.!ZI^SM^S;I_P 8_#?BSXG^//B/
M#X1\%^"+>U?7];;37O9S+<R&.W@@MT93*[LK#EE5>I-=7^V]\)?V:O OC;7;
MOX0?%^235+?5X;>?P3-X0>R6VB:'<98;A97C=00N5(5LR< @$URG[./[1OC[
M]G[2?$4-GX TKQ3X-\2QV]GXKT#Q'ISS6%VR,TD&70J8YE/F,C!L@Y.#M&/H
M?]L7X5_ +XU>#/B]\;_!7P\U/P;XI^&VKZ5'JLYU9[K3?$"WC)%A!*,P3)D'
M8I*X Z[\K\?B\7CL)Q!!UYR5%NT>7D<?>=*-IIKGNYNUU>R<;6]X_1<OR_*\
M?PC4CA:<'B(KFGS^T4O=5>;=-Q?L[*G%.TK7E&=^9\B/$OAS\=OV2OAYX"TK
M1]6_8W@\8^(?*)U_7/$/BV[ACD8NV$MX+<A8P$VC>26SGBK_ .W#\#?A+\/C
M\/OBO\$M-O-$\/?$KPLNKP^&]4O&GDTB4.%DC$K?-)%\P*LV2<,<X( A_9C_
M &:O!U[X0N/VH_VG[RXTGX8:)<^7!;Q';>>*KU<E;"S&02"01)*.% 8 @AF3
MF/CI\=O$?[7'QQL_$?BW[)H6FN]KI&AZ7:+BTT+34<)%#&.!M16+$\9)8X (
M Z*4(O.N?"SFXPYO:MSE*+;6D(IMJ\7J^5+E2Y>MER5ZDH\-*GCZ=-5*O)["
M,:<(344_>J2E&*ERS7NKG;<VW/[-W[]\>-(_9 _9#^-VG_LMW7[(*>.X[:TT
M\:WXLO\ Q)>Q7VK27,4;F6S6!Q'&H\S:H .64C/\1P;7]D#X/^$/^"K5M^R7
MJ22Z_P"#O^$@2)[>>]=)&@EL1<B%Y861MT;.$+*03LYQDBO0_P!IW]L3XI_L
M:_M)6'[-WPL^&NE7NA_#^WL;+0G\46$FH:IJ,;PQN72[D8RQ!F=E18"BI@!0
M,8'C_P"VYX?U;]DS]NW6-:^!GB35K34;6.'6H)[NY-Y>:9-=6PDF2267>79?
M-8AWRV'4DDC<? RIYC7A"G[2495\/-QDZDI<\O<M4:N_9-<R=HW7O6O[B/K<
M^6386K.K[&$X87%THSA&E"'LX?O.:BG9>WC+D:<JEG[BE;]Y)J/XX^,?V</"
MVE:UX:M?^"<$GABYN%NK/0_$MWXXUMA%*-RQW"1S'RY=I ?8<J<8/%?.%?;_
M /P3R_:#^//[4OQ4UOX#_M&^,=0\:?#O6?#&H3>+/^$B(N$TE(X6:.[25AF!
MED"JI! !;(&5!'QAI/A3Q1X@LK_5/#_AO4+ZUTN'SM2N;2R>2.TB)(#RLH(C
M7@\M@<5]'DM66'K5L'7TG!0;?M)U$U.Z6M36+O%WCMJGU/B^):$,9AL-F&%:
M=.JZD5%4:=&2=/E<KJDN64;35I;Z23^'7U[]C:^_93N?%FF^"/CS\#M8\8ZM
MX@\36>GZ<8/$TFG6=K!-(D1=_)'F2.&8M@$ @ 9'6N>_;,^'OA#X4?M3^.OA
MQX TC[!HNC>(9K;3;+[1)+Y,2XPN^1F=OJQ)]ZR/V:/^3C_A_P#]COI7_I9%
M78_\%$/^3W_B=_V-EQ_2M(QE2XELIR:E2;:<I.-U**346[+3LD93G#$<%<TJ
M<%*G7C%24(J;3A-M2FES2U2^)NUM#S#X>@'Q]H8(_P"8Q;?^C5K^BK^SM/\
M^?&'_OT*_G5^'G_(_P"A_P#88MO_ $:M?T85^7^,/\;!^E3_ -L/W3Z.?^[9
MEZTORJ$/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%345^+G]+'\IGQ1 'Q,\1
M#_F.W?\ Z.>L*MWXI?\ )3?$?_8>O/\ T<]85?MU/X%Z'\]5/XC]0HHHJB H
MHHH **** "BBB@ HHHH **** /ZCOV6;"Q;]F+X<,UE"2? >CY)C'_/E#7>?
MV=I__/C#_P!^A7$_LK_\FP_#C_L0M'_](H:[ROQ2M_&EZL_H+#_P(>B_(A_L
M[3_^?&'_ +]"OYJ_^"GB)'_P4)^,*1J% \>7^ !@#]X:_I:K^:;_ (*?_P#*
M0OXQ?]C[?_\ HPU]5P?_ +Y4_P /ZH^,X[_W"E_B_1GA%%%%?H)^8"HCR.(X
MU+,QPJ@9)-='\7?A5XK^"?Q$U+X8^-HX5U+2Y%2X-NS-&VY P*EE4D88<X]:
M^HO^"5OB?PWI/@KXN>'_  #\3O"?@GXVZMI.FQ_"OQ1XPGAMX88UN'.H06]Q
M.K1V]S+%Y:HQ^8_PE<,PZS_@L"/^"C>C:QJVC?'^+6K_ .%%[XB@N_"^I7$=
MK>VD<ZVY51'=1!G@W;I?W3.N_&=IV@CS7CI_VA]7LDO-V;V=TK:[M;[I[6U]
M>.70_LSZS=M^2NE\2M)WTV3VT36]]/G'X ?L#_M._M*>"KKXG?#GP590>%[.
M\^R3>)?$>O6FEV+7&,^2DMU(@E?GD)NQWQ7._'S]E;X]?LQ>/;3X;?&WX?S:
M-J>HP1W&EL;F*:WOH7.$EAN(G:*5">,JQQT.#7UQX?\ AIHW[3W_  2M^%7A
MSXS?%;3?@UIO@'Q1K4/A77O%;@Z=XR2ZN#+,\,4+&Y,UL^Z,N(6CPS#?N+!>
M6_X*GV-W\.O@7^SW^SUH,LOB;PEX1\*ZG-X>^*:30R6?BA[NYCDG2U,4DFR&
MV*)$$D*R#(W(HVEL:6/K3QBINUG*2M9Z)7L^:]FWI=)75_)FU;+</3P#K).Z
MC"5[K5RM=<MKQ2N[2;L[?WD<;'_P1L_X*+32+%%\#M*9V8!57XC^'R23T 'V
M^O,M1_8L_:8TO]ID?L=WGPV'_"QS(L?_  CD6M64F&:U^U &X28P#]P=YS)P
M.#@C%>H?\$COA)X9\:?M6)\9?B9%CP9\']$NO&_B>9U!7;9+OMXQG@L9_+8)
M_$L;BO"/C9\7_%7QT^,?B?XU>++AO[4\4:U=:A=A7)$9F=F\I3_<56" ?W0!
M6]*KC)8F=)RBTH[J+5I/9?$[Z*[VW6ISUJ. C@X5HQDG*35G).\5:[^!6U=D
M]=GH>O\ Q(_X)5?MK_#+X?ZI\3M0^'&F:OI.@PF;7Y/"WBJPU2738P"6>:*V
MF=U4 $E@I"@$D@ FOG6OT=_X)U_ ?P%^SW=^+/V@O@%^TMHGQB\;6?PWOTM?
MA+X3C-K<W8GA'FM<?:W0W$,'WFCA21V8+M&< _G%1@<34KU*D)-/EMK9QW\F
MV_GL_DQ9AA*6'I4YP37-?1R4EI;5222UZK===T>I?LX_L9?M$_M61ZM?_!KP
M,EUIF@(KZYKNIZG;V&GV ;[HDN+ETC#'LH);'.,<TG[1W[&O[1'[*0TF\^,_
M@9+33=>C9]"UW3=2M[_3]0"XW"*XMG>,L,\J2&QSC'-?2O['GA*#X^?\$N?'
MGP(^)'BZ'X9^$])^)]MXALOBAK,B+I5_J!LU@;1YT#B:638%G7R4EP0"P7"[
MD_;+\)P? ;_@F!\/?@/\.?%D/Q+\(ZG\2[KQ#=?%'1I(VTNSU 6CP#1X$WM-
M$^QGF<3)$6.2H;+;</K];Z[[+2W-RVL]K7OS7M?^[:YT_P!FX?\ L_VUG?DY
MKW6_-:W+;FM_>O:_W'PU7]&O_!'JRLY?^":OPGDDM(F8Z%/EFC!)_P!,N*_G
M*K^CK_@CO_RC2^$W_8!G_P#2RXKR^,/]PI_XOT9[/ O_ ",JG^#_ -N1](I8
MV4;!X[.)6'0K& 14M%%?G9^I!1110 4444 %%%% !1110 4444 >%_\ !/?_
M )(GJW_8]ZS_ .E)K9_;N^)WCCX,_LD>-OB=\-M<_LW7-(TV.73K[[-%-Y3F
M>)"=DJLC?*Q'S*>M8W_!/?\ Y(GJW_8]ZS_Z4FH?^"GW_)A?Q(_[ \7_ *50
MUZF24Z=7.L-":3BZD$T]4TY*Z:ZIGA\45JN'X:QM6E)QE&C4::=FFH2:::U3
M3U36Q^8?_#W;_@H=_P!'!_\ EIZ3_P#(E'_#W;_@H=_T<'_Y:>D__(E?-M%?
MU3_JUPY_T!4O_!</\C^"O]=N,_\ H98C_P '5/\ Y(^DO^'NW_!0[_HX/_RT
M])_^1*/^'NW_  4._P"C@_\ RT])_P#D2OFVBC_5KAS_ * J7_@N'^0?Z[<9
M_P#0RQ'_ (.J?_)'TE_P]V_X*'?]'!_^6GI/_P B4?\ #W;_ (*'?]'!_P#E
MIZ3_ /(E?-M%'^K7#G_0%2_\%P_R#_7;C/\ Z&6(_P#!U3_Y(^DO^'NW_!0[
M_HX/_P M/2?_ )$H_P"'NW_!0[_HX/\ \M/2?_D2OFVBC_5KAS_H"I?^"X?Y
M!_KMQG_T,L1_X.J?_)'TE_P]V_X*'?\ 1P?_ ):>D_\ R)1_P]V_X*'?]'!_
M^6GI/_R)7S;11_JUPY_T!4O_  7#_(/]=N,_^AEB/_!U3_Y(^DO^'NW_  4.
M_P"C@_\ RT])_P#D2C_A[M_P4._Z.#_\M/2?_D2OFVBC_5KAS_H"I?\ @N'^
M0?Z[<9_]#+$?^#JG_P D?27_  ]V_P""AW_1P?\ Y:>D_P#R)7I/['O_  4X
M_;A^*?[4?@3X<^//C=]OT;6?$MM:ZE9_\(UID7G0NV&7?';*ZY'=2#[U\25[
M#_P3\_Y/9^&'_8XV?_H=>?FW#O#]/*J\X8.DFH2::IPNGRO5:'K\/\9<7UL^
MPE.IF->495:::=:HTTY*Z:YM4^J/WGHHHK^4C^^CCOVB/^3?_'7_ &)VI_\
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M?%;]F3X\_L#I^Q!\=_C4WPRUSPUX]E\2^%O$MYHEQ>Z;J*30&*2VN!;!I(I
M6<B0C&-H]12?'KXK_LR_ O\ 8('[#OP&^-#?$S6O$/C^/Q1XK\3VNB7%CING
MB*W$,=K;K<!9)'.U&,F,8W#T ^1**GZA#VO-S.W-S<NEK]]K[ZVON7_:53V/
M+R+FY>3FUOR]M[;:7M>WWA7]'7_!'?\ Y1I?";_L S_^EEQ7\XM?T=?\$=_^
M4:7PF_[ ,_\ Z67%>#QA_N%/_%^C/I.!?^1E4_P?^W(^EJ***_.S]2"BBB@
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M9=\1:K'^S-\.HT\*7;A? ND .&7#?Z%%S7=_\)+J_P#T*%[_ -]+7-_LK_\
M)L/PX_[$+1__ $BAKO*_(:W\:7JS]RP_\"'HOR,?_A)=7_Z%"]_[Z6OYNO\
M@II-)<?\% OB]/+;M$S^.KXM&_5?WAX-?TNU_--_P4__ .4A?QB_['V__P#1
MAKZK@_\ WRI_A_5'QG'?^X4O\7Z,\(HHHK]!/S **** "BBB@ HHHH ****
M"BBB@ K^B;_@D)KNI6O_  3<^%-O#X9NIU70I@)49<-_ID_2OYV:_HZ_X([_
M /*-+X3?]@&?_P!++BOD^,/]PI_XOT9]MP+_ ,C*I_@_]N1]!6>O:E<W203>
M&;J%6;#2NRX7W-:E%%?G9^I!1110 4444 %%%% !1110 4444 >%_P#!/?\
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M/E4G X]*JT4#NT%%%% @HHHH _J4_97_ .38?AQ_V(6C_P#I%#7>5P?[*_\
MR;#\./\ L0M'_P#2*&N\K\4K?QI>K/Z"P_\  AZ+\@K^:;_@I_\ \I"_C%_V
M/M__ .C#7]+-?S3?\%/_ /E(7\8O^Q]O_P#T8:^JX/\ ]\J?X?U1\9QW_N%+
M_%^C/"****_03\P"BBB@ HHHH **** "BBB@ HHHH *_HZ_X([_\HTOA-_V
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ML-K3:RLW\2LW?5:KIJTMK'L/,::RSZM%/7>\KI?"[Q5M&[-;NR;WN?JW<?\
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M^2$ES-MMM;MN[TNO1:Z&=;%4<3B5.I!\B222=FDE9:M/U>FNI]W^(OA-X_\
MV&_^"4/Q,^#'[6,UMH_BCXH>*]%N/ '@&XU**>]LA:7"276HM%&S>2LD2"(D
MX.44'&X"OE#Q/^R_\2?"?[,_AG]J[5)],/A?Q7KMUI&EQQ73&Z%Q;[O,+QE
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MI#-(A*(RW6&<QY4H#MW D&O6?^(<GXP_]#-\+/\ P(US_P".4?\ $.3\8?\
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M .""W[3'P9^(>C_%;X:_$#X6:;K^@7\=[I%_C5YO(G0Y5]DK,C8/9E(]J?\
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MCR/A9_X2/_W-1_PI?_@M;_T>1\+/_"1_^YJ^=/J3\$OBE_R4WQ'_ -AZ\_\
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M?Y)_='_Y(/\ 4;-OYX??+_Y$_*FOZ.O^".__ "C2^$W_ & 9_P#TLN*^&_\
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MH OT4C,J*7=@ !DDG@"J&A^+?"GB=ID\->)M/U$VS!;@6-[',8CZ-L)VGZT
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MHH **** "BBB@ HHHH **** /./VN_"GB/QS^S3XQ\(^$=(EO]2O]':*SLX
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M_!9OQ_\ M=:EX5CC\ Z[\ M$\,Z9K(U& M+J=OJES<2P^0'\U0(Y$;>4"'.
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MQ  [I&4K(% +/Y)10S.H(!0/_!ME_P $HO\ A47_  @*_!/4AXI^S[Q\6?\
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M4?A?^S%\*O$/E:]X6.C:K)J?Q9UBUF(\JX:RMY/LNDPRQY\IF628A6(!*FW
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MU!8]-FO-/66Y=76X$C&1R6.]F [8K]N*_.G]B/\ Y6+_ -MS_L1/A[_Z:DH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  5-_P"CHO\ RR=#_P#D*ODNBOU;^S,M_P"?$/\ P&/^1^+_ -L9M_T$3_\
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M (3N+X6+\0'F-DGV#^R3J/\ 9P7S=^[SO/YV;,;>=V>*_-_X9?LT_M@^.O\
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M\,?AQ8-X=?5;FSM)#$FKZJVJ[I&-PP++;($0(!ACG<0#]DJ\Z_::_:R_9_\
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M##HIXZ8Q67^V/_R:)\5/^R;ZY_Z;YZ^>?^#>/_E"Y^S_ /\ 8G2_^EUS0!]
M?M9_ME?LR_L,_"E_C5^U7\7-.\(>'1=I:6]U>)+--=W+@E;>WMX4>:XE(5CL
MC1FPK-C"DCQK]GW_ (+;_P#!/7]I'XQZ%^S]X,^(?BC2?&/BF21/#&B^,/AQ
MK.D'53'&TC^3+=6J1-A$9L%P2.@KSS_@M!^RY^UAX\^+O[./[<'[)_P8TWXJ
M:C^SWXQU75=7^$^H:Q%8MKT%[;P1BXMY9@8Q<VQ@+QY!8-(&56*[&L?L\_\
M!<?X$_%[]H'PM^R=^UO^R=\5?@!\2?$E[M\&:7\7/"0AT_6+T#:(["^4E992
M6*JQ6,,S!%8LX4@'W=1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#5=<MM*N)=%TRZNA!%>7:QL887D/^K5W"J6_A!SVK5HH _(3_@H7\#?VK/\
M@I[\)-1^#>I?\$"K7P!\8-:N+5+7XU:]X\\./!X4E2>-VOH]3L7-]=*JJ0(D
MCR^>5.W;7ZR^ M!UCPMX%T7PQXA\12ZQ?Z=I-M:WVK7"XDO9HXE1YV&3AG8%
MCR>6K6HH ^(OVV?B9^T!XH^(/B+X,_%O_@AA_P +]^'UO*H\&^)K?Q-X;OH-
M022",R>?9:FZ26+K*73>-X8(KCT'RWJ?_!)/]N'2?^#>#XX?L2>'_A-:)X]^
M)'Q&D\2^ O@_I_C"VG@\':5-KNF7::&E_=2QV[B"*VN)2XD"LTC %F//[ T4
M ?)7_!;/]F7XW_M=?\$H/BI^S3^SSX)_X2'QMXDTC2X=%T7^TK:T^T/#J=G/
M(/.N9(X4Q'%(V6< [<#)(!\K_P""@O[-W[5'A7]N?]GW]OWX3?LIQ_'/0_AO
MX*U3PYX@^',6MV-KJ&C7-V(F36+'[:ZP2RC9Y3@,'"JN."63]":* /S<^%'P
M:_X*5?M"_P#!9OX;_P#!0/\ :!_94M_AO\--"^%>N>'=-T&7QEIVH:CI+S.K
MQRWX@E.9[EV;$=N)8X8X8P[AV8#V7_@F]^R[\=?@)^U;^UM\2OBSX&_LG1/B
M=\88-<\#WO\ :=K/_:5@M@D33;(97>'YP1ME"-QG;CFOKZB@#\W?VBOV,?V@
M_P!E?_@H]\0?V[O@A^Q%X<_:,\ _&O1](C\?>!KB\TVVUSPWJVFP?9HK^P.I
M 0SP2PX$D2NKF0[ONH,_07[!_B#XN>,_'FO^(O&O_!*[2OV>=#ATJ.'1M6NM
M;T6?5]9D:7,D3V^EAA;0J$5OGE8NV,*-N3]044 >0_M]?LI:7^W)^QC\2/V2
M]5UO^S!XY\+7&G6NIF,NMG=$![>=E'+JDZ1N5!!8*1D9S7PEXO\ %O\ P6Y^
M)O[!L_\ P3-O/^"<<&E>/-6\%?\ "!ZY\;KCXD:6_A9-->V^Q3:S'&CF\:22
MW+,+<0ATD?=@[?+K]2Z* /@#]K7_ ()L_%;1_P!GO]AS]F_]FCPQ)XHTS]GS
MX_\ @/5?%>HS7]K9O%HFDVEQ#=:DRSRIYC%G5S#%OD)D.U& ./O^BB@#\KOV
M_O$'[3?@O_@XD^$GC_\ 96^&ECXWUO0OV8]3N]8\#W>M1Z=+KVF'69(9K>VN
M9OW45PK2Q3IYI6-C;[&9=^X>G_!CX._MH?MT?\%// G[?7[4_P"S#=?!7P)\
M"O"6LZ=\,_"6O^(K+4=9UG5]7B6WO;Z864DD5O MLOEJA8N656&0QV_5^K_L
M>_!_6_VR='_;JO5U3_A.M$\ W'@^Q*7P%G_9LUT+I]T6WF3S ,/NX'&*]3H
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MT_P/=7,_[/\ X3MSI,=R"3=(HMF\YEQ]PE0?[PKU_P"''_*TO\1/^S.-/_\
M3_!3?^"[?_)QO[!W_9WNA?\ H)H C_;5M?\ @IW_ ,$X_P#@G5\>/VG/%?\
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MM-%0^,[WPP9(]*:[1?WTT'GG>D)P7&_! /.,5Y#_ ,%#?@M\8/C;\'8OB;\
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M?"KX:?&_X?:K\)_C#X#TGQ/X9URU-MJ^A:Y8I<VMW$2#M>-P0<$ @]00",$
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M8^'O@S\*O#4.C>&?"FBVND^'])@=W2TL[>)8H8@SEG;:BJ-S$L<9)))-;]%
M'G'AS]DG]GSPC^T]XB_;)\-> /L?Q'\6^'+;0O$GB"'5KL+J%C;LK0)):^;]
MF+IL4+-Y7FA1MW[20?1Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHKQ+_@HS\7OB)\!_V-?&/Q6^%/B'^RM?TK^S_L%_\ 9(9_*\W4;:%_
MDF1T;,<CKRIQG(P0#75@<)4S#&TL+3:4JDHQ5]KR:2O:^FNNC.#-,PHY1EE?
M'5DW"E"4Y)6NU"+D[7:5[+2[2OU1[;17XD_\/=O^"AW_ $<'_P"6GI/_ ,B4
M?\/=O^"AW_1P?_EIZ3_\B5^C_P#$)>(_^?M+_P "G_\ *S\9_P")@^#/^@?$
M?^ 4_P#Y:?MM17B7_!.;XO?$3X\?L:^#OBM\5O$/]JZ_JO\ :'V^_P#LD,'F
M^5J-S"GR0HB+B.-%X49QDY))KVB]O;/3;.;4=1NXK>WMXFDGGGD")&BC+,S'
M@  $DG@ 5^<8["5,OQM7"U&G*G*47;:\6T[7MIIIHC]FRO,*.;Y90QU%-0JP
MC.*=KI3BI*]FU>SULVK]62T5\1^)/^#B/_@DUX<U[4-/C_:&U75])TB\-KJ_
MC+P[\/\ 6M1T*SE! (;4+>T>!E&0=Z,R8(.ZOJ[PU\>_@OXT^"T?[1G@[XG:
M-JW@671)-8B\5:9?+/9/8QHSR3B1"0554;..05((R"*Y3O.NHKG/AA\6_AS\
M:?ACI'QF^%/BRUU[PQK^FIJ&BZS8,6AO+9AE9$) )!'2N-_8F_;"^$W[?/[,
M'A?]K;X&VVKP^%?%R7;:5'KUFEO=@6]Y/:2>9&CNJ_O+=\88Y7!XS@ 'JM%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 45YQ^UC^UA\$/V)O@7K'
M[17[0OBF32O#6C-#'+);64ES<7-Q-*L,%O!#$"\TLDCJJJH[Y)"@D4_V3/VJ
M++]K7P)?^/;#X!?%+X>Q6.JFR33/BQX)ET*^N@(HY!<0P2L6:$B3:'./F1UP
M"M 'J=%%% !1110 4444 %%%% !117'S_'WX-VOQWM_V8KCXA:>GC^Z\+/XD
MM_"Q<_:GTI;C[,UV!C'EB;Y,YSGM0!V%%>8?$/\ :Q^'/PT_:>^'7[)VO:)X
M@F\1_$W3]7O- OK+3!)I]O'IT*33BYFW@Q,RN @VMN.1Q7I] !17AW[9?_!2
M#]B[]@*RTJ3]J;XW6>@:AK[%?#_AZTLKC4-5U1@<?N+*TCDGD7<0N_9L!(!8
M9KD_V6/^"PW[ /[8/Q8B^ 7PI^+]]8^/;FUDN;+P7XS\*:CH6HWL*1M([V\=
M]!$+C:B.Y$19E6-F("@F@#Z=HKX[^*__  7S_P""4/P3^*WB?X)?$?\ :9U"
MT\3>#-7FTOQ-I]I\,O$EZEA=Q'$D;36VG21-C'WE<J>H)%>S_LE_MZ_L<?MU
M^&KKQ7^R1^T1X;\<6VGE1J4&DW96[L=V=GGVTH2> -@[3(B[MIQG!H ]=HKY
M/_:6_P""V7_!.S]E3XQZK^SW\2/BWK.H>-M 2.3Q#X<\(>!M6UF;2HY(UE5[
MAK.VDCB!C=6P6W8(.*]I_95_:[_9O_;<^$-I\=_V6/BSIOC'PM=SO;C4=/#H
MT$Z %X)X9566WE4,I,<B*P#J<88$@'H]%?(_QV_X+E_\$S_V=/BYKGP8^(WQ
MXO9-4\)W:6OC2^T#P=JFJ:=X;F=MHCOKRTMI(+=PWRLI?*$$.%(-?4_A'Q=X
M6\?^%=-\<^!_$5EJ^BZS8Q7NDZKIMRLUO>6TJ!XYHI$)5T96#!@2"""* -&B
MN/\ C!\??@W\ +;P]>_&;XA:?X>B\6>*[+PUX<?4'*B_U:[+"VLX\ YDD*-M
M!P/E/-<Q^V?^V1\)/V$?@?+^T!\;;;6)="AUO3M*=-#LDGN//O;F.VA.QW0;
M?,D7<=W R<'I0!ZO1110 4444 %%%% !1110 4444 %%%<?\*?C[\&_CCJ'B
MK2OA+\0M/UZY\$>)[CP[XLAL7).F:K %:6TER!B10ZD@9'S#F@#L**\P^$'[
M6/PY^-7Q[^*?[.OA71/$%OK?PBO=*M?$MWJ>F"&SNGU"T-U";27>?/"H"')"
M[6XYZUZ?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S;_P %
M=O\ E'C\0O\ N$_^G:SKZ2KYM_X*[?\ */'XA?\ <)_].UG7M\,_\E'@O^OM
M/_TN)\QQM_R1F9?]@];_ --R/Q)HHHK^O3_.X_;;_@D3_P H\?A[_P!Q;_T[
M7E>$_P#!S9\1_''A#_@F#<_#?P1XCN-'_P"%H_$/0/!6LZK:OM>WTZ]N"UP,
M]E=(3$PZ,DK*>#7NW_!(G_E'C\/?^XM_Z=KRM?\ X*:?L)^$_P#@I#^Q;XQ_
M9-\3^()-%GURWBN/#_B"&,N^DZI;2K/:W(4$%E$B!74$%HW=05)!'\A<3?\
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MPT^#UDGAJ:ZTFP@GDAM[K6O[3+37$\_EB5H 8XPC*5($F%^\?^",G[>?BO\
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MO@3X$U7Q-I=_\;?&GB;Q_I6IQ26-C<I<MI^E16,CR7#S30H5G=410@# !MP
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M^WK!?[(LM)@=-0E\UIQ%<>4Q VPO(S_P!Z &_M+>(O\ @I1_P3'^+/P0^/\
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M;P^:KH9+99$&W)(!!KZ+LOV'_P!BS3OB5_PN?3_V0?A=!XQ_M=M5_P"$LA\
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MXIU@1QL-4U9+N9I;E(G:5([1XD0; 3N5I!+]U_L;?&O]L#]HC0O%.E_MG_\
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MP3^R_P"(O$L.M^(].BN=1\8:U;EC'>ZO>7$ES=,A8 LBO)Y2,0I9(E) )(H
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MW>GSWBFWCNX9V<D28WIA%(R: /.?V)O^"C.L^ O^"D_@C]A:#_@IUX1_:O\
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M']JGXY6'@R^\9V&KWGAH:E873Q7D6F0)/>?OHHGCC9$ECVI(RO*SJD0D<A:
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MRO&$'@S5FT.RDO8HY;>&[O\ [+Y%I*4E0O'*RM"21,(RK  'V717R?\ $?\
MX+=_\$U/A1\:?^%(>-_V@)+:[C\0KH%]XDB\,:C-X?L=5+;?L4^K) ;..56^
M5P9<1D$2%"K >F?MA?M]?LK?L(:'H>K_ +2?Q'DTJX\47SV7A;0]+T:[U/4]
M9N$4,Z6UG9Q2S2[0R[F"[4WKN8;ER >R45X?^Q]_P40_9C_;DO\ Q#H/P+UC
MQ(FL>%(;2;Q#H7BSP1J>B7EG%<F402%+ZWB\Q7,$H!C+ ;#G&1GW"@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "J?B+0K'Q1X?O\ PUJF_P"S:C9RVMQY;8;R
MY$*-@]C@GFKE% 'G'[(_[+7PN_8I_9R\+?LM_!5=1'A?P?926NCC5KP7%QY;
MS23'?(%7<=TC<X'&*]'HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-20210930_g8.jpg
<TEXT>
begin 644 biib-20210930_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
M'[,5\V_\%3/VXM:_8<_8!^*7[6/P@L_#WB3Q#\/K.SD31]3N&DM_-FO[>V9)
MQ ZNI"RN0-P.5';(K\U/#G[6?[2?@O\ X-CM/\.>&_C'K%OXHN/BG)\);'Q_
M-=L;_3M)?Q')9";S<@JZ68^SJX(*+M*D,H-=)_P78_X(T?L+?L<_\$<O'_Q.
M_9/^'+> O$G@[2])MK_7=-U6X$_BBRFU.SMY[75"SE;T.\B3@NI*SPQE-HR"
M ?L7X7U6;7?#.G:W<1JDEY80SNB=%+H&(&>W-?#/_!3+_@N?X/\ ^"97[9OP
MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
M)P&^W/AW_P D_P!"_P"P-:_^BEK\V_V]/@5\./VG?^"^OPX_9Z^+VB+J/AGQ
ME^R1XJTG6;4X#&&:\="R$@[)%)#HXY5U5AR!0!]:?\%(OV^H/^"??P.\,?&J
MV^&">,X_$OQ&T/PK'9)KPL5B7493&+H2B";>$ W;-HWY^^O6NY\=^*?VJ=/_
M &H_ 7A3X?\ PQT"_P#A/J&CZK)\0?%%YJ&S4-+O8T4V$5O%YH\Q)7+ASL?:
M .5K\6OVE?CK\1](_P""=&D_\$R_VF];:Y^*W[,G[5'@7PW<WT^5?Q!X9>YD
M?1=60,<LLEJ%C/4CRD+G=)BOOG]KW_E8+_8]_P"R9_$+_P!)+>@#[TU/5=,T
M2PEU76=1@M+6%=TUS=3+''&,XRS,0!SZT^TN[2_M8[ZQN8YH9D#Q31.&5U(R
M""."".]?DQ^R]^P#^SK^VW_P6(_;GO/VJ?"LGC+PUX;\;>$O[+\#:C>S+I$E
M]+HGS7UQ;HZK<S)&GEQ&3<(Q+,0-SY%S]BGQQ>_\$W+#_@I)\#O@+#<R>"/V
M<XD\8?"WPMJ%W+=0Z3)>>&KC5)+*(R,S+;">!<)GC+'EF8D _5*Z\2>';'5X
M/#][KUE#?W2EK:QEND6:91GE4)W,.#T':KM?@5^RY\"?V=OC]^Q=HOQ$_:/_
M .",/[4?Q@^*?Q+\.0^(/$'[0=O'IT^H7FI7<8GBO],NGUB-[>&(O'Y"+'&-
MD2;X\EA7ZQ_\$A=6_:VU;_@G'\+E_;J\.:QI?Q4L-(N-.\4P>(,&^E^S7D]O
M;7$Y#-OEEM8K>5G))9I"Q))- 'G?_!9G_@K[JO\ P24\+?#_ ,1:/^R[<_%&
M3QOJ6IP2V-IXK_LN2P@L;474TX_T2X\[$6]MOR8"'DYX]_\ BO\ MD?!SX6?
ML5ZQ^W?-K*7W@C3?AZWB^SN8I AO[(VGVF!8R<_/,&C1!SEI%'-?'_\ P6ET
M'1O%/[>O[!OACQ'ID-[I^H_&76+6_L[A T<\,FEA'C8'JK*2"/0U\H> +OQ=
M\19/ W_!LQXK:^O)? /[0=V?'%Q=JS"^^%.DF+7M,,[=%^U?:;&S4#./L^#G
M.: /T0_X([_\%/M=_P""JGP%\9?&#Q1^S?-\+=3\&?$F]\'ZCX9N/$_]JR">
MUM;2>21I/LMML8-=&,Q[#@Q9W'=@?5(\2>'3K9\-#7K(ZD(_,.G_ &I//"==
MWEYW8]\5^//[*'[0GCW]E#_@FU_P4X_:!^%,OD>)/#'[67Q-GT&Z$8;[)=.M
MC%%<!2"#Y32"3!!!V<C&:ZK7/^"(G[%&D_\ !'Z?]H73]*OXOCG9?")OB$GQ
M^7Q%=_\ "0MXF33?[1-\;SS=WE-,"OEYP(SQ\X\R@#]::J:?X@T'5[NZL-)U
MNTNI[*3R[V&WN5=[=^?E< DH>#P<=*_&W]LSQMX]_P""A/['/_!,SQC\2_&6
MJZ'K_P 2_BOX?'BC7O#]P;.]\R72YH[N>VDCP;>24"5D=,&,R@K]T5Z/^V!^
MPU^R_P#\$P_VXOV._CM^PI\,(?ASJGB_XV0_#_QI;Z%?7'D>(='U"TF+I>))
M(PN'1X@ZR/EMY#,2R(5 /N?PK^V[X5\5?\%!/%?_  3\M_ ^H1:QX4^&]AXP
MN/$+W"&VG@NKIK=8%0?.'4KN)/&*Y;Q/^VYX\T'_ (*W>&_^"?,?A;1CX7UG
MX$WOCFYUR3S?MT5W#J@LQ"IW^7Y)0[CE=V[OCBOB?_AVC^P;\?O^#B?XU>!O
MC+^S!X9\0Z1=_ S2O%ES8:A [1R:U=ZK(MS?'#C][(.">GM6M^UO^Q;\&OV@
M_P#@O_\ "#]F3Q=87EK\.=(_9#NDU'P?I.HS6EMJVFVNLF*#3)VA=9&M0_D2
M-&& ?[.J/N1F4@'ZH:-KNB>(K(:EX?UFTO[8N5%Q9W"RH6'!&Y21D5!JOB[P
MGH6H0:3K?B?3K.[NL?9;:ZO8XY)LG VJQ!;GCBOS>_9[_9W^$G_!/'_@OY:_
ML]?LB>%E\&_#OXK_ +.%WX@\3>!=,N)/[,&LV.K)#%?Q0LQ$4GD,8B%PN&8X
MRQ-?-.H? 7]G[]D[XA_%[Q#_ ,%N_P#@DU\0?BO/K_Q%UC66_:6T71W\4Z4=
M!EE+6IG$-P)]'AMX,)Y:Q_(%&  %H _<BOCS_@H;_P %,_C?^R/^U+\&OV/_
M -G+]C&W^+_C+XS6.O7.D6EU\2H?#D=J-+MX[B53)-9SH^Z%I&R63!CP-Q88
M^A_V6M4^!>L_LU^ ;[]F'6;?4/AS_P (?IT?@:[M;J:='TI+9$M?GG)E8B)4
M!\T^9D'?\V:_.K_@LIX:_:&\7_\ !:G]A[P]^RK\3=#\'>/+C0?B)_8?B/Q)
MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
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ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH I7WB+1--G^RW^I1Q2  [&/.*B_X3'PQ_P!!J#_O
MJO(/V#;FYUWX.:K>ZY</>3+XVU>-9;MS(P1;DA5RV3@#H.U>U_V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_
M //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4 5K;Q1X?O)UM;758GD<X1%/)-7ZB2QLHV#QV<2L.A6
M, BI: "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5
MX7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">_
M_)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO]HGX]?LV?L&_ 3Q5^T/\8]4TGPCX2T@SZGK=Q;VL<;7MW,Q8A(T -Q=3R'
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MV_:H\7?M1>!?AG%XH_9*^#OASQ]XDM=6A:]\*^(_$S:.M]8;7$JV]WY4B17
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MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
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M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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MBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@
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M%% !1110 4444 %%%% !1110 5[?\,_^1%T[_KB?_0C7B%>W_#/_ )$73O\
MKB?_ $(U]3PG_OT_\/ZH#=HHHK[\ HHHH **** "BBB@ HHHH **** /"_\
M@GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q1
M6/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>%^/\ _D=-3_Z_'_G7NE>%^/\ _D=-3_Z_
M'_G7R?%O^Z4_\7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110 5[?\ #/\
MY$73O^N)_P#0C7B%>W_#/_D1=._ZXG_T(U]3PG_OT_\ #^J W:***^_ ****
M "BBB@ HHKR_]K3X0_M _&KX:6GA/]FW]JBZ^$&O0Z];7ESXHM/"5IK+7%G&
M'\VR\BZ8(HDW+^\!W+LXZF@#X]^*ND?\%!O^";/[<GQ9_:-_9L_8TF^/_P )
M_CI?:9K6N:/X9\26^G^(/"FM6MC%8R%8[@$7EM-'#&X"\HV02@7]XOPIT;_@
MH)_P4E_;E^$W[2/[2?[&DOP ^%'P+O=4UC0M&\3>)+?4/$'BO6KNQDL8V:.W
M %G;0QS2.0W+M@ N&_=^H_M0_L._\%-_B_\ '77?B+^S[_P65UCX5>$-1-M_
M9'@&U^"6BZO'I>RVBBEQ=W,@EE\R5))OF'RF7:.%%+^RY^P]_P %-?@_\=M"
M^(O[0G_!9/6/BMX/T[[5_:_@&Z^">BZ1'JGF6LL46;NVD,L7ES/'-\H^8PA#
MPQH ^OZ*** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z
M4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9_\ (BZ=_P!<3_Z$:^IX3_WZ?^']4!NT445]^ 4444 %%%% !7R[_P %=?\
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M\>E^7:RRQ9M+:,2R^9,D</RGY3,'/"F@#Z_HHHH \+_X)[_\D3U;_L>]9_\
M2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH ****
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M&W_ZM<<_2U% !1110 4444 %>%^/_P#D=-3_ .OQ_P"=>Z5X7X__ .1TU/\
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M:$_X+)ZQ\5O!^G?:O[7\ W7P3T72(]4\RUEBBS=VTAEB\N9XYOE'S&$(>&-
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MVCNO-U&UDFN[&[FMHT6[G@EB,;3,#*61PY^ZJZW_  5#_P"4C/[#?_92]?\
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MX_\ .O7/^$EU?_H4+W_OI:\>\:327'BO4)Y;=HF>Y8M&_5>>AKYCBW_=*?\
MB_0#,HHHKX, HHHH **** "BBB@ HHHH **** "O;_AG_P B+IW_ %Q/_H1K
MQ"O7/ .NZE:^#[&WA\,W4RK$0)49<-\QZ5]3PG_OT_\ #^J ["BLNSU[4KFZ
M2";PS=0JS8:5V7"^YK4K[\ HHHH **** "BBO.OVL/CWK7[,?P#UWXW>'O@1
MXU^)EYHQM1%X*^'FE?;=8U#SKJ* ^1#D;_+$IE?GB.-SVH _-D?'[_@E?^R;
M_P %H_VF['_@HGXZ^&\WB_QD_AO4?!?B/QE91:@-)TU-'@CETARZ2#3958).
M%;8MQ%<0L&8HRI]<?LS?ML_\$8OB[\;M$^'G[)_Q=^">J?$#4/M/]@6/A&SL
MTU&7R[:66?RC'&&&+=)BV#]P-GC-?,_C+_@IUX'^(WB2Y\9_$+_@VA_:3U[6
M+W9]LU76?V?K&ZN9]B*B[Y9=S-A%51DG 4 < 5Z)^P]^V'\+_BG^U%X8\!^'
M?^""WQ@^"UY?_;?)^)?BGX)V.D6&C[+*>0^;=Q#?%YH0VZX^\TZH>&- 'Z#T
M444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU'_D(3_]=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH **** /H'P_\
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
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M?GY7"DE#P>#CI0!<HHJCKWB;PWX6M5O_ !/X@L=.@9]BS7]VD*%O0%R!GVH
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M=4^([^(/#46ES:EXPO9--T=&O+&QD6UL!(+>,/"IW;D8EY'<88Y')?\ !O\
M:+X6TS]J#X02_P#!.G4_'<GPIF_9NLY?VFX+^34G\+1>-6M;8J+(WWR?V@;@
MRM*+8F-8]P7 WJ.Z_P"#J?\ X*+_ +&5M^Q-\0_^"?DWQL@7XOKJOAJ];P;_
M &-?;Q +^TO2_P!H\C[/_P >_P"\QYF>V-W% 'ZR?$GP-IWQ/^'6O_#35]4U
M"QM/$6BW6F75[I%V8+NWCGA:)I(90"8Y5#DJ^#M8 ]J_+#_@JM_P1U_X)#?L
M,_\ !-CXB?'WP/\ "U_A[X[\(:'+?_#[XC:=XMU$Z^_BC'^@*MS)<-),\USL
M5EY 5W=0FP,OW#\"/^"K7[!?[3_P"\?_ +3?[/?QU3Q5X-^&&GW-[XTU.RT"
M_@:QC@M7NY,17,$;RGR49@$#9QCKQ7Y0_!S_ (+,_P#!,W]O;]K"W_;=_P""
MGW[5VG^%_"_P^UJ0_ 7]GN?PWJU]#I4J,5'B'5WMK22"YU!P,Q1JSI;J>"6Y
MH ^J_P#@I1^T3^V+X-_X(K? +X<^)_%VI^%/C-^T#K'@/X<>*_$%MF"_TN_U
M6V#ZC*-N/*G98)XVVXV&5]N"%(X+_@J/^P'^RY_P1<_9V\"?\%(?^"?GP^D^
M'WB?X-^-]"@\5W6F:K<L?%WAZ[NX[2]LM2#N1=&5I8W\QAN4@E2#MV^U?\%I
M-/O_ -MC_@F?\._VT?V+=/NOB!%\-?B5X8^+_A2QTFQF6XUZPL7D\P0PR(LF
M[[/<R2[&4,1$0%+$ ^*?\%1/V_OV7?\ @M-^SQX$_P"";O\ P3[\?3?$#Q/\
M8_&^A3^+;;3M(N4/A#P]:74=W>WNI%XP+8QM%&GEL=S$D+D[0P!^O(((R#D'
MH:^)_P#@II^R?_P13T[Q7:_MF?\ !4KP9X3^U:D+;PQIOB'QQJ]^;4%8YYXK
M6*WCE\E'*I.^X1ACM.6X 'NOQE_;C^"WP*_:L^$?[''C6UUMO%OQI&L'P?)8
MV*26:?V9;+<W'VB0R*T>8V&W:K9/!QUKS']J/_@K'_P2K^!_QDUG]EW]L?XV
M^'O#WB3PXMM>RZ1XU\-7+VTJ36RS1SV\S6[P3?)*4.QBZL'4@=P#YU_X-^_#
MOAW3?CG^TEK?[%=WK_\ PQ[>>(-(7X)0ZW/=M:G4TMG_ +9?3%O#YRV?V@A=
MS *Q5-I.UZ_3NORZ_P"",5UX&^,/_!3/]I/]J_\ 8:\ 7WAS]F/Q1H6BV6D7
M$>@2Z3I'B?Q/"/\ 2=2T^TD2/:BIYB2.J+O:0,02W'ZBT %%%% !1110!\\Z
MC_R$)_\ KLW\S4-3:C_R$)_^NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4
M444 %%%% 'T#X?\ ^0#8_P#7G%_Z *MU4\/_ /(!L?\ KSB_] %6Z_8Z/\&/
MH@"O"_'_ /R.FI_]?C_SKW2O"_'_ /R.FI_]?C_SKYCBW_=*?^+] ,>BBBO@
MP"BBB@ HHHH **** "BBB@ HHHH *]O^&?\ R(NG?]<3_P"A&O$*]O\ AG_R
M(NG?]<3_ .A&OJ>$_P#?I_X?U0&[1117WX!1110 4444 %%%% !1110 4444
M >%_\$]_^2)ZM_V/>L_^E)KU?XF?\B+J/_7$?^A"O*/^">__ "1/5O\ L>]9
M_P#2DUZO\3/^1%U'_KB/_0A7)C_]QJ_X9?DP/$****_(@"N3^-WQF\%_L_\
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M_$W483N2WG.G0K;:5 <G%M90;;>-<D9$C@_/1@L)"NG*HVE:5K=6DW]RZ^J
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M]FDF91*VY%<LBQ@L-"OSN2;LMKI=;;NZ7Z@?H_\  /\ :"^#'[47PLTSXU_
M#XAV'BCPOJZ,;'5M/9MK%6*NCHX5XI%((:-U5E/! KTGP!_R.FF?]?B?SKX)
M_P"""?A_PK;?LE^,OB)H?C32KS4_'OQD\0>)?%/AC1[:X@B\&ZE<-"LFAF*Y
MCBEC>W6./<&C3)?*[DVNWWMX _Y'33/^OQ/YU<:4:&:1IQV4UOON@/=****_
M5P"BF7$\5K;O=3OM2-"SMC. !DGBN?\ ^%M?#[_H8/\ R4E_^(K"MBL-AVE5
MFHW[M+\P.CJ#4["+5--N-,F=E2Y@>)V7J P()'YUA_\ "VOA]_T,'_DI+_\
M$4?\+:^'W_0P?^2DO_Q%8_VEEW_/Z'_@2_S H_L[_!C0?V</V?\ P+^SQX6U
M6[OM,\!>#M,\.Z=>Z@5\^X@LK2*VCDDV +O98@6V@#). !Q78USG_"VOA]_T
M,'_DI+_\11_PMKX??]#!_P"2DO\ \11_:67?\_H?^!+_ # Z.BN<_P"%M?#[
M_H8/_)27_P"(H_X6U\/O^A@_\E)?_B*/[2R[_G]#_P "7^8'1U4T[0-"TBZN
M;W2=%M+6:\DWWDUO;*C3MS\SE0"QY/)]36/_ ,+:^'W_ $,'_DI+_P#$4?\
M"VOA]_T,'_DI+_\ $4?VEEW_ #^A_P"!+_,#HZHZYX8\->)X8[?Q+X>L=1CB
M;=$E]:),$/J X.#65_PMKX??]#!_Y*2__$4?\+:^'W_0P?\ DI+_ /$4?VEE
MW_/Z'_@2_P P.ABBC@C6&&-41%"HBC 4#H .U.KG/^%M?#[_ *&#_P E)?\
MXBC_ (6U\/O^A@_\E)?_ (BC^TLN_P"?T/\ P)?Y@='17/1_%;P#+(L4>O99
MF 4?99>2?^ UT-;T<3A\1?V4U*W9I_D 4445L!\\ZC_R$)_^NS?S-0U-J/\
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ML> /^1TTS_K\3^=8];'@#_D=-,_Z_$_G73@O]\I_XE^: ]THHHK]? J>(/\
MD WW_7G+_P"@&OGZOH'Q!_R ;[_KSE_] -?/U?#\7?Q:7H_T ****^/ *S?!
M_@[PK\/_  U:>#O!'AZTTK2K",I9:?8P".&%22Q"J. ,DG\:TJ*=W:P!1112
M **** "BBB@ HHHH FT[_D(0?]=E_F*^AJ^>=._Y"$'_ %V7^8KZ&K[;A'X*
MWK']0"BBBOL@/GG4?^0A/_UV;^9J&IM1_P"0A/\ ]=F_F:AK\9G\; ****D
MHHHH **** "BBB@ HHHH **** /H'P__ ,@&Q_Z\XO\ T 5;JIX?_P"0#8_]
M><7_ * *MU^QT?X,?1 %>%^/_P#D=-3_ .OQ_P"=>Z5X7X__ .1TU/\ Z_'_
M )U\QQ;_ +I3_P 7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110 5[?\,_^
M1%T[_KB?_0C7B%>W_#/_ )$73O\ KB?_ $(U]3PG_OT_\/ZH#=HHHK[\ HHH
MH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37J_Q,_P"1%U'_
M *XC_P!"%>4?\$]_^2)ZM_V/>L_^E)KU?XF?\B+J/_7$?^A"N3'_ .XU?\,O
MR8'B%%%%?D0!1110 4444 %%%% !1110 4444 %;'@#_ )'33/\ K\3^=8];
M'@#_ )'33/\ K\3^==."_P!\I_XE^: ]THHHK]? J>(/^0#??]><O_H!KY^K
MZ!\0?\@&^_Z\Y?\ T U\_5\/Q=_%I>C_ $ ****^/ **** "BBB@ HHHH **
M** "BBB@";3O^0A!_P!=E_F*^AJ^>=._Y"$'_79?YBOH:OMN$?@K>L?U ***
M*^R ^>=1_P"0A/\ ]=F_F:AJ;4?^0A/_ -=F_F:AK\9G\; ****D HHHH **
M** "BBB@ HHHH **** /H'P__P @&Q_Z\XO_ $ 5;JIX?_Y -C_UYQ?^@"K=
M?L='^#'T0!7A?C__ )'34_\ K\?^=>Z5X7X__P"1TU/_ *_'_G7S'%O^Z4_\
M7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110 5[?\,_^1%T[_KB?_0C7B%>
MW_#/_D1=._ZXG_T(U]3PG_OT_P##^J W:***^_ **** "BBB@ HHHH ****
M"BBB@#PO_@GO_P D3U;_ +'O6?\ TI->K_$S_D1=1_ZXC_T(5Y1_P3W_ .2)
MZM_V/>L_^E)KU?XF?\B+J/\ UQ'_ *$*Y,?_ +C5_P ,OR8'B%%%%?D0!111
M0 4444 %%%% !1110 4444 %;'@#_D=-,_Z_$_G6/6QX _Y'33/^OQ/YUTX+
M_?*?^)?F@/=****_7P*GB#_D WW_ %YR_P#H!KY^KZ!\0?\ (!OO^O.7_P!
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MA#1OV.WU;PKXWT[5IM>\9ZKJNN6&E6DUO!H-_-(OF:8L4ZI)'Y(5!AE7.[<
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MKY2_X*]?$KPCJ7_!,SQ7=^'M5@U/_A.K72[#PBEHX<ZK-=7=N\0@ ^^3&&D
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MO:3)>7'VJ9B\S>9D?*6/"]A1_P (#_P4$_Z+_P"!/_"4D_\ BJ /;O[.T_\
MY\8?^_0H_L[3_P#GQA_[]"O$?^$!_P""@G_1?_ G_A*2?_%4?\(#_P %!/\
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MI_\ SXP_]^A1_9VG_P#/C#_WZ%>(_P#" _\ !03_ *+_ .!/_"4D_P#BJ/\
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M%_"VK^>=7L--1_-U!YD\N66>X9C/-*R?+YKR,X  ## QA?\ " _\%!/^B_\
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MB!\9_!^H:+'.#J-E8>''BFECP?E1RWRG..:]?H **** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@#R#]BGP+XN^'WPGU+1/&F@SZ==S>,-4NHX+@
M,T,DY9'X/0CD5Z_110 451USQ1X:\,1Q2^)?$5CIZSR;(6OKM(A(W]U2Y&3S
MT%7@0P#*<@]"* "BJ=WXB\/Z?JEOH=_KMG!>W8)M;.:Z199@.NQ"<M^ JY0
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M0- IMT1\-(9,$(C[0S84@&U_P3L\<> /^"Z?_!&WP3?_ +;G@L:^OB*,Z?\
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M7/AFSU"XB2"VD@@1I2T88S.BH7192K*&C90 ?'O_  4N^!?_  0^^%_@F]^
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M_CUXU@\.^$?#GBOQQ/K>M7,$LJ6L;Z98Q*Q6)6<Y=T7Y5/6I?VX?^"UOP/\
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MJJY)PH'%1:'X7\,^&(Y(?#7AVQTY)F#2I8VB0AR.Y" 9-7J* "BBB@ HHHH
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MLW_L,:[XH\=_#&Y\7>(_&'C06T?B?QW\0_%MSKFLW\%NI6"!KFY8E8D!.$4
M'C.=J[0#W^BBB@ HHHH **** "O-/CY_Q_:;_P!<9/YK7I=%<.8X+^T,)*AS
M<M[:VOL[]T!\YT5]&45\S_JA_P!/_P#R7_[8#"^&7_(B:=_UQ/\ Z&U;M%%?
M78>E["A"G>_*DON5@"BBBM@"O@?]LO\ 8^_;'_9__P""@UM_P5;_ ."=7@'2
M/'^K:[X/C\*_&7X.ZMKT>E/XEL875K6^L;R;]S%>1!(T_>X4I$ N2[@_?%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-20210930_g9.jpg
<TEXT>
begin 644 biib-20210930_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?A@WQ$O-7\<>*].T*+7=4N?)\-6*ZK<(T6GQQR*ML[S"6=YE E9I "VU$4
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MQ_9H^)7P NM7\*^-]*@U/Q1\1;?Q&85\*64FH_86N9;06K^=$CM&S-YT?#X
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MH9U*RM NDHTWF6P=#)N@$J+\PVLZMSC% 'U9^S;^U)_P5$^)'QETCP;^T?\
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M\/OV.?V;/!7[+OPJ>\D\/^!_#\&E:;/J,H>XG6-?FFE90 9'<L[;0%RQP ,
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MTK7?!EW\=?$\7B+X@:K\;=][HF;YO.MHK!]/9KJ.W/R(1-&)!R%3I7O.K_\
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M2ZMJL&GP[Y8KB_C22Y01S1J9EW(S(P#'8<>L_P#!1U$3_@V+\01J@"K^SCH
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M/_8_B=-:T76;&]\-;89[2[$43[UDL[A)8)(U>/$;9995-?K=7Y)?%?\ ;M^
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MM$2W.C_!;XU_!>+P9JWCPV,LMEX?\265ZLUNEXT2MY,4UNJHCL "[-T6-V
M_P#9,^'OAK_@F=_P7&U;]@7]GV.YTCX+_&/X*-XZT3P,+V66S\/>(K._:VN3
M9K*S&&*:!6D=5."Y0 !8U _2^OS0_9*^(?AO_@IE_P %Q-6_;]_9^>YU;X+?
M!WX*-X%T+QS]AEAL_$7B*[OVN;G[&TJJ9HH8&:-V P'"$$K(I/Z7T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %9\7A/PK!K;>)8/#.GIJ+YWZ@ED@G;
M(P<R8W'CCK6A10 51TOPOX9T2\N-1T7P[86=Q=MNNI[6T2-YCG.790"W))Y]
M:O44 ?-/@']AGQ3X8_X*@?$_]NG6_%&CWOAOQ]\+M'\*V_ATP.US%+9S.\DD
MNY?+:-P^  2?45]'Z=ING:/91Z9I&GP6MM"N(K>VB"(@ZX"J !4]% !5/6_#
MGA[Q+;+9>(]"LM0A1]Z17UJDJJW3(# @'D\^]7** &PPQ6\2P01*B(H5$1<!
M0.  !T%.HHH **** *FE:#H>@I+'H>C6EDL\IEG6TMUC$DAZNVT#+'U/-.U;
M1M(UZQ?2]=TJVO;:0@R6]W LD;8.1E6!!P>:LT4 0V&GV&E6<>G:78PVUO"N
MV&"WB"(@] HX ^E3444 %9\/A/PM;:V_B6W\-:?'J,@(DU!+-!.V1@Y<#<>.
M.M:%% !533] T+2;RYU#2]$M+:XO7WWD]O;*CSMSR[ 98\GDYZFK=% 'G7B?
M]EKX/^-/VFO"O[6_BC1KB]\8^"/#>HZ+X5FGN2;?38;YXFNIHXN@GD6%(S)U
M\O<O1C7HM%% !1110!4GT#0KK5X=?N=$M)+^W0I;WLELIFB4YRJN1N4<G@'N
M:MT44 %%%% !1110!3_X1_0?[9_X2/\ L2S_ +0\KR_M_P!F3SMG]W?C=CVS
MBKE%% !4=Y9V>HVDEAJ%K'/!,A2:&:,,CJ1@J0>"".QJ2B@"'3].T_2+*/3=
M*L(;6WA7;#;V\01$'H%& !]*FHHH **** *G]@:"-9_X2(:):?V@8O+-]]F7
MSMG]W?C=CVSBK=%% !4-_I]AJME)IVJ6,-S;S+MF@N(@Z.OH5/!'UJ:B@"*P
ML+'2[./3M,LHK:WA0+#!!&$1%'0!1P!["I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"#5=5TS0M,N=;UO4H+.RLX'GN[NZF6.*")%+/([L0%55!)).
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M[0/AW_@G%I]K\;[GQ,^CS>,=6G^$B>-9F?5XO!KRJ=,6ZW$NK;?,95;E8VC
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MX(?\%2?V7/CQ^R)XR_;=\,MXEL? G@+5=5L?$<VHZ$S7<3:>0+F1+>W:5Y4
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M\M/O[_ALC]F__HHW_E(O/_C-'_#9'[-__11O_*1>?_&:^ :*/:9;_P ^Y_\
M@:_^5A[+.?\ G]3_ /!<O_EI]_?\-D?LW_\ 11O_ "D7G_QFC_ALC]F__HHW
M_E(O/_C-? -%'M,M_P"?<_\ P-?_ "L/99S_ ,_J?_@N7_RT^_O^&R/V;_\
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M2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444
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M-T\+?]>+_P#HZ2OSXK]!_P!DK_DW3PM_UXO_ .CI* /1:*** "BBB@ HHHH
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M> .!4M% !1110!^F'PQ_Y)MX>_[ =I_Z)2MRL/X8_P#)-O#W_8#M/_1*5N4
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M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
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M^)0!XCU  ?\ +[+_ .AFJ5 !1110 4444 %%%% !1110 4444 %%%% 'Z/\
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M* /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /S!\3?\C'J'_7]+_P"AFJ-7O$W_ ",>H?\
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MX8_\DV\/?]@.T_\ 1*5N5A_#'_DFWA[_ + =I_Z)2MR@ K\ZOVD_^2]^+?\
ML.3_ /H5?HK7YU?M)_\ )>_%O_8<G_\ 0J .(HHHH **** "BBB@ HHHH **
M** "BBB@ K]!_P!DK_DW3PM_UXO_ .CI*_/BOT'_ &2O^3=/"W_7B_\ Z.DH
M ]%HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE
M>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M,'Q-_P C'J'_ %_2_P#H9JC5[Q-_R,>H?]?TO_H9JC0 4444 %%%% !1110
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MGAGX+W/Q(^,<^G2F+4+GX0?#>^UBT@<$<"Y*QPRC!SNC=U([UUG[.G_!>?\
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MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.
MT_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S
M^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]
M5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H
M-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8
M_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_P
MF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_
MPF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_
M 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^
M&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@#\QO
M$;*_B&_=3D&]E(/_  ,U2J[XE 'B/4 !_P OLO\ Z&:I4 %%%% !1110 444
M4 %%%% !1110 4444 ?H_P##;Q;X;A^'6@12ZQ"K+HMJ&!/0B%:V_P#A,?#'
M_0:@_P"^JH?#.PL6^&_A]FLH23H=IDF,?\\4K;_L[3_^?&'_ +]"@"G_ ,)C
MX8_Z#4'_ 'U7Y\_M%W$%W\=/%=S;2!XWUJ<HPZ$;J_1+^SM/_P"?&'_OT*_.
M_P#:01(_CSXL2-0H&N3X & /FH XFBBB@ HHHH **** "BBB@ HHHH ****
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M$:#X8:==;\$7OBK3KVQE,]K-#$+R&%!+$59Q,FX+EX5/(!H _0NBBB@#PO\
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MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH ****
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MQ^14#_O"S$?>VT ?I117B'[:GQR\9>"-"T7X$_ N>-OB=\2[M],\)[EW+I4
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M -E7P3X5\*:)::;IFG:1]GL-/L;=8H;>))'58T10 J@   # KX%K]!_V2O\
MDW3PM_UXO_Z.DH ]%HHHH **** "BBB@ KR[]KM/VU)/A0B_L%W/PNB\<_VK
M#YC?%V'4I-)^P[7\W TYEF\[=Y>WG;C=GM7J->%_\%"? ?PJ^(_P'@\,?&#]
MM_Q=\ -+D\16K0^.?!/Q$M?#%]+<;90EB+RZ1T99,L3$!N8QJ1]TT >"?9O^
M#G'_ *#/["'_ (+/&G_QZN\_9F@_X+J)\;M$;]LC4_V3)/AN/M/_  D:?#*Q
M\3IKA_T:7[/]F-]*T _TGR-^\']UYFWYMM?-_P 1OV&OV-?@[XSO?AQ\7/\
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MJ$[JH4FW2((I=F$83( *Y9^P!\8/^"9GBG]KCPEH/[/G_!"3XJ?!KQ?/]O\
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M%%% !1110 4444 %%%% !1110 4444 ?IA\,?^2;>'O^P':?^B4K<K#^&/\
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MFWA[_L!VG_HE*W*P_AC_ ,DV\/?]@.T_]$I6Y0 5^=7[2?\ R7OQ;_V')_\
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M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
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M* /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH
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M_':U\+W?C'2+ZQT*X?0[VX74KN&W03;5M(9?*&9HS\^!\_!.#@ \9_X-B?\
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M%KI^A2:DWV>9UB=GMXU9I(E#Y?"MA QP<4 ?*O[*OPP_:)\6_'7QMXY\(?\
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MA:GJ,YDN)=(&'M%D<\LRJ77V4*HX45YI^RE^T;\'O^"<GB?XM?LR?M8>+/\
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M0O\ @J?^Q)\-?&FI>!=9^*EW?76ASF'7KGP_X:O]1M=-D!(99I[:%XU92"&
M)*D$$ @B@#Z&HJIH.N:5XFT.R\2:%>"XL=0M([FSN%4@2Q2*&1@" 1E2#R,\
MU;H *[/]G=;E_CEX56SE5)3K4/ENZY .[N*XRNW_ &;/^2]^$O\ L.0?^A4
M??OV+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!QOQ(L_&2_#O7S/K-
MHR#1;K>JVQ!(\EL]Z_.6OTP^)W_)-O$/_8#N_P#T2]?F?0 4444 %%%% '->
M$_AAI'A'X@>*_B'9:A<RW7BVXLY;V"7;Y<)M[98%"8&>54$Y)YZ5TI 8%6 (
M(Y!HHH @T[2M,T>W-II.FP6L18L8[:%47)ZG"@#-3T44 5[[2M+U3R_[3TVW
MN/)??#Y\*OL;^\,C@^XJQ110 4444 7?#@8^(; (0#]MBP3Z[Q7Z3_8O&_\
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MC_#-]XM^$7BB:_M-+OVLM46]TJZL9K.X5%D,4D5U''(I"NIY7&#P: .YHKY
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M:]K(\ZQ69XF5.K&*25]$^Z75L#=HHHKZ< HHHH **** "BBB@ HHHH ****
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M;\6_$GQ=\3M3\;^._'MW;3^+/%>IVD5KYZVT9BMX(;>$;((8T9@%!)^8Y8X
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M#]%:*** ,/XG?\DV\0_]@.[_ /1+U^9]?IA\3O\ DFWB'_L!W?\ Z)>OS/H
M**** "BBB@ HHHH **** "BBB@ HHHH O>&?^1CT_P#Z_HO_ $,5^GU?F#X9
M_P"1CT__ *_HO_0Q7Z?4 %%%% 'SSJ/_ "$)_P#KLW\S4-3:C_R$)_\ KLW\
MS4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^'_^0#8_]><7_H J
MW53P_P#\@&Q_Z\XO_0!5NOV.C_!CZ( KPOQ__P CIJ?_ %^/_.O=*\+\?_\
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M (9UJTU&QN5+6][8W*S0R@$C*NA(89!'![5;HV **** "BBB@ HHHH ****
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MZ@D%@"EQ+F\J3J*E'E77EE;[^8#G?^%"?%G_ *%3_P GH/\ XY1_PH3XL_\
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M5^-.JZ/):_#;PUJR7T6CP:?;2P^?<W$:)%-=SM*TDAC!7.3N)<A? OVVX?\
M@JU\=?VP?@_\8O!7_!*:YET;X&^.M7U"PG/QN\/+_P )/;31BWBD57D5K/<L
M8DVNKL-^T@$$UO0C'^T)-5$U9ZRDMW!JUVTI6;M=>NP'T=_P6N^&O@/XM_\
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MZ)RC/.$XNZYH_FOOMM?J![I1117ZF!4\0?\ (!OO^O.7_P! -?/U?0/B#_D
MWW_7G+_Z :^?J^'XN_BTO1_H 4445\>!^8W_  4G_9?_ &O_ -F_XC?&[]K;
M]G_1O!OCCP9\9)O!S>,- US4I-/UK2;W2[FUM[5;.?8T,D$I"AA(04,F0,(2
MWUM^P[^WA9?M<:WXY^%WC?X'Z[\,?B=\-;ZSMO'G@37[F&Y>T^U1-+:SPW4'
M[NZ@D1&*R #IG&UD9O)?^"E_[*G[9/B+P%XV\9_!#]M+7UT#7=6T69_AEJ/P
M_M-:BM94O;*,O93J8[B&-3&+AHR9%RLGW0Q(]:_91_83O?V:I_B/\3O$/QZU
MCQO\5_BK)!+XM^(VL:3;P?/:V[P64=O90XBA@@5R5BRV[)W,1M"^Q6J4*N 7
MM))RV5N:^BBM=+:)6^2MU \X_P""D/[5_CKQIK,__!,S]BBT@UWXR^/]$D@U
M_4&):P\ Z%.GESZI?NN=DAC<B&'[[,Z-@YC27QG_ (+ ?LY>$?V1?^")'A7]
MFKPE=S7/A/P;XG\*:=KEY=@ W5JNH1F>>4#A?,G82$#@%\#@"M?]G3_@C=_P
M4(_95;Q+>?!?_@L%:V6H^,M:?5O%>MZE^SOINH:AJUVV?WD]U=7\DT@&6VH6
MVKN8J 6;/U?XF_9#O?CU^Q1J/[(7[:/Q3;XD7/B#1IK'Q/XOL_#\&C27CF=I
M8+F*UB:2*WDA(A*8+#? K$')%4JV&PE2E[*HI1C)-V4KM]]4EILE?\V!Y+_P
M7Z_L/_AT%\:?[>\OR/['T_RO,QCS_P"U+/R<>_F;,>^*]WTOXO>$/@)^R1I'
MQB_:(\96WA_3/#_@BQN_$^KZK)M6!EMH]^>[.7.T(H+.[!5!8@'Y?_X=/_M2
M?%[2_!WP0_;0_;_;XB_!_P $:K9WL/A"T\ 0Z;?>)/L9!M(=4O1/(9HTVKO"
MJ#,1N8A\,.P_X*@?\$SOBU_P4/U[P#<>%?VP%\!:'X'U!M3?PM?_  ^AU_3]
M6U$,I@N;B":ZACE$0#*(Y4D3YVX&X@XI81PIX>55<O-)N23V:22VO=V[65T!
MRG[$/@+XJ_MQ?MB/_P %9_C/X-O/"7A.R\*2^'?@%X,U./9?MI4[EYM;O5_Y
M9R7()$<>3B)\G("2/]T5\T_LX?LR?\%&?AI\5]/\5_M!_P#!3RT^)7A.VAG2
M^\'0_ [3-$-TS1,L3"[M[AWCV.5? 4[MNTX!KT'PA\!OBSX>_:Y\7?M!ZS^T
MIJ^J>#_$/ANST[1_A?-9.MEHES#L\R\CE,[*SR[3D")"-Q^8UCBI0JU7::LE
MI;FM_AU2=^K;T?<#\OY?^"GG["/[2=W\=_VO?CU^TGHFG>);WP'XA\#_  '^
M']_#<-/HNCM;2QO=NHC*1WNHSA6;G='"L498@D#["_X('_M"_!CXO_\ !.#X
M=_#CX:^/[/5];\ ^%;+3_&&G6Z.'TNYD,K)')N4 DA&/RDCBOI3XR_LZ?#[X
ML?"'Q7\+;?P[HVE2>)?#=]I2:HFAQ2M9M<6[PB8(-N\H7W;=RYQC(ZUC?L0?
MLL:7^QA^RYX,_9PL/$-OK<OA71(M/N?$$.D+9-J3(6(E:(22%3\W0NV/6NG$
MXO"5L&X033NK*]TDDU_*O\VW?N!Z]IW_ "$(/^NR_P Q7T-7SSIW_(0@_P"N
MR_S%?0U>_P (_!6]8_J 4445]D!\\ZC_ ,A"?_KLW\S4-3:C_P A"?\ Z[-_
M,U#7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/A__ ) -C_UYQ?\
MH JW53P__P @&Q_Z\XO_ $ 5;K]CH_P8^B *\+\?_P#(Z:G_ -?C_P Z]TKP
MOQ__ ,CIJ?\ U^/_ #KYCBW_ '2G_B_0#'HHHKX, HHHH **** "BBB@ HHH
MH **** "O;_AG_R(NG?]<3_Z$:\0KV_X9_\ (BZ=_P!<3_Z$:^IX3_WZ?^']
M4!NT445]^ 4444 %%%% !1110 4444 %%%% 'S;\?O\ @EI^SC^T5\2KKXH^
M+/$?C72KV[ABCEL_#7B+[':#8N-RQ",@,>K'N23U-<7_ ,.0OV3?^BC?%/\
M\+8__&J^QJ* /CG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\
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MY_X<A?LF_P#11OBG_P"%L?\ XU1_PY"_9-_Z*-\4_P#PMC_\:K[&HH ^.?\
MAR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :K[&HH _.O]D__@DU
M^SE\8_AO?^*?%7CWXC17-OXGU&PC6P\7M&ABAF*(2#&?FP.3GFO3O^'(7[)O
M_11OBG_X6Q_^-5]"_LU_!G4_@9X"O?"&JZU!?R77B&^U%9K>-E55GE+A,'N
M<&O0: /CG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:K[
M&HH ^.?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J^QJ*
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M;]I3P#\4=&U;P%=Z))J]OXKL;U7LVLHU9I)BX^Z$"/O!P4*,K %2!XI^R_\
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M]G+P)?2ZI=VQDU#Q=XHO,FZ\1:W<$/>:C.S$LSR2=-Q8K&L:9(0&OE?]B/\
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M:CM0!^@-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'?\
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M"AT'5[S3+>?5-#:]2Y.G7+QJTML9H_DE\MRR;U^5MN1P:TZ* "BBB@ HHHH
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M=#TZ*TM+2/).R*&)52-<DG"@#F@#\VOVSOBC_P %>?\ @I#^S=XE_8:\&?\
M!)BZ^$X^(=A_8WBOXA?$?XHZ1=Z;H-E(ZB>6&&R9YKQR@(0HHVDAL'%?H;\
M_A-IWP$^!7@KX%Z/JLU]:>"_"6FZ#:WMRN)+B.SM8[=9&&3AF$8)YZFNMHH
M*_(O]M+X8?\ !7?X\_\ !2]OBQ\6O^"4UQ\9O@;\*]6,GP5\"6?QN\.Z+I=]
M?H<+X@U*&ZEDDNY\9,4,D<:P@@;2=YD_72B@#P']F[QW^TS^U]\&_&G@[]NG
M]@ZX^"B:E!+H\>@S?$K3?$9U>PN+=DFE$M@-L&-[)M?D]1Q7Q'\!]&_X+0_L
M"?L;W_\ P2Z^%W["L?Q&U#08-1T+X3_'BT^(&FV6CKI5S+,UM>:A;3.+F&:T
M64YA1#O\I54GAW_5JB@#PW_@FM^QGI?_  3X_87^&_['NF:S'J3^#-!\G4]2
MA0K'=ZA/-)=7DR \A&N9YF4'D*5!Y%>Y444 %%%% !1110 4444 ?%_[5?[)
MO[0'Q)_X+/\ [*G[6/@KP!]M^'_PV\,>,[3QKK_]JVD?]G37^FM#:+Y$DJSS
M;Y"%S%&X7JQ4<U]H444 ?%__  27_9-_: _9E^+_ .UGXI^-_@#^Q+#XF_M)
MZUXJ\$3_ -JVES_:6D3[?*N=MO*[0[L']W*$D'=17FG[;_PD_P""@?PQ_P""
MT?@[_@H)^RS^PM=_&;PKIO[/4O@S4+>R^(^BZ"\%_+J]S='G4)U=@L9C.5C*
MGS,!LJ17Z-T4 ?F5^TM^S?\ \%8/^"RVE:-^S=^UG^SOX7_9K^ IUZRU+XBZ
M1#\18/$WB7Q5#:S+/'81264:VUK$TB(S,6+*R(X+A3&WZ7Z;IMAH^G6^D:59
MQV]K:P)#;6\*!4BC4!550.@   'M4U% !7XZZ_X)_P""S_C+_@I'K'[:?[37
M_!'2Z^+NG>"-1GM/V??"\'Q^\,:7HWA2U$A']I_9II96N=1F58W^T2!#&>%1
M2D7E?L510!Y'^S!\9/VI?BO\#;_Q]^T?^QI-\)_&=O>74=CX E^(&GZXUW%'
M&K0R_;;,>3'YKEDVMRFS)X(K\W_%FH?\%N?$W_!4WPK_ ,%(E_X(?7D,'AKX
M07?@AO"!_:.\*L]PTU\]U]K^T^8 H&[;Y?EG.,[ATK]?** ,3X:Z[XP\4_#G
M0/$WQ#\"-X6U_4=$M;K7/##ZG%>G2+R2%7FLS<0_NYS%(6C\U/E?9N7@BMNB
MB@ HHHH **** "OB_P#X*V_LF_M ?M.?%7]DWQ+\#_ ']MV7PS_:8T+Q7XWF
M_M6TMO[-TBWW>=<XN)4,VW(_=Q!Y#V4U]H44 %?%_P"RU^R;^T!\.?\ @M'^
MU+^UGXS\ ?8_A]\1O"?@VR\&:_\ VK:2?VC/8Z>L-TGD1RM/#L<$9EC0-U4L
M.:^T** /@#_@L#\!/VT_%/[9/[)G[6G[(?[*L_Q:B^"^O>*;[Q1H%MXTTO1'
MVWUE:6\ $NH31@Y*RGY%?'EX.-RD\O\ M.Z?_P %O?\ @IU\)=6_9$N?V./"
M7[+O@;QG;MIGCWQQXE^*=GXHU>32)#MN;>QM-,7REDECW1GS9-I21QN0D,/T
MGHH X[]GKX&^ _V9/@5X/_9W^%UG)!X=\$^&[/1=&2=PTAM[:%8E:1@!ND8+
MN9L?,S$]Z[&BB@#\D_\ @H3\*O\ @K5^T;_P4<M_$_Q!_P""7%Q\9_V=?A??
M1W7PQ\ V/QI\/:'IVOZLJ*1K.JQ7<KRW6QFD6*VDCC1 !D,&E\W[Q_9)^+?[
M6/[3?@OQ9H?[;?\ P3[E^"4(CCLM/TJZ^)NF>)1KEM/'(LYW:?@6X0!5P_+>
M9D?=->]T4 ?E9^S1H'_!87_@ES^S+K'_  3:^"/["!^+=MX?OM4MO@C\9+7Q
M]IEEIL.G7EQ-/ ^K6URZSQRVKSLS(BE9 HC0X42-]G_\$KOV'T_X)T_L&?#[
M]DJZ\01:OJOAW3II_$FKP;MEYJEU<275VZ%@&:,33.B%@&*(F0#D5]"44 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Y[\6/''BCPSXBAL-$U3R(GLED9/(1LL7<9R
MRD] *YC_ (6U\0?^A@_\E(O_ (BM+XZ_\C=;?]@U/_1DE<57YKFV/QU/,JL8
M59))[*32_,#H_P#A;7Q!_P"A@_\ )2+_ .(KUSPW=W&H>';"_NY-\L]E%)*^
M -S% 2<#@<FO *][\'?\BCI7_8-@_P#1:UZ_"^*Q6(KU%5FY62W;?7S T:**
M*^S **** /E3]H__ (+:?\$SOV2OCIK7[-?QZ_:%O])\;>'H+6;6=$L?AYX@
MU(VJ7$"3PL9;&PFB.Z.1&X<XS@X((';?LA?\%-/V#/V\[B\T[]DW]ISP[XNU
M'3HC+?Z'$TMIJ5O&"%,CV5TD5PJ!B%+F/:"0"<G%?,'[%'_*Q=^VO_V('P^_
M]-BUR?\ P<2?#WPA^S]JW[/G_!2[X2Z%:Z)\5_!?Q]T#1Y-?TR%8;G6]'O1.
MESIMRR -<1LL84!R=J/,JX$C4 ?>/_#6/PY_X;._X88_L3Q!_P )=_PK#_A.
M_P"TO[,']E?V;_:/]G^5]HWY^T^;\WE;<;/FW=J]/KY"_P"&HOCI_P /[A^Q
M9_PG/_%L_P#AD+_A-O\ A&O[,M?^0[_PE/V#[7]H\K[1_P >W[ORO,\K^+9N
M^:OCK]FK]K?X[_MW_%3Q_IOQ>_X+=G]G+XG:-\2-6T+0O@%;>%_#]J^C6UM<
MM%:JZ:M"TVK22(%D9D8@[RH"C@ '[!45\,_\%"OVI/VQOA3XJ_9T_P"";_[,
MGQ0T9/C7\;S=VVL_%O5_#,4EOHUAI%C'/JFK1Z<6,)N)22T,#%H@0R'JK#U/
M]E[]E#]L7]G?XCOXN^,G_!33Q3\6?"+Z).FI>&?&/@31[5X[W*,EY!=V444D
M2*JR*8&#J1(#N!7D ^DZ*_+S]C[6_P#@J-_P6 ^"FL?M_?#7_@H??_ KPIXB
MU_58?@EX!\.^ -*U&VCT^RNI;2.[U:2\B>:YDEE@</$K*JA2R8#[%Y_XM?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD%Y\9-5^,9GU5@NK:DPW:5)8L[[;A1:C-U]Q1(,#]W0!^J%%> _\$XOVY/\
MAX%\"M8^-7_"K_\ A$O[*\?ZYX9_LS^V_M_F_P!G736_VCS/)AV^9MW;-IVY
MQN;K7._LB_\ !0WQK^V)^RE\1_VA?AO^S+/-X@\$^-O$GAG1? MMXMA:37[K
M2YC%'MNYX88[8W#8^^"L6>68#- 'U!6/KGQ!\ ^&?$VC>"O$GC?1]/UGQ&\Z
M>'M(OM3BBNM4:%/,F%O$[!YS&A#,$!VJ<G KX=^)O_!4?]O_ /8\M](^,7_!
M0+_@G)X?\(?"&_UZRTSQ%XR\$?%V/7+KPA]LG2W@N+ZV:S@$T'G2(CO"WR[@
M0&)56;_P4H_Y3,?\$]/^QA^)'_J.14 ??E%%?)'QN_:>_P""MVA_$#Q';?L^
M?\$P?"?B+PGH&H2PZ7J/B3XXVVG:AXGA3_EK;6R6<J6H<@A1<2 G@D*#0!];
MUG^*_%OA7P'X;O?&7CCQ-I^C:1IMNT^HZKJU[';VUK$OWI))9"%11W9B *^:
MOAE_P5J_9R\:?\$VM7_X*7>,=+UCPMX:\+:??_\ "8^&M2A5M2TG4[*=K6?3
M"H(5YS<A8H^5#^;&3LW$#XF_X*>?\%!/^"@7CS_@DA\5/B!^TG_P3/'@/X:?
M$7X>3VVC:UI7Q'AU76- ^VH%L9=5T_[-%Y4<SO$C&.1F@:51(GWBH!^K^I_%
M;X7:+%H,^L_$G0+2/Q5<Q6_A=[K6((QK$TB;XX[4LP^T.R?,JQ[B1R,BM^OS
M\^*OQ5^"?PW^#G_!/W1OBU^SE;^.]0\3^+O">E^#M5G\1S6!\*:FVB;DU-4C
MC87;*JLODN54[\[N*^A?!'[<G_"9?\%(O'/_  3Y_P"%7_9O^$,^&FE^+?\
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MC^WQ6^$GQW_9[NOAG\8_@M##-XV\ 3Z_'J%M<6MQ;O/9WUC?1HJW%M.L;<[
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M@TJ2&#4GA8!H_M.68 \D)N&596/[':QX=\/^(5B37]"L[X02>9 +RU241O\
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MI+%H.B6=BL\IDF6SMDB$CGJS;0,GW/-6IH8;B%[>XB62-U*NCKD,#P00>HH
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M]TP93E&BW*<J*_:RXT'0[O58==NM&M);ZV4K;WDENK2Q*<Y"N1E0<GH>]6Z
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MV.JR>#?^&9-(@\-:[?:7-:KK]I%JN6OK:.95D:W:4S1QN5 D$.]<HRL?FO\
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MS#YMBBJJP^?%(LRX"*-P<-QUZUYE^TC_ ,$K?V*?VJ8O!TOQ2^'VMP:A\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>biib-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20210930"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20210930.xsd" xlink:type="simple"/>
    <context id="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic2146328de3549768f889075bad51afb_I20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-10-19</instant>
        </period>
    </context>
    <context id="i28c7f8faaddf4de59fb5368e32d5ae6d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic3672251f76c4fb3ab491f7a64f2a7d1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6629e89c034a4d89883d31d567178ed6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie862c4e3d0454092bd193a5d58ea0c3a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc49896e8f7749f9aec4691dac20e8f7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b23d904c3ce4fde94a3a645d27461d5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf69f40f83ce4c9da70c57f9064c7b4a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i76c2b9076741473bbd3bced37f71ef41_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib36a038f73ce4e7b8013d75c309b00de_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i27692e0f487e42cfa48cfb9ec74d1c5b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i40db7f82bc1346e0a6ae09a03625fc9d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f2782acd53f4eca80ff87db16f55ee5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id6475881e6d0430cbc6e4826b376d1ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b9cfb542bbc414db0a805fe7b60fb21_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2438439cc2bd49c2a02917dc67d626e5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifdbdde9753524c0da660204088296886_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id15b7f4db2c14ac8ab03363218c293d8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i378cd243ed9e40c2932d604d62dcff73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6dd54a75bdf44146a9c81439174f3e10_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7fd41961e6e04619a145d1ae0002b71b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2504032f7755457db1beea26920a583a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5058265a969a4b00953e4a5f69286304_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i76f00f49e5bf479dae0717aa402863ba_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6ea0b81b62734c95b602b7181db99080_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0c76067d2c0e4450b18d7428a607dec6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie1c29f466fd44e7fbf5526fc6d6a77b3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib5c41282f9554a79a2dea81cc7c66db8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3134099b795d4facb8cd5e5dc6129d07_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcc5c637588f4bc8b93afe094f041d88_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9151bbf7e80c4955aa4b4abcce3d7ee5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0fcbd0aab3104a71a4ebbceb7c93d675_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic85bc0b5a4e146cf9ca22eeb646ac2f5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c1f2813a84947359d5e759ac017f8f6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic71a7f514fe345aa81befd7e9f359804_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idbdfb0e2e84e4397a54b042efb9de0f0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6fc83a08693474992b85d83b3ad03b7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i27c617883bc449228e61f30f99e937e2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i95f998449b3e429fb58bc7328de88319_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9035a5654857474b8da6be9ce64ca30c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6724df5e760b4f7ea87e959a62b322b1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1b4efc5c06194773aea1dd08796cbd25_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i35bb8cece69f42eb993bbe2ed7b30d9a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idb94a68217db4665853c23a8d028b610_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if3f7e3e5cead4308bd4010bcf303d6fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia82889fd7f49428faa0d8b8a9fe4787c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i435fb50e71d246339ab717cb193e55b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id008781cb78d456099bf8e65186045c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idfaf0c65c04d483ba21b7c25f4adaecf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fcb29f76ded42b1bdb5c06b5a612d27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f28a59afdff41658f03256c0a201a98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4891b33ee68b4d7abe803e2851cb7dbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9be762ec3a9f4b09864941280d00a916_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd71258dd6f04433b5f81b927d3b1104_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc180996f76c4531ba0c767a0cd57adc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06a7ad3e5c3a4b8d9bedc1dcb4f9f208_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i58fb5362e7a744d9a5acd4825e9a5104_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67d9c800cfcc42f5a8dd99abd463e2be_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i782d9d918ca94e65a4169da4cd3a12f6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b408fb3fdc34b0396023e455c198a69_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie4c7f17033684d18aefb36c4a3d6c13f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55e81dc8b9c744b3b947fb4da4f5918f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8b36a2284f3b473798aab3ac6e245627_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iffe878f771a841b3a6c7f704897f75ee_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i98aa79e9ae8d45b880df1e5404273f17_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i19ddcef7d3e24fdcb32788e2157a6ff6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2cb06b37c185452292925fd0417673c9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5d7ff60d15254b42afe32f65710162c7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7028acddd6fe42b6965135b35f8ff2f6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i13ff900cbf7e400ab0e7e04c7df214d5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iae6b13e615cb43759f9fdc6492935587_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4aa45623b9a24e4881896a979258ce6e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3c04a426b78946e7b3b65f4903d01c57_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1f841eba5163473e9f41740f7bde1720_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if307471114bc439a91ad32639f89c9f8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i751ac7dc5ebd4605b6778c1a2449f919_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie428e1222ddf45bf8896a772e454dfa3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie6422fd73db7423eb9f8020ab03bd577_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib45574fe33ee4aae9246e107a7a53587_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4928957245d3432999a97b44b5267981_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i72c55152400e4e4b94a99a817965d09a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9feca16144f34b3ea3e89a6754731228_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib4a8b077b45d46d1a2ba18c46f68e9b5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6f1490d7028c484bb7b887d3edf0bcef_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5244c955b7f04faa811cb546d3b19da1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i256c872a0ec64e8588e40eae87e54228_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i27afa92fb58444e9a9f1ab64284947bf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8e79a463f4584fb2aee6e8cdc33e7007_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4e7708356fae41b9a13302bb04211203_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i70705f35adb5455faecf1b3d1d84198a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e7b1968e93347ae998112702bfaf368_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc9ba742bf504e22bd14593ecb2ffb74_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a7e856aca6b47abb4f2a597838710d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide5fdd4520c74830933b03379f613edf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i607b477716754fa49b426a79cce7cfc3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e94a3f2f5aa4b088b330695096badd8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i327682b6937246d39b49fa2fe086a9ee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if699e259873a4362befe72d106cb46a3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i70699e64e56642c78269f5581e49fa63_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9cb259e3e655451594ddea75cacc3031_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibded2627ed6f476488944808f5be525e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94ed39bd20ce49eb845fbd4b5a6e399f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iddfc2c0b58ff4cc1b94d1cdf49392372_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id860c4b0dd10477c99ccee1b9a0e61f6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc3b6f7ebf2148fb8095a10e72b1c4b3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a4c5ca8b3b448168efbbcea6f070598_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03a9211cf5d342868594c98f4cc8953d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i820c4f6fd7d141ae849266e77bd5174d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i708a8258e90c451fae809ded20edc887_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc98aa5d5bb3491b844c904832b5e17a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1022bbcfbc3d402986b98be3c4a7bdd9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i73e21f10ab3f4997b59d6e47015ee1e6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i459ef874f9bb4653ad831f334286be02_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic401292eb9c341d5a7a48926df3393fc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i76acd6989c7c4783b9802597d4de0c06_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23640bd50272420a8b057701d4f91e71_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd886b210f074d43acf27a1993bc9ccf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if48a1d2ec8b247058bcdad6c8fbc6524_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia21b2da1eba940d2b84efc2f236e2b03_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i10bf3e3f7595414482ea7c8e4d6e9daa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f65789ed29a4729929922d2a49c2ec3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36476b37490e44bb9a8cd6098004a18e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a94855763b44929978fdfdb0d8035d7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a216b36a235433c9df3617fbc22b9a7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4bfa480df7914627bc60143003413b0a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7517010697de4c77b9e59ece300efd26_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia5a4376778b04d80abf3b1d76aac940f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0542ec377c8a46ae89671dcde4b12555_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i09cfdb27d6654e3eaea1f9fd048da603_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87aa8be7620b41a68374745f1299b587_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d1d4d88e5204d3bbd4f8c2df05bc123_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i11880cd08681479db15c4cf4a0e6a1b1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc711043de854adeaaa2267f4bb46ccd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a53327538a04446a4de09425ac19e0e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf06a525bc964241a3f2d2a390fe4a4f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib3f4359c2057476ba70d1737083d2a2b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie5c6a43fee8d4ad3b6c10202da96a3a4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i946868256a5e4b78bc18b85fe7d36a88_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6050c9c73f574a1d9ac74d02d7f8833a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia423a211a0e94eb2b77637ce741d2bb7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87e3d9cc76b44ab2ab715dbe9256ee43_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2ae132257ea54725a3d8996647c5f187_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9ca5e27d04c34b1b85b921b3c5f8955a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6315b659cf6e4730aa408da11bed5410_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i217b972b9d864b7ea3af5c2ddafb37c1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcb4fc909b874f1cad730a3ec955d0b7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i89ef0e02b0074d14ac43f42983797d65_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68820eb5ed4b440b8283a709119c6a35_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i634f1e6f45a54e05bd52b24e519c4436_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03c177a7d8bd40c3ad390904b9d500d8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8dd866074adc42c98b75fe2cc20acab6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4f60b9625d5649a094bc0b536c722ec2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i911336cfeca046fdb0594c9edf8d9d0d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib9cde429795a43629320e02fae4dc1f5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie98b919eea9c49c0ae92d49eae5d7e4e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00b7f7eef9ad4f298c8c291b3ecaab47_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7560cc8fc1a4480e89be78cc3735e0a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic82c486a127442488b1833a2dc7b7cd6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f5008e8c4fa47649cfe38e4b9ebfe94_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b9e403b349e4ca69958c093e19f74e4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i847c83d47690436dbf95bf269e8be2f2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0763a9aea2ed45ba8300cc34209c8819_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb3dce21712c4912bcec60f52a212be5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fd874439cb1425eb709f078c0dc49cb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6126c7bc669b47cab645fe573efe2379_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i52490028f86c4b18ae595bb12a3b413e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idfe93de388de42aea652b2d937d7b20e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff76d3e091a4417f87d3022f27f8c714_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3133bc8432354bdd87b447ab0b25da57_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5fcfb0f1a5aa4f28a82dd0078a64e4cb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia6016cc0326e45fb8c5ab31460efbed5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c9b12c794124230bdfb5c764ae089a2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i851e3d422f964199aae5ec5f16c2ed5f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2258c8387d342deb1dcd335b185c9c6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ac3a6cb79f144da8b8a7cbd1c451028_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibec078f0e0134c10ab04094dc10dcbb3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iddbd3b911c4e4a9b8d3b7b3370ba5be4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id95e5c1cfeff4eb999843b5ab142dea1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6147368b3e5448f387b2621a347ff81a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib43b7a7b6aff426e8b3aa44f10665331_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0d8c0ed6a308478f8a953ae999c37402_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7dd6c4bbab7427d884ea754f842614b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a3637540f0742e282ee41d72bd9661b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7f499618557b4da7acceb5cafb578dbd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide9ec1982c6d44839c60d73b502fb183_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc59dc95e0974b669bee2fa38de73766_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a391c9c52574153aecfbbfb7003c5dd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide45d117f94948c39924a1add89e7b6d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib90067ffe05f4ea3bef552a9c2baaf11_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3a69686d751b4d78856ab4a9b5568f7c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i265533229a0044408626b8fb90354de5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b240004575a41088f63cfd2893796da_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7dc59a1b194f46d9aab6abc4dad371c8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94113634bd1c4fd19a9b3f8785b02ebe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i04560d42c0e54986baa4ff75a03e96bf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b12493f4b214da88a80d6a1be15a5ec_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04c7085ac1e94084911a32c8c5150032_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a516cca4e1641a3a52085e438a3c519_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7189d4590dbf410981d535efbb77dafd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0aa621e0a5cf4731b69211ee0236dfa4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie6b298d90ef649be871440f8e5609a5a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i055192050a884b09af25bd948ce893be_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i819e179a871a47bc9b2742b59e816fd5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8870751b462a458697438c86f8eedbe0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3447ed88deef4013aef8152951e512bb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i955579c517df40abbdcbafae0a9be8e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie518ab0a6fb54b19acd0e5840d451a8d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icbdc18d489a44d0492145df9a238420f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6d5e1daf4b14aebaff40a7bfcdae045_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i63f797b3134f4dfeb7404b4045bf8dff_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78c7deeed40b495cbdd4163ba45d904f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6aa6a3fdbaa84285a4f2caf4e5f6c13f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba938bf7466644249a1784f67476b2d8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if5b6d6875e5849df84d386d1cbbadf8f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60a8b4a619ef48838cb6f537675db04d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae3263ec5c084ebdbf45685ad846b557_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7894b472498148dbb05439dbe1d0de4e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7de479d587354958b584fa532dfa50e7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0dd108b031c74d6293853d4b7f765be2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44e2681e4af04220bc5659c30f65dad7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i997d11776fa54ff88c622c8a39e451cf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4463689b8f13459fb262230c8eeaa642_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia53918b8ecd640bd9d91e12ad6779d47_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic7f69c1b12cf4aa48eb2f5495743e9b5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a344b1c3ded4c809b0bdc426f095761_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2961e6b3f8584e359cd5fac9d7ae1a87_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i018ca53b38334c258546194db151794a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id41fab9ee02a43b197272a5b13c0ec9b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9872f8c2bb2488280b710de2bd86613_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic21d50af206e442cacfbcc591b7db41c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6db43726d8244d069205c2ae2092eecb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i358a97db687a4532b4896a6818c1c570_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia80f3feab17d487ea2b255ed4e7fa9d9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a7281dfb87f4c759ded27994b4bc48a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48de9837733f44a7b1ae4335196cab8a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6500c755b0d48dfb3cfc643bc8aa24c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i80c2d0a9c88d4d4189622a44b28df36e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1ef513a65ec4140a5e0fe08899b47c6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i52d8ed76345a4acfaa73ca03e26f404d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6b8289bbaf4401ca50ee623561b21ae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0201097c2b0b4fd8b09bf1320302b0df_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icfebde8455d24e9dabbc61af5ac34b17_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2ad690c84e494203ad19621f8be2258f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i365b2ee8a85c4fd0b42ca8da39cce072_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ec836555e23418e9418b4c438dfbde4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7441b05974ec4515a4d0318950fd8c07_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34eef8f55bd84011bdd58c92bc395b12_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2050c886f441471bbf874fbf99723b8c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b58455f915944c5a8b42b07b2d4f95f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i102f99b657e24bda89929e63215714e7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f766dd011914fd7aac023f50c96726a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i390f7d8898fd40cbb7ae0d2c48fb5ed8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iacdaa759bf824f8ca47514fea1b47ee2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if66ceb4c3c8641618bd0571332ab70e7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id59ec4787fd04a5585eb63429b7020aa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id78748439d3e4bdc967aa5af911f7391_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64722cd85a514d76b846ff90832c2934_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic2f7c01250cb438abd665e9b9c94e743_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2eb565fb2ca4e59be0ae2c0d7f3db8b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9bbef3e76d1f47a29e6f947d82b47f45_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad39afa89ed54171a76ada18b22e630b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i95260bc99cf64ae8b8bcaf3a4e5e7812_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide3a1ac1941449be84c85e628ce9d89d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i50a8c5663be04e9faed2b5f0d97a0e68_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79795b771df34c8fbe099d241c96d9b2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0549e44337674a5ca08eba019050c369_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35f1dc85a6d443f5addb0eda7c8dc35c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e5d0635317e4c16906d390ed841b9b3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e281fbe905d4e3e9728f08aa41f030a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2bc6970c546c489b94382b832606b1ab_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b71a9f27e79480681fe58993506eb15_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib7d1e15250b64a13b47a432932d37658_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64007592035142748ac7599f7a664be7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f9bb0d6c15842358b1c0ddfa1c21b68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4e6d8ecb5194fa9b70da244b06c3872_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib378e0758d7a484581e59302e22742cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b4afb6819034ad8ae8cce9d2e54cf47_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i81f620d3630247a0b5778586f131544a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic91c47df08824717aead53a81a56dc20_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifb75ba94b11d4a699b755fdc629e6cbd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i42d2a9c8b03648879414ce30d6e746af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8aa3c889df0142bf89536f957b8eaee7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id4b173db27f4480e98a38ea719ffce5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1bfcb48e77b46bba81990b5298288bb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b18ce9f4621437b922497d189f85e55_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i701a2e8982b64d678d5770b22075f8b7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41b7ad7518d94ebca15cc87bd32825ca_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3408b069db1d42f7b345ec1b7498f89d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieec55d2ad3dc4febb73612f72beaebdf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic99dc3ab809743fabf00ba08bbbca28b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifaf7ab8592bc4011a62dfd0ea076ded4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id90843cdfc614862a52278ee45bfc131_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i414a6de3330847a1ba08416250b5bb7a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1bae232cfcf14b48ab44d669cfbf4ea9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icb1b9df4cbfa42c3ac411955189a9091_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99f198b587194af1b052efd3339aa9ac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5e025fdb4f53458a856e099d5f619c31_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i744aacd6ec9a4103922fccc0ecf5a575_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23bc77237cc245c6bb9b3fd9dcf68cee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia28924f2261242259992e93451202d13_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62cbf5b25f7f44f6997f9587acdb152a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3202bb6f2a554b45af9aa83e6ecacbce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3d6ee34a915d43d3b004660946221bbe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie19b8b42bc9547abaf105a4b71dbd351_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i790f18c0415849f9b387fb21e49c9fd5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4ecc275acaf4fe883a279d9a574b48c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i753c69a029d04474a9bed4a6271dece8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i805587f470f344d680991d5995876af0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if310e2943b1e4ccbbda6ed73c324ade3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3be3bc83cfa548609221fb923b77b012_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3aa487875e3b4688bd646e5ea13ab375_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1627155704354fc0a8a424c6c2790177_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i463cd8459c624bd3882e48393200fab1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd4c548cc92f48a4ac8e14803f6f43b6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i53f4f3120ef84eefa4d661c020812d93_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45e7b551c5dc43d5a333a321f352359d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i92d6d0dc9ec648d4bea25189aedec636_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic8e4d78e60454a64b89e8a75ff8f0450_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic21c7a6ec4ab4bd2a8bbfc0f4cd56f43_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80bd0b2b32ea4b5680c869f40cc11b5f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i326c80e9243f4bf493aa660e564a3122_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b7e99afec554a029eb237f033b39037_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i994f124b7f3741b2a6d52b940a0759f6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111AndBIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i47e67b006b354cc88698e7fe5664efe2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5e115d8322fc4129abe228330a35b1c0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3cd19afbd26746dca41eab54ab3017ba_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65c9878611a94c1e8dd4e4c8e3723f18_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2a7a60146fc349eab4e74a420635d5c4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i842cb6f355fe4d479461afd4ef4e083c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i876974683e3549eea5fc8f61aead1156_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia2fdb402e2824ce4a9bc71b9229835d6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8c87b4112217442caf7f93008b36ae14_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i913028ac08ed43abbe4437b3e87d4ff8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4e9850ad45354252a28687b05a4f7ba0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i69ac3585271c4421bccc4835e25238e5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i79db083a3de94f4287a9add466386aa1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaacdf0756fe34b82bc7e195e28ba5cac_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9cfaf234a7a04182b6f04ff79328e86e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ice2382fc36d44058840ae3e3e28251b2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1deebd059f4c45a7a55fb2f7fb75cc43_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9c1474a542b94f95b31adc32082b10e2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ida9264d01fca4283942cd3738537b883_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia0fdbee67b92424c881435c78e569bbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i378cfd98f0dd499089706915fc4d9abd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i293a13e81c3948a8a773c4a9c92f6de9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6fa3eb7611dd4c5180bf950d961937ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81740b779f254c85bdb56c3ede0940b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd88cfa056ee42b688c44148869a89bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b77bc2d5ca1423eb85a5b99d2103f23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i669d0acaf9ba4c9faa1e50b3d5545924_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b2b5503377e4d60a68343ae4a275eb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7aac397904bc47ceb520bf0b28475c0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i973902141e63471a80c622f966bf9204_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08ea1ef8967d4c89b99809a24bec5629_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9bf4f35802694c1fbbae2718a8f12142_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3993b259dd8a435f9cde46b68b063c55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9ab4f097e1a4677acea953affeccc39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3467f79adfbd4e57b9fa997886b38ba5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8d75b9475054c6aa2f4631f5a8ef20c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaefea2e4aa4742fcaf12b2e1a663a4b0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6f0a301c1d504d4cb75e0dfdc175fba8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacb3b16cceff4a69b162f9088df8f83e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7aedfb52da3b4ed3ae009c32d7af2f34_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica74fb523d614349a5924b06d1bb5822_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1d11beb9b3fb491897b7a82b6680ddb2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f2d4471ced94158a3b9461f37a5a9b4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaa563a8c541342878a6a7502812ce7c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a9933a802b04b7d8c62324f5f41c52a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i70a8801ef78b4c00a73f94dd2ce1a172_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia82ded1ca1fa4ec881505e83910f2470_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i819bef58752546e1bbb77cf85e7873c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86e1f0ba26984bf396b6de85e0803baa_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7fe6316e93084bcdb4bab71201828487_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53759aa6be6e42a1a94cf191019495cb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idec1430297504929aeba4396860a0195_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="icc42842da7bc45f38b433b05022616d6_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i0ad055f43eed4c1abc91e33ba1c4c608_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i333a0bfdd0ca4d5180e70ebdd613c08f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5dab2decb1da48ad8d4b8e3c14967ebb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7814cf51367420694a7166e5ceff073_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iadac69438a134e4685f396b8c53251d4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1ffca47ad8954ffd92872504490dcf03_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib77b83c10d6543c4999b42d941ff32fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if652d73e263246e5831dc57a670a53fd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib0d676501ffe4026b9c68ccd7f42aeb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13df0a9587724904b596ca62dcf43f6f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2186b976c0174d35bd3cbdf1c89882c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id82eeedaf25949b28400154944eb6b4e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ife2f354a35fc496eba95703d7b607384_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52475161692a4e19be21e73c51c53526_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i049d807889c149e8a50eafa9f58bb8dc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if153048dd394454eb1fb423f72bda912_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2a18efbacb6145cdb2a0021473063184_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if70a9c11bf614396a6522c901ecb08f1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if077767e3ef64c2484a2cc92234da011_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i44917b25ade349a8a5f06df642623475_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i470da7200d18439f98b62a166787441a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3caddce2c0c4c20a79927c2312baf96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4bd7705008143a9ba46119d91dce67d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bfcb2b7a789408ab7429d172cf3b595_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7673265729c248e8b545dd7073d36204_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idea3ebd667744c9381c73def31f719fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee2c365225e34a9da8933f6b3cbf7de6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4655f3abc15413baad6a40cd42927c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if87653e954194d689bd182fc5b42da74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i34d19a6c1cce48f890b4ff8854eb063e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia67769f4d9c64b70b1ee25a453d4c188_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="if7c54edc6349456abaaa90d10aa21a29_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if8b5d9e350944ffdad686ff95dd1085f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2f721455f7aa4586a968ec0031e919d8_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i8ea2f828e08946f9bfe96108463cde78_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2139678da5ba44c692cbccf26f3f86ad_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i2c77f922da23412fad540d818c968248_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6cf82a6b484d49e69065707a4f3422d8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic165a79eab2e42c1a838d2b473206e5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d4b70e429084cd896ddee8ad6a86f58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic55d56fb32ff46218a8edddf870dc788_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic059a695f5624475b5bce97e745827bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id661e83da0184b60b9078c3003d2d512_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57f88181fe304ebb96cc0a68b0ae12ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03aec522673d41f1bcbf6cdcdf6cac4d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if46410444ba14e6092450fb22efffc1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i882caa9f1b214f12a34a044e78765486_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib8af15663b9a4d8d94e49f9f51c463d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23d2d53f1521473fb2e87b588a892372_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i67cf121e430342109d49fea777e579bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ac6c255d1f3477ab244bffeaf22cfc6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i34a88eef09354000953b0bed96387192_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70ca240b4a8a434dbdfdea26e500aee9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i01b54841e3504571a9b44de5987e542d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie35d98789f1244be9ad4952ccbcc7c4e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06a80f6779864dd992819b8e00be88b8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib71e595781d44f16ac699138752f0bc8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3cac1f347b104a4ca1db20bec5c47875_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7c37dca65684a5e9f14392ae29cbaaf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c3ff6d74036499d8a7471834819584b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ica4d96484afd47e3875930a4f7e88de5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7805cce3a52041d3b30f7a27f60fda1e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic725003c511544d9beede7d62b22bf41_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i021468994763467d8c149cb0f1b5dc8c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if05a13a77e61439a8dd0d989c1ff1052_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7069a9554d224968b39144be715d4ba2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i954add7d31b64b3698c2961782705265_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i662080f3255e4599a8eb926798a5d4f1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d1ad6684545445c81eaf1e55b9da3a0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if04673d30367460fa2896b503cf49adc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i25c14487107748cf8adf0aa48b1089e7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib4f3485174db4d7c876667900c74e5bf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa2615942dbc42b59096307ded3cc0c3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icc31d40d106d4c9f992098cfdbc25314_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i32d14a7ea6f44f81ab85c9eb63555a65_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8b619c6a194a48d79f50c3ece23badc4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i71ead7913c08409dbc2595365e9f3e52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c68d2f0c36b4aa0873859e893028f61_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie613980df7054b379c880bbe236bd443_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad3d42fc3ea64bd198bebd63ceb7ccd7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44dd1a2f10914daa9af2e90f8b3c8807_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if1200adb5dbe47c7ae6a9a4a6961c216_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1c93a139bb224308a3c7a36175e4107a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic554f230362f471382f660791fcc865b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0a7748b009f646c8b31119a5c17aae59_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib61f3acadd75433c99101969cf66411c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6968467d8d7b4c5c8a741ebc7f01c64b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifdd697e3d7934db0959c809bdc451568_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i481db3700c604a1bb15870d0cef6b1ad_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic5e3b2b199db482c94d883952512475d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icffd2e05c3e949db9d2bb4ffb7775e8a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia0fd194e4f7a43a08b6a326d74102423_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe8a70ef8aa048c2a91453d9a5dc5e74_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i69578acd699b413fbb7d39b34e455de0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icddb8a04e2884668aba19d51821c5e40_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i10aaea33d60c4e62b5c5437eb9aeef95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib911d65ad5594eb4ac4bcf4afb56823b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a39e90d5a084a6a82c0789525824916_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8d23192df14482d8fa3fe146523c99f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib101119d811b445ea7aebef90a37dad9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15bfdcd49c954e93ab09b4090c28ce32_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9c6b9edb2b704d33991c8e9a2425f671_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f65716caa83413388dac812d8d3219e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib7a3fd2b017b41fbb6dbb92df1d7ee68_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7855fb28a23947d995189305bed5f12b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16b2d0a2aca64df688f77a7ea041914b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i237f7b94a47e4d618bf0d30b1872ccd4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i726364fc850f428980b41bc6bf6ead64_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ic94894775dbe4be685e8410ac06fb197_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic351f5dbf270449286ad0664853e2842_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i21dab209cac741b08e2660f13a98e869_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i75a580abd0df4408a90cb100e5c26f1f_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i889cfd06e76047c4b4d5833cd7016227_I20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="ibb73b7afe9dc4434b6d819770e912b56_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb5ca321d1584c1ca6bcd8f53d653612_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i274d98ffd7f54b12bbcbb430a7f6446b_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ib3a02d5c86ee49cea24a7e5760768b86_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i106acfed1b1d45288e2c252eaeee518d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4f828fb4a924f93bdde2fb608c2e829_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if5c2e8e8d01b426285c6bd058cbb4b5a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a59c92aa5cf4dffb7a826f5ebeb931f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i939d909bc5be42e6be0dc04dd1a39954_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34a8fc959a0849088adcffcd36d82f66_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="idc9d05f7c1a74459b89c4ececa72d31d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1948d85fab604db881323ed2ad598c59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73ce415c72f84e7faa6119e5db9ec7f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica50ab9119b04010bd04bd7d82bce622_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3612de0f43644d784871ebe849c27ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id753ed956fca4c9697045d3b819e7684_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i516bbb796f934334a222a0fa68f96141_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia61dcd7cc49f41c0936daa62cdcbb1c6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60f19acba9b346f8805c6bdd01935668_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62f0df97465f48e7b7873ed9e345c3b9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b0f729cc7834d838ef13e90b13032e8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iea582ea5aa4f4a669db07ca5961b838f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ife32845f8f56459b828af29f233cea3e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib3f6137620d443d38f5a57b1cc4509ac_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8488f37532d44598b640e3d982bd4d1a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if7aa58f98c924adeb22065e220c2905c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5170241300904fbea34b8142ff2a821c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8165a95911864bcfb5491d08afc84e94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i165acb4a2b0d43dd81d356c112615871_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28faac3c4e4b4accb6e60a468b175a53_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i13ee975c61c5467f9516d04c8a1176f1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife1921ce00c34a2eb95d9de3595c2be7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib3c516cacf404828b016eddc54887f05_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7179a8875e614260b2c6e1b4cf82c9d1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f1f03f52650459fa99a8fe57031cfe6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c86dfc3e9ee4f10af73ad81268a63bc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4b3ea666a48f4ea79d28dc480c0ac8f1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8d395dde98524fa2959805ab74ab926f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i41b817c4f2c748f4ad54ab609bcb7259_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia4e79c56dd794f2c98635556f462cf4d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2b67fb3aa82d43ffbf26b48ff2d8f1c5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e0fc8c7198a43d9b9d0c99f6121cd13_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5fa38f90595e4e8fbfab0ba144b401a0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf8e0d7f30d8409cbfc5630b9d2bc341_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idde20bc926894280b4ff61e91056fe72_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8175286262ae459f85852ea172fe0373_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia346a814aa4d4577b59b906128f24eec_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c2e8e85ac5a4488b1adc8af19f319e2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i143c1628336040789355760a0e36cb04_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib270c515c868406785b1ede039e1e002_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibade6508c50c4f938133f3c022f3073f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6013739ca1f54a5290b712e2dc11f329_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a6fcfcabe5d445a9761fb8678c669c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f010fdc6c5e44c2868aa793118a0276_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9679d28935fc4a48900189cabb13e5d9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39e962f11bcf4bd980fff4715c3da316_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id98346bd89964dedadb43377f44a0d31_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39a105cc514f40d7bf0743359acd5400_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id274468946a6454ca8c80e958563c1d5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23430e509b1b4117915b80c09a42657d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i379169127f2b4a9395ced61d3e36c9e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if014c19f237748bd8ee32127e024b863_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i477a6cb8b52f4f929eda17ce6dce344c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i150f4a13b0a145e8bf65f5c84097ec47_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia5ee866dd4344c0aa14cebd1e0c79e89_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75aa8742f42b41689c3d73f6bb82b7dd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7000526ec07f428091319155849fd704_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f6747564e0b4a938f03505b3f95f165_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i699b74e5bbfd4779a582c698d788d790_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied525c1179a741bb82b1d583a76e51e5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff1924f4ee8f43ee840ee57aff81df9e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6d39579533114f4aa354f18fd1f299b5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i654d114f9573429998ad4856d6fefb38_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i677267ca7d7e48f68e24c2371a4dffd1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie3f1075481e74bb98a9b2a2d1b4673ae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd96e2849ae7466dae303c5a5b80c085_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33f267df3ba84643b8bffb1e5ff56f47_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib258d211097b4e64aa9629510fd53154_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia2f98bd41f384786a46e50b06a48f2d3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2953a813c0d9467d9ae9f1e794ec1fd2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99e1e20ca1e74fe0b437961b9da435a4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if314461b1e5b4baea50b55cd17fd0538_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b90ed783cf34d47b1bd424e613386be_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idaae1cc404f343c5bfb355c19f2dd60e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i266dc39128f9407d870c90b7e77122dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2c913a6dc6e40f3a5994b325c0067d5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i790bc65eb68c43b0a56d4a861411da6d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fc3cf0a2cd74d61854096f0dc29d4bd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib2401c248b54473d9de51f32724fa7d4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05dbc5642aa740e898a9288a14e80f49_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i248e2c4fa3d34b269a285cb1c63488bd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id09ba7df5db74e13ba503168413abdff_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i444b41b2ae2d4e7cb1136b88ed82f8aa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia0e35f43cb26444f81cfaccaad8eb9cc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib1fa67b093a54744bc17319d4330b45a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iebee12b1fdff4baab053967a2a218895_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4e2515997127460a88ce3b7721c7f899_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if816cbeb32834f9c892e3d50f230ae8b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b3ef8424e944022bba6665e253acdec_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia410aa53688a4c78b85ff75528ef68ea_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie9f86bfff90443dfad344994aa697b38_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia721ab9e8edf4ed7a17168531a631cd0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id81620b24a824ca2a03f609c9a047932_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12f850ed68f24c55bf0e191cf454be49_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e940795a93d480cba3bee92ea71cde2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38006411cd644bd9bb6a9f6aff3265f7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i28adb3330230472e88334d479def96ab_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i92a13aa4f4d447958145380700133524_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia13f165b3be34174b50cecb4c27778d9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee279a7d1aed471ba23a5d4e8f28794a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i756f3f5bdda54726bce4b571b4493a2a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a5dec6bf41c4a37a79d8a1cc7f4a7da_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5ea2be25eae54408bbb6eef779a3bab9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e718401bed449ed8eea180efb806b04_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icccb66447d924c0594b928f60f204b02_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i590aa7c867af425baa597d7a5149c44b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4078cb7710e54f01b41c9089dc314b3a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i633b5b8dfba24438ad91750ffda4fddf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8dff1fe5988e4116a7e201e084821a57_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i69f8f42a6a9c41ddae4efe85bc2204b8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i648337729b824015ae37af96e3c8ea6b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i02128433756c4eaeb9a1cb904b8b0757_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00ad05700891493d918f048f148b8bfa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9ad97210ae5d418ca006b46280264849_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1ac80dac77b54f829d7ff2f034bca438_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i980538f09ea6402c88eeb6295f06a52e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i509664d8b5114111a796a1f9c9e4bf21_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i478b04cc484548cca1dda224d468b2e6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibbc6f9feb2e14b0b92a0d13fa4fa7b20_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e0983fe25984681bb8e932d698e54aa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if795d18582b54e3b9e469252f6bb23c1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a30db781c9c4e588e9c2f59f6c0abc3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iabde71d9b5fa451e97f28d6436d5b553_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i22f562316d0a4a2788f90566852c367f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia2747153b7ca44e2a5d47259de2db6c9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i487108ca40f748dd9b0bece4b437028b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia32e8ba2ceec42cc82a16e2cd05dab84_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c43205ec30542ee94946dc9109e90bb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i751d4a0241cf4502ab3497a8e9ec0dce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icad78ebefcf14b34899f5ddcb848be14_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idabf552e851142fe99517e02399fdd3f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa0eaf2019e44f0682994cffd26a0133_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief1572a6af6d488d9ab80a00623a94ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i15516b5b057f44e9944b4a39df3e5c9e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic776742915944b44af8f827099040080_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9d32af2650947b8b8a4b511bb7ba6ff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7fd0e08d01ac49639fc6727d3904fee7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69c7f3a2f08a498b8785ed63ef47838c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d833d38eb9f4e898a5898ddbf6dce39_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4efa6afcaf1645f6b58846b7cc88b340_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie06b3989f9a34f469041414b1f9de0db_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id9e7531c621947d4a9119f4864109e24_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3cb3160ab3ff42eaae7dd54fa3d456e5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i199def73fc1342d0a937f3d464cb4c69_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5281eb5b3f824e51b96dd0c15c3e9f04_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6944bfac8bea4cacac93ae484b0bd09d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i86671ce6531e4825b8e7437bac23648c_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="icbfdae3fc3af4808b767547c978da623_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f17596163b74714978d0ca8bb7716a7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i920ace51c79b4fd9aaea95747910f622_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i901cded39aad4bb796bd2e4ea0b84524_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0af199bf8cdb4db88ac9960dd490f47a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7b972473b78a41948835d5e6b4829ce2_I20181107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="i6d3585ab7f49447c9095cb7b649c5a3f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if2c3147acf584e02bc9574e010f74b90_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie1fbddcf67fa4255b76afc8be76c1ee0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45f34187e7424286895df7d07271d853_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc423654295e47e497b4d7f2985f4754_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i22878c92c12541f19e966187ae7b1e40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if50c9b8ddef6484aa041e78de26b485f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i869e4d6d217b488e998a60c8e87948c6_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i395c6f6eef504574a55e4ae26a68fee0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22ac8ae1aedd4701923500c02d371f31_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac1864f4ab43443795b18bf4e5518559_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i021e9d577199419a8902601c80f14ba1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22969c273ab1477cacb6c894c96e65ca_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4bab21bf098a42d1b19d7bb69acd037c_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="ia0b2b5750c244cafbf99dc052af4f8a1_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="id73a857cd2af440ebad3dee0301dca58_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if3c03d9b6e5a437fa43cc01794b646a3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46019d81d2e4485da3b49f6b7279b384_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i72ca0603ce78428694ea1e92d86ad2ae_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70c76f0606c54d3c92d00b9c6239054d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie36b8f43567e4ffc8902418be40bc1ef_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id68d34303bce4a2db8b2455c5f1c3285_I20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl8xLTEtMS0xLTA_dfdcb4e9-0516-4b30-9836-f1c2f3e08045">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl8yLTEtMS0xLTA_cefa7440-b606-4368-a679-9a8468858e39">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl8zLTEtMS0xLTA_e134e30e-c973-46a5-8e56-db7ecbebb5d9">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl80LTEtMS0xLTA_d26b3c84-c74e-4c93-ae03-0eec6e1b9096">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl81LTEtMS0xLTA_2f7a2d17-d9be-4638-8ebc-47ad8bcab1a7">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic2146328de3549768f889075bad51afb_I20211019"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80L2ZyYWc6NDBjNzhhNjY5MGU1NDgzZmI1ZGUzMjI4ZDE0YTY5NGEvdGFibGU6ODljMGM1ZDVjNTMzNGIxZjlhZjExNzg1NDNmOTVhNmYvdGFibGVyYW5nZTo4OWMwYzVkNWM1MzM0YjFmOWFmMTE3ODU0M2Y5NWE2Zl82LTItMS0xLTA_71709f06-13dd-4b88-9903-5584c147ef50"
      unitRef="shares">146892712</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yOC9mcmFnOmQzNzJjOWJmMTllZjRkYTU5MjY2MzkzOTNhMzhmNGM3L3RhYmxlOjRmZmM4MjExZmUzMzRkODdiZjc4ZmRmOTIzYmJiNDczL3RhYmxlcmFuZ2U6NGZmYzgyMTFmZTMzNGQ4N2JmNzhmZGY5MjNiYmI0NzNfMS0xLTEtMS0w_068d4f22-962f-4311-a79d-00686509e534"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yOC9mcmFnOmQzNzJjOWJmMTllZjRkYTU5MjY2MzkzOTNhMzhmNGM3L3RhYmxlOjRmZmM4MjExZmUzMzRkODdiZjc4ZmRmOTIzYmJiNDczL3RhYmxlcmFuZ2U6NGZmYzgyMTFmZTMzNGQ4N2JmNzhmZGY5MjNiYmI0NzNfMS0zLTEtMS0w_5773aef0-f7af-4a42-a3fb-afea3cf0fcc2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yOC9mcmFnOmQzNzJjOWJmMTllZjRkYTU5MjY2MzkzOTNhMzhmNGM3L3RhYmxlOjRmZmM4MjExZmUzMzRkODdiZjc4ZmRmOTIzYmJiNDczL3RhYmxlcmFuZ2U6NGZmYzgyMTFmZTMzNGQ4N2JmNzhmZGY5MjNiYmI0NzNfMi0xLTEtMS0w_0409e8dc-2113-4473-9e9b-ac484b25ee01"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yOC9mcmFnOmQzNzJjOWJmMTllZjRkYTU5MjY2MzkzOTNhMzhmNGM3L3RhYmxlOjRmZmM4MjExZmUzMzRkODdiZjc4ZmRmOTIzYmJiNDczL3RhYmxlcmFuZ2U6NGZmYzgyMTFmZTMzNGQ4N2JmNzhmZGY5MjNiYmI0NzNfMi0zLTEtMS0w_f85ec007-79a9-43bf-970e-561447008b36"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i47e67b006b354cc88698e7fe5664efe2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82NC9mcmFnOmVhN2M4YzFjYWFmMDRjMzU5MTY3NTRhM2U1MTQ2NzgwL3RhYmxlOjU5NDBjMDIwNTBlYjRkNWVhYTRiMTY2MmY1ZWQ1NzlmL3RhYmxlcmFuZ2U6NTk0MGMwMjA1MGViNGQ1ZWFhNGIxNjYyZjVlZDU3OWZfMS0xLTEtMS0w_6d0e814d-cf23-4bea-8f41-09ca4a65bb0b">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5e115d8322fc4129abe228330a35b1c0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82NC9mcmFnOmVhN2M4YzFjYWFmMDRjMzU5MTY3NTRhM2U1MTQ2NzgwL3RhYmxlOjU5NDBjMDIwNTBlYjRkNWVhYTRiMTY2MmY1ZWQ1NzlmL3RhYmxlcmFuZ2U6NTk0MGMwMjA1MGViNGQ1ZWFhNGIxNjYyZjVlZDU3OWZfMi0xLTEtMS0w_9400bc68-9cbd-416e-8af3-7c2132ea18b8">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="i3cd19afbd26746dca41eab54ab3017ba_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82NC9mcmFnOmVhN2M4YzFjYWFmMDRjMzU5MTY3NTRhM2U1MTQ2NzgwL3RhYmxlOjU5NDBjMDIwNTBlYjRkNWVhYTRiMTY2MmY1ZWQ1NzlmL3RhYmxlcmFuZ2U6NTk0MGMwMjA1MGViNGQ1ZWFhNGIxNjYyZjVlZDU3OWZfNy0xLTEtMS0w_2e55d9b4-d168-43a0-a161-17a2bf194cba">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="i65c9878611a94c1e8dd4e4c8e3723f18_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82NC9mcmFnOmVhN2M4YzFjYWFmMDRjMzU5MTY3NTRhM2U1MTQ2NzgwL3RhYmxlOjU5NDBjMDIwNTBlYjRkNWVhYTRiMTY2MmY1ZWQ1NzlmL3RhYmxlcmFuZ2U6NTk0MGMwMjA1MGViNGQ1ZWFhNGIxNjYyZjVlZDU3OWZfOC0xLTEtMS0w_c83cc597-0b07-421d-9993-c37c54630006">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iadac69438a134e4685f396b8c53251d4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfNS0xLTEtMS0w_53a0a5ee-e1db-4ee8-ac2f-9eff41076fe3"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ica74fb523d614349a5924b06d1bb5822_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfNi0xLTEtMS0w_40d3f860-2140-4949-850d-cb49f18ec0d8"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9f2d4471ced94158a3b9461f37a5a9b4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfNy0xLTEtMS0w_ad54a3a6-b9bb-487c-8c20-f3828836b6a6"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia82ded1ca1fa4ec881505e83910f2470_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfOC0xLTEtMS0w_cc251056-ac40-4074-a962-c15a2407931e"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a9933a802b04b7d8c62324f5f41c52a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfOS0xLTEtMS0w_0f53203d-831a-41a4-9c3a-94c8f1cd7f17"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86e1f0ba26984bf396b6de85e0803baa_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfMTAtMS0xLTEtMA_b4b0f2ec-e3f0-4f6c-8c67-515527e3dcbb"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53759aa6be6e42a1a94cf191019495cb_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RhYmxlOjczYzcwM2NkYmQ5ODRkODg4MzExZDM4Njc2ZWNmMTdlL3RhYmxlcmFuZ2U6NzNjNzAzY2RiZDk4NGQ4ODgzMTFkMzg2NzZlY2YxN2VfMTEtMS0xLTEtMA_b0bf98eb-d725-49f1-9c7f-3fea7ddb38c6"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AssetImpairmentCharges
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83MC9mcmFnOjY0OTQ2YWUyMGUyYzQ2ZDRiNmZmODEzMjhjZWI0MThjL3RleHRyZWdpb246NjQ5NDZhZTIwZTJjNDZkNGI2ZmY4MTMyOGNlYjQxOGNfOQ_a3f97b09-1839-4f08-96cb-9c4a56458026"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMzAvZnJhZzoxYjhiZTVjNTMyZjY0YjRiODBhNmUwMjVjZjJhMDg1Ny90ZXh0cmVnaW9uOjFiOGJlNWM1MzJmNjRiNGI4MGE2ZTAyNWNmMmEwODU3XzEzODc_f028f2e2-dc8e-458e-8788-509c4cfbfdf3">Subsequent EventsIn October 2021</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDE1_4d10d025-6448-4c3e-9937-d7f85cc47e04">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6Mjk0ODZmN2Q1MGRiNDFiMmI1Y2U0ZDY4MzcxZjQ5MDQvdGFibGVyYW5nZToyOTQ4NmY3ZDUwZGI0MWIyYjVjZTRkNjgzNzFmNDkwNF8wLTAtMS0xLTA_6d0e89cd-1d88-4537-9067-56763618d251">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18xMjM_e07a8951-464d-4d8d-92b4-fcafe29cebb0">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6YjBhNDc5ZGQxZDE4NDFhNDhjN2IwYzZjY2JiNjczMDQvdGFibGVyYW5nZTpiMGE0NzlkZDFkMTg0MWE0OGM3YjBjNmNjYmI2NzMwNF8wLTAtMS0xLTA_7ee18576-bc01-4a4c-a316-0ae167582e8f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDEw_9368d39d-5c62-45a8-86d4-870b664a2bce">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDA2_46c7a831-7a70-4416-99c0-6ce9b609bf1e">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6ZTdkOTlhMDc0OGNkNGNmZDhkZGRmZmVmODkzODNkNWQvdGFibGVyYW5nZTplN2Q5OWEwNzQ4Y2Q0Y2ZkOGRkZGZmZWY4OTM4M2Q1ZF8wLTAtMS0xLTA_39630c78-2b59-46c3-9962-73c6ebe9c381">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6ZTdkOTlhMDc0OGNkNGNmZDhkZGRmZmVmODkzODNkNWQvdGFibGVyYW5nZTplN2Q5OWEwNzQ4Y2Q0Y2ZkOGRkZGZmZWY4OTM4M2Q1ZF8wLTItMS0xLTA_7c05ebd0-83fb-4a5a-b9f3-d196441c4c26">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDA3_ccd1a8c8-bf34-4845-86b9-c37ec6ca9207">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDEx_b6f842ef-c8f7-411c-b14b-0e12d4077897">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDA4_e2bcd27c-71f8-481d-9017-10e61d5e0910">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDEy_e7b6315b-7548-4220-941a-65d7cd5444e2">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDE0_ba603cfe-4bca-4bcb-80ca-5dc60d9e2c9e">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDE2_44aa5556-b23f-4978-b7a3-0f93000e72ad">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6N2QxZDlmNjdhNDUyNDZmY2EzMWI2ZmM3NWQ3ZmZlMDAvdGFibGVyYW5nZTo3ZDFkOWY2N2E0NTI0NmZjYTMxYjZmYzc1ZDdmZmUwMF8xLTAtMS0xLTA_648b9896-fc3a-430d-b752-7725046a3355">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6N2QxZDlmNjdhNDUyNDZmY2EzMWI2ZmM3NWQ3ZmZlMDAvdGFibGVyYW5nZTo3ZDFkOWY2N2E0NTI0NmZjYTMxYjZmYzc1ZDdmZmUwMF8xLTItMS0xLTA_51bbaf20-1cb6-43e5-a1b4-b26a61247cc6">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6N2QxZDlmNjdhNDUyNDZmY2EzMWI2ZmM3NWQ3ZmZlMDAvdGFibGVyYW5nZTo3ZDFkOWY2N2E0NTI0NmZjYTMxYjZmYzc1ZDdmZmUwMF8xLTQtMS0xLTA_ef5e273b-dd46-4984-9e0a-fe77045ec089">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDEz_75923865-abf4-44a0-923b-4d3c85266ae0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDE3_e2879aff-83b2-4274-8257-82645b88a42a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6Yjg3MGE2NWJkNDNkNGFkOWE0NDBkZWRiZTYwMjk3OTYvdGFibGVyYW5nZTpiODcwYTY1YmQ0M2Q0YWQ5YTQ0MGRlZGJlNjAyOTc5Nl8wLTAtMS0xLTA_de47abe0-4be6-417d-b8c5-db5933532870">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6Yjg3MGE2NWJkNDNkNGFkOWE0NDBkZWRiZTYwMjk3OTYvdGFibGVyYW5nZTpiODcwYTY1YmQ0M2Q0YWQ5YTQ0MGRlZGJlNjAyOTc5Nl8xLTQtMS0xLTA_e83c25ca-c1f2-48d3-aae5-f73328a65975">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGFibGU6Yjg3MGE2NWJkNDNkNGFkOWE0NDBkZWRiZTYwMjk3OTYvdGFibGVyYW5nZTpiODcwYTY1YmQ0M2Q0YWQ5YTQ0MGRlZGJlNjAyOTc5Nl8yLTQtMS0xLTA_d103514f-dbf8-4991-8aeb-9e03f6f085a4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18yMDA5_fea98eba-35ed-4545-94b8-5f754f715ea2">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic2146328de3549768f889075bad51afb_I20211019"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xL2ZyYWc6M2IxOGViMzE1NmNmNDllODhkZmJkODI0NGQwNDZhYjMvdGV4dHJlZ2lvbjozYjE4ZWIzMTU2Y2Y0OWU4OGRmYmQ4MjQ0ZDA0NmFiM18xOTk1_71709f06-13dd-4b88-9903-5584c147ef50"
      unitRef="shares">146892712</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i28c7f8faaddf4de59fb5368e32d5ae6d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMy0xLTEtMS0w_59e54912-11e6-4d3d-b2d5-b84231ab6ff6"
      unitRef="usd">2205700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3672251f76c4fb3ab491f7a64f2a7d1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMy0zLTEtMS0w_7769f1e6-7259-4daf-9d52-5ecbd82337bb"
      unitRef="usd">2690300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6629e89c034a4d89883d31d567178ed6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMy01LTEtMS0w_f5fe006e-4432-4073-974e-c68b53ec11b0"
      unitRef="usd">6653400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie862c4e3d0454092bd193a5d58ea0c3a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMy03LTEtMS0w_6150ee23-0e1e-4a6b-b415-f1985e2a0350"
      unitRef="usd">8390600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc49896e8f7749f9aec4691dac20e8f7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNC0xLTEtMS0w_986148e2-6378-43d1-9bb2-2ff5312bcae3"
      unitRef="usd">415400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b23d904c3ce4fde94a3a645d27461d5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNC0zLTEtMS0w_a3f605cd-cf93-49fa-8666-592042778f07"
      unitRef="usd">560100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf69f40f83ce4c9da70c57f9064c7b4a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNC01LTEtMS0w_e40b62bb-af72-4977-9dd3-95573b611003"
      unitRef="usd">1244400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76c2b9076741473bbd3bced37f71ef41_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNC03LTEtMS0w_ecf536dc-4e04-410f-a99d-2d00a68aae03"
      unitRef="usd">1558800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib36a038f73ce4e7b8013d75c309b00de_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNS0xLTEtMS0w_9ff0d77b-b259-4741-803c-678b022e05d9"
      unitRef="usd">157800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27692e0f487e42cfa48cfb9ec74d1c5b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNS0zLTEtMS0w_f21aeea6-9f57-4ac5-9a8e-30cbe876ae96"
      unitRef="usd">125700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i40db7f82bc1346e0a6ae09a03625fc9d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNS01LTEtMS0w_2010c586-ace6-4bb2-bdf2-47110f7d9e65"
      unitRef="usd">350100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f2782acd53f4eca80ff87db16f55ee5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNS03LTEtMS0w_dea79b38-34e0-46f1-8336-5e77a8d6d1ff"
      unitRef="usd">642600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNi0xLTEtMS0w_24098114-2381-41c0-8bbb-58f83358685f"
      unitRef="usd">2778900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNi0zLTEtMS0w_04f70111-c20a-4c5e-a0b2-ccf14ecabb85"
      unitRef="usd">3376100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNi01LTEtMS0w_dac691a4-f2b6-4da0-b7f6-d4610e88841a"
      unitRef="usd">8247900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfNi03LTEtMS0w_031934a0-e87d-4f67-9894-3a0f888c18b7"
      unitRef="usd">10592000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOC0xLTEtMS0w_7a640ebe-9694-4877-ac3b-664db6b8491b"
      unitRef="usd">511800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOC0zLTEtMS0w_5e1bd94f-43bd-45b6-b2b1-b806d450b9f4"
      unitRef="usd">449100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOC01LTEtMS0w_be1610c8-bbd5-4720-a445-7b3552dc5e65"
      unitRef="usd">1449600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOC03LTEtMS0w_2c413ee3-e6b5-479c-86c5-3fceb8455acb"
      unitRef="usd">1314600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOS0xLTEtMS0w_50ebca44-1461-4f5f-b460-468de6ef643f"
      unitRef="usd">702400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOS0zLTEtMS0w_decdd01c-7546-4bd2-b4cd-1410f7031e5a"
      unitRef="usd">1140900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOS01LTEtMS0w_f3c2f6e3-6016-44c0-9629-c4824a9e9ab3"
      unitRef="usd">1801700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfOS03LTEtMS0w_d485dbd0-5822-48b9-827b-d7bbe1e8bd95"
      unitRef="usd">2264800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTAtMS0xLTEtMA_ac910653-c13b-4a88-b550-02d19f2332f6"
      unitRef="usd">654100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTAtMy0xLTEtMA_ac052197-5f7c-438e-bddb-5caa0db53c30"
      unitRef="usd">573100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTAtNS0xLTEtMA_bef1c4dd-1c0b-4690-879d-bfb1b6a924a4"
      unitRef="usd">1886400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTAtNy0xLTEtMA_e0f8337b-2aaf-4874-ab30-b479b3d37eb7"
      unitRef="usd">1698300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTEtMS0xLTEtMA_9e2b4371-cb66-4554-94d9-a51f1bbddf33"
      unitRef="usd">111000000.0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTEtMy0xLTEtMA_00842875-29de-40c6-b379-64a9ccc60588"
      unitRef="usd">82600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTEtNS0xLTEtMA_5547110c-3dec-4393-a8a5-cfbcc75bc476"
      unitRef="usd">813200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTEtNy0xLTEtMA_53a020ee-35a3-402f-9ba9-9a5d81ec6533"
      unitRef="usd">215600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTItMS0xLTEtMA_76025576-7900-4019-b50f-f67fce5bb346"
      unitRef="usd">21200000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTItMy0xLTEtMA_2f04e3ca-99b6-43ac-be66-856e6ffe018b"
      unitRef="usd">73000000.0</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTItNS0xLTEtMA_35f1edfd-1768-4498-8dbc-46da20517648"
      unitRef="usd">74500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTItNy0xLTEtMA_24d442dc-9f4f-4157-b0b4-0e68682dc469"
      unitRef="usd">166500000</biib:Collaborationprofitlosssharing>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTQtMS0xLTEtMA_a0bc14ba-5cd2-4f94-a12a-c5bae9714b80"
      unitRef="usd">15600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTQtMy0xLTEtMA_3d7c555c-2eab-471a-beaa-97640b70f4d5"
      unitRef="usd">29000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTQtNS0xLTEtMA_f1730e18-7b8c-48da-9604-81b8ae4bbb61"
      unitRef="usd">49100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTQtNy0xLTEtMA_e0038e68-e541-4005-9596-717db6ffc5a1"
      unitRef="usd">23500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTYtMS0xLTEtMA_15996fdf-2ec5-4d11-b42e-0b271558375a"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTYtMy0xLTEtMA_5871ec4e-7f14-45a4-ae66-6a47694dc04a"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTYtNS0xLTEtMA_83fe2259-6855-4c30-b7fd-cdf08b5dc064"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTYtNy0xLTEtMA_177448e5-0948-4977-84e7-dff07df81dde"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CostsAndExpenses
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTctMS0xLTEtMA_97fdc7aa-7512-4fd6-90bb-4c124de68918"
      unitRef="usd">1984900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTctMy0xLTEtMA_3834b94b-764b-48ae-b633-a2d35983590a"
      unitRef="usd">2289700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTctNS0xLTEtMA_66023d00-df59-4f35-b627-051d083dec5c"
      unitRef="usd">5994300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTctNy0xLTEtMA_6feeff64-c27d-45d3-87ee-04694fb8d7a4"
      unitRef="usd">5711300000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTgtMS0xLTEtMA_3fc1eb5b-26a2-4558-a050-391b2de9776e"
      unitRef="usd">794000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTgtMy0xLTEtMA_ab66d0d3-9a40-4af2-895d-12e9c3cca9b3"
      unitRef="usd">1086400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTgtNS0xLTEtMA_4f5b4ea2-2e72-4c9e-8bb0-1ede20950376"
      unitRef="usd">2253600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTgtNy0xLTEtMA_52d95e33-8320-405e-8b6a-6470ab4de550"
      unitRef="usd">4880700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTktMS0xLTEtMA_c6385783-ed00-4976-970a-4025413fea29"
      unitRef="usd">-502900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTktMy0xLTEtMA_4af3b50b-ec75-4c97-b58c-cbfe177400a9"
      unitRef="usd">-128600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTktNS0xLTEtMA_d02197cf-2ca9-4761-8e18-056bda60da18"
      unitRef="usd">-913400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMTktNy0xLTEtMA_45557ea9-90b4-4d9e-9ad3-0eaa5eab1715"
      unitRef="usd">-186100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjAtMS0xLTEtMA_dcab81bb-8491-4b28-978f-6d9515c905dc"
      unitRef="usd">291100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjAtMy0xLTEtMA_9c17deb1-f9eb-44bb-abb0-6012a9df7889"
      unitRef="usd">957800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjAtNS0xLTEtMA_42e69a50-98e8-4e1c-a5a1-b56eec1471c8"
      unitRef="usd">1340200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjAtNy0xLTEtMA_b01bd430-057b-4503-9ff6-250bd4f02b7a"
      unitRef="usd">4694600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjEtMS0xLTEtMA_21f8f2e7-971e-45f5-bf00-271ce86688d8"
      unitRef="usd">-25900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjEtMy0xLTEtMA_f57e949c-df61-4555-a7d2-f426a304fe24"
      unitRef="usd">240800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjEtNS0xLTEtMA_9ab446fa-056c-4c48-8d69-6c86960766ae"
      unitRef="usd">-390700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjEtNy0xLTEtMA_e79d79b6-8305-4399-a81e-767e1037d5a3"
      unitRef="usd">979000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjItMS0xLTEtMA_4c84cc16-b988-4486-945b-3281e72d056c"
      unitRef="usd">1100000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjItMy0xLTEtMA_0901aabb-fb61-4ffb-933d-377433afcbe7"
      unitRef="usd">-13100000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjItNS0xLTEtMA_283ef742-9826-487c-bdc7-2e6b10ae2380"
      unitRef="usd">17200000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjItNy0xLTEtMA_641a8784-5b87-4ed2-ba99-2bbbc6750d45"
      unitRef="usd">-12700000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjMtMS0xLTEtMA_ffd677eb-b5b2-43d9-9d1e-9695bff46bd1"
      unitRef="usd">318100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjMtMy0xLTEtMA_d8fe1f12-2696-47be-91c4-4cb2c63caf64"
      unitRef="usd">703900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjMtNS0xLTEtMA_984d33c1-a22e-4bb8-8ead-62873fe46f6c"
      unitRef="usd">1748100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjMtNy0xLTEtMA_0e192b19-e1b1-4aca-aaab-2fcdf889ec3e"
      unitRef="usd">3702900000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjQtMS0xLTEtMA_934264e3-ffdf-4b3c-82d6-be44b6aa8ef7"
      unitRef="usd">-11100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjQtMy0xLTEtMA_f97ab05a-ad64-47da-b8c1-d25abdad5712"
      unitRef="usd">2400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjQtNS0xLTEtMA_7e836608-afcd-49a2-a82e-ffcaddb8810d"
      unitRef="usd">560200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjQtNy0xLTEtMA_5302ebde-b82a-4a5b-85bb-faec6766a50f"
      unitRef="usd">60200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjUtMS0xLTEtMA_eb1219c2-aaff-48de-9820-8750f3709cd0"
      unitRef="usd">329200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjUtMy0xLTEtMA_5e844396-8c7a-4c36-bc2c-46d4eb61b3be"
      unitRef="usd">701500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjUtNS0xLTEtMA_18236b9f-eaf3-4caa-86cd-c51dcf10afc8"
      unitRef="usd">1187900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjUtNy0xLTEtMA_7a774652-573f-40cb-81c4-d3065d13e3cf"
      unitRef="usd">3642700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjgtMS0xLTEtMA_304d2923-5648-4da5-9a89-96500d043496"
      unitRef="usdPerShare">2.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjgtMy0xLTEtMA_ff6a4e5d-9855-4d66-970e-9e59baa4a68f"
      unitRef="usdPerShare">4.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjgtNS0xLTEtMA_a7f9e696-35f1-4cf9-b069-9935c2b4e0e1"
      unitRef="usdPerShare">7.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjgtNy0xLTEtMA_71f923f8-6224-44cd-8975-042dc50c8da5"
      unitRef="usdPerShare">22.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjktMS0xLTEtMA_727ba72c-4562-4699-a70e-105a6137e050"
      unitRef="usdPerShare">2.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjktMy0xLTEtMA_701e31ab-773d-4ebc-9c8b-09278020b07d"
      unitRef="usdPerShare">4.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjktNS0xLTEtMA_6f93aa30-58d7-4eab-9ec9-d5d98c793cf2"
      unitRef="usdPerShare">7.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMjktNy0xLTEtMA_a7c4f986-cdda-48c5-b040-56e6815fcef2"
      unitRef="usdPerShare">22.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzItMS0xLTEtMA_253d7685-d00d-4d52-b337-a038882da16a"
      unitRef="shares">148000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzItMy0xLTEtMA_84129242-b0bc-4b3a-9af1-ec873e073312"
      unitRef="shares">156900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzItNS0xLTEtMA_12998b78-b75a-4e68-b6c6-f24f83957ee5"
      unitRef="shares">149900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzItNy0xLTEtMA_4b48819c-bcb2-4609-b117-964d83ad7de1"
      unitRef="shares">163400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzMtMS0xLTEtMA_ad9d1ee9-03cb-493b-b317-426c91b8c75b"
      unitRef="shares">148600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzMtMy0xLTEtMA_4349f918-d4fe-48f7-bc16-8945c5fb8150"
      unitRef="shares">157200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzMtNS0xLTEtMA_ac8d46be-968b-4dd6-9d6e-cbda6a4b2d1d"
      unitRef="shares">150300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xOS9mcmFnOjY2NDgzNjZhODQ2MDQzNjQ4MzVhZDFiYTVkZDAxZmNkL3RhYmxlOmU1ZjZmNjA2YWVmNDQxNzc4NjEzYWIzZWJiMmNhOWVkL3RhYmxlcmFuZ2U6ZTVmNmY2MDZhZWY0NDE3Nzg2MTNhYjNlYmIyY2E5ZWRfMzMtNy0xLTEtMA_598cba8d-4cda-462a-8d96-a078bd70d76e"
      unitRef="shares">163700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMi0xLTEtMS0w_951815b4-67d4-4ec0-9a33-93558d0d70e1"
      unitRef="usd">329200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMi0zLTEtMS0w_604526dc-d973-4b19-8b13-6a7f12fbc42f"
      unitRef="usd">701500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMi01LTEtMS0w_4bdb5332-aac2-4525-8753-ca5ed0dc2acf"
      unitRef="usd">1187900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMi03LTEtMS0w_c82ac091-daff-4c7e-8b6f-11ff7f2266de"
      unitRef="usd">3642700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNC0xLTEtMS0w_f49aca70-f7f8-4647-a8c0-e643f0433a97"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNC0zLTEtMS0w_67a50225-e799-4841-8e21-02f202782a43"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNC01LTEtMS0w_42651841-e48e-4739-88c9-b0e02af66bdf"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNC03LTEtMS0w_2a79e634-8855-499b-aaf2-6e8b5b204f96"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNS0xLTEtMS0w_c65c6b73-ab2c-44f5-be3c-78988be05506"
      unitRef="usd">66200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNS0zLTEtMS0w_3fb3874c-4b60-4fca-9278-0a7e6145e308"
      unitRef="usd">-83700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNS01LTEtMS0w_5f08cf87-e348-4578-a320-afdd1ab5b5cb"
      unitRef="usd">205000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNS03LTEtMS0w_0744c5bc-ee02-423f-ad6a-709c6975c688"
      unitRef="usd">-101100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNi0xLTEtMS0w_4da4573d-97bd-44f7-ae18-ec2b20858cf7"
      unitRef="usd">15100000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNi0zLTEtMS0w_e97cba6a-5a08-4389-8f61-505ec4615929"
      unitRef="usd">-11300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNi01LTEtMS0w_d884ff8b-1b92-4df7-bee4-52fd8e663c92"
      unitRef="usd">35200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNi03LTEtMS0w_09671624-bdab-4efd-9ea9-d87114056ba8"
      unitRef="usd">5500000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNy0xLTEtMS0w_caee6e58-334c-4203-b82c-fe3e4519008a"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNy0zLTEtMS0w_629a59d3-4406-41aa-b0b9-607476f31407"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNy01LTEtMS0w_88fff180-3bda-4dc6-a629-84f22af11135"
      unitRef="usd">-3900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfNy03LTEtMS0w_505ca38c-3443-4f4c-b95d-7ae61142f2b0"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOC0xLTEtMS0w_77e98250-cbc9-4298-999e-3f9544cf301c"
      unitRef="usd">-47700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOC0zLTEtMS0w_6a23289f-bdcb-45c9-ae01-214decdab41e"
      unitRef="usd">50900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOC01LTEtMS0w_15e5e741-4d78-45fe-bed1-614df936633a"
      unitRef="usd">-80300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOC03LTEtMS0w_ca3a4c11-0e57-4a62-bbc2-40e2cf548f29"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOS0xLTEtMS0w_19a52129-45f5-4a7a-8bad-881c24c74db1"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOS0zLTEtMS0w_68f94d2a-434e-4e9e-9ae8-9a546db2afd2"
      unitRef="usd">-44500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOS01LTEtMS0w_bf1009d2-6dde-4331-9005-e169d58b5a0c"
      unitRef="usd">162400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfOS03LTEtMS0w_604f16ca-f90b-4121-9d59-cd1e2a274dcc"
      unitRef="usd">-90300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTAtMS0xLTEtMA_e3e24097-b933-46eb-86b2-491691cad7d2"
      unitRef="usd">364400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTAtMy0xLTEtMA_ae0804cf-2484-4465-b972-3b28b3f669ad"
      unitRef="usd">657000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTAtNS0xLTEtMA_cc134d54-609b-46d2-b124-fccb38ac8162"
      unitRef="usd">1350300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTAtNy0xLTEtMA_a607bdf9-d588-4117-8e2d-c7aa94be4d9b"
      unitRef="usd">3552400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTEtMS0xLTEtMA_e75818c2-33b6-47ec-950b-dea31923b8be"
      unitRef="usd">-11100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTEtMy0xLTEtMA_95b52439-99db-4323-8151-476dcca7d2c5"
      unitRef="usd">1500000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTEtNS0xLTEtMA_e34773e3-4226-4822-bdf1-730d9e5d61ce"
      unitRef="usd">560800000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTEtNy0xLTEtMA_f7b1576b-568a-4ae5-9532-d063df62c1a3"
      unitRef="usd">61100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTItMS0xLTEtMA_9b1a55e8-82db-4b91-948b-58dfcb90e18e"
      unitRef="usd">353300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTItMy0xLTEtMA_e8e7a3ff-c0fc-4797-a472-236474abaf19"
      unitRef="usd">658500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTItNS0xLTEtMA_bab97ce7-ab68-463c-9cc4-91110cccdb8f"
      unitRef="usd">1911100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yMi9mcmFnOjZlMzAyNTYyMzU1NjRlN2JhZjE2Njc4NTQ4NTFhOTNhL3RhYmxlOjAyZWEyYzA5N2NhODQxYzlhZWEyYjc5N2Q5YmY4YTRmL3RhYmxlcmFuZ2U6MDJlYTJjMDk3Y2E4NDFjOWFlYTJiNzk3ZDliZjhhNGZfMTItNy0xLTEtMA_d1f69eb6-de72-4d01-9a22-82d88162ccd0"
      unitRef="usd">3613500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMy0xLTEtMS0w_7be1fff4-2523-41ce-ab51-52c1fda9a385"
      unitRef="usd">1541800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMy0zLTEtMS0w_d594ccbd-3afe-4bd2-90da-4757499a155b"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNC0xLTEtMS0w_1094ec77-d4f5-49ba-a073-0ea65b4bd1f2"
      unitRef="usd">1413300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNC0zLTEtMS0w_62022514-f442-44cb-ad7b-6bd84bb9225a"
      unitRef="usd">1278900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNS0xLTEtMS0w_cdc0c6f6-ef91-43ab-b7b1-057d0bc9a4e4"
      unitRef="usd">1723000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNS0zLTEtMS0w_1b37d9ed-f89b-47b0-99c0-edf468a18cdc"
      unitRef="usd">1913800000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNi0xLTEtMS0w_8e7519cd-64db-4a07-8924-c3e9712fabda"
      unitRef="usd">400000000.0</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNi0zLTEtMS0w_e28a445b-9d80-4beb-b5fb-63d3b759c9ac"
      unitRef="usd">413500000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNy0xLTEtMS0w_683e6f83-a3d1-451a-99ec-c967547e8707"
      unitRef="usd">1347900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNy0zLTEtMS0w_f859c4c7-51f9-4d52-aef1-bc8238efa3d8"
      unitRef="usd">1068600000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfOC0xLTEtMS0w_76a3852b-be1f-4747-96da-9c492199b882"
      unitRef="usd">736300000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfOC0zLTEtMS0w_082cb61a-db4b-4986-b9ef-2b21cfa233a6"
      unitRef="usd">881100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfOS0xLTEtMS0w_d2ef382d-f032-42f2-8c55-c321a3e2d9e9"
      unitRef="usd">7162300000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfOS0zLTEtMS0w_66548351-eb61-4e4a-89c9-0fab02ee98a9"
      unitRef="usd">6887100000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTAtMS0xLTEtMA_7b61c290-704c-45f7-b9cf-c8f1d6bc936b"
      unitRef="usd">968300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTAtMy0xLTEtMA_dadbef40-2b10-4073-935d-1ec65c8c30b9"
      unitRef="usd">772100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTEtMS0xLTEtMA_acd00561-69fc-4000-b638-15ceba8258d4"
      unitRef="usd">3410700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTEtMy0xLTEtMA_0261c352-abcb-46c1-a351-e19dd5f1cfbc"
      unitRef="usd">3411500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTItMS0xLTEtMA_0a86b2bc-f28a-414d-8245-42db4a3fe450"
      unitRef="usd">389100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTItMy0xLTEtMA_7313b194-347b-4439-9d45-3014854fc8e3"
      unitRef="usd">433300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTMtMS0xLTEtMA_0056c60f-9fd8-42c4-b608-0fc9e4a8b5dc"
      unitRef="usd">2286800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTMtMy0xLTEtMA_8e5f508c-f48d-4ca8-a918-5a39543f527f"
      unitRef="usd">3084300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTQtMS0xLTEtMA_484f78cf-6669-44a3-92fd-ee6809b8d75f"
      unitRef="usd">5760500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTQtMy0xLTEtMA_4a44b03f-1095-4c69-8d63-6f66badcb11e"
      unitRef="usd">5762100000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTUtMS0xLTEtMA_035ce3a8-6b88-4b71-bc55-9b6499f50092"
      unitRef="usd">1810400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTUtMy0xLTEtMA_edd87e43-90f3-4a6b-b482-8fa690252f32"
      unitRef="usd">1369500000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTYtMS0xLTEtMA_46c3a6b4-c0ad-4d3d-901e-3f813e769d2e"
      unitRef="usd">2018600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTYtMy0xLTEtMA_07b09455-ec30-4f01-b904-49b3589af792"
      unitRef="usd">2899000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTctMS0xLTEtMA_295aef1c-578e-45ea-ba81-f5947fa6c2ef"
      unitRef="usd">23806700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMTctMy0xLTEtMA_a33b634f-3340-40b3-b047-875bcd24ecb4"
      unitRef="usd">24618900000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjAtMS0xLTEtMA_88f77eee-afdd-41d5-9b8d-c0dd93801699"
      unitRef="usd">998800000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjAtMy0xLTEtMA_44b1e6d2-7b79-4f5e-a240-de9fe8d30cc9"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjEtMS0xLTEtMA_ad452827-fc10-4756-bd51-e1810a8a2456"
      unitRef="usd">234200000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjEtMy0xLTEtMA_a9b57d3e-376c-4c76-be7c-97a0070ed34c"
      unitRef="usd">142000000.0</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjItMS0xLTEtMA_736d3cd6-13e5-432c-942b-184f445010b6"
      unitRef="usd">427900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjItMy0xLTEtMA_f9d2612f-0dc4-4d9e-b004-8d8a57d30c11"
      unitRef="usd">454900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjMtMS0xLTEtMA_b5549b49-6b94-4e46-bd59-dda928803b86"
      unitRef="usd">2550700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjMtMy0xLTEtMA_3a756581-359e-4145-a540-42c08244bd31"
      unitRef="usd">3145300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjQtMS0xLTEtMA_af4d8af3-2313-4286-ba6a-91fadf8f2170"
      unitRef="usd">4211600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjQtMy0xLTEtMA_13a965dc-ef83-40d9-a86e-2e9b98a5e6ad"
      unitRef="usd">3742200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjUtMS0xLTEtMA_7046a6a9-9756-4a2a-9026-72441a4e62c4"
      unitRef="usd">6272300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjUtMy0xLTEtMA_51b6e798-b57c-4226-9da6-79d8731fa854"
      unitRef="usd">7426200000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjYtMS0xLTEtMA_cc066739-6c3a-4615-95c6-6cea54624b87"
      unitRef="usd">774700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjYtMy0xLTEtMA_45733728-48cd-44bb-af43-59926e5feb6e"
      unitRef="usd">1032800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjctMS0xLTEtMA_c44345f8-69d1-4f91-91e9-c8ad63ac6e06"
      unitRef="usd">348200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjctMy0xLTEtMA_a8e5c614-2c54-4ba7-9cc6-e135555d1ffc"
      unitRef="usd">402000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjgtMS0xLTEtMA_71fde94b-8d8b-4d9f-b9cc-3385f87edfb7"
      unitRef="usd">1318200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjgtMy0xLTEtMA_ccd343b0-d0dd-4442-a172-0272699f9e13"
      unitRef="usd">1329600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjktMS0xLTEtMA_b844e1ca-f92a-4bf9-910a-c1afdcc3319b"
      unitRef="usd">12925000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMjktMy0xLTEtMA_24a4234b-5b21-4d32-8691-7b7737db0dde"
      unitRef="usd">13932800000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzAtMS0xLTEtMA_9b7a3ad5-f5ed-444d-b329-3b4636fac1da"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzAtMy0xLTEtMA_bd48107b-7725-4bbf-8ff6-a3a3ac34387e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzMtMS0xLTEtMA_3907be1e-6820-4bfd-8ed6-2c98c42c4c9d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzMtMy0xLTEtMA_39b05365-3a63-4d02-a2bf-4d49cc0311a7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzQtMS0xLTEtMA_1305eec6-0253-4993-949e-53c5cfacd6fe"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzQtMy0xLTEtMA_65205512-450e-4e8b-93e8-72e47577c3ad"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzUtMS0xLTEtMA_f25e5c81-1c58-4b8c-9871-5f8c066baeea"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzUtMy0xLTEtMA_0eed2744-e616-45c6-9471-0273e76fbe29"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzYtMS0xLTEtMA_c53f7968-701b-4798-9744-f2b78cd43929"
      unitRef="usd">-136600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzYtMy0xLTEtMA_8e3d3631-9535-47b8-9874-87f5468489a8"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzctMS0xLTEtMA_4ab774fe-0d86-490d-abb2-2b231e0e5948"
      unitRef="usd">13543500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzctMy0xLTEtMA_5af5575e-3670-4929-bf81-fd65935731b4"
      unitRef="usd">13976300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzgtMS0xLTEtMA_88c77dda-bdb7-47d0-891f-c56016297948"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzgtMy0xLTEtMA_39182230-4707-4773-bba0-6276ef19cecd"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzktMS0xLTEtMA_930a781f-8fb6-4564-aa95-2e85c28380e5"
      unitRef="usd">10429900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfMzktMy0xLTEtMA_0213046e-906b-432f-8288-69bc91ac12c9"
      unitRef="usd">10700300000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDAtMS0xLTEtMA_bbf6258c-f2aa-4bcd-b06a-72eb3c167fda"
      unitRef="usd">451800000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDAtMy0xLTEtMA_b930e3b1-d3a6-4aef-8a5a-b372cd9115d4"
      unitRef="usd">-14200000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDEtMS0xLTEtMA_ad636bba-22f1-4306-9a0a-6b3448036114"
      unitRef="usd">10881700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDEtMy0xLTEtMA_62783c04-f9da-4197-9fb7-611e40abf1b0"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDItMS0xLTEtMA_788f4a2d-22a6-47b1-bd00-5a51b3e4231d"
      unitRef="usd">23806700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8yNS9mcmFnOmNmNGRmYTg5N2VkODRlMjJiZTZiMmQ1MTcxOGVkMzZmL3RhYmxlOjU5NWMyNjJkMmY2NjQwNmI5MTlkZGJjYTM3ODFmNjA2L3RhYmxlcmFuZ2U6NTk1YzI2MmQyZjY2NDA2YjkxOWRkYmNhMzc4MWY2MDZfNDItMy0xLTEtMA_11e92ed6-f2bf-4edb-9b14-bba28d49b859"
      unitRef="usd">24618900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMy0xLTEtMS0w_a3ad1479-eb18-4809-955f-9e81b065c1d9"
      unitRef="usd">1748100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMy0zLTEtMS0w_204e854a-4fe1-4f91-9a3c-d67a68689c1d"
      unitRef="usd">3702900000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNS0xLTEtMS0w_4e55de6b-c9a9-445e-96ae-cacda14aa352"
      unitRef="usd">353000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNS0zLTEtMS0w_9e0f4e63-757c-4520-89a4-45a95275c134"
      unitRef="usd">347500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNi0xLTEtMS0w_06bf3003-458f-4dba-953a-4d04ea3e7576"
      unitRef="usd">629300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNi0zLTEtMS0w_4602636a-272e-461f-8796-ee0d813058ce"
      unitRef="usd">19300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNy0xLTEtMS0w_5b36ae5e-268c-4632-8c85-85f2a71aed31"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNy0zLTEtMS0w_385fabee-9c30-43a1-b05b-be72989960d6"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfOC0xLTEtMS0w_5a2bb312-7aeb-4976-b14e-a7c54901a0c6"
      unitRef="usd">179800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfOC0zLTEtMS0w_5ee50723-6ce1-4e6e-8109-043f32f17a5e"
      unitRef="usd">149300000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTAtMS0xLTEtMA_95f0b773-5ac1-448f-a494-7aac4fe79f6b"
      unitRef="usd">49100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTAtMy0xLTEtMA_a91e34a1-3d86-46b9-87dd-2a4f4d17cd9e"
      unitRef="usd">23500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTEtMS0xLTEtMA_e18d25a1-71af-4733-9a5e-1f2f42f7e1e4"
      unitRef="usd">-750100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTEtMy0xLTEtMA_45f688e5-e811-4382-8ca5-03a4f6b38fcd"
      unitRef="usd">211900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTItMS0xLTEtMA_814c89b4-be53-424c-930b-3b209f566b6e"
      unitRef="usd">-710500000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTItMy0xLTEtMA_5a06248f-c008-4e8f-9d26-d9da73a5b9ba"
      unitRef="usd">-41800000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTMtMS0xLTEtMA_f2b1638e-142a-4286-90c0-e20d179a5ec3"
      unitRef="usd">17200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTMtMy0xLTEtMA_9b073224-e663-4e96-88f8-bedc9700995f"
      unitRef="usd">-14700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTQtMS0xLTEtMA_bd31c622-54ca-4d5f-8b0d-3563cfe84828"
      unitRef="usd">-201000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTQtMy0xLTEtMA_389aa8d1-5752-459a-8d10-6e85d30488cc"
      unitRef="usd">-110100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTYtMS0xLTEtMA_9cc70055-f7b4-4192-afc8-0f4b22742e63"
      unitRef="usd">-157800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTYtMy0xLTEtMA_c09d84bd-c353-4af3-9ad4-2b466f700264"
      unitRef="usd">135700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTctMS0xLTEtMA_9c46c4cc-141d-49fc-8059-649e28bc5e14"
      unitRef="usd">-13500000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTctMy0xLTEtMA_e0b3fea4-d2e9-442d-9217-93111ab3d194"
      unitRef="usd">-63000000.0</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTgtMS0xLTEtMA_7282158f-42ea-43d1-bd4d-0f6d32e372ed"
      unitRef="usd">322600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTgtMy0xLTEtMA_43e28d8f-1f09-4786-a9c7-3950798fd14d"
      unitRef="usd">270600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTktMS0xLTEtMA_b5f585d9-3b83-446a-8d98-693080458502"
      unitRef="usd">-243300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMTktMy0xLTEtMA_bfc3f694-2632-47ee-aa9c-38b939424ca0"
      unitRef="usd">372900000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjAtMS0xLTEtMA_d14de068-a498-4363-a52d-0dfd81611aa9"
      unitRef="usd">260500000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjAtMy0xLTEtMA_dfec9af2-32a7-4dbf-a8c3-ea583dba2d52"
      unitRef="usd">15300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjEtMS0xLTEtMA_79e2239e-86ab-4831-bab8-2d0a12264587"
      unitRef="usd">87600000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjEtMy0xLTEtMA_95939c4c-446d-459c-af55-792aa4dd6e64"
      unitRef="usd">97000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjItMS0xLTEtMA_3b7126a1-8382-45d7-95da-b885b0c6fd93"
      unitRef="usd">2801600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjItMy0xLTEtMA_b8a34d17-5fbd-4161-b7d4-5a8ae8f6e0c0"
      unitRef="usd">4596900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjQtMS0xLTEtMzE0NjE_088c364e-efd1-4663-bbd0-dc542ee4cd72"
      unitRef="usd">206500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjQtMy0xLTEtMzE0NjU_357466e0-ff82-4854-b857-a402bcba5666"
      unitRef="usd">338800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjQtMS0xLTEtMA_3dfb9350-914a-487d-8125-271d465973d7"
      unitRef="usd">2028100000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjQtMy0xLTEtMA_ebb2e748-00ff-4d55-9c13-8e171d912e06"
      unitRef="usd">5240700000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjUtMS0xLTEtMA_6226478d-2fec-48a7-b8f0-016126072439"
      unitRef="usd">2372600000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjUtMy0xLTEtMA_abb608c1-e07b-4934-b7ce-4c929490c49a"
      unitRef="usd">4649100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i5b9cfb542bbc414db0a805fe7b60fb21_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjYtMS0xLTEtMA_c4fdc77f-2269-4ae2-9839-72cc9c06ffd6"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i2438439cc2bd49c2a02917dc67d626e5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjYtMy0xLTEtMA_f32c1345-4eec-47d2-b03c-596c9ead7b87"
      unitRef="usd">141800000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ifdbdde9753524c0da660204088296886_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjctMS0xLTEtMA_3df98a4d-a2e0-4770-959c-35c6814feb0e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="id15b7f4db2c14ac8ab03363218c293d8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjctMy0xLTEtMA_76d8b1f9-4cc9-4bb0-9345-91f7348311bc"
      unitRef="usd">423700000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjgtMS0xLTEtMA_2574b784-9c17-4cd6-8733-2cd6ded1323b"
      unitRef="usd">28100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMjgtMy0xLTEtMA_6ddf5405-7a18-4feb-8a0b-2a8546bb9168"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzAtMS0xLTEtMA_09c4478b-e757-4210-bc54-b0ef9576bbde"
      unitRef="usd">18000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzAtMy0xLTEtMA_c52fb3f1-e435-4e3f-9ad9-6e80262b4093"
      unitRef="usd">75000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzEtMS0xLTEtMA_a223d236-3fe2-439d-a4c0-3c42362daa1f"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzEtMy0xLTEtMA_17c76f45-ae83-4547-b93b-761bcce2f32f"
      unitRef="usd">37000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzQtMS0xLTEtMA_a3e1482f-234f-498e-a7e5-13ee434feb0e"
      unitRef="usd">91200000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzQtMy0xLTEtMA_dfda492a-b23d-4023-9ee7-eb9855a64c0c"
      unitRef="usd">500000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzUtMS0xLTEtMA_ec969a5f-2c19-4408-96fd-f3aecb3f8abd"
      unitRef="usd">-600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzUtMy0xLTEtMA_4bc4ed71-5f1f-4d4d-a02b-ec0dea3dbd14"
      unitRef="usd">18000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzYtMS0xLTEtMA_e5f809c9-9414-4aaa-85aa-2c6f328f6fb8"
      unitRef="usd">-451000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzYtMy0xLTEtMA_9ad44288-6073-4409-b32c-d5d997fcc22c"
      unitRef="usd">-442200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzgtMS0xLTEtMA_84044153-e6ea-4080-8bf5-6bc5f37c0d5a"
      unitRef="usd">1800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzgtMy0xLTEtMA_4ee77fff-3045-43b6-9b39-8005e11b7612"
      unitRef="usd">6279100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzktMS0xLTEtMA_8b2b403f-664f-4d50-ba40-9a12eab40ced"
      unitRef="usd">8300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfMzktMy0xLTEtMA_b132b98d-2ff7-402c-b906-2ea078dc0a50"
      unitRef="usd">11800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfDebt
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDAtMS0xLTEtMA_21560bad-2845-4f0d-8e63-c56c990378f3"
      unitRef="usd">170000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDAtMy0xLTEtMA_8a9f14c0-6f4f-4f04-bb44-3935be8f6ed7"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDEtMS0xLTEtMA_cb70f086-6b48-472b-a0c5-1d06f2ca147e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDEtMy0xLTEtMA_6fd57d7a-d68e-4695-9747-fbef2d3a1d06"
      unitRef="usd">2967300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDItMS0xLTEtMA_73b72f2d-649e-4062-bbec-9ef395457db5"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDItMy0xLTEtMA_11b1ec2d-0ac6-493c-8c4c-52b1937453e3"
      unitRef="usd">1500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDMtMS0xLTEtMA_3ede83c6-daca-4d69-bd68-3a34e7086abe"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDMtMy0xLTEtMA_4ebe4964-ec39-47d4-85dd-6ec4357a7aac"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDQtMS0xLTEtMA_5277aa5c-bcaa-4f7a-b00e-b9f6e6f628d1"
      unitRef="usd">94800000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDQtMy0xLTEtMA_54d3d81c-7783-4e35-bbba-59ba6f9151b1"
      unitRef="usd">70900000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDUtMS0xLTEtMA_faeccc2a-e139-47ca-a00d-8645facecb3d"
      unitRef="usd">-22900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDUtMy0xLTEtMA_da7189e5-a240-49c3-adf6-001f0e3b93d5"
      unitRef="usd">22900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDYtMS0xLTEtMA_c8a1cfc6-0a7a-47ea-a76e-85c447197fec"
      unitRef="usd">-2096000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDYtMy0xLTEtMA_20195a5e-3992-4934-bf65-8e059e41cbf2"
      unitRef="usd">-4871600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDctMS0xLTEtMA_ac596de0-fd67-45c7-8463-63cb09e52607"
      unitRef="usd">254600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDctMy0xLTEtMA_cdb11698-3031-41e5-a656-d9abf9412691"
      unitRef="usd">-716900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDgtMS0xLTEtMA_cfd892ba-deea-4a67-8b30-8a6f134f5bf9"
      unitRef="usd">-44000000.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDgtMy0xLTEtMA_e63e36ce-b280-4ad1-bb51-b17add254957"
      unitRef="usd">28000000.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDktMS0xLTEtMA_96f59eda-c013-4b0c-beeb-082821707f82"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i378cd243ed9e40c2932d604d62dcff73_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNDktMy0xLTEtMA_ff2aad8e-d892-4dfe-bf9f-3af39b16deb4"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNTAtMS0xLTEtMA_621c1129-18c3-48d3-8294-4c0328c7875e"
      unitRef="usd">1541800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6dd54a75bdf44146a9c81439174f3e10_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zMS9mcmFnOjUwN2ZmZTFkYTczYjRmOWJhZGJkZDc1ZTMwZTIzMTQ4L3RhYmxlOmM0MTU5ZjNhYjUxNTRkODhhNzNlZmQ3ZjY4OGRkZTIzL3RhYmxlcmFuZ2U6YzQxNTlmM2FiNTE1NGQ4OGE3M2VmZDdmNjg4ZGRlMjNfNTAtMy0xLTEtMA_98757e6e-d30c-49a4-972f-278ab25aa319"
      unitRef="usd">2224800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7fd41961e6e04619a145d1ae0002b71b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xLTEtMS0w_edf97938-b073-4af7-9ef4-355da1e2f91b"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fd41961e6e04619a145d1ae0002b71b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0zLTEtMS0w_fe6b3f63-85bf-4677-905b-4f73a5ad844c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2504032f7755457db1beea26920a583a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi01LTEtMS0w_7af7845c-40aa-41e1-93ed-df6296175c17"
      unitRef="shares">172900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2504032f7755457db1beea26920a583a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi03LTEtMS0w_92444c74-4cce-4295-befd-e7a514231fdf"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5058265a969a4b00953e4a5f69286304_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xMS0xLTEtMA_4aa2850a-f30c-464d-ae5d-3d8fe6220909"
      unitRef="usd">-171800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76f00f49e5bf479dae0717aa402863ba_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xMy0xLTEtMA_fabc3a3b-8f02-428e-bcdf-d9d4d4922a5d"
      unitRef="usd">13900700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6ea0b81b62734c95b602b7181db99080_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xNS0xLTEtMA_d3ce5042-012d-4664-a505-4ffde8bb1f26"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ea0b81b62734c95b602b7181db99080_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xNy0xLTEtMA_efeb7b79-b417-4aa4-b568-1d8c6e6e8977"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c76067d2c0e4450b18d7428a607dec6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0xOS0xLTEtMA_143a50fd-269f-4cc4-899e-7450839d073d"
      unitRef="usd">10751900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1c29f466fd44e7fbf5526fc6d6a77b3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0yMS0xLTEtMA_a30bb6f7-40f9-4db9-82d6-7a12f1933aea"
      unitRef="usd">462900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMi0yMy0xLTEtMA_2c2fa57e-e6e7-41e4-8289-5dc6c2bba15a"
      unitRef="usd">11214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i3134099b795d4facb8cd5e5dc6129d07_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMy0xMy0xLTEtMA_e1a49832-8e71-4179-ae6a-b515a741bd29"
      unitRef="usd">329200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMy0xOS0xLTEtMA_79411797-a88e-4935-89c8-f04782e425ff"
      unitRef="usd">329200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idcc5c637588f4bc8b93afe094f041d88_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMy0yMS0xLTEtMA_15bbb298-42ff-4870-b554-f14f7c78421f"
      unitRef="usd">-11100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMy0yMy0xLTEtMA_1601f5ca-6b90-42a0-9cee-03b205817998"
      unitRef="usd">318100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9151bbf7e80c4955aa4b4abcce3d7ee5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNC0xMS0xLTEtMA_328c30dd-e979-4c23-97c3-c1cb973dd70f"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNC0xOS0xLTEtMA_2d1189ef-cb47-4033-9650-1337760194c7"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNC0yMy0xLTEtMA_ba0cc9a8-9510-409d-9fde-426173ae7e39"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNS0yMy0xLTEtMA_cb63539b-cd82-4511-b29f-ccf205e0b8b3"
      unitRef="usd">0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNi0yMy0xLTEtMA_184c5980-61af-4de6-8fef-425ce982406a"
      unitRef="usd">0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNy0xNS0xLTEtMA_cb8abf08-8130-4b72-b14f-b7ed5116978a"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNy0xNy0xLTEtMA_93b39c25-6cd1-4be8-b6c4-f940c7c67fdd"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0fcbd0aab3104a71a4ebbceb7c93d675_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNy0xOS0xLTEtMA_e9178f1e-4f27-41f1-91f5-5beb79834df4"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic85bc0b5a4e146cf9ca22eeb646ac2f5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfNy0yMy0xLTEtMA_4260e149-4a3e-43f9-990e-6bcab114fdb1"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i1c1f2813a84947359d5e759ac017f8f6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC01LTEtMS0w_21d85b68-5816-4be6-805e-d82f6fd2d2ea"
      unitRef="shares">2200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic71a7f514fe345aa81befd7e9f359804_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC05LTEtMS0w_b9969a21-d927-43c9-9e5d-b000b2c7796e"
      unitRef="usd">68600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="idbdfb0e2e84e4397a54b042efb9de0f0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC0xMy0xLTEtMA_2972b65c-f1cb-4c88-b104-d17a17a3db7c"
      unitRef="usd">681400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC0xNS0xLTEtMA_a0f91928-bac0-4723-8df0-8721db99b026"
      unitRef="shares">2200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i63a664a40bff4ae6af9c7aeb6e84cd80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC0xNy0xLTEtMA_16dee54c-530b-40f0-89ee-11391fc21add"
      unitRef="usd">-750000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic85bc0b5a4e146cf9ca22eeb646ac2f5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOC0yMy0xLTEtMA_ab707569-d442-40ba-addd-51b60f617ea3"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ib6fc83a08693474992b85d83b3ad03b7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOS05LTEtMS0w_df2489aa-8e05-466f-a5aa-8c0236adba49"
      unitRef="usd">11000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOS0xOS0xLTEtMA_47f26cc6-31b7-4581-884c-930bd4fc4940"
      unitRef="usd">11000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfOS0yMy0xLTEtMA_acdd1cc8-2142-458d-8e13-a5e32aaea445"
      unitRef="usd">11000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3134099b795d4facb8cd5e5dc6129d07_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTAtMTMtMS0xLTA_ee636c30-3ab4-4a42-b461-f1286af55f79"
      unitRef="usd">-5000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTAtMTktMS0xLTA_afcbb78d-687c-4dae-8110-180ec83b4ddb"
      unitRef="usd">-5000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTAtMjMtMS0xLTA_42cf3561-b62b-4820-a77d-fa3b5f787b52"
      unitRef="usd">-5000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6fc83a08693474992b85d83b3ad03b7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTEtOS0xLTEtMA_d58f5b02-9071-4ee9-99aa-bc898babe4e6"
      unitRef="usd">-57600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9818b57b84a4ba9b8fbb232a14a9a9d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTEtMTktMS0xLTA_b02f0d40-4029-4ffe-9a31-97d92cfd19c2"
      unitRef="usd">-57600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTEtMjMtMS0xLTA_dec8ca6e-570d-45b8-bd65-bc7aaf420949"
      unitRef="usd">-57600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTItMjMtMS0xLTA_3d35a0f4-a2b4-4f26-bb00-e8858ceeb3d1"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i27c617883bc449228e61f30f99e937e2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMS0xLTEtMA_e8756765-e21f-45c6-96de-2fb95276e337"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27c617883bc449228e61f30f99e937e2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMy0xLTEtMA_0a4c0160-9540-4dbc-933c-39487641ef72"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtNS0xLTEtMA_042b2f5c-4def-40aa-a800-88f4c4779278"
      unitRef="shares">170700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtNy0xLTEtMA_87d1f159-9f99-4c89-9c7a-3eaec667f043"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95f998449b3e429fb58bc7328de88319_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtOS0xLTEtMA_cd98dec6-3c44-4968-a8ba-fdc6b96fa98d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9035a5654857474b8da6be9ce64ca30c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTEtMS0xLTA_3dd06dd4-69fc-43ef-bd5d-8418981abe83"
      unitRef="usd">-136600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6724df5e760b4f7ea87e959a62b322b1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTMtMS0xLTA_870e2d14-b1c4-42a5-b2e1-44fdd55a79e0"
      unitRef="usd">13543500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1b4efc5c06194773aea1dd08796cbd25_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTUtMS0xLTA_ea2ab345-596e-4990-8a3e-1a83e4727839"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b4efc5c06194773aea1dd08796cbd25_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTctMS0xLTA_fb92d228-bd86-49af-801f-c696166eabbc"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35bb8cece69f42eb993bbe2ed7b30d9a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMTktMS0xLTA_7b48e2ae-f306-4cb5-a81c-246766c437e8"
      unitRef="usd">10429900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb94a68217db4665853c23a8d028b610_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMjEtMS0xLTA_251fa91b-b2bf-4de4-b878-2b67b2cba0a5"
      unitRef="usd">451800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjNjZTEyOThkMmMyYTQ3ZDBhNTAxZjUzN2U5MGFhODg4L3RhYmxlcmFuZ2U6M2NlMTI5OGQyYzJhNDdkMGE1MDFmNTM3ZTkwYWE4ODhfMTMtMjMtMS0xLTA_78a141fa-9e70-4c76-b69c-ab9789dea2ee"
      unitRef="usd">10881700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if3f7e3e5cead4308bd4010bcf303d6fb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xLTEtMS0w_4d298f76-ec4c-4348-8e5c-1af2fe5d618f"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3f7e3e5cead4308bd4010bcf303d6fb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0zLTEtMS0w_b2fa8efb-22fe-407e-9938-5ca31d7cea0e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia82889fd7f49428faa0d8b8a9fe4787c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi01LTEtMS0w_7bcadae4-aadd-4b37-b64e-8424427d2a71"
      unitRef="shares">176200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia82889fd7f49428faa0d8b8a9fe4787c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi03LTEtMS0w_e370ac44-c438-4a8c-92fe-0a3e199d087b"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i435fb50e71d246339ab717cb193e55b8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi05LTEtMS0w_cbbd27d6-4014-4608-a499-1002c2661563"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id008781cb78d456099bf8e65186045c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xMS0xLTEtMA_aaa8473f-1c66-4abc-af72-75b3c02beb4b"
      unitRef="usd">-299000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfaf0c65c04d483ba21b7c25f4adaecf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xMy0xLTEtMA_79ee1b52-2614-4877-b34d-6a5b3b4cc3dd"
      unitRef="usd">13976300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8fcb29f76ded42b1bdb5c06b5a612d27_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xNS0xLTEtMA_eafe8ac4-32e8-4a8b-a43f-21ef48790852"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fcb29f76ded42b1bdb5c06b5a612d27_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xNy0xLTEtMA_07dfe9a4-8345-403b-af46-6b0172c9380d"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f28a59afdff41658f03256c0a201a98_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0xOS0xLTEtMA_028f39cc-2027-4dc5-a7cd-f78b02625712"
      unitRef="usd">10700300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4891b33ee68b4d7abe803e2851cb7dbb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0yMS0xLTEtMA_a6bd10ed-fe3a-4610-b5ec-9fb6168a537e"
      unitRef="usd">-14200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMi0yMy0xLTEtMA_545f9c51-a50d-4002-9d40-04c2d3b0f466"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i9be762ec3a9f4b09864941280d00a916_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMy0xMy0xLTEtMA_9b85f0bd-8897-4e68-a629-160ae2a2c37e"
      unitRef="usd">1187900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMy0xOS0xLTEtMA_c15b0f08-f430-41ed-9f5e-39df55aa5605"
      unitRef="usd">1187900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMy0yMS0xLTEtMA_57ba2414-fdfb-4571-993e-3d0f3b5d587a"
      unitRef="usd">560200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMy0yMy0xLTEtMA_de15057e-bd65-4e55-a565-db3df7e7030b"
      unitRef="usd">1748100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifd71258dd6f04433b5f81b927d3b1104_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNC0xMS0xLTEtMA_00351b74-94cc-4a90-9cb2-9b16a494f86d"
      unitRef="usd">162400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNC0xOS0xLTEtMA_02452f4e-5bd6-4596-8162-170c9f7234db"
      unitRef="usd">162400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNC0yMS0xLTEtMA_6493cc6b-bb80-4edd-b295-48d6884c7a12"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNC0yMy0xLTEtMA_ba3a7060-f0eb-48b4-8819-81d1a6340499"
      unitRef="usd">163000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNS0yMS0xLTEtMA_9a0f4bca-107e-459d-b2d0-086bbf4bc360"
      unitRef="usd">5200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNS0yMy0xLTEtMA_db468786-297f-4fe6-a7f8-13cb322f5d4f"
      unitRef="usd">5200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="i444fd618100341f5beaeefa69b9e3597_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNi0yMS0xLTEtMA_c0ba6dfb-8a19-4401-ba72-274a88a1d58f"
      unitRef="usd">-100000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNi0yMy0xLTEtMA_8f2b9c67-e0c2-4003-aa0b-efdc00b477ac"
      unitRef="usd">-100000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNy0xNS0xLTEtMA_248928d1-2c5a-4226-aa2c-fd5696d0dab2"
      unitRef="shares">6000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNy0xNy0xLTEtMA_a463e758-ea3e-47ad-be2b-2e2e192f7fb5"
      unitRef="usd">1800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifc180996f76c4531ba0c767a0cd57adc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNy0xOS0xLTEtMA_09c86f3b-e62e-493b-b143-c964df6bc9d1"
      unitRef="usd">1800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i06a7ad3e5c3a4b8d9bedc1dcb4f9f208_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfNy0yMy0xLTEtMA_77a43bb8-13f8-46b1-b206-31efccd3ede0"
      unitRef="usd">1800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i58fb5362e7a744d9a5acd4825e9a5104_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC01LTEtMS0w_979a065a-8aa0-4b89-8767-d2f6ff1370b7"
      unitRef="shares">6000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i67d9c800cfcc42f5a8dd99abd463e2be_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC05LTEtMS0w_778a3272-2301-48c2-8e38-7bdb2dbb4835"
      unitRef="usd">231900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i782d9d918ca94e65a4169da4cd3a12f6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC0xMy0xLTEtMA_3c3bacde-140a-4695-a96b-090592bf9cdc"
      unitRef="usd">1568100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC0xNS0xLTEtMA_c44f494a-36cd-427c-b29d-82275b0ee8e7"
      unitRef="shares">6000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i37ced59fc3844648a5071b97d89a0152_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC0xNy0xLTEtMA_57f5ebfb-baa3-48e2-b7ce-576fdac9bb56"
      unitRef="usd">-1800000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i06a7ad3e5c3a4b8d9bedc1dcb4f9f208_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOC0yMy0xLTEtMA_cc40b2d8-25c9-4227-883c-5cc17b72be51"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i0b408fb3fdc34b0396023e455c198a69_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOS01LTEtMS0w_110d4d50-815c-486e-9e99-4ddeacde011b"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ie4c7f17033684d18aefb36c4a3d6c13f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOS05LTEtMS0w_95819e6b-628b-4eb1-96ba-437f2c44d2ac"
      unitRef="usd">44300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOS0xOS0xLTEtMA_9a780386-611a-4cc6-8d98-05bced8b9c08"
      unitRef="usd">44300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfOS0yMy0xLTEtMA_5b7d0466-bdc7-481b-9909-6e309706079f"
      unitRef="usd">44300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0b408fb3fdc34b0396023e455c198a69_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTAtNS0xLTEtMA_3cd8862d-c8da-48c1-9c7a-72f1b71f29a5"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9be762ec3a9f4b09864941280d00a916_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTAtMTMtMS0xLTA_76e335f7-9a5f-498a-94d6-b98d48951927"
      unitRef="usd">-52600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTAtMTktMS0xLTA_8ea19015-9bbf-4a37-a724-86caa50c8477"
      unitRef="usd">-52600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTAtMjMtMS0xLTA_d0b93225-4c9a-4fb3-86f2-d37c2d0513c2"
      unitRef="usd">-52600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie4c7f17033684d18aefb36c4a3d6c13f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTEtOS0xLTEtMA_4377e6ea-2528-4323-a4f3-8735e80ff84c"
      unitRef="usd">-186100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTEtMTktMS0xLTA_c3b99734-dc87-476f-97bc-6005b3295172"
      unitRef="usd">-186100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTEtMjMtMS0xLTA_faef131f-b8a9-4f1e-8da7-c8aa6f6d8120"
      unitRef="usd">-186100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="ie4c7f17033684d18aefb36c4a3d6c13f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTItOS0xLTEtMA_4ee7d1c8-6f51-4f6d-8266-a1d47f54b824"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia7f2df214811434aac53961e0cdc6523_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTItMTktMS0xLTA_601086f9-cd62-4868-ac5a-afc5d9e3aca9"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTItMjMtMS0xLTA_a5a63282-ebf6-48ac-b72a-7a56dcfc94dd"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i27c617883bc449228e61f30f99e937e2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMS0xLTEtMA_5c3c26e8-916a-4452-a1cf-2f7053cd3b16"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27c617883bc449228e61f30f99e937e2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMy0xLTEtMA_31b95ebe-5fed-4488-a8e9-ab44fbe4aa07"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtNS0xLTEtMA_dad579f4-4e92-41d3-90ff-4715519f8484"
      unitRef="shares">170700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic64b5099c5b64ce1a31486e1e7a6ce9e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtNy0xLTEtMA_a4da241f-89c2-4f59-851f-2af58fa6ddc7"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95f998449b3e429fb58bc7328de88319_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtOS0xLTEtMA_07ec5b12-4e6e-4d3b-bd6b-c9eb739a9c86"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9035a5654857474b8da6be9ce64ca30c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTEtMS0xLTA_64b76966-4ff8-4c71-8cbd-822298a289fe"
      unitRef="usd">-136600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6724df5e760b4f7ea87e959a62b322b1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTMtMS0xLTA_d0997420-d52f-46f2-8972-b0a104c982be"
      unitRef="usd">13543500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1b4efc5c06194773aea1dd08796cbd25_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTUtMS0xLTA_fc776d01-907e-4b39-944d-c04d6eb78fca"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b4efc5c06194773aea1dd08796cbd25_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTctMS0xLTA_9397affb-3be1-4f48-85c8-c2b5e1374d8e"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35bb8cece69f42eb993bbe2ed7b30d9a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMTktMS0xLTA_274e08a6-6399-4d24-a335-16bb5854c5d2"
      unitRef="usd">10429900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb94a68217db4665853c23a8d028b610_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMjEtMS0xLTA_002d7a4f-f2bf-43de-a33f-d1fa78f852db"
      unitRef="usd">451800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmQ1YTdmZjIzNDBhOTRmNDY4MDFmZmRkMTk4ZWUyODNiL3RhYmxlcmFuZ2U6ZDVhN2ZmMjM0MGE5NGY0NjgwMWZmZGQxOThlZTI4M2JfMTMtMjMtMS0xLTA_bc558146-02af-4e54-951f-9814ec372e92"
      unitRef="usd">10881700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i55e81dc8b9c744b3b947fb4da4f5918f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xLTEtMS0w_5233e584-c21b-429f-bff4-79ac3a2e5076"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i55e81dc8b9c744b3b947fb4da4f5918f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0zLTEtMS0w_d2ce54ba-c94a-46b5-b802-a299ea48b081"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b36a2284f3b473798aab3ac6e245627_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi01LTEtMS0w_0d851f15-3000-4b33-896c-b87119d8e1cb"
      unitRef="shares">182100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b36a2284f3b473798aab3ac6e245627_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi03LTEtMS0w_9adcb463-4e36-4706-a5e4-9a3daff4f2b5"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffe878f771a841b3a6c7f704897f75ee_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi05LTEtMS0w_55b3767b-a5c7-4c83-b909-b99c480b9d66"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98aa79e9ae8d45b880df1e5404273f17_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xMS0xLTEtMA_381ca757-ed32-4e76-8da8-bfc842ddb967"
      unitRef="usd">-181000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19ddcef7d3e24fdcb32788e2157a6ff6_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xMy0xLTEtMA_80f1f215-87e8-4166-9925-ee120fe75f8b"
      unitRef="usd">14466700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2cb06b37c185452292925fd0417673c9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xNS0xLTEtMA_71e70ed2-d4fe-4370-9785-57ddb42e7cce"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2cb06b37c185452292925fd0417673c9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xNy0xLTEtMA_9f255346-18ed-4801-9799-8df23f0a83aa"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d7ff60d15254b42afe32f65710162c7_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0xOS0xLTEtMA_cde3c304-b062-4f04-b871-fa7ac1df210b"
      unitRef="usd">11308700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7028acddd6fe42b6965135b35f8ff2f6_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0yMS0xLTEtMA_3c3b0427-7e8b-41f9-821a-8171a964d939"
      unitRef="usd">-19500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13ff900cbf7e400ab0e7e04c7df214d5_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMi0yMy0xLTEtMA_01660047-a34f-4688-8ee2-fbd08b7f701a"
      unitRef="usd">11289200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="iae6b13e615cb43759f9fdc6492935587_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMy0xMy0xLTEtMA_845d251f-844b-4f34-abc8-1bbf748607f2"
      unitRef="usd">701500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMy0xOS0xLTEtMA_1cdb2331-051c-4a7b-ae69-80999fdb96a4"
      unitRef="usd">701500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4aa45623b9a24e4881896a979258ce6e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMy0yMS0xLTEtMA_13cc4cd6-bf00-4871-a2d4-67da849f058e"
      unitRef="usd">2400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMy0yMy0xLTEtMA_63c8ea08-7432-4ef3-8752-26ab5530e750"
      unitRef="usd">703900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3c04a426b78946e7b3b65f4903d01c57_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNC0xMS0xLTEtMA_3e9049b7-5195-4c87-9e52-fafacc36461f"
      unitRef="usd">-44500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNC0xOS0xLTEtMA_a3309516-2a3f-4f1f-948f-e9932c8a7c6e"
      unitRef="usd">-44500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4aa45623b9a24e4881896a979258ce6e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNC0yMS0xLTEtMA_08053ae7-6e40-4dbe-9ec8-3a96ccf0aa81"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNC0yMy0xLTEtMA_cfa41392-c81c-4321-a89a-076c2a958598"
      unitRef="usd">-45400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i4aa45623b9a24e4881896a979258ce6e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNS0yMS0xLTEtMA_f90c0358-e2d4-4a39-b1bb-ec82316d6954"
      unitRef="usd">4000000.0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNS0yMy0xLTEtMA_ef6bc9f8-e2cc-472f-bcce-6f9acee62607"
      unitRef="usd">4000000.0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfNi0yMy0xLTEtMA_5b3d6eb7-a226-4876-9949-c05a30022e9c"
      unitRef="usd">0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfOS0xNS0xLTEtMA_ed403456-b0ac-4793-9975-1d43dbaddb1b"
      unitRef="shares">4500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfOS0xNy0xLTEtMA_4e9845c6-9c9d-4170-b9a4-c73e0e99fee1"
      unitRef="usd">1250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1f841eba5163473e9f41740f7bde1720_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfOS0xOS0xLTEtMA_db79dafd-5607-4595-a51c-7c76fbe5674f"
      unitRef="usd">1250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if307471114bc439a91ad32639f89c9f8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfOS0yMy0xLTEtMA_eddae68b-c39d-41ce-984e-c1fa110708db"
      unitRef="usd">1250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i751ac7dc5ebd4605b6778c1a2449f919_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtNS0xLTEtMA_00a96d54-8bc0-4a17-ac0c-4350268f59bd"
      unitRef="shares">4500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ie428e1222ddf45bf8896a772e454dfa3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtOS0xLTEtMA_3c636f32-8f3e-40d3-ad36-a7b7de4c86ef"
      unitRef="usd">45100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ie6422fd73db7423eb9f8020ab03bd577_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtMTMtMS0xLTA_008b3187-0273-44c4-8477-40c091ba8005"
      unitRef="usd">1204900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtMTUtMS0xLTA_c6e13fcd-c698-42cd-8bf9-d5eee0c0c48c"
      unitRef="shares">4500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i01fe8128fba147e99646ac91dff39e9e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtMTctMS0xLTA_bb0d301b-1e9e-45c3-b1d4-82cb63474367"
      unitRef="usd">-1250000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if307471114bc439a91ad32639f89c9f8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTAtMjMtMS0xLTA_bb62fe7f-2cdd-426c-9f0b-ccb85424170d"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="ib45574fe33ee4aae9246e107a7a53587_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTEtNS0xLTEtMA_5c48e9b8-3b38-48a4-aac3-23739cc70f96"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i4928957245d3432999a97b44b5267981_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTEtOS0xLTEtMA_9d51a53e-4fed-43e0-b43e-49a4213c6b2c"
      unitRef="usd">9700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTEtMTktMS0xLTA_58d216ce-e120-4923-8c4d-b61c68a0f54d"
      unitRef="usd">9700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTEtMjMtMS0xLTA_37942a88-ec6e-471a-8584-587af99ab507"
      unitRef="usd">9700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iae6b13e615cb43759f9fdc6492935587_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTItMTMtMS0xLTA_b49f077d-e610-4f51-80a1-62d80ba82f1a"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTItMTktMS0xLTA_fc021d37-9932-4bca-a6a5-05dbc3e68d6b"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTItMjMtMS0xLTA_0705b297-63be-4354-af24-cc3e7eb964b0"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4928957245d3432999a97b44b5267981_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTMtOS0xLTEtMA_cb0de498-4279-4fe4-aed2-954d3c14b033"
      unitRef="usd">-35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac4ba9e1cab44a989b117a26b04a5c4b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTMtMTktMS0xLTA_be4e6cec-2191-4fde-8eb5-11d10cab7a73"
      unitRef="usd">-35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTMtMjMtMS0xLTA_8e328090-410c-4f77-a92f-1b595e01dddd"
      unitRef="usd">-35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i72c55152400e4e4b94a99a817965d09a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMS0xLTEtMA_754ee483-dddf-403e-add9-6a47a4d7c6d3"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72c55152400e4e4b94a99a817965d09a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMy0xLTEtMA_2432cd84-f43b-4af1-a6e2-630f58cbefd7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9feca16144f34b3ea3e89a6754731228_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtNS0xLTEtMA_8c228683-15ce-4d24-aaa6-ffd6e37d3e83"
      unitRef="shares">177700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9feca16144f34b3ea3e89a6754731228_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtNy0xLTEtMA_7e0a220f-b26d-4cd8-b9c3-f698dbeb6059"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4a8b077b45d46d1a2ba18c46f68e9b5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtOS0xLTEtMA_f69d7e8b-adcb-4952-829f-40753c8fee24"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f1490d7028c484bb7b887d3edf0bcef_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTEtMS0xLTA_5616365d-88da-4dcb-9533-860265595618"
      unitRef="usd">-225500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5244c955b7f04faa811cb546d3b19da1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTMtMS0xLTA_46a65e14-0bd6-4fce-b86d-a44c737f7096"
      unitRef="usd">13961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i256c872a0ec64e8588e40eae87e54228_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTUtMS0xLTA_9a37e21b-d4b5-4842-94b8-19bbc021a720"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i256c872a0ec64e8588e40eae87e54228_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTctMS0xLTA_ea1e9630-15b7-4a6b-af48-4787399c7d7e"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27afa92fb58444e9a9f1ab64284947bf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMTktMS0xLTA_b07ffe3d-aafb-4e61-9a8f-34daeeb92795"
      unitRef="usd">10758500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e79a463f4584fb2aee6e8cdc33e7007_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMjEtMS0xLTA_75e62d14-a406-4ace-a96c-2530f72ec352"
      unitRef="usd">-14000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6dd54a75bdf44146a9c81439174f3e10_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOmE2NTVmNjc4NDQ0NDQ2OTY5MjBiODk2NTFhMGRmMDJhL3RhYmxlcmFuZ2U6YTY1NWY2Nzg0NDQ0NDY5NjkyMGI4OTY1MWEwZGYwMmFfMTUtMjMtMS0xLTA_d0677851-9a23-4041-864e-aa2daaf63027"
      unitRef="usd">10744500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4e7708356fae41b9a13302bb04211203_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xLTEtMS0w_5ba895b3-c00d-4e0c-b2aa-d021e970c2e3"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e7708356fae41b9a13302bb04211203_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0zLTEtMS0w_afe3f651-9b01-434f-8faf-7341b78ac5f5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i70705f35adb5455faecf1b3d1d84198a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi01LTEtMS0w_799cd6bd-bdfb-428a-b64c-b1dff03be5f3"
      unitRef="shares">198000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70705f35adb5455faecf1b3d1d84198a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi03LTEtMS0w_4c17658d-c148-4cc8-89c6-320a921c60bd"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e7b1968e93347ae998112702bfaf368_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi05LTEtMS0w_2774ca1c-e883-4a53-99ff-37c183d2b618"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc9ba742bf504e22bd14593ecb2ffb74_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xMS0xLTEtMA_93244b4d-f795-47bb-9682-716262277451"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a7e856aca6b47abb4f2a597838710d7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xMy0xLTEtMA_009df290-1993-4fb2-8adf-7d76fbacc761"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ide5fdd4520c74830933b03379f613edf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xNS0xLTEtMA_6d3c2bdb-0e37-41ea-bfd2-aaf773495074"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide5fdd4520c74830933b03379f613edf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xNy0xLTEtMA_c98b6e3f-5cca-45c3-88bc-b657500b024b"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i607b477716754fa49b426a79cce7cfc3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0xOS0xLTEtMA_0069990e-a2e3-4f0e-b076-721a20e7802d"
      unitRef="usd">13343200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e94a3f2f5aa4b088b330695096badd8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0yMS0xLTEtMA_d855c5b5-31ee-4fab-a445-860efa2c1c6d"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i378cd243ed9e40c2932d604d62dcff73_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMi0yMy0xLTEtMA_eb1baeb9-de6c-4f53-89f2-49ca4dfe9bd2"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i327682b6937246d39b49fa2fe086a9ee_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMy0xMy0xLTEtMA_a40f9b78-6e59-4f5c-871a-e16d259b8612"
      unitRef="usd">3642700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMy0xOS0xLTEtMA_9471f786-5f34-4e69-a095-a1b441e2c867"
      unitRef="usd">3642700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i70699e64e56642c78269f5581e49fa63_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMy0yMS0xLTEtMA_d106b1b1-1c32-4cd2-a7c2-a0b66f6038c2"
      unitRef="usd">60200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMy0yMy0xLTEtMA_4e3bcfe9-6ee8-434e-b2d9-3787cb39f914"
      unitRef="usd">3702900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9cb259e3e655451594ddea75cacc3031_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNC0xMS0xLTEtMA_e5c51060-2873-4e4f-ab67-1e3d38cc6444"
      unitRef="usd">-90300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNC0xOS0xLTEtMA_91f81b3b-2020-41b8-8b5e-1743080acf95"
      unitRef="usd">-90300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i70699e64e56642c78269f5581e49fa63_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNC0yMS0xLTEtMA_bf0c7611-b5ec-48fe-aeea-f8143a30f2fd"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNC0yMy0xLTEtMA_0f16b2ed-bb38-4bb7-ac6d-62d3f3d1f58e"
      unitRef="usd">-89400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i70699e64e56642c78269f5581e49fa63_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNS0yMS0xLTEtMA_3ba9d416-3940-4777-9b20-55f49a482518"
      unitRef="usd">4000000.0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNS0yMy0xLTEtMA_46ec125b-4e9d-4325-859d-1d6fa5cd7608"
      unitRef="usd">4000000.0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="i70699e64e56642c78269f5581e49fa63_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNi0yMS0xLTEtMA_181d5a07-d588-4e00-af86-22f4fe0518eb"
      unitRef="usd">-75000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNi0yMy0xLTEtMA_82be17c0-4fd7-40c0-a855-ecba4616c1a4"
      unitRef="usd">-75000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibded2627ed6f476488944808f5be525e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNy0xNS0xLTEtMA_48715fda-ea3f-4690-b9e0-b656a8c8dddd"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibded2627ed6f476488944808f5be525e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNy0xNy0xLTEtMA_c35c7844-c13b-4734-b126-7654cb86f781"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i94ed39bd20ce49eb845fbd4b5a6e399f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNy0xOS0xLTEtMA_d81eaff3-4973-4c47-8a2d-e72b10f3e9f5"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iddfc2c0b58ff4cc1b94d1cdf49392372_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfNy0yMy0xLTEtMA_9a5672d6-6dfc-48aa-b3d4-95d767ad71a3"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="id860c4b0dd10477c99ccee1b9a0e61f6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC01LTEtMS0w_09c86d67-e3f5-4889-be01-5f25e3f3c8b7"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="icc3b6f7ebf2148fb8095a10e72b1c4b3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC05LTEtMS0w_4d4de963-ba08-4bfb-ae14-27da27f3935d"
      unitRef="usd">71000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i8a4c5ca8b3b448168efbbcea6f070598_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC0xMy0xLTEtMA_0acefa98-e189-4112-8578-f1db2bd193b9"
      unitRef="usd">1208100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ibded2627ed6f476488944808f5be525e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC0xNS0xLTEtMA_293a82e0-53aa-47f5-a9ce-29a983471128"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibded2627ed6f476488944808f5be525e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOC0xNy0xLTEtMA_7dd4081a-e8b6-44e6-b6e2-15d940ee96f2"
      unitRef="usd">-1279100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOS0xNS0xLTEtMA_35347c13-6085-48a2-b4e9-fda66c4ff6cd"
      unitRef="shares">16700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOS0xNy0xLTEtMA_ae1ea1aa-a9b4-4639-8aab-ff2c7c702647"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i03a9211cf5d342868594c98f4cc8953d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOS0xOS0xLTEtMA_790ff456-6d1c-4a1d-92b2-a61046e041a7"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i820c4f6fd7d141ae849266e77bd5174d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfOS0yMy0xLTEtMA_1c99c8ae-8911-446d-bfe8-51aa5be1744a"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i708a8258e90c451fae809ded20edc887_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtNS0xLTEtMA_39423c5e-3909-4428-8cec-3564e6ab7601"
      unitRef="shares">16700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ifc98aa5d5bb3491b844c904832b5e17a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtOS0xLTEtMA_b412fa07-a203-44f0-a670-bf4231db3245"
      unitRef="usd">121300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i1022bbcfbc3d402986b98be3c4a7bdd9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtMTMtMS0xLTA_af257baf-418f-471c-a3c8-92df88daa20b"
      unitRef="usd">4878700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtMTUtMS0xLTA_44da9d90-c38d-4e54-8e14-0824d2f6f052"
      unitRef="shares">16700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i93a6f21462324b359b031e9facdc3a82_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtMTctMS0xLTA_b009adc1-8692-42af-ab98-1ae11c39c06b"
      unitRef="usd">-5000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i820c4f6fd7d141ae849266e77bd5174d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTAtMjMtMS0xLTA_c17e3ab1-71e2-4d20-9ef4-9055ed15ed9f"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i73e21f10ab3f4997b59d6e47015ee1e6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTEtNS0xLTEtMA_5ec4ef49-42a2-49ca-b7fb-8f911af50be2"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTEtOS0xLTEtMA_cc6c94d4-715d-48b6-bcd9-ea87b1a37aba"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTEtMTktMS0xLTA_c308072b-8858-470e-a2fc-0d73399cf3d0"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTEtMjMtMS0xLTA_d9428239-c1c7-4016-a069-8c992a57a79e"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i73e21f10ab3f4997b59d6e47015ee1e6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItNS0xLTEtMA_bfbfbefc-a613-4d23-9a38-5c43ff5ab86c"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItOS0xLTEtMA_f88938b8-83c5-44ed-b802-6a624f97c4ce"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i327682b6937246d39b49fa2fe086a9ee_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItMTMtMS0xLTA_90b19b03-e079-4444-b0bc-343d16f2c3b2"
      unitRef="usd">-50300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItMTktMS0xLTA_f1dec7a1-fc73-4b2a-adc0-2a0bc07bc2c8"
      unitRef="usd">-50300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTItMjMtMS0xLTA_baa4b516-400c-44ba-9858-3559f1362ce7"
      unitRef="usd">-50300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTMtOS0xLTEtMA_9fcb6278-ebd9-4b6c-897b-6ce33b418ec4"
      unitRef="usd">-154200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTMtMTktMS0xLTA_312a8ae5-ad38-4771-9c9f-d5799c384e8d"
      unitRef="usd">-154200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTMtMjMtMS0xLTA_013f3888-2f6a-48da-b6b5-053c5acec12c"
      unitRef="usd">-154200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i7b1461b496cd4d0283971e26abfa68eb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTQtOS0xLTEtMA_40c83aa9-759c-45bb-bd10-7f8251d75afc"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if699e259873a4362befe72d106cb46a3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTQtMTktMS0xLTA_c6b24aae-975a-4f3a-89c7-18f0ed7638b4"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTQtMjMtMS0xLTA_7beaa488-ddf7-43f5-892b-50bc715e0239"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i72c55152400e4e4b94a99a817965d09a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMS0xLTEtMA_47c198f2-d999-4eda-a599-b93072a7e790"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72c55152400e4e4b94a99a817965d09a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMy0xLTEtMA_7ce4b7a9-b811-4a6e-87ae-34ddad922dc8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9feca16144f34b3ea3e89a6754731228_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtNS0xLTEtMA_1cecab68-c930-4202-ac27-138fb197116b"
      unitRef="shares">177700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9feca16144f34b3ea3e89a6754731228_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtNy0xLTEtMA_47de0963-a2c5-4d9f-bf3d-28d60c424b94"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4a8b077b45d46d1a2ba18c46f68e9b5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtOS0xLTEtMA_e2100cdc-05c7-453e-86c0-d8e55582dd0f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f1490d7028c484bb7b887d3edf0bcef_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTEtMS0xLTA_a69d07f7-8288-46c7-b4e4-a398f5d4ea42"
      unitRef="usd">-225500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5244c955b7f04faa811cb546d3b19da1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTMtMS0xLTA_6e464619-80b5-420d-b1fc-f547446001f8"
      unitRef="usd">13961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i256c872a0ec64e8588e40eae87e54228_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTUtMS0xLTA_cacce0b9-02dd-4405-896d-cc1d6501fc22"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i256c872a0ec64e8588e40eae87e54228_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTctMS0xLTA_66d48492-b1f6-4aa8-8beb-b5ac813d0c0e"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27afa92fb58444e9a9f1ab64284947bf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMTktMS0xLTA_068d4f72-6e1f-4aa7-84e0-7df4cafa4c3c"
      unitRef="usd">10758500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e79a463f4584fb2aee6e8cdc33e7007_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMjEtMS0xLTA_6f19fdd2-b15e-4e2a-863b-ebda752bb24b"
      unitRef="usd">-14000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6dd54a75bdf44146a9c81439174f3e10_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8zNC9mcmFnOmRmZTNlZjc5M2ZjMTQ4OGZhYzFmMzA2YzlkZGVmNWQ2L3RhYmxlOjkxNTliN2I1MzUzYzRlZDJiNWYzNjM0M2I0ZmEwNGQ5L3RhYmxlcmFuZ2U6OTE1OWI3YjUzNTNjNGVkMmI1ZjM2MzQzYjRmYTA0ZDlfMTUtMjMtMS0xLTA_ca9fac26-2b2d-41bd-bdcd-7fb2aff7e350"
      unitRef="usd">10744500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA1OQ_4440c393-d759-4ecf-9243-7e0281eb03d3">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:9pt"&gt;&lt;span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 the FASB issued Accounting Standards Update No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA4NA_25cda64f-aea3-45fb-a6f0-c5446b309a72">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA5Mg_7eb8f49f-d8cb-4c91-a85d-8d8fa932b594">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfNDA0Ng_cb05ad96-72d7-41ed-bb49-d7b18e8bfd1e"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA5Ng_a89ecc4a-11b6-4b3e-9d98-38a53a7bd8e6">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfNDU1Ng_7666bc4a-892f-423c-aa54-0a9c8139f2a4"
      unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA1Mg_d410ef8c-14b1-41c1-9351-097c95b9022d">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80MC9mcmFnOmI1YWYyMTUwMzgyYTQwZmY5NDQzODI4NGFlM2E2YjQyL3RleHRyZWdpb246YjVhZjIxNTAzODJhNDBmZjk0NDM4Mjg0YWUzYTZiNDJfODA3MA_ce000d24-799b-4c8b-a63d-3bc8c89fc0b9">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:9pt"&gt;&lt;span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 the FASB issued Accounting Standards Update No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80My9mcmFnOmY5NTgxMTk0YmQ0YzQxNTdiY2RlNGFjMWNjNzk5ZTI1L3RleHRyZWdpb246Zjk1ODExOTRiZDRjNDE1N2JjZGU0YWMxY2M3OTllMjVfOTM4_d8609602-7c1e-414d-8bd4-411b9a71ece5">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIIB118 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;amp;D) in our &lt;/span&gt;&lt;/div&gt;condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0 million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i459ef874f9bb4653ad831f334286be02_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80My9mcmFnOmY5NTgxMTk0YmQ0YzQxNTdiY2RlNGFjMWNjNzk5ZTI1L3RleHRyZWdpb246Zjk1ODExOTRiZDRjNDE1N2JjZGU0YWMxY2M3OTllMjVfNTIz_08f7be57-a16d-46a9-a2fa-d2df6add0629"
      unitRef="usd">75000000</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i459ef874f9bb4653ad831f334286be02_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl80My9mcmFnOmY5NTgxMTk0YmQ0YzQxNTdiY2RlNGFjMWNjNzk5ZTI1L3RleHRyZWdpb246Zjk1ODExOTRiZDRjNDE1N2JjZGU0YWMxY2M3OTllMjVfNzky_9a1ed2e7-a3f7-4042-9913-614b5896f46a"
      unitRef="usd">635000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA0Ng_5cca0ed5-82d1-4394-a8a0-f1fe7e6d0921">&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;619.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;684.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;967.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;327.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;516.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;833.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,556.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;669.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,984.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM***&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,205.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,498.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,690.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;***&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;805.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,750.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,258.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,188.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;696.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,550.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;644.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,470.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,157.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,568.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,174.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,054.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,229.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,464.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;628.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,554.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM***&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,850.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,653.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,803.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,587.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;***&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 26.9% and 10.8% of gross product revenue for the three months ended September 30, 2021, and 29.1% and 10.0% of gross product revenue for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 31.2% and 15.6% of gross product revenue for the three months ended September 30, 2020, and 30.9% and 16.0% of gross product revenue for the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,255.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(422.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,598.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,021.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(878.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;946.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;873.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,558.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from collaborative and other relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;642.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA0MA_701ba6f7-130f-4f47-b0aa-6b551b2658cb">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;619.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;684.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;967.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;327.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;516.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;833.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,556.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;669.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,984.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM***&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,205.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,498.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,690.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;***&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;805.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,750.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,258.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,188.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;696.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,550.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;644.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,470.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,157.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,568.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,174.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,054.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,229.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,464.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;628.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,554.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM***&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,850.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,653.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,803.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,587.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;***&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="ic401292eb9c341d5a7a48926df3393fc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC0yLTEtMS0w_6488530d-fa8b-4f73-bc40-13431f846482"
      unitRef="usd">299900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76acd6989c7c4783b9802597d4de0c06_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC00LTEtMS0w_2a298d0a-04c3-438d-b39a-3eeacfe0e516"
      unitRef="usd">319600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23640bd50272420a8b057701d4f91e71_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC02LTEtMS0w_057b11e0-84ec-49c2-aedb-041812fe644a"
      unitRef="usd">619500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd886b210f074d43acf27a1993bc9ccf_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC04LTEtMS0w_26709de6-c930-4f65-ba73-e4fea650f1f3"
      unitRef="usd">684200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if48a1d2ec8b247058bcdad6c8fbc6524_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC0xMC0xLTEtMA_12672c6e-a5fd-4a9a-8b48-fb60c251e87c"
      unitRef="usd">283300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia21b2da1eba940d2b84efc2f236e2b03_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNC0xMi0xLTEtMA_491e47a8-ba90-4c3a-9f99-8afbcd1bed19"
      unitRef="usd">967500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i10bf3e3f7595414482ea7c8e4d6e9daa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS0yLTEtMS0w_9a38ab73-b9d3-4542-a6de-c6bae50d2839"
      unitRef="usd">252400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f65789ed29a4729929922d2a49c2ec3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS00LTEtMS0w_5237b65b-651f-4320-b425-aa03a9d71993"
      unitRef="usd">135100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36476b37490e44bb9a8cd6098004a18e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS02LTEtMS0w_35d67fc7-d0cb-4fd9-b266-634c2f0b1f93"
      unitRef="usd">387500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a94855763b44929978fdfdb0d8035d7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS04LTEtMS0w_fd5e74f6-633f-42d0-9bd6-80fdce021be4"
      unitRef="usd">327300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a216b36a235433c9df3617fbc22b9a7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS0xMC0xLTEtMA_18bfb484-4817-49ae-a77a-6049bdba3648"
      unitRef="usd">146800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bfa480df7914627bc60143003413b0a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNS0xMi0xLTEtMA_8e72752b-4cc3-4978-9b03-92000366f832"
      unitRef="usd">474100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7517010697de4c77b9e59ece300efd26_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi0yLTEtMS0w_5e173314-8c35-4f41-86cc-facbfb5b1bc7"
      unitRef="usd">281100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5a4376778b04d80abf3b1d76aac940f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi00LTEtMS0w_daf4c52f-8eec-4552-81fa-78f946cf2fd0"
      unitRef="usd">241700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0542ec377c8a46ae89671dcde4b12555_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi02LTEtMS0w_5828ab96-e9d4-47a2-8fd9-06bea3ed7331"
      unitRef="usd">522800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09cfdb27d6654e3eaea1f9fd048da603_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi04LTEtMS0w_77f68823-41ec-4e58-a0e3-73decc382c54"
      unitRef="usd">304200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87aa8be7620b41a68374745f1299b587_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi0xMC0xLTEtMA_5085d141-9fa0-4878-9dee-39cc9e4489e3"
      unitRef="usd">212300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d1d4d88e5204d3bbd4f8c2df05bc123_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNi0xMi0xLTEtMA_c33d7aba-d175-4d7d-9e5a-c72105702904"
      unitRef="usd">516500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11880cd08681479db15c4cf4a0e6a1b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy0yLTEtMS0w_1a4840bf-8bc6-4b36-8e50-9402af80f467"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc711043de854adeaaa2267f4bb46ccd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy00LTEtMS0w_a3a9c86d-6ea6-4dee-b8bc-6206367be7bf"
      unitRef="usd">26200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a53327538a04446a4de09425ac19e0e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy02LTEtMS0w_8ca0629a-7ce7-4c91-802a-655ca90e2e02"
      unitRef="usd">26200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf06a525bc964241a3f2d2a390fe4a4f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy04LTEtMS0w_5d0bae66-c444-49f0-a3b9-df23f98112f5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3f4359c2057476ba70d1737083d2a2b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy0xMC0xLTEtMA_b64dc9e7-1e62-4094-90ce-001ae3b51bd2"
      unitRef="usd">26800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5c6a43fee8d4ad3b6c10202da96a3a4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfNy0xMi0xLTEtMA_d3f1852f-498e-4f27-999b-d809b08878dd"
      unitRef="usd">26800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i946868256a5e4b78bc18b85fe7d36a88_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC0yLTEtMS0w_09f832c3-e62d-4307-93b9-1a59dbb0203d"
      unitRef="usd">833400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6050c9c73f574a1d9ac74d02d7f8833a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC00LTEtMS0w_e0ab8e0a-48a8-484d-9167-36b546eaff6a"
      unitRef="usd">722600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia423a211a0e94eb2b77637ce741d2bb7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC02LTEtMS0w_6f083532-bdcc-46fe-90f9-eb21fe83a00c"
      unitRef="usd">1556000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87e3d9cc76b44ab2ab715dbe9256ee43_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC04LTEtMS0w_95d3f54b-5c72-4546-a8c9-51d4b5da7ab5"
      unitRef="usd">1315700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ae132257ea54725a3d8996647c5f187_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC0xMC0xLTEtMA_e9c51745-eff3-4f77-838b-234fcbf46482"
      unitRef="usd">669200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ca5e27d04c34b1b85b921b3c5f8955a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfOC0xMi0xLTEtMA_e0aea5cc-8b6b-4e27-93be-1e096ef86e69"
      unitRef="usd">1984900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6315b659cf6e4730aa408da11bed5410_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtMi0xLTEtMA_2ea1db8f-e49a-4bd9-8a2c-b494e69b1a76"
      unitRef="usd">139800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i217b972b9d864b7ea3af5c2ddafb37c1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtNC0xLTEtMA_5301ff00-4788-4b62-b08a-79792b4c9233"
      unitRef="usd">304300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcb4fc909b874f1cad730a3ec955d0b7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtNi0xLTEtMA_46d16ef6-cf57-4143-a6a2-ba7d3d35749e"
      unitRef="usd">444100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89ef0e02b0074d14ac43f42983797d65_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtOC0xLTEtMA_d09b1d86-288d-4f2c-819b-df905c3b5a61"
      unitRef="usd">182500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68820eb5ed4b440b8283a709119c6a35_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtMTAtMS0xLTA_11840805-4e91-4168-bd6c-4b4f7e3921bc"
      unitRef="usd">311900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i634f1e6f45a54e05bd52b24e519c4436_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTEtMTItMS0xLTA_660e6daf-3c95-4001-98e7-f7b1f09de156"
      unitRef="usd">494400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03c177a7d8bd40c3ad390904b9d500d8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtMi0xLTEtMA_74bd6385-ca86-4d82-8576-a011bcdcb082"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8dd866074adc42c98b75fe2cc20acab6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtNC0xLTEtMA_1f032b4f-128e-4477-9f3c-946c50523b76"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f60b9625d5649a094bc0b536c722ec2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtNi0xLTEtMA_f0ef2778-3194-4df2-afa4-54cfef80a3b0"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i911336cfeca046fdb0594c9edf8d9d0d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtOC0xLTEtMA_0636a4a1-8c56-4b7b-901f-a282e425548c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9cde429795a43629320e02fae4dc1f5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtMTAtMS0xLTA_c3ab84c3-8407-4e0b-a3bf-e620e837509c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie98b919eea9c49c0ae92d49eae5d7e4e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTQtMTItMS0xLTA_4f6629a1-5696-453c-afca-44ccc94a21c4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00b7f7eef9ad4f298c8c291b3ecaab47_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctMi0xLTEtMA_7856d4cf-e3e1-4f48-8916-b25ccde45561"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7560cc8fc1a4480e89be78cc3735e0a0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctNC0xLTEtMA_a96ec46a-b04a-4c55-8013-f7f5156f78be"
      unitRef="usd">120800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic82c486a127442488b1833a2dc7b7cd6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctNi0xLTEtMA_a9dc1242-8b47-4137-a96f-7f8205e97637"
      unitRef="usd">120800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f5008e8c4fa47649cfe38e4b9ebfe94_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctOC0xLTEtMA_943903d5-e330-4a46-bd6b-61b1abb7ac11"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b9e403b349e4ca69958c093e19f74e4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctMTAtMS0xLTA_161d4e4d-ed76-4506-9e4b-c20e2dbf57e3"
      unitRef="usd">124200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i847c83d47690436dbf95bf269e8be2f2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTctMTItMS0xLTA_84b72a69-64bd-45b9-abf8-18bc6197be1a"
      unitRef="usd">124200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0763a9aea2ed45ba8300cc34209c8819_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtMi0xLTEtMA_7228130a-f552-4db7-8040-0cf5f1c079db"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb3dce21712c4912bcec60f52a212be5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtNC0xLTEtMA_9487ce4d-9f95-4aab-9bee-ef05edf39122"
      unitRef="usd">57400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fd874439cb1425eb709f078c0dc49cb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtNi0xLTEtMA_50ed6bb2-7df9-4f24-97a8-d48a0e6591fd"
      unitRef="usd">57400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6126c7bc669b47cab645fe573efe2379_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtOC0xLTEtMA_c5bbb134-bc5e-4838-b3df-6a273938671a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i52490028f86c4b18ae595bb12a3b413e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtMTAtMS0xLTA_5bf19890-d5ef-4760-b6e7-d0b26733427f"
      unitRef="usd">56200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfe93de388de42aea652b2d937d7b20e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTgtMTItMS0xLTA_58932c05-4be4-465a-bd3d-20898ad1e800"
      unitRef="usd">56200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff76d3e091a4417f87d3022f27f8c714_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktMi0xLTEtMA_f9c48ad9-b466-4244-8aaa-2ae38c1ce5f3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3133bc8432354bdd87b447ab0b25da57_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktNC0xLTEtMA_2e463a25-ac9c-4d04-9ac5-2ebb0f1d3fc0"
      unitRef="usd">24600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fcfb0f1a5aa4f28a82dd0078a64e4cb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktNi0xLTEtMA_773d54d8-ee56-4da9-a1e4-d1e61bc01ad3"
      unitRef="usd">24600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6016cc0326e45fb8c5ab31460efbed5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktOC0xLTEtMA_f8dbd83a-09c0-42a7-83a0-220e66edc30e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c9b12c794124230bdfb5c764ae089a2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktMTAtMS0xLTA_ebf35dd6-4503-4ea3-8c4a-b2162056a843"
      unitRef="usd">27500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i851e3d422f964199aae5ec5f16c2ed5f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMTktMTItMS0xLTA_d013402b-f340-46be-baf5-9448f799129c"
      unitRef="usd">27500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2258c8387d342deb1dcd335b185c9c6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtMi0xLTEtMA_73b78d3f-8136-4e19-9704-193425f448dd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ac3a6cb79f144da8b8a7cbd1c451028_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtNC0xLTEtMA_90b4194e-90fa-48ae-a319-24f0822c6576"
      unitRef="usd">202800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibec078f0e0134c10ab04094dc10dcbb3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtNi0xLTEtMA_82eb90dc-8cc3-468c-aa4f-b7cbd5fecaff"
      unitRef="usd">202800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iddbd3b911c4e4a9b8d3b7b3370ba5be4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtOC0xLTEtMA_165e1dc2-1901-4029-8c77-8e5d28b2f107"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id95e5c1cfeff4eb999843b5ab142dea1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtMTAtMS0xLTA_7499855c-b231-4cc7-b527-457c7322f755"
      unitRef="usd">207900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6147368b3e5448f387b2621a347ff81a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjAtMTItMS0xLTA_f4e058a4-f83e-49ac-ba87-e7b7a8a2d406"
      unitRef="usd">207900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib43b7a7b6aff426e8b3aa44f10665331_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtMi0xLTEtMA_08d7549a-5f56-48bc-8e58-e7bf718b1936"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d8c0ed6a308478f8a953ae999c37402_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtNC0xLTEtMA_0f6116f8-bf83-4488-8fa3-df2572eafc6c"
      unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7dd6c4bbab7427d884ea754f842614b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtNi0xLTEtMA_d21dd47c-950f-4c7c-a652-2e653c1f06a6"
      unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a3637540f0742e282ee41d72bd9661b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtOC0xLTEtMA_42f64dd2-5aff-4065-b34f-d7071a501b0c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f499618557b4da7acceb5cafb578dbd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtMTAtMS0xLTA_4e7f11b9-f229-46c6-b4d4-85c8d766a1fb"
      unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide9ec1982c6d44839c60d73b502fb183_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjMtMTItMS0xLTA_f6486468-1662-4539-89a6-486d12b7fc5c"
      unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc59dc95e0974b669bee2fa38de73766_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtMi0xLTEtMA_e7d54666-a163-476e-be58-e70f49d1c918"
      unitRef="usd">973500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a391c9c52574153aecfbbfb7003c5dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtNC0xLTEtMA_1a2d92cb-3cc2-4c53-80e3-bd755c30342e"
      unitRef="usd">1232200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28c7f8faaddf4de59fb5368e32d5ae6d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtNi0xLTEtMA_ca9b896b-4324-4141-a773-de78a958ea03"
      unitRef="usd">2205700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide45d117f94948c39924a1add89e7b6d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtOC0xLTEtMA_83a02ae9-ecad-4f85-850e-1851f6b8f0e5"
      unitRef="usd">1498200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib90067ffe05f4ea3bef552a9c2baaf11_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtMTAtMS0xLTA_28d1f23d-95b2-4681-b71c-79ac8dcd5555"
      unitRef="usd">1192100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3672251f76c4fb3ab491f7a64f2a7d1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk0NWNmMjhiYmIyMDQxNDhhOWIxMjM4MzYxODRiMzM0L3RhYmxlcmFuZ2U6OTQ1Y2YyOGJiYjIwNDE0OGE5YjEyMzgzNjE4NGIzMzRfMjQtMTItMS0xLTA_c438df5c-62ef-45a3-bb60-c96ffb0538d2"
      unitRef="usd">2690300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a69686d751b4d78856ab4a9b5568f7c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC0yLTEtMS0w_260995c8-cd69-46f0-b3bb-f78d869d32bd"
      unitRef="usd">805100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i265533229a0044408626b8fb90354de5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC00LTEtMS0w_6e35b264-609e-4db1-8e44-6bf5545a37d9"
      unitRef="usd">945800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b240004575a41088f63cfd2893796da_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC02LTEtMS0w_4b5d6a82-64ea-4051-9483-8c8717c79d0b"
      unitRef="usd">1750900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7dc59a1b194f46d9aab6abc4dad371c8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC04LTEtMS0w_bf5dd2ce-7079-41a4-aecf-5b2931821e0e"
      unitRef="usd">2383400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94113634bd1c4fd19a9b3f8785b02ebe_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC0xMC0xLTEtMA_27d79d9f-138d-4ea6-b24f-f51d89fa9f16"
      unitRef="usd">875200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04560d42c0e54986baa4ff75a03e96bf_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNC0xMi0xLTEtMA_fa9bcc6c-c12b-423c-b1db-22dd4020cb8f"
      unitRef="usd">3258600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b12493f4b214da88a80d6a1be15a5ec_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS0yLTEtMS0w_e2e11f11-f84f-4512-880c-2a57b8aea224"
      unitRef="usd">751600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04c7085ac1e94084911a32c8c5150032_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS00LTEtMS0w_5bc9f16c-1cb7-492c-b897-2165b6b0aa71"
      unitRef="usd">436800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a516cca4e1641a3a52085e438a3c519_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS02LTEtMS0w_e5be507e-0710-4fe5-9337-049172e2f210"
      unitRef="usd">1188400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7189d4590dbf410981d535efbb77dafd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS04LTEtMS0w_02fe2595-5517-4a6a-b113-06fc0d3de03f"
      unitRef="usd">965500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0aa621e0a5cf4731b69211ee0236dfa4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS0xMC0xLTEtMA_9ef67cbf-7844-47c9-be66-fe90c2777efd"
      unitRef="usd">456000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6b298d90ef649be871440f8e5609a5a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNS0xMi0xLTEtMA_dd57206f-de46-4d18-8c2f-37e3d8163c6a"
      unitRef="usd">1421500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i055192050a884b09af25bd948ce893be_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi0yLTEtMS0w_15253965-3d59-4b7e-b8e9-1b2847263a69"
      unitRef="usd">854200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i819e179a871a47bc9b2742b59e816fd5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi00LTEtMS0w_3e841f88-0553-4185-b7d9-b3b897a0df84"
      unitRef="usd">696200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8870751b462a458697438c86f8eedbe0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi02LTEtMS0w_39c42ae5-52d5-480d-9236-3d1cc367bf3e"
      unitRef="usd">1550400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3447ed88deef4013aef8152951e512bb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi04LTEtMS0w_55b1191f-0efa-444b-a173-53afc43a4e3b"
      unitRef="usd">826000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i955579c517df40abbdcbafae0a9be8e3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi0xMC0xLTEtMA_5c18381c-4155-40f0-9d55-c68448d07c37"
      unitRef="usd">644900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie518ab0a6fb54b19acd0e5840d451a8d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNi0xMi0xLTEtMA_93bddb7a-a398-4cd0-9083-c2cf932f0981"
      unitRef="usd">1470900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbdc18d489a44d0492145df9a238420f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy0yLTEtMS0w_2c7acfaa-8e19-4fe1-b4ee-4921f632445a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6d5e1daf4b14aebaff40a7bfcdae045_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy00LTEtMS0w_020c776b-d5b0-4f2b-9bd8-dcad0e97d44c"
      unitRef="usd">78800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63f797b3134f4dfeb7404b4045bf8dff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy02LTEtMS0w_f05fbf93-dbf3-433f-b0b8-507bdc37916e"
      unitRef="usd">78800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78c7deeed40b495cbdd4163ba45d904f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy04LTEtMS0w_ef14c9b4-1609-4566-8dc7-bbac302fa418"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6aa6a3fdbaa84285a4f2caf4e5f6c13f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy0xMC0xLTEtMA_c5830c00-6013-4ddb-a94a-083301685a3d"
      unitRef="usd">78100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba938bf7466644249a1784f67476b2d8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfNy0xMi0xLTEtMA_82126703-d911-4a0f-a4ea-05d08e0d041f"
      unitRef="usd">78100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5b6d6875e5849df84d386d1cbbadf8f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC0yLTEtMS0w_ffd42591-9504-4757-ab14-dd8184d5e08a"
      unitRef="usd">2410900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60a8b4a619ef48838cb6f537675db04d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC00LTEtMS0w_dfd7dded-7b4d-425a-ba66-cf6299fa5103"
      unitRef="usd">2157600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae3263ec5c084ebdbf45685ad846b557_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC02LTEtMS0w_b33bc798-7219-432e-92fd-74e9bce9b2fa"
      unitRef="usd">4568500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7894b472498148dbb05439dbe1d0de4e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC04LTEtMS0w_15af686a-e865-400d-8f6b-e9a8c69bab7e"
      unitRef="usd">4174900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7de479d587354958b584fa532dfa50e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC0xMC0xLTEtMA_db9990d1-1358-4d77-97fa-2cc0b69e4726"
      unitRef="usd">2054200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0dd108b031c74d6293853d4b7f765be2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfOC0xMi0xLTEtMA_ea0c1c7a-0fd8-42f8-851b-e0e70536bf15"
      unitRef="usd">6229100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44e2681e4af04220bc5659c30f65dad7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtMi0xLTEtMA_a421a46e-c4ba-4729-a2de-e75a99e5aa22"
      unitRef="usd">437800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i997d11776fa54ff88c622c8a39e451cf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtNC0xLTEtMA_a8188f63-4b2f-4ab8-be65-abdcd511101c"
      unitRef="usd">1026600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4463689b8f13459fb262230c8eeaa642_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtNi0xLTEtMA_a597cb59-33fb-40c8-afbf-03850a9506d1"
      unitRef="usd">1464400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia53918b8ecd640bd9d91e12ad6779d47_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtOC0xLTEtMA_70c270fa-eb69-4100-b2a4-05baa4a44fbc"
      unitRef="usd">628200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7f69c1b12cf4aa48eb2f5495743e9b5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtMTAtMS0xLTA_2907dbd3-254e-429a-9c93-f6685464612b"
      unitRef="usd">925800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a344b1c3ded4c809b0bdc426f095761_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTEtMTItMS0xLTA_389f23c5-06ed-4516-af6f-4f8b2afb1668"
      unitRef="usd">1554000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2961e6b3f8584e359cd5fac9d7ae1a87_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtMi0xLTEtMA_06f4c2ca-ca2e-4ee3-bfab-1350fab621b8"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i018ca53b38334c258546194db151794a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtNC0xLTEtMA_9a80218a-b754-4911-a7ea-80b0f1a0295b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id41fab9ee02a43b197272a5b13c0ec9b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtNi0xLTEtMA_8385574c-353a-4687-a84d-827a164ce57b"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9872f8c2bb2488280b710de2bd86613_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtOC0xLTEtMA_fca501ce-2e7f-4e82-97eb-c239d19a4f9f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic21d50af206e442cacfbcc591b7db41c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtMTAtMS0xLTA_252b54e6-8f9d-40ab-bcb7-f5e8ea98412c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6db43726d8244d069205c2ae2092eecb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTQtMTItMS0xLTA_6f350810-8869-4f4e-8feb-6c6da5c10424"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i358a97db687a4532b4896a6818c1c570_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctMi0xLTEtMA_ec1714cf-1717-4089-9100-a601b9e4af6d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia80f3feab17d487ea2b255ed4e7fa9d9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctNC0xLTEtMA_bd9d97e8-3488-4d93-ac92-f7bf9b17315a"
      unitRef="usd">363900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a7281dfb87f4c759ded27994b4bc48a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctNi0xLTEtMA_969bdb31-24a0-4002-94cd-c905ab3f7cb2"
      unitRef="usd">363900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48de9837733f44a7b1ae4335196cab8a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctOC0xLTEtMA_22e5a2ab-c7d6-459b-8752-38ca99e0484e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6500c755b0d48dfb3cfc643bc8aa24c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctMTAtMS0xLTA_3d66c290-d48a-4fed-b763-a6aff0a8fa16"
      unitRef="usd">363900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80c2d0a9c88d4d4189622a44b28df36e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTctMTItMS0xLTA_974e837f-d02a-4620-8bf4-c79a5a154f9d"
      unitRef="usd">363900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1ef513a65ec4140a5e0fe08899b47c6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtMi0xLTEtMA_f2aa1b70-ded1-431f-a415-57ee8c0ecafb"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i52d8ed76345a4acfaa73ca03e26f404d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtNC0xLTEtMA_08047ccb-7373-47f8-97ea-1a98184bf9f1"
      unitRef="usd">170900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6b8289bbaf4401ca50ee623561b21ae_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtNi0xLTEtMA_4603adf7-1c74-4d4c-871e-7496f2ebf54d"
      unitRef="usd">170900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0201097c2b0b4fd8b09bf1320302b0df_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtOC0xLTEtMA_59856c94-f7a2-4326-89b0-3a31ae57aa0c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfebde8455d24e9dabbc61af5ac34b17_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtMTAtMS0xLTA_da59ac67-81ee-41aa-8f4c-4d553933ea44"
      unitRef="usd">162600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ad690c84e494203ad19621f8be2258f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTgtMTItMS0xLTA_71b96635-9737-4677-a66e-2d97658bbd1c"
      unitRef="usd">162600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i365b2ee8a85c4fd0b42ca8da39cce072_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktMi0xLTEtMA_fdd0934d-df53-4393-ad4a-e3afcbd87f28"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ec836555e23418e9418b4c438dfbde4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktNC0xLTEtMA_27b87ef5-e163-4448-be44-7507ea5d8e44"
      unitRef="usd">75400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7441b05974ec4515a4d0318950fd8c07_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktNi0xLTEtMA_a6d6d5cb-cf08-4ac3-95ce-ecda26da6cdd"
      unitRef="usd">75400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34eef8f55bd84011bdd58c92bc395b12_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktOC0xLTEtMA_d6123fe6-2cac-4436-ac65-c8f3dcb5adca"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2050c886f441471bbf874fbf99723b8c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktMTAtMS0xLTA_0f10e8cf-8056-4500-8044-1c84d4dcee80"
      unitRef="usd">71800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b58455f915944c5a8b42b07b2d4f95f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMTktMTItMS0xLTA_4fa33ddc-3b92-4e30-81c1-927faa4b8275"
      unitRef="usd">71800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i102f99b657e24bda89929e63215714e7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtMi0xLTEtMA_b420e5d1-9cc3-420d-885b-8405f3a816fc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f766dd011914fd7aac023f50c96726a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtNC0xLTEtMA_c9a2bf6f-8971-416e-8587-057b4928f23b"
      unitRef="usd">610200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i390f7d8898fd40cbb7ae0d2c48fb5ed8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtNi0xLTEtMA_6b37c632-d38c-4cd9-9994-dce4671e0298"
      unitRef="usd">610200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iacdaa759bf824f8ca47514fea1b47ee2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtOC0xLTEtMA_3c0c6433-be11-40a5-b293-216429bd5521"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if66ceb4c3c8641618bd0571332ab70e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtMTAtMS0xLTA_cc90fbcf-34eb-43b8-b5e6-e05d5951b416"
      unitRef="usd">598300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id59ec4787fd04a5585eb63429b7020aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjAtMTItMS0xLTA_d90619d7-96be-404a-825d-1b2f7f90d7b3"
      unitRef="usd">598300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id78748439d3e4bdc967aa5af911f7391_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtMi0xLTEtMA_29e4cc1f-83ab-4385-bf34-ba149e313b9c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64722cd85a514d76b846ff90832c2934_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtNC0xLTEtMA_8b17412d-7454-4ab9-a266-7351f7f6f59c"
      unitRef="usd">8300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2f7c01250cb438abd665e9b9c94e743_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtNi0xLTEtMA_6a8b2615-0ea9-495c-8dda-bada6328f432"
      unitRef="usd">8300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie2eb565fb2ca4e59be0ae2c0d7f3db8b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtOC0xLTEtMA_bca1ed8b-6c29-4600-adcb-5987cc6796e2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9bbef3e76d1f47a29e6f947d82b47f45_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtMTAtMS0xLTA_083239e8-228f-4cec-88d6-e3a11bf82c5a"
      unitRef="usd">9200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad39afa89ed54171a76ada18b22e630b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjMtMTItMS0xLTA_799cfec6-af23-47d1-bdbd-8c887237487a"
      unitRef="usd">9200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95260bc99cf64ae8b8bcaf3a4e5e7812_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtMi0xLTEtMA_944258f5-f778-44a9-8c5d-d02e685c80f5"
      unitRef="usd">2850700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide3a1ac1941449be84c85e628ce9d89d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtNC0xLTEtMA_66250261-85b3-4943-bec4-24c73d87c241"
      unitRef="usd">3802700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6629e89c034a4d89883d31d567178ed6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtNi0xLTEtMA_5a7044e0-629c-4fe7-a402-d4da71672b33"
      unitRef="usd">6653400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50a8c5663be04e9faed2b5f0d97a0e68_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtOC0xLTEtMA_014eb700-7048-4b2d-abad-c692e16e0eb9"
      unitRef="usd">4803100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i79795b771df34c8fbe099d241c96d9b2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtMTAtMS0xLTA_c46660b7-1331-414e-9946-f0fbab1dd72a"
      unitRef="usd">3587500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie862c4e3d0454092bd193a5d58ea0c3a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjk3NWZlMjg1ZDIyNzQyOGZhOTc5ZmRhMmYxZjg4NWJiL3RhYmxlcmFuZ2U6OTc1ZmUyODVkMjI3NDI4ZmE5NzlmZGEyZjFmODg1YmJfMjQtMTItMS0xLTA_b0e942fd-8b21-4d4f-b176-9db380592161"
      unitRef="usd">8390600000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfNzkw_aa79abe0-c036-4933-bf1e-caeb03c8401e"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfNzkw_b84d1df3-08ea-4277-ae56-36c5d8a36c07"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i0549e44337674a5ca08eba019050c369_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfODIw_6f83ce95-312b-473e-a38a-d4ce332507a0"
      unitRef="number">0.269</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i35f1dc85a6d443f5addb0eda7c8dc35c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfODI3_cd404361-9918-4584-8c9a-9c3474fcbd43"
      unitRef="number">0.108</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i1e5d0635317e4c16906d390ed841b9b3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfODg3_846f0096-e0eb-404d-9bcb-ae3c19e18453"
      unitRef="number">0.291</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i3e281fbe905d4e3e9728f08aa41f030a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfODk0_25fad52d-8428-4329-aba0-3703165ceded"
      unitRef="number">0.100</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfOTc3_aa79abe0-c036-4933-bf1e-caeb03c8401e"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfOTc3_b84d1df3-08ea-4277-ae56-36c5d8a36c07"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i2bc6970c546c489b94382b832606b1ab_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMTAwNw_342f1996-9d4b-4cd2-b303-19d908672194"
      unitRef="number">0.312</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i9b71a9f27e79480681fe58993506eb15_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMTAxNA_3a93e8b6-e10c-4959-8dd6-980dc95aba06"
      unitRef="number">0.156</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ib7d1e15250b64a13b47a432932d37658_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMTA3NA_0a15b55f-9149-496e-b692-cf5bdfb5344a"
      unitRef="number">0.309</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i64007592035142748ac7599f7a664be7_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMTA4MQ_c12840d7-bff0-4324-ad44-e8985df40ac8"
      unitRef="number">0.160</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA2OA_9b79c545-76cb-441e-b9a6-a5e5b9419855">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,255.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(422.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,598.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,021.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(878.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;946.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9f9bb0d6c15842358b1c0ddfa1c21b68_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMS0yLTEtMS0w_af1ed51b-1fc4-4d6a-9fb1-b07a2560b00f"
      unitRef="usd">141400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic4e6d8ecb5194fa9b70da244b06c3872_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMS00LTEtMS0w_feab3fd8-bba4-4e64-91b1-ac3d8d59a16b"
      unitRef="usd">1093000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib378e0758d7a484581e59302e22742cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMS02LTEtMS0w_b7176146-5ef1-4784-afbd-96604ad27424"
      unitRef="usd">41600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMS04LTEtMS0w_a6ce4061-d4aa-4b48-bad6-9bb1d799953a"
      unitRef="usd">1276000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMi0yLTEtMS0w_33f4e260-9b29-4903-bce7-6921c3204b2f"
      unitRef="usd">556300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMi00LTEtMS0w_62fd1b07-ab0e-4794-a1e9-f2fd5497e007"
      unitRef="usd">2255800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMi02LTEtMS0w_38ecc293-abd0-4915-9739-e22c7b2ac45d"
      unitRef="usd">11100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMi04LTEtMS0w_b0831b27-9780-4cd9-aba1-b7e09bcbe8e6"
      unitRef="usd">2823200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMy0yLTEtMS0w_beddb70a-5036-457a-8448-e59732faad54"
      unitRef="usd">-1200000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMy00LTEtMS0w_fa10de0a-3486-4262-935a-7a4c248869e0"
      unitRef="usd">71500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMy02LTEtMS0w_873a216c-7bf4-4024-b312-d4692f12ed34"
      unitRef="usd">500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfMy04LTEtMS0w_94d89cd9-9ae7-4790-8916-466857a53dfc"
      unitRef="usd">70800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNC0yLTEtMS0w_f9080325-9b1a-461e-ad58-02b01faa7239"
      unitRef="usd">422200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNC00LTEtMS0w_4c65bae9-3e57-4ffa-8700-cb4459f68127"
      unitRef="usd">1598600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNC02LTEtMS0w_cbd7a8a2-2b3e-4768-9091-9286970f784f"
      unitRef="usd">300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNC04LTEtMS0w_9fa3ffc3-e240-42fc-96d6-66c4278bcf75"
      unitRef="usd">2021100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i4c573e15d069424a8fd317f45c0b5375_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNS0yLTEtMS0w_b4b6eba3-afee-4444-b798-2b8b76177b5b"
      unitRef="usd">136700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i8f357a4d7e3f4152a3fa5df622bde507_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNS00LTEtMS0w_0f8d224b-7e0e-4500-913a-a528776af5ab"
      unitRef="usd">732100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i6ae3fa233e7b4ac39290ec509f719a6e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNS02LTEtMS0w_49d8fc59-79a9-49c8-ae01-2c0696c5d80b"
      unitRef="usd">9900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNS04LTEtMS0w_27329378-db2a-40c0-87c2-75ac52baf8cd"
      unitRef="usd">878700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4b4afb6819034ad8ae8cce9d2e54cf47_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNi0yLTEtMS0w_8de3b17e-fe7a-4f0e-95ee-43183602a1cd"
      unitRef="usd">140000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i81f620d3630247a0b5778586f131544a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNi00LTEtMS0w_708fcfb7-484d-4b6d-831a-4e187f5b36db"
      unitRef="usd">946600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic91c47df08824717aead53a81a56dc20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNi02LTEtMS0w_9d091d08-5c48-4bea-bb65-e2aebcce0678"
      unitRef="usd">42000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjUyZjkxYzA3YjRlNTQ4ZGM5MjM4ZDZjYjliZjM2YWQ1L3RhYmxlcmFuZ2U6NTJmOTFjMDdiNGU1NDhkYzkyMzhkNmNiOWJmMzZhZDVfNi04LTEtMS0w_cfae2537-5fbe-4fba-883d-9022d31d187a"
      unitRef="usd">1128600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA3Mg_cae92f67-5ee5-4fc4-8a73-2c82eb4629b6">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifb75ba94b11d4a699b755fdc629e6cbd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMS0yLTEtMS0w_bf3c276a-68bd-422b-82ee-f24eac8efc9b"
      unitRef="usd">146200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i42d2a9c8b03648879414ce30d6e746af_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMS00LTEtMS0w_1b784ff1-3d86-4da0-aafd-d4da2c6265c1"
      unitRef="usd">195400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8aa3c889df0142bf89536f957b8eaee7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMi0yLTEtMS0w_738237b7-a9cd-486e-90e5-dff5cd44469a"
      unitRef="usd">982400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id4b173db27f4480e98a38ea719ffce5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMi00LTEtMS0w_51da0c1d-4ddc-4890-9e02-568dce80764b"
      unitRef="usd">1080600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMy0yLTEtMS0w_72a7282f-927c-44b8-93ab-280f8d9b9643"
      unitRef="usd">1128600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmU1MGJjMWRkN2RlNTQ3NDU4YjBmMTU4YjE0Yzg1Yjg5L3RhYmxlcmFuZ2U6ZTUwYmMxZGQ3ZGU1NDc0NThiMGYxNThiMTRjODViODlfMy00LTEtMS0w_95a0a4e1-9711-4512-9211-5d8c36d74e63"
      unitRef="usd">1276000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA0MQ_cae03863-3234-4f16-85a1-a7e7b0015884">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;873.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,558.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="if1bfcb48e77b46bba81990b5298288bb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMi0yLTEtMS0w_4929654f-6db6-4b0a-8c34-f815df6f66e7"
      unitRef="usd">145800000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i8b18ce9f4621437b922497d189f85e55_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMi00LTEtMS0w_035ad6a8-4d4c-4fb6-ac8b-e2a06781377c"
      unitRef="usd">275000000.0</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i701a2e8982b64d678d5770b22075f8b7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMi02LTEtMS0w_619a320c-1e01-451b-8bab-1407d3fcd14a"
      unitRef="usd">498700000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i41b7ad7518d94ebca15cc87bd32825ca_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMi04LTEtMS0w_11b19c04-9bc1-4e5a-9612-68ce3b45d43d"
      unitRef="usd">873800000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="if1bfcb48e77b46bba81990b5298288bb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMy0yLTEtMS0w_396c68b2-107e-444e-a9c4-007db46168e9"
      unitRef="usd">269600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i8b18ce9f4621437b922497d189f85e55_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMy00LTEtMS0w_2e417cc3-10e6-4280-a909-3f9968d3d1ab"
      unitRef="usd">285100000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i701a2e8982b64d678d5770b22075f8b7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMy02LTEtMS0w_0b463833-29cf-48c1-9fcf-b5cfb918586c"
      unitRef="usd">745700000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i41b7ad7518d94ebca15cc87bd32825ca_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfMy04LTEtMS0w_b716370b-6874-4ec9-9910-ab8c28588d48"
      unitRef="usd">685000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="icc49896e8f7749f9aec4691dac20e8f7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfNC0yLTEtMS0w_7e2fa574-1d03-4333-9952-f24577d33597"
      unitRef="usd">415400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b23d904c3ce4fde94a3a645d27461d5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfNC00LTEtMS0w_1b7b9236-225d-4770-8abd-9d26fe166cd5"
      unitRef="usd">560100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf69f40f83ce4c9da70c57f9064c7b4a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfNC02LTEtMS0w_352aa871-acab-43a7-a896-88bcba580650"
      unitRef="usd">1244400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76c2b9076741473bbd3bced37f71ef41_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOmRhYjQ3ODU5YjY5MjRkZThhOTZlMDc0MzcwMTE2MGRhL3RhYmxlcmFuZ2U6ZGFiNDc4NTliNjkyNGRlOGE5NmUwNzQzNzAxMTYwZGFfNC04LTEtMS0w_d7209529-4b6d-4766-9812-3b1830631031"
      unitRef="usd">1558800000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RleHRyZWdpb246ZjNmMDFiYzJiZGNkNGVlYjg4ZmM4MDI4NGJlOWY5ODZfMjA0Mg_80bb80ff-891d-4e66-8b3e-fd8523d381f7">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from collaborative and other relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;642.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="i3408b069db1d42f7b345ec1b7498f89d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfMy0yLTEtMS0w_9b5d52b1-cf8a-4d71-a7c5-ddd2c879e452"
      unitRef="usd">6300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieec55d2ad3dc4febb73612f72beaebdf_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfMy00LTEtMS0w_d047d693-dd37-4470-bd97-ce10b8697662"
      unitRef="usd">5400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic99dc3ab809743fabf00ba08bbbca28b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfMy02LTEtMS0w_73f14210-8714-4958-90e8-15775a82c09e"
      unitRef="usd">15700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifaf7ab8592bc4011a62dfd0ea076ded4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfMy04LTEtMS0w_f4f365be-e627-4abd-9527-32f28f2aafee"
      unitRef="usd">13600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id90843cdfc614862a52278ee45bfc131_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNC0yLTEtMS0w_b659add3-3b7d-4f9e-99f2-5f7f654a5978"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i414a6de3330847a1ba08416250b5bb7a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNC00LTEtMS0w_4cbd1cf5-65fa-4eec-8c17-552573b99930"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1bae232cfcf14b48ab44d669cfbf4ea9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNC02LTEtMS0w_a66ada24-a3b4-4173-bc00-3760aaf36067"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb1b9df4cbfa42c3ac411955189a9091_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNC04LTEtMS0w_5c2ca5b5-1693-4ad0-a293-8ff4e99da6d3"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99f198b587194af1b052efd3339aa9ac_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNi0yLTEtMS0w_9fb4a99d-b4c9-436e-b0e8-63c5300356ee"
      unitRef="usd">7700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e025fdb4f53458a856e099d5f619c31_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNi00LTEtMS0w_f6786af0-78bb-447b-b9fc-fae670e5fa1b"
      unitRef="usd">10300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i744aacd6ec9a4103922fccc0ecf5a575_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNi02LTEtMS0w_87a20236-189d-4aca-879d-0e496fb6a8be"
      unitRef="usd">20300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23bc77237cc245c6bb9b3fd9dcf68cee_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNi04LTEtMS0w_8fcfda96-1f59-43b0-936d-59ecc8065ed2"
      unitRef="usd">28800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia28924f2261242259992e93451202d13_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNy0yLTEtMS0w_9e0a40eb-ebfe-42ab-b8b7-24511d021e0d"
      unitRef="usd">143800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62cbf5b25f7f44f6997f9587acdb152a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNy00LTEtMS0w_286683d2-7364-4073-8755-d0d22f2d2067"
      unitRef="usd">110000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3202bb6f2a554b45af9aa83e6ecacbce_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNy02LTEtMS0w_4098c5b5-1fc5-486b-a61f-2c97d77e949e"
      unitRef="usd">314100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d6ee34a915d43d3b004660946221bbe_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfNy04LTEtMS0w_cfa2377e-849e-4a4f-abcb-0c4321ba6ebf"
      unitRef="usd">599500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib36a038f73ce4e7b8013d75c309b00de_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfOC0yLTEtMS0w_84788728-70f2-483d-baa2-a2ec16773655"
      unitRef="usd">157800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27692e0f487e42cfa48cfb9ec74d1c5b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfOC00LTEtMS0w_96a54613-94db-4e81-876e-0da894bbd689"
      unitRef="usd">125700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i40db7f82bc1346e0a6ae09a03625fc9d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfOC02LTEtMS0w_7d17b478-4f12-42b5-a44f-3c70d6b3e33b"
      unitRef="usd">350100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f2782acd53f4eca80ff87db16f55ee5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81Mi9mcmFnOmYzZjAxYmMyYmRjZDRlZWI4OGZjODAyODRiZTlmOTg2L3RhYmxlOjNmMDQ4NGE1ODk0NTQ4YTY4MTM3OWRlMzg3ZDFiMDQ4L3RhYmxlcmFuZ2U6M2YwNDg0YTU4OTQ1NDhhNjgxMzc5ZGUzODdkMWIwNDhfOC04LTEtMS0w_94ad9896-c263-4d4b-bef0-4dd30b9ef761"
      unitRef="usd">642600000</us-gaap:Revenues>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RleHRyZWdpb246MjNmMDVkNzE0ZjI1NGQ4MTk1NGE1YzFhMWRjN2NlM2RfNzM_bd8fd2c6-c47f-4106-9411-c44ee354a9c3">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,347.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RleHRyZWdpb246MjNmMDVkNzE0ZjI1NGQ4MTk1NGE1YzFhMWRjN2NlM2RfNzY_c746cbba-f0ca-4ba5-acf9-1d8e4c0347f0">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,347.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMS0yLTEtMS0w_a833a2c4-ba29-430f-a0e5-3f256164bda3"
      unitRef="usd">366000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMS00LTEtMS0w_b5be6e66-81bc-4c69-b1fc-b6f30c28d647"
      unitRef="usd">314900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMi0yLTEtMS0w_fe3735e6-e9e1-4b82-adc9-e4274ef9a874"
      unitRef="usd">780800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMi00LTEtMS0w_d82705ef-eaf7-48bb-a545-6dfcdb51422e"
      unitRef="usd">544500000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMy0yLTEtMS0w_d3d56124-4b84-4711-b71b-179ebae979b6"
      unitRef="usd">201100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfMy00LTEtMS0w_de43588b-7a81-497b-87bc-80487a3720b9"
      unitRef="usd">209200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfNC0yLTEtMS0w_5705666c-c5c7-4b12-a587-6aba7b70a8d5"
      unitRef="usd">1347900000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl81OC9mcmFnOjIzZjA1ZDcxNGYyNTRkODE5NTRhNWMxYTFkYzdjZTNkL3RhYmxlOjFjMDUwOWY1YzE5YTQ1ZjY4OTIyM2JmYWEwZmJkY2ZiL3RhYmxlcmFuZ2U6MWMwNTA5ZjVjMTlhNDVmNjg5MjIzYmZhYTBmYmRjZmJfNC00LTEtMS0w_087a5611-f054-491f-b368-53afb82771c0"
      unitRef="usd">1068600000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTkzNQ_af1440a4-2c66-49e2-90f8-d74a68ca3547">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,411.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,320.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,090.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,257.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,607.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,320.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,084.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2021, amortization and impairment of acquired intangible assets totaled $111.0 million and $813.2 million, respectively, compared to $82.6 million and $215.6 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2021, amortization and impairment of acquired intangible assets reflects impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia, and impairment charges of $28.4 million and $220.0&#160;million, respectively, related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021, amortization and impairment of acquired intangible assets also reflects the impact of a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $19.3&#160;million impairment charge related to one of our IPR&amp;amp;D intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of September 30, 2021, relates to the IPR&amp;amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of September 30, 2021, the carrying value associated with the remaining vixotrigine IPR&amp;amp;D asset for DPN was $132.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BIIB111 and BIIB112&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ur Phase 2/3 XIRIUS study of BIIB112 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the three and nine months ended September 30, 2021, we recorded impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111, and impairment charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112. As a result, the remaining book values associated with these programs were reduced to zero.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, for the three months ended September 30, 2021, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $39.1 million related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,762.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,760.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ac&lt;/span&gt;cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTk1Mg_d2dc6f8b-5eab-4ee0-9468-daffb0aa804a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,411.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,320.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,090.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,257.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,607.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,320.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,084.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie19b8b42bc9547abaf105a4b71dbd351_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi00LTEtMS0w_f183ec71-69c5-487e-b37f-f3584400c1e9"
      unitRef="usd">7411200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie19b8b42bc9547abaf105a4b71dbd351_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi02LTEtMS0w_d538dc00-a08b-43d6-9b05-648aecde8208"
      unitRef="usd">5320400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie19b8b42bc9547abaf105a4b71dbd351_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi04LTEtMS0w_d7b03afb-7377-4b3e-ab29-85aa24e4e1db"
      unitRef="usd">2090800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i790f18c0415849f9b387fb21e49c9fd5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi0xMC0xLTEtMA_853e459d-a1a7-4b98-aba4-e47978b95c8b"
      unitRef="usd">7394300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i790f18c0415849f9b387fb21e49c9fd5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi0xMi0xLTEtMA_5760844f-0a2d-44c5-88fa-e3a63e7e7d20"
      unitRef="usd">5136500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i790f18c0415849f9b387fb21e49c9fd5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMi0xNC0xLTEtMA_dd581e89-d60b-46f1-9767-d5720ab96cd3"
      unitRef="usd">2257800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie4ecc275acaf4fe883a279d9a574b48c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy00LTEtMS0w_98204bcb-b2b2-4d6b-948a-03774cb544db"
      unitRef="usd">132000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie4ecc275acaf4fe883a279d9a574b48c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy02LTEtMS0w_2976e963-206e-4000-a328-e262a767a97a"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie4ecc275acaf4fe883a279d9a574b48c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy04LTEtMS0w_d7f045d6-d203-4cc9-a204-8ecefe8ae8c2"
      unitRef="usd">132000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i753c69a029d04474a9bed4a6271dece8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy0xMC0xLTEtMA_7992ba30-754e-4f30-9003-5ef70782b517"
      unitRef="usd">762500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i753c69a029d04474a9bed4a6271dece8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy0xMi0xLTEtMA_c1913541-3e5b-49f4-9296-81a7b4e4ff00"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i753c69a029d04474a9bed4a6271dece8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfMy0xNC0xLTEtMA_b43e90ca-33f7-48c1-b2ae-fa526ea76e51"
      unitRef="usd">762500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i805587f470f344d680991d5995876af0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC00LTEtMS0w_a7ec1c3a-074a-44e0-8939-df0f288c78f4"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i805587f470f344d680991d5995876af0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC02LTEtMS0w_c76cf99e-78dd-43c8-a38c-fa400aa9e577"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i805587f470f344d680991d5995876af0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC04LTEtMS0w_4bd7951e-3236-43a9-8725-19b344ec37f4"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if310e2943b1e4ccbbda6ed73c324ade3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC0xMC0xLTEtMA_cc8b66dd-7608-4f83-be1f-af54bf088229"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if310e2943b1e4ccbbda6ed73c324ade3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC0xMi0xLTEtMA_146b54e0-eb33-4a8f-9a05-16e4d7562862"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if310e2943b1e4ccbbda6ed73c324ade3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNC0xNC0xLTEtMA_4cbf0087-14c3-4ea7-9ff7-8ced4e148fe9"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS00LTEtMS0w_3e31386f-06a7-4267-9f63-5d965495ec4c"
      unitRef="usd">7607200000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS02LTEtMS0w_6f0ed23f-a746-4b65-b08e-a82c9b0cbc38"
      unitRef="usd">5320400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS04LTEtMS0w_579287c2-71ac-4ccf-9bdf-6d9ec50851be"
      unitRef="usd">2286800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS0xMC0xLTEtMA_bee716de-e562-48f0-b388-9f5c361a8c87"
      unitRef="usd">8220800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS0xMi0xLTEtMA_eee974c6-696d-4b3c-b807-9762f0599ae1"
      unitRef="usd">5136500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOmE0ZGRmYzVjYmRjMTQwNjc5YWVkNWJjNDA1YjNlNWRiL3RhYmxlcmFuZ2U6YTRkZGZjNWNiZGMxNDA2NzlhZWQ1YmM0MDViM2U1ZGJfNS0xNC0xLTEtMA_8e5f508c-f48d-4ca8-a918-5a39543f527f"
      unitRef="usd">3084300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjQ4_9e2b4371-cb66-4554-94d9-a51f1bbddf33"
      unitRef="usd">111000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjU1_5547110c-3dec-4393-a8a5-cfbcc75bc476"
      unitRef="usd">813200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjg1_00842875-29de-40c6-b379-64a9ccc60588"
      unitRef="usd">82600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjky_53a020ee-35a3-402f-9ba9-9a5d81ec6533"
      unitRef="usd">215600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i3be3bc83cfa548609221fb923b77b012_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcwODc2NA_9800c2f7-c5c9-44b6-bf7d-6501584115aa"
      unitRef="usd">15000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i3aa487875e3b4688bd646e5ea13ab375_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNDUz_bab970f8-fd06-4928-a69e-3c0d6a34d2ca"
      unitRef="usd">365000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i1627155704354fc0a8a424c6c2790177_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcwODgzNw_7db50372-ff19-46d5-8f1c-cf237fd41901"
      unitRef="usd">28400000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i463cd8459c624bd3882e48393200fab1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTY5_32246ee0-2b85-427e-9237-6713a9c94101"
      unitRef="usd">220000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="icd4c548cc92f48a4ac8e14803f6f43b6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfODAx_26e21b27-55b7-449e-8423-96e6636a8243"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i53f4f3120ef84eefa4d661c020812d93_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjE5OTAyMzI2MTczOA_624617af-1bc6-492d-af56-e36cb99fd285"
      unitRef="usd">19300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i45e7b551c5dc43d5a333a321f352359d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjE5OTAyMzI2MTczOA_e08fbff0-59b4-4117-8c0c-c2cc01d10567"
      unitRef="usd">19300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="icd4c548cc92f48a4ac8e14803f6f43b6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMjg4MQ_26e21b27-55b7-449e-8423-96e6636a8243"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i92d6d0dc9ec648d4bea25189aedec636_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzA2NA_b9faacc8-5f4e-4b66-8ad1-6e72cb6d2b3e"
      unitRef="usd">132000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ic8e4d78e60454a64b89e8a75ff8f0450_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzE5Mg_4ffb8969-784d-4a9e-b062-9b0592b7b1c7"
      unitRef="usd">115000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ic21c7a6ec4ab4bd2a8bbfc0f4cd56f43_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcxMzUwMg_214a8c01-fdd6-4f9d-9eb8-766d8c7223de"
      unitRef="usd">15000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i80bd0b2b32ea4b5680c869f40cc11b5f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcxMzUyMQ_15e4cf61-215d-457e-b8cc-5c44b01296ea"
      unitRef="usd">365000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i326c80e9243f4bf493aa660e564a3122_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcxMzU0MA_c153b180-fbe7-4b39-aff2-83086a44dd7f"
      unitRef="usd">28400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i5b7e99afec554a029eb237f033b39037_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcxMzU1OQ_362367a8-2827-4547-a40d-ccf03bd17d98"
      unitRef="usd">220000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <biib:ManufacturingAndOtherCosts
      contextRef="i994f124b7f3741b2a6d52b940a0759f6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfMzg0ODI5MDcwNzY0MQ_eb4eb5f5-afc7-466f-9a0e-b752567030ca"
      unitRef="usd">39100000</biib:ManufacturingAndOtherCosts>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTkzMA_e84ff91e-ecb7-446d-898b-817692440fad">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfMS0yLTEtMS0w_1410f747-0008-4917-872f-9181cb1ee05c"
      unitRef="usd">70000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfMi0yLTEtMS0w_6faf9fce-ffbf-4982-b648-529713539f69"
      unitRef="usd">255000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfMy0yLTEtMS0w_88ec512c-a7b7-40c9-abda-5feaa8f25b49"
      unitRef="usd">210000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfNC0yLTEtMS0w_b91128e4-a1d7-450f-a56a-e33add689f99"
      unitRef="usd">195000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfNS0yLTEtMS0w_8e96e084-4e61-4c68-8384-604cabb1c78f"
      unitRef="usd">195000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjJhOGNiMmVlZWViYzQ0NGY4NGNmOWVlY2JmZmIwOTVmL3RhYmxlcmFuZ2U6MmE4Y2IyZWVlZWJjNDQ0Zjg0Y2Y5ZWVjYmZmYjA5NWZfNi0yLTEtMS0w_b655b811-1b0e-4078-bdf6-c5a56770329a"
      unitRef="usd">180000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTk1NQ_0c660259-5a0e-480c-9258-e5c5b86ffb45">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,762.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,760.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjFhYjkzOTMyOWNkMzQwMjdiNTczOTc1Mzk2NGMxNzQ2L3RhYmxlcmFuZ2U6MWFiOTM5MzI5Y2QzNDAyN2I1NzM5NzUzOTY0YzE3NDZfMS0yLTEtMS0w_4a44b03f-1095-4c69-8d63-6f66badcb11e"
      unitRef="usd">5762100000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjFhYjkzOTMyOWNkMzQwMjdiNTczOTc1Mzk2NGMxNzQ2L3RhYmxlcmFuZ2U6MWFiOTM5MzI5Y2QzNDAyN2I1NzM5NzUzOTY0YzE3NDZfMy0yLTEtMS0w_56f771eb-cde5-4d39-98d9-5c0d0cb96ada"
      unitRef="usd">-1600000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RhYmxlOjFhYjkzOTMyOWNkMzQwMjdiNTczOTc1Mzk2NGMxNzQ2L3RhYmxlcmFuZ2U6MWFiOTM5MzI5Y2QzNDAyN2I1NzM5NzUzOTY0YzE3NDZfNC0yLTEtMS0w_34d986aa-2eb8-445f-90e8-b7a5fb0ab535"
      unitRef="usd">5760500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82MS9mcmFnOjc5NjA4NTFkNmMzZTQ0ZjliNzYzZjQ2NmVlYmE5YzQ1L3RleHRyZWdpb246Nzk2MDg1MWQ2YzNlNDRmOWI3NjNmNDY2ZWViYTljNDVfNTc3Mw_4b67f7db-1551-4ad2-b5e6-c837b335015e"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNTEwNg_0db4e4d0-70be-4094-8f8f-b7b1c616bd40">&lt;div style="margin-top:3pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;978.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;978.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,486.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,486.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;712.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;712.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;950.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,640.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,424.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,703.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value during the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021. In addition, there have been no changes in valuation techniques during the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for a portion of our Sangamo investment expired during the second &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;quarter of 2021. The fair value of this portion of our Sangamo investment was a Level 1 measurement as of September 30, 2021. For additional information on our investments in Sangamo, Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of September 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.83%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.83%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 to 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 to 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 10.8% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021, we recorded impairment charges of $365.0&#160;million related to BIIB111 and $220.0&#160;million related to BIIB112. As a result, the remaining book value associated with these programs was reduced to zero.  For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5, Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,031.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,054.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,927.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,003.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,365.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,443.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,536.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;684.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;465.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,046.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,515.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,426.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021 and December 31, 2020, approximately $210.7&#160;million and $110.3 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;component of accrued expense and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021, the decrease in the fair value of our contingent consideration obligations was primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2020, the decrease in the fair value of our contingent consideration obligations was primarily due to changes in the probability &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of technical and regulatory success&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the expected timing of the achievement of certain remaining developmental milestones as well as changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNTEwOA_a8ae26c9-718b-4ab4-b680-2be0646d0d84">&lt;div style="margin-top:3pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;978.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;978.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,486.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,486.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;712.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;712.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;950.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,640.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,424.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,703.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMy0yLTEtMS0w_22cdfa84-e26f-4273-88ff-310018a6f07e"
      unitRef="usd">978900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMy00LTEtMS0w_ec39d90c-3c8f-4b5c-8ea3-ca50a568d46d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMy02LTEtMS0w_ec482989-16f2-4a6f-b085-63d2ecd0e099"
      unitRef="usd">978900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i876974683e3549eea5fc8f61aead1156_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMy04LTEtMS0w_6684119f-b318-4fc0-98b1-9df3b3a3fe6d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2fdb402e2824ce4a9bc71b9229835d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNS0yLTEtMS0w_9a6957ae-bc55-4d7b-8980-7e511e91fe73"
      unitRef="usd">1486800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c87b4112217442caf7f93008b36ae14_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNS00LTEtMS0w_4d846c46-893f-4044-9b2f-26dfbbf8e640"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i913028ac08ed43abbe4437b3e87d4ff8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNS02LTEtMS0w_b80d077b-f991-4e49-b84b-6b0ddf11001d"
      unitRef="usd">1486800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e9850ad45354252a28687b05a4f7ba0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNS04LTEtMS0w_5988da83-cb63-464d-8aaa-a29032d25e75"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69ac3585271c4421bccc4835e25238e5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNi0yLTEtMS0w_a715f648-615e-4194-9799-83b9f812aa76"
      unitRef="usd">712900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79db083a3de94f4287a9add466386aa1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNi00LTEtMS0w_450fb5e8-0485-4835-8bc2-f150d7094b3e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaacdf0756fe34b82bc7e195e28ba5cac_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNi02LTEtMS0w_e810d83a-4c6d-4cd0-8a90-402770802610"
      unitRef="usd">712900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9cfaf234a7a04182b6f04ff79328e86e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNi04LTEtMS0w_e30c330f-93d4-4714-84b7-3286d39a0c15"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice2382fc36d44058840ae3e3e28251b2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNy0yLTEtMS0w_71fbef04-3dde-4b8f-add4-cabf1611ed52"
      unitRef="usd">181900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1deebd059f4c45a7a55fb2f7fb75cc43_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNy00LTEtMS0w_4d281889-9d86-4f1b-b4b2-5a397cb4e425"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c1474a542b94f95b31adc32082b10e2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNy02LTEtMS0w_8de3d595-e5dc-4d60-a8d2-b6462f4b7ee8"
      unitRef="usd">181900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ida9264d01fca4283942cd3738537b883_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfNy04LTEtMS0w_4a450b3c-f331-444b-88d6-232ca3c67a41"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOC0yLTEtMS0w_3c7879e0-521b-41dc-ab72-5df7a53ee4c9"
      unitRef="usd">1166200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOC00LTEtMS0w_5433474f-3c22-4220-a872-937f586f25b4"
      unitRef="usd">215900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOC02LTEtMS0w_29eae691-d592-4cc2-a1ad-b84347ccf02c"
      unitRef="usd">950300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i876974683e3549eea5fc8f61aead1156_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOC04LTEtMS0w_dd7d3184-e15d-4f5e-8cf5-680c9159be70"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOS0yLTEtMS0w_21690525-13ce-4830-8a51-e77304aee21a"
      unitRef="usd">80000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOS00LTEtMS0w_0307380b-1690-4193-8d58-007316d4a3aa"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOS02LTEtMS0w_40d3430a-9553-4c7a-8319-0af589c9d51a"
      unitRef="usd">80000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i876974683e3549eea5fc8f61aead1156_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfOS04LTEtMS0w_823ad3f8-3217-403e-9aa5-614b32a9fd9a"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTAtMi0xLTEtMA_9cc1e299-8025-4547-bfd9-188662ee8c56"
      unitRef="usd">33700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTAtNC0xLTEtMA_39329ec8-1d98-4570-971e-09cffff72762"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTAtNi0xLTEtMA_4e34ce57-b394-49c3-b6e8-77fcf984f944"
      unitRef="usd">33700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i876974683e3549eea5fc8f61aead1156_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTAtOC0xLTEtMA_7bca7b40-2c0a-4be3-900e-0ed0e841610c"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTEtMi0xLTEtMA_c9181b5b-290a-4499-8862-474be350b5ff"
      unitRef="usd">4640400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTEtNC0xLTEtMA_6484f6fe-ac10-444d-93ed-77766771a2d6"
      unitRef="usd">215900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTEtNi0xLTEtMA_446e75be-064e-41e4-a731-d2d505718833"
      unitRef="usd">4424500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i876974683e3549eea5fc8f61aead1156_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTEtOC0xLTEtMA_cbe6470f-8ccf-41c1-905b-5342f58bb88d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTMtMi0xLTEtMA_931209d5-098e-469d-b796-931ab1522606"
      unitRef="usd">27700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTMtNC0xLTEtMA_d792cb1b-982e-4c80-bbc9-131b4afbce0d"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTMtNi0xLTEtMA_bec3e2c3-1bc6-4248-8301-0d8f2dc198d4"
      unitRef="usd">27700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i876974683e3549eea5fc8f61aead1156_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTMtOC0xLTEtMA_cc0b91cc-d9b7-4839-8070-93203d5a218a"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTQtMi0xLTEtMA_b4fdbdd0-2e65-41d2-b695-9b13a407bfea"
      unitRef="usd">210700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTQtNC0xLTEtMA_80b304e9-d066-4d38-bc30-0fffe310150f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTQtNi0xLTEtMA_8bd30e3c-1430-4c8a-a85c-c8f167624805"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i876974683e3549eea5fc8f61aead1156_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTQtOC0xLTEtMA_896fb00b-f1e4-4f5a-8f2f-cd02e6ce78aa"
      unitRef="usd">210700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTUtMi0xLTEtMA_33b4e33e-ab51-478b-9875-608a102eebb4"
      unitRef="usd">238400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia8c216a5dffc4a4c9e7927fe755c8873_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTUtNC0xLTEtMA_e5ed0c7a-3a84-4b93-ac3e-ea5e9369c4ac"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i842cb6f355fe4d479461afd4ef4e083c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTUtNi0xLTEtMA_205f1205-2cbf-4509-b4bd-d4c528b2207f"
      unitRef="usd">27700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i876974683e3549eea5fc8f61aead1156_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjFkYjZlODdmZmZkZTQ3YTE4Y2VkODA2MTZkNDE0MjEwL3RhYmxlcmFuZ2U6MWRiNmU4N2ZmZmRlNDdhMThjZWQ4MDYxNmQ0MTQyMTBfMTUtOC0xLTEtMA_296eaa72-7a37-4023-a706-5b782a682147"
      unitRef="usd">210700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMy0yLTEtMS0w_86cc229e-197d-4a23-84af-0dff2ec8bed4"
      unitRef="usd">626900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMy00LTEtMS0w_2ebfe4bc-67c7-4033-aa22-ace5976af836"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMy02LTEtMS0w_f412b351-ac8b-439c-a532-9f892ca4b45c"
      unitRef="usd">626900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMy04LTEtMS0w_dde50aa9-fb03-4002-8af2-71fcd1eacd48"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81740b779f254c85bdb56c3ede0940b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNS0yLTEtMS0w_59ce4d4f-0f2b-4986-8867-29270e973b45"
      unitRef="usd">1301500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd88cfa056ee42b688c44148869a89bf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNS00LTEtMS0w_f9e6655a-3156-4f5d-b882-a03e9d2f2f90"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b77bc2d5ca1423eb85a5b99d2103f23_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNS02LTEtMS0w_a1ca30e5-e646-407a-b72f-18fcdfa1e54b"
      unitRef="usd">1301500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i669d0acaf9ba4c9faa1e50b3d5545924_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNS04LTEtMS0w_d9658b57-5cc2-4e35-a30a-d8d66f0f1afe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b2b5503377e4d60a68343ae4a275eb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNi0yLTEtMS0w_5e72ad02-a4b3-48a2-bd16-8f2e72f5f2a2"
      unitRef="usd">627100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7aac397904bc47ceb520bf0b28475c0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNi00LTEtMS0w_06c9fa69-501d-42bd-9520-58769248d788"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i973902141e63471a80c622f966bf9204_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNi02LTEtMS0w_d5fe7623-2a84-4e3a-aa0b-c29f0b17ca3a"
      unitRef="usd">627100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08ea1ef8967d4c89b99809a24bec5629_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNi04LTEtMS0w_5ea1af95-dbe8-4e7c-8fc2-e878dfc33e7c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bf4f35802694c1fbbae2718a8f12142_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNy0yLTEtMS0w_51bc0a4e-44df-48d9-b067-461c71030e0e"
      unitRef="usd">122400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3993b259dd8a435f9cde46b68b063c55_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNy00LTEtMS0w_87020555-fcb5-48fa-b6c4-e5441184f20e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9ab4f097e1a4677acea953affeccc39_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNy02LTEtMS0w_27189036-09b4-4cf0-a1f9-0f472d62d235"
      unitRef="usd">122400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3467f79adfbd4e57b9fa997886b38ba5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfNy04LTEtMS0w_f7ac01db-4445-4956-8e99-60a7ed6b9937"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOC0yLTEtMS0w_2f90ce99-0512-43d3-ba97-33635de24a4a"
      unitRef="usd">1974300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOC00LTEtMS0w_ecf3d167-4b12-49ae-8172-384252f90ec7"
      unitRef="usd">271100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOC02LTEtMS0w_3e449c66-088b-4b34-9dfc-13fa3cf492dd"
      unitRef="usd">1703200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOC04LTEtMS0w_58a23497-90de-4a98-bb98-8787862d404f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOS0yLTEtMS0w_b980877e-5b59-46b3-975c-f32a665da419"
      unitRef="usd">20500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOS00LTEtMS0w_34593147-0330-4e33-9325-6236a0f00a4f"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOS02LTEtMS0w_7531f916-01f9-4030-bed8-3c3812a9669d"
      unitRef="usd">20500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfOS04LTEtMS0w_66f513a8-fc05-4ea3-8d46-4ddf5cec5581"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTAtMi0xLTEtMA_1f1e152f-f75a-4f6e-970c-4282e2f07d61"
      unitRef="usd">28200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTAtNC0xLTEtMA_801b9334-bd17-404d-a739-cb491b20a527"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTAtNi0xLTEtMA_703661db-4e52-429c-bb75-952b626f2ed9"
      unitRef="usd">28200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTAtOC0xLTEtMA_c484217f-6da5-4611-b231-c0bf777457e4"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTEtMi0xLTEtMA_22ef57df-98ec-4621-8a10-a701b60aaee8"
      unitRef="usd">4700900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTEtNC0xLTEtMA_8bf3e0aa-4153-4bdc-90a2-4e05d3585c16"
      unitRef="usd">271100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTEtNi0xLTEtMA_a55ecb6f-0d9c-4d23-ac86-7fc20a6d04b1"
      unitRef="usd">4429800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTEtOC0xLTEtMA_17b07289-997e-454d-8d63-a82211e27041"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTMtMi0xLTEtMA_04c18240-866c-4242-b6ac-45ed10df351a"
      unitRef="usd">217200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTMtNC0xLTEtMA_e53da5f8-be24-49ab-913f-b4ae07ea2ab2"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTMtNi0xLTEtMA_aa0797cd-600b-42a4-b419-f9ecf2d1bc5b"
      unitRef="usd">217200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTMtOC0xLTEtMA_06753261-eb90-4429-9f9e-399e85cf7960"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTQtMi0xLTEtMA_f59d1ead-72b2-4741-8c71-328a51bd4d62"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTQtNC0xLTEtMA_a4eef917-14ed-4fb3-ad71-0ee3f7ba221b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTQtNi0xLTEtMA_a3349dcb-836a-4de2-a536-d2d90b36ea29"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTQtOC0xLTEtMA_45955683-95d1-4075-a2f0-7cd17ceb671a"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTUtMi0xLTEtMA_17823c2e-826d-4923-ad56-a3ea03105a0d"
      unitRef="usd">477000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i378cfd98f0dd499089706915fc4d9abd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTUtNC0xLTEtMA_5790e71c-ec27-4702-a1ef-f5f166c9d642"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i293a13e81c3948a8a773c4a9c92f6de9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTUtNi0xLTEtMA_af2d8ab4-a0d7-4adb-8f1e-14f92df13044"
      unitRef="usd">217200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6fa3eb7611dd4c5180bf950d961937ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjQ0OTAzZDhlYzQyNTQzZTY5NmFjZDZkNTY3NDE2ZWI1L3RhYmxlcmFuZ2U6NDQ5MDNkOGVjNDI1NDNlNjk2YWNkNmQ1Njc0MTZlYjVfMTUtOC0xLTEtMA_51fedc0a-df6c-4143-8a5a-6e3e2c64b718"
      unitRef="usd">259800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjgy_ab9a4cf3-3289-4527-9812-bd96885777e1"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjgy_dfc9fbfe-9892-4008-ba01-c32f8fad93db"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfMy0yLTEtMS0w_b4fdbdd0-2e65-41d2-b695-9b13a407bfea"
      unitRef="usd">210700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie8d75b9475054c6aa2f4631f5a8ef20c_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfMy04LTEtMS0w_243dcb53-ae76-4f8a-97ed-c0c30413ae73"
      unitRef="number">0.0083</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iaefea2e4aa4742fcaf12b2e1a663a4b0_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfMy0xMC0xLTEtMA_5e5c4762-8424-419c-81fb-083fcd2c9208"
      unitRef="number">0.0083</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfOS0yLTEtMS0w_f59d1ead-72b2-4741-8c71-328a51bd4d62"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6f0a301c1d504d4cb75e0dfdc175fba8_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfOS04LTEtMS0w_3f917d5e-5518-4afd-b6e3-c87c83969bcb"
      unitRef="number">0.0060</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iacb3b16cceff4a69b162f9088df8f83e_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOmVlYTdmNDRiNDRlYTQ3ZjBhZDQzMGZhZWUwYWNkMzhjL3RhYmxlcmFuZ2U6ZWVhN2Y0NGI0NGVhNDdmMGFkNDMwZmFlZTBhY2QzOGNfOS0xMC0xLTEtMA_32bd9a7f-0c22-40a4-924e-cebb8b7a1df9"
      unitRef="number">0.0060</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <biib:TechnologicalAndRegulatorySuccessProbability
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjA5Mg_0c094c3d-68be-4513-9447-60f079c65c54"
      unitRef="number">0.108</biib:TechnologicalAndRegulatorySuccessProbability>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i80bd0b2b32ea4b5680c869f40cc11b5f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjE5OTAyMzI2MzcwMA_b6e80e1f-f447-4b67-bbe7-e8e72ab37c60"
      unitRef="usd">365000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i7aedfb52da3b4ed3ae009c32d7af2f34_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMjE5OTAyMzI2MzcxNg_44b226d7-fad6-47e0-89e4-c47128e3d01b"
      unitRef="usd">220000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNTExNw_1f18c0ea-ccc8-4103-82c7-35580ad1c582">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,031.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,054.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,927.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,003.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,365.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,443.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,536.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;684.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;465.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,046.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,515.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,426.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ica74fb523d614349a5924b06d1bb5822_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfMy0yLTEtMS0w_5da47ab1-d7eb-4654-a4e1-7899838ca6f2"
      unitRef="usd">1031200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ica74fb523d614349a5924b06d1bb5822_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfMy00LTEtMS0w_033902dc-c32d-4ff0-981d-478c5ee4569b"
      unitRef="usd">998800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i1d11beb9b3fb491897b7a82b6680ddb2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfMy02LTEtMS0w_95e27bb9-3c53-44a6-8d27-56abea351c5e"
      unitRef="usd">1054100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i1d11beb9b3fb491897b7a82b6680ddb2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfMy04LTEtMS0w_30b1b04d-748d-4a11-8df0-18f93a8125c3"
      unitRef="usd">997900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9f2d4471ced94158a3b9461f37a5a9b4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNC0yLTEtMS0w_5dc5c718-1c5a-4226-b6d9-fb0c99b1995a"
      unitRef="usd">1927700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i9f2d4471ced94158a3b9461f37a5a9b4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNC00LTEtMS0w_23e3f44f-957a-4c4e-b4ee-c017cf8514fc"
      unitRef="usd">1742500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="iaa563a8c541342878a6a7502812ce7c1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNC02LTEtMS0w_683288f7-932f-41b7-8993-3069427e17e1"
      unitRef="usd">2003100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="iaa563a8c541342878a6a7502812ce7c1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNC04LTEtMS0w_81490900-61e0-4df0-a57a-1e6d6556adc9"
      unitRef="usd">1741200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i7a9933a802b04b7d8c62324f5f41c52a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNS0yLTEtMS0w_2a8fe049-33d0-4918-b453-474245db6ff6"
      unitRef="usd">1491700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i7a9933a802b04b7d8c62324f5f41c52a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNS00LTEtMS0w_4adb4419-7c6f-4654-a3fb-6dce47ef3f2d"
      unitRef="usd">1491800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i70a8801ef78b4c00a73f94dd2ce1a172_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNS02LTEtMS0w_83209318-f171-4aa9-9113-cd1900523b8e"
      unitRef="usd">1557200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i70a8801ef78b4c00a73f94dd2ce1a172_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNS04LTEtMS0w_3a035bc5-a6de-4aad-a976-dc36a3a73465"
      unitRef="usd">1491100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ia82ded1ca1fa4ec881505e83910f2470_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNi0yLTEtMS0w_6d5daa40-901e-44a0-b249-6fa3dafd54fe"
      unitRef="usd">1468200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ia82ded1ca1fa4ec881505e83910f2470_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNi00LTEtMS0w_e660f6a3-83e8-406a-aaf4-02a7fb292988"
      unitRef="usd">1099800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i819bef58752546e1bbb77cf85e7873c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNi02LTEtMS0w_5ed777e0-e012-48d7-8baa-6ae34617a6d5"
      unitRef="usd">2365100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i819bef58752546e1bbb77cf85e7873c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNi04LTEtMS0w_0c0c8a83-678e-4fd3-8aec-a0f8eb89b3b2"
      unitRef="usd">1723400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i86e1f0ba26984bf396b6de85e0803baa_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNy0yLTEtMS0w_725378c3-26f1-44e8-9d2e-cad5d734e78a"
      unitRef="usd">1443100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i86e1f0ba26984bf396b6de85e0803baa_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNy00LTEtMS0w_03149509-cc36-4b59-9e55-2950239f8159"
      unitRef="usd">1473000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i7fe6316e93084bcdb4bab71201828487_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNy02LTEtMS0w_95048d9f-22f9-4af8-a865-64577906f358"
      unitRef="usd">1536400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i7fe6316e93084bcdb4bab71201828487_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfNy04LTEtMS0w_b6738bf5-f338-4002-a152-b4038adc5b00"
      unitRef="usd">1472600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i53759aa6be6e42a1a94cf191019495cb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOC0yLTEtMS0w_ba54acf0-16c2-4a93-ad0f-85a9109a6619"
      unitRef="usd">684600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i53759aa6be6e42a1a94cf191019495cb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOC00LTEtMS0w_41fed5e3-9e7f-42af-a642-9f120ac4784e"
      unitRef="usd">465200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="idec1430297504929aeba4396860a0195_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOC02LTEtMS0w_5e952d36-c038-45c7-83ed-207f8dbc3a4a"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="idec1430297504929aeba4396860a0195_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOC04LTEtMS0w_5ea52fdd-6a4d-441d-922a-84426fb8b23a"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOS0yLTEtMS0w_6f7fd7a4-e9b4-44ba-a253-08e977ce4225"
      unitRef="usd">8046500000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOS00LTEtMS0w_7ba650c5-91c4-495b-8351-d0d2acd534ae"
      unitRef="usd">7271100000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOS02LTEtMS0w_192de73e-3784-41c1-95e2-4e4e449ea13f"
      unitRef="usd">8515900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjIwMGU1ZmFiYTE0ODRmYjJiMThhZWYyZDlhZmIxYWFlL3RhYmxlcmFuZ2U6MjAwZTVmYWJhMTQ4NGZiMmIxOGFlZjJkOWFmYjFhYWVfOS04LTEtMS0w_cfade741-d1e1-423d-923d-666a0562264f"
      unitRef="usd">7426200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia82ded1ca1fa4ec881505e83910f2470_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMzEwNw_abf5e201-92ff-4f09-8594-00da0b87a171"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:LongTermDebtExchangedAmount
      contextRef="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMzE4OQ_11a6dd8c-f06e-49cb-88a4-31ff7592709f"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="icc42842da7bc45f38b433b05022616d6_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMzI1MA_fc7f37b8-28c5-47ad-9620-38568f4de3d5"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53759aa6be6e42a1a94cf191019495cb_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfMzI3Mg_c93c44ed-027c-4ea4-8d16-c7b24e4b9b4d"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNTA4Mg_22c817f7-2eca-47e0-8681-0c2a5caa9a1c">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0ad055f43eed4c1abc91e33ba1c4c608_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMi0yLTEtMS0w_633e5a02-5df3-4332-a23f-ef751971b344"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i333a0bfdd0ca4d5180e70ebdd613c08f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMi00LTEtMS0w_6512a013-ec7e-416a-a426-0595fafccd03"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia0fdbee67b92424c881435c78e569bbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMi02LTEtMS0w_339519a6-f454-4733-9ba0-7df5547809a8"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5dab2decb1da48ad8d4b8e3c14967ebb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMi04LTEtMS0w_f108c6a7-55a2-4b13-b5c3-876d91b3ce1f"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMy0yLTEtMS0w_a0bc14ba-5cd2-4f94-a12a-c5bae9714b80"
      unitRef="usd">15600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMy00LTEtMS0w_3d7c555c-2eab-471a-beaa-97640b70f4d5"
      unitRef="usd">29000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMy02LTEtMS0w_f1730e18-7b8c-48da-9604-81b8ae4bbb61"
      unitRef="usd">49100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfMy04LTEtMS0w_e0038e68-e541-4005-9596-717db6ffc5a1"
      unitRef="usd">23500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfNS0yLTEtMS0w_089df3e8-0fa2-45ad-89af-abbd62cd1267"
      unitRef="usd">210700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id7814cf51367420694a7166e5ceff073_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfNS00LTEtMS0w_0d7a6a17-dd78-4d17-a5b0-e6a0f9a583f5"
      unitRef="usd">322600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2a7a60146fc349eab4e74a420635d5c4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfNS02LTEtMS0w_c686b7be-7992-4ebf-8550-6d7138699a05"
      unitRef="usd">210700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id7814cf51367420694a7166e5ceff073_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RhYmxlOjhhZDA4OGI3OGI0NTRjODk5OWM4OTNiZWM3MWIwZmFhL3RhYmxlcmFuZ2U6OGFkMDg4Yjc4YjQ1NGM4OTk5Yzg5M2JlYzcxYjBmYWFfNS04LTEtMS0w_7b74e523-3482-47d5-b057-839457323fca"
      unitRef="usd">322600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNDE4OA_8e33c92e-4202-40df-b212-7999ece935e3"
      unitRef="usd">210700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl82Ny9mcmFnOjU0NzFlYTVlMDU3YzQwODhiMmM5NzRlNWQxNjc1YWFlL3RleHRyZWdpb246NTQ3MWVhNWUwNTdjNDA4OGIyYzk3NGU1ZDE2NzVhYWVfNDE5NQ_ba64dc68-4f6f-4a6b-bba7-9b213c73478f"
      unitRef="usd">110300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTIxMQ_a9071640-e8c8-4c9a-b089-69473b8ec8b9">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;978.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,135.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,381.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,381.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,111.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,413.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,413.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,381.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,381.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities available-for-sale as of September 30, 2021 and December 31, 2020, was approximately 12 months and 11 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,360.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,028.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,240.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $1,222.3 million and $2,024.6 million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our strategic investment portfolio for the three and nine months ended September 30, 2021, was primarily due to decreases i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n the fair value of our investments in Denali, Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of zero based upon the fact that Sage and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Sage, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Denali, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, of which approximately 12&#160;million shares remain subject to transfer restrictions as of September 30, 2021.&#160;This equity method investment is remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#x2019;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Sangamo, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTIwMg_75b0f357-5260-474c-a358-e13a845c04a1">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;978.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i1ffca47ad8954ffd92872504490dcf03_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMS0yLTEtMS0w_e9e3bc2e-b9fa-4ca1-ab69-b675b48334cb"
      unitRef="usd">167300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ib77b83c10d6543c4999b42d941ff32fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMS00LTEtMS0w_294884ba-d5cc-4150-bac1-33472868a874"
      unitRef="usd">61100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="if652d73e263246e5831dc57a670a53fd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMi0yLTEtMS0w_fe293f3c-ffe2-456f-b7ea-c7f057beb6bc"
      unitRef="usd">213600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ib0d676501ffe4026b9c68ccd7f42aeb4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMi00LTEtMS0w_5d0dd715-b9e0-44f3-b5a4-5d1678d83b6e"
      unitRef="usd">37400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i13df0a9587724904b596ca62dcf43f6f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMy0yLTEtMS0w_64ac94ca-e1fa-49de-ba64-b47983778e74"
      unitRef="usd">485600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i2186b976c0174d35bd3cbdf1c89882c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfMy00LTEtMS0w_4013bcb2-c547-4d0b-985a-de8434dfb2f2"
      unitRef="usd">505100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id82eeedaf25949b28400154944eb6b4e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfNC0yLTEtMS0w_c4281cd2-6494-4709-bb3a-72f6d4ecbf23"
      unitRef="usd">112400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ife2f354a35fc496eba95703d7b607384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfNC00LTEtMS0w_ad5b5a4f-2218-4124-8974-08648fca2375"
      unitRef="usd">23300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfNS0yLTEtMS0w_81416ab0-b4d4-4384-82f1-a30fe54f4458"
      unitRef="usd">978900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmM1Y2NkZmVkODZhYTQ0Y2NhZGFkNTBiMDQ4YzZjNjhiL3RhYmxlcmFuZ2U6YzVjY2RmZWQ4NmFhNDRjY2FkYWQ1MGIwNDhjNmM2OGJfNS00LTEtMS0w_6432f33f-855c-4a7e-b757-ebd4405e7796"
      unitRef="usd">626900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTE5MA_373986ba-93c9-4198-835e-c90e33f2bc06">The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,135.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,381.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,381.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,111.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i52475161692a4e19be21e73c51c53526_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNC0yLTEtMS0w_f0b0baa7-a30e-4f85-a5dd-184bc4533c07"
      unitRef="usd">1135800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i52475161692a4e19be21e73c51c53526_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNC00LTEtMS0w_c93c7de3-a5ef-414d-9201-40df5752e6a9"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i52475161692a4e19be21e73c51c53526_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNC02LTEtMS0w_52a5b956-7620-46c9-9a92-9865814b67df"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52475161692a4e19be21e73c51c53526_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNC04LTEtMS0w_d3c7eab4-5a31-466a-b78c-a2a8fdf488fa"
      unitRef="usd">1135700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i049d807889c149e8a50eafa9f58bb8dc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNS0yLTEtMS0w_bff6eabe-4f59-4948-8962-f4235c9e5fe5"
      unitRef="usd">350700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i049d807889c149e8a50eafa9f58bb8dc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNS00LTEtMS0w_be99eba6-e16c-4745-a8d7-261570a5b8d0"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i049d807889c149e8a50eafa9f58bb8dc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNS02LTEtMS0w_6a3aa706-dbee-4f6a-a9f1-b849abb82c19"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i049d807889c149e8a50eafa9f58bb8dc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNS04LTEtMS0w_54d9956d-a679-4fbf-8230-fb0ab446d855"
      unitRef="usd">351100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if153048dd394454eb1fb423f72bda912_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNy0yLTEtMS0w_82f84ec3-ae3e-41ae-9ab3-9f837bf41730"
      unitRef="usd">277400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if153048dd394454eb1fb423f72bda912_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNy00LTEtMS0w_89aedec8-05df-4f3f-988a-14e50dbbf746"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if153048dd394454eb1fb423f72bda912_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNy02LTEtMS0w_eb6bf91a-2374-4317-8d37-dbb76a4ae1e2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if153048dd394454eb1fb423f72bda912_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfNy04LTEtMS0w_05ead992-6f81-4d54-a7fc-456f856250ea"
      unitRef="usd">277500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2a18efbacb6145cdb2a0021473063184_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfOC0yLTEtMS0w_1c28fa5f-e52a-4e54-94db-bb4bb2537539"
      unitRef="usd">435500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2a18efbacb6145cdb2a0021473063184_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfOC00LTEtMS0w_93c89ca0-5654-4df4-b618-d218dd71b539"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2a18efbacb6145cdb2a0021473063184_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfOC02LTEtMS0w_1eea8df7-e18e-4bc0-9c6e-63e1c71ce5e3"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a18efbacb6145cdb2a0021473063184_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfOC04LTEtMS0w_22059eed-9eb0-4720-99f7-6288681ea642"
      unitRef="usd">435400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if70a9c11bf614396a6522c901ecb08f1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTAtMi0xLTEtMA_41def94d-d716-4b3f-ab2c-2404e1e4f47d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if70a9c11bf614396a6522c901ecb08f1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTAtNC0xLTEtMA_e4f4fff9-c5f0-4905-a7ee-4bd2d5dffe4f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if70a9c11bf614396a6522c901ecb08f1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTAtNi0xLTEtMA_3a022fd9-8d91-4253-a0e7-ed3b0428d8c8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if70a9c11bf614396a6522c901ecb08f1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTAtOC0xLTEtMA_ba43206a-905d-49a6-b530-5d71c2e2c7f9"
      unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if077767e3ef64c2484a2cc92234da011_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTEtMi0xLTEtMA_203574df-0865-48da-9b1a-add42773762d"
      unitRef="usd">182000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if077767e3ef64c2484a2cc92234da011_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTEtNC0xLTEtMA_76bdcb17-171d-4fba-889b-36a758a79834"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if077767e3ef64c2484a2cc92234da011_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTEtNi0xLTEtMA_2fa00ab4-baec-4838-91f4-50d4f057e80b"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if077767e3ef64c2484a2cc92234da011_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTEtOC0xLTEtMA_514ef904-fb1d-4083-aac3-fd7c75d0b5a4"
      unitRef="usd">181800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTItMi0xLTEtMA_f248895e-185d-4bf0-9266-61f9ee31efab"
      unitRef="usd">2381500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTItNC0xLTEtMA_46794737-fddc-4aae-b6a9-fd6ea004d1aa"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTItNi0xLTEtMA_eeb3477a-efaa-48a3-abac-dcbc30a04b38"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTItOC0xLTEtMA_266d35be-f8c5-4c52-92a9-70a892204c7b"
      unitRef="usd">2381600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i44917b25ade349a8a5f06df642623475_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTUtMi0xLTEtMA_f1b66c5e-1e96-46b2-b905-1d577e384310"
      unitRef="usd">35500000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i44917b25ade349a8a5f06df642623475_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTUtNC0xLTEtMA_4cebc78c-071d-4b1a-b354-db95445d0ceb"
      unitRef="usd">19500000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i44917b25ade349a8a5f06df642623475_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTUtNi0xLTEtMA_0a02f62e-3483-461f-8e6f-02c347dc8890"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i44917b25ade349a8a5f06df642623475_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTUtOC0xLTEtMzAyODI_a8836105-6b69-499d-b329-cb0f7fc83d35"
      unitRef="usd">55000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTYtMi0xLTEtMA_03156602-76a9-4ea0-9cbc-63dbc12d67a5"
      unitRef="usd">1133400000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTYtNC0xLTEtMA_41b2b79e-069a-433c-ab4b-97133b0d8958"
      unitRef="usd">238400000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTYtNi0xLTEtMA_1a686ead-7096-4e3e-a43e-a080d6741f63"
      unitRef="usd">260600000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia2e6f46d9b0a4f2988302c331ab0ef26_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTYtOC0xLTEtMA_26f53c7d-98d2-48a3-b5db-a9c20afc4ca8"
      unitRef="usd">1111200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTctMi0xLTEtMA_e745a4d1-1c55-40f2-8592-34736373ae4d"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTctNC0xLTEtMA_99cec9da-4e8e-4ee0-84d8-7d52d0391e32"
      unitRef="usd">257900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTctNi0xLTEtMA_15865413-ba38-4bd8-9a19-45991714dc4d"
      unitRef="usd">260600000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmQ2ODVjYjRkMmQxMjQ3ZThiZGZkNzQzMzFlMGRiNjczL3RhYmxlcmFuZ2U6ZDY4NWNiNGQyZDEyNDdlOGJkZmQ3NDMzMWUwZGI2NzNfMTctOC0xLTEtMA_32daf9cc-e42c-47d4-b89a-8c7630546843"
      unitRef="usd">1166200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i470da7200d18439f98b62a166787441a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNC0yLTEtMS0w_7c7a4ebe-30a7-453d-a89c-ee893493a416"
      unitRef="usd">897800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i470da7200d18439f98b62a166787441a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNC00LTEtMS0w_68a50595-20b0-46b6-8266-1e738f536caa"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i470da7200d18439f98b62a166787441a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNC02LTEtMS0w_3825b000-0191-43d3-9aa9-99ceb9a68b81"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i470da7200d18439f98b62a166787441a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNC04LTEtMS0w_c6bd7dc7-f6eb-4247-84c9-580b760aef74"
      unitRef="usd">898000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie3caddce2c0c4c20a79927c2312baf96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNS0yLTEtMS0w_6fdb2d16-5d54-4b37-9de4-51abee022070"
      unitRef="usd">402500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie3caddce2c0c4c20a79927c2312baf96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNS00LTEtMS0w_62ef4e90-6862-47e3-aa07-184815be73e7"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie3caddce2c0c4c20a79927c2312baf96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNS02LTEtMS0w_747a4972-7bf2-490a-890b-79a2f47ab2c1"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3caddce2c0c4c20a79927c2312baf96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNS04LTEtMS0w_5dc3f539-8a3e-48d0-a530-53207d02dd19"
      unitRef="usd">403500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib4bd7705008143a9ba46119d91dce67d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNy0yLTEtMS0w_7ff7d727-242e-4f70-82c9-078d974f53da"
      unitRef="usd">380600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib4bd7705008143a9ba46119d91dce67d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNy00LTEtMS0w_ecbc6bad-b9fd-4a26-a594-dac3b1b545df"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib4bd7705008143a9ba46119d91dce67d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNy02LTEtMS0w_873f3cb5-4af9-4653-b99e-a4503e6a613b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4bd7705008143a9ba46119d91dce67d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfNy04LTEtMS0w_e7a519ad-7f86-4caa-b078-9aa6be27843f"
      unitRef="usd">380700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6bfcb2b7a789408ab7429d172cf3b595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfOC0yLTEtMS0w_fe98623e-f1a2-4dcc-ac24-3b5ebf69a309"
      unitRef="usd">245900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6bfcb2b7a789408ab7429d172cf3b595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfOC00LTEtMS0w_d4cf15cf-c97b-4d2f-8209-f8d6f708aaaf"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6bfcb2b7a789408ab7429d172cf3b595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfOC02LTEtMS0w_94c2e014-d520-46c7-beac-98c8780301b9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6bfcb2b7a789408ab7429d172cf3b595_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfOC04LTEtMS0w_3b5e112a-f83d-46c5-8055-f5c64108385d"
      unitRef="usd">246400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7673265729c248e8b545dd7073d36204_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTAtMi0xLTEtMA_9731bccd-338c-4b45-b6cd-0ff4df6db0c1"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7673265729c248e8b545dd7073d36204_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTAtNC0xLTEtMA_bfce90c3-6a62-430e-a209-88921ef8a3de"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7673265729c248e8b545dd7073d36204_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTAtNi0xLTEtMA_ab6ff231-138b-4ba4-9577-29d8c0104ae8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7673265729c248e8b545dd7073d36204_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTAtOC0xLTEtMA_6f6175eb-6164-41c7-ac7f-a7e74d4e71fb"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idea3ebd667744c9381c73def31f719fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTEtMi0xLTEtMA_b11c6bd0-7f4e-44df-bb40-05c8b33635e9"
      unitRef="usd">122100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idea3ebd667744c9381c73def31f719fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTEtNC0xLTEtMA_01c4b3f1-05c2-4a4e-8fe7-e1f39c7ff5ba"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idea3ebd667744c9381c73def31f719fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTEtNi0xLTEtMA_a7609db6-1c5f-4e19-aea3-3da022338e85"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idea3ebd667744c9381c73def31f719fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTEtOC0xLTEtMA_a69ec626-7273-4f87-a226-e3631e79277c"
      unitRef="usd">122200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTItMi0xLTEtMA_4db7c4cf-94c1-47e8-a77b-4c234703f612"
      unitRef="usd">2049100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTItNC0xLTEtMA_6a73760d-36c1-4f6c-a7fb-714c9f938406"
      unitRef="usd">2300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTItNi0xLTEtMA_6d6b5279-41d9-4823-8b3f-40b36c855f3f"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTItOC0xLTEtMA_134f7440-920b-470e-a575-e8a5d7f73761"
      unitRef="usd">2051000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="iee2c365225e34a9da8933f6b3cbf7de6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTUtMi0xLTEtMA_e1c1a366-6fa8-48ce-a7e2-e2446c702b88"
      unitRef="usd">70600000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iee2c365225e34a9da8933f6b3cbf7de6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTUtNC0xLTEtMA_03adcbde-8334-4092-ba0f-d0976044f296"
      unitRef="usd">15900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iee2c365225e34a9da8933f6b3cbf7de6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTUtNi0xLTEtMA_9d61462e-35d0-49a6-a437-14460c9ef52b"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iee2c365225e34a9da8933f6b3cbf7de6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTUtOC0xLTEtMA_bebd9ac4-e55c-4033-9ab8-1f134dd276e2"
      unitRef="usd">86500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ib4655f3abc15413baad6a40cd42927c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTYtMi0xLTEtMA_6d240362-4d0f-4852-bb4c-5eba266cc30f"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib4655f3abc15413baad6a40cd42927c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTYtNC0xLTEtMA_48c7b8bd-35d9-4830-b9fa-6c907f0b0cae"
      unitRef="usd">733800000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib4655f3abc15413baad6a40cd42927c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTYtNi0xLTEtMA_a2175604-e726-4f6e-8a57-05ff5b124fbd"
      unitRef="usd">14900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib4655f3abc15413baad6a40cd42927c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTYtOC0xLTEtMA_99ff0a04-8ea5-4b4d-847b-e17d441bb02b"
      unitRef="usd">1887800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTctMi0xLTEtMA_b49285e8-77b3-4a92-96f5-a956d5ee629b"
      unitRef="usd">1239500000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTctNC0xLTEtMA_abcf3c68-9928-4d6e-906a-2b3f90f8fb93"
      unitRef="usd">749700000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTctNi0xLTEtMA_dbf0381f-fc63-4a86-833b-c22623971307"
      unitRef="usd">14900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmVkNzhjNDhjOGMwMzQ2MDJhZGZlYTg0NTkyYjJmY2RmL3RhYmxlcmFuZ2U6ZWQ3OGM0OGM4YzAzNDYwMmFkZmVhODQ1OTJiMmZjZGZfMTctOC0xLTEtMA_8305a51f-5cea-41c8-bac5-d6eee533115b"
      unitRef="usd">1974300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTE5MQ_54ed28f0-dbc9-44da-bba4-519b2be451f2">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,413.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,413.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,381.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,381.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMi0yLTEtMS0w_d97f743c-e119-4338-999b-4ce1962438f7"
      unitRef="usd">1413300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMi00LTEtMS0w_62aff1f5-f85d-4dda-9916-c636086e710a"
      unitRef="usd">1413400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMi02LTEtMS0w_f981478b-ad3a-4957-8b34-c7727c2de157"
      unitRef="usd">1278900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMi04LTEtMS0w_aeadf1b7-77a0-42b7-8d6d-9b584ebb4f75"
      unitRef="usd">1278600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMy0yLTEtMS0w_cdc4f9d3-0778-4119-bf07-558c3a2d5090"
      unitRef="usd">925500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMy00LTEtMS0w_7c899fb3-a9b9-46b9-bb2d-f33186824662"
      unitRef="usd">925300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMy02LTEtMS0w_9dccf430-c221-4456-9dd2-58f3000b6064"
      unitRef="usd">722600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfMy04LTEtMS0w_238b749b-208f-4898-b078-aa53674409ee"
      unitRef="usd">721300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNC0yLTEtMS0w_8d265078-d43d-479c-a6cf-c06aaba2dba8"
      unitRef="usd">42800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNC00LTEtMS0w_8c0cd720-6326-4d9e-9231-8f58c2aeece6"
      unitRef="usd">42800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNC02LTEtMS0w_05644fe5-dd81-4bbf-9df6-49d704a0e481"
      unitRef="usd">49500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNC04LTEtMS0w_568e127c-34c2-461d-aecf-f01722596801"
      unitRef="usd">49200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNS0yLTEtMS0w_6d4b2633-e385-4f06-9f11-c9a855adbb05"
      unitRef="usd">2381600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNS00LTEtMS0w_e037bef4-6c46-404d-968f-3688ae36fe66"
      unitRef="usd">2381500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNS02LTEtMS0w_651e41a7-aec1-4a6d-80f3-94ff6ce86917"
      unitRef="usd">2051000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOjJkMDhmNWRjOTM5ZjQyMDFiMDZjMjY2MDQxNmI5MWIxL3RhYmxlcmFuZ2U6MmQwOGY1ZGM5MzlmNDIwMWIwNmMyNjYwNDE2YjkxYjFfNS04LTEtMS0w_9619ae7f-6b36-498e-9dbe-12c93ebe948e"
      unitRef="usd">2049100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMTAyMw_31dbc7c9-3aa2-4c48-80a7-382d0653f886">P12M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="if87653e954194d689bd182fc5b42da74_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMTAzNw_e0b82f91-7754-4159-8389-b01a1790a43b">P11M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNTE5NQ_424b02fb-09f8-4ce7-ba30-1bfc7c5b7fee">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,360.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,028.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,240.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMi0yLTEtMS0w_9cb2fa8d-e923-40da-8dfd-151d894b1392"
      unitRef="usd">575400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMi00LTEtMS0w_7243fe40-a47a-4d4f-85e9-1deec71c90db"
      unitRef="usd">1360900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMi02LTEtMS0w_29b6d45e-a8c0-43f5-a24a-0ac7958dc030"
      unitRef="usd">2028100000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMi04LTEtMS0w_d52db38b-0442-4b38-a5b8-976af777d086"
      unitRef="usd">5240700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMy0yLTEtMS0w_d13b8c59-47f7-4462-a62a-c548bd526ac6"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMy00LTEtMS0w_3c83702a-292d-4424-8705-450e13794bfc"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMy02LTEtMS0w_08759dba-c444-466f-906d-4dc2eac3b2bc"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfMy04LTEtMS0w_686a9c57-3905-47b4-bd12-27474cecb367"
      unitRef="usd">12800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfNC0yLTEtMS0w_ebd7078b-18c6-49b9-b7d6-b4f09ca696d6"
      unitRef="usd">500000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfNC00LTEtMS0w_c031f0ae-d132-443d-80b0-1ec0dc072db8"
      unitRef="usd">900000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfNC02LTEtMS0w_10e1089b-4b5f-4f6c-b54a-cc7bbc1c91fc"
      unitRef="usd">1700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RhYmxlOmU1MTRlYzZhOWY4YzQ0OTFiNjg5YjUxZjUxNTRjNDZiL3RhYmxlcmFuZ2U6ZTUxNGVjNmE5ZjhjNDQ5MWI2ODliNTFmNTE1NGM0NmJfNC04LTEtMS0w_a2ab5158-5305-4c58-9fec-345f22046186"
      unitRef="usd">25200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="i34d19a6c1cce48f890b4ff8854eb063e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMTM1Mw_ca857933-7eaa-47b0-9dc3-29b04b09de48"
      unitRef="usd">1222300000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="ia67769f4d9c64b70b1ee25a453d4c188_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMTM2MA_1d3870e2-ef84-44ae-b898-d56d6f4c0143"
      unitRef="usd">2024600000</biib:StrategicInvestmentPortfolio>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMjQ2Ng_888c760d-b56b-4f3c-a845-e6175728d0ed"
      unitRef="usd">650000000</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMjQ3MA_fc3f42df-4272-473c-973e-c57e8f141cab"
      unitRef="shares">6200000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMjQ3NA_2d81b58e-e068-49e7-a1f5-f14808704a17"
      unitRef="usdPerShare">104.14</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <biib:DividendYieldPercentage
      contextRef="if7c54edc6349456abaaa90d10aa21a29_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzEyOQ_243fe287-d894-4637-8854-7045fa9399c4"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzUzNw_6e20d8e5-d23e-4ffc-9078-d9ca338a5278"
      unitRef="usd">465000000</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:Investmentincommonstocksharespurchased
      contextRef="if8b5d9e350944ffdad686ff95dd1085f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzU0NQ_96dfe927-f8bf-4032-a8f5-9f38a647d366"
      unitRef="shares">13000000</biib:Investmentincommonstocksharespurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzU0OQ_1346b44b-01ee-4e49-bffb-63c454ffc772"
      unitRef="usdPerShare">34.94</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <biib:DividendYieldPercentage
      contextRef="i2f721455f7aa4586a968ec0031e919d8_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfMzgzNg_ff79a3c7-b93e-4ff0-ba91-383d8dc7ee90"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDE5NQ_8b76c249-5726-4861-a144-6e5f1c2ea28d"
      unitRef="usd">225000000</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDE5OQ_96b27272-81b8-4f50-8394-25e5b1a99ae2"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDIwMw_594b7d56-d232-4ec1-8da5-ebbf70f9cdc1"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <biib:Investmentincommonstocksharespurchased
      contextRef="i8ea2f828e08946f9bfe96108463cde78_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDI0MA_f736b3cc-d8fc-499b-bd25-5c9a22c3dec1"
      unitRef="shares">12000000</biib:Investmentincommonstocksharespurchased>
    <biib:DividendYieldPercentage
      contextRef="i2139678da5ba44c692cbccf26f3f86ad_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83My9mcmFnOjU1MGJkYjI2NzI2YzQ5NjY5Mjk4ZDY0YjEyOWVjNjlkL3RleHRyZWdpb246NTUwYmRiMjY3MjZjNDk2NjkyOThkNjRiMTI5ZWM2OWRfNDkxOA_ea45ab58-c519-40a2-8299-e6999cad5bcb"
      unitRef="number">0</biib:DividendYieldPercentage>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk2OA_455b93d5-8d99-491d-80ba-7d8887a72fed">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts in effect as of September 30, 2021 and December 31, 2020, had durations of 1 to 18 months and 1 to 24 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,901.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,979.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,080.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of September 30, 2021, reflected aggregate net unrealized gains of $21.9 million, composed of gross unrealized gains of approximately $38.4&#160;million and gross unrealized losses of approximately $16.5&#160;million, compared to aggregate net unrealized losses of $212.5 million as of December 31, 2020. We expect the net unrealized gains of $21.9 million to be settled over the next 18 months, of which $9.6 million of unrealized gains are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of September 30, 2021, had a remaining duration of one month. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $25.0 million and net losses of $21.2 million as of September 30, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.0 million and $0.2 million as of September 30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,400.6 million and $1,158.0 million as of September 30, 2021 and December 31, 2020, respectively. Net losses of $13.5 million and $26.1 million related to these contracts were recorded as a component of other income (expense), net for the three and nine months ended September 30, 2021, respectively, compared to net gains of $7.8 million and $13.7 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i2c77f922da23412fad540d818c968248_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjIz_035ad2f6-3216-4d19-8788-cb281c15b8f7">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i6cf82a6b484d49e69065707a4f3422d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjI5_6008b8fd-1f37-4bd0-821b-be169dd5e779">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ic165a79eab2e42c1a838d2b473206e5a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjM2_2f86d7ca-3b27-4fae-beea-49fd1654f41d">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i1d4b70e429084cd896ddee8ad6a86f58_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjQy_56fb7550-4a8a-4e65-9a53-bada8ecc1413">P24M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk4OQ_23eea25f-4af2-4d4e-8a90-d24a10bce64a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,901.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,979.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,080.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic55d56fb32ff46218a8edddf870dc788_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfMi0yLTEtMS0w_16bfff56-709d-4684-9319-0ad3b8b79b35"
      unitRef="usd">1901500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic059a695f5624475b5bce97e745827bd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfMi00LTEtMS0w_13d3fef5-1085-42e1-a472-4fe3abd05416"
      unitRef="usd">2979100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id661e83da0184b60b9078c3003d2d512_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfMy0yLTEtMS0w_10376261-379e-4e54-8752-e9467a506e67"
      unitRef="usd">63600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i57f88181fe304ebb96cc0a68b0ae12ba_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfMy00LTEtMS0w_1f792083-7a45-4ec6-8392-25d0019ba159"
      unitRef="usd">250600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i03aec522673d41f1bcbf6cdcdf6cac4d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNC0yLTEtMS0w_c11cb641-37bd-4eaa-9adf-295d344af250"
      unitRef="usd">60400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if46410444ba14e6092450fb22efffc1a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNC00LTEtMS0w_3d6e459e-b6b9-4bce-a41e-eafa2fb0ec8e"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i882caa9f1b214f12a34a044e78765486_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNS0yLTEtMS0w_ce2d9f78-ed82-4e53-a274-0f3bfc94a725"
      unitRef="usd">30100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib8af15663b9a4d8d94e49f9f51c463d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNS00LTEtMS0w_d5833593-5bb9-4ccc-bd3e-98b890a10dde"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i23d2d53f1521473fb2e87b588a892372_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNi0yLTEtMS0w_ef9a5de1-c0e3-43a8-b089-028e4c328e32"
      unitRef="usd">25200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i67cf121e430342109d49fea777e579bf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNi00LTEtMS0w_f27ca7f4-7be6-47fb-ac17-9850367811cc"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1ac6c255d1f3477ab244bffeaf22cfc6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNy0yLTEtMS0w_08a6476b-8466-4950-817a-01819a5f9ea2"
      unitRef="usd">2080800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i34a88eef09354000953b0bed96387192_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjZmYzZlZjBhYjczNTRkZWFiMTRlYThmNDQ1ZDY5MWYxL3RhYmxlcmFuZ2U6NmZjNmVmMGFiNzM1NGRlYWIxNGVhOGY0NDVkNjkxZjFfNy00LTEtMS0w_071a8a98-2370-4e7d-9f98-c7b2a1dad672"
      unitRef="usd">3229700000</us-gaap:DerivativeNotionalAmount>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMTgxOQ_f60a37ca-8980-44e0-a8c1-c5b77a9f4f4d"
      unitRef="usd">21900000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMTg3Ng_0ff6741a-84f0-465f-b501-29acb96de9a0"
      unitRef="usd">38400000</biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMTkyMw_586ff4be-c85d-46ac-9583-24db9fe34a0d"
      unitRef="usd">16500000</biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMTk3NA_609ebd86-8569-42f3-b793-52d4f5bbed1a"
      unitRef="usd">-212500000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMjAyNg_f60a37ca-8980-44e0-a8c1-c5b77a9f4f4d"
      unitRef="usd">21900000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i6cf82a6b484d49e69065707a4f3422d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMjA1Nw_380c7109-0ae1-4472-8a89-2f7055526838">P18M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i70ca240b4a8a434dbdfdea26e500aee9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMjA3MA_af9a35d0-d09d-4b25-8c4f-afc72435559e"
      unitRef="usd">9600000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i01b54841e3504571a9b44de5987e542d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMjEzNQ_6f567fc2-1609-4491-a065-cec9fd455fe2">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk2NA_2482d18e-8899-4072-ad8a-621821d815f6">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ie35d98789f1244be9ad4952ccbcc7c4e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfMy0yLTEtMS0w_394d65f4-655a-48b3-849d-9c9b99c073c8"
      unitRef="usd">-14900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i06a80f6779864dd992819b8e00be88b8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfMy00LTEtMS0w_6114d87b-eea0-4c90-98b8-19d3fe42e4e8"
      unitRef="usd">-9100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ib71e595781d44f16ac699138752f0bc8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfMy04LTEtMS0w_121ccfcc-53d5-4f2d-a806-0e89d2234951"
      unitRef="usd">-700000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i3cac1f347b104a4ca1db20bec5c47875_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfMy0xMC0xLTEtMA_f96a8b83-9849-46c1-be05-5a2485c430d3"
      unitRef="usd">-8700000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="id7c37dca65684a5e9f14392ae29cbaaf_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfNC0yLTEtMS0w_69bb84b6-a48a-446c-b9f0-5ee2e743d36e"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i5c3ff6d74036499d8a7471834819584b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfNC00LTEtMS0w_a9ac3f84-93f8-44d2-ba87-f13d203c9545"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ica4d96484afd47e3875930a4f7e88de5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfNC04LTEtMS0w_67f8d827-1ffe-4d84-bc91-6fe4a31a9cab"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i7805cce3a52041d3b30f7a27f60fda1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmE3MDlkYjVmNmYyNjRhMzBiNDAyODY4Mjc1YzQyZTJhL3RhYmxlcmFuZ2U6YTcwOWRiNWY2ZjI2NGEzMGI0MDI4NjgyNzVjNDJlMmFfNC0xMC0xLTEtMA_058bd27f-c032-4a4f-a657-9baef9037eb4"
      unitRef="usd">400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic725003c511544d9beede7d62b22bf41_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfMy0yLTEtMS0w_6d75584b-f8e8-4ea8-a8cb-88fcfe23b1cc"
      unitRef="usd">-68700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i021468994763467d8c149cb0f1b5dc8c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfMy00LTEtMS0w_4c362ece-5730-487c-a02b-da4a147b8c7b"
      unitRef="usd">41600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="if05a13a77e61439a8dd0d989c1ff1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfMy04LTEtMS0w_286cf95c-34cf-470b-91f9-e2e019ae2bea"
      unitRef="usd">-4500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i7069a9554d224968b39144be715d4ba2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfMy0xMC0xLTEtMA_3d85cbe7-59da-4c0b-9be3-a8e97b940201"
      unitRef="usd">-1000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i954add7d31b64b3698c2961782705265_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfNC0yLTEtMS0w_27d45d7b-1498-42f0-8f4c-0d06b1cb19c1"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i662080f3255e4599a8eb926798a5d4f1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfNC00LTEtMS0w_a4ef4cb1-e37a-4a15-8b37-488acbe06e07"
      unitRef="usd">1400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i3d1ad6684545445c81eaf1e55b9da3a0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfNC04LTEtMS0w_bb598dbd-d342-463c-820f-85531d9fc82e"
      unitRef="usd">-400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="if04673d30367460fa2896b503cf49adc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOmNkYzQwMDc2ZmQ2YjQ1OWU5NjRjMTdmZDBhYmViNjczL3RhYmxlcmFuZ2U6Y2RjNDAwNzZmZDZiNDU5ZTk2NGMxN2ZkMGFiZWI2NzNfNC0xMC0xLTEtMA_9ce7802b-a1c1-480b-9618-63b0ce2a20b3"
      unitRef="usd">-700000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iadac69438a134e4685f396b8c53251d4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzA1NQ_78d51bac-1fac-42e3-98c0-54d3b1f3ab0b"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i25c14487107748cf8adf0aa48b1089e7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzE2OA_7d552f0c-1026-4e9b-9d95-35a8f3019368"
      unitRef="usd">675000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iadac69438a134e4685f396b8c53251d4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzMyMw_78d51bac-1fac-42e3-98c0-54d3b1f3ab0b"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iadac69438a134e4685f396b8c53251d4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzQ4MQ_78d51bac-1fac-42e3-98c0-54d3b1f3ab0b"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ib4f3485174db4d7c876667900c74e5bf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfMzUzNQ_3314b152-054a-4418-bd6f-4945ac76c5bc"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="ifa2615942dbc42b59096307ded3cc0c3_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDA0OA_7ab0906b-cc1c-4313-b171-a2e493889692"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDA2OA_9cf11c30-fbbc-4cab-af2a-eea0fe4cf3f3"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="icc31d40d106d4c9f992098cfdbc25314_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDE2MQ_22b20347-bf26-4484-9885-4f1310055d04"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="icc31d40d106d4c9f992098cfdbc25314_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDE4Mg_68f31942-cfe6-4e09-9f78-97336e227413"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDU1NQ_26b9dafd-213b-401d-94e2-ba6bbf6739da">P1M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDkwOA_304cbb65-1865-4846-a904-63d257065131"
      unitRef="usd">25000000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i32d14a7ea6f44f81ab85c9eb63555a65_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNDkyOQ_f25713ec-1554-43d7-b93a-f6f435d86569"
      unitRef="usd">21200000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i8b619c6a194a48d79f50c3ece23badc4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNTM2NA_a4d7b5ce-061d-4042-b4b0-3078da66d91a"
      unitRef="usd">0</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i71ead7913c08409dbc2595365e9f3e52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNTM3MQ_a8bd2028-b31b-40ba-9cdc-68b0b8adc58a"
      unitRef="usd">200000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk2OQ_2bba5fa9-99ca-473a-9533-a809a2647392">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i4c68d2f0c36b4aa0873859e893028f61_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy0yLTEtMS0w_1540f903-5a53-4258-907a-54c8d6622d1b"
      unitRef="usd">24900000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ie613980df7054b379c880bbe236bd443_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy00LTEtMS0w_77571e65-e225-4cb3-ae8d-ef8c1f945cbf"
      unitRef="usd">-10400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i4c68d2f0c36b4aa0873859e893028f61_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy04LTEtMS0w_8aec8e6e-d61a-4ad5-951d-673e177c1e69"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="ie613980df7054b379c880bbe236bd443_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy0xMC0xLTEtMA_e146a426-cdfe-4ca9-924e-92b76fc30408"
      unitRef="usd">-200000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="iad3d42fc3ea64bd198bebd63ceb7ccd7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy0xNC0xLTEtMA_d26ac8e2-13b1-49f4-9a11-2b6f86afb614"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i44dd1a2f10914daa9af2e90f8b3c8807_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjcwZGRlNTdiMjBiZDQ4ZWNhZjg3YTk0YWJiM2M3MzlmL3RhYmxlcmFuZ2U6NzBkZGU1N2IyMGJkNDhlY2FmODdhOTRhYmIzYzczOWZfMy0xNi0xLTEtMA_3c60dffd-088b-405a-99cd-74c2b70c47bb"
      unitRef="usd">900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy0yLTEtMS0w_6f4f8c80-bd98-4270-bfb2-fd4aa5b85d8f"
      unitRef="usd">46100000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="if1200adb5dbe47c7ae6a9a4a6961c216_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy00LTEtMS0w_a3d2b41c-8869-4592-8cff-2205a856a584"
      unitRef="usd">5000000.0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="ib8e0e853f66b4d49b5aa0a3052ffbafc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy04LTEtMS0w_372eac42-bed4-4e5b-a36b-a8bf6fc3859d"
      unitRef="usd">-1100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="if1200adb5dbe47c7ae6a9a4a6961c216_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy0xMC0xLTEtMA_38214b85-8758-462a-ab8f-8ac9383891e9"
      unitRef="usd">3100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i1c93a139bb224308a3c7a36175e4107a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy0xNC0xLTEtMA_327e45cd-a5ea-42c9-a87f-b3c06074538f"
      unitRef="usd">100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="ic554f230362f471382f660791fcc865b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjg2YTFlZTM1MWE4ZjQ1NDNiMjEwNzBlMjdjZDE5NzBjL3RhYmxlcmFuZ2U6ODZhMWVlMzUxYThmNDU0M2IyMTA3MGUyN2NkMTk3MGNfMy0xNi0xLTEtMA_e192674b-1601-4176-be0d-c4a8d31f514a"
      unitRef="usd">2600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0a7748b009f646c8b31119a5c17aae59_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjA5MA_cf5fdc4c-89cc-4be9-8324-8055609ea305"
      unitRef="usd">1400600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib61f3acadd75433c99101969cf66411c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjA5Nw_e3959888-ffe2-45f0-9d73-17422f293db6"
      unitRef="usd">1158000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjE0NA_0e796297-c3c1-464b-9a4b-03cfd82da11d"
      unitRef="usd">-13500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjE2NQ_18f7292b-d8fd-4361-9732-6575376721ec"
      unitRef="usd">-26100000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjMyOQ_df99a7a2-c8e4-4e0d-8712-0ce3c735c6a1"
      unitRef="usd">7800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjMzNg_9763b831-62a8-4587-ad24-d6248de238db"
      unitRef="usd">13700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RleHRyZWdpb246OTcxOTA4MWM2MTNkNDAzZjk5NjczNGUyNTRlYTFhMjJfNjk2Ng_c37eb5dd-98c9-441b-af04-3da212675678">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6968467d8d7b4c5c8a741ebc7f01c64b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMi00LTEtMS0w_ec4b39fb-ed99-4ded-b77a-439c99627a1d"
      unitRef="usd">34500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ifdd697e3d7934db0959c809bdc451568_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMi02LTEtMS0w_fb568790-e6ca-4362-a531-33a3ea61fa7a"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i481db3700c604a1bb15870d0cef6b1ad_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMy00LTEtMS0w_1214f71d-3e63-4718-9a8c-e17e6f17c0d3"
      unitRef="usd">14100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic5e3b2b199db482c94d883952512475d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMy02LTEtMS0w_875af8cf-7aea-4a3a-b759-87cf2dc34ead"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="icffd2e05c3e949db9d2bb4ffb7775e8a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfNC00LTEtMS0w_f737580e-7817-492e-9baa-cd6e5c7244ae"
      unitRef="usd">11800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia0fd194e4f7a43a08b6a326d74102423_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfNC02LTEtMS0w_c37c9133-e51c-4334-b50c-bb0a55c6c054"
      unitRef="usd">157100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibe8a70ef8aa048c2a91453d9a5dc5e74_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfNS00LTEtMS0w_d3edea73-5573-4ecd-8988-2d8a43b9807a"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i69578acd699b413fbb7d39b34e455de0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfNS02LTEtMS0w_886e9b5e-484b-468c-aad5-a2615bffec89"
      unitRef="usd">35700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="icddb8a04e2884668aba19d51821c5e40_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfOC00LTEtMS0w_c9a91e99-2fa9-4b6c-99cf-69dfbe08d5ad"
      unitRef="usd">25300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i10aaea33d60c4e62b5c5437eb9aeef95_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfOC02LTEtMS0w_a48c6150-3344-4797-824d-8b19acfda3ca"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ib911d65ad5594eb4ac4bcf4afb56823b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfOS00LTEtMS0w_fe5abcf2-321b-46db-a4f8-0188d4ea6a82"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3a39e90d5a084a6a82c0789525824916_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfOS02LTEtMS0w_6ed949c8-f314-44c0-96b9-92b0e2ccdf71"
      unitRef="usd">19700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib8d23192df14482d8fa3fe146523c99f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMTYtNC0xLTEtMA_a0bfe09d-3359-46ad-876c-0698eb03ca45"
      unitRef="usd">6100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib101119d811b445ea7aebef90a37dad9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMTYtNi0xLTEtMA_ed14edc2-8ddc-4348-9706-c5c871f1461c"
      unitRef="usd">20500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i15bfdcd49c954e93ab09b4090c28ce32_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMTctNC0xLTEtMA_f63f9e8a-034f-4cfe-97cd-48b653e12ca1"
      unitRef="usd">15900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9c6b9edb2b704d33991c8e9a2425f671_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl83OS9mcmFnOjk3MTkwODFjNjEzZDQwM2Y5OTY3MzRlMjU0ZWExYTIyL3RhYmxlOjA3NGFmYTZmM2YxOTQ4YWE4ZDcyMzliZDY4YjE5YTlmL3RhYmxlcmFuZ2U6MDc0YWZhNmYzZjE5NDhhYThkNzIzOWJkNjhiMTlhOWZfMTctNi0xLTEtMA_9857a2ae-3aba-48c6-a33f-5fe7b41bb703"
      unitRef="usd">4700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMTIwMQ_13e52fc7-086c-46f1-bb2b-03b81f764bab">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,944.2 million and $1,782.3 million as of September 30, 2021 and December 31, 2020, respectively. For the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021, depreciation expense totaled $65.1 million and $168.7 million, respectively, compared to $51.5 million and $151.2 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2021 and December 31, 2020, we had approximately $661.8 million and $1.8 billion, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2&#160;billion of fixed assets being placed in service during the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMTcx_3dcbe556-764a-4dd6-b042-067ab578eb0c"
      unitRef="usd">1944200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMTc4_ebf2de70-70d0-4de3-ace0-1e4fbe5acb34"
      unitRef="usd">1782300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMjc2_c1308655-ed47-4d0e-bee8-c47c2a9932f2"
      unitRef="usd">65100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMjgz_e64bb7a1-9772-425c-8321-11dd0dc2536c"
      unitRef="usd">168700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMzEz_e89816f4-e817-4226-9620-a070325f80f5"
      unitRef="usd">51500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMzIw_936a7685-7b6f-46fb-97cb-b3bfebac8fae"
      unitRef="usd">151200000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="i5f65716caa83413388dac812d8d3219e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfNjI2_0055d5cb-db46-4a38-b6d3-dae9541ccbb1"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="ib7a3fd2b017b41fbb6dbb92df1d7ee68_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfNzAw_3d4b5708-de6f-4a81-9fd8-e80c5b057e01"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="i7855fb28a23947d995189305bed5f12b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfNzYx_8e230958-e017-4b2a-a2b8-89702189a61d"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross
      contextRef="i16b2d0a2aca64df688f77a7ea041914b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfODM5_b43bea80-6957-4251-8327-58e95e27a416"
      unitRef="usd">661800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i237f7b94a47e4d618bf0d30b1872ccd4_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfODQ2_d2ae910d-8b2c-415e-9ebf-94b7ee5a504a"
      unitRef="usd">1800000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16b2d0a2aca64df688f77a7ea041914b_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84NS9mcmFnOjllN2MyODBmMzQ3YjRhMjZiMGNlZDk1NTIwZmVhOTJjL3RleHRyZWdpb246OWU3YzI4MGYzNDdiNGEyNmIwY2VkOTU1MjBmZWE5MmNfMTEyMw_c0b54e97-6e25-4e55-8d91-359fb88b4b99"
      unitRef="usd">1200000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMzU2Ng_abfb09d2-d930-443d-ba91-f5e04a306bbf">&lt;span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ended September 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt"&gt;$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt"&gt;$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred approximately $24.4 million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2.90% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with our 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Derivative Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <biib:LongTermDebtExchangedAmount
      contextRef="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjYx_059dfa3d-16a9-4876-b0d8-dbcc89221336"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="icc42842da7bc45f38b433b05022616d6_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMzU0_a15eee32-63c4-4df6-b34c-63e312086ddd"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i726364fc850f428980b41bc6bf6ead64_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfNDI3_83b78f97-8f17-4119-bdf1-5edbca6fbe2f"
      unitRef="usd">151800000</us-gaap:RepaymentsOfSeniorDebt>
    <biib:DebtInstrumentRedemptionAmount
      contextRef="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfNzM4_5706b248-86f1-446a-bf7b-04b65126c7f2"
      unitRef="usd">8900000</biib:DebtInstrumentRedemptionAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i6883430fceb848d2a0a2b96d63ecfe82_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfODEx_f3fb8a56-de35-47dd-a76b-8cc14d1183ca"
      unitRef="usd">12100000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic94894775dbe4be685e8410ac06fb197_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfOTYx_80c162ad-0c58-4d0c-ae35-4165757cc940"
      unitRef="usd">3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ic94894775dbe4be685e8410ac06fb197_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTQyNw_0f608d33-4bb9-4c44-aaf9-764c287c5372"
      unitRef="usd">13800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpense
      contextRef="ic94894775dbe4be685e8410ac06fb197_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTU5Mg_1e33569f-ebf7-4567-a2b3-4fded7d81366"
      unitRef="usd">6100000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic351f5dbf270449286ad0664853e2842_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTg4MA_7e4c2fa2-485e-476c-b50d-57f9158de2ab"
      unitRef="usd">3000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i21dab209cac741b08e2660f13a98e869_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTkzNA_274eec0e-09fa-4c89-890d-241a95102037"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21dab209cac741b08e2660f13a98e869_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMTk2Nw_e38beae6-9e21-4ba9-8025-5a7af9e0d872"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i21dab209cac741b08e2660f13a98e869_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjAwMQ_f99c942e-f132-4b81-afa8-25a167d63fd1"
      unitRef="number">0.99973</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i75a580abd0df4408a90cb100e5c26f1f_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjAxNg_dd425f43-2472-4c91-ac41-19cf15bcccd5"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i75a580abd0df4408a90cb100e5c26f1f_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjA0OQ_49becfa3-dda2-4dab-ac6c-2ef9f2d89dac"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i75a580abd0df4408a90cb100e5c26f1f_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjA4Mw_543de700-4eba-470a-a4a5-bc66242992ef"
      unitRef="number">0.99174</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjEyMA_e96d2b2a-5f5b-4712-bbc9-048175539799"
      unitRef="usd">24400000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjUxNw_592e0268-9095-44ab-9ce3-b13faa3bc26b"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjU1MA_296fbf94-84ad-4538-ab2b-c25b9d6ea547"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjU5Mw_a9438c05-864d-49f6-b0d6-652d202d7cd4"
      unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjYwOA_293362bb-8a03-4901-81a7-d4b9ab06856a"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjY4Mg_296fbf94-84ad-4538-ab2b-c25b9d6ea547"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i889cfd06e76047c4b4d5833cd7016227_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjg5MQ_ad872204-c77b-413c-8993-d0fc88d44971"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain
      contextRef="ibb73b7afe9dc4434b6d819770e912b56_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMjk3MA_4b22d4ed-ad7f-42dd-8eb1-9f69a610d699"
      unitRef="usd">9400000</biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain>
    <biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts
      contextRef="ieb5ca321d1584c1ca6bcd8f53d653612_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMzIxMw_b3129ec1-5be4-442b-860c-0d1777f26579"
      unitRef="usd">12700000</biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ib4f3485174db4d7c876667900c74e5bf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl84OC9mcmFnOjMyNjJlNWY4MWI1MzQyYzQ5OWRlMzhlNTM4ZjNmNmMxL3RleHRyZWdpb246MzI2MmU1ZjgxYjUzNDJjNDk5ZGUzOGU1MzhmM2Y2YzFfMzM1Mg_3314b152-054a-4418-bd6f-4945ac76c5bc"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTgwMA_8910d6a1-7270-4d17-a2ec-0c6126576fa9">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million and 6.0 million shares of our common stock at a cost of approximately $750.0 million and $1.8 billion during the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021, respectively. Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 4.5&#160;million and 16.7 million shares of our common stock at a cost of approximately $1.3 billion and $5.0 billion during the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million shares of our common stock at a cost of approximately $1.3 billion during the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(101.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(90.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(225.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i274d98ffd7f54b12bbcbb430a7f6446b_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTEx_7462722c-61e1-4e50-9fd9-f94aa45b2610"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib3a02d5c86ee49cea24a7e5760768b86_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMzk2_36d6c5ac-20e6-4921-9822-740807781116"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i106acfed1b1d45288e2c252eaeee518d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNDAz_1e084d7b-1d62-4d3f-9f31-dd9d61ce8533"
      unitRef="shares">6000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib3a02d5c86ee49cea24a7e5760768b86_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNDYw_872f64d4-a937-46f4-8d9e-a28c4d849362"
      unitRef="usd">750000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i106acfed1b1d45288e2c252eaeee518d_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNDY3_02de5e30-0402-4e1a-bfb5-396755131aa5"
      unitRef="usd">1800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ic4f828fb4a924f93bdde2fb608c2e829_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNTM2_10ac2939-1a3b-46e8-a9cd-6173c0edbcf9"
      unitRef="usd">2800000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if5c2e8e8d01b426285c6bd058cbb4b5a_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfNjc4_18cf3bd1-f9d7-45b4-95c3-ed9f7ca988bf"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1a59c92aa5cf4dffb7a826f5ebeb931f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfOTUx_f7fdd6b1-ee2a-4654-a2f1-e9cc860b83cf"
      unitRef="shares">4500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i939d909bc5be42e6be0dc04dd1a39954_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMjE5OTAyMzI1NzM5Nw_76e4292b-2a91-4403-b022-90bc28cdf0dc"
      unitRef="shares">16700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1a59c92aa5cf4dffb7a826f5ebeb931f_D20200701-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTAxNQ_6b295904-3093-4a6f-81d8-1aaca9105dfd"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i939d909bc5be42e6be0dc04dd1a39954_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMjE5OTAyMzI1NzQzNw_e69340e6-0aac-4da2-bf6a-fe37c0c42395"
      unitRef="usd">5000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i34a8fc959a0849088adcffcd36d82f66_I20190331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTE0OA_5aecfcb8-8c36-434c-af39-9f7574bfa00d"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iddfc2c0b58ff4cc1b94d1cdf49392372_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMjE5OTAyMzI1NzQ3MQ_00b125bb-7eba-41ad-83a4-ccec148dc966"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iddfc2c0b58ff4cc1b94d1cdf49392372_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMjE5OTAyMzI1NzUxNA_05da2d07-6b1c-4fda-84c0-b743cb88904d"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTgwOA_ff9507f4-26ce-46c9-91d8-b865a51e6ad9">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(101.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(90.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(225.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idc9d05f7c1a74459b89c4ececa72d31d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS0yLTEtMS0w_4d0578cd-f210-4f28-811e-d1d2803eaff5"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1948d85fab604db881323ed2ad598c59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS00LTEtMS0w_06a9eaab-aa56-47df-9e07-6252181a92ed"
      unitRef="usd">-179000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i73ce415c72f84e7faa6119e5db9ec7f1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS02LTEtMS0w_3a75cbc5-7689-4e9b-b1d9-d1e7a726f774"
      unitRef="usd">-8500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ica50ab9119b04010bd04bd7d82bce622_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS04LTEtMS0w_6b7b4e08-f477-4cd3-b899-302a3c7a9134"
      unitRef="usd">-66300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if3612de0f43644d784871ebe849c27ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS0xMC0xLTEtMA_7f514187-682f-453a-95c0-3aa0560ce5fc"
      unitRef="usd">-46600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMS0xMi0xLTEtMA_8e3d3631-9535-47b8-9874-87f5468489a8"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id753ed956fca4c9697045d3b819e7684_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi0yLTEtMS0w_569cb6f8-63d0-40ba-aebf-4cf5d823e016"
      unitRef="usd">-2500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i516bbb796f934334a222a0fa68f96141_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi00LTEtMS0w_a4cd7321-e44e-4366-846e-b1df32f23fe0"
      unitRef="usd">143000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia61dcd7cc49f41c0936daa62cdcbb1c6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi02LTEtMS0w_e0347495-8a68-46a6-ba6d-7bd568545d54"
      unitRef="usd">35300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i60f19acba9b346f8805c6bdd01935668_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi04LTEtMS0w_9fc98fa2-a3cc-49be-9f67-be514807e73c"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i62f0df97465f48e7b7873ed9e345c3b9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi0xMC0xLTEtMA_fc20f917-1d29-4e53-b6a8-fd7e5ccd32d1"
      unitRef="usd">-80300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMi0xMi0xLTEtMA_a2a61c17-2e3c-4741-8eb7-a1f6025eb2e9"
      unitRef="usd">99400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="id753ed956fca4c9697045d3b819e7684_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy0yLTEtMS0w_d2ac4c86-c7fa-4c97-bd73-5ddf411efacb"
      unitRef="usd">1100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i516bbb796f934334a222a0fa68f96141_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy00LTEtMS0w_3ab96fc0-4d13-4285-b842-3db3c21d05e4"
      unitRef="usd">62000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia61dcd7cc49f41c0936daa62cdcbb1c6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy02LTEtMS0w_29b13df0-2d4e-48b4-afa1-82e716ca4d22"
      unitRef="usd">-100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i60f19acba9b346f8805c6bdd01935668_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy04LTEtMS0w_b0bebb11-b8b4-4fbc-b722-4172c9e7fc31"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i62f0df97465f48e7b7873ed9e345c3b9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy0xMC0xLTEtMA_82ab282b-eb8e-4bfc-8fec-29d4e83cc488"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfMy0xMi0xLTEtMA_b4cf8664-e6b4-4186-a7bc-7b1fd4cac61c"
      unitRef="usd">63000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id753ed956fca4c9697045d3b819e7684_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC0yLTEtMS0w_62b0ebd1-28fc-40a1-bab2-b59a5696dd0d"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i516bbb796f934334a222a0fa68f96141_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC00LTEtMS0w_b1b89331-b827-4788-b0e4-e06b6d86b713"
      unitRef="usd">205000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia61dcd7cc49f41c0936daa62cdcbb1c6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC02LTEtMS0w_35d06516-e754-4713-a13c-98736ee43424"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i60f19acba9b346f8805c6bdd01935668_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC04LTEtMS0w_86dc8ab4-e131-4ea9-933c-a910027b2b6d"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i62f0df97465f48e7b7873ed9e345c3b9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC0xMC0xLTEtMA_1cc71c2b-fdaf-4846-832a-f2c79cab2b2e"
      unitRef="usd">-80300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNC0xMi0xLTEtMA_13dd0d4d-c98b-4f82-aeab-de09eb386c55"
      unitRef="usd">162400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4b0f729cc7834d838ef13e90b13032e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS0yLTEtMS0w_091b882d-5f85-45b4-aa02-32bb6dafe508"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iea582ea5aa4f4a669db07ca5961b838f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS00LTEtMS0w_e5994f11-71d2-4a0a-9c73-d7faffa05ca5"
      unitRef="usd">26000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ife32845f8f56459b828af29f233cea3e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS02LTEtMS0w_d6fb8af4-823f-4c98-ae90-9d6c668f54e2"
      unitRef="usd">26700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib3f6137620d443d38f5a57b1cc4509ac_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS04LTEtMS0w_8d5a0d16-7761-4955-beb2-748ebfd47ae6"
      unitRef="usd">-62400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8488f37532d44598b640e3d982bd4d1a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS0xMC0xLTEtMA_ce9f0315-0acd-43e3-9abd-dfd05c0abe64"
      unitRef="usd">-126900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjY4NjA3MWZkMTg2MTRlYWQ4Yjg3YTVhYjZkYWQyYWQ2L3RhYmxlcmFuZ2U6Njg2MDcxZmQxODYxNGVhZDhiODdhNWFiNmRhZDJhZDZfNS0xMi0xLTEtMA_3c9a04bd-b9c4-4594-bf21-b8634e7b5665"
      unitRef="usd">-136600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if7aa58f98c924adeb22065e220c2905c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS0yLTEtMS0w_951f4529-d040-40fe-8bc4-e0c3a2f4de55"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5170241300904fbea34b8142ff2a821c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS00LTEtMS0w_01b1217d-e9d2-4cf3-a457-954cb70a0a85"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8165a95911864bcfb5491d08afc84e94_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS02LTEtMS0w_e683e92a-be07-4c15-9c09-559deede1036"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i165acb4a2b0d43dd81d356c112615871_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS04LTEtMS0w_f5b03e62-bd76-472c-ba71-977af5c6b4fb"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i28faac3c4e4b4accb6e60a468b175a53_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS0xMC0xLTEtMA_085dce68-fc19-44c9-88ab-c8c9de55aa71"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i378cd243ed9e40c2932d604d62dcff73_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMS0xMi0xLTEtMA_7ca05fde-31a4-4a58-abc9-4ea1ca5f2843"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i13ee975c61c5467f9516d04c8a1176f1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi0yLTEtMS0w_6629d72d-8037-43b5-baaf-4f6f29f820dc"
      unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ife1921ce00c34a2eb95d9de3595c2be7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi00LTEtMS0w_a9e73b3d-40ad-47d2-a541-0db97a9afa02"
      unitRef="usd">-58000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib3c516cacf404828b016eddc54887f05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi02LTEtMS0w_429ebdba-c388-43e6-921a-77eda4fb3d61"
      unitRef="usd">8100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7179a8875e614260b2c6e1b4cf82c9d1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi04LTEtMS0w_b8e8aa66-6745-40d6-9794-2cb0e6dbdc17"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0f1f03f52650459fa99a8fe57031cfe6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi0xMC0xLTEtMA_a2508e67-cf6e-4e21-bd46-12d5fc1dfed0"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMi0xMi0xLTEtMA_acddcb30-2a6f-4427-b3e1-f85818de2e40"
      unitRef="usd">-54400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i13ee975c61c5467f9516d04c8a1176f1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy0yLTEtMS0w_a976e7e7-0ac7-4398-b6eb-48edb1a1e3a6"
      unitRef="usd">9800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ife1921ce00c34a2eb95d9de3595c2be7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy00LTEtMS0w_cdd6a715-0c00-4c68-93c3-2d624f3352bd"
      unitRef="usd">-43100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib3c516cacf404828b016eddc54887f05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy02LTEtMS0w_c271fd5c-c776-4197-82b6-633404620777"
      unitRef="usd">-2600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7179a8875e614260b2c6e1b4cf82c9d1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy04LTEtMS0w_4e60f310-5023-4ff4-9bda-9b0d6958543a"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0f1f03f52650459fa99a8fe57031cfe6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy0xMC0xLTEtMA_3563a14c-c901-4954-9313-53d6bdc8f193"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfMy0xMi0xLTEtMA_e4fb042b-3f70-43fb-bb7f-a7eb1223c82c"
      unitRef="usd">-35900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i13ee975c61c5467f9516d04c8a1176f1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC0yLTEtMS0w_d12936cb-093d-4377-a706-616b8071e877"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ife1921ce00c34a2eb95d9de3595c2be7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC00LTEtMS0w_51c0fe21-0441-4940-a077-3d6e6ee92eb9"
      unitRef="usd">-101100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib3c516cacf404828b016eddc54887f05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC02LTEtMS0w_92452e49-8313-482d-a112-e83c9f44c98f"
      unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7179a8875e614260b2c6e1b4cf82c9d1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC04LTEtMS0w_f9709c26-1de3-4153-95fb-8a97df9a1bec"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0f1f03f52650459fa99a8fe57031cfe6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC0xMC0xLTEtMA_a1fe6fc2-9b54-4fd4-acc4-521d9e8d9a2b"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNC0xMi0xLTEtMA_159f0888-7308-43d2-a5c5-709c5dc4c0b1"
      unitRef="usd">-90300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c86dfc3e9ee4f10af73ad81268a63bc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS0yLTEtMS0w_6d852207-971a-497a-b14f-324ace6a3774"
      unitRef="usd">5200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4b3ea666a48f4ea79d28dc480c0ac8f1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS00LTEtMS0w_a36e8bbc-e554-455c-aff1-577c1bbd731b"
      unitRef="usd">-93300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d395dde98524fa2959805ab74ab926f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS02LTEtMS0w_b4282685-b17a-433e-a432-98b7e6e649ce"
      unitRef="usd">30600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i41b817c4f2c748f4ad54ab609bcb7259_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS04LTEtMS0w_ebf28916-8be0-47df-8e48-e1e3885edcc9"
      unitRef="usd">-32400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia4e79c56dd794f2c98635556f462cf4d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS0xMC0xLTEtMA_a7a6b799-3a41-4c4c-9649-13dfd474ec9b"
      unitRef="usd">-135600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6dd54a75bdf44146a9c81439174f3e10_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOjBjMjEwYmMzNjYzNjQ4NmJhZGYwM2U1NmE5M2Y1ZjM2L3RhYmxlcmFuZ2U6MGMyMTBiYzM2NjM2NDg2YmFkZjAzZTU2YTkzZjVmMzZfNS0xMi0xLTEtMA_754b410b-46e0-4c04-b973-9925d3ed6500"
      unitRef="usd">-225500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RleHRyZWdpb246Yzc0NDAxNWYxZjkwNGU2MzgwN2QyYjE3MWQzN2M2YjRfMTgxNQ_891cca8d-9e0d-4196-a939-db85bf31962e">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2b67fb3aa82d43ffbf26b48ff2d8f1c5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMy0zLTEtMS0w_a1a2e98a-e73b-4500-abb8-7d71df91a317"
      unitRef="usd">-400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3e0fc8c7198a43d9b9d0c99f6121cd13_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMy01LTEtMS0w_ef1a27a4-f9e1-4348-b02d-d4e2b6ec7f56"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5fa38f90595e4e8fbfab0ba144b401a0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMy03LTEtMS0w_63191598-d210-4ea9-bff9-08f918d7a012"
      unitRef="usd">-1300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibf8e0d7f30d8409cbfc5630b9d2bc341_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMy05LTEtMS0w_a8957ee7-b297-47db-91c7-52a6a2eab303"
      unitRef="usd">-12400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b67fb3aa82d43ffbf26b48ff2d8f1c5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNC0zLTEtMS0w_5f095204-8e73-48d5-81ff-971a17ea7b5b"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e0fc8c7198a43d9b9d0c99f6121cd13_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNC01LTEtMS0w_97e24f8d-bcd3-414e-a3a9-224597b2b237"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5fa38f90595e4e8fbfab0ba144b401a0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNC03LTEtMS0w_73439122-f12a-4423-b1cb-45408ac6366c"
      unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibf8e0d7f30d8409cbfc5630b9d2bc341_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNC05LTEtMS0w_1106b558-6ed5-4bcf-b56e-8933d518ceb8"
      unitRef="usd">2600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNi0zLTEtMS0w_a78f49b5-5762-4b20-8afb-2ca61bcaebf8"
      unitRef="usd">-14900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNi01LTEtMS0w_97edba0c-b25f-4024-89e2-97e77d9b5ed7"
      unitRef="usd">-9100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idde20bc926894280b4ff61e91056fe72_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNi03LTEtMS0w_6684dccf-14a8-487e-a5c0-84793c55fb88"
      unitRef="usd">-68700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8175286262ae459f85852ea172fe0373_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNi05LTEtMS0w_8dd9019d-b990-41d0-b7f3-8fad55b15ed9"
      unitRef="usd">41600000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNy0zLTEtMS0w_cac58eb1-507c-461a-afad-6e210962e082"
      unitRef="usd">300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNy01LTEtMS0w_35840408-3059-455d-8b02-923b365c86bc"
      unitRef="usd">-1500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idde20bc926894280b4ff61e91056fe72_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNy03LTEtMS0w_e6be18ad-a26d-4666-baed-f100766b15c4"
      unitRef="usd">300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8175286262ae459f85852ea172fe0373_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfNy05LTEtMS0w_eaa56c46-5acc-4984-ace0-527cbcad1b44"
      unitRef="usd">-1400000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOC0zLTEtMS0w_c3129ebd-644d-4ade-8f1c-f011fed8b8c6"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOC01LTEtMS0w_6bb491bc-8b18-4303-b8f3-9c0b1f584db5"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="idde20bc926894280b4ff61e91056fe72_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOC03LTEtMS0w_aee613da-301d-40c3-bd12-b9ba0c716d12"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8175286262ae459f85852ea172fe0373_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOC05LTEtMS0w_1985d420-9305-41ea-818a-414b9c35b760"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i87d2050599394cf9b44b44bb786f127b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOS0zLTEtMS0w_4d8eaf8c-6529-499b-af66-09246f4d54ce"
      unitRef="usd">1500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0fb6d73a965347639c1ebb6d15a9fcb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOS01LTEtMS0w_a53e1848-11d5-4cc6-8c61-e4cf5cfc0504"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idde20bc926894280b4ff61e91056fe72_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOS03LTEtMS0w_e320fb06-348e-46c2-ba21-c4ca0621986a"
      unitRef="usd">6800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8175286262ae459f85852ea172fe0373_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfOS05LTEtMS0w_edb094fc-8662-48a2-952f-2113fcbaf276"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia346a814aa4d4577b59b906128f24eec_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTEtMy0xLTEtMA_8597a4d7-4af0-4f84-9e7b-5f8e60b64bfb"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4c2e8e85ac5a4488b1adc8af19f319e2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTEtNS0xLTEtMA_e4a83212-a8f6-425c-9c51-b4c7cdf934d7"
      unitRef="usd">800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i143c1628336040789355760a0e36cb04_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTEtNy0xLTEtMA_a5d7add0-f15e-4bb2-9967-5c3ff0c6f256"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib270c515c868406785b1ede039e1e002_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTEtOS0xLTEtMA_992074f6-4d04-40d1-b11a-3684e84672c9"
      unitRef="usd">2600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ibade6508c50c4f938133f3c022f3073f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTQtMy0xLTEtMA_e871d765-bbcb-47c1-938d-226cf1d58d29"
      unitRef="usd">-14000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6013739ca1f54a5290b712e2dc11f329_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTQtNS0xLTEtMA_f5230586-8d63-4225-8840-e2bbdcb592b9"
      unitRef="usd">-6600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a6fcfcabe5d445a9761fb8678c669c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTQtNy0xLTEtMA_370eb868-10cd-4511-ba4b-131d9ec8d58f"
      unitRef="usd">-63000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3f010fdc6c5e44c2868aa793118a0276_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl85Ny9mcmFnOmM3NDQwMTVmMWY5MDRlNjM4MDdkMmIxNzFkMzdjNmI0L3RhYmxlOmE1MDg0ZGZiNWJhMTQ2ZDNiNTNhOTZjYmEwYjFlMWRhL3RhYmxlcmFuZ2U6YTUwODRkZmI1YmExNDZkM2I1M2E5NmNiYTBiMWUxZGFfMTQtOS0xLTEtMA_d8960e54-c288-49ad-ac8e-b0008eb562d8"
      unitRef="usd">35900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90ZXh0cmVnaW9uOjVjZjI3NDJhNWQ2NDQ1Mjg5ZjhkMWRjNDgzNzUyYmYyXzI2MQ_53264f4b-dde6-4a1e-8489-95482034b179">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;701.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,642.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90ZXh0cmVnaW9uOjVjZjI3NDJhNWQ2NDQ1Mjg5ZjhkMWRjNDgzNzUyYmYyXzI1OA_2d49e6d2-9a19-49eb-bb4c-0d59b80cd943">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;701.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,642.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzMtMi0xLTEtMA_eb1219c2-aaff-48de-9820-8750f3709cd0"
      unitRef="usd">329200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzMtNC0xLTEtMA_5e844396-8c7a-4c36-bc2c-46d4eb61b3be"
      unitRef="usd">701500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzMtNi0xLTEtMA_18236b9f-eaf3-4caa-86cd-c51dcf10afc8"
      unitRef="usd">1187900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzMtOC0xLTEtMA_7a774652-573f-40cb-81c4-d3065d13e3cf"
      unitRef="usd">3642700000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzUtMi0xLTEtMA_253d7685-d00d-4d52-b337-a038882da16a"
      unitRef="shares">148000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzUtNC0xLTEtMA_84129242-b0bc-4b3a-9af1-ec873e073312"
      unitRef="shares">156900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzUtNi0xLTEtMA_12998b78-b75a-4e68-b6c6-f24f83957ee5"
      unitRef="shares">149900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzUtOC0xLTEtMA_4b48819c-bcb2-4609-b117-964d83ad7de1"
      unitRef="shares">163400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9679d28935fc4a48900189cabb13e5d9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzgtMi0xLTEtMA_b2f36d70-ef0a-41b8-8d4d-dddff69350cf"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i39e962f11bcf4bd980fff4715c3da316_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzgtNC0xLTEtMA_653b1807-f7aa-4310-8726-57fc42240179"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id98346bd89964dedadb43377f44a0d31_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzgtNi0xLTEtMA_a0ea4f3b-9cad-4325-bd16-0c21c3f578ca"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i39a105cc514f40d7bf0743359acd5400_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzgtOC0xLTEtMA_2f80d8be-d6b4-4ac1-bcf8-4935c3b41b3f"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id274468946a6454ca8c80e958563c1d5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzktMi0xLTEtMA_bf62fc7a-e036-47b9-b83c-1d3167f0ed0d"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i23430e509b1b4117915b80c09a42657d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzktNC0xLTEtMA_ecc3b83c-9977-4fa3-b4ca-35333c555183"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i379169127f2b4a9395ced61d3e36c9e6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzktNi0xLTEtMA_b6992d55-a01a-4d80-9d04-d3d4c261bbaa"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if014c19f237748bd8ee32127e024b863_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzktOC0xLTEtMA_48d2213c-d1ac-4e5f-b57f-f10d23951f4f"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i477a6cb8b52f4f929eda17ce6dce344c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEwLTItMS0xLTA_d8c22e21-f33b-4774-b427-01fbe26938f5"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i150f4a13b0a145e8bf65f5c84097ec47_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEwLTQtMS0xLTA_5038a19e-df23-4084-b437-5f6859a1e5a5"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia5ee866dd4344c0aa14cebd1e0c79e89_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEwLTYtMS0xLTA_634654d3-24d4-49c8-abc4-139423a0b342"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i75aa8742f42b41689c3d73f6bb82b7dd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEwLTgtMS0xLTA_d30fec87-ae70-4255-bb86-cda79b4b088c"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzExLTItMS0xLTA_b43aa29b-fa8e-4957-a241-e5186b4be754"
      unitRef="shares">600000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzExLTQtMS0xLTA_5ee0606b-6895-4fa8-9080-86ff345f208f"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzExLTYtMS0xLTA_558ff2c7-d244-417d-9f23-ac588351f940"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzExLTgtMS0xLTA_6c4758d2-ee6a-4739-b288-074d6228639b"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEyLTItMS0xLTA_ad9d1ee9-03cb-493b-b317-426c91b8c75b"
      unitRef="shares">148600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEyLTQtMS0xLTA_4349f918-d4fe-48f7-bc16-8945c5fb8150"
      unitRef="shares">157200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEyLTYtMS0xLTA_ac8d46be-968b-4dd6-9d6e-cbda6a4b2d1d"
      unitRef="shares">150300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDAvZnJhZzo1Y2YyNzQyYTVkNjQ0NTI4OWY4ZDFkYzQ4Mzc1MmJmMi90YWJsZTo1NjBiZmExODNmMDQ0MTA3YjNiNmZmN2VhNzhiNzYyMi90YWJsZXJhbmdlOjU2MGJmYTE4M2YwNDQxMDdiM2I2ZmY3ZWE3OGI3NjIyXzEyLTgtMS0xLTA_598cba8d-4cda-462a-8d96-a078bd70d76e"
      unitRef="shares">163700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90ZXh0cmVnaW9uOjNiNzY2ZmQyYWQxMDQwMzliNmNlZDRkODMxMmMxNzIyXzY1Nw_9c2663dc-c661-4aab-ad73-34525c7772de">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90ZXh0cmVnaW9uOjNiNzY2ZmQyYWQxMDQwMzliNmNlZDRkODMxMmMxNzIyXzY0NA_5f5c1d86-ccfe-443e-9713-71146e363c41">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7000526ec07f428091319155849fd704_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzItMi0xLTEtMA_20e10872-1163-4e4c-a722-3a6073dc1254"
      unitRef="usd">19500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f6747564e0b4a938f03505b3f95f165_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzItNC0xLTEtMA_3451de84-a21e-47b2-837f-d64e8e34b5e8"
      unitRef="usd">14600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i699b74e5bbfd4779a582c698d788d790_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzItNi0xLTEtMA_4d356af3-e8bc-40b2-9e4c-98d3bd961ff0"
      unitRef="usd">72200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ied525c1179a741bb82b1d583a76e51e5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzItOC0xLTEtMA_baae39d6-2754-455b-abc5-834a95d0cb83"
      unitRef="usd">63100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff1924f4ee8f43ee840ee57aff81df9e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzMtMi0xLTEtMA_3926228c-fca7-419c-8f2d-aecd3c6496d6"
      unitRef="usd">42600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6d39579533114f4aa354f18fd1f299b5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzMtNC0xLTEtMA_e81e2c51-9225-45d7-a5ff-26d7873e22b7"
      unitRef="usd">25000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i654d114f9573429998ad4856d6fefb38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzMtNi0xLTEtMA_e0edbba0-a661-4186-901b-ea24990bc915"
      unitRef="usd">127800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i677267ca7d7e48f68e24c2371a4dffd1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzMtOC0xLTEtMA_9aebb04f-7ad2-4f3c-8fa7-3a456ab0936c"
      unitRef="usd">98400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzQtMi0xLTEtMA_cfdc47e0-1ddd-454c-a524-c9b2f99ae3be"
      unitRef="usd">62100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzQtNC0xLTEtMA_c36a9427-4abd-4c2b-8fb9-e3a312a86338"
      unitRef="usd">39600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzQtNi0xLTEtMA_381ddcc9-a745-4d03-95e0-22aaf7eba64f"
      unitRef="usd">200000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzQtOC0xLTEtMA_cde51b46-ca96-44b1-8525-ed6a59645211"
      unitRef="usd">161500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzUtMi0xLTEtMA_c15a27b0-bade-4196-87f5-1ce113c69e95"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzUtNC0xLTEtMA_51d9ba0a-54f6-4d14-b43f-c34176767b9c"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzUtNi0xLTEtMA_f6c9944c-70a8-4183-adbb-4cf16ba6198b"
      unitRef="usd">6300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzUtOC0xLTEtMA_0c5a5aa4-b826-4775-a599-7e69118101ac"
      unitRef="usd">4900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzYtMi0xLTEtMA_c2ad3c0b-9609-4a1a-93f0-bec5428143ed"
      unitRef="usd">60200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzYtNC0xLTEtMA_df0accd3-1acc-4490-82c2-eb0508891ab3"
      unitRef="usd">37700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzYtNi0xLTEtMA_8f0efe8a-8f49-495c-85df-02665aec18cb"
      unitRef="usd">193700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzYtOC0xLTEtMA_6f645c0b-8ff3-4f39-ad7d-ab73e728b2b3"
      unitRef="usd">156600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzctMi0xLTEtMA_37884d48-76b7-4721-8e3c-7fab1afa4a2d"
      unitRef="usd">10900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzctNC0xLTEtMA_b8aa2839-d3ab-4c66-b285-cb3e268be6aa"
      unitRef="usd">5400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzctNi0xLTEtMA_3e32a11b-c509-4512-9d77-f7fb685e2b90"
      unitRef="usd">35800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzctOC0xLTEtMA_4a447cca-0bc4-403c-a987-90da3d89ba00"
      unitRef="usd">25700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3f1075481e74bb98a9b2a2d1b4673ae_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzgtMi0xLTEtMA_5034b2ed-f92c-480e-abc6-70759b4affe4"
      unitRef="usd">49300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd96e2849ae7466dae303c5a5b80c085_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzgtNC0xLTEtMA_9350fac8-04d9-42a1-a343-80499f178115"
      unitRef="usd">32300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i33f267df3ba84643b8bffb1e5ff56f47_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzgtNi0xLTEtMA_8c127faa-5591-47fc-aecf-22825e23ccc6"
      unitRef="usd">157900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib258d211097b4e64aa9629510fd53154_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3MzI5MzgzMzZlNDA0N2U0OGUzMzhiOTg2ZTcxOWNiMC90YWJsZXJhbmdlOjczMjkzODMzNmU0MDQ3ZTQ4ZTMzOGI5ODZlNzE5Y2IwXzgtOC0xLTEtMA_2a27de54-57ce-4b99-94f1-2f739e5dc369"
      unitRef="usd">130900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90ZXh0cmVnaW9uOjNiNzY2ZmQyYWQxMDQwMzliNmNlZDRkODMxMmMxNzIyXzY0OQ_b53b5fab-f69d-4a23-bc91-f34106d2d523">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia2f98bd41f384786a46e50b06a48f2d3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzItMi0xLTEtMA_dd780476-6c40-44ef-9202-5d4fa7d12a44"
      unitRef="usd">9700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2953a813c0d9467d9ae9f1e794ec1fd2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzItNC0xLTEtMA_3e126013-95ac-4d8b-99f0-408f6d145671"
      unitRef="usd">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i99e1e20ca1e74fe0b437961b9da435a4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzItNi0xLTEtMA_b3b88653-a279-4cd5-9f2d-9419fb90e360"
      unitRef="usd">35500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if314461b1e5b4baea50b55cd17fd0538_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzItOC0xLTEtMA_76f6c218-f5af-44f3-8fd5-fceebbf165ff"
      unitRef="usd">32000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b90ed783cf34d47b1bd424e613386be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzMtMi0xLTEtMA_45342586-dee1-4618-b787-df4701eefb2a"
      unitRef="usd">38800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idaae1cc404f343c5bfb355c19f2dd60e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzMtNC0xLTEtMA_aaabad11-c32a-40d1-bd0f-57c3d15c8003"
      unitRef="usd">35300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i266dc39128f9407d870c90b7e77122dd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzMtNi0xLTEtMA_42cd0b3b-11e9-4a39-a5c1-15e49d2a737d"
      unitRef="usd">121900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2c913a6dc6e40f3a5994b325c0067d5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzMtOC0xLTEtMA_4a8eb34e-26e1-40c8-b326-66ef4b505e47"
      unitRef="usd">107300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i790bc65eb68c43b0a56d4a861411da6d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzQtMi0xLTEtMA_b5a7fc7b-7f46-4509-9e41-740d90184837"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3fc3cf0a2cd74d61854096f0dc29d4bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzQtNC0xLTEtMA_c1dbebac-8f9e-4d54-be76-d9558bff802e"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2401c248b54473d9de51f32724fa7d4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzQtNi0xLTEtMA_3fa51e7b-05e6-41a2-aa73-046b73cf8031"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i05dbc5642aa740e898a9288a14e80f49_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzQtOC0xLTEtMA_503b3860-1567-4d18-9c07-884eca3ee13f"
      unitRef="usd">-1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i248e2c4fa3d34b269a285cb1c63488bd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzUtMi0xLTEtMA_39f0fe6f-067a-4dd3-a712-1d72a5a08203"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id09ba7df5db74e13ba503168413abdff_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzUtNC0xLTEtMA_fe3f5667-206b-43c6-bcac-7090f1b0fdf4"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i444b41b2ae2d4e7cb1136b88ed82f8aa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzUtNi0xLTEtMA_0afa5adb-e4b1-442d-8a0d-425f4550b4de"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia0e35f43cb26444f81cfaccaad8eb9cc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzUtOC0xLTEtMA_c907b1c4-8aa0-40df-9066-8145161a78ce"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib1fa67b093a54744bc17319d4330b45a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzYtMi0xLTEtMA_a4b7e68f-72ca-4830-9cbd-8f589d862e17"
      unitRef="usd">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iebee12b1fdff4baab053967a2a218895_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzYtNC0xLTEtMA_3a58ff6e-03c8-457a-96a2-f52b171b8d27"
      unitRef="usd">-8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e2515997127460a88ce3b7721c7f899_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzYtNi0xLTEtMA_878cc984-bc66-4c69-9374-93c22a6ffa38"
      unitRef="usd">14200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if816cbeb32834f9c892e3d50f230ae8b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzYtOC0xLTEtMA_37f9acb4-4258-4226-a4fe-6644343cb552"
      unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b3ef8424e944022bba6665e253acdec_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzctMi0xLTEtMA_30f2bd3f-6122-4308-b80f-9bc7f15b46e4"
      unitRef="usd">4400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia410aa53688a4c78b85ff75528ef68ea_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzctNC0xLTEtMA_26f61322-4190-47a9-afb4-8a04d432c007"
      unitRef="usd">4100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9f86bfff90443dfad344994aa697b38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzctNi0xLTEtMA_63c8fe69-8cfe-4765-8cf1-85120bcdb6ea"
      unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia721ab9e8edf4ed7a17168531a631cd0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzctOC0xLTEtMA_26190a28-f5fc-4811-8957-04638e0cf0f2"
      unitRef="usd">9000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id81620b24a824ca2a03f609c9a047932_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzgtMi0xLTEtMA_bf75e1b5-5400-43c0-be1b-7d8d8db232d3"
      unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12f850ed68f24c55bf0e191cf454be49_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzgtNC0xLTEtMA_0494928f-6d32-4e50-9d4b-50e434e28e15"
      unitRef="usd">3100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e940795a93d480cba3bee92ea71cde2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzgtNi0xLTEtMA_d8320362-e820-4c8b-b26f-6a24762e048e"
      unitRef="usd">14500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38006411cd644bd9bb6a9f6aff3265f7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzgtOC0xLTEtMA_cbfab432-f159-43d4-9b35-7da1b270223e"
      unitRef="usd">11000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEwLTItMS0xLTA_200a3b31-b739-478e-a004-dc39b855387e"
      unitRef="usd">62100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEwLTQtMS0xLTA_92dc5898-db89-4dc4-bf62-808990c9d45d"
      unitRef="usd">39600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEwLTYtMS0xLTA_54aae79a-ddf5-4a91-84e6-b7cee998e4d0"
      unitRef="usd">200000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEwLTgtMS0xLTA_b5355a51-43f5-4195-8ed8-f83d04273ed8"
      unitRef="usd">161500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzExLTItMS0xLTA_e2251072-7c63-4f23-8cbe-3ac085c08912"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzExLTQtMS0xLTA_f2283b8b-c310-427e-bb77-df3098d52e2c"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzExLTYtMS0xLTA_7613591b-a29d-4bef-a0c3-69bc668d3476"
      unitRef="usd">6300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzExLTgtMS0xLTA_014c7fb6-e703-4279-8fcd-d2e967be4ecb"
      unitRef="usd">4900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEyLTItMS0xLTA_2514bc16-b15b-4438-ad60-b37650c7c00f"
      unitRef="usd">60200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEyLTQtMS0xLTA_86732372-525b-46ed-9a67-7f1549fd1748"
      unitRef="usd">37700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEyLTYtMS0xLTA_47aee989-33e8-4bf1-8885-642ecb74de7d"
      unitRef="usd">193700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDMvZnJhZzozYjc2NmZkMmFkMTA0MDM5YjZjZWQ0ZDgzMTJjMTcyMi90YWJsZTo3ZWVhYjY3N2RiZjc0NDIzYjYzY2QzY2MzMTI3YTI5Zi90YWJsZXJhbmdlOjdlZWFiNjc3ZGJmNzQ0MjNiNjNjZDNjYzMxMjdhMjlmXzEyLTgtMS0xLTA_aa2ba233-518b-4dde-ac9f-1a19d0a08235"
      unitRef="usd">156600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzUyNTE_b165067f-f5e2-4b98-92a9-27c1ff9e2be6">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Litigation,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $1.7 billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $1.6 billion. We continue to assess the realizability of these deferred tax assets and have recorded no changes for the three months ended September 30, 2021. We have recorded an increase in these deferred tax assets of approximately $92.6&#160;million and an increase in these deferred tax liabilities of approximately $88.7&#160;million for the nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:13.5pt"&gt;&lt;span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset discussed below, were primarily due to the change in the territorial mix of our profitability, which included the adverse effect of generic competition for TECFIDERA in the U.S. market; the tax impacts of the BIIB111 and BIIB112 impairment charges; and the impact of the non-cash tax effects of changes in the value of our equity investments, where we recorded unrealized losses in 2021.  The tax effects of this change in value of our equity investments were recorded in the current period, as the changes in value of equity investments cannot be reliably forecasted. Our 2020 effective tax rate also reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, for the nine months ended September 30, 2021, compared to the same period in 2020, the decrease in our effective tax rate was primarily due to a current year deferred tax benefit in Switzerland resulting from the accelerated approval of ADUHELM by the FDA in the U.S. recognized during the second quarter of 2021. We recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit discussed below. The deferred tax benefit relates to Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc. For additional information on our collaboration arrangement with Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we increased our gross unrecognized tax benefits by approximately $375.0&#160;million, related to a deferred tax asset for Swiss tax purposes for Neurimmune's tax basis in ADUHELM, as discussed above. This unrecognized tax benefit was recorded as a reduction to the gross deferred tax asset, resulting in the net deferred tax asset discussed above, and not as a separate liability on our condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $20.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <biib:DeferredTaxAssetsValueReductioninValue
      contextRef="i28adb3330230472e88334d479def96ab_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzEwNDA_8c151713-0721-4fe2-8ee2-6934799896af"
      unitRef="usd">1700000000</biib:DeferredTaxAssetsValueReductioninValue>
    <biib:DeferredTaxLiabilitiesValueReductioninValue
      contextRef="i28adb3330230472e88334d479def96ab_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzExODU_5f6d1ec9-218b-40b3-9b78-5f5260f1e101"
      unitRef="usd">1600000000</biib:DeferredTaxLiabilitiesValueReductioninValue>
    <biib:DeferredTaxAssetIncreaseDecreaseInValue
      contextRef="i92a13aa4f4d447958145380700133524_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzEzMzQ_13079c19-8475-41e4-b65a-35b31d3f69b0"
      unitRef="usd">92600000</biib:DeferredTaxAssetIncreaseDecreaseInValue>
    <biib:DeferredTaxAssetIncreaseDecreaseInValue
      contextRef="ia13f165b3be34174b50cecb4c27778d9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzEzMzQ_3ee62982-fbc5-4f89-9e94-e7d2fd083fd7"
      unitRef="usd">92600000</biib:DeferredTaxAssetIncreaseDecreaseInValue>
    <biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue
      contextRef="iee279a7d1aed471ba23a5d4e8f28794a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzE0MDQ_01911dc1-71c6-4fec-8d08-626461578761"
      unitRef="usd">88700000</biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue>
    <biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue
      contextRef="i756f3f5bdda54726bce4b571b4493a2a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzE0MDQ_2851c16d-af1b-4686-b4f9-e0ec5092503f"
      unitRef="usd">88700000</biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzUyNjY_43c8e483-118c-4511-b496-24cc70825865">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzItMS0xLTEtMA_626c8a53-2266-4d11-9757-60c6fbcc0970"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzItMy0xLTEtMA_23364fbf-3230-483e-8d62-9f40f92bd552"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzItNS0xLTEtMA_02d64532-764e-4d18-a67f-6ef3a8e8f4ae"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzItNy0xLTEtMA_4b414697-aa06-4c80-b9fe-21f2648ad993"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzMtMS0xLTEtMA_8eae01df-da10-4605-ba9a-329114d81f8f"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzMtMy0xLTEtMA_fda0f282-3ccd-4d9b-8d6c-bc8d4354964c"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzMtNS0xLTEtMA_5d84b2de-a6b0-41e2-942f-46348258cd5c"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzMtNy0xLTEtMA_de5e9e28-1c9f-4873-956d-26e22529105c"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzQtMS0xLTEtMA_b89942fa-1959-4159-ae8d-8aa616c3b514"
      unitRef="number">-0.202</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzQtMy0xLTEtMA_ba11843c-0401-4de3-a39c-6724ad3f729f"
      unitRef="number">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzQtNS0xLTEtMA_46e13a53-017b-4822-a082-8f93840a3b92"
      unitRef="number">-0.115</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzQtNy0xLTEtMA_d5b1d962-9421-4f79-8b16-dea9771dd51f"
      unitRef="number">-0.036</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzUtMS0xLTEtMA_f7d35dd3-430b-4ecd-a0b9-2bd9c07d7e78"
      unitRef="number">0.071</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzUtMy0xLTEtMA_dbb3a288-5a65-4cca-a86e-a14d3a44f886"
      unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzUtNS0xLTEtMA_4788defc-32f3-4f67-bd1c-c2f633201f2a"
      unitRef="number">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzUtNy0xLTEtMA_a480d8c4-967f-4889-b650-0767613c678f"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzYtMS0xLTEtMA_cb5bb650-cea3-4175-bc2e-4d94c092b489"
      unitRef="number">-0.062</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzYtMy0xLTEtMA_f7211c22-9e82-4fe0-a023-0b8e309722a0"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzYtNS0xLTEtMA_86ba3594-9824-4718-999c-d4c177c4f25a"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzYtNy0xLTEtMA_8f8bf1ec-3ad6-41e4-815f-0551ccec6506"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzktMS0xLTEtMA_e34e18b9-85be-45d5-9bc3-d0e4988eb0c0"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzktMy0xLTEtMA_4480f7c5-d769-4bdf-ac40-2331e1e9ae27"
      unitRef="number">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzktNS0xLTEtMA_165fe3b5-b751-46a6-a0ed-97d15e402a0e"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzktNy0xLTEtMA_fa6797d9-64df-46af-b5e2-b042a1461c49"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEwLTEtMS0xLTA_fa93226f-06e2-4e14-9ecc-3bbe70d53b45"
      unitRef="number">0.026</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEwLTMtMS0xLTA_b3fd660a-aba3-41a6-b9b0-714fb5446dd0"
      unitRef="number">0.022</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEwLTUtMS0xLTA_8d670715-e726-45bb-a1dd-9d9c0c903b74"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEwLTctMS0xLTA_3a85319e-e306-47e3-85f4-f0a18d7e5672"
      unitRef="number">0.013</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEzLTEtMS0xLTA_b87d7cfb-80f8-4ab9-a3fe-56b9f639ebd5"
      unitRef="number">-0.005</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEzLTMtMS0xLTA_2356b83e-6631-4687-8a4f-7bfe31a63aa7"
      unitRef="number">0.002</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEzLTUtMS0xLTA_886a71b6-aefe-459f-9206-9130c4c57324"
      unitRef="number">-0.364</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzEzLTctMS0xLTA_89ca36b0-7380-4f45-a451-0e63d2ddf2c3"
      unitRef="number">-0.001</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE1LTEtMS0xLTA_a57c2bde-9c66-4bfe-9dac-fd0a0e61dc72"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE1LTMtMS0xLTA_abef6015-177f-46e5-b6e4-7c889e4f89d3"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE1LTUtMS0xLTA_b4e6ad70-6a42-43eb-9cae-a59f707f3b70"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE1LTctMS0xLTA_14c2ef1a-f2eb-4815-afd1-5cc1f7f9fa9e"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE2LTEtMS0xLTA_7df0488c-5f74-4831-938b-063b88774e6d"
      unitRef="number">-0.089</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE2LTMtMS0xLTA_b414b1b1-3ac5-4541-98bf-d27f8e486450"
      unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE2LTUtMS0xLTA_5b77f7e6-18d2-4b68-96e4-326f9758e7eb"
      unitRef="number">-0.292</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90YWJsZTplZTUzM2Q4NjkyZGU0NmE2OGRiZWNiOTM2MmUxMjBkNS90YWJsZXJhbmdlOmVlNTMzZDg2OTJkZTQ2YTY4ZGJlY2I5MzYyZTEyMGQ1XzE2LTctMS0xLTA_655083da-0661-4b8d-af6a-36a7ab4928f4"
      unitRef="number">0.209</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzE4OTk_ec1fedeb-27ac-40ee-b0e5-ecc368d9f485"
      unitRef="usd">500000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzE5NjA_74a68c4c-18d0-4903-9c72-c3b14fc3c937"
      unitRef="usd">875000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzIwMTc_c80857f1-89f9-42ae-990c-0a69830f3359"
      unitRef="usd">375000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzQzNTA_c80857f1-89f9-42ae-990c-0a69830f3359"
      unitRef="usd">375000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i5a5dec6bf41c4a37a79d8a1cc7f4a7da_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMDYvZnJhZzpiYjFjZTkzNDE5NDE0ODA3YjYyM2FmYTYwMWM5MDRhMy90ZXh0cmVnaW9uOmJiMWNlOTM0MTk0MTQ4MDdiNjIzYWZhNjAxYzkwNGEzXzUxMjY_c33bc4d0-2383-4391-8061-5672c4e8bab4"
      unitRef="usd">20000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE4MjM_ff2912f2-72e5-47e1-aece-7e555d2e0c07">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(187.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(166.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(424.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(707.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(502.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(128.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(913.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(186.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $426.9 million and $2.7 million, respectively, compared to net unrealized losses and realized gains (losses) of $82.3 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended September 30, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Ionis, Sage and Sangamo common stock of approximately $424.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $715.2 million and $9.3 million, respectively, compared to net unrealized losses and realized gains (losses) of $40.3 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Ionis, Sage and Sangamo common stock of approximately $709.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(424.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(705.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(426.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(715.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;713.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,550.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,145.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $1,318.2 million and $1,329.6 million as of September 30, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $657.6 million and $709.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE4MDc_b4c99085-5964-4944-a079-40fa64e32433">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(187.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(166.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(424.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(707.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(502.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(128.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(913.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(186.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzItMi0xLTEtMA_d315d35f-0c95-4a56-9dda-3ea90c9a6e15"
      unitRef="usd">2600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzItNC0xLTEtMA_87bd4248-90aa-479b-ab44-499e40458d6e"
      unitRef="usd">6000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzItNi0xLTEtMA_7f967946-a94f-4e30-a739-c54b7aff4372"
      unitRef="usd">8200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzItOC0xLTEtMA_4e934778-1036-49a1-8a5c-a0a093d6d7ca"
      unitRef="usd">38000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzMtMi0xLTEtMA_bb9892d0-410b-4339-bd23-7ad1dd85e9f8"
      unitRef="usd">66300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzMtNC0xLTEtMA_7eab7181-5f37-40f9-b4e2-20b77ec7e1f7"
      unitRef="usd">56300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzMtNi0xLTEtMA_98f8368c-e8ed-4373-9f33-383d64569f9f"
      unitRef="usd">187300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzMtOC0xLTEtMA_ce188f0e-7d73-4744-abf2-a97bbe14e3f2"
      unitRef="usd">166500000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzQtMi0xLTEtMA_bdbcd833-8fd0-4cd1-9a3a-53e99f2d9632"
      unitRef="usd">-424500000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzQtNC0xLTEtMA_f628e7ba-9d32-4ace-909f-3314c9b63128"
      unitRef="usd">-82100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzQtNi0xLTEtMA_6c26d267-6b6a-4290-8537-e82266fc0900"
      unitRef="usd">-707200000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzQtOC0xLTEtMA_c4dea341-b5a4-4655-b40c-43fa542b0cab"
      unitRef="usd">-52600000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzUtMi0xLTEtMA_b7ba488f-cc3f-4d5f-ac1a-3f0a9d296f20"
      unitRef="usd">-13700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzUtNC0xLTEtMA_7003b595-921b-46c1-9412-876f772286ca"
      unitRef="usd">3100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzUtNi0xLTEtMA_eb46987c-7d36-4587-b24a-8b766e979278"
      unitRef="usd">-23100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzUtOC0xLTEtMA_0681fab8-5b81-4ee0-b293-b71a1c16b297"
      unitRef="usd">-5400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzYtMi0xLTEtMA_ed0f0e54-5a3f-4073-a1ed-2e7e4b602427"
      unitRef="usd">-1000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzYtNC0xLTEtMA_d644e50b-5300-41a8-abb2-06ea023ebd6c"
      unitRef="usd">700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzYtNi0xLTEtMA_031b32fa-7de4-4be4-b1a8-eac8b1c23cc2"
      unitRef="usd">-4000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzYtOC0xLTEtMA_6e810b63-a7e6-45bb-a181-a3de6cfa1fde"
      unitRef="usd">400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzctMi0xLTEtMA_ca9bc43e-d621-4df3-bfe7-b94a2e7a3ebf"
      unitRef="usd">-502900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzctNC0xLTEtMA_9576f080-14df-4e19-b7cd-486a66c768a3"
      unitRef="usd">-128600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzctNi0xLTEtMA_268ea3bb-6537-453e-ba63-45250c3badcc"
      unitRef="usd">-913400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo5YjQ5ZDQyMzQzMTI0ZDA1YTkzYzJiMjFjNDFlOWRmNC90YWJsZXJhbmdlOjliNDlkNDIzNDMxMjRkMDVhOTNjMmIyMWM0MWU5ZGY0XzctOC0xLTEtMA_bb1072db-96ae-418a-9210-6b973855f481"
      unitRef="usd">-186100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzUzNw_8b5ec894-b134-4458-b177-f8bf57ca75fe"
      unitRef="usd">-426900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzU0NA_18309bfc-bb47-4a09-bab2-451a50803cba"
      unitRef="usd">2700000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzYyNg_70b7d39c-78ef-46c6-a372-0ac54ed28074"
      unitRef="usd">-82300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzYzMw_ef916116-15dc-437b-ba0a-77ca19d12d27"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5ea2be25eae54408bbb6eef779a3bab9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4Xzg0NA_96cc864c-5369-40d0-9dfb-80fd5a77c508"
      unitRef="usd">424300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzEwODI_67f5794e-e6d0-4012-a00e-02edb429f14e"
      unitRef="usd">-715200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzEwODk_9301f35b-8034-45a7-90cf-59b94c52d036"
      unitRef="usd">9300000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzExNzE_df5112d8-501b-47d3-b3d6-28c6c6cd10db"
      unitRef="usd">-40300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzExNzg_68d9f3aa-5e40-439b-b010-e5c28b43747b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i4e718401bed449ed8eea180efb806b04_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE0MTM_3256ef12-7ce0-4c46-80cc-c0848b4b3f06"
      unitRef="usd">709100000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE4MTk_21dd7f67-61c2-436b-9b91-0033548fd0c7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(424.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(705.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(426.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(715.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzItMi0xLTEtMA_fe48c328-ac56-4b89-afd4-3124cebf9813"
      unitRef="usd">-424200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzItNC0xLTEtMA_eab787ad-f879-42ea-8e16-649ce7c4f7d0"
      unitRef="usd">-82300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzItNi0xLTEtMA_2accd7d9-5d4d-4719-b5c7-aea0ca467d4b"
      unitRef="usd">-705900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzItOC0xLTEtMA_fae1108e-4426-41b2-b8d3-8511675ce27a"
      unitRef="usd">-40300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzMtMi0xLTEtMA_18309bfc-bb47-4a09-bab2-451a50803cba"
      unitRef="usd">2700000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzMtNC0xLTEtMA_ef916116-15dc-437b-ba0a-77ca19d12d27"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzMtNi0xLTEtMA_9301f35b-8034-45a7-90cf-59b94c52d036"
      unitRef="usd">9300000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzMtOC0xLTEtMA_68d9f3aa-5e40-439b-b010-e5c28b43747b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzQtMi0xLTEtMA_8b5ec894-b134-4458-b177-f8bf57ca75fe"
      unitRef="usd">-426900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7f17cf5f23db44f4aa1f5a19a594b93a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzQtNC0xLTEtMA_70b7d39c-78ef-46c6-a372-0ac54ed28074"
      unitRef="usd">-82300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzQtNi0xLTEtMA_67f5794e-e6d0-4012-a00e-02edb429f14e"
      unitRef="usd">-715200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i38ecf3a0e1a64f00b4bccd0e2f42058f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTo0M2Q1NGJkZmVmZDY0ZTM4YjI0ZjkwNWZhYjExZjU3My90YWJsZXJhbmdlOjQzZDU0YmRmZWZkNjRlMzhiMjRmOTA1ZmFiMTFmNTczXzQtOC0xLTEtMA_df5112d8-501b-47d3-b3d6-28c6c6cd10db"
      unitRef="usd">-40300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE4MTE_83d727ed-5d61-4d0e-bb7c-b3c0738a4c6c">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;713.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,550.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,145.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8aa3c889df0142bf89536f957b8eaee7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzEtMi0xLTEtMA_c6a1027d-5fbe-4581-b788-d1a19103a22f"
      unitRef="usd">982400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id4b173db27f4480e98a38ea719ffce5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzEtNC0xLTEtMA_b68b9f78-8ddb-4653-a36f-4dba663e72e7"
      unitRef="usd">1080600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:Collaborationexpensesaccrual
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzItMi0xLTEtMA_45fd60ef-dfe4-4914-a6ef-1ce4d5774018"
      unitRef="usd">289300000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzItNC0xLTEtMA_42959d93-7fa9-469c-a49b-ef0a330ff6aa"
      unitRef="usd">389900000</biib:Collaborationexpensesaccrual>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzMtMi0xLTEtMA_dfd28e1b-b657-4f0d-9899-f5abc259dd7e"
      unitRef="usd">299200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzMtNC0xLTEtMA_ae1c8add-e118-4710-a981-c1e7a5814989"
      unitRef="usd">333800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzQtMi0xLTEtMA_f7ae1638-0142-4bdb-9e69-6094fc6d8bab"
      unitRef="usd">238900000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzQtNC0xLTEtMA_29a8259c-1e9c-455e-a5a5-bc918ccbf06d"
      unitRef="usd">218500000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzUtMi0xLTEtMA_4ef1f127-c400-4563-8636-41d6b0d184f7"
      unitRef="usd">27700000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzUtNC0xLTEtMA_08e42ea3-9c3d-4b76-ba15-571cd0d014aa"
      unitRef="usd">181500000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzYtMi0xLTEtMA_528cbba4-fc1e-4837-aa00-dfad27a33323"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzYtNC0xLTEtMA_52ca13ed-14ef-4884-95d7-2c993b284f41"
      unitRef="usd">149600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzctMi0xLTEtMA_89f603b9-2d3e-40c9-9dba-8dba2fe2f1bc"
      unitRef="usd">713200000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzctNC0xLTEtMA_8a99ff5c-cb58-4787-bec9-ad5be1f3a817"
      unitRef="usd">791400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzgtMi0xLTEtMA_3ca36418-8464-425e-a150-95457fc45da1"
      unitRef="usd">2550700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90YWJsZTpmZDY3NTcyMGYwMzI0NDFmYTY2Njc1OTVjZTA1YTE5Yy90YWJsZXJhbmdlOmZkNjc1NzIwZjAzMjQ0MWZhNjY2NzU5NWNlMDVhMTljXzgtNC0xLTEtMA_3a756581-359e-4145-a540-42c08244bd31"
      unitRef="usd">3145300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE2ODk_71fde94b-8d8b-4d9f-b9cc-3385f87edfb7"
      unitRef="usd">1318200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE2OTY_ccd343b0-d0dd-4442-a172-0272699f9e13"
      unitRef="usd">1329600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE3NzM_7e63272d-cc5e-4ff3-8920-da52c310a0f2"
      unitRef="usd">657600000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTIvZnJhZzoxZTdmZWEzMTIxYTI0OTg0YTQ4ZDk2ZTZkMjM4NzRlOC90ZXh0cmVnaW9uOjFlN2ZlYTMxMjFhMjQ5ODRhNDhkOTZlNmQyMzg3NGU4XzE3ODA_4c2cb91f-4c6f-4538-ade7-6e4f6875be69"
      unitRef="usd">709900000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NTk4_9b374421-7945-4021-8cf4-c39a81008e75">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lecanemab Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the global operational and regulatory lead for lecanemab and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In addition, the Lecanemab Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;nm&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; - For the three months ended September 30, 2020, sales and marketing expense related to lecanemab and elenbecestat was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our Lecanemab Collaboration, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ADUHELM Collaboration Agreement, we lead the ongoing development of ADUHELM, and we and Eisai will co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of ADUHELM in patients with early Alzheimer's disease. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred under the ADUHELM Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019 we and Eisai announced that we planned to pursue regulatory approval for ADUHELM in the U.S. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In July 2020 we completed the submission of a Biologics License Application (BLA) for the approval of ADUHELM to the FDA and made a $75.0 million milestone payment to Neurimmune. We recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. For the nine months ended September 30, 2021, we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expense are shared in proportion to the same region-based profit split that is utilized to co-promote ADUHELM. A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM collaboration third party milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;o-promotion Profits and Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2021, we recognized net profit-sharing income of $50.6&#160;million and $90.7&#160;million, respectively, to reflect Eisai's 45.0% sharing of the net collaboration losses in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the ADUHELM Collaboration Agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0&#160;million to research and development expense in our condensed consolidated statements of income to reflect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the premium paid for the Sage common stock. We also made an upfront payment of $875.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We may also pay Sage development and commercial milestone payments that could total up to approximately $1.6&#160;billion if all the specified milestones set forth in this collaboration are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#x2019;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Denali development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to the LRRK2 program are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#x2019;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, of which approximately 12&#160;million shares remain subject to transfer restrictions as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $83.0 million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this collaboration and all the specified milestones set forth in this collaboration are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;InnoCare Pharma Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2021 we entered into a license and collaboration agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#x2019;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the closing of this transaction in August 2021, we made an upfront payment of $125.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;that was recorded as research and development expense. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We may also pay InnoCare up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should the collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties in the low to high teens on potential future net sales of any product developed under this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021, we recorded $7.7&#160;million and $84.9 million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to $38.0&#160;million and $47.6 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of September 30, 2021, our ownership percentage remained at approximately 49.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021, we recognized net income on our investment of $1.1 million and $17.2 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax, compared to net losses on our investment of $13.1 million and $12.7 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income on our investment for the nine months ended September 30, 2021, reflects a $31.2&#160;million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the second quarter of 2021 based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled 692.8 billion South Korean won ($586.1 million) and 673.8 billion South Korean won ($620.2 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2020, we paid Samsung Bioepis a $15.0&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. During the third quarter of 2021, we accrued $15.0&#160;million in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; milestones related to the approval of BYOOVIZ in the U.S. and E.U. that were capitalized within intangible assets. We may pay Samsung Bioepis up to $180.0 million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 c&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2021, we recognized net profit-sharing expense of $71.8&#160;million and $210.2 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $72.9 million and $200.1 million, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts payable to Samsung Bioepis related to the agreements discussed above were $125.7&#160;million and $99.0&#160;million as of September 30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2020 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:NumberOfProductCandidates
      contextRef="icccb66447d924c0594b928f60f204b02_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzI3NA_686d4ce4-8939-40da-83c4-20a89e028438"
      unitRef="product">2</biib:NumberOfProductCandidates>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NjEy_d93c47c4-35cb-4d1a-bf1b-4ee35394e595">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i590aa7c867af425baa597d7a5149c44b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzItMi0xLTEtMA_9e186ee0-c28a-4cf1-8d3f-c9040b2d719e"
      unitRef="usd">118400000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i4078cb7710e54f01b41c9089dc314b3a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzItNC0xLTEtMA_5982bd03-e73a-4ccc-a7f4-f67a241a5a5f"
      unitRef="usd">75700000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i633b5b8dfba24438ad91750ffda4fddf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzItNi0xLTEtMA_da563502-fbef-45cf-a9d1-2ec3523202d3"
      unitRef="usd">236100000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i8dff1fe5988e4116a7e201e084821a57_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzItOC0xLTEtMA_391f94cd-1ab8-4966-bc57-c8233ddd7e5f"
      unitRef="usd">153200000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i590aa7c867af425baa597d7a5149c44b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzMtMi0xLTEtMA_cd33d76f-96c0-4fc1-8df9-b36867871b04"
      unitRef="usd">59200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i4078cb7710e54f01b41c9089dc314b3a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzMtNC0xLTEtMA_face0b29-6f4c-4701-be2d-813706f6856d"
      unitRef="usd">37900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i633b5b8dfba24438ad91750ffda4fddf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzMtNi0xLTEtMA_d4b3fcb9-7ef8-471c-b9f5-655bdb37693a"
      unitRef="usd">118000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i8dff1fe5988e4116a7e201e084821a57_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzMtOC0xLTEtMA_cc07400b-4439-408f-8ca4-01ce53a649e2"
      unitRef="usd">76600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i69f8f42a6a9c41ddae4efe85bc2204b8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzQtMi0xLTEtMA_222323bf-728d-4b82-a954-af10047bab44"
      unitRef="usd">5600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i648337729b824015ae37af96e3c8ea6b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzQtNi0xLTEtMA_a671104c-dffa-43a2-8d84-cd12e275edbd"
      unitRef="usd">15600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i02128433756c4eaeb9a1cb904b8b0757_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzQtOC0xLTEtMA_cc26873f-a35a-472a-a472-bf9d4e6d2071"
      unitRef="usd">6300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i69f8f42a6a9c41ddae4efe85bc2204b8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzUtMi0xLTEtMA_c49b7e8e-aca4-41a0-afe7-b2cf522ba655"
      unitRef="usd">2800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i648337729b824015ae37af96e3c8ea6b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzUtNi0xLTEtMA_1cc91169-5621-4e48-839d-8e4162ca8ff5"
      unitRef="usd">7800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i02128433756c4eaeb9a1cb904b8b0757_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTpmYjAzNTEzOTYwZGY0ZTViYmM5ZjA0Y2U3MmEwZWJkMy90YWJsZXJhbmdlOmZiMDM1MTM5NjBkZjRlNWJiYzlmMDRjZTcyYTBlYmQzXzUtOC0xLTEtMA_ad0457ed-08c5-4156-b595-45fc94f16468"
      unitRef="usd">3200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzIzMTA_c3804989-841c-4931-a463-a02badf20462"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="i9ad97210ae5d418ca006b46280264849_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzI4Mzg_2e3f39da-c01b-45cd-91f0-2012e224ea1e"
      unitRef="usd">45000000</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzI5NTQ_c3804989-841c-4931-a463-a02badf20462"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM0ODk_df2de88d-1e15-462b-ae43-3f77fb1ea8ea"
      unitRef="usd">75000000</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM1Njg_cf90149b-536d-400f-a857-02b83ef86513"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM1OTA_c3804989-841c-4931-a463-a02badf20462"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM2MDY_df2de88d-1e15-462b-ae43-3f77fb1ea8ea"
      unitRef="usd">75000000</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i1ac80dac77b54f829d7ff2f034bca438_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM4Mjk_2e32b0ff-0937-463c-a7ec-62b4fb34f282"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i980538f09ea6402c88eeb6295f06a52e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM5NDM_3b7fea9e-f9f9-4e9f-86df-ddf25f425cd4"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i509664d8b5114111a796a1f9c9e4bf21_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM5NDM_b0e9c8f4-9495-4b3c-80cd-69d956ed149f"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM5NjU_c3804989-841c-4931-a463-a02badf20462"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i1ac80dac77b54f829d7ff2f034bca438_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM5ODE_2e32b0ff-0937-463c-a7ec-62b4fb34f282"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NTg0_fb5ba1fc-5980-40a2-ac62-848d66f33c51">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM collaboration third party milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i478b04cc484548cca1dda224d468b2e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzItMi0xLTEtMA_cfaecbc7-b27c-48de-9d2d-35714d33bc47"
      unitRef="usd">43700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ibbc6f9feb2e14b0b92a0d13fa4fa7b20_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzItNC0xLTEtMA_7495c9a1-cef8-4aba-8f36-5523026fb35b"
      unitRef="usd">37500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6e0983fe25984681bb8e932d698e54aa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzItNi0xLTEtMA_159d498a-4d5e-4369-86d0-231e3efeb186"
      unitRef="usd">132800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="if795d18582b54e3b9e469252f6bb23c1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzItOC0xLTEtMA_3591dc29-ade4-464e-bb48-4a35894683c2"
      unitRef="usd">92500000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i478b04cc484548cca1dda224d468b2e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzMtMi0xLTEtMA_9b2bfd63-b2c2-49fa-99b1-15148383c24e"
      unitRef="usd">24000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ibbc6f9feb2e14b0b92a0d13fa4fa7b20_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzMtNC0xLTEtMA_f259a2dd-92c7-4854-a419-faaef604574d"
      unitRef="usd">20600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6e0983fe25984681bb8e932d698e54aa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzMtNi0xLTEtMA_ff7b313e-9b8b-42f2-9933-3edfa5cd9a7e"
      unitRef="usd">73000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="if795d18582b54e3b9e469252f6bb23c1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzMtOC0xLTEtMA_d5bd7ef6-05b7-470a-8b15-b4e1289eb811"
      unitRef="usd">50900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i7a30db781c9c4e588e9c2f59f6c0abc3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzQtMi0xLTEtMA_37c0ad68-fea8-4e49-ac7d-4a9633dc5923"
      unitRef="usd">154300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="iabde71d9b5fa451e97f28d6436d5b553_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzQtNC0xLTEtMA_62246d6e-9e97-4ca5-af8d-3d770839084a"
      unitRef="usd">90900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i22f562316d0a4a2788f90566852c367f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzQtNi0xLTEtMA_508de187-4ba7-4e8a-96a9-05a231c071ad"
      unitRef="usd">391700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ia2747153b7ca44e2a5d47259de2db6c9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzQtOC0xLTEtMA_080d0dba-05bb-4007-af23-08b651c85b49"
      unitRef="usd">158800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i7a30db781c9c4e588e9c2f59f6c0abc3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzUtMi0xLTEtMA_97da5629-040f-467a-8859-433727c34b71"
      unitRef="usd">83300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="iabde71d9b5fa451e97f28d6436d5b553_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzUtNC0xLTEtMA_74334533-6684-40e6-8225-2a79dfe1b147"
      unitRef="usd">51300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i22f562316d0a4a2788f90566852c367f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzUtNi0xLTEtMA_8b4e310a-8f3d-44a5-8336-7fd8b959e1a4"
      unitRef="usd">211200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ia2747153b7ca44e2a5d47259de2db6c9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzUtOC0xLTEtMA_e9dd9be6-57bb-46fa-8044-7d0892bcd660"
      unitRef="usd">88800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="i509664d8b5114111a796a1f9c9e4bf21_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzYtMi0xLTEtMA_4fb33188-2696-43b8-8b2d-b03367fb0c9a"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i487108ca40f748dd9b0bece4b437028b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzYtNC0xLTEtMA_87c57730-be8b-48dc-9087-17ceb27d3b61"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i980538f09ea6402c88eeb6295f06a52e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzYtNi0xLTEtMA_ef724865-40ac-4523-85a2-96f9ca17286d"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="ia32e8ba2ceec42cc82a16e2cd05dab84_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzYtOC0xLTEtMA_29fcd137-1562-4001-81e8-69b8cb1e4cef"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i509664d8b5114111a796a1f9c9e4bf21_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzctMi0xLTEtMA_744c58f9-8571-4eda-a83e-5724a35e4fcd"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i487108ca40f748dd9b0bece4b437028b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzctNC0xLTEtMA_ab3952ed-dadb-4489-bcc6-1b9df36adf53"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i980538f09ea6402c88eeb6295f06a52e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzctNi0xLTEtMA_5e5a5eeb-e699-43b9-8397-d5a0a2a184db"
      unitRef="usd">45000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ia32e8ba2ceec42cc82a16e2cd05dab84_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTowYzQ5NmVlYmY1YTU0MzFiOTNiZGM5MjhlYjQ5OTdmMi90YWJsZXJhbmdlOjBjNDk2ZWViZjVhNTQzMWI5M2JkYzkyOGViNDk5N2YyXzctOC0xLTEtMA_9c089bc6-3c6a-4041-af80-2e9d73093869"
      unitRef="usd">33800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzQ2Njk_c3804989-841c-4931-a463-a02badf20462"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9c43205ec30542ee94946dc9109e90bb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzIxOTkwMjMyNzQ0MDQ_06819da8-b466-4621-bcf6-f24a1104525f"
      unitRef="usd">50600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icccb66447d924c0594b928f60f204b02_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzQ5MDU_27629030-6a7b-47ad-9637-21cc8de7f9ff"
      unitRef="usd">90700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icccb66447d924c0594b928f60f204b02_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzQ5MDU_f8661ed2-d36b-480c-bd4f-c8fbb42acd40"
      unitRef="usd">90700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i00ad05700891493d918f048f148b8bfa_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzgyNDYzMzcyNDIwNTA_37b9aa06-d344-4ae8-82cc-a5d7df2aa0b3"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:Expenseincurredbythecollaboration
      contextRef="i751d4a0241cf4502ab3497a8e9ec0dce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzItMi0xLTEtMA_4a27b06c-1e35-481d-b769-099d5d65ab23"
      unitRef="usd">16500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="icad78ebefcf14b34899f5ddcb848be14_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzItNC0xLTEtMA_63a89669-2841-4e91-be55-eb71f7817b3f"
      unitRef="usd">10200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="idabf552e851142fe99517e02399fdd3f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzItNi0xLTEtMA_e489a023-6360-48ec-8999-567c4869bb06"
      unitRef="usd">49500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ifa0eaf2019e44f0682994cffd26a0133_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzItOC0xLTEtMA_0017d040-b5ef-434c-bbf9-622b856c014a"
      unitRef="usd">35700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i751d4a0241cf4502ab3497a8e9ec0dce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzMtMi0xLTEtMA_1abbd240-17e9-4495-ab61-bc23c59b9b51"
      unitRef="usd">8200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="icad78ebefcf14b34899f5ddcb848be14_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzMtNC0xLTEtMA_6d929202-a3b1-46b5-b1d1-f9e5b58c5d58"
      unitRef="usd">5200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="idabf552e851142fe99517e02399fdd3f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzMtNi0xLTEtMA_16370e1b-d923-4b4c-8b33-033a3136c880"
      unitRef="usd">24800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ifa0eaf2019e44f0682994cffd26a0133_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo3MTk5YjgxMDY1MjM0MzhlYjcyYzJlN2JkZDg1ZGE3Mi90YWJsZXJhbmdlOjcxOTliODEwNjUyMzQzOGViNzJjMmU3YmRkODVkYTcyXzMtOC0xLTEtMA_0e80f0ba-ffa6-4b66-a029-02ce8b7eb7ef"
      unitRef="usd">17900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzY4MjM_888c760d-b56b-4f3c-a845-e6175728d0ed"
      unitRef="usd">650000000</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzY4NjU_fc3f42df-4272-473c-973e-c57e8f141cab"
      unitRef="shares">6200000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzY4OTI_2d81b58e-e068-49e7-a1f5-f14808704a17"
      unitRef="usdPerShare">104.14</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzcxNDY_8394026a-32ba-405b-96bc-606c6ec94d10"
      unitRef="usd">209000000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzczMjY_4d6297a5-3162-4c15-9955-b8dfdb9703b6"
      unitRef="usd">875000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzc0ODg_710790b2-c11c-4d35-8d3f-036888d4416d"
      unitRef="usd">1600000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:Expenseincurredbythecollaboration
      contextRef="ief1572a6af6d488d9ab80a00623a94ad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzItMi0xLTEtMA_7d439ae1-3673-49dc-ad1b-ac30ee092968"
      unitRef="usd">40800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i15516b5b057f44e9944b4a39df3e5c9e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzItNC0xLTEtMA_ec6a2506-1886-4a8a-b585-aec641dd306a"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ic776742915944b44af8f827099040080_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzItNi0xLTEtMA_8a4cd644-c033-4202-84b4-957ead631589"
      unitRef="usd">134900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ie9d32af2650947b8b8a4b511bb7ba6ff_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzItOC0xLTEtMA_f6fd6b9d-fcde-4576-933a-2cced5009fb9"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ief1572a6af6d488d9ab80a00623a94ad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzMtMi0xLTEtMA_8bc9c68b-3af9-4f65-8b02-68c04d6522f3"
      unitRef="usd">20400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i15516b5b057f44e9944b4a39df3e5c9e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzMtNC0xLTEtMA_1772717f-78d2-4edd-b772-41fafaf0424f"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ic776742915944b44af8f827099040080_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzMtNi0xLTEtMA_161ff9c6-c67f-4be3-8c37-225ce02de812"
      unitRef="usd">67300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ie9d32af2650947b8b8a4b511bb7ba6ff_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzMtOC0xLTEtMA_779eae88-85cd-43b5-b970-cf341a839311"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i7fd0e08d01ac49639fc6727d3904fee7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzQtMi0xLTEtMA_3d207131-c388-4462-bedd-7cdab8f98747"
      unitRef="usd">7400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i69c7f3a2f08a498b8785ed63ef47838c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzQtNC0xLTEtMA_9e52e280-aeab-43f4-aafd-472816741397"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i3d833d38eb9f4e898a5898ddbf6dce39_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzQtNi0xLTEtMA_8167ffcc-1779-4810-9b36-1a1af55f1d2a"
      unitRef="usd">23200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i4efa6afcaf1645f6b58846b7cc88b340_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzQtOC0xLTEtMA_d93b87f8-f8fd-4a13-8e84-c49a09aac5e1"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i7fd0e08d01ac49639fc6727d3904fee7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzUtMi0xLTEtMA_02ff0152-ffb0-4c81-b7cd-6d82a48e4ff2"
      unitRef="usd">3700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i69c7f3a2f08a498b8785ed63ef47838c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzUtNC0xLTEtMA_a47619ef-8290-43d9-8d5d-57602952176c"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i3d833d38eb9f4e898a5898ddbf6dce39_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzUtNi0xLTEtMA_f783502c-4125-4284-ad30-36e91425abf2"
      unitRef="usd">11600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i4efa6afcaf1645f6b58846b7cc88b340_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZTo4OTc4NDQxN2MxOGY0MDFjOWRhMTkxOTI3NzU1OTgyNi90YWJsZXJhbmdlOjg5Nzg0NDE3YzE4ZjQwMWM5ZGExOTE5Mjc3NTU5ODI2XzUtOC0xLTEtMA_cabaeb62-42cc-4f17-a6fc-f8937b0b5245"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzg3OTE_6e20d8e5-d23e-4ffc-9078-d9ca338a5278"
      unitRef="usd">465000000</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:Investmentincommonstocksharespurchased
      contextRef="if8b5d9e350944ffdad686ff95dd1085f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzg4NDE_96dfe927-f8bf-4032-a8f5-9f38a647d366"
      unitRef="shares">13000000</biib:Investmentincommonstocksharespurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="ic6e8565fba3e4c6eacb2b1dfc8268cf0_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzg4Njg_1346b44b-01ee-4e49-bffb-63c454ffc772"
      unitRef="usdPerShare">34.94</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie06b3989f9a34f469041414b1f9de0db_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzkxMjQ_28e54ab9-9438-474d-b2bd-5437285537be"
      unitRef="usd">41300000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ie06b3989f9a34f469041414b1f9de0db_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzkzMDY_d2fe1820-ed17-41af-ae5d-987e5d19fca4"
      unitRef="usd">560000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="ie06b3989f9a34f469041414b1f9de0db_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzk0NzA_ec9cba16-7411-448b-8804-ee2fcbab6892"
      unitRef="usd">1100000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NjA0_b9dc81ce-8800-4362-a98f-71bf0025210e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="id9e7531c621947d4a9119f4864109e24_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzItMi0xLTEtMA_5e0426cc-2f77-4bfd-9a0c-b3808ca1637b"
      unitRef="usd">8500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i3cb3160ab3ff42eaae7dd54fa3d456e5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzItNC0xLTEtMA_c9906217-3351-4a7d-a1ab-21d72389393b"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i199def73fc1342d0a937f3d464cb4c69_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzItNi0xLTEtMA_710ec523-3c5a-4f8a-a3a3-6159a1a1b4d5"
      unitRef="usd">27200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i5281eb5b3f824e51b96dd0c15c3e9f04_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzItOC0xLTEtMA_d44432d8-0eca-4fad-b85f-481db23352a6"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id9e7531c621947d4a9119f4864109e24_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzMtMi0xLTEtMA_10f3ec0d-2681-4057-81c1-5c798d1d15b3"
      unitRef="usd">5100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i3cb3160ab3ff42eaae7dd54fa3d456e5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzMtNC0xLTEtMA_e1a510e7-4db4-4b39-9c9f-0b8a1d664665"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i199def73fc1342d0a937f3d464cb4c69_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzMtNi0xLTEtMA_9858f4cf-7187-4800-b03d-45b54bf88813"
      unitRef="usd">16300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i5281eb5b3f824e51b96dd0c15c3e9f04_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90YWJsZToyMzVmZTk1ZTA2MDU0MDAwYWE4NjZjNGY4YTdkNTRlNy90YWJsZXJhbmdlOjIzNWZlOTVlMDYwNTQwMDBhYTg2NmM0ZjhhN2Q1NGU3XzMtOC0xLTEtMA_03725c73-6baa-4203-86dd-2e2270b23c76"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Termofcollaborationagreement
      contextRef="i6944bfac8bea4cacac93ae484b0bd09d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4NTky_dbb177b6-b9c5-4263-848d-615452c9c6fc">P5Y</biib:Termofcollaborationagreement>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwNTIw_8b76c249-5726-4861-a144-6e5f1c2ea28d"
      unitRef="usd">225000000</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwNTY1_96b27272-81b8-4f50-8394-25e5b1a99ae2"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwNTky_594b7d56-d232-4ec1-8da5-ebbf70f9cdc1"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <biib:Investmentincommonstocksharespurchased
      contextRef="i8ea2f828e08946f9bfe96108463cde78_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwNjI5_f736b3cc-d8fc-499b-bd25-5c9a22c3dec1"
      unitRef="shares">12000000</biib:Investmentincommonstocksharespurchased>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEwODg4_b79e36d8-f45d-489e-a822-58053b476da3"
      unitRef="usd">83000000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExMDcx_3aab01cc-34a1-4cb6-8ab2-9f8bb3fe046a"
      unitRef="usd">125000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExMjU4_c7ff9111-51fd-42e8-9a93-d27afa50f291"
      unitRef="usd">2400000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExNDI3_6af5162e-3b9a-4d2d-809c-f02a48832822"
      unitRef="usd">80000000</biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExNDY3_add32537-c667-46ef-bfac-4839a76c692e"
      unitRef="usd">1900000000</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones
      contextRef="ia8dcf308e6854ca09ed2892763a0371b_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzExNTk0_1b1b1143-2538-4921-a08a-6682760f027e"
      unitRef="usd">380000000</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i86671ce6531e4825b8e7437bac23648c_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzIxOTkwMjMyNzYwODI_e63d4b02-7d68-43da-9458-eb0f3ccad757"
      unitRef="usd">125000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:ContingentMilestonePaymentsMadeToCollaborativePartner
      contextRef="i86671ce6531e4825b8e7437bac23648c_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzIxOTkwMjMyODQyNzI_e9e51a1d-3f18-4f58-b235-3d026d68c8ff"
      unitRef="usd">812500000</biib:ContingentMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icbfdae3fc3af4808b767547c978da623_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyMjE0_6ab4b16b-20e0-42e2-9b2e-d559440a78ea"
      unitRef="usd">7700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6f17596163b74714978d0ca8bb7716a7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM4NDgyOTA3MzA2MDE_9e1346f6-cfc9-4f5e-99aa-9395eee22dce"
      unitRef="usd">84900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i920ace51c79b4fd9aaea95747910f622_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyMzc4_e3098bb9-ec9a-4039-90ea-b2fbadd2689d"
      unitRef="usd">38000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i901cded39aad4bb796bd2e4ea0b84524_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM4NDgyOTA3MzA2MjA_2793330f-c3c8-425e-b90c-41c05ecb4f97"
      unitRef="usd">47600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="ifa2615942dbc42b59096307ded3cc0c3_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyNzk1_7ab0906b-cc1c-4313-b171-a2e493889692"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyODE1_9cf11c30-fbbc-4cab-af2a-eea0fe4cf3f3"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="icc31d40d106d4c9f992098cfdbc25314_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyOTA4_22b20347-bf26-4484-9885-4f1310055d04"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i0af199bf8cdb4db88ac9960dd490f47a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEyOTI5_0762254f-ebef-4a62-afad-c167cecf1b70"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzEzMDE2_9cf11c30-fbbc-4cab-af2a-eea0fe4cf3f3"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i7b972473b78a41948835d5e6b4829ce2_I20181107"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0MDMx_8a63df33-e224-459a-8889-6d1a18f9195d"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i6d3585ab7f49447c9095cb7b649c5a3f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0MjIz_bb046de5-3a0a-4073-8a12-929fde84a4f7">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="if2c3147acf584e02bc9574e010f74b90_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0Mzkx_71a7a36a-0961-4bfa-baa3-f899af55c6ce">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ie1fbddcf67fa4255b76afc8be76c1ee0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0ODk4_26e9924b-5f43-475a-8326-632330caec4a"
      unitRef="usd">1100000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE0OTA1_c0440fdf-f6cd-4491-b4e0-99b19fdc932c"
      unitRef="usd">17200000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i45f34187e7424286895df7d07271d853_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MDc3_d850651e-3a9f-4efe-8cb0-decea3007e6e"
      unitRef="usd">-13100000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="idc423654295e47e497b4d7f2985f4754_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MDg0_fb13a59b-9223-46f7-ab24-bf70f2a540f5"
      unitRef="usd">-12700000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MjE2_a0e46982-14fc-4519-881c-4e3af02d5e04"
      unitRef="usd">31200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie1fbddcf67fa4255b76afc8be76c1ee0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MjE2_c8df83a8-90c7-4d63-9f8d-cc87d9951c18"
      unitRef="usd">31200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EquityMethodInvestments
      contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MzAz_d7d06e85-80d4-41f9-bf2a-80c4cdc9032a"
      unitRef="krw">692800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i69aef7ac8b0f4465b8296a34c3db2a63_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MzI0_9453be79-8d14-4a24-bc01-06148dff6ae6"
      unitRef="usd">586100000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i22878c92c12541f19e966187ae7b1e40_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MzMy_87a4bf20-76be-4a02-93c7-ba60b8f2938a"
      unitRef="krw">673800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i22878c92c12541f19e966187ae7b1e40_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE1MzUz_22612427-f550-4610-b11d-4c52416297a2"
      unitRef="usd">620200000</us-gaap:EquityMethodInvestments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="if50c9b8ddef6484aa041e78de26b485f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2MDYz_e4c35a5c-f976-461b-a5ae-adcb1a987be4"
      unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if50c9b8ddef6484aa041e78de26b485f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2MTEx_aa1b72fb-5157-435d-83dc-48383e14a160"
      unitRef="usd">63000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i869e4d6d217b488e998a60c8e87948c6_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2MTc1_5511da13-a028-453f-9c7d-954ca45439a0"
      unitRef="usd">37000000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:AdditionalMilestonePayment
      contextRef="i395c6f6eef504574a55e4ae26a68fee0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2Mjk3_1969b8a2-4dee-4e48-800e-cc1129d84fb9"
      unitRef="usd">15000000</biib:AdditionalMilestonePayment>
    <biib:AccruedMilestonePayments
      contextRef="i395c6f6eef504574a55e4ae26a68fee0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzM4NDgyOTA3MzAxODM_12de3de5-47df-4b44-8b08-1a08f46f6939"
      unitRef="usd">15000000</biib:AccruedMilestonePayments>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i22ac8ae1aedd4701923500c02d371f31_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2NDYz_baa102a2-36e4-46ac-bcba-e58f0774d596"
      unitRef="usd">180000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborationAgreementTerm
      contextRef="i22ac8ae1aedd4701923500c02d371f31_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2NjYy_200217af-f455-4217-b39e-ee8033ebaa93">P5Y</biib:CollaborationAgreementTerm>
    <biib:ContractOptionExerciseFee
      contextRef="i22ac8ae1aedd4701923500c02d371f31_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE2NzE0_1c5c6f0d-3299-4135-91d9-82053ffe5b11"
      unitRef="usd">60000000</biib:ContractOptionExerciseFee>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3MTg0_2746480b-eb4d-4379-b0f0-1189c6b9c1c7"
      unitRef="number">0.500</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="ie1fbddcf67fa4255b76afc8be76c1ee0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NDUw_4e1e3e8d-6428-46fa-b75f-f62d7bdb95ff"
      unitRef="usd">71800000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NDU3_5c344063-095f-4b0e-b3e5-ea8cff4e91cf"
      unitRef="usd">210200000</biib:Collaborationprofitlosssharing>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="i94f176f9dc1f4120991a18779a99e81c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NTAz_2746480b-eb4d-4379-b0f0-1189c6b9c1c7"
      unitRef="number">0.500</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="i45f34187e7424286895df7d07271d853_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NTky_59c0beca-bf41-4213-bb41-663d3583ea41"
      unitRef="usd">72900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="idc423654295e47e497b4d7f2985f4754_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE3NTk5_086d2b21-9865-4824-bfff-6c547fda00cb"
      unitRef="usd">200100000</biib:Collaborationprofitlosssharing>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="iac1864f4ab43443795b18bf4e5518559_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4Mjc2_3c272947-7800-44ee-b869-3dda61ea7f02"
      unitRef="usd">125700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i021e9d577199419a8902601c80f14ba1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMTUvZnJhZzozZjY2ZWI4YTU5ZTU0OGUyYTFiYjc1Y2E4OWMwMzhjYy90ZXh0cmVnaW9uOjNmNjZlYjhhNTllNTQ4ZTJhMWJiNzVjYTg5YzAzOGNjXzE4Mjgz_80a7d7a7-b756-4de1-848b-7f5fcef2b607"
      unitRef="usd">99000000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzY1NzI_bd4d4702-520e-45e7-af48-3013c37a282d">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15.0% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM, by an additional 5.0%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$75.0 million&#160;upon the regulatory filing with the FDA for the approval of ADUHELM. During the second quarter of 2020 we paid Neurimmune $75.0 million upon the completed submission of the BLA for the approval of ADUHELM to the FDA, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2020 we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $100.0&#160;million in additional milestones to Neurimmune, which includes $50.0&#160;million if launched in three or more countries in the European Union (E.U.) and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021 and 2020, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021, we recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit. The deferred tax benefit relates to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ADUHELM Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on commercial sales of ADUHELM to be shared with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $17.2 million and $12.8 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="i22969c273ab1477cacb6c894c96e65ca_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzc0Mg_e2356dd0-5f41-4f71-9381-3961c78ef6b2">P12Y</biib:CollaborationAgreementTerm>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="i22969c273ab1477cacb6c894c96e65ca_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzEwODU_d586a60e-34c3-4981-b65f-66464c12cec5"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i4bab21bf098a42d1b19d7bb69acd037c_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzEyNDU_11e4cdf9-e66a-42b0-9f1e-7a9693140161"
      unitRef="usd">150000000</us-gaap:PaymentsToMinorityShareholders>
    <biib:Reductioninroyaltyratepayableoncommercialsales
      contextRef="i4bab21bf098a42d1b19d7bb69acd037c_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzEyODg_28e44950-4699-4179-a2fa-2c364745db45"
      unitRef="number">0.150</biib:Reductioninroyaltyratepayableoncommercialsales>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ia0b2b5750c244cafbf99dc052af4f8a1_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzE1MDA_7e28cca1-1937-42ab-8682-ff88137b2ad8"
      unitRef="usd">50000000</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="ia0b2b5750c244cafbf99dc052af4f8a1_D20180501-20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzE3MjI_9cb234a8-a150-4904-879d-7497cc40aae3"
      unitRef="number">0.050</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="id73a857cd2af440ebad3dee0301dca58_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzIyNDk_635c36bd-aa71-4519-a464-1164571a4fdf"
      unitRef="usd">75000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="id73a857cd2af440ebad3dee0301dca58_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzIzNzQ_635c36bd-aa71-4519-a464-1164571a4fdf"
      unitRef="usd">75000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9ad97210ae5d418ca006b46280264849_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzI3MDc_fdce66e0-7af5-4e87-89e8-99aa67de78d2"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="if3c03d9b6e5a437fa43cc01794b646a3_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzI3Mjk_de3fd3c9-7670-42bc-97f4-ec5309f30d10"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i9ad97210ae5d418ca006b46280264849_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzI3Mjk_ed2e4cab-e492-4c61-913d-c0ac4dfd0022"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="id73a857cd2af440ebad3dee0301dca58_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzI3NDU_635c36bd-aa71-4519-a464-1164571a4fdf"
      unitRef="usd">75000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i46019d81d2e4485da3b49f6b7279b384_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzMwNDE_204ca9d8-6e43-4fba-9b3d-d961d2672716"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i46019d81d2e4485da3b49f6b7279b384_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzMxMzY_204ca9d8-6e43-4fba-9b3d-d961d2672716"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i72ca0603ce78428694ea1e92d86ad2ae_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzMzOTc_bc887d2a-5a1d-4ad7-8b56-a57ee2c4b8c9"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="if3c03d9b6e5a437fa43cc01794b646a3_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM0MTk_de3fd3c9-7670-42bc-97f4-ec5309f30d10"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i9ad97210ae5d418ca006b46280264849_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM0MTk_ed2e4cab-e492-4c61-913d-c0ac4dfd0022"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i46019d81d2e4485da3b49f6b7279b384_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM0MzU_204ca9d8-6e43-4fba-9b3d-d961d2672716"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:AdditionalMilestonePayment
      contextRef="i1ac80dac77b54f829d7ff2f034bca438_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM2OTA_fd9b7565-649f-48c8-8562-a1964c200385"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i70c76f0606c54d3c92d00b9c6239054d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM3NDg_8c86543e-afce-4a5d-90a6-79b86a1f6884"
      unitRef="usd">50000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ie36b8f43567e4ffc8902418be40bc1ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzM4MjM_16de583c-6767-4e16-9cc4-324dea942e02"
      unitRef="usd">50000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzQyNjI_ec1fedeb-27ac-40ee-b0e5-ecc368d9f485"
      unitRef="usd">500000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzQyNjk_74a68c4c-18d0-4903-9c72-c3b14fc3c937"
      unitRef="usd">875000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib5c41282f9554a79a2dea81cc7c66db8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzQyNzU_c80857f1-89f9-42ae-990c-0a69830f3359"
      unitRef="usd">375000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzU3NDU_570eb012-7121-4c7b-a0a2-cb7972814033"
      unitRef="usd">17200000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="id6475881e6d0430cbc6e4826b376d1ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjEvZnJhZzo4MTMwNzRiOTMzZTE0YTdhOWUwYWMxNzYzYWRkY2ZhZi90ZXh0cmVnaW9uOjgxMzA3NGI5MzNlMTRhN2E5ZTBhYzE3NjNhZGRjZmFmXzU3NTI_f5110a93-2d79-4542-83f2-a910698ce103"
      unitRef="usd">12800000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjcvZnJhZzphNGEwOTFhNzMzZDU0NTk1OGE2NWU4MDA1ZDRlNzk5My90ZXh0cmVnaW9uOmE0YTA5MWE3MzNkNTQ1OTU4YTY1ZTgwMDVkNGU3OTkzXzEyMzQ3_b9da27ec-fb7d-422d-9adb-79b2ed0d8de7">&lt;div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020 and now pending in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seeks a declaration of the action as a class action and monetary relief. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. We have filed a motion to dismiss, which is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#xfc;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the '510 Patent, expiring in May 2035). In May 2020 the European Patent Office (EPO) revoked the &#x2018;510 Patent. Fresenius Kabi has appealed to the EPO&#x2019;s Technical Boards of Appeal, a hearing has been set for June 2022, and the German and French proceedings have been stayed pending the decision on appeal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020 the Danish Patent Board of Appeal revoked certain Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled in the appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 Fresenius Kabi commenced proceedings in Denmark&#x2019;s Maritime and Commercial High Court alleging that IMRALDI infringes of the Danish counterpart of European Patent No. 3 145 488 and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid. Fresenius Kabi has appealed to the High Court of Eastern Denmark.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed during proceedings in the EPO seeking to invalidate that patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of a German utility model. A hearing has been set for November 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks damages of $981.1&#160;million plus statutory trebling of damages, civil penalties, attorneys&#x2019; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Samsung BioLogics Arbitration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. We expect a hearing in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ERISA Class Action Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA.  Plaintiffs seek a declaration of the action as a class action and monetary and other relief. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Humana Patient Assistance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys&#x2019; fees and costs. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#x2018;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#x2018;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc. On October 8, 2021, the case was dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016 the EPO revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018 the EPO revoked Forward Pharma A/S's European Patent No. 2 801 355. In September 2021 the EPO&#x2019;s Technical Boards of Appeal announced its affirmance of the revocation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of our European Patent No. 1 485 127 (the E.U. '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for June 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the E.U. '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annulment Proceedings in General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul decisions of the European Medicines Agency (EMA) refusing to validate their applications to market generic versions of TECFIDERA. The EMA&#x2019;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021 the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="id68d34303bce4a2db8b2455c5f1c3285_I20210715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjcvZnJhZzphNGEwOTFhNzMzZDU0NTk1OGE2NWU4MDA1ZDRlNzk5My90ZXh0cmVnaW9uOmE0YTA5MWE3MzNkNTQ1OTU4YTY1ZTgwMDVkNGU3OTkzXzQ5NDc4MDIzOTAwMDU_a69a17e9-ea34-4e1a-8f20-599e6cc5c866"
      unitRef="usd">981100000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i378cd243ed9e40c2932d604d62dcff73_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgwNDZhM2U2OWM4MTRlN2Y5OTY3Mzk1ZjYzMTY2MWM2L3NlYzo4MDQ2YTNlNjljODE0ZTdmOTk2NzM5NWY2MzE2NjFjNl8xMjcvZnJhZzphNGEwOTFhNzMzZDU0NTk1OGE2NWU4MDA1ZDRlNzk5My90ZXh0cmVnaW9uOmE0YTA5MWE3MzNkNTQ1OTU4YTY1ZTgwMDVkNGU3OTkzXzUzMTE_d10cb317-d230-4dcb-a745-31cf0a63d97d"
      unitRef="usd">200000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197664678344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,892,712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197663212264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">511.8<span></span>
</td>
<td class="nump">449.1<span></span>
</td>
<td class="nump">1,449.6<span></span>
</td>
<td class="nump">1,314.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">702.4<span></span>
</td>
<td class="nump">1,140.9<span></span>
</td>
<td class="nump">1,801.7<span></span>
</td>
<td class="nump">2,264.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">654.1<span></span>
</td>
<td class="nump">573.1<span></span>
</td>
<td class="nump">1,886.4<span></span>
</td>
<td class="nump">1,698.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">111.0<span></span>
</td>
<td class="nump">82.6<span></span>
</td>
<td class="nump">813.2<span></span>
</td>
<td class="nump">215.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">166.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(15.6)<span></span>
</td>
<td class="num">(29.0)<span></span>
</td>
<td class="num">(49.1)<span></span>
</td>
<td class="num">(23.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">1,984.9<span></span>
</td>
<td class="nump">2,289.7<span></span>
</td>
<td class="nump">5,994.3<span></span>
</td>
<td class="nump">5,711.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">794.0<span></span>
</td>
<td class="nump">1,086.4<span></span>
</td>
<td class="nump">2,253.6<span></span>
</td>
<td class="nump">4,880.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(502.9)<span></span>
</td>
<td class="num">(128.6)<span></span>
</td>
<td class="num">(913.4)<span></span>
</td>
<td class="num">(186.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">291.1<span></span>
</td>
<td class="nump">957.8<span></span>
</td>
<td class="nump">1,340.2<span></span>
</td>
<td class="nump">4,694.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(25.9)<span></span>
</td>
<td class="nump">240.8<span></span>
</td>
<td class="num">(390.7)<span></span>
</td>
<td class="nump">979.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
<td class="num">(17.2)<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">318.1<span></span>
</td>
<td class="nump">703.9<span></span>
</td>
<td class="nump">1,748.1<span></span>
</td>
<td class="nump">3,702.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="num">(11.1)<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">560.2<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 329.2<span></span>
</td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,187.9<span></span>
</td>
<td class="nump">$ 3,642.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="nump">$ 22.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="nump">$ 22.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">148.0<span></span>
</td>
<td class="nump">156.9<span></span>
</td>
<td class="nump">149.9<span></span>
</td>
<td class="nump">163.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">157.2<span></span>
</td>
<td class="nump">150.3<span></span>
</td>
<td class="nump">163.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,205.7<span></span>
</td>
<td class="nump">$ 2,690.3<span></span>
</td>
<td class="nump">$ 6,653.4<span></span>
</td>
<td class="nump">$ 8,390.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">415.4<span></span>
</td>
<td class="nump">560.1<span></span>
</td>
<td class="nump">1,244.4<span></span>
</td>
<td class="nump">1,558.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 157.8<span></span>
</td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="nump">$ 350.1<span></span>
</td>
<td class="nump">$ 642.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197747710904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 329.2<span></span>
</td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,187.9<span></span>
</td>
<td class="nump">$ 3,642.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">66.2<span></span>
</td>
<td class="num">(83.7)<span></span>
</td>
<td class="nump">205.0<span></span>
</td>
<td class="num">(101.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(47.7)<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="num">(80.3)<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
<td class="num">(90.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">364.4<span></span>
</td>
<td class="nump">657.0<span></span>
</td>
<td class="nump">1,350.3<span></span>
</td>
<td class="nump">3,552.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(11.1)<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">560.8<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 353.3<span></span>
</td>
<td class="nump">$ 658.5<span></span>
</td>
<td class="nump">$ 1,911.1<span></span>
</td>
<td class="nump">$ 3,613.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197663124744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,541.8<span></span>
</td>
<td class="nump">$ 1,331.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,413.3<span></span>
</td>
<td class="nump">1,278.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,723.0<span></span>
</td>
<td class="nump">1,913.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">400.0<span></span>
</td>
<td class="nump">413.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,347.9<span></span>
</td>
<td class="nump">1,068.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">736.3<span></span>
</td>
<td class="nump">881.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,162.3<span></span>
</td>
<td class="nump">6,887.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">968.3<span></span>
</td>
<td class="nump">772.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,410.7<span></span>
</td>
<td class="nump">3,411.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">389.1<span></span>
</td>
<td class="nump">433.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,286.8<span></span>
</td>
<td class="nump">3,084.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,760.5<span></span>
</td>
<td class="nump">5,762.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,810.4<span></span>
</td>
<td class="nump">1,369.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">2,018.6<span></span>
</td>
<td class="nump">2,899.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,806.7<span></span>
</td>
<td class="nump">24,618.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">998.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">234.2<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">427.9<span></span>
</td>
<td class="nump">454.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">2,550.7<span></span>
</td>
<td class="nump">3,145.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,211.6<span></span>
</td>
<td class="nump">3,742.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">6,272.3<span></span>
</td>
<td class="nump">7,426.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">774.7<span></span>
</td>
<td class="nump">1,032.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">348.2<span></span>
</td>
<td class="nump">402.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,318.2<span></span>
</td>
<td class="nump">1,329.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,925.0<span></span>
</td>
<td class="nump">13,932.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(136.6)<span></span>
</td>
<td class="num">(299.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">13,543.5<span></span>
</td>
<td class="nump">13,976.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">10,429.9<span></span>
</td>
<td class="nump">10,700.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">451.8<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">10,881.7<span></span>
</td>
<td class="nump">10,686.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 23,806.7<span></span>
</td>
<td class="nump">$ 24,618.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197673297800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197662840312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,748.1<span></span>
</td>
<td class="nump">$ 3,702.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">353.0<span></span>
</td>
<td class="nump">347.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">629.3<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">179.8<span></span>
</td>
<td class="nump">149.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(49.1)<span></span>
</td>
<td class="num">(23.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(750.1)<span></span>
</td>
<td class="nump">211.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">710.5<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investment</a></td>
<td class="num">(17.2)<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">201.0<span></span>
</td>
<td class="nump">110.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">157.8<span></span>
</td>
<td class="num">(135.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(322.6)<span></span>
</td>
<td class="num">(270.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="num">(243.3)<span></span>
</td>
<td class="nump">372.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">260.5<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(87.6)<span></span>
</td>
<td class="num">(97.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by operating activities</a></td>
<td class="nump">2,801.6<span></span>
</td>
<td class="nump">4,596.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(206.5)<span></span>
</td>
<td class="num">(338.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">2,028.1<span></span>
</td>
<td class="nump">5,240.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(2,372.6)<span></span>
</td>
<td class="num">(4,649.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(18.0)<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(37.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow used in investing activities</a></td>
<td class="num">(451.0)<span></span>
</td>
<td class="num">(442.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,800.0)<span></span>
</td>
<td class="num">(6,279.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(8.3)<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of borrowings and premiums paid on debt exchange</a></td>
<td class="num">(170.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2,967.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,500.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash proceeds from settlement of swap</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net distribution to noncontrolling interest</a></td>
<td class="num">(94.8)<span></span>
</td>
<td class="num">(70.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(22.9)<span></span>
</td>
<td class="nump">22.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow used in financing activities</a></td>
<td class="num">(2,096.0)<span></span>
</td>
<td class="num">(4,871.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">254.6<span></span>
</td>
<td class="num">(716.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(44.0)<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,331.2<span></span>
</td>
<td class="nump">2,913.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">1,541.8<span></span>
</td>
<td class="nump">2,224.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments subsidiary and affiliates stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(141.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments subsidiary and affiliates stock</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (423.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197668968072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>2020 Share Repurchase Program</div></th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>December 2019 Share Repurchase Program</div></th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">198.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 13,339.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
<td class="nump">$ 16,455.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 13,343.2<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,702.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,642.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,642.7<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(89.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90.3)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (121.3)<span></span>
</td>
<td class="num">$ (4,878.7)<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.0)<span></span>
</td>
<td class="num">$ (1,208.1)<span></span>
</td>
<td class="nump">$ 1,279.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(50.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">154.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">10,744.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(225.5)<span></span>
</td>
<td class="nump">13,961.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,758.5<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">177.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">182.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="nump">11,289.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
<td class="nump">14,466.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,308.7<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">703.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701.5<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(45.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Distribution to noncontrolling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,250.0)<span></span>
</td>
<td class="num">$ (1,250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45.1)<span></span>
</td>
<td class="num">$ (1,204.9)<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">10,744.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(225.5)<span></span>
</td>
<td class="nump">13,961.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,758.5<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">177.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">10,686.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(299.0)<span></span>
</td>
<td class="nump">13,976.3<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,700.3<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,748.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187.9<span></span>
</td>
<td class="nump">560.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">163.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800.0)<span></span>
</td>
<td class="num">$ (1,800.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (231.9)<span></span>
</td>
<td class="num">$ (1,568.1)<span></span>
</td>
<td class="nump">$ 1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(52.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">186.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">10,881.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
<td class="nump">13,543.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,429.9<span></span>
</td>
<td class="nump">451.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">11,214.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
<td class="nump">13,900.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,751.9<span></span>
</td>
<td class="nump">462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">318.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329.2<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Distribution to noncontrolling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (68.6)<span></span>
</td>
<td class="num">$ (681.4)<span></span>
</td>
<td class="nump">$ 750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 10,881.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (136.6)<span></span>
</td>
<td class="nump">$ 13,543.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,429.9<span></span>
</td>
<td class="nump">$ 451.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestIncreaseDecreaseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase (Decrease) Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestIncreaseDecreaseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660668008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197662339448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our </span></div>condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0 million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660830600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">967.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">833.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,556.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">669.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,984.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,498.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,690.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">805.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,258.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">696.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">644.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,470.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,157.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,568.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,174.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,229.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,554.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,850.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,802.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,803.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,587.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,390.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 26.9% and 10.8% of gross product revenue for the three months ended September 30, 2021, and 29.1% and 10.0% of gross product revenue for the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 31.2% and 15.6% of gross product revenue for the three months ended September 30, 2020, and 30.9% and 16.0% of gross product revenue for the nine months ended September 30, 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,255.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(422.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,598.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,021.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(878.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">946.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,128.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,128.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,244.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,558.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659240264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:58.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,347.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659610136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,411.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,320.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,090.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,607.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,320.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,286.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,220.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,084.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, amortization and impairment of acquired intangible assets totaled $111.0 million and $813.2 million, respectively, compared to $82.6 million and $215.6 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, amortization and impairment of acquired intangible assets reflects impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia, and impairment charges of $28.4 million and $220.0&#160;million, respectively, related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, amortization and impairment of acquired intangible assets also reflects the impact of a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $19.3&#160;million impairment charge related to one of our IPR&amp;D intangible assets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of September 30, 2021, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of September 30, 2021, the carrying value associated with the remaining vixotrigine IPR&amp;D asset for DPN was $132.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and o</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ur Phase 2/3 XIRIUS study of BIIB112 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the three and nine months ended September 30, 2021, we recorded impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111, and impairment charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112. As a result, the remaining book values associated with these programs were reduced to zero.  </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, for the three months ended September 30, 2021, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $39.1 million related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span><span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,762.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,760.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span>cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660671096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,486.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,486.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,640.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,424.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,700.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value during the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021. In addition, there have been no changes in valuation techniques during the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for a portion of our Sangamo investment expired during the second </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter of 2021. The fair value of this portion of our Sangamo investment was a Level 1 measurement as of September 30, 2021. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Financial Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of September 30, 2021 and December 31, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.83%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.83%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 to 2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"/><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 10.8% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, we recorded impairment charges of $365.0&#160;million related to BIIB111 and $220.0&#160;million related to BIIB112. As a result, the remaining book value associated with these programs was reduced to zero.  For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,031.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,054.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,927.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,557.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,536.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,046.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,271.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,515.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, approximately $210.7&#160;million and $110.3 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued expense and other.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, the decrease in the fair value of our contingent consideration obligations was primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2020, the decrease in the fair value of our contingent consideration obligations was primarily due to changes in the probability </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of technical and regulatory success</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the expected timing of the achievement of certain remaining developmental milestones as well as changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197661418536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,381.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,381.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,887.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,239.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,413.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,413.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,381.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,381.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of September 30, 2021 and December 31, 2020, was approximately 12 months and 11 months, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:43.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,360.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,240.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $1,222.3 million and $2,024.6 million, respectively, which are included in other current assets and investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio for the three and nine months ended September 30, 2021, was primarily due to decreases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the fair value of our investments in Denali, Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of zero based upon the fact that Sage and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, of which approximately 12&#160;million shares remain subject to transfer restrictions as of September 30, 2021.&#160;This equity method investment is remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197661316696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of September 30, 2021 and December 31, 2020, had durations of 1 to 18 months and 1 to 24 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,979.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,080.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of September 30, 2021, reflected aggregate net unrealized gains of $21.9 million, composed of gross unrealized gains of approximately $38.4&#160;million and gross unrealized losses of approximately $16.5&#160;million, compared to aggregate net unrealized losses of $212.5 million as of December 31, 2020. We expect the net unrealized gains of $21.9 million to be settled over the next 18 months, of which $9.6 million of unrealized gains are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Contracts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of September 30, 2021, had a remaining duration of one month. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $25.0 million and net losses of $21.2 million as of September 30, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.0 million and $0.2 million as of September 30, 2021 and December 31, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,400.6 million and $1,158.0 million as of September 30, 2021 and December 31, 2020, respectively. Net losses of $13.5 million and $26.1 million related to these contracts were recorded as a component of other income (expense), net for the three and nine months ended September 30, 2021, respectively, compared to net gains of $7.8 million and $13.7 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197666206824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,944.2 million and $1,782.3 million as of September 30, 2021 and December 31, 2020, respectively. For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, depreciation expense totaled $65.1 million and $168.7 million, respectively, compared to $51.5 million and $151.2 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2021 and December 31, 2020, we had approximately $661.8 million and $1.8 billion, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2&#160;billion of fixed assets being placed in service during the second quarter of 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659465720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indebtedness</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Senior Notes </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $24.4 million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.90% Senior Notes due September 15, 2020</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with our 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197666206824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.2 million and 6.0 million shares of our common stock at a cost of approximately $750.0 million and $1.8 billion during the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, respectively. Approximately $2.8 billion remained available under our 2020 Share Repurchase Program as of September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 4.5&#160;million and 16.7 million shares of our common stock at a cost of approximately $1.3 billion and $5.0 billion during the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million shares of our common stock at a cost of approximately $1.3 billion during the nine months ended September 30, 2020. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(225.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.006%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660861704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">701.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,187.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,642.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197661317256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660668008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $1.7 billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $1.6 billion. We continue to assess the realizability of these deferred tax assets and have recorded no changes for the three months ended September 30, 2021. We have recorded an increase in these deferred tax assets of approximately $92.6&#160;million and an increase in these deferred tax liabilities of approximately $88.7&#160;million for the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, compared to the same periods in 2020, the decreases in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset discussed below, were primarily due to the change in the territorial mix of our profitability, which included the adverse effect of generic competition for TECFIDERA in the U.S. market; the tax impacts of the BIIB111 and BIIB112 impairment charges; and the impact of the non-cash tax effects of changes in the value of our equity investments, where we recorded unrealized losses in 2021.  The tax effects of this change in value of our equity investments were recorded in the current period, as the changes in value of equity investments cannot be reliably forecasted. Our 2020 effective tax rate also reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for the nine months ended September 30, 2021, compared to the same period in 2020, the decrease in our effective tax rate was primarily due to a current year deferred tax benefit in Switzerland resulting from the accelerated approval of ADUHELM by the FDA in the U.S. recognized during the second quarter of 2021. We recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit discussed below. The deferred tax benefit relates to Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc. For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we increased our gross unrecognized tax benefits by approximately $375.0&#160;million, related to a deferred tax asset for Swiss tax purposes for Neurimmune's tax basis in ADUHELM, as discussed above. This unrecognized tax benefit was recorded as a reduction to the gross deferred tax asset, resulting in the net deferred tax asset discussed above, and not as a separate liability on our condensed consolidated balance sheet.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $20.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659553576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(187.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(166.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(707.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(502.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(913.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $426.9 million and $2.7 million, respectively, compared to net unrealized losses and realized gains (losses) of $82.3 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the three months ended September 30, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Ionis, Sage and Sangamo common stock of approximately $424.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $715.2 million and $9.3 million, respectively, compared to net unrealized losses and realized gains (losses) of $40.3 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Ionis, Sage and Sangamo common stock of approximately $709.1&#160;million. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(705.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(426.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(715.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">713.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,550.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,145.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $1,318.2 million and $1,329.6 million as of September 30, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $657.6 million and $709.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659549112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the global operational and regulatory lead for lecanemab and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In addition, the Lecanemab Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> - For the three months ended September 30, 2020, sales and marketing expense related to lecanemab and elenbecestat was immaterial.</span></div><div style="margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ADUHELM Collaboration Agreement, we lead the ongoing development of ADUHELM, and we and Eisai will co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of ADUHELM in patients with early Alzheimer's disease. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we and Eisai announced that we planned to pursue regulatory approval for ADUHELM in the U.S. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In July 2020 we completed the submission of a Biologics License Application (BLA) for the approval of ADUHELM to the FDA and made a $75.0 million milestone payment to Neurimmune. We recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. For the nine months ended September 30, 2021, we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense are shared in proportion to the same region-based profit split that is utilized to co-promote ADUHELM. A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2021, we recognized net profit-sharing income of $50.6&#160;million and $90.7&#160;million, respectively, to reflect Eisai's 45.0% sharing of the net collaboration losses in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0&#160;million to research and development expense in our condensed consolidated statements of income to reflect </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the premium paid for the Sage common stock. We also made an upfront payment of $875.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also pay Sage development and commercial milestone payments that could total up to approximately $1.6&#160;billion if all the specified milestones set forth in this collaboration are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Denali development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to the LRRK2 program are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, of which approximately 12&#160;million shares remain subject to transfer restrictions as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $83.0 million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this collaboration and all the specified milestones set forth in this collaboration are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a license and collaboration agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of this transaction in August 2021, we made an upfront payment of $125.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that was recorded as research and development expense. </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also pay InnoCare up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should the collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties in the low to high teens on potential future net sales of any product developed under this collaboration.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, we recorded $7.7&#160;million and $84.9 million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to $38.0&#160;million and $47.6 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of September 30, 2021, our ownership percentage remained at approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, we recognized net income on our investment of $1.1 million and $17.2 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax, compared to net losses on our investment of $13.1 million and $12.7 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income on our investment for the nine months ended September 30, 2021, reflects a $31.2&#160;million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the second quarter of 2021 based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled 692.8 billion South Korean won ($586.1 million) and 673.8 billion South Korean won ($620.2 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we paid Samsung Bioepis a $15.0&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. During the third quarter of 2021, we accrued $15.0&#160;million in</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> milestones related to the approval of BYOOVIZ in the U.S. and E.U. that were capitalized within intangible assets. We may pay Samsung Bioepis up to $180.0 million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021, we recognized net profit-sharing expense of $71.8&#160;million and $210.2 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $72.9 million and $200.1 million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts payable to Samsung Bioepis related to the agreements discussed above were $125.7&#160;million and $99.0&#160;million as of September 30, 2021 and December 31, 2020, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2020 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660912584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15.0% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM, by an additional 5.0%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$75.0 million&#160;upon the regulatory filing with the FDA for the approval of ADUHELM. During the second quarter of 2020 we paid Neurimmune $75.0 million upon the completed submission of the BLA for the approval of ADUHELM to the FDA, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2020 we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $100.0&#160;million in additional milestones to Neurimmune, which includes $50.0&#160;million if launched in three or more countries in the European Union (E.U.) and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021 and 2020, amounts reimbursed were immaterial.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, we recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit. The deferred tax benefit relates to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ADUHELM Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on commercial sales of ADUHELM to be shared with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $17.2 million and $12.8 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659532952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020 and now pending in the U.S. District Court for the District of Massachusetts. The action alleges violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and monetary relief. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. We have filed a motion to dismiss, which is pending.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris (the French proceeding) and in November 2018 against Biogen GmbH in the D&#252;sseldorf Regional Court (the German proceeding), alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen has commercialized in Europe, infringes national counterparts of European Patent No. 3 148 510 (the '510 Patent, expiring in May 2035). In May 2020 the European Patent Office (EPO) revoked the &#8216;510 Patent. Fresenius Kabi has appealed to the EPO&#8217;s Technical Boards of Appeal, a hearing has been set for June 2022, and the German and French proceedings have been stayed pending the decision on appeal. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 the Danish Patent Board of Appeal revoked certain Danish utility models that Fresenius Kabi had asserted against Biogen and Fresenius Kabi has appealed to the Danish Maritime and Commercial High Court. No hearing has been scheduled in the appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced proceedings in Denmark&#8217;s Maritime and Commercial High Court alleging that IMRALDI infringes of the Danish counterpart of European Patent No. 3 145 488 and a Danish utility model. In September 2021 the Court ruled that the patent and utility model are invalid. Fresenius Kabi has appealed to the High Court of Eastern Denmark.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which expires in October 2035. The case has been stayed during proceedings in the EPO seeking to invalidate that patent. In November 2020 Gedeon Richter Nyrt commenced additional proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of a German utility model. A hearing has been set for November 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks damages of $981.1&#160;million plus statutory trebling of damages, civil penalties, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung BioLogics Arbitration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. We expect a hearing in the fourth quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan alleging breach of fiduciary duty under ERISA.  Plaintiffs seek a declaration of the action as a class action and monetary and other relief. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys&#8217; fees and costs. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Petition for Inter Partes Review</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc. On October 8, 2021, the case was dismissed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Office Oppositions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 the EPO revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018 the EPO revoked Forward Pharma A/S's European Patent No. 2 801 355. In September 2021 the EPO&#8217;s Technical Boards of Appeal announced its affirmance of the revocation.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of our European Patent No. 1 485 127 (the E.U. '127 Patent) which covers administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. A hearing has been set for June 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 Polpharma Biologics S.A., also affiliated with the Polpharma Group, brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the E.U. '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul decisions of the European Medicines Agency (EMA) refusing to validate their applications to market generic versions of TECFIDERA. The EMA&#8217;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021 the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660922088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsIn October 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197673283432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197666933624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">967.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">833.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,556.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">669.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,984.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,498.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,690.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">805.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,258.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">696.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">644.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,470.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,157.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,568.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,174.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,229.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,554.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,850.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,802.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,803.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,587.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,390.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,255.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(422.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,598.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,021.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(878.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">946.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,128.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,128.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,244.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,558.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659572728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:58.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,347.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660869720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,411.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,320.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,090.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,607.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,320.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,286.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,220.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,084.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,762.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,760.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660854264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,486.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,486.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,640.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,424.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,700.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,031.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,054.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,927.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,557.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,536.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">465.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,046.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,271.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,515.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197673125752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available for sale:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,381.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,381.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,887.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,239.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,413.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,413.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,381.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,381.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:43.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,360.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,240.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197673094136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,979.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,080.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659532952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(225.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.006%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660665352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">701.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,187.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,642.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660726712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659242392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660916728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(187.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(166.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(707.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(502.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(913.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(705.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(426.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(715.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">713.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,550.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,145.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197673085944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660731064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197674355624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 18.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member', window );">BIIB118</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197662618360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">619.5<span></span>
</td>
<td class="nump">967.5<span></span>
</td>
<td class="nump">1,750.9<span></span>
</td>
<td class="nump">3,258.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">299.9<span></span>
</td>
<td class="nump">684.2<span></span>
</td>
<td class="nump">805.1<span></span>
</td>
<td class="nump">2,383.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">319.6<span></span>
</td>
<td class="nump">283.3<span></span>
</td>
<td class="nump">945.8<span></span>
</td>
<td class="nump">875.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">387.5<span></span>
</td>
<td class="nump">474.1<span></span>
</td>
<td class="nump">1,188.4<span></span>
</td>
<td class="nump">1,421.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">252.4<span></span>
</td>
<td class="nump">327.3<span></span>
</td>
<td class="nump">751.6<span></span>
</td>
<td class="nump">965.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">135.1<span></span>
</td>
<td class="nump">146.8<span></span>
</td>
<td class="nump">436.8<span></span>
</td>
<td class="nump">456.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">522.8<span></span>
</td>
<td class="nump">516.5<span></span>
</td>
<td class="nump">1,550.4<span></span>
</td>
<td class="nump">1,470.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">281.1<span></span>
</td>
<td class="nump">304.2<span></span>
</td>
<td class="nump">854.2<span></span>
</td>
<td class="nump">826.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">241.7<span></span>
</td>
<td class="nump">212.3<span></span>
</td>
<td class="nump">696.2<span></span>
</td>
<td class="nump">644.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">78.8<span></span>
</td>
<td class="nump">78.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">78.8<span></span>
</td>
<td class="nump">78.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,556.0<span></span>
</td>
<td class="nump">1,984.9<span></span>
</td>
<td class="nump">4,568.5<span></span>
</td>
<td class="nump">6,229.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">833.4<span></span>
</td>
<td class="nump">1,315.7<span></span>
</td>
<td class="nump">2,410.9<span></span>
</td>
<td class="nump">4,174.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">722.6<span></span>
</td>
<td class="nump">669.2<span></span>
</td>
<td class="nump">2,157.6<span></span>
</td>
<td class="nump">2,054.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">444.1<span></span>
</td>
<td class="nump">494.4<span></span>
</td>
<td class="nump">1,464.4<span></span>
</td>
<td class="nump">1,554.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">139.8<span></span>
</td>
<td class="nump">182.5<span></span>
</td>
<td class="nump">437.8<span></span>
</td>
<td class="nump">628.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">304.3<span></span>
</td>
<td class="nump">311.9<span></span>
</td>
<td class="nump">1,026.6<span></span>
</td>
<td class="nump">925.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">120.8<span></span>
</td>
<td class="nump">124.2<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">120.8<span></span>
</td>
<td class="nump">124.2<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.4<span></span>
</td>
<td class="nump">56.2<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
<td class="nump">162.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.4<span></span>
</td>
<td class="nump">56.2<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
<td class="nump">162.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">202.8<span></span>
</td>
<td class="nump">207.9<span></span>
</td>
<td class="nump">610.2<span></span>
</td>
<td class="nump">598.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">202.8<span></span>
</td>
<td class="nump">207.9<span></span>
</td>
<td class="nump">610.2<span></span>
</td>
<td class="nump">598.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,205.7<span></span>
</td>
<td class="nump">2,690.3<span></span>
</td>
<td class="nump">6,653.4<span></span>
</td>
<td class="nump">8,390.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">973.5<span></span>
</td>
<td class="nump">1,498.2<span></span>
</td>
<td class="nump">2,850.7<span></span>
</td>
<td class="nump">4,803.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,232.2<span></span>
</td>
<td class="nump">$ 1,192.1<span></span>
</td>
<td class="nump">$ 3,802.7<span></span>
</td>
<td class="nump">$ 3,587.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197664661720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,823.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(70.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(2,021.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(878.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,128.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">141.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">556.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(422.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(136.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">140.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">1,093.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,255.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(71.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,598.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(732.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">946.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">11.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(9.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 42.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197660979320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,128.6<span></span>
</td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">146.2<span></span>
</td>
<td class="nump">195.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 982.4<span></span>
</td>
<td class="nump">$ 1,080.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197753478824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">145.8<span></span>
</td>
<td class="nump">275.0<span></span>
</td>
<td class="nump">498.7<span></span>
</td>
<td class="nump">873.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">269.6<span></span>
</td>
<td class="nump">285.1<span></span>
</td>
<td class="nump">745.7<span></span>
</td>
<td class="nump">685.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 415.4<span></span>
</td>
<td class="nump">$ 560.1<span></span>
</td>
<td class="nump">$ 1,244.4<span></span>
</td>
<td class="nump">$ 1,558.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197663212408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">143.8<span></span>
</td>
<td class="nump">110.0<span></span>
</td>
<td class="nump">314.1<span></span>
</td>
<td class="nump">599.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">157.8<span></span>
</td>
<td class="nump">125.7<span></span>
</td>
<td class="nump">350.1<span></span>
</td>
<td class="nump">642.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197662672664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">31.20%<span></span>
</td>
<td class="nump">29.10%<span></span>
</td>
<td class="nump">30.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 143.8<span></span>
</td>
<td class="nump">$ 110.0<span></span>
</td>
<td class="nump">$ 314.1<span></span>
</td>
<td class="nump">$ 599.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 157.8<span></span>
</td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="nump">$ 350.1<span></span>
</td>
<td class="nump">$ 642.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197673219080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="nump">$ 314.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">780.8<span></span>
</td>
<td class="nump">544.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">201.1<span></span>
</td>
<td class="nump">209.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">$ 1,347.9<span></span>
</td>
<td class="nump">$ 1,068.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197773057528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="nump">$ 49.1<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">7,607.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,607.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,220.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,320.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,320.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,136.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,286.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,286.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,084.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.6<span></span>
</td>
<td class="nump">813.2<span></span>
</td>
<td class="nump">215.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629.3<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,411.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,411.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,394.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,090.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,257.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,320.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,320.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,136.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">132.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember', window );">Vixotrigine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">132.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.4<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">28.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member', window );">BIIB111 and BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ManufacturingAndOtherCosts', window );">Manufacturing and other costs</a></td>
<td class="nump">$ 39.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ManufacturingAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Other Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ManufacturingAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197747660344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,762,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 5,760,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,760,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 111,000,000<span></span>
</td>
<td class="nump">$ 82,600,000<span></span>
</td>
<td class="nump">813,200,000<span></span>
</td>
<td class="nump">$ 215,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 629,300,000<span></span>
</td>
<td class="nump">$ 19,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197667371352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 2,381.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,051.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">978.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">1,166.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,640.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">210.7<span></span>
</td>
<td class="nump">$ 226.3<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">$ 322.6<span></span>
</td>
<td class="nump">$ 351.6<span></span>
</td>
<td class="nump">$ 346.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">238.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,486.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,301.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">712.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">181.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">215.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">215.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">978.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">950.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,703.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,424.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,429.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,486.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,301.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">712.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">181.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">210.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">210.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197771780856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 210,700,000<span></span>
</td>
<td class="nump">$ 210,700,000<span></span>
</td>
<td class="nump">$ 110,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TechnologicalAndRegulatorySuccessProbability', window );">Technological and Regulatory Success, Probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TechnologicalAndRegulatorySuccessProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Technological and Regulatory Success, Probability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TechnologicalAndRegulatorySuccessProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197673556296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Discount rate<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0083<span></span>
</td>
<td class="nump">0.0060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0083<span></span>
</td>
<td class="nump">0.0060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197674331848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Nonrecurring Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 629.3<span></span>
</td>
<td class="nump">$ 19.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.4<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197663912136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,271.1<span></span>
</td>
<td class="nump">$ 7,426.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,046.5<span></span>
</td>
<td class="nump">8,515.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031.2<span></span>
</td>
<td class="nump">1,054.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998.8<span></span>
</td>
<td class="nump">997.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,927.7<span></span>
</td>
<td class="nump">2,003.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,742.5<span></span>
</td>
<td class="nump">1,741.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,491.7<span></span>
</td>
<td class="nump">1,557.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,491.8<span></span>
</td>
<td class="nump">1,491.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,468.2<span></span>
</td>
<td class="nump">2,365.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099.8<span></span>
</td>
<td class="nump">1,723.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,443.1<span></span>
</td>
<td class="nump">1,536.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,473.0<span></span>
</td>
<td class="nump">1,472.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 684.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 700.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197668644648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="nump">$ 49.1<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">226.3<span></span>
</td>
<td class="nump">351.6<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 210.7<span></span>
</td>
<td class="nump">$ 322.6<span></span>
</td>
<td class="nump">$ 210.7<span></span>
</td>
<td class="nump">$ 322.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197664330216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 978.9<span></span>
</td>
<td class="nump">$ 626.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">167.3<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">213.6<span></span>
</td>
<td class="nump">37.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">485.6<span></span>
</td>
<td class="nump">505.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 112.4<span></span>
</td>
<td class="nump">$ 23.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197674830696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,381.5<span></span>
</td>
<td class="nump">$ 2,049.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,381.6<span></span>
</td>
<td class="nump">2,051.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">1,168.9<span></span>
</td>
<td class="nump">1,239.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">257.9<span></span>
</td>
<td class="nump">749.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(260.6)<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">1,166.2<span></span>
</td>
<td class="nump">1,974.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,135.8<span></span>
</td>
<td class="nump">897.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,135.7<span></span>
</td>
<td class="nump">898.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">350.7<span></span>
</td>
<td class="nump">402.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">351.1<span></span>
</td>
<td class="nump">403.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">277.4<span></span>
</td>
<td class="nump">380.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">277.5<span></span>
</td>
<td class="nump">380.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">435.5<span></span>
</td>
<td class="nump">245.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">435.4<span></span>
</td>
<td class="nump">246.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">182.0<span></span>
</td>
<td class="nump">122.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">181.8<span></span>
</td>
<td class="nump">122.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">35.5<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="nump">86.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">1,133.4<span></span>
</td>
<td class="nump">1,168.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">238.4<span></span>
</td>
<td class="nump">733.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(260.6)<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">$ 1,111.2<span></span>
</td>
<td class="nump">$ 1,887.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659263096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,413.3<span></span>
</td>
<td class="nump">$ 1,278.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,413.4<span></span>
</td>
<td class="nump">1,278.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">925.5<span></span>
</td>
<td class="nump">722.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">925.3<span></span>
</td>
<td class="nump">721.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,381.6<span></span>
</td>
<td class="nump">2,051.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,381.5<span></span>
</td>
<td class="nump">$ 2,049.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197673265480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 575.4<span></span>
</td>
<td class="nump">$ 1,360.9<span></span>
</td>
<td class="nump">$ 2,028.1<span></span>
</td>
<td class="nump">$ 5,240.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="num">$ (0.9)<span></span>
</td>
<td class="num">$ (1.7)<span></span>
</td>
<td class="num">$ (25.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197758943272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">11 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197746828776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration agreement, shares, purchased (in shares)</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global licensing collaboration agreement, purchase price per share (in usd per share)</a></td>
<td class="nump">$ 104.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration agreement, shares, purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global licensing collaboration agreement, shares purchased per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global licensing collaboration agreement, shares purchased per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,222.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,024.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DividendYieldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DividendYieldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares Purchased Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197663628456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (212.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.1)<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net losses recognized on the decrease in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,158.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,080.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,080.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,229.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68.7)<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,901.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,901.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,979.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197663619096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,944.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,944.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,782.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">$ 51.5<span></span>
</td>
<td class="nump">$ 168.7<span></span>
</td>
<td class="nump">$ 151.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">661.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 661.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets placed into service</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197747734616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="nump">$ 151,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,300,000<span></span>
</td>
<td class="nump">$ 56,300,000<span></span>
</td>
<td class="nump">$ 187,300,000<span></span>
</td>
<td class="nump">$ 166,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionAmount', window );">Debt Instrument, Redemption, Amount</a></td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">624,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 700,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.973%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.174%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts', window );">Payment of early call premium and write off of remaining unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain', window );">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Derivative, gain on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197668440856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="nump">$ 6,279,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember', window );">December 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember', window );">2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember', window );">October 2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197747795720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (136.6)<span></span>
</td>
<td class="num">$ (225.5)<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
<td class="num">(225.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
<td class="num">(54.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="num">(35.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="num">(45.4)<span></span>
</td>
<td class="nump">163.0<span></span>
</td>
<td class="num">(89.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(136.6)<span></span>
</td>
<td class="num">(225.5)<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
<td class="num">(225.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
<td class="num">(90.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179.0)<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="num">(93.3)<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="num">(93.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
<td class="num">(58.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="num">(43.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205.0<span></span>
</td>
<td class="num">(101.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="num">(93.3)<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="num">(93.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(62.4)<span></span>
</td>
<td class="num">(32.4)<span></span>
</td>
<td class="num">(62.4)<span></span>
</td>
<td class="num">(32.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(62.4)<span></span>
</td>
<td class="num">(32.4)<span></span>
</td>
<td class="num">(62.4)<span></span>
</td>
<td class="num">(32.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46.6)<span></span>
</td>
<td class="num">(139.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(126.9)<span></span>
</td>
<td class="num">(135.6)<span></span>
</td>
<td class="num">(126.9)<span></span>
</td>
<td class="num">(135.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80.3)<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80.3)<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (126.9)<span></span>
</td>
<td class="num">$ (135.6)<span></span>
</td>
<td class="num">$ (126.9)<span></span>
</td>
<td class="num">$ (135.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197674360072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">$ (502.9)<span></span>
</td>
<td class="num">$ (128.6)<span></span>
</td>
<td class="num">$ (913.4)<span></span>
</td>
<td class="num">$ (186.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(25.9)<span></span>
</td>
<td class="nump">240.8<span></span>
</td>
<td class="num">(390.7)<span></span>
</td>
<td class="nump">979.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,778.9<span></span>
</td>
<td class="nump">3,376.1<span></span>
</td>
<td class="nump">8,247.9<span></span>
</td>
<td class="nump">10,592.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">329.2<span></span>
</td>
<td class="nump">701.5<span></span>
</td>
<td class="nump">1,187.9<span></span>
</td>
<td class="nump">3,642.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(63.0)<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(12.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(14.9)<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="num">(68.7)<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197662050760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 329.2<span></span>
</td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,187.9<span></span>
</td>
<td class="nump">$ 3,642.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">148.0<span></span>
</td>
<td class="nump">156.9<span></span>
</td>
<td class="nump">149.9<span></span>
</td>
<td class="nump">163.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">157.2<span></span>
</td>
<td class="nump">150.3<span></span>
</td>
<td class="nump">163.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197667548488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (57.6)<span></span>
</td>
<td class="num">$ (35.4)<span></span>
</td>
<td class="num">$ (186.1)<span></span>
</td>
<td class="num">$ (154.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">62.1<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="nump">161.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">60.2<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
<td class="nump">156.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(10.9)<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
<td class="num">(35.8)<span></span>
</td>
<td class="num">(25.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">72.2<span></span>
</td>
<td class="nump">63.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">42.6<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 49.3<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
<td class="nump">$ 157.9<span></span>
</td>
<td class="nump">$ 130.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197662344328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (57.6)<span></span>
</td>
<td class="num">$ (35.4)<span></span>
</td>
<td class="num">$ (186.1)<span></span>
</td>
<td class="num">$ (154.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">62.1<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="nump">161.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">60.2<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
<td class="nump">156.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">107.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197662667240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetsValueReductioninValue', window );">Deferred tax assets, decrease in value</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesValueReductioninValue', window );">Deferred tax liabilities, decrease in value</a></td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetIncreaseDecreaseInValue', window );">Deferred tax asset, increase (decrease) in value</a></td>
<td class="nump">$ 92.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue', window );">Deferred tax liabilities, increase (decrease) in value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetIncreaseDecreaseInValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Increase (Decrease) In Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetIncreaseDecreaseInValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetsValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetsValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax Liabilities, Increase (Decrease) In Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197774830808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(20.20%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(11.50%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(7.10%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">TECFIDERA impairment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts', window );">Neurimmune tax impacts</a></td>
<td class="num">(0.005)<span></span>
</td>
<td class="nump">0.002<span></span>
</td>
<td class="num">(0.364)<span></span>
</td>
<td class="num">(0.001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(8.90%)<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
<td class="num">(29.20%)<span></span>
</td>
<td class="nump">20.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197666128664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(66.3)<span></span>
</td>
<td class="num">(56.3)<span></span>
</td>
<td class="num">(187.3)<span></span>
</td>
<td class="num">(166.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="num">(424.5)<span></span>
</td>
<td class="num">(82.1)<span></span>
</td>
<td class="num">(707.2)<span></span>
</td>
<td class="num">(52.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(13.7)<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(502.9)<span></span>
</td>
<td class="num">(128.6)<span></span>
</td>
<td class="num">(913.4)<span></span>
</td>
<td class="num">(186.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(424.2)<span></span>
</td>
<td class="num">(82.3)<span></span>
</td>
<td class="num">(705.9)<span></span>
</td>
<td class="num">(40.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) realized during the period on equity securities</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(426.9)<span></span>
</td>
<td class="num">$ (82.3)<span></span>
</td>
<td class="num">(715.2)<span></span>
</td>
<td class="num">$ (40.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,128.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expense</a></td>
<td class="nump">299.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">238.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">289.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">713.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">713.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">2,550.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,550.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">424.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 982.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,080.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197666464984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="num">$ (426.9)<span></span>
</td>
<td class="num">$ (82.3)<span></span>
</td>
<td class="num">$ (715.2)<span></span>
</td>
<td class="num">$ (40.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains (losses) realized during the period on equity securities</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,318.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,318.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,329.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">657.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">$ 424.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net losses recognized on the decrease in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197747527896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,140.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,801.7<span></span>
</td>
<td class="nump">$ 2,264.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfProductCandidates', window );">Number of product candidates | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236.1<span></span>
</td>
<td class="nump">153.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.0<span></span>
</td>
<td class="nump">76.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global licensing collaboration agreement, shares purchased per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration agreement, shares, purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global licensing collaboration agreement, purchase price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration agreement, shares, purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global licensing collaboration agreement, shares purchased per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets', window );">Global Licensing Collaboration Agreement, Payment, Selection of Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84.9<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember', window );">InnoCare Pharma Limited (InnoCare) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContingentMilestonePaymentsMadeToCollaborativePartner', window );">Contingent additional milestone payment</a></td>
<td class="nump">$ 812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
<td class="nump">92.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
<td class="nump">17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391.7<span></span>
</td>
<td class="nump">158.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211.2<span></span>
</td>
<td class="nump">88.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Milestone Payments Made To Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Selection of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares Purchased Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197666222648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390.7)<span></span>
</td>
<td class="nump">979.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">166.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,376.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,247.9<span></span>
</td>
<td class="nump">10,592.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="num">$ (12.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 692.8<span></span>
</td>
<td class="nump">$ 620.2<span></span>
</td>
<td class="nump">&#8361; 673.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.2<span></span>
</td>
<td class="nump">200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedMilestonePayments', window );">Accrued milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197666305672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.8<span></span>
</td>
<td class="nump">$ 70.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">$ 875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">$ 90.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | Neurimmune | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | JAPAN | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | Europe | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140197659499864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">$ 981.1<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY@(XOY92GW;,#8I%U/%_4$L#!!0    ( '6"5%-YF^]%E@<  $L@   8
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M#5&[ -HOE;)'QPU<_[YFSU!+ P04    " !U@E13HT*5)9P(   ])0  &
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;+6:;W/;N!&'OPI&O>DD,Y9$ J H
MI;9G$OFNEQ>YR\1-^QH2(0L-2>@ R([[Z;L@98$2_MB^F^1%3$H+Z+<+[#X
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MOG @*-(@^"N1/W1=)B)_,)F=%"3L)^IT\")*P]5=]WZ.1MU3CO[MC>.GQW>
MWG=OOIQ]_B%_M^S?Y''=]"\6?6(*ZI!&-=] E]FDA!FC^G=U^ALC=]WK+BMI
MC&RZRRUG%5?6 +[?2&F>;NP/'-^8NOX_4$L#!!0    ( '6"5%.@"DH,BPP
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MLJ>KM+:(5?(FV;Q8_Q\\U=CP()BLBC);U(.%!HO9<O,S^5Y[HC$ $<L 7 _
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MV*:J(#=ZWN5V/DBKN7EU'2YKN?]V/B#++&O]<BX .6!9"^D.EK600)!Y@]Z
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MN<]VTUU!+MM0CO-%MFYBK/8JDI:L@VF-D#96+N6*71D;)H,3GP(]-!PGW2"
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M&N55S)"?Y8$1HSPO>^M59SUYQOH7^&A-D![>F0JKO]OGS&2@,SG164U>!'Q
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M5.#WG>6R]9?H8/BR+?X"4$L#!!0    ( '6"5%-'/+GCI@D  $$:   9
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M?ITA**6F"1@G]%Y^T +=OT;[_P902P,$%     @ =8)44P< W(%V @  -@4
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M40<TX85TU/2#T8T#MDI06K9@S)4J 1_4..XKXZ^)T_641#Y9+U'>5EC 'Q(
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M2;Q<J$=ELF9V_W!UYR&\(8*VK]$DZFUQ;\C^G-Y-?[O?WQJCQ(2NG-.E(-3
M1!#FH@U-@H7&A$73AJHF1KCOD(:VQ#SO!\<YA1,?VW.#]M16;!O!S'LQK&-K
M(OV]W\P'!46JFC::J4+"T70]XP0&A;HI5\?VOW]&JS!F_"3QC0Y;W_:8Y!-\
M6WUV$Y9N1T-F/T7I7CC6U/'0",LDL/^$AN>#7A?7;E..@I._?&[:S3N";!-F
M"*CP<A@M\T,U8S=<+2_R F8\^LLE3/)'P_-H<*@@D :[&8_B1Y-6=?-%&>-5
M"6E=S[CBD0) #)#\-)[LVE794:5PRZ51Z\;K7>GHBO&J?7P"[=-;/6IQHB&;
M!S*^1Q:NB'#&71T\:M5Q4N(1=9GN,L(]&3IEL"6X8R9V;O=V+^N>O>OS?XZW
M$&N#@>Z0S@B]V!2S>#P.CT,6#ZK5$1N<5ZOC[>,I&TQH0W-7^^"[ BGF1="T
M2FY=R51XY^,36;G&W%+W\M;,3'%>U*RJ(\&+[:MUZ!ZXSSQBXR[=X0W8KQXG
MQX/H]*1%<8!=(.E'X\_TX;6H#D:81@]=/?=:U_TYC;?THP8=KG @"3?_S6KS
MN\E5^+E@NSW\Z/(+<D;B/)B).4C[T=FX$TZS]8O3A?_Q8*:=T[E_7 J>"D,;
M\'VN,8M4+R2@^37I\G]02P,$%     @ =8)44WS?V4Z""P  %"0  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&ULQ5IM<]LV$OXK&%]R$\\H-$F]YY+,
MV$[29MJDN29M/]S<!XB$)5Q(0@%(R^ZOOV<7)$7*LBJ[U[D9CR6 P&+?]UF(
M+S?&?G4KI4IQDV>%>W6R*LOUB[,SEZQ4+EU@UJK DRMC<UEB:)=G;FV53'E3
MGIW%83@YRZ4N3EZ_Y+E/]O5+4Y69+M0G*UR5Y]+>7JC,;%Z=1"?-Q,]ZN2II
MXNSUR[5<JL^J_&7]R6)TUE))=:X*ITTAK+IZ=7(>O;@8T7I>\*M6&]?Y+DB2
MA3%?:? ^?742$D,J4TE)%"0^KM6ERC(B!#:^U31/VB-I8_=[0_T=RPY9%M*I
M2Y/]IM-R]>ID=B)2=26KK/S9;+Y7M3QCHI>8S/%_L?%KAZ,3D52N-'F]&1SD
MNO"?\J;60V?#++QG0UQOB)EO?Q!S^4:6\O5+:S;"TFI0HR\L*N\&<[H@HWPN
M+9YJ["M?OY/:BE]E5BGQ04E7606-E^[E60GBM.0LJ0E=>$+Q/83FXH,IRI43
M;XM4I?W]9V"JY2QN.+N(#Q+\K-:!&(8#$8=Q=(#>L)5TR/2&?RSI&^V2S)"P
M3OSK?.%*"^?X]X$S1NT9(SYC].>U>9C0EY42I5QD8'!!@2,0<0ZDA"Y\(+)'
M+Q!EPE162.=4Z80L4I%IN="9+C6VEBM9"FD5HF=99=)FMR+W;*6\-I'6:OI>
MBBOB_)HYIR>Z2'4B2S !1C)UK<@ORY4N>**S>*65E399W0ISQ<]HVK-7JF15
MZ&\5&-DH497@ZG<<5AI$3:DLG%DA%R2K#KD7XMP1(=B^5/E"V=8!Q+/W!?P_
MRT#9G8HOII29^&=E2E#\9'6"0S[K9:&OP#;4]!-8L;V9<U;1"W$IW4JH;Y7&
M@60;\43,I[-@CL^__VT61_$_]LQ\D/:K8GN ]T4IG$HJRSH&06/7QI*N=AZ)
M:#":38)92V5W_)VY5K8@#^GNFD8QSF[6]$<?C"V7R)5L(\,RLNF1F)*OT$3W
M\%G4V=@?=<0A392W?:ZCR22(11R-L64^#H-AN_&-LM ;Y5&1(-HI;)R8A4'8
MKN@-/F6R:'P3;DO94EEROL3DJ"K.^\EP&$S;+;V!M_(3,1I,1F$PPC?/%,V,
MXE$P[ICHQZW?O]C/)W9/0;QKYYV)2ZS5Q9(,@FU.I_!M9M$L,KWDKPXLA!T6
MFT\_VS <#V?,[IV3_#+OY&]44OMXQ#X>_I4^/HDG.SZ^._-8'Q^&$0RQ]?'^
M>+^/3Z".J%W3'SW$Q^,8:FZ/[HW^P,?GTQ'\.IY&.#D:3,,A//Z@E\=A1ZK>
MX#@OCV>=$WJ#K9=/PY!-XMGR7CY'PGB@ET=34.\YW\[,<7X^GG=R5<LYS[8L
M3Z<(]WU'U>M@/=0("0X72A6B,, NR/T:NW6^1M[G^DC1T"EC1]2H%)8LEEQP
MRI55WED*JBBY1R&*4,B>.A((Q)A,4TU"#HC +H/)2D(U#B5P?RW[$T=_Z==.
M2/TCE]88AP&$5%X9208](*1):(QV8YF.R^^-5;'!GK:^IL2BJ98K?&J;/E]+
MBT!8(Y>0"$[9:\HJCV,L/Q1@5M6 Q;%A=7&M7.FIU!@"P0%]"0#<Y"N7?&A=
MYH9=1JX5X$+B!C!6$HAG];/3 5R^D)GN+:K7^">GK)[/E#[V$UHJOX10$0N;
MBLJ1,A##9LVV;M2SM7YN4BA#.F:\*PM141(0QE6+_Z#/('"3*%NB&1(KDZ5$
M9@UW-RDT D5J;D5JA1]8P'E$"N1<'Y8^/!H5;3D0ZF:M*5(Z3@DK& CXK8*M
MX7W8>Y_SP2?<$6>01\G:(:(F./F)O >L!>(=\5]'&<5Z![72WUV7J,]M+=R:
ML>LG ['.<#SA69F*CRB,8CH0[W0ABX12RONMLP[(%%"'X]R8(@US0BZ<R70J
MJ:)>M=M<B0G>53.. '*)U>NN8J UVN@=Q"0JY>[!JHR)X;"UK]!X>*TI 2QN
M#P:=+V\@?-CK]H@,M/#9M]"L_6[]3Q)3<6H7GR!G0I'X7-S3E+"&B($_U KL
MDV05R:2][1BL4%,LHO#Y#[5KF0Q]"CNA[UM\FP_([[VRPV95F 6I@7.'+M;5
M-BMT'+3K:+4-DF/JUGU.R0J_@[F.[C@Z6ORU-=&7IBR(7[HRO2>9GF'3SU1*
MQ&]\-0#UG0,+D4_WJO@1Q;@%CM2XDH7)EZDN7%%KV$P*!FAA,!L^K?^_O5DC
M*9%[ZIPL SF1K#0BN=%J2E%MUCR$K(A(4R@".W%,[H'/+=0]#K7^O_7$N.,H
M/4W"I_7_/Z.GJ-;3%@]2-&P:460M2MH[?,.%/4LJGSWH6BFEQ$@AP"F%,%T_
M61_K_SL !YVW7*_1^%\C%DW%^6FQO2&@*D"V,9E9(C@S#A)_6U :)!CTY\A5
MR!46%B+57%E#41_,GG9KW9;H;9-X=Q.9HWGH3>?-M<)6/O<P 3^:PA+4X))W
M3W;C1$ZG'(/,6$T@:2PGN1:8$A:T2\_>D^%D#*Q;.WHW\5^\?W\113Z_/(GC
M\-"J.* PDE3LJZP<U :GRU.2A2XOFTL8YPS2,&VFBY>ZE$'/2RMSC_)0]ZO$
M$_]=67.HZ.ZI(F/"1"59E2+Q?'N!])TQZ0;\B\>6T#>$2#NE>(L\&CQ_VQ2Z
MK>49QNIN_=ZL-( 5(:P&BW:NM@;\H"TQ#$A]!7(',OH#,MAEPV9_- PF\?@I
M:!<:RB9%4D.@.H=%XX%/GT]0J,-AQ-W0?#[C-@XSXQ&W=O/Y%*W>* C'X3'D
MQM2R\AT"FM51C.XS'H1H6KEY'=$A<1#O)?5!W@J6<QC2!=0\8AKT.</G>$SM
MFA]'8AS$X3'LC,;B671*VR8SWA[.*>O& XH19BD>HA4'>X=9&C-+(R_&:#H,
M:#P>3K"7QG$P 8W]8KU3"UL1!/(<C2/F:#(;8<\(7,1W.M>F9YT-PM&$KXZF
M@Z;1G@W&]<72%"TWW7X1-7A%>PS[SX;A*$*),SM!MFM*9N8*#3^GMQO?/(IG
M;YMO/]&S4W;QDM(/@?6'J)G_=U>>4F2 #. E$KLU-YQ0D>"?3&(2ODD]=5S=
MV0\AJ&FI^4M]I]$G1-<0TRXA*0JU(>1:EXP'&(7_]_@_ICGHJV\?!@XI?5'2
M4"D*L7MTLOIRMQ!Q0U>K;ROS71WNZ;)]3SP0'8S#.<]8%$B^0$N% UUNN@^H
MH5,WN"GKGJV=JSQ:.(<#9DUV"WW+M.-"]/^N\N*^\OZ'G4 'I%WV"OA/'82.
MN,))1?V[')<WOOU)OE7::;\&&@<!@"?02KP6+[3!@*J6LH6LM?915=8X=#JT
MZKM\\;V'/$NKO/IR^55UM;R6MUX2C[FJ=8VZ=O!> VQ:K"?P<.LP_5ZGZ?FX
ML.,1Q=1&VK3Y2>210*<I@;7.75T'A]W."-6N 3I?^#*J^R/<3@EL%GXD1'1@
M7;\:<N)C,V^_O6L%&HB% BXL:M1<7V4 AB.)#O$Y'$?(20TLQQBI-Q*7VRNV
M#LA]AA0\.47*F <A/D;S(*+1,!B?]DY41=H_BULCT(YC?U9O?"\8V-L.#G9S
MH2?6Y$*&>%%$/XG44P."<M0] +%G +]W3-Y8O.3R<U0'Z\'=5>9[$KY]H;(#
M+ZQ;8;X4STRQ?$X9J/>37QV7]^3 A<PD!0K_7NQ:9-F%H/6*0^?+)+&4@M0-
M76]W+NJ#UL<>=C/J<7"J$LN9ZNY=P$/Z?](>$B,!0QB0RA+2 &-E_[RFWFE9
MVB[H0 ?$TVACY&U+0=WM&@]DDJV*.[TDCNMTDSM9_UK?F-+J)2FP ?Z/U'#X
MUVNX<VW^6/7^)4J55*TSOKW=85%3(<$R;LF=J)Q7O56U1@ZIHQMR#>MK]&S4
MZA/+.E?!OO<)SCIO:N14W.A]%'!&5P/^I8UVMGWEY=R_Z;%=[M^7^8#6% V3
MR-05MB)+C4^$]>^@^$%IUOS>Q\*4I<GYZPH80%E:@.=7!F"@'M ![8M K_\+
M4$L#!!0    ( '6"5%,G\CSOL H  ",E   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;.U:;6_;.!+^*T0NN&L 5[%D^27=-$":MKL!KFW0]'8_'.X#
M(].6KI+H):FDV5]_SPPE67)LIYM=W/6 ?H@M4>0,9^:99X:*3^^T^6Q3I9SX
M4N2E?7F0.K=Z<7QLDU05T@9ZI4H\66A32(=;LSRV*Z/DG!<5^7$T'$Z."YF5
M!V>G/'9ESDYUY?*L5%=&V*HHI+E_I7)]]_(@/&@&/F;+U-' \=GI2B[5M7+_
M6%T9W!VW4N99H4J;Z5(8M7AY<!Z^>!73?)[P<Z;N;.=:D"4W6G^FF\OYRX,A
M;4CE*G$D0>+K5EVH/"=!V,:OM<R#5B4M[%XWTM^R[;#E1EIUH?-?LKE+7Q[,
M#L1<+625NX_Z[B=5VS,F>8G.+7^*.S]W#(U)99TNZL6X+[+2?\LOM1\Z"V;#
M'0NB>D'$^_:*>)>OI9-GIT;?"4.S(8TNV%1>C<UE)07EVAD\S;#.G;W-2EDF
MF<S%96F=J>!O9T^/'433A..D%O/*BXEVB#D1[W3I4BO>E',U[Z\_QI;:?47-
MOEY%>P5>JU4@1L.!B(91N$?>J+5SQ/)&.^1=EK?*.K9N(%ZK&R=D.1=O?JTR
M=R^N55*9S&7*BG^>W\ -P,J_]BB-6Z4Q*XW_J'/WB_F4*K'0.?(G*Y?"R9M<
MU4F4_88MZ\J(1:M)6JN<!8I<"IRXQBZ]$+FR5KA4EN)D*.;RWHJ%T05&%.Z<
MHBFKRB0I,"ZR,LDK1!(7(I$V96_QA8++;F5.EM!#4IYH!+VTF(TKJ_.,Q,V1
M+#GVA*T2..T+\>RR!(+S',EHC\0Y[PEA=JJX4::-=?W@M4KJ\9#'A^)"%X4R
M;.-*KO#D4(23:3#"]R0,0O'A5IF2<A!<@4L8851KCUP:I=C](@I'P42,ID%,
MF%7W\)+Y#/9;5.7<BG@VQM/Q< R)UZDV[KE3ID"> S%V#9,PC+ ^&D'])^VP
MI4-Q,IT%)[29:()OBEDBC;FGD,%?E8^!=U??D$'M;9HID\14[':H!6 '0G^=
M60-1/#2&@F9W&R%7*Z._9 4%?R$SX_<IYOASFG"!H<[R-9H"\0%V>%6,1N7S
MJ"-[B7I@Q;-< XZ(MC2T[T2;&E,:T@W9K0LEGJDO*\+/T4"4V/M^5%F'+Q])
M^--+",26%+'K'&%YG>W.F_Q_L.^!2')D4+;(H$K"1;<RRWD-ZI^PP/V+W<C=
M '@!ST'Y7/QHX(7Z\RWY^=W&5CI^N]!FI0U%9./)"W%1&0.["?>#<#0.9K@:
M,OZ?#8/XJ!V?BO>Z?)[4LT?C(4:&P9AFA4>XIV3YD6%%;MRJ(II2>F"^^.M?
M9E$8_< CXY[@&*K&/ >"HR.^IY0R;HEJSN[U469& ALDGRE\6[1U]33?--;5
M%LZB8-AH&QWA/H0#?.YM1K;CSD,1#4:8.B;O8#%\%0;#HW9\THW%0Q3O>PBH
MM %A5T##"7\U-AR*\1B;WB^D[!J)^(V85V;X?!9-AL'DB$;#,(@>&OMPOPR!
MB>>A:#SE[T:,?S:!H%T,^U_#[^QD6J,W]NB-CGAT!F_U(#:,X-#0!QW8C8<C
MW#^"W=$,YO8P12/]I(CB,7Q#2='B.YX\&;W1%O1&??1&$?9#H]X0NM\2T&WH
M'<8GC-NHE^D81Q[OQ]97HW=*#@,\QHR7-7IG$SCH=Z&7H3<%AF?(LS@X(?#.
M9M-MF;H=O-'(I] 45D\Y6UD*/3J9QG#!M3\\$( OT'%2IU9!\+NV-H&?&\Y^
M#LY^?@W.]@U?I\NC<H'JRJ5OWJU]%'?9 C_1UC55>T^89$\A%0EQ<T]5J]U>
M73KON0ZV98DKC*]:=D]9^;IT?=.:LT[<;6.O*\45ME3B7DDC4-:X,207Q^&(
M4>:O8A^1NJWQ5Q->+Q=H"-8B7&ITM4S1A-[Z$2M.(F)$^AR)*< ^P6>(Z_7J
MSN0X D#\!T4?'U^9&Y[!NQS?Y,4Z<RC4$H1!6=V&X4DQE;L"1*!Y$)Z!N).]
M%BN_1]I3ET;')%H2AO7= *V172D^G^;W@;@R.E%J7O?GG03<!N-5;W*GX^?F
M3^:^[]QG*>9!/TZQU#KA8)\S3GP#1P]]#[</NC@?\S'B4XIVM'<2W'!7,_$]
M3CC[YO6AS4YFR*^OKAXW&^5W.JY1/$(-//&HB&;,I^-!%%-9^-@WF.I&R)U&
MC' !DNWSV@U@X/$1?8*6T$M,\0F4HX#AQ(8H+[-$=,Z:N[-Z!V@(EK:5E+62
M!*JJ@\,SS;A"U[LR&37'W 2O]3G*&PKD(1(VHJ)1^Y$5'I+],7*F'NPC#Y!-
MLR3E2'</@+X0-C1?'S!)7%?Q1L7\?8=#?Z!XQ.YZ2[:G%EH>5A+X)%'&(:#B
M)M-.)6FI<[V\9[?)DBO7VE2C%O2.")NB0W.][7EF$T2\,JQO[8OW$"<F ]\'
M_<PUXYV2-*\^AOF3$\YF.PQ?G]37)YF!N,479.#(N,J(^/SY[0[N5)PPN%4F
MY\-DS^D<J2=Y@ -&Y7M?3?8'J[E*0 M6-2%])$Z+.LD=LP&KH72OF4]M27=*
M",^7 #41#+BR/H4VNA$%4;+83K6N:7P##Z]5B108B$M=9E9<I=(4,E&5RQ*9
MP]6791* 8.@A#IS73;=W+<LE*C^?SI$MUNGD<^ ?PP<&!W62T*R_)"3<>@N8
MC^[@/3ZS\]E="RF6N0;((2]'':&6N$G"/$L(%^O#NW]90ZI8,.!2UN\L^0$9
M35BDX,-B0!1I;F1II9_$)B?]O31O")#R$QP ART+$!F135TS!]0$]"L5'1.:
M)18>)+RXC3F'X3 .PEC0NQB>TTTJ6]W\&T9P.M!>%YA$+S1,QIMF9&7=5!:X
MVSA[B[\KT)*(=K>-+4P:L*<ZY_<HV%.FYSV-GK&LH$SEA,7Q7V*W1A%T.XO\
MJRYC>!NN@S>?#6JQ@&&]%-NG57O4=@PE]ZR;SXKC*A&9%4<3&9 T[XP\9@H]
M5[G775!#:K-E"2<ETI-Q5:R\IIJ]',_#$E;$B4AO;Q@YZJ%':)!1P)J5N-4Y
MU.;P;1-.^.R&H52ML!M$S6E#N=292M)M!L!(LV:80/P"D.=6PT9<, TZVG3;
MAJ&"?48!5^IY\[Y+\-$1 <6<)*UW3/];X-<ZN^S0Y08/4$X\@+EO[L'LMQF(
M>2[N,Y5S_?Q-&=TUT;,,@3=%_%N&>&"@6*H2S) C%U*TF&!3UW$/1I= /L68
M7YPV>N$7:H/D?)[1[N''K/3_7.'\;*IFCS4,!"TWN&(@5CFS,OTOQM>E$(7I
M8KWRUN_[ U?ECRIG83;-5E8\K4X%-;?V&+$EQ/-J62&".^CPJWG0JPBH<UI)
MXUK*ZPOH<=P&+\63<9_QZEWWP$ (:8M0W7MMLF X>IP$1SB@?N? [QSX37*@
M!_[?[)_!@W42?6-,V#1[3^?"IU)ATS!N[P[?JAM3T8NJ/TJ'M9JG=H;G0'2^
MK2V,HO%F6_BP =["B5'\.">>!#C@=B@1TFM6?/ ZI"_*X_Q1XMSY*J9FU)H@
M"^52/=_@UZ=37\.SA,KV5P5U*G8/)4Q%WWGR_XDG:^SSJ^_I#W\*73;I](WQ
M9;VM_P%A;OL]Q7'GARN%,DO^>0ZYORJ=_PU+.]K^ NC<__!E/=W_?.B=-$MZ
M@9>K!98.@^GX )CAG^3X&Z=7_#.8&^V<+O@RA?'*T 0\7VAXH;XA!>WOHL[^
M U!+ P04    " !U@E13HP3.#8X,  !G*0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6S56FUSVS82_BL8GWL3SZBT*,FO33QC.TV;7IIVXO;RX>8^
M0"0D(:$(!B M^W[]/;L *5)OMMK<W=Q,&U-X6>SKL[L@7RZ,_>QF2I7B89[E
M[M7!K"R+R^-CE\S47+K(%"K'S,38N2SQTTZ/76&53'G3/#L>]/NGQW.I\X.K
MESSVJ[UZ::HRT[GZU0I7S>?2/MZHS"Q>'<0']< '/9V5-'!\];*04W6GRM^+
M7RU^'3=44CU7N=,F%U9-7AU<QY<W(UK/"_ZNU<*UG@5),C;F,_UXF[XZZ!-#
M*E-)210D_MRK6Y5E1 AL? DT#YHC:6/[N:;^AF6'+&/IU*W)/NJTG+TZ.#\0
MJ9K(*BL_F,6/*LAS0O02DSG^5RS\VE,L3BI7FGG8# [F.O=_Y4/00VO#>7_+
MAD'8,&"^_4',Y6M9RJN7UBR$I=6@1@\L*N\&<SHGH]R5%K,:^\JKU\KJ>TF:
M$6]S5]H*"B_=R^,2M&G%<1+HW'@Z@RUT+L3/)B]G3GR?IRKM[C\&3PUC@YJQ
MF\%.@G>JB,2PWQ.#_B#>06_8"#ID>L.]!!4R3\6/*IWJ?"JNR4-TJ943K[5+
M,N,JJ\0_KL=8#N_YYPXN1@T7(^9B]*?5O9,.A>JE*V2B7AT@%IVR]^K@"FX*
M)\S%;66MRI-'@8&%M*FXA6E( B>^;81M*^%UI41I1#E38IJ9L<Q$+DN2W4R$
MJ:P !%A)0>1ZHC"6G^HYJ^Y5COVDR+ .U-4#4,-A%$2L2HR%4PB=PZ.9-5*Q
MP7$69\J<#_X]NHM$:K),VDC\AH%[F57,P>X3YDJ2F9AZBX83VA%=Q#BT LP9
M?P(.D)0)3ISB?*R?!(4EM<+4@Y\5.$2Y"$H2Q+JE?7-XQA3#1!7G!C(]L5"B
MPN\U6I.@_*11/HAD)OE,)W</$M(YDV@\I@C_<B9DK>9:RT0]D:YD.4ME<S8'
M#+53.9%X\S17Q,UD0LJ1;%0$7JGF8PA=1Q\3?ZV2,!KS*.9F,A5I%3R#ML8D
M8GPNYAX*:!L/#49AJ =^7:$8B;-'MC.ILN%E)A$88Z5R *L#WZP1L 719V*"
M!")F<%_E25<YLE"F_X4E4V0?<&"A7^?(M[Q/M93HC?8<(\UDR6ZK\R2K@ML2
M,:\D,)XKAV7*E<&[Z12_3"9)-:\RYMJ[=V+FB,\9);%[)FGF2KP@+H_$"_BF
MLN2Z4!&$O/[E]FU]6"G'&>084](\BL2'KJ D?2WI!+Z=S%H"U"$WS7F'SAL?
M68 /INYDQI%56)-6,'PXM-'*6)$3L:I3BJ,6.3H:R]?CL"%>#SR'*,%")#ZV
M&!8RRU;-3;,90D1/=!*<;6+-?$]U$^<3J6T EAH&H 8$H[=T@VVZUA.V$_0*
MC9!@N2LZ!"D.$K+7.)/IE#EP)?YX/ 7-<#9[TTPZ[]1Z#LBFM>-'IE\K _L\
MYN4FA'4#?L_UV 603BB"!@\1AIS*:Z^%';NA%$;QM9FW-+0,*#4+=RG>UWQ=
MSTV5E^(%@'&NLXR4=22NM^&&GUA##O%]98TX%''OHA]')W@:]"[.+J)8W%B
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MCRM ?*QPYV(;'/"^U-H?!F&"X1:W^AM02P,$%     @ =8)44X>:VJ6(!@
M:1,  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULU5A;;]LV%/XK!UX[
M=( KR[*=Q&T2(.D%*X:N1;.N#\,>:.G8XDJ1*DG%R7[]SJ%N3AP[2;&'[<66
M*/)<O_/QD,=K8[^Z'-'#5:&T.QGDWI<O1B.7YE@(%YD2-7U9&EL(3Z]V-7*E
M19&%184:)7%\,"J$U(/3XS#VT9X>F\HKJ?&C!5<5A;#7YZC,^F0P'K0#G^0J
M]SPP.CTNQ0HOT'\N/UIZ&W52,EF@=M)HL+@\&9R-7YQ/>7Z8\+O$M=MX!O9D
M8<Q7?GF7G0QB-@@5IIXE"/J[Q%>H% LB,[XU,@>=2EZX^=Q*?QM\)U\6PN$K
MH[[(S.<G@Z,!9+@4E?*?S/IG;/R9L;S4*!=^85W/30X'D%;.FZ)93!844M?_
MXJJ)P\:"HWC'@J19D 2[:T7!RM?"B]-C:]9@>39)XX?@:EA-QDG-2;GPEKY*
M6N=/W^D,%QXSC<X=CSQ)Y/%1VJP^KU<G.U;/X;W1/G?PAL1D-]>/R)+.G*0U
MYSS9*_ "RP@F\1"2.!GOD3?IW)L$>9,=\EZ3<_!:NE095UF$/\X6SEN"PI][
MA$\[X=,@?/J=L7OX:GASE>9"KQ ^+)=HX9V&M[BP%95)B 2L$5)3E II 9C*
MWEY@EF'4(PFU-"6)IS.X0"V-A5^-1P=4OV%*$L_&-[\(G4$J7#X,3T*3,!;I
M#925)2T.'R*;)41P1G6V6EE<"8]06JE360H%HC"5]FRE*$MKKB25$ZIK>'*0
M3*,#PK527**-%]L*UL(!-AYG09UXI*+#.(X.MQ7=%8M>+OL$I;@F$O+N#J'C
MV3@Z:H5&\&$[+Q0]6" R^Z1L66L]:0)./Q0FDTN9"J:HESSNJI0RX?-&.V?=
M:-+?BR+:8DXC42PFRR2O)=^#O(RP'D+ GDC' ;%>_MU,)CNROXA4V"%.L"2+
M+#I/P266YT1?<N9).8T7.\,4,4!;S4,&)^$"L<#LT7DYBN;WIS^$[.%92:)Q
M*W/(L%%5)O6*4V"K8&(&E2Z%S#K_(_@MKYTHRK!9W)LWO/(DLY(N9S,V,A>"
MD9J5KH-.,<#G7EP!P<(2+,C<)Y,HZ7RN*+LAX#<%\CR6MQT,-I7R6HLC=;FD
M65P?&UJEWLXLC1G28^F!,(7PK/GPTQ T[?W\F6*?&BIR&LWXR1DE,\&^.T]_
M7;P;"1P0MEP3L1&.PS[ ')&1O25-7Y"RELJ'+6I=6-)D+R1/ PI+>4N%4ARM
M0E9%R!%/7%OI\3D1$D_U(4?<:7 Z*]UCVUBYDET-2.<JH5.F3.?KFN[*8B$4
M?Z)1YTPJ@W=KZ?.=T?[,"7+HO0H!" D6RAG:A#-\#"HG/55PZ=4B@9W> TQ8
M6E,$QY5POA]N \CI :-WU(W/A2=[+6Z0)WULBS6"+XR+M+),Z[>9N2\B]J8)
MY:V@;>]$_QM$1OP;WXS7!PUGQ%FJG12';#.<6&,]LR);*&(TH'MNNH_TJ.1C
M6#31?+:EF#QFYZ1C"FB1OC2*.F8:> $__G"4) <O"431K!.S7V,2);.G-[W+
M*H3WXAK&[!M[>"E4@)V'^3R:'TZ>\L)2V)<!B=^A=!*-]RJ=W58Z/IRV2O>"
MD;J$Z?UH]$R,H7FAJ+5 S,4EMOMF:FS6[(1<!%5],*!BK+=;:Z_#/M'YP\.!
M4<Q>+#:< J$+C^ M(Z+?EJ6NCT[!]+92;P%@"-3:<:/%YZHP!.-D"#=:Q"$;
MVEC1ZUX2[5$>2,]&15 8:<^KRZ[3QX<8&,?/?R'D1_/XCCSU13*>U?CGBK@]
MRK]]53P*D@_4.FS0<3A/>G1P<W6'A,!N6Z5I%DJN0LCK7H5"IIMC8,=;V\*"
M7QAH*C#P1G]DV2FW%B6+"@<(4IVS[GJ_1SI:\FZ_E%?T'V9S#04N%X1Y*\6"
MV)X_!(.X)$* :7G%@ JT1:Q'L$\1,]<3OQ,*^];H-F61D36=[_"),V%L@W%I
M:=?R%>VIU\&\&XU*K7VK69EO5-Z>9H5&";ZZR2H78&T\<LW -SK)^/J8PB[\
M=WJ8.@H[.I/02O:'AOO:%&C:E'^K11DR\#V5-FDET=0PP.*:K9I$D\ZH%:DB
MC2JXV#!9WZVT)+;!E/L@_1#NVK?^#AH[&L)KXN-+P9<OA'PZ?5<A"</&6H>[
M$G87M45W'=M'&]<?!1*D^)*'X,71K&]"NM'N'NFLOC[II]>74.\)D5([4+BD
MI71DG W UA<[]8LW9;A,61CO31$><W(6+4^@[TM#7C<OK*"[73O]!U!+ P04
M    " !U@E13LTEKT5H&  "D%   &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6SM6-MNVT80_96!:A0R8% D=;'DV@9L)VD,)+'A2_M0]&%%KD0V))?9
M75IVO[YGEM3-%T5.@CSUP>:2W#DS<_;,[(J',Z4_FT1*2_=Y5IBC5F)M>=#I
MF"B1N3">*F6!-Q.E<V%QJZ<=4VHI8F>49YW0]P>=7*1%Z_C0/;O4QX>JLEE:
MR$M-ILISH1].9:9F1ZV@-7]PE4X3RP\ZQX>EF,IK:6_+2XV[S@(E3G-9F%05
MI.7DJ'42')SV>+Z;\$<J9V9E3)S)6*G/?',>'[5\#DAF,K*,('"YDV<RRQ@(
M87QI,%L+EVRX.IZCOW.Y(Y>Q,/),97^FL4V.6L,6Q7(BJLQ>J=E[V>339[Q(
M9<;]IUD]-\#DJ#)6Y8TQ(LC3HKZ*^X:'%8.A_X)!V!B$+N[:D8ORC;#B^%"K
M&6F>#30>N%2=-8)+"UZ4:ZOQ-H6=/7[[I4KMPV'' HN?=*+&[K2V"U^P&]%'
M5=C$T-LBEO&Z?0<Q+ ()YX&<AAL!KV7I4=??H] /@PUXW45B78?7W9@8_74R
M-E9C[?_>@-E;8/8<9N_59&VTX\(Z,*6(Y%$+E6.DOI.MX^M$:$E7LJQTE$!7
MALX+NHBL&DO-)/BD*DVG2NB8U(3>I!I"5MJ0J&RB=/JOC$E0J=54BYRL0HG,
MH:@J^<%.W_-IG&89RQ\0C!>I/,<==!5]IK9S\S@0NJPQ=SVZJ)I07II#L4+@
MA;*4B#M)HB!Y7Z9:N(J+A94>G609&6>N5W*M(!OM(MJ,/T/X-&9;"P)BCVZW
M,]RCV:I#4%7$<Q 2)6B[3U'3,GN@T M1635+/&L UN;W+G#S+'G"@OY(&<MO
MUQ%W]OO^"@B#[@3><+$6<:738DHVD?C34KH9!41#>5U4DHN*4!)6YBR'>5WL
M(0532M?)L@=PN^XV7/&A);=D3O9.I)D89W)KSH5+^*EWCQ7Z1D;UT] /1C]!
MHNO^7M0JUCM)HX1F"!X 928M.W\^$W]%E69-)4N*MO,+E>EGQ;F=^2M4VO/Z
M:X(*!M[^]\HT\+H+\IU(5U?C6T7J/Q8I1/-1(,&?I9@59]\DE]J^&VPME2T<
MOJB3+6Q?)9+@1VIB10+;+#RHBJ(JKS+!9%[ 3-,9R-4RX5,<]H?S G%(:G]0
MQNS2#7 G*L.YT'GA'F6:TR&$X-PBXV**IRF?WY;8RF%':]AI@YTQ]AX5TF5G
MQ3V-']Q45<C"'E ;>FPX0@RW!8ZRF=/=[^B7IHY-X@WROY81&+ I CA9=%$<
MA.E:9'*//M4N;N!B(\R9, F]0YKT7L;(9LWRZ71^>5[<26-Q^+6US2-GDZI>
M BMLY9;X$HM92\+9G,I"3E)+EYDHUMV=55K+(GJ@&XU76;U1G\3_5+4W0S?*
MBHQ.!2PCN%WTL7D]T X%7@__V\'^R/-W>33T^NXZ&'A=-^@-O($;A",WY^)K
MZX4M'KRRS*-,&)-.TLB%!F9"!@]Z791]MP]Q=KT1//KL"> ].LE5Q8$O3<',
M1*O\=8I!5@$-0GAI^UZP2[_^,@R#\+?%=< !,)&18]!2*76JM@%N@Z]=<->O
M,PA7,PC@L;=D^^F>"Q+G$>Q0R$<3=]EW=(<,S"N!)Z-ZU'7,_Z_Q[] X6O$.
M.FF(__LX4('OOL?KT.[B?-6P/&H4'_""?I^^APS:[@^Y3H9PY$,03B']'B_O
MCY+W"*FT4460-DIJ\%3@;:0"$7V3Q ,NF\ /&+V/@\HBAY%3^<OZ9CGW'=7M
M4;=N'EW?&S1L]Q8<-]T$*]%_=M]8;AO&[1OBQ[#V>+=H]B_69"W"#RIJY-4X
MO'KB\'5[XCM4'B=PXXY<J[^Q'Y$WG_B)-^8-\UP3<4PO1TT]9LMZ-,LN(-:Z
M@$$7:,*>,X-?> A=NA7QZS7RZP()FO8?N*5K$G,[<%.K2UNVF"L/&L&/L,$S
M847<52;<51+754#OG2PJ!!'T6*SMD=/S8.CM[U(O ,8%-(L5@2X:5QPC-UJH
M<C[JO930XY+P73F&FS,)G-ZQ=W"!N:WC:1Y\&$F7[<XE\[4@?. Q+C-3-ZPG
MS6/ME+/C2*DWY/GVRYN6JRF4-CWW :2S\N4HEWKJOH_QD1ABKC\B+9XN/L&=
MU%^>EM/K[W<XR4XY[TQ.8.I[^_T6Z?J;6'UC5>F^0XV5M2IWPT0*'(1Y MY/
ME++S&W:P^#!Y_!]02P,$%     @ =8)44W9Y+AI= P  ?P<  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&ULI55+;]LX$/XK V$/6R#5TX\DL W$31:;
M0X.@Z6X/10^T-)*(4*27',79?[]#RE;M(O4>>I!(SN.;)X>+G;'/KD4D>.V4
M=LNH)=I>)XDK6^R$B\T6-7-J8SM!?+1-XK861164.I7D:3I+.B%UM%H$VJ-=
M+4Q/2FI\M.#ZKA/VWS4JLUM&670@?))-2YZ0K!9;T> 3TE_;1\NG9$2I9(?:
M2:/!8KV,;K+K]<3+!X&_)>[<T1Y\)!MCGOWAOEI&J7<(%9;D$00O+_@!E?)
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M=3%7)$,LK(F52G#O4%J9]+@2WHA6G<]68O*+<]23R+3SV"H(<F)16E=B!UI
M&US8<BZNK(Z5>&/RA?(Z%!QLN I[WRJ;BVN%;+:2GYW%GA0>'1_M]07\EYLB
M>Q _"K/$.L=2WTL?IR^^R?M<\OP^V?,-,L17;>>ZT))WN(#V2VE5A&<BE7=*
MR,5"R0SZDI36:U@]-3YE'#"%BP2J6L@D865E1O[A,L==7RPRA5(7!'/BD_%*
MC([ZX@.FSJL)P71,B0U2OW#8#E?.9#J1Y*N9+F01:\AU'@.L0B0^ BLT9'?\
M/%>%@NLHGI:C!EL$_%!'[TMT$Z'@[0\ --G+)B9*+>"O!"EMRH)C0^YWY,J%
MI+3HQC(2MQ!4;Q1W0@2+.ZJD\+S3\T+/= Q5L $DE3&DF;([SZH[592*U=%.
MJ/L%(#;L&0( B$>!00397RCR&88U5*.P%UO$D3+0(#-(Q9 #\ 3D;U \$F>.
M\N="Q:%")B.&# #'$OL[IYRK$@ AS/0O.=69]@^TAC:G(K'L)@ #3?>TG_3L
M_$2AXR64MN2ATA-B-#8Z9!9OW>K?#12YI'8:#=[)#)9A>JRL1XO<N//T@7+6
MFGN-]%-P^S]'T:& QEE=1AM%KHC*=#!10SN(-4@]4G>ID?'SS$PYP1&2N9XB
M_="*7V 5PP>CU\X?EQ]N+W=Y,Q(70Z[>HMI!K1J7'+(>X &-$/W@^,UN#]6R
MR?PFJZV*C44?0?J+."7X<9P4),^G5BF1AVY#X>GB8]TP6@QH1 $[8*+E:@Z!
MVJ(%5'QDZ?$8IN:=*#POJQN%=8%'1PAK+; VK$!#>-XN:F#7$"/.V#0@"[;B
M$IXJOU2JDX(SE2A;X4X)P'U@S2PM)B,H_=5LII@-M8]09X&7Z5_D-7)\ABQQ
M+QDF2?@M1Z#;[Q]I6D_\1!8],8\L"BVMO;IIE&5M8/)0_+;YAZ:RXO#Q,)K@
M[[CZ.PA-6 3O@H\50DE;<)/;&0^C\:[8F41#_!^-HGV^.=AEU];IOG,8C3 ^
MCB;XO\?7([J^*BT2TG&]-$54)<[. 0D>0P/,W=N%'D==< #H:<L]]U__.!J/
MQJ_$)-IOKD=8QJ4G*-G&T5A0?6%/\4F55N<Y,0(*4@!/[#8DS6$+M#^@[3
M-3\36F+=F.XG-.&0G?-V/=([1]'Q+KES/QKA9V=\3/KCGISXFWA3%1X2O$FZ
M=RM%2%GT5[*VO]*-:+V3@)H%P-PDO$% [,!:0EWQ\.84[0.$XZQ,F*FD;3L)
MM*?CKO7JYD99<DN8TC&D'R@4>B8E/#72@%\D* !/#>K@6%8C+ZF1Y?J^[A\H
MZYGV%;I!6JKCE+ !ZE4H+9,[90$/P0Y:]WS_7>_XKX(2G?A7YIY?7IZ/1B..
M1;@>=U,-1E@$\57 \S5G%:9X$4N7LN2@(4N.V]BO=!H.R,^2D%P7=Z!@3&?(
M;G+CL@.W91& 'Y?@VE4\*PBK+.GLYU/ 3NOP9_8+06NVJI2,2\2:&"VG5;]F
MCQU3&K$;1(+G%,8C*X@% [R1"P0=< ZZ9R0^EQ7YWH"8,G.&CJ59( :A.5 O
M92/!%PHFD)GT;0%@7^RA7<I1H@[!V@4DEP2X((T0/0=5 -%]@C3TNUV6ET-:
ME8=N(X5YAKG@^%&3X?[_U)R>+//-5;Z]R,42\5NK2]E$^0& ONJ.*<H*M4@B
M;\!V?BF;!<;DB&L#*V;6Y*$DXUAERG(\N#/#]>2/LXLO[]]^^$A<AZ:]NUAU
M#"4<.#&E=%+:&GT<=>%$_"RE!4:0F(: M-P#W-=O@J-U:K _'**YY36OHEK9
MLE8'DF\UH=D&CG&XWPIBV+&HPPV"^@VI7.=XD\="J*P;+W2]_@A8@^8;XQ,J
MP5$X.UA]4TX_X^?LC]_1VMKQW;!4.LT57$7H_\CY.L9,XSJQ)X%(&\=(X/D<
MR!XJ?0K0)Q[7#QP:Y0WXP&/F4+,9/,C9)7,Z@)%+03=""5#@:EI-( A6[;W5
MTY)JG_,9^$NTV8)BD0S-1WE'15V$[&#$#S6RY7S9GBII?MBNW\EZK)8"Q5"I
M$^!_5;G'6IUK@QX%((B?.AO7Y[<8RLMI?9Z7EE\7,*RQO]I8;CI,'_:Q38O"
M4/8K"IX5N:R< >KH Y'^NX?MLY@/QXP!,.=+4<$IMP#1?6U#55MS8SJZZD1#
M'17.XM:4D$%UH>YEKHM0,7>88$I'D>(T:!.&,6"F,]7M!U8A'XNJ'865#"ZL
M;S@"X=$*?V>%F-;59/8[7.H27;^_^$9^GJDE\2*@,@V&XR^_0.!SM&)[OJL0
M^Q7QH4N10;*A(H2N./,IVA!X-CH4&&05^Q 74\E8)@\L::7=-8+<1DGC@ Q5
MIT&$*:NNJX/_C;)W]/*HM3B(6B_&]6!PS+B N L5P'!DH@, \2L1B@WG(U)J
M4;F!9F?4M:F< 07H5/ZA[=2TO'I'%.+"F+M (3/KY]<$4/(!%(W?P,@YD6+>
MQ) ^%@V3R*5Q.@A95F=2+W^@O!YKXTK 5T,"$-:+YYH,":S/H2%G \9O ^E-
MI_@5A.]W:8K<U'0HI $F:6Q16EA7'<[;0O_=;4%MM/2V3P S[A1E@]ZN,;.
MMHTB#J%9<:)6)..IOM8!0;^]DS[2J1\.-L:'#9T"IR%&4I_I'UKDVPA"4YDQ
M>>-W\<AR3AL*$A*9>.5J!BTI93)4>?*]='Z=;I<U6@6/-\G4B50SX5'"]Q]A
M,V*.['&=\D(@2WY/5'%W111L"]PS?=J.=OWJV$/#,#9.Z8*:8U9U)\YW3O+'
M& F0YWP,#M%/^^LOI'EU0'1D#/?$T$C('666M.03U5 N.-57:V+<H6!MZMQ[
M@;-5Q8&K5*3\HBUJMTC8#[8>OBY CZ[]Y'6<!K1M& M7-K_O8#TSG>,H&8I_
MT^>(0>?C3JYPK*-/6$0"T=O"=YYFM/E*=A8^#K73PR>VCY)>G#N1J1F6#J/#
M_9ZPX;-5N/%FP9^*IL9[D_-EBJZM+$W \YE!^ZYN:(/FV^'I?P%02P,$%
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MX.AZFH#C2XU5:?-!"MI_,D?_ %!+ P04    " !U@E13KIEDC"H;  !E8P
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MR;'&Z4Q'1MSJB-W*: DK%5FJ]R]N1P>5_? "##:;4S9PY;S4A/(9>Z>A8K9
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M^'U=$L@<D.6@]W<>IU;0B$N99,JD=MN!^-4N)Q_62>[LY*= &@AF_3&]J$@
M9M,;!3(F4(3Y*SXL=%9*<<G1I%(MAY-,WDUE<AO6\%*8U/>LF=84XU1#ZE<&
MA7V;0>)M9J94>O[GO"=NC#\YVM(!KWSS>4OB<;W/NDB1AW2UW4B(D?>?.Y"P
MM>XNU+,7?'1B,K[+LU39G>^2-^ Z:\ZI]OYNU&_66(<K3_!' 1&OWN5\P_(?
M#!_?%VO[?(8UB=]UA9Q"2[_9^BN_(V)<[(Z.>L$S/#!6* HKL/,_ZG3.7H((
M\%0V'<:V<FCJQP=<;-MQY'4RPA9&MPZ<VC:EXZ+\L^IT(+%<0T'P,)LN-C;3
MHYON.-6;+:G?S]<#^A;&ZV->H3)*;<MX,SEP?)\ 04ZFVR/V35\5\FX$G0+9
M?.8;*(1".IP&&^0?P5#6GJS=*Q3[&/O?&E-^_W2)_/_FWU\)*9>R0M#B1+E3
MA9)'K7(5S4M<T,IX'YS)=\2=>\G9"#N[Z[F-I>3F&,G-Z 3E\_/>X/F@=W3D
M6^G#06]P,N@].SC8VXI66Q**3=%UT$0KO5%+N>5&SA2<ABE]#<S>Y&/;'C[Q
M]\V\G7&'F!*^<"2JX)X>.+?Z6#;734(T/VZZQO'<AI*G^]K6(S$\>":.#IJV
M-:=N/I#^[>3M6Y.V;91Z"3]\6!:-AUCR1QX/'YW)(F:#HWX7BDB]-Z7RQE0K
M2I$#',?[DR?V 3&=#(;BX.CHH5.5;SOS$U13U-Q\UV2.T!^UQ9.F)B'"?+$&
MA_3OR?CU=7/@?=U\:NJ.]7X_<KC)"DAIC&N];?6VQ_MEFHM'UB7GRB8K0WB%
MYRI[G50VZ?;+.B=;34)[3;=N-L\CD#TY/&V?FCP$P2$P=22&HV<^&)WW/_7%
M$WH,Y<8Z,&6:PW%:U[89P"(=+O,9]6X0VAY#BO!+P"7$=(YCN@7#P:.'$,TQ
M+*N]VUUIQ0;WEOD&F<^I^-;6-TEZRG?9W+:LZ2)A>Q0;K!P,>=BR(->',$2'
M1Z/C@]:,8_NVB2J;@OV*6#HG!N2&;&U+[C+&RO->(KNUT; Y@Z8K@KIH%,:W
M.7W+,OKZV.0=%T6=L<NY6C\%>ZL*'\@C]M;.\3\5#Y<^&QGF9[IEWM'%9(P"
M.3[Y/,MG+DULHL1P=^W=GN#^6+"4$*.#[KZ%T';#]=/!X<D]^^N-0SV&MB0Y
M-;6LW=J'TW2ZH2;&?.%8[)Y?CNENPXPNKK&$NB:K*Y^"Q#X1/M-Y+:Q@3NSH
M1)#MQ9T:V7J08.7&]?$&%.A6BB[6W9,2M8J98ND9N<%997+,G->9[P*#*MFY
M!\<QDNYO'/4Z_C9RNBYOEDO,>T#8$\O-K,!K]T#'VV7G:FVCDP>RJ&9B-*=(
M0:/IW^ =R B^DF1R9(^V3P>$:^K>.!3NDR'P79OW.G8G:)AO0+WGRZ1=4PDW
MM</5T?:2=KRQDS6K=.ZD^M;K]LW4N9<MW_=.Z(JLHTNPONU8T'7;K+T(V9X;
M0GZH%7THB%<SS>R1JYE-HTTF24V)!#8L*T(P%Y@KR-X(/P19\M*O7&>AFP<5
MFJR.OF5M%_4%@8+@'J^;K_@6Z.;5SGB/5,UFZOXKGNW=S00>E5.M_GU7\O<[
M?_^0TX$6_96']8'0_RE$\[;Y0Y*Q__N)=KC_*Q1D+:@0++0RP]1!_]G1CJC\
M7W;X!Z3\_-<44^.<R?DGXACJ!!J [S,# PH/M$'SYS6O_@]02P,$%     @
M=8)44T.SJUS@ 0  7P0  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
MI91-C],P$(;_BN4SJM.D"^PJC=0NB]C#BFHKX( X.,FDL=8?67NR6?X]MI.&
M<F@%XI)X['D?OV-/D@_&/KD6 ,FKDMJM:8O8W3#FJA84=PO3@?8KC;&*HP_M
M@;G. J^C2$F6)LE;IKC0M,CCW,X6N>E1"@T[2URO%+<_MR#-L*9+>IQX%(<6
MPP0K\HX?8 _XI=M9'[&94@L%V@FCB85F33?+F^TJY,>$KP(&=S(FH9+2F*<0
MW-=KF@1#(*'"0.#^]0*W(&4 >1O/$Y/.6P;AZ?A(_QAK][64W,&MD=]$C>V:
MOJ>DAH;W$A_-\ FF>JX"KS+2Q2<9QMSTFI*J=VC4)/8.E-#CF[].YW BR+(S
M@G02I-'WN%%T^8$C+W)K!F)#MJ>%02PUJKTYH<.E[-'Z5>%U6.S[TL%S#QK)
MW8M_NIRAQX9%5DV([8A(SR"NR8/1V#IRIVNH_]0S;V?VE!X];=.+P#UT"Y(E
M;TB:I,L+O&RN,8N\[&]K)-\WI4/K.^+'!?QJQJ\B?O4_1_B/B'M-/E=H2K!G
M#X&=7+H">XBM[4AE>HWC_<^S\]>S&9OF=_KXZ3UP>Q#:$0F-ER:+=U>4V+&=
MQP!-%UNH-.@;,@Y;_P< &Q+\>F,,'H.PP?Q/*7X!4$L#!!0    ( '6"5%->
MENC8X0T  " E   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;-U::W/;
MN!7]*QAWVMHSLOS(<]=)9F1;2=SZ52G.;MKI!XB$1"0DP "@9>VO[[D7)$4Y
MDF8]DT_]X@<)7-SGN>=">C.W[IO/E KBH<B-?[N3A5#^>G#@DTP5TO=MJ0S>
M3*TK9,"_;G;@2Z=DRIN*_.#X\/#E02&UV7GWAI_=NG=O;!5R;=2M$[XJ"ND6
MIRJW\[<[1SO-@Y&>98$>'+Q[4\J9&JMP5]XZ_'?02DEUH8S7U@BGIF]W!D>_
MGKZF];S@LU9SW_E;D"43:[_1/Q?IVYU#4DCE*@DD0>+7O3I3>4Z"H,;W6N9.
M>R1M[/[=2'_/ML.6B?3JS.:_Z31D;W=>[XA43665AY&=?U2U/2](7F)SSS_%
MO%Y[N".2R@=;U)NA0:%-_"T?:C_\F0W']89CUCL>Q%J>RR#?O7%V+ARMAC3Z
M@TWEW5!.&PK*.#B\U=@7WHUC,(2=BK&>&3W5B31!#)+$5B9H,Q.W-M>)5EX\
M8>EN\]?>FX, +>FL@Z36Z#1J=+Q!HU_$E34A\V)H4I6N[C^ =:V)QXV)I\=;
M!8Y5V1?/#GOB^/#X:(N\9ZW+GK&\9QODK3/X/X.)#PXI]M\M!SQO#WC.!SS?
M<,#-O7+W2+]UOMN^\U3;F3)">R'%++<3F8N)MF4FD;^)J@(BEHO$%J4T"S&U
MR"^5"M1&JGUB<2ILZB&G[U&K)=DG38I_<QU?48'E*?)3"6V,O9=44")DRLF2
MG "($*6R9:X$MO &'3+AL=E67AA5.9O;&2M!DOE!JJ Q)+ LZ*%08E#?BSDJ
ME7X[E<L ->,Y;(20Z5?88\CU?7%3.=CDE)C!SSA/ IP\-$SR"IH6*$]-*ODD
M5\YZ^&;W:KRW5$ 7165(K\6)&.1_9 J8X_[VE]?'1Z].?*-1[0F@4=#R)&XL
M*I]4N72TQKI4.=^K3R73/1P(.]M%,C@$8B%VQU>#>+HL%I8?PB RT6%Y1\G!
MY7CO1!0("YVZ_I!;Z;YIXZWY>ZOIB8#$D,F\J&UJ#2W](LDT]%CTQ6^*W"1D
M[NW/SP-MA$5,H+>;T?*5N  ]NAZ72154FQHKZLI GBG16/KB OB=IIJ O(?,
MH!R&]$3+7/^A*,>]+C3<S/)E>B]- HOPG//-L\&^*DOK NN6NFK66KNH[6-S
MV=EJBEP.'C8Y6\TRLHV/U(%?XPS?04"G/&0FL#S8I= >/5?2)=D/XDMG9TX6
MGE],*H\J]GYEA655*P.+FQ0']GY35 C8G59)6*;XI^'9^XOSX6C0$Y_OKH:C
MBT]?>F+P^>9Z^'M/W%X./XPNSO'DTY?QX'1TP8>^'US=?AD-N&3)N(#8M+9=
MC4_$^/;B>C3X]X85R&$4R_G=Q^'EU?H5;25U,Y-/OKL:0-<-VSQ\@+PL<_F]
MPB^DO):H!HY?)I%EB7(!&;'T&LF<HM0,)8-PU(1]Q!VXOT3OIZ# )7>_#Z[7
MGVFLV?]HTQDJ"<KFBZ+,;"%[(D'P#=4F/TD6!#RYJKZI0DNQ>W9Y&<O84N(C
M.TQ,3W_2GO;QR]GP<H,'UQ_* B'Y1'P8_/O+YPU[L2":;7.T'T:71L")N#D;
M#3_?C=?O+)WF%LX)".]1W5Z-61C!;.FI7"G\2\-*&QCT"+*#WC\[/S[LE'I9
M.5]1#<#)EG$XS^7$$IP3Y7).FAGC5QV3#\!Z$U22]5#225_LM@_V>NA9\PS[
M%_MV;I#GA2HF4 !JDQTC"SXJ/J >T<U!R%H\@&;:1'9*9UKS5$70' CAB=**
M:U@KCE[WQ-ER_WU$_QMVQXBZ$84YTR6@N#9; HZI-)$%'I0@Y8:US$H?\" >
M7M=LVH#DP)@**T8J0I,ATPIQ=+C_SS:""X"(4$2&Q+E*HE.>'3&=.12[_+/=
MM!>QH@/+$>DZT$*V=.%3+MDQHPTW!N((.:M,,+I@59<HNZP^-!J@Y0/X1(J-
M2<+/+$*7@A<9Y>O4 EX1.C**^H#MZ&2&#<R4S$.6T)E^X>$EU/JG&G79L\C3
M;MS&@,T*20JFHTJTR3/;[XG+D"*5'KU"0I& KU;#Z'M(J'#&8QF7W!XV2(DO
M][CA1/1E<SP1D]/A]?!V<'F!K#5"!0D*DZ@R=)V$\0)8A@R M.'UZ6AXB:2_
M&@TNS^,NF<+]157(R:9='^^N+@C5&3<O+WX?G,:=R/=</^@M.T?#JXLSX"R1
MA18SF;:ZND,/J<6JGU%*C_R^KJ!>_MF"VL*>7[3L^<5V#DP-(X(=^J\)+'T=
ME=XN!HR#\I7X#_MBBA0P,AK>J_V"FC3^*64/PI43><5<Q\][O%5['B:X*\#W
MZ&(JJ1PS+924 SY@H5%47 3>5#923*5VRQ-H,^FT]G#:@"( =RO ST'&4\X
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MS2>VBNY/4)E,U\E:M<G[T=D<@"79YWC1AC41Z8M!$BJ>M:)Z%/54(^PN<M[
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MO=B)@TGS3[ E?P<&,Q/@E/_,%+#3T0*\GUH,)/4_=$#[I:AW_P-02P,$%
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M/T^BD_$%Q%AXDXXU](4K);[;)BT@+8D9KN5A]H?HZN;S.!)__E. [N^%]&@
M-6L]0=M,FFE-1AZ*JTGO==UM1&#;4,S',IZP#-?UAB9^;<O%XIX70J!EA+ O
M%),RS=E35=)DL191K8MR_GPH)C<7U^/HYPCFA9VRMG <,LD*))EJ69COA Y6
MBK+?YPH$J/]2B5E:*7#/H8C.[CZ>7UX=P%$FYBY-6']^^7N28I.PT[$&4$[.
MK\]OHLN+_JLE36C2MJL^<F+;7ER-H\NSU7C7AVK<]#WD2VX^7%[\%)VLQD*
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ME/\'Z#0P7<9;Z+B( $*@[YI,L-*P Z(EC/%=1J=M2#= R&V0JN]:Z')L(CG
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MJE'Z$6WUHHOG.*N?>X>!3J=?G1"J]JYT FPTD(4H4&5*,/'X#J^%BM7=DM@
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MQ^23J$[35MH/7;2X3FBDO#'J!K8/PM!F@.J=@L8&+\B3GW]*J$=_L2WAGN(
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M"*!_(83>5,P$W>^>RW\!4$L#!!0    ( '6"5%,N!DVU3P4  ,T1   9
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M$\IL75^3Z@^KUNYJ,E>6+CINF-'-$C4OH/]+I>SF@PUL[ZJC?P%02P,$%
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MYO<,K6?@^\IP6/8'KV!X(5?_ E!+ P04    " !U@E13NPUUJ"D$  "."P
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M9ZESEK[!62X;$$ES5XOT9-?$*I'7'0X*"RC@R$2O*K2LJX(;;+2!Z*]%;BQ
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M$6IG0-\+I>Q><0'Z?]OL!U!+ P04    " !U@E13"Z&R%;X$   "#   &0
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M(L N+L">2_O7)K=H7/?\OD*PG B6@6!Y@>!;)W,POMH&6FV0Y0+(J-^>J^L
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MR"J5(U,%LDO5<*J43Y7QE&Z.P(067L)"8)0:XT1/S16"$XPZPS:G# F AC,
MD-4MBQ24EIJ1.0,)IG8X9]:/&\G:BSQ'8)QI/[Q\F):T':P) K-*GF*,029@
MX4S08*RO,C*074;'I8Z!"#,VF+JZB\:%S[TL-,=@0K4E+T9@@GNPI(9)%R9/
M[#X8) (63@3__/U^=GEW%5HZT%@F1F8)])>%][6]6)+>NDK&VNLZQV!4>;M$
M!$9EM4ULBR*&$]K=3C:G#'F A?- S52W(C+06:9')@S$EX7WN;T(,\A.@OIA
MY<,X\;>*",Q(#Y;4,#>L##L55I  6#@! %E]Q9"#UG(R+FL<=)>'M[M]6*N[
M:+ FZ$2W6,-@E'EY#($IJSS6,)@0IX*,@_KSL/I_FMW<_GXW"RV>XVB,;&EP
M4%X^W-2HNV@0X"WL'$>U4Q:"TL;+6#B*6/?O!&&0"'B'P;$GK%L5.0@M']GH
MX"# ?+C547?A"A1ID]8)B;LA21#2G"#(/N^P-X[T]-9!T%@^LM$A0'+%<*-#
M()Z#'U\XJAU?" J)+QS5)[X$9  1S@ W]]%A\G?HY)O]@M"*D;T. 3HLAGL=
M=1?NM5_M[MI6A_#-"6J-:)M9,8*KMNJFO:=,$)QBS#H[GN:4'8\[G \0UKH5
M4H#HBI'=#P%B+(:['\+W(0SGWC=I!$8YE>V=2HS@J@V-;P@C.$'UR4V(@*P@
MPED!9Z^O@ H09S&R(2) J\5P0T0@%D;U?<T+0A^FE/6V_PB,4:D]1P3#D<;W
MA.8/+Y S9#AGW-]>_7PW^U=H+RE!AN7(!H@$99;##1")6!;",Q+G&,R*=F#&
M"(P*Y>$2Z3L@E4B?\/0EY <9S@\'HKH54H( RY&M$.G\PC?<"I&(*<&M9X5@
M,,,\*P2!":Z][0D"4\R<#"Q("3*<$AR^^FJB!.V5(ULB$N17#K=$).YU\#9Q
M"(Q2;U^"P"BIMI]M341PEKF_U31G#%E AK/ +/[\4W)]$_HQ&N15C>R"*!!?
M-=P%4;XA03R::E#H>QH":7L?P5Z:4P315V'1KYGIED %LJI&MC\4J*T:;G\H
MWXQ "!+=!/D0CZ!0+\TI@LJKL,H#07TU3SD'.T8V/!3(JQIN>*ANPZ,;$G=#
MDB"D.4$0=146]<ODY^1V=AWZ046!7JJ1'0X-<JJ'.QS:]QLH(]XN H7Y_CP"
MXXK[QVZZ8,T)@ZCKL*@?B.J6/ TJJD<V-32HJQYN:FC?U&@'4C<D[H8D04AS
M@J#I.JSI#C]]%4^#FNJ1#0P-XJJ'&Q@:<2:PP,)@2& AAT&PP.J"-2?LG-[K
M.+QQ<S>[CD,"J$%-]<@.A0:MU<,="NU[!5)[/A.&\HS@&$%1C9PZ1&"*G3QU
M"'IO.@YL[%GJ5C\#BFI&]B@,"*T9[E$8WRUHJU\W).Z&)$%(<X(@[R8L[T!/
M7_$SH*QF9&_"@,Z:X=Z$0<Y?^$&%H?R@0E!84&&P0%"!UINPUG^ZOOIM=AF2
M/@,R:D8V(HQS!'FX$6&0LQG"\V8QE'_@&D%I.1'$^6L?Z,6:T%.&A '1-V'1
MKPGK<?@:A-6.[$M8$%P[W)>PG9;#O!L2=T.2(*0Y09!YVW$:XTA/7Q6TH+!V
M9'O"@N#:X?:$1<Y=^/&%H?SX0E!=\84U.1E?%O3?AO7_<ID5R_5RM<A#OQI;
M$%@[LE-A07_M<*?"^C4AC/@G#%&85P 4(S!%B7?T"8%):QPKJSEAR *VP[D
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M_Z3,7G?WA?F2E66VWCU\21>/:;X%5.\_95EY>+(=X'CWHHO_ 5!+ P04
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MO^PIR["04Q9;O&" =QJ4I99KVR,KPR0W9A.]=L-F$WH0*<GAAB%^R#+,_EU
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MEZSL"LN)H(5N>QZHD$V4'B:RDP:F#.3W/:7B-%$$=6\^^PI02P,$%     @
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M:2NDY@MT5!OA#.*-L<K,2^55DQ A#;,[0'7#*_T/',9P4W6=E\IK-L%FO#M
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MGKOGSK&ODZU4WW4)8,AMQ86>!J4QF]=AJ/,2*JH'<@,"GZRDJJC!J5J'>J.
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MKI*M4L\NN,NG0>@$@8#,N@P,7T=8@! N$<KXV>8,NBT=\7Q\RG[K:\=:MLS
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M"I"_+TO9^/I$#=!LPD]^ E!+ P04    " !U@E13"0"(F@0#  ","0  &0
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M]AM4?@+%%]&$ZR?:EK&A;:"HX(*F%5C.("59^<;O51X: ,G3#G K@'L(\$\
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MLL!A&;0+P.=;I>S3QHUCW?B]^@-02P,$%     @ =8)44[+:SIA/!@  O2,
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M%/3,A@@E'\.)A&P\,:#*MEXOS2U,G9&!D:&D9&CGY FG!E09>G FM#"U5LB
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M;M4*17J UYKME;!H 2Q;]NBF \RU]&GMBTPGUT[8ZK9=E1I$-5=0V5T%%@O
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M/<-,)Q=Q7$LZ23:(:JZ@PH[1!9P^Q!%?'T?F9$-8GO<?FOQ$ZP&,^Z,7>GS
M9G]HH6>8]>3J#)8.B5\.HIK[NF)04YW:07I]-#@C"5F&)$'+-(I(]A/-!T#N
MCUX/"@"4@U$/<@;R 4U73DH'4<T#^1!GA_D"" .!/@S@26 8OZ(;FH1IQA5B
M8[;<TO)>EFZ\ )B#T6M* <!LH,^G1;>3LMN-=832%GIA?"A^517U]N=KJ@/
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M_MA!I-]&Q"&XSA\8_L"S#J+.7OCD<+A3%XVWS7[UMMFO8?A%)D#XS0&S8\_
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M*$UT9!B.GN(XFZV6Y=@C6RWI7B1Q1AX9X/LTQ>S]GB3T<#N#L^/ ]W@7B6)
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M"0?P&YB#'T\;\/7+-_ %Q!EXB)-$)I@O=2&M%SKTH+9T7UE")RR9X(%F(N+
MST(2*N0WT_*+"7E=>MVXCHZNWZ-)A4\DUX!I_ *0@:!B/NO+Q0V5.S]GW?^P
M]5XPS*8.S%*?>4I?U2@ W0)>E$2Y^D(0T%2V)([+14W>BF<",.<TB+&0WP^Q
MB$ 8;[>$R<H!.:,[AE,._KY[YH+)+O#/Q-RL9FY6.3=KLD9/3TA5BY5&I]18
M-,O7U=QV-6>IOW8SK$"9MF;U41L%"GJ.!OLP7P6S+0TUL)[S=N.\/>W\_EE0
M@1.5DY6DU['HH.&TUF.0N1@&8E.![ Y(,LW O[$BZ$#-5KOG-.XYD^ZM<1Y+
M[^+_9&[YJ3P'E MEQW%&4YI#;3$(P"6@C0+D:.8@ @J0U='4"X#;!,#]J>*6
M33=(]K+C%=VWK(0J' !GX1&CC(T[+@ZC4XQ5;,8@T]7<06S&(+@PARA?@;*=
M3J'UHN,UT?$FH_. V8O<+4D:#%[ /HN'9=!3NFB4+JZNUT&C)63CT[M=K;(;
M?+G&%[V_0>85(G9G,=>,/ :9(Y1?H[K=PSS1]6!G7P(GP_"'W([.7PDO(L_D
M#XN#XO&R2H"H-8.NKQ9:4H;FY]>".<Z9IWG#]"M0]K#A;10HB$;-TU?!#+>C
MK>]^R_MPFOC7F$> $R$2Z7].6'DNR@)2I6JR %IZA?;U%4#+CG":'C]4 ,YH
M.1K#[)^%;,Y#?*AD5O=$UEM"A-.,^-A)]-F%WA()]*XOSRTCP<7GYWEQ/L]G
M(9OS$+^&]/)L=/:9_=-72W1HFNBZ>>ZT]6;!R_U..3QUU&OI!,&K2S]J60BA
M3T]_K;*;%6NT]U6 YM[H@*- 06NX5_1K5+=2K!,UT!(<FB:X"VH@D"0P%>26
M39!U?270\A Z<\[[2 F,CV36,+EK)0@.*T!QN#-'/(_&Q\03IQ_4,AR:9C@_
MS1/Z3H[IS_<LB&000)[@;"JP+9T@]_K2WM(2FC[@?"CMWNBFP1INW=8*D#E.
M^Q@D%_YP?U^CW"YJV/WUSA5D2MBNO/OETJ5])JI;J&:TN5^^*V]5!^/W\&8-
M%>,;>.-7M\>M^NHR6YX1=W'&04*VTI2AN;(^674_7+T(FI<7H,]4")J6CQ'!
M(6$%0'[?4BJ.+X6!YI9^]3]02P,$%     @ =8)44^2;_/QZ P  7 T  !D
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M?T"D!OK^C'.UGJ0$Y0?5X!]02P,$%     @ =8)44^:KT20,!   I1$  !D
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MQ]'I!@JJ;;D%@5_64A74X%;ECMXJH%D-*KCCNV[L%)0):SZMSY[5?"I+PYF
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M<"[Q$<DX&O6"-ZE<9+6,CS(9N9/>:]E+9-0E,CJ;R&<IF+XA*RIR6L@;DH#
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MVDR_CZA,<%.2I/BO1B-KHY%5:V0I-+HG!0GR<%XK,"3/M*);U I<_J(U8D'
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MC/W= '%E21Y/62J L#CP6>\%?$RY4S#9G%3+GL#/()\1A<8BI'DJ?3F@67I
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M?/6BCM5%F2WJUQ@\9F69)?7'.0FF)*\(Z/=/65:N+ZH!-J]+.?\?4$L#!!0
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M@;AC3U]($= PM>>S(,G^!T^%K-4#_BX1+"R4I0<AC?*_WG.Q$24%!%L44*&
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MU75U'U3S@9!Q'Z8T\:AI1U4_@=YQ>D6*])&9*C-0S9Y_),3C_C:[R[F2#6C
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M-AI8[9&U]X<S1(%]+V/?,[)__1XV'&^0SZ5$H.WT6Z2G**!JS3UH:[NV6#6
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M@=V((Y@"T( A05"^!_?>1][F/>4UOQ./_P)02P,$%     @ =8)44Y>*NQS
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M7U__!E!+ 0(4 Q0    ( '6"5%,'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ =8)44VD8'=;N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ =8)44YE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !U@E13 PP?$"@%  !0%0  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ =8)44WF;[T66!P  2R   !@              ("!:PT  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( '6"5%,C6BJEB00  /@0
M   8              " @3<5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " !U@E13<SV1%^(&  #>'   &               @('V&0
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ =8)44P^Y[7A.
M @  :P4  !@              ("!#B$  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( '6"5%.C0I4EG @  #TE   8              "
M@9(C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !U@E13
MH I*#(L,  !E4P  &               @(%D+   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ =8)44V(4&:+W#0  1"0  !@
M     ("!)3D  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M '6"5%-6HO></ ,  .4&   8              " @5)'  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " !U@E131SRYXZ8)  !!&@  &0
M            @('$2@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( '6"5%,' -R!=@(  #8%   9              " @:%4  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ =8)44]"("MTW"0
M61H  !D              ("!3E<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " !U@E13?-_93H(+   4)   &0              @(&\
M8   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( '6"5%,G
M\CSOL H  ",E   9              " @75L  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ =8)44Z,$S@V.#   9RD  !D
M     ("!7'<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '6"5%.'^BJYAP0  *\+   9              "
M@6.9  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ =8)4
M4^!(-)2["@  1QP  !D              ("!(9X  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " !U@E13Z) ^;#<&  "?$0  &0
M        @($3J0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( '6"5%.NF62,*AL  &5C   9              " @8&O  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ =8)44\Y.PQ-7"@  ;R$
M !D              ("!XLH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " !U@E13M:U!!BH2  !J,P  &0              @(%PU0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( '6"5%-#LZM<
MX $  %\$   9              " @='G  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ =8)44UZ6Z-CA#0  ("4  !D
M ("!Z.D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !U
M@E13P6-0^V0)  #_&0  &0              @($ ^   >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( '6"5%/:&;'P@@(  $T%   9
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M970S,RYX;6Q02P$"% ,4    " !U@E13<@Z!@1,%  "W#@  &0
M    @(&K&P$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M '6"5%,2184I.@,  "T'   9              " @?4@ 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ =8)44[L-=:@I!   C@L  !D
M             ("!9B0! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " !U@E130M\(MB(#  #G!@  &0              @('&* $ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( '6"5%,+H;(5O@0
M  (,   9              " @1\L 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ =8)44Y@##K:8!   ,@\  !D              ("!
M%#$! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !U@E13
M[>H8]T("   6!0  &0              @('C-0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( '6"5%-YMILXYP(  %()   9
M      " @5PX 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ =8)44_S?9'LM"@  R4@  !D              ("!>CL! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !U@E13?%#4EUX$  !$%
M&0              @('>10$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( '6"5%.>;^<': (  "4&   9              " @7-* 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ =8)44X6>\JQY
M P  IPL  !D              ("!$DT! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " !U@E133 ITS;(#  #Y#@  &0
M@('"4 $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( '6"
M5%,;$C"4K ,  -T.   9              " @:M4 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ =8)44WN[QR)B @  *08  !D
M         ("!CE@! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M    " !U@E13Z!2SV$$'  !T)P  &0              @($G6P$ >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( '6"5%.&-;OO( ,  .X)
M   9              " @9]B 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL
M4$L! A0#%     @ =8)44RI=S*Y?!P  1#,  !D              ("!]F4!
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !U@E13H8&0
M9U@#  !5#   &0              @(&,;0$ >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;%!+ 0(4 Q0    ( '6"5%/2?#]04P(  & &   9
M  " @1MQ 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M=8)44XB)K%?Q @  ] D  !D              ("!I7,! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " !U@E13_1AD>ND$  "0%P  &0
M            @('-=@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( '6"5%,) (B:! ,  (P)   9              " @>U[ 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ =8)44^-^0:<3 P
MB@L  !D              ("!*'\! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " !U@E13LMK.F$\&  "](P  &0              @(%R
M@@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( '6"5%/S
MG9Y !P,  )P)   9              " @?B( 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ =8)44T'!L@'A @  ?@@  !D
M     ("!-HP! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '6"5%.<EO?(1 8   PA   9              "
M@5ZF 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ =8)4
M4U^U8[G0 P  Q!   !D              ("!V:P! 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    " !U@E13\E:V?1T'  !M+   &0
M        @('@L $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   ( '6"5%/[DMO=\@0  .@6   9              " @32X 0!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ =8)44[,>H 0#!   @@\
M !D              ("!7;T! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q0
M2P$"% ,4    " !U@E13_B#QD"4$  "O$   &0              @(&7P0$
M>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( '6"5%/DN37>
MW@0  +$7   9              " @?/% 0!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&UL4$L! A0#%     @ =8)44^2;_/QZ P  7 T  !D
M ("!",L! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " !U
M@E13YJO1) P$  "E$0  &0              @(&YS@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( '6"5%/^YEH9, 8  % :   9
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M970W."YX;6Q02P$"% ,4    " !U@E13;:_+M1X"  "5!   &0
M    @(%Z]P$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (
M '6"5%,_WZTG70,  #06   -              "  <_Y 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ =8)44Y>*NQS     $P(   L              ( !
M5_T! %]R96QS+RYR96QS4$L! A0#%     @ =8)44ZZ?7R:X!0  PC,   \
M             ( !0/X! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( '6"
M5%.[2=+?8@(  +0N   :              "  24$ @!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( '6"5%/=)VL+& (  (4M   3
M          "  ;\& @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !7 %<
*V!<   @) @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>703</ContextCount>
  <ElementCount>451</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>154</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2142110 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2156114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2160115 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2164116 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2168117 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2170118 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2172119 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2338306 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2345307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2350308 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2357310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2361311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2365312 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual</Role>
      <ShortName>Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenues - Revenues by product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails</Role>
      <ShortName>Revenues - Revenues by product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Revenues- Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails</Role>
      <ShortName>Fair Value Measurements - Nonrecurring Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2436423 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2469439 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2471440 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-20210930.htm">biib-20210930.htm</File>
    <File>biib-20210930.xsd</File>
    <File>biib-20210930_cal.xml</File>
    <File>biib-20210930_def.xml</File>
    <File>biib-20210930_lab.xml</File>
    <File>biib-20210930_pre.xml</File>
    <File>biib-2021930xex311.htm</File>
    <File>biib-2021930xex312.htm</File>
    <File>biib-2021930xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20210930_g1.jpg</File>
    <File>biib-20210930_g10.jpg</File>
    <File>biib-20210930_g11.jpg</File>
    <File>biib-20210930_g12.jpg</File>
    <File>biib-20210930_g13.jpg</File>
    <File>biib-20210930_g14.jpg</File>
    <File>biib-20210930_g15.jpg</File>
    <File>biib-20210930_g16.jpg</File>
    <File>biib-20210930_g17.jpg</File>
    <File>biib-20210930_g18.jpg</File>
    <File>biib-20210930_g19.jpg</File>
    <File>biib-20210930_g2.jpg</File>
    <File>biib-20210930_g20.jpg</File>
    <File>biib-20210930_g21.jpg</File>
    <File>biib-20210930_g3.jpg</File>
    <File>biib-20210930_g4.jpg</File>
    <File>biib-20210930_g5.jpg</File>
    <File>biib-20210930_g6.jpg</File>
    <File>biib-20210930_g7.jpg</File>
    <File>biib-20210930_g8.jpg</File>
    <File>biib-20210930_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20210930.htm": {
   "axisCustom": 5,
   "axisStandard": 32,
   "contextCount": 703,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20210930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 709,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 15,
    "http://www.biogenidec.com/20210930": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 23
   },
   "keyCustom": 84,
   "keyStandard": 367,
   "memberCustom": 76,
   "memberStandard": 68,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142110 - Disclosure - Indebtedness",
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "shortName": "Indebtedness",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156114 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160115 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164116 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168117 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170118 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172119 - Disclosure - Subsequent Events",
     "role": "http://www.biogenidec.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338306 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350308 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365312 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Business Acquisition (Details Textual)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
     "shortName": "Business Acquisition (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i459ef874f9bb4653ad831f334286be02_D20200301-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenues - Revenues by product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
     "shortName": "Revenues - Revenues by product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i23640bd50272420a8b057701d4f91e71_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id6475881e6d0430cbc6e4826b376d1ac_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
     "shortName": "Revenues- Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "ifb75ba94b11d4a699b755fdc629e6cbd_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "if1bfcb48e77b46bba81990b5298288bb_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Revenues - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "shortName": "Revenues - Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i99f198b587194af1b052efd3339aa9ac_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id6475881e6d0430cbc6e4826b376d1ac_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id6475881e6d0430cbc6e4826b376d1ac_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i2a7a60146fc349eab4e74a420635d5c4_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "ie8d75b9475054c6aa2f4631f5a8ef20c_I20210930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "ie8d75b9475054c6aa2f4631f5a8ef20c_I20210930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
     "shortName": "Fair Value Measurements - Nonrecurring Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i62da2a34c97c48d6aeda37f1d81d2aa4_D20201101-20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436423 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "if7c54edc6349456abaaa90d10aa21a29_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:DividendYieldPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id6475881e6d0430cbc6e4826b376d1ac_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id6475881e6d0430cbc6e4826b376d1ac_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "if5c2e8e8d01b426285c6bd058cbb4b5a_I20191231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id6475881e6d0430cbc6e4826b376d1ac_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i378cd243ed9e40c2932d604d62dcff73_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "ibade6508c50c4f938133f3c022f3073f_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i4e7708356fae41b9a13302bb04211203_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i4e7708356fae41b9a13302bb04211203_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "ia2f98bd41f384786a46e50b06a48f2d3_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i9dfbdf5f58ea4f80b7d120f4da5dec4a_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5a5dec6bf41c4a37a79d8a1cc7f4a7da_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id6475881e6d0430cbc6e4826b376d1ac_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i5d18c26ba9bc4d29a05c6475a9ebe3b1_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "icccb66447d924c0594b928f60f204b02_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "i7b972473b78a41948835d5e6b4829ce2_I20181107",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469439 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id6475881e6d0430cbc6e4826b376d1ac_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id68d34303bce4a2db8b2455c5f1c3285_I20210715",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471440 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "id68d34303bce4a2db8b2455c5f1c3285_I20210715",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210930.htm",
      "contextRef": "iae01ce2ab65042b092f71daff18fc95e_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 154,
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2.90SeniorNotesDueSept152020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "label": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "terseLabel": "2.90% Senior Notes Due Sept 15, 2020"
       }
      }
     },
     "localname": "A2.90SeniorNotesDueSept152020Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3250SeniorNotesDueFebruary152051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.250% Senior Notes, Due February 15, 2051",
        "label": "3.250% Senior Notes, Due February 15, 2051 [Member]",
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051"
       }
      }
     },
     "localname": "A3250SeniorNotesDueFebruary152051Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ADUHELMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADUHELM",
        "label": "ADUHELM [Member]",
        "terseLabel": "ADUHELM"
       }
      }
     },
     "localname": "ADUHELMMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AccruedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Milestone Payments",
        "label": "Accrued Milestone Payments",
        "terseLabel": "Accrued milestone payments"
       }
      }
     },
     "localname": "AccruedMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions [Abstract]",
        "label": "Acquisitions [Abstract]",
        "terseLabel": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "AcquisitionsAbstract",
     "nsuri": "http://www.biogenidec.com/20210930",
     "xbrltype": "stringItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Additionalreductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional reduction in royalty rate payable on commercial sales",
        "label": "Additional reduction in royalty rate payable on commercial sales",
        "terseLabel": "Additional reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Additionalreductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdministrativeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative Space",
        "label": "Administrative Space [Member]",
        "terseLabel": "Administrative Space"
       }
      }
     },
     "localname": "AdministrativeSpaceMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111AndBIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 and BIIB112",
        "label": "BIIB111 and BIIB112 [Member]",
        "terseLabel": "BIIB111 and BIIB112"
       }
      }
     },
     "localname": "BIIB111AndBIIB112Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB118Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB118 [Member]",
        "label": "BIIB118 [Member]",
        "terseLabel": "BIIB118"
       }
      }
     },
     "localname": "BIIB118Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiologicsManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "terseLabel": "Biologics Manufacturing"
       }
      }
     },
     "localname": "BiologicsManufacturingMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Term",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContingentMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Milestone Payments Made To Collaborative Partner",
        "label": "Contingent Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Contingent additional milestone payment"
       }
      }
     },
     "localname": "ContingentMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentRedemptionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Amount",
        "label": "Debt Instrument, Redemption, Amount",
        "terseLabel": "Debt Instrument, Redemption, Amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionAmount",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_December2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Share Repurchase Program [Member]",
        "label": "December 2019 Share Repurchase Program [Member]",
        "terseLabel": "December 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "December2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredTaxAssetIncreaseDecreaseInValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Increase (Decrease) In Value",
        "label": "Deferred Tax Asset, Increase (Decrease) In Value",
        "terseLabel": "Deferred tax asset, increase (decrease) in value"
       }
      }
     },
     "localname": "DeferredTaxAssetIncreaseDecreaseInValue",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxAssetsValueReductioninValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Value, Reduction in Value",
        "label": "Deferred Tax Assets, Value, Reduction in Value",
        "terseLabel": "Deferred tax assets, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxAssetsValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax Liabilities, Increase (Decrease) In Value",
        "label": "Deferred tax Liabilities, Increase (Decrease) In Value",
        "terseLabel": "Deferred tax liabilities, increase (decrease) in value"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesIncreaseDecreaseInValue",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesValueReductioninValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Value, Reduction in Value",
        "label": "Deferred Tax Liabilities, Value, Reduction in Value",
        "terseLabel": "Deferred tax liabilities, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DenaliTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denali Therapeutics Inc",
        "label": "Denali Therapeutics Inc [Member]",
        "terseLabel": "Denali Therapeutics"
       }
      }
     },
     "localname": "DenaliTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DividendYieldPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Yield Percentage",
        "label": "Dividend Yield Percentage",
        "terseLabel": "Dividend yield percentage"
       }
      }
     },
     "localname": "DividendYieldPercentage",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "label": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "terseLabel": "Payment of early call premium and write off of remaining unamortized debt issuance costs"
       }
      }
     },
     "localname": "EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "label": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "terseLabel": "Neurimmune tax impacts"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationNuerImmuneTaxImpacts",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "terseLabel": "Equity Securities, Current"
       }
      }
     },
     "localname": "EquitySecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "terseLabel": "Equity Securities, Non-Current"
       }
      }
     },
     "localname": "EquitySecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Axis]",
        "terseLabel": "Facility Type [Axis]"
       }
      }
     },
     "localname": "FacilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Domain]",
        "terseLabel": "Facility Type [Domain]"
       }
      }
     },
     "localname": "FacilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "label": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "terseLabel": "Global licensing collaboration agreement, amount, shares purchased (in shares)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementAmountSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "label": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Selection of Targets"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentSelectionofTargets",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Purchase Price Per Share",
        "label": "Global Licensing Collaboration Agreement, Purchase Price Per Share",
        "terseLabel": "Global licensing collaboration agreement, purchase price per share (in usd per share)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPurchasePricePerShare",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "label": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "terseLabel": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "label": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "terseLabel": "Global licensing collaboration agreement, shares, purchased (in shares)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "label": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "terseLabel": "Global licensing collaboration agreement, shares purchased per share (in usd per share)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchasedPerShare",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "negatedTerseLabel": "Equity in (income) loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_InnoCarePharmaLimitedInnoCareAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InnoCare Pharma Limited (InnoCare) Agreement",
        "label": "InnoCare Pharma Limited (InnoCare) Agreement [Member]",
        "terseLabel": "InnoCare Pharma Limited (InnoCare) Agreement"
       }
      }
     },
     "localname": "InnoCarePharmaLimitedInnoCareAgreementMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Investmentincommonstocksharespurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in common stock, shares purchased",
        "label": "Investment in common stock, shares purchased",
        "terseLabel": "Investment in common stock, shares purchased"
       }
      }
     },
     "localname": "Investmentincommonstocksharespurchased",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "terseLabel": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20210930",
     "xbrltype": "stringItemType"
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "terseLabel": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "localname": "IonisSangamoDenaliAndSageMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LongTermDebtExchangedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Exchanged, Amount",
        "label": "Long Term Debt, Exchanged, Amount",
        "terseLabel": "Long Term Debt, Exchanged, Amount"
       }
      }
     },
     "localname": "LongTermDebtExchangedAmount",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ManufacturingAndOtherCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and Other Costs",
        "label": "Manufacturing and Other Costs",
        "terseLabel": "Manufacturing and other costs"
       }
      }
     },
     "localname": "ManufacturingAndOtherCosts",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_March2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2019 Share Repurchase Program [Member]",
        "label": "March 2019 Share Repurchase Program [Member]",
        "terseLabel": "2020 Share Repurchase Program"
       }
      }
     },
     "localname": "March2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NoncontrollingInterestCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Capital Contribution",
        "label": "Noncontrolling Interest, Capital Contribution",
        "terseLabel": "Capital contribution by noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestCapitalContribution",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NoncontrollingInterestIncreaseDecreaseOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase (Decrease) Other",
        "label": "Noncontrolling Interest, Increase (Decrease) Other",
        "terseLabel": "Distribution to noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseDecreaseOther",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Product Candidates",
        "label": "Number of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Square Feet",
        "label": "Number of Square Feet",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "NumberOfSquareFeet",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "biib_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholesalers",
        "label": "Number of Wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_October2020ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2020 Share Repurchase Program",
        "label": "October 2020 Share Repurchase Program [Member]",
        "terseLabel": "October 2020 Share Repurchase Program"
       }
      }
     },
     "localname": "October2020ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherresearchanddiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other research and discovery [Member]",
        "label": "Other research and discovery [Member]",
        "terseLabel": "Other research and discovery"
       }
      }
     },
     "localname": "OtherresearchanddiscoveryMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "terseLabel": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20210930",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Completed technology"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageParValueOfSeniorNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Par Value Of Senior Notes",
        "label": "Percentage Par Value Of Senior Notes",
        "terseLabel": "Percentage par value of senior notes"
       }
      }
     },
     "localname": "PercentageParValueOfSeniorNotes",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential future milestone payments commitment to third party"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "label": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "terseLabel": "Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain"
       }
      }
     },
     "localname": "PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20210930",
     "xbrltype": "stringItemType"
    },
    "biib_Reductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in royalty rate payable on commercial sales",
        "label": "Reduction in royalty rate payable on commercial sales",
        "terseLabel": "Reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Reductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Costs, Percentage",
        "label": "Research and Development Costs, Percentage",
        "terseLabel": "Research and development costs, percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenue from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SageTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sage Therapeutics Inc.",
        "label": "Sage Therapeutics Inc. [Member]",
        "terseLabel": "Sage Therapeutics Inc."
       }
      }
     },
     "localname": "SageTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Common Stock [Member]",
        "label": "Sangamo Common Stock [Member]",
        "terseLabel": "Sangamo"
       }
      }
     },
     "localname": "SangamoCommonStockMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TECFIDERAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TECFIDERAMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TechnologicalAndRegulatorySuccessProbability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technological and Regulatory Success, Probability",
        "label": "Technological and Regulatory Success, Probability",
        "terseLabel": "Technological and Regulatory Success, Probability"
       }
      }
     },
     "localname": "TechnologicalAndRegulatorySuccessProbability",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Termofcollaborationagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of collaboration agreement",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "Termofcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "verboseLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax",
        "label": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax"
       }
      }
     },
     "localname": "UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax",
        "label": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax"
       }
      }
     },
     "localname": "UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_VixotrigineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vixotrigine",
        "label": "Vixotrigine [Member]",
        "terseLabel": "Vixotrigine"
       }
      }
     },
     "localname": "VixotrigineMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "terseLabel": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20210930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r383",
      "r384",
      "r391",
      "r392",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r383",
      "r384",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r191",
      "r295",
      "r299",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r315",
      "r318",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r497",
      "r551",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r315",
      "r318",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r497",
      "r551",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r191",
      "r295",
      "r299",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r188",
      "r295",
      "r297",
      "r499",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r188",
      "r295",
      "r297",
      "r499",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r305",
      "r315",
      "r318",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r497",
      "r551",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r305",
      "r315",
      "r318",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r497",
      "r551",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r295",
      "r298",
      "r553",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r295",
      "r298",
      "r553",
      "r578",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r261",
      "r316",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r472",
      "r474",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r18",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r15",
      "r505",
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r61",
      "r66",
      "r68",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r66",
      "r75",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r66",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r64",
      "r65",
      "r66",
      "r532",
      "r560",
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r63",
      "r66",
      "r68",
      "r129",
      "r130",
      "r131",
      "r390",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r56",
      "r66",
      "r68",
      "r390",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r331"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r320",
      "r325",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r207",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r109",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r116",
      "r176",
      "r180",
      "r186",
      "r220",
      "r383",
      "r391",
      "r442",
      "r503",
      "r529"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r52",
      "r116",
      "r220",
      "r383",
      "r391",
      "r442"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r198",
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r202",
      "r205",
      "r526"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r202",
      "r204",
      "r525"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r195",
      "r199",
      "r227",
      "r509"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r197",
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r197",
      "r227"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r321",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r407",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r314",
      "r317",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r368",
      "r369",
      "r371"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r368",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r368",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r106",
      "r111",
      "r112"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r106",
      "r447"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r374",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r260",
      "r512",
      "r537"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r83",
      "r518",
      "r545"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r82",
      "r381",
      "r382",
      "r400",
      "r517",
      "r544"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r81",
      "r380",
      "r400",
      "r516",
      "r543"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r511",
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r306",
      "r313",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r86",
      "r499"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expense"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r504",
      "r506",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r118",
      "r276",
      "r279",
      "r280",
      "r281",
      "r456",
      "r457",
      "r459",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r109",
      "r117",
      "r349",
      "r355",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax assets, gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred tax assets, unrecognized tax benefit"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r109",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r109",
      "r173"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r53",
      "r54",
      "r409",
      "r479"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r53",
      "r54",
      "r409",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r408",
      "r410",
      "r417",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r406",
      "r408",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r415",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r120",
      "r462",
      "r510",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r84",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r144",
      "r149",
      "r150",
      "r151",
      "r155",
      "r156",
      "r519",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r84",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r144",
      "r149",
      "r150",
      "r151",
      "r155",
      "r156",
      "r519",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r338",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r338",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r338",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r338",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "TECFIDERA impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r338",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r338",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r338",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r158",
      "r221",
      "r275",
      "r282",
      "r328",
      "r329",
      "r330",
      "r351",
      "r352",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r32",
      "r177",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r440"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r215",
      "r547"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Net gains (losses) realized during the period on equity securities",
        "verboseLabel": "Less: Net gains (losses) realized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r215",
      "r547"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "verboseLabel": "Unrealized gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Net losses recognized on the decrease in fair value of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r429",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r430",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r429",
      "r430",
      "r433",
      "r434",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r306",
      "r307",
      "r312",
      "r313",
      "r430",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r306",
      "r307",
      "r312",
      "r313",
      "r430",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r430",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r435",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r437",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r407",
      "r412",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r242",
      "r244",
      "r247",
      "r250",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r247",
      "r501"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r242",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r247",
      "r500"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r306",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Derivative, gain on derivative",
        "verboseLabel": "Gain on interest rate swap"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r408",
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r109",
      "r269",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r234",
      "r235",
      "r502"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r236",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r406",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r109",
      "r251"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r119",
      "r176",
      "r179",
      "r182",
      "r185",
      "r187"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r78",
      "r109",
      "r174",
      "r216",
      "r513",
      "r540"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "(Gain) loss on equity method investment",
        "terseLabel": "(Gain) loss on equity method investment",
        "verboseLabel": "Income (loss) from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r341",
      "r342",
      "r344",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r339",
      "r343",
      "r348",
      "r353",
      "r359",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r140",
      "r141",
      "r175",
      "r337",
      "r354",
      "r360",
      "r548"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expense and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "(Gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r243",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r243",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r241",
      "r245"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r76",
      "r172",
      "r455",
      "r458",
      "r520"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r50"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r26",
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r88",
      "r171"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by investments by consolidated and nonconsolidated entities. Includes, but is not limited to, variable interest entity (VIE) for which reporting entity is or is not primary beneficiary.",
        "label": "Investments by Consolidated and Nonconsolidated Entities [Axis]",
        "verboseLabel": "Investments by Consolidated and Nonconsolidated Entities [Axis]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments by consolidated and nonconsolidated entities. Includes, but is not limited to, variable interest entity (VIE) for which reporting entity is or is not primary beneficiary.",
        "label": "Investments by Consolidated and Nonconsolidated Entities [Domain]",
        "verboseLabel": "Investments by Consolidated and Nonconsolidated Entities [Domain]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r116",
      "r181",
      "r220",
      "r384",
      "r391",
      "r392",
      "r442"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r116",
      "r220",
      "r442",
      "r508",
      "r535"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r116",
      "r220",
      "r384",
      "r391",
      "r392",
      "r442"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r268",
      "r506",
      "r531"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r262",
      "r263",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on research and development contracts terminated with Eisai"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r49",
      "r116",
      "r220",
      "r442",
      "r507",
      "r534"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flow used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flow used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r106",
      "r107",
      "r110"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flow provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flow from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r79",
      "r110",
      "r116",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r140",
      "r141",
      "r148",
      "r176",
      "r179",
      "r182",
      "r185",
      "r187",
      "r220",
      "r442",
      "r514",
      "r541"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r72",
      "r140",
      "r141",
      "r387",
      "r399"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r282",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r14",
      "r506",
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r176",
      "r179",
      "r182",
      "r185",
      "r187"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r58",
      "r59",
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r66",
      "r75",
      "r448",
      "r450",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r57",
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r75",
      "r80",
      "r275",
      "r448",
      "r453",
      "r454",
      "r515",
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r70",
      "r73",
      "r380",
      "r381",
      "r389"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r407",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r40"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expense and other",
        "verboseLabel": "Accrued expense and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Payments for (Proceeds from) Derivative Instrument, Financing Activities",
        "negatedTerseLabel": "Cash proceeds from settlement of swap"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r94",
      "r98",
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r91",
      "r95",
      "r196"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedTerseLabel": "Payments subsidiary and affiliates stock"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Net distribution to noncontrolling interest",
        "terseLabel": "Payments to Noncontrolling Interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r100",
      "r103",
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r91",
      "r92",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r105",
      "r116",
      "r132",
      "r140",
      "r141",
      "r176",
      "r179",
      "r182",
      "r185",
      "r187",
      "r220",
      "r380",
      "r386",
      "r388",
      "r399",
      "r400",
      "r442",
      "r521"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r259",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets placed into service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r257",
      "r536"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r75",
      "r448",
      "r452",
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayment of borrowings and premiums paid on debt exchange",
        "terseLabel": "Repayments of borrowings and premiums paid on debt exchange"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of Senior Debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r334",
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r282",
      "r331",
      "r533",
      "r559",
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r221",
      "r328",
      "r329",
      "r330",
      "r351",
      "r352",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r77",
      "r116",
      "r169",
      "r170",
      "r178",
      "r183",
      "r184",
      "r188",
      "r189",
      "r191",
      "r220",
      "r442",
      "r521"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r66",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r203",
      "r206",
      "r209",
      "r210",
      "r211",
      "r213",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r408",
      "r417",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r320",
      "r324",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r320",
      "r324",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r116",
      "r219",
      "r220",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r242",
      "r246",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r114",
      "r159",
      "r160",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r383",
      "r384",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r158",
      "r221",
      "r275",
      "r282",
      "r328",
      "r329",
      "r330",
      "r351",
      "r352",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r158",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r275",
      "r282",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r17",
      "r275",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r275",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r16",
      "r17",
      "r275",
      "r282",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r16",
      "r17",
      "r275",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r116",
      "r194",
      "r220",
      "r442"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r116",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r220",
      "r221",
      "r282",
      "r328",
      "r329",
      "r330",
      "r351",
      "r352",
      "r378",
      "r379",
      "r398",
      "r442",
      "r448",
      "r449",
      "r454",
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r282",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Stockholders' Equity, Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r47",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r17",
      "r275",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r17",
      "r275",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r47",
      "r284",
      "r285"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r275",
      "r282",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r306",
      "r522",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r122",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r143",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r142",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3444-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r593": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r594": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r595": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r596": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r597": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r598": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0000875045-21-000052-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-21-000052-xbrl.zip
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M^>#1?O@^W/EQ'_;OW3T\"/?3G7OVK.<_^0>/[S_?OW<_[/^X'[Z)!X?WGY_
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M7%8L-X"W*24?KNZ]GK0[O7U<ESC$FT]23,4E5 ]<D<7%F&,8J0C%AKLSQ*>
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MUCG.B53S:.2[8U%+,X306XE-"H2H8B)DUQ\'74M+98$)TF2%:SO&+(&4RFA
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M)8\*P3'0"_;6F[B&+J8VA];$.R0'$QT*%GR^."H\)HBQ4NLQ^V)Y00@VWA=
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MZM0U1Y_5[KZ!4YN L!3[!AX# I89#Z>IP-E@:7LLB9BS:%8(?'%B5_>F39Z
M4I59CYR0W!O@6'3[2F5]SNMG/AE$<^EZU+1ZB"[0N'44B%48+,1A=FPPS6 A
M>4LAVN >)QP;0ERO*A;16F#'02BW'+5VQ<LC5L/E5&X(.#NLIK<.OY[I#>\_
MTQOV FYBIK>"259H7*1"ZM'2K1C%HGT(V1O<2\!Y@C$Y/;".FTNI0U1M4#U+
M):\&+?L*-;O+,S7R]LK@7/H:&69Y,[H88V0GO357&=KH*J+%J;26?:P.7^ZO
MNL9L$T*Y*<Q28PEF:,0W!N2&#00UFL&A7%0N[*:YSRWV,C/!S-/FVF@4])84
M)!]S&:>Z$G#Q.6L:%0SNY5FA;IM3A)E@-L;9II99&E<#*B+[" H9T\6D"-9D
MZN[;0I;'AOT<-O1@=?P;*RPS2?%\'PU!B\5#2M![HX#%7!@ N5:[FT%?T-O'
M3_3T;+SH7ZN!OCPY.C)T5GSX+=M-F0DFH_,*FC*YEA/$"D0D9OT)#*P8^@SJ
MM+8%D\WEV3VGT$K4D&, 4R",OM54.!?'*?8V[W%R5W\^'W54IWKCX5I?",]<
M!HN-DI*3L[&AX$(6JAEK;:5#8)49;!3?*F V-V)\;-TQ)2PEP&A%D2A7SL%D
M!6+/?=XC9O_D6)_M\_HG/?OJ_+C-9;0$CS9"2J[.%V@Q28M56O<5"3',88%Q
M:T#98+= #*K:N(=$0*-+BW,^ 0&H9($9' KT[T"9Y1F+74./"3B.7M6452R0
M%1=;D6QY)\Y<5>;9"BM 23[[3(%!1Z%$\%IB3=Y2RQ3F<.KZZIB/A_%]9W;Y
M&XW*OK3L7V=SRJ0#:N@*XC@PA10Y.>7.U!.*8)O!SKW_"*2#D^-YX=1]B@ZP
MM6@JDTQG?+<4,_82I#'Y&6P<^/<XO6[[,M>1%-BC=N$JV4.J30*[T1"K1)>C
MQQG,H_UQA.8WC"S[MTCGI8_]-Y0YIQ J.:]5'/8Y'*K[;T':/UF?/>2'>N.X
MW3E[I.MW[G"?&62NE)*+1NW_G[TW;6XJ6=:%_XJ"<]]SNR.0=\T#O2\1!ANV
M]\$V;9ON U\ZLJJR;($L>6O F%__9JTE>88V(%M:0DVT;6E-M2JG)[.R,HV*
M0CD%(D8OA%0)&/\Y2-8X05/*<QN$AH1EFQOABLQ,(@H*0X2S3>AY_E6J;?YG
M3(-MJDR!0).523XP4%EXYR0344H.@6%N/C2_3IWFB8]E":Q@+!%RD#Y[%PP!
M#&.LLTIQ6'QW=F%]IQE6/9$14HHH(HMDF1A8[X6-1!01('NSI$1Z(&&:'9V"
M"LE:IFD&"?1!*2YO./?)<R*>L4WH:K:0OM,,DV)#CD$$"]9YQ1P$JX1/W(J8
M9=!-R%M>6-]IAOLZC97":"M\0>'H@E8Z)<NL3-(TH\)S,WRG&2Y48.FFE@@V
M$&J(7CH>B5J8)<^6^R8D)C3'=YHAKB!$(4M@0I/O!#Z!\U)F$V0,V29L/*Z8
MA^\T2S1AM,X20N2E,D$ 2 84BXE,%J&_QMNJ.?E.,\S\<=9HB9ZHXU4RS@=R
MHD2..E3;,>IB26Q:+.E!*'6'J;BRL8'=O3;1M7G[@8T-4B7NP40>(RJ7G6=!
MY>Q<66U@1C9@5?OKC+T_*K[,82=>K+0V974;R( ;GU7RT:A@6>!D(S0H+<L6
M%-> +)"9D^;.3WX&77HR[A\ACE[U(XSHZ-75]0HZD)J+M9JK0$13%MD-J30!
MDL"=C<J1)<($TF:>'$\"8*+L^+FRXXLKO27M83>O#P:E8M]U!B&0=T!4@A,<
MCSIQN-6+][RWC$CT#2J8SZ8\7";\H#!%(Y57V@"!"_ L<08@. C?@#I_BTG-
M^13[,^BT*055)2KZ "7&P5..3A@7,YL $3^1S:92<P-[T.T\M'02D>XJG;.B
M9W9!)X]2,Z_*U@L"_L[D['4B"74Z+^[NIH2=)Z_P$+J;U7@>GGCWLG-)9"NX
M(F?,DJ'3SH W#B-CDJ/G/KD&R-?<"3-_J0*78I;,H2%/(P+SF(0C3]I(8-+R
M,*&BF%)1"+]H5+R;S>L=PG'_&D'7SG<)W#]I[[I5OCI5^!F0UB&([(1#YKPR
MV8>,WI"J5$;&A-8MKD?Y9;F<T+%LBNKW]D?]^*$A/J3@TAOK$N@ BN"(%S'$
MF(7),I/N3 V0L_E29?[R)**UV8OB\DG%18:D%2-/ST6R?$*Y!K@'MY1DW^[T
M.L?CXV7T $PD]0<F**>2\F@\,]HR"RI+161L*L'@T[(2+'*CP7J$(%")R,%)
MET105@IF4,,<8L>-D;"Y!*UY*O%0HI4G6!&3\R8E1%?69,@WTZZA!'L0"9L+
MP:+629L<I,A9&5%:DV)**3O+4K1N@3%A(4R]$C:M Q(GGYYLOMG[\4#U!DWB
M1QAU/N)%C'RO,_QPK>9(?X"=P][FI])%XQ"?T]P.(/Z=^W#G0?P+TV&G=[B!
M0WK(+;'RZ0%,Z\/)N1>C;0@2CDQ[,%YG;8125@<=(GJ+5FDG;%C@?+ 5"\Z5
M!6>8F&,,1R?+!@:G@F'!,^NB9$PFD?0B;^?Z"@L^_]>+%0LV1@MJFQVYCCRC
M9 I#\"9&!J7K,V!)8&ZD%ERQ8).T(). 40MAK$R*9QYBR":FF.@G1-6 &CU+
MSRH_)(SK&PNO!<D'49PII0)PA89YH33+00C,.<<F;+19L>!<6'"&'2F<B ">
MU)_@*O.2S0/$D:6#B-'*+?!FO*],_,MGKU>&N#%8,#C(7!LC@P>57/(*E<\^
M:QZ5D6F!,\Y7++@D6%!4GJ\D-JQJ9I )1F>#=@Z<%](VTR/^]^NW*Q9LC!8T
M-I+YY:@DDZKP6B(EB&"M16U]R(W4@BL6;)(6Y!!-%%HGGJ6R%H(@SR03$V8A
M8HX+C 57K/+ VHJ\!.<0,S&#5D1*KV5@ 9,WTEGN&]')<\4J#[-SFT40B@7B
M&%!2I9!R0A &-6. Z!=7JTQ28:=\L@VCLBOQ2N;747\P&N'@.%V<U0P!9CR0
M>Z]X22A7VO+2BUPEU-X1WE B-2 Y:$'(,_^\(:)A(KHY3P"2+#9Z(.RH12PI
MEC8JG-#2+C M%THK;_5B_QCW1T2.\OS;]^WM0_<^BN%>YR;[X-S$##B6C;7>
M&962]Z+T&7;(R+X[%Z9)37:!-S:LN.DV;F)WYZ;9;; (EI-1T=;QI%3FIK3[
M\5R6GM69A>@:KIN&+Z'3>]4?#I^=3?#9'G8K^@Z/.B>7RUG!\"AW^Z?# 7[$
MWOCO[-"*Q9NC,&6$6'G,@3,%*@)/09"RC#HJ2VS8<(6Y8O&%8O&Y:/%DH[0I
M@M'&*=!(2%-)+P"%CP$@-TB+WXF0NS0W]'7O<//3"=V@$:S<2-VIH\S9)*N8
M-,K[Y, JRYU4A#FU4Z%!NG/%6(NDL4JK76]*O>Z<E,4".(EW0&5+3DQ"O=)8
M\V>L!X8E_>D483U%2PE&K6,Z1I2@!5,\R2!9MB!L-BPGX+A2J"N^7TI]7_K0
MLM+?B6M%JC\@)K3)B"!$R(HW()Z]4*RW,/[.7"+JI76.<=XK:Z0R-KG2GRH&
MEGG0*;IX;6/GBIN:PDW?M.MT9J6;F 8NP5JL^OZ 2XDE7YJ>Y<R9%@W73:L
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M_KFX:+CTCJ5LF59!6A^=8R&0KC4A*24;E(O;0)+/)0T5DDQ*9#*I8%1(W+N
M(1D9,=@8DVV0E-]MZ6'2O?8\OEY?]0 +$0O.?7-1.$JEQ$%DXBNN$H"'+-"S
M[((LJL<V2.&LN*]QNB]S8BE(0:> RD8+:(@#%1AO>!3<-&C9M9DD?_@51QZ]
M! (Y(0BA)',@B>S2<*M1D96#!@6-5@JG<?&KJ+7*HJ1YB*PLETYD8Q@YR#E&
M9W1HD,)9<5_C=!^#DF41B*VR4282QN*<>]"16P#4"US7[J[9%L1JZ3SAHB$Q
MLF!XEA!+IK964D;O2?R]\9%4@^(\+GZ,;'&H,KO@%T% 5^VC2S:HJ&,I\\ Q
M1)L9C^0H-U]6'B0SZ1ETH1=Q_PCQ:R:B+L8\6A\.<70/B6[WTPHE)>,MRF1]
MJ1'*O/;1,1]25)IKXYHOMS\GA\PP@.YX"M(R%@U3P$/@NK3M9!&S"1P:T*^I
M21Q"5B8V4(U$C3*(P+U/03D1O4K.2:^%YD)9O<#=-5=,\F":).:<!#(=)7I%
MC.*3"$'E'*RU&AVL-,F,F&0]QL$8TZL.A$ZW,^K<1]K]O:@18#GQTH<H6U 2
MF L&I"AURC@32LB5&FDFA\Q.AP32$Y9A=@!,N2C <Z5E(O\_D0VR#4VD>?#=
M/=]L:.[.*3\T$=\2\"J;C%YT^Z?-2B8RI2@S1/*Z?%!<YA!LDCY(4GI:)V2+
MK^)6#-Q !IXABDLI.%*^*)Q3QC@(P'W2W E.&EBQ9FK@>XZT+Z5P-3'>Q1D
M@I3)L*C0B*"C5M)B\("8O6ZF^EUQ[R)S[PS1K^<\&0U):_*2@H*H0LP*<M#&
M"=F >/Z*>YOFN\VP>1U(CYXE38Z] @-.1&9="1(ZH3Q?X(;#*^YM*O?.4/>Z
M1)SI1<JEV(-(+H/,R)71HBQWY\77O;-<X6ZN-9YAS@-G)?4D.<Z#4AK! @8"
MD0RD39#\XNNS%4?,N).O#CG%I'ST6J&7$)@/BGD6A8LH%[B?^3TJ\+EPXZ+H
M"!]-\)B""):I)*7W/#KT()30V5B^^#IBQ1$_K"/.BT8,_Y-'-ZI&C$>#)^7
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M'P[@^!)-=^.H3]>6][C]W/L.R+ 9Y:M(8"+IZ RB\A%!E)K#F@"--2XXTZ#
MPB+2;/X1!<X,Q(R)!YZ4%H[\URBT0$!$S5UJD$9O H'G4&=)92=<#@J\4-G+
MD!**' QS4: 3#:ATLXATO9\R&KJ0!%UB/"AAA-/1A,2T*^8QZ&IK,_>+N"1Q
M9U)M8*PN+B_R\+3B?G9)6J!]] ) QZQ2V7X.3IBL,6#PDN<&5>M<2*+-OR*F
MESYYYD/4 95 $Y"ER*HBK=)[K1I4H*X1%)Y#BU4%+D>O?=E*X)ESD&+.,4F3
MJFJ$M;Y=Y,X9?TO8;: C<U.V5QI?_("R3=&3&<PV<K!*:1^<CXI8-H(52?(&
M%(8Y#QW5K8N>]X]/^CWZ.+R1!#D^'G=+(N(.CM[T!@C=SF>\U/IHND^D(0OZ
MW"N7G,Y @%.EX!R70F(2D+1W43<@N_W;*3<E$5'P\N9L? TE%;TAA+,RHN(Z
M6I&=0IL!#.<>=0H>H\T-2#G^=L+5.P;HO $>E;N535 E[EN(>;$QZO<QR60^
MZ_0.Z^(KN/DI=L<)T_D3Z"KZ@DYXW1]48>+1:- )XQ&$+A[T2S6!LF&JW^U6
M=5OJH'%#V"*"9E VD/K %&$?<D]42);L98AH1 .ZV'P[6VQ@[O0P/<,>_3%Z
MW87><#V]']?ZN"%TRR4ZGY!E)8U2R;K2:9A\%<(]45B$9:3;P8 H56^B;!R]
MDM5D)KTV.8**WGA+TYED<*2#K7&J26&YQ8<^\X_2:6Y""-:;[*62Y)@((8!E
M,"Y[PQ5?:GH_-&":/[D)3*68;(S*9\4CD=,D0E@BIA@"CTW*!/C98=;\F:FD
M&WJ( 4H!,).=8U7<.)$'+K5IQ,:?QH"S!:"VR"QE;Y7163FTP3I;H )*I:,,
M?JFI_4"0;OY45H%E*WR,UDF5G'28N43/ I=,"G0-6+5;?-AW+XMX"-H)^@&@
ML@)C? K,DMM,,"X0'1M0X6/Q =S]K+ZB%$[I[+(V58Q9.,C"9R%E1)"XC(1;
M+BAV/_599#9<6B-8Z?J:2((U:$L@/2K-"'8M(UO,+^(U.[HYY5R65DN1RI*1
M"T8QE,D[$9)*O %UXA<6'MV/^K5 EC-[%[U0D# (P8Q&^AF%)X^F <DO34(\
M,TR%T=PRH0B8,L]4#F0K57!<B9P%E'J^RTBY^2&>&1+.<:/!:\^Y,Z4$:-#*
M\\0(]D2GT*ME)-RR(IY9IK815\2@0 2"/#(EQY/4)G(N3.G:Q)>1+>:&>&9(
M-^$R0)11H2I%?6,P:!@HXP(O^U+E,M+MP1'/+.5,(GJKH^%1*V.SU]PDIJ(#
MSJW)O$D)AHL/?>:?;IB1>X)#R%@L"WP8O$X^H=1>1Q'0+C6]Y[K&-Q=R!QEU
MJ:L7LV+*"1<8-Y@2R;IS-C.]U.1>+I@U?V:RW'H@OM%HR+,R+(AHD <5<^F3
MF);;5LQSC6\^W<DSSTQF+4R9?)_!$_$S:LLDCQG-4E-['FM\<Z&RC\ZD7/I8
M(JK,&60K@;PM81P8&2;=SI>+N//-:I]5K%(%B6", >6R0K ^"9>B<BPRB&Z:
M'+U<E)MK5OO,%@62)-"=T#LM5 ;AM7=,0[ *@A<F+R/AE@N*W8\\\^"XC2J+
M:(M(0]*J[%CQ(08KIKM4EHLMYIG5/K-.OPJMC]JD9'TAGG=&:JU-5D:4;;G+
M2+=Y9+7/K.9N,#8'">!$4C+GD(4))'"Y-,+A43>IFL@#0Y\[#VP/8Q>&0WJ]
MND;5[GBTF^]@#JZ.^WOOLHPE4B2R'%VTW#M0,OG@$RN]F@P7/"8NF[35?\6U
M<^#:N90OT!FDRYYIKU&A(UT+@07@2@7%.+"ESA-><6U#\YY#=LB2S9(EIYB/
M(1.\DXQ4K@A1JN6.<ZZXMJ&1/&=3*4NLO9=>Q>Q#4;(J!.M,YL*&I<:U/Q08
M6C'MW& MR\$D*\$;+94UTD>.I6D4U^!S#'JI8>V*:9N):DOQ0A:B%\9Y)4I[
MF$Q^&'K.M,EHFU2 >,6T/PNH==QJX8PP K LYSKM2H55;D5&)JU<:E"[8MIF
M8EJ0RH#C"D EI:T-V@?/#!<N"X48EQK3+O":V4HDYH:855V>5T/4H)1S@4.*
M#C+W67*/8JD1\THD%EPDYH+'N9*1&^&D-$PQZ[S4I3D ,)0F!K;<=:I6(K'@
M(C&?$+:P+&I>>F8XQ8QU.G!,!/0]<F1,+#7:7XG$@HO$?+9"0$*CF8N:Q=*#
MPG$ILXQ,B"R9E;E!OL12,\=<4+5A7%KI(_"L%6CA6;!<H$B1\RR%;Q"J7FKF
MF N^%&!RS!$"ZE+& [PU/ ='5C4:XV.3:MLM-7/,!6G)3(3/*9JH49%S3H +
MP'K)N0,F;).VR2PU<\QG=XVIMF600YJC N4\,8(C*Q,"EZ1,?(,PQSK=(76Z
MXP*=]S&.!YU1!X=3S/QBT#\N-"5P7-$\;\*@1[!X^!H'5=>/9V>WW^!2FY #
M>N@?!*$Q[='/02?27_NC?OSPIM<9/4#!Y3DD=7KT1F3.0\PJ).]8SEE9<MMD
M LE-@U#'DK/'?-:9O9/*A.2\-XIF$5)04EJ;E0*69)/J<2\Y>\P'>7C@3,>H
MN<J*)1LRL\0?VD-,6C'6(.2QY.PQ%^R1A%6J9*@8,$JK""XZAEX[;63DJ4G[
M7.Z?/;9A\ %'RXTVA%22H68^\* XMY[K4'8+>U#":)M6:&-^##$7?"&)!8SG
MPF91.O-*KR,FPY,LZV8>F]0 8ND88BZ((C.N(B_5IJU5CH GHA3$'\B$"LXT
M*4=LZ1AB+AA"60LF!A>TR"I[X<D)X3:B21&E4DW*O[I_AJ!3<W]P#+V(%URQ
MCZ-1%U.G5WVUC+"":Y85<!D8<*71A6QTUK'LG+(8E5W!BH7BD;D@#="(SIB4
M5-$:#(A3(H;$D47KT36I7\S/P"-S 1]6 SBKR- 0&N7DN$:9K,PF!">"36D%
M/A:*1^93@9#(I87!R&PN.V\\EYS<6.V4S\F>9_HU 8_4BU[GR4VO^O5JV?6U
MM"&6YNGK-&7X$;O]DRH1ZM,)W6TI\S!$-E99;12RRB5UF4G-=)#9Z\Q-D_8#
M+CR!YX($C/?!*M0AY$3>A2^-JJ+Q+EE'__LF5818> +/Q8QCTD+'$EX$JWAE
MO'G23H(UJ#DVJ>+PPA-X/A7$,_="946(/BM)/Q5#U!9R=CQEC\MF@_>Q2O!]
MB3T<0)?(O)Z..[W.<#2HTH@GE%[*%0-3*E5:KZ7D98T10&J5N<N)9T%Z?.FL
M\6*0>CYV6:M4B$STEHJ(ZQTDY;1))F,.LDDYC@TB]7R:]UHKC(U@DT7ELG$H
M5!32<E IYT:5<6\0J>=BJU%FLL1:.8Y6A4!"[8, D7A0QDI8.EO]((T\YF**
M<_(&A5,>B)+&)$#)9-10+^&[I3/%#]6290ZK[C*3^DU9!G#**!E<R#F09Y1S
M*1ILE\W2/I1,SF.3I79)<"*1#0H-X6-OA-=E.X"67*ME,Z3+VR8)1/8N),6S
M=,HZ \J@9H%5S15$D@VRD^NG,$@'9R?XLV6WD9L*CLO(DB=PD\A0^DRPQRN,
M/*<FU<58 !+.Q3+ZLCE=L @%K>:R B"M-SSX!$IJ:%(=AP4@X7PRR"17BDA&
M<":H  BD1;6.B=N<F)Z$$9IA$A> A'.QA3)XALDZ&;-42=G R3 *PC=<2F="
MDWS&VT@X[WTB#V\9$P#R&!531%#R&4,.DF2RY'FF9!@VW#+.>V?''/:CD_\?
MI2]5\+QB-CG+8BE8@-9R(2:9,LVUD_.6T'DXDM%S"415@XIE"=I[%:30D3&"
MLDU:,UTX@LXG3XG$,1J-P;BH2F:L-DF!,UQQGHC.#;>AI8;J)-GL<B):R5U;
M2@LJ<R0TQ$#$9%4RW&G%O,DL1>&3"HW:.;58Y)R+_0Q",1Z%<D$K967I?ZY+
ME1];VC':U'0_<[[2^?#6D^D4HC9* %C%T)55+N$<<(6.9>4;;CWG*YT/;SM)
M+E%$DD29I K">!!.Q\"CD:7<;8-MYWD<_6>PF8GY0,HTDW!:A5P&T$QRXQ0!
MW9!R;J[-G!<9YV(K5>DBQ(, %$FA)3GDT@3G,#F1'4!S;>4<I?'A;62IA:RS
MDI$4*I$T.QXSQ B0' 8?8W-MY!RE<0XU3'D&8P.1![2R))J16\G)!Y&2!:6A
MN;9Q078US<548D#D@FA+9E$%@,"T],:" ,&=\TW*[5E,JL['<J+07'MON;#*
M,' NH@S6"AYM=KY1>UX7DJKS6>!TW,2 00HG5?;1>8$R:9:%9( N-->0+@A5
MYU.G,TC,KJQR>J68$"& ,4:3!$N(J5%]AKZ=JB7 L(QF%11G %H:YT!%ZX+3
M.5NMA<.2] Y+;58?@*ASL:KHLS,AY^R94C)E2%(I[Q6 \;99^U06DJCS\4X)
M%$'PZ#!EA<D"M]PX+3D8R6-J5"7+123J?.I/$E(2+ @%3JA(S@R3V3 ?/3!E
MO10-MZF;QR?=_AG6%'T]'L0C&.+K+O26T91RD9UFF$SINQBU#IDA]SQFI55
MU:3V&(M$R_GL],22-.0U>)F48S& #(CDQH E78M-ZEZ\2+2<3PEHQYA1G.AF
M5"D@'X(!GPWD+(71V3;<<,Y1+N>P[ND@!2DE$Y(,I$#G9)5_ZQ-F;R#\M;6H
MXC@<C)Z\'O33.(YV!_LX^-B)5]*_-I^_V-K8W%N?/=4Z/:(-G7M3J*9'OB<8
M((!+ )5I]FGZM>-*DZ!9DB,IM6A">LC\*#)_G4C$*Y6B EDUJ;A50;.(,:@H
MK+6N$3U7%H=\<U@,05%*!R4.2,J/!Q 2=%)(R--9\O,; #47A'QS09=6FRRS
M#BF5%4IA0D220**C4EZ2$]@ 1+(XY'MX$*))UC":D!6/"J0%@A\.>(PV*Q)*
MJ$"(6%2JG>]?WH_8 WKIFFS5H<DW+_H#C/"W?5I_#(N(F6$1C2 ""OJ%6BGF
M B%\Q%P*Y\D H0G&+&'GR2L\A.YF-9Y+DK35[W6&^] [A./^!I&GVUGOI7TX
M7,K*E@HM=XKQ0&9->2RU]8$[ACDX9IK1I'PA*?D@ '/<Z]1D/*GMPCEECA&&
MXP'6LS Y.+W']-CT<[G)K:P18PR&''B;O%"1::^"%RX;E@53@34I(E,<^-V\
M/A@0+U2:^+(WWQE"9TD8XJJ2]@S 1F<L9"5T -#>)@N:*Q^5"@U0TG^#>3:%
M81YZZ=GZ3MD[\3=$;!*WS,$0,.MBL)8S,NF9E5Y,T3/G4Y1<!;D$#LZ2<LM\
MHO52!AU<RN0(*R4=),^)CCDG4#FEW #;\'-RRUPL$?%)YAFU=PX5YP8L"L:1
M.>4$!]V$]8"?DUOFXNP;GQT!%C! ,(6G!*@PH],AB@(\W0JW?(%;'K#L:&,X
M>#X%JI4K#9&%#Z[05P-*PN#>H(P.P825=5QQ\&);;+J7<*6KMS91(6#PP&/P
M1?T&9E<6>\7!BXXB&(/$M"6.\EQY2?Z)RTRYS)4KI6V;X,\N$/WF4'617$I+
MMA%0)\5=!,9,4$8X)LB\GN?VJ2G]S(I^7Z&?NCO]S(QR,R$ZEB!:&[3*3OAD
M<Q:9214BJ/.,>#/%0 M(O[^Q(.L;;_ZU^6I[6;0T+Z2_,\Z8$9=X5\IO9N8)
M%BLFHG.(H52KSLR %MA\I+Q\7#*'E0SFC5')!<U+J3(.UAO@V4>/*F3!FQ\1
M6#XNF<,*AB7?1,5(Z$ K%R.4V)$0*BGC@D"SXI*';B2WXM>O5LT(T62?D7B3
MJ\""%\ 2EQE*N;<@6 ,\E!6__D0>F4'FG<PHM'>D4DL33?12).,=:M6(FDLK
M?OV)4&.V7B?NM!/D@:(,!!:-%UJ4WNU"QB8TE%OQZT\4L;0@60K6\>BC0DVN
ML(\B:Y]-9!!B$[K]+""__F2Q]OF4- D)+4\^: *OFJ.W6;ADE#1)!ZWE"LFN
M.'<Q,:T@!6N$Y"8Q4""L<]DS;8S3(DICER"/;<6YRXENB5F5Y5H&&T$I%&4W
MHB77+*%(P<0FE!=?<>Z\.7<N.%<YRYDCKF79*I<(-K" 93^FDI:)\UJ%*[2P
M0%SR\)89I$ 70$3$J$2,3@ W*&)B.D%P3>AB^]-QR1PJ9$8E!=,8)=-*('KE
ME4G1$U)#ST(3]C@M"OWFXCE:S9,")E15M(L)"%)Y"PX]1I9BD[HZ-B-Z]N;Y
ML]=',#B&_;7UM67DJ C).@R88R[[UI3S/NN4(ID,%Y"K!J"+%4<M%!(AN)&U
M)C12LD]$1N\UM\B$),Y*238A1K#BJ(7RW3,PA"P8]ZA49L8)[U7,.0D#I9I7
M [#MBJ,6"@=CYMJ6+7/9).5<\N0BL9(R+21X!4WJ3O8U.I;:'0='.( 3'(\Z
M<4C<UYC%ST:B*:XU-T$'IFU6BDQ?Z;L%TJ<L44??I";=*[Y:($P5K356"<]U
MQ5$*LLM.6.8]4T1\UB!,M>*K!4)6Z),4!*V,9E[9X((#5;+&0[ !S'E[QR8@
MJQ5?+1"^LCDQ9"XQ#E%Y(WV.Q@J;).FKC&A7^&J!EM\:B;2,CS9+$)F1RO*D
MN*S3F(S$K*R3+JZ0UA)QV%PPETQ.RB1+9]6LJG[DFGZD%,AGC"B;U/EOQ6$+
MB;X4YA*"B)"Y43J3X^B<,L'&Z%R0JDD-DU8<MI X#)D)TCN?/4B5E2'XQ>E?
MX-DG9*D)E77NPF%UL=IOX[%&:HSDT6K)HQ&<_+6DP'-.ULD955;PSYM:-!U7
M?P\]E\=CFPN>EC%(;A@$F;,2"( V):TRR*2TP29UKUYQUD+A:.Y+[R,K<^12
MB<3 2_+<DC*JM',QRX*C?V[.FD^="^$X!DTJRPF%F@=O4F*1ZRC19]:$G,<5
M9RTD;C9EF25#= %!1:!_7@(J5^H.).;3DNBL2:^':ZRUMGXXP.K4950:SAC+
M(QJ"T410H8-#JZ0-$(4TRDV;Q+LI:9WD323M5J_7?PX#K/,X7G6..R-,TR\?
MD,#N[@1V;<EG0. 8<@(DN"&!/"/F@C56*QN]=0F,:,*^X+L0>'=$4CN8*&;H
MI=09QOY'')PMHW=B,K?:&VYD*-NX5*$EB^!"Z<!@P"Z)/IXC31]>$7O!(!)J
MB]8'E9,GEQ.\)O)ZSK(18DD\SGG1=#Y52%EI/ITD$3,I$DYO0A*H$%AP:MIT
MM?F(?(XTG4-E8,CDPH?L8@HJ!><(#'O#4E*>965O](*4BP>8ZM:!1YC&7:+I
MYG_&-*AM'!WU"1%]Q.&H\F9N?(NX \=X!2X?#\>]PV>=_I#P5!<&#X6COHWN
M<C8XR@9OA;)D<1TH[I5S4B>-)A!J]A%%:2+)'2<DM2+W#Y/[HNTD=VU>,-;Y
M1'Q_VTF3I'8:@LV*_%E"P,SK&&PPRD<-C=J)\0(Z@S^@.\9G9^O#(8Z>=V$X
MO!JD*%3LC?J#SH_O-V\@ \T?SV516I]9B%D[A4R$6- <$GMEJX)O4H[J';AM
M$@?#=(#QJ-?O]@_/]CJ'1Z,5[\TECY7GD%+,QF900FOR^2&7Z)TUD2.R!OC\
M2T#WAX\+>)6Y-=FGR+/B@GG/@;O25]E[=#PV0.<L =WGD#FELU1$:+1**.&,
M\SIEFY@5EB?7F IJ3:;[?/861R6DT4IXC<JB\I9<4IN%=YI<4=V$^,(2T/WA
M8Q!"..NB%Y$+K7CF'KTQ)/^ -G!4K/BBY#J)5>AAIKXH49"+2]&$'_!%LV;1
M!Y<2YM*/"( ICM8E%"6@H&_L-%K *-+=5E0;(98S"A$YXU$EDP0G/5P*\'H'
MAD6'SGKEHJG%DO$5+;])YHB2,Y$YZ74TV2#F,FU6@2:K"21Q8%QNAE>T:'2:
MO\LC!$0'R %34D0Z+Z1F+#*1I.59\@:X/(M.U#E4)XW<&945!"65DM;KP%W(
M"K7F3FM?*=(5+;]-D5XCSP\H4KH7^J2MY=XK[L%Y)@SCT;%2- OXXL+/!2;/
M[+"E$-[X**R$P)6U$6(PT7D5O4&C8U,ZK3SO]X;];B>1#DF;95@='%XBTPZ.
M!YWCXW%O*7-Y28R"X"$S@I!*)!ZX3S8$XR$F)FT5R>.6LXJ&Y8_%D[4%HB&W
M;<[N1L/ZU)FX \""")KF,PJE(N20O4^1:0%990<5-.&.Z9J&I97EBH9?H:%K
M,WU'&E:GSH2&B;2HTS:F0C3%,$"2B7P%R7B*H-W$I5O ]K,5<5Z,1^,!$@5'
M'3)T9,$Z71R.^CTL!O R%??P<-R%47]P=G[*3);NYL@\5WU(,QOHDV5D,OE@
M4 ,!TTP_8B2EX54PRL TFU8M<%_B!:H8?->^TK/K&*P(I_KD>$G#4TXGD$'Y
M;((5U@?IU,2S6$"R+88\WW]!\EEJC466A:N>V8S4DQ41F&$RHG5E(= K!/+5
M1'(&R(1A ]33SU7V?BY*T+)H328^,5&K)"/Q!V/!1R.D9_3-XH97%D,)GF\/
M?(G]PP&<''4B=.OGEL.;XT'_Y(=5T]++P;V$IE":X+*2VEA4.<<2FE+<!50L
M1(YYQ=KSYKB_$:#8'_=&@[,G_WZ]8NIS)]2X))5D,D14(%)P02BMH\X\2N'T
MA*DMU_?-U-\\ [;-];?.P#\ZGYX,<-@?#R(.ZX]'"*EZ?NI\?/I/^C%9<&7%
MYT+CH^,*;?;>6.EU-I(;PZ/YJP14+JX9CLZZ].K'G5[["$MVZA/N3D:_G7;2
MZ.@)9^S_>U2=]_2?PQ/H/?UG&/R#KJ[_KF]R\U8P.*2[C?HG3R3=J8R_#=W.
M8>])I#G" =UP!*&+T_-#?T#OT8[];A=.AOAD^L=OJ3,\Z<(9S5&WT\-V==%O
MD[N'_FC4/WZBZ0$?<3 JLC)Y2/6\^O#D+;Q?<UJ6%QG1=(W2],&3=URKWO$?
MHW3SF'=KGGWY,%OCY\?^4=U[,#UA,I<T 8^JZ^BERJ3]OT?RT;7WGKR).!FU
M*GS?^B]6_??;":1$&N\):_'J+A>/^4<U%;=,_6US71X[/4ZCZ ^>3!^0B;G:
M&8X[W;,G__<%*80/-,^ME_T1J9[6LW[_P_]]/(3>L#TDGLSUV</.9WS"%<UZ
M]?&T?DM+-ZM(-.4@4>;LS<[6P>9&:_]@_6!S_RK/+.J0]S>?O]G;.MC:W&^M
M[VRT-O_W^;_6=UYNMI[O;F]O[>]O[>[,^SW$G=[C3Q@>$>N0!7S\W__%#?MM
M8^WY6DL0CO5??(%+8JN_(+;W\#[N3N_SHC\XKE_DGZ3X>OW>SOB8[A1;$_VX
MA[G$EI'QB *"(54M O,B6YX@9^YR]!IO6^-I]:!H_H2=)QO]."XVK5C(1Q,C
M(_\X"QO]CZ_$WL>W<GN<WF]^?/?2O]]]?WBZL_'N:%N\$;M_;JOM@[WNCGBK
M=P_HK,\?^+OW;S]O'[P5VW]NBU=RI_OV<U]M;_PNWA[L='?>=]_O;FRR=P?I
M>/?@@]CYO*UW_J1S/V^*G?<OWN]TW:=7XMW9VS^CV19;GW9?_M&A8WSGF/YM
M=+N[&T<?WAW_^\/NQA;;>?E[-8ZW[[<_II=_J/2O?W??B>['\+[_^>W[3?7N
MSRT:QQOQ5KQENW^^4;LO]X[?'O^NMM__SMYMK+.=XQ>=;>[.MC<V^5\J<9:8
MT&VCE&NK*+'MO;3M9+/3,2J+3#UZREG[]\K\7%#A:>N.3-4@S:_6K#9W4OS?
M9$_D&E/J6^S)%XT'Q ^' \*%J3V1Q%S]=VXUQ,FG8C<NRW$7\XTYJZ?K[K*]
M/NA M_6FUXG]A*WM_;OJ6W5=KFNS.FMISJ0H8$17TTL3A*/7ZW<#=+O]4>A_
MNDW8?Q_#@)1;]VP/3_J#42/E_D4GO'QCMM]_8+L;[XYWQ.]\^^5>9V>#9/MX
MB[\5;TC6WZKMS_'3N_>_:QK/Y)H_Z%FZ]^Z@?[9[\+O:.7XKWVV\.7WW<HMM
M_[EU]O;]'^_?'>Q]V'E_^'GG\PL:PX?3G1?N]-7!^FA[GWVBWW^9Q-#YF-H\
M.5(9FK2%9\:VR=,TTG"7A":T^=__Y:TROUW7&N=*8R(*MW#Y-S(SJ9DY6=V*
MFW]_L[YWL+GWZFUK;_/U[MY!Z_6;O?TWZSL'K8/=%D&+ \(/M17CLK6[U^+Z
ME_1K:_=%Z^!?FZU+T.,<=JP_/RB'N9?JRF1]'01.)JU=9NB)-)7:O8<Y87>U
MW*W1$;;^,Y6S5NWAM+"7,+7N4P$\*:'R]C'=\JC(?3O!6?L,8=#&WFV:X'4U
MKLTZ@MA(/?#=]O_3]OOMOY!9<%[SMC(JM55RJ>U%4.U2>QC+;NX0&"%D/!G5
ML07)'K?*O'\7&% /AS#OQJ>[>RL,L\(PS<0P!R0-PTXIR==X$//V_;.CG8VH
MW[W\_=.[C4U%((8^'[W?$5NG;S_3R,2_.SOOX^>;(.:DL_URD^U\[GYXM_'B
MP_;!(8&83;;[<EO2/=_3T]^_/=XJX[T!8BPB=]J:=HA$!P4JMD%RTV: W%CM
M!+H\ 3%J^4',P=[ZSOY6@2KS13&7M*Y8-&/QO']\W!F6N'KK18=, 3%#L8CW
M&)NH%OS/RL/J9S52Q'\H/G'ZEY<EY.]36T<CR-D UW8FJ;:S+!BC0(2(CYZR
M-C$:OX%*[F+=[:+QV3F4ZAP?MH:#6"^(G3/(7X=\[?W)X:,6=$=?.G0M',U.
M/GT7!B'=]>@?<XMZBKM%;^]=_O;PL&H)T1N5K9<_G0RNB[^4B>0E2-ZV8%E;
M*3*3WD?6-A%],,R'S$D&GVWMOMS<:6WM/%^[NW?P,*QT'F^N[OJD,Z(GQJ^C
MO(JW?MG\!'%4<42KGUN#<TYHP; U/,%8%@-3B\;0&0U;\:CR=G_]D6![8[P,
MN^:5F[F;(=:TN=O*VS<-UJQQ+V;AO'P%U=4D?#!<][>VY&'<E&')7S@9]#\6
M&;D:8JFU9RDC/B#_I"H>7F4[/*_S&IZ3&]9(95K[+'3?#[L'W:/MC4C^QLZ'
MG9<[Q^_*-:1(WQW_<;R[\>'S[@9]_^<-GX7>X7>]^^?FZ<[GW]5;\3M[*]Y]
M( 5,U[X[?O?G6[5[0.\J?N?OKODLTAO)HG5M$;1ODU:6I(<)%5D9#0;T43K^
MZ.D&=N$4!GC_3LNWNN#?H[&_ZH5/5@=_Z,5^#KF]+I8'\&EKDLU2U_5OL(?Q
MT *Y=1%$B$QC2*SM9 YM!1K:P6?93MP;@DE116$>/96RS3@7],U717+6IN<A
MI//N>*IBZU\J ]#J#UK]4BBW]7X\Z Q3)Q8&)(!5Y1EU+AN,ZM3!(?0ZGZO/
MOZZ46,,Y8&MM;VU_K;5Y?-+MG^&@(OE53=3:Z:_]^GTQHUMG99Z^_+WK\?64
M!C@<3GZ]H@'P1NKP'_)0Y5\Q)@XNNG;(4K654[KM3/#M*"U&$\&+4HQ8"-UZ
MUNGU\*RU/QH@CJ[KX\?W'\V;4.HY_;D[..B?]GXZ<FU^^BN8[)3 W(XNV[;B
M/+8#5Z'-D(NDF+7.$[F>PW$8=-+A#23[<&2J[-7NX#4Y.&27FNFO_)!HJ;]0
MA)B$C6W+LR/1XJGMZ[WA:'C2R#QGCYYNK]^,^3P0C5[WR0GMONN<--:C_"%I
M.OL+;3"2Z]"VNJ3P"<':7G%H&YUL3%HIA>+14YI&)18M,'=',_K+/?)2T<3K
M X2?DWO87P'*+LF,;14BE!^A[1C]I5,T+'D4T>.CIX;;Z[SSZ[WGYI:><]W7
M1_W>3[O^)?Y2"D!K;=I!R-PN_8W:P0)YE)DFBS&T A*1QWJ:0<86/"WGN^/P
M$U7_N$56N#LN7E#K<^>D55(Y'K>@EUHC[.))X916KV*52V<V=.T!2"=-7O#*
MTL-__Y<3W/XV;)T,Z!4[)]!MX2>,X]*QG,XD+PJ'=UJ">+ <P=O?;Y_&/*CV
MLT]>#@>86B?CP7!<%EA&_1:=4?F#7/P2?BV34%(*U^/HR5W>CO/Y9&UIP[]G
M/47J-67D=ZU\?/V8EG?+VOJ6P7*SQMSW+=,\_&#]FN%^YG>58LW;;]HC-K.H
MSG$GI2[.273K;*'.J%LMB"+$HU8L/3"^(7QU96?;\LS) "JSM']V'/K=7X;?
M$JG\XHR8)L_(SF35O&(2_%3ZH1W2%[W6*=W_Z)+2O]<H^$/.PX.OY4QLZ!D7
MH9+)1@+D>OEF1Y3<S^[QSOMTM+/QYHR.'[\5FY^W_]P2[XZWY<Z?O\MWQ^^Z
MVQOKUS>RR)+[N4MCV1&;;.> [G],;W*P_>GM>[K'Y\C?;:3C=\=O3K=?N$]7
M-K(H%[SSIEU:PK:59(FPM19M:X6N]E-+K>N\/^+:_5$_?GC<^C]LC7A&MTY@
MT/I8.@']P#)KTS7A@_/[1,G6.G;%['=@]HNU2LU#@%R*J\9@B-E1MX$'17ZE
M <.%LC&:DL2U]>P^.+HAEFQ.633%.MY,H)EJ]\V)[6QL^N%#,_WOYTR/6:.P
M,K134L3TWJFV1P;MC-8RI3$RYPF[D5^Y \,$_VF][/8#>=3[V"7GL[4-@P\W
M5XE^<&VRTRO+G4]$V:@S7Q=\JY?*FBNVPEDK'F'\T*+Q?B!\AM7J?'&W+Z4\
M_L(G$;\C&+9RITO>.G2[=$;9?5*<^/^,.\6%)\\]X.0$NO'$BS_?/- ?3#8/
M3!SZ2W& *:,7)[\<+IL'6HF.$JXNIYX,,&*%LKFH[U?M\QNV?J&;DDRUAF,"
MEL.C?DG#G&XY'!W!Z/JKG,+5\9;!UA=/WN;7.JKTB[CTRH'$DTX*[PMGT$75
M^71E&<_D9F5?SK :235<&(Y:GM5W2' V?%+_>?/GO2^5/!\/!C2V>J=0L: C
M&(V'C50F/Q1/_?R7U5Y(9\CXA:S:2@%KTQ>A7:J_.2V,H?E^]/0M#K\D]7>4
MUH/.,7'T#IZV]OK'T/LQ0;W"*]\VCC^)VD5DAC\V@D^+\OH_,!6S5Z [_469
MEOEP1?^.<>9F&[ZB_$GO'W=&(S(7%3(8]'L%H7;/6EBZN[>V"G"%6,7@-V $
M]0ZQ:R;QXAZ7H]Q[XR[6-%3D5I+5FQ2T.[>9^^V#UB_E3_N;D&)M<A;-1+7C
MX*3L.'@0(UD/_]SLX?#7^=FS2_-=IGMBWGX^>R;_0N&LI]EK.QE$6PFKVDYH
M2S^,TL&5G@FPLF<K>[:R9RM[-E'L9#B@U:47PA;$2/9L4*J+5SI]4/R>6[]M
MD>IHWWI@>$R&D)XRF#H7I.^/:2;.'A=?CVY';E&9O,/6X:!_.CJ:'EXCUP^K
ML27,G5Y5RF!83%M9X1;TFE\88768_S8][6]/^/+XIB<65^_1%T;YJ.SN*S::
MS&EHBZG7>ME5O=-Z])R*B%AFOV<Y6O U+V:_$8_N:F>_%JOXFC;WL!?1KC%]
MMUV#WS@'[F[KX]^_%/; ^QSNN"!X_V'4"AM62J!HP\/^X.RV+8D%FP^>3TYH
M)&:<EDTYE-LOZ5Y__OO#3MG9]+($23?9SL:S#^_^W.N\.WA[NOW^@Z2QWBB;
MLKL13]\>O.6$*]EVV?'TY^_Z[0']_7*O^^[EOVGLZV>[!U'3&*]L04RH+ 1D
M;170M!6WJ1U<U.T4M)=22T*C[-'35[>K[L7;D?CCN(%=09/WON@W*$]=/-%>
MOTGJ'R'M3-[RK@6?KE?(^=(NK4DEH)GD*BRF@MZY"O%J)#X#<CYD^:[OI^9/
M*+;[-32N"7V.C^N/$_R[=((\O\IM-?JHYOS9>$@#&S9S!>9!T<?5Y5PGH] 1
MVI%GT58NR38 ZG:VDI '&.VMOEO1MCNJ[F^0^OLYM3FZ9/-V_WFE/V:L/Z;S
M_+*:YN?G48J5'OFJ'CF[K$<29U)SE<EM*7L:O>=M!QA*;HC,)C.G07V#'FEJ
M^D?^2G2N;*"Y-:C8R;>MCU6K8@3^>_UJ46L\K"-[],)UR>?1>;72Z9)368HJ
MS^J>E8>?=NC1]-A6#T]+V'" 'SO#RIGH02\6^25@6@H'E9-+\YP$@U3VP/0_
M=M*7]HW(7^#7VP)V:ZU5>/F>P\O#(^QVI[S4^H4XI KRUL72+I8\OQA3_77M
M2XLD;W'X PL%=URP^%M3<#_5';X52I9);K(%^*&MZ?JOC. =!FA+C:FMM-)M
MKX)KZVRUHNG6".)OU?B\5[H69.FO'L9._SZEZEM&,N=EX89IZ)+!6F]\+<IT
M> 0#'$[5:F<X'!<??[)M]-;M#/6<G^]I>-SJCT>5E2WF%JI;[<91/TQC!=S7
M;0 >5UDB$SWXHLK(H'N/>YU:"]8#>715,T;!E2%W+:'4REOCLG.>61T@:0XY
MU#W\2#'Z1V0T8H?\Y>'_>[2U\^)JGP=ZW7;JC]J34V[)>:Q>M'K/_6H<NQ?O
M1+X'^1-T.ONY].8G&@?_RW++?&:FS64BO1F<:WO/9%MKIR)7%K-FCYX2E1X[
M+QY;?EXV8DKAIQ,66[O33ES6J/X)#]'];U+?_,=;_UUNWGC2KP'VDP&6]+&/
M>*.=X\4HJHED%Y= H*&,1S<O^;L.D-_:AM(^FEYS-+CP_P^Q'08(']J01SAX
M MU3.!N6TM.W]ZI4HE*X7QCL+0HXYQ_?OO^5 B6U-2!%-*E:]V1,AF%0SJ)Q
MP4*-IW4T*$KXO^Y$J8-*9$GWES:\);7]G_^ 6[G@VXLJ:.NX-]]O%N_6$?%*
M2>H?JP+Q, -^L;NW/;&PK/U[E<'"Q6^M\WYEK3J#OR$O,]D'<3'ZNMM2:[,*
M"=QL*G2G:B7\&\J5\*C!IOM^SX/U9Z\V2[.+Y[L[!YL[!S?;GMX',O3? :87
M,$'I.ZVT6^-B]K4B+(W'S+YYDENS_+YK13SPBO)U[KM]X^0L2ILV^\6NMGOF
M7\1\BU#3]6ZO_AI*0<:_6TKS/]8(Z<&K--WQW=?W#FK2;TV#-[6!_IMHQ0_@
MO;L,["'QYP^.Y^[XDTM"$%L[ZSO/M]9?$80KT&C]H&K&?0.$?I\S]H"+O+/5
MZ_=5G/YO(44E!%N$VEI\;?9:_5ST'T*.;GNW><K1-X[G&^3(D!R=KZ)5!6WK
M;<J_C'LP3IT1IE^_(%+?SN"-EKX?2\M8<?2#<;0O17E*[+VL$--?%:2J<D\O
ML7<_MTKOF6.\:JFG3ND!/0ZKG1\5\S=Y+G;HDL:_1&N[7^U2K6,#C7^=\^!&
MX]_D(CI3A(7^8-]E+68 _ZMDL"\#GY4J_3X"ZR4&U"N3W@P^%.*.)KUDNPSP
MB,XKI19J ]]:4MM>)J7QMKV\Q!+9]O(ZRV';*\*L;/MRZU2SLNTKVSYO/M1?
MM.W/H N]B*W](\31\*JCOE[9^V:K6+TTQD)?-Q8;&*O7JHDF^>.5^5@^L;4K
M\[$R'W/F0\GOZAK"\*CUHML_O3W@VVC]6R:A\:Y@>8DE<@7+ZRR'=:\(LW(%
MEUN'NI4M7]GR>?.ANJ,MW_S/N#,Z6]; ;IF&YEMSM5S67"V--5<K:[[T6M2O
MK/G*FL^;#VTI&3?"82FZ\06S?EOFX4H5+14+<+G$NJ@Y&=EBE9'=$*'A4CYZ
MN@T].*STX7EEAHW.,(Z'PU)!H:"V]1YTSX:=RA^Z4*-%S]9UE,HY>S@<=VN7
M:?<$ZS&M].N2L8I:YE7\YBA8N5*P#9$:P<E#^KV4@^N,JDH8E:ZD+[K3ST75
M=OO#<2F3LQ[ZXVFKQ]9>9_AAI3^7BQ/L"J N@OY4*_W9&*FQ59Q^-" "5;KS
M]: ?,15UN5*.RT5F^VW;/[B^H1UO;O7_>SVV].4!5O4![KL^@!#LT=/=@W]M
M[JV* RR8I5\5!VB,"1#RT=-7> C=VL17C6-7-G[)"&Q7 :0%4(N3NG[K*^78
M&-DQCYZ6@%#K!<11?[#2BTM&VY5>7 2]N%JY;)#4^$=/W_3J9A\X*&F;T,7+
M&9O[&,>#SJB#==SHS;"J'SS!EBL%NF2LX/E*@2Z  C4K!=H4J9'BT=/-3T>=
MT%GEP2T;7;WX06UH[E?%W;S]2A?,E6?<HZ?[-+\P6BVL+1]E_5>S#FYT=/ER
MHY6;[5ZF_4_NI>/+PRZLW;&_E9A%[QG.'DTO6C6?6<KF,]?:A-S.L0_3_&1G
M]V"SCOCN;;Y<W]O8VGG9>K&[]R?]V7ZUN_L_Y?/^P?K!YO:M'4-N>2,]U?.+
MU':N,VS5?>.K'F_0Z0U+D[93&*1VEVX_Z=8ZW=DY.H)1"P;8"EB.'$/"*YU;
MRQ[/JJ5K28(^;V#W>M#Y6+J/7HHMO*)?AQ5[M?:P=(4K/4/+^=Q[W?JE7%6:
MB-9M9:LF>!4/E?/II'XH(RTC*(<"]C!W1N>/*VOV@OVV#QE;_X)!Z%>]\P3_
M[9:A5<UD#XYPB%][[6,XHZ=4'6Q+K\X.IM))=3B.1ZW3?FEC"\/I4Z%S_'CZ
MN.E7-.[8.:&[73\2L-O!CS>^COUQ-UW_$H>CSO$M]\!/)QA'U[^EE\$(PXOO
M'QWVH?OXT?1X-9TWGD'O>?VKDR[T;GS7KVA!][MQ8#CLD-1?__ZTT[UQ[FEY
MR>EW)=34KWK13N:3/I,N/Z[H-.P0^\.@=8Q0:+Y6. 8'6.I.=88U#Y),G$!!
M3.-R(C'B5X@YP$,Z4L#777M%3L!:NR"S)T*L71?D=FG?-D\QKJ;1S+L'Z=5Y
M*FKVT=,B8Q?\GUIP7'I /VX1+U>=*8G.E_I"$[$') ^],?Y6J2/Z#LO9-%YB
M_WX/'[<&_3/HCLXN<<P)G-6$K>Q4J]N)I;AH[_!QP=U="!,S]I@>])]Q9]+#
MNC]H$;V+3!7LWH+# =;L\5MK!)]:4Y15<^+Y4"*IKM^JVY+(0>AT2\2T&G1$
M4G'$^<.B9+ -)T750)<8DUYGU!^<E<N&E88;0G4:>0P(@WA4/2'16W?[)V4$
MU7G54XY/Z$7@?*M(_;9#[':KEZ/AX*"TU2Y3F&@VJ_;-57)T40F](<TAS38)
MQ6>8ZDV2>N@=%@DEC37$\IBB* @BMD@S%Y$ZHXLG39P'G>&'WUI3M9-:&3J3
M[J+E5O7UU=.[G7HJJLDI7W1(278&U<N4TX;#>F97XG;OXE8;@WH7T>-6T=TU
MB8@;A^5(T7[%TRB6LU]S(ITV(/&L6*IN(%_1%,8]XLUB:\>#JELX5N);[M4Y
MP3*6<M,TCBO"/I0>/3>[E8#5<*G3B^3ZE%V[$VK4>F-4:SD:4[FP)M^P?#RE
M 1)HP<EII%#I#MUQU2;XXEZ7[Y$'_>-6#T])97:(F#"J2WD,X*13F*=20YU8
ML5$_#<:'-<.%3G]BMBL3CI](.Y5G3'EFRI63#Y6ZI ?7*AP"^7,?.Y76(6M-
M-KUH4%+THZ/BVET>\^3Q19]?/++U$0?G**_P[XI3'XY3BYTOSD!!;X];ESX1
M$XR*9:Y54_U]/V<RUZVZ*7'-%+4**[KF(Q Q)T:V8I>Z^61E;\^9@LQ5=SSL
M?*235M2]?^I6TG1N5@JZ&8YJ]$7/+0=C?U#OUB(X52;]\-RJ%-U2'*530C#E
M-RFQ;H6YSN')Y/J3@MA*#\ORZW!%U@<R+XF\=-*;!1%6-*L .5$DD'CU",1=
M5KO7V6#JFQ.H(-MQW!D5>$LG1;R*.%)G&$G1#\X>?QG_DK(^',#QQ(Y,'G[E
MC/Y)"5B4)O55FL(%2UVUDN=Q@7*CP?E&Z\>U=WG-,2DFKXL33B37 0<EQ'#[
M\XDQ"9C7.FO%G0_#G5>1[15^.>?#R_0DKZ5"J5?8MG*M:O+7_B<IG0M^B71^
M67,A^M)'NC!WBJLUN??$HZ.OKX$*&@W!GE:DLZJ:*<,;*+EBYZOCN.28#J=!
MKLX@M:LH1AGT%[FZQEXXIE=MD3"=X#24=7E.:J_UF%1PJ3EPR0,L Z^<R4K5
M3D?1'PPG10Q6Z'Y>#%YS)''7>%3U1)DZTC7.O^KA/[Z$@!ZWNE7Z_Z6 R,5&
M@%KY%G'HUSQ;P:[AU9/)_\,1#,[.=7D5WAC3/<M!4H1GK6J-D;BRQ$:JGH,5
MAYZ[]M650QR-:H-^X5.2ZS$B[$=?5+[F%/4?]PL_5@\H:C3BQ'TH_LLTFG Y
MQ#.YRXH5'P;@30E0XJA5W1*LF*=_7J#DJFGN%$-<\>6$L:KH?"N3,U=8H.")
M*E1>2/VQ#A.M"'GOA(14T!S!:,A(M"QAU0JE?^QW/TXAW'E<Y\*6W<VAOG%A
M.1]Z9Q=*I?ZV"AX4[38$4FFQ2SJC6+1^#U>N^9Q0?F= RGVBZB<?+LQ,.>/Y
M[A];&VWNR5C0C!X77NA=<01J(3]7!I>!S22B. E #VN4/Y@J!NAV^Z=%G11+
M4IAB?'+2/6O%(U(7CXFG>N-,XQ@/ZN#]6<!!FQ0_Q \5>TU9J_,1XED5P(<1
MD-6IUA3/RB ZJ38^7P^M/[X.]";NZDFW?X8KW33/:.810G=T%,L"\Z!>%9Y$
M,-_T.N<UAH>M7]ZL[:_]6I'M&*$N E,O2(_@ _;*&F(WG1(W$/&'G<->C7\&
M2(H&+S_CPAWH=HK/6IY4O%/B4P)5Q#9E3(?EFU[%/A5;IVK%Z K75^O3YR\Q
MA3Z7@UKUL\OOSG$8DUJN[E<LXTH'/CR^N:)IR'$CRI$&>=P:#R?.U-03.ZN6
M_@I&O79-?W (O8E;=66A9>)77HYYU,MIYP&RFP^?+IX]OH20RMEUT/TB=G[U
M2OIK<MUY/.,\=#IU?BL.*T?V:=)'1^-![_:;5% O(+'8M>.7S?OY L-51W?Z
MB (<)L[IV9>>TBG9'A/=?$"ZMW?8Q=9KPA*/6SO] 3G!SV'0IX%#/9X+(P/=
ME6P\C%J^B@7JE>]QM3(S"8G5*][50=)JG1I*()W8+U A3JL;5AP\C:)5"_R#
M*:M.8P\8IU&)20K \-)">KF\\AK.KUUQP/US0+>L_TU"N%-/?DS26K[MA^XD
M9>M"XUQ*XRB9"L,,YS2MX=I4?Y9HPJ4;5'D"=Z&G7=%S=A)=#$H73@E 7<(N
M\.G7R^$D^O,_8W(+)M1_3V=594L3QDGFW+6<G>&(OH!!&JY]D9X_;=:S_'+6
M\RJ!>=D3F,TBIOO^3:)K'1ZJ<[]J2;^P^YWK3D]_B!<)P>1IQ4$G8 DK_%VU
MK)F\:'7;)YT1R7J\PZO7=8W6UUI7ZT',56,_>CJ9SWK61I>2L2M0U1WB*1E1
MO';P<3WK598PH?'BM4PL['21LUIIS;F.G&,)<G3/IK&X0C42@F[M*4Q1U@4/
MK+7>]L>MX5%U]UZ_6E\CMYED:%PN[';J>'#EEY?PXJ4+7WR9L88GI-_H*AH'
MG"=?%R=BXG!-WVVMM?DIXDE)')Q:HBK7FLS6XY*VE/K5F"J)+LY^'70\!Q;E
MS4_&]#'2@\8GU0/*&5]F>;KK$590I60G3&9P:BP[O1*$F*2/YG&5*GHIGG01
MECKM#/'+]F_!=C6T+C8T/-_=?KV^\[:UOK/1>KVWN_'F^0$=?;&YM[GS?/-.
MFQH64,N=IX</KTO5J/]].=^*K4#GW4'G),'_6:=_B!=[!R[MS*AW4=S8:G!Z
M8]_ >'AY@\#D2W(?I]\."J6+S-?/:FWUXEH=VB;9C)?;F S'8=A)'1A,DY17
M?/!0?+"W=?#F?]=WKM"L,E&$[H]:DZ/UEA]R%1.V>F6MJ(25!IW1^%/G&,)Y
M&'AM?^UQZSGT($%%YW\#O6X="=Z&<%"B3W]SI_YX-"R1X:_<KC&*_/KVM(.]
M]8W-[?6]_VFJYE[_8W=G\W_IM:SZ[7'K]:O-EWM;&V^GG\\9Z<K'UK_>/M]\
MM3[]=O_UUL[>^KOSSP>;SU]L;6SN77SQ=G_]V=Y6_;&B^A]OMC?I9F^G7U6K
M#^<%<BI.*NN=%6RI%<U:JZD3O/'F7YNOMDD6E1,T&<\V=S9?K[_:NOCB[>[N
M'UOOSC^_>+7UO^O/+HZ_>+--/+8WO4,U?UO;>^NO-K;.OQK@[9/6T#G;W'FV
MM_EJRCZ;;U]MGO/2B_7MUV_WUN]/]YK*WOR]\KT142ESV9;5U==*"0088NV;
M'VS/W?]YW'JY_N[M'^<3^J\WVUL7HOKJS?/-G8.M_>GGW>=[FW^\.?^XM[F]
M]9RXL?[<4"(\B*_\51I<I%E=DMK!%$/?]$P'.-WF6^>&U<Y<9U!\I[+^5':@
M]4][9.2_HB9_VI"@FDDA!+DJA+#<<<0[\BR/&FRZ;ZQYJ2Q^Z\76SOK.\ZWU
M5U>+ME\7\SORL7GT#>_^I=HJ=WR6_Y9GS66>GVWMOMS<H8E]OE9%9/;?/-O?
MVMA:W]OZ2BQFH=[@^>[.QN;._N9&B_[:WWVUM;%^0!\NZF2T=E^4]]O=WFS&
M"_TR[E7YSIA*[+ML1._6*1]8ARE/RI;LHV(3ZYWMPU]OO->=C<U!YQB'K1T\
M;>WUCZ'WO460)E&!(JYWK$I2JIA5.NK<Q@Y(T;6K_0$G0WPR_>.WU!F>=.'L
M2:=7/;&ZZ+?)O2:&^1:P4Q&T/GQA:]98;6\F-<XF3YX<7JL.3<MG73FFU1KC
MYHN'V1K_XK&OW=:O:2N^ZZY?/Z;EEY^Y&NOBC=7=Z:ZS+4!:B\8<:Y!>4Q;7
MJ];=J==/K:KG^&JW=_1Y,<E..R# AJUM.O]HV-KLE16W?=+?>!Q(@4OV^!OJ
MKWZQI.,RS--.R1J\XS3]7%)P\6(!XH?# 5G[U)Z,+U7__3:QFU5XF+!!M?K0
MF@Y^ICPAM(48[IDG!!/\+M-QE[>^0QW4AYN]!Y$HFCTV"ZVRXKL5W_T0WRV9
MFMZK"X0]N7=%/=M"]O-X9*-?_]O8ME5^VSJ>N>@<_+K>2/&XU</1=2[^,NE"
M^7=%'['6#&1VQAK]]C?^/S_TFI=?K]J(OG#O]\_.IR>]?N_%8)+^7DJ3_/_L
M?6M36\>R]E]1L4^=2JIH,O>+LU^JB,'9[ K@&)*4_24U5R,;)(XD'-N__NV1
M  D'.RP0TA),=FTLT&VMU>MY^NF>GNY7)4%\/HQKXQIX/(/Q'[K,!)U-=GB"
M6<0D;?:2*Y,XB](E%?_<+NZ/:$)A_,!RLC8NOCYU)\/_MP9RK3.I2<//^CAZ
MUCL_A=@?9ZG+*];&)0_E>^&M<V?/+LARB+#!RY7&+>3'Z=+(?__DM_L??F&O
M/KSF>^?QW<Z'-S_;=P?OWOZUO_WF>(_]Q@[^V!-[1Z].]MEK>7"$K_K\GKYY
M]_KSWM%KMO?''ON%[Y^\_MP7>]N_LM='^R?[[T[>'6SOD#='\?3@Z#W;_[PG
M]__ UW[>8?OO7KS;/S$?#P[M:3A]T3MX]YKM;[_]O/_NS?$!OA\_ Q__*O8^
M_W[\9OM%]_71[^_?;&]]?'.Z__X7_NKX]>G'DX/3W_#[\2_OMMCK/WX_W=_^
M]>/^YR#VW^U\?OW'[N<W?_RWNW>Z?WSPQ^]7[\'O.G_#?E-OCO#UIW@L>&YO
M_GA-]K=W^/[GMVSO:/_X-1[9Z]/=3Z_9CGSSQZN\]XE\_.5H9[1W2/[Z4]HD
MA:4,*$T*1.01/)H*O!&,4^=5S@J=[CHC<D/_^X?K-\)78HHF=_\EMS5 P1T8
M^P92G0N[+(1/O\8N\R.1A9Q& Q()7&G&),U:!9$]=QYOT:R=$IDY'>F81,@E
MB9!*(DLAD<]7)**ULKGPAV;2(HFX##9*!C(%'PWC7'M?2$19LL&;D<C2N*)*
ME,<J491B-AD;"!=.1&.-X9'3*)6FVJ2H+B0*K1)EF>Q"K]@ERYP(40F$X P$
MT1RL%@F",J@M4Z#4D[5-M:XDWQ!5HE2)L@@224:Q(!*/1$A!+/.16NYDE"8Y
M$KB[D"BT2I1ED@B_(A%%)4F)<2")(I,XY<$+*B%3:V1BCG"))&+6.4H4M7B)
M\GBS01>W[F1[7NE@"<\1&M?:/%ZVD/QJRI-]*^=W2U6V\K(E!&&-5<EDK87-
MUJ4@E*71!4;*'V^16:FD<F]2V7\^DSRQ1E%A$@/%M0'!(P7K/0.6L^24^> 2
M7]M$FEEA77(#".>/M;9Y=^49CY:(P$,2.28K''=*R,BT4!@JW"(!4;$V#ZQ-
M<PR.9T5D0$!DRP$)T(%12H&TC BFM<E$KVU*139HVS,,U:_-8LUG9;,@V12L
M!1N=)D'J;(D207OA:CC>!B!.P_$DB%?,>W!98SANM08;(\;D4FKN%<4; )T>
M76="5+>W6FY/J\"\)5II004:TT?N0XI<9TU3%K0&M6V XC2H30%UIHH!1"("
M!"49G+416"3$*>-<FD!12K-A:E [/TP=E/"UAJO?=.M<.<(Q+BUN/6EO".51
MR\")]83$5,/5A=#%X6RXFC.)6GOPXV4Z)'DPA =0VGC"6"(R6J0+J9N21?7;
M2RZZT<JB^;(P.@D6LA,F9&]3T"+2('T-5Q>$M6FXFAEU*3D%-DL-P@4)UID$
MG 2?C%8N68588XVK:EH!J2?LUP2)7F?#?*!<J(0Z"U6615>GF,P8OMXB7*U8
MFP?6IA$IPZL=I%'@0JEA*QE8'S/&IAJ#T:RC34JN;7+9.#54_=J2T["9:<-<
MB))GD8(S)&>CHZ<J2YF2O$4\6K$V#ZQ-0\Z8G+:>&^ 8<X)0&34DYPIDTMJ9
MJ"+->6U3";8BJZC4KD"X>=0?C;N?CF_>^X2=M]X+]#A]MXS4!*:\LSZ(R-!K
MRZ"$ELXFG[BGM3A]^633G0E8F2#64"J <4-!T$# >.]!FHRD@Q[?R%SJ2K4V
M&W9.KKW)=KDEB>_%@KAMHD!GJD.6F?'HA<C".9JEH]9)*[R]JKRJQ>%+!?$T
M$B8BHRTHA<"( Q%D D=0HH>0:1%UWINBSM>Y5HWU>?NQ6CWQC2#&F)F&Q)Q7
MD@CFB659T^ARI@:#:)GJHF\;0#P-L:,+RE(G(#-?MHDY EYG!5$H2I(Q1E!7
MRB>9T-43/Q5/S$T*F3N2:-F918@7/H1($LN"$=1H=;FX#2">QNZ$4\L%0C<9
M'4%DI<$:*P!-F!'"@1JOUS8I69>6;9"6N>)'UN;A>7]X,05E,DOVCOT>&C#E
MLAL>/$2_AQ4Z_<=;##&^E?MY.ASY<H22.^WCD4ZFB$[&5IR>N>Y@/!MV/!7Q
M8OY-MS=RO;?=TJ'1#8=I5#<"/'06Z[IG+08\R#_W^W&XU8N':?"A&]+PL'\2
MJZ]MX&L/9K<&E,WJ!.T!5J&'%49K<(%[4$I$K[P1EOJU34EIK;5H 84M-OU4
MT?<PZ)OFG&2B/EJ107"/2E=BS.J9I^ -45%(XFT6:YM"V+I98+5\WV+S1A6:
M\X+F-)/D$U64! />1PE",P)." G:<RE9#')<K$'7"S@;+B%7U_B4\D$5G/,"
MYS1#Q(*@/"4.2?D"3AO J""!YY!0LTJ)SJ" DU.Q(O4=*Q)#OTK#Y ;A>!PF
MSXQ@K9'P0B/A2S,@H6Q/C; S2='M7"8VMBX2%[N]EX,^<LZP4%$EG2:D,[LM
M06*<'% # !6*@L#8"KQ0I;C,Q*125H+GM4U-6-U.V *F:G&E1L7N@K#[>:8<
M-,2((1EH*4KI=62(W1 1RJ7RFG":I"N"@0K2=%VX%2!]PLYUT24:%;T+0N],
M9ST>6%8H]Q6AB%X1"%C%+ 1AF$ 199T?[Q\VA*YP\]\GZ7L779M1T;L@],YL
MQ1!&(J0(2,,8".,M&*8]1.U]HLGX:.6X=;<2=??_/&%XF$[PCV_7.V]3+PW<
MR3AH=_&TV^L.1X/Q?-\:MR\T;K^PR,\3>R +;5VSQ@415:IITCWS:*O0S"1,
MW_K3!4N)DAP"Y1Z$,P:\E 0(B]1BA,=9F1.@I*A[+%O 4,M<SZY8?!@L?IK!
M(I&,6@TRZP "I1[X&#W(X!R)7O* -MJ4FM?5[=7RBXL-N2M0'P2H^U.GZ5.F
M*' BT$#0:2I+P&@;P6=/O7(6@VPQCJ^-JKGMU7*;BXVO*U0?!JI3GYI* U*.
MT3-S+I=Z30'.<P)>E'8'D>LTWANQKJQ9Q@B;QQM,;]4B\5:'V+[;]<]FC83L
MLWMEHH,\3>I=VF=K;)Y*1HW(:&<VV+:)><$UA>"5 B&E "NB!2=IIAZU?N8E
M+T]IXUU:534\CF"[HG)1J)Q*!$*,8$9+8#8F$"0H\%Q;4,+9$()"V6?6-LU2
M.A_5J'NI47<%Y4)!.1-BHV\L7?X"<+0("&XY..,DA(SQF)8H?K1"4%*^P:JK
M7"57.8< NZ)RL:B<NDJ)AF,D)>#2<725+(/%4 10Z$1#4U"R"%A&9:TBG^].
M[),3Y_N#23!]-NCG[J@S/'8#/)\:+B\N7+YFAXD93OK#X84E*K$T(I;=V<A8
M*\*DU JT)02)A5KPDF3(2N>0I/=<E''UM'K[%M#1T@+CBK_YXF_JV%DF(O'@
MP-K2!XR[ #XI!4:JI'+&2,KXM4W-FR:F6@&S)^S_YAL#5_S-%7\SX2Z7F::8
M(U"M# AA#9CH,?!5T6%8A'\5!O$G-F3U?ZOD_^8;[5;\S1=_,_Y/1"%8#&!S
MZ2Y"I0:/Q@*2E%$&GQ"JC%!2JBD %Q#8QN[P[,1]*L>4O@W-^LKKKWR\&8/O
M?G;=WO>=P@X=9*CLNH/.!W=RGCJ#=)K<\+S\,UF)+WR%9UE^PX?#;DP3?GF"
MB87OEEGK_@)M]'LQT=[4/G]T1\>_]?H>3^>#\R=IMW=V/AJ^2G@DH7O2'=L)
M?SL?%/[_R0V[PU^ZSN,SHT_E!O@%S;_;*[MT2AITQPUZ^+*: &WF)WZ]5BY/
M?*#".Y A,A#9"G"4.0C2NV0U/F5(&;5W0_[S^RK1%LA_RZR4KTAN+9*GBH]'
M':24 5AROHP4<^"3<V QU")>DRQBV65G;\AX? W)K0#L4_;)<\MV5"2W'<DS
MN1.D;XX!M@'M30!A(H)8$0&&>N.2\-XKNK9Y8T_(ZI-;ZI/GEC>I2&X]DF>+
M]0D:7AE(4E# NTB"E5:!ICIZE7- 688^F=^0A'E(GUSS+S7_TG3WPW1[ YQ-
MFF)T!K47X/)G.^;NQQ3A<QKT;]?KY*JG2>7U1KS^>C9K0J6U*L>,L5:0("*E
MX 5+0#S35$K#=>DF]K__,HRR'^L"U]+9:WF] "L\%P;/F:I.HVD*(@$:4X"0
M3H KQ1_*":VLB(&(N\*S%2A\PMYS[AF1"L/YPG FCV%X3HQ)"\I(])*!CV<Q
MXCT;,S%>(@Q5Z2I@ZN; U7*1<\]E5 S.&8-35TBU%L(D"<0* \)J#48D#3%G
MHF,V-$:,7K5<1AWD':)E:E<@5C[JC]P)GM'UP8GWB8J?^!#F.8?,MYC7429U
M7#0KJ?33C'["M08!Z.^#=@ZTI*6\("JPQ'L4 Y2)F)2QU)1N)=:(.H[YJ8QC
M7FR[_0KG^\)YIL; <+20\* 5_A#&)?"*<W L<FD-_I^X<2=?8QOWX6X_:JMW
M;D$SP KG>\)Y)D!7BB '$X+1 $;I(G.)<&8:B*21F-*H0(:U3;ENK6C:2ZQZ
MYU7USHL?CE?A?!\X3[VSRBGEK 0$ILLPV<C!Z)2 "&5%]B;JTL53KFM*&\/Y
MH5';+!?0^A3 ;B_T3U,G#_JGG?[9Q0:$>W4"?.(B8^Z[$PXF5NF]G9BJU#Y5
M[FG$/6]G WV> TU>>F#*L=()T ":B "WU+.8K-:JY!E12,PKV5^%1,N%Q&+#
M_(KG.>!YIG6_5RH25!#6"0+"90;&R@B4)1MX",C#XXE;Y X=P=L/W.J$6Q#I
M5T3?']$SP;[(THN$SIDEC1XZV 3&>P(TQ<2(E827!H1LG4D^MWGV*P#UI^VC
M%QOL5T3/ =$S96XL(NERC/(Y*SW&9$&T<H!Q$7%>Q"0E6=L4Z\:0UF7C'UF\
M?S Z3H-.=Q+U?W>QXO_]>J>7GF(U_(+;#@SQI/'1EVRSW^_UKQ-.'3]R%\YY
M/QOG!\6-U(9#*NL&PFH%%MFFM$Z5@O*, L.N;4K";EC.KYL36[HY<0Z1>L7@
M0V-PZO<Q&N=>$@\IZ%)7:S5X:0($GU.I]R/$E=Y.S#1HVM$*J#UE/SB'V+IB
M\($Q.!--1U(&6X8,+#@+0BL*IFS9)U+YZ!2)KA2V6<IOR(Y5/]A2/SB':+AB
M\*$Q..,'I90ZE6[]I;.AB#:!=9$#2<[)Y#S55);]):I!HXP:VWYM+=NGW!^D
MRQAWY#Y>%K9/BMS_[[P[^H3/7K3HR_CP0QJ.4AH'P>4/^):Z -Z>!?!I#N[%
MH'_Z?-PT\1ROX<%5N<)/8XM/7G?D/J;A7K?7'Z"9=_&X!FC<,J#DVJ?LC.^"
MO30Z[N,SQ?YE(T]-\C4BN7?7YMG'X+RAWH,1EH+PS&# ;3*H:"65P1(90VGK
M1><VS[XF[5N>M)][?[]*!2VF@JG>L8'JF#R%C)P/0B IN+*"IPAESL:LC<&X
MWTJ]85J6[:\K\H]B1;[R1'MY8G:EGR6%SH" -<F 2#2 0_\ 7JJ4 A6:AO&F
M.R[(W,8/K0"%/&W1L-B5_LH4+6:*J:+PA/HH. $B-2H*23C8G!4P2?#OF3"O
M7:D@4%8TK@FJ%01WR;*4O,IW/O52[HZ^GT?K@!750.TH(;BBIXML[4\3PU3*
M:40Y.[/Y#$:SR2QIL)HFI)PLP:,[ H:J)!FEC(DH3IBL]0,K(RT>*!]187=O
MV$T]?98Z66$#Q*QHV9\CP>G( -6?<IR(G)A V&%$T#!WT J,/67O]W"% Q6&
M\X'A3&AN'3*DRJ[4"000092QB,J""D991;12+JUM<GM3P6YU?^UT?W-OAU=Q
M-R?<S33BUS;J,@G8<")!<&O!&=2?6NE$"==1.KZV:?5-TW%:U@>O]9'LSE4I
MP'>38H'O'ZPFX FX][FM^X\'KMXJH[:?1@<9Z:<23B/"V9T-<T4P(@2JP%M3
MYA\;!59(#YPA[6@6B_]?V[QIT;ZZ^7:Z^?D7R5=$/CPBIQ* 6$*=\QZR+Q%P
MSAXLYQ&XUH)SEX-/&A')F];1M )^3]E#SJTE?,7C@^-Q)A1FAJ>L!0-KF )A
M=  ?@P:6E*?$)<;'DV?U#4O4U46VTT7.OWZ^0O+A(3G30$Y09[01(+W1(%)D
M@'&'!>:]#TI+$D4IJ&=-=Y/7(/EOJ,+;]:*4OM;$MZ<F_N6@G[NCVI>B,8WL
MS<:^.4>E=?+@I6<@>+1@(TU@E94^9Z%\I&N;G)I:LOY4JL_FOD1<D7IWI$X=
M?C0YT4P9,&51@VN/(*5!@ B>!<6#RV5"DR:\\7"&]@.R^M065)17&-\9QK.K
MRD9$S@,%QU@"X;T!DUP$Q8SF.0F5Q\GF=2VJRWTR+G>Q!=\5R'<'\DR..E'+
M/+60J*<@7'#@G// <HC9&)L"+^4AZ_K&_DJU'GN^ ?KD>EXV=2MKV-]WW&@T
MZ/KSD?,GJ3/J=_#Z%]0-^B?X$6\QI)]L7AB.5[@G']#/DW_K6O<2>\&ET32+
MN#5CPZ/^_C4+7NX^J2S6B,5^O3;TC0NF1.*0RXATX7D PZ("GX3PRCF3<EEI
MJXO?JR,FYAZ_5T ^."!GBK^M=IY(%!-187"OHP-O,%R(3#H?792:LK5-UK21
M>RNP]]C\Y3)GH5=0/C0H9X)VG0Q7BAAP*.Y!6,? &0S?<PYXYWIC*(EKFU+-
M;X]V*_#Z^'WEW.O!*RP?')8S3=4Y8<G'A!Z2.0S!I0<C2]682T&5_1F2Y+7-
MYJBL(?8WUL#_%E;_U.V_3;T.WO8;#Y:8O)%]FEZHA6B"_WFX:_"H!-'<ZP&N
M,6]EU4:L^MML2B!YRJ@-*'%0GH(PR*_6, )&(YUR32PZR+5-SNQC;4@SES6)
M5K+X5\EI,1S4-O7WL)F2RD%-.6A&V24C!+<*3-"H[ )7X ,+(%04R2OJN2\C
M*@G=D"U;6KD;U52!5 724HL[*G/=A[EF4D74,*Z\S9!<YLA<SH%1 >]I26/(
ME+@\:>A'C6Z\+%SU4]5/;=)/BRU;J11U+XJ:BBOMM!9*,I":8X!'@@=3*DDC
M)PK#<IYXR*5R18G&NT<65;ER^7V7=ZX<$] =$]Z\4:$IQR./_?.2_/KRQ&[Q
M#4T.9AG?N>(7X/%F7<\2WO3';I">?;4PZ19F?!A#+?A>7."1-;N?QHRF-[1<
M@5OK)S?$CTENT,,3&$YOKWFF]Y](@/J(8M"7:7!8[H+Y)NO9EU)NY^*VN_RZ
M\<UX)>E(E72WD'1O9W/VG!2S, Y2"0,B.@G6&0M624(B$5S8,C!^@ZUN?<)M
M:Q):R;9?XY1'%!M^A3KNF6.OU/$PU#%3<)B5$TE&L$9*I XUGA*=P"9IO7/"
M*8/1H-@02V@D,-]D>I4CCT2.W#,U7CGE03AE)@GN=+:I;%/F,E,0(5OP1*$<
ML5P&YD4BB:YMZ@W+JQRI<F21U''/E'6ECH>ACIGD-,T8QV0#BC$!0H0(QFH)
M2/0Q2!(,QC88R6 HTW#U;/%%G:N4#MKNGIR/4JP)H:K VI 0NK@=*Y$V(M+W
MLRDAS;1WNM1,2<5 J-)&O<1UE$BG*->)2%)30E6#/;Z44"6/.Y+'C HC-''J
M/&C-(XCD ]A@/&"HK0W:Q!,=QTFAAI,&:U*H2I(530I55KD;J\RDA51&=G><
M@#2Q]*Q%?K$I6(@R6A.TY2&S<5JHX6"7*DFJ)&EW6JB2QQW)X]-,3CF(;(V"
M$*,#88($3P1RB4K*4)E#*N11$D,-MX2L<%GBTFNT5NPD'EEYX!_C7U($AT?F
MWJ9)PF[8.1^F6&9ZX:&&\Q,W*N=4JP;;>INM4IIX'E6#3[DQT 2@#[T5_I(7
MMB:TL']^ZM/@((^5R/#@?#0<N5ZYK-<7J^I.BEMHDL_7)L<QR:-61D(D)(*(
MDH'G7(,CW!C#HJ/*K6U289J.JFQ11/,$^@+=B,JY;PZOJ'Q05$XC!2,HLTP@
M%HD/I:>E ^LRA12,YHEHSDL+/2I5TPV8K0#?T_:5<^^C5U'YD*B<W1C-K#5>
M&_"H;$!@T Y>!069B6RXE3JE,K!*V+EMBVX%7)^$KYQ[&[V*R@=%Y=17"B^,
MH3: #V7^DR(6/*4:K!+1<!=U+)6:5/%E-)Q]O''T?,JMJCI84B1]8;Z_T5%E
MHD9,=&T2G8ME\%RR0'CP("SW&$LC$PFF@J7>!"W]))9N6'-0]<'2<;FH6+KB
M<EZXG%$(7-ALJ8$H<@)ALD:M0!48*V20V1M:Z@BIO&GX<XVFV^TO%Q5-5US.
M"9>S>ZR"B4*5*9#*H+^,48&-*D'PT2DG/(LT%ER2C=7=9/54_>6BXNF*RWGA
M<J9UJ37!.Q-!A%*GHI@#$ZT"1[3Q49.H59I$U,N:S/[#.+;$?V/WP^:_\<?E
M-\Q\5DAE/L$%8#;_[0<_;%X=5GW;O#F$DG\B$59(Y#"EC@NA?XH'\ EOA4ZO
M/TK#DB08':=A0E)QY[%;\@K()C'UAI-'XRYLKOPY=WNN%[KN! \?_W"*9S3<
M^.JY7WQWZ0)7<BIG_6&WW*7/!JG4E'Q(/_[5C:/C2X*;>>/DGGM&IF]Q'@\"
MJ>:K;VG5=9;7+\GLSW+(8T8T1"C'D[+!4)%TME9I;F56G"I%@_J3L;7+-QT/
MIAA^F\ /DGL/+N-9/G,G?[E/P[4?KEV,TVX/OKCX7UZWKUZ=G.]\=<P7%T??
M<'$F?(.NIC]P8\NB3$B#\BH\+M>JX^D<#XHS_=<_FTJO;1Z-TVW]W'E>_##"
MXM\_N,V;;H/F]RP-TNEX]WN6W>(RK&W^M'OP\\Y^9W?_^49G:W^[<_C;3X>[
MV[M;KW9W#N_+;HLY@^<'Z&7W#W>V._CH\."7W>VM(_SE\ C_V=O9/SKL'+S
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MJ-_I#H?GJ 33I!H%;^L"DL[PV T2>%>R5*%_>I9ZP_'FX(X;#,K X/''U('
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MT[8Z$5XW9^*JWB@KENM9 V;P^KIE_T4OY-\&PV'+\[22UF]R[[0CSL^2#RR
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MT^+X;$P8 $JKH%8O5""*#AES+FA\\%EI;V]APF2ER['2^6RSM@$E"& EE<!
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MUTD@0<$FBB% S4.1Y)Q39U=]/OM9NX)"KH)J8"TC=A\&0\U#4-J$R &]09N
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M8DQ.R^!"$%2P:UC,5Q1J-I;&\UE#8[NQ,XJ]O)N&>_G ?:IV\QQV\^[S"UT
MD@P2_55*N-&"0(),G%>:L"0B.JI! :#=;.F:N'8=9H5=);8JX2KA*N'E4,XW
MD)ZIRGEQRGDV2<.R85[X9EX(,&^(\3(1ID%00UW(5E;EO)Q!Y!M/SE2PW3S8
M9M,V/M/2.X811%@@8'(B+B5'$((@G*"9YZ;;Z"U$CQ\NX.;:)/CC:9NJYQ8(
MO9F>3IDISU,DW@M#P'M-7%"1*!Y%%I%E:=+*NK&7]'/ZF7KNGB5MGH^/6VY
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M=ZK[#;%8-6-NA^].9QRZF*A5@CA>.BQ&FXG/(A)NHJ(!>#%=2RB)5;:K;/=
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M*&?1/P)AF88L$J/5"KS+/+@S$R*TV06N"/<\$F ^$A]#)+KHN9QU$I*.K4"
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MPO,)$&M<+W]4[$%""AQGJ+Z4XT*"$,'&+!33V0?.2VO@"JD%0>I"J-GX[,$
M <,T >L2<5H[HB@@N+Q#F\.4+HUJS510+2.H?':ECTK6%B>):Q\492 H%<"$
MIZZ":F&@F@9L3=)<2UX.J"E59F@[H*:B@EB< "J4RD;PE770,*_/5@.VWX+-
MP=O]C6>OMVNL]J;J5R5#WJ#*ZI@@:.UMDC:%A.R2<N2U?G4QW-*>B=7*Q+00
M#(@)0I:66XP8%0(NEX!Z7'KF@RZ985:C0?<=G4XZ$%II;3P%]$J=S\*SJ)5S
MP0+-%9T+0N<T5AM=AB!Y)B:58D\I.3$L.Z)-MJ!"YCE21">P-5W1>;_12264
MA(G6P3A0+AFK-(L!%:EG7$I9T;D@=$YCM=)PX[Q5)-ER'I%VB,X2L*7*)R=2
M+(IU95UR/J^K6V.UMXPU&W+T7$>E)"217'(L6^1:,-&I6K2T,*Q-8[5:9V4,
M1^>7%4V8I"&.)D&T0+D'87B0)59+[T!!\X.$E-'.&9^TXM0#<\H(#1ID9MQ:
M+TV-U2X*4K.Q6DF-C Q=/IL=)6!*6"FF1(0-P28 8Y- \Y+QF@!92E#1R")Z
M:B9)CAZ;\#Y"-H''3*4/C%<]M3A036.U08BHG7<D,BT)1!V)3=*1H-$JEYIR
M2U%32:9J<>V-=FS9V'GU]O5&C=7>5%TM,X:&2(TR#+2-GLD (0-:7<HQ?YVM
MO[/G\.3VIQ3)Y]3O5<ZY"<XYG8GA,@<&J,_$^* (>*$(J@1*+%#NLJ$9E"[]
MI UJ\J=+[XG6.-&/[;\+FC$*Z!89"2XFYQSG2F<HQVF%$&N<:$'XG$9QG7 V
M&!6)2@[Q62QLCU EZ LIH31Z13ZCF:WF=5TK..\:.*V30G MA7$4 )0KC7LL
M<.D"LXG6@MM%@7,:Q#7!E0. '=$A:0+!,F)0;1(E97"6)IXHOR/@K+[Q#-1\
MILI)CHZP5<"!.9'+OA-A:4[@X#I-*:K]^C,A.(WMRDB]2TJ1@)Q(P&9*G/"6
MQ,Q%MH8QGN5WVJ\5;(L!F\@@I V<2EVVE#A-(]-"4R,0<]S70-2"0#4;W?4*
M8K"HU%A2G #:&<32D BES"7A)?-QK-EJ(>XR8BK)@/:AR"F9B(Z<\"HPQ Z/
MSBKT*&HCE<5A:AK<C2(S4PIRP)I$('--K+6>1$.MI\9H$^-M8>H[8KN,K_&[
M$-S='_EA.;W@26MG__PTS/X79[?^W(COM0]#N*>>*RBC#)=H4R?PVOC C#<R
M)QV%<L94SW41;+0WV^N:VE+V'P1!]1X)"(I<5,QFYJ2-WJ-.$,A%1H@;:[,P
MSX$@=R7H],!QK:BDP08M,EKNCD7K@H:(5H;.!I=.;9^R*%Q/P\6).F_P#P+&
M&?P#(K%,:2*4EZ"2RUFYE77-^8VUE*ZXOG>X=L"%XXPYFBPDS[W62I00)[#(
MO==SIF^[HV,2>T,R^48%_<V ?AJ&5ID:(04G/H9 0.6$SGJV!*>.Y62$HS2L
MK+-5*=4:O=NPGP?=BP7QLH4 C$XBVA"T\@#.<^<UD]$GBW9X2G"=^JX*XI\.
MXFD@V\J(=A1X(H/FI?&9(LX$2R2+X&5TVGE90"R8G'O#3L7J<F.5N\0$1S,@
M.0F:2R>BL58IT$%F5@N<%P;'V1!XLD$R#9*DG$4Y#DH3(XPG7$ ./D^.@U+*
MSIW=K7!<;CC:X&3B.I9C>< S;Z2WG'F!8#16RNNTL:BJ<P%8G8;6T>-%ZD3C
MUWCE"23>A+,288E:E;)12=FB/*V!N0]O^]EHG83>SYXW6;2BP>@/G\OY8X>F
M7M.CKO=8[$PMYU?G2R$M?]KHI-UUG=;.:!!&'==O;0S[O9.CTY]_YO.=7>S+
M<H^']-7[NR=G_]7V[NN-=W53SHUE:P237DD;LDJ@!74.J(F.E2,;)#!:LS6+
M,%QWBL$Z-5QY<BQZDTD"ZPCX6 [2X(%XL( VJV=.J])0V]Z!-A"UOO_'@D!,
M>ZNYM]$H\#HYX;(,/$:7O="AGI>Y,'SNSNQR%Y3E3"D!;0SB4W'BJ7%$6VVY
MAV"Y$./6$7/N<J_XO&OXC,%##I9:;S1D%EPL2E2D8&4I0K].5K3B\V;P.7,:
ME8I,I:Q(R%(38""(4XZ7 RNCB$)JL&EE'6#NYJ9U"\XMIR]MRC11[FDY%Y:!
M"R R<&L$4F]4LJ9$%H6VO:DVC$A^#,T3PHV)I8(Y$,-*!7.V5 ;AI5,,K57#
M;Z,]1075W[N QG":O$P1/ #UAAOA-+6,V:"<J*!:G MXL%'2_@BLC?>,&?3$
MJ220+$,=I@SQ406T-B'K)$KJ*:"-R=B\J8N*J@4%5M <3"J#=!(2E3Y*[CDD
MB:@"$*JB:G&HVCY'E5(T*?2=B4 #G> D,V)-TB1KSW(YWYQ)A9:AA7DKW&O.
MK]YC2:+_M_[5>Y;SV^A\QG\?I_[_';1B>Y#<(-5\W]+?XR%]]7OR?7<!>)MO
M_KWU<N<?]6SKF^OO*0+3VNEH? 0:A(O"4DO!VR@IC773Y8*LTM]FTWT:T+,3
M1I+@3.GF93@Q4BOB*$,G+P9/2TTIK<F$^XY.$Z-!#T6#BP%XL,9KF1,/@5,7
MG+_.:4:UP]!/1>U,$A#]1<$]9,)X:=P 6A.;12#E&!5))1>^).EKC\P'@5S(
MBGJKN(Q2@774@@_42Z&"YCP%7O7JPA ZU:N9ILRU-D0P"ZA7,R<N.R 20D[9
M4"<\O1MZM4969S=B,"806#D%1T&5 Z^EA6!3S";:2&/MPW?;&)Q)#I9^M X<
M(R;(TDE:>V(IR\1QPQ-P*<&$VHEOF>'F;3D2C%MMRVE^BEO!2PH^NP0QL'R=
M]&"%V\]U)6?2ANC2>P-!$ -4$TC4E\Z7N73TH<D(+:FM>%MJO"5T^RRS*3D;
MP ;JDN41;'))1IT@5;S=/MZF"44T_$NO9T:DLJC?)#J +@>'_F (P8+C+, M
MXJVF%._O/1[25^]92O%9NS=HX[U=?U!3B4M_CX?TU?N[=?#9UN[6JXV7VS67
M>%.Y1.IUUBEEZR)D;DTP@5OF10K.>9BW(5PU5&_84 T7<HQ&J@@!'4&1&($,
MAAC+%/%<AN+?2UF*M&NVXD$@5TM%0S Y, =@:#+6)VU"$%K(1%W=]+LPA,[D
M$YU5*8!RQ%- _S%(20QE@F2=)9,J:^/3RCKCM&[ZO>_X#(8',,HQK@$X&.-9
MZ9S,8]!>AWB=.H"*SYO!9WL&GS$P#IP8M&T(,*$)0C83G0VG,MG2#?>NX+,&
M7&=W:F1)J4DF0':@%=B0DS )O$T^)WN=8U&J'?M343B33[0@+!51HATK* $'
MJFR+\D0QSYSWR./L>^W8"K>%P$TBKH *+P#_#DY9*TU 4"5FLX943R%:G'LX
MN]U0L8C"CR1%7?(85!&<'D\"IXE'GZ5.HF@WF+>O:4758DI'00<C(NHO2T$H
MG#$K?>;*)G0;>.8558M#U30[:,!KCA1'%/B(J/*6.)\-8>5<=6:U3\S=&JKN
M;ZAW>^?UQLO-&NF]L4@O^C;.NN1XBKB(G1&4AB" 4QN,8;9&>F^7= XO1'HY
M-TQ01[*4G$#TFA@*E-"096:!:AM]C?0^$.0F+V)(G&G& UC&?4A!T2RYP]GW
M2=9(TJ(0NCOKPQH=BJUM<VE"X)PGUJ=$4J8RQ2QPGOC*NM0W=LI>A>>2PE/D
M:#2 L,$SX#)Y36VF&OWA6&K_?(7GPN Y5:"2IJB\YT3';$L_*R!6.T,B&$>3
MDI;E>$?@65WDV3@OXRIH=+R4]>@M.Z] YB2U2#EQH6V-\]XV"&?BO$%Z[YD
MXH-,!(PP!$V93)3C6EAAE"Z><XWS+B_<) =+*3?9J ">&9>DQ4EEW D/3%RG
MCKW"ZF:<PYDXK_2966,IB3)E EI1XE72)%+/E1;HT^N,RDW5,.]2@BKF9$5,
MPIBR)\LEITI7N6B%CMIS6D&U0%!-P[S26,%#Z=7H$Q!0TA$?1<0I,-:XR)*A
M]+9 =7^CO"]>;O]GXUF-\MX4M^2L512)VE(5R'0V.@K*>4:-8()F4*.\M\LY
M?\Y&>;,-Z(Y&2SPH18 #$..<(Z@3A DL))E%C?(^$.0*)H0/!@07$GR,1GL
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M^Q9X6:Q(6(IP)7J=OW-4VM;T!]8T.$C5N\DXV?X,9.U%F[5ARD2='-(/;HG
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M&C3)[,ZYR';S>+<\R[7IR0JYEBZI49^YEGY]N[/UXOWNRU>D.3_6K_:>UO'
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M'W1P1CV8?*UW=(R]8:T%6-LI8_Q_)[TA??>K,(7.N(8OT%_^UP*<H)-PD2@
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M%DQ]KH*J@IW3Q<ZA-TJQ2 3^0C!1"7&!#7+<!12X%U0[2K%*4RV=*L!9@+,
MYW/E:@MP3A4X1]*RU,AHK:)(69:;*%!P.A662#BEJ97@:W(UW;3L_)&S2NK^
M<6+AIO!O:/Y8^U?U5_6;R_'W1P%C;]GC7GQS\>+/T.P=M^SYFV:[4HWJ2W\>
MV>[79OOBH7+Z]]H(JA'VW_[SK!E.#K,RU7%?H08)YL&=!V_7J[>N2;7_7N9
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M@P0PTI02$JG"_+$5'S/'H<F27XL )]55WS1/X(Y^#.7[JVE=LS6++G@C<\-
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M"'^Z,58?;0-^7,#RF)"UUSR*O5HCGM4^=8YL^VEH59OPYM/'RR/XQ&&O%@'
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M 5Z'S9^9=0DF^T.G$\Z:K=:R9SR? #^;,/;U\^U?6S .?P9N/02]&D>24,H
MQ)U4R+FH4-11@6E@RDN\LL:DN+,IWZ#F9I36[.W6UEM"^I1+DRPA96-(3M!@
MF>,Q,+!0V'A&@[*))L;+$EJT)?2S\?4+YXY2&13@6I"(JXB1-I$CSQ6A.K*
M<YMY2O'D2XC6:^N9$K(;>Z>MD]6!'W8$MB]CMP.\'#ABMM?K^&;UY;/FR>&
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M]MIJAJ32X+VF /;01H\L3CHZ;1QSU?%E15F=OY@4P?RH)LC]&^^B;+Q/#80
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M=P+_].D! !7Z5P ;.-L#XQM@K8<$ .L_;+.5G_M]I[L+GO,K/RZ^*;;7OS!
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MABNF@,4&<$*MC<A):^!/&<$]Y8'8W,!@;G&E@GT%^Q81^V:)P#TU^)4(W+W
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M2.&\?91[&EN>?V"-P4ISDB0#G99X2BY6.0B^T.J\##R[J.Z,JGLAD3()YE5
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MN!(9>0@U'$=&HG=>.AN0,RD@;JD$PF@X"M8S1YS@(J3I/EE1PF56PIN[))6
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MH@5SP6I_H9P1-U2+J)%2CB%N#45&)H&L$3*(&"4U-5939F:-6LY#2YXB>[^
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M(1&GD%(6(T[A-QUD0,8)S:-S/"DQPJL9RVP_5B>4Y=MQNC[26&>JCH.-Q_M
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MC(A+@%O"J13C<I?&/[H@EH?GB0(UMF:[6UO=FRPU? XT]J1S#+2G&K7QJ_9
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MJ1%F2E))$%,F%Y\2'&DE*(J&2V4%EE&JE77)IC3%NQLO*NV/'T7CA$I:$TW
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MI#MA2FLN9?L@[H":\?"H?J>8U,67OW=\>XXF=166?W#2.6Y:UU>VVLM,'.3
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MO@3R(S=)O]-'6IZ.6V<PF7X*MIWDU=?+>@>![P8F4-.1DJ0(&EF/)N)3,B2
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M\U8O-[X<([@4&AL85&^0_%J]\3=/D4R'$SM3XU9,ZOUO[E]5.+.2FJG@G!'
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M@;4DK87,&$%3B1-PU!$;M"!19[2<')5X>$LK7,TZKE;C:(VC-8[>W@X_"6X
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MMI*I2"$8QYA6>=#CGHX:XM$9=<)\5QW?U3E -98]",M:DP,O%+=1\T@,%9J
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M7DK-A<_D5S8I9.%H8DY!IM2##R'2Q#-P*DVN[<*%X,>QL]D%-":\H(0[E0D
MU\2+Q$@VTC 3$T^ _"AABIY5M3OY3G9;/>R<'/5[$][B%!NYVSELN'&,Y;EG
M+2\H=#VO:[F>&S\?"'8VX6)V5JNDDRY-HHJ+V1KB5?($3(J>.9:$4TLK=MH4
M[%J?6'0_<\V>+\>>8\<S:A?*Z=+#+5!*("A#K B"\*@X9"$D]W%I!<0-GJ_:
M\?S2?6@?[7FN67/N6'/LDPY<LQQE($&7O%MF-3'<*Z*$P -7G&JMEU;X%,W
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MVX+X9@S3DAO%%7>IC(,RTDB>'-,\)RJTF-HW4W/9P[AL[(PQ,5K*;"3>6DJ
M14J\SH*8[**4GJ%0LTLKP%[0&_,*$Q:V1NDZC6&:0FW1SI%%>V6^U>BLAO[A
M&HRF J/)XIC@@C3),R*I#@04<\0A#A&5RD$HGJCA-X=D:HD_GQ+_Z>S9FNT>
MR79CPU9( Q2H(0)AL<SAB,1XBH8M%UXH&8SRH6173SE$>2Y8[#6+NAE8MS7/
MS93GQM9M4CXQ@[+-<151U"E%O$N19#QFK10JW@%J4;=(HFX&QFTMZIZ&[<;F
M;G).J@"*2!=0P[2FS#=.E$BN@P\N,K0%BJB;<A!Y;>W.5;>,5Z '/*_%>[_\
MX+K.:!9XM369LA\$XS9Y-($!4$UP,9%23$$R92RG:+P)ZH$9PK6^L/"F<<V6
MS\J68XM9>0^6^8!V,BN#U:D@WF1!;)FHGM&<CE[6B?L+*2UG;C37[#<C]AL;
MSRXEQ41T1%"&4I$&9+_(./&VY&=HAB#*ZT*VA9.(,P\/UZPW(]:;2-ZW1D;@
ME.#F2P(L.6*8<:5XS=L@I->*%M:;<D!];4#7]>USKAC,/'!<%Q;- )L^3QC+
M$$URV02B)+<$K/7$9:4(M1Q4ABBA#%R>.HY5JP4+;RC7C/<$C#<VAYT4B1DP
MA+%2T1>"(B8H1A+BI PY(&S" _3QN>"O5RSQ9FX*UXPW$\:;B"(+CNA(%1%@
M$@$5T 9VG)$ P5'%45E7;FE%+9M:XKVXQ)LJ2?')8LDU"\Z$!2<BRM%3"SD0
MHTH5GG&<6,DSX8P)U$Y<YOJ63KI/6154%[*_WH?XY0O9CU*_T3KZ)_7ZU1"[
MJIK]%RQFK],BGE2[=0*4,PR<@PA2:R^MMU0Q;C*'E$*=%C%70G>S"-RSB[GD
M1EJ-!Z<)N$P)9 /$)NV)S"8IZA7X[.O$B/D!LRD8$P)/)AGI@G0 QGCF8C N
M,UN&>R=>SX]X,09L?KY@P 3."&0NXDQ6!+@,Q ;)B(>@0\Q60*P&V4QI>LX%
MC[UBJ<A !*:X$4)1H-I8(:56U-$D5/ 4ZO2'EV.^L?1S,FHD14HRDXF ]VAT
M6J6)#")G&E3F#QO?4DN^E^U=R#5%#"T55P:HTD9ZEF*BPB:6*.5U L2+,=_6
M6/)9RZF&(O0B!0(THM!CS!&!AY8,*,V#?=G^A;<Q6VSUCMONK*PIW<V6]2>?
M_I.UC^[U/L1T/KH*"_2RE@O@M=KN]%V[T4VA[7J]5L:E%>CKO:F\=IU<DI1F
M.ZW[D</?!AM6V*X1.R=E:/%HG^KI<#/=I/DWDZ::UN1B4I*:(&D M'8-$R*+
M0#G/@FJ1'S%T-_4'JMJ?G5Y=Z3F=GO9ITD68C&91*TF\+VW==6 $SRD2SE7(
M+$H3N:WZ8]*938V; 9^\Q%BY><' 9Q%0/YD[]^)0-W?)"(HRH84-CF4)3G)+
MO68\\1@8RX+;A_=PJ:'N,5 WX8S-D@LJC2(F*D& <TF, 4H2]SX&+RWWMN0!
M73=)?S*-;N$ K=;V:FUO]A#(G<HA!^>3C #26:U8]D9I$Y2RP3QB6' -@8^!
MP+&V)S1->"*&,!HB <D8\0X\88)%FX)!?2\C!(I:VYL7#*RUO3D,08B,*)9C
M4$$F@,"1HYS35C!F'.5:31^"J 'N$0 W$7:(QBJ:)! \%$/ EMYAP23BD7Y,
M\E+Q:)96A+QAW,/=0;\7![/*&?I;W^%-\;^Q]<_*Z F:)X=(\&'P=Z'3UM%)
MY4]<^2_\V!7/.13WZ'&GURH?>-M-;?SD/^GWTU;L[X\88>);PP>FXZ\XC\]V
MTK_]*Q./%1(R3?=)>)K1GS$U+PL3].) !ULV\;.LN>(O0T$YD8J.PB#I7*+$
MPLJL!%.*!;6+#[DT^M9^=RQ(]I"PNLE])R[C<[YU[5-WUEOZ[=)V'+:.1DM2
M>KGL_M6-NW5[<IX9Y.D;=F= @ A+G6Y%+F]1AJ=N^12NR\W5>AK[W0*\_^?G
M1Z675K8+CQ0O^ON"V4?]WG_]YE8ND\'TY,J"=#K.CEQOVH"EE7<;6Q_7FXV-
MYOOEQFISK?'YR[O/&VL;JW]OK']>C"=H;FVO?QY Z?96X_U6<VV]^7E]K?SV
M>>O/C;75;?SCPT9SM?E^8_7/QN=M?&%SO;F]((_WKY,C=Q);_13?-(90F^*_
M;\*820APW3U$@4HV0('?@3@@11=\R_5(06PAN1_UWY+RRLW/*+5A5CW\&?F]
MGI'QY<$!7O^Y[KI'N/)>XSAU&Y_W73<U+C_[)8ET)94X4182=UY)"MQ3R[-F
MT>7,3 Y6IAO-P\MJTNCV?Z5N=?-MO/B[=B=\?UE%Z<?FVNH_WX[^V/]VWF$[
M?.>L>?[I;&?[/]^;!Y]H<WL#MK[NP+>U#]]WSC_!YGE@FX=_'&ZV+/WV/_LT
M'/[GR'VU)UL'_SGX=K"!BM8?^\VOGS@J7&SS8$]^.]C_CDK207-M[[QY_N5L
MYW#G['_.-_CFIUTIN(*,YEN,21%P+!$#QA(KP7 JP#-MEQH)M<GCPD?=D[3T
MU"?T.>RG>-).6_GJ6;USO598/8IKK:(]Q JD7_'YL:W571[!)A4YL8Z54OSD
MB?<0"(W2>H,6N@5Q[?QNQA5U!40X5('PEU2]J@-ON*/8B(,C;_0*'?0:G9-^
MKX^OE\D-)SU\'>_:.>DVTB2X5)]MH#(<3MJ5-M"8_!N_Y'J-W&FW.Z>]M[>*
MCHD-&FQ&I3Y?T>EQ4]KNN)?>CG[Y?92'TCJJGJKZTN_#:PT5XJ+'75'7J^T?
MO#U6\9;I0,T;9C$,[SQ\>[EZZXJE,7A/RF7%Y:UOTV7VP/>DN/VF=WWSKL6:
M96MTO=;7OE8+][KJ[#L0W?I1>Y^RMH%2^8+NJ&M:6 49'SK=1G\_-;;1]$F-
M3?S\?J^QCN@>&Y_3<3\=>D1)0=_,(D_H5]BG)KYSWVU:V.+/F[?@7QM'#;QT
MNZ20S:3T\<XTP.J?V_U=5YU=CR.A&0>Y;MZ_HLS>8]M^_LCWV=#GV;=GH;OB
MVWYI<GN=%#<KHOM%Z.XG>/[0QW\IL*^N^K;5QSN&>P2N*EO>]7$%\\2,,TY'
M?X%;+O3C_[JY\\VJL475[\'U^]V6/QE8]?U.XUVKLY>.&AM'8?D1K'#?"HA?
M/,]IP3*5I@C?R\A,X,H[ZP-$;AV508&6SB:?A&=3-RF=R_#]@[V:.U__Z'W;
M[K#FP;O6M\/U'UMKS4.\+]W<7A4[!\U6\_#;89/_9[]YOM]JGN^<77SG?_[8
M]X>QO77PA6]^_.-P9WL=-OD./N,G7$ML;?(-_NUP1WS[NBZV/FZ(YL'&V?^<
M;_8W6^-L=,\XLX$3YW(F8&(BUG!*C)8T"TUMB'1I17 [;>OD.2K:O0&!%S]3
MZ-?-]=&9Z9!EYB)Z@ RN9'@[9IVTX*UPTS?:J,'B$6#1?'\!%C(9 &%+&U7M
M" 2AB ^\C,2-D+QB7OBTM((',_\S.6N5XQ=7.1X46KV]C];1R2&)G2I9IGRB
MAIB90LQ8'V&&"^5M)LEE@1#C'#$J(-E*%D-FU.5@EE;8&V;TU!F%M492:R0/
MRSXV*63A:&).0:;4@P^H%R>>@5-I\CVRCVLL>28LV1JK*]II#4IR(K7(91Z3
M)X8%(%%0A1:I2")DM&W>*.#+>NZZHBR^FW0M'74.6T?/XRB]5 )3W'8WI(P_
MN:OP^>ZYX!OPZSI+OU9_E'0I7)G;2PU$^Q(1[V1\T,-#%#37D[+JYKD/$M2#
MC7QJ5^/H0%<'Y]FLCG,K5RF6O:WQ(5;9=[6XGDI<?YET17(IHE9&DDAI)!!1
M<'LA-'%4&&-X=*Q,C6!@;JB57!3%_P9V_=7Z!][(E3/WZ=5<^91<.>'S,\"X
MY8"\2'T@X(4CUF5&4C!:)*J%*$--F533FN-SP7RO6U;.P$=6<^4S<N6$FXQ;
M:[PVQ*-F0R I_$T%13*';(25.B599*5=8"?9:Y65,_ VU5SY?%PYX7 "#\8P
M&X@/GA-0U)86O)I8!=$(%W5,#+E2B66HW4V/Y*GUG%.H6G=6Q4ZM?U*CE\))
MM]5OI=YSN9M>O&GL@CU$W0CZQ3_YZWK>MEN'B93Q6RDV4+#UNZU0U4#V.^%[
M)7)[M9]M=EJ*5=I&7@9QY  .C$6-Q-C@O&<BR6@?,G>\F\KD--=^7SE*!_K)
MZD3&Z79G5-B<XE_NK'QXM8O;L%=]KXZ53:>Z[$TZWSS/0D5-2<H4#0KF#3$1
M(HDQYJSPE&F)E=%I%9?:G'AQ1A4V6<4S8SYD\-$:FG,&S600T0FF'C*GO&;4
MYV74"7^<DL(S0S7)VB&C"E9R=;DB4B,.<PZTM*"HAYHOH$1%UA2@?#2VV(LI
MNNA!"*TS@*-1L(?,-:\9]9D9=2Q1'4T.LO $E:*(C,HE\9$I0@-G062I37"%
M41<WK_[U2E3'J Q!,LA H_:9:N14:5V($F\PM8.N9M1G9]0)KQW/AD;C$XG*
M P$7&$%5J?2R%*@C>=2%17XAB?KK&NN;KOL]]6OC_(E4":X!E+&@G ()P9E@
M:++22"4"B[(VSN<=H;Y?,LXS&G"EY"91H0AH;XDW(A"&6J'2F:9(8SU7<SZ
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M)GGB!=,$N J6>1.T](/NF#/V3<R HUY:%9H;4)A#7>FY.G/6H# S4!A[-4"
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MPPP_VW&$&=Y,8$8H(Q@CI#JTR 3/.PL#210<G3H$LR2J.%T;29-(O2#(4"J
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M+VP5J93!,T.H3H9C%;3"WF"GHE*$@C;6<84E4<4IJTA]P(XY1$C,!4IRFF0
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MMA?C;4_M!+]8^RX[HX]K)WQ187J2K%0.D,8*KH!%>*(8,8$S!I9&V'IK^#(
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MQN:']<MB.KM#\BK<TYL[]#AHW^@4?PT[L<B<J0*WG7@\B$<. +'ZZ' 8]D>
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MC[I#>"6H$/CT(P:3L7C,/W_+U/OWP@X&O=(-*^>Z^D:WDY6FUX4!AF>4H#]
M-S*3[(R,>^5GC"A.9@F9O^907Z>*.U3\ ]@KT*B*.,/W1Z][,45:X&Y;Y-30
MH^:,G([+C;O:JE=E%SRCHM'QJT7V,\_9''2Z[(RTLQKS\W:UV]9U>V/"W.ME
MDE]QZ6J\)G/YHCAN5YP-)BX4Y^3V(6GJG,&!9A=H(U$OH.<3;P1>^3=0R&IL
M&N/Y*38[@THF'J,3WVWRBS%3AE&]03Y2V0$8S,[R1%)NY5F8J^$<LDIO]"RH
M4,S9AYPR-;/_Z]YGM:O8.4CJQ\[8/:M<RF(4A,V1GLE4/:\PSZ=1;"?K67_H
M^F4H018!R6SVNKM#Z'BVR_$;-* SLMA?X0O=83\C1P5+$P"K7(I4MN.T4]R+
M@(^=L4\^NK/R52IAZ5<OATO51YFF]LZ!+V^1K-QR0+OB$%2\'\K*9N379+U/
M\21'A\#)RQ_F\$[5Z$ZW:'<!(*K^',81%EUZ_,A5SQVR%P&9[*SUP8+D%X)[
M1%0!'U9-? &/\QG">U4(I7K2)9__XD']F4^B=_.RGUPP6N=.985)&9H_Q*^Q
M U[N3NQ]+7V<FJ91_Z];M.L25 E:984J3[P#?BRTO ]6/+O2/@M4!>H @L?C
MN<O?;N=X2[:)8$_!6P?ENXBQY-M'9&(L3)4O<@S6L*H(/CBP@XQ?I\61/<TD
MPN[G>&;UDFYN3Z\XRC,%-Y2CAX <'=C*S_\"-NIJ:_I#X  7X9O; =WR3>[&
MCZ(#>11 RJL0R @=1FS^)GK6K[G\,^?R[\^:K?7%<?D7TU%0.RMBD,%R1(CS
M9\?#'JA@'&'HA-+]W_X-_-SVISP"8(=?8_8(RILEM K73>)= !8C-[02S7$T
M\'L>ZQ3='=P<!KG2IA>CA9/N8/3"?CRV5>BP/0Y1G4XX[DQNY6R[B@WW#V(<
M7,&://Q^M.Y;"?$E]!EK.P><^?,<VEY6,U)^C7^>E&%P<+Z</777>%423VZQ
M#AHS'-Q\R]3:HX\9UY\2UAB[,D13/P]ZDPT.^Q$Y@+8OR"9H\4O;/K&G_94_
M+N,W@/?XX5)EO+XV!#=V-*6%K:?.(J4C6Q*R*%<3_W((LM/+WX)VV:5J3W'0
MR_C^KU)C+BV+TGA->%3)&*F8$4DR(B7Q\K,"QE&Y0&" \FZ&[$7\YP^[=J-]
MO:7@$2^L"HL3O-E>PJO&]MO-9M%HOEXMUIL;Q<['5SN-C<;ZA\;FSO/H07.[
MM;DS0O#6=O%Z&PQ-<V=S(_^VL_VNL;'>@C_>-)KKS=>-]7?%3@L^V-ILMIY)
M]WX;=NPPE("I+XHQ:,;P^RRTN(*J(QK M0;AU<Q;:KC$SD6L#8O."JN-D'+E
M.:V>500Y,SN@['GM\S)7/LGDN U.6'4\[?J:\/#< QZ9[0O:/&7N+[YPA=J_
MN!+* >(&8M&?<B2 #0RS4]@?+S#'O.!V0W2H6BR[V1E],5Z;SQ]#9_U!_B7'
MTMKC8%;%["LZ/^W"/M,ET4_5,G-%O4?36'Y_EF_!Z,=[+_IY"JK WR@TE2=Q
MV Z3!5(@_L/CBN7=F?Z+:CU0NL2)YY8I\ ""MIG^)_ &PFB=D-Y[G7#4X$;G
MXU27P1EX->YPH__A8KC^.QZM7]@AR'OJ=C][QO*!LUP24C/$F0'7 $N"<O9N
MSZ-VUHWVP5WW!XKSL/X%9?XV* @]7Z0?4_#,J[-\G6MR!=.%;W?[PU[6XFF5
MS4 1OQV7O8N8?.7!#NP *&K^LUT>E8.9GOELMEQ-Z0^Y"2%TY?N(0'CFV:/-
M>2B?V'Q)KVY60_F3V1 AE"9&WATBZ*U,(!&K(_M^_6=U'CG3KHGG\>8BJKMS
M'M4M-B+ >KNX/+"7=NXM8#_^9:5=O\#^BP8U)C9@ [RMD:"TX*6OVEW_Y:G5
MM-48JVGW6_[>WJ=->%[CVVZK@;=;^W@75&YOXPO=:^U]V3K<XLVS#^WMUU?4
M]/ -M&FOO=O: A5\<[!U^%YL@SHW-PZ^;+?VVLVC]Z=;9_NL^?8CSXO\\)S/
M*5%#:*)(T2ARLGV"+)A/I*(0(M"(/58K$^:SGB'3<V%)"D8!QG+EHM..Z>"-
MMCP8[ND*F!1OCS.5ZPWCC13G683Q1Q(^#M?_-BYH^/N+HAD'CRG.._X@AF$[
M;J>J0<UNISO:K]W9'[5MW++*%?JE97K#?W;<&X.U0,)(CKCA'%FL#.(X6<DC
MHYRQ6\KH$C*VU]VCXV[G?%EU3'_'\ADOY+.3@T]Y6:,_/,H;S<Y&L:O4S1'+
M_LO;L-51/T=KKY<WH5=L_+@?7Y[_\N=YNK^R4S6XNNG/\;/&P:$<";FRO[P:
MV='E29!D%8\")>/L!^,WCR^O5I>N;(T?7>-D59B;+^-5<L=K@MWMJ=]K+*&K
MW,BZL75C!::W>NPM,X+<>/AJCJ^:VZ3D'(5FGO#$R#5[C:=/'[2JTP=;(X]A
M\_JVWD6<9_L9QJF9UU9O.4S/-G_K["'XK=$Y]S3[UTZ!WD_%9AP>K?YW\R&M
MJR>T[B=""SX3.GO\,E>]Q;#]N,NW&=#'&;='D;M\5J 6MUK<GDK<?@#C\YPC
M72*,GWV ]&)?Y,A#NH?:W3(MP!U/K,\[>(]RZ/_?=TR-<(LQ6/Z,!_.L0MPO
MQ5I>CK@<[9GL\AT%=\ZE>'D6%>X8V1D=S.^*W</W8F\C1V[>Y_OPWL8ZV6U]
M.=L]^ZO<RN_8>-/>_O3AJ/GZRL'\PW;9W&A_:6XTSIH;.2+TX<O6QM\'VZWF
MX=91XQ3Z@[<^?11[;W?Q/V>-P5:9#^5O#K;6/P=&1& B(>R-0-P*B4P(%K%H
M#7QD920++7O_D,?Q[P%?CXI2CP+Q-Z+4XX#1TZ8.N0Y&]TRN5H/1@X%1\_4%
M&&GE J=<(X.M15P9ARS,%N+&1(ZYT$'&E35YXU[)^XK\XV).39EJRK38C&LU
M2CT<2DTHDTI&*L,ELH8GQ"/#R"IFD!?<*9@KSG+A%[VPPB]+"E\U9?K)*=,]
M4ZW58/1@8+0]H4P\&L:5THA@)H$H68*T%1Y9;&%"@@S*VY4UII>.,SW;59,?
M1-3&>PT>*8WM3Y>(]E'"2*.I&N\-JM%G+O39FHX>.6>TH3FU"<$.<08LR 7*
MD+*!A*!%-$F#PR;G**]5E_!Y8GU[@$A)K6_WT;>I (F*UBFB"1*)J;QQ#_2-
M1PH3X92*7D62U,J:F$??ED*M?F7[]@ ^?ZUO]]*WB7TS.FDFM4=1QP#V33%D
M$F.(::#67$B33%I9(UK5!N[Y&+@'\&MKA;N/PDVYLSX2K1..2 70-:[R'G67
M*+)&.1<)CRSEHLK *,6C6KB?S%M]FX^3CE.<50?*IA(2=Z:.<-3&_>F=UQMJ
MJ'P8YXB>!-7RI/;?51FC:PB:"X+>7_)I@_-!@Y'7*3NV/A!D++-(L&A,HL%(
M!A#$*9\#@FJ;__R=VEH/'T$/IWS=)*F.REED J.(6Q^1P28AQ@CWQDE&J%Y9
MTW1&6;7:UUU2<[@ 7[=6P\=0PXDYE$!? I4*22<MXM1@I 53X!%3*F7RV&"\
MLJ:P6D01L:50T%_ '"[ !:[U\!'T<-HSYB%:Q@ERPG+$I1#(<>P19\F*C*7>
MNI4U,6NG;NT8WUJ)WHP3Y,9OXXHZ51&9D:L<^[_7WO$S\8['\_BZJAWC3UN3
MK+89CC(:O:HR"K?LMQJ4Y@*ECY=\9>#G7.N$O&<)\2 2LIY8Q!*V!B94)@KD
M@+!557.#9[+K:^'+O[4J/IPJ3B\-8\R<, (92ASP T^0X80BK612BE(MJXU@
M\Q8A7PJM^Y5MY,.YS+5B/J!B3FQD=%P:K3Q2(>_0%%HA1[E%VBDIHU&&*KVR
M1F=I9FTC?SG_N5;*AU/**6\:2TV2=1H)IPGB,6)02L.04\023R3\D3=2K?+:
MF;Z[1E4Y^6J7^9FXS-_/H%B#S5Q@LSOM)<> $XZ"(V&SEXP50Y;$@&A4D3N)
M*:< -F3&$8V: /PB3G*M? M5OBF_.$C.H\ ."8;S.06KD76.(BRCQ91%%Z1?
M6<,S(E2U7[S,AO#A_.):%Q>KBQ-#B!EQC"8+KG#DB#OXX;)"1NNU(YXR[_/6
MJMH0/AM#N/"]U+7R+53YIEQ>&37!3@+W5#''H9P#%@K.KV4A2I]RZOJ8#>%U
ME_?!#>%\?N](D<PS<(!;W4&N='IS+O*'3[PWSC+.8-A"=YASEI]WO4XSL]!!
M^KG8U<.%&6IL7PRV^^D(@Z_FB444)"6(A\202U$A9[BE45EP<]+*FL!TU=R?
M6BU.:9XB8<VR .(R9+1Y<MQ;NH6=ASLG4./>HG!O*KACA)():XP(8![BD1CD
ME ^(:VFE]$IJRU;6"-5S[(I\KO!6$\&:"#ZG,%L-B L#Q D1I%)'R\"UE_F,
M!A= "9T%GY\+*K!GS@;O5]8,87.L;-=$L":"OQP1?+@=/C7N+0KWIH*;SA&L
M:'#(2!L1)]KF?; 826<4TT(DKDE.U"+GV67WY/!6Q47_J*H&KDW5W9T4U+QM
M#=$EJ,_X@Y03+W(9QEY,[>ASN=QQB>-1E47KNE_CBW%%]%P9.T0'PQW]\+PT
M>?S?83DXG?HHUX \+YONRNX@^H,.]';_%+3\"(:@NNLKO'W8BX6WQ[GP:9'
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MV28RFCT$OS4ZYRYQ_]INL?NIV/Q5OZ_N++N?""UXP_GL\<MLXA;#]N,NWV9
M'V?<'D7N,OFJQ:T6MZ<2MQ_ ^#S[7Y<(XV=O#F^"TW0E'#X[:C6*=F6GZYH_
M]?#'^>M#6K_@&:R'.XP_*VKXT\3/Q\<1\!9]3YIO__JR=_3WT=[&+KQKB^\>
M-O#>X9>3YJ>]@]W#S6][AQ_9UNG5XPCOS_8V/N+=HP_PSKTOS<,/[:VS@W+K
M\ .T=9WL';TIMUIOCIHM?_;/66/Z/'Z*7'M&-;)>2,2=-LBFP!$CE/OHDM&$
MC;9.+*!HSE*?LOJ%#E']<F>D'NZP?(U+"\2EJ?/RN7R\5C:@I)5!G$:+="02
M26Y\5)XG%? -VUQ_<$IJV="GYE$UCWJ\L^PU7BT2KZ:.LUOO@PH&B< #XBKG
M]Q!>(1LM]I9+%;C+2[9B@7F-E@W):A[UL_.HASMK7N/2 G%IZKAYLI$0K"/B
MG()_1QQ%3@>&M"!$*@%&1MD;]M8]&8]ZMFLRLQ7L7>SW7Q8SHW;CO6</'K/[
M!3)R/VZ4ZA?<Y/FX(+8U':2Z^WG:[R8$KE-R/_O:%/4F["?3S^E@S:W.I/Z?
M?VE*Z)]U]8KG9"L7$(FH=?'A=7%B*^]^4JNVE4ML*^L#2\]9/Z>+6]SJK-.3
MV<H[%+A0U2F$I7?#)V>,GL'NF65)^;G4RT)/G@MTZ=:-'G?_S4]XE/EQ#</[
MZ2#'?7+'U0F1GP0=EV$-ZLE!<.D6J1YWLT\-@O<&P:E(TCVRVRUO<N2:(=8,
M<5G \7%W%M7@>']PG##$^R3CJAEBS1!KAO@DVYAJ$+PW"$[%3^^1+&QY&>(M
MRF=\IYS&6 ]XCL(>=_ME[NS+*J-*^35.$I#\S^7$,N/NXLDMUD'/AH.;;[EV
M,/0I4\\P?CG9R_3/@][$7.Q'Y$ !OR";H,4O;?O$GO97_KB<':;LG#]<JM4\
MCE>'X,:.IO1P9UVAGR-! NSIYA1F,$FC4A_P+6B77:KV% >]C*[_*C7FTK(H
MC=? 2%0R1BIF1)*,2$F\_*Q6UEI5^IUN*EYG8.X,^O_YPZ[=F+WGEH)'O+ J
M+$[P9@W RMJKQO;;S6;1:+Y>+=:;&\7.QU<[C8W&^H?&YL[SZ$%SN[6Y,UI*
M:FT7K[>;&YO-G<V-_-O.]KO&QGH+_GC3:*XW7S?6WQ4[+?A@:[/9>B;=^VW8
ML<-0#F)X4=G]LC.,X?=9: &8.OY")<PC8^RYR"7FC>(V+\9%IQW3P1MM>3#<
MTQOS<Q%Z)4$7(:OTQ@1=X!HR9Q<P%M5C7^:Z0*6_Q>BL>]^#\2C&M;RJW%G;
MN?#[8Z:*V_$',0S;<3N-F_.NM*YL5YRI@H9?.VW<YF?-@J(J!B2"S'6RP<US
M3GG@.AXK!J((7.?YIHT[E\$X)8/=+(-9T/IE?U E>AM,)Y?[*5.[Z57!S3-)
MZT7T*N/\.356+3()V?(% Y8A U3UOV>8>&?]ADR2BQVPYY=89S0N&]&/AX54
MP_+KYMKY$+]&8(]HE)\TYZ.'YWR-_;R9K@ +XD$;!J-4]38;*MOQ=7*=^E#X
M0^P U=8RK[4)"1-@W4D;P60R0CD=;8SJ<^-V&[#_MNV1M[-^(;#KG?!A+-BO
M;#M_])-$*(]S5)(U6_YTZ^WNR=99 S<WWASM0GN:AYYLM_X^W&OEBK^;8O=J
MA/(H1R4]:9XU3O8.U\^ L^.M3WL'S4.X]^PCM+/9SA5_MUKM0^#LTQMYO+0$
M4P74/;F(N- $.:4U"L020S"SE*:5-:/IC,KF=]N#O=1+,;_02LM/L9 R!R0%
M[HABP5&5.-<X&FT9@)$B)B4?1:H@"1/*R#WJ!=1X]1!X-;7GQDGM3%(:Z1 <
MXE(P9,&R(!Z<E9)%1:-:62,OL,:K<D[$JH^*SZ5[KW-PPHU#Z^?1D?K<]X+@
M*M<$#$DD 1C%D\Y;S0C%B0<K 'NX_1&#<F7I7EZ:HO$,]6V.9V7HJE%H#A2Z
ME(B0BQ0DC@F%%#GBAG!D)?Q)?.1!*,4QT2MK5-<GUY8!J.8A"?D @M8D;UKB
M#'OG9>2:2L>4!$KL;R8)M=8]C-9-V7Y.C3#!,*22-6#[C4>6&X=BPI8QG)*T
M=F6-@=9=/W2P9&?1EMZX;QX=M[NG,585R4" 1T8^AXY<[,14#NH,+\MBZ2^V
M<XVG[,,H_#>U2/EZV.O%SJ#&GKFPYU)6EY "U9$XY*10B"<<D-'&H"2L\Q1@
M*:@(%M^8&=M9:XO_$UO\6OL>2ONF++^-Q&L0110)T3EA)4;6:((\B<H*33CH
M(EA^QE9U;?GONXK4/;7MJHQ=MO;MTH/US\?,4ZRSNBV=S1_O3;F8LQIK[H(U
MEXXV)P5H(YE&>>4*<9!'9*(T2&+#DY=!.^O TC,]KY=16_J?P]+7.K<8G9NR
M[]18#23:(Q+A!Q<B(BNL0,X;HKUW"<L .D?TJJCM^STU9@/N^CJJ,-Z>D-3:
MLB^997_=[?0'O6'UOO_:T[SA<PPTZYW0['9\C3IW0)V/EZ+X,9%$J$(>9AU0
M1S*D)<N)IX-T.!#-DP+4476JUB6 K2<P]+4*/HP*3AE^K&,NE\.0\2P V582
M.4L$$HKX@ -0\!S2)YK4AO_^Z_4C<2V.N[U*@[II?.!H/W]:G64(<;R:WW70
MYNK7FAD\/3.X73+,5\,^-*_??]T]<F6GFKS7%_/[>GIZSX.3I[7K<A<$VYTF
M$8)J[YSE*'D2$==,(6N!3H1D U66,4;9'5-DUCSBY^ 1M6(^FF).40M!O24,
ML)+PG)U+:XZ," I1;PQS%,@])T MN)EWGV!-+:XIU>4CN3516(X00C4KUX\L
MU]AR%VSQE]*?FB0Q<P;1P,#H8V^0"<XB#3]HBC01YW-R*U;O!E@"='H"DU^K
MWD)5;\JL:VM,2L(C[T3>"J 5<A'TSP;A(DG,:J) ]0R9]\#2$R6D)^89V/=6
M=V#;A;TI$4*=8GXI#ID^>>Z\GX=(S7'DJX+Z&N/OB?'[T_2*><LD)QII+CGB
M-"\'$X'!?^-")<]%L."ZT1="X(6MS3Q]7KTZA6B=0G3)2&T-@X\.@U-4EUDE
M9#Z1SX0!+Y-P@:S(=9BHQYIR[@+,V!I[ 1?F/F?VY&AWBRRBL]-F\>>0MZ[2
MAN)=M[./!K%W5+R;L=/F.ZG!EC +VJA'[8L>3>T=*DYB+Q;_7G9B]A.MV-\C
M81_=WOCR69$4HN$.Z: =XL$DY(SWB#$MDE81IJ<Z1<^(GA'!.D_953F \TS[
MDQBB>MI'T][:_>Q]8)PYC (. 7'.*?#J7+"$*BJ-22825DT[G;4H,IGV&_*1
M5?)P+1W7BYR'ZCCZO..P??JB^E+9\>UAB.$BI  ?=(]B,;#? $X&.=J0CQPL
M':2,(WJ-JK6MW-A:NK)T,6C'9Q4E T$"Q\J#P\938D@;"L)F!?6,8(L375F3
M0GU7MI814NIIOV':MS?6/W-/O3,D(>YS'A;!-+(A*@3SD*16PD5I5M84GG4J
M^WS:+V/$ZI7LQU<2'X](4S76/TS>38A8^3[5(IE/C@DMRN[N2ZJNL"^4/YG-
MO832Q,B[<R]ZJQS11*Z.V/SUGU.Y!KY.I4<NJF.(>?O607G<+QXS6_*E%JWW
M8##VXQ$,XT;9]^UN?]A;HG3)'\\UY@R>1?<^-?ANZZ/8:WW$VV\_GNZVWI2[
MX+KMTDT.[P>W[^ PNW>7-:9YU#P$C3D\.&BVVNUFUK+67P=;G_XJFV=_'^ZV
M]L7NV?K9]MMF3F7$FZTO_+,!= +C2Y RX--Q&$BD?>+(,V,UN/<Z*K$RR0:^
MGE&*1@ZW!2H2E=SFI,I8.1H#=L%IF^0M\RN;Y^ ];99]6Q:ONZLOBG>#L'H;
MCTE<[1=;O;%; %&4B8?LUFP7ZEWTMA./K"LN90AYI@[AIU@<V(PYA;^4",KN
M]V*E\,5).3@HKLQE\5OUP>] \HK#;MD9M$_!+@/J=X\K] (+"[#DRZH&3=&^
M&+'?7JTW*<?D]TP@X?\');)'I^UN&:H_7#>,J65LQXX##MH?V,&+*BLW-*Q=
MO%I_O5G\YFQ>MAK?Y]O1?LTT,W;.3H_B[T!"#TI7#KJ]%\6-#.2XUPW_G[TW
M;8KCR-J&_TH'SSO/V!$DD_OB>8(()+!O/ 9L"]FW_(7(%5J";J87(?CU[\FL
MZN[JIMD1BU7C"5F&[JJLK+/G.=<U]J.%*,1[[Z3D7 5#N<>%NY'J)"'BP=QA
M>@-1V?;NCW/Q"+P2GV.2L_X@#&-O#EP&S#9$UWOIUVHA;^&9N\&.XHRG!W]S
M9G6;[6:N<AFXCQR"3F; J :+-/,<-MQJ$S'5G.F5]=%9_W(44LEH_6H[?KJE
M!3BWT&OW,^T'"&5G-(AV5*0;4J"-XPM0"9#7?PXSOF[,TO5=_OP5FOY][<:W
M>XWL":)3TSFK?'>UD +56]O^<OO#X[Z#>_]ZE&_ 0-O'(9==8 5-:0?Y[40[
M (5:LJZUSBLU,]66U$#&D'DV]J-_6K=-YK/I7L8[/AQ#U-,?G(/AL*&\O9D%
MJ6&/07&'H^%JG8)F]<\PR7;@CU8GABB_WM7.$)2IFH&'#?H41\525"??8&D&
ML3,\@C]#)ER'RYYW7!R=Q0BF8CA[E6N=[=18P@#>5#<_Q^R*]A3$[K,]7IT7
M@;-N62F"7YZ ["T\1KESEM>,PS-9 -P+#"/$L:,24%\CAOF;G[L!UN'@+75.
M[:"JXF5S[>-@9.']E0IN]22-68 L8OG"&6BZ:  8_Z,<X.5?9)D=](^+6'9+
M$)JOO!C-WU+PZ-7N^VGD;O^:_0.CW9]LXNR-P>[!6ONGY2.W<F\;F^__9^N7
MG<YW%@R/!8-OW?>=[R8_W2M7^KYR:W>\<K]7^(KZXT'E*T=VW#GI]_H0@5?:
M4EQF?NO?;>3?[\/OZ_L5.=KSHWYMG%3]@/%+OOPP%VM ,.87658  EQPXDLY
M!U9I.[UX=F5P,#&MY5F:FG?I:>QD6F7Y=N6+3'XS_YHV)C?[_I7*8+7Q)_9\
MNOEERQ;>6*=PA16@KN,XV:O\N<I?$ ATNKU\#@/.*[LP^.UP[(^N$XSS8KCF
MW_NP>N_S]RYFJQBKVK9E01V?ID$_#QK9\^I5@Q&K+U;D)'_<%6'ICHZSB^M/
M[18LX6I1R-4"\'19MNM+#]?JZ\*3=GK]4><\CA8%=7[!BWZP9:I;9*H3+5/=
MBUI/RU37,M6]B,=[(%/=S06L^8)7,(%1A7DDWG,6M/$J<BL3)-%<D"1>%848
M>-P36.)Y5LU%!W=-HM&94+F B[PNH.^6U*BB'QM>)A_[6B7?4I!X5SU9/VWD
M\GUW=%XCX(WZ6U1B \]5EV[FEOS">/.>H1#\<>O\(!CFN?(<,>'S.3RQR*7,
M%!PC$\SP*(RX5-A]/8QQ?(T+\4I(V,P:U?>[:KO6O]-:;R>OMQSTN /MVI4?
M-:^8H>W'.LG?AQ@V=G;@\T?#SE8O5TWFVD<>8W3T[[!/N_";VV[3JQTA?CE4
MD%<VN;Y"DLA;$D+>_,BWV="GV;<GD;M+C)&MN+7B]H3B]BT1E%9CI,W\=Y+G
M=JMVNM!QY\41SI\:+&3!-GS.-&J34]CYL['FB6C+;=IRFS[^.)4PV%KEM50V
M<2J<M<*HH*P@W'C.75TP45<T>RR0!6U5&K!=*\";\[DRR0OJ+KU?B60R/O7A
MX\;%[O[6!:SG[*^?/L"]_NA^.-D1?WW<P!_H>[9SLG7VUY\_?]JY/#[5W=G<
M(3O[L*:/;S[]]1&>Z\^?NQ\NCD]V-G__^->^AWN_.?YP\MO% DF7B43+&#'R
M5%O$?2)(!Y:0-YAC1X,B)JZL$Z);:M._V03HMS;@R;'2WBE%<!0\8>(X 2'7
M)GA&N&.V6"0\L4BXM4A/:9&:D&1&4Q<P0U&Q;)&\1U8ECA*X$LI)ACQ/*^M*
MW'FH_67:G39V:F.G!4LE&7/"Z9 <"#QGV@9#E, I!<M3".F&1MG64GU52]6@
M.[-",H$I2BZ#)PJ?D#4!7DKT3% &[R:P3((BUT@;.[6QTTM[QCM8)+!%B:0(
MKEE'3HBT*E),(M9<4_#(JHZ=2!L[/8-%VFN 81B2#/<!$>LTXD9*Y+Q0R&O*
M6,CTBSEV(N+ND(LM[?N==.M-MW\8>_\<UEWHUQ;@EM;Z!C'!-T:E37C:?%^^
MNKPR6+J806=#_N]0@.KS.RH5P7R34@@LTQ#5%'F+0_N2"UW3MY\;YKN]V0OL
MI^KUM4;R3D9RCJ76!["%2B9DI,>()Y]+7LD@QR2\1:V(PWQE7;0DM2_!D#YW
M@:?5Q,?6Q$:I)UD?L:,&R<0]XOG-N$@#TH0I+)/4(C/:,?4<5/6M3WQA!8Q6
M$Q]=$QNE##"0R3N#5$R%.]HC9Y) 4@@06::D8;8Z!L*M4WQ-3O&K9.ZM*CZV
M*C9R>.^Q@M?N$%C./**O$]+><I0'$ 2SDIM(5]:5;!E9'JG5YKK1DL66FYO0
M2=K(X8&1@TD:TF@K+23/) 0;>4Q1"^=I!@G1]\JF)R_1G<,K]&VM\=YV:HX"
MGE+**',)*:HS*Z6FR!K!D4WPUKERUO&<1M_53+W$@.%6%NYEA@J]D]8V/99M
MXIHQI:@!4>>8"!N9LLG(R+R.5KI[936M;7HTV]1(9ZQ4A&#N$42_%G%F:0;Q
MY<@'0B-5 O8[Y'.0OX-Q^I:R&5"K#%'%E)">1QN=L02RUAP9.*SNF<VT*OAH
M*CB7QE"I%4O(,@$JJ*A%%OY$+IG HPP4*[*R+N^*R=]F,0\[:[Q^CKYQYCB,
MQQE>>K4#UXZ#&CS,AI-NKSL<U4BJ[?'CLUO$KY(PM?6=QS6,[^>.'[EQ*NJ(
M;*[J<&(QI$Q1(4=]$I0Z*X586:=K^O6')FW>U)JHKY0WM2;JL4U4(WTBWAM"
MI$%"4H)XY!II9@+*1PB2>JM31A92?P<3U69/#\R>6D5\;$5L)%$V8"Y4# AK
M+R!6$!(Y8>!O(GG#$Y%<ZI7U.W=S/CXUV0) Y'4(HE?21#Q0763!3KP)9FP)
M2&5>%"I(^)>>V$(65. .9^' ,^AY04?KH,X$ &54@&).*@24>!D!I684NB5D
MVC7)XID==KHG)_#)C(EZ*WS815J0Y\>'S;O60$[M]BH,^0(!6^6M5QSJK79.
MCPM:^2#C9'^]]W]OJH3=#'I-]&ISV5?SFSS% UR[W-4L;76=8%8= "]A>P6X
MME$GF%)?U96%+-!9_$\Z!*/_W$H0+W%XO$"NBQL0F5\I&/W[C,K:N07B=,%%
M+B#TA8&B=]C/)JK9WS[#LUZ=H&=?#?\^N5L%,IZ![N%N*-OP4,/ =X:GQ]W1
M6N<-_*K7RS?[V?;&&7&RT+ 1LUI?NCN$KW=/W'@PS)\:%Y*#VJ5>%6_U"N?$
M8LB%P84+A;$VA!L6#-$)<YT(UQ!TI9MZ4@OG12/F^C4.,F2+/8S]E,:C\2 V
M=JM@]@^FN)+Y0::Q%Z*O-/AZ -\%K'?CP#.-N=$&:4X\@E= D.62(8NILR$S
MCTBZLL[%DKZV?U0O? &,M.SR#5 L$]CV!0R6*33[Y"]+1CF^?[4<%-N]SDX9
M4JD4J=*[#+P.RA=1)B[KIFXV^.-1)IT\!TVVQ^?#[K"8@9OH/ HJ.WQT:V?K
M]Y^V*BNP^]/&3UN9D&((P5H5S,3/]G@,"E 1,*0$P9P_KP%D4QR=-U\#//PI
MO*_B<(K-N(879+NB=$C=P7#4^2^8C PF#]>JGA7"I&QOAN/CT016/NOPL&8B
M:#Q; W*>77Z6^BEKC-IL><I-EV[8A!2R/-O8#>-_Q['P'9S:3/>3&3.^='/H
M!C^Z$T6D#491@FT4@1/M+<;2@9)H3"77W-06BT\LEGP05^0O_>%PKY=QN//2
M]N/@!,*!O\71VP,,%]^Y.#R@D25F@D4>9ZQ;X0,R)&&4>1HCI9"_DWB%X9KR
M1"Y 0HUFVYO%]+,==/O@VN:9#X8U2\P5$V>^?E7#3B].A3W;KG)NU#K'UR)C
M G[_(.=81TJ3,&GJY*[QE>/;!H;W8R)Y$2ZPP0FS0%AE>[W^&**![-YR;ATA
MO82?5>IY"ELXCDURI@GG40DF&BXK;]_[M7=KG8W"'#/Q"17/T#%L#]P<,BOP
M,#6G"'PA4Z+4_C.?T8ZG9[P^>S]PRWXA@"GN,-_IQ\V-U<[PJ'\V6?82_U41
MIIS _3*5R+RS/QUT"Z)[\5(QWSS_5^R%T\QH,RR.]><QN*B2X9W%"4%+'02
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M&_7]I]4\,%AFP[[ 2QM%,"I72E ICPY?N!"UXC,3'PAS#I)GB=.0$*>*(JY
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M$,U>1BVD2,ZRR.$_(!VACH3D-97:ITF<86X99[14;(\,OGS((+PXD)'BH*-
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M=B?*SF]9F]C.IC](P4<I(T;*)H%XU II$S4RQEJI0D8;IROK;"F!3 /_?#(
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MLI?L#/S[^>.?UW\P6^\SA_7.C99EG]=K"'-;PRD<MFTVVTZG7T=GH+'<&>
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MI9C5)DQ/^,+')J"W=(.SR4M_T+!N:L@/9WF@;1KW.;IA@T5MBTSOF=FPB>M
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MEJ7-;"EQ]24L]@DK!;G[&F+UMK [$98"-/<O(!K1P,9K\'2H:-WA5S;2/G
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MF:I FJU JJL*I$*M1U4@J0JD0KS>EA5(IUU1M*HG^^N7FZO;Z_O?3]&1O2$
M9DHZ9)+9Z,<%.(!4^!'72 [X7+@P&WB[N32<<G;/)N-9(0:TFIU.Q6CK%:U3
MJ75JE4:#-\?IM4JM7:NT3//UC(\\LZVR8VC2@)*^P3U[M&:<E\L4C5I$/C^E
MO5-M.;0TDNU3&/@4O?S,.9V4VYSFY4_C!.JHM'QOU/1FTL\F>W<Q6IG74&=H
MNMG2&F;24$>Q4AX[63M:NFJ4=-9<YNP]O\U;6O'X2KR#='[3M^7)\*M1X@9M
MJ;WT]LQ>OO>#)\PN" W6_?'NAW#.YK9KNF8V&O-::U?KL=<PI1=3,R/.'+-
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M8&.Q3<BM>;X,,<@I;TZE7!Z5'0DH[UEAN ?Q9\.Q-N+>#IMJ<LD_RJ4W,GU
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M M;_YZN_N>U:O6F9K-FQVWJ=M?J=3K-E=AK]IJDWF[K=_*/UZJ=[,C_ L+B
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M1",ES77W)9? <S9C[AZ6?4,.52107[E(8&;S<DT:2GF3%RI3/A3Z#//W;\(
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MCFH W6T#:.=E-("JQMF5Z/:]=D$3[13MUJ?==WFT>TF-QQ,I:7LF<"$38IG
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M/3"/!:(MS\K4/3^J04F+K:1&?5/0<R7H6T1I6N82LBOJ;N7C*N+NB[AM?4D
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MNI.QX9X3L%J%+M:@W:BWR)P@]@Y<41NR^X:7O+A.JK_ 6>84!T:2J(C)NV!
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M-SEOI3E4)XTMZ/=[@X7N]^#@:&\8W</+TV6[9CEU3^_X".'$5:*N-V\B1_\
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M(G KI['4.3XMKCO\BV!<E!8;1BDY!>6EP@]'"XX&7;9#3,2E)CL=1T4Q1Q$
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MHRX>6IG^G2J-C]_(LG*A^V#O>+!W\/BMJQ]-0NRTK84WJ^9]UCF=T[,OB,C
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M1\+Z^PO/RM%Q_^3P[N(T6,&7_N&?Z/P6$4[J3(./PQ3'I9O($59JY[5,6;W
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M]/7G\PW5D;\S7:F((A_9:?2GZCSSH"+[Q[W=OP64S,]JIF]+1]=P\LE5PL"
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MVR&[D@UW69?$7/IA&0UD9LG4^.2<$JVHN<5"K13(46:K\5SF,;K.EVN 46N
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M"1_D ;CVVQ(H^W*+AW/!U'C/L(JE;V@=._C .<!B('V4IN0[&I]OG",,]AO
M245D"PVDYF54,MX;\Q:E$,TUCBI$.M* ,LL3M+QRX,UIZ/3?;J]7KATF%2J2
MDH=RNT>Y0>ND^)PW:1R<P^9K'' %%GB%AF%HA<5N"HW!<#F"Q<P#CJ)B=C6:
M=['#H[\T_!C.P155OG'4%N%J-%? $/]$0@A!5_2]#OE\*HWY2?;GD\##-Q30
M^C/Z"YDAP=4)V,2#7RQ#KU-&$LPJ4Q^!*+/!50*.1M2_5_BWGR5N I]4S7X7
MSANQS6%U,4J1II$)]$MVI"B(H*OF1(D*9QYY"_&H3<P;>92>="Q1A\@M$/T^
M1P=!8T'LTY*A"+%=#B'D=.:0UP:)VF>P)*P+D;8?=415",L[3B,H,41G"$1&
M)]CRYQ$T-C=X2NHP #65X/DM5%7D$?^!OV68]DIGUCHRH=8SVZ%@9_XY/$-)
M&4L_-GYAR*!<_.:5*B1%/8O*JOET=$$-;($M G-HRDZCHIX(CU::@^;:H2F5
M!L;9(,LW+/X&YEDJN5V)ZTV\+=1-*3D"^1-F/A@W:+[(O/FH.X4Y4T/R41S5
MB./B)'/JA/F0[LU["4),/XS VJ.HVAM%3@G." !N/@:A>0;FP0J8KAP:'C'S
M+$)WI%E:Z"+#6CI=L#(B=BOU&E^<IR7G04FW/FER^XB&!I8E1;L!>&;D.+KD
ME_RX8ADF17Z-'K_FXDTRXK_2Y\[LJS8Q&FX@?2$8LR-.>Z;LFZ18RL?@ U0'
M;!$=-I$E/'TJI9:+NZ%ZUD +GKLT"6,U(I9E\@LK:E=1DZ1,"9,/JRX**=(3
M1SCB="QW-,^+TJP\=P/$->D$_*6FK+M49MRKH^-ZP7NYFU83SI@)$#U0&K C
M(42?L&UF4A8<*FPB=G4EN"1U05E" V-TE(;;V<2B3>1Q$ :!C,:4R4,7R\_[
M(&"MYJ-[B;'6O'TV\9IQD0PQ=8R""Q>[1!4%2H)FB!J=QY!MJ_KUJKNO(&]E
M5+:&.T>CW&6W8,.BCT/<\ VMEFQV=,GJHI7!_TVFPQI.*UF.L0PVM>^FM? U
M\C )395Q3'U0W TM&:R9.W!S+J<P'CH7"V!ZR\S#YYE(Y[ >3= ZFRX[^^[T
M@=+9<]C$4JD_A3)11L[(%8(RNB(J.=T?-E48="3E5*[-2H8L"68Q>/ZLMUQD
M*71[[8@WT><)Q]_0R\GQD"?!AQ*39"T8#=K%MT"D1LPV%$T308NLX=7TJ_;!
MG.DY]$!WTDJ#Q7G!QPMEC?QYVB2REIMHX//I3%4&9#G%SC+MLM'19D<KF6 E
MF\O#130C7#Y1QB0Q.R=LYZF^D("LPGM%1<F-:V*+O.-@?] #O(7_<#A$OL*(
MP6Y6=T75)59#I6WVHK:$V"P6%I^""><<2<\J:DRIHDRZ&\C]T$:2X+?#(F*8
MC5Q)KGY*A#DD\*'0&%>6?%NGQ>WM;3\G^R#LY]"-1GI]W??'8^;K1O%6A[D@
M!5F8-1\$B;W,P8%#5<C\YI:*H3Z)/(5(D@VT]C0PUDQ3KV6C#>)Q"D?- 49R
MB!S/ 9,!>ONWQ?_EQ?_];?%_6_Q_H.+_$[<0@1*RRI[ZMS0G2F;2G48-):4S
MC@W[*L(@89<#G;(:#GE$BX!>!NIM[),65DWG.NQ8=RE/%VI,41JE91VB94)0
MWBDS_>36_ ,"W"$""[Z\/7MW_N;MYU.C?:E)W(X5O'99VW1,AVM&7N=(J5EJ
MXWQQ:QNE=W,/#@+UC5Q' 3?%/LJECWXU6S*B/;&?<V&T#1)@:11Q#+8Q40W_
MN'TY?!AX@A03+MR=R6YPQX-OZ/9_S, KG@<'NMM&-T//L#SY,Q/W@8*J"]SJ
MK$Y3&1[^]L/I3R4U^5U%%%)06Y"*$SJGS19K:]'!)TNQ$RGQQ]G;I4^<X7[4
M>M3U3>H'NH;3C=5*_3RFUZDD:BLL**!O9"[]DS<9$7/3NGD.+SF<XWG&N([G
MB90Q)M10[J0XP74;B,005>#VC;>7ZJ?2+ 4+NL^BT7UI^2.\B"?!IH<9!Y/X
M+6F-*3\0H.K-N>FI6H_/.PQ7_<^ZQ(8VR\U%UZ4(65&U<4/E_'=I.J48I:WJ
M&J&*D<!DO$QFI"VMGEVJE/,*U\I,O^&Q.XE&$BT/S>T3X< A">L7];$]G_+N
M&9-*;S#Q1@?%D$.4;7*S ALJ94AKQ-EUH_Y<+X0$@-5&LZNKZRI,P$TW\J[@
M&FN./5&F)'_* Z9<'A@&1#J/KN%0#@D(40PA.8_B1XI!5T#T5I22U^;(GDN&
M?@1IPU@F<$!755PZJ=Y2<L#@M^!<8FIPAGL4H3+GE'KW^VOT/7)[C'1"_/HR
MAT7 X5VV3N$F0^$)JB(9@F^(M!2S>@@"&USFY0QE%W\#P? T,GE4OH!;PA&>
M<B9 RK-$$AAN7HW-2:0)&GEUK\%SO&0Z"<WP9Y:QS$U@CLPGF%6%P&(N5D+2
M@N4,>Y--)5]O=&(HVN%KXR3E1D-=#7-*:,TR!G(DT.-T,T6Y?$NK,$*%].@V
MU6<:CG!2I^A-/7%)Z.!- LE91T;^=CR#9")T'V9SN(A?()3W43:) 8=.75$?
ME=DGDWP0_EU<"UY0DQ3VE;7F X%#FJ--4':HA^Y29E[.$9$IN>E21 "HLI."
MQEF?Q<=]4Y'*OUOJ49)P>CT$+M/I0#=[E-?#BN>-RULC9LK4R!;UAW>C.7K!
M+_DU#J6D&=D>^95NO8MCJM&QDW,509@Y-*P)SCD?RQA/.=U^-GYFVO_-Z'CX
MW/,!/#QQ T!3Z=J!Y#*4T&0N^>@0>$A8O\5LU9)IMCHVD<$45@TN];4LU+A9
M-%6C;Z"3/+J)3G*P+G22^POI)#%M5>0I+^"G(@=]YXY=6_9ZQT]+]6^Y+H,%
M+T$_"M='JC_$&%;+NOJ9FE% .ZSXRAO@C]]]2]?3Z)!11F;JA%)&%<UO,HW-
M>C(6!>7U#!%MAFC74"LP(B.9>1,4; ^GZYNPTRO-D^ 'J+B67E"P/JK0])WR
M=^N!R-]#[50I4C#P3>TFXB\9@^Y2'=C'<9@18G<+9U:@7Q ">4RH/ECDSS6X
MQ\*,NQ?M] ]>J)?TE?[!2'ZR:W-AP:2&+/&4X<K]D[U]8BZ+IN3FO0R7C"1V
MYL>2%^#NQ#>N'44SS#2 E]9/0:N9C1JC\:@BJZG(#"=!N.I28LAAMHA\W,Q
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M!M*8@L"B\YM&USZI%.A)_ITCO7*>N$G/#E#0U]"8E!K[>IW,+NMSB*G'-$N
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MR52EVALLJQW3>^LT@^OI4QP@-SL7W0D(.LENEP-+H1GJ'"F9&_3"S-(?XKC
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MLD?\%1PBO+V(?H;V"_A6KO,YNBCTM#B%B&4F J^F8]G3J(C2=4VJDFD+WR\
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MF+CY)[00]K;[ -K5TT6H>"'V)M0!2R8(JU4_0"-^UK=*6:A=S1,LSUG&XEC
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MXO$@W5.787[G&X8IU.H.,R.*^<IQ/S7TC"5>C&^ZEE@I_8!V6^!6L!OD;.3
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M'*GH&QZ,<_A\('6XMO10YS(^3>3.J(H^8S7:QJ>#- D)[!1.8/$X%'$/" S
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M69+6.HOC5SJ^+RBT&38M2:Q;;MG&W_*((DXOQ7(1L6A*$:HYY1O?X:J<B4^
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M.E6J8@.1##3Q17=2EJ@)RE'>9H>J80;[@8_>: LH!T@.:46$,'V=-RNQ "?
M;7#@A?.NR=F3/7%OF>YH7>)?AW*W2Q4/)]N*5:WW@EX=,T"$=YJ:>P81=;+&
MYT2893@("JPX..58<9 2)\\9<>A=IUW&,:1$QA/PM;GHG\+$_^(GI9W3AV.
MQ;S^9O0]']_0=&\RH$IF^L-B%O\ZGDV0^/-5U=9.%+'!<LCH^V41>HIP5''*
MDFPI!QF-\+R)1:\#?^_SY[=0C#@D4_J@D9 !B!0X%T%+2KQ@6:+*!\Z:V//;
M4(:T(_$$;+MU&GT_656SSS?KJD<ZHV+(AI(@F"0R4T6" DL2!G<!@'DJFT3=
M-X$,R4(.@"][R:E>AXO;K!7:>^<3)=IK060,Z"$HA,6<$B8JGW-H<GSX,0VS
M2Q4K9.BZ$K+B1_?G:D?9<0H&_1^ LOEO<&&&K!2"8AD_ 5TAV^@TSBTLPU:@
M6_'@=G'K?C-?,UHYF4VOH A<RY2\)#2C8I;24F+1_23.@.'1:Y93HS92UX$,
M6QON)?R]YKR:Y(\2.K<X=C]YY\?IU?2%/QTO_&2$PP*'UK<</9"E,-9B )0Y
M0>5KI4Y*VC95CO?@&=)N864>U)! /3K$N#PI4PMIDV3Y2'B7I):HHPPUI4C,
M$\=8(%DR88%"3%$UH<EV.(?4Y*<V?1I*K&+KGX4?3R&=]]6X OHEY'$LY]0L
MXS9E19(N+:T95\1B+$"T$")&9EJU8WD<VI!VL"J3I[)<*E;)](U=OEZQCI0S
M(UG)W29?HL1@<)A:$2:S5BP!*-:D(N VE$'UU:E,B#TGOIX=6K54$1HI)K(D
MGC*&Y).)!,XP]@.+GC$W*8@F2N&NUC:[#F*UJ[L8.1.<@\!(BOA%)AF(#YIC
M4$RE4]90#6U,Y5440PJF=I#Q+>.W\PS78^J]U;0O(2PN?RJYD35.:Y(4%CU[
M5CHB2X,0+9>(4Y=*6TF5$4V*U+>'.J3PJP9=VLJJ9EN44^@67TNU4^GX4!3[
MZ;KL8R2M2,RK0(1.I5V[H\3CP$D*7#$370ZV"7L> C6D\*P"3ZK-?_TV7Z]+
MK>?[,HUO\Q_S5>NQD60@K)&92 _HH[G($9+5!((3E 9N;6Y[/<-=J(84<U7@
M1#T)5.RV<KT#';+SHCUT:4O^>3R9C)B6.@N1" VE-I@%1YQ']RTI,!$,AT;J
M8A-P0XJL*E"DNCRJ,>7BZ3'D2+T.A#J'YDQZ?+I#76:XLE#:6[J;G2+KL&$;
MB>MO1^([S6LUJ;Y<[QY<M/ZYH-V( \TI(\'P"QHI+BA&[=Z0G*TV5G&>39/
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MHE@V3$JM7R]?@I_#/_[V_P%02P,$%     @ =8)44\5C;$\?K   D6 ' !4
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M)*?&J]H],''#0-#***4KX"PG<[A)VM=]P'8_UKF0Y\ FJ*SG+&M>5\G@F?>
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MK?UFT*R=85W@MK3CM\1[&!N^F?Z[\ZPWY>UW,5OO<M36O4))YE 3[!@M"RX
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M\FL=P&7GL X0]^V(K6 \N/O5CWX[V,9]*&=/'M<JU,23 &$=4RH  8QU=4[
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M>I^*9+YJOK5B;,A#F\_0N+TKC!@+.N,A$U107))99&T$SA4+#KU3KLL\]L=
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MF' R/#GT9.;5Z13W1"KI<Z3>P1BKBWY77LU(3)_PYE61.B1??  I:ML&\CS
M1>' <,PA2V5)$EWVGFUHO@M#[' ]=.A4=@=.?7_(G0BW/UF^62$MA7'-Y2%P
M>UI:>^(]C3'50-.;G:N/H*8>PR/VA.VT59(G!3R&>GXK!AXUTNZ;R66UU@;3
M91;;BV#5$S;/Z4FUCW::&S7A$VZ_&0M>B%2LA&0#!Y4STHE-$BA"EY(P>Z'=
M,)MFUR-.T >_IV:FS<7:Z<)Q ]C?;I+>UG>B-C@MI2(S+9&MEE( 3PL%G8I'
MD62T?%@[BV'/.VL:-!?X,1,*+-G0,=#.SK'0)H@,:PXT@5/&!RD,YWI@OO%+
M2"@XNO9;B7;G=63C MXW.!O_$1;C/_!A0>E]+,.J=!_]O":EN,,1;]3;&I*X
MUSD8<CQ4)'LMDQJE4JZ8$(K1HT<_^= I).N/GO\2QK/_%2ZN\+>;'%3:!@*K
MYT/6+-!>4#)XRSTX%%QF1^ZRZS(-XE%4!^TP]_O<UU[C.'\W^64ZP_&GZ[+V
M]/7.X]_BXK89N8XQRSH,B]6)QHIY!XX5.CU%%)EIDA$;5CUU"(I3=/QNQ9%[
M.]+15-$AW'(+ZW>L,AQ//OTC+&J#A*]\E"*+R56#"@N=H#ZR.@);D42T9<7(
M:&P7!^<Q4.? FN;"[^ ,U_Z"MYOTKY,%SG"^^#TL\,.B#CNX4P 4O<R,U@J"
M?#A0PI$(7'3UZ,TV".X\=ADC,!SB>9&FBV(Z9&>M=\-WDZWG/FV#[V=T]O\U
MLC8[\MLTH&<&E%$) M8!03:A0^O(.-R2,WTX@88"/"?Z=%%*AQOW6W1OIU76
MX6)5N3X27(NB!8*7LM:*95J\S +(\N3)Z""D[WPHW0=T3N1H(O36=;NKMDW_
MP,7G:;Z]KGKWYP1G\\_C+[?[W<JH>I7S>(5]76=XQ_L<662.6Q,AIWKG*J4
M7RRM2R>A?+(H_;":SY:HSH%"IU55P[KBM8@&KV64E=*&R4+V64U?$Y@@FJ3
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MD/KN/?FXLPF>+?MI"\$U[OO[C_#772"2IV19 <M%;7\0:SJX=F"]U]P710;
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M1>ZZ=)C:#N<\*-% U \)\.SA/\MM[_XR?\>,EU^6@EU%!2R+7KBLR,1/J@X
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ME*1OEFW[:+'U@-2/)-[_A7,RPW^G/V?C5 WR.F'^GZ2Q=5$+G0,."]G^Q?!
MMC^7X,B* F:S+8PK)O-&G?:.^_,A3WLIE^?/5="TIW0[3$?^%RX>0"H^)"F)
M[GDY-R)Q 8&4"8G^<QO0."W<((5O__QS4G$#";9^IVE'*]/999@DO,7U 1>+
M"R3W>OFC:Y1.2T13G?K@R-PSO)"C+?*RG*-D'90J9I">!S_RG%3?1\['&G_\
M()Q\2/O'W1_6)+-O(-:-W+Z8N10L)B-L5$QQ'ZSAV7)9N N*B]'NCSVPLIM$
M-OV*1+?9'V,BQ\UCJ@%"ULRJG\?%\H.6MLCOF*:?)K6P=#69[_5TOKC3L2-K
MXUPFYG"G6.T%Q*'.1P"MI3>*LX"Q2[_@QNLX."[WQ/-?3?+K>[FWOTY^&4_H
M]1R'BYNB\MOPN<W:2V\]A!S9*J(9?!%0HB].H$Y"J"YQN:;+.$%1X G9_2!0
M=SI*]*C>7N&^#HD_6-9-JTI4)!F")36CTP0=6W6I3F1$&DUK*+)/,>P@>,<G
MY"E)L.GKM==@C[C"()0WLS)11L^L\: YN;SD_$8(,BLP)9J8135F^\QLV OF
M#][UT6B'6]PV)\CK\&6\6+7C>'4YO9HL1D($K<FT([LZ)5 A%HB%2<# )!;K
MF--=PF&=UO-=,_HE<*3AW?+287STY5RU,:BM99;(2=0WO4!S]BX*49L<D5VD
M)%/@>"A07U/R' //40URTY\)X+LDXM$TUJ$MYZ"7APZ"Z[[5Z]CXIIGBG>;<
M)P^6,UJ%B1P\>@4V1FL5%ITZC3!L O^[9.T)&?"0Q[I=)DZ;XV!UR>VD16X2
M23-Q34> "> 3JIK*I#!$EJ3N$D[ILIICY>6\**__Y+1X*5DZJTJKF[WCM_5&
ML[RS9(6[DA&$<QR4-06"-A&D0664X IUE^[*CV Z?9;,R0BS=8+$X8KK$!W8
M 6V=&C$ 7,],ET?1G2;-I9DNAW'D $4<G2TJ!J5%0N"Z7GP%1R^+*)'LASH,
ME2FC0\?Q-4=ER1/9*:<AR3[R[]+N9H[T@9]KY2C^@1?3+\N^OBOC<GTW&FF-
M5M74FD2+U\:3JU2O7XNQN7 R.4N7].@!V([O0334YH.^-&U5T>'ZXP,N>S3^
MG5R26;@@H*_R)4F\>D/U\G[M7%^#Y<8EY@*#I)BLU2^"#EY5)U\4E#JEF%D?
M*WX?E.?$H'[JZ;#SW&NE:ZU@V2A7S3/B-2,?VCFD398SI;PK)I0N%8ZG;6'<
MCPG/%N[)<ULVRH8.3&[AG;-;-M!NI+?X:))6-EE6E-+>.-JBBTB:?J9M]'%W
M>@M_8?DMD;AH<F$0,H]D_]@,WD4#FG'#Z 1RJIPNSM@_OV45:;ZZO RSK]<E
M>+M"SJ_F\VD:UXN^_QHO/K\9EX+U57P_FWZ:A<O;T"&]@=X$6T DSFCWC1*B
MRAP<.I$,]\H8\13MV\/Z]G-5]F'J_8N$DZGW='DJWA9M@O8@9"(30*,BL1D$
M:TR*OBCK99\YY2\L3^74!'A>CLH^VCM]CHKE7EJNR;YTM<\4$Z;*PD$T#)4+
M0;$^ Y=?:H[*-\FY9VGS&\I/0>T8,N;!)K*7E?=8;X451"')Z$Y."-UE0_SF
M\U->&)M? C]>2FX*+S9)*R4(7_U\P@@AD",HI(V%W!!R)(?U5GWQN2DOA(1'
MTU:'O)0^]W RV<"T5X"^CH03].X$%PN$J(0O/B5GNC1Y^7&??Z!G]')H\5+N
M\W^ZFI-$Y_-7Z=]7X_GXYH;(2+1%H !OZWO+8\V6B A1*Q]8+!)%EYE_._"<
MUSW^7D29ME=8!^]I&ZSZY0S758]# /:\QW\2X6GN\IOH<P!'#E?&:5B#AK9W
M;T'PI,@Q"Y)>%4[?(N/.F1B%ZM)Y]$1L>>)._T1DV4,'K4O+W]9&;O-%F*W'
ME? @BLM('DNHA<TI@5?1@2_.D3%@O!?#.D-L?/#Q(\6-Y3YM)+0>T=L_PRQ_
MI%]><E6&VB?-)R#7P)-'D"4X9148;A)S4N7(NE3!WD/QPYXX7#D=XF [I'"G
M[>Q/7Q]VI:TKN%W&)+^_"),[[1:&K*FGX=%C42=JK_5\K@PKHSZ^HCL8-5W6
MYF76*G$.G*$!%54!AYSH)H/%XGU,JDLD]]LA[U/-NEXV=_?1;VL;:T='(94*
M1T&22<%S4)X;J)UKP$2;DI7"23VL"/"E]&0ZO>(&]'':1^JMFW,-ZA[&-#<Z
ME P*R1959)&"<RY"LKQD(8LBB(-H\3)[L[TLDC372.N]XW68?[[N0'6W.]6R
MP_8Z7X\>'P)SX#1#4(7^B#Q$X,9D&Q4/7@Z[L'GZ6=\[71IKHX.%OPL66BDQ
M:')<R#T%)2UQV))'HPRRR+F7JG2)\_P@TLZ<VP:::GUG/+P!7F9":X<.Z.]E
M,I&'8#(=J)PS$9P6)@_+1WS!C09?#&4ZZJ;AG?  E'7_7(,TF858!XW$>JAF
MF2%JR:L<5!&H@O?#.I(.?>(/_G303,,6 4N0-U&[BO#]U2Q])M%4":R[L 85
M.%GIY$BJVF=+DE\I% ?MF*+U*Z;TL&WGB0=][V1IJ8>''#%=:D16Y3$?PU^X
M+HOXB'\MKL+%?2##2D1V?UB3"I&!6#<*1(+-W-BD%=F6JN08ZHPP)5'$F)B1
M.-K]L2UJ@NES7T\GBS$1<I*^_G8[F"7F;)CS@*7VNQ8Y@$L:P8BZ8RA%KA/V
ML"T?1770-O0&"\YFF.FS7\WGN)C_KW!Q163,5ZEJ>SQ9?C\*,CF> D*PR8%2
M*H%/-D%6)2$:$YD8YJH/>]ZI*LY:Z/W>[M)!O*U#-7<@_C8.<7RQ;#*]':>/
M+@8E"J NO.ZR"KPU#JQ+OC9%<:X,"^3M\=!SY$)30;<.Q&QR=CGAD0[%-[CZ
M^]=KC+$VI482!#.:K*<BJR#(>G(E6R.BT'ZSE^O /6'' \^1",T$W## \@A9
M=R'UQC$N<ZES(#P9TMF!=]*!DUJCC=9[D0[8%[XC0C06=H<1@P^.M#N0W^)B
M5#!*1T8:Y&!EO7:($(0TX.A;2Y8S\YTF/#^.ZQS(TD,%'5+E'\#[^VPZGX^4
M-S;6,;]*:3)RM+<0>(7FHQ6:2R]TEU+I[7#.F@_["[Q#!\2MMN]-,M*?-3PS
M(KLV&D&KEB'2JH-D$&VVD.H,FD! 2^A2^S@ VUD3Y$!5[ QT',*6]2GWS\GL
M)D'MMLWG_-?Y[_3OTTF(%U_?$[W'-5\M&19#]AYT]$3Q8C-$%(H8;Y'L9.98
MZM(>Y5EHSXM1O=7UD&.V3<.W^^)8Y3T:<KAJ< ER1A*%3@*BB XRC](D&>EM
MZ#++?2>B8]52]6-(&V&?NKII/EN,WL^FU3U_-[O.L%WE?=44FFP#*34S4+0F
M<$QG,,PCJP'+Q(>DT='GWV$+?;?)E%T 3I5WW$BMTX;B;1@ N8.G%I]>(YJO
MTT('@-HC_W<?W3]$<]S$W3:*>JCU1E(^&@4*8X''FO2"9$XKDPP$I1@D+;+V
MV43!AGBW+U'U.])>CZCY?83;?)KLSZ]_^?7-S[^_NJET,3ZG$B F%^L8A SD
M/6<0R6=>N,O*#QP<>_^#CV<$-I3UM)&@&MY=U-7=- C\D' 29N/IDI?:<LWK
M*%J#OG9@D0F<K9-II9$Q2J64;_:*;D5P/D?SX0)N&)=> KK&\<_)_ NF<1EC
MON;S$%"MS^:=:(Y_-C?0U+27F!L?SKO!.70J)9& VUJ+@4&!%R5!X"J5J+0E
M]-^H[A\YG(^E^GVDVTGEOTQGF,)\W;]5NL!"X-4"(1RTI *1J01"15IB$E+A
MD +0O?1]'\)Q3_-&NMFB[0,$N_-,;YST]&[Q&6=TLLVG%^-<^Q,]G#^TR@0Z
M8!;TWL]HDB)UV,HV,J>X245;&0R717GE7;+TPBNK!,\B.3[:^VD'UC#>-'&^
M[;?CK8RB3AN)=8Z=*QY",1HB9LT#2X*5/NW/'T Y/*"XP!G.%RO+Z[85X$V7
M+,^5LY:<HN(B+34*0XLN$IA%*4-(M0"_3USQ<6 GR/H\C </HXL-)=^A4\&O
MDS\(75WO"N$:[R@G\H]9T<!=$: \K=?EI$"*1.]GIE6'+C,C=@$ZQ:5$2]4]
MX$4#N7>9-;/"L6Y1JX2Q1=(Q36C(_7:1X"0OZ(0MV<60N/)=-X:3#1KLK/WG
M2[E#B=KON.J1>4O*OY.(YK]-Y[6A86 HA& !O/,2%-E<X*V*I+3H2W&&Z-EE
MP-"CJ,Z,$.TTT"&3JAK=XT^3UU>SV3)4,PN3>5BF@5:0%>-/6.AW:EMALKX#
MFF*!122HRG&(JI:J>*:*+IE+V\5FV@/CF5&GEW8Z)%PM3?JWT\GT"]:!-I-/
M]P1"NV Q.?((LC9^4JPV]6&&G#OR\KAE-FC?Y7+[<5AG1I>&.NB0B[4;F(_>
M2<$=1%&KN%,=*IZB R1S7!LGT9@N67G?"R_:2+Y#PM7/_[X:+[Y^P'0U6R:.
M_O+'V_%Z9WMU01*9+&=CW0C!.,VE\YJ,I^2)P3H"&=$<O&1U=*BS@7?IX[HG
MSF_>L^VIEPZ.S6-P1Y)E+5RR(+4B.?!4\X=<[:R<BT:OM=!=3I['0)U@DD]/
MC>[!GKW4<22JK WT&XS.HB#3*4(*O YR9 E",@6,S+Q8+"[%+B660\!]?]0Y
M2#T]QIMLP5@34#=09MI_=>TL$HL*-2>!CM8B$7(PDAM&1E>?^>'#X'U_-#I0
M11U\[U<IS:XPWRF<63EZMT:?D=:;9"P$GVKNJV-T?),,4"-+FAN;>9^Q3$\A
M^^8MG+:R[[#+/*R.J E4=0SQ[ ^<_Q0NE@43J+6QIC@0L3:?28)6GPWMC"BR
M99K1J]+%(!Z$[O@D::S5:6^5]#!PKGN)_(X7]6+UH2A&QHOLBDD@K*2-U3 '
M(68/S@=CR)7$X+J$\9Y$=FY\::N*#GO,]?)_GWX-%W=AD5GEBT<'"I6E/[P'
M7[MV>J:E*IE.Y4$)QL\]=C;QG!LO6HB]=2^ZU],+^M%TMMS?\'K>5:A P\7(
MNVRMR 8\)X8J8S*98D*!(8,,N?"6^XT*MUT]+Q]YRKEHN:TX.T3JUZ,:7D\O
MXWBR1'B3K+NH23GCC"O@:\E\73.4E6A=D D04P05$IGCF!-PE;3S&),078Z.
MYT,^%U8=67D=PO\5W&*V:C'S/GRM.>%KP4SRV^DDK7?!J*Q5:$#[&I+FI7:5
MR!8XER(7M(JVP1X<&XCOW C50RT=;@J65UL[)3'B2!RV'FNC"5LE0%NJ(@E8
M(0*708;BNN0Q/ [KW+C24 D=*JN7Z+; \BZP*'WM(F X';<A@O?:@LW>.64-
M%NQRN[@#SUF2XD"Q/V2#.WANR3I>M*H^0EH@^DQN.'-$4+1(W*2-+ 23H@U.
MY]0E&GL?QK$JZAL'RPZ0Y:EKYV_LIE5TYL-GQ,5OUU.H5L/FDF,:@P9F<@$E
MC2!CW!@(6+A&*Q-YY5U,VAV 3C;+ZP =;]JH+63=8S[C%ESKX70#D'4=Y[D3
MVHGF>#91X0!>'"#_XS*$"9NL1 ;<U![,C@6(/M FZJ3,2I(]K+MT^3DV,YZ:
MV7ED8NPC]@Z$6!4JK2R:.S;.=8F:#MDQJ6A_-75>3;")UDS;I3:265%R5*9+
M'<6CJ$XP^[.1^K89EDUDW["V)N-X]!M^"A<_3Q;CQ=<E]45*"A.YQC)6*-HG
MB+5<T6HT)F=B/]^R-<S7DI]C^MNGZ1__01^]H@!]L:GY+8_]A@V%0X78\"JD
M0EFAN&;L$!R[+8&]E7KWV<<]Z@]6PK2A!!MNW0_Q%&FE8052E(3'T<GDT D0
MJ(L53-9,UV]"DSN.YGZ*W$-PK5OA_#J=C.<?PN13N)R^P4FX&-?V,>$37F__
M2101-.>@66"@F-/@&19P,3K'BA#&#;N2>N)!QSM-#Q/_M)/L7EQE_2%C1O9_
MR'%KZP>-)?'T1I-)Y4O07F41?%$E1G2<950ZE^'%]8W&E6P)-O%:C9"<A1Q%
M=08T$KF, RE=O<MFD@R#KM&VWUI5UP_,))3>%,R9%FQM!&4UF;BA"-#:*5&"
M0/KG[RG9\T!./#.?<Q\M=*BW'Y2\G&+BD?$"09#1K+(,X+FTA%$JSB3:V"G[
MZD7FEA^!)P=IX$@5"+=<7B+4O 3+")QE4=#)+\F=*HE@,A>+2\)$T26N\#2T
MLV3( =+OD)2W>9]VYPZ^9'*U:\U#$8H,-V$0HHX2"B<2BZQS5D/Z_1Y\DWG*
M;(C&?&@D[7[5 7>&S-W!EH(D'FHB992Q)AD[<#XBL#KUN(@D0I];J\= ??-<
M:";Q#DE[&U$W)C4/RSF0*M6AL[%.#<T"F)1%<U>=@R[VYHNYSCY$SP?(\M37
MV=MB/5FQZ(0B T;%ZLXG0?9,\D"+LDIIZT7<8BV<2?AY+^4]$G[>1X@]@Y5#
M<)QM^'DO)>R*6CY'@CTU&DSD2J("8FEM\$,*B)IYR)EA%H&[Q+=TV7J!FMPC
M_-Q$D?L([MCA9R]]88S3/H-U4%&QKG9RRY"9LLR+Q%48-FSPY8:?]Q+_/N'G
M?61WK/#SG7J-/S!,\M(M6-9MT4?//X^_S.]5=,P/Z._ZW$<U"44W6>=&0-HR
M=,)),KI45@IE-$BVF4%52_$CTZ/G/O30>H,[3[T[V?TZKWW'/]_IL36_-3=-
MC$PX%2 Y2>8F\PF\)-<P1\94<I@?#!UN5930;A$';8AOK^J[^ZY<#W-X36I<
M7B[,1TEDJ^OU42F61&/K<#^E(FAI(T\Q2A.';84['W%\Q_)DW+FWD;:1>>M9
MW7^_F,9P\=LX5;M@\NG>J_OJTPR7DGAU.;V:+#Y\#C.<O[^:I<^!7*,1#SJ'
MI#-P%SBH3-M_K-EB,7(?1.3,<C>(*L_'\+URZ4A::VV'#8*]"=B66$IMJ2E1
M^#HQKD H3$#D,8?(?) RMJ/9#X(=1U.MIXL_!_![G"U_,BHZ*C)N(G O%2CG
M.81DR596CJS;[*16PR8S'8+B!]4Z:ZY#5/]]^+H4V,?IJ_3OJ_$,5Q=2_\#%
MY^F=#L'SD6("?2X9A.>$DV0%WCH/UA2DS=B1>]8EPC\4X'=(OJXZ;'AGL'Q)
MKCM\_KJZP,@_?;WWFHR*%$PG] 1-6U <)03F%'BG:$>6/* ?=D8^_ISOD"6M
MI=^P%/\NM/$UM/B5O/%T#QW9=5D5,O-R=IG0B0C1ACI7+S@2AV'TW3[<V/VH
M[YP>C730L-S^+CK2[ 6F!>8_QXO/X\E\??$RGY*:ZA7I"!ERH9V$I+6CLQ0U
MN!(E&,Z%L+XX[O@^1'GRB=\Y7]IJI&$)_A(DF5ADD2W")YR6<K6X(F+C'W@Q
M_5(AINE\,9^M&F$MIC^/YV$\"B4G4_O@"%YO"4QP$!0)QKH<N4LH @Z+'.W[
MY.^51ETUU*&&OZ9CO5OVMZE="C[B[/*ZY<U(FQ!-BAP0:XY62>0X1G108DXI
MJZR<[F(=[T3T'5*JK98>TL<?M!O]\PN);-G$YA_C"[+(IQ-<V^W_"!D_3N_)
M[WV8+28X&V666$1#/J&NA$^!0TR\U /86J^SR9O-AW9L2<]Z_'=(HB/I:DM<
M\K H^/:@0R7_R.I29S1X4&3.TZ:I&;B8,P27R+9'A6Z@5;3[&=\K41I)?0L;
MCA"FKHUBZ9F?W]R>N;_CIZN+^L%?PR2_GEY>T@$]#A</WH(1ALQ4"1*L"B0Q
M(S-$$Q@8;4,*0C''&X:T#T#ZO3+S13%@"[^/$"N_AOH!JX]"_S M'\/L$Q+V
ME'AFIHXWJQUN51">[(#B0$OZ<9U\&,.3:1,-</S@9G?M;6'>87UI]\'^*GT>
MTYM5OYR67\:S^>+VA?H0+O#FI2)9>EUD<1X*K[.J:Z#%268@>FL%URZ6S7%D
M#1@Y'-\/IIY,VUL8?%@@_MEK^K":KY[J8N8_U4NL.TLJ&5,.4H')3(.*'L$Y
M>CV3MTC+TD)NSJ]N3>#'X/W@[ZETO86^!W?N79LM),H[ELMZA!QWV6I,#HR4
MB:QO)B (C6#1:HD6C=!=VFL^BNH[)&![;6WATL%]?-_/\$L8YVLXKZZ305_-
MY]72*(D;&;,$5LSRJD-!R.31FUS(I_=2B<U-K=&=]R.@OF,F-=/5%B(==M4P
M;)^]SOUX/Z/?N\G_2*&DK%@"&Q59LUY%\)E),%%DGP-GT@R+SCP?PW=(J6-J
M;0O;GGT3L<1=XTO3<N]^-JSACJ*622M6\XF<)1?)&O#!.GHMK(FF]A(PPS+!
M'GO*]\J89I+?PHG#KA=NAR[L$[)VWF4ID@7.-"='1),C8D@0+B;+.4O.\6&9
M%<]Z_/?*HOZZVI*;>MCUPJN<EZIY& D<^43T%BK3WE?GB[E$%IR1&E@4@KS9
M:&4:QJ'=S_A>B=)(ZEO8<'#7F$>M^I__2A=7F2A^G8^8?YV\GTW3<DS,?#'2
M)9FBHX/(JSRX9A"42)"-9S9+EHP51_?0'L?\'3+PV)K>PM*#>]=\2)\Q7UW@
MN]) G*L"_RBB=T+5!$EBF/)%0D2A:@=A;8P.PODNDUW:+^58W3)>#)-/S(93
M]^I8BV'53^:VA\G=KND\>Q&0*V"N9BX(DFSD,9 A6Y"I:%SLTRCQ$4PG:^QQ
M8K9,^VBM0P>Y'="NZ_:'@.LYRN)1=*>99M%,E\,X<H BCLZ6HK5(WGB03%0G
MVM#;83WM[R6HH)$'W6>BXPE8\L1DB].09!_Y=R#'H\;FNETT1FXT#Q"0'![E
M%5;SDH-%KG.I%U"LBP4V -OQW82&VMS'[G^&*CHTN/V %_1/G_Z.$YR%"P+Z
M*E^2Q.L0N7H67V-=3^B0 G/Q3 -:YZ!V!X&0E 7!33V78[&EC^6^#\IS8E _
M]738>3[2[[TK=\RW5>,H%@5C/H#A9*RIH!3XJ 44U#J%VH6@3ZAB*YH?EG C
M3?487?] &&'[^J_9/@1N3ZMX3[RGL9,;:'JSI>H1U-1A<]H7=BC*!JL8!!DS
MJ"(=>),M6*F8B:R$4N39LNH)N_KTI-I'.QW(M&L37Y_#7) F6 #M=02E48(3
M28#16B65;?:YBYGT.*P33"GNJ=4'0\^;J:1U>ZUEX>5ZB1R1ITS:,\* 0B;K
M8A6(+(R.GH[TL#&Y:E=]]>V'GJ=B#Q)=ZZ95JZ:7'S^3%?X%KQ;C-">;_QI7
MS$E:&1A8;6EQB=RX$*4"20:^3H)AQF&%/(\\Y(Q5W$JTK9M)/88K9^=0A #2
M% 6*2P-.90?))&T)H(I2M%7YGN _A,OYU>333^/I?'PYO@BSFV2LZQ4X*5@0
M+$%DM4U7K/GSO%A(/%B421'2,F@%3SWIC)G;5,BMFP75[KS;R>M,1N,2@^)K
MI\D@:]Z#1:#]U6LA4(@X[ C:^8BSUGD+L;9N /3/US^]_QQFE^'#WU[];6WQ
M!"><S@C1HJUM] OA"1+J>+GB&$_,#'O#MWSX&2OX4%&V[MQSW75[@W-_V]QJ
ME&9*%4?G8S(U]%>;>29M0!:IO4C9\<VYU3M?ZB'/.V,"=!!XZ[8\RZ3]V?7E
M0ICD/)ZGZ1\X^WJ-#:W1+I"S4Y#7M>L,L6 &ORRG=PG=9OW.#C(\\: S9D%+
M$3=LH[/JQC^93%^'&:[VJ=_(]EC4K+'5#S=YRF) 5XP&$7FB8RDI<,M8,2_&
M8/9&IF%EL?L\]8R)T4WX#;OES&>+T76'\7>S#SC[8YQP%:(+7HJH#&0;R85V
MF:#(8,%8YZ)+7.#FB.6M@2GZ_#M!*?IN,R"U"\!W?OW21"\-.]C>P5/7?XUH
MOIZZ,P#4'O<K^Y#F(9KCWIZT4=1#K3>2<L/HUN/@Z(R3FA#2+NEY314UX(5*
M]$=R%I.C[6O()<A+5/V.*XXC:GX?X;:.9_XL#/-DUOSTZJU0C%\?5SH:X26M
M3 A9$6GR<Z1#LFEKX_;(N4C#7,:M'W\\HZ"AW*=-A=;Z9N'5FW_^Y\^__>,:
MB7'%IQ 8N)P)2:S=TVSQ4)R3 @7YJMD/*R.Z^['?O-J>+Z3&,^0V1ZJ50$@8
M^8S)6$;6(?-0BXY((9E,T<0TFBW6V#<[Y?%EV&"'*J)AG/;!?+8A.,YV4N1>
M2M@U8/ Y$NPY*3(A4Z5@@F@(E(IT0L12&'C:KA ]FF#--Z')/29%-E'D/H)K
M;1Q=1P!K[ZGIY,-BFOYU?78(EM DC\ 5>E!2)-IJ2@$KT;-DLD8QK)7LKB><
M<#;D7@+?$B\]3%H-#:-J1=R>-=OG>#S\*>+;<+FR]-%:(U(6(# %4,;7L>!<
M@/'&:\S<^\V*_N<[/8< _<X/\J/JN>&%7<6]"]?UNS@$6>O(R^.0CA]^.9YJ
MIUWUTCA6\P1"7^^@ T'BOO8T*"& 3\Y!C$*5G+VU<HN]\>TPYI&HS4LDS#[J
M.&;*F@@^>!<M8!W]H'*VX+4P4 B8LYY'L5DB^))3UEHK8FAVVCY2;!WY&7A+
MS;4*CGM%O&8"5(H)G-$6"@\>K0\.W;!Y+"\M+:"GSCO(=N?+??2AYSL&VW6=
M?O[$,X\T!GV?E6_,0_?>E,)=<DQS9:2(,>J<=62HE4I<#9B'_L336S5IV?&8
MWVZZ?\248I:T2R6%JG8+U>"<SX"DS^ L9\SB  OA@.8K3T$\;&+5E!2W&(>+
M7Y;#D!YT!ZMNZGCYP(_T@H]GN?8&^_KJRY?9]*_Q95C@Q==1,#'%>FL?E76@
MZA3NN,SR\%9%8[/U;EB"9 ,PQ\^DZ,2E^U.KCJRE#H73NT<DT;IM#+D VMIE
MSAM.YXZTP,B@5)HDE5WL\8:]H$%6G3G45@?-[U:W+OG=GQ.<U9/@=F+;3UBF
M,[SM4+?NDWHG/C*RW@AME"1E)P9*V% OKA 2R8P5\DJ8&&; M41U=H0ZK=XZ
MU%(/7LN(\:!YW481:\O52#MH)/\72(@ZF&(LSUWJ7 <C/#NR]=71*0><H\94
M$QZ!.22'.)4ZE"/(.IF#-ES'+3-=;,N7.^#\2%3JHJ&&-]V/4_[-N!2<X231
MSKKX$W'R.LQF7VM'S,OIU7*&X#_)%YM=U!^M/F%$2\#(K8)L+=(;46LSF,@0
M; G%L> -#HES-MJU]E_ V3+Q)!IN/D]]">%RN8CQS2)BF(_G^68EX7(Z6XS_
M>VEO?L'9>)I')"_O2BF$E,Y[I4EZ3L8 4FAK<S:1#:RL>R: LV/5T;31L&KK
M?E.HZJ+\0F+;(9ZWN'A7WHS_&&><Y/F[V9O:VFD<KY9AHY%4,B7A'4C#;$UY
M*^!42D#'/9>V6*\&I>L_LY/?(=#/CHDGTFK#RK&]5C#B,1F?DP0?C:WSU11X
M= Z<L(G^YRKVDU'O^V;77KKI,,)]%ZQ2F ^"12"GA$YL47N6FU0 C2.7Q4E9
MRA%MLO,E20OYOXS1["KP;%/4M:1:DC=2YS>Z$ "+<MYD[Y /&[3SC8QF/X:U
MU%\3+0>OW]_X/H:_KCM:_H03TL=B5&11UFH&7)/MKRSW$'(BJ2RG(S/%_O_V
MKFVYC2.'ON^_8+?OEY>MBNTDFZTD3CEV7EGHF\TJF521DC?Z^T63ND46I1FQ
M>T0Q?G'9DHMS!@ ;:'3CG)R[=!1VX#FZD&EI_Y82[(,8=&?(=3*,"=!)T8HG
M&:.H%53FFV0]3T+@,ZB@'&V,M/-%2S'SZQ;80\J&/%A;4$KRI1=U6K^>%28)
MKC#K0R GB=0C4 Y+A7*J9F0K3S17'G] #,H:D7CMA')6^0$-M^"-]5 85VA2
MM<<P1J]#DN":HMYH9-/F&MW?Q;@ZSU\703-:E40H.H((J;; LP/$&HO"1:V,
M4$'H89[>\80C]7,+>[:4LM[V!M=GF_L@Z=9I["6P#Z=D\AM![K?E5M*B1>E&
M6?Z6+'<02F4R 66M@+0Z4<2&Y&FCS6(H/@GGE1T4&VUQ'6=$/:/O6LI@7^M1
MUCLH;T_KBWS_9T6WSC_D/"M*")%- 1NI>%8E(<$2M,?2A$O6&X5WNR(/Z(/>
M^XCCC(XV%FTN4_UJ<_5T716,JXKM*=EFN3ES6"UIO[1>KDZ65.BL9UK'@)XY
M,$I5LEI:'YTR!DHTPMJ0;!ZH(3SP@<<9!#VLW5Q+^B^BUUMD%59%/5]\G!GK
MDA5U)R2Q"@V%")01R1;:%DJ<A7XYC(#KX><<9P TM&U+O>B;+?&7O#BOR2=F
M761&H'7)@G)!T;;&" A!.BN8\L5TZ7U? 3@Z[^]EX9;:S5= WISG]\O-C?Z\
MN8T\S^O7YZO5MB"IPZ[;?] &UT55JHH3H@9E4P2,N0#RD$5@*/G="YMM(F$@
MOJ,-E![^Z:'Z_*@YMA/1VE@FI$C@8J6.ED:""UE#UI9[;WWPTO<(HV'PIM*]
MG2AV.OCD<)1JKU_BU075U.OER3QM-EV7(_HW/]G00=#79C,0ZQ(ST1@'NE1S
M1E$O"CH++!@,5%+Q'+H,,3P1[_-S(;2+G*^.9OI[L(M&Z6C8EW.;0X#W5;M]
M(O+G4L*=(#[VC\D]G'M0T6E2\B(G ::8 "H(JB0B2D 1O!$L(,,N9XX'%I6/
M*N^^I* <X]/6TV*_YO/5_//G\T6^9A40-A9*$XZV/'5L78-'ZX$QP[C(W.LX
MC&3J[B<_AR[J)!Y9MC)G:Y*&[71K[63.%Q_)"M?=ZBJ@MPUX44H25=3*)Q9I
M6^LJ4)<@>19R*-9I,XR)X_%G'6&-U,/*K76D'H9W&>]# -Y?\SPI')ZC7NGB
MJ^%QL(>A6R_Y@X 6Y8U1R"#P2)E0<45?C$"0F;#&8D3M^(%'PHX:X3 "88Q]
M6P? N_SQ_*3^AXN;\\LK%2F?B@_"4:8K]10S<J@:X2!TQ.@W8D/#I%MV/V.Z
M.J"3-Y;M3=F!(.('G*_^P)/S_.IB<_?I]0FNMX%=?#2L\D;Q6-D.=96-J=?Y
MI3#HHK%*A"XCUSL1'6%ET-8+'8:JKX%M+\;]DG%-7Y/T=O$NUU8U?5=>U0FW
M#XME6.?5EVJ(GQ:GYV?T:ZJ<YR?SS9'8[;>Z^BH->*^>[9->+_8\W95&\;,K
M*@_!^1W:*]W>SUHLL7+$2J<2*,ZI)E"N@)&F4KL(8Z7Z%M2/-&=>6$R/\7FG
M5N&"_LO\NK HW*42= )AE*^W#C)@%J+J2 CAK-:\=#GB_0K)]!V=PW#R/8V_
MIWNH0^EW>5LQI_<Y?EHL3Y8?+][-/WXZNX(G3.#6TM=,<UDOP5?B:^4B),4R
M.J6#LD,8QL??$7@8U[=P:NZ]+NO1;ZMES.OU_?,X5ZI$UA5T$B&+JIQ.6R#:
M6LD"U@B,(HF<>:?Y[0'HO@5:)T]V8!*KN_2WY19[_Z900,-BYEY2H8#T'3"1
MUE9O?)4W#Z9H89+KLH+=B^:(MZ_[6[\#B]-HK=4!<'ON2$?B?9Z-9@-/+Z=W
M4X?\-A8VP8LAL0Q!5ID9GB-]O=!!4-G%R&A]+%UN*AU$5#VRTWO^H!KCG>9$
MK/,USJ]D_[)5MF0.,3$#*O( #M$ 5R9SJ5V. XGP;WWHX:M<C[+^LH'IVLL<
M?%Z?4W$V7Z[GG^<GN+I+PH^8LZ;"&YBN[!7.(86Q%5 DU44Y$_0T[+SDL2<=
ML;.;&KE#1M@E,W4ELH[>^20#T!J6025=E<N\ BW0"95R9G=E3]LD@(=A'6>\
M='!)PSW+WC) ,C&=93"@7662SSJ!I^T<H)14K>OB(QO2V?L;2+\UW_%,ZKMI
MY=R&(/LFY];*M</5N9[BEVGEW&+TS'GO(#)5KT78VFJD%5O9K*CR2I)G]I(C
MII><6Z> &>..]J*TCQ1I.0O/A>-0B9/K.UM:=+T%^K'41G&3<9CZ^^%4PJU=
M,JKH'6//QO*UOZV6Z3R>O5W]GE=?YG$;TYXEP:U%D'[3!TZILNEPR+*4F#(/
MU@^APANT%MP'X$AKCKUMW9 Z^A:>6L%?(KHZ:A@"JG49L1/-]!7$_H[ZVNN-
MK-RX*-@-3BH5=9(*+"N&@EP)\#DP<,S(:#W+O)V\Z\2N?Z 4F,CS8XS;.KM_
M]^;#?[[_^9?+U..U#]$PI$?;4"E9ZT9:YDI?+U+A1DH;!J7ROWSLM'F[D9V7
M38RT,S\WEM^\E97FBS]P-=\>))_E%?WX>L3IZ5*;HSZ_B:SFT]_HCH0F2ANU
M%TKP(I5A/B0M G?9&4[.SW(VZDG[-13O_?2+GZ^Y!(I2A2ON@ N!5%06I BE
M5<:&8@K]$FV?(Z5'<+5C*;JN=:MFWBRXXKDKFDHGI>EU U6ZF2,8C4$+K'>F
MANT<=C]C^FYH2Q_OIB1ZNB%;GY3<?X?D]7)]MKZE)!;HVR:\JT,0JE2IS +(
M@@9,TAH6D <S[!ALT...R.OMS=OAH.1&!NR7^6*YHC?_O5*G?5J>T.>O9U+$
MM*%BE3RF>I!7V;*B@B(LA2W548IWN;3S,*SC")(.+F@]B/HNUX*,+#M?K)87
M>')V06M8/L6+:HLZC7U%JKG&D[R>,1&-XL5#E)*!RAD!%?W-VT#%-:))9>@D
MVICG'D<X]#9XPX&D.RS.JW&@K=0^HQ.@49)Q>'3@L 8T_2Q$SU6Z*R?^*&_V
M. 1'%"^3.*'A?<!F4MZ5=0UMS%"*#+5W1VG3Y @8I+;&FLS=,-KE%RFXWBV>
MIG9-PU/5FRO20P2Q$JH@A/14>^2:59VD13-+,"HEE;F0(C^?3MYQ!%0_AS3L
MGV^C_KH<7Y:R"?QT4[#'6K"OMBR19\O-+;=9-DP4D14$'7UE#DS@K&4@=<XA
M:5.X'28(,/;)QQ$9_8W>4 3Q,<D*S8S2*0BPN@A0Z!SX(,C9GJHP$Y@3 S/1
M(<F 3%"P[&7(#AJ%;W+)*PK"]_CG=N+G9[+ _&330_PUG\VB3)$;P:OG**UQ
M5)31A*;W5H5V8EXEW66.^!%<QQ$;/9S04+!P)[P?5Y369BPX([4TA"I%4%90
MQ:.R!GI?S,BXQ^ F"8T-G"./B/$F[Z$^^!6L.BJX[>^>G"S_AXN89XEG(YG+
M$!.RNJ!Q\%P7VJQ;*;RA[;H?<A5K_[#X&MN1Q\B>SF@I2[C)>C>%[D^+5W/:
M8UU-"=-^ZA07M+B]_X1GWZWRFTS6^4Q&2>^7K_*'O_ =[CK@FIF,5J/W0-DS
M@\HJD^G00#3UHKU,2KAA0F1=81Y'R!V8.WO((M[<GMH%<7M]*I9Z9L4+&&?K
MH;RW@#);D"7'+(N05+#U6-X&XIN*<+[GPM;#%8=",W__H*$3EB [6I<QY:K/
MQ,%)VO-I[PV7G$MANU39!SHEWM#M@\;$QYC_$ 9Y!\#]-B:^OZ?WG>A]@IL.
M(+I4$E%Q%<%;YFGEKHUL9Q)(B\X6J1+Z+@GN(*+J26/B4P;5&._T'!.O&%+Q
M$40V=1&6$9RQ%G@R.@B=BXIJ4/7]HL;$1UE_UYCX&-,] ]&ZLJIJ3S/0(9>J
M&ADJK[ &>C>1E#6A#.SLO@2B]?:51@\S/PO3^A" ?Q.F]5&^&DVP_11#/PO3
MNC NJ.0<H!4*5' ,'!<!+"\NQ9 ];>T./!+V9%KO&PAC[#LAT[HU*9B4-&"H
MG9FJ8!Y<H:1'F4LQSK@QPU+]RV):'^6-@4SK8TS9>%3R]S,\VY0U/^;EQQ6>
M?II'/-D$M=9169$\>,0$2O  @<4"2084-K&<Y)#;KL.X'':A.,92H)W9&]YB
MW(#:]K)N0[H,^B&@6H].[D3S#.0+;;RU[&7JQO.3N\&9)- Q6OQ<HG5/R4 ;
MG<PD,,NRQ,R9P"$-R4/T_T-4"A.Z?XR%&[H]+L\79ZN+V7]_FYFH#'->0E:I
MOI,5@-PI* Y]P*B"XO<T>M979E[G^,^/RR__NOS$K9\O_W'7S3=/G7:VLI'Y
MEWO9KG$B__Y\M3R]$FTSA5G'N  C%0>%6E):<@*2\=JGPI2.O-7W]/:#7[(;
M]S)BXQ7X]2Y]1^]B965 B-S4&8=@P4?/(/I8K%<.I6I&:+,+Q+'69$V,WG \
M8!>F*Z*% :A:UV2[X4Q?E+5QUR/^W\/6$RP)5X0 )AJ.#($6O4CH$"&86'O0
M5?#5JV)5,U:+J2/@@;)LR@ 88^+6/9BO)%F5\=YIK8&2&R4F*PVX$!0@$\$H
MB4RE84/(SZ=PV]+<#\K7CK'5%"Q4V6&2T2?(HHZX9^8 $U46/BC,P>M26+.N
MRF&R4/5)WGL;NS&EY6[ZEB&@_FXT5*,<-8B,Z"E6GHR&RCFCL[0!(IJJK(D9
M@LWD-.FCB[Q*=C9KHQPX#55[SX\Q;E\:*A&<\ (]B"(H]Z2$@.@+%.&YLS(H
M+=.@/'V0-%2C[+R;AFJ,D<;24%W^N/X1<)W__8__ U!+ P04    " !U@E13
MI#+#TJ.^  "B]   %    &)I:6(M,C R,3 Y,S!?9S$N:G!G[+P'N.-6F3_L
M.WUN<DDED #),*E$3&3)EBT/::J6;,NVBBW;P(*Z935;EBW)M*4O@5UZZ+ $
M%@BPL)0DP+*4T,O2.RR;P++4A00(! +D.[Z3,@EA*?_G^S_?]SR<F6L?';WG
M/>>\]??Z7OG6K]QZ7>'X!LNSA8V-C<+EX%_AUO\I/+@[CI)H/HZF!TH7% LX
MR0L[_Z>P;L>O*0H;A8W;WV^]7CIKG"33PS <SB_0S$BW+C"B ,ZT*8Q<4(0+
M%UZ2337#LY(#NN6XX44'?_*O[SUXP#4O.JAB0E&84M;8Y5:Q):_:BK'RC)IY
M\)*+MS8OS YGP32P$NU %OCA_'!VT<%M[H=!?ST,'SRP39)X%QTDUC<.#(3N
M 2J*K0/8!:5#1A%!#E0J%R!EK%)!'GP +2(H7 3_*X>0\F&L<ABM'KBM'03+
M[;\P-NW#$LW>MAJXNNC@;>=*T_2"M'1!%#LP4JO5UEQ0]!"@.#3/PT3+#H7S
M,[=Y'&%"6W,C=J>)&X4'UM>:'BV2BPX>O(VS:=S!>+J(_6VVI@%;OA5883('
M0D/@(]SV7V@:A^TH#K3D8C?0' N>3"WG0OC.T3NH$C?QK2.71S9!^+?=O>W:
M=]?+'_:UT+GH8';(M&QMX2<'+R;=R+'"1[0B)WH$@A9+2/E"^ C][=S@N[#;
M7OW.U8[</>K$?[(8@.;ND,,]&LY1A'4^</YW8@=V ^<.L8$IAP5@(J:6:+26
M6!<#Y9</(>BA(J8@Q</EVF&T"/J'B\4+X=^C/8I%9+IV_GL,L&T&U=%M<^\D
MNG,F%5M@X$]9^BC*NTV/8B6*_(N/F#;O^XMY$J]'#U!RY<!Y@F:XX=I%'W04
MG]NFW,E(&2\"/=1<?_Y';&/]-M7BN:7D4^NB@Y(UCQ:Q81V\G6Z;W5H-AU/7
M3,87HUAE>]VCAGZ/<FRYSCBY&,?OI+QMZ/=(;S/G1I>IWTE\M(T?3;SM"A?#
MM0E<)@A1]D8-R2%(PF'(%L',"8*&JR(Q[]7'2[->6VGU6LK3PD(@B++H^6T"
M*A+;C20 _;HQQ-8F(:YG@B82) SQ@LKXM(C4Q)Y7J\N]C 54)+@KR$PVU0.<
M8L"%KF)%PV]PHDL.U7[DD#C8CT,T #=B2 @B>%7;*X-!%,D7MYG+O3[-<VU9
M*O+$[[6NKJ[WLF[%'.%[%. %VIK;7]RD88G,S76OOWV]VMH<U?NK80KZP_6>
MR+E9DM)M"GN;HC<,DB/7SO:>>X8_'JGKG8RWM],;(;==N^F1O?6&MU-X1SB,
MZLABM.YMGYI,P;6W?3U?7U.\&?;][>OB>AM4W0Q\WTRW3UK;7M/3N7ZBK;OP
MD35UM3\VTK7*TNW[9KT_T=:\Z>T5!<.79'%]GU[?=X01(LE;FT>/#.]& 3B4
MMT\)1O02B1D@U&B<Z#3KPI2G&:RC.(Y<[Y?T>K]H4HBXM0ET&0\'#8]GVDM]
M0([U$!RW+OD&*MPA;B;<UJVSUG-[PF#MR3 1W')V-ZV O1G(MMTTI)Z "HJ'
MMMUBWIHP?Y&2[V8A+-"&>_L%O>H!B][N2KJ@LKYV#Y:WEL*V!=_)3:\ .GJ"
MK%EX=^%(N@'03%+N@>Y$NPM'2EYSZ([!2S*O>:-!>W+4WLC1^K2.QDE%@XZ6
MK9)9,G-L.E*%Q1!U[K:=>Z8%UGM/U']FN]T#[MC;8MLOZ6'6489H2^$7@DPR
M(W4T-M6LR+/;FIKH:+8T![QCE,CQ$.TY+9E<]3R3NIWK_TO<[MKN9F\MMN&/
M@GX^4K')2"953>V7-!4+MVTTD*9FW5_J+@GDIO\Q6Z,R&>S1-X+^8KV?_MHG
M47\QRH%_H)BG#:2ICI8=32T[6YM_Q+[OH9'H>F^W72C3;IE@67P!G*^[M0F"
M*UT%[DV2 @C(;2/<5B][AT6"V0+5'Q*][6'#QE#$'P[NE (AWMF]N]R:W>VW
ML#T=Y;<1(XT>7V\C1CB\G>@V4?0(RB&Z!"D2=9&P"$H W)K E F:)]HI45W3
M22+9)!@<A%-R1+!E8IB2$5$O$H9#E@@N!4&3JA/\'(1"JD\T(B),*8]H>D3L
M4#G86\L@E@1-$L*0R%-:)-H] DUIA^CTB$H*0E-W2$ IR#2B0=(BHQ"21W(I
MXQ/RG!0<IDPH95(268'H\^36IBJR#J$:I.ZP"#%(22>MMX@13P9.?4QH'CD7
MZQAA,&0N<A)A>F19Y*:$S9.0P].$DU(LP9N$.Z1:*5\&>_,82DX;/<(O4J.T
MD1%A1(V)9H>8.E3D-.=$/*12L=4BDAY5)EHQL>R!Z LTE@UI7A028N708MKN
M$DA$ S]UVCE1*M.NTU&)"D_'3J="X 9=3+L.."(-B6(=Z)OA"3$AZ3DC$U*?
MK N,(4H0R:=,X,@1V1HR&:$H6YMDAP$R5R!2++(<T8M))6)EL3\D58,U4[5.
MCH;LU%$1TNBQB#CP27M8)YVA2KI&O9T"D?A>77-&53)*ZUN;H:@MR3G0FJA/
MR&6/(U-C1.9SKBN:71)E.).PZB3F<3%AP62-YS#1+E/$G.=2)Z>8(:\ZXP7%
M\[SON+.M3:I5YHO.)*2Z\P9#>#ZE1 TE]3UJX#4F:>!1>M18I:%/V?,F(T8A
M-2DV^\1T1D5,,R!F"VK>:Y:(>$6E\];6)N_,,0IA6IJX("C,:<V))4]!3 L2
M4YFF(D%,,X/F>L+$R4-:( 147*UHL=AN. A!]Z.V2: =6O/::5JRMC9IV^DP
M:7E!>UYG1& P/9UW$J<JTXMREQ)QGRXRW8%3J]#8L#M/X2X-I2(E$0'#".)0
M(B&F,1<7$CU@NCUI:Y/)P+\>+ND24)062;G$18QCR(UQ@V4"41Z3S0DS%^1R
M)M!,+BAB!F)$65"F9)=EH%Z/'(LARW@];2R#D[+-8F\U5E)6XOMMLJ^R Q!T
M,K7&6H0*;"I@/4_52:W+QKR*C/4*FQ4'HF3Z;-D;Q&-;9F%C6,_&1+W>&VYM
MNF-W66_WAM#8<^J]WDC+ JFN&Z.2%#%U-])ZTK14GY:U3(KG]4S4.UDRJ9<C
M?3Y>:AS!&\UQ)G/<W(BRE;"UR75[)C=&.&Y F(%4HCDKM=@Q1G!!9/ED!>(6
MGLUD.,2AGNV3$,Q!D</*),G74R>@:(;O$F..8GE^T!MO;48RU^'MN=O(&WT^
MXMTX;YE\&DTZ5#O@,7&2NMVT0>*>(DMXHSGW4+?7:"B.KU'JH&$8?BT?A@T0
MF<>Y5MK:;"R<L$Z9C48I"F>Y;32)8M3-QUFSR4<(Y=6;BC/5\L!LFL2,<".D
M&3BS((^[S92/VVXR;6+%N"BG;(OVYNN\D+NMMI'0%$*V!L-DEI?&K?%PH5 5
MJA4;BZJ+>RTD6GHRS+7@<MI6R+G0%%-TQ<A"+\J<2;TBV'S>G#1 KA>F\QRA
MA;90'*[L5:<LP$RQN9+\=J-<1.F>TNX5D?%J0+7M(MI>C?+VK(Q6%,-KHT0I
MI.U!AQ3+/=H5.H*# :]7?*HSP+$E'6*=R;!BTK.\L\"K+26).Y6H6J'3L%OO
MX5-Z->G*?&VHH..N14 \C3G=&0&5:7S<11DXFL N0(-4FQ@Q5"!V3++98V>B
MEI%5CT_%L$$EO59)7$UIN]<E)*+-2$6Y*0D8,-9^7QI-V9(W=*7 K,^*>BJM
M^MS6IE6T"1F$8;GH2G+;;' ]?R)K?@-GHI(<(LUL[0A(NQ5X2U>AIH+AY15%
M;+1E#U44,^LT>MA"B<TNP=1 O:!@[6ZI3X0]CA47"%/O]4DI0+B@-V%EFVUQ
MO:RM#)#.K >/>J(O=_OMI-]D^TC?:*@T,C+Z,U^M(2;3QQJ#K<TRZRQ5#AGF
MB*>IJC]:L!$'WK2I'R-JL:_[_:4_H/O&V%^I ]DT+;;4&(RGELY6:H.T9@_[
MT&I(])T^2H'X-NQF8P6MNT.[[\IJTQ@NR8F(=@9#*/%$4!N-.K[?555Y9)E!
M5]7DT6(<=E5+&4%^U$5=5>MD4Q$--,UF 3>Y/K.UI1DKZ"+4X-J\C^9+71PG
MPSJ*Z>/&0D.KC)YA2ZL.2P:5I..0=@QEFOD#+C6\))^& FD@R&K!B;VM39,C
MBRNN%YG#/E(&.S*G"0IQIFI6VV5F,%Y80H8UPZ!A669%"F>^E4K586E)V12+
M.X/5V.ZQM6A0)NV@ 6UMIB$^L<L2C U)SFFZ)!6QL6.@E, W96<IT_URIS(&
M"<+AE<FX9[&S\K S#IMUI&Q4QQC$D_QXZ@J5AE .1B BV97FB(^;[HIJ^=$2
MG]0[0AX5L\G(;<-E+)C,*]UV!%D>H8GZE%8]!9)F#5[RPIE<QMIMKZKU^(;<
M]+MR?VMS@ T:P,+4$#.:?DD=E!MC(6BYHT8C$ ,[U[1&W ^*33W&4B/D Z.&
M(5YH-BVQ45F$&6J[&%R)ZH&#-EE@O9&NN8U94XU2;6+.NL&4U;RLTBM/M2"H
MS[36=(F&^LQV9FPSRII>::8%,ZXYZ\[29FQJRVG,YO-B$V%BW5UL;;:TRCC.
MM*5;!24>IZ:5F'7FII;+U18U7[FK.!;]I)$C3%5M)DX=M70]35"W5&Z-1XMV
M'9/CD%I,%I5$GP-NBXJ%\WJN+R6U-JF6F\M(AN!JK;*$!X0AT/-4M<DRWK#3
M9$FK0A?4YARSFO=;F3&I2W.=SHH<M\2=6MY: <_JS ,LGTR:"3Y'\ZHNM(T<
M62F#=F*4T56L=]LX5"[2H;A(&+RH5^5NK446BXJ2)5(#$99])1E(B#]0T;9I
M;&TB$#T<M2<1JJY&N#E%T>52=]HI6^)CDVFC:FF\LJ($GY8JL-->4+5R3QFO
M.@VEG"PG0Z@;8US7@SLJ@SFE8&O37P L6PDC8>'BE9X^+7:F>F4QB(W.LEKE
M]82Q4*/J3A9)IT94\56J=FD?'[0R&&X*>!:NIK!8K DMI-<=@%Q?"THH!%M-
MB S+LZY7A@R[TH?C$"K9. GG0U@.:XLEUH*3%:S;, Q#Y75IY^EHPR?JRA$(
M;,,ZP8L ]Y*."&!HCR&='DLZ7IT4APTJ=0"J<EHT$36I-&JN<2Q-I.L?D2;*
M78; .S0I*"PI*DR6ZO5L;G 9;H-\"EZW?U)FC;;:-%$< O;#^K@GL5)DWW'_
M3_@YBMM1/S .8+P(X/ :I*>,1!"\1(B"!$[$$$<J5(Y8'TD\NNX168![4[X.
M*@B.(CQP*G!WC8[O3BD2%#@DD(3!4V+4 G<HP)U>PWTP!@0!>(#(!+@Y@@3*
M;9:7^$SL,W4&95QCR/2$:7U,9FHFNEVREW!C(1NY."7ESI+QQ96D>+-F/BQU
MJ79/#+U*9]4>FR"^C3B%+BYXOA$)#6KLC,8-(*Z97.PG[7Z3C/,RW&60CE(<
M#=9UN(IDYL"OJ2-T#!PYF>LJMAR6),0,S;(%\L*T:G,(9)<ZS'BH<2X?--UR
M#JP9HCQ,[OM3:QB,9GK80*T0:TZF33685MSI;+:8QUIE&:UE"D[-TZ388X"%
MB$.& @:@K^4T9FB26B,"ANU)[3'OC#)GQ.21SJ6LP$EEN4VQ_89K+)E5@Y9H
M9ZS)O5QUAR!"D*6NO+79MAJ,DYD]+W6V3]J8C-BZ:WHFVROAL\XJS9UI$>JN
MQ@W92P2EAW4EWP05XE0?L(@U0"10!YN1IDYC'2!\9*&CMY_[#YZ:]AL@.V+N
M*)@NC'!4L;U9QYMJ6CAK!K-9)4_B&;2$M75%F=)K"V#6]D3C1$TLU6!=96>U
ME9%D$R4M-1H5@EXH7B0)$W&8>[R;XT4$3HERI6J4FCF*QZK!*&04@7RZ0OAN
M=01KT$!I^VX1)]JUTF DX*Z9!&UH:'>701T.M$YYH3I.5RXYC8D<+D4\@#S,
MY.1RVIRA,RL*6[-L:W.<UX?S>LM(*F%<ZQC3N%8WF H\[C:&>=)I,SAJ#6M-
MOQ]W:AXSK*0RLV2DLE&?=1>K^CCP.4]%Z[*(L542(*XN7E71I61-!"=))+%O
MU9?I@D0T(;2Q21)DJ>8I:&5A3G)CL!RU QE=9'VT>8\O6YM_\-;1+PZT&.B5
M.*;12I LM?FP.)@/ZJND!J$CM-DEZ]#4:#5 O>#Z U&PD47.\/PTD":^+GD3
MA3#M<4OL5&S=G:6UM!.MFI5.&Y&;V3+-B"%,68NA%:=T>R)82Z4TS^9YLYAL
M;4+]]KP\,YWB@)^PGC415^E Z.%TO:,VG+S3R0"N')'SCD*U4%V)TX'OTX;K
M""XR!"D('=IV* V-D"-DPP>5T4B+YWW3_4M?0 E7+?+P;*'-@4XQ!L)**VTT
M7"19WNL*;'D^'4(=CJT''56A],19A0+:<ED'B9I*ARV)@CBMS:HCN5Y<2LL6
M.TNR8:N)06DF;FTZZX\5*I.0JR4I(T E7%S6N HG%,N+5E-7&_V(9<D@HGU'
MP/$90,N8UY5&M((Q!+;LK%:5)HYJYBB<55D00X;KM[_D!=>7EA54?%/5]3K5
M]SDH!JBFK-3XTLK(:CUQT)-K#5Y>]EHX*ZN:P_7"%I]IF#R<S!91+H\CW8IH
MO=VH6JC2J 8\!?"E7X$1JJ*B\[(*\JG754-)*L\MAUOE8<.;3":9W";G$R9O
MDY7N%/4YI67J;<?NB5[.N+[:'738JHA(*TSAW8536\WG:M=A&\!"M*PZ$51>
M=U:K'":&2:?G@;*;A:,*75-U6!)CKEI<DO!JA%0'K0&>MOM.8DJ+B&>@&.>C
MZ901^TF4:\TIR*>LK&$(Y&1BI][@N4$UQVOQ?#X.>+*K5(/F-"X%%<F2M<F,
MGEF35EN0('KDA^RD&L%\IRDLE*5?BT.DNC)!?%LV:A)"LEP_" ("9N>2F]6*
MML=V!HU2#B'MA(';W=5R*@!?D/WEL-_-T%HY"_OCLA'.RC#:HIO&8IPI7'.Y
MM6F@Y9KN.Y8)U6J4U>NVVV,L+':X?DMD.U)321E$:_;MA%=*%82L3CHF4B?*
M4[QA.>DH\R<96;8AO;/4, W>V@S(V9R-9VV$)$+$'K-LFW>I)*DK4I\G9@!Z
M52.A1X]=F40@?.$AJ"JN&"*<UE:(CH?5174!\Z"B,!5Y ++,2E;&TY':FFOR
MG.P'C8XV22B^/G1T(]0JE-0!TM;;0AH*?]S3MC;OZ'.FAD\J@QDTH^!%H\&O
M4BK/LAXGQ,5&@ZSJ(V]84YJ,1D] 95;OQ2T2[G0Q8U"THAGJI8&5 OQ6S]DQ
M5!GJC##HBC71R'%UX?#0O%@.=#DO+Y6\9PIP<]:)/$0&A2XT!D?V\RZHD%M=
M-.WT2%Q&AS7&+KLKP"TK5I5$2#(=%2A1HF=L'>.K<V6109;6;8>AU\[;"Y,B
MW";E6Z(XX&KE1.6D,<(5,5<A6OS8G*KCI-LAJ*U-6^HAYLP$FNDV*K92-Y8-
MMK=B^WV6FC6;441TTKI>I,;R,IC@Y25,4$,H!B!*6J[SVUPU%=2$#0GJEGR0
M%^*$AB ?[RYH!,;]-?4 F<"9%\)8MQT$51E>3G!.KX5VB8=:G7I_T(O*=#/E
M1W+3<6JB%!#8"BO!!!WC .%K@Z@4:)2B1%Y2CB$:F;9,4NI[-"OGL[9/ZSJ]
M''2\JK"20P(?B,NN&96':9@@(PY>39:&PM4Z*H0Y' (J<=&B%G:/A%.*(F!:
M&"0.70Q+"PF5E<JXZB%XQ3*Z>5J$5VU+M9(*5:O.C,$45EN^;E%B.W<E#VI@
M[+"XCI8ZJ!7:4QR/B-3OV99:ZFD3LCX"97VK1 :V9_<2$FGE&&E66 WH#$$]
MIC_/&_5^<R%FY6@5+U!X(+3Z8@AT.F)61M@N%LNR0P,TG2$3M=8L:ID%(1U,
M1I(>VEI8TVISYH((G[)&G)6G2EMB_7D^XE,6A"VL9,$X1E@@O@VGKC\=#OJK
M.B55IF7)@2J./U&PXFJ851N!M!"Y@5SM._2<Z@VB)5:Q>CID#EM9H]8>3:31
MR.'<F2+V1Y3<!6A0#9>>L!Q9,C_O-\))5<GR-C>J--@6VZI[<R5NL#R1=Z9T
M,P\-AM$9KFU(RIS0>U6TEK3J17]1!;ML:2RH/GKSXK@\BSA7&:^C+1VXO3&C
M6LIJTN^N0%Y!B[&$MF.C!',PP6G$O#>"!@(.+WNC>63Z(WK%TS%(8L,L!RBZ
M23DPEH,5 K@XD:INVZYW^ERWQ#2\%2JUIKQ HC$7,U,S7L(=L9_#S:Z8M%7>
MGI?8LJ78N.OQ1!=:==0RL+=<@NNVAV 6HL!$-UC%^,P6H,@:P@ FF)+/(!AG
MY&F^8/MD(B$$Y="C ;$B$(CJ=!L]J]\Q(R/+A]5N9VNS.,!FL##($VRD%V,(
M$WQ,CN:Q84U;LB_EK#A#X-P5QD[14EH+,BG-<0BH%1J5JD$]A$-^('7ZY+2_
MRM81R3),S6Y!):$$R0UXY91MG&C.;6PZTK$>+)3R&/-]-M&4ME[*H-6HQ%-R
M6^QW"6<>VWQ]F01<6%05=F%FI34:Q.OS#&N/5Z-!P&/*RJW W4D^U@<"LJB%
M,])BT<DPYFAY5A]/U:%5USO=D2JZU4EM60F!]2B9@_26<UC-MS;UE8U5\274
M'S)V;ZIJ99\4V"E%%&-'[T<RP=;0SG 1%N?XM-9MY 8T';O<;#C2P1DZXL!'
M,%\M%]'*V&T W#MB!=VS,'6&!7FU$:H9/9XD*EMUEE*MCL1R30/XOM<6%NQ"
M5Y4J0%HLU9G-IU&?Q^D@R8=3L2VS+ HT C+@<-&8\Z4FJL_[AD@UF3Y9F3#C
M'FMHJN<K]1(!D:7Z<*'(#IYXJ#,HRCBH:SKA2H>"85;L07A+@^@<BG@-6*_B
MPUZ<0. ,;:I;=I-IPK(<XP!)S^B(#,PZ#X(NB\I]? 43C<R&% ZQX:@$8DZD
MMCI1M0,O>)@#61U!@19@6X:X$NG9'HV7$@9/(+5ER_HL7XRFT< ;3?FE4@X#
M;-C#!+JT8A%[A,\78D[27F4PR+*4D:F<&@!;4;8V<XA'!348Z#EA4W'0[C=J
M*-U6JO,L0Z7N3"R%( L8 Q]=:#$VP2%H5%\,8PFK^BE?M8I.;\%'?J,<#])U
MO= 2['2EE>=&NTO%J D@1K?;J92L*NQ/,%[/IU%CO)!CS;>$1ISY)<JCW,RI
MI0$$NTK@((LIKIJ3BI2;5:#36KO<:W:%);M<N7!*-R85D!O:=1CNM=@ OT,J
ME<&=^:.$!R-F K=F*\]T9GPM70F60_A#;VLS;+=1K[7BRIU2M=NM>C9;CC&0
MDSH^ADT!3L!&>;L['DZ'*BRVZO0\X_!5384 GB@%7A& W3A&S-8L$8TYP)85
MLZY!"IRW8+GCI95Q;&(-+3&B!A_+;!^;3?398+10L3I<#] AT&&O/#($TNSH
M4Q WFB#9JEX7F]C^R  6TN>'50A9T)8VX.'IO-ID/==P9^.*S@!=#(HC3^L.
MZ*;&SQ1I5F,,<5XO3S%(@D,+<Q#&4G6TMP1S1TD7Y-/Z<IK/J!7?A.>+9A!.
M0+JI*L54L!E.,%!X7NIYG-/E<;^$P1783&:^'_5T7Y<[S*"7T\,N7Q5F^!*$
M<]T&51N)*BY'C6J67)N-E(SBE, /,='VL>DR4.4*PO6=HC\>S><]<QZS=L_C
M,2[(B[H;38N=FKU,  ;VYGUI G!(JQ^U&UQCY.=T<;!B(<7V(#@E!7]21%?L
MV)Z-H5C)%K7.L)Z:ZA"D=PC22C0Z\28MI)Y6N19J3WRNZ+H0D!LH0]C$$DND
M*QM2)P[J?3'OL&TY!BC#"DRNV7;#, HF>J6-EZRAV<!#2U:7-79>;C7M7H>8
M1WSD30;(J+?6Z:3I$ V)'%3'8;MBTZVV/Y,:<5!CPSQ+R[%+M+ N#3<Y/^PM
M.W8PJ,R*56/:Z6=VR?,'PT;/"-IV(F2:4]O:Q$N+:)6EZ6)I</(VMTY<PZR5
MC<\$?&+W8+%<ZL:&9JNPVIWU<:O=58#'LRO9SJ<^B*>&G8.R,RFY,$"#H-J?
M:Q.LBV=!K@W]"!)JOM7H4WD?8C,1Z3NY9UK1RJS87:Y-P0&G:!/*$"J04B'A
MUF"EPH&>)Z2E>'4(X)!&4D4#9,00W18\ EZ^6H6)[N M7NP,A Y<M.Q,&#:P
MVF"EQ .8&P'<!@>\#_;7"#M!9LM= R]Y4 35*J#ZB&Q/'\ K'J&J> Z*,+NG
MU\O>:#AH!E) U1VY(?<YLCO'9S6;058#S.S3BL3P;EZEN>FTX@3&1)1#/+-!
M7E@NX&93+'G]5<TL IBHU'IQ:G7D,=]WJ)3GR<A(BM:BKFLS#]&6$L<NS7';
MSNO(S$+QHJ*I@RZBP<YHJ51!!HQI7$[@E.-'?32>D!D^Z+'SJI S2MD:6_!H
MM5J6?J^<A$;K3U>6\#KD ,0*0@[!4B"^C1!N5*IE7!FV!L&BV*U6!BE4;H $
M#S=0%,^A =\>V'TN"0)-4J@Y;]#%4A/66C$R]>NSJM1ICB;]! JJ79!E9,(W
M&Q7 FYXL-5Q)D2PM#8,2"9BEHPF<IS:V1!,8]R:069NL5JL1)N*I)9O],3//
M>G+?RA&J-/)H0^MO;4:2Y(\T-UJ--%" KC(([RQ6%<NJ#TIL904I)<P=V '5
MU*6::B-M.6%J:KU<J:L,T[0&4&_*EZH.E*UZ9@1T*@SA/E>1J_H<[H>-RLCN
M<<$ NWMN:D_OP/%(J'&U6JML&W4+4G57!GB<JB]'_$H"UBLMBG&UV\PYO [4
MGUDQMZ3#L@)B8&9U<<*OK.0: BLM(,J&43*85JOLRJ"D@[GV*O#3M%%U!KUA
MA/=2@)'P<<UT (Q"B0K=Z5C)< 6-_"EG6F)-FWB5AA[T]#[4Y%W)S@9"+,EQ
MFRLMVC%?<OUJN#(Q=1$D70'U2DV0%YRTY-%5B_#4"/)&1=1JES$Z;ZT"JJ^X
MMM %AIWA7LF*TLP:KL.;E8V%?HV%D$IS/N@CG.VJNE^U6R"_;&T.9A*#DQ4\
MU&M3;9AS]4[8=CA,MX-V"Q,7NMO12FUDFI0RH:@QS4HG$3EYD:%MBJ[JV+RM
M1W"=B!"^0T:U]2<84MM-5<,:VJM:,5>41F32\]C7T3[E*B5^(@USM,23G-=B
MS$4P['#S0/2-O(F'[;PVDP3-I>T +^(>!')]6\&+E26GH46]-8K2=M4L0E2S
MLX!@Q9-JOEWNKT:5L)=E$@"5D]AL3['1J-<9],,07G^8WZX8T%@#8)E=TNO?
ML%>B3H!)+'" 8%EML*Y469CHS"R/,6 =?;L3)% ?:[D#><+,_2*K]J<,7>5E
MD1Q,D=40J[6YUH M&C0YV]IL#..R%?, #I8A&UB$G8!<+[@2*'9T2,:[(5[B
M8;_5P@0#1RPCT8"GITIE-D2]Q!_QZ$1LX*UZ0BMQ $[J%(N&R$\0P^[.&B.9
M;D6U!MB3858#>;%0IZ4)"'%]>P@OV6ZI:IM!4AU,:HU:=6[E2DVLK7)=74*=
MU?J#?^ +4@OL1>GH.EOC:ZO9/$2XTG(&D.](0KL@;[;Z;-EM%L<T#6S>=5I<
M16UTC.FL8:BRA.<U:5K&.QT>#UKPUB;1*,-XQ+5 A,F$;F45]-$1;-O$HHWZ
ML&FSV @"ON.E.@=/." )/%!7NCFU2PV ^A8Q@#W+,3XH^J&P!)[U^Q]Y A 9
MLC FV'V F8"C5L;#>64RKT+E"6XO6ZO![7[*Q3#6LB$9F@-$/6ETUWL3PF"E
MK!?+(#J!5LLU3 H[0SKL<DO(<!*U6(L'BMGL(Q8L]V-7DL2$X[+RQ"\;N;GT
M ZS*9\&J%54F6YO)@&\R5LPL<TD=0G8\S)!RB^R ^)3C31VN\A-AE7269'=)
MNV90*D=0DX4[:UD'W1F0?%&'UQ\6*&NDM[6YC?72J@@OIS9==6H\[E9&C5F(
M-5<5F^GTD(RU6E14S8U2DX8=1T""69AJ$;>8HFHPSC1M:>'M8J6J9:"N;R++
M3EM-1A&VZ+I#E.[!=+O:Z;+,9&ERU(#FN84]\'U+1:J:6/+G92^ICEE_['&2
M9_1)"-#Z3-;F BX&2#5GQD-, .4?;2 6K2SY1=2LCD<Q(FEIHS3,&6-F-XAL
MU:IVLT#M66K5U6">+T^P:I>T^4X@5WQL5;20R< 'T7+:,^8AO/:SG@V/>QV3
MG&%XIRGAH5A1.8 -NVV W3!+:TL+6YA4J/E$JMC#:7TENI$JJQ+9 )6([M8)
M#M0+RX!#!X[+&W9O,4+]H!&F)I&'^++;7&):98FUYVB8Q%9YV>0J>'$>ULW1
MK#AD9OE\!N>3=,4@@=T%Z+-!K''ORM<4<AQ.6 ? )I*$U"XV2&5*:G>=%ITT
M#!E@XK25"\OR:!*JV KIYO"P!"(56800?Q&B08@FD5</TZW-3%0!LB=+'#&+
MZ]VZ,]"%CN$JQD+W,Y=H<@V06 D!HS4-FQ3M'C*HH5,_F:HXE?;+&9S&V**3
M-T"F*B^F6YM5=5P3/! W.H9M]AP'"7NUMF>T&E::Y:)3-2:$.B.K^(BRHWR5
M6"1P[ 4L(S5?(;QA#:YPBT!C2Y.ZW0:X%QM#*MRL(3JZF.:R!;#]B)@WQ_F,
M*-*=)K O4%%*JV:J=:P>DU4Z[1 Q!(GP$0GVEZM!9 <RXBU,/M2L)HB6L.*W
MI%PJ:CZ(H#,$+:'YLNV$;ENFNW0X\=C,;D*)C9L!#"+5T!W [F@U XX^*74!
M[)QUE[9JN39N:.D:#5)#K06[Q,HSENM@U"_#4VXQ'$%6%VZ2.?!\0:&A.1;4
M KM42EOC&O#I06:IMI> V%#/X'*V@K=#R];F'P@N]QA:_O3ZE$^Z '-K[7;2
M3UITOQ4@B==HBIDLS)RY%CAD-6QA%9OCT:'C1^,P9'J4R(""L[J:Y[X2^U41
MX#==6="U<D>"F\,E%D%*"T=\..2P:1^D#74V6%+UCE9;CB8#-])4*;<@1.VH
M7N:V:PY"R)Z9Y)#3S3VXE0.=YLAHI8UG0P+1:CU^Z(BV-"8QHSFI32=B@H_#
MKAEIZ4A),\@#*+CN=81!J^+BTW582HEU6(()1H>);F_]-V9!Z<XB].@/,4&M
MJL/Y__8AYFJ%HW".+,T.TBPC)1G$$+HU-8N9OQB64UFWI*34Z-G5> @BW2(<
M!UFUBT0^(WIVKYN8=ERK#W.A#,OV?)A@&BS8*QTS$T733% _ U_H^;HU(GG7
MJWK3@:E!1%O(<7228;0Q7I077!\3AA$WHK05YN!%2T_D,;3(\U(-J;EK]T35
M94_*HJ9>+ &=SHQPDI9QP4R<+!^-L)%>]:L ,P(+4(NAORCI_7:O9T_=BN+R
M8Q$:U\T\D1!SB<X +N+BFEZ>EH>P#+8.:L#(Y,K#\M3N@<UW(2O),#W$4ZF>
M^Z/:R!4ES9T1=;[9+M+M 82K"45T0G5<'\&C8<#KL%(T6HF0"K7EK#('.6O1
M)A 4[;6-BFF*LY0FI_R()<FIB/ U'"7RM,N/4]H-.L-F'9H.0@AJ="%"AP*Y
M/"[-.TPM3Z;HK!)/^R O5&IC4U'-=%S2&H$(X+[36>8=RNH(F<2.?<J(ZJEF
M52'55$!50:QLWB]-T9B0*F-*XMJ"6VL0G9Y0B=$8U%G%Y:I"8)& TU,C\CD?
M:M%+0\AFAC1IA5"[-.DLK %0GD^K?1E3960Q'&"H7^5Z/,Q4NPP,,K/:@?08
M9)ZMS6"2+#I8$578+MVRA[4J7X97ZU_UZ!23JZL%J532(H\AN.DR,3PWL@DZ
M&"]J)9[35'4QX6I=L)\^5D(0%&1GQJ_9RIP&:#LH&L.*$0YIUW5,HNN1@=1M
M3%*QZA3%L;=2JCGDV0W8MU;XO$+KE;[.!</*TE!ZT:BA0B@&LDR93ED!BWNC
ME1^,V$I7*4L3AQ_CB8; &;KV&,QM@-.L@]K\GH(:C(TC4&NM0]K6YCT'-9SX
M4X(:T6WX<[2D#6JY/:Y5 ;9<XYBRS59'F ,+M)20"X![>KSN2UP*VY';F=0E
MSF0)&J\D%;W9C!$(;G/CHC=W%NU.):_,.D)1'[6#)@:\_JZ_]YG5@^)2:6"@
MO-?$/$\4KYI%J[H3-3T7C%/&.&\QJ6L-53M2I"6D4BB,L0U8H<OS!0Y\ >]T
M#>YN][AL9(*D6JZE_:I53/21G"PIKQG.0(7MP ;I*7P8Y(S8D6-''D^35C&W
MQ!QXENH)\[B'=7!- +Y+3?FXF(LA;[B9 &:P&@6:((E2S-8[+A_UI0%:)[PP
M\ "\7Z8-6:W@OM5K+7JK :A/)ZKAQ;9FI!+NVH:C8S;7P\AY@\,2(>E..IC;
M]29MH<A)[199#U!V.<*729UJ\+D=](D&%/)*O@IK4F.TSO72I,83$MJ?E_+V
MC*D!G#MJ!18V""VU5L:]/'>730GL@::7_?$R'(J$0) Y;\F!W/#"4*^(> *#
M(E1>9YGBQ),A-VE-G6YO7O61B==?E+F6RW&+A8$$156I6_W)DBY:G#K$)J%4
M]2!;;3=D05Y::"6K3^FD"?!&O%C_!;A@##$STU?>I#0NCR 3!9;HVWU3FO>*
MXW(<X$G&MU#<B?I#;I(J"#FO-9E:9;1<K 159I1,IR-.JDU'0YD'OF"ND-$:
MN9>ABF2JD*>%,V/F#T$AT^R4XB1G%QPF='6_H52$S$+FCC#F !#!!B-5<!M^
M"8ZL*:BZM($![$T<&(R9$24TFO;[Q>ZJ[TC!=,([:#O49)=J-A6[3.(>OA@
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M]Q5.V+=Q<.=XY\;!PHX3-G:>L''K!PMG $RS>V.[W0YH-G;LW+5[#]C2YC&
MX*KCP?9W[MP!-KM[%\ S&X\!]PN[3MA]X@,18L])HK;WX.QD]/'/?N6^,\FW
MO/_>TF=O.*NDQT_8OWG*?>Y[ZFEGGW/N>0\ZOXQ5JGCM,$4S;)WC&[+2ZZL
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M,&4?>]TZIK[?Z[6*PZ&Q1? N 1E RX7>A+47DVR_NLC_O$)^*N,6"5/=/\$
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M,ZWWJC0YO%5^JFTKK6< -OG(=KK9,0JI?5Y_HE-?5\IO-M%B2:WJ46'%_/W
MN?A\?7^OJW*=^X-2I^_KS QU+@!8S4Q<R(U8UFV1"I)MAQ]= B^6=-Q/^7V(
M;I:I.N(V:%:8]WC3Y)3U[A"\O4+A)T$(@?4)^$>NPC>F(\><[E'R=,^&JYY5
M.^B_NN_5>A3MB&PG37<Z.TB@9?ML/XB6K=4@2,'B\_[+H77F'9+9I<^/TG6&
M@XBPR.+]9L +#)*J1U+@K!9-SS#K\?3IK.X@.J108#YTA''M"J]-R)3C4H?7
MY8^#_!TB<7+(53<KSH)S-K8^H5SYJ<I"76\M*8\WR\[96"6.F6M'O^F3_/TM
MMN!156R!VV^=D68V4Z7H@J*.D6:F=^F^HR4N%'QW[$S?YX<MB*Q EDV6[&47
M4)R]BT9O)OJ S:^Q^CVS0OK4,R98R$-KZYZBR0Y/MIV8RQ?SR  YJ<,$UE95
MRS1)6QWKH&;ZRG&&9O2KO!B:7/(*D"3C1,V?[H(<48H8@(TGEJ0P2/T\S@9]
MK%<?@]HBFC#C\7LI_@P*BD/1=108 &02\\IS*.^B"37>@<YR_/-/_XB/2I5
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MT984XPZAK"] :S$!P0LL*_W2&:EC?I5'\ET'/ZA!7!/-SV..OF4)A17N6?]
M_0CMAW3F^#F0G%JGG#XDTS@GK1X^[6, [L:3"&0.MM]Y,>2,N\XCD=4%E],=
M<Z_K7+;Z_'^?Y87D_UL6(5#H[-8,@ 0!#Z9!-YAT#N:!7L/LS?$R16LA[&B?
M*5I-VJGZ3-%:!FM%J;)<-H7D Q&(?Q6_ZS%T3ZHFGM*3<W'X\Z@/0C"@T7!T
MY]YC=W?%V*AG'[CUV6(6./4U.+^,[Y%<@-&(0U,-7P8@; M)5X7 5X7Y,9V+
M)<]Y?'ZLW+)-W?"'TIVV^+@N?L7BQG"[L2&)ILT3=?I^H'Q)J>-!!B BE_2)
M ="YU ,A_8F(I118QR/J0V;@1R\AJ4 [&+YOB0&(,H]B #XS$?TMZD -M2C^
MBPF87 S 2<@R3-?R?]&^A*"EH&- [LE 4O12'M=IH: M!#7Z24[CHJ9V%^^\
MR]C>GJ]@TLGC>O.:D:<^@O\DVYKB"D/F6SJE O4@70S IVS/2]A^2IDZ*JN&
M>I',7%\6#F:*PCB3X9&*7&>H@M^_9QB.N0;/7[KKSM8>&6&K\Y2ODE_8]41"
M<9(V<E5=:2FY5R,I>%@'FIGT0N5A2>2W]G*BIQ]U?J,*I#*D,&#E9#O]/&=:
MK,K>D.PF40H%XG9S%P==IHU&RCP5-77QG7Z$NH\UH\9K>7D2TCV_.3 ;0.JE
M#OK9XJ",;L2225Q:HK:GQ^(BNGW@?KP"IR7R;%_X5: $MXE>ZTRXDS6!2RI_
MQ\NLWG&<+(MQ'+L3 N?]9$5X_(K<$CM.SVR)U&&2J#KMPVT-P4)@'/16U2O/
M(T._>MQX4W]$Q&RW:..U?8XPB6RMO]<^;KH>OOETV?"TX567KU$G2[ZV/E(#
MW#JB8K+7>*HU7E3ZU@??[G5#E<].TBXEK=RMFA%]71/D06E!DB>M6?X +\NS
M_P#>/U5 "D:3>L\$7B;?+Y2!F(05#3M:\602UFO3CTQ713-W%G*=^?':$#/)
MVS%W_C0#<)@&/<\4R[0G,-EPZ#ZL31S%)+_SH*T_WF&PAFQK^#<'7I\"BAB
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MZ\@AG*%*=Q[^WJ(&(EON[JC-/QC=V9&1P=;6UL8_C^#[*/HZ+TZR)('G+P!
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MW*Z;):BQ6]O+#DTAQT,2*:P1@1]6C"O8;'5'[,'#=/B>.AF/F.X@?!]E !R
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MS#G[.W\1*7^A?P6QT2R0J_:*;=*WO>TO3M8R_=-3='YQDB;4]KLGND]BR+:
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MUD)-'.PW5V_RRW& TAOND6GQ'K>2)V(DP,-[>,9EX3N_UD):M45RR/;('HN
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M]Y=_$)23@2 GZD?,WWID0?]"$ 2<44%"]UNJ![0K=(_Q?R8SI!WVOP:&C3Z
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MEZ*G?ACVW_SL6L4RCQ2 >F02?IO5L[.I*<F\@1]>^8?V+P0OB"[/?F+#!EJ
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M)_-LOP&^/:,FH/KIM4O<IFM_"B8_#I4!='$E)O_V9F-Y+([*01J+[7\E*OK
M+NE$A6Z!_?X+QA8?5+^)9(3_Z,1^W VIFB$I^&'PDW C?IB1T=%]7-<Y,8CF
MSW9<W$\_<EMMW]-Q< ]AH=JJ"*;C27SQGUU/N#DZ/A*J8L,^@:&S0RN0NU(+
M-NJA?,4>&"RYR<K&<#N<VD?]*Z:D]^"UHNX,N\N,F)DK/==Z-^ -J7$IQY@"
MK&\(&_AA3"L;)K@!WTO/[<A9R;:X\.MU@@\=.QI_Y+23!CSHBC['7US+@62
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MO6?1KQ0UI#GY"\NXQ.2G\H5O-(T^_3HL;"SX_%IO@W^((!MF-_)]]LLO)&S
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M"[3L,2'_9]ZWY\F&<1V>[Y$(PARV)+-AFE%$@R EQIW^;]B6P '<+51&#)7
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M;)-#%J[<_)\;RNMR$.#FHQHZL=%-U0<IB*"BTC2$3*_Q\]BWK'DBOQRIKGJ
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M"FD87Z#)^MX:$9;3-"%IT7=4^Y=F_]\4B_\?TNP_*_9?])J!B/+Q@,[CDX3
M(&Q62=H!R/^.H\J"D0K@N1!A$0:&/MF/ !RX$#R!)$P++Z_&^L=6?V &3E&U
MFGZCY[._K_]FK,_,1A25*U3UM45PA+6YD ,LX!<7<BVBAPOY&]+\3/P1-I
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MDDB=JKT6ATMW+^DZ1Q-9T@B.4!%3AS,+^D6;^GII>&;]_:>E>0U[]EL6O!Q
M=O[]_.*&2;O9MQ3O']MA2P_/K_D[-*8/W1A*#><-FV/&P:[*/AX_=GAO1KSX
M+K<43C^Q83T1>UU<D>5'"TQBB;\*^LU2 5['+,:>#5V]_S!2.3V(_+!*7>CC
M<ZDXV>;%R5J'Y[\,?X:22FL1[RJ?-<CUY'2XSA<>_9;9YO8-R9*LY@CY@+[8
MI&=399D75HNUV;FL@S%1M$;&V_'Z]>2Q3\A]8<(3HSKNE>0$\:[^?;K&Q4%\
M5"YD&LF@T@/[JF=#&27L0LO8DB E6'('WZJ: GXD\DE9SM%JC?'-OM;'504.
M!X1;$KV>VXL?M9P<<XW**\@LC?H;.Q[1:220%'3%Z%BQS:X;-G]DMTV9QS#O
MN9"Z82H8'/P5[!9_]FNTH4$ZRY!4+8E2?&LI]LI[J,6Y=W-&0+[1C%Y;.53C
MH'BJ[=.@0K&O? 2O :='33>7(]1*S@8.:K^'QC4TBBT:3).[NON(HFT:L5%Z
M0\>N3'(4FK\&UB4/!?C'#8??\QM6U*XPW M]W8C1I%&3*G<GQ%:[V\;>;JV\
M_K+%+L]GY=59S^<_#U$QNS@#1'Y88/:,!L-DU$J;,PZEV1O,)"RY]4)36Z16
M%S0 =IA:H2GU^Y_1[1'OX"B#BKZ)=]TMAKRZ-^-J](%M_^JO1$"CKXQYA0A&
MT9$.Q6G.O+?JQ"8Q[9AW4>1+( TFQ</87FIH*Q9Q2OT0,*^;]SJ<\CTU(,#7
M<7_<(7 Y/!CZ1!*BM]*I"S01DB75?PK +:XZ!6G6THN(_5283<ZO&:WH<]/.
M_CK]WYNO#42TAI,RR!UH=@9AL19!<\'.]B\&)G,AP<CI#8Y@>VF(FB!=]6N/
MZ['V2:II^>Q >LQKO9=^NV8\!GX/R,3Q[J8VJTB$;L:X<B$/+@VS8PB<^-"-
M98Z8.Q?R2 6MSH6\2TZ%;7(AK\X)-&$^0AN1:9PCG"EH/1="8=,%[+Z8A/$M
MNJ7>5K6PF]B7=^I;:QH7<M;\PO&QT]]YW+JJOKP0^*<X]%>%4ZL3\_+ZVW"_
M L4'EBXG28_',^(%%^,M)K\-4]J9$,YG0@.1)0=E++>QWZ!UM#/:3$D$912<
M:?!^YC&E^U3.7R_I'QU-C?:7FI]JP/4U]I,4\GQW+W^@8!?S%R3&L '#:8C&
M?HHTK6_EMW@25@3/MN)"WJM!6]MS2":G_F0*>PX6GE)R#;@L=Y+?17M7S?>G
MJ1"V_KCIO+AC"[[F:V2A4_#ZM=^4YTU-%T.3.2N\MY:+$TSF/7N*5;]H-29X
M3;Y]6[P&UQ_17\LQ-J;_?N9KKN; -T'0@2W.(X'] I2GY&I .^I]]:SYDD&<
M<A].6CW)&=Z-T9K$ZSR%)Y$;QJOXRZIP\D\T&E+-HC-DL=&ZM75Y<Y#M9(;2
M!$<2C!-KC!PJG3'&;N%"%K,(:H1@I"+K+%V_:@0@P.MK6D8VG?4MFL.HFT5:
M 5^OQIRB3AB5Y9GD#AELO!/NX=OZ^]H3E=O=6-##4:V??%LVKO?@^*>,J%-C
M)\L5=./6SG_XED4FR*-#F7;@2B<(O@; 7O%>N#B0WX65;A.I<D?[(W>QE,8M
MPS3AY#"+SKN)\]73FM$7 EPB98R]//KWYDO6.M2\SSSUK>,(9P GCH8Q+?NA
M%#ZPEIBR7W<HH:-H-0GG:0)][CYC2>7L2IFT=;,7MUK:LB-5EH;<'[ZXK>XZ
M$P>!"*Q]=YE@V3Q#A0PRG7KN?B_&A349S!A47="<NRLV9/TI 'U@TM*+C$SL
M4*)K]XB+%VE[CYN(6!0A3_LD^$=I"F[8CK,'1 Q<1@G'02.5)C#VLI_#PK>M
MQ+194I,]4'Q47[4@L/M#Z-W;=S_A\]))7H>"J_8W.*7BE9O>DIJ?OGS8-S7C
MEJ'O*?@& G/4JPI;UUMJK6MR]'W,UZL;KNAUZL/>+$&-=K>OH(@ YLC+R3^M
M3C+%/C(&T;=JA#2/2SI)YEDE%+#:P/8@M J5P$AP9HEX>8IS#-,J%"O 4B:]
M0AN0$2)HZ 3Z9AB9G_9H)K'^!U6OJO)EGFG\8JE+BNU#M9MQCM6FX 0*V$X-
M+L07.VO+$2)&TG48G<!5HJ2!*58%57WV2\EDI!-.N]M5Y\V<AEUYOTI:P^<-
MH<#H1T+NI9"&<3L(M$YV \F2-6:0)P@^PU,"Y'RJ'RU^N'M!DR[>O6IQ5-IA
M?$W)"6L6RHP)<.S94U6J6V4]M^?BG0_5G^![,!/8>EP\:, I*JR[6!GH?^L)
ME"R1_\$)74=C36>5V1:.6,F!:_LW;@FWN&?75<0+ZX^6&B5X:;/D_3B"(TP1
M3#^,YF  99UEYW)4&N/:'!>I!HX-A,G;\ZZ+<'+Z0;R%130U\L1GUTV+#[GQ
M*Z>'1?W-,N)YF/*D6->PJ.YC=QIO*I7FYTE\_EDDT[)[;V"C*6V8)3/($<$M
M<B' ?C=J(:V?$00\IO&NNM&J,S=?F<)DT':-=,5$]$'__2\8<LUY7SP(15(6
M]D,+M]%6$&V>CCD@B@O1Y$).@+7*M)J3YL&:9;=;\:./L,NQBQV$/;# ZO09
M]14K17H^Y2&Y4ML=?T34IX#^I59JSX#,@Y]+CR-=5>Y90SVPG:<(R%>P11R6
MK\V0_F:6%(_Z#)-BV7]AZ:CFA';U^GK9NRBT2*7L7Y 0FS7+W&:N3K3B5(%R
MQNLQ+B0$QH-R(7$AW:J\7 C)ZOF+E5JT#=WNQ_.Z<Z/K?G9FDIZ]/[(-M6Z1
M/O?/0+Z'TD,9CX%5.O04& ZW@V&T,X09I&<H+HU8ITT]OX@0FR/"'V,E4/YK
MUV+E7:W[=6L]$C/^:'P\L7S[274'-I2X?=F  >9!;2!=A MQU/O)M^X,OS1F
MXB04Z15X/GYT0G;>]-/XH,K-C"7=(6N5OV-4?:H!U:^CICDK*,":[BR=Y';!
M2% C7G =D0NMW:+P,8]Q9K&TR]FSQ1N,U[2WQ4:TR216&,F 0N +,:_3?ZBU
MV:+]*?9F>%9%A)%]\15[YRY#W1ZQX8<1C(/TWG66]*UNCK CS6)1U]P(I<&(
M2+7TH35VS23.-9[[9>2-"EFZF/-10\-8[UTQ?U=@QG^4WPLM=.WDZY$H2U@,
MV(JQM\LJW_JWV!7X*WX_5S1TY+A 2"OB'J)V^3UN>G9IB^)5PCK)?@$&;@8,
M#^T33\-*L8Z*IUC:,&UF^\OAK[Q#W&ZFD@EC^KC+F5122AOFA.[-S(?[@=^7
MW5:A+"EY5W8E'@EH0[N^LUO:CKX-QLKJFJ1G6O0>1B7L_HNH\X8CPVX>%9W]
MGC>A$^T^H%5PHB?'&0)".KE CC#S#5@WM2SU:%Q(CP>,TAI!MX<KKWC\(S4U
M@ZIFZCL)ZH;9C8]E;SIE@X PC+"?5^TL:HL+ 1MA@T/G<"*NQKN&&?7I;=E6
MO DQN9+,M'A2*HBD9);/7+T\,#Q\.&A$X&BP3 0""JX2?%M5N1?66$U1)F5+
M_GJP\.MO=I^7[P3G,XG/P=(HV$?-3.!-;8[@INGOY#A]EA==#LZ'[:Q3TPE=
M'4#S,6WF<2I7O"H.=P NI4_PU,.?Y^6IB.":NG/&V76+RT>?B8^( QH$E@S3
M"XRZ-VA^>GZ?N SFTP9:;YRE2-^_U?DW.RG<$LZNV%L\,3$:K1EL-1A6D^"E
M,!2S1]1]+NIJ[ 5+1])8)4Y,[.Z'E1.PPR"="(%;:GLM>$?Y$66!#>8!S)?B
MX^Q'L,5"$(=DSPB0SG0XI%H:,MW1SCB;%LDDIM989<;Y*_Q[$[Z;Q)^1L)G^
MT!?Z9A*VF(*KL<\%^PD&QT@<VZP .HY.H]61*8[T;;0=F-M"(JBG)D2J-!II
M.;_@<D9X._I]!GTCVR@.YA'R$D<6$W!K;7DW&MGJ])I2^GO=I['9+29J^?L-
MH0,H2Y7;U7W$6>.^!3!9XN]SP.)U9EB!Y43/JWB^RH5(<70 -.J%-XW=6=>^
MH37Z(VLM)EBCLS'GG-:UVYT9'X79(][9S*N8;D0M%\*2%F>0V5D<"TP73G0?
M$/$&15BZ!A-G!2.?(ZY$J^T;^2/BF%Y&=M00279(.?9A.^R;L=2'1&NK95HU
MM96$D,5VVEBZ@4JR&FE6S^5J2/ DAMKA)KK(W+Z&8I&*EXV7904^JYY>TZ2G
M?6^#,\-1&S:@R(TH)$=H YI8[T>*#5QT7L\*CQRP)#;:1>UYI=MS*&H;XVC;
M]#TJ?#U+AXP%[F13E.E,SAYMX.LB,H-0)Y"$MBWU8HF.MKE'^+RRIJH4?%VH
M4)\CJAQA4Q+B[\:X-E*13#F6$OL9F%<$+D00%@"7O^SMP3HZ"KMF43J.AI:N
M&'MXALR$5=7Z)IPI>A[YL-)V6\K$)PY;]\;J6\ %GK_/7X2V:*>\32HCL0-&
M.5/-YV\&WJA][M.I_.CAPW,A'?JTXL17-J6K&.VQMVMK-0S/T(JII9SK_XB]
MZ9%;SM+9B&'$L(LX4MA.2^PB(8]0-TE))?G3D-T$,'GJ$HDIELZ+7D9D.*7S
M[=3*@*@;_<30R0O1HK[[;C0%'!F41IBL0'FP@>O3%F1H[[H$F#\@=US,14A@
M=(:K6783IGGLLGHO599+F>IN=R>/ISWFO+%JRJC#Q1[]O_D5(/S/Q.?2@ V.
ML#+(0HP!(E.#,T[83? #*<\@P[ 1("P99$P<^_/Y87 D_1!TCT.(22MJ3<M%
M<R+BQ5IBZ?6\,PHT<SF%OU"&QU<K_E58'2(.20A0#2"> R) 6V**H/>JJ.$O
MBZ"GG:XY(8IO^?NJ7Q3X9!5@0]P((!P#L7JQ$OMY&P)<^S4[N>TX\Q#+^0M+
M=6DP4X"LS8"FL!R?%YW^^$4_)]/\Z755T<)G4B6L[M!CC4=Z(;'N3#/..(YV
M$9X*5;R=O9L#LF;:Z3 H"9<0/K&XLF"*9S_;I-YQMBQKRY:0.S?5LQ&=\_;F
MC:6KN=$?+HB/M515E_YTE0II^5&.# P5W.U9V#QQY(OTO3Q?R+=[P.00M!;7
M60WH),=S#L^L$O#KU'):?]^"D-/1B75K&J%;?G3MVS\OU2.;C)LNN7[+N'6D
M.I/@FPUHXRA?F==!'SB!%%XLBO&.%H,B6H,ULR_TP&WXKI7).C%UY0&3KT;$
M@>M9KX_WYVEDF3\P?]01,*2H\$5@-0S_J?U[6]2=W-*:T_?(>6:B5:77)!QV
M27X.S0*FZ0&#I/*N=46@X@1A+/P/000XS85<3G<L_B;GQU_WL=A71T#P]"OM
M+/'=! ,NY%IUFO<A,'<B.$.@7<Y7)W A$.2Z>!(7$NB%=?EJ)1%\[/'@@G9R
M[T(:4FK"V## [,MGOON^$1LYCG?\0M]C:?;(J=];',$)7/VG/AR:"U$U78^_
M@/K+A2RUKDXZ5PU6S0?OYX"+#SS5<R\]W";&;-ZKJR#G^XUOG0CLYT*H%F3B
M+(PA"R"8%U'KUF/UE7[]5K()%\=-J'L=&:'1*N]TH$^&F"C.?NV%]H0S8!>,
MK&@M%%/VKFTM_NB<_V#62S.;+^)WTX73Q>("JCIT*!E+Y:.[D+ LY4],298H
MX-UA*(D.HALDL?:1\4"LD5V5]\]1D:=5]6PK1\U,OY9F2<U#3J_V%3EV*R%[
M#>(FN!"1*@Z4=0FTR4700:+8(&P\0I8E0F8;Q2"E3!_?E_/XG*%M-VXR?ZZ_
MXNS63>?=E+H7'7\03VW\K*&-,QWX%P"F\X]7C&M#+3Y;S?_3W*I,:.Y.N"RG
M;7<-,N9W$( L P%HW[=2'$%TI3/-^NEJ>K&B+[?7"[V/(1\6<<XG?-SFK%&)
MO5DZ/V I6-X.,.4ZX;#%%JA4!P]GJN @W:T;/KU*PMR+((DG*V4.)3BU?_T3
M&?WR:V#B99%4C91HB-5%L7)%1<LM2AA3FV7"SL0N?@=)C0:@=S,J=/$7UL_G
M%8#LV@B1FO,$0A31Y\,UW^$WW MT(H[!;]4$AB@W"LO>>05A7_H?WG@#PUID
M:V?C[7TU< I6BR69TL++P<(9PLX=9D)G];0:-]HJ?_VXOF%^?:ZU)K/[:%5?
M&N0W=LJ% :9XTB%V=H<JYR.4]@^V"YQ)4#Q);Q-+!3GT<$ULZ\==T1T.A0:/
M_V'/4[-=O/V8T=C.HY;.S#-H'YH\-8IIBOG2"!/"F+),&UMJOK1YMXC>K<PJ
M+YO;L'KZROT4/771+\]U3Z6RQ6'^AL=_"](@VP*,<Z"O0]#N-"PU(HJ)X<P1
M\9I8>:N#W:1DVG)"[BE:05"!=J))8RYZ(#AD_]/B:$^+\JAY_-/#]F)@OWTW
M3#'F0D019&PF!\35B2#L$C)@Z2,R/1I[Q+69TA3L%!<2=LJ%<G3C.]-^6-OJ
MCL9\ZYK^T:V_!R#5&;<-@/W:5 V: Z.)3J3R,:$8(HX6#\#(^5EAK$MT 5)#
M,ZUV[$K6;T W^/9$8V6$:$/Q77N;[6M3GGM5G[E-?RTRR+#4VMW6(5?8>^Q6
M2+A1003"7MLG@ZX6I7;TE[6:!M.(TPVC?<8V:%-%F)>YD*X1SC0H);T"=7>+
MR0>*QX5,8:?OQKA3-EA;3'AA*P;=U. 7KEQY$= &^^_VEPXY#I@3]8U40W*V
M:B?9RYB1!=]C]PJP6K66M"OK+/MU(7CTQ(;B/UZ571\N<];T$KYO;[1TI)7$
M6?$!+N ,K:!Q4SA]'(7<10/*3O,P'ZTWN-^PY6)^GV5(UR:98/:.6Q[<56N2
M-#/S![G7W%#'0L9]G*IPI1C/"'QOP,-R /QI"2=IYKWK&9,X"9:S3_B2![V(
M\9#_?D$I5:,YES*Q]/&>_6)::M>; P.K7HDR/*IST)#ZO$D,T<C,:^JSD6'!
M]@9'R)W)C^VN@_D,"V+Z8#0\@63&A=QW7;J0SY&"4PPH1'QL%8>\ 0W<6)ZN
M&Y[FU#2&S??=L$HNB;/D8WBRD["D C!\N9 9$4;QCI?9>##$9WN.F8']B)W*
M0%)@[RXKPPT^;Q"I5@%1:]-R"T_"\4]I41RA=2Y$N)"1S7[)A009 )Z$&2AM
MI/(%E))-$=?A2*Z_"[X0S(6L8KX00S?,MW&W5)MF-P(C8[7L(*AREO2+'>*2
MQ,M.:^-A0K%=/:#,=1R)L$.>,. 4H=:JDS&_931,H'!N+WA;SC=M**\M6RZB
MMTO @J&+O2X^#>OG&+2##O#'+"C!N]<A*&*/V[$_6UWK:BPS9RQ\)%(G1XD<
M9G:MI3%O0=NGE=)_.^26S;+L5J3?*E:BC8]4+1.T($"'9IG$PCSHRF<[U$;6
M\4=*6KZ*"FH^\>P94HM0DEA_I_KFUHT#?._Q8%N;:&2>Q'1[Z[$S88O/P:A1
M7>X[B [_W5%'KD"(>?P4"XCJU7I7V]AHI D-R%/XEOGD@U,5 J4)U:6M4\!F
MQ/^4-IP8UB$.&H3F[BS;9NHG/#.#JMI8-"T;3A,KJ1IWU,[;G!TX?.5@4Y#[
MDTR*B)3.6MH!7AWEZ##=Y_B"7\NHDHO1W_I^"2KHWIS[4YV)L<1VFF%#1*"S
M$3W$1CA%G.D?C! S74_I4!FKQZ9ZJ]*CXN018WB_JYFJ193+S?&G]J?M-Z2*
M7KJGN:0)K?OY3#P;NX@CT$X3I#&]"#RBMWIFJ9^ KZJA._00%.J+U&#25U:+
ME=,^^L0&:&UHVR<%9%Y%&E[0N98J)UB2:3Z0V?\%Q%A/=XH$RZ*:<;&6_11&
M"@*3T(<!DUQ5JF80&=H,#!?2B'".^KYMA9Z:_D&9)_R8_4?_QG%.'8%D0,,Q
MMECJ1-JC8.(,:I@1->NW0<]8'OR\]L\F*)N5$NAG.8Q,,()V)EL!VVG$,4$[
MM] #$LGK$BM_NU'Y\-'=A9'E<_,KSJ\\!X45RWF=@MMJ%6K$O[,^RJ9-YF)&
M<30[!'! F_J)J;_ ^8!K,&?)5AU'=DT\\,R46K8!;,6*)LHB=[VZVC*A@ C8
M\-61% T3KN_5NA,AX<K6>W,W*J4-5K$P']QRMC4P\J;?_L$IO;6'"_/-VUX7
M<Y(3.OM/0RPM2KF0JRA,_PFF0R%#Y\BSC3MAQ!K>M;ZSQAE+^]OD^V'O EG[
M<307&,C-[ BD$'8A1X*0Y)%]'T;:P^DB,H;Q5Q0[OC((EM$Q$8V#OSV/1V4]
MWC25X:'!6;+F',%+B]G 07&J'FV,\8JVU9_*44'E=QI[]))MPTC55$&6BT]H
MC"RULOZ]E\WW^@NEK=>L J5^$]0GV]#>;!#CD$)!HH$1Q\P3:/56G6"BXKJM
M]HW"2+*<G@TL'HM7SX*94ZUN;:NYY1=U7"S<R*C2F?U3+0,$=F?OPNRCJR8F
M>%D-^K>WG<JH_-F:,A>;B'@F#F'G<2$^.""@>H; B&>7@ZN +@_#=C'H>S+?
M8'VX$-_80J8X16[WV.!&&UASGQ8Q&^P:7RI7G@<TP(+YF[;519R)8.0!3/*Z
MB@VY2)OQH/"D4OE]_7KH?CVCA6ZG6*M3:LCCG(FZTHS^K9MANZJ4U]V^F*NI
MT]A5->+)X?C9(W]$G@S.3@W<C@^^&*C[ZNP/%35K2@AIKVANW+%<:R@/ZP!8
M$\!.VVG/A?@1A'!Q4#! 9;B0TR,=TAYP Y:ZE1KPD)9C(!&"D6W(L<?6SBY4
M?H.&I(JHQM^VL)=_H$-9OZ?&#R33QDARR8O8=)@"TFHO*A=>KU.)^@A.$]_G
MY7KGSIU'L[/W9/A^S-24"[\1.![Z;,023JJ6UJTF$22F5D3X*/],S9>6F'%6
MP[0%$CHW*\9Y-H:IR<S=V.[+G!%8'1?2/PQX$*:@M!+6S4BR 05',<!CP[8G
MNJ :GS:6F&:&K9CIB+&@5>_^0%H420Y'/[&^%)O<-;S'9LF)?3BX<<$@V;;1
MZP)YR.AP0\Y/[0(ZGY*DHF^SW9%%-P<["/HU4Q_;J</BHYF3S*FJ-%MR>99+
M?X<2^P5&#ZCH.[96_'??&*<SN+)7YL*OY_=_/ST3JMC[_O> KN#)0SI=_J !
M#3D+C82Z6FRGE:D!H*/U#5?W<5H_8^86VK !(>=(ZOR=*;-""/K-(AP01*]K
MW,RX?O#=H^I1I0-\/Z#9.-H9 A_K/*S./I4VV'<3T.G&U;EEF<Q'V'SQ'7$F
M$Z>GW?&E9KRVE@'B#ZK74QZQVEYKFW[!S&+?$5EFL*P. =0D1RZ9I8&CO;0Z
M?!FU2B%.X:YSII@F+@Z,XPNWL8'S/Y8_]3R9S4RVC/DCP_,;2@6!U*ZO(#O@
M8PRF,VCL3$)8,&8/ZO?&>T, UGOP%=H"3]<O>AL\XF4ZKCG[R5),=$##;\CM
MZ*7S]S:0*YN$*8T>4%.;-EFP2O/1<?U!?[S\NJ&\.!*C\H4MZ?SU@LJA_-=1
M^J]J1?+D2$6717R4[[6RD0I6&V]9)VCBR9;N)8!(C]61$8HI42JVG",Y+[?E
MDJ;3[D*AI^I;?1(Y',TJW4>\:B$3/R5;8ZW&1ZZ>0G*DD,!!Q'VP@H*MA%9O
MF0W8<600@ $')*\49V(PTWEE/K::BKDQW1@^K//Q^K)%_VDZ,H7P#LN29?9[
MR]/E.X.QBY4<A<).J_WQ:WU+%\:M>#T:V@/+KPC8-V0%K><(J9SL,[3H)0 I
MND>9?A?H\*3;82=F'2<L'7R"(U&S87I52*FCVE8I;VW\-BLV>98)M5&4KS0F
MXRB[T%*6J<\Z%#-@"5O$BG>6!=>M&"4W%?DA"H+=K7<[W/H\:WVEYCT?!/T'
MM)<"&"Q^Z-OL=]C@]00L?I(RS0QSH 7VX793(E?#H.?R266$5+G%D <.2$/#
M.2];);+LP\,#^]%SF64VU57]*6U6D=6 ?5]K(+M$?<,Y>29W>)I-?3J?C?:M
M=-)UI9ML?'R54E8T_TYF3VEQ5YS5:78AR.M@P*'E;A"%0C-!W($#=(_C>HB[
MIP8,)UAB\I35%S\SW^C8J-N7,!9^?4NX5JG2?,FBK;T\:7]K]K0(0Q'$'!>!
M;?KZ4C)+#TI=![PXEHUT;0:"H3V-K4%7V#4R84^7!QC_4.<)UU&?S8KQ:QX@
M"3].CK$GT";:_5^]KY4)?AN><TWTV.L#ISYLOOZCZG1V5+=L_$\H$!;VW&OL
MRI73DAH(UX"]/'^>B1=V"(.ER*Q-E;9*CJ*:D]=3,";IO7\%J 9O[6Y6H3QB
M969>X@),QGQ,"T]K1]S2S'R2+R*I7),PT8'>::\9Q 9&)O/H"I0&!WM-_*L%
MZ#1UL[ (ZC0JWNT904ZI=W.]O!EM"J]/#/5W_3T](?N0M%O+4$<,5U* >>Y3
MX>[P.CCJR]SL4.'SIL9'QTYU/$_>%7LH! *0ESF"2S1"+Y;F5)T,!J#S<"I4
M]D]H17527DMD_WVK_<#=H>"6K,>5EUO;JRK")'/.RZ1Y/7I^YZ-%W/L'@^+W
M0!\@ %W?4(_]J70X1WB:E$X4_:64V-92-)S<P>OAOGJ,77]+QT3:6>O;@YFG
MET[7/^AM"K>X<<-ANOZ<P <<GLB2CB%O96-#CVLS #8H08B@E33Z4D(7D9:!
M>K7"D?8*M:>[9FEME"2M37Y.S DJM<BY'3O%<TPT SG%Y C!Z# &%C1(8BB1
M=L$@"]H0N]Y#4$)UDYQ03CT,8\#LN-GX%6S0[%PIXX1%LJ?GY45\_'S8'0LY
M<>.SGS3T8E_;063._WL#A67)U+FRG]<;[)")/CT_!CR> T^9((KCS6D/1OT,
M4/KWQ9(:SN=,"K<6'.;9;QW'>T/G]RQ'J)<&YXA%L]\0 KB0W6@8\/@52N,"
MT%GQ,Z]BJ1_()S/9!KWFWAJH22J!T%RLJ(:LWRZT:Y5=#/M0/94]P[>$3,2"
M=R:H:0"K2T7:E]M'6 8O\8SR,!+;L-I 5-A^0T5HX]1%J5Z'(RYQ=]V^$U@R
M^1QA/G"M!<P,K):0&0F5"%'C!1*7V!'=47<X$@TC:+Y;'0:YEU'N81KW.!_S
MSSDM;U_=3G3)L'+;&Q<[S+R"F<"*P1;!SE\'N]>F]PPET&-U=#)2A&KP'B?4
MQO.2*&0*EPJQEY2M%[MIV'4@2WWCRL"#9W(63Q][#F["@8.-U%2:SA*B>S@9
M1[L FW)R! ))V>EJ6@G=WE+TR80.+0>RB#/,J\G5K"7@!73Z65"![]M4(V1&
M4_^96I8CTP4S ,.[@FF_JXY]GW,,\_6N0P_SJ=7N$!&#OE $7PBHPZ$OF\H_
MT:_67Z#$9^1"=5#4B4LN/P[H*T-.#<Z@S'>V3WG0T4 1;;A+28 EL[6$Z*V,
MN4!?R(Y>Q.WV9OG0U=K*+SF]FIF)23]Z?F+:+Z+YVS_V&N>V-<H@L7 ZDR,\
M1F_MPM+.K4M@.XT) =BINXB48HMWM./)J2;MWDO]YW\5A'B>&=(N8!=__?3V
M,.>7[;ZG/W*NV=D-W&QGZNSLA&',65> 0KHMXQA 9VIX M*,)"!ZYSF7XVTD
M;W5FSNHI>E+AWFL-K77CO4V_GX?B](7<27XBIX[<V9.Z(0Y6N>OK"80:!Y9*
M,CVP'U'O/#0#C<=7QWFKC!FP;C&,!OV?>^$'<N:1FIF>E"_.M1>ES21.U^A(
MMBFMP:YEI^TTE?B,G;,L8,6>?<'P*8X-) ET#<=!:=4XLJCK+3M_LMC=95=F
MQ.R,91HA*$VPKGUR'P)YZ:%BW)%UP'R+D;5#=($*DOYK$CN"X32*)^[V8D72
M+;W5@7MO6&'$F)* [;;5H+=0>$!+UAPKY>1(JL ^E[*8S]5@B[!D5\&"Q#.L
MC@.QH!.'V4GUA-0.)0!!/LJR(!-2BDV 3&CRYNI\^!Q?1'GP![WRG.\ENF_&
M&CYTJXB^=D6"V"U>"S.-JXNBE,.RL(O_8.L#>Q" ;8>Q%V=D04<)%H__M']-
M\<^I:H.,AKK94[Z_R](N#KB)Q^^^:Y2[(4\AT) ,778&1HOEMO-$HIS0D-^/
MB.,8U0"XRE UZ;;1#OU0C!J-F&&BW,Q:C3T]4)G2$)Q%KJVR31+><_G8,X&?
M6\F$Q7?%JG0H2SJ?O$X%6;^PP*71-@3M*#[6@@SKTHOPR%*N-/8<>^P1*AVM
M<D&C[^//D;FWUZNJ]GRQ/? ;L;/'%8Z]#N/!?/8 X\^XAT [(U((G?[,&'-J
MGVBS->]YHMQS9R9LZ21NYF&P[Q2R0=SHR==21_^,TK?O*HJ* Y?@/" 2V\0!
M^X:I170+CM#..9P.RQ'+\R]"NGLQ1O2JBE=$IXJ0=\&T]3R==&#4Z9'D)Z6G
M^;>,-2#]/OUOP?4=SDMSQ-+INT+B#G$^'P,5X&,K]<7IH:^#UAWFC$/YK*"_
M" W#Z6#3*:J;Y0PVMA3%?Z+S8M5Z.M03'-J+CX3A^T<Z/I^Y\UNQQ/_>RXV&
MTXD])Q][PSDB_O2Z\X DZ&<K]CV,+N!"*JY8*CHM%DB6;4@@A?%>SHGU_KMA
M5U>/3_1_D$+*?-F4COY\IU=M>\^)AU[R++D:2=CB+%*E+X6WN@LGDGCN"!_U
MKG_T.DMV<@GSF'D$LX"EG85GJ6G0JEZ__>6MAE6Z$GHCZ._U_'RY"8$38Z,K
MF[92=1\:OECFZTJZ-UC/VAR1X=G4[B+NE!WC1=C,1B>BUH EX\DP&L/(76&Y
MIE'0!O3D1$M,"^?Q*^*LPX_!LKGFAGO4*LLV&5_ACZ<N*?ZH9H6#1GF$^:*F
MSJZP=&&"$*?3 GLM%);&T0:B_ -A/>LRJ,*^U\]^6JD4KQGKX;,+]A8[M99G
M(*]E0C*@3U-%*T"P[\3T1(-5-[Z.0\35YK^OGE+N?X ^V0AXTET-4G%2:'_2
M:C3"F?:CT']7NEC;)/^)[<8+1S-]+UR658[[A,)F6XEBAHBU"):L 2-Y=.>@
M Q=2/]R'B^=  ?R2(!I!PY'%$ZPT0_X*)*-M1+]@RR[/.5]#E[4UW'PG].[T
M'D$7-9KXB,&T 4?8LP(=29OL$^=G!;.+JZU4T%<!:4AN/Q>R1Q__<_TYJJP^
M9^7CVN>_1[J&0R-4PO"L=Q]L1,N_Z_W O1-GR2(98Z 6#U">I/5^1#R.=E;!
M!)JHMK?-$RL+=/=P(=+/W9_Y/RYI"3,;]RC-'['^>&Z(##6R>R@IGM_<1)R"
MOR?2SBBOBW-&8: =K\)G;,D"O=D2YMV)HVU12S %H.+BQ+/'_/@-CTXQZF_^
MIJ">6^&2%BE?OZB$\[;'<,16TPY@%S.@=;_M%,ZAY2@G,FXA]85@J9I?!*9:
M,A,[*LJ'7WHE&5[I&CDM^;'HK> 1C0<W[J:QKNPXD/,11@L+I#RDE??O'*!*
M8BF6_H1!ZV,E<+N"K62^FE8,RU>G5.FYQNKV'LAQU,QQ]&_$+AB>L?+D)5QC
MQ2XY*Y,(]TRK4XHU///&-L7V+Y\G>%H$%/B)2II4UYIN%S6\[LIR?*\:NF'+
M6 "7(X!1P@,+1DY']158X9>@0BR7R38WTFRAF$;GA!5/*ZY'J;B$ID#U23NJ
M)Q>D+17MH^E;[')@W[WSUD),+.B:9BXDD #LD^\D)$(EVV)>_42H=N@243!2
M=8KEN?P8O)C9QGGRBNMC<7/ODT9]ORL"AZ(BK\=][077=2$L%A'K!%B2Y8S3
M-+#A)W.$Z+2_6%Y@=C$P;5-^$N\,<VT*;O,IF4?8^,7XO5Z_U>@=<\6>0C'G
MW3/Z F*^5$V)8M[<(<U-.-YG],:$R&H)5@ @60%$D$50IQ<M6Q[W' N;&U:]
MYWUESK;\RJ$G-$1DL[7(59 QQ9=A.T]R(0%00'>8\I2$!?:OLZ27^ANMCM(;
M^Z%R00?)8D;=#LV.:-62&:)-;$SLZ_4,O>H'$_07^S1SSLY/*4+84?4MC1WU
M:7\GK.G.2FWAL-13'V"/';V-Z43&5T ;Y"(W@:-,0]2D\Z369(=Q2.,,/-YO
M5%<JR"]&03TOH,E/O?[FVUO[YMZP]]R<:"^(L[( *L%&8P3*=IGE#J0N86?X
M&'F 8+$Y72 =J8_\LRX!3/::CZ8K>.KZ-O#>SOHHF+\/C7<]=]0O8W(803M)
MR%[0_]<.<0=(F TNH\H]Z%&=7 C(UB0L;]YDPE;5]K?F!..A@K_N_/"\[8CX
MD3=G>:'$W._' 6&)0\ R2]:8(P)E'N2,$1N24V"+3V!*(, =X(BPA&C[GTW@
ME-&V>_)?#50 O]<.F@V05J4#D3H>T[LO-,J+X\L@)?Y'<]?ATUODG0?-&QSA
M2TP>M#6[$+98A),TB2'PS *'F.]/Z&ET;Q7$5F7HUT\F'<G3>:+N6Z'RO/;9
M\C___(BS.LY.(8#4H6Z9^A54HKJ674D(=K8X1X=2E>GYW?G>QEQ(8O_-MW,O
M*U^L-.YVK.^KO?U )*ARDO+^1-R^*7LSZJ4M!*#-R%PD /IN+$FGQ<^5S-#Y
MT()QCW\0='?/7P5_^HK_LB<>1T65-\Y\:[CV<.F?+NV'DKD1[[[QI-&RIW(Y
M(N9,&*<+1W/2,9B69SQJ'V\[RG1 *]&^3R;(+W[[JS5>T%#SQO/IOC'^',UK
M5WIOO)Q*??!(^<ERD&OXUF)YWZ !8.[ $5L&;E9C1JT$.CKHX;DOV\X!]G.4
M'*1$R*3;W8P[T@/Q[W35W=RO+0<UQCZ?>O-.H)A#1+Q;I^! G4GL6I"B9-IR
MA,(6C6D;2PX9&)-??^W+20BAD$9[J 1@>&G6+?=<0[2JM^!%^S,]O'RMUQZY
M9J]G P?,6=()C& P=A* &/MD1F%R[[&LQR1EY]-.2/&@CL/MHY3(W4VGG)1[
MZG/,FJ89D=-YRE$#[ U$$<BEH,#!0)94Z$F@WX#JSKRR<\K.!)Z"Q<-[!RKK
M6RL&$?RK+^"T]K>C;V91$0Y2[F'QTZI?O:\D&'^?3MG._@6EKH)M5)*=25C$
M%?./_4',<"%+%]7$&NDA"^[ 7<?-F%5" US&NH4G>%?98<VSGD%'%T&.601V
MAPGBM@VB4WR+Y<R%O-:O0#R[M T&\.Y*,#>Q?F&!'*$-&E@45E^R0N(1&1[.
MY:D&IN*[Q=0 R\-%H>?:Q!D) M/#?RU'K':5LJ;Z%JW9H;=(0IDVU]'/_N$-
MXELR2$<T"+#D1+H*&E,M+]&('"%34CNR2PU*:/54=B)DW1D)G6$_DCKL61$3
M1"E-D\LS77C@>##WA_"-_J!\D&?+69"R[V$7LS9 BUS%[&$9MM*3DPDU)JM,
MF!!B9>E,4["^Z663:6I9D6_3Y=+X8'_7F:RW7R3V*!QF+;"?6FF!MYEW'&&)
M3Z+]0 /= 9[27?IW2*16P:?\%"LA'!3U C[^_*L<XW;-R&:LSIFF>--$$O.(
MZ[D/+QUT?[ZY\V4T[S9(F53P057JABW.Q^IC4J>P)#_1*L?C&PMQ5JO )W#:
M;'8U(1#._Y,+:1#H-P#VUW.@[,(_QSWA2<P^:=;)>+A44$L89:0W[,U"L C/
MY1<!!;JSJ4.O?T"^>^IXSX(30,"@2042&)?HD]VXZ49&-" "Z\5F$.6JJB8[
MBT72O;*=Z^,_CAIJ+93%HGZ2%Q:TKCI\]#@A7+WWX7<B[9:4.K93V,K</H6W
MZEX)_[DC"A/U*XM8I('*+\2[29:L,N,F.'\.*Z*A+6&1W=\5YD2:3$=[B64T
MRG&D"4T/]=^N5=T/^:3BTGQX^TD7U2)E::^*> ]NQIB1!=2!TJVP$W<>=R%J
MR6@3>O5]*D9K <: I8YYC$06*A/%PI)BG&IDX.W7ZIH<K^:8HNC*_GF73/_.
M(W(08)$/)\9A&Y99*F),\2N<H8)I.OQ^FUX@??]N.@<7N'?TC]X)I%B=LU_8
MC96*&Q,C_>&_%;;4"\>]9AMY_LY:0X598&N)%P>]J"K=C9.P,N: @(;?;T(_
M,INJ&M&'E;0,75+>:JNU-X+K_KH1>*D^2U8[*/7\I7.\XD=IU8!V-36;Z< 9
MQM+"HC)AH0;*0+['Q'J;\G.@!'Y?:2O]T4!L3*F#R8.@27EUFQ8[*<FX>9^3
M?-]G0KMW>!.@VTA1!9<39M='#D_;,EK8;^!=Q.EL$B)%U$J3-LFPJMC_FNYW
M&5]T+SZ@MC&7TG+&J#]7V6C 4'AJU^M&)A="+D\A!,  73A+RH!, *&E=G76
M[?:8[I;&!#Q4&'6)8I*>:?1YU@6/SW+R-$W[H7#FO(ZR_P>OM,K^^5X(NC "
M+$@7V<6Z._LY_8RFQH3+B)F[T/M$6CV,%)TM,<^%=%FCSYEP(51;3NZ/#2'T
M;%B?):%0+7 8X<;2!W1H!AP1+#C''"! =V%\HG'**B^O%"N-H1VJ@(@SD^&W
M5U7AE\R2%'N[9MJ0NKQ^.F\]XY?#;7G2MH\M<T3<F<<7L)U*<$HB<G\]$;^+
M*,2%D-S -3/45-HX1+4#Q[ ,=R[$X3=A/.G39\K2X';$#S1^%5LO3WU:!KJL
M%4NS W.G8Q<=E^PS::4^ \#/TLJ3-\L#.,/'MJ8M9U^O!60_#!8M#BW"6<8=
MJC*7MQ8_"K0SM3B?$30X$M 3H%0OB@-:Q,1O-(<T=*19!1<BDO_>6V%\#>K<
M3KMOQD(@9BTS'LH\.+WO 95XZ&;^>:\MJB-MN8L+H;E@ 7W_1LI!YDG;FV]9
M\H VS<- ,:28+W3:MW:2Y1AS]]WL .IA[3;=-OSCSXQ3>RJ_7HNT%&=)+C/H
M8,39 .+DH#:Z/$M&K9^\176C$]WQ#?3\S'):.%Z(T/;X:]AFK.4GW]3@\JY9
MC4RA3$_?.GX1)8<%SCA1DF4(6KP/G.2[)V:>6'^R\1BL$YF)Y2?3 BJ7NOUT
M&[RA=*W'*Y_"\S.E&G-E)E9>9;WGI<S+F5\%R\"T,6D]B;#XE$B[$N;)X&?C
M_)I'K418?L"!A6,CEJ(&_GG#W0OJ=830T-R VCH%WP+^8-6+B\W6D,OCXJ-_
M65_8.1W[ "1'V!^,VYZO!"1Q>GLM$AE/%, (F]^[;:#"3KI\G65'UFEE-#<S
ME4^_"4A34'QQAX^G2^+TAU)._A<>.YES_U.&.QT%[WH7&D:^;&E<_K)DF_A*
M*T=H5D/ R._F4A;^N1U$UL&)1DBZ[328Z6!'HR86]<Z&MQ1/C&A$9T7D^T,:
M-8MC0_[(\&S X[ ^.!G CR-\CPYC_)I@G7^Q "#[B2+U6.%9X/9[:H1,0X3%
M@&9K_F#0G!5D%^X\PN'73'C1BVF'E\%*:+F&+U7JC0TIZGM7X]Y 9(_+0"X=
M1W87J]'U:J=1V2=JQ_<Y+#Q$>)2^J1S;>WBO&MSJSZTTR/7#O4BISEVG4])D
M)>5YK!<A C9G2](@!\#QNBSHF%I\3O_SGQ-Y3I8OW2=&Y_VD3MUM#>/3C86;
M4#WM1TU7Y4?_S!^:8<R<$,W;NJ'[L&&/_:5[ @(%=7806Y_RJ6#7F[]FO#+,
M)FA54U<;0<$VA8_P_7(Y#UH$)WZ?I1=624@-8YF6][_Z()A[SLE$NL%^SQ6Q
M_JQC$XF@\,XPZR_UA8-%MDXC>GI5!HC8;PS&QVR+B,%WBGX#WY9?5]P^)U"$
MPC$\ -@2?":TBX GI)F$IA,5 (WNNUGI)/?RYOU$YZ1M<NCK%^G/BNT2-8PB
M?V\9V)O^K#]OS2]SWEI6^XN)3J6W*F;Y9'T.9U[8<V'@^LN@1\N'JNR_JQ3S
MK(7,_Q<G\\, ATTH%0><XD)JP")5;UEM0 4!/=PB<"MJZ<[QNK1F.QG(Q:B\
M.W<S2_.4$M]&=!K)%"B^$,TJO?I:(%Z0$G+Z *\J[.S89OJ!S?E#7<J>*+?K
M9@SZKI-J]^PAT-,%_W%XAK><L3O>%%PE*368_<SW]Z>MZ?S/T^QY8#[[.KER
M!#2<& ?G\V;:L3PD[_#<[%!K0#QY[\_5GQ=I#A,O2^+4W[VK&:4LC=4/'JBL
M)%F_Z]SE(RESF\<!$B.<][_\E;RRMZC<[@[54!/Z[G9_WTB1\;IW\OF.DLU-
M-WI]LF\J?]MW^;ZBYL&E-$CK?Y5@LJ>7>XI5:R?VTO[\:/>7>WX[D?JOD\^7
M% <N:D?L$=][YYE(_<YV\R5EN#00SH6XX;H95OMJ"CC3$1%^LC,F(^*NUE$&
MY$-__JV=[&N 1;^W))!0-E )&'@GG*]/6O-TUV[4?/-).>SV<I.ETD2U"%@(
M8[B0 >FO!$K,!':S=++E?TZ!0:1S(3*PH.&9%QQA':;KRH($=K8#>K^"-LL8
M@/. Y-<A"6U<YEPQU1V(O*U.-QTC]NN./1U^HF%=,B6VM*RAP8@G*&,7JV'*
MA,5$1+U;;[7P+R)>NWOU.%__#+3/,PQ*-NU/:1-X\[-E\Z]>K;>M9FHT4M@I
M)MQ=;T$^WEW(-:/*R Z"*4&K D?I^:?818& *?,,9L0-(<&RC0[%^K]";9RE
ML93XO_;64_>FWI<K[16E]ZQT7$/QYZ(N?1[9?DUS8@BPBV!7Q8$C&R1D'$CB
MBPR\3K79,H^&MI2GF!I(H8HW+K6-(ZWF1J)'G2(U'MRQ?Q'"[VV<D1/Z,QO8
M^WBR#RF*Z>4<&>?HKRQ8Y)(^Y?=Z81#W\K'22SAF%$?BI*2R?),TC]E0ZI"O
M-33@,&^T;\=A .S,_""\B7<'$C@B_30"HV,$Y)BK1SM4 .RB7"6)BNAYT?7W
MG6?LZ=!?6EES76&[AMP%+1X+9_Q^_T5@C1\%9\G8,CZE,PZPB[_1RY/08+<3
M,L]FP=_, D@2/-X7N0"D]T1=*RM[]<UW;X1N]<-:A=*CGWDJF:>QG:?!X@";
M3F=8T;:HG\BA;*0W32 =5N/9[>:M.'JFT>/^W5?VM0_W%I7<4+UF?VCJAKC.
M [MH>>HVV%#)['I8$'$VA@2"G<?,PYSI#D6:"G$/2S:J%(4]00_L[JRV]<=&
MF>"NCS]S;<K4*/#$JL\UC':J7Q7_',3W P&H;U$FR<1I-XZ(/].1900R ;75
M/C635L"!%(OL[SC8\@!'/7Z+S?D:HQMB_7M1^O2 %(2W)\7P0>@*%CB([86I
M<+[@I-!'05ERV84L>.1+ $<.?_(WOY<@&YR=BE9>/)D[V/H4490?]:E0![/'
M?'#?[#M3M!]3A*6XLPWV"T:[0>@[;MQ/;*B^'QF+/$ESN(^TT@[)(XB^:,SN
MF3$4]*MI3#F#Z58O_QC(GVI)[DBLWWF1%-OI J+O<0(X21!QNI4C[++H)=1A
M 'S]D]Y)AB4X5B!F+]L]J6>;4XV\>'WPC3U!;]XTZT\-*D&^PQ;G*JA.)"A+
MTK/W;WZWEP UJEB!7IVE]<6DK@5^S#.X]+#M9,2UDNHK_TSF[;QJ"%M\PH6\
M<Z!.@DHF01NQU!M4,C$=)E$?&]'3803,OT'%+X;,R)4A(V[+>4;G6>M.#%D_
MR;2&SZ,_7J2JEK.4\A<1,]E.[,>6MDOBJNCHD4A$<@1JMB>O("HAK&U_P]:=
MOUTK.LM$T\4'^9GO'PB:Q;7V:\M^P]6+@\1UUFLW5CD4MHOEOI0M@ZJ^,EE5
MC)V.>']L.+7R]KH\ZJG7X[!PDR-?U6?&2I(5+@N_[GJW[S+?VC!@3F1T :E,
M)*C  8P"*P#HK')^@ZJ=$/DDTG.LLGLM[V^H\FN]I::'V0::#S3U*=&!@<=7
MLT%@FH*]CI3&#!%J)^]U2*,LEIS0IK@EAQXJK.O85@]J3=0(\+2.C,8?/Z$H
M</"0C8*UVS*OZ\%DX6 B#8X0_@5B3%L8L.]')IDXL^74D;;>I71I.)6S[Q='
M#9\530W'*V\<Q&<=_Z5LHDY6N*P3-G3FXL.T;]C%=J*0,J.6G6[%CYF%B6/D
M5SJ,OEC)L<[3)GNP$L!IXEGIA14KV4BW]LRP<9R1C73/Y[@'DEI']P;$6<XR
MY&E$EG)1"6:,*&JI1<MF!-/+NX=3<3,BK]#:=$+/L!@J_22NS^U4L[G<5G[&
M:_1HLO;@$\B/,YK1A_!_5Q$/"+2+XK/EC M@8#7U,ZTX'Q&TL[ 41[HQV82H
MTG:<_'T<?;SLRKW%]D.]I3&59W^[JR-JK[OS;H<E:S[,[+3%M/];-5L@$?31
M<2[D6^H*D7%\%?;W0NB\#@C6%XNYD-\G_R"9:G]P[(.F:X\@YT'<\.\.-W%Z
MQ:);,L9\'F6TWJ/43GV!TNZ7PVB/]3X] [^)E*&_O1#NPJS5]KV9\.#HVT'<
M+!\CLJXY9W2)K#:M?BO'@&$WW<T7?R3M*1<B]I!ISH6,V',A'^V6N1#%*B)E
MKI<+&00_6C1@91LNNQ_#KH,TC':$"WGZ:]P-S*+N:YA/7,CF><+OA]%<2%\0
M%Y+T8><$PL\7V._J&UQ(QAAG:(BPO'.\7)YCP\;G8K\XPUA[8#\\V,\(_CL'
MSNO9_?>(2VJ9-U][LJSH\[CT367^YH-\(0T/A_)&/R>P;_4%!,N*#[:?3[&P
MNZL5G<TR<Z 0N1 [92[DH#R.%9 -7,^>)G#2S#D7#&# )^CTTWS6-H[#RX5\
M@#74(O\*E7,A]_I9PV=+VOHYRAH,,(%*,KF01^G#'&.'_V8RRM @!SW,A?!@
MOT%GW<W9N\:XD/=+G,#R2YJTY>22"<^>FS_-G%ZU7(_Y@[<Q-H >1(=KW.N+
M<<-A_U\M,<)^^A0[_!^V3&"&[N="GA5@ 17LT.:*SA"65 L+X$+^'B!NGVKC
M0I9,_IOY_CMVO"N73Z+RG2P@+]E]H5"^M>8.M<9X7LL88A5]OBC6GSOPQ_36
MOZ7W^7._6C*+J\L]5V9N+_BWCPN92(5IW#HL6BZPZYKD9$%!4T'P='%.R.F?
M(&VP%3XDYG9IS$3/:-ESXL\!7<K;Q>BUM;67E\GQFA>&-5HE9"_9:.;&\>PO
M\L'ZO9GJ?A,<57-E]DI/[>R<S5[4]\RX0RO=21<$]V8)FO#HR>P ==<[Z62P
M\0(Y/\C#W1T'QJI_X/=ZV?G'J%0*;=XH?<P*XK-/._",]U_C4-8+,E;LEU)B
M0VX%*JEO8H5>$QQV\TZJYO*(;(H><(Y_Y4!)G/!_9U@:_.NLKB;<%<3XZR#=
M'\WU_H4XCNG$*+_[VK$G9-+-^(J.N$JH3DKY(4-&'D5G%DL2&(4M_]CB0GAG
MXLP.O,4"-IO9V]OMH-T:7G D8C4X&"26IO>*SS>MGPNYO_/^(JZ0R!()@?V?
M&_^WO'&CK@?WVQ#!A4Q2"'\5WUR*Z#DDC>BP^4=DP'J8^>/U)/4<(,GZZ@)D
MCQ\H>3BO<6&M\Y*]HS9$N(2_I'GX/DZ&I4.O(*T5THT[+YR9"7^M?+RIZ9*[
M?.CC??$Y/!^+C7]=::2J,GTPG[F0VMBLH@AZ/UGFKO_GFH/I]J-AUW^T=1!\
M,K;-)G[^/J((:9A_]D!(4?:?B@N)L."#6FKK?D$^J^.5%#^Y[_B<UK$/FQ]U
MA@B!PS/,17/J<1(UL <GU'8^VL1;]:GO9.6?,*E5>$'G1WG>D\V9>X1YIZ]D
M[,%_WSF'D 'VR]A*X"+0C_D;.)-8!SRVW/>Z2$]+K_Y@"Q.6GT%OM8A95IFX
MT.>SC__@Q31X8.3K-B-*5YGC"9/2N:@K52M,Q-EV"QQ\Y/+=]9[AY&(E(-J\
MMS*F;^8_L??F<4TUVYIP% 45$&4>E*B@((AQ %%!(B(B(B HLQ G9B$J(%%"
MMJ#,DX"(HA(!$94A,BM#PHR B PR0TBB()/L,(0-F7IS;G^GW_<]WK[G].WO
MZU_WUW]L?E2277M7U:JUGF?5JE6.I%"-^>HW+:26N\1KTB$"$0\^]I][NV:3
MV:W]SR.9U <KCBQB;QM#.W:>%$80@Y(#UO(1X5NR0IU[=+6 + ?/D[>+4T<E
M8ZUU+^L/]B%6>XR%IYF=.9AB.GV[^$#6@WKK!UEFSSQTBIZ5OIWILG#"L UY
M?>C"QJG<74F7F8F-8IYO)[^TI/VT=WEZ$WB#26(WZ 1<N[,A=NKX1>9SIHUE
MYM%SH\^,_5U\W;KK+IS+E-FM%^&8FF9X)VQJC'V5UX8NMOCFI2>*^Y&WL%70
MT-3'H*MH($J8O;IO8'1@,/VT)",4\5;7=5OD_/+NKBSK+5_=\WZJM6>?R @Y
M_:')U^,S5Q&"=:_RS'$8<VJ0>!'V_7EHVMA]S;><56F?%[4OD>.NUVETKOIL
MXH $[X\CY^9@'AGDA8GIYFE6VG$50OF(VV'IG)A(=>0?I/%/(OQID -#V> 6
M0B]ZZP*R/]D6+MS&&;">M/,V0&<8+.<>O,\;*';1J/ CA5G<&Q!E09M4(0O*
M OX*9Z;EBWZ87-\@.+&<R%N?#.JPTB$T"!A50GUL]PFDE*Y6-J1R,K$FY53Q
MR L=LW)PB7UH_"K;*K*1]:G/:2?FP+[Q'UL*O1G5E)%B/D(*/9*<XE]K+@5W
M6BD0U+< D;=0)_B(C7Y\A QNQ^R,*1O__J*1O)V'NT CUK>@5G'^P*D;3.X(
M#J1"VVV"*C;+3&>\&8#A$UH+")<@M#!&#J7P4+R!#UV4]U>AX)[]=R(RBD&1
MWI*YL\/6/^]O<54\C5C)"E$%2Y"96%\6[?KP:FZ9YB?\^;><4TS4-)JFNK-K
M@2KK-&3?ZV!^:WIG<6[&:0U:]).,JG6V7B/1SWGU/0PQSA88AZR5Y 9YZ>K0
MS/MV=;*"-)@**Q1,@'8,T^ DGVC29>)>AE?(2KFZ^WY3XO7S)WMC^F*G$*>W
M$:)YK=22L2D+]B5>&WDG]PW@@HI.=MH'8A[DD;S\*JT[.EA=]3<]/:4&V]?-
M*(4\?7#P9%]#9X5HGQ!"\07;B/"%LH[BB0[N'YM:8$[6'IC4V\14OE&?.V[A
M82,=.G%X+-8ON@6K?.M=<H3_VLL?;V4%&Q(T"/!HB\(X(KX;O9F@@!/CK5--
MN4UDV[AC)#797NOUI(<]CCO8&NAIH:?]XV,HO=T[=YAK/KZRFO/IFM \!6;%
MH"6IEV3)#?(5@W:[1G#T81LKRE'O&3IY-S8_XV*3O[."4Y-+H3G6?>QH@W/T
MB\D/:YRO!CTGW 6J'0'WE>0#VM,_0*0Q!,_2-64?WT.)[+.33OO:9_2D/-"B
M')T;R;PM'V-YZ[VUY&8>K-/8;BMM=6NFVN_V.:6]]Y"PZ);,<"0&6'=6]AE#
M/OJ@^?2NX=UE7WW5^[S-PN!>EQYVMUZ.B%\M6<96ROA\;Z/,C6KE15(29:3;
M2\7\*WKD47>9="+V>[\=_ASSK'0^5J- L\O1ZE9=XCU$DW)/)[*X<3J(C02J
M=0ER/]&;^ BON-@XFH:.+=ET;^>%  7VJW+RIJ*<R,</FYN28@:45S4<?+Z!
M,P4SI2L EMKK8,LE%F%[W7FZI1P-XB:./M,Z(P,Z<4S[G/7'H@.#3A$GAXWZ
M>KCRNY5K3RO\:-#>M$ZHEPK"5".2<(2;1E"&?'CK5=C:4.J8*1-=-[1_ 15%
M4.M$BD/:51$JR?X'2O4<A^9<FJGW8V:;9J=$G:[R$8(%/\NP\#P?>=Q&&Y*G
M-A>^AXKIV9ZV48_[Y#%25DW*SQ&"YEJ62$@9X$C.T+*FCS&C6"'<YY213(+H
M5PKM.O3%U/XG+HJ&9&5RBQ\X9'3.,VXM>M@K.-Q2.BYURJ3D0$/% $_4 4*S
MC5%3^22(2A=J;-4^#P6@8G2-G%]#AQIKB2YEI=\Z+3!Z2Z0U#RJ\USP)<QNH
MP#=*KEK68-_E==PB-!+S7>M1_9$]9I&SDU5DP2Z_P*-?\$O^,C>/-PRK-&Z7
MQVK8QA[?19$!7%H]>>O,&>A[*48-L+#LAG65WC:.!Q3$B IP6 F@*EK9T[UI
M&!=@T(U:?=HW?$'']+V]1MI3KZH2!8L,I1L(-=Y#7$8]4@B]HE1 $SXB1E&!
M^T29*?J^IZAM,T[[+%QEFG4O'W%]X*3U@>:"P[/X.9G/IW?Z5)&BR%(KV2E&
M4BGKX X-FV&OPYO)OTYF9AE IOX@VX9+_*6+OL,M#:"[%B=\K2L)WK'5>R^F
M;<Y&;4U=8H742[$^9 @K=7TG3QYWNY;V.E-T)FS;UUPED/NC>+$_([7N1/!Z
M::_6T>Q3F\*:!C?>\DD9(CU9V4K-1Q2BZE!]? 1O?3%H,T)M-"\=P)4>AX#+
MV-S>)IR);4OAC:+KX@<W%-0<5Q:0JU:2FE?A;%LVXG"&X=L=S@G62R6[TC0.
M-8SOI7THTU!P-AC,1X;GGOF;._ZO%TB!5"B<^&,.O,9*5S[BC&E )@[#D:#R
M3J?F\A%7APOYB,Q=E1W_+MK]5RZTEJXQ'Z$DQ4=P"2U\1%I*I@W^+Q]@B@U&
MC.:LS.GH<Z0X8.0M08ZY*Y>!?I#"1\01Y'"D!N):S5P'RT0Z,51W^YH>"5,E
MAY>=8Q]*0QZ;1+EESLEUX3.@^\X7N"%.KLS%1F+1V#T_4Z0%) $*GX&",DTD
M)TGN,_0/\]GL.P=23:HZTT(O*'T6R?GD4W2_^R.SB&$CPE ?,$UBN4]_\W?,
MN^U<[&H@)U>O/EEN,:3UZD5.]_C\;;V5/ XGB)#*J?Q7[O9M57*:#LC(;J>M
MJ9UURU[E0W:.30)F<M&/"Y*,6=-1B^]B"@\/:F_"M:WC6$ P&<-"ZNA&3V(P
M<<T\5@;76%MRU"7JI:?>_F[%SC-@7OP6A=>K,F*-G1R>A0V*:PFMMG3P-L02
M:HFK"3H<?^@^>) 5PR35.*I7D>4A*QK715W4B.VMT&I3+W:WX$1^6=6A:B_I
ML4MY4_415;4)Q]0;T1LH;D ?FM7%)$X[@$(CYSG&8&.]*=(\K$$1V5&<[:EA
M9-)U_6&]U.<3/Y)VA3"NR!D(#G]N1/C0+4/<+^_6<[)M,"Z5[2MN8=[JJQPJ
M"?!1&O?\5MOY^>;FT?//1SK.I[BCW2J'KW64JI79.,SJE<Z@K\7U#]2A%?%>
M#%+?#*.M1AT0PAN!"@XJX46>@<>=>B>D;53MA;/=S[S%/9%X=#EI^.7S_-44
MCJ0V UDS$X0N:,@&OP#K'":/4F**/G(.CIB'+?NE5)35?V?*7@U5E;PI&?#M
MQ;V:-PC\YWMS0(%V-:9_)UF7<X%;1CB&URX!Q\(Y[IEVXZF24(!@H=3G$FOI
MFR^"1T=UZ\?.TL2:3YOY] C3B&LT 6@W\0%/=Y)2;-,X ^W*;(PC;)O8.:TI
M/ ,Y+$ME)H?Z%CZWZQTH2EBZ]J/TLVWY]_G!'\M9$75[U!YD[/K^_>-'AR)L
MAKM&?W'2X[+R+9H@SOAJIJ5X9+0D!J5KZ5-0%IV)"CFSZ'_;7OUG*Z5_@.4$
M4<!"WCH2C1344R)#V-&E*R48=8?AI7+VJOJ0G;YOX9##:W2WLD/8L4/ZY<4^
M2-":-$!AG82JV4*UKPA?  E-RF9<RC'S,]VZ^[&TWI9!Z*97GI*/_P&UT<8K
M+ILIEX<.O!%20=X8P)_AOLP#7 \RU<S[LJ>HF]8F?M:3-V4(G]IE]>3-?;;^
MJOL:LAL5%/0O93WT_-$605P/N%,&NA6P08H[N%%[>.LXNET+Y;"6C"A;X'W,
M&O20GY+N7%\?4G';[L@=J_4I!D'1L?K6+7)AC]P/GZ-0UDH^O\:J+&XW"KQ3
M,OBS)?]&$NY;?7_7Q!FOM_585Y2_S<[7S\N.D;QL^LEK>_;BS4=>(.M*WX>/
M=FEF!SR]*J!@?SKI$V<]*9IR74S:')3A;0@:,8^E;,3OU*ZC2'M01;SQQ^Z
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MV=?*O3/A?E]1A_^ @\/Y#^ED'V8I1\J'A021D7Z \ 1&4DN!1ILL]*1K.!B
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MO.LP+A FFO:4$6#Y@KD^7.U<YT+5'[95",PIT,7JS2%5Y)322A(1B$:'J3O
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MAY&%/F9I)YIW?!;H^@4;>2)R29./6%)J!O[T^XP_5K7@H<I'A$<TH.=AY)8
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ML3A@:Q'J 16&Q",):%D]V9\II?WD 4:<Y(2TN*T[V2JG4"4E_XC/J*[[AI'
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M3R7O73POYIPP?_$$S]97=B%7_X&,_Q]JVO[[@<>.Q.GS*PM4=&!YUIPKG]0
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M;%:DPU?5&SH_P1CUR\RP5IE2-BXKL#FD)1.\4/25V#I8N5[BZ/UGJ)U0W,S
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MXT' '+\;'MC,I/O%OM/)A;R6_KU!@"80$ZRZ.?=!O4"%005 >=ERCG'&T*(
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M4F1R8:([2^;2GA#-Z_<-^[(^+&]#?\=L0RNB]E2Q<_5YZ.9F_76\H5F6!:-
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M7O"M!@Q.O-?:P[N#2BIO2 YY(*='^:&COOB:"6)HQ99O+K(2;Y?\3M_RE=T
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M<NWF A2/T>DS8N4I:]0B(,T7\+\EUE %1V_U6--+<I5Z[D:&/^\O+=FCG#J
M(%>+O(%S:,C>%O2&87,:GI:'DVK".ZDZ\X,%[*TZ'<%@R5VPNGT5&$.!45+3
MX,:$%;ZQ*- 59LA=DBH@@H2:%V$."ED=JN13D,&Y:74J0:>AIRS"X<*N&7?C
MYP5OA$.N?:H/&M<41+H;7R.QP:P/>)\1L9_(46S9TBPTIJ:89V (7!W*BN^P
M]8[CD=FXOKF0VT</,-I\?GJ=<L3 >JF6KR<XS=,0JWE*%?T$2:[0-9%:0E$'
M01X;6JL3(=4;$L?P1$0[6F:CG:';,\BJ@E?@KMOK?C9[;G+(Q^VM\[X#AZ>4
M280>AN (&M*S38]^QOYNCFX(W4/-,<9/< /*U"]"S8&,K)JHQ=E3.L4I26E]
MFS5S/EI/Y$\P'. YQY-A\I%3A&Q%NQ(.<8WY<&<MIPLE<?U"H39.!ME^"JE"
M5LO$W8H[OZCN991=NKO8[.72SW[W&7EWCC\9IS,(=$>R+'1(=)*L-T+93*8(
MY&A4C!XW -M ]-=]5#T=>'2GP_TGRMDU3[]\]GX[Y.<6(DMFPJ+0L0D[=<<_
M/KU4P+XNW4S4W7.=253+8V92](D%6;WWY%YTX[_O"+-J3IWGJ7:A+#M/]\NK
MK=3V'=:.Y\,\OU<BH6+G72%8[<K&$\/$V\\-(B$SI'C'_LY0!?L1"JI?+SAM
M:;RKGD].1/N+9'H9]8LO&=<!M'B[R MBOF1'"ME=E3K'6!VMBV#A>V!4\&5;
M%3[\4\DC37*WBV:>=HUEJ:?U#/H94ZSJ*558%@6) PDT@HX4@5K4O))F8B]V
M+X8:?-[N7WA(D_A[K)&&GK<H'MB2WW(5H8U ;!E@-(=U8Q6 CGVPP:BDJ\!D
M>R,!MD8B8XXK++RRDPD:/+FEV@62=;7-1QQ?2\(4]IE:>(:V3^U++%C 3J5@
ME<CA@,@"*@+7H+<EC<TP.T2@M<XDK"-\J%%!3+?;OWTCJD4)>D)5W99?:1CB
M-^ZN9T-$H4BJB*^< S9J6H;"_+@_O<,_/3M6QY.+9JI<@&43IZ.^^6Z\S/&;
M_6$%4-&W2/D1N9)3ERS.K6WCL)'G*=L$DO14S,'2KN"RN3LQ_N&@SROU0PD&
MAV_U7HWU]D9L?7E2[O6_.%_[__%_']CUT;\#4$L#!!0    ( '6"5%/F#+H$
M !<! /M% 0 5    8FEI8BTR,#(Q,#DS,%]G,3$N:G!GW+MW5%/=&RX80#H8
M.DB+4E5*I(M@8@-$1%24*N03I M1$0D2"()4*8H*"A_$ J(BO40!B701%2E2
MA9"@HI) (A@.YN1D#K\[,_>?F;DS=\J:F</:68&<[/WVYWWVV0@F!',(N2..
MSHX((6$AQ#_P#T*PA-B\_QP^( @1A( O(<$TXB!"6&CCVG@5WK@VB6R\BF[:
M)+))3%1,[#]#7%("'N)B8A+2$I)2&Q?\3D9:2F;CEXU)_LM7A45%1$2EQ,7$
MI?X/7X(W"'D)X2_"5T6$=!#"\D(B\D*";@0*EE'T/^()(?['2TA89).HF#@L
MAC1\0Y,<++Z(""RT*"PQ_&D"_#EBD[RHPC:S_6**)\Z*ZUQ4,K]VZZ&$[H&Z
M#N630VP]BX!+R9)2*JIJ6]3U#0RW[]AI:65ML]MVS\%##HY.AYV/N)\Z[>'I
MY>T3>"XH."0T+#SZ<LR56$+<U93KJ6GI&9E9^;?OW"THO'>_Z-'CLO(G%4^?
M/:]O:&QJIKQ\U=+9U=W3V_>V_]WPR.CGL?&)R2DZ8_[KM^\+/W[^XOQ>6?W#
M70/6_V[H)800$?J?KO]%O>1AO80W?""^H9>0<.S&#?*;1+>9B2GL/R%^]J*B
MCODU":4#MQ[6=4CJ6IQD*P=<&I)2T;.DZW,V5/N/9O_[%$O^[]+L?U;LO^HU
MA9 1$8*=)R*/P"+XX*.L[8C_+XYJ.VXFT"1 2$ES$SGC?3C 28!HHM*EV%$5
M-:2@A)JWO) )EO[+W\29O&_+O[G+4]/1)15JU;UMT9"4H0"Q'01^"A#GHKL%
MB+_AKQX@[Y!"J,!.*JA<P7T$Z-/)4QISXZ"\AL.HO0F#;[#7Y<!K,K=\)'(V
M(L[6PZR_//T@\XTZ7V@XYL8@X! 9LZPV<?#QF6*)A<\FYUY[Z];??!"F:_&/
MT75;#;90+Z'F'1+04WU# TQ4* +$IE^ %@.50J6D=T8BW[@#IIU^&EU%-9UA
MIC61YZ]FZ+U2E=)+>*7!S7UM-"1 1 D0Z2V&H)(()$UBCT"2/;R#9V9Q1 UV
MWAL7:I8/-5D%\HW'*H>S7FA9SQIU*.XHW2V<>5>R-S99JD%8Z"^V;%']V.NS
MVI4/?Q6,-]<G![QJ+#F7P[YPX=UA^^$(]=D;]$7QSS%\_['>,7/[@>*!U"RK
M_C<#9@C/[R%ID"AQCP"1["M =%S&2(-R_.S50G9%%W[JX)M$0S<-HO5(]==(
M@Q'WH2J'+^J-<G;R>*/JK7:[RL3FC5WC:* B#I(LX1E!T[!?#%G/Y@>GEM]\
MF)_1=>2_ -TJ 'S'WX^/+UB^MOZ:X?]]/7+^UHFE("?*C?<7WF=&"4=^X25A
M_U&^.[IGU];L9.0FSPRHC]:\G$HZC]P"!K)#TD#DT]#?H";P+'XNX5C$XO5;
M,1HW0AFWJG4DWSU42%)^-3=>[_3PI]F/"'I9/:ZVZD&S2G=^N\=,L>W7G#;/
MKWA0O@:2/ O[8I63QU+FG5PL->3?!G?$Q[(IW!>CC<OI(Q_PVR*EQH:-O*L8
M*<C.OFW&%J6A(BP!8A+/97%">FNF([B/^,7V"8]"U;'I[2*+VFI-0S'WRO-M
M:W1'5WM;[U87.6V7:DGU>^B(M+4?'_&(+2C**8O]FS :W6$NGA9ZQGQ/Z?Y-
M%_;_45ZWXNU)?"- - RRX. 0K>2W!/&?$<W0-T S>HT\8<L+>]FG_N];7'M6
MI\15*=:<^JKW=4Y;#K=]&% K#5"-%D9#W=K&MR')5D8>L,/P#2JIF2([AYYD
M=';UTF3:=!-B3=[O.3,.J;WZ'-*0_CXX*&DPZEK@X!;#2K.MJ&>41#TV*ZU*
M+"6AQOM@PN76JO-/6AP*SOYZ>LSWX8^=K,1-4#]-%!N2-Z7+M1S&&$*C*+8C
M>BIEWK,'E=FBL#BK"_ CM8NM6-_^#*\/^8?%HBM[QVJ[6LR$C2\FU9D"ZT$U
MGVF ;F\Y[PP-CJ+=[5LFH1E_K;%56M8>_Y*8)T 65D&(NS[?W%8J[9+Y-GC&
MN.!9%/-;9G!P@+-!TDYXN28X]&ET7$^52R=L(CRHT'<8(,\MNH3JU7-*:'TL
M[/[\GU/Z<<<G78.,^KZ].M<?W1I%SV:T$_G9U+EZ'-N=--TW%Y(N0(3A)U<@
MB==EX=H2'*W/W1Y[7H^SK"JF^V_$/S-Y$KAIRJ?_=[]2DK 8ZY6F7,1JO(<
M<?/T(#^>"B5'K"Q LMX"Q!U-HHX 49N>B5T5()X>%W^9^ Y%P6=!NZ$)5*,
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M[^6SE%>>\;$+WRY(;B?8:UZNZ:5-6_3.PLF2?!V"B]?10370A5-0^7!1@%"
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MNS-M5[[Q' <-,5=T9UJ73&W7_FY'U&1?1@,&ABQ=MA/W)8?&$N&A$FED=C*
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M%O%+/W]XL0OZ>7#;_>_YYQP<^B^^YAEM[(0EVH!G@&+.0>X>@,/3]044N6E
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M=Q.".[%5,K!MD%7"L8,D-\[AM-L/V9]X'-[5DVC.J:Y\2G.I#*\-8R\7&-T
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M=@[FF"4P.HS1UO?C.I!KH*L \<RT$O?@]#H<P&)5<&Z2 B-#(,D5-EP4%I^
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M@O(+7 X<<?L!)".TC:,**FGW,=98GAR:=U,SIS"G@AW5)$EMN_LY<C7!_D-
M9EA%Y[1NCF2.;T"#J+2ZTRPT2I,'S6"+]\*3?/--G*$U'J+LP7;@<TBB#'9P
MU7Q7H'&S/XJC?_?7AZC"' 7*;:6Q7T]SWP@S9U1L_H'+P*0%?3F-.G>?QCX3
MZ<L5Y9,#7PUCI,% 8/OLGB%[&710P6#7K$X#-2+B=G!]@UI D6B8UJFY5_L0
M7J/(X;_@)WY^^S8 #TD%P7';_9F*ITVN+\7@DVGBB5(VURZC-?EI7N=!!X91
M*_?5*Y[&D>?!66I;'E\1$>J4._*V#"K\).2@=/S_DN'-(;AUUD9$,KSL+2J>
M/%JG/=7/EYS6%3</O#B?V_30 :'LY,*FIEUV&<AQ<F"S4DMZIJ-:2L>&=.-R
MHPN#$!2]TH3P/TI"*VY)I+-D)2 0DKK&P7)_CH$G'L\"^#Z:="-):AJX_(85
MK=0<;=>OUUHX$/H%@]A$/H%S^CD55?)XTNE)F#I1I?E3M0ZE.4-GZV+2<X3R
M7B7$Z;WXKE)MCDG])"'O0/WH-J?96SB?LN=5(UMW;=5VP_RYE(4XOZL'K]"Q
MZ4A&EK*\JM"^.83X_F./LA#;X?&L/'2/=G)^W\,?8P4N]D^\QX9G A4.7VV-
M%#%.<+-D^3H.6RVJ#O^9V3G%G3H@4[!VP?A6\V;'T]?$Q8L:'! 'SU9,A'E<
M_#GEEVT]QJZ>^(<""[8JM5ODI_L)V")DY'70)+**FAD)6E7T/7TK<?NXBZ5B
ML^/F,[)]N7O&4F'A7;'[/C46#Y0<=!DR,:E&XQ*^<KGO\NRB!VJW!/9_77A6
M>?FX> F!S/4!L/-N4Q&=U"9JEF7$#9H:H-MU-?<&W;OBE0'--6V=$?'L\8T'
MI0ZINN8QO]?0CE8_&D_L$U4ZL4_9\).E496_5N+"H<9\:$;*=[;__)/0.PL[
MJQV_:98*+87/_%<GBV(!IU44BPP<%B#JX"+5:%^#9L$-O9M=R%KL_)6]#5FO
M')00IV(+KES-*2M03WT1W6&N5+3EL4QNV3_/Q),EF.%'M@MK88^-K-[8OCJS
MLU/#E^!YWIK+V71(^YHC G6DZ+\<GA&NX(HE6\&KI&6&\1\$_/ZP-EGX<9(_
M \SDG6=4#<&&DX7(9Y]/.E>$%^SZ,OV^-3B9L?7'XH]3;*>Q)X^2=&IKZX:9
M\R.- ]NKJNC[:CLVG957NBSDA(B7*OA_P;_D_3='>PQ<2])('2ZD8"I@2.VJ
M+*9FX>29<YSJ2CK?<?E-._+&T=91M%7\#8)6!\_J#G[G=+J4=K"DNLRW<64L
M4Q6N!+H;SS[P-3+.R$Z\BC\V:W6OM.MKN"I;H:7"KQZ=BICI[9$J!^6W!(3D
M'L]W]#OLUA8J\F./$7U0&YHAL;U<J/*$VYX C.:;(BBCQ&WTF9-+-+>7'%)O
ML0G:@V,I=^3GPM3DC3C,1SW)%C.+H)0=?3JO1R#);[PKX*Z-#41H8 K+LF!3
M#WRV]%I:6KK,BNZZ^G4_^K+?L:F#6CW_OKG@[26L%GAICX)2_@.1Z1\U5OPJ
MC 7H"4BSC\$@JMJ!G&SU 1H8=UJ;FX;MD0_#+TRZQ.N-&,?/?K\02,D448W3
ME'M>-OX6HP,O]A*:IM6'Y+8I1F\<R83_<,$+M &BYVE*/L#5Z3Y(!GB,9RBQ
MN0\O'YGN>?JFUK'3>NM2B=KSU-TRAT\*_95W(,!5'P5)"<VY32#I3])KPC&;
MQHCX>3<-( N%)%H#%^E5U"F,_N=RWDU'WV]I^BC+V[5&ZO-IP:>C?+FG^&74
MN6<8>^!U(!T]M0Q)-M"7TTL51YF&9$AA$$D\USA&/E*B>/D*Q;IR4^2VZ+LK
M ?I*N02=),R31VUD[B2_FBC.DTO\>'6A3X#0_$GQ>5'@:(3=3 AQM7W-4:F[
MP- P,?^\3_]):? A-8\I:5N-$Y4IL(XG21W[8]# CCQFL2K+[ 6H /.T^#@!
M0M*QXM$,X1QP,[S]4$%TW%%:J I;K']0:)?9*-S^EV^O#IS']2QO2ARDB=O#
M(,<(?L!MUV*'I*-C/ESYOIW2=J6@UG[%_.FWX@!KI4O'Q*^"?[%L;QJP/3]Q
MH N2,C$$%8*1P/&0P^KK]XA^%,QV;4T8^%BD6G[AN^FOD #1OQ)[?N$*K30)
MZ[*].F)NL*=F$T@$]M-QN239&/%6]G)VFVU0=:CGR4,GRAM:KQFFWG?;>>3P
M*_>WMLK#_QM81"ADRC\/OTKMJ/)8\!@-:;E%Q+_0Z;]H82>JJB<ZH/A&2SR<
M._6?>OW_Q  W-G%>0[WDIN\I'&H/F7V2-JF"%P%NQ#)'JHA[@)2Y&LTO@Q%Z
M/F;Q-[Y31TP#/*4OE;\-+9/*KIO7HP[0_G,L::[L;UYOC?Q/5&T?2YEG0DBA
MB_>0-H,&PZ!#>=C5)S61S[V &UT369,QTD;31*.\70]"[Q_<%F#>HR<Y!$]P
M#!N$F^(Q\$EM)(X--X3_$G28X]E"*N%[KM2Q>_'"DQ%_@YL#*2WGIRO78U4H
M%L;MSH0RN^;>*PJ/+4ES11L/\@0(>5")<^4^+R)Q!-5H\)ICP6BO9#\^RBXH
MCGX&7*4YU;/;DTO]!KE!57=LIZ +[GKU=H=[L.FF:B*/8 ,4P%(X+)'.?< >
MXI=20[!B<*/XAO\(8U Y130&8D([,@*V^)X>W;R/,L)B?_QM>QSRW;Y54B^/
M!$EZ\B1@[MS M1G"("+:S;7U.*?''L;6 &O=&>7N[N/H<RO5Y=ER9FIV@4>3
MCAQZL2_ @5A%'P2V"1"@DAV=S KA6'![ *N-DU)-0Z ?Q^9D[&B3:P3WPDA,
MY<#>W4=\8,1CK!P/E&UT_O8@5S]3X]T!]V_'J>X Z0VU>9G)XLD0G9H *L]I
M!DP$'D<\C/"<5?R\BD+X$,*_,W"U L3#GQR?J7><]=*K"@;&DA8R<ULMA58O
M;ML?O!5A:T UQV )16N0=!?OY ]< _+-<3V8>4J"!QK'(%/BL?W%I"T18\;^
M2.1/M^'0$\4Q/9TE;=7#9O+DSX.@XB+W,_ 'KJLX]C+3C(/G?N>@4MN-%J$M
ME#R&:G?_^6*O]D![5G1<A9G-KL8,A8/!Y[Q/W9O_<3IK7)FWE]1A #.#2EK]
M6A=6EB@/P(VG:-.GRVA1P&?*R,^BJP7/+'SHH/ZFJL!/@(@T]NL/CO-J:&BU
M4PEP1OP>!$Q*,WF'"31(VI,G#^Z!*8+*=*=Z=4,YH7=\'R>2>UOK[X]+SF%J
MH_BME,*UDW[Z^="/PU*9ZN9.RK._V@WY=:2YNS3V"6023@P,X84# _/IG;@I
MI-<HT894 ;HTU]_V9"\U*$E;JEZA>-1V^DMNZ;0T;CTA$J-_A'\0EG0S'#2)
M830*.MU>@X&4))X93=0 CP$X1A!'O N5\?<86>MKB]723'Z?26/YR5]3YSH'
M1,S3)^[OWH3:M:'JIG;^(]";YT^P^<\^<PXT>86L F-E*M?F)KB+34DC2FM?
M>QQ::',BHSI&4G?E>WQEX3XEE9UUK)-"VZXD$?OG!0A@)^R#948?J-S:G;B5
MWXP-EQ7O2)3F%_Q9I")!2S;FE>R \PM"FUC*2<XF3I]B]<")EN%/UL?F+0=J
M;Y4L U8NW%I^"9C VQ9!:PA)@7;\7(-L1^SC&#AY&G!)Z8[;YL*+3Z_)#ND+
M,P-U_A$AW[N(J_ DR[1K_%*]1/N%0C;:+A0=6'&UOBUMGWW,Q<PHWWG!H T%
M26X0OY]#V+DB<L.'\3>+.-04T+*TV%/47 _IY'6Y/.G_-OLEKG/B05& !T9)
M"S@?$K[Z8/, )"7/0<[%=I(G0ABT/%(87G:PBB#61^<^M?=]Y'/1M#Q0OZ%'
MORQ$-^(=:L#C;<>%2V:WUO>CF3#4B!:BV(<XFE0-HGFB*+KKXG.;#GJT&B</
MW"H\S4)-D-DW$]*9 D08-,@?2^P;^4J;HKI@%.&4QX ;S1\^CQJ(G3[(+>*(
M][:B,U1]WE_-RVB*]VQH;1[!ITTP&;2+%SR9\_>^SB1-;!,SP^TF;QSJ I6F
MW"8ID)H.#C!6<IJC< U!W9Z^CD4\< 29WD8UY%G W63$)/1X39M42 W9#:DC
M>*H0S$)A+?-Z\!,D.CJ/&DS=//B8 %<;.O>N "&1>R,&HKC6N9S*-7*R/=]V
MI-1=LU9?<E/*[<7/?8F#).%V[<3W.!%[?9X=:#!RKI$]GMR&C7C\H]8-?7\K
M)5D_Q\?I#4TW\LN'O/OW2O],_*]BD'@JK/M> >)KYB\:=^\B]N_)B!DCF'?.
ME0H0OP_]P?.T_Y#Y.ZR6[B!.P"WP__TCSND&I ],NW#V<DO.5L5=Z+HTH)Y0
M9)&$/'KW0]QZ;M!!XR<5IZV+FPOX/B*??]2HP&G2Q!&'TI#@G1L"1,9C2&6\
M&_57#?O[)!K2:<O[TV *.?,'!(A\D:G0_\;=_S^\N<:=;5T1_X)P;,!]-&3%
ML$CG7,*#<TNZ#Q">B7XE9Z/W5)=L[[>L>>Y?HB'BD[6]YA_AK.T/_LLP>D^-
M0&<)$-H8.7 '](5?1 V1)F=AS*FC#VN'B;M;5M7]7ACL^U:]M%3Q-FUJZ_6Z
MT[$!IT\[1R'V6F>!_%$!(G 00/?UK2,S$[>3.KR)(NQ31V-K4MJ1H$:*3W.2
M=A;^C_=)^L3%?(2'[1L1Y1!'($* $!>"WE9;+;I-V=%C66$/?$O6($T..E6'
MC<T(SHZN?_?]T\"Y<RPHWYI\/%1DN<A(@SZ>9875 #&?VL*J )L3[&]+-8]]
M9F> >,])[FM3[P!O[3&2R7W[B<DLZS&C5\<D-<<^( BX_X&]+X^'ZO_W'U1"
M3$*V&$5)UA8IR;39DE1"$E/)'EH(&7-D#3&A**HI2Y*8[,DRR59)LC.6,2.[
MR8QE'&;FS._X_'Z_>S]]OMW[_7WO[][?X_&[]_YQ/)R9,V=YO5_+\_EZO=[O
MPY&@0*;/\N!['"SB(;*V5;55:O_1R*UB:0/[@!D['J(MR7'B#QKY'[X%8/"P
M]?G"$IMB\A!/@[+^\@&6  _J>RL>0GI\S4')TY@UO[5D1PJC!3KF< !Z1^"N
M[;YK6\:!&4."-,PZ\E5YB".Z"P:J$!?-@%Z)DK>G5W/^>9RW/T=&[FD!MQ/J
M?*(<M;B5AII8.Z9724LXX!JHD<' A/TH"A7PWL+XX3^[^\3=;0^)6B^%TWI#
MZ=:']K=$XV"0#/O.H6Q,$;$!Z'6E^=##V"X7L&8PDO-<J[V%B:E=Z10XWVLR
MU'S$0M'"\=/$S%IDJ>Z]OJ]QX3]*9>CJCV&/G=F.'KI;+<;-(59>9]MP]H$E
MP\!=U]J]M[OKD?Q8*>EN'0\YA:AFKT":>H!S3,]AX6RDQEWHO-K^0Y'5[\"L
MUU C11SP(O6:-*+7^V#MG6E3+<@ _!E0/C-333%.)7%"7)YZXU5>;/';I)UJ
MUUX<R]IU])1@Y_Q* ]-_J\*OJM" !M5(#1@8T=08&!QF!X$FK.<,FXI++W$=
M%#'R,!55QW;@#^H3-5XPV$4^]UUK[ YJ.LGD6GFXV=VO-U-<[BD&47JS65D,
M5X[4358^-\EWIF?L<'<)$8%K7G;^5L'4HT4,WKEYZ>7+S&41]^1EW;3^=-VZ
M!KNG67RW[@[W9S5<GT(5F]!7FBI/=:%]\'=1!6731FPIC@:81"6N=E]V:"BA
M6:X/: O:V@;UN6[Z[(65Y1>)<E+/U%G*^[%T9M]AI99G*S4G"_10.6D=#^&F
MB69=AH/_AC&JY/F?+YX[>!I*?']CN./@ZX#\;^T^9&J[UK.]9=+KHY5=(KT2
M5R=<4-YV#H'+.NUXD"V(Z\4)<JM(+A8BK/L,DTA="P'VD:!<!9]:N1^7?'P/
MGFGS+ZTH>((<CG?K%[A3?JMTS33RTG.D"(S@@F"^*-%)F@[J N8SN]_;MF#>
M8B*G=7W"4DLZOW8+US;*?:&I?;D7G%4AS** A^?Q2TM5/,2'TN>B,>HH:'VP
M,H3S 1B:KWB(\)5)\80T"D?$ ]&37@!C \$V]-CH(@_!3\;_]R__4_TRQU,.
M<X>CW^5.0TH&AT]*Y[A>U-8]+5[^[EK])?QU^1^;SX7+JJ@-QR FW-X ?[I*
MQI^N(' YIO&7J\2/?91;_;1B8&!2;Z?1!NED.^WCK[?+JB1>0RB,"]R(&2T^
MJ%ICJ%H(M3$HT:1BS;(';*/X5ULM:E_UA]]C6Y4\E:BI5BC0)]PU.-:U\4O-
M>=J<U>Q]B>_>E]=8('Q];30<UWT?BW8-7::W=NS2=]RY#GD$>?WD_R/1,D@H
M'N+31 X/T0T3(/V%EC]]351D9A7?PJEW:%YV45=HVI%R]5E5R^TE0TT>PC<;
MTOZ^[@OL^M;]V?7]TU9%HA(X=]_[<Z^CE\6)ZXD7&,CP^3X8F_0,6ESWE:6I
MA)<[HP+FI?[)C8I]C&DJ8B2G.?FF7.MWV!A7^.+G.7R=358P^&?GCB*@I'#R
M0,T)'N(BJL^>1J1KLJ5P3>^EZ:L9P\-^K+0W ?@/,\.Y/F)3S^2[O*Y>+@A\
M_J[")I)&/O<B.N8&-?+[>JT)30X"M/XC#5H*^&A'H4I)]$;V?C<T7Z4"P]:B
M6S $VD0.:$.N]Y1KR'Y-#H[TK.C+M5YOPF^?W"M'K2W;'/75T!_V3V]6BH^,
M4^B8T[ANC(0A/]1SGO+1D@_WI6O9."4#!&K>7^'G(>KE2NKS\@8&.D?Z8YPC
MUR:.;S'9*!#1?^WPP#@*B4/@>C KO5&H(2-" PG<85)/C*6(X-2:\B;TM6)I
MZN/66[K2V[2\-\<LZZ[VSOMQUTSEAM%(\<V:]<[.7A\$IBU79@=//QYNZ14<
M2KG+46=:U>D;9M!\9#A63'2<;AF#??SJQ13KCM'WYS;O2M]_-CKCS''B5_E-
M%PG/MZ>'&/PN2#M*PV03UI1$U5R@9_$-#S%A1O3]VP'^MVPD:6@[KI508L*1
MM&7E=58J\1!E6+20+;6,GOB,GP%\Q*\#78^GV19$?AL<-Z)Y9I/B[;)W$W2,
M[QB]E6_\9FQ"7XW;"\<E1YP>4"-,<B/&.DJUDSPLH[IN"^*+T?=*R>@Z3[QX
M -*ZU6]BWOY*9:39AME!R616?Z%]I?:JP@UYLA>NQ""XQ\ #C)O#6@EL_1:&
M)^L1-SV_>C,8.=L%-9UBCCZE@GM$<F/=R8<EUFJ:Q<@.1W=B/S%$MC%RGV;,
M60VE3"-7UAI#,:Z/?:3P02WZCN\3 J)8-[K]+-=[.*HP#X[F!KX:#"Y/G\M,
MGC11FHXS[A"N=)55Z6Y%,0ZK$^\-RG!C.==S. Z=E?ZJM6G:,>\Y) $M2+41
MS9KA*-W=LE?[VC9^K\<2C^I"#+]>7#5;C[W$-(=$HE:ZEIF"'&D\%: '9T"=
M73>Q^QFPD6K:UY))T281"Q=+EQ]TMYDKE(>3A1X5KO??(24[<N<YLE^8T\E#
MA-WA:'OF8X]Q4TM\R'>G\.RM$X/[.BBLJ%C3Q'%[C3BO]:TJ'3;=BR_K'*(W
M&K-C*[V7[ODM8.AJL)FH<Q_Q$"[:/>Q:2IE>-'&A*NB#H@94[R/J$.!JMFO
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MW5O#X*CFS\>>P41YKUTB-L%'Z:<SS35<T#MVBNS3R71^6W=G&E7@,^W$-IS
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MC/3961\1^_P[+BGK+3Q<ZL,LKJF4KT5W::1CAHFNX"5V(/9_=:0?@=:8L0_
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M4*/OI;L/YE0SO6,G&$\'BU_H!COG__0I$:D3?6>\:'O#7"^E8G2V=M4G0>_
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M0CVDP'WZ)E,VK$[_;<$SBC7393 ^)+?7KN#3VJ)/_+M=2$=@*WJ(FHUMZ:V
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MODO84EE<'C_913T\H6)5+_EJP+K5](=-'@)K2<7WRK,BP)6(_0$.(5X\!)Z
M)!56;\)N YT%(Z#59H9Y[OL[M6<6S5Y/QJ[;59G\->9*<5V3K*_O#C&Q SZ@
MAN"T[C#0-\7:4P$Z,X+JDF^CZ] B 2D63*#6R_*,BOW1O(FVI?MO,OFM58R3
M-7L.G'CQ]LA]7'IZ"%J;AW C"JS,:@:&WNH#M03X5F+@,0>:&-K4P91A!^TZ
MM#S6,B]@T:)3N6M+^X\YXX=9]:[*G[=8ZHB.F2*,C%15HV"4'SK-,8#_YN!:
M(56&SW0S>P?T^7UV/,0_N3$:8"94[F2:F#*Z<F@&%CMXB(NQL1/)YIXVQZ)'
M$_?U?RD*O)3BN8:KG!YB:+QR::P+]YUJUSRQ=Y%6QA'_IMT[1B5&5>ZY]'TA
M"'7OO5B9E\>EV381F>DWB(2C:DZCP:U%S\Y7H3[H-]+=F;:L$)#"<&7%@2(9
M;I0U%PO:KU9O!(M.=BD'421J_5R5.E?77>^O3!Z5-8T3,1+:7*@W?&UQQW:!
MV3%6-0\1YLI#7/9"LW;!7,6G5X0:%3_&_!* .AWU04Z2)%UB5)1R1@?=^\+M
M)W%CWZ4DMRT73%J:&SPG,:"*]+0\%::AJC/3!X<($;'4*HPITS&;ZB7'IFFE
MO0:?.9RR]QP^41K)VN?P,GD[S<[)64@@4%GVY%K=!=%_SK=8U:%F^>#[(.X'
MY@4P:-OOADHK'16+W$!8O9_++:DW4HIM/[1$L-L;,9+SGK(9W]B6)='>@MQ"
M_$T>8KAD]C%D_VCT'7F/SEE7&R_T+?$;R5.95JY:NQ7N-(V_[WE=D+VZZ\QI
M3)"[0I84C<#H2:G>R>W^0.QE-QAJ#$#9IU*_NG=MN'T9#C.O8\12V+Z<8[ N
MSFP(0%-'GCR5MBSQ.K.\<[SAQ!%<[CG@56"I](6VO$U;)G//'O?LNG<P:Z7A
MH06V3OO9:>/'P?J/4@8?H)3G<PV/8Y9.L1[_$<DSSQK)NCB%".;HCCGNY^:C
M7=%1A?(60;32Q[K?O=(;S6\&[L0U%2)&+-D]^3?0/2D?%;<F>$-[.; FQU_Y
MY%+:N9 =^17%4@K/;WW6=Y=HS-"KF8G K*.)@P+447SF_7>[[<YM.4Z9,8MK
M!I-,.@,$M:"]6TJU''*,]VR>S;$B6W#&CQD6-.R;H9[.BL3?3O1SG0O?OZ7:
M^O&2(.S*ESN M!J,'5"C:;B=<X AEC<L*M$ [6J?3WOJQ#[ UO43N;/AFQ/[
M)$/V;;GBY6LG3_[<W8Q-P]C#YJ-MJ!@@03N9Q$0>92Z&^W(O=T-;[2]U:-H<
M"N<6/51Q1KZK(7[&^D(PM[EK]R@8(/1 4VF]LW,\A.+#U-'6WMYBNI]?0)G?
MLDDXX @?$Q6Z3- NYHZ4SS1QY%(L4ZS]?%.KGCY]^@8:BS<=C7.)-/+U6VUW
M\K#@BS5/';=J3T?G80\F$'D(%R!.?RQ<IS[E</7]27U[_P^1E\\;S&L(*9?H
M0=*-="D&81&M6,W_.?><22V81N5$3AH@:4&V=:\$S_0V7A!3YS!X""M&+Z$J
MP<F=AN*PG[ZRF?^1]B-M-LLF8Q9=BN[R $5W8S5@'HO3RS7G(?A#QV+F<DZ*
M?&4MJ\>"E]A'.3)@PQT<"GOH;55Y \;27V=@F_ZH+#])\5UCU:V'L^61]H]&
M]F5'-IY^N",VX)O6+L><S);T&J>W=O$*MA^MXTP/9FW,)#0[2+A39M>'017:
M<U+SNMBY;.#3$>3R-.FK[??.!0-EALT"?M)O)5ETY3]U_G6IDXV%.E!%KW'=
MJ91I*EL?J%'PQ9-SA[W3LGH]T.M?*J):I^E[MK^,P#4J9KS!]'W9$*ATS(UV
M$?"5%HQ[ 5RT) ,L/X \=XS[!'##@\K5">P='.\.W]P!$^H\B8$?7TQ.G3[U
M\2/KX(%S;\ON&4P(E"<J"?Z,O3)7W [&#5N2VR$A2_9MK#LX\P+Z^ P-3C#"
MAALR,J>F<CA*;RW,ZPSE._-\P3?;BIY]**RJ$]MLYY1P_,VEF)%H)928@3/;
M#C8-:Q["!Q-*42RA]-C"S(T?6L\1[-#U"F*;T[@Q[M6;F=OR_+.;+HEF;N1[
M3!^Z=Z+ML_)&._Z(+_?Y$%REWR=HI@>W=9&H"M_S_8A%@1370X,VW(IR@7PQ
M_67;>W^#&CJA;<"GV%?P2,,A_(7P6/VWLV]+5!4Z[#$J@IH\!$R]H2QM#H&'
MH/L"\*5XB!Q8KV&%8CL$-DLMM2S7/@%:*)QD] _!C+]\CV*0>(C),S!OA\_1
M[7C3"#4E=IV'0 .SYV"WK1CW=TZ.T^ZF*ZYG;+Q.(W8#5/-)B@T+F!W5W5^5
M70S-:WI;'J!DE7"*ZD@;> B: M>*F]3'!MQY".W]^P/WH\L/4 A?NJ:"T8$D
M*L!#=&3Q$$D\!#<?#\)$84$-^+%R,4]B3:HZ"P\FGQB&8*"[Y(F"+N#@,9&
MG_L,D0/[BW[+09]??I$!P5R/"[MLF#&0I^:R(2$8A.J*0%0T.PCC"!(:GB$9
M%G@6X5ZE]<N)O?T0?**J^%6<_CN8YDV!#\?ZI1O>Q2MD10=$G_E1_'"KM-;M
M:SF9T@=L1DM_LJI3"M@M@DP'K1W4\_L'CGO<\[@YJ'7ABT'1 ]VDTY1DMKKC
MH.L;'N)?DS%&W8-4IEJSMSI8GMJOOQA7LFK?7ISX]Y%R)5;3V[.-[[;!R/1C
M([>H>C.V>@TH^R+ L!."*=:]A3"#+*!2J50^H2K-H.O4IW>L)U(G;L9OU+:G
M;3T96^8G1,XDT3^9MEUP3CAY4L:L25RKPVG':^Z3YT^48>TU0YW[ZVU=!O&L
M%M!RZ,"[=/ A34&^EGE M,U#GZ8>L7#N2R3P7):8BJ8^QNF 8XL$.< #+SYP
MC%.=0MVNW/9<@!UQ?[<IZ8(<'1+$-0)%KG<X7B\ON%.$YOOZDJN,$^?.'PU6
M+\6Q7+7#YOG+:FDW-DD%F,BFFHMO:QNI;3VN[?#T_)<G*:\SM+< Q0&Y\A ]
M-$YF,>_T?F#H_86)9?T"5]>515U505?:9\I)[A-H [A(\_MP.?8ZE21J+A7S
MEH=XEB+-Q[^.6>$NV0*:H8=>4C:"K8:H $&J,4';SF_ ;"'/3+K *&3M;@H2
M8]S7UT<^E%SZ5N6T\0NG>%WAUX*'$.-J"XM WV-#B1-B_-*01YN?\V+0@^KE
MJ^BW14]<WG$^WH+.[XR3X4)<S/O7AJXPW+\(2(!CIN])W"R8OM]5U+UT=48K
M*7O@95S6IUM)D:6EWTPX:VW5AE"]14-ZM:+X(7S$>=TGK=RFLA*)"TBVI]88
M#]&8.X7_"VD6:.#8USUZ955;>3;#+/OV-=RWM#[(H7TD"CKN-P3:1KW5?>@1
M$/ EG7VSZC@!W)4!D[;9B["KGFT?YX_Y87@0[*/A:XGAJ8WWJD6PLDDTZ1B-
MX5@VJJ;5\[M[U.F$4=,O:3DU\5+6+O>+!.JN(,RD9K7C24/9A%+B]--7 4 #
M4#8SS?<2/$HMK2*2)Z2?Z3)<ZU[YO63,+VH7;JPHG55VO5LVF" F+</WZ'69
MT2;-JT<6-3CY2;CHBK>&$^F50:QBL)Q]@;,KZE [#W&%V+NMA1;,RMOZJ3/?
M#Z-H/WXK=8NQ\NS@48T;!J-'?O(;ERO:J0Q+C:"+LCF2ML/>6>QSYW!UZ-+%
MZ732.H.;-&UD_Y3BVHYYRXU&>>Z*F\O*/K\[]E Y;NBQY.Y ;S%KH:TW[GRZ
MY'DV<]*X6;W"P;')WY/"Z',(61Z,4:>5DX8R*27X1OP]@G@U"O<!76#X>)B$
MQ.Y@[H'DF7KW#!R8P@<WR--=^I'%YWJ-6(%V7Z^$.-]X[:\VM/Y$:VT'$>>0
M3"].7*K@8V5)S6)J+4%UX"-!!O>!AUB/]J+(87=U&^R^R2">[O#%H +$)MU&
MJ]H7^HSCY"W-SJYZ4)GT(7>;)&YQ5-@ZI!<49U_%XBJXF<7:O?ZL.F[:/(#P
MA/8R_%JB#<3]J"39O05>UY);UE>TYYN3^XIM[VLP]V]75%U=2D+L3:RY?#DK
M@*-7G?LR?V"ZY-;$*\4:)IKE#BHS@YO'XBH%7+="_MOR7$2KR#KC@[[.YX9F
M!38<S(V%:=UNMB56A3M3@XE7ISGL19=3*7=W/GZR?3HE@3H7CU#:/JSK1$73
M+7(YWMQ<;##C)G4LW"O?0(+1UB5ZH ZW)^CE-F##Y^@K;?3OHOF:=/+>9T=Z
MS;:9LG[L5&S!F(0-BVUNNM9:TYF:=UA3S28F=Q5A-F>@W<OO)55[]]CU2LVD
MRTRDQ%I]:P*G,G-@/XFYKX_0YF'^B1FGSOJ$X?-()@-T;4:2 V-/J*]-9V42
MD%7^:>(Z8I]J_MXGKDF8JP&"-$QM2TSJAH T*C%N/B_($GMYQJPZWE>0G?GB
M@'WGR;4_U>LNEI16O8O_-CNP+<;6.E'MU*[W29^4&"8E;@%L2*B3?1",<@ V
M876B;$!/FE-BZDPMW:B8I9JO*,5M4CMXZ)"]ZK;JJ0BF@4+:D5Q?U]!7=)SQ
M9&MUQ1$?<HT_KHWXX"3&N;X7PY@\*KVZ[5:6+1SH8WQ'.>5J^;,'1V.6B-#>
M VQ#X'LYDU0+0\R*]*G787-E*0*3/TVN=E%"@*%T4A'EKE\' UVW5.(36;UM
M'_(%]G![FN7EV\[;?/H+D[ZGK"[449^89+QTW>%=NKI1PL)C0/IKV\P.KQT%
MCC="'5T>!%2HQQF9;,J*>#5_^DVY57#&:;WC/E]V^WS*@F/_IR/ \C3E:\>>
MI9]Y1&^5RJ)W9ND/>S.25=?E9S(.;Q*?.4$<.Q[].LYPK/UEZGOA[>G/+_UN
M)N!WPU];W*T-?JVGD)PR.#++2L)_63]HI<WCEP^6XO]IM:#;_\>K!?U+\R'D
MBW^9_! (T-V'D.18FDFMN84@RX3[O)@4.;@-[UCZKJ)[ 1 V>E.O&QHUEW=L
M0V&$ZY?+)T9N$<XO""]E0,+ESW$?<2K<E"WM*\U5TC\YX@Q.0'KK<-<;CH5?
M9GG'*IB>!;(R#65/9+L>+7L6&K+?AQS%<H%I7QWV$#B5#U:P[/\H):"I,R$S
MHF4L9-B"96C7[>+E 'NW1*_N&Z9R#G-O"N_A'YA*I[=!380B-&>C/'6QT4L$
M%F<)FB-)J8$=1J6@.XM(IPA.8%9/SS]>$&459LI[#]\OME=U<]Z'TKE'-":&
M -33,-"#!W8^ 8X*5&8W"7R]4@=6E:XE@GK=A[E%E?*OH3I4:7(!C1(C#JR\
M.7TGE4V,>5^=I3#H.Y5P,\TS<N?GTHYO/(3>P':9&^DA:*O?]KO?)M6U+(G[
MH99IZ/G-CJ?_MGIC"SY>&98,>%A,H'#U)!0T;,O9Q7FDN!G&\S\._3'7%R1A
MBE?^D%''M)>> OUET#2J"6WFL_00Z >X'^%C #=4DVH[AG$2B'#< 6;S$$)Q
M\;%,O ,C*X[$ E@/<(J]FQ8KJMN+)#8]*O7"A8P!!U<'.U#Q/6FL6]^U2:4E
MP!HSFH7I\-<.K'705DYB4.$G;!$/@>T.6UFMA33Z NB'@8N/)UT85C_.;1JT
MM8EC^?7M/H.SK]H<OTP^S2EWC-BV-+):UM*6U?_F37+T5F[%T(SHE7V#B \T
MYKZ CE?<ET65;24>T3<:+!KD@Q_D_QS,*RQ]F#&A+Q7CGJJ8XN7J)5-WBW5?
MPXUD= J1N^<TYEO1DTF++][TGX/3W-*=][9D2%T)+37@6YF("$L,$\V94OQU
M%RO-'D$SM9LE@[)@:D>\\_?2(<O5J%A2K'DK% (+$!NP&F>S\K(V+!_;%ZO.
ML'D(4S76 EA&)<60BK+#("5W<G8<3--5S>1@2'N_N[7>6:--_X1/>J2=$\6[
M\.CHSC.F C=P,5 ;013:B;4&K?RHZ! 2*AM&4DE^JY;]8R\R.'*OPIKN[S9F
M%=U/,MD2>D]HU9I/2G<P.U9J^T( VP7J-L_B&*YD6E>F0'H97&)\:SQ;2NJL
MY!O"1S+</&EJFC\V'$M)<<3B?\Q8:VY (%=).=LH/G,X\U X)G-,DOC:O=R>
MG4\V_#;E\&%YBC:073<CPU'J].(A7&<VN=^6CIZ97_ 1\R17/_+1],J\_$8E
M4?3+%8?R8>57Q):6R%1MNB@#"8E(,;Y9@FJNL<64:,6ML!C"%O+4AWSB#-3D
M)I9=HP;)4H33I2D6LV$:LPU#P9G-VZP[^1=V<@&V#4>,6VBX>0J^#G#%LF]+
M"S6ZC;XU[.QW/P!A[WE+[IW+D7M]/^+-;]U31S@91-9L6A?8\@$-J@HVK 4\
M@N59;=QRM*==M0;8]U'?82 J9$_S[H_WQU/U(MLF#"H>7P[=K^*>G6CPXF&/
M0EZH_%7G=9K'S[I9IGH.6IQO2:7;>7H1/:=<\F%$0M(@.?NL@WI)\I >[CL/
M(0,,/00D#'8R2-3X(J:)55EU,1B=_?2B)VY'Q&GM!<_MRG%R'X7.-=8E6K[+
MG]$T^=D]@U^+70,646?(4_648L4"]G&/Y>RPRL/4BH,'3$",;E)><JR?6,LN
MUOX3TV]FZ?OY592O+\5A%V##J]E-\L3T-M'0\0NP+QBC-V>#R(\H<0/SFS0%
MJQI%+=!_8YE8TNL+0_T7SC6S[CZ6^B03_> U_?3<Z?"G<CN?!':2;=Y['R1[
MM%BWDOONC*$8)PF]*VO-T1U@WS$/SK %L,:M?LT"C2),:?NV:CV/N4DFI06@
M/5:)=^D:>GPY0E$O@!HP/-ON%N:TAH<X![L;-X /ZJ+ YAS/46-.#4LW NNP
MQ\&1H/1^K"[W*5:/2A#\G'5>*^/5DE<0T4-$L[G6M-6^;VENNG?5]8]GM:Z<
M,4SCAO 0E^($63*@>SYXVS):/SN.8S^,D7((2&D<W-?EU2:[D&<S[/-X>[30
M.64^XY[:O?T%G_L]CQ[B)OL%'V5U= &>/$1,M59IE[TEHQ^' C$OCGHTH2*G
M?]2EAO\HV&*>FV.CZRZIU7/)=&EU=%M 3[!+QDE&)[FO--$=<Y;@4-7I]6%I
M-Q5/-V&JL[: ZDR1C^@BY'3?2W"*ZC_=^ZK9E1G5*#=S+[.HFW,Z;ZT3J5O[
M#;V^.*%9 ^.^V]1[&S[P@/*^4Y[SRC6#&M\Y0511]49'F0JV\>,\][>8B7:Z
M\M=0MR[3/L&7UG<:J[ 1S Q(*(B95/^^I9["S]G(S;W*V<P@#8^^\=..QLF5
M,S!])>I!T7FTT@YYBTKV<17TU4A)D[D7:4W[KTP5!P=3D<+CN%6,9RE#^'5V
M(EZ[C=N?%[3GU4J,'%[GN<D]Z?/'5ZB(F\.JD3E2VP]\GB$Y5\U7S9020N26
M?^U2FOA3$BL8O98C5>6T'&*CBJ^6PQJ .2_0D;BM <K'NXL7OWGI>LJ,'0(J
M!<)*JF0NQC>4CA-+LVSRA&.R]N_[[)%ZR[,U0[_8_;*:OM_E+.D,"P?=T6=C
M-:G$:>]J_DXM/V1O!FVP8LA]U<^FS*4&'L+\9E+7X(UKEB=^[FOA7Z'$H]SL
MZ@VXJ6';#R-,K304A2E=.['NFZ1_T'Z=I4:54,F;,8L.?VXBB4W9Y+2SN?;
M"TLY4FKZ];Q9HJ!<'(L5GVD[2] !+47#L;T6[E3,;$TV3(A76QP7\O]Q*F4Q
M7H(:1==DF-#8L>A5X/(W<PX]>!LC+:CX4B?V,7]!S=##54'=_A<P=3Q$[_!0
M8\,>3:8@E1M!_Z:3&KHY<F)GNX2Q-3C_[6!N. S(D6PCK"IW\0,&?\:C2WSV
MF2QX1_8]7@ \,[%S!]]WK9WMJC'H0E!O7S=?;/)&./BF!$0T(XT<'P#S[_?0
MWG_%D#>=3G:_5ZMQ3+KO^9+SY'@'L&QD5]:F6M;JN%6:[K^2+[V*=L>'DL?"
M=6KL'0ON3>K;W_J<NOZ\P8+P8>4JK G;)Z"B5M& FUUI3J.LF4HF)Z<%E&IZ
M!KDK!?S@;Q@XB7QU\6S\\U#DENJ^$(/U+0%-!Y\)2EM-SC_<?S;.K4%WPJ+A
M%%[#53A&M,30:QOY?[#WYN%0_F_?^$@2DIV0)DN4M<52R%2R)8E"$5,I:TR2
M*&.N(F2=4!0A),DRV;-.]B1DSY Q8\TZ8QD7LSV7[_T\]_/Y?+Z?^WY^]W$_
M]_/\CM_Q^\-Q='5<<UWOZWR?Y^M\G>_W>9YO\RMS.=]\TJ,D3?@FA9I)I(6/
MNI'"V8=TM>3>N*J[G[GK>XY:7F1&-"&N*48RD)GXFVQ8Q!DV+'>0Y0"LUV^$
M,\Y7,,_AE_%LF _"[2#N.P JY3#2N)\B%F79L/?T9.9QW#11C'&<#7MVH^ER
M,:X@R#GMA<?*O4 ]WPMW)ROTE[S-1YE>7NH0F%"F8Q&#C/CW-]8 YS:KWLGI
MZ=HL'B?&)U:@_2^=P:WMV.^6=?^5G5#LIB"JI\&RY(18W[H &]8;5!90"SC<
M)79[,F^01O9Y,G%M:Y&79Y>9R)0DPFG+1-8OI\&R>5QM8NO*@\#5IZSF3NI5
M@(9"%.7JHD<)(R/Q/K6U"64+@8[#U5O":=ZD8?\BGN,),V4LW-W%8UJLP>G-
M6N67#S&X]H[YL>EVP'LAT)[V8+3K^M>ZY^G#5T<E-%@=$[1^6<N48612VCF=
MBF*[LB7/O'63W\T0*VE36GWVG]W@Q4DQ*^OD!<*0W'?6!IFQ?EVQ*CYD/7,3
M"A"^&N4Y]':W0L>*B>_R3G(+I/&'G7-QMZ&Y@#$_ &Y8 4Q7NHP?\>D^;HAD
M< 9,DYV2LE)N>(ZC=C 0W>D6?37#;N]1"FUEV,0>38NX=;)W?Q9=DC5@!Q=!
MN"/XMTX#&0O%"QOP1Q'+7<G&^+%:Y9Y>TR%7_?2:Q)&-B*GYY1VC!;HA]5HI
M5'G:6^@5!9@!H#RG&1AJ9/$L!5*B2.O!+)Y97>\X,E*"8=ZSY*=FZ-"O/G^S
M]E99>86?Z=O8$R_-,%=(+Y_=S/V-+]%IZ )5E\(-=-R2NQ9NT.W0(E2-1A#3
MR\1G!IB0%B9CLWQ3W&T%E!\JW;:HV"%Q)_>;RL'Z_3^X!^[_?8D4DNP*!418
MI@]\4Q GP0QFZ-S(0^_M+RQT^6R[[_B G="%R\X+:C_M/H+TAD=>X2%+.-G/
M5:IQVSA'2@1J=",G6MFPS_W0+.$5N>,@==P0Y!*];%<Q8._U+FDS9L*6<K8Z
M._GA-CD!:TO8Q>UE5("A*\TJA$!1#<&:PQ5K=MB9#\P[]ZUZG1M=)%B]*E1S
MN2K46G)H?W\D_8(@E2_Z.-\PY&1O!F'+)Z?7#W4RWHS@FYX6>+M[>1(=AN J
M32-BC?HWYO%E,X'(VQWM2YW:4Q4Z]0='&7F!!(*?@08;%FX(]#< DQ )^74?
M:,S SY(0R[ULV&(5_4PDW1)\A=R#F(&"DA=W(;/\L($"@^LD@1_<+!M(1.T"
M$LSG^%L:X&U+T!0@DP 4@ I*8-U W%[6Q^JQDMNJ_5,78FI76DMM^)"BH,NZ
M75(C#2/W*9D%.S]PQ$G>8@_W]F+.SQBY B?B5??$> ^IEY! SH1.I4$".3AK
MIL^QZ+FB+D?>.QU9$EGYWO,2X:;RO17SQ"-XU<ORB_7&RMV1]@<"'><>!-',
MXF^_T4N\U+Z\B7YQ W-EU+I"\TU:L5=U^2B.<B SJ[2Z#%\>2VN9.I'QDK-9
M\X*DH^7^X./[-_MLI5KB/EKXHMY[E \>O=HQ\>N=2-XKA2]Z>SF7RW<>UQ^+
MI*IV72YQV ?;2D8\#X4%32P_K#V&KSQVI?E14'Y^_:U*FYLQ(8-%"X['-=:_
M 61D,N?HO]G/.&^-HO[GI!M:@6=]\F4IK9$VWP?G'$R_:/4*-213[?\Y%^>O
M?Q9_W)Y::8X,KPW=???V19\U'.I/78?_1Q+G/W521ORA$W'=5P&A/Z2S)&Z<
M<?H><ESXD^1FGPWXG:7-821Z^?&0?*P;03++SL1:\LHMP4?!*LM0K$/]L6K)
MS^IGJ78S3F81?MH;#UC(%*16-4LE%5<\D+T,XW%Q,7B7,(J_F+<"9_%*L&%*
M3\AL&#T<BF+K"/@<5J28LH;@D?N]:!R?CG>2C=O0<%5U11X"MFE\1B#D<&]Y
MGI 8IOS^["\,WZ*^$P1HJ]M91T_JT72HMMECZ03#QC2E'GWX!\]U<?R=Y=74
M0Y='+*LZ[^L9"AI<;,86)]-Q+*D<,H(IR88U:3"XH;=&X:+P8VGIRP'[!"&[
M#&>E+'JNDO'A!@F2[\V?C-=HZ3LAI98#W+0.7<X33RHK6"0(1W:_7_*<F\#.
MH3CN,7HEZM>FPUK.10?5)"F'GE!DIJJACE=,>@X;-G<M.(^[L<RQ0P+D*QCR
M274E^*M'"%(!^@8;9AQ%U8-X.!044;_1(E4VANE *&+&4H A@X3">H07JX6L
ML2FYE4UB#6&Y)22EL!JJZ#5'3!M"[,E)_?3=[T+@5DJB0.-U3_BJ.R#.AE$2
MD2P]IVXC^/#( <@1!$ 0NXF?@O]DF+%AACI;21&0OB)-H'\\F=76-<K7P7]J
M;:79E!M=53. 1X3<,-&_<'P]#T&APC>+L 0(!?B3V+#[=J4S=;MZ<KH+% -3
M/CD1M&6]7^V^;(/[8Q_J_M\N-=J_35@B51H;08=9;>3;;-@Q#4869R."1$XL
M8@RF%T'QH'?J1 KI-=\JV=?)"IKNX1#C/GW+H$?X$F3+SJ<5J@V'&+S?YKK.
MZ'?R!VT=#6,0QX8A=/"@>/_XJ&9Y;%?SH]#\\\W.E;>M%Q(&*Y>0>DT;>%X3
M/NY+JO?6J^R2?[/$X4/7+N*G;N$IYQ$;"@%*#.W",+PFOJ2K^55?T#2PO5ST
M4?JH%?15E6-LV*8<7@1/B4Z 0@F<6V:="MTU>'3C<MV5"&"Y'#Z$MB[_[KS5
M@H<-:\N"N &I0E^&.(9K(BU! [N5SK#18.A(-&(W%?&"> HVA>$Y-)-%=PYV
MVKC,NI*TV7.#^;K9\TX#')0%EILPMJRA?2=Z,0J8GGWRU/=Q[SW$'ZSCG9<7
MRART*SY;)-XU]C<>*3P7?_(T=^W#F$"3OR$D.0P.7;'C LJI>^Z=)GTXWESG
MDE0<FO#RY7QI[<OU8L3CX]^T,EHDHSW:D\_5>I;FI]#BJ\M^%:Z5_2K_;%<*
MU)]$3%#T(8?K(\#4&1F,&OSK?PWL4P#:JCL1\Q)"$$5Q\?R"7W:X#="$#-FP
M"TW,XYF1*HP$1,_A?Q"&ORS]-:D,ZG.23FYU?:;I)%QSW!$0(:M^U63T)-<?
M.,>GS.)YQH'W/W\=&-&1,,JZ\R$P49XJ]M=4_TD@&@WQ%RX19BXP5I"^;ZMD
M8_LH6#&6_D0*U?CJO@8?PVQ0_W1&6[XEE=/:2U>OW7WJ$[I1L"S89Y<_S^3W
MKV=*OJ8XA_^&#_F.<3/$G>L1,J4:(JQ^(N6B91A+A\*%(^ K&!IOT0<MCBZN
M^^7G<B?=4U \F5!Z=)_![9@D,"^$F8482T)2K'!BF%$G+68IPID(*F/2*<'#
M+;JV*3F. =8:(>*Z^;ZG73WB9*L?%HII* H_7-J[!$_9Z_M0F67/X3@]7TE7
MA&3A:"#)>/"C!D6WA"[L5X&(T1W%=#O:]),%#*?[(]7D1/I5YW")Y^=Z#"<[
MJ1;+(9_/7J2T/#; __TF\RP;)H*8,.H#YIY!;"[TH<F_2T<*SP/T&"2E??EZ
M0"A$$^-@=L]8_4B*I<:0,XU 18;KF]$M Y37F[7KQ(/O]S!.^A2,U+]_?>"6
MXL/K3WY8[M\IYI]XD0]=>0+GC8.@<:R$2+')$P"56I_J:U&2ZJ6:PY*HW.1+
M[3LBR%Z83O?[^%U7\^0L/U[+M_JZ\HI17[S=1/5+XG;U-MU/]ZE:/D=B]\U:
M5HR#'-/PDM9Z7!B\&,F0V,_J@G\Z*Z&+>*+.$NKZR/"D7$CY8&$0]VYVQS7W
ME:=QK[T6)W9H/!=$YZC"[#R6-881]<0B-8AIB N,ZT3@O:&@30^*+85K$/ G
M-4?@X1.4G*=K%D:J2@XNGN$O\Z]NOV[LW+D<,*,[^".=8KI$"&?QZ)',7R%<
M$) (\E#/B&)HE(]//MC>K%L17G:\S%+<PTRDR]=??U![]N/'S#-Q$@WJIT;F
MO[-ZJ0XL/BY(#:=!(:I)4SI7G3:FQ]9 E(H(5;RRYJ5BWX-ROBFE%><D+OCB
MLZW=GN7VO1/7A2+74J\YZCM;Y6AO"-<5)=@YT3I6BY>+MPTRA"E;.0&*S&3I
MK1:V'@Z_$UD<^,&<2GQQ[V3UBEK9,=%#1Z\9/6AQ.\"S]X3Q%X+88]D0N#]U
M/5C_)/78EZK!1JR$@[EV IE?<=JB7S9XDN1?D:88:7157O;'BP<<+\*XGY^6
MQ(4AQJ*UD_YQ9(V;!B&<-D1!/-:RY&>H@+7C08I N#;A_1N:ZV6Z3"EU=+;H
MR]C15E_5W/WW.%Q&! Z>VA096V>(>M+\P%ZZ!HBCU5+&J/PY(362N;/:]O-)
M!!6M/J^;7Z[IGN8\UW.PTWBD",:H)-<P''F+FLT:%CL\UMS+ G5^Z>$N<T_;
M,4018Y8,(8TQ8F.Z('HG,QI]PO,=IM=^7S9_>&.0!JDSXR/BV0+CU '+0U*.
M"\N/S?Q??I+PV6[0BS0%ZD^/5947,9^O$L&#_%-O(*:\H^[2^ @AZT.WPJ"=
M(6J>#5O@;$(ZZSY[SEI9UZNI9=RLF6/Q0HZ."X*=X%.8 7BQ1 Q&DJ'2IX^@
M7B);QFCJ12'#"0*A:$D?GX*VPC9)![VG"%?A4]1SUL8NRLU62?S5SD&3] .@
M$ED[G+X7?9S"O7"P_6- 83N)]M)UW')!T0&KNZ%*=GBBLC?"(>#Z=]_/P8&#
M01[];C]R=#_:74"*K)=%VD5YGJVP=]O\9""QU97=0T" U0[GP;LYHFB&W6IK
M$*L"P\=O&>QE)J*/Y7R]D)HW5_'@\($^W8>=Q/F^NI4IEV?/;(][\PJ%(#TP
MC7@.-)RNSI (&2NHP'KIFXUS525= >,*HUYXUB*=:E"ZRYM^W/<VXH4%#V\X
MF_9F1FXLD<J3Q@6&G5LQ)Z&X3N)G4YHT&$CR\FU %#<_/?+QM"]&-EZ:*&3\
MF;!]<&?Y@X4OR_OC/NF/#'Y'%&TP7TX-(&X.(W\.M%MB:4_*!RT9FAR]!=_F
M/&]JMC\A:X"F//O<(6S[MEPWV,FLL_.P<5<]JYC@GG?"K]]H^/7OLK('8,K\
M8V9X 18&?/W]'A@D [JM?[Q8_H1<>@%Q+KPF=Q7$8#=!,?V_5.4%<?ZY=(D$
M5H.EM?"9K?K6UK_+;N;0AAR1[$[$7#$;=@1I:->E^Z=E+Z\&!!?J"NLM1(V#
MGL/U9_]G2I;%'W;BM/Z5S-I]!THU&"()+(FN%GXD&<]01\SC%I 0QKX%&DY.
M;SC9U-QELF&EBO,;@74S+3Z=QY FOS'R%%JE)FU3L?;VPP-Y\Y7F#N^>-XU&
MBZ;F_.PG;&)$Q]45QM M ?.)^**\@\=UVGE&U5HL['WB1X_XEZV.=J1Q"U'J
MC)H_[QE;L3?H>7/K?9)FUI)"C__33%J";6W9L#-$E<#[.LQK2BQ[@#EH\J=(
ML/0@[@= OH&^SH9EI+.LMC+'LJ#[R;P@Q,!.P3=L*]@P50-G9AI^[$TZ):/N
ML#M<#&(S/I!JLF&W@[*8G"RA)?F.%:^)\"5F!FW\^Z_U"SZQQY(W[^5ZL.0I
MZ^'?#9T&\_,Q/^C7Z;=[C*9T,A?EE=*""P>G1ZZVZ)NW2D8?V?@%>-D>OF@]
M^?1DWZ1"P<YFU"$]PN;2+6PIJ5/BZV=S3M5]-B9#O2_>$*9>U$[%>Z^\2.L^
M-UB>XBUJXZ5SM4?KY<O5&%O"_.EC1D?*4V\)?=7-\E+:I1?2(9#O+N11-&/M
M4=X>I*JF:>NE&^&DM5^"Y\W+[8\O'.816Q%WK;OZ7]S\2^R<I1#X2.V&OIYZ
M[:VJIQ&UJO:_MW^OO2>B]VR]&88FT<] >'X"04(SKO>S5-BPAG'6-U8_';')
MS9 ?!5Y..K0*$.EGO+N2JA>C7?>.:T$#^DLLS42I40>;SV>I9SUN<-E;^J'A
M\-.@E]QN]0>;'7N\AA0*AU%Y=QC#,B2)\->)NH7'1(*G<JVMWZ27YN,.:4_,
M?X1N>&"F_A7$LV3XV3 ["/H2T]DPOT'WK=-&H8$9HJ_W&/S+P/I9W^@F_QB8
M2<K4<!LT,,.%UM?5BV_&][IJK4Z*NCCI@KDID_V?]M0T)K]T.R>"+7Z+D\R1
M5/EHEO>^O]?BOGL8=X.&P-$1/U47::YVZS=9Q_'N5PE6[LU#?>Y#[^9['7]8
M&=E*=3XGY/Y(LBG7:1=('KCIMW+V80OS=><(]<U-O +"3+7;INRDLVFWK'F,
MJTUY:>S5^#UILW[1^K%W/_ ))2H]UDVP=?L;COF7U,7_646Z8P&:J#_32$YJ
M!2V?F02X/"U-H,4RW]5P4IA^,(N0@.$6;?N+E:W<[?3+N?A]0X7^)!1#5(G&
M!8Z/5\-#\5P(;W@(ZS#5('>*#7,)\&T@"J\6G&$MM4=,)7RK""9-)-RR:I/W
MNE1F]6ILF^?*[+H1Y&=LW-(I5W&$<X,LW@H<8\^@OEUA3M@B1L*,"ECU:FC.
M\?/<_Q!O87 <=_5M495#3,^>=SRJN3ZBW6%7]PP.($MTPO%CH0\0TJ7FN)]$
M0V:"+/@\W1V*Q^]9AMF.[G&\ZT*P\J$YW]2'$("VL@[YO$0GEZ4D/UB0Z]^7
M)?PEP7 9^^_M(%^#'-2Z%)Z4-/&%RGLP$R_WCQ7!C_8580P]G":JT$W;KH#G
MN^)BO\+!(.,Q']"&<-#B[3^:IUT-\&Q,=LE0+W@/8KZ-SJ(WU@_;RYDI7K@P
MQ:F4;E^A:F4I<EK?8V;6IKO%D+-/:.32A\SYG9J_CEETY\OUE 89\)D[W.?A
M*BLUW^OS8>;C1QCG3VL'=RF;U/G-E^]?H\0Z!HBE(R:\>1U/GE0^;K]^O^M<
MD9'$=;&B,8$-&<VN38;E])6U/US\SR667P<S(YEHWK2_[LT^H7(S'J/P<YU(
M)FRPJY_"<&38.V%7MRI8Q_\V5_9_5_$/#L%\#RE3>EAZ&;Y!K^L)<8^T+6JW
MAYWM\FQBE7:16G22NVB>TO/E!MO3(B\Y&HKC*R4E<:=PTLPZP L1GDZQ) ZA
MFH!2R&<6**Y;EW9;'\\O3=6_Z4!O>V.R7?JKG):K_/UPV<M'&@5%?W'9VF3F
MHNULR]=GN.N)%&N-GU$T&^;C&B.*"L25*1>(,"Q$YZ77L%&ZMEC2R6,-A.QN
M0/#W=S;L]X_1,\N'D_LO9B2:[-UQL2,,5XOP9,-^HL:0"VUO9^H$01;:Q#=S
M9C!^1 9^EGIR((5KPX_7>GJ^$ZL,.RX=QJ-4B[F'J8=3K+&@8@+C2CIMDED)
M>!5(-"'A^H[>JJNUZKT-R>V_ZSAZ%91<L#F<+I<1G6<'8?'SWSD/:RC@L^%E
MX0LE= U68]KN7C1 OXR^'-[PR!B7RX:Y_AY,<$_R/^.9KO9NF39L)"\0MV?B
M\?&YY+6B*)D+!<H/$I+QM:X/-C^LN=]?0[EP?X=3O,5?.V="EJ'E5>IU5$"9
MT$M6BI"MP/IX/4M:_'C43 FVVU)K/15S!;JE"JA8GX_0^!*C1#N"'1?E)KM4
MCJ<+STIM-8(O1OEWW;F=1C%57$:_9,-,8B8:307:H[V_X.K0LO2;:$4J;L&/
MO/0SSZ2\OS4:+4&J/NE[)=%3TT&QK')H\MG$[JOITY)<L+W+GKMZ0OU>V7AK
M/*#]#D3V,$\Q?A916ADB[6;,3WBW=BRH?LP]9KR:"!^UI)!1SWP=F<&6G"_A
M0\2A P))+YFSGZ/6/W[C)A(=N;_\$J%]IE0P!$W&^P"^E)9<9_427!=%_*3%
ME.Z($Z>[%R,F@PU#1WL9S37MAGO*7N"U0?VLH 4SPR!?CX@DENJ$ &,?B]VD
M)%K4[,@MN ].<T@AANZ@DA-E/H4K_*=+O(2P_78[GFWWM]]XQ+&(IYRVT+O&
MAH4BJ*B6?<*4<MQ;!IP*;PE"6H/P3 ]:O,.&U*Y0TWB"I(&;E^.R,_;QSN=/
MVI1ZFSKOYY[0)$2%V($R^(2*\6P:9P?@2MS+^H+@0: 0.QE;P'D?3&I(1C6D
M"M P UH:6"GL4Z5+V?9#7P9ZW'T]%/7?]H7P%8^Z;MIV';O;XCD#@$J+<8%4
MZ19[(D.4F_9X^3Y6FG&K/%8@O$Z\OU!(G8$8^[JG-C3>N/5N<E +;4R#4?I:
M],DDQU5D:5+XJL"P-"UWJQHV*$# L*0"#"(=FF<XTPV[<H95K3S4KYEG!V#.
MA.P>/&JL7L@Q/4^16V0NJHSC"+^ VRF!V&&]"\S">4T:,].5>@.2!@=M^!Z!
M"OGOD@63L-;PK_O<MJV:3S$3P(J'M7-<7%'7JG(U<;3L;Y/9M-'UH,RL7T_H
MTD:^Z=R#K2J4A(9VJGX(V8K4+D06/M*Q/M3;1:\!\HF]D3-S7SPZO_RO:P&4
M_\.U +B\WT5SNA8#<6I-/[+[JQMZANN&!(^^5,TIV36QKP6O#]SI N6G&<*^
M- ]F1-U^]&6J1.-531G+QC2IJKZ%N@._P/>;CO=.VL@K$OPJXV\Z^7]>;FC9
MT>K/*_)<957#:6"U:]>,?YW"P"(Z1<V@QSRELEQ\2-3CZC OSW'8&Y@%YLCP
MUA((,):.I%Q,)]Q%7V?6 F[#2![&?M"_8".=C\4[ZB;ULM=SL)OYR_>J]D#/
MV;%;&]HIKS1D/Q.G-RL=]6^]FS1K,]:^-UE+O'V[EK'J\ EQ&N]LR8&V9'[$
MC[T !&JXZ=<]TPZ4406B,/N&<B+*I&4NF*O9C-_1M-:<HW^=#A"7EP\B=V[4
M*]9MG0OGS/J^U0+W%@I4Q2XH40S'O$/]<T# $O0G725'LF&VG^N2S=YC.Q)-
MDDF_AEX/O9H8<X5Q- >507,SK$%SIYK,ERDMY+Q%7X@<)T7;G^S\R#HDY=7S
MMJ3BH; [.O&99:C;&^?VMN$O)\0V4BC<+#YN-FP[F9+$$%L9)RX<(,,)]@/#
M]09'*3IA]]DP?L_PQJH4M86.?%G7:./RELN$@/:/(3^3A_GWW@ZXZ;Q'3Y/9
ME_JB,BN[.GOE$_R3UDH2%%;3$L 0"K'128:9C'>I?I8^KM3"MZ&)XD19_,X<
M_KA8-^CJ]&/HR_G4]7,W3TDKV/ELY1\U@19T;<9%T)F")<N4%V[BFM.%S3+
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M;@)*-(^J@D64! ?*5,C)7^_#QWG4R]Q)L()\Q1T7%[K.4YWP__G1;B6E_-T
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MFR>PH>F@J2- ]:,%B0(ND\25*3C("SFC_R#(8>='JEEHR-]S(">XZ^%2=3Q
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M' FG)+9@C"''S 2V2DTLX> A8"$B%ZW"A-#!(X E@_D.YV6<P;N"#[5#/G8
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M.<;A ;\KA""-:SUJ,4TTA&<,KYDT+M&:=#&XV-7[M#UL,RT2]*1MG2"3AB'
M*1=3I4G$5E0XG'*!CN)E2%&-/@&" 5W-<&$2_8YZT>?4_#NV0TY3HRI/#T=,
M')$\4Y)_XTQB&[CE>.R9%<"=H;6N""3% @K:8N/&<4^KU,O\WKLC!6L>4B\@
M!" <=M0J#3M$M"@73_CTV#0_3_^=RIM@L;C^4P;C5'B3!@Q$7.W1/T$F[G7;
M=,H@\[TO^W%'2^;"0<6^')N1;H>L3^YO-+[;<.SWC?R):T>!JD K(!.@-*XT
MST$=AR:MA%8+CQPF>_5W##8PI39'Z1<M[,=-+CLJZX7>#K:3$,XWP$Q&A<C*
M<F@M +N!L1Q$&>XQ&W8'&XXO3F>("M#V]!KL<4#?= #KI -*(+(A+$_ERNU3
MDZ4;_J[(\,HX_.TFO5C=ZDWHQ4;?_=S#?59()88_,QL8RT^&-^$%?R-*4 P1
M1(/! 4I:Z'WG7JTN489W1:\ZX]P3#C4O+YEWF3_%OQWZ'&<F[\-AJL YQZLR
M@=L&$4T[!IPJS^()'X<<V,&<L+K='HE5V$8+[J:C =6DM,H/!653J05N;8>J
M>[(_7YFPT1N'G9-'Q9^]^7B2.]PSG6*/'TX%;O/K0*9 @J)X_5XTK^6NH;DJ
MYMIZLTI S6GF&VJ6(Y)P)2A)V+[!O-1+I66E*=@Q3I[Q%OZN'TO&/3/@H*AU
MOKP]#DC/;&H2%M\G/XC8G9?;[$T('0^V)G#(<VKFBSV+.=K*S1FYT4[KA#0E
M X33O$!.2B\958\+2\8V:X@S?/HTZ0(A^[AZ<-;?+ 6['FX;,5%-^)I?7M[&
MI])V3&7[2.4>!>PSQ%@&4$I<"!I'$?"T@^ !N@>F-1'@7]M >'AQ.E!8922D
ME&)MED=BM\*/D5,NRS?B";-*E14&#AE7Q<]\G7:&<=!YC,2H&DT"X*'!!2.J
M#NT3E3C?N-50@!EYOROR+EH^F<\R G.,BFQ2H+!2=N2J8J[WY'<-Y7A&A5JN
MQ9XR_2EVXUL)+"CT+?H,12"RYG1^@'D#ZWCWFII=8XF1P#/-=OX+APHUVQ0L
MJ-E-;LT9+I:O#1^;3MRR;<8@@7I1A%N0'MER(96.9OT !!G2'Q@(4WUW4B[:
M)@/,-&TB;*?I:E*(1IIQ\;%Q9BCM ]8VW8:Q>^Q\22A0!<X051J?;N3#$Z9I
M6RUC;"!SL*%8:Z;--6Z&/S,X:)@-)C7;WU&M7\HO[2K^*F^[<T'4^NN^ZQ(H
MHM4I>(:H70M+'?I9*T.E"'2E'V'U.,% ?X,*2@HMFAI3$5:H[^Z;SV=6(P\\
MB"WW&7'8>>MJB:\HK2==5RLT4T'S\1.G</H#S"B2TIJF NI0*AJ0O'C2<6IZ
M2WI$>9T81.S#PRJ9Z31/ZQ@U6IY"VMFF1D]!$S^>A"D-^813\#,]9G)G8U0+
MQ2X+?V^%"5Q"PC$_D!1KRUA_1%E8-5U@ZT@FQ*TY5)33<8IQG.L'QOD!AN&X
MPH]2.*\:65)U(3N]+=D\*C?KTOXP3>F+82,//CL2?W:Q>+G("$*4'9A%U\'\
M@,,6,6+H6^!5% <5")X8E.]74U?%[?<O[<O7<#XKH;W\] XCLOOPSW$%88Y5
MX DZ: P9N4^LE$ILM)3Z;2#W8XW+]T;^C/T+NP=)LHYQT;YGOV/#;2\%W[T<
M^W:@#&,'#5$>\,*&(BF6 *B-(IDLG*8^ZKJ(_]2]RK0F7NC6#'B:5-62X4/6
M [WR"WZD)YLI7#_6??G8/M'!]P$A+%XBW9/5[K]O%[BU^R\'S83/$/H(>&G<
MZU&7:4J+DS28L;O2=VPNI7SXCE;@#4_QG^V".,T+[9)[&H\I/Q?X<4YE'#$<
MQ>*M&.\:<J"-4@3FI2D)-/T^C!+82'8-+ES#\J8(B#?G*!%(J<_K?::&JT[?
M^=2JN>PH<4!<+D\T^AM$8TL@'4H??Y]#O]E,Y\00$<6IZ0W89[IL6%@.E;NQ
MUKQQ](BCKQ'5)K62#3L7)LEXYB3]P=@Q\[Y"9LGD:<CKWNQ&PMP@CV6')*S0
M'H-L&#6'AMPZQCWU 4N9*E&/E>G*\'22A>SKYVJ'E+G?J1NOOM[YGN[^.O&V
MPV6[*P-JR^<SXAQTQI ,<0=:%;.$(9T+^M*.0[+PL@2HQ[[H%DQAJ>FGJ(--
M>^ZG*C4\JBU=;F2F<%&>=&;[*,4OZG_NEK,UE,^]O9USU3ARPY!V"_IE&7H/
MV X9,)UJN?";BFVH8,-VJ]5)7YO=]&]&\'GH\/G[DIAVYX.2;,_-B%ZK5$1H
M\&9__UIM$\'9NH8#55 ,4?-Z^'8$J=) 'JA7O-UKP&64\[XDUTR@6<6]!IGC
MMBO3\&-[-O.5T7+#V2ZOZ0CY:XLWRI[!F *9=2>8E8BQ0A:<F> -N+:QQ-#;
M^PW4?K*Z=1*&P=.,(_G994VA^1F516[.B?^-L3</A_)]PX='2)8:NQ!3ULK6
M8ODD&1*2I TA)ENV-$D8&3,B9(]"428A%1J[LLS859)D'S&+4!B>4<:36?P>
MW_=X__L=Q_O^,77X8YZYG_N^KO,ZS_N^KNM6RTY-?)\@;J>A(U:=]21!K88D
M][^;M8(V82)\BKD@+W,31GN!JN(_!5I)!FY!!D!OM[D"F(YXH#O?6A//E/G=
MB&F([3R4E//0S^.!DXC&:Y').RX_&SL(E&"^F'LQOOT6,JA2@8Y>\BO&C%2:
MF= #+G4T$7LSER9/&+?[/ \QVO&T;N)1?W.:J.^]"V>U9X_8IX]LM!?_"'*Y
MZU Y6ENF^?QGP\?UB*P?4>5"I9:^\'LM@EG-@O]]%8:YOB0= 9NWDDIX+[G!
MG(N83K;U_VZR[!U%RH5G)@8&$63,?!C$/5KQ10%YC5+_JGX/GMY;:-]7C/A"
ME]6]NOW81Q7D$J1DA.%@$N<RJ,WHC5TF7S<&DGH'XEUTO!@K]Y764WTX1Z<&
M;HPIW7FXD&6Q,!H94-(;^C.[^<KCO=NOP=^\)M[+Y"H,T8IQG=7\;]^P>T81
M,T*DHYNP^Z)X?SASKQ$4^QQ:!O;_ZN96/&CGS5-:*DG.NP8._3,:YU,)@!-J
MSQ; _"7<DS<WY66AS9P8Y+2-F8!+H&.'JK[KW)"13U"F2FE=MMM+*OI#EEY7
MFMYCP;D],.=8\X\O20B P)439+\%K3@7L"=X!.36]A"T4(UGP/8WYH^ Q9YI
M63"M<%^UA_]U\&\!U]WBFZ,:M_IC4;8MW5)@PA1!@8*K-:O&@-+IQ$M$7H-/
MG(&GXB6QFD43"U1I(X?H'M&B $^I1*;]1/N)]L1 [::G(D^J;&(?C)LS!!-@
M&_R4?_%L56C*$\!R=AIXCP5G^_.*_V=Q7#_0?6<I-=EL3SBX9J]GY=!D$^QA
M[]AZRC)4J$#QBNQ.&2_E_'_-[##HV^/X=@M(J$\<Z66W\3*0M&S6HJIJ74/K
MHR[C:36P=>>SO#SYVL\U;H&(7\=73B=+I7VW%8MZ![S(>GE]+^*5K$LW'P**
MN&_8 ULJ-1B[Y;4)6 W0O@+3@$^E?,VCKR1-;U-*,[XTC8ECS]D[#<TWQ0RZ
M5X2UW\H\+$%NTA#,\B O#;$F^6))#'RJLZHTKP)_#2\$VG?D)Y2LVC,@3^!>
M<W"M^W!!W%:"G3W1L1J5]),J(UF6?>@VS/SI2Y(ZRX4K2V67@U.LQ5ZJ,.0P
M^<AJ_:<LY!GP$M'\W@SY@><1\'[^]FRCCSEN,0<_6;>L>CA(^KEJ[),VH?T\
M<O3N)HPK,\]>^4Z^B4\JU&@=Q<DMX.$MT5#LZLY350#S@#^N+1ES,2+."4XI
M&JS8/.?E#*)<1VS-@?\$M\>>8/_?&O'_WS[OR1GDU?V3^'$[Y-^K.10GO<C.
M)F1RI7RG>^T?AIU02J&/_NYM1W/V_M5Z_T?"C(4Y,)BXZCQVS6Q;"IL 7B;#
MR;\@Y??I WXKX>OB5LOP(D@7:LUNI7LQR"-FO?_HZV3^*8F5>ZC5_3\V8>.0
ME/Q[-1SZ'7'H=Q)#E#I/U:ZJ14FD%?H87XD]FJOQ=]N[,<HL&$4_=+[X!*/R
M59OL!>L(F,N<"U=^G6[0:9!!!B[!Q^%T@Q[';8$X+>!KXTRFHE7Y+[>1_!]N
MTS:&?2;B&C=V7%.\3%O?1G8(> '_O#)9P+X%;C6M/@8R 0Y?+)TCBSW2 +AT
MC(TRL9J<LR"B4[Y?]7EHD><9]?K1W G<Z;FZ]Z&?85?[E "EBS],N+(K=&0'
M'(JE+DP#]C#O'<X >QE M:%34"(WZG8>9U [4+L7W/P:4BLGIQ35ZH9O&GYW
M#='?%YYM@LXJN?'7-IR7\GJY,@1=65+3VI 1X'<RN_O@=I>+ARQ%XG8P+1#Y
M!, 1+@3YO HVC!,5J&K"R]Z$A1"3(6%FOA^TZC!]G)M'4@-3*S!YCM_O3'!?
M^SM_:'*.TPI3"WE@UYJ22XF0-G?A%>$,H$?L,4=@C[#&F$CH=5]OJ2RN-:C#
M.O?7<V'#H ,IM*B4-!Y.E:[24\D92$2'4.?R9VZ<.EAR(>^CLH+(^E&;;W>0
MNUPW8?Z8:)NZJL8?[A]K&Z\\"EV(>"UHI RZ=TH'^W0-T/NV#^?<:KI7:_7?
M[AZS+S=_][K!N)C_92'_!WY@G$"S=:$_'O*G3?V[R#M 'SLPQ#R3<S*((!JN
MS#OJ!&B5OAZWW-^*KYIC**/J_F5=/3C?Y[0CLE:M,9AC@K'G[PAD1;([00<_
M ,\7TV%%SMAV.2"Z\).%@M_J'5.55I)#=/5?Q-DIS84_]51VDBI_<Z3.=UGT
MTS7XHB@L3>KAW?C+=QPE,,&=]@<Q89VCIICGC6=U*Z7W[5L+>>'[9SH6J80-
M9SFRI<%D#A;WW5,6&NL\?W#:"."7TAU5_B%$^"J>F)DN)=4TOM2JNG%D$U;I
M;!6O82YBVK<]JT]8(.PA'%3G-2;<(-,(D*0_CH)QC<>X*O195EF:<B=?@>70
M/]R4^]Q[6G7[M,ZKYFP[[B9,IT]?,R+<VRE9C7P=W8)\L9 W2BDL>^GZX^I$
MPZ)],C-K6K!W?Y>?HV!9J?L+^$,R[6&A-$H1WR[-%P'5*,"$B@\M)OW)A^2H
MA%<UX[Z"PPI3:\0\,BT+#UQ"3<CP15LYT@%4P!$%[H_L*D?&(^7,Q7X$F3H^
M,$,RFG4>^(SH4?@,C)&RJ/R1QH<.>UXDIN5J'/4)UC%96+LX8F9$[[\]-[WN
M!O!R?HYF-HVZEY_**KH1_UA7]-)#T[MB,.XR-$497'L U4.EK/!%^UAX.O-O
M(PG!<NQV;T59-7VHR9V"/&;0[)=OP"NG;+4+CYGASI[WMQWV4.#*BV=.1K)W
M>8WQE91""9R$?A3N@H4P;M\OJNQ642$!^C> 0%%%@/J13.$9#CYY6A'L+@_D
M[P!=PF<RI0.-&_@*SI8ESY4Z3^<C&IX.A?X@^69G5[@8M&["T >?#R3]59YR
MWAGQYU1M_L;(F4E/^QOINA;S^ZZF$2]]6W\![\*#VJ6MS_.XRN6<F"N_IP5'
ML#HA(AFD [TA])#;<Z[$.P$]F3?D/S/LGO^,>HEHCHB\KIOF^B3;D8*2O"##
MWYDYHGY*P(6]^]9;$4%5.+'E]0MX[TK:HP5\[?K2)\C%R%L[SYB\SOS<4F"1
M%AG[=Q&5_"@P0MK#/+-LL5"VNL;#[72QQ)QR9*;^9U%5;YIT()Y60MZJ-)T(
M8X_R:C9AWF@AW"=/P]3>C7-)G/,!+M/JK'<)@3J_\_VZDM4F ^=F'ZI?/5.(
M?:6IF1520X_4QZ-^IFO:I%R6J-CAY_70MNCMADUJ\2]YG5<!I@[U.372%Z>_
M"Z?+/LH^^1KF^TTXGUO)2R??0$Q ZW: X\4?1=0Z,CFL[?"D(UQ+D%F.=0*C
M& 2IR3.YJIJ#:P%T+9W@!!N7[ GZ*D4W\<?/_2&5F2,'W[P-,%5MN!82;%/7
M8OP].21]I.G3[&E3TV61X.B, ,%59;XH?>N\5'@7RY8K)VX#1KX(4E5XQ%AP
M^^TIZX'KL#\PJKRR"^4V/MTGFZ)QWT&Y,ZP^]E:M1.QMG5ZDMXHM7]0#&&*C
M@)4.Q&0Q7TR38\L5!NN!=>ND4ZSU3I6PF;P'=5YE4Y2RQVX=HT=G3U2DQ)W.
MI=Y^:_KZE\YZX>L@3P7@:VW,]C<5F(B.Y;GA.0IC;E C6S5LM7:;2R'F!3S.
M" 5J9R[5<R AVBY4#Q_GL*7R4(_:FS(3ZW<&T[<7,0SJNG%-;X..+D3D*;^[
M>(PA[9DA?K QY\#,]A8(CV8YEB"9+Z[-N?N;#)Q'):ON::[[CO<GQ%'0\89]
MP8L^2LB,\-.G\M=^'K2Y7!(0\J#MG^:#=>*8Z7Y!UM$9?#M^8H -Z=^X)FS,
M")E63*CS[T''DR3 P=>_/=7!2RSM-K+D6HB(Y<AS/;."?N.-8)G9TN%=Y&89
M*4[%L]=WX&LF7.GY-BI@?\)]QK8;G8:OBF2>8,$9ZZDA+8HA+\&^[FD#%J[\
MW:1FL9UN WO0DZKUR=5-(:3Z^)+S_$T6X9O');OO]7T*W]<JCTRO4JY&Y:Z?
MK\@B[;)QNB?R<*?^\U>_*2<>W[V95=8>'"+9Y<P>%#JE<DO.8ELL4@(GPU4!
M*UG:_)U7>/DX3>Q>8.<F+!7-E\0Z-( )KS&7SMSO"R__O8%.KK<*D[B0N9:F
MGE,Z.?R@ /9,<'%+>SF"![27MC3D=5Z"-S0'4?AV,_X^[:Z59+**4;_8P+EO
M=](/SO<#4R5*SRN97XO>)*5;/[Y521K[L^,:*D*L7&J#>?DO))) O%WKA^&Z
MREU?*0S6NJ<C.NC!GP:[OBI8]2<SPB4+1"YAJS\$LHU:#5'O178,V,CR[+N8
MUZ&$6EJK=,64=3DWW6GT/UF7_;?'Z,!W37])W>DS]GN%;!X=;?S\JH&(#,B\
M#PW7R0#4(R[-SV2.$[K*9Y""N'Y/%58$D27#T,I":[/=/!;=L!'&^5=-=(O\
M"/LU_4YV]NE]O=#!<YJACJ?V>&[M6+P!X6QN(RLQ3_4>'7G_+O$^VE#1Y^'4
M0&AX1&W%9XN)V82KDN?"**3DP;\G%#I'K<Y],XQV5[[5?5\^8E%ZV]WG;V&?
M((O=2LD+B&<7\YI*Q$P0E$)0)N.TO#'(]_]3S-_A_("$Y#7NV2O$GRP\+'3O
M$Z\_#R1\)?%?QB+EL((<?>X%7BV>]A /7%B9&*!5/IH"RUQY-=RHL)>!K/]<
M2+E]%[^C^9_OT]!/W W/B,+JXC5V!<NT36_=>RR-M>05[FODO4327B/J"/>-
M@I]+!A::@K8SB'3^?J7G"4/6LQZ!MW\GN"[#O%DW3H6'_Z<H(L=)O:P)D!/]
M1Q]U/0(CVM=VC]V(7 E(]-O=(SASB_M+\(\5NQ10Z("4.Z$>SI5>I(^UIWJ<
M08H$Y'\M#Z2?#J_:A 5G.J9V'A;W>W):,%G(2W"[P#TAR1W$D]"0:O&?;9#7
M?*A\!>/& 5Y[(8D+O:<^UY[CRA78TN*03X>3S+D7>0TM=Z9A +$;G4"21&\#
M"4[?;U(=ATNK,@+T7[C2DP?];([M[]H3]L/_[XKUJ.& 5 "[<._@S5'&UPW*
M\52[;WOL9%[[>17>LA1AE1N>%Z%_+09\V.Z\+ BPJ761\4A:*;E>NX<<=Q??
M#4]V4?T/=)K![^">'35#THG25Z:)3XW*^WQ/J:V.].9V7*QP"4#L=Z!NM0DR
M-8,(LA".5V@XD(EOZ%WJX[B"0SV4ZUG%@<6,L2XR E-\>8064*G^(3C@10LI
M3?F#E/B+*V[G?%,._SGDQA,?^>N@W"6O]RJ88EVY5BOI-KTZY7?2=F_.-5LY
MO9STW*>!JH0RUVZTT'[Y_7O3U-0R8@7:9 5 'T2G(Z6LDZQ"VX3%OS:SY1P+
M)(]'WIUQ?(U5=(3;A+<BZ9,3E<]PZM*"7]_N102&;\((D;U/JI>=UE= /4>F
M"\ P2$54:3.3@,_3\[VD7>B4,?.]#7D=#>AHH[G'E" [O?Z6_>*?66V^3TYM
M7_6>C/WALE")G>0$X;I(AKPR<B!YHG.F++'%K_1W U+8#!]-7#1V&?SH-[RO
M\%/EZ']GM@EN/W:\ZK %0@4W16Y +\U#&!'"*]J$^1$G$'Q1'DL:GJR4ETA"
M_D+*M$0R$+LH7]@XN6]_$Y[_#'XZ)>=5Z&.2M\=W>;KYRH$[.V>1=2@(9E?^
M=VU7)S>"A>?*NK 3P#X@J0VOG)%4R=4#G](,'B@UQ+\,4I ?15UO^;ZF6+&K
M^T/RV)V3WK#4T,__4I39J0[?[IQ0<D^NBU'Z/K@\>V3J1'U3S_6PD6>OE3-/
M.!IIE94&YD^EY7O6OFJ/#-F_S3WZM?/I'X)9.=<L?PI:(" V:(\4Q+?K&&52
M=!@F/8[CE]BE8#(KOB?74R3)BN6?:N8QH^+B69_88??EVZ1U]-W"JQD:"06^
M%\W;NAXV]T!+0!N_<PIZ T6LV(X7@B&,;;>.$Z2"PM=Q!:6_\XT@B,XLLPS\
M'T1_JPB()XJ]$+CT;>L\6>;15IE0I!MD;55D(;.M-L@G FB@#P,EMYCOO7!Q
M$B55%H0"LH,?47Y$L<_XU1Z\=DO[\VM=J8RQO4NX+L*>OT0!?/MYG"SN*P2"
M9Y'@ 9&N3 H2,IT'=>E!^#1/9=:K&KYZ#:!7(E]0MU@0XW;:J;*E+W-*[T.$
M]FXT*0&/*HM3?N))F9/+/B9;D=445U%R+0Y^/NA=,IT*!X,F*EJ.%;G^!II7
M FY47M346S@9>W3% I& %^1+\'N1U43F/E8?&_+DN.?\<?(>DA"8= $D5X)E
M;:9?DU@^;L!*(M;K!>ICK564("7KQLWA[$?EDK2EJ]6VXALJD'/=!+2Y,HV.
MW\RUN2Y;I?U8/Q:YZ[B!+.8M!:&$&>MI^EKZNJ'L-642]DJY'!Q9=O)^>OYC
MPM!!A8CS]]C&]72>8%=N7&>7F\ISKAA]5'G2-T=P5WJBD/^C@5;7QL;&NGMZ
M(==.OTS?UKLG2,[)%@8S%8/%_+^WU/U_?EQ2H64YR=?E6H#*' 2&S,CKF,)S
M##R_;\)J^9TQ["MEJRW])RD*_[1L;;[<-ETM4_S8#AO#N>2-]O\QW:VD=V#D
MF9?\BN^\IERT%C.R\E'$KP&D\9< WW\>V!C?'_L[+F4[-Y]/?72&J3,1&)&S
M44S93^Q> :.UN;(B_-05OEL3-"5J@YLP^-;^8^PF;#!F$];G<F83]M.-5\#7
M_).V"?NE#M^$W1O>A,W:,E"LPUB939@%F,G=1MB$Z2,# HC0&] >DNOSF *<
M\YNP#@C($W[/;,*8 TO()<(2&<QQ<X]2C9S$4L'UE!,3J\6<B9[IPX\(=3JK
M."WZ$EIL/OQVR]7B@X__W:1-9K;*&5T?]OSN,AB,O[2VK, P@\O_O!QV=8^?
M4OBQBE?9><T'+*>T-5L\*J9S_XKM?]FB3A7;3XS%TZJH"&0(? =_#%F#7RKC
M[.,/_^%JH=+X6BRMYPR\I#O&P'Z4ZO<\I[)+R.JUE5IZ:0E"70O[U8X"@W$V
M4KBC4/2Y!\U ]E;/3>A]BO$"Y.L(2B>[XSLR )%$KM,;K2P9#XI$[;IA=KP"
M1%^H:<QP"O= 2EVUF NXI_M!@+"<<TE[?!/6(,+\P]G/[S#=GO4.-X20?61-
MZ(I,#Z0_W]5[]L-PN,-UNH6>2F5.R6U'XZE/'W*,7ZW]Z'OO*SC^F@CG9>)I
MQ8@:)',DE!A KJ5V11<\C^X@*H&$#MS>;VC#=)2]M$3/']?I;MF7QBH:8N<+
M3?S56HB]2, 3#FH-W,.BB1@=OGQD2CW(U7EC7P82NLQW@7[O@DUM\L*ENJKM
MHOT#-70O@6DW:+>/%NX77#JC\XE_ O>#4).YU ULZV6_ !=9! =@/<[H2B7*
M=N2=U].?P_ESR",[*BN+;0H9+HY/K/?< "4BZ.?^&YBPXHL1.;*X";ST3;X8
M5PU,?CN!&1UPX ^:[V(1[M>KB%Q\7_/5?$3(!#AU4TWD36;$= 5,?2_">A!E
MP(?L#;B"&D>SKX*-E5AQ,(E!5E@P/P!\N67'2#?I0.PT:O6[<Z=P^OB3_+G@
MXW;[,N\<Z=6:FHVKTI!(68,GD!LREUI9C6S?/'8OZ,"*/S?&5[8L]EC(4]4<
M\LJW3J2,J"Q'=M9^M5.7(OTZZWW>QMA_6^R)DRG__.D(KGSD5F:W!=<9R&NG
M0@:O&([8'40ZDBAZ9_*Y>'M^1:YQ83B9XFW?]ZKA2L5L0-7TV2\U[V8E4JX(
MVL\8<.7G^:*#@#UC] -@[PK6OL/$HX"2'H/=UC0D;&&#JR089Z7Y8R.FHOK4
M@M7VS- [^]L?2Z7 -KZF<%<AZ\KA4_--.E=24=4&O9F043TCJ8)6,RN*U"#2
M_M&AB]F]YT;J!%\6O"]I<C5^)/^]1OCA-M$]@MW1>4N]$&CC>7'DX,ST3G88
M:,MR=$[J<5&ZD9^17@02V_-?)>O7^NW67-8E4=&2'RQ>-"C,42HF(\HE!?Y.
MR;I\1JI"-EV/J%)8FF<=[4*(8B-G\+M10=-2[U>Q7MH)_-W!396O$OEN'ZW[
M^RL+.DK4M^_S2(G_*"NP%BXWRT8TY"TU5^ ^K2,;M>)92>>&2;(3X/7Y+@75
M0]^+\A?DAIB#E"BSUUFO]!!Y>P/B%.6R'KZB.;? NQ# +8C0%73>+7RJLL+<
M%ZZ?^29U[_3A>L"9J)7DI?<C4$-RBIJ*4AN]6*,%_O0+L-/9GU8.$V#[R<TC
MZJC,4,XQ7"]2V "BWQ0KQKOG=,(.UR=Y'.>8/S&O[/ CUFC9@ZM7SW!S,C2O
M[Y7>+J!.@U/6^>("0#,[%OS$T0&UV<=!%F, OI!/8)Z@]Q_OG98:N>-AVTE)
M9R>%"\_W&57^O'"B^UGF;N5AL^C'VZRNG1=9,))UZ<=#-%2NF:W >\@_;,U!
M8EW!@G(/<(AC%*YGU8G;!424$3T"(_32KDZ](J /-YS<<0TAX10O?-#R!;QT
M/S&.3,LF-.QZP[F*F\0W;"?2R9D*YO^!X:5@6<<1K+'OB!*CX_/G1>NCI_4N
M/SNEZOAT#)8D=$ABQ[M>!IRK4,87Q0/47K>!N'I\IFD.CYQ8CUQ:D<64=TYO
M'UD[(6[3+"';'?K&C?+I1HFTH.2L"_+P[O]@'.F4U15%/@5?*Q)K=@EH[E#5
M!ANOYR&5;GI2Z0DCSTN[1W);U28K/UY9V9O.G*'*E/?X90E-=$5_5"/B!E'U
MJ#;'":0M,-W,6N\EC-_"=/88F\L!';:E4Y[];X(5$A+J2RZX=6LD_"@.:PP0
MLY<\]@)N];)%G-V\57:*ZZ%6PU/J\$E(%7--3X0")F[D71U*&./>F4>9K@Z_
M49)(6,H]U*<1ZG=55$/L?C',[J(.FNW/>X^\3IB,IV^O9=FRW<%2^=; DOY0
MK_+)UL=LEPWKOP'V[E-N/TK")L^8TK_YWB[)"-A"R40D+1E9_ZJT'-\.)RGB
MQA -CKV!-S7B3XX2N:@9HN+"[!.K[;5XR>RHG\>.^Z1+^L[/.BG^)S?.W0$-
ME0&ANS$Y@)""4P4M::ATM]+$\ID#9W';W[/\[ZV%R/=U]??(]RQL4/;[7_^<
M8-'^K"9!XMQ^P<4@G0Y\$ (\D+1DR=D-;@S1T4P]UBBU4W7?L)F)5O.KWV$!
MC6/2GA.E'9.XGY-MB[K]1RL";Y;T[T.JF;@1.0A\N\,FS(<PF=>=OPGK)$"H
M(V6P":/K BVBH43,\6YS)=)@>+"[_U[-W@ET48KM_5S+N;U^PM\."S^6A.->
MDBZ"6TG!6UTF;W'WL4R2L0*5W)O#X8ZRH&U7GIM\*]U@)T;=93C\/P.];)/W
MW2WR%0-"P;I^[UP.;6O'=E#UG%F096GS10N*N?N QIYT^ R7KSV$]?,)BR[Z
M3=H%O"I]NY!(F;92Z1H:GW1O80?*Q%6,B>Z6V"%4^+^W'R#!<"/(6BK3&I Y
MRROC"V,O#QFM""R,'IFB@.DJ+Q+4'M3TSR7'&>Y45D]RW58CMR^V&[M8"LTV
M#L*=' HY-:1.'$U1VCBA]N>*D@,A\R96JKR3GKQBO[2:YQ)](3"]+=/PH]I_
M'[%A%@B_04]KSGG<-*H&N>0130]&4%)G/ FT%?#L]#_LL; WE!]&K9]J&S@.
M/;^+TXMC=5&'CM1LUSBX["U\BU"SPI6CLB5Y1+YA'\<,NQ<DE%O-''UE7O;J
MEZHN<+.L:.#M.''Z0YT"&^ 503/Z(>1%P]3;T[ -;X@"  -<A6:(U=[?*DQ7
MQ?NCTC=ADD9/S/> B'.#E5C5)I?V%<GI:?VW0F_>5)!]JW(O2>; ,EPNR,;/
M)?^\E,_;.[CFKA)M5S]F^$F%20S)CH[(ED]/,4V\Z-3F]Y]Z(BSCOJ"%? #Q
M.21GX>#!I*5+'$6L535XC)7$.%<</A-BT\ED\\6 R(3ZG9%.[F8SS".3XU8Z
MEO*6G79UQKM^T&9*0#T.GO\)7^>X-%7.'T4)\0\2I#$ZG2R/AM:PTH#((53@
M=[>RIZ%HX\*J@J[WUIV[S0B'$B^^M3JP5_63->8' 3B/'O^*&-\Z/?L)<HHS
MXWNME5ZPB'G''DP^-:LD.>;-_YM&+Y,&9K?^8Z/_!67V9(('#):<.,<PVFTH
M*=();K"C2 !51N\GH7V,I/[-2-GR=A8EIIJ[EOW#*$L2VWWSE"U2WP1;)[!\
MV>4+M=:$*[?(WL6KX!\M6_H#$!D9E8$S.JW'UG8J6+*2XHT<Q&*"^@7T0GV-
MQ#&X[_><"**Y8E#4>J..9[="QIX'L?^JE0=U* %N%)AWAZ3#4FF^&F N#@PD
M$<,KO=G"&H:+_CZR-246Y9E&'47[VPX?M(9%C\C])-0X,@<X^K@?.-@P3AW7
MCY29&;OQU\%RR<S*)[3LQY4%I1,4B3J%B,C#O2>:@5LJL!O2I;']&"W(RT2V
MZI&UEK!2K[!VWS9A :V7NI1V%5];7S<E)/)5%O/>E+CIKEKX#\L?/\*&?9(H
M< ZW]1,8<56\$AM3:1UEVT6>?,2V!ZTX^MV<0*PEN/C2%6OP84BO7ARA8*L^
M(/Q301F;N4_-.3ORT>V$#"-_C9F;ED1S7CZ25DFMSF.ZLZ[WTB([8]Q[-B*3
MUX+MENL\D#T(B?!6Q?#=7E8:1(FQW.JNR?,W)UL.JPBTMXD,0=$*4;<)X\H-
ML65YV22=/@#!0'7UNU]FU5>FH((*90%D?+T>;OUL_37%Z\T.YJ+6;W,.MIUQ
M2JFINKC#:!%?BV(>!Q38;:#E*VP4+Y^O]9NO![RJ;'%=:,*M=1916'9[4FJL
M#A8J'9#S<'22%9B^<-6?*<*QY")X.7SX(G(KI;K[#ESTEZAX4%.YJ^-M[S]E
M&=.:5RH'9[,*77VL+]MX?X7)T?$P,JT6585@RK (9W@$,SV6<I<I/)5KI4Q.
M^(M7!<6= 4YP2NH'TL=U]J#&%Y'C@N@3CVG?1(;_N@QLPNKGN;(K;%/>@Q:_
M8JX!.#7#O(C:C8EWC.8AV@NE@4I^8_E5UV+9X$<A/A)$V>,YC^VT1KPK9+,K
M,VK9IWEU6Y6$D_@VM[PNQXD_7::5S-S42O.L2LIBX6[R=_V_G)^)!_)%0U:*
M4BPZCC%"VL\\G)&(:A-Y>^&J"Q/.L>*J\!Z3=BTB$#AS\-/6FVZ#,QTNCP_<
M]C[ZPS9$K,*9]4DWXX^#;-#KM.YG,)VYPQ!2S_,2?BHSN=JLIBN3CW.1$YRN
MV:L17OSX;VLOX'4!_Y=^8EN??^M7P-2M=)HDEZ:D4[QG)(2C;YY^PR,'QC^Y
MGP\.CW\Q!L[0LBA;]YQ^AIP#BB2#=5A(JW1\=>1KD5)>DO+-K!+L#):6CO]S
M@K1:65]?TN';C_"4*PE_("3^[/@<3_># A'^%\5\#Q1\_+4W83*>>M /2K#(
MS,$*7.^TP1#I,'<7X)E)_X"LW835A:MH=PV$ANXR$O=1_?@Y=N*A&L&BBTUL
M69QW!'6TN<4<B)6NBVW"ABJ?QR!V^(\'_7#/&[HB)G6S5?/.6P_/DG"7MR.C
M"[_+EY_^,?/O!-^:(9X,1R5$[?]6\<^]U#_H]B E.R+ZN"&SUI:Q)GL!-34/
MB+(SN=(*7>0Z:A*9[H7O/,8U!.8?M*PL$9@$\+11;AW'W'QR-BK:DMI\9'XH
M:&.,@@1JR+17Y+\AB%UXH/;1)BR9^ R*.5"(_>.,7!;<A'U0XLD39PSD_E28
MRV2R'I?&%5\@^J\X7)Z++'58[+NHXY"3/;2";&A1^W1X]P#\D%-Q1J4#,G"Y
M?6C6N?)"8/\Y1W>/J5;WWT5_B%Q=(GB R%.V[21P=7]NPA@!D-+=VKPVVH05
M!X!AT%_/"%R'&#EK7"2_V@OYRR.)\W83MCKTE["&5MB$6>G:4NTW88]SZJ+"
MC]6ENM8W!]!:HWV#WWO%?-I3:K-VZ<?VC]O)A\BT5H18_4 Z%8#4]/A1NDLB
MR0"3U^9"&4C'^NPDIW(1H7O<<I_8%/CR?>%JIN62I><N SWD"^5?27JX3UO7
M)_<B4\F[^,>YEP XNRR%+QNDT$B"C>#K;]+X?87+&HET[FN_T_-4I8,,OUOO
M/\?:&?TY@OU^<]3\I4[N <_Y.63R)NQZ:S1?%"(MPL$@@N/ 'R>K<#U8G#:"
M9"%: (-D.':?.&=7CTA4W==DLRKD;>SNJ/;O;)9AX9DFX:S4_9?F?O.'1U$-
M\I#=B6CW^@'J#'C'RBXP"WKN Y%.^\S4:976X1OS#?S!APL'RO0JOP@;1(KH
M6^J'C/08SY'M-F%!J E;-HY7CY,(0M;.,X\!"PA9C.WE]XV%*_;9&XR1KJJS
MM=8:89-V>[XU-0DVF5RTN9Q=T?8'69_$E1ECG^(UML"+0!GV$_ L22VS8S6Y
MY7"%BN?RI/-W+;'B_L;AO3GZQ3[5XHBCZPFR)(;P/H(I5X(7CZ2]( !_'$5Q
M5$0]N9<<MVYR%]G9[]CATN32:2"Z8.KWM=[K: 5+=VYY 6WD]5YT[^]&[6&7
M[-^;,"$DK6RK(2QBHK;;<Q\OJR4,P,_8+OVF)8QBO>#W6X+E1C,9(4B[;+MZ
MY2>5]<IAFO63^Z.NVIDNX^D75GM1WKC/9, >/M['/@8^#V<UT^%Q7*OP&?M6
M+0=]E!Q([KW;\.%N@SZKV;T8]>-S];Z 8FWO-\>WV[41#Z7R=VY5-[FTE;]L
M!_R[=>CW;NLKM_DSB _<+2(E$'-5P3,R6C3E/G7_D/>,6/.S/#+_&/<:KQQY
MDPAJ)S'E  4G(/*^(>&!JO!H^$J2 RO)YCUIL*+%,JK,W6&/@I2[PZ[%=HD'
MN4RR:H1$E%8KIXM09<"5DYF)9"8!"'8>#[+P &KLA;)VZNZ!UU?(L68R;W]O
M/%^K'*F%'I'\CJAU:4]U^-E=YU5CQ\8(=4B(2QS$C9 %U7CY)'/NSF\MEK34
MR_?N3 E7]C<%OA*:$*>8"6O488;V$\75#V:_B#UM[L)!XMN5\=<V81-D!CN9
M-=]>*,JZ3F10)41%$M;0BER[T37B4JB&@3BO4*?O@UK:DY]WIJJJ)"S4M6+-
M@MM1=09<6?36N>%9;CB@O93#L<6> !5IZ#BR5"EP.<^MK-.'$1/I,5Q)3W^G
M/YOAWA<0PDR^5BVI^$3']WD+EK55VS5FI$P=E^&+'2L:8(79L[[(HV3,[LYT
MF^Y*5BTH6Q@S*!((C0H)ELVV%0HSB^XHKJ'%B8H8K;OT$D%U$:[,$#L3I%;@
MOI$E^5(+;)(6RU#*:D:4JS>3[FX3WQ7:4W0!3:O^D'*<D#>KF:?[GS?F'8>V
MPI4ALX_P"*0]6 O0"G"G^64F<@^S3KHGFX44_<Y/I[A//V7*?[5./]N[]"!D
MQ$<4/7OP7HY8U OX5LJ"+F:G.:0Z=D'&@1>N.QZ\TQE"?*6@W&"),R]#G!<4
MW@<2:H\Z:MDA/[IH;L*V]T!1I X!G(;#B/$M$- F5E=N11EI"$H@;J&!I+@@
M C@1*X2!56Y:%,$D9S:B.Z8:L*4U=B(G^N@*2>9"6$5@C&V28*998O4*@S_#
M\1U#^-8EG^Q%%!QOR;X&,SE^5/7GV%>"$I[V  6<<\Q R==3TZ$0UJ$2?'*,
MZVI2,".*%9_I1UG$H[ _6W\HQ0Q?.+-D+_\H(%*W^\FC?!AK!=0=B^.JL$38
ML[Q[+8<9SW<-7/Q> C*C;]V83_945-IIYBAU$'--(UU9Q=QM!)J"%E?*.$3E
M+)#7"+M=)TONEB!4PG>:Z_R\>J:AT?1R',8J?)RN<.M71,I&Q@JD&!X;A/ E
M*0Y _F&%MNMI7.T4/6^VT3=LLV7 $_%#"C"+HL/()_\-3,\UD@[Q^ZC;^.88
M:AM>BJ\+*G/<74$_AM88%A[%*PL78=]\X7U8L<'JH 957:KF_.^O$?/YL)7%
M/P0:@2F\E7GXOYR @1GX5H\ (J663FY#)F[")'"ZP9XB0R$&YE"DZ'"H6+@4
M6!''8/\K(S4FCO@:M%YP.4B._F^:6BRW&MF=":J9<&7P,\@>@B0WDI79[G!.
MQ;W'Q!X2$<B3K(;*5[]Q&L_\U_-&C1L/M]^^DHVZ[7WRRGOO_H?P =2X>-?.
M=_CV#ZC&&\8D9#7+YKG7#"+E80!E^5%I:7H.LSPPZZQV0[WMG89$YYS9*TY/
MS]O7R:01WG)=@4;Z<CQD+75!JJ+?L?N\=N7!EURU2G+M;A293VS"=HQ-.GS:
M/7<I_&G?VA'IJ2CBZY:=_^O:DHI3Y ]0)3=A?G@8%M[P'8?@.@W7!V_"5##7
M^UQ:3Z/GAQE7T&=#YE?J;-/E3D4PI6UDHX)R)B#H-VC?Z;ZUS???L)G,'-:$
MT%;6_AT,XYSY>7-P)V$\G4@1*L1LPFS_F0T<_<+7XY""8-QF,.^-6] ,?\>_
M"NS-)E>N8'CI1/^[@;?&(24L'<R9[CKCAXV?_4QL?%2CIII5%H?QM"9;NC;7
M!+4D9,!OWX2)SG,-2_/8+E,<%[:--\>%XXDBL,U;;OZ>)GT%BSG;^!\A*_;E
M'64CP"+ K=<5]'D9T*#DF4J?[.M+##&?[I%+_-89/A?S\IAWNIQSJ'9!VNS7
MN8$G_^O0I8%O-R'MQA1WDB5U<:)!^0,I9@<8J0C) %5=EFW&6KK]I?K6&FGQ
M\_K:S?Z';.<^6E=_$7K>KWQ("!;CA2I$ *?P2V@P&#'Y'C,/4<"$@DW83OLW
M^*"8,L0-2+;Z++'P7OY(DZS9F.(^_AY_N0T$RA@WC 3L#,9=V*U@IP)3@(6F
M)[X)F7%<&AD*ATMCK'I,"^/#WUYY=S@D8B.F2VL6)F##K7(2VPT3AF'E.$H-
MA22((<8UD)?.J9O&MC:;2ZFJ])JNLU7?S$6IHI0ACHC]$<+7S\'S116  ;Y8
M# L!T0:@L9-<,]]#G#B"2J"4W;-^],MMH-/A^O(,-N43/N2UH5M*K]ZGIV6N
M'ZUWS69\VR&W8<31X;=MPFH02W8QC!@KMA-XP(O6PTH>&GC@-61PTTW\D0^:
M'1Q2U:?3NVN\!I[[IB5[X$-R$&L% 7FX*)*6CSO!8G]@[:+2X0_,#$(9J3W-
M+)L"FL&#IM'XLJ"AZG\_\[]W+.^/-#F><C#WD[;&7*SY37 -,LXV< I0YN_<
M #9A;:WJ#!QA!IZ*JE4M@82_N0JFW";1(6[=;D2?.-.8?#5/4[<D?_ 2,NIR
M1+<C0& G 6BN?#Q?K!HPZ47!]WAP#T-H#7?CVHU5WB_T#04[N^07\F/NTT+G
MW=R3M2^UNTI;IO!40!U AVZPQ 22K$%QP*==O@EQW^R$%UM/W>K>].D7L;G>
M3W.>$C2?9'=E7\D^%WSO?QGIJ.I,*!QT\O<"C4MHX.18N[/YP1&%"V,OXYU;
M6TPNO96U(BT'NDI=?EA==-GCR\FXWKV(9U3!.V1PORI$!X6[>;5,O#\\!;_=
M[/B,5S@]^R'V*E!8_)IZ%1,0N,BV&7(;78;E%J7\:[>"&[W4M_(F/>>EXKT<
M)^&T3.93%H'=RWO#-^3JC1@9I*C"AI:,,N'80P!SN4"HT5G5VWU!QC;<[,MJ
ME)Z&^_KMP[_"F/AZ*'JILPUX[[D.+[F6( =X%8AUI7\\:ZJ0;F9"G/Y%Z7^L
MD>WEWJ?HG?.R[YA4\Y%M2Q;"R>6H&D>N3";;CI>LW-5(A;4(OYE<*#R2LH/K
M0@3CN_,SJE\')<.?SNHV*@Q]IE_Z^D@LP6+ZW)$P"T3&6S4D$+BR5 ^Y+VX3
M!KI 9*SI;R;HKC@ *8(=\US-_#S"_ S?-8IZ_2MFJI%"HF_"XB&=0/=$@!I:
M)4WP"21=S_PH0.0>0"^U$@+Y/_C##:NX]D:^6TPF$P.AF^ZZ-ZD##.1(0!1;
M%.G[$>^%%N;*#R5U!!CV59[ *I1?=7SCWEK_9=71\.9ZMKWNO=)\V[YC!T]3
M;$9ZL[!;U]BK;&T^(OU16YN/[32#.-/GRY6T"7%0%2X'4IU';[083GP,5G9?
M?.IU[W'"0;K]/J>#E].^B0Q0Z[W ZTC:+&'"A:]@RXYDYW'W3T7SI8@-(:N;
ML(:6OO1FDU!R'\?F*Z>!^:_:PX19RTO#T^CX\1:LP6%\QU4SJ1DJZ(KPZ2W8
M FGV75X\$S/_B1-)F/7/-#FQT,MLA#R!7\>KQM-J\+N,!M()M3QJ"DZJDX-<
M5/*LKS3MDVO->!M^NJS^\H>$;/?@K"J[/5DU35DY7B@;7._6D3!A?(:MQ/(D
MLQ1H!IT%=,: K$7NQGH:]@+#G1GLW-QX4LR]H/QW:=8^X?/_ ISLK'5%G?8*
MSI%!-6*\F4$()P@WC9>D#^KUU$=QSEP-'%/*>VPV5I\XHIFA-Q615.C<>[9^
MZ^!6&!*#B/M\/?X/3RV FG"C@EC&JS&[\,HN%'WS-=6G<?5ZXH]KH4IVD;<^
M%\?ZW=@5S"3&46M6VH@3\]VJIBQ"^XH@WF<!+\UUTH9(5!@4K$-YI6^:=$-"
M&Z(\O#Z_3,\2.F>^' #*<?2Y8KQ\-!?]%BL#F&SEJTJUH*,8FS!%,OOYR  [
ML?Z.U$W]:K-W^WZH.TYUUQQNG+5\]!#>TWJ.RM#:JA>7VSI)Q%RBY;1VP5_B
M1J9-JVJJARZ_KAM4N/S=@7NZ?-U;WB'BRB[CO %%8O'?@0D3OMAS#@K?;EI!
M]B>(X+ZA:E3&VHE[N ;Q=H.7K$&?2F:277[_15&]28Y=EF9RA*GY4,V5D>H<
M(IDDBON$JNU=6GP)3G82=N"4+5^-8VU8K]XP!I0F?E"O>O:^#=IX8!E]:S%<
MXY[\^12) PU[M\MM/X<+;84\  LIY=Q(A;RJ0 @EL/:E&/S%YFC(2@1_H636
M.#NW!>Y9QH-Y[7<?OI09-70Z-QG:#<.N<[QP ^ET@PQHX>V1$Y,SUUO+,'.+
M'6Z\_HRRBG_7[6/<5AP 7JTM1O!G56#ES&/Y3]I"8Q7X=N<*YAW(-P^,+8DP
M.#IW4B]M%=PM2?]3D$YU_>NME13ID2;K>X=!JF(AE_PXAIC>+JJX&8K(-4A>
MX8N9I0,=IXUT7LM8&00UI,G_5WKY*3;ALOB1CS!%F&JP+6-LJ14PF"%TH6%<
M5[",AF8Z2F(-1LM&6L1?XP.G+'E/HPRU1#57Z3G2-WK.,',\;,\+0$$ R<N:
M@N(;C8ZBK%(B134'.J@P![3R'D5U]\"<I[:W=L<Z>@>O;/Q;9%=N%:GQVY$-
M UWVB%1J762;5SFF_-S0]N<A# ?UKHU7J=@0P=H'&@2'#XU1/A)?3GZX)K['
MQV@E7S^K#,3;UGV[\R3_N+MR ).9-1LHUI,B9^FO^82VRTYC32,?QKW+>U"7
M">Y?AAQ1^#BOD<8KP.EAX5!02AN;45.Y/< @QZ^=L'(ML)"G!7RW8#<^%/#5
MJY*+>&:B07_L,D8%SL''(]G%O"?((%0FOFZ,:<<BT%^5O\9Z9UJ21PP1B125
MZ:=>/I$^PMW-GG4FE\XXS:?%K33/8YYFJF?:\2K(M%Q$M3:SE"5X#NQDE=']
M?IH;?[_![_6:P>\ <S=A)T=&)S7^P<.]#!T-L<\T$N*6CX<^NL#5@N;D(K^3
M+&PNCEFG&<22=B\>^H67K72F,C1'!C*-GM:?N'LH4W6B7J39Y(RQG5I(QF5E
MW_">W7$"X$RQ R _PQ=3]&=15CK-#\;S17MC.+9G-@YE+R- :P1#;%+7RCGX
M=G/>J6"Z6M' 1$NWQL."(L0=?/O=2;HR;FP35N7#O14L2(_GG*QN,2VDUD:1
MSB+]_T1B22B*V;/E?Z'/6/F<U$N\-*1?JP_[ GH\[ *H5_P)*&HQ;!+A[O/R
M"$F(>RUVKU-4KEV@JYT[N%=:A/K'Y2,*N(@&M0L)+"2#N.0!&+038/4(!:XF
M@$@/UX'O_KU1,F9:IX1+I!QWMVE\-/5)XUW2@\Z/2Q."S^Y92.';,?AJQ^Y-
MV/@3C,$GB*!MW2P42E\!;<P',AOPWDMY')^R?C;*8&D:]U]O7J%.)U\AD-"X
M=0>%\ *O6@_O;Y""W-YR? :Y! 6RYZ8&J239X7#E9H)$^C%L;6F!_7MC=]VN
MF!>PMB^#-SO%.&7LZ] 2G.2W$VK\>^[PBG"R6)T1?:Q?<)GY\Y>+T_JLW#?O
M!HI=W^^K7,HH"C69.%]^Q.]0MV)>Q.C>%?[8%G!#0^UCSX_5.2KCON'%?#^P
M;!.+#X/1/9ZJ8VC#&'_'M.RS=M$^NA>?K'[%-ERW\'APWLY0@$&H]E_2YOAA
M57G-N -\"KG>OX><<+>PF(6@=^=FEH.1='R20=W'=S=O^&W";(:U[=_,'3E=
M55>%GOKV&G9M_B&$/-=(N['(>/Z.2T!#/U;]VB"F!9,QT[V#_=GFC?JB";O"
M?S=O+H2>HH^/,_*,(Q%XV4C:,T2-[9(UGJ&"IR'N&9TV(LJW2YAKL10>M+B_
M"39-+-UC_<5.8WU,NLKIB+F<<5KU?P-&D_POR%J%MI7Q,=KU!(X1OY^T ^+)
M8>V>BO8)@X8HID[!0*WHLN:'O/6QBW9'E_,#E><C>I8D8# 8=ZO5H!>_.S^3
M*ZO.W]G(>T[:_9N@7 +8IIGIS!2LR'!/L,PVL)$L]Z -Q^3ZB#J[2E\_A<,[
M<MHSS81W)NZXS(,#Y>Q%Z"%I_'YDHT@'8=R?+^8$K- ='WB!_:K5\,Y-6#)^
M!]K@FMJ\0QWG[*?7@6-%3\5M;%?VH?7L,XHC!FY *I:6C0 <F3YL"V!L:9]!
MVX<BT(O6?]O!O^.N2EEJ?< [P^?6<TU/IJSN-J*"I:/R&L\>/0 [XZ)L<9XZ
M 5'RHQQ)W">$/)(>PST*1E4L%!YS.+&DRT7-9"HNW.7QTLM_FAE_#U*0YCV]
M(B_A(_9%\7&VJ*S /VC40GF#2%K9QGS7"J4*UT]5-!?XY7G D1+<Y<_0*F"9
MM+M!>/C ;&@O1R-=KWY)?6F[I'65:%5(0> Q(_8\5[J6K<PK(OL0%+BA+#13
MF.73YC:[">LF(*P8'^H<DTR-OA)>_799=8^*O*VK(/WQXYCROJR,F>R2=5@X
MH6Z%*XUDR_(JS?7@F9LP:9+"PEU4IEM_B'Y+( VM$.2)&":&C)RL<)'^_:>;
M_5#.R?+QT8,O7^^ST2'QLC9AWJB)<K8BH%\,_&'[@WC])*^*A<HWBV&>BY'Y
MZ:/%=P=+0D)/=/_\WJ?^.%TAMTT,!CLOD@\Q,W=R"%F5WT&MX3^=(=XOE/X6
MCMX-]C'DDVD#.PCR=FJ!\DJ)1;<N'N\;4H3_/"7U+,%/(T$YR8W+@Y;X$T:9
M#8":6_4IC?\[$D_#*/>L-Z+JYN]?!XCWN,<!SYW2<Q2V3O;W*7<4/L#A6(J&
M)N)P[#36*R7W/-YU$Q:(FBB@.3+O ?ZN/ (RT"!)WOP@D-BJI%5:@CKZPCM#
M1<-.W2_[@-3PD8]I[TI\I5 G0%O^#EMHH7J!WO'E->2]?'*RD9[)Y:&5OZUA
MW51)H\HS_/:EZS*4;N&N,3_Z/4VQ.2&U8V+$)\3Z6P+)''=^.[E!F?_C(K[=
MBDQ[AJ]#QMY!(:YBML%%,)WM"-F_HBMW/)R_*N<VW^-R3!2,+VZ_M</""E:6
M$1E. ,[")_\PQICQT2P4K9%Y / Y#?AW(^)PAU([IXWC.RA]J%\;\7TBSW?V
ME[PK&G&UNJ[=IZ40VB?G0:1$\T4-.++\4;("8683UK4BBBES9-51?$W#J<E8
M99;,E6_+^I5J4[.=^ZN;,H[)11J+'[AY=^PE[A.YFK TQ-G%-<R#Q%,[T#39
M:7IBM%BK^(U<4_["XH76AP*:(R/]G9^,OE3(;EL]O@>V'7+B*#17KI%- >,Y
M._G]=Q52S>$81XL1,_^9@60WQ#WN/NU4WZP[Z<?/#U_WRV"O?]['?7#_1I?.
M@:G&K*L5R!HJ5_XK)C>:#.H@.X]'>5C9H]&<HQI97;UORXVK%!^K"NR5WGY:
M[B^>>91S"+N=5TV2"-J$U<XS=8#IOFZ<U)C4]J*2Z=I7KKM-(;I\Y)/$@[8C
MGY1U#NR10AFY0P8GC/2R/XYAZG(OL1KVO[3(LH;4.2/\\OE#L@(QL; 960%V
MSO_O),+_)1*V;?7NI02SU\ PSEW<1VH-?LF2A3X#D+GZY01E5TSE&F$G9>&0
MKK-;3%HU-23';.#(UV/O;OJD'%.W*TF7]AC,WB^XLJ'SI^P\F,4)Q[<?P=\D
MQ^$E-F$!B$GMB^!OX-$,FQQ&MWW/0B7<82*=@,8'+?%&)56?O&3MC5K;MQ^5
M(2YWY%XJ) 6S!OABZ!B.'7]J$R:_"?./'H#F,([L2TU"; _'8(_+.!BGF-G.
MG/"U;5J]MO%NMJ&V\='Z0;63OM?LT/3S\%$QG3\HOBB$&,*'P2*68R>^'KXT
M1<2-D*3 @7=<<>!SL*<P2*?U1>\3>?!WL=^<@=G99=S-3)BJ ':74K8=TUE]
M=O3(5HG[_/_3R@-?Z]B! /<CF![0(\4(IP>7=:VYF[!=9L=H>OK*(3=[%#72
MEXUT2I-1_>_'_<1OJF7(KK9=G/P$XVF_)!\A>T^A^6(7H*\F@:A(3M0O/'!^
M9S D=#*E@YL>(W=@!6AHP=\FM?H%@9%Z+ZE!D:;WC[3\L=>0OBXWN5L\9Z^Y
MR-9W+7@D\^.X=O(N:#XV81/;%]EU@&T2?S_6D_QA"&O%L<3,6]=5?:\[KF(\
M?2Q\Y[7Q3WL;W)]*?*LP7N9?R#[YC%LGL*%LC3N-@?/%[%_S/R,AK=ON*(AQ
MX8L;T58H ^T02XD)IF7*@&YVAC+O,&$72!(-;I7EO_==H3SML-:]7:XF*GE@
M:J_.;Z6R;B1XP(6)@D9UEU>,],+?1S4<Y!J"[L!Z)TEJN'C4<$7X-Z21GVHN
M/].(MM<N5"'_/F)88V?46^@M_SGK8%3"8\&_A>\W8?>0"-Q._A!^YPW^8:P@
MF% &EG4JW5^7= UV<\]-#-S[E/;4<N^>DNHF5=,WQ%3R-6H*I%?YS:P^]@MH
M83RP&%ZEOM&* E:O]ML*216+;@0R"/(END8%QZZG_7#=W5]2Z];B91GP\5&8
MO!!,IQ=/FT#&XNLER%7X3L>T0_QI5;7,MD.8@B[&/%T2T$^\\>[,PL9]78=_
M#9S;RP6\O<S'7B3+^_\"!-<R4K@O> V;L* 0$]I\#UHIT-,$XB %=>0DW.&Z
M,0-?8+Z3IT,?38IZ!=X\JM/:0'A]*G==0:8EL%HCRM=..7?\@[B'7R97GLH8
MA0*?D-A6ZS=9?RO@7'(TR[]K[ )H:_O]I8N2+U\CQO5OZ0>Q<W2!5<J2;>&3
MS%N<-L&_7U.X^5N[OEOY_A!CHSU! .<&%'#CGELZL>0JUYJEFN=_C71X:&T3
MEGA7PY@2_&/:4K3U^S9W;N'5FHKKR@DYJHH:-S0>W+_;R)5SYXMYS1!B^6:@
M(F</]@2O#"L'H*Z"'TJG@E4-P)&9CTS5L8XFZY(=7T8!CR.3?5%A1W>_E/:3
M+?;#7?LHL(&PQEW$#>"!"SQ'&IS) S+9H=^@,55.2_(J2*K<ZZVM@P8^=G=L
MQEJ4RWMO7J__ "\5EG&[>N2)JZ;E;(-8]4^3A8E]EM?WPHYIQ8JU@V4LJS:D
M$%\I>!.V&W<0DT^U!L82_D8_=_$<>=>XFZFW-[TTUUE,7.5U"=U2^X700YT_
M8>R3+&VN+)4O+@/4=J$:\1U4<']$$:#=MM&;7.]N$&<N!O3&WJD\(U]5_2%[
MQ&#-%>T===/3M>@64*ZV_^3E]$G;?-PPJA[)--JJPX<6,HIOC)ED*'2- "*9
M),D%<W4@LJ=5O=-4L[0_,WG%L*/:X69EN')KQ<6*;V?=MF40/UR^SXA%GD)Z
M$\#]MK'(FQ]7UO")" &< 2;2HG&HDO@7+X>U!*-#BP-)>QL(YE>;L+5[?APX
MCSAN^WGA1Z+<;X*"N3E7&81K)S# =I:X(\#!C'6/XA2 U^3;R+JU5,A&_&LR
M87-V9HUM_R$.S+7X\T7]@.@9:@=Y MW12%;"!Z<',\+?U=.>;\/ONA(T+?W]
M3CVPM*W;KB&Y#E0+3M@WXS&4Y_4S;4^M_RP9_&^ W@B)"@5,)_OXL)D(QV:A
M4+JNA?>N!5%R)9#MJ3*T/-KI\F3:B-1 #!.ORYY\VU39_ BM_<2^6/*0P$:X
M-5:$<YL;S6M T@H(-0:)).4 5-T7@B+)&!L,#I9B%.AYD'BE[SQZ-MZJX**U
MQ>IDX$,KB4$+O?F'1]_X:':L4)5NO!-GOV!%<F4AQKXFTKE":6;T<F7%+X)K
MP-@%UM<<^D":YVX6^MZ=UB/VN]&SJS;EK^Q]E S-+Y? :X^%7Z/)<,\(;$A3
M(;0@]M;S\MP9\H7F>\GW'5,4.@H&*!D9^J2/Z-"T*!Q^^<^S9:9' NXL]@:/
M@ _*5,6W?\E/3 )ZV1LLQ+UP/2NV90SJS.C?39A @,OW0+?3K),==RYG+(^>
MGGWP=>< 16-GZ(<&]/BVL>\(X(*!#*: ANC )QW"!D".-MP.(!QJOOM6LVR3
ME['J19NP&^#B^=,T1, ]__3B>HJSJT;&Z(^TK\4_G6"Q,43/"YS#_'%(AR&#
M3X0Q_)/X\I/!4@- ,<-Z/<[L?+B[80+J4MWIPDL"+N@C>\Z\#ZLKQ%U [<2W
M[X6<J:R)W(.<G.S!5_DB&W.?<LYB3AHD_I_RSNNKJ>W;X_$$01 (($6)$!00
M(6*.%%%*8D-$Q A(D191::+&A@8-V5R.A6H4Y' 435 $1(2H1) :( GQ8(F(
MC7 @34&0R(XE;DWAMSE_P._A/MTQ[L/:CZO,-==WS3G&W)^5+R?J4[<3Y_.K
M]_L>$V3;77]#/W61;WG2U!]*#2Z;(^)9!!LQ_@>6ES4SB)(J-1D8FJ#4SR""
MIVXCI_NQ'XB0^UN%L[)6M>%?'GR\MHJ3"BR:0?0&R G&Z5&>::>$JLR'XB%&
MZ/:7!OC0IT<W_;P0'>_[._K!6@1]S8"&J#Y $S";R@L R6UF2Y"B[+3L4RA:
M&C#:>9MJ @O:F;M>V@7;V](<&?-#3E=''%MQ6[)^O)^WMJQB3\Z=2DQ6&*G
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M&\MX</4HE!O@]<^*/UV/.:SJ_KS2PPZL2IK.H7%NYA (G(/$'%CW@C26M:H
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M:G!G[+MG5%-1V"X80+H8Z9VH@*B42%=!8@-$Q*@H58B =$-41(($@B!5BH*
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M[EJ"X6G=[OO^KG8NZ?"M7(CHH2C#7 T&UNI",Z5@UL"OA=EW->S*P07EU:B
M1>+F5C$Z62ED5I*#R+:(0WEQ-$^TZPPM->QYW/QYHY3>/>_N]SJ1&IN77FF_
MN')IA]B;!JBMC5%X1^*[?(T%6:BY1U#4:"_T[B1$_&FO8U1BY+Q^R 5%]^B_
MJJ50S/00005J7[/NO76NQN#U$$;L)2;4C,3OLP>3L>UPR"!L3Q?E5LL F:DI
M?/7RG&7Y8(;<X^I1)X."E>G^W>=V-H5XWLMBRBH8_L[8(6JH&8,U>M10]',!
M__A,S-?>GU)J1I>__"5GQ=L2.ZR(8;*(Z<AN&@7-A/,"0S%REDMI[5HC]<1T
M7VU.=((J9J0AX'R6=@G3XW7BT>T9VTU9&\_>T)O70]3]> C/(<Z1J.QC5,7X
M'DP#IH<\-=]';:BNX3AV4]7J2W10BN<62S4SWOG%!>DO&SBD!&6=QYF>-KR0
MKB+U.,NZ/ZOO$X2Q[J\7";X-F7NF5G ?10^!DM"/BY)?U"!S:5P#;KP01L&X
M1'];LR-,3'YGSE"_3S\PN;0?K*/2D6P2=Y6_C<:^&TJ;P@]RHZ<#ECF9"P,?
M?S]8@62STX#\K!*O%(IA'\]1(W:8@18$EV9.4#)C:?.O?UWX0O2P1'%4Q9>9
M7R[/O =DU"M$G4-;:]5JX-_X[Y0SQO/BATEL>PRPPX#U@6<R"[XE-5KSE:OW
MXSK';GMG*2P<! [+E8R51VUX=KYY3 T3M.QO*+\1*U/?HW\M<K.;P/C%]>BT
M5E3E[$QH\XF6X*C+ =L')HQ_WYF=>;WF<R8W-:FC[QC,UJ9,"#N/C^\[Q',L
MYAKN>;A\#4NK$?W=>\(\<WY[JVH?ZE4P?SN)[8J"N)D]E1XF* 8W4U.\<FZB
MZ)O 3AIWL.&<>OMG+M4V)C:2,O#'>W]T=OZ*I9((&\U7M@:ESL[E #OA+&/V
M"/<9>[4O'=3"%W:8>_4P#F/I9)84W]4O/%:9557_QN?@M_K392T7[((5_E"W
MC;<2? 40QJ&'0T0C'AX_0V77VW5 B4KJLMLZC*(K@]W+Q 9BP[9LE#7+[LJ:
MCGMA2?N9XN7,:L/IOV0E(+@K9T/\5HYV<I*/W4!@6^O1S*H?+6E?XI(Q#^$P
M08$0YD<"@LA35&ZBH ):!7(YEMC)Y6S*>D'T$\+\XXIY<*:*Q,C <BM4<^^7
M\!KM*4\UJTX!NE#!_,->[:1-17(+ !YC2>L@H\2 >[OXB$;%39-ZQ'9CL]DN
MYSB[HSJX_>!875EFW^IE[(9JS27W3]8ZV]B"ZAIX:D3#])Z_LO<&IB?ZKR:&
MG@DV>G;BNY;. 688?<O&O(1]>0<0(OP=4$V .FV'@Q 60)4F)2"@ %42PHX-
MM2MZH9'\;78ZP!UV+G)S6+QR8ZX#L79ZMNHK(BQ=5COQJHV#ZFU#YM(-'7$@
ME3U"5TF=(]Y"J>'LMN#ST/6&5?AWT#2)O3YNUZY=NSL]?4-)[/M4387,"\G]
MX0^';-%TLJ(1F4[=//%+5HSY8&*F[+$5N(@UD$SJ6*D<%5D>9*7R)(A='N 0
MJDX(ZQL$O*@3"/9C_N4H!I))8B(;B-BUL4Z$[H?E>9Z5:4O\9.1(R*)O7S [
MFJY"XAQ:FH]+[1S<='#>6; [E#*+3#U,\3G->&^VNS'WAT$11TQ#7MW_M?V>
M.7='>QCA.<^$V&'(%V-;TZU9VNS#C(ILU[YV#<&3>&.@LG??[])_6T? CM"J
M'J73/Q_=_'/_>+AZSYL__4921W89=@9"!C0%9RG4NEIBAYTE$C#4_TJJ>S=I
MDCEUA6#:B%%QHG?\R5+Z10WYPZ?ND"(LZ5[.O+CSU5WRL,8.L>^('!+[.%6,
M?PI5YY#.'NB]#!AVD>K<LRUF(@]^\A]R8= F)ST;RJQ$#]L&P6^3E]+N\EN?
M&UA^BI\FOJ+QK5#9[9+X<5 EE:]+8C^UV^V!7V32)D@7P0F>A:LC=__L56+P
MS/>%#]WWIK-2;6/_*HG\0; @(+7A,\0.Q+@#M[AL0185&QJ_"?]G^8TI@.K9
M^8Q@T\ Q*7D9.N1C.:HW_<%6;F._;L![][UG3]U8QOU:H4[H=D.:'FQ5AJJT
M&(?4%_+7)Z +(4JB<ZN>'*:?NEA4];[P>;3)LUK9 A5ZB8>LG^:-%@%.S6[Y
M)?\0&YYJZ_D8D.VVVS/$M*0IQ%6 \C,JJZX9AFVN3$ZZB=T'V=TQ_+*MM/,V
M2HD3RC4'=,08Y D<J( #=F)N0A44:B7L>ML<P!Y4P@!($"*O3!=:*,_EUTP<
MF15_:9(2,6CX[N*"3=\Q#BZ-^HK(5^;U^:IR5#M"B7-5H%IQA]WVQ-^]\Z='
M[42]&MN"*\Y).C1FARSE2FL=Z36UZ:$":49[>0&G.>B4J]A#TTYCMHY^H5'X
M::QQ-4YAKX%=VLN# 2N5*R(+U-IHYF<VC[M74&RKS#/A[XKMMT7-$>$=Y:%U
MO\Q2FTH",$6AG@<D'*]\G#YPKN:-&(SP%[*7&A0L 82K@E?$T*4D8L,X<Y*'
M=60']Y(DF%&+6,3)0GHY-5UE+NRV(\[4](O/80V&\IW=_=L)7[+*#Y*K^]):
M[:+(@$-O2[#@\;9EE]2IO,%) >O^3 [!O\K9R(UCL?SN65IYR<PKI4UEI9T)
M=L<$Q1"O0P&[%KH@%(K(@G '"3#:3^JF24STFX[QY529BT]^9+TP/+C-X3%W
M]N?7I M56J_/VK2V5:1L;\F9E.6J0YCC#+#&69I/Y1LC6$N #VA+X1AP,5R#
M26(-H=*>PD/=7^CG/F#-4"_B/UJ5-OSV@DCX?D:L Y4]UA;X[$VM4NC+B-P+
M&_<]WW'T[<KSO]K.)X:-RD?_A@-8[".?D7/GCLGK8MR"MHC\?0@O;I>!2I%5
MJS9[D1'-LF8LI<5;W.KY)\E"OK2_7(WWBE.:>DH*LACQLRP^9A!Y12_K7J&L
MO&9-TE@[8;V]9M(:N5F\O;\0;#34:Q*?S2(F62O%)0CG87B7=R0CK=[=S6,E
MQA)=GQP>Z/9G<DSY#EU"W]10CO2X*/Z17Z6GX_/0Z$]?IM\7/VJBW-UWM/U1
MZH:X76$P@+$ 2LVSJ3U$MC,Y%0I E\%TA/+?\$IR2D%S5-]-N^W ]?>AS=GY
M51XM;=656/G<4TH9/G<?77MGD_#F]@#\!N0##&#D'^ZU/9V#!F4FZ;=H&W]J
M)+<VEPRFMHMZ>2[N$]1?,;10=-'_>GOJ_MEC];=[FB)L+EURG*P_*?F6U$#C
M*\8R5G.(X?L-N(  DB!,RDZ1<#:ID\;.Q#_[!2KZA#MPW++UEQ^G_![_F)P;
M4F:3>S5N0F3?QDS<! ^41G%07")DD.1P&OLT,AO1&+?43=7 =]&=\<[=7'/
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M! WVM_$DU;FO__1'BQIK7GC?WSHBGJMWX5S/I:<3Z;?O:MY;"'&+6)VKZ!U
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M@L#!?:N3MM//?P?EW G=6!I>0K)-V%5MK7H OA=HX^F#'S%L- XPEF22Y^"
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MXW2UP)GW:,LNO9!^+??8%P")VP,MYPXQ33L1@B:'Q*J<1V8CI(DA^P-.L6=
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M7QDB="(;35S;=ITBR+D^"-XM6CW&I@(&5/Z=_=Y@7UNP$';,);;\?UKW(]R
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M,'6RT>.$_6A0TYT+ >?'T'_NAB-!<T>^%9EE+H39(X6P'6,8?E!K;0;L+PK
M8J:"P0P,>.HE%?B 8$]1ZP<%2E3^$T\BI^C/NQUBHU#[_Q\K&>9_8^^]PYKX
MMKWQ("I-BO2B!$5 I8F"J$ "*@(B(A80*5$1$1"BTH*$#()TJ0HH*$$442F1
M+C5T5$2J(#4$%)4B"24,))G\AG/?YSG?HK][SO.>^]Y[GOO]8_/,'K)G]NQ9
M>ZW/9\W::U^$/D#J=)[8&H%O\NITZ\>,O(.,C^F3X^\.C]2;V,\8BE_C,52=
M3Z^99R>Q5)Y1H/81F:K4L6][^O=OT; U6>G[MIV[]TIN)9K/M537S$^PJ?/*
MX$[Y+Q$L8[>?.M%X0F%38<!!?(Z<I# ,IM K)]V'5>OA5YP./]'A12Q3?I'(
MWJ'SX]ZO4,V_M-A\M9F!K832;!.9L8G(01PD=9YC3;)A+/VY&BR#&NYR$-].
M<S7^LODW]#0,SI2_4[$K=("]68F _],IQ$WU?TJSKW)J> J\%?M(G@[H!1:>
M]E7\:[R7_UG!/,(4$UDI9$D.XM,-@,U/-G:?SV' (Y"X-$9A"EER$(]/\&S\
M9>L,#J+0AI66'4J>@O'0@G?2,OU/Y^YQ?2O^]_"-$'P(7<"<(\L.9A-OX:[O
M9$N0/I &+"%S2C0PO1\-A1IN,OYEXQ#H+6;.,QT>21+\CCN[;+XV_>G<"9[,
MSO_QN%UB^2/3#!;& #J6'0Y/E(Z<!6OR ;(K>EF3H,Y!O/K,0:Q((*[_LOF*
M,%,)>%N!LX-65_2:F&&(?SIE*!_]"YGZ2U7\I2K^4551<Y,=O!C-% Y)+98<
M6-?T#L85UW.)N[=J$8O+-O65PE7S'%A\'\/#%:B.N&IUEH.@)4["-]KNR$%0
MS$U8VRK(;'XI\E)7Q_HFB3@8M&N0X'<<.LM>* ;^:OM7VW_GMG\R9LPE2-0!
M X4*4)C?W5=1<:IY7*SCSG0[WTCBN?O%V(\$S["@?>^V9P;Q_ZRP>=B)Y,_#
M^K %<(0![9.GI/8H9CO#IL]'%=//;-A+ R]/^MBIK#GMW$!87#G!D]MIZWN3
MD>7E'6]!37M^)DU0M9 :V/87/OQ+Z?^%#_^GXT-[FV9,'%$86MM&W8</]-)W
M:7;4**5-Q'>\%-%4B;4YM.6R0\&89.N&^*,T+\/->1*6C2B%3GV5# PNI['B
MZ=X#O@]<U$<>!UQC.I4%:VMNNQ.P\_DVHA%F+_2>3+.- Y7#9Y+H,^3+EOW1
MC*>OZ.$Q4L?3F<P]QSITM 3L&LK>^U0F]GNDR:7<VJ*BSVV(M+0R]D?/ ,QK
M4"OQ%;8A&AL%E)@T!6 VN/JM!+NN',9<2O\Q?ZKJVM'!@8'!IW?M3:]WBHS>
M^+2I@R?7"K,/'F':&5AZ0QC=8 I ,Q^E-%8?[6LYX$ED,(GK<"WU%6&A+W72
M#9F'3V .;4Q%'3D64/I9LE91EWS5$MRQ-.W"%, ].0P&T)?&SDR"I$9?DD\F
MB&Z0WU33Z^.>=FF;04O_U8O)IM1U]OZQ$F9'^,U.(G@ZQ&W2".^ $LKT5Z8G
M?FLI^)6IR3I12,>$Y6M<*@FHO/(TS,[N/GW";LAH]]/2>8TOROLWVFW(ECYO
M&8?3A02NPRJ@!(QD6K@"!5^#T.XQJO9@9.YDH6NJ;^C3*S>3WM]P:-Y4=>2'
MGM/5._IE'[X;+E_AGGRYG:3,)I$]-?OO,H1I&FET%486?7$VO-@#8RU[F>CC
M1/4PMW;5N'/RJ$A+]F#[5L&$\I%W4G=<MJWAFM*V:79<PT&$!*-'$\EB*&6<
MT^AL"-GUT3E %-?J6-*)UWDVQ-I)-R -DO*5SCX.O42T.&Q?^5SMO811JPB7
M#L/C?QMOL)E?8CI>(19EU\<-ZC83%&#U_!%J1VF1/Y9@![)G("28-484<I,M
M"W4&+Y^_;_L]^>2@?T+MQ>4-I5/(!XD">R3.DSN4"*L?-@S)5\C@#F(X*X#V
MM7XU0B[8X]N(4D$7!W'%?7^5\)@E/]ZQFUI"%S>7S%";R2ZK,9TH>#!Z_M)%
MI0AM;$B8E2'2GE +B;/#/<B7'*0:B*]\GSR>PO#,&H]?*7"]^;XB*_GM1,(/
M]25[,\67D?+&N_:S*5HS)RI-WB%%];6H9!ZX"ZV4M?IZ5*3PV>_G LG3)?EY
MU;&/KL0?$H&Z4T(/<YT.7'=SEB6*9.P$.YG"4#M%M$0SNF83[4MX-&$'_FP?
M0:&5QJQ+*>_"[\5:;Q1*\-BS5?7J67'M6V=T4>(2AFUSFC&+PJ!Z^QWTZ/,:
M/OCY8D@LD96Y$6%>O"J9YH4[#'6.2+A4N*<](\X<_/J>:\V/P2_++OL^4+N"
MT!C5>0PD4/+B.P?! [@!_<*,:EJQ"&YPC*=A=K.[[\A&4&QSR?N!N%BG'C5J
MV*0YU]H]O#_4DO=]%7W_@O^S9!*O(43E(-:M95>B74G]+@P]T(6N2:5,,Y\*
MWP'$\,Y4H@!\Z0T^[&.4)I><25/'B<:A_@JUYF&GU^^_'3YLB/F1.@:,9A,+
MEV;\G)GN^/5P]U,)S3 J4T.IN'$0O+F+U7)-R U8'="[]9'EL9Z,N8&QYHEQ
MD:?TRP?/O*',<:4;(6@4'I8[766F&NX)!=PXKCF 'M4H8NYSQ_#K\XW9$=?@
M;%H*DGL)V\R *^=?QXZ,#<NVY4UG:FI%V.L//HJ[)UZI F./.@V//&@G4.?$
M06"%XQRU0CU+9K@;(1F:XRW]J91N[[0 /AEJ.#-2.Z%%]5:#_H6*B1>Z]>3!
M*8C_%'Q?&5"0>81U@WW'LV8-2XM-U-3QN"Q)MXSV9A^RH^_-]K\:KUYE=?;M
MUL':T(T/'M5<?[WAX;H^,)J&87R"']D?J#-#[2 ,8 JQTWE>]#(JN86-- 4V
MX]"&=(/DM!PP --]P1U'VF+79_JU+%7%@VH'W/\2*ZDCQ&7'X"TM6\W.O8[!
M+H+XP)WKBFF42-:>40Y"UO[[-<%7@Y-= \LV>W;&2GQUE;45MKXJUG$QG"6A
M6R<O0$.RQ+LAOOFG(+)>UC'&7:6)(MJJ5'HWNP4KI^?Z2K3)Z82 6,^BSB22
M9H[L5V7<H[6W(&,Q-"O-04Q=*A"*4L+C>K5[2FB2Q)R6Y\+\5V2="\H*BQ(G
M-(?-KTWZ'75Z)QK1L.Z!S<3LX H%$E!D'B8,(=>B]N-X(%Z*S]Y0I@'^4.^B
M^MY1%D!;)9=VKM=%!P_MS$U4_/3#M-<AOW 7I3C(2)MKI<T8OSR&C2&7,0J8
M"#>T+%Z *>&Z(M72D&VAG$1SP=";8A][IO#A+YI^Z<E(%? 3OIHYOO6P0-46
MO7LADZDN42@U._RZ,OHS,NVC)]X+>5N4L50WX/F8G\_G@MNV -[L1,L=1D0M
MM1CENO@F>G*&<$@<ZZH4)"3-#:%12$+3R/JOX&A:\\!G8*G5?Z_K#Z=42H$G
MVE1UG QN-9F^0$]A'&(G^A@$,'*Z+I:"G72GEIOD6)0:[^R6\KD2O=:P?D_E
MT,\F9T=-7YM<$IKSV+:)6/ ?X5=_0#>8S)(_JOCGW!%_B]-ZC1P(8(337*9?
MT/8X@O3Q0?/6//2AL#T,=0-N2Q_MPJ>[ZH/B=?4+MWZF<6VCJ=;6\!&ZD&7/
MRNA+30R"*CMAAFCJX70XW*I+$22N+9.7"@XP;36-8$QM;GG3;"NJ>ZIRB]]#
M4:[%88EYE9DI>MDX*1S2Q&]FIQ#6@1.#=7X8B9)'1S>;M-@<N.3G\:S.V?.N
M]/E8[/"#9R-GS+G?(&[<V$\6 ,<9C]@I@"<Y'"A2B5M5K\2H=$F0F#G9_<3]
MG%)>:19U>?K\?-6XTDN%1#Z<497/<*S-!&(%BJ*1HI%%E)FD<63$@93(&EF@
M[J .<OTWFY.*9W%NR+!S!G.?GL><N6=Y+<QL=QU1#3=\JU:B%IZQ.PD[H2Y@
MD[9F!'DC:C<+1VQQE"RC/QS0;)@Y#@A^<FW^,=#YZ'*-@*NHL[*+(?<>CSF[
MS<<-44699#3Y$E&6T$\LP08_I<<LL21V4^IOYE$B2\SED+RDAEEA^^,%=L-O
M^25$CQ2B#L9161:!5.KF/0Z=^!U9WT:VT_>XGWOT[-': [&%C$C/OOE<MT)[
MZ2?+BAJU-4W+-KX\:X*TK^0K,F[1.(@6DA@+Y8%DW !#,D%,X\F1ID<N]ET6
M"R<&YR<\PA6TB7YRL0<FJDP@OFRZ%R."SBB@WZ5^G9&BW\*[/\>CP3B-D NY
M*N$SWAVT%I&W(H,*",FWR]$)#SVUN1;5_WTPKT326!PW3J^YR_4&2&[8>^[N
ME=3<F^GQ?<ECAUS\92NR&OV9A3LK@QKBI5?Z/E006>+A3+V3K[LY"*H%=DYE
M-<5IO7',H)E,2S_X_030T I,1G$07UHXB*$>KD4=B;EVEGX9])P$V0/L-I/?
M'!LB+=P<D1T^:96J;*?#195$B]>ZLMY]>]\J#KRSBG\K<_[HWA;GH=?[+AX0
MLU']0@3]L6PK#.LU!\%,C?MM)0CU++,&)D/AR1S$1PD.HA46\/+G?ZQS3[K]
M/[G(<] )OLSMN(9S0 2A[3.[IEDN3H4PJWES_>###>/[/JQSS%CS)V1(B.K[
M(_'.$-H:M3U#",F( \UH=\?;ZZJ=1K^VK.;5HHCD6J?(S1I7\MUYWB']627R
M<*O,\?+SZX6N$83H4#;S%%!WP(<2191A;61:FH\3A4 ]>]J7_'(J$''SZNY)
M69:N),U$.@I22 S,U([?&?-TU\%IOG5V"RIC*?7$<*2<OF  K7NL)>2J#YO'
MBE?3N^W(9KI92<B+Q0VY+^O">!5$C'%2=>V@TM?I=EK?>%D$:KL#2[[;<^9\
MCYH&7D ^*]?1#=F?)U&H1OIB_^9;OO*ZA)J+&8)9UQ"(<1B39@9KQE&*V^N0
MGZ*;_5YD@";-<VZRO3FY@8G(&3X-M0NB1JXN^L\IE^X7+#^-$[U0G[,A?N@S
MA;=*D\D%U!VN$?V.6:]O\GRJE1Y,L>ID666!^=-NJ4E9U;FJVC;6?8DA7N)&
M;RDR7G)K]9V-,+G %<M^8-1FQI+JCN7%>],VR'[,B^DH[[[,/%RZM'=/W++K
M!EJAF=BU/25!^V1X)-I8O.Q@X+)P?W?S/,L2]!^U>U%E>=W-(ZV1H-"GL:CW
M:=3 *=;\Q:;&[,?]P49UVZX;2B-IIRBQ*^VUQ$_,QCTXU?> !%AA6J4^.G5%
M2"G-BJPL,<=!#)J^+]2LNEC-PS@'RCTFM%**PF^CUG_??5B!UAPJ43W\CO5"
MIUE@R++=8EX[$;F4<V@,4ZMYFRR-/T5%R^!-:43&L\>C@1CFJ091,T#_>O_(
M>:[]4?LE]]M>V[L<-7C\Z.A=!V=VS+,73GL? (AD@8C4'4\\8^_P*M+7=O"T
M4N31HVEHVG%<S7J0:-M7LP'$-I06N-H<N%.SN\0W=JZI7CMXVD%JY&CIIO47
M\SJ"A50Q$-\3>G8CI 3#GQLL [":>1@LU;,K>'*L(KF<Y*AF-#-6E2K@/Y%\
M<+VC^.T4IV3U1#.W+&'6QEG&VBC<1>#VP-,!A^K:=*30$-A])N6X#8\"^]&/
MHPE$*EKSJE/4DG $>0TDQK(&#_G3Q)HA@3)BO=0 WG?/-^O$MZXBI7=>F,8/
M%FJ[54IQ\8]J'+ANN-D@9C$YVUDHZ]F(\77L==%6[/6UM[I.7TAROM"PAE<A
MEE=G#L,2TX/,4V9@ ^W<-<]!&$<MS482BTSJ+.^@UU]D$PE;P/VS58IK)5\U
M99F\'+9+,O>H,9U_G*2T[*M)GX_UNNMH,RH,;DMAB<U3_6*U21'06G"C05A1
MYN0KMW,>7UG*YQIK''IVJR6\.6E>:K;KG=#FLYO.!^_+$'XRM8!D'.4@[GK3
MRM@X,A2;2$:I_O%4D($D/)?7_*0(_\2[9?,3.O<O"2GGGN=II,QI32(7V9I0
MF%N,(UV7=>=F.!LPYR >IS[Y==#T,^0&X',:+@"J]26N**G>> 5)PUW>2UMB
M!\V@%XY:?_EOYK_MF%<.99%*X/Z<O7=?V#5)L51D/UB?-=_$SBIO"\!^JL)R
M$$:5FJSUZ'%'DY^X&#,V  4X"A3BBP$W ,UQOSDNW?[7__[-_R?\7GACF/P6
MLI 1VB-EV\U9G:,D7!ITQ. 01,Z"Y;3-ZJ?S\F]SLY,4QB#LQH;?Y NQ+3Y]
M0#V_R?VBJ?S1\6J/P&B8!R_(%7(0M4Z0#K(!N:P\(@^+^>9L*/+HT._[ P/:
M*Z'EEK&..^W>GODBVS/BE#DJ5OF*U)GZSSC61X#":E+49S:Q:C=#-B_W6IK*
MISBN;<(Z*ZG@;K+1:K+C95U+ : O&K[.]^W<!47%=#<'18I;+TD$.[+5+MZ4
MH?/BOQUI$LZ#OQOZG!%E#B(A[@0,A[\#"WM.7X&UU/)=Q@+[,:2,UP=+:'<9
M@325)@]=:ANQ\9')*0O,F$;VA74MC!OGC#9%>O /$48M],P*SAD:*GAL.+Z=
M^[NZRMDN'?8!=:>#']5)'BH.'0[GCA>:*'S8G?LTY(UBW%$= _<CG59*O3[N
M=L8)C.:^4[D7TCH\%95K+L)J^ I+'1RGQH5 XO3D2J;E")@"FZ6U8\*\DRB9
MPCL#QSV%WF96W3IY,$AU0G>#$"M8*Z27=7 UOR[43)2LV39%EH)VL]10JKV+
M+>O'OF(^_K@4VZ43<\(8*YUP<BV75Y)<H=FPH?P<KZ+"9_G;9P)B,&9%U>''
M*WMFQEZ_;D]8>_=E%?''B_WH4+PSK*.*Z2XL!;(@I*MRFV7TPAW-6R4VGG<0
M'6;CUQ>'7A&L4OJQI2QI[E+9$?Z-A49*L6;J]J1I#)./M9G]&KA4RLX&W SD
M/0+&T$T[2(O*=/N4;H%'?,;O"_I;G,+7B(<ZF9SAEM$[?IK+$ E\=+=P,NW1
MR"Y\]5$].[6_=.C0ALFVC0OGA4ZSW><#FC E[2T84:!.;!IO]Q+W8Z6A\?O8
M%;S4& <A-?B^?FS@HPZWAU+?@QX]PZU'XA\F)\0:*?1R$"QQ'H83.XT\FHXN
M.A+'M"&\2Y</KY?7H1TG9\4@3Q?V?-F-"][A<CB]ZUM1@G=BXZ6$0KY&%VG[
M* 1;X#F)-.W=:D+N(5TL"]9ZH)QN&/%D*'V=$778L[NQ!EE WQR$.O+81>*]
M7L5T O<&:*U-,UJ\BHLJ/# .\9<!-&Y&XJT2['I0D1I:4T+%K!L>/F#KIELT
MM#9UQ?1C>/H)K0CN^%W[IN*%2V;R/4CJ73\^4)6BC 4W%;QV/G]3Q&3MJ:DQ
M='_R5!VYD,224&DB%R#K*EM*:<K5M#EA,2.J3[5_1H=/Z'VU@MK\]Q=LSU]0
M5;Z>? R!X)YYAV#O ITXB&V##10&=S%,\';8)8736B"SLG#R-(\K!Y%YLNR?
M\2S\I) Z@'Y5R**[GK((OX*5 T=9X)].(1;._>)+IO[//B Y_NRSVR^UXC]3
MA-\CQ8 W+<^!O@7RBLQ+G8#?P0^$Q!A0:M.$Z9>KOXEZ0)MGO*'=]AN1[6OL
MJ@O( 8][F!P+ON*+4$K>]U2R*V'+]K:R4/RNK=6%40@6>=53[%K#7\)^7",V
M1&B4JMEV8-O ^E<<A/SCT%F[ALE!N>FU_AQ$A=1EAZJ#.*L.X3T&X2QQ),2_
MF9;=3"X6G)W>/&89>Y*E33M^_R5J!UBMYOFTIJ<SZ>QWR36\3[7";=:8?>(*
M?K>;RY8P!>K1&DQ!+5JW&7@A8U)*USK5N-)X7=,(1:O.%U_:P6-ML,Z[F&N4
M@R@D-Y$^D1AW0+D<O!@[EG7&R8N*%?HV]62HWS7US,?"L\;7Q5^&2&U\['N^
M4 M[/_FM4_+;90I#BUV)$H(:B(5.A/?($OD\5"@=2?7N6W&E/?ETS%/GH^[N
M5A>E6)'(1.>$C6<W7?+<=U*0$ 2K#U7SRJIHJXINCR^O0U"'YP[FTK_F]RHJ
MTC*$X\F7+$,@?G8Z>319, L:0LG%JJO8EM7TH11<;5:\BP3.SGK>B8H3=^M2
MS=16*HVA5R3NLM&9EVJ>O8UYU3(C0WVDR;!CWZJR'"-&HM3Z2.H>VE-YYHX?
M==15J%"\BDEYE94W/@<8SD[DV7WAW1U1;D*!"&^=!.9XE_:C+?(&*N9E);9(
M[VCLFHS+BWJ&;S.$#X!Q3$.6&CN5948;'"5'Y)7LN3X>8WH%)<7<7/A6UFR#
M:]S^Z!W& S;Q<M\=C5=S*52L[H<3%^$H;3DP/R;1'LQR<LDV]Z%:2KCJ]JWX
M+%@/OGN[R2\YYXYG^X^A1-W$)Q/*-2]?KL0F94V)"#C869151.RE;GZ_<XIH
MOTM1FXL&TX.<49<&S4W0 $J!G5>#P)G;EH NF3A]$&@84:'+#1O,WBDQ^[&V
M[^:+Q*D]1Z,R#FY^)22^7<[69O:=\1ECWJ@UMX(0H_SG_IKA_]0,_R40N(_7
M@KOC09UE<@T W^[EO6OXX[#>^]\4B\ S(1Q)_NS4@YY:P; W?)2=Q1O1Y,:J
M5A87Z#B;G4N)A<0RHS=JP.!+@):QRJ<ZLF%ZR8#-[(V@?9.J!1Q$*#<="X6B
M6<0R#F+\'E!_"X0/#A(ART$.@OX.,?X\OP42%VXBKXAS$',$"@<1:[6:QFZ,
MPN8'EM$P/VK9SAV;68D$3Z EX6$]!3\C$X#VF["V(Z.!A1WPD+-AI;LI0^A
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MQASS*^\[OF]\'\PSF[6;I;?^)HB[Y0?CO@C?W2[3$H6>3A[+<*ZR[R:83K_
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M/),EQDF:9O(1UO:CV;#FN=B,N)72*&!&LY+%!RVN--RRD0U3HP\- ?_IH$)
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M U!(B6^L4^7,!X #7=P=-<45J:@^$IT73H=O_4:^,YQ.K8?=>=O$L[E&6%K
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MV>/G#K2[^W,*G&W=FUMXO('OPZU"[0"R$ ?E8"STCAXQ7VFJ!NF [I[0TQ^
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M+T+(W( -^Z ,7>[)9(F;TYZP81G0Q2.4$NNXG:4V+ #+4,&1C[-AVDILF-P
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M.]5%C1,;JH4;+WV@+ST1T]>SF+*YU?)25WB:^*J3G#+%/SRN).E*$-#<K-I
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M[S=\>NHS4.D\WQE,_Q7S8?PP$WL;*]22:3?G::WOD&O,DR#T;/RK_..!J_
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M)W*B:O(^[T(Z@7L$C7>[YAT(WTH^QOU>?? AJPW8!:$]>#22SY%J3#Y$_\6
MDMAX*-]@,T8DK=G,ZEN@X_E#7K0TQ%CLQPX\<ES2SGA<>([%R8;%;QRGQ36R
M;G.0@7_VC(7_\U=#;9@7<9>"@ODD(7+/C1>;77S]#D#P5MV.H"R_PM4(7^3
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M3_6,(6%M923C'9R-J87@9N[U+",2+6J*XC('0S[-/ED,8AX9M&]WY)O>4(L
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M[;Q^O)9&@B/OVZ2A?5JMR6ZZD@5=R6AO"Y?,Z."W!EH7%$L+([I9,&,EN>=
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MP"X0^[FH-W_@H25E<WS"C9;'4Q"O?'2PYDX)\A3;=-YZ5>SG[QKOCZN)7?T
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MC!(#OFU&U8M2;Y)CJ-2"Y,D@I*#C9_8/>J$[@OJ-W%4,26\\S]-(93S478P
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MQE!O.)GV^%%.R!@8DO.,'TH_:/&VH]I7A[0&52DV1=</5V$T(!'THNI'-%Y
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MY2$"B=V$V5@:^K-#FEC:X,TBRK7XG?-RYZIF[+QWBWG6K"RM0'O$= )$=,M
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M^U-9]M#2I&5BY))),X?SO1Z$HK5-8*#@,=OX61:36P&))U*FD/N0@VA1F%V
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MO3LD@9?SIHE.OH[-'J-?+ZLN[JS69T'<#9S.I]\]RLRR_'ZV=_-!"C0M$42
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M8$*^^3[2.(VVZJ6*$2C1*I;:"OM,';@5)J:#\H;O<[,HM\1.51<+!D>SWO9
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M?)"S=!-#E4(!LFXT4=WZ;JHXBI*"Y8D&T/L:BS\2"]_X\6(ZXL>3!DK0-BN
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M".?W=?OO-E>WH4R4A[C-L+GCAKW+GTL*_["YZ+90)9;(ROQV%;Y+K>+O/0Q
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M%ZG^I#Q1$6)LF*;IU*NM&J=95EO]^^,W"U_=S[O1Y;$:N9Z]=(<^ B.:C[\
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M1POH%C%!<RQ.1RQ$7NP=0,F'HI __DDX_JN[T+/"T5FY_%$J1/JB<M+4RJZ
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MO.PR$@HY34C+1OZD%%CE@F!G2OW-W8(5)-X]22/: ?Y (JIQJ=L-V8,3XR4
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MI1YD[6)19?A"+PE@O*1HG^[;?2RF-ZPI+R@_E)U8U#39,=OB\4NGU$E'36]
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M-B&Y9,XK' C'_MZ+_;+!<V]/I8\7OX$+HIUYR&OL0JX3/S\T_WK 3]LQPL$
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MZQD\F>^ZU][R\<Z'MA/Z*M=??=%#E_#S[THQL^0&EW3T#IH+J+?(EB.>!$.
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MFF&19;:#U?][8.87&+*ZF+%P)DOKR:E;.W^^"PB62;LZ6P#:<T47:]!7.3P
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M]M+-E<\5S6AYHOOWL4SN.KN0=08SH@'C>0)G]&EP $BE:A1&AF(10\FM.FW
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M\5^NA[?)__^?_Z\^T,V9_P%02P,$%     @ =8)44RO#6P01CP  ,[T  !4
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M# 0)U@--QROR#D%3;8YRCT[UEB-?^H2X7T^C4X:-"1<RF;345MPQP^N9]_6
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MMYLW;SZ8FKJM+/9SLJ9<YK7DX="G@S9(&E')D$BCR(__D15C/!F?+GUV0+"
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M+6U@8:Y(_\+;09[)"Q*G'$WCFQ)--LO8KVR77CEQ3K';X:!K_"WW'Q2><KY
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MMI9=CS2Z;DZBYXX3)N\'7Q['-$#-'GTM=?3/*'U375%4'#B'% $[L54"L'.
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M<]:@46Y;$%.+M;WRAE?E].9=*%[6 05^FQ7,B;46ZT4-KSJR'-]IAJ[8<F;
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M CT$O.7J"CZC6$@,8"3)(,Y" 5UJTG>60SHV\D"%$"*;_\Y';601YOR6=><
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MTJ[?RLA/9JQR^[8V5C1AM7XAD66.J#)<V*Y@EL]_5N'&/<S3*F6ECCDQD7&
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MGY:-%B 6WGS'U&Y<1Q'EGWX+)*-@G_X4QD&#;FB8S0]I(B$$3)3J8,$GJ<4
M^(N/"A!5XF@PEOUF80^^ >I3]$>88Z\T@SF 0PW<&V(PQ0Y;]B=G> UB!(@=
MR@!KD0.D40'3E\ZWC7.K9M&0#1)F)I'7650H?!-,?Q:3%_A+ 1%F2>^L4#S$
M=9B?4%0S2#.%FR&;T%:8@_P7F_#@_U4+4M QU*4GDHZ1]E\IW"1A7JT%EUJE
M?1]JZ1 @OC:@N-/:7_DFT$X9H.L$=*PRBI+QJO"PE8]*XE.[E%Y,+K=D,;J'
M!O! N/W$2-1?O]I;A@P0IAXC]+XB@*9_;"S$;,+B6;Z_Q.NT-\OL'P:OW<QO
M<Q8@"HO@VK*C(;Y$W&_5S"+4V#@:(L"MI.ZLV-48DP0V.=J\7Z>$"Q-!?'G9
M6:'7"-]E? J8 06(EDKO.*!OO0 1-RVL'KN.$O';T1S**1!WPD?O\O3PZJ*K
M-VO.-RNOYC54./^]U9"GUR3\<5K=9-N-Z)WY899VE@JS [\]"/G7D8KOLS!E
MW2]:,INW=T',PX;,TX3%O,)KF*B<RX:6$_<B96!M-KE28DZ/ U.-<#OH+;DX
M)96)C'&WKKZ[$7GU4E_#;0YE6>]H$,W;JWY),_7F1ON'3[70)Q/:]L;6'3UK
M)81R/^#>1G%!'MAWNU#X,O\N<**U9Y9CQ](F&/'O0 I^1/FVS^78[.Q0XZWZ
MGA\W"3U*]Y.T-;V",'KUMAOA@W"Y1O"''VP*5*.IOLBK[JWU.'6>ZLN(0VS3
MRSP/I>@*CR=^SFE<X;M=*9P@V7H#]:#-GLW/4U9/8?:U[=MV9_>&[0W^MM^^
M?:N:G+A*S\>,O60#G//1'!LVM4;*#%)SK\9*D:.VO'[T+.J#?Y\7<GVNEU',
M@PW/-E1].OYU;47M0!9/M@D2Y[*TF(]2V86U&#&]&9*\K\Z*VOFL>(+;XU'K
M/4??%%<$77^M>N;AHCRE\S>6V!C.+)$?C*VKD9:];?LM;Z92@, O.9N^G'^K
M4@PT&9R]2CVE)XW7&NLW9B?>\'L$D@Y#[2^ 8AHM;"7IM=_2S>,(PJO8QA>&
M?6UN5HZQ?B:8L]M0TM!;E+"I%G<7&,?)@>GG9:AU<$)AJ(2VCTH!_/K0M)QQ
MSMSF8*GUD5O',+=D70>3L?70@JI41 ^D88IFZSV]!WT:]7K:0R_4T6;:#Y\J
MB^9IN7\N:-Y@E9\MYC_AN.[5[@.3&M.MCO:A]I;8I?O6_O'B_M:[N0&TCM*L
M:^H^W W$1FIAZ9@]:V2"@1YK'EA/,+F'P>J?*G4VP*;2+H>\T(C5NO[V99J?
MB*-8U+MJJX]AXJNY6G\!LW?G=RCM%WEGQ/O)FS/CKT_Q]ZL/P[I]]-XAMB@O
M#$<=;<'P$5VM'Z:1,>A/PJ$"A-=Y&&E$*HF4:.8$LWT:N+<$9H[JBTP>VAQ/
MJGD:7[BY2KCSA<-EZG*>$G<G0:>=J,<S2[G8'G@SS>Y 0&S!8Y?CJSZXA=]Y
M,J@5[]*(8;FUBN$+/<#++).%DU+-9?"]3.383 ;V4@5<@MJ 7?"WK.<W<KU5
M/.L_Y);KE#I?>[LFZ,#DY=F($X?8:-;.*-@5'4?GI>,HT-OS(& /?L@"G;\T
M-1C;YZ2FA4Z7-)]72_/8'FM]H?0TNG)WZ"W)BC,KY[67H!Z'A)3P;K3WN94/
M%X2<[IP5'B;3E"")#UPAXAL!0HE2*<P[#_:%9.(+[0M+RRK;3_.0N:?6*OO8
MLS<GM[2X0B>^KB@P5E69=NBA<E[RR50L+DJ)K@P)X=LGW%C?;C]N]@X.#63T
M\LW:\1F);O*[@A<[/A/?H/8F<M]9\967)\EUE,M4UD&]*W26(R8.71PT=HME
MQZ#'3*-40+O:^<-Z@R1EV^/M*Y1=7ZU*[%.+4#I_K^D9X<4GU:X2V(?, 9P;
M<)JOW9"^%(QFA<\RZ'4342KS0W19@E0(,?580Y"SKT\4 ^&6^^70>=+ENPD)
M3<5]737O$I<?RLQ+\I_2PF8"%[O<AY^K;J&RO.C@FN.R6Z:@-O=VC?4^0>!!
MYEEYZ8?DL?XEES@W8.HBQ$\J)O?(0'T<E*(MZ+@J&&!LN&WQ7N-C-O[T5<56
MQ(O3'Y$Z0K(Z9ZUVB%0$09*1[/)Z",&/.PZ*LA)/P] [2(DY#:GCS1>?7T&\
M!WF^S5)]JEN:EMGXT6__E\ID?CHD@C?@G .E!@2(GMEJQ6P^:6 "V3-\<<T@
MXHWNH-/432#TUM[X2RG'+KW_D!61J*)PZ/CME!;;/EWH34E>4VAZ&!Y3 X"Z
MHCRYK\S9.CZ*(9+*QCB_*Z8N.ZRCOIS4X+7T_30^,-@U[,GBKK.K3[]U<SKT
M[.1)H1VK)>8SJ##V#CQ%%:7646E13=7H @%B?#-W-3YZ %T+D^TXE=.IY!4\
M_PW][JZWL1&?<BG=R3O\S5K[;/-6QVZQ"FU<?(-_.#.^]N"#?7*QV+1Y3SO<
MEN2Y,Y6^2#E^#ESR W2^P]AFL\C4<2?VE#WK;N>3TUW&@5=*7%R"C&2BNH_;
M^!]+WEE^>7EO?.PT+@*M#*D2WP$2TWH)@!C!FD]AD.3\7H=FG *\T^CC6R=F
M,4UWE^UN??"4?&J >H8NAM\'XS98."A)EQSN.-5)%:_8)57R1/</_POR/ON>
MKU'<:;3AT_6P<\G8F(45!L ;'?,E0(]9 61UOSV#Y=5I],6Q\(/'R6EGOBMJ
MOQ]]4B8"*M>;4I@V)$QE :]V(N?'J&]=WGV8.:S)<IXAC0C!L- C--7R_23^
M>]KW9R+] ZLU#_UV D[[Q\FU/NU_?++M5_W]=W+WF;;_D^GZ=U7M9HGR$M-\
M^$2MJ9Q+WWW)NZ/$_8QFZS4+??OC@"6Q<HF##/!*A M5P.S_G12!C[$ (R +
M(_K,5STH#/MU!"1NA'3UK.<1!RP5V /!HN/;V7J<&M [Q]>= BOXS4-TN6FW
M^\\=E@TGXVFZ2@>+4S??7%V*_6/KU"IUWX"@A,O=.QHL"2:PP/O,OXWV<Z =
M9)+&&%P7WDY0+8-GQ")58Y9B6<-E%-[J_1BLE_[U V[^G5H>)WK]_42&E742
MW[J6R(N+8]ZK-+. B IMV+*USNG2+.OHW"VY&VKT4]Q#XQ=M.^IH)_-TF_!J
M<D.Y[Z!9@OC.S2Z7,!X]C\@>I\=+!X^8GP&[N$>(=+IXY7HPHAI"PGWL@05D
M3+?CC 6(FO5,NA3/KOV(_1X#E65:I2^T=9^X;'QXMRIRL?0Y5UAI[M7K.<BY
M!OJS)0?1XS>XF&$5JT@V$@:>@-'R5I&A2^'].QA\DWVER?UO>KXI?4H[F_SL
MXMXGM(>JR4JC91O4-[SWW+;#BF.?W=?KE9OYU+YGI;DE^^M8-;MUD,Y3&*U!
MH2JU\*@QLKBY)%YDN$(X>&N6_[H/%?:/%1*9Y\XD%^4_= 8MVC.@287CJU5)
M!'XFX0*[E]%8<YNB!+4 PD= $A/K\=R4*M;,M FX'G+F^"+_U(,1*C:/[=81
ME?/T#=(F'C].UW!2W9Y<Y&B+Q>+ZYTMZ"RV(9XD]SAB6(PK<0*U^@C[F!P,*
M>18M0EC%O'MP'Z#&LV W)F[I_9)?6%(>._R@H*C0)_B1S^6++VH&%/S+9RG=
MY!45#MQ#H!P364.1(+:018LHRT#K_5UIK<PS^4]/)=6;1V0^]-5\'NF%I_EH
MG5WE?+"QC^*1492N=\MJ@[@EQM[_8DY_WFQ;8$D88>'\5QTV,/X'7=P0""<7
ME(Y9&]7;$ ('^C"V'XH?0YI^:2O?/4S_6+U"F6)CM'U9(4-,N*E:\ZPA'(;5
MJ%[.&&C/LJM!%1B-VW+%[5FS5BS4Y67M78TDMI[M!Q>GBEC7MB.*%T]/[GBI
M[F94J$_2\MM^%./3MK-^321'-2Z$WO^2.X'3#;N];V$Z#C73 ]RDW,_^>O=[
ME9+-0(67Y@#[X>"J?/4_?$'E?W >T C,H]"?+-\#HS#LOXL,MO['A@!_5]GO
M%?T/Q#%@@$J'-=55HB\R  :Z&=8&_ _0-"]:AYH4@@DW93LP+8Q!N]2R@]A^
ME]#O%L$-(OVN08O\OS=I>L#$G-@.V(BI<['S*I6]5X@2_?G\!<MQ5_X/GZ;]
M;M273#V"D_$M\ZG.=>_=_]X[U@'<%YA"^WHG-/,%Q0F,9(8NFJU.Y92DY3C:
ML!&/LZY/24RA0:W/F3 #61+HDT8S0K/N8C5UPLC@G.$(?9E.#I-E_F#UQ21M
M,:OEW@C239>U:'X#!3PQM\G4&;;+J]^>(ZA]L%I)QAU?ZO#BQ;75?@&9W=/"
MAJGND/#NZPWNIVSN7R[?&ZZ/-.SX:[R'!,FAE@+O3B&Y(R1P+V&S +'C,7KB
MZ0O^73B=M\:C9X<._/6KR^C \=%T7=9'FNZG UB90L.<RQ9FM@>]4%XPCKGF
M15YJ.B&FT;Y75AD:IBS^47K\KML7ERQ]$BJ97[7LB1:;$BA 7&FL14VK1$#S
M%,F.*B/6(O1GF.AMQE@ /C"H3@TB^?,*G(]_HSE+T-]5%LW8S&KDB]P3("J?
M?N5<) L0YIL$"/I]Z^]^QQP7;>T:HX0:/'FEGR_*?OS4WT((V"8,>?RGD[8A
M4=%P7JO-Z*G?F"]10&M0EGL7J8#]J]M2_\,QD7_C3%G?S;-X&0R&Q&SD>3P^
MW&NC;E1V+-Y8-FU6[S\8)/EN4$3C[P^*' %#81]KJDY1++V4<^!5DLRKQJ0I
M%?8\AQ+%<3X/HO8EV]G<BM?2:0MW^&YB0^5B_SH6_],H%ONT;G)[C4:Z;?;,
M,M<>J^K!PJNN =K*BP\5_T_D7[]KD?WW?'JJY2[,H,70HW^ZX"Z7WK.D:H].
M],(N]057^A\Z_?_]"KU?YK&!J^1)C1'T3!TPM+/BP:\;+RAL QA#K:'G)+[8
M=V"U\^^#E7<5:M+8CSP#DEOR1[_[4G86,P&GYCKJ%M$RN#/G0073'0L+BR?F
MIU(%" O#J9E0829R#D$'NNY0YX4HY&P&6 X6O40-+<B?QM\V9^N/]FPU#N)=
M60E;L(E7'RJ%\:]!+\&Y0O=@,X5>0YE^-\/Y7U_2.(W\D85\</@QA5&ZAP0(
M$?.813\.>;YL_U\9 OUI]7/=SS;_:P.;R#CLLL3?KF+Y=:W=!V@M\"H.;G*7
M+%R*Q"3IIP5=EZAUK7.R@:AY)GIZU>&; L2L"I61^JF*#<<J5>.W5<TE(8!7
MPX^ +B9@W/C]E^%JH!).S,MX[_XVF#7PCPUF_3:CT'ZPJNGP=WHYM%2,I_#2
M>WXA/#D6_Z/7O'_W^=VZ*!?PUD(I<)L/6T-7M#]3+]-+T&-M7+4AX\9J"@W#
M?)EZI6)?^KKWAJ)M,Y)^_4XESV^^7AK])B%,^LJFY2UB@VET=BM/ 0>)C^;@
M]\WN[:#Z]2G:?HD1ZQ@+\M8Z:[9WI<O6K?KIT@^/Y7W$?*KJS*CP@-37<^6!
MMAI?ZNPW #*RYID>Y, 9XL&5-F#B(XQN9ZBZ4/-;X.O"C*P29!%BK\"DL]@.
MW0^@1#E+."E>$"#896@&DYQOS5=="_<T\:L ,1@ G/R"GOH"@)*P"<P>Q;)Q
M(#YK#$XPUN(9,,"]$"# /M2OQ11>0,U-H7E+8#NJ=UCB'RQL=T,?"SAQD+L#
MCM#-575&HE-UA(/4_SV/*_VE[:3?%-/S@L2;(T.+8)=!^GT?-7/<G_K2W7SA
MM7A)4"T-<W4L<(4 0=.R3%0^X_006#LP(-RUR+3+2F[C6\W81WW+5S^L;)H8
M$OWXATL+P.),@%K6?+6%UH4ID7DG26!($$\.KOIUN.I5DJV0 >;)Y5]B\"FM
MD:=P&Q+O#7SHZ5[-W3^4,^EAG,&/8AV_L5+Z* 5V\>A88CUJ^FR:'I\+LZ^$
MKL9S5DIR,=FV[1$WKO<8]3[[+_<!@<(Y X.I.>SR8=1)89HO1?&7TML$"*0\
M/Q8]Q-B"X<["D;CB =<(YH5DF+]78>:$QK>XQ &U]>ACI/EM]DH0OU6 :!A>
M>)F?$O_JX,YQV. @JB_J/+!*[8<>QV94' *J+8%CX4*HHK4)K3D'%RR)^<_L
M]%]Q=-+8QT:( -=#"/@D6M3FI?MK"WXNXX=NZ)W^06Q)%RR\$Y%8U^9EJ4,N
MVABK<,*QL8D<AN1?H)R >ZL4J#9&#PUOP? 0%; '&W)4=:/JCC)<:-4-G#Y#
M^O,_CSP7(&I[J0-W4=,!:7H0P@M@IZ$9XW36/M*\L3T,'P@]--@<ZBKW'<W!
M?YC@R7MSUJ9,NGGS[P<XYFHKF!_FA0.C=ZU_:0[E=6;*EXT.L_^!189^L2LL
MW_Y9H0W_\QC^73GQW25ST=FC=\BOK/>@!S*H^3L0))J<U=?.];_8\=3_"3O^
M+[GSK,M/ QW-[NB_A2/VH3NM%0['I^Q>C3(X' <B$8FKLM&_1#G5Y6%:ICRL
MR^-_H)4YP"_1[^4 TQ9P/6K,["D^G7O@&3\CP&U5VN<TH\DS(CO,SGHW$R;D
M&*/,3<\.W?LTT6;4\0KI^E_IMTKM_S1 ?W6'-O[MA;6)<-H:T..%<=*TZW\#
MSC^7\G-"2?H;S@>[G(?>7=KV%;7%2'BN<=__GF?]X\GKQU1_58#X^?K $:((
M'.NY"YPM !#O\4LCC9MD-)INEM4(31P;^*;U^$KL_#[EFF//P)XWN=LMS\_8
M!WI6S<?&LB@(H'HO^B@NULNPPUP-%.5<;0_4Q;J5VWGJUVC;9?I]\8ZT\%IY
M[_J(94ANZ//?L0A5:FRE&$&1W9G7OY)=6H.2'%7Z%DL*?0H2:<R33LK[O7;K
M6*B)X',F0!AT>K*@A,$J*F@+RP+VTV^^]Z170,N!A7>1/<"S]*!ES@#O%.G_
MT(7(5#1\50]LRZTD=O3 A\3K++N:K<\P8*<KY7X)J^_IFCK Q[O (C]L-/WL
M>6T:3&9AY"'/&Y$6+>R)@F.U(=NE08"0(&BR1>N\5-G6,8R[>3S=)X:<Y*-W
M,G+J)9;5@E'(/</KA*-@C87AIP%#_::P1:_<@'U)Y<$OU2Q/^]>5/U])T>,7
MH7T V$H6_!137,X01MA4[40P+L.DM\\=?ZQ]NX9_TYN"!@GR.<SN3JTZ4G2_
M*I@]X.G H,=EW)CN<^^NQC_;<^#-,N128W7X": _UP!J40*DIR6S*3W<ZF5-
M&^-.3=IJ1>KTW(W?8+NZ,=EVP@-@-0D0A0[\%8V7 59R(1Q?3MV^-*='$0]H
MOI<N/0M_0]NV4KIGE>S./(<+81N:$6?IO]QP"*C5@YK1TSAU.-W4[(%Q(,'E
M@N7_KZ\DC'-]B2WPM=!EK@Z>[O:N4@1O_&:2OCNHM*R(5?_P_.[>U!LGXA7,
MF>68*'HA>HP1Q)JP*"OCDRMD=0J&2BBKD_&.S;>Z:QXF[PU>G3[SD6<#AC):
M8RN7O(?4P++U&/L/N?%*<8LS5>^O9-7>9Q85^6_HV-$VOL7,S'7'"7]5&='3
MUV+NNVB]J)(7@C7U+W6$^<-2*G>+ -%6@8>9C;@V&C+T;)87JOVU.?^Z].]=
M.OEU3).+YHFP4=7CCMPZ].(*3< 8W^5R=>U+5E].7GYNM418T?%(X3!C"0[E
M5U3^ 'JPLFK0HA4FZ$B>TM)AOW-/#F-L-FKI&]TUF+APO==,]-3_=32]UH;V
M:0TC+O^0.R- 2!-D6%'D4+^5R9V<QEKG?'O)Q/C$_/"LCRJC0__Q'C53)4A"
M 18;HB!, Q:/@2;>;$WFVL@<\+HG>V.Y2,0 2@CTZG9X"I)=[S!7F/CRYPO3
MY8\@WKY*F(JN0X$;K'D*FIP3+%5J$3 >#)<09J_%.$-6HO%<S@V@XSAI7UXR
M;DM3 LVNE29L=#;\LD,^;.72S^%/#"/@9VIQ-\%L@4>LBF;NHX.6YJV#E#%,
M,=!(Y= Y[G-NK>HG!8B"TQ/4,R9=0T"=W$#U@-I9GA57CZ=)[YY%]])QC4D<
MO?6P:# P/3TYZV-6:*%^E"W,R6+[Q**/KT#2XC@RX YDHR19=KA3J7\IBT^.
MS9UV+?; /M$4\2DO<TP9E3_3;ER0JNZQMH_G\M:=SE-(Y3#Y?Q#7@$B8=(6G
MP#S&>+H5@1=F:L7E\#9G$7:Q].K P*$ ?\>Q)'^IF=(>9F!"S.FW6:<BMRT]
M*X4&#4.@913P?&KM9J;L!0YZG SKWAHS#N4E!SD>]_)E2'#Z&;.R<[$L)+C>
MYS(P< ]=V/*2%<V!'Q2>1SC+HC20>T:K <6BN.:0&K3T] '&B^EQ^Z^;_>8S
MW^-4FY]X]%9$!Q8TBUT,>'7BHX7H6"@>$RE ^*-!6_3  W5M?AB5X3Z'9L43
M-G008%X@CN.T3!3Q\^:QF(+0U-<KM@:;\.B&I6<:JN/) 7E:>_EW*B5A(END
M_H1[:+A2/%$/A?52*F5]RV+*!F_WFWZU-IA9.ADWMT?15JUTL?2%\+HC^T5?
M+;Q<,?PR4.U],MH-O,IJA,0>EZI+MSVZFWNZPIJ=\::ISOASSMZ>-$GYDNNO
M+CJM.9H4GU"%2%GTLF/AW8?AX01C?B'Z2#:NMY83RM**,6S2;I4:4>) $K'R
M*D6IG&.'4NTDRX\^-ZAI6]72J1,OW2GR'.ZM+)Z\43T&\2V U$WG;&.]]]K*
MSR2NI=DJA?'6RXE$["C9;FLX?N"%XL); 0RD>&^&\W<(]82*0N))W*5#*-8^
M3#>Y&BBX2&*Z=&V<7N&79[J#8I.Y+_.IY]Y9I0MAP8?T7U7+3VH>6IPLOA)6
M!PMKXCT$"%_TPE(NT0O<Q<0V,FM? F8@[Q'<JU_8'%)H'F]WT?MOWZ9GWA_+
MC[?UP^)*/E8D&$EM#YS<OG?;*6X:U>0,]?,I+L#=#*N()UB7H1L_[J7]3"Z)
M'D]@F7#$^7<(EMS]T#L:K\1\!6M,PDM[VY52EZYEFVS\=1^L#KYN\VE#GL5R
MG7HGM^@G75\:>:ING*-/H(:LQML  X$JT8M$,S9SK7DA_F_[7<CIIB_)OBWX
MAM#'P@_1+$<,J*/!@S5:5!P.U( Y?HV(+KH(&2W:H(T!]Z(+2[Y-P8FPLJFT
MM6>*3P)ND_OX(_-& ^1Q^@")]I6CBBK)&G-A:%-CL "#FTU%X@TIC [<F9EU
MN]:W9R4?\RZZL[?RH$%RW+6! @7O;Q_F* *$R.?;%[3&84$@MI8.6J 9^02X
M(\7<2@4($DYOT\3DYL8;A:\:MC56^@K;#3KP%$B0A!]7"5Q);$>5ZO&61=B]
M,U_FYN61%1=(6L0[4=QEB)'R:-;?6;J,QD];4[;_6^SN?8B^Y"J7(9?H8CZJ
M_M(24JRI&3'5G9CIH_ AX7UP[Q;]E0'GTNMMT G$A7<HX!842;6#=14F!B5O
MOI47PLJJ0_:D6K)1G(D$2 IOMU==M:L8*;GC4F'FK0_I)J3-&4Y7,[M7^3EK
M"54?R9K^.F"=:"K*-AH (HBK>3I%6R%E-C)RR[A#[;4MBS35KG#:FLZ4"ZW:
M+'>OMU?Y'G(K^(0+0W5-(;_27(Y8"ZNM7&*O "&YJR9]52>5H07U3,(]CB[H
M[*N@% ;K?@VN!/JGY$[V)Z2;/AC4&[^U<#@V+LY\/2MU+!]&T]N%;-%(T\U/
M[/W\8*6K1L 4MJVHBS+//>'WR5;#RN%CBJ/L5%*85*@VD]33-$"-AXSQ+IP4
MME&X=QF;&A[P<M<^5F493LLYO_BE;-SCNE-,K7Z-?9[*"=3URPT_HUD'R. Z
MTF7J$4JT\?&MZHKE[-)Z/54O-2T&NN:ES+?W!(>G6Q<]/G!=H>C$C4?/CY9L
MF3EI>03.O>'G@6K+"EFXKDM 30K/&A=]B5([(0?*U;OT*X.I [AE'S4/XW&N
MA1(^ES_OS]8YLDG#\ZFTLH)CCFCS5CK+ ]DKR6RLF9 GTC %.)[<!D 5:JF4
M?TD]Q$Z@U[D&\"_4I87&)Z:6I=]^9%@^$66@FGG@$U+O#PM:CU,OB.1*\([S
M8ZD#UU%%9XK9WO5;Y^F-J+A*=3:99*XQHK*MOLB=S[FUV</. OWY#Y,#\K.A
M8YLR+2:H ]$^51C6)P'B\AJHB0^K5XD"]+AG]V0AEUX\(4"4I)^9(+P3;2<7
M9C5.1 '%UE5D<:B-*C+SZ+VIWJ"9--VI+>^X?7*P_CW_Y(W[7LM\5C.X$7AB
MW#.3& I4YU)[J:Q!>@2UUPN7RB') C[!]) Q>N]\%+W6)'\\_EPL?\E?0^8O
MT(F0'GB7!4L^^E7".98WX[CZ-O:^I ?-01EX\] +W"U8N8;RR*<?YPS$/*LV
M7&DX]&)__0X=XS?KA+_2>U9 $I9<,^('\K,Q=*G[Z#GP8&W9F>M!:-+IP-=L
MHRL4G6MW=[9,;,CT6I3[VFECI.HZZ8P*30::IR '27AS]_!4WU%]*3W1D-@@
MCHE:@B\):2))](%QG+""=Q/? A[>S,R<[DQ5P0:C_2Q.N'[X)"1Q;4Q590Z.
M4P7N$CS@")O_/8SAB815;"-7UM?J5AKT9;1>@%"%U/TLUCPJ?@R>%]=SS5ZD
MHO!20^%Y3U'AJFLI)CNAAF'C?3?N^3F7*48^ZNUQ[?%XJ'CQXK6<<SN6K3N4
M(&LA\?0> E&%$+) W<84-O(4+T 2H=R#^.M,U!5H*5"ML"7!BLOP2?A6L69P
MVS>TW[CY1_=3)>#4L5UK_UC\5-\\X$UZ0SF5)@Q)U'-/$O3Y.9 Z5$L5 P9N
M=:H;@;>8]/"M=!E3Z_NM[)JN/=$6USZ^]@_*RGV;1DCRG%O6(+\O)]WW=$R5
MZA3 VC$QIR= E +\=*T8:G+'PI;.-QWIL-(NU*\4(-Y'74(,34^ .K-UI,MH
M18(NBP))1,.!RF6[C,UB!Q-.FFG65)K'-3B;KV/5E4[ZO"E]02UR;;Y=*=VV
MVCORI/_CG,$)%1 )28?B$"10PZ%A\R"U$*=IJ2)S6]V'$\VI)]_X'$1/F.MM
M:35 ;QSA&G!"U/4P85ZBF!CS( [((M[BO^#$SY%/<W6(%\>FRM_VD2\AIIX#
M_F@C2.+H.;@FHP)$))94R).(9AKQUJ)ZT2%O.T]TF%=S'+3B@XFXNU^FRG&I
M#8.,RNW\"O3 LR[WUAB")<L!$FN&(_O*%BFKD16B;)^&V[I&;NPU%<OT@SF=
M._L="N<N!VF\[3EB):I127& L:8"*"*0BVOP&IO9RS"+M:ZL9FOU:GT,.%2!
M_5 T63JW34FZ'=?SY4)"+YZRL-<P=6&4,U"OYUC7;GX:]:2#*(5$]:5?;7N-
M9=4R^-DBBG-+*3FGM+:5=HRS6EH^$VI7K%NI0U(6Q7"5%E[M7JE&[$/GZV!*
M<-4X(7SX?AU#H="!D!CY4R6TS)09\E[MNX^\-?QW75.VN1+Y6K@..($&M>GC
M<NQL2&)))E2#*;+FR?EX@ ;GF,CHU/1-[P)QLKS=A=2*YP7A QXD_8;.12MU
MM6YNFOJF[G7Q6E57 ?Q,'>"H,C!P%Y6?&@WXZ.YJ0+&2P)C#?5CSK6QEQ^PG
MHRX%M_(>65AH;*JSNH7X(\%.JJX+5I4*Z,^^0"25XTNC0.F9]Y!M*M]Q[0VC
MA:/.M#6?6Z.F1['-5B9N*C7MD^Q<1OK9AQFFV:I1JT]6;91]$V[CW(!LA?D&
M!5P7%$T]0X\BKJ>R'6JO5JH2=H'GF"%4),$1]'\ZTA1XCE$^Y,F10Z?*I/>[
MIKY-/!M+BA8V$:<\P$YJ0Y*S7)V12C5^=B628,5/-]?'HJ5FT+3">AJN&IEP
M 4^41_=>TOV8?_-;S)DE[_<WZBS:>\;WH?@+)YLCR'M$=;@+W*BG*33*'K9+
M/1+4:N3);>Q@9M7ZHQJ5S-58C0G%0$)*OQKL,W=U7?Q;'O@O:2"OY*Z\H_S@
MG/:MK?FK) JD5U2A66ZMX/K9NE9:4",]?_8*>B VS;*19+Y\F'9B-FZZD9]5
M! X61T&RAH4ZS9EBGW6N+)-)?BFM/;UB@%*]L#NOL<9!FK 4-&-@0^5J(/GV
ME1U;S#:^)SSSJ+M\:%GPR6U-VYL,EM4EVU*NH(^AYURIG(\"1+X<8P)*2PXS
M=J!A_P0$8C/ :D5)%J/!M8%1F>R(P?Y,ILEJ\*SY-O=ZD:MK4[R3T>"M!#/&
MBZGQAVZ58UYN<^87FO>SNWB*.,YM?I(4.1X8>$1E[2$K\5:#08& 5":]CBK*
MV]G!\WDTC-2^8JO7WK[.IR3ZPH:)R=XUX8\OKG3VX2E<@ XJ_"T>\UL;@7G?
M0DHF=>#I^,!B.!Q.$M])L7>-4;L!5A;!DM-:/'@&*,R:Y'R%W(-O;_7^0B_%
M;;N'O,""J/=!RHX"MD.488C_+OOWN1IE'1-C7]Q6O0BW1*H^'K$Y?F)5A+38
MRJXXPD5^D0#!V+/ -H30WAC0F4H#6!6ZIAY&O-7D7G,'CAYG34)QOWGKIU(:
M8:+H=.LM5&HAVOSL-@=PU26P&ABXABI\SFXE<R9 9Y6@ZYSX;]RUM9Q]U%H.
M3DN]FX)G4\<^LS!,= -Y$?0.,F3M#NK7![&*V:APPT<5=U?L]=PC-O!RT99S
MJNFGSUEEO77I+=4N2K81;2&K :<=P TWJ V ',&<?QT]<".%N)9%C3I3)P..
M-F(4<[=L*YZ5U7Q64#RY.O6(SG[[56*NJ%V>J7#$0A*Z]X#J'95J8-Z4$VB=
M0]C&%B!J28H.#/)5,M)P].'SV[O>,Q$W[&)J<NN6&A3LSR[WYCU'W$7"D<.3
MUV*0>'*S##-RS$SSLMEZHC';D]5NKDS0?V=]ZRE8ZD+0N?C.ZEY!P_)K39O_
MGUZN+:J)<XU.%:("$E$H!92(-U2$>"F*-T:P@!01%04!(0B56PR1*A D9 X7
MM1 A4F\%CJ2@B.4BB$@0D!!!Z2%J%.0F2FX(M28R 0V_3C)TVO-R5M<Z3V>M
M\S /,R___//M;_][?VO6-HS<[Q+UG1<Z/E"I700FL17X [YMJQ.;U:=.)//X
M"R/Z6V*5HM*%+]\67NQ;SPUU>I&1['5L]HZV?S:[6EU<M7AA!P'U\:%92N;I
M%CJV&V^'45\$!-%F;#.ND 8)<JF<93MOQ!4[Y#TL8,;7<V<R[*^:I%*BQN:N
M"ZV8^=X#HVG]]3=:+3B#M#OE67 <)2/XNH!CJ;F1:UM2=K_CR(H?Y@?L6KYW
M5U!$?IC]WEUD&VC/!MIZ1'1/BN8B[3_B,Y#P3Y1(HA<CIB2#N<6(]NK8RPU#
MKLD%?'8_ 4*2($6(_E9CFL:#!X1H,2C'S:K2)+4(_15C$)<4C.*;_\94_W5:
M8//7M,   #="_2T FR/1(<7&>U6L$X?1X7ND^S*J+2MLQ*T"1![ZQZB-.'9[
MTWK;K\(SJFZ^0\DZ\TRM'X']5[%\4LM6=$AIK\ZNT26!I17@C-0+B*^SYX-0
M>BE03+5/U'I==MYYW.G V(*'D/O>\SL]N\WUR<3RLQ145;4R$UL,O&14W8(>
M9;T0XIT.[R&0O^#%!9'9[]DDOLF:C$>C#\"UM8G'#_\:$/ZN\>JGFF*V-_'6
MY_5W$;KT*["',)1C.O,HB8+27C.;E=<3RI,CZ:Y6(8 C.2QL8#QSUDOX:^H>
MV%1!AL=^-#H_6V_P[^W#:UWG$[PX%Y9=AZ'6+6P/?2EN2CR@5Q_;%JJ! S<5
MK]28WL&^?GNJH>3K'?CH\WBGCY8LM2*THK:S;JW9\<RX]"E*&R4+OIO</C[8
MA<D%G;PA4\H/R+RQ/!#$]N')>XOS&JI7YQ^3#M9^BPK/[W)QVO8X7.G\[N+>
M6:-_!FB9$YKQ%QX64J/NDJ*'Q3 (RI:1@7L_C?!X8=U)2(2^=EA?I)J&7KKN
M84_0'@^.)KW.<_AP111,RSX)D]Y:4\_I]CN_CI#L%F0>[.L3,3Q+OL^O$">,
ME#B0?Y+SQ?O=W[<M,^KY6^4GI$.P=@M8A)W"G[HNT5\1QC#)XC2YT&Q'J;?C
M<K/00Z\\1?)FP859XL)-1ET#BV65I("CKF4>$,>?\Y)_>TIGJ=2FZO,^(G/P
MIU)TW] XMXG$-0GHM_8XV]X<0K8=CH&_5SCX^K#%"9SS(VN*@R5VAI=:GMR4
M!G,>$_0Y#67BMHAH;0N,.7/:6NTT2-MM^.R11E0K5"!SYCCKE^A'0[)O.=O8
M]'H4OADQK;N6;D.R6V?;]?ER#J1# 6$^#0CCGE&(#PR;(H.85DG<U ?]3E@
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M1O/CMXK%"_<U?ZHCV:>^_URN70.LL%CV@FZV6S1V%'_=0#CP6W=MN$G/;LE
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M=_GO<^\^_Q[?./N>O<^Y8Y\Q[F),!K RYWS[\SYS+?@3_'E YJB#LP,@("@
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M1A:M7[/-9D_9Y@4#U^MDCCR2)U;$UN=-0W[1HS]?&)A:?OUA85;+@5O%052
MZ([?'Y]<-F^S_)SF\W4#M7#WY,\ 1^+M]Y??IX<+HF;8"? +B@]&K/=LRTR4
MWG0VC==';EQ.QEZ2WLKQ9P2E<*2?!:]PU,'GL?-QQ\.6;MV-4KL=3+U;LT/L
M;8E<@F+3_'B=8\EWDV]AE+(ZY,OJQXU*W;GM[K.%^SYGM9[]C.;(XGEBOI O
MUI@Y=$7VJ:5B/>X]SJ[8: :15372L)PZ_ &]'24^-J3O44U-DN[LVVY@5APL
M1.<#DV@6G1G4BY\.8Y5R"VWC2H-5X:GM0DN:*H3!J+_*<_?AM4;6>EL>U!0X
M[A1O3O8N<9#>9SL^[!Z=5Y!5%OT[;B2BPU0D)?B\J77QP4V7#_Y2W+!@6\>_
MY@/U W0H.(0KN<T!W.<8$^/;'!,*7C9F:Y6MU#.?]\VN/6M3(LI$2V9=]?M:
MQZU.K1_>J13[*4<(&O.Z-0WN\<1:J#G@+KW7L(1&HM2\\22ULZN7+-FJ%1=M
M^-[Z_#A/I6DTJ#[U?6! PD#X3?^!K7J5)MM@SXGQV@QZ2O7FI#B\Q^&XR);J
M2T^;[?-\?SP[[E7R;3<]?A.OGRP,#\J9TF*9#]GI\49@# ?CJ:2%LSVP]&:Y
MI3DMD(O2++2@?_DUM#'H$Q)M7-D[]K*KV430X$I"K1&X$8 ?)8-:O>7L\V0H
MBO:V;YWDS?IHC*V1,ZQ]BJ*>@AEP.0'6QD)C:[&$2_J;P%F#O.?AM"_I@8%^
MSKH)NZ'M"%#HDRG(GFJ73LA$:(Y<GQ.(FU]R"=:N8Q:1^^CP@[G?IW2NGYAT
M#=#O^])TL3^B)9R226W'<#-)\W5(AAMVNF\^*)4/A* G5WFB;66AFJ),C=%N
M=^NV<;I%Q73_[=CGAD_]-TUY]J_T*R0(;J8WJ<N$K<6Z\X$[9P:XL21>8MCJ
M(D_*@P_<5\?LX ,O4]/A:WS@V0F15_%O841T!F\O;P+6P =H7*:(_2=SE-#\
MV?1(#1O[L>UY3I];,OC <:M3^X>/?A$XVUGSZ8G(H^*P[Y4N+2[L<\M5X?X%
M6^_8NAVA/!C)3!2=3[09_SQ :V,#O(^D1C)'"<9:;.6^P.CK9;9:4$AJ,0BV
M\>NI![0NI]S?WO)?VU\1'<XT/=1"&&GI4E3R_#8OOJ%AY_/G9(:Q@0,92&(?
M39[1^V-%.@4K0>#:\8'7FK"6MER*N=.O+'&O=X5.JNZ!YY2."+OI;:K]\C =
MX!J-6,Q*.S<3:D>C"EU"EB^NT$I>O3H=ELK[(7AUL3C)?-:KNUCCDPXQR7N\
MJJKX)\)HT.AGKID9<^6QGY6FH] 821\^/XL&=45H#ZEX4"_Z-7[::L$X0:T7
M)[\CQ171%:\S3M!_B$BA-H[4")?7X)3_TFI,M[R>J8B];E!7GS<#;*2R5,=X
MLE"<'(A7BKG-&N8V\X'Y;)(F*02]E7.<:50S")(0#;7-@VNN1C9-*/I:D4[@
MZ(58)_J8:7F>^;WWQJLOQ;N%UG\_]XJYUT4LZ.9I-(Q7E8\8WMG_(3/::?A(
MA8I!PL^3;SYG4TG*F#"V/;33(9*?,;A-N@<A#>9W8N5;)6H\, 'H31S5$5N4
M-H**LNFXD3R+G]2^?BK0+4K!S-NS;UN^;)UC[>LLI\_M>WG].&D,G&W;!Z,)
M0;7$@ON\7143S:A-.LD0Z?7P'4ZIX%8K9"Q;/KG:W)H3I;[PWN/ND\@=[E,)
M "#R\XO;&.?@XYC0=VR7[AM?BG&H5\93QC6GM&=N2+T_\"$0LW/<UIN*3FY7
M9>IU2TL7Z?F,F$O8%*&/^B8%1&N+KAX>X?9+&+L-D?9#1BI+8FWCEL##-^RD
M]#ARX]TP0G0O7A3<_";L1N2-#X2\VQ3OW2$UNHTNZ02U5U64IH=/[_9.3)W-
M-/(2?0' G0UK4,N&"RWUKYS]'@CU&(1O]79ZLRU;5*OM["@D(AB_]^GXKQ87
MA6)?!>/K5VO%M/?+NLCFV245<%HA>!!;@LG$R_"FR01EFFLLVRX,*\)1HSS#
M&%.1$AC8&.8*BBK,N#^5W/"5;EA3_33/(G&^S"WM\%W-*PG.> MH 15LAQ8?
M\,-.'^:)D:.8^JP.\ )9UM@"JQZ#/_ZI=#S*!:?7Y:[_8D;+OJ)//:/QXZI8
MT/7[8AYE0..(/0"K5UQ%<Q3-6-0QDN_ A @UG^[/2!SHFM-F2G<MV>R3=QSY
MJ>J"M0QCQP8Z=V^I*3.H.3"SY?2U-_@/B"WQ8]@&7")DP DZO*M8#>RK\@)+
M%ZB/<&*7,%B+:36NC3-6MO^B[NI5\6:/G/K*1'&CH3+3)&\]CK(_3W20+1'?
M!V<X&L,XQ[GW>.K$A%;G>;JQ<R-I/'+6?1Y!O;V+8&-SG1YUZ*/[FLV;>XD_
MC@Y(!EAF)@JPE2EQ[JCH+NMKQ"NJ9?EY,A^_%2DT;]X61+1@#' 4WO$D</-\
M -0]2R]D]+&"P0<,P:6S#'S6VC,+N +&GLC<FHS9%:#[A*74E/?)DU0D9^/P
M?BX28P?H";3/@-%\0)L/'()JE06>E^')F>:VV0EC]G(KL//MI"WP(/SMJ1T_
M[+8R\VEWJ=5Z'H2]DKX%S$]U<EOZ%>Y\6W@0Y:Y^\P#,$]OA1$(_@\_CL$*M
M)LP7TY3$F(]P.8[#)XZ^1FY89X^?MX.;2K-<FNZ<C-2T9=8&>VFL!:<!5K">
M#_.!4+A C!N%#W1I"/(!BEW)DQ]UF(-,^Z\E]2>&EOWM+66]>K[FF.A<I7SL
MFP*^A#'#6 _ )2;,"0J'R! XXQAI"NT5ALL@U^O13\XCI6;(B =8F9B GQ?C
ME-T/]!G4>29G_M)Z>V@Q\B]\.S:,O''.F 7E05T04X(/.!M^$UIV19P9-G<1
MB_(..IDX-*8X:_%AY)WZE<P%@_<'U'\/TXWHQG3_]MJF[.#  TQ7^92SITQ%
MM1)%EY'W8'7K-"&V-6\:RSB7,UV\RGK.J"HV98RG<% 48QI)*-2JWNBNSEJS
MWH>X*^'9E1&F#L7G'5P[30RZI0;N1K!V,7N6.?)7NWCBS@R;>0,KTQ@M5D2Z
MK2^#V#F5/$,\\=W4)R9TX73N6RTM,\.7Q<*=09G_4GY/-3/U4B]%Q=C"8R$H
MQD:65U<%--L7!&S]<J+H_=[](J$MR)O(NL77N,GIA76:=RGG"/<)%+B9< *L
M5SH#*\?9)YUF>Y!]<+JO O',)_3LE70J:=@(=RZ+3DEKC3]D<"7KKBZX<N[L
M$HPCI^S.K2:@03U8YQ=N<^N^JA"LHH'Y[2R;GCTQ29M_(^M]$&C4E7V2TU_R
MQO2O>_3K%!SJSG4%H)9.*8@GSGX!U4T=6T,&'^CVA--:(I@."+4?GH_D)J9B
M\&PC%U$#E/W(<,Z:2P[4$*)(NH*:QV/6^0 $A(V.'0/)N%J?6G;TAZKR]41S
M<FHUE6WS5YDHFI95,77A7/_ P)[@09%](0H12!BT2TBDAEH/G(BGJ5%R9+_?
MF?O^.Z?7VV^,]Y$BY&AK&N*K:2GRHBY7=,UB)37!B./-5$((83OJ-?7#EOHQ
M0NR#LSCU\]Z5>]I!M[*_"/0]'V>5Z<B0VOH39CGU\XO['DL/2H-:)(X"VQN*
MNA<8869^K[1"_(=5C.$(9RM3=[WC=TY*N"V"6[FM>&QLZ+IVB-T[5&V2M\K[
MV"V2'C/1%^).V3I3AJMQ4E(WWOPX!-\#T8E0A*V>]YQ/M#]9$5QE[XS_5+R?
M>Q\^7PCU(3E3(I1C[8[IMB9L#XPK[F"S; I;9[@Z\^1YX6U)7\P3C\D<G'S3
M&_9B'#Z?AJMUN ?A23R.E3R\5@FV[YO$[$"G.3,W,/90;HM)Q#PT)]/E,6C;
MV3FW8^(;UU]G,E=S3!/@GJ%/<50ID;,MS2^'HEI<GM/*5I9]B4UG8Z,7OUP6
MVQECJQZ)[R5/F_7.0<F2>(L'%:]C RH<%V9>9<D2'Y#CZ8.8F"<^#&Y'?=NJ
MSM#7[)^Q(5H=Q-P3.A<C.S+?BG,'?7+8%^*[D'5\@",OS:)RLWDV\9TXR>U@
MQ(L8TL)%N#0G!%V"/']=<_O@+PGGV^549RV)5,<TZS<;J,]F<F^2#]@M,O#T
M%@I2$=MQT/8LI"2'R+ K4:JE(%)8FGM>,25FMC<62U0^)9Y3%/FH<?2G-C/C
M2RN"'1ZS>A 2F1B#YHFMPI(;_"EQ0?.NR]GA4?VV9*)]])9G!MV[HS?BG0^_
M^A(=OIRM3\6"UW)H:DPV;XL>.#J/SB35BZ1@#I=Y<R2'6CTB?)\=H*L7C,Y5
M[I@AJ^_ETI(2;\2Z$^EHMA)'E?L8RBL2'Q"%!R*4S_EX<O8-P2_:E(U@8&4_
MS#R]0J=0-75^2<>*2J+N5A_>D#/W3<#6O[#[''A*X'?)D[!FO;2JE'(*-W"(
M-]%T\DK0Y;H2WPZU^W?OG@AM-V(4)S\[6+84KS=<]?-G+<LKK')B(??2(ZD7
MW4J+V?JKL:Q8;A%/#MMABYTGY9'JQVGIE  &NHL$)4]],CG-UG7>VY2*H'54
M3?SHESS+//3^R*GKDG[;+[\*W/M.'FG^ R: #5J>M*'">I9EH/R!N./\/:1,
MO/X GF,_9I''+6_PUN"XE6ML]G#Q?-AM)1BGJ1:SI]BS;T58!1!^+#V3 :[R
MQ-4@%F(&DME:O!'29I(_1'G>L4R((&G!.'/,^M?'NR%1S-VP+8ZAYBTQ/W7<
MM,<BGOQ,+KN4=TR%8:6D\AO&\ARU$UZ"UR,3T*1 C4#R"3 "LF5\$>QF#3W\
M:1'LJ,M%%V3QU0"_':=%/M@%'B2O!I*LH5Z]6)5;THJ$]G[.36W=S][-<?W$
MT5AXER5"U6/!TCC.)45'WWXRRLVR>GA)0[+PL5PIIRO,FKBW!XCS8%OR1G",
MTXATV-;(G,T\B#4SCJ)@%%Q2^-C\CSD+ O?Q&OV:JVUY:XZ,THF)[M7KN557
M+B]<N'?]S2GIX>8:?-DW=[G0YJ\5Z* PT<U>A4UC>S_)W\SS S[?!,??P^IP
M'7A0/S61MV=JB418IE<P^GKGQ%SVC2T?8)"ZE(=^?G[T=$?4*[-79]P_9U[=
MB\\B^>6 >CC:*/L2Y ,7B,)+1;->,F)CR >@FMD;MC,2L>G'>+W4#K5^\U%3
M<O^E[.?[^_*TLJWN6-UO#WR_5>63R!**\*'M2VOTM7MEM4=O4O,L)6O*+LHX
M;I+]&)8-3C(#WU$J.I>W@I6'2,/AOT@2X%$^<.ZV<_%G)7_A^K?%?OHBHD>?
MZ65+;R89\X&+^ R?W5#N1/#>0W8YB4_B P!Z63J%#P1Y8]U&[61"K!^\F]-+
M[9G+0,N-F9D$6G[Z*'3++V(UU_F:?]AK+,,!/;&RSA,=PS5\Z,5A^("&Q7+B
MJ9C??&"A96G<M>9=S6R(+@_:O/^AH4?9GE8I=M,V Q4EO\]"RV10EP_0;:CD
M:3A+$42R3\<L'QANJ/;OLU-,.CUB3M_FS J[KOY2'_;7>W8,3U=OKBWI&(2"
M494MA5)J/G4MQ6]=\^],>VOG"$6LO#IUM%A:1$.?":-BZ4),-PJ6H_:!+<N1
M!'W:360QP4SC%,YV*@&,,[6O\?DV)/&PIH%KYZR=Y=_<)*N]V^79]B+G+E5T
MCW'"&!^0J.'!.&<@FYR&'"2)#<8F(A4Y$E2N:2Q:SN+!+27/CYEZ]B/FLR?Z
M*H^O7W'=3*M_TOX+^?"@_P$8<:J=\ 2,[_CE'>O>6$?(T0SX,+.D$';O3[@L
M9FQTOF/-_ND %%E(4.^6W=9!9.=MMF4?4],P3O+IQG*ACS7Z;A'O9-+;#=Y/
M.KDG6_\K/ TKV ZE7 <"/M\,DVL7X$T4[&*>[4),+E'B;T90I%-5L]XGN;2-
M_HJZ_G0T*/F<1+I6VG7 [K14Q=:MMNLT%%N/8\[-PLY_@4B-%FAX)3IL_CO6
MW_<9B.Y<#96;\0)#MV).AFN_)*QZ%.A'6".NU@:%JA'%%:\] [AG_L,';U!8
M2ZS_.7A[C0>=X'58B@4CO (JG*'<>P-LV+2A#G&UM?K[UTNK5I=F6FJSNO;5
M]&8 *]@)-Q:4XBF[N3GM&KRW,,8C;">TDJATBN$:E@YQZ(':N):WFZZW.Q8:
M/WC$G:7GN/GXLZ]C._;9NK*/87P9RO1HMD7\)R)<+-Z"8T%LKOW4ZM,L>:,Z
MNZ)\9M7NX3,/)V;ZO'^>^Y9J-9L]PHT/?A=D !LBK!.0KT,Q'@PL/2*:'<^;
M(1.TL<IVN[HHJ8S%I'M.C(+@ KUD<^(]3'](J.[#XNM>-A71LX2'>QRD(+Q]
M.4 SXP.22"HVBP?UU<E0VR5FS#%"9GD2NZ7UV/(T[ 0?0#FYT?:M?F$[#.C9
M7=.:;?EIM&_]]TX GQEI#.KJT;48CJQ73#)=B V+)^,8B2"<FI^-XIQABE :
MFQAUP^>S5T"#D,@Q8G6$9&/Q#8>#&Q<GO+9I/#X[.5IDG&FKL[FU7:FPQ_IJ
M:+AI00320<\WDZD9K;GO^P%-+;8IKPO.^(AMU*-+L,_Q@<Y!WB0D);,RYL8Z
M6P@2CP],8"=OQ'K05CGK;$1A2SSF5:-_N%KU:5 /PM^-3^U*/"@G&HAT$VJ.
M1@?5VXR5C=AB_PRT6SH@:U_>4?[]5,C0H=6MC[RK.]^<X_TT3/JRL=K<GE&:
M8"<$ND$KM$#&3>/U\E3NS1O3_H"'U5"#\:W&=3>K6QP3IA[%/'[;B.VN377F
M*5-3O]#;K$ST;10\1N@JYXL)K*#7Q@(<1S" D72$8=6SG#F.D^&X^H8O>#*+
M6'>%;Q64T;6:[M'&%M[>=)C/2.]\L;-_R3M904!C!A;:D#<>3S:U])[X:&I2
ML+'*$_-@"V.[ZN&^ Z+QO7 &@42QY .WW!=.Y?/D$#1C&ID05\.CKL*"5A<G
MZP<F>;5$U&SO9;O4T@1;(987-P5+*8#"EP],2;"*_WB92X!"?+K;VA+"(VXZ
M"TV#OSRGAC#^N$JFVP5&_YQ4FOLKG/"0$<T36^8#XH6L'.Y3/A!L#'J1IF",
MP>HG,%H.35J?)[O\,N14"!]8BO]$#ENUVL!=U7@UO1H4%:=C#\14<.2?_"$N
M*8+<C%8!-@S;V0W)7,^30>WV@H-.I#J[#M;LNND B<:+G/.QG7VUJO9ST78>
MLU$*%0P#["7I27@?S[@-<D! _)PJHFL9B"%WG[7^M=ZYK,FQ=,4B!J/T<U6I
M*,N+S<2\.3W?%EI?9.C5@XN*ZU'^2UB95B$*7B%X3H0)RS:/@WLRU8ZW:PXN
M$_:6-H]*BFK_Y=7]7C-"56;YI<:+JY=W"KTF0+ V1F0?B>_R,>1FP>=+H*C1
M6.S=A0E?::^G5B*E/+])!4;WZ+RL(Q)-M6&!>2J?L_YZXU*#C-&&&3"6:1 8
M"3]D#"2CVJ4A@S \7!5;+?S%IZ9B:E;G+<H',J1*:T:<]?+6IOOWG-_U*MCC
MKRR:A)S^SXR=@OIJUU$&)82"[XLQI:>O?^[]+JIB<&7F%SXKWA;;88D-E8!-
M1W23B0B:-#L@!"EEL9S6KC[<@$WWT6!&)R@CAPG^%[(TBFCGFA*==#-T3>B2
M9VYJ+VC#ZK\]EL[!SN-(C*,D^?@>) '9@Y]:Z",1:FJ9CMTDE88B3;C\^:5B
MM8RWOG&!.JMZ#BF!61?0)J?T+Z8KB99F6?5G]7V">JR'?XH$QP;/.EW'?0BG
M!$-)Z,N"RRZIXEEDEAXKG@\0D:[17S;L,!.37VFSI*_3CXPN[^?5DRC&#!QK
MG;.#S+@?0IZ*&6!%3_NO,C,7WWW\^6@-DLU.%?*S4KQ""))Q+$<%VV'*,\>X
M-C,#DZG+,C]^=\7D(X8V%T95S,S^<'WF]4Y\:X6@2TAKG4JM]!?.6\6,\7OQ
M0SB&/1+<J4?_P#::X[W!-5IQ%&OVHSO'[GAER2T>! ]+%8V51VUZ=J%Y3 49
MN.JG+RN)$F_HT;D6(>/.-7QQ(SJM%5XY-QO2?+PE*.J*O^Z["<.?=^=FFS:\
M3^>F)G7T'05L;<KXP(68^+Y#;,="EO[>QZO74.1:P9^]Q\TR%W1;E?O@+X,X
MNCB&&QSB9O8D2BBWD"=#2O',N06G;.%UDED#A/-;VT=9)-OKL1'$=RM>^Z.S
M'ZQ9* @P$!Q%*Y[HF?D<<)<TW9 QS'K&6.]+YZG'Y'>8>?90#Z,H>+HHQ\TW
M+%:17MWPVOO@EX9392T7[8+D5D@[QELQ/ERHQZ&$040C7CI^EL1HL.N $A77
M9;=]"$Y1Y'6O8@E8PHYLN!7=[NJ&YMG\HO;3A:N9-?K3O_ *8%!7SJ;X[4R-
MY"1ONW<!;:U.F=7?6M)FXI*1CZ4!;AX?\,6!@?@I$BN16P'M KD<A>UD,;=D
MO<#Z\@&_N$*V-$UI\_"[U5:HYCXL8C?:$Y^J59\$M:""N<)8[R1/1;#R0#9U
M6?T@M4B/=:?PB&K%+:,&F*ZAZ5R72YR=DR9Z/V^LOBRS;_T*:E.-VO+93U::
M.QC<FEKIU'#"]-Y?$G^]FY[HCTP,.1UD\.SX5W7- [10RC;)>PG6]P[ !#@[
MH9H (6V' Q_P)XGA$F!0@"KP@:.#[?*>"&/.#CM-\"XCUU@F-%ZQ,=<!6S<]
M5_T9%IHNH9$8:>.@?$>?MGQ34QA,90Q3E%+GL;?A*FB[;3'W$ WZU3%OH642
M>[W=KUV[=G]Z^J:"T->IV@KQ%R+[PQX/VB(H>'D#/(4D,_%#0HCV:&*VK-22
MMX32$TGJ6*L<$5@=H*>R-V.[SO$&X?5\H&\ ]"1-P!BEG"M15&,:CF9,P*(V
MQCIA6A]6%]B6)BWQDQ'#P4L^?4&,:(H2CGEH>2$NM7-@R\$%%^Z>$.*<<>IA
MHO<IZGO3/8VYW_0*F$*JLEO]FNSWSI]UM <PS]E&V Y]CA##BF)%UV <IE9D
MN_6UJW*?Q!N"E;W6/XM_;Q_F=814]RB<^EYR:^7AL;"M/:]7^@U$C^S6[PR
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MIO8-\VSY28STE%*8?@Q][(S;UYU&:H#3NZD8JS_'IP*8ZV 18Z!3582CL+Z
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M$[*#?2<U#MR&0*>H?IKWCMA<E/B!*8C5[&[?D>385KP71>@;;/]X[-K*UM*
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M'J'0&&'3K]V2_RYXQ@[8A#N)=/P^%5[T9-+Q:8@J1JGQ4\T.8F/:CFU+"2\
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M<HC&/!;N4*>CVF"GNE_4%&85C)+M4?AH%'R/77-I>Q0WB80V1+ :QMNW<]3
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MX'\0_>Z/_\]*Q__A3&_<K89IM;*6%.JW!M0#Z:O=\3L(.TL3Q/]FV/X=Y/M
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M_R';F87'LG\9^,+*7U9#*>L(K?5P(V[_I<;Y&VOA7.7_A+7P',JY&G]I*U:
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MECK&W );#=YCA^$Q.RQ W$N"F@#.B1\"!%__,.88;@A=OBJ;ZP&U&^_F9_P
M%#H?4<$FFY3N48>J"IFW?HE&U^X^ZWAT5Y6Z)_1#6*O$J12YHS<_A[EI)_0/
M6A;TUF68&"72VV8BX,QUP52FOS@I":"G7;>),]I>,NQ8E<?T%" \)8Q_?)]:
MG9!1+5]T ;_;8H!R;YUC*6ECYE(C18?B,R>)HZ)9YNB8_>8SR73:4%LK2I:W
MDI'L?^PE>(,UQ=R;?6GSYXG43N42[FIZPMZJ]+VAG$>*8P'R8G 0.B87O>W\
MQZ2$SG7'Q7876ING#8?7#A6Y\M[73-96"H\1ACPX'& PN@6W%I1B1=-;\]CF
MS+EF^8>@>?UZ^WRYNUF>JSS(M37W9"NJCN>X";^^@< 6.]AP[,!V;D H[)U.
MI%C ASC0;P:&>?F>R]AO?@N+9LM+>%.7#C&<!G.ES#5W/@_Q-[!?)WP'(PU]
M)"/XN= >H*&YGR(.R?.\J\$PY;'IK][]Y)T]%>-^>H8N$GK2/8<+^(^=MEU*
M9]\YUJ*8NUHLB161R@D$[W"M<6]HK)-6&%"]H-6?JNX(5M()REA]0HO**K9"
MHI9O*REOV.F#6TXWTR<PV>_"1?NKJMLV56T3EJAY'GK4KC%?TD%=Q0/GPR-_
M2,RKH;U!5A<-0>M@<9I8 /3#!//Q>K881X"(!>8W3]!^P)8V;E:G O\?1P"!
M4ZMF9.TPN/_F@D"CD0<'2M6G!0($!L^;&O[#\[=])'XW :28[![/30!W&45S
M'H+BW(,\ASY=;3FH$U6UM9Q5?J+K\:O8V3[T&L>I_>XO-CS=8]SE$U Q=QCU
M5NV:*F+68!79<WD:'V@P)&]TGA @5B_O>:6VCZ;4,;/#Z]>ORO=E334XJ"C$
MF96R"NN\-E<_R#W1_?FSI2)5+2WRM)]"C.J<M\9SQ7>?QO?;5=5=)OKZ$7VF
M<%RO<F'Z7#*%90E0Q]IHI)1*;BA/$RXHK8'AZSUJL]X_)G#8C5Z74VND4S!]
M.CS<O+IN];K@D?>;CZ2,^$19N ]_!Z;Q+'].-7C8K:2!ZP!1UV(OY$#.P5WJ
M<8P7&7'HLJX5.=YIE>D'T?>==-);:=I)LWK3I^P<UKE6ZJVFOE6K&QAI_]#/
M,P$5. EPN78X&E"AWT99@PWNA6VAN*K/ 86LM7GF+4!(3,?5:^VWF=X4,!]V
MC/ECY<A E'GU:8.A&D0JYL@D97F7MHL5Q[(,/$(@G73FV5>\EFEGXX88=7>W
M?-@Y<CKY.V%7O<R;[7[UQL<[=3;A549-#49]/B6Y:3@9AL-!5\LA\'N$">C3
M@F99$:DTSG,V.O:[  %NRYB9\1WMC!M9US?SPQ]TP$F"89)QOB4N]2%'^GOB
MOX1M%BG>Z&NP;YN)WO>X-@$BDB:/T\+:@6ZCA#A*Q5,B/5FC044MU8YM$Z<[
MI9ZN+3^T9Z-\0%FG8K)LH8'&MI_X=M<BTV/LH&\]P=T<2[5*FI6S*Y=?CV5P
M+^$:('60S?9I@%F8^?04NQL3BU; 2K@%%'CEJ.^7O9Z=4Y#_(<2J .-D6) E
MSRO;=<[-W1V1G1^ OF0#JH\U:\<!%56EW,O_=.JZ(YC'MK)E4<$0LYHR%M5K
M/R8N\(9V9E]?>KO:S?*W"[HE0RG?%'_>)WTZ95L:U*OM$:'EFS931_09>D>7
MFQ$@UL"N:MI#F8H7(#XFA\:$ TWHGU*!<TM,X+LJYF C,-<C0" G(X=S$S3F
MZO_]NSXQ3 _>K6H\_RIJ:6UQ42]'=LN)_J_6_'=TORZ,01=F$T02('KPO"RX
M2X3'WVF,[=\F0#C#Y*T-LA8@J#>^7Y);R)8%X R_P[1H^5((DZ4]"3\_)*#A
M/EB">6DJP'FT_-G2&,Q3 ?X^F+92N+;&2;GD@%S\#PKT$/A"XS]#F=EA#/K:
M(M%? GO04VQTMI=Y K_2LX>SM\:*"3-)OQNS]^Q,(R+_*\SYUFK#1C>_WQOX
M 0H0'Y9GKW]])KLE L/;!8C$[\(J"=N(T7\]O></P@.R>6>V ''6!KKITZSQ
M!X!?ROEWX7DOM!5XDP@WN5\*SD5L'O\' [A.:>[\*16$6F*BOV\Z>U^ 6%Q/
M861\J6?#I)VR&?$\\QOE<:C;L50G]LY*KX+!YC=EP[2SQ7:;@D4?E=\6TGR7
MEV.%,-#SHVA0Z'E !;'-ABK.B0%'N:I#4$\?6HQGP*HT4@P$Q*CCG!.3(_LR
M[*HK,JUZT]EGBN5+QG]S)FHJ=&R4+BA:'9.^D[@CV,J>5Y)ALY?B@N#;Y=8.
M<3Q %_8B0S\F2%N2%\%_6F*\?=CR^;I WVO<QO3KUN]?$-(3M+XY[RH]WM [
M]%[T9AR"V)[Z<X)K!S6@RN>F\3!WL>#?P:EA=R4VA^2HLHDM$E=KS4M"LUH<
MKB<M[DCWV6R6Z[&[.:&;_-L.UA5+Q(67H/?IY^^R<MY67@J<SIIRKYJ9%_YQ
M(N&K\3XLB@6#\\VEL89.!>^EEM@'1&I$)F>J:2EOT%4M/ V?803H7IQI4'TH
M;=A?CV8=\Q\D,$2F8>6U\C8_WUB$)_FQ!$8R)!PUD$8:1G:8R7Z%'J,>\V_M
MJN^OS$YW3'=<NZ(3B:@OS#N4[:2WY;V7J6M?5U%^W7=:N?#WIPGL.:H P5D/
M*G"OC>_7OHE#DV[-!KJLGW6.SAO/4:_N.4?9^?CH6?Z#KJ\F(L)7&M3[R+X"
M1/25BG9E!6AU@5>>U^TP^S["6IZE1&UX_$ B;C)/[>X5Q)>%0X^/GS$_;76J
MVWMXK@]RB>1^>#YY?38^5]&LO)A*C<BUV8FL/*N)@ST@*$0J=7I'+^X2KFGY
MZK5Z-*BAGV1L  VB2"(W'-I:QYA5I?2YN&HS(H >Q!HR^.CVE"V5%L-'3EI\
MZ)C?J73-;Z45^;38VL+5I[(JW'S3AD?:@\;Z'Z&>5I;2D3^5=3N7>#9C&%&@
M0;8V8K0()<3#\/&UP*CRX68MEM*H?"%#6V)J?V5#YF3$ZJ-O+Y0;?,V6?4-^
M(V4NIC$K0"" -Q-/@7XFL)^:K1#7\=BZAFK77UWMPQ(>AE&/?W'561NY%S7#
MQ[DG=#5GDNA"=T-+ $B^OVEN21$]?P(#;:XR.K@\[3JWM) A0)CH+?S ?@O/
M8EY[VW#"<D&];NFZKDB% -%(73[-\[ (=!269\TP117W82SRUZ!^;H>5NI2K
MEFDH>LK=C7>;"ZMLM;\K >J_T?N5;6SG^CUO2LV)EQY$VG$<P]0A81<)[$(!
M\.80<FF:TN'PL?>[H[S/K8Y1NU[+:T,^/RC!RS%JL?X_=[)<CH&#W[K3<Q+6
M]&U0T&S:[Y\7-CA#$S8\S"/%[W:F6,6_C""_B[.NFUQIK$[HB(LA](K %^W_
MQ")P8<]N6GJD[YF;P/V[)S^(;!TX$W/H%9XOZG /^-_#]A<XGKR"R=@:RE:1
M6W:F<C_7KL1Y+]^9A],%&K1Y$0Q_69XJO[!V]24OMFJ30J8U.;XHM*A!/WC^
M\Z!EB)?N3,&DE_S@^7FU;,<3MH>+HSTWRBR=/@NT$:*=%."L8_H%"#&LU7.7
MP<%)A;T![5<O.+P_Z1LB\4ZH5BKJXS.C0/4-"RYG=GQL8JH:8(Y_Z 3,%X78
M))Z4U7%*CU$(^UT/W?7QJ ]^\+'>^TVX5904B0D8?BZE<FW/*-%W2MRZWZRJ
MW="V@G3?YB;08(6F/Z>\W$J!D7$5_T&EBRKG9E4FC;[8/(S%6MSVW'\+:D6[
M6_G?5[KBSI_VHU33%@-Z5E'.;BNYY588X=O_4*FZZBYI\*LOV2%X<:+D49A'
M#. +#,:UTLHJ*%7],=#VIB 667GG@EU&R^%C-:><?2SS8YDV6W)E>'</;QYM
M?SMT6W0CX3TJ$L4ZHPVJ*]RDT(D$%0'""[46ZNZK&A%C$V[P= I G[/&RI\&
M_?U\SXL;7="KVK.U;W3G<^0%'\ZJA$[DK2:[T[*/J'=)S6EI/9!#R-.EZT)?
M@<JXF4JN-M24(]F#!;BGL*?B&J^;$0L%"(^)_E2OC)!#/@2M)_.<(5-5Y!W%
M+Y'[IC)!!4BBFT\!+EJ2A;U0I4F XB.TC!YE0VB&;3=/FY\:3@YWTUR,LC%\
M.^_ 5]''ZD;R7K5.B_&/YS[-V7QSU]TG]*&T[)]I)41? TQ$4/\;Y Y6W$P\
M*ZN55MF92+E0MW[(0647RR%V^D?=!<?BKLO)E1\Z-<TW7NL0(/:]V8882\4@
M<<V82B*,YFHD&,UQ;2@2,D4DDMS)=G!@XYO>N]GWS$H0;]6BGX5=,_-UU3VO
MV56VI]9GP2_BD70ROL>[J- S<V_Y5\!G0IZ$.Q)E8=SC5Q;FAXX/$8Z>W99_
M*T_TG:1VNB7&Q:^ZP&,LO_H&.X,G95ZO8EC'0K7,#0DSD=%!2"2ZC9CD5)"(
MU<_S[ONF]$QWJX9RXK&XM! [U?#'9AMV$6MX0LM*[@&LY.)Y4RI51K\\3D[T
MA2:]DUM?^5794.,)!7&@&V98?2:%3.1/! WH?TA9$B(2BL91:X$WJ[A0[5>8
MMTE@^1AD"ZTE'R9O)K!WDHU^(^N KV%[K.*GD)5Q7?NU&UV03+6<C5U:7WMG
M:L-*P( &*KE(/C7(9X/9OKS,#R,63YL,X[$4G7:AD,N=Z(O#)B3[;J>:ZOBU
MA9Y#:_;LOAV.NLZ[Q])N0B^?K2B-9VHW4"*OZT^/,3J31Z18NL8Z&?49*F)L
MT>X?PU;'7WN6^#G-CGS341HV_?:;]%9CSW./TM<9IV .(UW:"0Z^<I_\\_IF
MG*V-N=^%OR,YT?PZLA#4"0/)UGQN^,CDPE3.JBH6OZ0HWSK_T)'J7!>CJU0U
MJVTGGCINC;]&]UUC=4X88PC.06*/N9=Q'>2576A8Q XY0*O[O>AS-ZGY_'OK
M^\H?88\FGNK%:LE]3MR@XPHSFUVC ;DOD^?S([D#)VA#39Q/_&3 &PUNCB5Q
MCX0FUJ\7(.)K5[,E6VG'NK';??=X+67YB-B>V41:$+VC]36*H_SMD)K-9VEY
MVT.4*-QG 4*$0L^GP.KE E$2I$!BUFRW)I0L;DWHX9-=<\9:H'##;@E#IT^:
MH]4Q%Z1IED)6/Q+<Q-_=R2_,.+^I?TZR=JMT]%&]"ZD!5\O]EIPMJ.T/]/NM
MACJ0%+2/#56!4PIBB*%  U"&F79!MUCQ_?K"$V?<%UOW+NU,S3-7VDS,-GHV
MHT&>M]_7?U7,YB@=AJ9E34EL\5? ]<K@FBA5P'0M30Q2.QOJ^V-.W/(IF'G
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M?![D^H0]#-C,:U=5?M]UZCKE3\.._W-EC^WZ6;LER,QY"\NSFSK9%^[_2DZ
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M%KYA3K*3 :QLVN]TUMM!H5L\OB-Y[!CW\Q=.YT'J?Q%P_:)K,[A 1\4&^40
M38051IL*:$X6:I5UI:S>XI.'1O-4B\\5+JZJ7OH;.U%7+E_:"30<A*2 !D-C
MR0&>!1C_V,=8K1]K5=+P"!2IQRE4R4R2U?O4]\5^H*)QQ6,QB@B=/:I8!EL$
M$KOS3VO8#[ BVC,HKBO0L%'&$G0N:.%0Y#Z'(IG\IZ^)H>Y-1<,V%[5&K=*2
MPVZ;;A05-CCWW/H<K-PLH0XTG8)ZN0E,)4%2-N7@%%=A!L.>XY/XZ63[@+8'
ME.DLP[FAE!]+*/8*<%>HR%FT%!FV M%%SH%.SN(0^TM$XCM_=$>GDE'=8.?E
MCR+WL2;\0IXC$S^XJHF3R[]IO/8PNW&L^7I0S&*T$=J#610AKV5/G;1H># [
M>R^_ND6I(J4XORW]+0F06Y GP2VYQ']%N82*QPGW+$\(LX[7Z=2K(,!XYA1Z
MC1=M+4^<;:Q\75GI5(V:\^$(7TYHMML%)9WMU,?'A3<(VT 2KO#H%$$;\ED=
MH3?/\O%<CV8T"Q]1-!<1S;TPY^\ZXI&%]WMXH588$G.D8\!MR.D%(G83/Q\F
M4(0-1AKL LYU%J;EQ>8%5Q:^J4XVU"_"\&18AQ.N,$BI3<?;GC.W:?AR^2'E
M[#WK0M8*<5&N"@Q@R :2M@&WM27 RD\;M"?;\%118A6T=; _.//+:V;0/N3,
M_FG"I7FS]SG'!0C]][Y#I2_=U(<UXGO0'MI12^@9D>>XWOW^46Z);=3^F!F>
M82%XT_6X4\2>U3FA+WBYT(F8N^:^#<(/Z:6*LD+SZHEH^B,,Z\S@XS[<9BPL
M.Z)V:+5%5W@5^#AK2_$\R\K8DJ]]9/:Z1[5H/9E73K,\<]%-]0IB2R0QD)\.
MT!\1)"F7.P=V#'%8? )V-5/BVKN%INLQ?$I4;LRJ%UOX]].V=#?.#OBM8558
M!%0FJ@I7WBB!^PKVSI42;(=ZPVQ5CCX_Q4A/(9GBA8FONFM*1XL=:7CTT3?E
MA'7X*3_3NC1*1Q.PI_JRK4DP9OF&T8NXIOTB/)D,CCH+,YV=!Z;]:*];1?7!
MK_7IWGZRT#OCY(&6SW25TVO*=ID:W>H54HNR$$G M0(L>P&"BN3$P#G<^ PU
MH"H\8 WJ &H44AK#:B/R:#X4*2T]PYJZ T&*Q6[23DY#,R1M5>NFXR[8E).2
MZ\G?B!^&B#^=R#2HXY@ ,>G4N[3E]\NU81XSC[EN6$E^%."!DL)]0E?LI6CA
M8WF&OV4D?-BDU?NC.4E:R<KSK<K%;@.QHMNKK':?MC\_&?2S5( 0D8^X[PV4
M%K*_T4 3D9E$A@UX# =K&I6A /VTL3&\M@=5)V<WP1LQ@5R^8U9<E(*$421W
M"!)]"(>9&XDV,\*,!G9"/R2#G)ZIJ87#Y5S9S ('*T"XT;Z-+0+7R<F@.C<$
M5.6\YL>)S!1RY<"C<\SU-! W.=<T(N$#!@X-U1U=^RZP\,O]^S/J,MKW.K[D
M?MFG&7.&6XGS@5WZM?OGM]P+L/FM)D%KD>!E#"S!&N5]8;0>:N\PY"5=_7IY
M?G?*[KE,1#?8LWSC$-S)F;@62!15$3>S? C(H^[OR)OI#ND3S&&W>LHZWZ#W
M#DWV"\=NOVBNHKC'^]TSS+TC$ZE_\:7<DAQC!C!GN]YP8^*1F/P^0J%C2Y!;
MD$KP^S6WE#=XE)Y CF+NP8UVIMV@L$YVL128(BW(9(H*;SM;F'.I"VO.KQD%
MHEVE>T3B]&8.-WYT+9YP#_)(&>WP3+O@%2SJ=#J^_LJ9[7P#4&H4+\2S!E%T
M6CQ:7$N"$FMTF&%M>)+U10)QJ^W\@8IK0R7U%L>.C._EM&X3?D_>@:,"+)A[
M^.-OTE[".DL#4P5WP4=6P:T@(F@I0%1A*=.=TY4D?XWI$:NP$7_"8FWS("G/
M [\-;.>Z PUGLIB="=@M7$V@8>LT[R##9HWW22>G4$H;1F'ZNQE[$[[(T2E,
MVN).ZN*6>S>Q7\X)8XZ">9QKH/8H.B5'CI]?:TV_/UOK3\_6MNVIU2[)>MM;
M[.M_Y,+D[O6OXA=OI6:8J?J_,[,.L^')>D!BJG3_ 0W&AP<2<3$E/%^V59M"
MG"5HPR(>,:Q$R4PF1SZ7O=CBN^Z25XFB;_(!QSMGA #Z0P++SG\%'"]PHE,"
MA-008Z2(Q6V&5K!/+\8:;P&5FDFB_2I*?9J-#^AAIW:T*ZX1S?".CEUYJDAH
MP9K$DV_B-(*EK)H65%7&]/(%PN\(;>AR8HRV?Z^16PA;7AE]EKV5X*::/UOP
M="+9C\M(:MM^*DRX_>O:O56G@R%AJ)&R#GV!"*JUS2B]P)YA6Y-)[#;F7%RM
MQVCGK>K8E-V^\I2(I\?LNS\B?UZ2_&1Z@!:^9KNMX1RX:9"EP#- TRV!,@'B
M M!8C.<Z!!L50XLSX0+$3$%6#4U7Z'O!] 2;RR#,V+'4&X$*_X8ZKTJD.-AY
MF-0;Z/- YF+.L6=*%Q-3RXX8F!_[ZN(8[N"%(6!8/OZ<.=Z^1?H<IS_K*S^O
M&3,X$C+"U>= CTFL#]/A;ALN4 YZ_LL^NA*;44HBI(Y%@_I,S :L(N@HDF)T
M\HGG@LMX#I)P%GJ_OIE=PO F&1]K5+@B]GAWVLY3NVVM),L2$#\7.6:PM]S!
M=6(J/:8-D3-]U9]QLJS9K"?#G:-#RM>PU@R-=C5UV_*:=X4.D4773EL]-A<3
M?D84!6V6#]J!D]Z'NBDBNMI4#<YY^&G?$!C7X*J5,S_:2,)MYC_2K##D9F_?
MNMTK0B^_-7/$AFJ[SEXO#''HB:'(*O*RG\;@&EQ1GRCT2I0DQ8T@BK7N,S)@
M!7 HKZO90!LZ+M-VM=<+;^,-459].^IC8_PM8OSV^FJ^N;@EY2.EM/IX:K[G
M^M,E,8^]JCCV>^TG5F9G/]'88'LD04[UB.UOSY\A$+L0"%N1;_W3;+BV,%I%
M$7"?1M3 . 8Z&L4RM5:U(X..H^'$U:$?#/'4<!N2?.8+LM' [;?Y0CN2\-E[
M"DI+YO[IL+12W"!A#<4''4=Y.=>( K<&Q25#6T-)]&12,U)J/(!WI;+[\4<U
M_3W.+A-3 5L):@ZX(Z4Q,D7JF4J;=XD8T7AKPR$KV")H H1'/%/[2\7<+?1\
MQ5@D9;J#2/FQ*2=R_P%#2/P 6Y5NTT(0QVK )3Z&<<^8=YI[@ J..N(M6$1\
M+CL-GV"T6XOW8/[%K/^,O([[7'2%I2+#,<M;8Q^WE2PL0$03G.M5(=%4=E+H
MW/30FRZSFUO;'O ?\TL]OH:Y+([B@A?*.SK;J\D=_)RVQ'ZZPHU^)C*;3S9"
M/07\(O*,/8:,VU'9-4:S"_H>(Y%&LZ@AF_?+(WP6:-@/([[3**QM?GL,)@L0
MJ^,XG2,+>@\".U]&I+X=5<%DC875S@Y]9;\"_5, ?R2HJ==7SD1)867@]#H'
M 8:$L%UU; //D?VTW;H/:^F_(BDGHO(V*74:.N?RIGSO&:D;;XA%/<N(@YI!
MJ<]<R1%-PA[):%C-6&UDR7F[J"RGO?Z'K]$+Z/C*IHHL3MC#T> 1C08!@IZ_
M/ GJ8L4Y4]F%=B<.IC9,C<Y1]9F!UYQXNT# NR&&?%AC:GW\!ZWO7*Q.^6O,
MKM9WHN*JK4+]4 N<TI88AR'93%LIS&2QG.M=-]X3ES#!A*HP5ZY_455XJ<ZC
M1VS,Z_Z;+-LOJZ0W;;IFPD8-VD!BB]PC/._E,.X%O,R8D8+A9K /6O,Y-)KQ
M=2Q)5]FY&9#2G)O;J?GHE?QH1VEEY"UQRV]KC+AQ&=E/=NE-4UA6J $S%*AN
M/GV)01MLMV7'\=1PFQ7TG3J3:\UDGT]>[YU^ZE-X>ZUHTFZIIR9;5$\T7=5;
MH+38_'1",?SYF<O7JA44>@I_-_N%;HM53R_U5L6'!3#J]E,7[%+ZS%Y6U-;Z
MA'H\W+X-OZ-M4_RZE^(WKSVZ*U<:O3#&DRF"Q)09<T,D!B'!GW>2Q?2/0ZV%
M-H3FS#719,E*WM5EPV=#_984(FYV?FU6)Z5O65!]N#F/4?^AT6><REO>+,^'
MVO<3XP#ON6B:%,4#GY39V11APREF!V>Q#H^>'4'%(#DCB2&:[H:Y2C>"9'>W
M(U*5,K?_YG?ZA*+P."J.PK+W']+@%'77GF8?AE;#KKFBO0(L9 V9LULZX["[
M1WTQHY=(<0!#W>KT4,"SH8-7"]X8OU%?M>WST6_6Q1:'BJ-C64B>?  D%L'6
MX62S%Z<C&$AP\],[5T<[8Z\'/XA@\F$6Z35CO&_F/.6F]>5V':]#!E:;5MQ4
M(QY.X*\"-5@^L/YFLU*;",+&R% GVA$6)4;WENY[I%4E2E.>O?'TBAS'E#T?
MKG4TEZK=]6$@!_"0O3:?A)X^ L*X_O3)(\E43N8_HT(YAJ?3UCAC ZW./E^(
M/0<N%H:FO#7>@$R1+SV8:YE__PL>VNIF$^J'Y7K)^]<HI.-L'BZ<,@J"X2B+
M_U2 N'C88Q0%;B?RI M@@UQMK#R,:?(*86O#MKVV0H!8-U%]^!U#VNI[1<*Z
MF<>?W]7PJMZ>>ZY\2^X!G,%9 >)>RS^YYG0 FP9E:DY-^(,[:D*%T/0'A IA
MK"U7FX/B;:=)193/A X1IB=X=:\%B/0<]_?W?Y)FACYL$_[,0Q/'<1H?+]>>
M9"2[#MGV!&E8E%1PN0;I%G[G[AQNV['_[KIU%N>:HD3UF#1EBB\:/$& B4>]
MS4 _)$?D$'C:XC;R,$2L5N=TIO(3^?%NOB'X\I]:'(+AC)+.-_.OTYV=#R5E
M(%%7\BX,J"8R/6L4,,:O@>1BL[_P\PS);U_R4XDL?M;;MBJ-$2-_K@%6 <2S
M"^HI%>ADK)3R8A)Y?<OS-GJR%U'=K$?A1-0^;9/D#>;J61OL"A?D.#/O9M3N
M"BT4M&&&9""Q?'\VH9F&I%SL!+=<(L37:C.R2E<8[V?WMQ192VI%-%M,:[[
MQF\9$)>5L3@D+_*Q_]*RYRZ?-N6)8MGZQ^$T:GMQ4E,H22. -=J2"GHP/9K>
M7Y_8N?7CCWV16TXP=Q5=%5XS?6_'[(  L1.A?ACV(7@,5H-NRU\M@C8>S ,!
M1^K8F)1:!ZPN/A:UID+JFS=9JY<FKEPA]4RS-/;BGHZ#9SZEK'L@Q3/D[.#'
MX8R@MY27!6W$1(**7HW+X=&Q-L7*N?6A+,^XO=7N^7I)N?U6E1NSNX9^6[M+
M?6=G["4Q"Y'=L-F'<QK (8;_>J@'_;*3)X.!Y!WJ\;]-DOI\1ZUH\6LG,@L2
M1DO=G8=>;*X?LAP[K-(V^+KIF(-W)/<.KI\/<U<O8@RFRF%Z@H&DQM'3"[5H
M,3RO//-G7OY7%2US5Z3=77U*6O[,$X?X3]+"K?4R2?T=!)9?"$\5P_I"B20,
M&)O#S6<HUBUPW#P(_((P3A*G,_N;!TT/-L07(_Z\_1I-!+=.CC9/G;P=%JX^
MJ(!I%'51*1@H_Q9&2?D#;/VKLP>K_M?L@;'Q6J#A""1YAK<73"[Q4=G0;Z1?
M<I 8*MZ6H_!ZK3=9L6^C0>P\U<8O*2Y6<6/1COT\. :NW,A/A0,#:;U' U$2
M3@@K!UA#*)-%)\F;2%W0G@G4"K*"TSAY7QV+5RSU-=GVLWB:03/;9.T]M;5=
M%3%HE_%'2"$PD:L12H?>&$LM+Y"L^ [.:->K,L[H"A#@D1]JK"/7<P\6-(EO
M+'W]DKRM0_FLPAZY^_MGU7$^8P1IH$$-[8NA+K8:RT1#8F%PA=:5@W&LJ485
MU8I^-Q!#MXFUAU#E_=HS68$20,!8N^;+V"F$D+-:U)/?T ?_N0,ZD#<IK,,V
MX'9DO78*00KPI$136$Y3SD@%K$WO^[$$H\/%T/O]KB^>6:]%OZYP3JPS'3$,
MS? NWCV=M.+L1NJCB#:6" ,YX\+B<JZ105_V**<ICHEJ-A@ERV.D1\$@C[P7
M14>?..MS+DO7:G^1EA3'ZRCN>W_]JZS0SQ0X+IJBP1UN4-\4]QJ)I["G$Y*_
M$"H,K:WLAX<^HR*;,$"YK$]QYZ(Y^%2"4<;"WK!LDEL"?PO+/H/I@FRH-DL<
M1<LFAYPI[]&B]P95OG2V>W;VB7?9Y[!M1YN^[?.8_W2[YN7JWRK&?S_NM21.
M)S^%+((;H93C;U$NS5&5FN9IH?[-MMON6ED><;#7EWH9ZC?SI6'^6W)C697H
MOAT-:0]L"NU,4/=H5073RY]L@OP<6'/681J!<A)/-IC+G+V1VR17V7KG/&NV
MKZF-E(G\_"JAYP1MSV?,$P-Q]?3R-P<O^>MXZ_<1RM'3 %V B".PCFDCH?>8
ME]JWL!B6I@UCP,_H !$D-!ZR!BPH8>E,GV2SUA]V[J_#A(N?T<T:;ATS+R/G
MYT:BC8RU8,*VG4)_2JG2CR9P</Q7L!&^D+].:<SZ>0$C[XF2)".=/)TRXGWO
MF@+E[T/]MG#W[+9[979SUT^+C?VT''%62"Q.)=30DB42]3VT@J]TJ&=CS_<L
M49TR*E6Q;U_NV848T],JC<N]1M$G+]^4+"M ^"6[06)2H_[@-O\&&J@108GA
M63,]LVQ8?/)K+GH"V@B(CP_%XZW+TN<%B,O;A#:-;,OULKSP<^<@?U-NI-%)
MC@$HQW7%;F;YU3%H0U:<WDIP*KQP1,,K,XJWLY35?<;I9[CK\./*]-.OU@SZ
M=AQ4WIWP<RL-$GW =>5M!S%,_ "%<QSVU8<NH0J<0+;+#%<[:I:L?/"9#VY#
MS]R3D+J>P&'K$H7VV,-JCUU&M14RF_TNET.WNTPV8*:G6.(,PG0I2P,>+4)#
MG>P$I,!RC_//]ZSZP/U\6'HE3?6<_YT/+K0B0QV52NH?#RF:8+=S8&>/Z82'
M70Y4XL+#WS@ P:$H9G<NF AKDYLV7)$/T #46[YW".H=(P[RBF?;TK9"#UPK
MO[O(VHI\(+P$ID4$B#56HP($7F7YHKU2.)#I\W9V)CGA4Z!V?C1'>]J_THV/
M#"%H4_>.\OU4.Q=7AA7,+-\[7LW/-S: :#DJRU>LX-X12)4%<,26]<2(VT2I
M="\R]"CQTLQ>XECMW;.=X6*;W';L-"HSS\BF[16A?K(5:5QOSI,"EO=PD#7
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M#KZ_A   ZK$  !4   !B:6EB+3(P,C$P.3,P7V<Q-2YJ<&?<NP=4$^V[+SJ
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M)L4*+R/B_>.(;[F!(\QM]0O8R9QO\PN<^;'QB*(RM<JNI@A(2E< [."!/P7
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M\>;)]#=Y1/@^.\3<6/!EJGS+!'7C/CXC,>%ZK!N9B>&J\#3X#^&\H@@ "60
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MUA1]]4Y)E>,->IZ93&7)A0UVZ^0_A6:#H^R ][2RMGEUL/P(92#\#T4:=!0
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M_FX+HT/*MVEBV_;HR1(>%^ >^99[V#T/COX\,?ZA\%$]^>X!^^9'*>OB=H4
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MZM&^-/'-KJ6QGXAPB;#D5R*#Y#*M#H)QL!-[^<FUE+1F#1!-W\^SH%-2BTW
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M["1958Y4"CSVWW]G'C6Z3%][T;P(29WF"F$/\0N1TT4$>9-8BM XN(O;<L1
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MO?I*O\TK+_"#]-9/*N<=FS9OO'1HKN+>8*F;R;V50I<OGN8+T<._W3UO<&;
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M, (3*"OZE+?_H2#(H8T$" >;NEH ;#JHD;Y(^,>5_^G>_X30EF1PD9.1.BT
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MB"?ZPY^([!^NL?RANF-0,XQ!X_4HSC>M'_Y<0OKA&A3S#N@.73H$T.S.<W;
M(4=2 *9;,O[R9[HH\.=+C@)_>3 [ZE\>F?B_YNFW!E/EP !_N1FMDEBG>UUF
MZ:J9.60D.;Q[<J/#[M<>A9<E?32%$X"@[BB'&E8HR^<"N@5&!#(13I0@=7B<
M*]?/-@:#.7L^442"T+%)N$M[RE(<2EECKQA4(=^%7&>;SMRS"L/7_':$K;V_
MXJO&#)>Z<=E@D<F4)1(KT9<M-]6#+-(BZ[*H#915N$MLWV*0QU'"ZQ:!1>?S
M''NQ(-;B9NV[AW5/G0^^Q4\7#^P>UBG8<EW;,KF_+ HWK_VG67?%0)4YQ4-'
MON8>K9X$JB??/IZFP_)/B<;O"/3BF/>Z4B-R!N4DWMPP?UR4%&*T[4W#NAO.
MME7#6U:VE$S[;;= ORQ^PUOVJ.(\FPR^XKAQ]4J8WV,F'W+4'+D'.X)#7RC6
MU6>/3$1(4<T=:UU4]R:O2QKYL(F^T>_&QZ2S=6'823A6ELF"_3F$+CE4 7+J
M-4>+#&=Y93"^9LZX(<I 1[KNAI^S9:S_U$R I,:^$9RFQ8HAETNW=UL=2P^+
MEBO^O+V^2?N5JUMCJ!^-V>\:N3 4IST2J A4[4/[$*\"JO@(IA\DPN&L<N)B
M"L C!'VJ,BZ[5M4DWKSXIH-8N<VFQJ"MJQXGX/,G[23! -$B&T59[;+&]I ^
M*_S@==2I5K>=''%"K]LR7CEAB0O7EQD84R(N^I5VM+R5>X3A?QQ9ZFW\^MGE
MEX7WE>4.VUU\,W#M\A7U)VS%N%OC^P.D[;U%3J\ZO"#O'JEQ&#/B-O&#X[K)
M9T<&TI<"C1[0R<K(O[BK]B1H2<^;0'7\8WY8^19)(O>Z+7@=N>YQ$CEB>[0O
M<@ET1HA;&CCFJ\CU!)1@?]M@-@H9X3V9V,E%!+-O;CB[5F23O'7!BY)HH/!1
M\97\36IE!Y9["(W?MAJ_LG0VP<'F_!.G/I\VWZ*#IE093?O; B>>KT@R'$W;
M:=P]0N;*OJJY(!2-]EU$))B:PFX4R46R2%>YJY[T@%:F@KAR'<WIPTQ:C([:
M/1K'4R1IB7W7%R^IU.:$K^E75F^-Y@G#MYSN@RF>"9IAXWMAG"OM9=_RF.F6
MEU\RE.63[NNPU=P'?S+12?QUHWSAR:NK9D+JMP^6C:DO&#!M,RXGNI01<L++
M,Z?"O^9W]3\N%ZANA-T(YEA1]KND,>@IV;RU:Y-#@2NFZP3,OEA!372'5J H
M>VH5\SR[$-R1B2> @L/=W7@-<M@BHM>XZ'.H/> M0567DI3M./L>9MW';B&F
MWKY=37J IK_ *G%=Z<B>4DPD2?CC(,QSKE6N*0+#Z)R@<TJ$=,CU0[;R4YVR
M>UD- SZ'QEZKU0_I@W"26IK%B]+OD:OWRU-BC$>?#D*+>Y=:07?)7P3DQ%SV
M'5KB-CQV3B\R+/3\&W>+ SM%&(P-MDFWLD[=/_@9Z'_VK/#;\2"4Y"(B4+=7
MEZ$[I<T([.$TT!3\<RO5<<WJ*365\L0#KUXD,91?[)XQEZY;/B)S9]95K_C&
M#;?7V!MPAEQ$>&*5N=*\YX [)IY4K/(!)CT*E1NX/IT5YBPCV\M?K<.:4T7[
M?0XI/W!QVE4Z9/!NE=0V]$["BZ/NF[]Y[[W_>#KHZX*K8?%,NYG).C:_9R09
MJ@,*,-?TR=&+B.+LNOY4H6-=WTH[@EZ;ME<[YV?..N=&&]XT-"Q:)E"E<!)9
MJNW%/LQ[A?:@]0?0CI7S[A%6#TVT@OY3[4Y&:3(=WRBKF]6W',?V[SY%O;EN
M8+ L<-M;:B1_:2U,8:<F:4S;Z:50-ZR'NF$H6#K!]$:)3%=LQPUM9VGW]&^<
MDQ\Z6_V&J'<]EE(M/\X9D'2E3*+Y"VO 2ZSND< $_JJLO@PZBJN-3C!=WGZ\
M,U#?;Z='L,H.YS;/XU>?.!U;=MA]Y=O<!)'#7XSDAG(RGQ>[21Y,*RRA511W
MT<3)_N7?!;_LUWI4T;*SQIP5&,UH/3V<XGC%R=]]A<BGW7$E/P2Q=;JC8^F5
M4TT>(IIM)C<5H$_/@-X^@ O"Y(-PA=!@"6[Y9@9KR<L--:AOBI>@!?(JUNM:
M>8).QR;_3*32X):]*L)-X2GL$)C&F&Z&A?-#MS4CM?NX'CGJOC)B96\$$>>Q
M6_[<O7>#W[WW.T&-<'B.-V697O2@-XJYO+;7&MT7>\K][7PBCA?N4!.NO1V/
MS+;2R#Q0+YWL7;5NS."[R?_3:[$C4 9'F DN*>D\&:;,D,2H=RY<W7@ZXSBK
MMS;76#9AR0;G'R5K/HI]E9=%$"2\PXJ6(!-IQ2EU-FI50W+MAO%Y6*>7/=%[
MF]]F'!)KTCY^)<[ Z]SFIS:(4!F'\:^P]RQ["3)8&LW9'%F@2H7B'7@U#672
MARMR:WO$+(G.O#OL9QYQ5S,A@9'@?6Y+7 LSA2M_OLI4L'/JFRZHA9FT9F6S
M ZQSNA3P+B,D,8/IZ!6Y_8<-.T_/-4A+[3T0&YL^^D*Y16CHJ!T:"5XR8P5<
M=!\FBTXD7TA+R>FM"WW\Q3GBO4U@:.!:H6O>F;OM]WBLN7WK^JZE4N+'_GF]
M,TNR8]&C@C!E=3L'<\+EE01R.AY&Z]5*TPNS,%\W,YC]CD?+ W(I&3R^D@.9
MJX*7#+I8^7[]HKX[*^/TYK?UNR8C)F:.O*' (I&>3F/N1\=2ED,"GVA%I!A3
M(YSEFQ:P&;OD&$Z[5LVZ.UC'^..CER_]7H7?^1 8+']'>-^=^8=148ZGH!*W
M?J7&[?[+:F^$%6P->UZJLG7+2\Q)XTM8$EH6.#$-:EVA3,DSR55]EER9FMJ^
MZ!35V\,[PM$*-/RZ]NQ.?>V0LA+[:RXO>M<F^Z2(WK22"/9N%/]P<*=)>>;)
MCR(O9HJ_A7:U)C<;?PZ=FQ.<1/8*L3- )XXWH9FP"O:,%?&US$7$U;Q324/=
MMF42 WW6,M05S/V1U\G*!6]CEN;TWU:7P+PW-8$S!JR9HD9PYQD#P&<W8=ZM
M"@T>)>_)_*.4NGM/+WI)CT2UNFQHCGE:<7CE.-H1>H<NG*[1[:EAXYC4R7;F
M1=V#5QCQ3FI1(X<?6)\/WEA8,3MP@(YHL])/VG$<(78<@1",XUVBP&_K[H*,
MO4"["L&:JCIP! GK;@ERA<,P6:8TGHTT&%]MX7M]OOUTM.R 1" ZXCEB]8K/
MG36MJ4[M$1VZK^^70+:4IHM?2(I!0+SJ:M ISYNVA.OU&!=>URUW/TC'SZE=
M_&->9G\,57W-K;>O0E><"I:=9S&I%KR'! '8@TY6KH+%XK*-K)#[++7:2C23
M4)+)%6=E7U%S11]@<OIW%WTQ+/Q<><@CS7$ 67PW\WUYNMMC]'.T'RH*6^I5
MFPB8LQPF;W(\G?'Z$89=WL'^2">F>.5+]]Q CU.AL^K7]JEL?J- _:"T](QV
M$R0 5&TSW;R+<^03K31EZAW'N8GE53\DV?9UTD3@L4^:3,R>U@K#%*N/ XTR
MDN_4;$QN)$4[' \I%?8ON-4N=OBVHM38@XC1SMSY_,[DTE:W[JZN<L&)"Z E
M) [!0O@,6&F@#)Q>1-3L!RF0E X-F*KTJ(1S[=3IF05V780> QE)D\/OY!P#
M7[$O=0$^-MBCS-!8$R.O;&]8N(T5!A>V!ISH'7-K6)]Z.\TU>_6>RP'H+>05
M+#)7.I1]"_1GC3?05E'H)%II!+EZ0C>N>^0(BWJE9%K /-]9,]?A]+VLY/F,
MS0=&QH*.O_]Z;F"977/\HR?-\?>.#>2S0\H'=RI-]/4)- %52I11.OKT;(8[
M1QY2/&_'0:= Y*E*9QY9I2R@EU1=.45&\:(I[M@EA&J:@$ZE*$ZW5C'Z9;!I
M=G N+J-.L6KYK&MG_IV=39,]=#V)IT([;"6D:N5,JYS<-U27:AZ.[M-]J0&D
M1MX_N(BX?AGUO1>X0W[X;#QU![1; NCFL[AH<BX#%566"QR" 1,F9&G!J'EA
M6%>XWI^_%_VX QA=@^:%_,3'0"PDFL(BLD>8I#]Q7F-D3[\U"Q.IT:6_'H\>
ML1$<ELW+^[#?0$QH)G!CH*SP^3-Y"KC4;K\,607?233] :DPNP$3@U:%MD,]
M-!1!U5L5T4G0_U)NDDP1KS!XIO'-V40QHOCY_)R1Y",+@X$I;:LU";+-!X>/
M75FX7S>TDDDF%HM4:(]@D<Z^Y?ZU-TS81BTB:T.N621O/<K<7ZZ&W)W.SMLP
MA6L\$9%P\O;<A2^ONSO[@_/34LWFY1LH14(-:"*)Z4 2XD: ]^E (5X=U*%K
M/V:*C_:EYF;8LTS3[7=<K2O?WU9_PX4AN#^>\];N^O5S.U/8KWGQD  T0%L9
M1+M"*K:,F?XNKK:/):,X]J#<L^3L"7WYECI]V_<:94%G2[QN)HRHJZ8[/&UU
MLI9U>K]R4[/H^S[ IK1?<*:?G0^C" *_OI+W$%KF"E%I*TT\GH"&_74IB2PW
M]MQPUHCUB>P[$KN9]Y]5;2VX>4:S1_[->(+# $K*BY=5*39!6UXI S6BEQ=/
M2X*R!@K?B+'&I25Y6N4M^MZKKVT+6*MW3&W@_9E=U>\; O:-K^OSSO,=8<F.
M++.;U<I^O4!SR/^R<&&U:0@O:Q'AB^QWH1/KCCS\T]+P4%^:K,DJP[LK2B%-
M)HU8W*]])^#=68V*TM#3N4=/"-]V06U1>#O^@7*"VMO-+@/C.2%@/R3JSCG%
MW=Q.4/8UID0>9UI>)"@[313XAAH3DLJLPM3G4C83/F>%W=C_])Q@^7/7C-"^
MCJ.6LN^LJB6L2CR_OZX,Z/M>"+N4]BUD.A[-3SRHA=EX./'(!CS% 9"9(?K[
MN#P4N6'P/TG)W^CXGE7^5W5\OV=A+N*E1VYDDQ/QJ*P)0:N.C(Z@@J<^K(&(
M:S.;&U5JW4Z2-MFMI!LS(MTOO<MSUA*L,9'FA'$WLP)K%Q'$2A%*J^ZW5'EV
MF)\Z*S2>G"J>U=B8E7B0OONI]?#0\EUKCF]MNO)V%3D5[4X$-[)?<;!X.R:Z
M>KI/$!*9& :B39> LUF^1_"2K)2K>'./G#ZP?FAH,%\]^DN;OGAV<>G%CXGJ
M6S<^7=GV)MJD;(H_Q[^ O[ -G![.;B"*$.H!E*F\-UJ$XNOQ'"4KE# 9O+S;
M9/M:QX9LFNDMG:IH^K&^6L&-DR^\-F0)4=UF68'L%:RT5YQ=T#M)_.:;%L]!
M!\X.JYQC7T+F4@K%]X;:B!>_WB2&ZU)36CM_K:W(^,Q3V8,'$:8/F=W1%3OH
MU)4^$)(9?<DCR\?8[I;]!;>4;.=,.79(Z^I]C#A] ?=$23N[HXAT!&))?JL%
MXG<=P16_&UKXHR5_^9$U^86Y1 @.(^<1-*#[ 65!@$QZQ@!?@<6O49\$8$+:
M\-L1'L/41<0:8?1$X2)B"];<@6H<RKV\>A&1W\BMBQ#'^E>CEP4Z0NDRMA81
MUU$F7] S$B3HE=&L@;C-DT7$V]W PB3M0X<!^ $RA*LX^ML:OB%C8(HFZ XS
MKK/ IR5YG1@D?.OR!JAB>!'1LLR%W/-I$;'<-/9O#6>X_ZN',X0^PI0(?8(B
M"%0= .@YI.)U-610"U6'5FUZC-^)00+5CT"7#+!OVK(=>)X?]"TL^,Y(:9!?
M=GBKB:Z6^E[6G?YMB0Z?4+WG(6$/V!W9O&N5.[RQQ:%OIH5PU>UUILH<![9K
M_3.6DCWE(J'53R?W?OJ+%SC:%LQJI5OTZS5+!;$Z,!LY15@"5 GB13@.V?6T
M?LZP+I%8-ZW@4G4V"X=]4[FN*\  M58;-W78<6.ND=B^7IW( 7S)C=:W&ZL*
M^-,Q+H"N\&]#,)5CO8NU@RT%MK(,1X9#(W6^!FPRD6:)U3N/.H2T4/TU,I/>
M97]9(3>\.44]T&9"J>+4[9,O$;S#<",*_F;DYO8?!P+_,.3QZT_.SZ[X"24!
MO%W.@2K@5FX1Q_.PR#I:719L>C-^"C;YW0"72/'TO##LX:XI\W$+BI5A[931
M-4*\$.R8]B=?3H DJ'VAX3L?22<CY\=M^:E^$?&]EW+WB:^_);0;MG.W)^3Y
MD%SOQ7H.5Y'YVS'?_]D0K$76Y>69:A#: 5%(T1E'9!_BW=,A:..272_T]4W7
MA!+T2EN2Q>21XZZ\1PPGA8;+O!:E^X!0' +4QO!R*1[3H":2*[N(8,>Q0KDR
MVRB7-A&V6J7[HD0J-_DI*L\I$AYFN/B<<<%D9'784GI5Q6)3T_1*L.=VH+Z[
MQ-/Z:OA[E$6E\9=I4+RPJX JDP-I>B] _:'5%+"$%6C9,E[6/JD?GK?)SR]"
MY6M6HFG7[+&WUVXDOK_OVK&(R.O_BBT-A",8W*!#K*-*X->!VV'7]&1FUP=&
M=Q4ZER8.DR3PIUN+1SO%7"S4<_LB!E:V*HR'G50J>F%1<:8ZA;T9Y(_E+-M#
M 5^EXS7!1OAN;U@0$:.[,2%]#7%X-(MLV>%@[5&2O"_N,_NZVGZ/U#67I^I;
M-\U>?QQIVO9O5_Z?Y,HSTWW3#*,I#=9]QFX<FNW R_T(;AD.[CSQ(E#!G!Z.
MDI KL3NK4=8;2 DR2C8?B_@XPS1ED6W)=V +YH:@F0?%C[!/%+91Z#GRI@XU
M?F2%'G.O^,&3-$+^N\VEK@OF.@T;/+[@*=,AZ<B-BX@8/.RU?L#G$RKFBPA)
MKVK2B.OX9!-'!?[V4*4L-Z#5))QC 52Y!YIN  UKIM#]JDM2Z/(QWRPZC?JM
ME9U>%YL&F1ZCRM#6T69"4+=A_L.QAIIH3"_:9!BKS(7W@.+-V6ZB-X)9J70V
MSSL)K!F6;70)8[<>J[NK\_548IFY/F:FH'Y26<)L&J#?A5-K59X.)P#4 .@/
MTM1F(3V@MA&2Z*&45@0:3H/)@Q'DT4YUPQ@><FK=7$:"!R&B6&"AZ9\YKBYP
MI!8U(U )VW@[\$T0BW9H,85S_'7Q.5X8'%7IBO,+E:AX2KQU*Q0)9WH\[G=V
ME_:AS4A<@E[ISLI^,\#/9@-O=R,7)BD?'%HZV0-J3/OOQ"]\EM$K,-L,)Z(U
M(HN(B2) [U!'WX\CI0G4$?Z8^[[?58 R W]TV*/,100W\C0PT:S+0]B5\ZX1
MF>Z?_M:@X-BV?]F@H*SL8&+R0XDHJ'E]R^;C-_<J+#%65OVN(R/ I$[!M&29
M%9AX@G,$1V';\6)@HU=J\A[BCS!G=NB"CGUU9;'%4T+[6[]N2G>B%\NG/*T>
M!M2?;=52VE5OM4(^D&W+(\-6?423J33]I+H4A(G@4DP%:,FPGBX!?+F[4T94
M8Y[FWRSL\EG;E)=KO;'R=(XR:OT\?JKAXQ&L"2SE;_%R"6*PKSA7FH!^D(@%
M1VH(?[JX,GY/.<CQ((-IC35]GC>&[=I'K!W:2\2NHG$SCK'+:I>OJ[WQ3'L3
M%FU%:"25I'!EVX>]&OS%JOBG.'"ECEB"[G0_6@D0@!ON'FE.R;-Z/ DC[5FO
MI=;J0Z<^RZ#7*^W)HHIZ"TXL_'.GQHBF_>J;%UE"W,A RD0SEH?HIG8RN:Y<
M9S?B-SY>COQV]L5?$_ZE_Z#P_UWY"T(_CUE_R?Z9XG9/!@&74'O^^FS0+3_/
M!OU]=_'?GMD6@8%#C8+AHI\*AL"\F/(C'Q:<#1TF703H!=@B7:Y,S BRGMJ#
M9F\!PX:GH['2TGM?=CYD6=;B<CT[@EU<#95".M8<6%YT4J LR5!JXZ.^[0[N
M>@%L=.]Y^*FY<N[U-)5BW16$3AH30XF&A)G+NOLH95S;=+R#S<&OC?ZY9*&4
MTVK+;69SMZ01[&[<!_U@QT#\.PG_3TK"6ODN(Y;UTY?11=DU_I8C\@W 547T
M9;QVIL+>[&%QPKQ.G@Z^-TFA[.WHAJ_)^UJ\GFU3^20XVU"++=3D[]VRC3\_
MGM"RB!!'GT;V71HNBZDP8.9CD"YX ]")CE%J>NADD^7FT[AC0D]X<W>B1DO:
M&DT@I.7=JG6^3\,;)E_R88UW<Q%Q*O!:G_R4&+-]&%,O;NX" WU?99W/,"G.
M8>'VY;2(W%+J6/_[.O7J Q_/SSEJKSSJ\ Y=$GH)H ^B^\78Z1T4/^I5---^
MKJW"_8E+S=)S((8=2<1$52M,,2XUENQY=U%Y=_Z7O.AS'\(,^*?M[*SD+S9=
MQ=7A8$%S-]XM@/[,;3-X>P1$%Z.?F\@^A5HP^;N>?&W_:A_1M6<8V"2H7\.)
MAB&HQ@SUN,/VWW+]?Z1<=]/A1'!=>:F5*PC-W6GK8)4DB@4G&+4+J7F4>'T.
ML&0146WIE]T?K:?#F[INM2KO1))6;Z;CZ);2^OYZR^)6,Y0L5Y[9S57JY>S!
MG4/)XF7 4(XZ+J[-N^9V 9,28P*>[W-47+-1!_H0E[MS Y&XB/ &P-6ADX+#
M'*3*IPM&;W3D&]AM)J;*;9 <3L_Z->M >Y.2^6A?_^=#KUM\[/?&;[,[L<;^
MN AY#PAGP*7\LQ7L">T$35(]:17E1"#BBV+=0+3UH .FK?G^^:#1T8HV)WT;
M;>6(<75V4PA0),25CF$C>?%?70[S4H!3TTMQ>H=P'\[Y&=O'K.I001[U>REX
M\!WT#A]^2"@';\RZA#<'(Q[B>-SUN=XZ^=Y=Y1=;N!:>.M_%MS5)O6/[/;ED
M=-LDO-3XU%3PB9L)74W_!;4<)_=LZJ]-XBIWWK?JR!N.AZ03O;0W:EPCM V,
MO2Z;=#."\_%@"B2(8J6+QVFC?OPBXW_Y?\4J?R$EKY\Y%[&2/G5[1GBV7G>Q
M>FW?$[6W/>W[<,D_S$[B)>K9$I<%Q_)%OC>% ST5@8N(7:]TN<O1(W^.Y].V
MCHN(DRP*;_DDA:FPB$A$_?@AXKJJVH_AK<,\$;[YG,BLB_J%L4?_6+IZ.2A'
MK;?)<%8PN&]A[J]:YW=RG]+>'9WD AP-NA2"!5< ]13W#*["PFK#7YAWMVG=
M"+ @W@O0MRPB%%G3BCKO<>1#+N_L/LKKC!EO$M@^J?UG<JZG]0^0\_-O#"NU
M;U:Q=4\\[6L0B9VTC$Q:/M+Q0X[;(:J]J;F]+B>(&/',N6(7!7<U8)=:3U?6
MOWJ]T#+,+P3$#+P$F1G1OH_K0I%^XU] PB9(1]=R 4956=9OYQ;:_"BB9IM_
MAO;^,\0JER[T$_BAL:>$J,8_R*@COG\!=H(>.A'&<=G5OZL@0I !$TY$#TQ=
M'F 7$,^"?YUKR39&5Q$?_?7%!G?^O[78X.C/8N$;\M?A_ICAZ>&V;T ZOV%5
M?V?8I7T_)563SS\(WX@R8:[L:_<%?I.SS?"S/\:=X8^ZMWM$#^R!JSC\VPGS
M+:8H/IP0>6%U,)R(EMF9_!R'_QEDHDP*?-W;SSFP 6$2;LQOD9^^F+^FLX@(
MRH9T6U9<@%GOBM]JJI_UK<2O2??+?^<BNW\'S;\X:-B#F".%K9/J'=]7<5^L
M.?:68_6FV1AA@TOY XG%#GO!7D'DG44M2.1N,="P%#>^,:@)C2Y%_SS970;X
M>8JW0[PM5@PJ]42_0\*,?L8L',/5(<?0OFT&1C,I7 O4+U/EASML_W==;)/-
MM68>S F72SV1%W;S ,,=4[1O*^;T[3K<E=,X0<C21@^B2,]W]1"T/FSHOJSL
M[MG6^QT8%AR$;<YYO@'WD[LO"/W2,??KQ.,_3E_R_[$S(RWH)T7;?YD@.E3
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MB E_W+"7:PX&,Y"2?7X%7%WFNAIM -D[D<)N*E].>3G[,=G1/#@2D9>TZ[
M*OW6?S3 F% U%ER3S96)H<LW8&(IQ=@J&J@3G!<37[GNR]ALG>J:+L S5=>^
M0S,6-="G4S?T:%JEPKK$7H&]=\DF"?]#IB.@(#.&G0]&<+9C\88@BW.BAH4<
M5F;1Q'2OGN4:%[5V=68=UKG/,11QDY\1$5K6<#=!V?/UN3@$MP$ UY*XLK!7
M^P7S7KI 8G>]8 _;8@*WK; SG#N9C7T'J9/84B5:402)8_F.FF8]?]^DN;^@
MCI $:ENS-L70!]4L6*2XO:]RG3XG,WW+^WITGG1L.FS@%&!R2^/$K++>O.\^
MUYZE%YV#?IGD[L+Q@AJP@I1 ;"]_-?7<E#AC/K#":%A+QDHC\Y'V,Z78'A.C
MD)GC\^?W,IQ<EBK+'G__(;OC23KR?6#_$39_SV8N@0H4#)$9Z-Y^2'1'!"O4
MK/5$7-_(ON=@J-^)D?XFH:_'+'QR N\&Z+8I7[G9Z#2ZNK#L;HG2!*:7Q$8S
M@1HJJ"D/JUM/<H]\K:DN*+>..6FDJMK-Q3#6:%(RL16-9PWJ,]PO/"DZ5G&Q
MZ^@9M>.UFFJ]V,.M9J@TE!Q,VV[1F$>P_4I55 Z:,  P[>-W8ADVW +=>'UD
M#%8H3U_'NK;TW5I*[UB%D13OKL*3 ;7="OA,";]IZC)P1PT:::*2"0I673!Q
M)B0^]+GNLV!S>56OO_\*/V7;36'5CYX23_#;#'N?)@77%0>4[87%[C)A5AE7
MQH@^S96MI%5#FBQ]FVR00#O&(WU;1$B@KWSSKVUXW&L=!I3*(*Y/R]CJ9Q;@
M4TY#UUO-5-=SE+FB/+*I),[(C3D]E<7Q[>,&O^Z8EBUNVD60=P1]-NK@7Y,#
M6OH:-PPL/UTZMOK:G3K\S4 8T _PR 09KB[+<A++60=4'=Q4(<8QQN6S>2E5
MH=B5Z1T&E)4^<VT[ACZ7!SSN%OM8LR;I4#XK);[II)&ATR)BGW?Z2EUV,+@,
MED:.H"QL+2I]*"X(=C-0S[RLK=C%*^+KFJM+IF\\-WH[OFFZ,_4NT7GJUWEG
M0>!'#NR3U>.PV>.XXKS*103C- "GH^H[K7@+."%7K^-=&@=. [Z]]_T7$;ZS
MW9.0?:C[^YO  ;+SPJ8X+<%Q3 ^:+;B(B-9@+2(:B,KP+3UP-KL/R7O5ZU@V
M !Y0%4>>;=17 ,6\HJ9,*9V%RB3'.5$5[7\Z L^5T$:";PFD(H&J710/3']?
M.YRTX_1UKV17(7W"F?=HM5?/^G;/#EEM\GI]1:+@MKRJDUIC\_1]P2E?+4&&
MN!HD3!E91"329+GK65A(]")L2@%6Z!02=;$$]SU0#+>J0N,$@[3"XHDEE/]E
MY&"A+KML]\%V]9AH#_]/'[*_+FBE+Z%L-5&!K;&3?XHV=QTOAZ !=:.6P[Y1
MU%6.X4-%X*:"9Q/8HI"[N4-5)]5U K,MSH8]T;/PEYKW7AMKN6KF^JUY&=W/
MKV4$1H$BH6I4WRM&X)O^1<02_FG3I<IH6;S_V;!@#2+Q)!CLE9Z7B5',W1(1
MW><0AUE?8SK\II*7C7"HO5#&E<1 HG?S"9WW,%/D'#BCGM\X"MYXA#,.%/,I
M_\1+*;Z]KSC'2Z\"Y:5(3*I]6SNM=<Q+ ,:+![9F"B3Q(,PJT(O1?)%!B1W:
MCI4&8S"M.OXETU*/DY/5[%]?DW7Z6E?LD31@O=K')$OC"*%EWZJ\\A^ZOBJ#
M>!6+B.-HT)^FS!5F97-UB.!>-,.*Z]EN$LX.G$25+B).\XBA"W+3IKI%T]2%
M :LR3G1E/.Q&\^UTXJ003$<"(5%=UBLV;Q%QI8"__:78S5U,]GT8\$ALY$W>
M#5Z*KPZ76A(VQ28:*97.VTY^3I[ 6L!!OQ9^U_T4^CV*/,6?D@!; NV-B:24
MC**$*UR9YK9=TT$V^\<9HVYKK7,,%'323]?I# C?EQ)";8X8"F1.C3?S.ZR6
MGN!EHOT""W!P&YZ'?<"61:I'(9Q])=U<\09,4F3Q(F*YCW-1W>H;:I6&F(W=
MAZ+M=JR(,]?R\%BMR$,\BMS@;2QWE>&_LK'&5+'-/U=_RKAMAZMI=;/L-25O
MM4-7%==&RMJ9'<J(1"SAGQA+.(^'*XG2@?K=^'@9!Q(A41TF (E2 AFZ$K3/
MBXA>-\GV$FIDJ2K\<I<QUCV"SDY6800IG8:P,/<X(\#0K'8Z@G84JB,)HOUU
MHRY@8C?"[4OI+Z6-W.[*.!O0)SN $IW$;]*_TWK,>I6U59:\ZHE3VT_[SS#U
M7G2_L#5#/8"#K4J>XC<=52G/(D^V<L3YC4ACD-X057S+NHGT^]1HIN\%TI6,
M2D^_?E>U0T:2=T[<#)\<N/)PHY-51#/M-.$]I<BHFMS3SPZ&R3F%:;T_F5H-
MB;5FM'\K?G'=I"W2VDH_%R&^L5#O_21BV>A)1+-VRW_#.5/_Q!_D8N__ 5!+
M P04    " !U@E13G$DK_%B+  "^P   %0   &)I:6(M,C R,3 Y,S!?9S$V
M+FIP9^R[>3R4;_\W?"([V27;5$)EF>R)3!N2-)4BQ(3L,95$&49DS5(JBI@4
MJ2R398Q]LJ=-EJPQ9E0J)C-HG,S,.<_9]7N>^_H]UW7]\?O=S_W<]^]^GN_I
M=7B-UYS'<7SVS_M]G"?^*'\:D#ULYV '" @* &?A'X#_"UB_[QS6QP_P ^!+
M@#\!'  $!?Y<?WX+_KG6"?WY+;QNG= Z$6$1D;\-47$Q>(B*B(A)BHE+_+G@
M3U*2$E)__OBSR+]-%106$A*6$!41E?A/7_Q7@)R8X&'!:T("6P!!.0$A.0%^
M)X" 913^FW@"P/]Y"0@*K1,6$87%D(1O(,G"X@L)P4(+PQ+#W\; WP/KY(3E
M-QOM$U$X[BVZY:*B\?7;16):^ZO:E$[T,[>:^%R*%Y=0WJ"R455;1W?;]AVF
M9N86NRQW'SAH:V=_R.&P\\E3+JZGW=Q]S_GY!P0&!8=?CK@2&77U6L*-Q*3D
ME-2T[#MW[^7DWG^0]_A)<<G3TF?/7U37U)+JR/4-C>T=G5W=/:][WPP,#GT:
M'AD=&Z?19[Y\_3;[_<=/UN+2\F_V"KBZ]D<O 4!(X/^Z_J5><K!>@G]\(/I'
M+P'!R#\WR*T3WFPD(K_ON*CW184MQM?%%/??+JIJ$]<R.<%4\KG4+Z&\U92F
MS?JCVM\T^X\I%O_?I=E_4^SO>HT#4D("L/.$Y  4P.,^3ML&_.\X*JW8J2")
M#TA(LF-9(ST8T)X/D"@T"698*1'O%T-\S0D896C7+^(FL[XN++(7QB?""TI5
M*KN;PR$)73ZPC0O^X /GPCOYP%IPPR.9N_@ "KB#PE4J93\&M6F$<;7I$:Z<
MFNV0M0&=I[/'<7\+@5TR&#H5<M72Q:BW)/G _"M5GL! Q,T^T#8T8D%E],"3
M,_EBLY\,SK6X:57?>A2D97)6[X:E&E.@.XKX1@;<NN$5%310)O.!=3]!#3HB
M@4).;@^5>>4,&K9[JG7D$=N##(FAYZ^E;&W8(+$UID&-G=FBU\\'POA <J,N
M5U$(DL0S!R'Q+LZ!,U,8G!HSZY4C)<V=$J\,>42CE((9Y1KF4WIM"ML+=PFF
MWA/OCHR7J!$46$,5SZD>;?'6+"OZF3-25QWOTU!;<"Z#>>'"FT/6 R&J4S=I
M<Z*?(GA>P]W#QM9O\]\FIIGUOGIK!+A^"TB"A'&[^4"\!Q]HNVPCR97EI2_G
M,DL[L.,'7L7JHM5PYH.57T)U!IW[*VP_J];*6LEA]2HW6>TL%IG1=[I*Y2I@
M(/$"CAXT ?M%E_%\IF]\X=7[F4DM.UXY%UT*8MO6/CRY8-IB_B7%Z]MJZ,SM
MX[_\[,DWWUUXEQHF&/J9$X<ZJW1O:/?.3>GQ,NM<4Z >:MU"(OZ\S$:N+S,@
MB2OS+'"1JPX^CYZ..1HR=^-VA-K-0/KMRBWB;XKDXY0:ID>J[8M^&'T/H157
M8UY6/*I3[LQN=9G,M_R2T>SZ!<N5(T+BWK OEEE9#"7.B;E"7=X=[O;H2":9
M73Y4NY \^!Z[.51B>$#/K8*>(-/>LUG?I#!0B,$'QK!L!BN@FS@1PG[,R[>.
M>1RHBDIN%9K35"'U1]POR;8D:@TM=S?=J\RSWR;1F.A99"=C:3TRZ!*9DY=1
M'+D6,Q3>9BR:%'C&>'?AOG47]OU66C7C[(Y]Q0=J^AAP< B7\1K]>,]Q1LB;
M7",:42YJ8[FU]#.O=XU.7<OCHAO(YJSJBG=5]AL/-;]_JU+HLR%<$ EU:NK?
M@<2;Z%G@=MU7B+@ZLO0T<HS>WM%-E6K6BHDT>+?[S BDTO IH";YG;]?7%_8
M==^^C;IE1IL0S\FQ6YF,I J1A!BBVX&8RTT5YY\VVN9X_WQVU*/H^PY&[#JH
MERJ,"L@:UV*;#MCH0D,(IAUR/&'&M0N1VB@_-Z4%\D(U\\T87W\/K/9[!44B
MR[J'7W8T&@GJ7XRK,@17_8B?J*!6=PGG#!6.HEVM&\>@22^-X65JVFZO@HBG
M8!I*7H"].E/77"CIF/K:?U(_YWG8_-=4?W\?!YVX'?!V)#CTJ31,5X5C.VPB
M+%>^YQ!(F)YS#-Q:S2J@]C!0^[)_C&M?/3;FY*?7\[7A7&]X4Q@MG=Z*XZ53
MIJLQ3&?\1,]T0#(?",*.+4%B+<7!FF(LC4^=+KM;1AAFI1.]-Z.?&SSU73?N
MWKO8JQ@G*,)H4)<-68YVX0.W3O7QHBE0?,C2+"3MQ@?NJN.V\(&7R:FH93[P
M[)AH?>P;!!F;!NV"1A&U?&">QQ*U_6@:*C3MFGI9P\IV>'/.H2]-:7S@J,6)
M/8.'OPJXME=^?"+ZL##D1YECDR/G]$)YF&_>QEO6S@=I]X;2X\6FXZU&OO3-
MMW  Z .ECLI51K!GFWDO<'JZZ<UF-(I:%)J#?#5^;[[C4/::I\*WUGJRW:F&
M!UIH0RT=FDJ.C\CLZWG\=.Z4["#>OR\-0^Z95V!V_UR42<)+DG@V?."5)J*I
M)9MF>NAWAH3'V_Q#JB[^IY4/"COKKJOZ^B 5X!D.F4W*.#22JCY%Y#L&+9Q;
MG"^JKS\9D@S]%+PT6YA@.NG16:CQ49N<X#E27E[X"VW8;_@KV\2$M?C(QT+3
M7FB8HH>:GL2".J+S#^A$4#?R%7'"8@89I]9-4-B2Y(3NB-4>(>D]0"?1ZX8J
MA4LJ"1ON:]6EFE]-5\)?U:^NR?D,K":S58<A.3A.]L8J1]UD#_(:^<!T)D63
M$H3=R#W*,JSL!RGHVJK&_F4G0ZN&4,9R@;;_I[/1AQC#QB4YIG?>(9=>2G0*
MK:P]]XBZTT'.ZX0T:D?*2X8,;NUYGQYY:/!@J8I^W*_CK[]DTBD;<"$<6WBG
M_10?)+A)I@LM ^:VXQ6:)2O=<'[8=5S5(>O0K6AZJ%7;M<1)XMC6JR?\G2,4
M33S=>S;ERE7;5[W*./2E=1?42Y#!H3C6/8AY(;B6F/&>MZKB(IE5"<>9HMUN
MWH-)I;P*Q;0%\R>7&INS(M1GWKG=?G)YB\MX' "(_OKJ/,S=]R@J^"W'L?/:
MUT)":#UR'%EY8NOG:]+O]K[WQVT;L?:D8Q-;55FZG3(R!;I>0Z:25@78P]X)
M?I%;Q98.#/%Z)9'. Y0]L)&*$]B;>$6HL%4;:5VN_$@G@A39310#15Z'7+M\
M[3TIYR;-<T=0I4Z=8RI)K;Z<UO#@Z>WNT7'7=$,/L1< RL&@,G3!8*:IIM[!
MYYY0EW[81L]#KS=EBFFUN'Z"101C=ST=^=WDJ%CHK8B\>JE*?.L>.4>Y')N$
M/&XSW![$YQ"RL;+0!)6T8=XIFF,3@A?EJM&>X9!TC"0.,8R[&$H79MX=3ZS]
MQC"HK'B:8Q8_7>R<<N"VYL4X!Z(9O( *ODV+#_C@)PY XM0(EAZ[#3Q+E4.:
MX=6CB$<_/AZ)<"3H=KCHO?BL95O:HYY6]V%)/.#J77&W8J!NR!9 U"@M8;E*
M)FSZ,,6[;U24GLOP9<;W=4QM9<ETS%E9*M@/_5)UQ)N'<*+]'3K75Q;K5^[]
MO/[DE=?$]^CUL</X6D(\;,!1!JJC4 WL*?< '\_0'Q+$S^/P9A-J/"L'O%SO
M.9VE2Q*-;EDU9?$2A@/%Q@F>NMP-OI!8/T<RM@?%M$<BN$=Y=R!U<ERSPS0#
MZ5!'&;D\Z3*-IM_<3K*RNLJ(V/_!9=GJ]9WXGX?[I/S,T^,%.!MH,2ZAD1V[
MKY OJA;GYLA^^%Z@V"BR*8!LQNSC*KZ%) G3? #4<67D,WO8@> ]IN"<*Y.8
ML?S,#*6(LR6S-B;BMOOI/&$K-^1\=*<4R%O9O9NZC+,!= 5:/X.1?& K']@/
MURHS(I3FSIW@M=@(XW;Q2O'3K93UJ #BS?$M/VTVLG+G;],K=-U(NZ2\\U@?
MJ^77]RK>^CYS+\)%_?I>A#N^[1 %^PPU3< +-1NQ7DS0XJ,^H.2Y=A^Y>AK9
M(>U=/IYVSBJ-\BDZ4[+2$^89JYRYX2:"!EC*?C[(!X)1 E'.-#[0H2'(!V@V
M14]^5N/VL6R_%=4<&UCPM367\^CZEF6D?8GVH6<<^!K""F'? ^=8B$-P.%P.
M0C&/4,:Q'B&$-&J-+N/X-$;Z,Q5]#R\;Y??K7,P&E[T]^M7NB>F_M=[LG[U\
MG]B*#Z&NGD:RX3RH#F!)\@$'@^]""T[H4X.FCN(1G@''XP>&E2;-W@^]5;^8
M/J/_;J_ZVB##D(%D^+96-60&^N]E.2DDN9XP%M.*%UO W$%4K\P+<79#$WCF
MZ:R)PB7V<V9YH3%S)(D;2D/.4X2"+6H,;VLO-^J^C[D8EED6;FQ7>,;.J=U(
MOU.Z[W8X>SNK:X&K<*D#DG!@6DWK6QA':;'#4ZV]F>3V\<3/Y&,_C+VB@F=.
M9K_1TC(Q>%DHW!Z0_F_E]T0C2S?Y?$24-2H:;L7XRR45Y7Z-MGE^&[\>*WBW
M:X]H<!/F.J9Z]A5A;&)F9=[S,?<@[PD<N.DH$J);)@TOS[642;'>Q]DWT5.*
M?N85['HQE4X9-"2<SF#04IIC]^M?S+BM RZ>=IU#<.4WN/ J2%A0%]'^E=?8
M;%D>A%?2-[V98=6U,RI!9 U3XX7&AEZTE)KXFC.L=]6M5SMO?V>V$P!#.N4
M2(+S JZ;VM8&3#[0Z8Z:;PIGV:'5?KH_E!\=CR)R#!W%]$-MAP:SEAVS8$ 8
M2M$1U#P:M<('X$989]_6ETBH\JKB1+XO+UF)-Z4F5] Y5O>+Q;#S&:7C9T_W
M]O7M#.P7M0Q2#,<@X%V"+FNH=:'(Q'DU6I;<CUM3/]:RNCU]AJ$/-"%[:^,@
M;TUST1?5V6++9HO)<89<3Y8R6@C?5J.I%S+7BQ/B[)LDJ)_Q+-O9"CH7WR<Q
M=GZ8W,# !%75'#/)JIF>M7PDTR\#:E&XBAQ/..I>X(19N=TRBK'OEW &0]R-
M+)V5MK6LI#!K-*]L4^'P\,#5K4$V;T.K$CQ5WD6OEW+[''DVYH2U VVP@B M
M?>WUS_VHG3"="$9;ZWI.>47Z4I7 )<ZVV(^%>WAW4=/Y, [)&A>E'6FU3[4V
MXKCAG C[&N62.-J#%>G'SPAO2OAJ&G]$=M_8Z^Z0%R.HZ11"E=T=N)_$$MB)
M@\ME8*OE&&X+-L6!M8JSA7-;7#+J@2F5H8##6D]..1^16+WZ*IVUE&4<AW(/
M?DJ@2XNZ-C6^'(AH<GP^7[RXX$UN<(V.G/UZ07Q;E+7Z96(W=<*D>PI.EO@;
M$%R\CO2I<!U9.65%<WQ 'M(#<5%/O)B\MIJ6)>V!;YF_HH.TVLC9Q[3/76Y+
M?R/!Z_?*XIR-[<!4\P&N@@R;SLN$K&+;"5*;P? 74929<R@9;A"V"'/FJN;F
M_M^2#C=+Z Y:DLGV*;M?KX9^,9%_G;C79I9)9#31,$KXMGW6KK"27#+3IDBY
MBH9.8FONK&=)?MY<5RA9]I1\6DGT@\;A7UM9:5^;T9RPJ*5]L,CD*"PDOH1(
MK/6EQ01,.RUDAD7T6E/)MI'KG^EW[HA<C74X4/\U,FPA4X^.!Z]DS:NQ.-!Z
M7?#3-#:=4B.:A#M0[,F5&FAV"_=^MI>AGO=IJFS+9ZKZ+MY\0ORU:!<R \M1
MYJKR'L%Y1>$#8BA_](;37NY<RP'4.:OB(1RB^*>)NT?P>&AEM4_"D8*BB-L5
M!U;E3;WC\#4O;+[XGQ!8*WH2TJB;4IY40N/Y#T"C#<<O!ERH+O)N4[M[^_:Q
MX%9#9F'BLWW%<[&Z@^6_?E6Q/4+*1F>RSS^4?M&I/)NIMQ3-CN850/+X-FO\
M-"6'4C,RGTKS8V([*'#RU"124ZR=ICV-Z>CYMO+1G[U2KJS][PZ>N"KEL_E"
MO?^NMPH8TY\( 7S PI@5'=&U( OG#\P=I^]@9&/U^HA<VV&S'%Y)K:<&U[E$
M0\3-T?U!IX5@C*9:U,Y"]YY%815 ^)',YS1P"9)0@UF("4CE:$%#%!&*+TQY
MWK*-R"!E!ID^O/OWA]M!$:P=B/7VP:9-4;^TG;<.AS_YE5A\/N>("M-"664-
MP7;_9",\AZK!Q&$I_AK^U&-@.&S+V +$]4I&V-,"Q&''<XZ8PDM^/EM.BKZW
M\=]'7?*G[(:Q>J$JKZ@9 ^_]G)?<O(>S@^OTD:LQ\S9#E*[+1J1P'8H*#K_Y
M:)B=8?'@O(94_B/YQ]R.D-WD75U C!O''!HB,$^B4Q$;+V>)0#!K9AX.1= (
M"6'#TS^GS$B\1\N,*T[6)<U9LLK'1CN7KF:77[PP<_;.U=<G9 8;*XG%WUWD
M@QN_E6(#0L1$//(;AG=]5+B>XP-\N0Z.O$-4$]J(H%YR/+1S?(Y"6F"4,GNZ
MI\0=+8<7]C(I'1L&?GUY^'1+1+U)_2F7+^F7=A$S*#Y9H"YA_A/G/.P#1YC"
M2T>R7S*CHZA[X9K9';+M,GK=SY$:Z2UJO::?C*F]YS.?[^G)T<JTN&5QM]7_
MW4:5CZ)SH:3W+5^;(Z_<*:XZ?)V>8RY567Q.UGZ=W(>03'",Y?^65MJ^L!$L
MVT\9#/M-D00/\X'3-QT*ORC["M>\*?31$Q4[_$PW4T:$@N0#YXAI7CO@W F'
MWL%V.4Y,X , =D$FB0\$>.*=/]G(!NV^]W9*-[EK*@TK/VQBY&_^\8/0#9_P
MI6R'*[XAK_!,.^SHX@HD-DRH?=]-P/$!#;.%^!-1:WQ@IFENQ*GR;>5DD X$
M;][[P,"M>&>S-*=AD[Z*LL\7H04JJ,,'&%9TZ@2*K01B.">C%O8.UE;X]M@H
M)9P<,F5L<F"'7%5_J8>X_XX3!>GH3K4D'(&[8$194[ZTFE=U4^$;I]Q;$YY;
MLX3"%^M/'"Z4$=708R'H>(80RYF&YZJ]Y\AQI4"O5B,Y7" +F<3=3">!,<:V
ME5[?!R0?5-;R;!RV9O@V-LAMW>'X;'.!0X<JM@L9-\P')"LA!/<4;).3L(.D
M\('X>(P25Y+.,X[&RIO=NZ'L_B%=UW;(=/)83]G1E8M.(O,U3UI_8Q[L\]V+
M((^WDIZ L6V_/:-=ZJI)69I^[S_/*8;<^1,NLVFK[6_9DW\0@!(; ^K>L-G8
MCVF_R3'O86D:Q$@]75W(]]J-O5T '4]XLPK]8E"[,O6^H5+P@JUPRK6A4=.-
M"/E6 6@T;SO+M0,]-D>+O1Y.DTE6S7B7X-CRZ7?$U:>? A)/2Z9JI5P%;$Y*
MEV[<:+TR'\K1Y9KR,O#37V%2HP4:7(P,F?Z!]_5^!F+;EX+E/WN P1MQQ\.V
MOB0MN>7IA>]&7ZH*"%8C2RA=>0;P3OUW'[S!82VY\N?@[141/(2JQM/,F&&E
M<.$,YMWIXR F#+3)2\T5/[Z=7[(X_[FI*J/#LK([#5C$CSJSX11/VL'+:M6
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MZ>81X?VKY!.6&3XG3BNIQ;V/PF?92,6^HU9CN$I(=O+ GQ<=^$!M7S<A'D*
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MVR1D=X"S7"432!+!V0X-4NN24U#3]U&J,,#MA22YXDR=1\,$-=R!];G/>LO
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MX*N'GM<$O   !TTJF, ^Q1KI((R1V5=!2507/IVJ7%DYTE8H>=,SRZDV_LV
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MI+RMH:JDSB*MI8:K.Z<BM]\5:>H#]9,9 IR]7 D0S\0X\ H@:V)'Z 'Z!H9
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M1RB*766&+^\W-UGGUI9/L[BEUY!(/TYI%MW,?.&ODR?6Z37#07-7<')J>7O
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M5EQ6G%&W#/4;C8[">:7I&)Z1/F*;'31]<>+=;%76EOHCM-T6F4 "A\#0;B4
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M]"J.DO]0G]P_5D5D\JCK#2'LUPKA_U@7![%B1R_;/U4(.5Q+]D$NZ*MJ"WY
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MY^U-3_JX]7C\;/&SOS/#MPRJ1P*N80\HAVLPLY#YQ#\ )#\,MM#JQ]B6-#P
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M/Z"LC"/S,EC>R"^N1>_Q=_7;-FX^WIIG8.MCB><%=W#T!P09\NG.3SI4+EM
MP$@PI,^]G6FZD" @QSU*6%Z\7G#W]OKNQJE/H2O8%0?"*E,U12LOE4!]!1'A
M9=(<UU=FV9I<8T&ZN:%R&CD0E5QUPXJ.E-S7\.!#2+J3W<6CH5;UM\GOFG#;
M:TX[[(Y 07X4YX-M,A7CRV=PM=DH9G8N</M'>_UR2C!>-KA[TY&"H(PCNUH^
MTS6<5Y1MM3*_TBNB%7= + 7;BF.["&$4.#<!NL*ESV #HL*?+Y_K"N@6D!NC
MZV)R:<%D.3U#L]KZ7>&KBKQ7NKM36=7ZFG9-ASTQZ4=D5$E?B.^IQ'EW$@U\
M=T@(^^;>N[#^U[Q"M#_K(<\;(R.(P_DCY+ ?D15&9#U\(M]L24;*^[5ZO3^:
MKZY4LPUXH^'3;2)9>&VY[39GEY/?PN=+A3 QI9B[0;C2 LX7&K!;C)4Z; \<
MPG8)81K4,./;X^-X?7_*CIQMA"#8!)ROD %*B9,A-!I^1 7%[T.(<2G5GB4Z
MW,!)Z0?EX4Q6;9T0QIPN8\UP,4*8-^W+^!SN BD-T.9% IK<EX(D,58!3Q$X
M.,U0I0'8;]--0]+!P'DJM?Z@[-OS!:-W[[*TY?5OO1M]-+IS<X(;KQ(;#+GT
M2[_/;WBG(/.3J 9EX<!IE!+T7BE$"!NAMK\SXU\].W;Z^[;T;=.9L&Z@9_'P
M%:B3,[$MH#BB(HD%N?;2!]VS\,MW7.],, :]7Y%50L([7)M<9@Y=*VZN(OLE
MA]XR>W1=/M;8Y[GB@N(P"V?-\;KDS<##47E]A()C+>'>X1H1'2NNJ*_V+W6"
MCZ!N08WVH%TBLX]TL9498BWP-+(&?Q-'E.O;A;$6U([@XKU6]H@E&;(L&S]X
M%4WXA?NGC[P+N'TJ,$+<W3GYU1FW30(30&X$+\*W Q!T6C)22D^:G&AN.6QG
M=H0]*@V[TG9R5\4Y:LFK X?V?37BMFX4[2#I8"DX=I$0AL9?ICV'$%T7!=&Q
MQ@_L_"OA1 !2-%48,K.365F-UF4.V48/H0ES=<T#U;G^^(U .\\/U^"6Q>A,
MP:SG;<8U;&#R]PS;KP@ZXNX>16Y#*3-G]W/6X@N/N4>O/'#]YMSZ6Y<QHR=$
M40>!7.XY0'\$F9ZC*,BKLZ/?G:I#T[/U'7KJ]$NRWO06A:#WG?JV3?5%\MR5
MFQG[-=%O]]M%V_,5_$%)33KZD^[P^WO220DE_!".;9MRD@U@SR;N,ZM$R']+
MBWVFX-,2HN(;6+(J)&W7L>MN(CCZ?0+;$;T4BA=8\4DH %&'APK9O&9P*<=Y
M+M%B/:#67"W>KZ'6M[GQ'CWZJ$[[JA7B&4'QB<N.%HK,V%7SE9JXC4 IN[8%
M497!7-PO\);0ABPG)NBC>\V](SE*ZLCCG T$;\V\J?PG$VFAO.&K;9N.1HNV
MC\D:53E'@*)@(UD%>8H(:+6QU(HQ;AP[4C6GC3&=5.<_TGFE)C%]6X@2.>;)
M(9?N#_!Y7YF/5KMH%U=L<C";!M8.L)7Y)DBZ#:Y,"#N%:RS"\UPCS(O .=9%
M(8R5GU5+,Q"9S6=.<'C#!)8C6[L15X%NJ ^LA$L!G9;5O>>#[\G[Y!QZJN:3
M>K-LGXGUH3'/8Q== U$$%#L8S9WF[YRC3W/[L\8$N<VH@:'((9XQ%WQ8S7[/
MO.B]^A1YS]^>EE9B/T).!;4Q2,"8@5J-604<$TLW/_(X8,;S:PZ<<!SL4&WF
ME P'55L<:E0^(_EPV^TM1[<YV,J407INCKO_+^G_3E2E/],,SNJK^8Q58$]E
M/1[L'*&JG\/8#>NV:VD[E->^+7"-+3SG;/O06E+T*5$<L(<<#5+$<7?!;K*8
M@3Y%=_&4^KB=5""IP4LOY_M(8S5VG>#!Y@HS7O:F#9L"8PSS6C.'["D.*BZ&
MT;"]C\W$EI,6_30!V^"%^$BF5R)DR-X$<8Q=G[D).XQ+?EG#P;4ADS(=) *+
M@RQ6Q]GVZ;Q*3$ ?2 @U"MG\VF=]^@=R:<WAFWD!JLXE"0\#J[@N1BX3R[*S
M'^NN=MB7HJBYSV')LZ<PV%88S$'L2S^3 ]460JLX O;CD!:0-(R,1["M[#0=
M2<"QD8M$B:CW9GC*1?MJI<QBDOFG:V_R1'2NXK.WYY>63'-CH9^58@<(*\C!
MR"3R\^E&!+ A/"D-W!!534^K;H;+?0WCGZGL?OA!RWB[A^?$9-@&@I8K=E]I
M@GRA=J;:NJUBYC2^[$70%K((FA#FG\S0'ZV8OH+\7C$>2V:^(Y)_K,V)-=UE
M!DKMXFC2[5L(4HO$+>XAA'L6?&?>+@HP<@Q_@$W$/^+<QJ>8;]/CW_M>/(5F
M*>WPFXZOL%DU?"PK2'<GKY4D*H3%$SQ>:8+B-SE7HZ:9U-==^R]O:+LG>"@H
M]1^+]IP;P4;,E+_K;*\AO1/DM*7VTY4O]3/@V0*2.>()+C0FU\*?:M&.R*XU
MGYHQ]A^*-9]"4.T[%D?X.*[!%$)\]Q&F$+;D(9 FA$DD<3N'9@SOG>]\'G/S
MS8@&*FL\NFZ*.L9Y :#3<6@XL-FPKYR!D,/(0[_?L0<W+"WJ6)/8P#_&>=)N
MUX>Q02^]FA-3>:WZ)A,\X?FZW,A-[M)K8F'/(N(@6 AMUID<\:N8?1D-$L,2
MYC;<-W/JBOJJ/T+,B\'#RYHJLKC1]T<BAG0;($Z<!X&QHZ<MUZVR"^E''+C9
M,#DR33%FG#_GSM\*X((:$DB6NI.JR>_U9GF8'>4O45M;WXI+:;:*](,MT"\=
MB$FH:GNFK3(KB^WQRFO-+2GIW:@H#<8RU>*J M]Z_Q[)\<"[K[,<1I>O7+OV
MW&X.8L >E)SC[>,'+8;Q0-SS#)8<!#<#?>"*SU'QPV/C5PW4/9IQ<INGI[=L
M?O!":>1=:67L%2F;+RO,>4D9V8^W&C+);%O$I_T(0-N:Z3M,&VAWX"3QM;#K
ME(W=.]/J]BL\^W:AE_DDN.":K/C5;7)/=J_7=&HZ:SA#;K&?=T<,HP69BT\[
MSR\($)W=__-&DAKF0F]5<G38<+TI9<8QO6__\XJZNN H__N;-N)UVM8FJSR7
MNGSNP0W%TOB9<;Y\(2BI/CQ-K1XFI*#Y1]@,=!)"%EP=E3/=1%,@J075E T>
MCPI=4(ZYW#G6K%U]9_V,YOUUN<.OWC<&?Z7P%W?Y"L!V4V(2+F@ZGB9']L=?
MS>QLBK'G%G$BLMB6(\>'$ EP[E!JY&8_LT=JE\(5MK7#;JIE;EH2ZNRT2O0K
M(HG,=D%3=;F%W77.'$M0 G+-I>T50 &;:LUIZ4S";!L)08WX5B?AAK5MG:EA
M3ZE[SN:_MGBMO7SCYX-?[(H.["V*3V3#^4IAH&0,9P<WFS/'C!F& ^N>7#\[
MTIEX(>)>#$, L<A EL5.UDGR9;O3[3L"]YK8KEUZ68MHF2)8#NBR@X>KF1SV
MS2:"J 4\RIVVCTU.,+ABT &WK41L5N*L<5Z:<RQ]^_MS[YI+M6X$#\,_X4$7
M?4$UDKD/@'#]R>,',C>YF?^*"N4H_HZV1I8]*)%]L@!S I@KB$I_8[$:GJY4
MNN>13=[=43RXP=L^*A3#"U1"URK?P=K?GSEJ'@[!49;@B1#F8^D_@@ V$?DK
M\R&#E+!0'T0U!49R]"';EJT0PE0F:BS?#J^TG:U(46$]_/RVEE_UYL0S]2N*
M]Z +'!?";K7\Q36981P:F+EY<@(-Z-1&B2#I]P@5HA@'GCX7P=]$DXLI9T51
M"<P)?OU+(>Q.CE_'W?EJ%O7]1M'/?"3Q*U;WP^FZ(\-I7E2'GG#= R45/)[)
MG0.A)ZY;MNF8WE!1.7"B*4[<D$%3)X<@ 2<"1#Q>V7_J!Q6)7 )?7\I>"8((
M"6UNYTU!JB#9.R027SZOQR68L=1V?+$>8W9VWI>1!\6]2%M1@)88<\H\;%Q0
M"RHF9H\*<LU(;YX+;A+9@JPW;56Z0^9HG@E&&<!S\E^1*Y!I&#GUN:LDU99G
M;?2T0*+V_AYEI[B=^KO35EMK9ZUV+)A1Y++>LK1NB,SDMZ&H\J!D'II#:*;!
MR3Z=P'I?0G*=_G!6Z5(+4TY_2Z&=C%Y,\P'FYF),\OI/4@KR!_8JB7WH]UWT
M7&@44P,0; =T$E:WKA<K-XF0,<>Q1UIN OX,_Z:."Q-;-GSXL3-VO1-C:^%9
MT17,6SI3GX2P+3!M2\B'H#&0 * @ME0 V/LS=H7MJ^>@TNM<,0;X1,2*"KDO
M022]7IJ4>H7<T\VEB3[;W^UQ^YBN<D^.;\;5$21AS<$WY.?Y;<14@H9AK:?E
MR'C;JLIIU2AV0))1C5^>X=5'_;:5:[*[J$MDMVIOZ4STE3P@M@TR^XO<!H Z
MC%8%>Y#/._GR*%#)]15^R;?JOI 16UJR[$1F?LI(J9\'M7C=*ZK-N*5&V\#+
MID.N0;&\Z]A^ <1= XD)J"I7YL0PG))$OU.@1TO@!^9:/PU$GUUE\VCI[1L2
M1U<JN3UV3?ZX4K3UE?S5_G<$=F@D7Q/%'B7'$CY96$/-'UY5/\/U]B<(\J.Y
M5[F=V5_\:8:0(18/H?FFNDT$[TZN/E^;M D2KL&(,":",J<6@2O_$DU._P-L
M_9O9@^7_DCVPL)#%->P#9=SX1D!:2;#&ZGYSXY(]Q"BIMASEE[)!I%5]:TP2
MOU/L0Z\F):Y:4ZACRA==/+%&<!,*#-6J_@U$&>B'D'* -(0Z2?P;:6UU%[A]
M K&4I.S^E;2SGLTODAM+<_@L==NDF;-;]I:6;%=% M+SZP.X")#*TXVB@Z\M
MY  I:'QG 9;^*\UA-P,A#-CW0XN][\*C/?E-4FM*7SXG;7RG?EQYN^)=TREM
M;/ X826N00L9@J+,M5K(QX.2T5"%5,J!)/9DHX9F1;\W@*+;)[J B/)^?5;6
M>6E<V'C[YN>)DS 1#ZVXQTN0>_ZU ][!+Y/9EO; )O@K_72"'"Z '$]FNT]Z
MP)4Q]KT=XRGFED5@AZE7\5,[6>3+"H_4>JLALZB,H*)MS*M+CZ^A/(AI8XL-
MPUF>;![W' D(X8QPFY(8B&:3$9(2:N4($.Z?6UQX\+&',??TRCK]T94R4O@=
MJW9V7!A3$)E/A^*B%1+0\0;[)GGGJOG*VSM!I5-1HJ!L93\T]!D5V81/Y-/&
M9#\>DHN_23#/F#&*SJ[V3A&L9[MD,#SA#37[4T>0"FF1;N4]>O3>\,KG'HY/
MCS\.*OL<O?%@TY>=_M\_7JM]+K&DXNNOXUY7S>T4I)/$L$/D<OP5LN\T1:WI
M.RT*W>RP\8:MS3Y7%V.YYU&AK-&&[U_2&LNJQ'?J--R^9U_@N!MQBU:5SXR!
M.AH0Y$":LQ[5B"NOYBM$\!A3EQXU*5:V7C_)GNIK:JO.A']^D=+C1-O^&?78
M1$K[3OGK/;[H'4'&?81R)!-'%\*2".Q#^G"P _5<_PH&Q=YL/_PIU'P7$2 T
M[K7#'2!'WV$$I^UO_>'H]S):M.@I?7_#E4/69:2\1[%(<PL]B+!M(M.?D*N,
MXPE<K. %9(3%2A?(C5GSIU!* 0@9$MP]P#TC.>3&_U?<U49#F8;AU['B&+)J
M)A7-^(C$,FE"-F>&RD<<4;83!M-)!Q-FMHXR%C,(NVA3.C@5WHS*5BOK8S)9
M9M:HU5)&!LW'FI=Q2HH:0[SVG7GMZ]^>_;>_]L?S\SG/N>Z/Z[J?^]SG>8)X
M[2\Y+&=DK]<Q87#1GM50^]=0/4Z;5<(E<@X<T9H6+G$Z#+8'9?:RI5MFE#:E
M<NOX?G[\8G'0":)DW6IB7Y$S=AA^#6#]F(2:6T^S85=V+P2[YXF+]1&:U%N1
M6H/H"4*;1>UYN'>JTHJ(MFK=&I#N:N2@=N4SCYQ>]508'/CY_M'+?C !2<QU
MU+)ZIB!5^/*8 /Z0<U_MSKQ9J/=LU8[$Q*WF)$XT"*I/""T4&2\"=WB5K;I
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M."%_1',C4? 1BQP?3I+A^H"RY6 H71)W?,:BZ7ZG6=!DG_I-CPN31\HN['[
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MN]27NM9A,C&,B*$JBR@!L^7V=M?IXRO2_/V#CZ3;;]Q^\)4Y+<-1=V6G]?E
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M_![6!' NK0IO/V-K,;JCVNZFF_WJ02__G@;Q&NKT [5O*-V])=%\.J<<59R
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MTEYB?5"T$NNY2ZW0R$>,! ;0!S\VH%2L]C.@SPI%K1XF/S7\_E_S$ 5@])R
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M9B.,([\)=*U\I%.%Z>K'@#<O$\=B:_'(:GN)AH'H%*S'*H*&,+H_*WR/(3^
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M2 U,F9_><R3E3=+9.'JLG)4B\[[?J!&J/"$V_EZU2)I3A:/ND*83UON!*C]
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M9U)NF17EZQ0/GLUN.6]RWSA9X"+GT+=J]1U1I&V3?^L?IK3&LH;ZQ3.P !V
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MO>T<=?T(V><K<[D>9KA[>="IF \KT"R+WIJF^P.=0!1M@%.N$8.>J$$J-(A
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MQ+Y'7[\,A8WXQN5^2#</Z7R]V:OCV_3+XNLG)?+P)*XKB)["C 0VT2BT)./
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M$G1A=*IVXIL/A?D^&6W5\]WJ[7)R_17;B>62XB]<1:W3@]\=!!\FKB#9BT(
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MZ\#DB>GX.D/?%_@^1F2JT0CX%"OMIA<B=V"I,L S"U_::ZBK5>=S2#;*UIY
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M_Z1_:G8-L17]7;\;F(.G0WNPK^'?N'HP8PZLL$^Q; _4ZI;\<P S&@,V+][
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MB-;*SC_?5]E& L.P3HQ<XI:KJ&-\9>?HHO#UA$('6*<[$<)+))>3S$-H5/0
M^?K)'^YN2JG:_O[8&GDWW]?1]\Z+B38%NG3-M:PA7( 'F TD)]+ &@(#<3//
M^*+!<"COQH?RP\X;>AIJ4C5+'.V4)EXX6"3IEGE=#.%U@B)TVP8-R3@M\Q+&
MW U="_;+]4*@O4UA)&>DG 5VE"%6&"!4O"!<D^-X"&=7FC17X[TL<:'PZ^/*
M=_I>BX=2+<:\M.OVK81N7#5GB5\>'ZV/#1T5PHDPC^$VT<^M*M6C8FQT"T"?
MT%_-FO6KNS)#X?X\PMXN<#L@\QYQWT%F,=VP0=:!T0V/L@F4..Y XP7'&5^3
MQ\R#=;C&T'S7H/@:0+PHTO<71LQJF#RH+UJ772N**6Z0>77%=4?OX?EMV6:K
M5AQ^X2X+H.8*^B8F;/N0J/XKI3 =EZQS2M;I*J=^G@YW%2$-'HA"_+H\9_/M
M[>75;_OT#1.?%;O,CO,H:Z@FOO,;'D+"IH@3*115[!ZFBYSF<+.CJXXYCO#1
M>:HRW"4RQHC;'*/SOK"3$A8SYJ/[^=PL,3M*/]\]]275PCP<J)' HSE=:#E=
M$=:-+L"9&%775+4#\F6>Q ;5>.-WRLD6=M8SS"08.Y #-(73UIU&ZB\7;DZZ
M'JC1#WB,@:&Z9C,\?ZZRL]'S/W5@BSS-Z5>=439EWYN$&$UO\Y[E(3[ $8@$
MBMMH"K"2.?X1[B@<3H*=\092H[H+L X$-9!;29G3$HF?FL*^)TV?V%GB4H^E
M/M2)[MR9,)*;M2.DQ;1?<KR)9DPE#2;^93_U(",":D8V&&,0D+]1'PM-WSSM
MO1JP=,@&N<([:GAGX^X+FV_?X#Z<<:B5DCTQ*HT7@QPX_/IPY4_IF/D.^F!]
M7]7V=OPF+*])-PN%?#1EHF;59]]M:U#V\=@357)"I^K!4^VGIH,9:O?CO-"4
ME!&)+O0M -J7V  #B6&M-1:*KUY>0PB[XN6'G%>++K3ESAPK2GP\>#R:MKJS
MV7?2\& JNDCR\9:WEQ\VE&>=3^R1V5_V5"S/;EC7S76PU*2X>.F]>!&!K+J>
MIN-A*,N 3HS5E<./6&+F::!M;95F!9CX4*FX4WTPVKPQD>%O-KGRIENXGU8?
MM=&C_C ECB+^A1G$\ #1L$(/16WV;.-E>4%S:P@!I7KO)Z8,@I16:-Y2"2GX
MC7>05V79(65%?87]%4=/]?-\P#PG@'JFT&[B?"S=D%+:4,G-^ 09ID,+37*B
MT(<\R/12%\L:1;:J8]PM^/2ZZ#S0@1NP^YC<%J6L?:@.]])_F;4E=DP,+\>.
MU]V/=;" HOI(@AP)ECM=-QB<:CCVXXV@,M5?;6OMY)A>T,:;WW>>&KQZ+RWP
M^=;G%S,SCEST._D:?.T_OU**]QG%!P8 3 -'0(YE!+I;M,.\5E5FVF8[O;)I
MH,^@#V?TNIB6DL8\;>^-%0M2\-UP(>C(R)54+B),+BD)J.W '9H/@\3.0ML1
MR<N,IT%CMBRE<O"IGW">*V505N)(:X:=K]==">4K0X;-_,A#W]&?/@^6!0<0
MJ0NP==] %B=$Z.S-'YA-LG_EEBBQ/2;%,[[F_M:HW,>?'^5D;]Q2'7=R/9J6
MDD)83%P8;.;4$I# 4HOO=:R+SB[L5^73*?/Y!!TS9IYJUG/9!998XCBZWG1@
M:Q.!E^22HM#X*0K/4T"OU]T*Y5#K/$=O)I[ML= 3?M,17V3BY/D^;I;[\+EI
M(QGSZ>4Z](J(Y\+J&+"D@$E$@7=9"7THT @5GBIE==_CK4OI"*IKR5B=N2P9
MFV]1L!,H?F2_NI?8U?:PMZ\7P^\I??S\>&M9Z/G3'Q.9/X[8L\Z;!*@*&APX
M&^"Z:_&\$#!CPM5]45^<<>.W,:]_NPCZ1V9,7$^]X ]CW=8>TKQ_+["4V9?#
M.K?.V2_"G!V6X5/B7V+7$!XY'"G\.>06F/XNRO]V^;(?Y&7%)#FP\4H_<_W^
M<)/_4I(Y@::KMG#]>'I1'U_US^QAY&T[%LMZ!!L,^2VL%KW+SO\&='@U=#2,
M:^+RO_O4 &XJ3"\0_6N(OI>8542.U^4_FSESC&/HFMAT!%$ )N=P^PAL//HG
MT?//M\_'1I?/ F-L1%.^U;AA#>H1J<B\+L"0RMN$"EUU#V>IY>P3TC/H2?NY
M(]$V-ZQ_-C?_W=?JAZ]/;A2Q-A$''S_-4.PJ/(%S!;DYFQN8<C@4^S7K,CUI
MF;(['K!S?>?D PBE]VJP]:YR/CO>Z=@=I^>K_CCSH9>*],T(A.;3:NX>$N45
MJL"FF&F#XRT%V^H61*]-V^B L>%+:PAQEB9=."W_1E=Q,Q_N\W;KP-*GL[>#
M&0]/G:W?<()W:#H_W/:06M[V)_%NFL6_!OOH/WB?<SI0!;$UA$$]R@2A5I5,
MHK+\>E\PDEU/_3S;A3L9X"3CTY$AF,DH.*F6GGA7K>B@_#/>!]_1/&C*NI%]
MSGU@< P?34^D3,V/>F1 L2>Z]3G/WB+E7$H%Q*NW_12\/*IS2<[OV'O=9[_L
MQ \VW'+JNON('#F=;/R#NX[D#$!*JO/AS-O8G#-0*+V<FKF(S3H96),!E=:M
MTB;CWUF=,M*]4%:8H(5=;#UUU.[2_)4-];V$>0*3#]^,_K#[14X_IQ40W&I8
M1A>J;1N3=?YY\2.IV\O(7-O2/R=;,>&$P"&!<N>$6XBA^W/=E[!1>J_G7XZJ
MNI0'5./&F:=AH%(";A+(06/6RXW(<!+_ H4N]\$Q(75G=\6AL3Q#0U?GC5QF
MV@T%J;L^<IVP;A5P1;A5(_QL4IA*G%:RZGR?%Q,UC>)?8FM1BZ="W3R5"0).
ML;N*3&T]I#/I*X\/?]U^4B'AZ9&XPD25CS^(>NGAMSQ$(R*3"P;-L]+D[/+P
M34 A(0QM]Q:X-6Q._4FJ.Z,N;;T=)6R89]-XJ7&H\6;8]<S:J8G%^,F?/C+W
MSI_'2=>AP1/ND&);4(6)RSA*B-/LHTE^]FQ>RWM9;TPK['EX^HV.PDW=FW%;
MCMPPO'4(8WOQJJ#-@2?.XHK$G$)G3AI6B7:3J82M8V1#4Z#W7+W?Y#/).G2H
M[EY TH6L9K2CLM>KW)$QXT$;F(ATM#&R#V@U+F@L/RA@/HSYDSF.#?8'_JBL
MC&N+E71L(P=.#JXA-IP3(N])KYK_7VO]%<V, G"4AAE'!:/!"$X32I2E1&D3
M=][^]. PMK#ADV+2$R=-'DSKQY(BLRL?/_$Z),0?C$Q0><FCFZR/P.-G":"[
M>?4:(BH&I\=TYI Q15J-IENNXY9]_);KLSWG-K]\^=CIYJT/34YR)W8>M. >
MR86Y*:B/#D<7?"> 3]>3-*P'69*VX5&S$E,X&R$H- ^HM:9J?[L_86SK*6'A
MP^Y-VOLH0M@\3KF1LQ_^_5F=74P!ENUZ9#0V9URRR3] :<SL^2=U B]+FCAW
M0V.)M^Y"TQO ;N!K_PO+U6N"G%,RFI;GG[7@OV'>YZ^O9%3#Q.<61A*2;AB!
M39?@4OJ$5P":$5'26W'1!ZMS396ET#EK;JZUI4UAW_&4L3=-)[*<I)M%C1!L
M)\@3+U]:1^.K4MD=4[7OF :1I=A,[7TZ,WYA,9&VH;N%6<>;O)Y>@& _/#19
MXI@>J.O'?DBK,%*M:;E6E')V9 ^)>J3W7D&MQ11-I=6E!Q?@,O:1A<(MK^;E
MQH6%+)W9K.@F*[1^CL'_MAN$\+!W@F6>E??RW9/D9XO#??(RR^(OK.00,"AT
MP<A K.=X=3U<0^"R.+M6TH[?G[?1@FG@<"*'&T7/^.--WKJKY!"G81Q8%1H
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MJV8DJJMS9Z-Q_WC<X)/2A"Y#P<C*@J\06OZZ43>^AP2>7T.0M<ZR<W7TF0Y
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M+)G85MOPT(5FNM=W6<QH]?&<2HYL.;;W^H-V-SNE#>_6$+5O(/,UQ.FN];Q
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M1)8WI/ ."ADUA)HS<:*0M4LZ-+9<M_C>,$%#[^Z!*U-;&Q"G+L3I&72*(1@
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M(5O5C_#%S#5R^#I_"6G7KLY4I%@V]BX9',@0R0DC8,./>M[29&7>[EM/#F<
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M7X?E"PN+@FTC-C\^E>D8@;AZ%8'8A$#PK_P<3YSG74,($#C\RJ 6@[F&"/[
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M[4$D"^8 5^$]7PH_)X  NNZ,0F8?.QAXP!1>=&<2LE9?6" 4,'8DUK9DS*X
MW6=LI==YG[W(17(V]A]FKV'@$#VA]FD@6@#1%D .@[7*@L#/\.).\=K@FS'[
M>.6XN7;R%D00X?;DSE_P;:Q\^EU:E9XG<9^T7P'K<YW<EGZ%.S_F'T2YJ=\\
M"//"=1PCHU\@YO XD593UJLI:F+,)X0<U_XSUT C-ZRSYX*/O:M*LUR:[NQ6
MF2G+K'7.XF@+7@,H9[\<%D!"$4(QKE0!I$M#6 "APDN>_:K#'&+9?2^I/S6T
MY&]G*>O=\SW'5.<J]5/?).1;&"N,_0!89,&.@>%P+03!/$&>1'N'X3,H]7H,
MESF4S#0%^0"W-2;@]\5X9;>#?89U7LF9?[3>'5ZX]I#0C@NCK'N8L,$\J MB
M20D@CD8_1):<D6>'S9TDHGR"7!*'1A5G+#Z.O%>_DCEO^.&@^M]AAC'#A.'?
M7OLZ.SCP(,M9/L7]M)FX5J+X$NH>K&Z-+L*QYD_AF!XY4\4K[)?,RF(SYE@*
M-YQJ0B>+A%K5&]_566W6^QA_)2*[(M+,OOB<O7.GJ6&WS,#=2/8N5L\25_YJ
M%U_2D6DS9VAE%J/%CDRW]6.2.B>3ITFG?IKYQH3.G\E]IZ6UUZBF>'-G4.:_
ME=_3S2R]U$M1,;:(.!"*<=?*JBH#FNT* K9].U7T8=\!L= 6U$U4W<(;_,34
M_!K=YRGW*.\9&+B9""*L%YJ!D^/NAZ;9'N(<FNHK1[[P#76_DDXC#QOC/;(8
MU+16[&'#*UEW=8%E#_=%&%=.V8U7140#>K#.;[SFUOV5(3A%0_/;638]>V*2
M1/^BZGV1Z/ K^Z6GON6-&L1Z]NL4'.[.=8: +9U2$%^2\PJLFSJV1DP!I-L+
M06^)9-DCU7YY/98;GXPA<(R=Q W#[4:&<U:=<L"&,)RL*ZQY,F9-  &!L-&A
M8R 97^M;RXG^6%FVEFA.2:VB<6P>EHJCZ5GED^<]^@<&]@0/BNT/48A$P<!5
M0JYIJ/4@2 2Z&C5']N>=V9]_<WI]+HSR/U%%'&S-0OPT+<5>U>6*KUHLIR88
M<WU82D@17$>]ID'88C]&A'-H!J]^SJ=B3SO@6OJ0R-CS:4:9@0JIK3^U-Z=^
M;F'_$^@@%- B<Q4X/F#4O<)L9N7W0A6P'U<P1B/<;2S=M8Z_.2D1MDA>Q?;B
MT=&A6.T0^/OPVB0?E0]Q6Z0]IZ//QY^V=:0.5^%E9&Z\_748L0>D$Z%(6SV?
M6=]H?XHBL,+1QWXN/L"[CY@K!/N0G$DQZHEVAW1;4XXGQAE_J%DVA:,S7)7I
M<F[S]J1OYHDGMAZ:>-L;]FH,,9>&K[6_!^()%L].'EZM -KW3V!VHM,<6>L8
M.S"W):1B'IE3&/(8M.W,K.L)R?78-YFLE1RS!(17Z',\34;,O:6Y9BBJQ>DE
MO71YR8_TVCTN>N';90G]&%OU:X1>RM3>WEDP61)O\<'B=6) A>O$RJLH611
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M^*N2_^;Z=\47#,3$C[_0RX:*DDT$D(N$#-_=8.Y$\C^ =G$A) D@$/02-$4
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M(J:LM?%*C43-\2WBKII,Z*#)A E?TKL"$\4<ZX5NYH;PB@EP=<QY0!YRKT\
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M57TS/1!,8218D,[PB@TW]G/ZV$VD) _4Y W8+0JS 4&-S=DZ(X!T'L2<,A=
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MG@V435-"UH2#&03_@YY57[]Y!U_8,CHY=?T.U))W#X31%DKM $.#-="-$[6
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MNX*S)H?#FM\OV-4DZ%1]@U3!H%7QDUMBU7,\R7HO^C!?$&\"2>$+;$.I!G?
M8L"R$%?SPU/V[W"4F@X^,Z9\1]"'N6):6C'*&>5I.]XXAU9#?+]C*BQ]N;.
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M+,]P_G*S6FRZ7NCTH5#YLH7YD3L9LSN@L[JI]88Q9.M6&.="CL3[AH3VT5N
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M/7U?!\@YW/UA_)$Y-/9M'E.CM-CF20]GA#"CV&ZGF"C#.O #"!VEGQ_"'_
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M7<!ZP6BM8,10ESCBH:=!(Z9&"^GTBF@!LZ8%)>&G=Z:M*>!!\^7,^7%[ YU
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MN\&P5,Q6-\OS_5JM;?R5WX6'<+H)_%A3-& J!HMG?1M42^,A/J^S)PS_@)F
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M=7\F,XZX%=^Z>J[HWFI8VNN9J8>/U0S-DC$[W^0K;KBX]8?A6]WDFV?^60=
MGM&"BA9Q;NTX3[^Z(L#>W776(Q3CV3EG-S3C.4X.6CW,]3^R^?W)$PP=RQD!
MV\L]3ZTO<W_IG3M<Y&7$[]X64L'2D(,]@T\G#\&7# [-^@&1R-/K6Z23?W>]
MYW=_#3[]+RS__^C7M@$!V6K&ST/I=@,T$7:S\2U!A=:*OUX/^Y]=L_=?^"Q/
M_G:I]+JW(712$@8PUZ!KSPBM;LPWNFQ6,?<I1XNM G7A#L.PQ%$LRX72+>)X
MW?NZG$=URN'V.$2H9HI7 M)&^BNZ3"<"Y:UG 0G6/7= M:GD@",3B4JZ)_QI
M&&E2W>*+NX$OSU=I8.1+#HO;G]@1K;)>TN^4KH3G/1@W1/X2VP0^@#:PF6E-
M31<_++0XYSE>N)]D4BO;DM"'O[PS<9B]A_#*&U+&:L.@J^&E_O[K]<I]O_""
M]D$!>M8F3JQO5RHK2^;7YE@'O+<4IWQE%7_(VRCE)AWPG0-)%=9CNR]4\E/$
M1F&LW' >H*2C$9/<=Q@B);</Z]C'V?-Z:K(5XF,&-G$/F90-JOGX4"N<W91R
MEM-25,_G61[8TKZ+/@QU\1#K=G +ZU&@32MR#?$J8>18\V:<))-(YR,XG?">
MT',S,FZB=JFWDE0?C_0.FHYU^I9>W9#BJF^S]FHT^A@#%8/UA)LH!(DYV$ P
M^2G9'5W:?5MKH!^G$&1O7N7N@U.Z?N. ^/30_3<='CU/EO>_^?ANW\3:ETM$
M4 4Y>RB8C;8#)=OP(CB-=@:;!L!*(J%=QIAI%<Y7^FIV@1F5/1@:Z"IYXN#.
M&+,3W&'4P>@SLP]_G*PX/&2<X>MKM[=C9LQ$R:UC,<2+WOL^J)"'D.(A/#&@
ML@[] 0. *3Y]'?N2$_8*Z,ULLGK'6"Q:NJM[Q-7E->CK>*FGB'1D7\_FT."1
M9E=YWZU?%;J6\G!G<"/HM7 3^+L P]QT1*X!64Z@'Z#BMP8M&8-X#.T8<BWG
M**,_$_?XF;NLW_TQ\G4;)[_>C_.?!ID&<D=.*YR/NQW_!%>LTRS&IYQD0XT$
MR6<5E,)TV 9877^5^B]>2X^@WNUCWX/M&]"'?,::MG8Y)^=+"YE;W[KI/6+K
M3KHPZ*A95XU]O_R %C,;"<MU-UC&5&S.5BN!:6ON&%;_,]GB":C:6"\*>KSX
MTN;L^799+?!FP,9T<^D&OV7+;5%Z4T3&.5,2?@)#=V58T%!-<Z1K*XT+K7BA
M>N49E!CG!(T@_*R\<DCAXW:VWT[=8(G]][[N_BQ4H.(X:H-BC7++]-5 -JT/
M:#A"I&17:2\!F_V/*3UHA73\%OSFHC,M(]?/4Y(4%OLAVNBQNWOIM\MUWD*M
M0*ER8_=P* OHX2'<YNZ\\M7*SK[ZKG\Q[(SIP85+_4K'BC5\T."W^\MZ#]==
MC#+CL[YP^)B5D=%H6OON](!>^U]U<\2706ZS(FS+U8)?_!P/\ BSS[Z>Z99,
MO-:]:9IDG?O*J?UQM[C'_?=+F5:SA0(K(_0W"2%IL27MU^?1D>AR##V#HB&X
M^NJTHKLYF90ST[8950[$_QJ3:R&*NG[6!#7'%/3L6K__'#0Y\#3*9Z<V[ER;
MQN-]X^[[[#T:BA=8,I6KIR,CFJ#1^GV]F_1C3<-_%60<>/03\[3'X3SQ4L-P
M$Y<0TL%]P4.XHD;*6&)5C,E8^'>-F)4L'J)E3M(S71_)S>;(%8(U9O4]V .O
MIS=\7S K[<O/H)145=WI\CW4ML7J]+"0(**8P/*/?;C-/S-^Q'X\BD0<,:H9
M\TJ_I]!&Q23@)8D>^-$)"T9Z8[+,ERFR4+V@@5I,XL_9 :&@W)9 \3VREV\)
MSGMM=TUS3'C>K7NS\N1^0E[!0@$5_7XNGF33Q@V$!%L8&JQ*)JIQ3I2S#;1]
MX;GDI/CY%U??V[3527D@OR9MPH:8LB+(&;VYZWSOR<?&NLU;$9;"OU876358
M*<PV>C!;@*/%S<$IC=@WT,3$W<_[1[IM_N#V-B+8.]L/334ZK^]^\;T$XG#+
M39?]TYLL(AU>=W9;DC 7JNO&*G\(C$/_RJL4BW_7JY3_BB'D@+X2YQ@CO64N
MQFZI$8_T, Y[!J:?>=>[&*\SI5?4;"+UBO[PRB%2K2(%,[MKB<PP[30=YF>-
MIILPEV)^=:)G=[WM\S_6>6W S]@X-4SS$_.1:P1U1]S8U4M?BG^\#=AH$*9D
MX*!JF2]ZJ>8Z/M?1#"G3!C.1):!AIW.B<PS+NO:T 9\5;G?0/83 <0%68BB9
MCF1+XSZA*V(:U10I0.O<.L?K"D@&EUO'BI1/JPMVO>GLOU;"OD4S<//\\YJT
M/7FF&;$[/E$\!]R+E!-:^E,>OC:JJ!CM^RPFP7V(HF212Y5GK5Y-C^\&^1EE
MLW:LVMM:!,D9V8K!_-=.9S;LU*ZN23%:&VRE;Y=J;F6T-MR3\)AU&=R*HA^0
MH4=IW%Y@RB(%\,(&- WZ,4*Z$?O$.[;."(>\'5J,#\Y&9WS2<8F;>UGXS:G\
M^[<]VN.)9/]AL11H-]"P$9[>=.06_=U@S 2R66,D)Y0L$42PP5L,+6[!AA'L
MPXJGW=Q23FV3:9=US4@:,,L]C!!:3!X)9"EQGQ"=\6MF<!NY*=!6X+*]I\PU
MZ'L'NYF4..W@&'O'W<Z^W4=!J?'EL</;LIXO+G;LG8QOL8S9-6W45N9#OJ$@
MN?KRAIO".<7>S=DVX 4I!R4U.8!1$P29:=@?WB=XQ-%("]9UZ;[[%"Z+;H_3
MBMO2Q-<<W/AS>R I>9;):+O$?:9))H7:]?E@=&URP&MAPJ<ROS/'R1<JLJW2
M B(D @PU\Q1M'HG,QK[*RI7^<O'BT44W<PN,#7$YA(]&+L_G2"ZQG+D%''O/
MB;EX_<V#+D/>Y;::MA7XC4%5%WN*,7ZOMM5FAGU,.]3LHY9Q%[/7Y/UF+Q=?
MM_Y:?HK&>NP^QID'C%'J4'21IK? R3Y:2<^O@@T1ISPP$FN3-"]^7H>PKI/*
MLRY\^O0KR5X]/(S_#PLZ%C#1G.># PSA,/$7G_7,X@JJ(3EG]4BBV=]Y1?W'
MS__T(N'_\D<LVQ^YO,&4AW!\O)P9_>(WK\LYUP Y>!1[_Y*XKPC\?M33^7_
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MDF(:TK,H\D!3H'E0')G5RXQ^]6J/JX2<Y_#LUXI[D3V.XB.A5\+U0EGAW&B
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M8-G:/+DW;X?)P9R=S]U.#9?YF7@?BXX^?#XA=;?8-O5TC<2R;-%VX ,"566
MN?YJG-#:<3_FF>G_ +7/C/@/EU0Y=M-D?PR/9*:$5YC=?CXUZ=5FQ78X?-UU
M[SK[GNBSV@\E[I:D8&@(XL"!)Q;0E''Z.O@4P*'%*Y+W0/'@9/L210MZ#HZ=
M&4J?G6R+Z*N?TP.,-ELWE!L_WLA6QJQ?$ZZ(.S+RS0U67>![#)$M!6YD+2A5
M8$6^.$S1F 6J_9.KF#$8]6D0W@K4_/9ZX[MK7.ZKS(O<.^X2C[[VVRM>>76W
M&;,?MD9D4$D9Q57[/.24)6% 9T2$WH4=SG$,[!TCLB6;JH% =0W#!LMEE/0^
MS]*Q[",,F52; _P#>W8=X;CM#KYP4/GB1HMH@%5) T\M)-*J%JATWP4IH$79
M-)FJ1389K.I>4/U!%3CC>5T$67@+X9)'UE'Y#QY2.IMU;VQT^V[1@HO%R2+^
MX%;.1D@-C&P=_J=_&]Z6?Z @X(;WB[_G:A-7O=#Y]3$T_6KZ)=U$G?LX*4H[
M\*L<X+Y91EW0;V,*S711UVA5(_]Q"L),)!+GV*@& N"QG[*.DY)=C8[MX0X@
MBWRY.DE6P6E'EP[ ,U&/;+LZ,V9?&?6EH?(7>28S=[(,VL'D6@BV:& WK.1C
M!E@/;8PA!W!^5J3A2$^DH*';A5"OTX"6FU0:[GG^B=[@]=-GF%,UCJM/S.TO
M[H6VS\ %!O^Q25_:G674[WY_G"/0<F:L61J)HQ^%3S4X\:/ :Z1KQZ%D+HW0
M^15!8\Y3W%ZX:M$\J*N''C(1NE]KABT$#O%\8OTXM'6!?$9<UDM/V[!"YNC'
MBD-7)9*T]KI\OOONPZ$U&^4.E*E 7 $>@84/$,RQBM))!TN *J1UDB>IA@@Y
M8&O(M#G<G*,&H2&*]IY8]9<9,$K;C36^1"&S+M/ @W]X"$9NV83U#YVD(? (
M+#9=T.>JC?.=XN>R@?BYB>/6Y3Z\26"TF[6R4&VS6I@+$U@)"PU^X+"A*U:"
MX'1]G_FCMP_D6VY(!'#V6GWAI#H_*JL-<</KW$5GV^P3?:&!9PR %)$>%"70
M UH,=L!.;&#=>,)FWLB=)D//@%#"_!:[\WZ$;PY&S>Y/,P_*O;:)JS>&]'IA
M):_]B#;&DBUYWM-%(-4="IU<1L5K[:"U815MM @C#J'F\2_;Q;9GR-_V2MC@
M?S'7+;SK[V6Q?1C$@*"MSFT82'^A-1(K_S-3=R$)#N/4L_/).R&_IU23,[R0
M4LB=^S3U@%^*R>;T"VL[\R]_?$=E,\O=YBQY,WPGX6T;:_)9B%?"F,5@;/9T
ME)$&NV(/[ZT>--M6[*?RUONEQ/R=+W(W;^X-)YML/;E_;P*B\,P:="=3AC3"
M?[RRF091/;"B28*D>J:IDJCN ]O''QNR<M-,WCTQCE=9PW#>MX%OT_-)_4+]
M:<FOR7SZ7*' B;Q=6$'W=Y:B?,9*5#N$P,:33NK6AQPC$UJ=Y'2*[QY]>K>B
M8TO#\:=WM<Q13RXU740PR%4Z6QV1B2XL(6KY9=.%^/*.!5JEAM4RBFO96^5?
M0UXPL?E;:B"2#5D$V/T^&P5:0#G MN8YP]KN MHYT4C=6*609M(#7_V??-;_
MY;*!Q<JR@30/C!6MU0>O=+%KVX.ONH/3;]B-5V0CFWVLP,9WL6? SG*QCQ;I
M Y'7+EKM;%GMX3+"PD#;).=H2$RH&[21)46P:SN=QQ1Q$!>T.\.3;:+R,NPA
M7?#MB"VO8R%^ZAQU1V <Z^S+3_I)J%NYF^)2\[?]6T >CF['C7IU2?(/@-1F
M'*1?V(6GB&'6MB"0OU7_I7Z,]I""K,T&C]6I/;=Y1\[-LM[<+6X9";5<Q%E!
M]T72FP6!HI&F7> 3A%CV0EM[:.W8>!\YGF9!/:8508CDW;6@,.<-$#3VE""@
MV7CXW;)P1ZT=U5'>)/]/^K\&3SE'UD4T4AUHL:>(D:]!R0);6!/YQ8CG%U(]
MAU)*M'+A:/KS\0-_@@\&W!3V//OJ/6O$&VNO/W.>>O'<%O::(?%Y;#16"@A<
MB&=6/EQJ(U(Q-1NQ<J+-O9I@!92!:2NRU@SV/+-EE%YY[B$;V'3W\MGKCUHZ
M"2-;GZ(_1B!/VH:8ZBD,OQ8W]I#.>I,.@)6*S1CP=BE]&;6N,7].U"$XWRBP
M&%U&59&?_/U&?USYD5N_T>V'<4P57>$[17; %*<&Y1/>=N0\)JXI*BF)8:0>
MG-(^DS[Y_J K9E<;-CW_]GBTO7+A_U1-;(I>LY+]Q9+_1_B$;"LPIO1-8-(%
M;90M-P^G>1[=\K:\+C6V+8*HA\XP#5%^^/I B^NZX@]11Y-0<(&P&NN[ !EW
MS2T)-&=%BL)L.BNOEJEZ359E0TFI:3(Z/KQ&R[JACS+5[IJ9_C>=(]S\SL.J
M.N>@C,'U+)>F*N'CY96:E)(PHM$QYTD /U!XDWR(LXRZ>0%8WQ;*Y@+M(@4%
MPC];P<=:Q;.!YA:ODLVZWVGZV:TR7W?P@O7#/X9*8G_9/*)(>J5RH9FPO&'C
M,JIRB8M8RNJ RB&1$K-; :K<#X6!-P8/?FYP#$HS$.80VD*-1^\EI;::;H[_
M<&!-$PSB8AM,P,46AG.TE6I>1^%WALKC-;3\+P>RTX?[.LL[%&:>;-_^@K\B
M-^6_C3QCD52AX!H!<4-4#:#E$&4],FE>7-B80U0\S #BN7]ZD0ERYHE#N"-?
MC]T(?E";(3B_7WH]SU;QJ*/J^_#>'[)*8AQ:>6]S&6.1K1H;MK!>Q,#5E)1U
M>8T?YWD=^ZS*#J/&I;6.=#/X7-GBBI+F2]TA%Z1^I+B]-T><SN%>!D)W$8U6
MHG0LHRHB8"7.SV9Z96'2 G&4K!H&SLH>\@*G:5':C?-9!;/!EYO.[E;37;N@
M1FH8UK[J1_L=EX1"Y.N/B\8AE,B/>M-'4?A$)/N]T!FDQYI:1AG8UD1,<#;<
M-?JK(4Z^<V5>Z#'ZZ$_IP/]TU&/&^0[N-08V J"M9<W,L0612A>?"&]+56WW
M!. MP!>;"'X7O^1Q#9-?9DWIG?(/MWII\?O#G[)GWY]%VUP3QBZCSF&A"S@,
M3.+UPH94R('.#B=?^$R.X./F,.6 ;U01YGMDPU]*?RWF9Z@64&?0@PU:1D&Z
M(]QMO%X^#"[!2AK\T\+&$ALTE'<0\B3+\3/HTB6P?89*"6#]+6TZ\HN+C)I+
MZ%2:5</\W]<VP\ACY0:PK&01%AKGX5IIR@@I>(',($:5TL>#--RHKF#MS:Q6
M5RTUL-WS%C [7VKZ<\LRBG!-A[O;GG3)=2+E V5A98EG4;N%"1YB0EMIK0 C
M@X/CAH)$D8PU(1]"/$3!KY_J3=4""WQFSYS*EH/#_ZZYJ6;&FKKV&Z?';+T5
M2MLF[7SOH"BK?[^6G6 G>;.PJ$D%EJ6#QEQCP?DVGEOGB&K&27>(;QSO>F,M
MXS#O59OJE^#GI/Q?3TSF=\@L,"ZO)ML5 2U*2-]?9LYP/?)%C'\T6'7W)^=$
M=?W8 K FJY0Z&NEP.OEH^E7+%G[HB[\[CJ4<_W6[\[(&XB0ZE,02P9'#/%H<
M9>-W+0TH=?(A#YMP3:@P/.;#VX['7S C?&&?R9GS.N)AV%ZQYOZ'DV<LN!(W
M,\?^QQ6N&>>Q7K[X,BING-?;3%4'6K\LHV[YBI1HG<$F7?1+HA8!D=_[90G(
M#5GD"&S@951)>Q901_C^=BNJ+-M&2M0,@ 5(]Y\A()-.9$)>& 8.?&.*0>/I
M8"*B%'^QHYC1\&?,CP*W'&; 8F@]\:'6I\<AU;^]E<1^&<-*12+I(EXD?PSJ
M!0_Q;T$R I\#8'('4\),,V3I\.=2BI8M1^?M?9<8QIJ/)\>;$\LWA2Y*CB,$
M</T$>::3!A[!, [Q:P2JMY N%&+!,Q@U^#RXNB!7>6JD#2<-R3B#EQX669V4
M5K"<O/BK)TS*[]3K=_F[XUQ/BI7UK=VZJB V-R!'I6^NP81=HL=H.SY8HET]
M.+>#[<ZNB3&3NO=LJ]B9TZO7[D&AMH\KG9"<L>C"0EN8W.I)!*V4):R,FBFY
M4@>&+U+@R8IHPH=L3<NSD,QYCC%T^'=CM-GS!QD9["U?(S+2]^1%+%Y<=WQI
M_(_SG =HPA^ ]/.AF%Y^M[ ^6+37.]!"A9OKW0*6=K5..J0JMY<_J,IT"9U6
M.93>R306MTR-O(UXQ5X,+!_);X(,V("ZJ ?SF@DKE8C48"G><%$4223= !'7
M%+Z$/"VG+S56#YB)AZK%J5DT];SS5.AXD/&5R^^:*Q*8((@EE>Z/8/!N!-E6
MO0R"C5F-ZM981\=$\9ZM$E7WCS:C!KJUK4J;43Y'-JWC-*[Z?W^RZW]=__UK
MD9FLM8=G%T>VE8U+?'5=WCKMW?MOVG[)=9\\'+ZOOHH!:YHV+:/Z6I91:?<
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M'\_@HP/7#)AHG^]OKZ7+*I7/$M4_IL7O7I-Z9T*R%'LHX"FZ9V$#;"2LHE]
M'("!72=QS+&9_EISIHLI2PX F7$L<+B2W:N$=[U1%C,S&)1:S+AJE+<CTG >
ML\35<:K=GE5K'HHX0HEA:,4#*4)8 5[TA5;3Q8T26(ZV #S?8V!<+HNZ'G+L
MR(QB3&1CG1JI@BW;+F;NK&PN(P0M?MTAUVW^5^Z1Z/R_S8A$7<:!%C4Z88%Q
MBKV02$>(IB9\8T)66$-LL$4G4E3-XFIJU7%M @+:+(ALI*X?X%^3N4W'\>6:
M;Q&T4(7@JQ8_).>Z)JFI@+QH%0G7B:N*:/&PT2+-+SH>XI1)-I7A*9E1LU,7
MY9WQIOT.,CN-U=9[^;ZX7*QF=]T6M;)DNMI1&$?9"XWP<Z&5=3AE88:-#,F-
M0TML4L=GQMWD,&_E&-?7UL1W>"K/]-0,3T]Y:D36Z8YO4;N<2D__&^Y0)MA!
MFIDDMCLSQ-O"1Q \7F0<VZ1>2T@,6T8E4/1&R.:UF4')A&VW=Y0@8,@</SKS
MZ^X[3[/#_E9/U@H\DU#P!-2%"+,"6MF+1!3F4;; *U$^G73J-(AK*Y/!C^1L
M$.9821:2TAB$HFVZ9TQ(K1$5F?:WQ]YV?3LX1ZZB!MW[MH8,,.X0QXH.+J-B
M 7I [RTL>,)9LA#6RUD-ZA4]<X?W5PZ5& 4W1!2TYP97A]W9ED/ YZ>([;CZ
M;%=H _K)*\J3$1F!$Z47BP8(V&@M0V&6S0Y#'LA,-?6XUAB K[5QZKJWJ>UZ
MR '&!&0J]O=-[G_ZV 8C0#?F'(G(7P/JSTFNR>-@5&&=UV -C3<F4EF3K1HW
MV1_R^UMTX*!79?*7^8$A4>1Y10JL<FA+\)$%@("#=)S;RU;!BL*'5MX"#.E4
M&U;>BB#0Q<<?K07M4AD&!(PFWL)<;G1VI^E]R:2)Z4-2Z:IW-TQ&7'"6P3U=
M1JVWDLXE&T+7G\*[P==9 I.V3+/2C,*H9TZ_KJN Q2[S0;(]U6N.KW$*ZI-L
M9:+( &^&(]D)K,6+BZ0POF#7\>3323@%TF*'S6:P55;VE/'T:(?O=&^$T1^Q
MM7_W*VRXEZ)5QG=$U&$?O!L99IUH!%.UE K+\C'B9.<!LCCZ9G4OU](#J*(Y
M#134-FH=NU+5]_?*VU*_P[)/"M@]45&(?KF!L?P0X4L*XIQ:$&I"6$8Q)H]!
M#L3KSTB+S5KR\>Q;(S>$Q:$$1GI6P5D[P\I;]YY7NUC:J:6Y?S[?;<22)9<@
M2K$6DA2<01HX05'Q(6_*$$D9!(-CD^O+HRX&B_;\G-@'_K1E[]5^DV372#WY
M^FI4^*K<5:;[O<*/9M>5C3"VBB_6\Z>$,?0 YBK** U-9^5C$$UKIJVG]*G'
MW0/+*1CR&<B?4U1O:5ERI4-?<'I?]:V1W)(!GIZ1]]G4][=.95RPQO+W\>([
MG1,P6H9&U3A(6S>^F;G._4?M;L?)'L +7$;Q:8PD"4<"P<FDYZY!?-1 54+]
M >^2>NKK%_^?I.+X/[\6B8S[[E A&Q=70>IEXQ(R/T09N>CE*HRV662%D"ZU
M)WS9>OFK[]1X3DP3P@+BW@GSL=_S@*DMO<NHE)':C&_NQ1_BJY_O8? K0WZ"
M_CV7OIZZ^;[<I[5Q[\2(T];1,H/W-X*BAFS)9KX";]'@C8=S^\+BJ9GX>5UW
M5J(I8?>GN<M*:/V7.FL%CBWA/CJ##=L*1Z$V=U'?T,DAH,JHW3[&P;[[_(G5
M*,6;-_O6+7I<\K#1-DCQ]K!=#+H? 9^T>%\7+YUS-/"6WH.(*PZ&-_#Z+PMM
ME=S2(EO^<_:"XD>ZWT4'3V$8(R(95<%!41=3#&#EUR*PUTH1+&JS4?Y\+=B\
MBXV-_S-H,*M.OG)L74;?];REF\P,(CT:A7(;0/Z3;" X2FFE2/+*.E?6N==B
MR\A^8..=+(G7G?35Q=?^5@57R.N4M^4V+ZG&.?%*>^ZX7=K_+1/U[T82O)*?
M'0>T.%%48!)/I4@0+AIA@B>(# E2_'&><X(1"SK [EU%<&;5:\J&Z)17WGY:
MT9^OFO;,2>G)6=/N+2_#QC?>XF/! T3&%):XH(+'5JW4-1WKG8PKX;FY9;1[
M9L^TO/OMU8U!_;AQP<?9G[@NQ'2HZ@V)': CX6,:X]P@8Z>+HE2YX-0AJDAF
M<875@[W)90V688*#N/$?-UQ+A(^+H)FCX)&R"':]1@_;ZJ590+!GGVS'@;OV
MOAIQ9]=-?N^]@ZDVGEL06)#1]<)\T1[R^3[8FN5HL*<TGV<]SB+@?1^@M[;Z
M?O7'6QAUI)@XU*V6O;=?\X_R+^;<7\3LJ,);RR@\H-4&]K*9*5;G"<4^/RP\
M"U*)'%S<ONGTM]7957KX@NJTV7Z%J/(8@=*"]OS+LAPZ*Q,'^C!O8:IP[<Y)
M@*S(FKQ_&.>"K0HI85-O[?R!DX0/EG>S.?SR'[2@3 .5.\-7?KW340U>=R]%
MS757['[,<U.W][2URZB WIL(.*#LH@P#RE81@A!21@<#V]9CY_29',J669 )
MO.)%WEU#/69B99ZK?7>\:\?1$:/@AS$/+>-LHU39Z%2,C-5UT-])F$O>-NEE
M6;9Z5J2>W*X.)%SI;]%[K%M7YWB_8<WA77(SER76/Y6S184IN<4;PTKW^3K.
M7R9Z16O%7L+7*P9MY /-.Z.P'8R)C.OG^<\7<U;+,[X>S#!:T G2MDUHB%UW
M\^%-*_I<&R*N&ROB(N"2S9=18B(ULL/P-:9:H#HYXY]^O%4PJ]%Y_YMAPQ,J
MUXL[<XER;\4.7"A/O_SJX^FM.J@H$UOSZWFUM^=U=;9ON[3988^XM:0>W10X
M1X2,EUIPJ3C-IMUD2VB*A_8R=Z5MR#H,'<S$M93)A]RW)W'<*5_ZW2U&G^^N
M%^>7Z7Z^\J$(H3>/7'"[* , Z,;\$LMW@\I?P;)0,J=,-=!F.PC+.7.L#1#Z
M*%M=0A#H;<MUX$0F!G$O)EGWVU-K*=Q\A36V-["MO6.1"&!G"W8Y"7QA#:@0
MDT31\OJ1X3;XTP<S4#H_?<?2[U*V[!,7LY$G-X^?^]4P$7O)_IUDD8N/A?[*
MZQV3>+XY!CRQU\;F^R2+UW_DA15AZM,%\VEG ^+]J;^BB"Q!6>5?"O+1F"7R
M_,U$D6;:F(IDV3SX")B207U.>!ND^H\PJ^[=\8 K\4)S7?K2MHU]Y:X2^0FE
MC6MC.U"$?A]E@0O0XKA2S/M+?9<K31:+[Z6JY"B-F*%E>TI__(L:OA>YJ[[B
M3EBMGEZ,I(>NR;XCZ;/'!DQ0"4,?F$@L.;>,.I^MRB?U(RI.5R!U=W@2XQML
M.0Z_-5=U+K"'*X4E+P)WYED>4'F27G+E>(?1ADY5XMY5T3:T9TU1PKLK+Z"
M<BJW<3+8E^W6O)# N$79W;?#=<D-=$NVV@4\"^SSK%RMNHKQ;T..?>WN&-[\
M&:/<A!UO_AYBS< ;Q<'C3-%:5<$Q6!GZPT.?C6?/W"QK,,:#E0)MUDC"_(+5
MJ.D/+W?5@P.M'B=DJEP4C]TK3EP\>-$Y,QI[+*!,6EB&93W'E,_,6;X,\-D
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MQC=7*(Y'Z#Y^+)A:]%C+TZ=@.V7:$ WYCQ&(-J5C\V!#E'$&9U[#/JC_H+N
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M5P\+H%L#\U5YQIY[C]X<$ [,WS.Z^\;]X#74-?KH,H>XGC7P +ZBBX5'IH%
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M[<WM7Z%)NOUPM:O;VN(TG2![_/3-XK<S/P UN T+9@,MQXF(@!#>B'P]CT.
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MWR_=49G",EZ0= >1860LZ%060P4O8)-J,FNHFXAGP2@NTR&-YQIP1;^#&F=
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MZ5$Z>ZFYZ\">L7?[]VG<9$%,\_ON3O:4& N[N4[;%NG=W^MY_]L5DF%_1FJ
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MTO=NVT>P$)%@#&FF44*9ZN?EE<FU?OUCE'IA'R][%&[6/OC$M]L1A E:+9D
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MH#-_M5+YPNE\>.;9Y%P6Y-98$0N2+E/=7?4K O*?$Z#^,[58_$ 5H@2#Q(!
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M)T:9LKO=I_:U8A+.\(.S.4 #L^6;YIH04YMT%T?<><3A=GR[6[(;85E;I3U
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MP'^&MJQ_@;;(_Z'0]A<I^[\B9;^2##^%%WE^C@K]6R)AE=\,?A> !?WC)X7
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M)5BD$%09+)-H7Z]%B(Z%J[1.0&X'0_F=8 (PAUSMB86!1B[T4) ;@N->I!C
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MFQ8ZPI!LB <2,@-TU38O%W^EJ>HW2T&\S=/ZYI]G($O GKX^A&X5U9UV>FX
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MC/--#/KJ;']QU3YBQ],-9! C9@(;5/3=1T%-R]G<JF>XM7AB9VMQ%AM[<M6
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M(%8(3F84O0 HME-*9( 9'@^)1B_L@/]2]P?!.W\!TY\1(>3_\+0YR6_7CS!
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MO#]*ME4T5J6F\9]K9_WV*RS3]';YB5C:233A!D!K?,S(9S;6KH5*$IZW37/
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M)3^_-*!81>FV"W!7$A7W.S&5*WG[>+#$0T[;6?C?%01/P(;@FY<:C!D@1T,
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M\&<C];YLK81.P.'YE4T'!PT&MY_CD>S/RCP>%)?RI:/FW[HD*30>>!U._%G
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M*87O_\\<30F 5NNPLD!0L]0"^^D?T//_"+I+6<4<XZ>P+BA;6=HN@Q5?C(E
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MZ41N] E[D/N4#]X<Q!U5S.$9+BEU=$MR@&<_?R+R[L%Y]SNYQDP89[<C4["
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M>S)IZ(N-XZT.+W!SCD/85B^_&U6=9,])L-8YV7Q+Z>OB6\R+CS8:J^Y7/H!
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M#OE ,I%OP*L_>O[='>MOEFUDKS"M7M29> \&UYT<_XG1W#)%,VG947L8=8<
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MH/1BOOY"=%V&YPG;/I3YN6#5&/T!7&(BD4$A DY()3!VPAF 75'%VW_EW_.
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M4VX7<&Q4)36X?EW!$<(_+?:5.YOL#:YE_7F7LIH#+.XU-7N]&M*?]O%N+Z]
M2%U#7$-.SIT W).H <CT"&_5:C"YLKT8W/_SUXI[0)E7?U'QZ>"KV7UI9:[7
MLV\X-H6$/O1"91 #43%$6<HA4)EWA9N;0>B;(R>[T9[VQNU3^=-71ONWPT8Q
M?]$N9U>^ON_Q\$YG;J)>8$C(+E%EWEMA M'7>+JQ/3\2UKV!@W'C!/VJH7HY
M8K']Q,1^=X^[GV8HP>_&7E2[B,JU3R[\M^F'J$HCS.N<B).Y'L*'1<)XZ[.
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MNP3!RDPOL5/==!C:ZM]XY^@)K<;"H7 +Y>R!Y/BZD1,ZAFFE<W'>GG.H% P
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MWI. I44Q#[B$CND]RK+-8VH?>+9Z(YA4S?^KY[11VOSN5H5>1)4?>S>.[H2
MN)DUD1S(R>-*$A/=,N\@R-NX'23F0/U%I;;/3*+ES:@P0O^*^Z'(C$=K)K)\
M="1;SHPK?'XN$]P+H^G21Y@OZ>N]*=SMZ)QV([=NRK%@,IXFS';R"HJ2HU74
MO?4X\JWN;''+%2L_Z16B^G@KQI,#]3CD((AHQ,!B9HCT.JMV*%%QG58[AQ%D
M.6[7*K8>6Z^>@3"C65W?4'/)R6\[E[>:5JD]_1LO"_IU9FZ)V<E038CWL.KW
M>=-Z(JWB1TORE^@$U#,8P,GF 5XXT!<_163&<4JA52"7!V,[F(QMZ:^P7CS@
M<G0>"T:5WSK2O]H*8>Z3?%:#->&%2H4CJ $!Y@I]O8,T%<;,!EF4Y>U'*/E:
MS'MYQY5+[^C5P7?K&LYVVD=;G5 +/<0=JRU.ZUV_%KRE4F799=!,39W.J:R&
M)8743Q_X+?:X?WJB+SPNX)R?SLO3W[>K':8&DG>(/X@U?W 8SL?> V$"5&G;
M;7B -U$$%PN' E26!YP<:I-Q0^JSU:W4P/OT+'W)P!BYABP;;,WT;,57>&"*
MF&I<N(6-PCUMZO)M-4$PB3Y"ED^:P]Y%*(9:[4 _0-9I5Z#?0]/$]7@XW[AQ
MX^'T]&U9@>]3U:6BKX0.!3T;LD22\3(Z>#)1<F)13(#Z=&*FN-"4NQ2L)13?
MOE8^RK<Z0$MB;<5V7N .(6IY0.\ Z$:<@-,+V=<B*/I4'%6_'AN\,=8!U_BX
M.L\R-6B)F0P;\5_R[/6C1Y+E<8RCR_/121T#VX[,VW/V!Q!F]9..$3S.4CX8
M[F_(^J&5RQ!0EE*ZW&1]8,[%UAK E+'TL.W:; &Z&=F,IDH_1BG-<.IM4^84
MQ>B"Y3WFOPK^[!SAM@=4=,N>_?G\SLJ34T%*W6]7^G2$C^_3[O"!#&C G240
M:VNP[58F^J"VYE=<[?M)O;2IZQB#!I2\';E])5UVD>B_PB;N$<8L:UQ+N[JW
MZB%^6'F/P'=X)HY^BBC =D34VJ30^WNN@=J=N%J7#..9L".#EX<<**3)2=?Z
M8E/^8Y:^L'OXY>2'[-8R+9/!F&EL%8EMBLAH$T*/<^63V!HX^@NK_1?02U32
M!.XJ=X)E[&3+/#0;CO6;^;[PL>OQ='J29=1O6;X5. UJI+9\AMB! +/_+I/.
M22<&!\1L0Z^LOC4 $=U[7V(LZAEZ^:\#ACQ,1G=-?[24$._3\/[@<O"\X^W5
MT,4UXH1&%Z3ID58Y"*4%&+A>_]\>WIUP?AR965%TC.QX-;?B0TY9I-[+&K%L
M>7+^!3$OE=LMG%!%J]77[*-T6)*E:R$HUF5U8(AJ0I*.+N5*S<BO.Z5JOW&B
M,E+TK#Z*[;_)+MY)NF0A&S<A5WU838""GPCE2H>">U%W( 2%2@F]SC(3M.;*
MHD!]+D1>J0ZD );#XDPTGA;SUR0A9$#[_=4%B]Z3C-!D8A66+<?J]51@*+0'
M8.<JN(IY[5:[XW[US)\=M>)W:WCC5WI1R*8APW\Y2V3[\1X#BVXBF*QSD.5]
MEH%,# \^.FTW9FGK%1"!G@[6K0R5/JAEE?SZB/=:^1K? K$FDOJ9SF(>Y.19
MRK'TV/NB^BP1<UA8>TE [:)A4F.^-RHWP/7P5MOKGZ8/7ZQ^*P!@?D/V4H2"
MQ1L3SJG"!BS'8^O'J9.L8%NZ7P]N*S5B*1A^)H=<0DR1GPN\9QMJ8/#%XY@R
M1>[^_K[=F"_I)4?PE;W)K581>-"FI\6/4ZB^ZI T]6!@DD-[,I.)N5QAK^/,
M,%Y]_S*Y)'^F2G9;<4%'K-5)3A[$ZQ#@OH5.J N%IT-]!P[4.83K(FV=Z#,8
M8TLH4)>*?J2_TCZB;E/(G/WY-?Y*Q?:F\Q:M;TH3=[=D3HHQE:">XQRXP5B>
M3V+KPFG+H ?7DL#08J*86I/8:DRY-8&%>++0QWQ*FR%>17\R+:C_Y0:1\$.4
M*!LB?>R-S\NW-;(!KT.RKHB;E^TY\6ZM[+>J_>EAG9+1WT%@</!SCY&+%T]*
M::"<?7?P_7X&RVL3A:#(M%65OD2)I)E1EI-CC.]V_Q&BZ;^VOE:)=HN6G7J!
M\S4>\3+).ZD5=GU7^N,<,2F5ZOBQ-LQF>4TC-3#360<7X70D5&OB7L[")VEK
M>?EP^V%8IWL8);G.Q?G"VDT39%U"D(_SRN28W'WR5DT#;0E<86[,<Z]R5]NR
M@,C!+],?\IXW$AZ:GVA[GK0E>E\@ %(6N,+S=&(WEFZ/3X("T&$@!2[W.Z@<
MGYC='-%[QVHW>.M#0'/&HXH++6\JRX.ELAQE4ST>/K_QWB+V[;U^V&W(!RA0
MYW*0V^X4!I(K.DF^2Q+_J9S0VIP_D-3&[^:Z9,ZINZYM+..@^?7>U)/S)^ON
M=3>&6/SUE^UDW1FA=[AZ$ELFBK*>B0TZI,4$.9 $@<)6,ICS\1TD>AKZY2)7
MQB/(AN&<H;E:F/AK_%-"EG^Q159X] 2?N7A:Z 2+*X)@()A8R" )023Z6?T,
M>$/T<A=1&=U)MD?;=S&-0--#IJ,7L?[37XJ91RV2W-TOS-7'S03?L)"'&9W^
MJ*$;768-R#K^OQMH+%NVUIGSO$Y_DTSTZ'HSD7%<9/(8"59O1K\W[*V/UKLC
MD=C@F#4NVI*[GV_WX5C^O[17IKDBW70D5^(FYQ71EP=LQ2# 1R_1&F?!]O(?
MV>7SO6 .A<71[S;SU$"/TXC$I@(EM="ZC3SK%KFYX'?XB<PI@?G0!"QT9[R:
M!K@TGZ]UX<T06_]%/;,TF,PQP.N+B]JL;A=9/7%.NMOV@%/L+9=O1+9L#E=4
M %IK-F8*44-,CX!+!JKQ@PGSG+#.R!M<R88AC,#U-OT'%]"NP1JWN>]SSM@O
M;%S:2'!*LW+9$1L]P+H8,X:50,Q!E;\6<;M5]QE:J,OJX'B$&$W_+4ZDE>\%
M2<0$*1UH(R57)W'-H&-/AOKJQ;Y[S^0MGCQR[U]#@GL)M!2Z]CRJ<R )1S^+
MF+"W _W(F7?5-.,[/:49X_%MFK84,0>$1Z.S:;-O$7SRF7_NY=<IAJ%IC;VG
M:MAV+*>8/D2],Y3V6VHY=[CF,9]OV7:QGEAM#133[PE""01".NP;7%/Y@7FY
M7(2&3<D'::-I8^>=ON_14P%.]$^AS38?G_)A;H+Y]($.92&V[/H\JKLBZBQC
M-O/F'&ZK)]N+H=9:>M[^Y=14U-V#CF.3WF%-7Y_::)S9T"@!HI$,%E=TA-'2
M@:6?69;$MAL1?;$3MU#)!195]$-)*<9O/.=['7_F!KJ?^J"5RRGX_/'U?N[/
M8SN??,^Z8FW==^T-2WOS25B,&?LBF,<XQC0'&2P-=U"&F0C>W'S/91<>RH]/
MSUHZP4C,VW&EH:5VM+MQY7D03D_$E>PM=N+ C6TIJS (Y:XNQQ.K;=G;DQA^
MO:@ZAP]3\+AZ?*SG]A%]]G6F8;_/<X_ZOJR9T%WI[M1!AYIS,J:2)ZNUI5J5
M?R&N9*9N%I6XM,V]+!!B3Q<QO0JB_<A"'0.Q<#H>1Q%WOF[M0Y&XM>#,"IN>
MLDPE^J<*U[X9WXD*/7]?*?; ,FBVSLS8)+I@.5FOC,P)8]H/UY.V>K C&):>
MZN#M5^Q@4E2A[T;KDO]K.-*W.>,+._GX4(K03J>2J$]XJ$18<BH1_K TJT-@
M-.3$ 4YB'3&E31E$40ZR+2C$Y )C,!V>M+8T$_)%(*PTX)UN:=:W0IU7(PWO
M.K>+ESF'0KU;G&;,)*XVDEJ*R,#./<76^76AP&-M1A[<H5EM941<_<?=OY1^
MG\#KIS743I^XO%*2>J[/!1:W]9;A@U4%*I$>RM3AI,5HLETVWTB4$AMR>E&Q
M7,-J$%<1I";3.MRF%Q2C1B>E&:LTL9>B3_95)#<$9%!J*H\EBFZ[8/Y,Z,=Z
M$G&NJD"5 6?+Y%"6:1#K%Q4Z/]R*HA^LC[:@(#ITP]PR5"J,W$<>N07)W-Q^
M5J/G_8^A+Z^O5E9N&SRV9P6U^8PK!'L5P1?SR0V*/Z,N(OV46!Y\\A-SQ/[-
M6.LQLZ['*ETWIH+GC^.F[@=<G@AM@!D^_EQLYY-6_+JJ/+_ ;Q[)!W5B:SAP
MYP MGV'!%=G<A]-F.63I6!38V1UCR*@L?TFR+P^L"J O9VO?!8?M'TI]5'Z2
M<]U( ^CUZGT-K6_K*,.5N,O8$AB[C_O)'%) @*/<$ZN+N0I9=X ["A>P@O\D
M-@S<A8I.?NTTMY_0G!_WD<&/5>MJ4X^W?5-P(+B^=ZCMTZD;*TJ%/K=?K#:<
M3.@Z_L@3R17S8=0Z@E*0GZTXMV-T0"=R0?E\_DD)/XI<0SPYF/]"5K3GGU7K
MVKKZ!)][R>3T%XUW,9]N=*MM;#MZWT.!+5\MA9B;#MW>D\R/[\"))9PY($"[
MY7-SF2TW/A_SB'4@9A9+/XW,4-.@5Y:]_NFIAE6^&/27_Y^K.3GR8T)'1X87
MUXY)U[YK&+3,T9%R;3@\?>2 +-^:5@=I$W:,YA!3J^VH&GVVK#O3<"1&_B+;
M.96*T6<D)5C&-',?O21-VW[O+_G2U'";5FG9*GM9]/V)\TK?\>P0R"@/8P;5
MU#GEEDXLJ,5IM\!>"4*D<K7 2!\_1->R+#JOI^S9#ZOM!;^,=.LS<W<4V+>4
MIH5>20?2X$]2Q,NA9M^>Y8Z!4#>NEDO"U>2\Q4^H]-[#'"> [@QG_12<-,:'
MO'03Y4#_GN>SY:Y$Z[C@T0W"V8/IE\]>D%.)_8C&9EJ)QWP@U:#8<OK,I.'-
MC0X\H&Z@!Q?'A8/U\\(8%!U'@<5;[0K\(Y2$.2(^B"VY\,7A"J:DM>%:E4C5
MR6W"3FITV)#^I#Y7U+T<$T$?[X$)L@,X!7BK[9A+H SPH)<';-.K_['\'%U2
ME[7X_M>G/P<Z!H+"M@?7LZO>'1$O_:;['5<%8\N%,D<@+>ZAW<G+O:@X'/VT
MHC$\06U'JSM6#NSLX@$RSUV?^3PJ; XV'74KSADZ_/[,!PK<T/J^%"RGJ9$T
M@7Q+HI]2689QAQ&0'2\AIXY1A+HS)<TZ$X9;(^<1BF#YN;%GCP3K5]W:)6@K
M@HW^7==#I"R2/P]N#^%_$\656$K=@YU+@]>N6"N>P<A3CZ9=#]430:3L&A2:
M:$Y/:"LO'7CAD6APL6/HI-3[_-?"!S3N_74KE7UQTX'<]PAZL!_U/KVT=W,#
M52);J?@' EX7+8G;$F E^]FD?$ !GURIZQRMT[TGRVY7EIT/ 3MK<,K*G9]X
MA1T][Z!")MXVP2<7:+AGCZQ)[%YP)+I;^.9ZBTL9XVM,-O(;RCHR[-ZJ!JT>
M8\Y"RQ&A*.%#!(1.1O;D6M7/PT783N.M+N3I/ F-]C$KOA9<EW)!(5V1YI5Z
M4%?>7TOZIM>NRP5.>W;>=CPLPL)"KFGB 7Y$<*=".S$!+M4:]?('2K5-AX1&
MD/')EF=RHNHE3%<=*8O.CV!FGL<->U;*_3Y$1ER-_=P-K>M$G,LGU0JQI4J9
M)^E0P4_BBC#H?[#\X/2<7^J:PGB] \*Y,:#5JW &=<0[RKML^3K!,^JB#95J
MQK]MN @PF\=3(UG7-DES(X[_&8,0'X&79/N"4N5@&$4,?7+.LOE1EWGPEP'5
MVYX7OQPKO;CO,1T5T718[!+$F.)*L.W'>8 O'-09H#XA8\'=RVR9^5Z"U4$&
MH1<N[[^7(F'8:=MDAU$MG"(=B8Z*+EM.T\7?&V,4[=R5=7IF0@G@1-8U$]KJ
M4O^,'68X*+>&(%).O$,\LO,T8I"8GT$MB(M< P^R#-#C#N.:XVU&@80I9)SW
ML(ZTOW>4HGJV;Z.W>MVUU]=W?GG%V79M[$UNK)4%6 $5&D-(M@ML5S!E'CLE
MP,P&A0O,&$)W0_5"?R]+@N/=9L-W%=UU+C?PAV>\%\[9B:EW/G/0.VU\ $4_
M3LR<U?O;$^(VB##K7T"7NC$BVWD Q-8D+:]=8R&6U':W9 74PX5_WOCN'FZ'
M^I[]Q?)LH9GW]SVBDOO !;:<$5<,SMK+'2$U)"4CYAXCE*$&MX\KQA:A[WXV
MAE/!'-N6\[*O'%SYM=>TC[PDXQ>J[3:Y]2Q! 59? A3Z''RPC)Q<IVR^:%[E
MBIYG\6$.<_(0<_DX*>,H(M\TN(_U]JBN1N=Z;G1EFE[=>.*!;.W'ZI?+MS^O
M>;;P].GW6*M#G&0B1!UJ%VB?(27P-9P*8H"#Q1D&G*;"R.G,\33B 0F]UUY_
M>5%1M$C8:E?74Q-^3\R_8ISZ]FCLS@D;4]KY=12HQ4R?(X)Z+FPI^[E/%:R@
MF:#<4;>G*(:K^\_<WST%?SACCR(C2PE37QNNW)]_VJ%U7^I!6-57OE1ZYL0#
MKI@9"\'MP-'MM?4G%9@/WXRV'F398I3IW\;C%>:^_M$<S6VH?N7^9.>(8-:N
M*Q>[_WHQD7+OH<KC!7_GD/6YTIY^?=#,EBNQ %[#QPQ;";6U,4(>O&@] ]I\
MH6:%2@:.N]Q*NR'3%U>EH^[B>F7!GQ#]?.)5E5 !EX2J6J;B()W)G!J(HJ0?
MXXH$SQG15^=MTV*,?_ZQ*26C1 ()-G!)T.#\M,N#,PTW53V%S]F<ZN(7:+GR
MT#ES.1/<8\:6B6<&0+$3#T;9)#'SDKK-,QZ151Q.VH?"_-OVOQFF1FQM/&&O
MTE679=HXR8R8S%:)[..LHO(A+@4']_JQI8..@[WZ-%?6Q<U==L;(9&P]LKNO
MHJZEO!\EN%2$I+]Y/?QJ&AUF*^T:'#>I^MGS8KS1M\GDC<R?<-H25$:E..G$
M.5R!X,AOU!0/F#^G)D%@!,ZZ@K?LUJ*6B U(V</-? %;2O;O.NWN?W .XICY
M4'48(VT<0;7#UMD./*!,KQSU[/P&%,!;*Z#<Q'H'^W%%5ND0*"R]8 ?&H=+<
M'$I3]$U@6R740,O]^4%G6F',>*')@3^60U9;BMD3/7.'.4'7R2+I1ZYBGCWE
M]Q>8U[^+:A!BRXMUY!)2+,_325P1$_*;T XU.+'%7<6>F'%C*&B*\U!ZOWMY
ME#^U.%4^VV3VGMW>!]]%_^KUSX%XMKP%.?,V=BYC%;+(I9AM;(,61E(2L=IX
MB84002W.GVH,T#.Y8#Q)*\F_W'BA."[ QWDJX_6@Y#;%_>Q9SA,K3>@VL[8#
M;-@XQALRT WP"<.I=Y-$:N9^S$FV$L'!T47(T>>?Y9GAU4-KT=JG&N-,$LBL
M \YGWKVPU?GQZL;@<'8X1)FVU_M7JALT.YC71:5,8,G>XI5VAU9G8ZV6P(_0
MM)D</-$/*?B#!S0(]>J#N^NX<$[>[T/NR$16CPS[>!Q2VK\YF#K4'?QJ-D",
M[T*1;Z[.=,J'LN_ -W=MSVEH @ *FA0PGGF>,=Z)FR0P;X)BB&YL&DF^LG*\
MO4#LKD>F0UW<^V$#S=F2:/0/RNRLYB7;]VY'1?$[[G\CT:]+JV/;1:W,;)+Y
M*V\7"IXYH#A6MSB'#=7?_A-5-<Z64V%>@^;/8H<UM,;/<7H[@NW)XW<Q'A)I
M!'FN#+'QOM[K7Y5W C]N=VK:O_&X@V:1/+]C.ZP+-V7$S !K(>D6.0F;K[M0
M-12,,0-_AQ:C.8M@(E)&W(8B\E1($L&)4?;5LL@W5VH;[2YEF: 9*C[9YTW^
MS*"R4!#(AY!BL0T+[.T2+-A%[H?<20;R3JNN'V/W5@87Y[=C^+?NT5")6@?O
MX+\6R_\:&^H-65%<5\\;]9@F\/V9/@P794.E)0X&>5%5IA,G:67$A1H:0>\Q
MO8A,FFI8#U;*,FA>9;VUQL80J?/S+[_S=1ER6OXICN?/\,,.TO&@%IZ6R;+E
M#F#IP9'IB"!]%3#';6RY5>4Y6(B\H[Q^]V%?=%2QK?$]_W$%]2/-UM)2L3->
MQP6^305U;O(F4(= 5866$^7410Q,'F,V<UXA.TB3F614LKC5+OHXTZI\=QG#
M^T)]_NTXWQK" VKS*</>!RJ&?0:B$UO*""P>0"E-)OHB0!TD6UJ?0H1:2RU\
M1OB;J,YF0GP]7!1]GFI\-]WPT[13?7V&O;M)ZG?%4X[:*C[O/%(K>F>Z 4Q>
M& 1(YS@%.IO/<WJ9C83X"ZBI6_ [)'H=@GPS4W*&!W0<QIPQY@&T8]P'WU=%
M,-/!/9;$/#6_ 90+6P_4INMSQ;#0'%] (883\R.=6U)Q8;% >01C6PF&G1H/
M"5]219XW353J[IAJ#=7A]]9^[1ZW$'*,+W7#?($KYLHZ-(MM5T92$T)WUY'J
MMY!$> #9!5HS36U[*Y>DML<<RW3E ;8KQ-'$CY^H\_T;8=\Q]4O8.@7:DQ+(
M92U8NC64.VU;&+@DKW$K]2D0>9I>FK16ZLL=,%^?M)PN^^6;>3] O" H'V<9
MNZ_23.$P["#XAJ7)_82B(T-!72$J?@X&:I(2OM)M4S$1IN4\0"SGK:?BZ"^X
MPQOZ'5,V"C5MF79?]M[)G?=HI'W7<AP]UFEV](4.'D!WPH)Z/@3J7M;Q8]=>
MLQ5 +;J;OE)@@4#0Y.6:<;9=U*VJZ3[T_9H-QK&0]S_23FRK^'PEPA+&EEI@
M,J"(.P+"*/ZM# 6VK%HO99WFPB"YUC<P<M)+Z2'U(L361Y^#UZ(M/UY."2CM
MF-9(%TEWOUPK**9L.\L=)4FQ#2"+]T"3?'./F2'5'2>8(]I#T[&"%+IOQ7RG
MMTZ#)YRA^6CQ8TA.NC3A@>S8XLN,M_S4&7FS2Q ,3!J1EQ.)<T](](O![DQ!
M#LZ[:=A*C.T-[IDU'[(4U_?)'NB<5:\E!@4]\*VI5;R<*QB@>FZNZ3!P810V
M_(<]R,EJVPF&<D5]H+CM^DP,)4UN_(H(C2,)Q8B:W0[7W\Y)O'"5;4W1;F$V
M-;%43K[R3554*KHAP-<A>?)=,3=GD,]:]LS_EN'*0",[JH*"*1<LC4I?%&Z0
M7FIFB4QK"!EZ7YO/J']N#<C9VM.)B>'V_>FVUG1:0G[W=$ASP=B0QLV,L!P?
M@+"K(#KPMRS?*C(6ZX63!;VYHK<9".;/,;9CT2P8VDL2J\.*3H/A;VEAL@UA
M%GV[6G+Z_;]8 5MPCBC;GU,A^463MB\"E#'R#8.5ZH2&9/4=2[&O +E#LL#Y
M0Z&=!6H,W9I)=.;1FM&=MK/W46[%KRI&=NS?H8:T^GT]%;BZOSM4NGW+R>14
M.2D%OL-S@-"1TX6IP!YHE)7XFZO%9?4^_S&6;6_YPG5L>,9;^L2MEF !G6BD
M,<W=9MAD26'X]\R^*>;44?'L];]T[C=LLSE_6T@HM]8:..95.A'@?.WGE$>:
MZ1B]<N(2 1)L3?2 P$\G1\@B.-@=MFYP!3$EF&U2VOORG?"#,_;&,@TVVRY*
M]&:8CR5 PCL@#@_6Y?7G'[,?TM6MU$=%?V4RWV=:A/57*7GW?5TH*P\_(Y2/
MQC'=0,0\<BJH@UA/3#4.NDM2!#4Z;V7<);N6-NTF.21N4(+*BNX^*[!.T#",
M6%G7MS'Y4>=X6%#6\;"<UJ"Q=H6G:LS"\;HL[HRH^VS?U1?^#Q?V5=I\VU[
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M17C 8U7X?[  A!?>$%Y D'L; >'%OYFM",*N+OC?L$N?J][T'D*+#]B%-1Y
MUX+@ OO/L\EN0E/\OT"3-01-+@<W 2.3S<5QM_" #]LR_VFR3 B7)+%_PZ43
M1#!U80^$%A#4XT8@M,!!:,$#_LUL9:"*TYLQ2RV?LD6CC0<?I0RM!@TCI08!
M[8Z@::X2#WAWMQ0[+@.91OG/:<5N2K7B9$^%G=WUW\&_/=[.%*9JT][^>]E)
M)X):1/;]0^[<WC=^/."D0U0)YC=+<$F!"1<R\=>M$[O["*IP\ZY65XY[(P)"
M#N*#H9\Y+M R1]>Y?]R B4(HM,F:GWG CS-OH-*4G0G:16#_R.ICETN>2:1J
MP[G2'BAN@AB)]=/_/_.=+?^,8E/U>*G &O_Q:\0$O4&3NM@60W*,TT=T!0:A
M@)7/*>)LVA:D*X7K2=3%?;SONP?SXI[/,>^T^88@>ACY>R9+&K,?K)B#;^XS
M\[,2!._:@3E6I91V!K87(1/N8?.KMRO'R![.#.Y.9UL,3N^ZHJ[86I<<AW[G
MS>J.8@Y4]W,*-,S4G&ZJW;@1VMO?LGW^P"?MU0?SI%X(8V#)"']<@J<\F, #
MMGR@CY52(@8M7;R# F#=P598V%)AD/N)[T]:P3'TL\-RN4KJ>HNL<UDB>-2^
MLCU-W?ZYI"?6/TIJHRTV)M<$?B'C9T5 D6C6(7306Z+H_'"K-?TG!A$DE'2,
MA V<\OCYX^Y7*>,*K2F%P+)M'[KFI.V^M]EQ'NI<K1L ]6$TB]*?#=?<ISOI
MG>UEXI(V4AJ.(8VB1;&'$FZ54@U8)NS-/:OAV':C.OCM7&12!5<#7&[_H_;\
MID+2VD<O'=UZW:.4Q:B!*O<O,T!5%Q[QL.8=T/%K9]CM%7Q'WC*H/=Z9">Z!
M=>M/7P\%-7Y_'D5(8XP*?XJ1VQE+G?Y3D1,:PCY&&TD?26FTB99H!]F]+QBB
M1@[&PR%VJ-F[;14AC]YR5,'/\R@9C#'H_9I]C([LJ+#M:?[TZ,J5$;9!T4=9
MEUOQ\F<NIWS;*8M[LRIIA2J)N<66!FLI\*E^KIC/W$ RJ<ZE/6\YMDV+#N\\
M='JZ/4:(<;2U&9^AT;A-*S^D,-GMS9L:R[2==E?N'8A\>X85T\UY'6,5,\8#
M!.HYVY;F8%3[2$94YWIV+3:TOP@]U7NJ;?B[,TK_BAE:8<^BN\4%.>U/1^87
MB )L=4X#,00)[D%TX*>%F%F<W)V@[ESH;:;R-!IU9!3C%/0JR','<;0B>\HV
MAWJG-YA??>_$QY;K6,E[#Y\JIYO+/'R-5PKZ@&_X0EAJ&*]]\Y;UJ6USE\,*
M^EA'C"H'9Z48V :GM^5[1Y3%C'A*YCDVU=9D[-4K,4+FW'_(3XUVW]U62D]*
MQP:R>,#40O>L(".I?4:]ERR8F4A=@$YXC18%S=@[1>/\"5E2%N;J/O0>62'_
M3C4>L!V*;T^,!51H=3EEH<:XVR0![%S>R)*G$MVV^Y!,M[E+!I2/(?XW^BNM
MKXBG2]8V9AT,OFOY.N_ITYM1#?<ZBO1?D-/CK]OYDUJS"!\K, 2!M9#45<2D
M$P5'DV%$DC^34H@!N$E/U!USMOF'[+$VI;R>!G-&8]V%PBLM+.N<7R-AK67?
M<(]O6F2*:X]H#SQ5/7B@+3\7FSHH4K>\(0P5$H^<C=0_RFWHZLN$JJJS)QZ=
M$"":T"!\SUKD 6M[/*&FVAX5T($0#+W ?7;5\<(_G[%E[VHF<D05B.O#XY-\
MU=90)>FP+X<JPO,H'A"M"__':P^KR#HC_GX]A.\B>G@><#1AF;-6]Y_SWG\J
M[9Y-_WBV?G[6.-<^4VY1IC]DR.A+M3_IU>K@>!\CE%6"8,3$^CI:R]$O_7L[
M-.4@XXOS@*_6(\2E%$BJ='3"K878B)F3X^U,4SKHN^AS(5FZ2$_E^R'M1322
M\P=+YIQ139#+\<,'NIC9;9E5:DYPK1INT5/X,E82#6X^5OVW0TT!PL5UJ&1K
ME6,GUE_S@)]V^'"\&)0/D 'Z9#X3J5%CV+7B\>;_\$F[(/+?M+*'P7CN83/2
M[P5];FS0PB(8H\?5U;?] T#:,N;D\LK0%AW-O2GA XJ+!6IUC9_#_1<<M,YD
M R-N.F1G+Q6U<P>L)3):K ,<'4PWN_J]T'VR_SKX3/^Y1QLPCV3?@9J/RGYV
M=[0$*OB_L??=44UM;?I'41$0@U0!)2HH*B** B(E6! 5$5#I0E14FAB5%B3D
MH A(C8""HA($:5(B76D10E$1Z5U( JBT2((8CJ3]#G>^-9_>Z_V^.[-FK?GF
M-_/'62LY9^US=GG+\^S][G?_343A+@R\\ZM6_W1AT02XB[T[!< D2P \#DC_
MW0T<458 E,/45FYLF0$, I?]&OA1F2W\@XYZ_!=$WO*>VS9EW%T"(%;N.%PI
M55@,M+[IJ_)Y*"8_2[P?1O;<Q1&;4WY_(7[1[3:PWZHQ@*L3/D%E&TRBYD]X
M#/[S>=?,VZA1(9@7.EV#??NR:CPI90$FKE.<GO\*4S$CK:_??G;-,-D(^OVU
MJ8,\NEZ8YXO^I#;F_OTSW) [MY#?^L#[I"<YC!<FM+Q)9"=<:U+A/Z5/)#&X
M&[DQ240>'O5U0;I^_!L_3)T["@[S@$88E=%^B<K4?H?H6*)L 1 *SFP8IWZK
M@QMXJ#KS%JR@F7QDUZ(*8VD;:M /HO+O(O-'LO8+M/=/8Z9/L82Y01CRY'LT
M#^AIZ9I%_+ZGPX:GA]MGP90%NJ#T*TE9TO^3K.J/4V<D@OD5&E]E9K4"RY9S
M9:J<Y^$&R+"-_EE=9.AX%"QC';!HDAKY/C ?_>G_#,Z!/V[.1:>LGK4TQJW^
MI>P'@!34]U7>T_/#X*RRT_J?A;B32>3 Z)XRGZ+CFAK!^:64&%[GW614'M&H
M:;8K?GQT:#.9OJ?[6F&M[6>&^GN/ 7S]"#@OW@?28"RO,(/Z8W<[\R(;8 .K
M".OQ*V?^[L ?_VD5&/]__]RKO(L8E7BH8M>D=M3-?K.)TCI)[4=S))G_C,)N
M+%B!.;O<R-"=1CS=4_;3A[6&?VT@_TGU N^L%@#G6&3>LBDR$_X9C?SQSR5+
MH_\MC[%ST;(?]6VRU$>?S40F?%TK!SQBRTQK_<?U#?;>GC@;U> I)XI528S4
MJE["(A7QQFR2,@D#P3JQ83OLUTZ;\V]Y_+L[E[W$T+=//#S77Y)3ISAW.V%4
MTB#:'?9K?_?F_HF,"\/3_6FU*%%<2^\ '1&F?W8D^L")T+?O-59C0XH9:D?#
MNYHFY#P5BHN,5UF]VT'0:@I*-]IFH!T!<'E=*%HBR#Q%(JS$F7',P)K+7"\Z
M9Y+P&*?#U*EA)R,[O#\\NI_VN._+]KNK*,UAZVA=CY'LA<#$-O[K&;#6E+,7
MK#GJW4)0L'I)15$(!+Y,3+_'TS7/@QV>;\)^.CN3^5#Q8-Y-BOPSN$S-@4HO
MYH%Z*M."$$66X6\4BT3<0*23;E2NRJIT6T9$<I6OGAZ0 80W\>?/53R(.2SZ
M0DAF%%6H%,+QXC>@UH+G,1&HM0NA/.%D*0T!X&Y+RL-OP^FSNK/*]EX.#]@>
MOCUO2=)!16$VMC1NYXIG#VQ.7)&02!'ZMHO>73;<(H4S;*T\,D)=4A;J,WC@
M4,G+[LH]_5%^84<KXC:ZY:U@X>*_'[='[32TZ7MQQ?A2FS& 17.EJ/S#R7D"
MP'FH2 "D;ZIJK]3X;<NXBKFU "B8MA, [?%.X_\87RPL9NO_3IL#A7YFT'2H
M BJN0H[!#L*F\9?NZ[\9\<C,S,%8%*8N1WE$\)S9WL\U7M#[@9-0U/K"BE*F
M9P(A(/MXPK6A ]+Q']0?>;)]9@;?RMOI/+>H*%S4':WP(B)"NFM :$)![3WJ
M(J&_A:;#\*<;'&@ %^F?]7K6-Z[PI,,'2YI5&]S[J8%Y*&[UA9LSJ],/B6S0
M4;NY^DS2]Q18=.Q0KNH(=A6$X>CBS&'QNP(1:IS60,3AG$$I2K(62R?&4](_
MJ7^7\KMR[QUO-M56+*>J^"-J5%;9'Q"YG;W%V,1VHL/-D*.'/OXJL,K87P P
M=%@NP^@:S"V_Y#T0BBEL#3T<UBHO*VWG(M/<)?K>^,Z\S7[Y9=.[*P>#$OU7
MG[4RP[W,!VO,R1[3?8D->(F'?%$ISA([2/@57INUMC3$<P04P1T*/FVV<IX6
MN\2O-7=GK**$E^;:9]*TG;5Q,9(EV"%9O(T-/F(.5!'^X&WIM)1SC(OC5>'E
MN0<C*>0B<Z[49S/H"?U3QX8DM*0CU[FPU6Z[W0<#<E]&R;W;5J<PNWP1#Z+$
M,W5/9FXM_!A=[:E17QPTUZ\VBNR%JV+,V8_O0)6JUB'ZA$9TILQ=F),6D"=]
MP/% 77])6/UR'XCQ)?^=F=OY6L7-=_3O%!=^?J=W4$7FS<CDQ+/9K6<_OS&8
M2AX?8W=I!_USL$7X<["UZ+LG+")6+ VN1,PD>[0PC)W*B\$YL')&2*&S38I5
MS@<A![K!2>N7Q46KXUHG6NW-9/)J&5N;UKZ*K2P,(B6\1:3CY'A5H#-U8(0]
M"1UYAN;7@L7Y(2-DX?K\S""<S<ATJ-_\H; G#Q_O-2_5;V83UND_-SIC$J?M
M^3XKW2_>R3273W5:B&)TA$7&'G031]11"UL:B IC2!D-G%[>$+;H%77%%TQ#
M8C;EZ3ZQO@>:.7ZNYUQ'CVPXUW:THZZ-)HPRPS<1F?;(OFEV(<1X@F\9$N8E
MX_5=[3/(;%+A1/4NR-POP^VYOVSAA[+'7NL'E#Z&W/.:>QQ[O00(!&%X)_P+
MP*[VB\6#NW_K,UP%W&.I3 S#F27$%TEDG:Q%%JBY?QY>^RG^4KFWDE(EQS#-
MZZ+&&0](_?Q$T9N+VRUW?I4<L/FD9J0T0#,G$!'\#5P[%KD&7'GZO0\Y;$YV
MQ^2;K2G[+S,2/BG+KS %HH0DY<0;#=P)##N.!6XC+XH/8 GL.&CPV>D!K!_%
M.E+]K>W ]QZ;:V\VU"_-J[13NC3SEE6O</["A\5&;Y Q5*;Y0MPI3HLX$%!G
MN)1E7F,#&8PXH*4@^VFZ1AA>U:V_+,R'([Y_Z*W0[A..AVGZ+=<-7=,?\%M;
MYLXC@MEHK@S9,G&XC"NMQY;A192<)%/XZA I#QHX78RZ]I&[*T-LTO8ILE$^
MX5S]RGT[\_>]2D$\$P"N+0,N;#=>#%_4C8HD>Z##K:DK<7K9YA@/Z>2-A[[&
MS;BJ/+[T[HI_R&<1Z:=/8<[492@BI.7 5N-5H<X+ &@S6#MX8,1\RH]EBZ50
M]MK<OM Z_6WG$ZJMOPUKWY)I1&+ $DUMY9<WRI[=U6.NOO/JNDN$OA2M1;'>
M33A:7SG#?3QS*._C3?>$51_$/.Y9&R?MW/ X;JF?Q<@2X;./I-  6%.>HA&,
M\NBR#$)=;D'2$/.?,UJ%Q^[A<CAV"SNE4+0$\G-JO1CU)KD8MC17T[%^]4F8
M>%XZG>.).-&9G\L=.X&M["PHO=]8OD7Y:H6\S<FAZF>D9B*TUZ-&2:P=18LB
MRN,N/(5,3$NZM1QM*,C^I+QJHL+IH4O=Q5!'\]W-;MJI&Z+KZ%9&-%& I]2%
MN=#A7?'XD+CV,(O!&#I85"SVZ;W5D549;*L/O:\^O#H?=4<W7XAMQLOF2_+[
M48N\4?UJM'3&:)+2BZ)U)5WJ^): LUXK6I;6I[_3W20_G* 3W:&Z%*LB89[6
M\WF.*]EAF4B7X\H@V>.\:.^;)RG770@X/9;0OE+T2_&6V][D8O?U)LPMR2KK
M5FK:TLZ/"LTN^QNC%4V&7=0=\3F>?Y, 2%'X/E]]XV?^Q.0Z<NV="+,P3U0;
M^27Y>_@3\?S\6(^_7P+LN< _5QU**J4C;Y;E@A8+:V6O?\6H?[HJ-1IA%=SK
M#GZ#!,#[!5?^X_]J\TAP<(L B)P54H)9;3! >H>!MJ"FR!PTOUD K*K6P7=3
MB_C1-.H:[*X1E:&5F-6N"I_2-Q'SW'3*'9OSJI[UM10\B1,Y;%&[7U1><YE$
M D^7=)M,2Q< A9F,^&&-1=B!!G )RE,]T%O<S[KM(AAJ3Z!PS-S5[$ZPWVJR
M3V;'#*_N;-BNH'G^="[1>Z=R:Y-[@/Y1LZ>/XZNFOAWO=R^Q^;YH$OU\FD&_
MP#GM@=>%'$? &_/3%&0X51R3RZCTIYGA/RDF%G-.F:GG,@?W<2JR5 Z>*P3V
MNBC:R5>B^:+A F"+W$):C:D,#P$PCPFM:F'OXH71>0F5)B.DR&H]J#$7=PA*
M9.WEO__<J*33O6U=$>=H__[6?@>'_E?Z%:X;HN]O7=SX2??<XI#O<^P(V,I:
MXJE@,:J1O +GVP6;N-S2;ALDHM(\RUT B$^%O5+?:SZUWFO&_]CPMZ5#O3=-
MRJUT!RJ > >+A)6K>S8W']+V<'+)B3S>K^-173[P#E$=+BJV\]7:(Z065#1^
M7<5OV_K:YG6FOC%/BZ!<B+<,=4N[^*JX TYG6!=++OI14MWRVFTM'WI_S1YX
MW7](>5= 62.FMY']E)<"TH@]8*%J%.HR)P=<,[FSBGR;K^[FM#BT^9N8=KF_
MP@<W]MS.W*W=4PGO3IRQL[S_.4#=7^<5%=J$X4I7L'T@D"X ;J%$X":1%#9%
MTS7$!QHQF6-[P:DW:28*KS*W5?![;2OBZI^><WSPX'Z"ROW:;0:KWV:61"3Y
MVIPHY,\4.U61/"Z_XE2_),$XE[N>J4I7#>=K8?ES4_.JMV85J]!6]U?%+JTT
M4PMIL5Y_6.CE.K]\U C,NC"1*-GJS;B=K!9*2_])&^:A>S2"Y)$L*).2Y!/?
M)!?I^<!";$N?2]2AH&Q=M<W?"4VV1*;%="_'GE>)NNAX@'VV$*)HW"QN!JT*
M0"EWV7[4P*;*CI3'%^/>HZC&H\5Y:\XT)2XZL#A*,6;OE=2) \GV!G-M:%:'
M(\!J@=8GUA+E^O!OKY<Q EB^34VL'@9B>*!%R:.^9E \O8DXQ;F@RK=3KU;9
MQ]U B[E9W?$,K\3D1](-%C?65BMVG"OL*&[:D[=M&\TQ>\FJE(/1)A>L@$5C
M6S]N,W.Y3=KZF/JA7".N=7$5F4[DWB[WXUU%S:\B2?R>]HQ!?Z,]BL4_<1SX
M0B[%MZ)+! !7NI&=R'M>Z<-9F$_?KK^+V4%)LJDU[F#P-^'LH&>)-CL$@-N0
M@WKG==^';I[\PL.T..VX(YHI!>@[(9K((BH#A#VN!B^)? FUF-] 99X"Q7&[
M6;(/6&Y:RPWEN;;0J43KUL?'W_?EIW>4*)HF.\?2CBCH*M?&/3DT8]M )1 +
M82EI89_F%50&<,[ ==A!XBM %?NA2F\.,1PE:JAZ^D.?OWW>XT+[36D9@S6U
M\NMB=FZ[=O7>-J&/N!)H*6<37.88Z*XQH/@*78KD2L, BTZZY8VZA>K708KC
MI7$[7[ZL^NICVG2Q.-ZR,_\SO7^/2NRY&$/-FMO[%=\!G/Z%N<)H\ )I()A]
MG$>L%,[!"H_H-*K+4?I;N)L42EK8@9S#*C/)X[7DMT_/,%#WKJ.Y!BB^" S@
M36SH!,[WA5@..^+SGEIJJ.$.Z$B..^R2O5(F8![X<%*$G6=R.-1?.S*A]HN/
MJI JX?HW#7GN6LB$3A4;\G!"0G;T)L4F+&6?G\N3@?IM+NLNV%E(7#E,F\O-
MZ6)+;SS1\]&,]Y9V!<F<A=VP:AEO+3H4-3WZ6X#'[^^<2*T^P,,(@$SD=QV8
MS2VE0M=!KM0 /X9$0<[-H/D;7FCT._!%Z4RA6N)R+<0J_ENJO*$BEMS@FRC;
M;@MYU"NM?]FA[K-\R3C[=DC[/M7X+6'O9OIBX[&.%/G\V@A4-VSEK@J >)"=
M@C?@=R!+2JO@D3?JKM;AOU/:#AG0$"%)?G4MLI#A5T<H; 01KFV?Q<39^^3E
M?_<>FTKSO_PE_;"=9>/=9X6%NHZ-2%MXV&Q1EY&] \>@ <Y6_@?8R*%< Q4=
M']+0];ZEK-,2ILHM<J$E%1=@L7DEBMA1)RN\57>K+5N+O?(>;5ITS)Z?,YRG
M2.E.Z$]XJ:*1BSX V&$4-M=9RJ^^5F^Q5'YLV59S*:PS!;^;^6WN%LZ9/KG6
MX4@GPVG@1/LWO8/)0U^$3Y"D"UZH;=BA(G-FG_ 2F)\YP%8W^-]:>!59TLB5
MS:2IUK3<RAY!]=DC5W)=6;O<[[S"(84)ZI6&QCDYB2\Y5K-XR^56RUHJ!V;V
M*D!"_.74!66 ZCG*N -0"'-@)'$J/F5<219JYAA[4"5\"(J$F"296LBZYY3I
MF3,>IEXJ91D:18&CF]'OZ')K^,GC21<?IKJ5SFM'9^YS<W%;?,#-S4.T47KG
MAI!3QA:+LP  >"6T.#.=7R8 .@C<AP*@1.CM=I!64+W8?*"!2D\OBS%$HEYI
M0Q=]Q BW&^$N#K^))3)R@\UD^9C[9SF;[7 MRI='"+M0ZC@; 2 L!(^!L;X;
MQX/?4JT'.PB0WP0"W@@9K /:4W:",MS"W:ZN5*]@&I#CT7>.WURQ\]B.MMUZ
MD4%XZ#6-?Z_-9!YN[G'4#(;?B=C 6]@I_@)<P=?%>CAT@1Y4  )I3D_.!JZQ
M-TQ$U0T@)4'W_:]-WZD\)US2<Q K^:[[>KAR%U_D+,<'W]!?QD!S;/GPZU:1
M7=6%#Z.C4%+;B@E+!X9VW_B"TZ-S4%,<TV^+5M:]N'COYB-MY24QQH&)@<[.
MSVR;,]Q]KYX>.'VP[;1#RVKO>ZO/WKO+?'5SG_!-\5-,TBVN.@V]T@ZK5Z.D
MT#'KJ6Q6YA"H=[0]MWVHOWOC:MN1B!TRTBLC4A:9\S#6? 3?3 #TWX ])6*!
M$@> ;5V0,Y__MTBP/]RSVMK*S+B7X8%7*6S7RMLKUF0:&6(:Z9!E??CCR2X[
M6PE*;U?;,-G3?C<O.K\=@M\ZD+*+K[2P&1&V4&DYS$8>][= KE_<(\'"&"+,
MU.#?+KM%9CZ"S?2(-U@;#,D)@(,.M6CHN+T 8)5S /T\,BT#?.X2W@EY&/$R
M]75]P"Q"D9W#H9DO26Z&!_?=G;"] 77M92,@"W QS#8CL7#%19K0?!T3[F;4
M#7#6N'(C[)H_D@2 (@FA\X9<XB(2<-S)8;9: .P6)K0Y+60)0]#0O%48$9"N
M"^.<AK$_U,P'=K7/D+,+TQGPRQA!K'FU7A1]'U=, *2JTS6XJNH@-(ADIO"7
M"H V668B7RJ!S+U,^': #[=[E,Q[KH0R#A#^0WW2^-+(5^3Y#4.2 J#V6H\
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M36GFR[@[(NM[(G6/''7DA:+OJIS1?' ]^PYB&(;M9'?D"K@UZT%W\YCRZ<9
M<_[*[2SSFRX]T07@"IPNK] [4,VX<,8SM0SI4K*B5GUXO3*WT3N&P;7-#V.+
M0L*P)O0Q;1C.=',IW")8/9G<PU#+\ "F##S/U>I9R.&L5U>:U# I=BOQ7<?9
M[U]P64FF-PC?/!>_QAXX+<S5TN%*J?'O!?)24*REWO/?P-Z D<]3&B/H_DB*
MDCRD"[]>":IA.M<EHCSY[Z%[P\2^_2T4:P7#@2U#YCHG")]*OSK;E)T&<]VZ
M#6-<A6:5?AVW4(1]: P+7.3^EVWXCE'>D\7?*W0\1Y4>R(]/+N1N^$/$25;V
M\J[@6Z7N+9^$'\%B&20 LF'$J(+B7(#E S7A";\<P>]SBC;V1TZP8:MD2)YQ
M ^\K><%*),3/H'+OP IR%_RQW'4M:3"G#\6=AXNF\\_XMW W(^8?@C,'8"&W
M_+'8O;%.2S[IO #X.@E;P\3O-SZC?OBDR0_%;-(L3>:KX@5 "XF;A/YG-?VO
MJ*A5LQ"-Q%8J\<P%:TT_\9+.\-&]["^-EZ;WY$]$9)W7-=/-;DC.<?S(7X@>
M"OA+2=]P7[,$P.O]X/P4]5VGEG:: %@O(@ FB\!=%CTCNZ!>F&J?^%78@G"K
M(7)A+H_ \Z\7 "FB95;ZJ(4U+>3\5QA'&\E<)CNG<5?/+P3AE_SEP'J2!B\/
M]G:7(E&A"7%\2I(YY6&+W./KO6ACEF' V"PKXRR_]?4ELO_GX(]3PJ.</H;3
M$[@%(,=B$LUT,H45B$&><J.1^YRFZ84/,="A+X;*[D[K"?97V:Y1 L#58=]H
MU&G_&FVP:<>#[T6FG.T><#%%<DR_#)GQ&"YVKH.>$YC#ES0EA"D0;I_OCN?)
MGL2P?2J5CC2WW$&"W")-YT_U6%)$-8(/$RWF"2*TN:QQ.GAH^T+>/JXMI$PC
MW9Q+6DFD(Y;BUG2=;=<HV8PI[JSPM/_"2/-+UMVHV1"QK'Y'(?/U0%4.>R&A
MSW&HB.T*,9[@/#MA7YZ-+D'587>;EV"8+G5@>.R$PO:TS_9-EPW;+JO?>?/Q
MP<'LK^*%QHI>41((TMBOHY-_M43YA\" _\QEZ-\)CJY'\7PQG]P5'EHNS,$*
M@&]]Y =9'JP'W$N+(S9G_W*;Q!@2 8O7LD9^Y;  :%WJ\"SY9ZE!%[3Q5P1*
MP%)F_ZMESC^[%GU'CV!Z,74HYBD$I);8:-I"():$U;6$Y#$/-1UHK59P)0N7
M9.T6/_'9N'.;Y(P#)Y(EU.R#46]]++.HE[ B\E&.T"QAZB5L>?R9Q*DBUL!^
MB)4!UAB![J!BRY/ ')<0OC+W?+Q5&P;'L?-LZ5<W*Q?Q%8D*AP? 1-&K3.8>
MQPJL$4&=Q_1_9:?"7''Z-BAKJ.FFI-FEOJY$"FLR?&S>6];"!".M9%:X06K)
MY?4V/M:4P^]&+^38_#;P&O@6L!#3Z"G&OL%$,<19(XY=NQ$E@8E'6<3ZR"IS
M,V)+24)?Y:3;LC[MW'=-Q/*)Z"Y7H<EY>"#T?[7@C#; U_@.J232/N7V'T_'
M2*.9CSQT[<YN\V(G?-9BD'\,70!^B]/\TUB'_WO\O^PQ-N9'D]]95A,R5?-:
MM?E2[&12!%F>V+"P"'/GEQ;A!A/&B$&7P,GW&CS JORSMP-*7CO:]4RWIXQX
M<8!,7O@ZS]73UM4_AGSQ8@A,Y[&@WM0"_H^W#7_\T[FPTV#*20<V#X.)?"$D
M*^W'/RG_0Y]N?]]1G^U-",RQK]Q'QH9?WJ?<V_US="$NFW-V8<,#ZBRR]^'P
M&(]HJ(KMJ5.8)O28Q\Q/UR0+,:._E( 7+M&D$^B>:>>#K]VI<0R^=\&SPNY(
M$R\112M%%H(,+]B2\9*K%7#:4$WF)'X=QZ8WGWN262H S)X37I<D?.0.A)]2
M\3]\>CO^JXQED^AWWSF^Z"[.0BS.0C(7$EC<$XK?#@DWS@^6U8NUB$_&0V44
M)&):XWV\W\KH)689[R>(Y. FUXQPFN82MXSP+M%EF"SRA19(?6[*F(/F^K:2
M7="WM(F2<G5.ZSDV;"^8R*SXIF[8ZB];.'CDTVESR4;D%SKNLK*7I^4;Z47?
M>/^E(<=_Y1)NV4O@WE(5 /G-W.8#)]U1,Q)$?H7.5RUQ_"Y4]$*@Y;I?P:1
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MB3'O3Z<T?F<8U50_+S!+6BAW3;>[JQV5Z$0P R=0PW7H""#^N!D[OB0EAF7
M[@ N4N3A9CA-#.'4EZ<3,<YX_2XW@U>S.O:5?9J939]7)8-OW)?T*(<TC=I#
M8 W*JVBN\@$V;9SL-S@I3BMD!#"3!KOF=5G0KF4K2T7'T=_JSCCS<$Y<D%/W
MUIIRPQK;V:WGKK\G?$)N31C'->*30 -.,A!=I1I WVLOX.DB[3%>\C(69S:C
MP;-RPLGW7]JU>E6JQ2.OH2I)RGBXW"391Y^K&L"7&.)()_0AF(YP&/<4[QY?
MDY38YK3 @#LUD2>NS;DM(&E9>XA65C<8,4<_NZU9O;^7].O$H$R@>7:2$$>5
M&N\6$=MUZ#HI2KV\L$#N\X\2I98MVX-)9LQ!KM( 7QJ_((  N]P9Q<P^=@CP
M@"F\[,XDY*R],$,H8>U)K&TIV#V!NYZQ59H+OGB22Q2L'#[.7\/:0/2%VF>!
M6 %$5P Y"F*5&8&?Z<F=X;VU$<,>Y%7B%MK)6Q'!A*SIG;]LMK$*Z7=IU?H>
MQ(,R?D6L+_4*6_N5[OQ8?!#CIGG+%N:)ZSA.1K] +.!Q(FW[6:]FJ$F8SP@%
MKL,7KH%6?GAGC[^/@ZM:BT+ZKGDYV1GSG W.\G@K7@NH9+\<$4#"$$(85ZH
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M *FE).D32QBGW=V^,]GQ;>G!"&+?4/OGD]?_;'L:>.OY:M.)E.YC#WR1?.E
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M:=,H YXB;ZNO9]WOCX\K=S2]$S*ANO-(B[V"?.*<WS&1;]/A79N\"3 DT;7
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MG@$M@H?>YAI%5),S(KAFE7TOWDO<.^ULJMCDL-5;MB_WT'@**+P+PO9+8_%
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M\%;R$>UK8W_J+!:RPZX#OE[@(]X?)4&1$ZH9;',8C1!Z^(A:PN*=KO]X\E*
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M?Z3B_N:[!3!<_-A7;#C:Q4FL3=WX3:/^U5/]]4OH>W,4TZP8+20KW-B1W6F
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M7RZ]IA+Z ;%Y5-3HMH@&O"@40IVY^Q$*L0PY3\ X]1 OKSL,:C^5.7'L8;S
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M_([Z9'?L^.+IF7DM.^XV,\((3; 5UD +$ 3,0HC,8>^A4(E6/?1.$& GN5S
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M_>?OL.IJFDK^K#R]M>S-Y*6,*P4FC>=DI3'+ (03P1I?!9854H,3\G:,NJR
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MJO8/S?[?*1;_/Z39?U/L7_6:!"2%!&#G"<D"*(#+>9:V&_C_XZ@T9Z5"]7Q
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M>LNG?XM6N<$VQ$MB[$Z0D52Q,2&&X'8T)J*IXO+S1JM<[X47ISR>_MC+B-W
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MW#* ;K_#-NUAJNO&2#Y?7RKP.AAVKY#GF/!AG?>+0>[*U/Z.2L$)ML(IU^:
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M!,Y_YOO\I\Z'4QG)%M&_%026$0P82&T8@=F!$*OO#@OD9I!" F,W8997WAE
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MO?AO61'M"L)6*3<29QO.5I:K.0CKN]\(.3DE:\L/I D5EV:>$Z1),05,:.>
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M$EA!"(@\#0K1-EBI7FX#@;3$_BDJ,I!IES*O:]8MKSA;6<5]A70_8+YG)\=
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M+&,+))?BQ%;G?7P\CFE<7ER,^KAK=_AS?%0+0V5KM];.8J"8H<KT[B"<]4T
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MDVCC,&0P:0X6..-#C?L!3V( O%R?FNKP4IZ3W_]R:_TZA'J\EFZZ2^BD?ZZ
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M*EW !-7]I>(#)W/FCJ[S=GTASLGLAI%\Q&>#9 N!;<*7XU,2!,^E&.[IFC
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ME<+QYN,?Q!^RWWMF(GGF@OK4-'N!6Y.OK[OZ^?%LV]3*"L_B"A.C0$6;M]S
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M453(RW[OP\&NWO70,J279JZ(3C@;88$$)IL6PK UH%5IBBDTM)H 2Y@9HY1
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M@S_N?>9<Y>F\W5G90J*?[)DRVD(8#EL8^S<WYW?]>2U-.Z49O"L\Q  @?1@
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MJ#X53(PJ7VRA(2SZ%QR^C;?G7OKMD%BVTOL##]E)$+)L,#7-)R8:2[^,(11
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M9[TA[NK&P_6K71-(ES ?YY\IE,O;_^6(W'^2+4 F)"H!2)4#C>RT.^ZC#U&
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MZ7=T.I$,6GU229XZ,G9(&'D4RJ?#@W1"HN6$7_[H6ZWV'E^\M?-DO(1!@\T
M"[7ZR9?MG$=<Y@OM*O;+9O'&*[-R':;PW/?&12\J1XS#S4ZVF#\3)US/V)_%
M-V3?"P\.]A^EP0 WI7#TD>H!;7M*WL2[;W4F!2.=O.Z^\\;::J+>FX-54;<6
M'!-"X)W??)X'<C_.. (EW=O,32E >HEXGQM:""VNSH)K1%P_IJ%O=>VR079\
MT>-GZ8!$5&;$CY=G>E_H6/87!56KYQ*J_+V2'IRU?"O?)' B[G6O3WUAO.U2
MIF7 O/_[GI\/8#$Z:D@'3+@O2AHPHC 99[/&QW/&2Q0&L[V*O:?@:^Y=%A<R
MTR\\ZM_5IC&]!A-$NM-)22D3:8@=MB-S25;+W?YDOD1!K\D[BT^3;QQ3U#LP
MV?>FV#>R-XF36T]6]RQ4;;%RT:,JJ%YKS'-8L+_5JN#XU&!!LK,3-DC*0R'(
M#GO_05@TM?M3ZE)(>>Q>ACMP4SU"N*GGR#W/JVW6'H:#HZ^B G4L#SPNF7@W
M$:#:C7(&:M^A'*C[B]\0%' O<F<?H.X+*<;=_I%55@FO28N5#_P1(4B#<$S)
MY.<DDVX/TDILYSWM+M.'U9W1E;H@]W7OI?D^< OF'ZNLK1BKL4^N.]F",LK[
M8&J >_)0BT'&F^#_K1O@%>ODME5'P;B/ +.*G[?P5AX3J'.LX]!>!-UM_>A^
MAB:KA'D%\Z_>DL7BL4>P0CF)]%F/6Y&,G_2^C0(@H@5WS*/0/,0_+?/\(GVP
M\,&_IXTB]QWOE!&&J%"/5/74;\LH142F=S9KBD5J%*E@^2[>?-?-5?OT5)MD
MA)?XWI,B5@'RU6:I5(*<MH7LT-L3/NY+&UE?ZOJLK&I65)HL0H7F?*]V;B#D
MELO*JD;1SS$-%U2Y!489>X$,ML4$-Q*UL*5H5I:BYV;9XS]H/T^;0,6."YN(
M_G*!(M>D.]M2W6VYF_$CL=MWSO D_"<MER'4>4J!5;\GRH;$J94MX,W57=.[
M(>:RUV" 4_]%.]=2ZXZV]HS#.A(@(T.+S64<6JL5#O(HLO21_V;[:_G;$XO&
M7Y*K)OV#_"^8M#3?JE3_A<H5Q?N=NT./N#X.T<"^:KB[>$5M;Z)Y;SZ[+#9@
M-&IJRL=D>KB@LA^G]F,J>*\R+"^B=2#A\;T9 ;:EH$6_E;ROG37W+\^3+NNX
M#D$KU</]E4(1)4,-2L.<9)V<V\1#][XBS/K]]TLOMLO]/)SLRYHFN)I>ND-_
MG-C=^6'F&:\529\!DC(61RAEA"SZ,IV3TE5%,O]0;Y1(Y7.0#CFKUGNR(964
M$^,HW%8EWZ%^^'ITWAEL0DZ2S0^WF;C78U%:M4XE9PW/?H4S*PI?P^C'YH9@
M3F#>CCA;AZNF5[?9+L9816<]H:G,G5_1Z+C>/YK@EY!0.F-Y>4G_*QH;M&RD
MW##0$N2>.%UM;A[HDG"972K@\Z^QI(*DL<.#],I.6AXS [=] ^\.%JV,U+?N
MRZ3HLG+O?36S*3U1&:TR*+=[_69XYP\F=L:-C6L7SD CAYD <LLM",&*=H?Y
M47]1FMIQZ1OC$,EC3-]R""<V[EXBK'!UT#J7@ZI9K9SR)>H)I*K[\U@+ZI!9
MYWMWOV']7/B[+MJW5RU>*Z<N:2\+G!&!SURO..-[.;8TR[+#/$O/RV3:ZY3Q
M\=<#.6YG^^S<<NOY@!#%JHJBJ[]4G2U/G/YQV;3,K4"KE6JGLCYD?U;I B!,
MQA..H4R )DH7$5[VK4[D*&$\RRU0(\9@X4?J1:%+[PL%'QYI..8S6"],2EX,
MH,O/XDO;P.#K@G^64:966YP;5V0_-[1>H_2LZ[5H3J!<:9O*NP\E+C'[GQ=;
M3^QZYJ6Z<I9_;JCS9E2L5*#ZD?+)CA\"PGJ$#L6E^YO>/_R^O'W9S:GXX-1E
M4^/+LX9:M;.'"RN-BL?OZ_S<@H2D $VT^SAFJ@ZG#=)Q8K#(,=\==L#3E1*Z
M.B[E9F;P@3=D<#FW@18N%S?-\['+!\'9HRMXU>YH =N:O[J"TZ^1H,K-JHVY
M7^MWE*\TVJ0KC7Q\]_-%O)%3\B7\A)Q"'/,0NBM=?,"1F:'-+H0T76P$U(UV
M-"D*,WD4/4K!.),,,O^W%]99F[9-?TPKOO]S6J'^SVG%D2T()7X.S$5D0-P@
M&B$>$2G7GF9_9%:A9;H5:B]U3\HU]N M-C:%6"$>?U1!ZMT&L[@*#&6[Q<]*
M,W&#_]L6!,HB=!_)C)1;EZ#>^%.S$NP8!I :K\VW97TB[O<D4;[VS]6HO+G\
M[*/W:GZ-%4GW/Y=W!'FFU^=?'Y/D1;K,\;LT75[XB/"S3?S/''XISJ*U@DF4
M*]6;B91FQ<148_YV],4?1 %&&BP*,]\ 6[WG3WR!^=P;#DR":9)$U&EP_/[>
M%*-EUVGF7QO=I$>Z?#]'6\0_0Z2L#QYQ$H*LP;A8[0@^?^(N>R!IY:*=7)6=
MFXJ'UJ+IX'"Q8]Q+Y=.7YSH_"0=XCG4I7Z\*07,!W:WXPV\ 9?[W-O,\#NV>
MOE6*'",OFU1"(V>T+*RIKR9W%06YE)&Y0S#E8>%DK. 8$ES!1LWT8H+I/'N!
M-3.S:QS9I'_DZ:1GH]I(^PVU2<D;U%;&40!.-2/-++JZ302)N'?"!^]II)-G
M3..NT,C]Y^R)7N8U=?"'I_-F6LV?Q:9DI9#'N"X620G%1;DK*OA6'%FK-36L
MOU-1$VRJ$U9L'VKQ+DBF^H*I8;NA5IYT;WM+>3G>X]X=8RCM'F TR;RU]"F#
MG:5A]!Z9-"[HT-N[?LXCR%,WR[0KSFA:[<".8Q\:=O7%=:!$ &6VYJBS?BTZ
MTE2G!VSA=:K>1VM:<VE%6OEQD6U">MF'76[HF\0V<X#F\)@E ^S!,JQQ?3H[
M 8]KE/7(-:V@=W7*1>Y?7,O#+*,[/9_HW)1/"TDZ[=E]L;<:/MS;QCH$VXFZ
M,(0^?@O.=O[H85&QGGCQ%:+]1EZ[]4O-C2NQ*]Z2#[G'SNIA'%K[<BP538V#
MM&1E5NB]9:5&+XBWB6Z(U,]]<TB-@>S^6WVT9!_?J76+@1%4QTC'2.M@K<82
M/^H Q;F[2>$B&=_(';$\GR2D\.7D?))M6)*GHN?NHDH-R'C'W->VW8Z4,RLG
MUH>+4=QDXG!62Q*TC)7BGWDQ;\S6'L U66%TR*Q1C8,O9W;+6(\>EOT@2J^%
M[L3:R179%KKK97FV6EX?-+W<3A_L*W K3IKW^_+E76_."=_<>-/HU=JH  ^C
M^1YI=-6LXY".(/IK.CL02ZKV+F)I?=<O;'EKG%_YV".K4ZLUKMA&\GFIN/HQ
MQX3NBY'+FC2E[V4L?2+/%N1[Z'O,3UD'+3B[YA;$ 7LY>S3^A_NLG,/F[:14
M_]J5PR?X='+TLH]E$D_?][:SL[=;ZFVP7UJHW>Y9/[%$YP;][Z=%@U4071&$
MA29 B]5$VX)L\GN_W()\QE4!SAO*1]GH:TI4_17]V6#0.;I=?^4)T TP[;7
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M%K'KN9O6S!CJ07E1WZX2M&RTRGO[-SHB-\-;,?MQ>]%]F%*E*)A;;$C&7@D
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M=M'+B3FGDK<:&MW.R)8S=@ENQZ<&$B*OMN<559NL"C0N[4$B6.Q]$T7JM#B
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MF%M73//0KJDT"2N>L_3UE.K\U6H(+W#K4C=:F"]^U3$$;V.I@9ZRM,A&A=L
M351E"X'4KNK[+C7^]OE'("=TA:86HP^>D&EO?#>U5KS.8A_>KMM3L*PV(R7F
M@8_8&$PY6PN6 &]]2N6<A$7R6@U,EL1\5<SJ4RB"A JF6#F7^^3M&7E=K3%%
MD:L G>P^!L1NN6WL[@2QN\CG^;U2H0]W32HTY'3'Y'1_OL[*7'4(0VJ\3_DA
MFZ_AD&T_53@V5>&^A$B#O;&5R<0GQLY.1OV)UO>T_5[C9F(;8]>O6 %9&\I4
M(A]L_ .1]$^G8@?AG7^J]^_/"(<N7UN%_HOX[E5\:O=OCP3_-7+.CPM@./GG
MN9D?93(C&4^8__^2U?UOT7C1%+29=UN0#IC.<3 K_$M6I_C?KW3/36&6M<
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M-<9)[?Y]IM[]=_2B_\2'HC&L/@3% #Z<1]+_!.=CZ%*&8EF2[9AL-\^S[QV
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MYD8F]=IYBM+)]QQ@Y3B*_>O1!;%8\Q3/W57/"8'/CC;/<?RR_O+VI2N8#-^
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MR$&;/2^>?VSR#<?+0)8#CW*';\_G7.]4MG-P/]QWICK,0S=QFN\BOL/"%!G
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MA-')LS6>8;%Y=K-"%J_NTRH_2*H-4MZ81ZKNL# _\! "$1U0Y8-831;C)S(
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M9WOQHKS>:;O73_,I\;>6?*7C!^<:_<#;I<<#[ZV^Q4HF%:9'!KT#GH1F<CY
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M+=**!X;NVOO]"$9 F5U@2G7'P";J_.G28)G@%B7R'9]C"S+$&JP&9KN (C$
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MP\X.-7@4!S&?3=K,[XS57I,KFHXSLU?2E'U]94SI(>P7PXT^SCJ(1C"MLYG
M,/9H8"5;-=H6[XR3#91:)7\)]G:),>E$R:>5BWVT/AG;'[T+5NS38>8"H2V*
M\]3\!#ILVK\92L"AT_/E9>A\:S!T6NC,8-M]W;B[$@/4W('OUK[QS@&NOQ92
MNG/*O[;I?V1]_0+SF\(U-R$!^T/+*]HWS 71&?8 ,__>NO'4KGYS#1339.?
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M?\/>-*$XQ3@J@ .J,KC[P[DR1.X^ NUK.*X%2A\QT2PW>CVAMY.)6\:\BGB
M2S*MG&B*!T;9JC@@%4K=P$M./ L)B79H"OQ"6<83]T2,N\FK$0_6@W]]UX/2
M^$Q?-*XZ@\XS30)U,CITQV:0C"T8 2"WD/CN.#RP !:8+F\B,\Y_RC7,"JW2
M.A7^L\2Z\^D3_U@)7+,+ F*-O,P0SAO<]= =;"GH1J;."P9BAEX8;Q:&XKP(
M#.,4%IA=J9(K?#PA3YA)V#Z$S=L'Z',NWW[[++\EYNP/MO^=+ Q9%.%W0FVI
M>0L6="7:F77PKXW9S6?KL\C#;AK')\5KC@CD<P5/?+B$[H$4'(L7(PP,#WBC
M7['#G[7]#3Q*4PRHJA>\LBZMD_\B68>M]\7<8\;4 P:WY_;C !?"F"[3&<PI
MQHB#5$8?2[?CLG62_P<[*BI4.,@XO/;)+UO&Y+LW'I.?&C(GC#G?#LZZ6-]S
ML=*"G,='!-0(I^6PL('>2HV<+*QR7Y$W>(:CU>!&Y2!/UP^LG5 ,W^OCD63_
M:>8%;TPDL:I8XJ:PR\,-%+4PBJVY+33[$.(8W^+?KJ,FZ?$LK8!6V_I<I;X
M_V&9@P%=K.2O]8+"]RIU;K8IP&-J[M7!V?*?&;?)MK7VUR&@]W6 !*?K);>
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MS I"@9-J1Z.Y1[D&1-E,3SN$OWB>QS;X$:61]VC079=HT9"PEJE"4!(62&C
M*1@T(+NQ*E(]RD EBM]L6T/&"53?-:\)Q90E8(7W! 4*XA;0Y?O:C!<7=;9:
M=SDRBO7?R>N!>*GB:F7!)4DY-L(;BC1*KD0@T\A!PM[>6LM<7I^_P2[/.(VK
M7I,>*'R0; %.?U^:J2;CD.OF^[#V*P+<ZWM<F31ZYC(PLQ2KCV(+/LR2=1V#
M'@'M]EOO-&/97OG"RMH";3F%8.M+<JI_AG :8#'F</'IV(@5!%+:H]N?1Z9G
M4LQ!_GC+;2A^K\VT7XE7XYG"$\T]&]-E51BNI=\"GQ_J:C:;9(E12E)%V$J)
M?07RC#E#\NEAXB] [I5Z-^P[&+J-#>$3A6_W2_IRG]4Z]:9O2,NYY;?AT0'S
M=</D-:)UE%?X#2N(4S*29/%OH+LW[)A<2J.&+X)^#\_'/G#ZL(A2._$Z=_M0
MG0>SS^*5]HM3P3N+V,]?2XJQW%*@%C\3.-&O":UFK.W=>>,.B?U6":L>P69E
M-WA&OY]E:Y:KK9&KBHW1/_S7BQO^NX:/#K?]R?!5IF;AFQ)F"L$2X<$2(5]0
MV=7B(-4TW1-U;TGPI# JYF% 2\L;04"'\9:_S_9N#2VUVWRHR'16J:&6NX+0
MP7(?T^LXW4:P132@H"@] *JAQJ=3J@KMYK6$#7;N,<N(4WCVRJRV_EQ8P["N
M9F-%Q'W2JY^G*+Y7*#X7Y59O$0MAZ6S;4*(;2F40U=FDR-GOL]&.BD$"=Z;6
M\KJ#4[' 3=?$IZG;W*POJC=^C#E9(O("&+]C@RO9+";%0-#4:84@%)_<!%9<
M+#7*@'>> HES]-WLS+/AX/:AO;EO]DWVF*GHZ7"SOV"#\\=L&4:*=&XN1P'[
M5_X8;K)@Y!BU?3O21P!<%GLFF+[_>,*3H!7X2METWLWDXD9G!QKB9F'V4H9T
MO?P*0O8N9"V@M\$#;G80H<@4 9 FQCV@#$CE4XX/Q&&1TQ3](7N\RJ=//1K]
M^@E7VJ-G[F[9^.;"D):3:#5E^:<D'\8ZP"A.J/8NK@8EC(!")?G8+.*1>>;R
M^)WJP$C_BOHS%U,+IG_^= LOBPAG/Q;Y7(@Z_'QJY,'_8LFJ\LHQ@M0;S9N2
M7), _Y2LNL[Z@>SB0)N(8DOL9:GE:L!8&2\I7T$HXK+F?N7/K""@?>2Y.LG]
MKV[-5%M^+SU:0FM\$O/W!MZ+?"A#3TJ%4;SUU J";"%XX[U^:MA:_5K$MS%
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MA6]LZ/S9O ]Z>GM-:TK%.X.R_JO\GFEF&Z5>B8ZU0\2!4(R[_J+J34"S0U&
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M&;Z[P=R)$GP"[7*:D"2$0-!+"BE"2) /SFT4KAARX,''.:/4GKD,M/+87O-
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MD)1_C%447&24;$G*Q_2'A!H^*KWI;5L>,TM\M,=1'L3;F@'&7B%$#D7'90O
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M+@:_@2(#FW-F>&E'!],EM[N]B/M" "'"CE^-"%;(@A\$XD$G#O!3&LCI[5H
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M\4Y<B+ 7R5@_L""0]>0>G,-U:"$9R6C#!@IQ$T5:"*%Y@'MFZ6YM%5!T=Q[
M<3R%$*=E\DC*YR^,^8_K43\PQ$5<PQ;FHQ>@RUIP+ <P=]HWL?&I?N/P'5,
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M_\__)8_7SR]'4"MQ1$)O;A8'*P>6#:S@8W8EX$$#J_IVR00B13LVE7X\^(;
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MLB:Z8#G>';%U%K Y^76,XKJ\PQB2=/*TRC/5 I1- =I61RV,.C"9N=&CM("
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MT)F/"V:;JG4N[_GPH\OJ]/ZM=Z06J;!L(D*6$6JN"L CZ;^><2T&,(L(S$A
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MO5!)'C5(I>E3O7J+QGV7_77&NGYB]I'9RM]Q/J\0M%/SE_!5)NG/4>&_9K1
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M8H:JU LT08=G1&:VF(Z]['J>W/H\-9F0OZM\[5OW1XF;2W3;K0*0BU3$>X<
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MJZNTF5>51EKV1=Y&9A8?.VH2<OW4>?O<#N[GVM8WI<FQ)&ERIR:@Y$!V:4!
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MORM+'"^J979/TK$WJXRNO*?KT2Z-CCIZ+'>J3^U CEX8"@JO;8Y^R0H1KX%
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MM_^8M<.T4PS59#%,=L9+1?LX2T3S(.3>2U\$M1MH)E?  0R!<[">BNXW*"3
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MJY.AB#%>RL#6KP],AZ 308I'J\+<8]ZB+X9BPJYW(^+8Q)/QUS2._MGZ*IZ
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M,&T ?HWS/SR">=A^].\#*TWFFI\!ZZNQ=TJO:!4G/-:$KC7AG_[-[3E\ CP
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M9(H[2>Q.^;>$ G]GQ,YX96SF97](=4V8C-N"-< *<6%T.9J&IP\UIC>]IS,
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M?EK=:I:#7SBFH\G&?3CA,VM]M0"Z$U: ":.SIGD&6#'*7G0>0AK584I1L#Q
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MY#<RIFZ<[=;TP]X-VLP#YXCHLY5I=R.T()E.KUC./JUAF1^66B,SZZ!D2QX
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MA')^<SFR6*U*B<G Z:1^H^&>Q X<U^;*A.2\4LJ$9+-!ML=VMZLZH2-2U#@
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M&;F>Y3'@QO^[B+?GTA8,8I*LE2U8-8$ILVH70(!OV/FV(EDN-N3-5T2D*T>
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M4RJ&,48EA_'$.#K?]271>H/I'9<9+3$>^6[/-/Q5YZ:_D:0B#_2]/F=R],Z
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M796CD$-JC8^M^E"<(W[YUFF8'-_EO?_MBO?_CO_G(; U\3]02P,$%     @
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M82G-9&4Z?)+9V=5+6]=FG)Q@^6'7J7&1SNLOX0V9'\)"4P9CKX8,ZII5[]@
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MG811L[MS3<O_4ZZ9ZZCM])&^ZL,K%[QD60V/V_^B[^T)<8&1J>U-CP%\Q]_
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M5A1CP[I;*;MNN< D!%O F@!VV@XW,22$HD!,@8$!JB&&'!QJ5_='P06;$$;
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M=/S)T_A-B?@CH&R1QRT:7\@]M_7E;=*PWA:I'[ "(N<014IP%-G@ELT9Z+T
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MB!C7WK2GQ55--64Z>+_4=VITUQIO BS(+$-P.45A8_S@Y#Y>B_ YJI,V6<!
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MJ''#W]^@U8 _=3GV[ZO8)2C#1>!]]>!>+#A!):.H)/0=+N)K; ZN<1Q8$Q@
M1H]Q$1)ZO[]9384DT.,8S@[RJFDY%S%^]^^K^=T ""[C-["+6<FP8@?#WI D
M%_'9&QZ-#;%@YQ_N^EJI]"XN0A*8].4B/GD1X9]9?ZZGX>Q'8&+8K!+%_@UX
M#0I^2QXBKTI/X7^'(;&_^TVZ^>>90?Y]#0>E3+@(O>E@>"B^UG-<WP/_B BX
MUO41M6/#[LZ=89HNFCEMCR<AAEKO)SQX_[5WC97B8[D_I]QCXG/3>7-3WV/0
M'X9.9VQM*+>!XXN1L?[50S4P)O+^Q2 ^EBQ)!^SF(F2<&Y!,D>35O@GH(!?Q
MH3(6Y"(,L'TB0"7\4&SRSI*Y/NX<]M+/E@6M>Y&;O+#6<G7!HK,:]C8TS;:W
M4AN-) ?S"(DS,V38K8*,?H1R$8Z%7$26! G6!?*JI"47 3MT79G!<ML!DAD;
ME:]U:T[7+MEHA5)6T""Y\CCIJ]#): ^XSKK@]S^I<P,-H)L!JP?O$3FQ]SJ@
M7U-6SM/)H!R9'7?2'FJN<>4BSIL&O?QOV5/ ZA0!'SP6(5(V+"_1E@5V$^PP
M FIFVHS#VVL'7<]C&T[C3%#1H2+FEXQ^UE)FQT/@ZX4NU*P8K!V97TIGU&I1
M"[+N2"8_+ 2=GG:^'#5X</S",]FQ7^2Y"#Z]QXKCY&C4@I4NS/Z<C(&TX"?H
M?6QW6(??C@FR^$S8,Z-L?2XBSA?)@*)6V^$BOKF0RN=ODYD1[,?@BY_MTA"*
MN AX2%:E*\4X]XA0E,>J$*F*@X>E+F82O3Q-73M6,,_6@=]9AJ:C. IR7;\T
ML[["\[26]38S0I$I_..GMO4G3J/U3Y:C_ULVFC;1AGV@L];XY64YZ)%'H5T?
MZJM&(!>!O@Q,&N3W+8J:C:&N+-BR;\EG1CP\\[/&EF.%N8B#-^-@KZT*X.PN
MR[5-WP9W6,V(BWCC0(8B[;H)4\]56*4GQ;[BWAJ"YDNG_S3HL^?!^7$S=F+L
M3J#_,GH"S3.FPHY\Q47$+KFVWS9D%:(8N' 5?1'KKX:-/_6]@_U9*'BP]GTF
MS_22EYRM/R3^/=]! S0J.SJ?BW@ ^^7F>@EA**H<A.S=%RUBCGZ#_^6G1SS0
M;&$J9)0.ZY;S2 D7\5*VIJM:Y6=<YM];$?BO7,@=,_@%B6JXO7FH)6E+CR\5
M7,2!@HZUM00NXHR&%?FW?&#7&CZ^8]Q)7\1"Z&?M#2X9Q:\*J\>RML#0.%E6
MJ-U*-V,_23'D/)R#,<[N2QIP@08,9TR2I9<C4'6QF7Q_'/7KULV !/#U=4 (
M5!?/16B#J%W 5P=#-I"EYQ.!&H8G+'+IQ#WY3/)!/7GY?]E)__VE^/=X=.[O
MM /F\CM@&?:R9@O"./)DZ?DQ:!5%AU[-NF5&<!ZQ[O]-+A=5*"V-U#+#1SB1
M5?Q;8AUR1T!]LT382X'$YXY'&?SN%*M$X8+DGB,4#?>;$0<+?G.2\DS></Z^
M#>*>E^@J*Q^H/<)%C.:AI?:"J<P46)V&P8GZE3ZD-H@9Q83,Z:)RIBI.'#/4
M*1ERD)<.3]UQNK9 &S6['G&1Q8F#%?11,O/N>A3Q%%Y*O<"'!(0CD6S%?:5]
M1B><MA*O76"TUG\ST]1\8K\E3.T4$MMI0]U11MX=D$ICAHZ928$RU6I%TQ(:
MA>UEM*8>YVIMRZ$X15,WU\BO^$]W.E>?+)#:ZA\JWKRO=X_SD*WE5(#=VUM4
M=/.=E=3Q+]:[+EHXSRGW6\.6L4XP&^AHFX>VE 4B_UX4[\.&A\;3A9KXOL)%
M;*3$@J>78E=7:V!+5EX(:S42VADL#>$P %T95J5'ZQG&\*E4-K]'?^8_2_XO
M+$EK<SGC*>:F]L!GOS@7$=#K4?8'VTGXKH!OP.5^+0'[S?5%-X?^#&&< E"U
M*1;0KJ[O0:EOT!<?/!:[P'.LT!WXFYR9_ E!H&=U7$35V4Z<X8P($(H\Y_Q[
MH<2F,7 4'=23M;G7%QJ=>VY8'ADX&92^S#3]HR\=PA"#]'N YC6UB>-9G"]X
MD'PV&39]"])C#W]B33:27H&2M).:Z\GS(@,U&C^[EE\_<[4XEC2\!4M .T =
M,)\UO*NRMHSA[.E=@?;!?(I" )%0HO#4<6?. D#CF%>YTI0UFZ:.T-Y5*DNZ
MG!UZBWQ<>%Z>T&_V[E\WPM8OU'I<Z</P@(G1\$CR: 92'*?(/B^V&[D1:8+>
M%"!M'M EH(<"#<8JRA40.TPY2XW^:GN?BOZR5?$#<.,D/W."$X73ACY017 Z
MT#!9&">+AGK>HNW8-F#@>*&Y]]UA(::#D(/=-O7'FH*S#*]#U\4M58NR1_<?
M,)A@BUHWD.EG= B#\9^0E$CF"0:FB1!#DNQ6\EZ.%J9A'BV;VGWO:KUN<K;@
MM+NZ%9&_M$#)?Z/!PJ>-)'MYO40ZFKG,B04PL8,$FFP>P-H&=56*Q;"1NRO3
M-S#0L21QZI2$5)CWW2F]_D4MBN[]A=H-#Z2,!HC:F8DCIHA@+N+_]M[V!OJ/
M/]JR0L_?6SK/U8A<!C)O50G2A*W8Z0,_VXH?U/L3HWC=L1F>^6?90/\1*MRC
M0O>^I78Q#D4J<@%ED\667]M/B('484Y@P^#AA,I ODR9?U0H8W=PBE"W'*R9
M]QBQ#_3XV$= E,\X]3%9J&C>F4X(Z[:)O5B^<Z"NQ,'AZO"'H@,1ZBZZTFH)
MH>*B\/#5:I!TH0&D,$DRX&8]\P&X8;NV\LB#V[Z>C(/49L:T2J#JD)>-7%F
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MW0E2=[48YJ5C*W2>TN:''?R-YNGISSI9'?_X6^+>HCJ1U2=5M'E0SI M0FY
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M;#'%02C#9Y%:T6 [O?U&Q ;V/]>L_(BSP_ #O]A&L6[LQB'HMEK>T3+T?8F
M$3M^/1BQ0E)NZ)MGQ_\!9YW%[;S+O$W:I2UU8]!+5"#TX7+48/-SW2Y9K2';
M_UZ'<G$=&P+]([@ ]B1(^F]4,5'@WT.&&,%KHQ).7*4<&;^,/T:S)KV:^[)K
M=4EIY@N>]>-W+F-'-RP$:M4)]@JPFNV&3\:W"O Q=P..>6@;FE-M,SWHN@D[
MUOU)5IJ]O-UD[(Y)Y95,Q2=OZ7@%P 7D,H7];&4@:L29A3ODI;V@>=N_ZG[
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MP2'LX@!V_=90&O;_9P^O!+LE0H$UP%@*;[^0-C5Q$RE3/2] P&3?@YWD86Z
MD;<:[03^]PF8;,(H (Z,RP$GNH<HW.&GUK^<"[9JKN.O>NH8K7&JP/5UOJ]H
M]-WG6V>O2%J:ZRO%5D)PWW.G=<^C%7HQ%YCJM8 ;Y>#EA1\_MF=^>)Q2IF]%
M>:UD5)JK[SSMH, =]VPH/8F2<X/V.4\7>;0L>AII/;524+4X.M]H$[K_#S>E
M^>&1=:S/FB)3Z)9)S7$\$T4 C (G37'#W6T6?5F -MJA(O[PL(><YZVFY<=7
M!Y\BE(VJGQI)HDZG,+W!WF=@&R39I]!*@ZY .(4#X0_HW3BIL:Q S1_GKTRQ
MK7N>8UUF[%HA]*'Z<V[S)\.&T2]?&7&_O]C5><]GR[CG[H<%A0FNIT3Q31\4
M*SG?YC"7[!)6$)-\)%\!ZS=:8C*74(-3JO:K]B2.C3BI!>1:*U651->]N3QR
MJK![>64\%9=:S/Y**@N/)9!)<'ZF,@T>7N88'YDF&@9BHO/!?L'QC1NE_>,S
MX^TOF6SW(BU+9>]=\G:[;GABQK!4<\(3#H1JCO@Y#+L=#]*/+S2!%H'HDGFB
M'?59T$/*;-.G4^G)="?]^[N?'+(;DXQLO3I1J2>W'I7GZ+YM\&Z)F)26XB7:
MU:W;ZR/#@S^EZ7WC+"D6M7^%OZ(L[_):K,FUV'<)]TM*;/QC?_A5/5HL3%5N
M/(7^%4I,3"@I-ALQRJRJ<B((3Y&(6NQ]#'#R1R9GFW"QB)+L98., $M86!J7
M)G?X.D$H0-F3-G+=V/Z4"H7OK/+]]IU-^R[(*]_F^B6UM4F_#+@P4!XDJCT^
M<E#W-"M'6R/',]4VM$;]P60G [M3_CC>X\-Q4V,7(5RQ)GZ/N5UBM](Z/:HC
M+C R._R=9.O9JS(Y:ZT+:Y;C0\$/ZU88&<=G1%TNFWMHY9T42R65$V9S9C"B
MK+PZ<:")GD6#+X5^&%G(;,$<H+(^%N69J&44I%=\&9F.F.*WQ\U*[KXHLX9L
M9BMB&RQAY$2IS,4T66"29M4DA)A3'9U/[0ZAX/=>-_67;EU*N'0X83@FU_C"
M<*7= 3T-?.&)=Z3P4EX&L.&XS-^-_.0S-=IU-_;(C:F;$5]G?WR9&ZQO]'^K
M4 S<2238^HL3#/JJ3V=K:[L&&JP3;8;P1H2)&70HJ"Z-?E=$.\,X![39$*A^
M11/X70'1E+J*/*8"M;5:N,WG8X"G?VR!BV#E-V,[XXYW_*8QX;M8DU1']N6V
M<!"8CXO_*G2NBG]*6K/1AG$@-XT)[WPM6[2] WF6'5-]_+8*:Q'^ PM>/#V"
MKUHS;6I29N*+?B_G"-A55>V_R.N2/QUOK<4+<B#C]]@)S%Y:C173P3E^'<09
MPGG=:TJPQC1A:L^3&AWD!(S;W:;JSNO;H2>5[Z8+MO DF/!D/CYKPD1>BO+W
MJ[A87?8TZMB'?]_4WUT@P-:WP6YL0-G/E%9. /[ZOS]/P[&"C3B0=!Y&%,&*
M2@+L<';8Y;:?]_[%4T-!*?^;C>[\$QNM^=..*B*N9]*M6:?QQ6MK4U4(I%U^
M/0N?!O/V$K<GT!0?JZ%$ 25GFF*3(R]CB-8=.3'W(=E$ICGCAWUZ3'BR2/!2
M_3VMD.?\7SR5!.WUJIU_Y_@G$VN3JU,NR_Y 5Q0MDP28ONGHR]187"SZW)JT
MTM3)O:\O^H2=T(<8<\L-%@"X9J) B+96,(4DLO#";K[**V^4Y-1][W-SE/VK
M33)_2"*QSOUWYB/T)\.B+U]-)53@(Q%8&S%*)CF61&:7?PF(28\,@'IVQA@Q
MZ@LJ+HR>U5NJD[N"]2#%ME,5X;JHIS7B/GP<2/R,LTL_*DR^[,>OWB1CX2L:
M,D=DA)W4[OF$G3+WMX@K7.A2 ;1.+:=V1\6Z';1T''O(+M=1GU!IA8;#9)@'
MH?%LL8!HAI5Q<N!A4T)1UQXG?@FOUX)?=&A1OQZ!*CA^*=M+PT,;E2,M\J8C
MT0[!2V+%0K7NN:[YQ-#2TH#\>.#H#2ZZUQ<(]MM$'G9>KT" V#09W]RS(P#5
MK'N VK/4E <DF@;S328ZV0OF'S&1.S%C_,+9QKA!(<E\BJNOP/WS2S'=AQJ.
M)L./.C017?:$+W@7LUL*5[L6QU2^KZ]*H%T!)!D1+D<9BD!?Q5'C:LS;9;-O
M>IVD&"<D"1:?K*K6+'*=UI/0F'=&/>! =DNSXO*_F_K3KJXI*(N<2Q,<N"84
MQ.\5-*3'D  >-8$XD*(MGAY@U/H9B(:'&W_3;*DJ_K#T0^N+]=VSH7ZWB?6G
MAY_NV,4O0(_@0*+G&8YH;=9;KYXW'P W_YB:ZR%)NA9K2Q3OT:]7KVW8[UB^
M' ;=2Q/.5CN:^6TEU4%%43QO8^SGM?E>7P5)1==@E)=X4GQ&4LBG>_Q[OWYM
M8,;Z0"6P[H1GB)W.C7T4E4@B[YCUZX>UISHZD'G5&;67]7E*GL-J+AXL25U1
MFE$ABB-2)FR7:R=04;K\WQ5H'PE8\NO2Z/A=\U];MP>_7S^7:1%;_FK2J243
M=2;QT+L/4Y.XW9<DHKK/UG7-9RU5UXKGJ:9?55-T&^9 ;.<>J3>L$I4FQ-M0
M%2-,#9K6=6>/JWFY'O[)EL0QHMA\G632=:XXB9U:;FHC0]^P)86U*BVP$;<6
M@DC-S?<FY"Y,9\,]CP,!<A:&XD-B.'?[JYE*7H)?JY^VUCGJ[N$27)N=[SA3
M>CB\H%.V?;&@L+H FLNS/J Q[(<8V,;5X" @PP@%5-@M)]4Y$!.7PN)*V&/L
MVB6F. =R*_D-!_*A:,@>D6O!WA\LN+'.WCWW-\)N)(IIQ*HB3-%TY;$_1_Q_
MWV?0Y8-@9/W^4"CI+7:/;G9BKX$H-;OGM:PF53P$<Q1P7FQPAE&G"PNRG'>+
MGU=_L6)$;'C).%!_P.C08X- ]:;XGR[DE*>8$YYLC2^ KYO/+EN_Q ![%5_I
M-SU%(D_TR]O'DNR,]UFU.Y\VA.#O951D1^(-^0\DFFP1%K-'/:3*#HM+U$KV
M,*\"ME3&I,JSCU3UYI[]>GD>B575CM_L+VNRAHPN2:E+7G ]%),6J-;%5&0E
M8?8RQ6DBXV>HB-#9X#N/L"7E^#Q/?_$*)0'F+Z-W/UOK.F,V>T3G7EYKK77O
M>]B?&CT?K#MQ(DDDT,I/.Z0-\=E_*9NFV!H4WZPBR51)6+4;N".T(!Y).7@)
MJM88RGW7*C<.0H8H?0+.,#31!UFXDQN\B&<8X<3+\=<"QK=N#YPJK&F2N/%V
M]#+#I[9N137MP1.G6M'[+91L^'#'A[>/G$;@AZL&LF1M%;V'M%'-T,_J2Y44
MG5L,&UR]OTUD;O>=@7,L%>>:TM+J^_=-&T1RWVY"=CB-EU!M)[QKJ3GLO21
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MZ<[--5KD%ET;B092X*KK>T 7F6O:X,(!)7F@/(!1\<W$S6'F:E$ AC[90:K
M?#U8/LLMV:H:@G@)HU)QVQ\06P@.9"6(90EL_=X4:\71CWLBMDT5,'Q#];0T
M<8'( H-^V^)@1F%;MUNIQT .OV^PY'H*4UN1G2/.MN5 &&GQ0 "<9:G"!'G;
MI@YZQ !M2[_#O0439[N%;&C#UMC*VZ9L66$.Y%HT!Z($#KS'Z-];U[GUJQV$
MF90B699L:?<#GP(+%?9&F?#L4'R2<%'VPQ,K"U;*4S:\A0-Y%0P78!*B=1-
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M$/\NU2T8]I^1_.[_020'7[+[$ >2> 0( 87Q*\+Z1ZGPO^RJ66$;C&%37^O
M'_X\JL(Z'E9Y!D1U-6R32OLK"FQL=@Y<T30_\*WM\;$\K;3-N(<J86PQ7 M;
MWF-W5LWG-L6$]^6WDVY=WWF1T:W:<V6P"PUCW)D/\DND1;>.'V%E,G<4+A!%
M!^IB"/P;'TI2%TU_3!C%+_=6M1I'N6EUVYN>_BJQBVOD<6.;."(!OC*VD)0\
MMCKWNDXVH< JB; P.[+0L7!00E3N4$B#Z#01MIS#.!T03K'&-Q[DHK04K$:@
M3J42QUM_M,X8>-AJZ)]H=;$\GY:O>8U4/ HK,6(>&@H*7ZIXE%T7&OA)LC"]
MSSOK=A@YX^G'XU?G]EE;E?!H3;[%Z; ^/722OL3*PD"([JEF!6_-*&,FJ5IV
M8FK*7HF*/)">6FL9'<E;"I<]';7NIGJHYPY5^/1E<5LTV@YOW7TSX/DHNUDE
MPED L":/K$;(Z@X:XCYX?"T(]+L9J/VY^Q-!V?-;<\FQ^EV_G/W)I)%,^ET:
M/EH9+>HQR3L&SO.UET99IRK3QWZV!4T]%M,X&GLMP1@BM$\>LD]M,3]B$OE)
M[A YCCQEVT8HFVU1$44[A.@!9C1;<G<6]5>3K>R9,@]F,/Y"FO0#D? ;T5]M
M!$U4+JZ=/;:[..@Y]4+0A=?W36#7?A2#[ JO\D=;>#8//@G_;FC:"V/4!Q-C
MGT>? 20GYIAF-/V6,Q[E0^([>8V9V<G(G'AC2I2:VXO:ES*^%T3?4</I"8 ^
MK76;84@5CYCQ@E\Q"-8WZB_=RE\AZ_=^L\HHLGKQ"V)T2#C1V8QA[;EMVP0C
M+DX8M>(B%WJ!4XT]EI^#+>VB1W[?)<NHO%VOI1Z;*UW>&#"2.JU[A!D,!$YB
M@6.*C3I6Y-9*5%Z&WB</3799%NXL<?IH1)5C8.?:5Y>&EX^-+1?'R[,>ASKL
M^S#B\[*RKJ-L/2C0?Z%T]5[3\3XSQ5QOUKDZ7#@F>VAC&G>  [E+ J7C1'9T
M(7-? ?"1_LNFSUPWSR/#/<6VM<7XJ^HYP>*VM@N*<E_P5OCG;!$FG"90CXC&
MB3%/4G_?:4'3_<%H]7?HFBF:2"];.C4#:<^^NO;)R/WK9(?'WO'[Z9$6/4^;
M&@E:"=Z=R*S!D5KQ!;=++SV=MT>Z2=&Z[P%?FF(]0:Q&#CG9$RZK4#Y0^N:[
M6>UTT05Y&='#CV_?"#A1?R H:A/^TY8-%YX@L&++<=L'T;^_Q%KJ>QA0Q[>8
M=K1O8T1CI<9@,M;4>F#]C416[#FMG,M[^CHN1RSTAEZ?MDV>5 J#>6(:"2 J
M\8%QP*L4A*6%I&/?N^2N:AT_R3+O%]5VB)H;FL&,@H%Z.WUC5I'VBVV,B(4M
M6?83UI,O,Z7QX_!X'"AD/7X+V2R0HA?;DL?0<#&L6$HF2X!+ YB8:P07_0MM
MERD5(I:2W0R-A G58*FW5*+%V =^,(^<4_D\1[._N)G*&.W:'WM/]IYQG-B)
M\ZT:A[RUR:SCU+Q&A&"-] <G#YQ@G9()92MUJ38NW2>SP4W9W,O\B,\>H4L2
M9TAE)F,Q/HED6(5;'.%VCZ"'%"%$]Q00- X5\5 =;KGY*-]=U7!MI/1[31AQ
MZ:@L[.34+J6I Z.W>499STX6>FGKTW9"PX<TUPD\0^;%4(&1YCWW'TQ5$%L(
M1%B 5_.;G<GDR9AWK;55ZUMK+0JRUZI;D-2\')0_(6NC6&O!$+BVC Q$E??T
M8 E%K>CKK'<8::8$JU"7%\AL],B%YR+'E?OYLS]Y5M4,65X6@W2\UQ(UV#VR
MX^+BDM((S,L)1BG,8:@ =4WD(C H/ LSW<4X^_.,.-^!U_L7!6563V\]WM'>
MS2UO^X0] "W;7)K]Q/Z!X\$KURG\00,46X(B:/I8M^OQG]GSMV;/H#D0S<];
MZ@_7\8:LSV@76!O^9X@5K6)I,\<9&>2<+F]Y_>!129<T>J-208IQ5 >>R2]Q
MP]6Z*J0[(3O*]W1)/LX@4!$56_J.6>5WPB)_VM *H;[ @>@WZQZ>(Q7O2:=.
M-MG /J]PMSSY-(QM/$?4&N4SD!=2(4HQ_,?TH*^NM]?+,2KQA9A3["[H/ET=
M3Z)S'NW!I3>V\<91!F5]SFR[9=Y*R]L!O2G?;E9P^5W<14.<9?\@B'$@+J1(
M;,D [C'VCA?L:BTM?U-,OY[H%E9Z)]RB;\7&?<3/FNNB-5>8? QC V_.*L8B
M1TC#N 9=6>K9A>3G 9W-]$ZA1=OO6O8>GNDVR&%1T52S_.9\SVS%A-/GRVS"
MSI;FG+C>X=4QVC->GDK"( 89299J'\GIODJUF_, MN%TG60 M!&[!R2U=,"-
MH=EV,B7\#M5Q/&!5KZPR4#F_T)1"O)AO''='6M>BNU5^OS#"<J@;6A3?@OLY
M:Y0, \GP7HP*3A@@."<[+C^PK>GS_K%J7W7-0R'51"$" MEOK7[3Z$J"R09+
M?!(5XKL:LSU4'RV!-ZQ(][B'(&D_/_:XY=18M:.?*;I)CFOQNN0S9'?96T2U
MJ%^?65:V:EWU7$W^@UO6)M<&=,2=2*]I-43X4I8+K8+27<NXRA2F[2F%QZTX
M]SF4]*I\+"LKXTF/;M_! [DW_K'N*\ MWO 3(SA7Q-R9T%4C-Z7E#A+JI/'3
M!7*J,5]-0VIQ)T9SOAYR$6U>Q%+-!8;E+FJ^2R;0G*6172<HCLCE4\'GIZY'
M6D05*V.<$?+W; ]-/8AJ!\F%+V#4C)$"E/(7'89"5QYJJ0@!(Q:#:)V,L9;I
M=M=LL^D(E^-,KJD[7+U/5ITNM#F4"Z?EOO3J2/ :GO<2OCQ(NCI3MC5KE.J1
MY^B?V9>AF_!GM0"J 0%0#4BS&P<YD&TUY.9";9H0H(0=(>2,)7K!4A9$+ R"
MGRSC'M?]*56X "6+_4K+!PF(PR0'8EAV>VBR!!BF"=S+B#KQM]],8=;0?\X4
MGF+O +D3+Q7!BG) L1/:G%PQ!"/@S+H1L0\0?_^73&&"]]]\K*#6@EUY^;N$
MF:R-#U-B.PUN(&+;B-/]VT)F#% /[B+]BUP%@^3J-7;]HR?3Z>].2ONH>,;Z
MOZJ7#8*S,*XPOYTY\BDCBM$W]W>%J/Y:3:F?1+44 ,EB!(R^#U1ZEV\6HB8W
MF4)]=!]61IV"$]J"YA;!1&8YCS6)W!\&D,T(EU)I<>GDPY([XFUTVA5S"E78
M,J&_RZ#W&@+9H.X#M=^D=5*0\_BSG/'1=GRM7=1S^LO11WG0Y%+;!5NF!B\=
MY(T9L30X!\+K\GOO E3-AS'MA'6+NN-@4+V+!0;0*=M@R( 3UA#LGS1"$6%^
M=@*T!K,,C\,B<=),3"]3@<(G!'M"3R6$RS+@P>I.?36F^RW?BY]?+D8&-KYK
M-;]V]HR$J_Q^*=:WOS[]&N@^Y&>X(ESDPZ'>&OU):*1_>4+QN>0AYS/C,=8A
M.2=N-C2=>#%W4:T.&CK D^N=D53=PDY #.E?MK^<K::HQ"20<=&P$H%&@0A=
M"2":QC6);4;Q>=3)U-#&IA-;)KQ.4*\KO/3KU0Q,Z,C]],OX>HFH1(^&_-O
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MD[?$R-LHR!(RCO6^3I*$=@54*"JAVW>R19-:*[+52FVMTF_')/ ;R[QH09>
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M=_J&GMFY*VC\P61=@2_[H\;QP19D,3W4QH%R/RPP0K/UE6_?Y0RE/57GLJ_
MU';FP59K^+^@&4&OG0[%]2!M#:,C.3(S*_DTO&R-=RW$UKVZ,LNP1/N&QV/%
MTCNN@&=LWKF=(&M-?W=DYZTB^/AJT5,Q;/H1@NN]F+BV(R6#G_!' A^Y92SX
M3<M6CUDJ0=GRX?!*YD:7 (S%YZ^E8V=C&AX_,].).+:+M.=#^3!?GQ,+F=,C
MT1U*)#Q%!:EN9X?;V9K;0P_):[I&8B'DL34>7U:V12@7W+&+R.CR_:RV?88:
M>+UG#X,=#5WW6I1$N2"&*?]";"6@4;<=![L+=S0([.I8Q@2_UA'+\+?_EKVW
M]AITT7$\H6V0>#95>\?#33=L54&IHCDX1U,0/3?PUO>.Z%5=6*$"/OBNR\&+
M=YW.6\G#<>H5,PBZ!KC9')IQN35]+]PORD:&4H@4"1R<>X8VVS'H/T^2ZT]9
MF8SU2)6:BG]Y,6>)KA$?>._-%K5'AD%/HA8)2H3I; +7E92^MJMIV9"!ARD!
M27]&8G/]=3^W>%>$&<<?>FF_(7?ON4E[N2\H8\G%K"4EPZ H"-41E.ETZ$H"
MW96%KQ38"QT EPHZ4-Q5S_,%VF8[V_8/UY[#.2A=VJH :F@\*FY<W31P+C)X
M)@5V08*) ':J5+R:)U6K"I5<.F>94X]9W^N!,I:5EAZ7GZB5'_C*W[GHSMOF
M^MI49]U$O>Q#'>[CKAOV?@J?<P7T3C$R32C3DPSBH% YSQOG2:GI'L!>&+,*
M!H=\=X]L/$G8]L2 YD95_MW/_BB X]^CWO20F!D(?@A@7H9UI/;$5<_[ZPQ>
M%:1,C<0GWC0>#=KWCC?Q--7BB-*)K!MVBSY,2.=3UKX#7"?0$OKELXCL+UPM
M5ZGP08=HU=SGV&8OFZMA5XX\<"ISOC;B'G0SXUX58Z8;AEL'K?0)KJE06;*'
MP#W!2.(CJI$]C'$?)/&/SZ'ANJDT)C+I;_?WOWZU2VD_+?72W([E3+_O_Q&L
MM*^ZH/G$:!56'Y0JYL6?7#-TW [1O0NBUQ::IDQ,^V+:?>RO&6+ZU5;9J3G/
M/Y_]ISYJIN?$[L/D2(&C1D&1QFH.\TK%\67=<$";+%0D,#.[)J.9@SB]4:%I
M!;9\K@KGC8 "9;)-/Y%C^?+1]Y*W]:^;4E6N[4K;?S;$J#M%WW($$(#2E@()
MG*,H3X@0[/R%DOA6R[6F<HXL"A7+?K89#+$CKX8WF*N^35J0>?!VG_GYD]Z%
MCE^#+HY_A&%GV:L"+,@0PZ20&-1:ROQ!R-=*Q#"9-M5Y];*N?OE+]#+J8C)#
M<D5FN.ZMS67_B"[K>NNG?9$_3'#=!-/KFY]5=]MQR5#8#38%=A'9W@(-W/$V
M8)B;-C-5<9V58'\*_$3JP9OS(HO)EU+0]Q@AJ0E'K_M(]<(>9D8N6*,E$,?^
M,TG-WT40*(;U6@^*8>P#"# EK_52HVDZ088P$X&-9% 9$Y1QT&'IZW5&\')L
M@.8UUK^LQ=D#''_'A$1R1N\OMR+R;L-=14+V7:.>C!. ^H.YBOI:N\-%K1/@
MMC*P' 6Z4P0Q"&XW<L4#"F098MA$!6]QQ3R%,$L#3\'!XP"!O7T43 #WBF'F
M3T69R&^/_ EC_Z)$RG)Q=?^2)-NV0:2KC-LRI0%^%1#R<7^T8L=;7D4>\WO[
ME?'U4_144Y,H38?JU?%=*=33\T%@2&V<L-9NUK34(VESP8$*B[K-!D6M@:\-
MEQB@3"N7Y+=6Q7JCH>B6G1* 9L%36M8EO )(-'=?@-HQNK7[Y5SIU3YIF?8E
MW?(W4F[?7=]S4"^59U'*E*#%<3&,%=OC2D352D(T&":&A0'-,X>^BT:I(I3
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M#K?T->[*&*K0E9^^=41KI0MG*,K%;\0I L4\"983%2%!",'F,G->AKT %CW
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M"U^;+TXRG_;N*-;\IDM.\AE]\Z9X"6G4;[24:V;&_O/4WTK+462$HH^8G<8
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MQEWA*)$P4(=]WU8U?F%?+I?$0B=4PO5CF2/G77_N,=* '.^=B+7:W#X5PMX
MBEA];>KB/*6U.51G9=Q9]DS.C5F"F"_/CZW57'[>^>7$1-R=@V=&Q@,BWWU_
MXJ!]>EV[#!*/9',%4H/LIC8\Z_2R'+[5C!*$'[N)2BNV?LLZG)IN_MYWKOO,
M0D&8]\G/>@7\XN$O;_8+%NQV/OZ9>\G>ON?J>Z[^YDX8SHIW 2ADVW$. 6RN
MMC>@R$D!;FP^YW**P@@3LW(7C[-3"G=<JF^J'>IL^/,LG& DZ4D+D#Y^X/K6
M]!4HB'*7EY,HU8Z\[:GLX&Y4G<OG"5@BB9C@NWW0F'>-8]H;^,R'U),[C=')
M\F9\<ZDYIV@I=Z):7[Y9?0EQ*2=CLZ@D9FZ>90$1>[*$XU<<'TP3;^M+@+&(
M!+J,VS7[0+KLS7DW;N3DA$T&)21#HO;]Z$X4YOR];0D'E@&K-4[V)M$%*FA&
MKVC\2([S (DJYL.+9MOX[@)NO>:AJ7'/@]:;%T/>P)!!C=E3O+1C_>GB.UW+
MXKX2P1)APZ]"A$ SX8>!>-")??R4.DIZBSJ HA_D6=,I:<7F0!8L=75Q.F)*
M)+(\]*-A>>Z/YP:O!^L_MF^7>>6& 7NW1%W<.*$VAE&.R,;//L'7!7>@ +L6
M,Q]!_XR^.B*1]&7WTK:_QXG&F?6UD\?]_Y1EG.MQAR:*W32]OZ+*H+ P' -^
M)DZ7Y[[Y1**<4I_?C4H0F%8#A,IP+<7F@1:C<)P6BYIIKO&.MQA_HJ<RK3XT
MFUY399<BM=7CT%/Q7VNIE-FWQ9IL&$\QG[[,!%F_E/CY@684ZR IWIJ.:#.,
M],K6J#3S'GSH%:YX8_M9[:Y/O_JGWERNJMKZS6[/']3F'E<$_C)""/?5"XP_
MLPX*ZZ1T(6S\*V?0^?U(LYU5QR.-CNL3Z+ECA(E[H?YCF'JHZ:/A4J? S-(W
M;RN*BH/GD$)@)[9* ';V,8O8U@+)S7,X+3;]-F=*PMH[<:;LJHJ75.>*L+>A
MK.4\_3O @/,#^2_JC_.OF6E#NOVZWX#K.YY1%,C>86\)2]@G^'H(5$"$K]Z5
M8(B]#%JW3S $$X'#%BCU?7? HE-4.RGH)3<6)7YA"^.U.EIV)3F^+SZ )G7W
MMWP]>?W/MN>!MUZLU)]([CCVT!<ID YDUYX!Y$$_P_FW< : *ZVX8J[HA&PP
M7;D^B886]LB-]_VW8E];1TH.O)M&RWK1< ?[]7JGUOK6H_=\5'DJU?*(V4G,
M]JXT86(;03KY] $1YLW &\L\Y=$YW$/N =P,GG4*F:VES:IZ]6;!5PNO?B'\
M2LB_R_GY*B/B1P<'?J_:*=1^K/]FDV\@[UE_9-+V@)+0JEX;=1-VS&81$RNM
MJ!ICGI(WQW00IW*!YY;!P!JS4Y-M<(V"AR^IDXX_>\NFWM7?8E;9-"OY2WTZ
M?G[;3R(O C3* ]PWK5W\"AM7+MCBM%KC+X4C,@1Z0$Q@,*)C62FVL.O5TU_P
M[<5+9H:DG((=Q<Y-Y9F82UF03-CC=)D*L-EWYGIC0=1-K!50"37Y'XAC&MUW
ML<?(@#?;S3B=H( -I"W>0+FP?A8&;KDCVSPJ>G2=?/9@EO]9#V6-A"^Q^!RX
M#.XSM0;%4S;FI YL'G38@-3U=1$2!3" -">!1;$(=&@27"?LGW@JUE;F&[[,
M8\KE$K:LN?[J6\FW)[9*N&JQH/W&X\8"*>\*;#1KM LJR@OE%Q/AV[$7 47(
M_>X-R%8CTJ_E9[%E=;F_/RU]_7>@K2\\<CN:Q'O[T5:F_(?A3\);*$\9PQD$
MM;@;ZTU;[D8E$EBGU,QAR5H[FKWQRD![QP9$\9GGT\"'SQO1ED->I?G]1SZ=
M_DR'F=K?DX?FOVN@CB$_4%DG-9:A@@$$:,>+R D[NGAGCIQ5>_) <\P<0@VH
M.#?R]*$H:<6K59;Y1[0AI.-:A+QUVO"W[1'"[^,$LHL9>_"SF;#:/_9JI[$J
MC*.9US!&DHATG6_B8XU9R2T5Y7TO?%),+K3UGY#_5/1&XH#VW2LW,W@7-ATH
M^(1@H8,9]UCEW9L'J%)XVTI_(6!U\7*$+:%PI6&+BCY58EJ5H5N\0>>>7">=
M7*= ,G[&Y"3<6YARB1<_YZ)!H]RR(*85:WOG#:[*[IX_0_&V#BH(D)$W)]98
MK!?5OVK+=OJ@&;YBQYD!EZ. 42*$",6,QW05P$ES,$F>ZVBS.VVR4%:[=00N
MU$3H4"]^SE)C^F4<-%0)T5.XX:?C7^RZ9^>M,T<DN7C0->\V(,$48*=J*R49
M)M\<]_(72K/%@!J+H!'3;$[GQY%D+5?.T'^[/81:^1XS[?I3$?PY)OIRPG G
MN*XK9;:(6BO.DR_GG&"!!3]5(,EF_<,+ Y.SP1FKJJ,D%X1;0VBSW_-IE&U
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M1#/Z.]&O9T*EA3Q*@@H,)M,_O_H)^>&M[SL)3@ !@R8=2.*<9X^V$\;)G!N
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M4$2XY]^-41U?!O+,QYOJI^MK?KF\773\&MEE,G$1MVOP@<EK1US::L%A$A6
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M&S0*ZT:=9LDJ#8#I#[ T#2DVZ*=/QX["/M#]+^\&6D0H;O-NJQ744R>!1++
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MOL._Z^WLS#O&_"DR9+LC,@3=MMN'^%N1S1X6]PZZ<FY)#F3^<1RS7LP]RL]
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MB6U)>)4/K"PS;;GB^W8%S803UH2CA)CIA+L((?0/M"XS[A?5CAJV"'W.,/G
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MF<&2YEKBV'<D1>90@1D?WOG^-7I@]EOS0-YQ_^TI7?V:L2_596PDOHU&\3;
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M)&6A(6:C,?MS6O&\N\( ;(U +*NF1ET_6.M%\C./L=U)L\G#6:$]JB)(-&$
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M9X9GF^*9]!$9 ]7X P=/RUS0^&[915JOKB()= /\^C4$DVUFR4O/9HL(+KX
M%?G/T_X*"O0'1 :([XIX\M,"L7JN/S39J$3HHU:'W"_#Y1Z7 QOS_4,+YF\]
MO-P_2_&3:C:HOZ!@*D7;^D)\U8)L@J%])]TC($8PM*P=N_EOJQ),J# I!-W.
M?3&S!']WUAS4<4U\?B.S\$V RN?-OU7?E''?A:P\4J4]E?\;VD3=/H^4%8A!
M&(8[R:OF+T$=K"&63+J];(JW9N6G/14>V#!#D!-Z081Y@3'&-P[CT<9^1="P
MI%U@/\U1$_3539\('WGG1JJ"4<!(='"%X/V\@Y5U8_@WJHT*'3$5B#F!I9TJ
MB_>#24DFG_.U'AHJ7\>[O89"Z=^KB^<HFNPZ:QG&_-1@GJJS5(C^U8^)R+$/
M(RAHW]%.GIR50$$SVE<@<AS\(9!&,2NJ+QZ]>MF.1?7]?3OEVE(#"57#XK&*
M".- M22S&?:5'_QTP\7'2(5EEJDM./FZ=S.1'J#7L@L5:ZB:/6O =?-$V-Z\
MN2LH0VEVLLLQ!*'V-Q+C@XG$R#2*NA&^Y A!^?E^4QOJ!S6'63PGC[LDKQ&'
M4H-41>2=G593$N)RGO^(/S$[S\&N[U"'G<40$X!,DB7T(=\MLHY[3".5FU_9
M%:.S7OU4R6P)R-VKF1Q86./FW9Q\Q$7,F+9=A093HRA,16?;XKB-0"SI)6\/
M/X^G&E0P/[5_.#A(:G['QIR#FBJ;R@M-;78\[6I%:IXQZ^I:<;>6BHJT>X'K
M;R6H@4F\[520V"J0&]"IJM\"C"LZNH6KF0SOC-[%KT:)QVXH7A5'\)'_S??#
M#>7U;\9QMT\TL"7R,G2#KOCO;EOP]M3]U"YM<^#4E8LI3DU'3EST.B(NMM-)
MEGM \)6*(%_OCW+U9@EQ#? G:]AV#ZI]]R3V7X@<"0_YO2LM+]UXU_M3WZ,M
M@W<6Q+XY<J1YX^HF@CG0;)''+\/0DI#5[F7K$<L:K,HB;Q-0/BP3D'!6*\'J
M*$QMA3+NL%LRO^[O<>I^_W F_11XH0^A9Z'C<PP] +7#B?0];%5/O B;'->X
M V_%SUW,_\I38VP::+#A)\!1I5)6G5YP];=M;EW%VTR1M/.F@VJ/KQ]N'&&\
M/X6AS5 A#=V10G12 -=I?LG=]75UWVO\3O:5E)VM^UU.9J1MO-/O^I>T?M:'
M*?A;(+; U?%!5F;<1Q4.Z[$>9\8\:G (2PUFZ ;28AJ^>GOM?CZ3^HK1[N$\
MI+G3<(G,M%I#:"L*)H@<=?S1-<30.7N1*MX)^&V_P3YPJ%$.KP:%LQ<9(JQM
M0!&$9;SY4."^H0$CP3/77,V?&XI%B8Q[O/6/Q=>)(AL3C*+JC% &9 2&5DL%
M3U,I_@S;HN9%.)G72,3B'8I/)_M2%..J$HZ;US4D?Y8Y<OY";:V^Z0YY69W)
M^R3%?ZW>Z+E*IF4#'&-H<0UAJQ#,0H*NP+@1C<B"O7+C%%1;@'<%H[.#(^C$
MF-7&CW3;D'!/[L6X$I?Q[MN;/LEZX+%FI[?O4YW6BXDV$/KC>:/1%&848CQ]
MB$Y#CK=V" RXB@EHK?92&UJ *O?P=SN6X=#.Q/#I'U:JEI(9<H.UBY>-?K4$
M[KP_0P:M@A)W'.7GPUZ= 0@3]/$.7XL:V1(5(*?+7R5A2"&=@[LP4?WIP9\P
M/.E@TJV942MV/T>O&B8'U_&B_'>[H;@]V:CF+5CY5L68#!N9\@I^K4>0GS6Q
M#ZO1S46SE]!\:.5FBM /8E403X$K$.OFHO#_C!"$\.90?9D?^B X-<0(D&Q!
M;QRNCAD<?G+$/Z.J!C>]HG10M5:(\K&3X\XO)7L'3=C0^#&=I/%P1LWS::2X
MWR$S>[],W^"#GYY1MU:<*M64*;_P;,;QAK*UTL[G@@-X!SZ<=*^A'@AT^;EH
M;7\59!3^8&'['A+CXZU3,O+)8.EW=/.',*J8RCT5:Z6\O9KWL3#?;%8WTV"[
MT9',+.YYH-GR%T'I&T[R+#3*8 $,HU9LS-^:EGUW^'JFQNY?YG%6O7*C)\1<
M$,T.JAN.(Q!'?TQ;\13/"\2205G&2!UX&Y;[R,"I-41+9J0SKM-QT SYVL_5
M*:;\>8TH*J@LH*#V?BO^3>'28]&( BET.3@:AS\ZC9$8PY%;3%BO2@K]:AS<
M?3/3B3<JS4.#U$42G6<L' ?3HK0WF&^4QHK []H(;$"K+"#!XZ08=WDV-J:L
M^A$01]E168);(0V<HLRL)LQ^^6;8N\/30_J4]?7LBF(6+"J;*Z90;*U8#"W9
M?1M(C#,,(\%"=@O;*A9O7.3^[?"/E,\3YXE=RLLG;JHDWO=PH-S#'//Y-UMQ
M_F.#%@7BW=R->#_^JU]H!<(P4#$:;Y"@,4ULPLCVE4&BN ?OYBC#92V:H:NV
M0T5]*I>L5/;>'-I:9[XK&7V9_Q'V/!( GK/;PM,9P'C!Q =^4;,9_@N> SOJ
MPAKB@=[$-+(-&9M^-^8ASS#LUD.5X/=#*198W]M;3JM?;@V3J'A/&O%K@5+!
M>CJQ RLRB3>#R.""!6R4Q7C52<FVS!-&(Z&;MILH1@=?BRA_W;J35JR1? RI
MCS\"";-O"\36UQ[/0 #7E-!,KGS'\_O:L&V&,I^YJ3^^[,Z6!!>ML"(R.3X\
M>U"S[/:^Y"NW3HZ.J=X;_HUEI='_=0JE@G=+HS(_">\"WX99#XF 7^Q4?%W[
MVS"Q.TS9@N? 7=WK1;)9MNC/[=F?/O<<U)=Z$1"0&X<LOGLQ[97/7<^:N#S?
M 9=QEZ8GKJZN+17M&T_E.DC+(5Z_1""4$(C]=_]E85[ @)D&#*YO1@#:2PJ5
M-<F]N,YR]!IU_ AJ'S([:8%1BBP1>H3I2?#P"^>HFYNJ4CX-^<DB"G]1_27B
M8S?H *^H",(APE>R-."MO1A'WD[VL&[<#@E$%Q.(K<KHG;ZKE9<-3MM^6$/X
MN$E6%N4<4\;,_TZ?<Z^S1!#,>XN!YL!K,&Q5P!"ZR6 -$8.<$M6 ML#,=5H@
M185\%L47=?GEP<C:B-)/'0?P9.V>-80_ (XNV$568Z47&K=],>Q7PMG_-/GX
M_7D0NB2W>OY2MLGL],7TL3YD-RI]-O4NKZQ6(\KUSG^8BSP(-,-6I1$I1)A"
M<%P>T3OOF84C'PAVX8S:+^XX +DQZIY4W74G7_T4,&7_LO9IS]+)MLW:#4><
M]LKQ3>$W=Q4, Z +%=H?Q'3DHK[ALCBI<"]LC6(:;'QU:Y(BV"8H) 6+T_O\
M*T2J\_69FDBWK@"S#HFKP9M"=;SL/^G#DOBM%C.)'200JX9'=VA8CR#<GH^_
M"S5/;[L(('$I2RAIRR)GW)#;UVO1-M&U'Y-/6XG5BE><:?5_*B.//5#,U6]'
MRX/D1+PA0.M7Q06V.@_^<;/6#3ZJY5AI\\B_2^UTP[GVG=KJAU+$W^Z,BMR/
M%(9DF]806_%:'C1D]-2V+PU'<WUOA)EX/<J=&X3]PRHEQ'+KZ1*5F=2'B-O'
MD%G8FM!V)*3=SY.+X02R44Q#6C^DV3[:<I,MT<I5;0>D&C5X#E_TEB<W]U@Y
MF+UMO=9O./UTXRY+5>MM4?'\;;"S9IV%Q$#M9NR&Y8B+_@MVFR ;VX& H$ G
MF4M6WOYJ'[I:M;:V'+ [:AM<!8]',E"3T;K^J:Z3".T+QSM#ZU9Y]1[J XWH
M[F^N0=HT&TS"E-K@G?J%Y2-8*3_[21O-C-O3>_9>2S1\('4XM:%[=<X2@9-D
M3DZ3*=Z<1LAHVDZ$,(EY&]S9?.+KRPRK)/,LQL4LAG[IV"6W=[9[TYL"HE3'
M#Y.UBAF-&I!D/M#L _QC-P;#JD L&*SGR"<Q#N>^;"[^B143F+GBCPU=KPK^
M4N[YO(QDN,7WQ:56P[R>V^*[J+/[2\Q,!64.QW:HPN\[PG^\3(:T.IDHD,HY
M.F3X[(\6Z!4U,W_WZ=Z+IA\MP@H^-#P7FM&XU*^_U^SA?DGUCSW_82X75K04
M$L>6_Q*M"0>A]QK"TX[2V>R.X*[7\8F>4F)G%R4$KR%8;J=@*?^*/.2J:KFD
MF>:=A7^@=S6AY<_5_$RNQ?]Y&TB3#">;8X1/9)@4^&/D>$&@"&=W3!N58N?*
M=HK4$@Q7U0F^?-&:F+W$JDVCJ(UAZI]J1GV(_VTW ="U>'*2]"2>0E(S%;2W
M&_?F*-1#??3+1IR[&<V9#S]FM$4HFN-0L\._ I-,'LPS%?25>SHNK#S;EJ9.
M/OGSI>0G$L6-$P2'PUN@V;.J3)43R'^SAO &M@CZ *&S'SU+\)9?=D&/1.(:
M;!C% 5XNTV_C;?:.4$;V)$L_?Z1P\<2-2_L2R#;+DX=;K8;*EA/V?S8-=W.6
M4?7'V>^W5+GW^K7(,01"TB\S'J'-'L6"=CP%H ,+GCOJP1E:GTA+S, JWEG<
MZ*=/(?0W*D9-_XTV^*C:DIYG@:D2]!F\J_Z<?^A-$"=N@U*_>/PYE#9G?SQB
M"3,>-:W%LF%C:0%KB"2RSQIB[$O0 X%^;<.'Q,XF&=ZQH3\=]?%'AG,S6#4>
MW4E]M[JKZVR?FTECLP0Z7V&FAH:58>0KR$D@?H(,'E_H^@<<;=E"WFCT0)*E
M1K\8'IVY\JMQE$,\L$DXA(KJ->X(E4A;7;%$7,4;CN*O,(@Q)B)QC;L@Z09=
MTKS)[K*1.GK,5\9'$\N9)Z5]7H&[^-^^[]MB];VHAVN$VGAQ\K^%,<7U"M'
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M;0$>L%Z4#;KR-GHPZ%= N3*+E"(JK7'J54V*;J&<MM(WDOQS[F;!"+9*I .
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M_=-=*:/=M=2PFN)N??>=:F4PI^3@38.DZEG/E9II'W'T,=CRU/4B8IB@_H>
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M*BOD=H='.NJPB+7&M\<G9SROO(C<A@C#\&1B! X!7$-8# B!08+G.@O?B:I
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M&J]FNZ_?_][[/_><_SWG?_=[S[FO\\SAF/=YOOOW\WG>Y^6/\^> ;2?M'.P
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MCMU_7M,NKG7@'$/1Y_J@A)*V*46'N:G:?S3[[U,L_G^79O^S8O]5KTE 2D@
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MYW*X@18D9.8LGF F%>RXTMA<-]+]=N5Y"-Y0W(WB*WGBX,VMJ:LR4)6[NIQ
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M'J'0&&'5I]V<UQ\X#0>VX,^B[']/AA6^F+!_&:2&56K\6K6+V)BR:\=BW&M
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M@A63SIC=G1]2GS5_*G?67!*3'>87)?6FVW??Z3$_=#,<AFO?0[I"UX(DI\#
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M&ZBADM2A.^;!BB.)X79R5J<JB-])#(S7?3DD,P4.'/4K*<T'ZP3<*^YXQ11
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M$XJ[ _O-A@(,S,_<>(A\.UCM'KGX;^5@?E3P Y\ZD#"?R(-_85R"^X0I'FB
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MI/GS/Y=56CR[S$5R!(''P!\NI 7A\SP$(F5YNX0$[$[_8!;\/Y?$S4X!NJ:
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M1@+,PX(KUL)V?)\+HEE?@TV-SI8SC2-FE6UM[2\IQW\4$Y\SPQ _=O7^]N1
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M<00+X[L/K)>CT(GHI+IXS)QFQ^I%:O.1JTFWTIRQ.[DS=+;N=QY"BJ-'ZWH
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MH_T[I;V]+1M'<ELNQ'U##UOH8)0E?LY,_^QG5N/+AQT'\./\K./H6I!OS(C
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MVY"_&AI1.U=:*]8H'V:6+<CU^.5<'%WC=['5(=AOL+:'=IE]0)%Q'7D?""]
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MQ>CJ1-5\W*24U+]36H<4J)KGP^KF*F\L6;"7.[$P\X 5?$S!17AG/25F4]2
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MTN9J)TX=]9>LEMWFF@4]YENMPST8Y!%JR9UQHLQNV+XS"ZM(53'OW9JE6U#
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M6IE!@@]=?)KADYY<<0D6A#L!5]@+[@"*Z)S?6.QMI%=S+8!(91\H_NF:MG)
MQ78=I?I+6CRM.'WN]+5L3Q]UG?T/K?+>XLU!_B+T)@^J7&3+@A5T3 Q"FI<,
M\TZ.=,SL')T?9ML7D=&'&?N67*YW!&LA31KSM.Q3HW[<+2K6<J[C]F":JE:"
M66%@P'(GIM9F59I&V./F_\.Z4"CKGM-:][U[D<SAQ_F0"?/SB:V-KWR%'EK>
M2_X+9S[C_=TDAF@.]W9(O5^U\H>A29^I*XZ8.FX[QY!,L-"@(MVNO3R;;CMV
M]4%\76/FD4=IH]5N]T2.5/ESLC&!A$D"<QH\Y<\#;RY@W7NPNWT\Y..';Z'
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ME+]S0SY'A )IX#CI4*!XQ4\"^=XXSL=HV7G<,/K?F)U&U&#_?YV8@D MEN"
M^T#2,46VE#:MFRT7?G&0;81BF---5M2DA@F-A2R#%"%\F$J%E1LKZT.D4['>
M[=N3X3=VB'[86<W I$,!QP%E;CM%HAP3Z, O$B)"=\'][9U/CNII@;' U3?
M%^F(^/; 1%J+\K$)Z>! "UW-LP_K'Y9[?0A"HLZ 1_^C&EC$#M^""/U"'^;$
MXS5_MCC'6)FRC1AQE%2T45'@GV?D]+Q=%<*)8;I3MK?SA^:3;7T;6@Y.*3$C
M9^]FIF;_Q*N!V:SKR\I1.3'K&.H41G(RHJWV1.E2#OX0D!MQ]WNM_)IGL_UF
MG]17A@QI7GIC0;T!XLII)?AC0!WA) R5AXF$,+?@$T7,Q\-L>1HJ"2%B8A^"
M& N#B5Y;PDS>4DE-.RN8>VC#7:2=M,=>/0%-F[,1.<&"\6*Y)<.3ZML>T2;
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M9,.#D^Y5DU^&A3+(B!=3 KNA=>-8O#G[)#A.LX=Q]^A[ DUG4R[9H6UFU^7
M6)).Z/%D=\M7IFI!?^ZBKEZ]^6/'5[KUH4@HJ%^T@F%%@EAZ FE]"L,5#:;N
M#EM/48;%69RAPF3\NSWJ1EQG3XX&>6\8I(YGG5)141ELDNZ"AM@=S"N\6KWM
M''6!+>],WV +<VKAU"**5)LUF4)$).3KM U9[0"/25B-B:Q?MDMT[;_?Y"^)
MTPO_LV']YEVXM&!4L6'RWZYUKM@V1C=7*=YAB@>2J+/86'%&-%P")],-[)V!
M2D!W_HV!UF/:C]8WXR-%>+R#99,W_S=!<PR_.8*A/E6#($!-"P1@5[7Z;J3"
M&W0W5LF[.Z:ZE$N2K+<K#IJ-,/M1*>9U6[#2.@1AB99MXS1QMZ/W#<%]UU-Y
M!)D2S]6,F"4INRN?C[8 PI/0^D*Q])O;13(Y/]HF+5\\4?>U2:R^97MQMPZD
M@>7)BQT7X('KB3@(X99D*KP:FUB/$PV@U&-3?RVK^IYC[,K9P7EJ%UZ4DZG4
MUSW_O&)^>N[3D-U>4OWAM0J4,EC%%9/DQ1(RYP/<=]5H5G%UL01]!PQG3'6-
M@$:=RM"D-LG"Q1"_?^7/!DP*5V,GNN+VSJ16B#^[^#"U[G!]U,)J DN'.XS9
MP[[)D@:GB!1(?=X>MA'XQI,.2_HG%%MQK3 G[NTQS\*..XI^T:-[0IK3T$_U
M/@E-;)OE;V#D1_./'/IATK8@M3DI7,D(%9;G!3"0=<(%S.EJ@I+O-6Y!)LGN
M]^JZ_JCX9BL'&15/2H4?I07G0JRV<[_!52WX A+/0!9+!WS9#?<'A&/PRA&7
MKP)=L9P7 ;A;;6TRG/<(R[VR=H0 =JWYP=D?V]^ SJQK:-]1.+46MP?N U5"
MGW "D51LK(<:0PC[%O\B**9KC7[MS)?YT,0+M&SAWK5>PXWB*DO.FV@E[A2B
MIILM[]F!:!I?F6)I>;!O _Q^0<=0"1:(UV!X!U/Y=L6;@%ST5^2:/,KK=/Z,
MK9N_V.1.E\;!4JT4IC@G%XZR1W'%4A@#S %. \%W59LXHPR^ 9I.#QM+0,\S
MKK]_WW*?J%GF7V=AH)49AOV3V:OI$OZE1[;E]:UMFS9$+'A@(9% ?3TC-\H_
MI*&,(:*CU;A]3BWY=1@HR2%VS(Y64EG_4D0[4^5!12#K?/VX[,"/)%>(9ZKF
M 4?!YX@V##45U\27S:6^WH+4/ '?,-0V27_P^@ NU00A#%:Y $_;[;6=VZHS
MCA/J;M@>FCZE);M3M?G)ZM]@Q'YN[Q:D#LIO5"18#>A35E!T**@5C679@KK'
MQU _0%_&Y?8F+A1[L67DMH'7A_2!JTW?R <<(U++WWO[I%:.NC_NX8APD@<Z
M K&/@ ""/,:K0ICZK"ZJ9+H?1N((N-01SMDV"2;;%=6FJ4?FR5^+V:X8-ST5
M<IQ/LXC]& G\H0@<5;L=)P.:,=-'+4S>PKHE11?K0(]Q4DO4%R-$?S&F8,G'
MG^Y_^MF<]TV).0*CS G+EN.Q>;9<'W,7B&0=0\-X(93WR;2W@W$,,V9*+="Y
MGH1&4I%JPS/,K@WR3=7"#@6GXAKBGN):XR<B"]X[!6.3F56@OB2_GH19R\FS
MV$%UF-R"?*),_:ODS6-[M,:W54S]*A*=9]H+](18+;_P=)IXM>)XO>5@5J<V
M6UZ7Z0XNLZS9KIQL"WO EW>?*5R"X,?1[K0RP;$NC%%8YG;Q,S2MYBF+8A_2
M,:R!^L8>H$CHH441CV 7\6L@#F"\OI_K(&-7XR(9"W1"%SPQ7Q6 MQ/ \VB-
MF^\66Q2:BRU^>MGJ7?&12!X6F6Y4%MSQW,@WDU.%YB'6'29\>5OT(6!A=9+A
MP!53*4;? PRRZ%$&W;/A,>Q+5%5=^R0]5*5GPP/.03>=S'.^R?X7]79^3=7:
MD305^ZN;K2#)U (+6'>XO:[1CP !Q$CH>A)B5UM4 <BBU;?T2?L:U+VW'9 S
M.O3#R7;NA4#HSEX'R/B7+4C#0AR!^IX"N.#BK50X<5:Z&*+%.EX0E+W*,,W!
M,)JZ\O<SN-DEG?O2TGK=&W&%9SPU>^YLVHO)YXU*GX1\$IJ&F*.F0F8I;#G-
M#MY3, E;D&K%E1>L,XO<[0 O5 AZ@ D=+864Q^5A1^M?:'R;T2QV+1]:RYQ[
MVWT[HT?C$7I3UT;C>-'7-OBL)*B+(*V#!X3X^L28>D[;7H8!CHZ)-Z5(_\*F
M<?<"5J]FU('WJ3EU+M<G3P7*^?N'!^N3/Y7H]3KMGO.9F#LH^:[-FZ7/#N4%
MC>9\,4[UK_7MZR#J7?17Y9RX!DEIB0O?(H_5M[1/VR"9(3IY=5+Z\WH^AH/5
M%I?@/*_A?:G4CSQFU)@)JL!WCC!M,#N:_N=SR9R%_SJ7?'P/8D62D<-L 6&\
MZ=,%^6NWG9P2C-\R-N5?=!XP8,_#AZQN97RL?]'2/::1ATEV?]I@_>GD(/MX
M&[(*9"%>#!=^731W[ 3R8+=&ZM_;LQIN>V3,D_\JDG"U"]UNDJ#!0!(\J(P@
M$ 0B,:Q#D^#9D0X<^5[1ES'9ZV8.@<Q@&%E(PYQ-VHVM1DX[#V(:M-L'9-@A
MG!<\8B$+^"9CJG]C=X.RSH._*E!Z\+JUVRN%,;JI55\LFC(0Z=$>.@(;VLQ2
MONC"$B^H;T$>L\_-5@GSOV"N&F.@<T#TVK1'$6G22L6O%D1Y-#<YKKY[7/UH
M9KKW2GNM>.92A\*-$S=_X=ARGOPRL,L3O!MY+NR]3F8Q=0C5P)\4*U/T>4"U
MS(]<\4K1J4GA7^>K$;O"+R.GYX^0$0:FN>JUI24ZO?:1"!)_LHDNQ@[@OGT+
M;)D<F@-;YMG I_P##:!S))7C2;?LQOZZ]'I)G*G8E,N=U,@9R&?^#4?*Z/GO
M^6/E57NPP'?(2@]#A&,"JV3Y:F$W"9/CIT&[!;"/NMX)B[]/Z$!"6?>)F%J]
M^N>J)J+HL5=G@G\8"@3!-.& \&LA[O#,7IX1GF*(AEP]MA2X!6&8\Z!H&".!
MN 61QA_^.2, 9E$M$33FB\+)R<K281M5YO.QDH7C^I-'DN:>X)T?-)ET1@_!
M(?  ![[L>^\8&4Z"3HUT> @2> S4VRWOLO4HSQ']P@<*%E.J;,07156_UR<9
M.QPR$XH\=4&I45AD^_@H%'#A)=#PV:)59Z" ^B<>OYV78>__:2?48V+9EZM.
M<(H" YG7]W?1G5N:^SMJ$B;*)9_%O0MBEXYV<<E;D.U;$*1#'!2X@A' $,]B
MO*&3F939_3AA8LHZ#T@!5YO25D)U66>B[%"TC\EN&]5G"VM37Y)VRDY?%*KJ
MA&,I#3P^#!X@K#QB*<VPHUH8"H]F4=O!'JZ6AP>(LH]!R2+\6T)EW+X3LB L
M39YC= ?=2ETC.KX6^[>_CTGEI)A DQ# >^,M")E%"^4:<L>1NESI(VA,D6D1
M\_>3KC&<MVPD/N+.Q>ZF.S>L#QLBCJ'/@SM85]CW_L,KNPF-M\M8< =:A231
M0X"1C#Y7T\(PS0O1CH?]UC\FLKHRT6F*DLRMC#_GG2$TG;E-")]2R^'%F5O]
MYG1GMD$4G'D"O"Z<BFF8NLISXUHHQ+^OA//QW6$3"OFQ%2K?/>?P[6F7K%>O
M!H7YY16V"(F?A'HL6UZ%.<9IB-;W9P3,& 'AG7^CE4 #.D<PC<:1M7=.Z:L7
MYMA^^'N]=S;8"=[%(EB'K2?@!1D.2:%P)3"+V.+-K:*EE%2BCY9>G^C>U_5"
M;] .I4O4E!A2C+^F>>O=;6?U.6402O==:6;=PQ#-^?IIB90F8;;L,C7]!2.%
M]J=KO=8#?16TA"6K#S78PUT;K4^4+C8I(CZ$95PCN[C$A]\5LB9!*Z._4AJ@
M;+E-9CPOD+/@RCP7.X;DBJ-U:UA7\+!QB\A9EKZ-Z[>!26^W!X'BEA8M[6?Z
MCJ_KK3>\O;;]X<1G82SO!FG"W 8&A6,=;<5RM$UZ^$@4KQ9QBGF>9_[/W"Y"
MH_ GY*YQTLP!L&!V>1V"/FN_5_X1VO[]=QL1F];3GU[0?'UE#NEG)VC_L4OF
MT80$.+4<7@U;#6-= HMH16R9=!:]*AX/0_LT,\SB+4ZA&%6D7#V,UT'/D\#T
M^4T#VB;Z<_DQ^?[[<")E(H>YR:GC60.[C3>,$QCJ^V@U(.&AL4,L,Z>(IDB$
MB03VE]OY%W]_G8ZTN4R8R+ _6/J^\S'RRZ57^[LW'UH-@R4,<2I\I0*8ZB34
M2W:J(DX"F(30GU G1GBB;YRZLTX*]*6NSG?C0J<CW]!?%V[I:)6.$S& =948
M^@R0TXX@YW#%KFNW+^,$(\)GJU*KV$A@X%,.\ZW2V^&*"I]# ;(GCR2[#<\$
MZBS)NR@X7W;GV;Z(!F?+9_UGB31A\GH$@2N:%,)XR?0'?<,D_CQD"Q>Q?0%N
MG"<][X:-BL1EIW/-N6Y/D\A7TH?HIU6VF6>_D^&,LU30@9QJN%^:>.<QQ"J.
M%_(VLJA!"L%3;C\;G>&ROZID*EMW]AWZ &7 (&Z),5V'MB"8KW^C::\E\^#4
M:<QC*Z$Q7GI*RM^!ZU+>5]D$[[Q)5_6D[_GW^.3E*O>9I? G7\>/;D%<7073
M9?/+=LOA@*"<Q(8^'+AOM(AD[WPUGSE.6^C R8*(,\W-60\:TO %6AD&L]]@
MKZ[</_CP",3Y);>/J\A[/QZ,)^Z/WAX1RQ6= A29(JC4%H64BH *0)N>783]
MU:<B?MWJW[S;\X+1U;5WUX96"_-MHAZ6%\R=A.R*;N?=?X%+<L8!%P@3<"*<
MEU,2V\[M:J);'M/-L^E2'FWV5%VKB@S>US^B<4-\;UN^HZ'8M;V.Q[62(7_=
MN+O.@6$,W\X6YY6:$E"1&?>-?< 7MNI)73TH83I 8BK:"958C$.]QP2F3Z\-
MDU?N5,O<R.JWNF4ZVB7,5@RD^:ZJ D9<D0'Z1W[-@$TY.H@ARW8""N>QI8$S
MBL/USDE"95Z:M:+OB3O/G$_LGS^<\^6=KQCD7R!7W)"EC4;S*VQ\*9  7)UV
M_*_O#[IPHGA3,)!ND$6+<G9R$_E-6>GQAGD9N,O%Y?EHF;,),.W<#1RHD\/#
M*SJ2;+DRKFA!!?I(*^?1;UB"!SR%CDDP"+)0+&';##8H?ARI,!$_5[+NM#0S
MY_:V-"FG-UP&JD.[\$-0((/3C+;AP8<+_ H%M!70S993H?-<3L-*W;\1;SZD
MAS^(YJ6GN*BB23]-^V\PS89,?0.OR^&RQS?5T^V\PK-4YN#W39<PU#("X(B2
M99MPZMMV\+QK 9!<S:'B)LFJX419<( NW.6@)*Z8V6VO"/-'%OG74*H; WM^
MI-\Z%V_8E7\KMGZ\G#?Q(1AO2CJN$<:6K>M ;,?X0@4P[3;T,A[]O[LQ?I8[
MTE!'D:BL\0\VCVQR[-X])7=A0D]TZJ&HNIH 5^P42PH=V<AI:9/@O8TEYSG/
MF@AQM"]^J$T@F(I*)(BTV4?Z^QM4%9A,>;A]7]R<.="4OJ8TV2/C>?^F7&HN
M9!,W\9(K9E0.BG/%'*C8"5=)\,#X8TS %D0 [0Y\K0FA$63\A_V%W8'TJO=N
MG$JWP.[AQD[]ALZ6WJ'Z1"@ZJ/1>UU19]!<//;ZF&H9H@_&#D3&T"AZOD,'$
MX23QLNCH,;8)#7F9A)#\Q==HT^F-=(W,]#MI@T3NMMD4^]C1'WKJK,(AE9^(
M28$NA!)>'8T>J32!@GN_)Q E=TY,3/>$S6Y!I)9Y1&XX?:[CDOXJTIABZ@B-
ME-"U35:\0[I-[V;+X/[#(DPC-IE%8W@37@Y7F*+#5RWID@K@8<2JN1MN555M
M7M<[9EGJ[+QJEYF:^QNMW3^LST B,6RYUEG3#,"!ON($5R%0\0PT9,1K2']7
M"E5"N/V8'OE5YD%DUL7F2/J'YLRC7A(-\IJI.]05CO(^.J(:AEJ(D\8$\O?+
MU2RTZ5787&BG*HI:V6KY+);Q@$066QP$R^QS>RKUJKSJR)KQ-->CCJ>O2L\?
M@EC4W9Q$FW(^P&\,@ >J5@58UA':7-'92,:F-4@+*Z" Y[JXRHQ[&3>+?UJ/
M=2(1MJW*J37UIK2'WIF'+ZH[GC+45=V"@-J2*Q]9H6PE1M%J"6.920?#"GZZ
M)G2R6/JH$RC)Y6K$M7K#13,=YM!3C)E"ZVPCS#A8Z;SUF>L5Q]7X)R071N#4
M>GZQ#0S41CPF!%6$<\7BS$@4^8!<) UP2BE &P]YUWZ;(2_Y.:V[P)";+WXD
MY?0UN<PFRZ<UMJ7^G6)@V8I8NND+WK-< .AJSOY'-(0$&\%8P+X!O=49J@-9
MKW]Z:"DZ*_QQ3>M3^*LWFSP<6*Z@<>*,C[JAU76^ C_G/8%:3(%@J$^@.[E0
MM!+_P'H/(YER97!]S4H![+-AS+\LFB3K_1G77B%WF&7:&%N+QVK(G/FX[W&7
M@&99QO(Q"EN*1/]=Q98FT 96"FA;$+4(U"60 HS3]0F=YRP=7!_VO5W*UW5K
M32DI7U"Y.U:>XS@E=% @R,8;D@U1@_//Y:+HL G%]G_057L:"H2MD];)P<84
MJ<4A] 7PA+&5<MQOI.G\_!$#@U"OD>!@E GAQ7SYM0PQ3:,Y#2=6YC*S )S'
M 1YNL(DNF"JFLX[?>KP+1:MY[YI'GF#HU"IB_#;P0[QQ+?CFS$<B.NO"^STN
MT>")/ IHD[QOF*W(7Z*F^-V')7HWQTL\<!YE(VB&KQ>77/2:# >D(M<RK*]Y
MNIQJ$L_H415>'05\>;27ES%V' 4QO%\X)QONLQA]:+&&K?411#*$/Y&=$Y'&
MWR^,]?R6+IY"N#9,O;M\"Y,]<N=&J2%)X?BN[BYX_7CW',_.<WZ$&H\,AFHY
M5VT)4=OY)WENZ+)M_=T6\O+;K^9#1AT^O>WW_GKX/KW_5#OW+Y0KTL Z'#VI
MW-2-("=<'N0EQ4*/@\/E;$/6]66GF<,C-T$4K>=RE[-4Q<OIZQ<VKN74!3[N
M"'KVWOCXX4=NN4S49 &5QUE\Z12VPML!KI@&RY[[18''DP7,5A;":?JR-BE=
MILK9\]BC8S>;TV= TGZ/^8O:KYY?HJ8;R?DX/3G$2Q,^#O%0X"(6U/ZSFLWH
M)N&E. EPFA_;"/S.&';8<XU]:I"[S_]8R$^I)5&4ZK=P)[/*K'-SD=[=66T?
M'!4S=T#""#S\L_J#8=W-[.6TA5:E<X_F7 +#69:=M(_GVO^=5[Y:[E XT4-;
M;!#_?4TS3>M5:X=+Y-<?#F)7@CU0K#W\"-G-,[DF!V>,F&KJI ".' ?J6_:)
M1J3O)ZB$A3"P;O/-^+OXN8R7*[B@9US%EQ<S;1MM__IU#SQJ>OO/887%$D9?
M^LCAI6>4A-ML]R/O$;QJ]&!&!,H>P%<(E05J+CTS!.\CK3C/CLQ%JNML9*O=
MU?#LC=\SGLOMSK?DS5@]OZL4W/>[(E.&X<"6-7,$)PB2%5_3J)))T3O M()%
M\NW60LWJ>I:7\T8Y&5W3X6C6^]GJ?-IW%X%?GL1&M7W#;1J%_M%&#$'7QAKD
M>Z)"12G)1W]XXX?G);T^*:W3JJ1#QVTO!F<E#Y=3A"A@SE4@/KL$'#F>8C=F
M$#JQ;[3^ VQ'^[7I^@#O.&^(Z,FCWKL@TT)WC%RO_#=ESR-YYK=A76*+<E+P
M.P)Q]4VK^K,XT+I-ED;@&049B)C,<<;YL,Y\<ZKFSH\=\(D:<9!!%P>W:HN)
M0M0>G4%G%_&W\C#4%_^P7?;FU!8T)E_I=T5DO:5DIUFTW#<:L%94(JR#1/X.
M;U((,?WMO;/V^42JKNS#*',F?RTUCMM%J=%.:H/1H.2BV>R$6%B;[\VRF0B_
M "=%!_DY5R]1RX7UMTFS:1G[L &VO1MUI:>U[BH\M,Q/_DMJ1P!.\ G/#D+M
M>M(6)*C?E]ZP'A>M&F%S':GI,FZ!I$6=LLE:/:FS[TK\V)+@!]S]Z<YJ&Q6C
MS*LG#AXO8AE@B C"C77R)OT+?!M>@>TPRIM*Y9G%_F)_M=V,JM@&?:%UI[J+
M+@,^3<!I@Z<'ZZ25?,3*.T_&^ DLMN@N#)"7N6))+*7HCFB+(2L9-@I,*K&;
MA4E-FJQE4RFBH,<6Q'W4J\[Q:F4NN5W)0^=NN<"'BYV[#58KTF"3(5PQ.Y8L
ME^QA\HVK&OT%LV<5[5SAUR+?6%,V,>6O6*UB?FTN(NN+/_6,W>F,S]AM5J'G
MX[Q.:\IM6S-V_NS+%:_@A>ENPECH@$2$T>S7 GK4Y<MCWB/P6K8)%7EKC=YE
MNT;NGVL]T]#_;F]HJ$Q_#=3SL.)5+3\V+SK%#$83H77AG:H8ZA^LA?^L. ?5
M[E@>#5-3 #TK \;(2H9ZI%4STV=8,9S^:*+SK6US/&!8F;S!$68.<W+0SBSM
M[]SI:#F05!1 $"M'PR+I*E6*BW?Z0^3NA[V[:Q>BG:ULW$F7ME66RO?S\CKP
M 5DE.(JA$BC V>O:5X?4<YA9'W)LQYU(O8S':CM'7YZJS63J_&B*7]N"K.#/
MO"O<=Y+1VSN8>;K]<#E$>#+4F<?/^%L931C GL?IE3$TVP@*\V$F>0TN5?DH
MBF[;9EC<3V.I7FFDU#B4:0E]/7H5[RSD;GU"1N[@I_N^JW%\71I*=7S"FZ4M
M2#VN(]*X#"N'L,R)J[>$6;=^^VWI0Y,S*FS(>^78;S#8UQRS:K_<'/_CLW#M
M)0\H"XHAGH;[P*<RMR =QR0_??3L2"J/<%2Q:SOU)J*.J)R?%.DKW_/TA,:Y
MY8BVSA#!U[O[ME4O*"G]$?O?=CK]O[D.XA+K=:%R$=%;$)+K^RU(78#I7?)T
M)#)^8^YD6NP$-3_@A]RV!6@M?*4!:&4>X+QJTV?IL^6OGXY $)F.KC]GG=H4
M%=7<^K6ZT8^<@[]KACSJTAWZ^=]HP_&_ND ![J[T+<A3.?3=?Z#O%L0QZB!^
M"U*5@J'2"(\0N^'^"%!SH9,2@]MFI;J4K\?PJ9^!<GL'C0-#]/O'L^@2II'W
MU)<;==Z%_"RVAP0C@&LCK/TXT(S0C9L0/L6#].AHA44,4,X=^/'7"O7/C F?
M#&:[L=-:([L>^+1-,9\":H4,61Y7Y?E]R2#&[Z-(P+$?3;'HP&(P9NIJR@,)
MGQ&2,G(PFX3ILUW7N+;-(B%5;?37/)]:\N4]?/TI2L:4M ,L*WN3KI0JT^8W
MX*WUSONO9E1'3/;?G5^BV#Z(]19?][E1)G5&6^,$46V9(<S#KO(,A]EN$H7L
MVYTOQ,*D<>7WE^.W\ZAG_=I;;I]R7NT40G+_42<E]N=+SG\^LPR?DN_Z"= Q
MH,$A7B:FE<-OQC(2>.X;=W,+(B&%H6EQA[HG,(U6'9@:-H>B_6\=KO*A:X61
MBV(K3K%$V Z<%.&8-ASH2@#&9G@X\O&IE0D6BGE!BSNVN!F5A9I$\Q[:G=.:
MS(IEIG-RHP6CQQ$B88B'A/H<DJI9YXS,6(;UFX* Q*EK3]?LI ?+.O=6[_!*
MR_ZV42X1\6>%OX@<PXF%>\%2I-$1X%6@[@J>49C_BAR=1<<H@23'\<I?9::.
M[\6M"?F7 @K/'3",NU79:^=X!A)AL[(M^/4B ?! 36'.@P5ZHK.M''.BHIJX
M8H=H$="^Z.W%4HL\5-']=/]D]\NZ\"^Z^9Q')@ZQ+4WL/?XL;W?TGI<.V;*?
M/.13.C(7O<_KE[W=T:+D\/2SR-4L0FZMT-\FYV!>_D:"1P$C.K8+*DY!W^>W
M_&);@W_\W_N)D;4[4'''IA5:\E_>'?FB->(M':#@?$OJS;Z=UVG[:9\NGII/
M8$LG,!7 %  UB^JD3$EV4VJ[7@*ZUHRNO+<\_(,E+IM/\&"BOO@%NW/N'A];
MC7WFER)3O[2^&&U:U^O/W':9*_$"@#YF&['$(\8[R?L34$*%= >L&NS#6)6C
M^KZ6B :AII0'81J>:<=5A5RP;7?1:IS7!&HA%'#$)!&4&["3"<Q",!A0I%':
M42FYW0^#7N-!WIR+FC:4?E]\;Q@2%;XP,T5"[DG;_W/(^8Y[_%<S,S*A#K72
M"N@R3X.19NVXR=E/% #KIZC\?:W*)(&9-SJS/-6<.BZSWOS,1F7NUM0II#OM
M^![G!'YG]9C]&.)1JR/LP'&N9<04M:M$J('^-Q.E3([ =/UKS"F*R#RSFX+Q
M]0_9HZ@UMSZ-:^NAM 9_%EY88,L6(++<^7W5"-0WU:<8*@Z,V[B;LU4I@+_:
MWJ'Z=]4UW_1?GHB_&8(,5&EQ)>J>W=32^5*3="_^QN&H3;H9"0;YB0#\$X'\
M;)KY[M!9%G3Q7YWKOI;'@0M#-/R#3$.L8>7SKVY5S\/#JFKQ:KQ!;D%NK3^F
M;+?:%_T%)X$7=O7#"X"MI8'*"5BVR<W2F7?*C_]5M$PA(GV_?O?)/)F8HEIW
M.F.'FFMA*)FPDL.R6J;4%K$-]U=0)<UH"6P-PP@;KC1VU:UA"Y)D?*\OX!G!
M7R8E7>.,@]&7S5V'W?/]!&C0*1M:T<-?DJ")XQ_B,8>XH#?#*P2?/*&-F7[U
MZREW&\?"K:(-O\2C>Q'KBON2M+*N_^G"3CS@\=A5,]K 9!9SA).%\9>0)!*4
MK>381P0<L%VYTJ.A%;?[KHQ4%#0G+QF'Y<J<1SLHN,T'IU*KQM2.<;+@ONM)
MF%HVI0:;UK:-28EO4E.()65%H%A.:Y9D+\-WEXC,Q!]NCQZG"3'V;Z8^T\KR
MB&398H@'>;;!DM]2B$5T+.G[;?$M2$*+^A!;J0+T[59NS(@JG%@]<TB/&6[8
MEGS:'V?<_#?DU>9QM3#6=BX%T^#; 2/_Z:8 #M"I<>IX3"@\66T'$)>3K,Z
MM7-NT9=/C/UJ?='VI$>5G))BIW"2T/JDYH8+[63,%L37.3F:+^KJX# )8\JE
M>'S@O,(KGRM:PA_,/]IVF8[T=6L;#4->GQ6T8:;T37J_&-UF?OG.F1Z-$UJX
MP/_'1ZW___7_^I+<FOP?4$L#!!0    ( '6"5%/Z,)SRZLL  /\) 0 4
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MH" EMDGTJIC(%D!4041,0438!2!A&<7_(9X(\+]?(J)BZ\0E)&$Q9.$'&C;
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MOTC_T#L!? WGA'/O@/,<Y&$X'"Z%HME'J1,XGW!2!JW.D.4Z@Y7_3,/<(6[
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M9J(;D#V(#*(B?S<BS6X_;_]D;QFFW"_,XT(Z@SID2O+,8M'36N(/&%_(NF4
M+GIZS"/YBFKN@JH&'&B([/@J:&K971E*5#&VO)%EV[T#GR3Q!UOGA\%%7-@M
M-_DU?\3HBE>??N&!KEP7 "[I5(,A&=XS&#?U[4S80J#+&\ULCN(X8#1_>O^M
M.#:!)_-,G:6,(^R'AW*6G7/@@C"":B"J\Q=^10C B;#1L;T_F53C5\.+>5_Y
M>"71DI9:Q>#9WBV5PC&SRB9.>_;U]^\(&9#<':H<A47"LX1>TM;L1E/(3$UZ
MCL*/F],__N3T^)X9@3[0Q1SM+$+]=:PEG]7F2BU;+:8FF/)].:H8,6)[G8Y1
M^'P?08RW?XJD=<JW8D<;Z%9ZMX&UX\.4&@L;6E-W;&=.W<S<[ON( 02H2^4K
M\WSAJ'M&$.<4]""4X]\O$4R&^1LY!BOM?W)2(NTP@HI-)2,C@U?T0E%O(VJ2
M?-7?Q:Z7\_H<<SKNN)T3?:B*)"]_]?7/ ^@=,)T(P]@9^D[[Q0305, EWM;X
MCR5[!;?1,T5P'9(S(4D_VN:8;F?.\R*XD/8W*:3P](>J,EU/B6]*^FJ9>'3#
M_O'7/>'/1M$S::0:ASPXG\23N,E#RQ5@V^YQPA9<FA-GE6 /KVUI6?P]2QI+
MB8"SFYIV.RJS>N55)F<IQR(![1WVA,20E_1H;GH^&-WL_)19NKC@3WGI$1LS
M]_6\]%:\G=8E<@]M<F?/-+Q8$J]#,'@=[5?G.W/R*Q[,"P%%R @DX!_YL07M
M=:U+^H/?LG_%ANJV4W*/Z9^]U)[Y1D8PX)?#.QW?B:T5 GPE!)<AR(9LXSM(
M<IO!J&=XZNQ9-((?BGN /75%9_/ ;UFG&X\93KJRJ8YI>UZO1GS9J?@Z>1]J
MCDUF-=.Q*L3V_78>L))\"AOU0+6&CDGAZNQXP9']O+FQ1+;B"<531?*#]I%?
M>IR,KRT87B1^:3\L,@6/@Z27D,GU ?2XX!F7A>S(Z#X[&L4^9GVY<=?VF-5X
MIX,OOL9$+F0;,8C@Y1RF)H<'K3<$/\W@,JEUDBF$@Z6^?+G!%J\H__)]+*W"
M3],56S[3M'8)F$F)5V/=*2P<3Y6O(;@/KRNJ$)!"!V'4//V\^;L'T6=M2X<)
MR-*?.[U]PB8BJFO/)!TM?A!]J^K@JJ*E?P*Q[AGJ2]!QD3\/'H4W&:95ICRF
M"X(&H;&7KA>"S]<^\&_7O'WKUK&P-E-V27+Y_M+Y>,.ARE^_:K@^X15CL[GG
M_I9_UJ4ZEVVT%,N-%11#BL1V.^(,-9]:-\I,IP>R<9U4>/'4)=/2[%QF?"T8
M&&9[Y=C//CD/SH%WAXY?D3NS^?R+H%UOE;"6/Y$BQ."%<5L&LGMA [Q^8.XX
MDX?=$&_43^;;CUCE"Q[7^VKSW1YK2W@Y>]_KLA&-T]'$[RCQ[ET45P?$[R,^
M9X!+D(PFS$)V@C2>+C1,E: &P)3G+=>< E)GS3)']OS^<"LTFK,=N=XQS+(9
M_TO?36\DZM&OY-)S^4?5V3:JZG^07.]/*/%Y=!TV 4<-T@ZB'0.C8%O&%R.O
M5;,BGQ0CCSB?=<:67 P\L^6$Y'M4T'[:4A!U#URKEV@('K1@X;F?"E);]O*V
M\UT^\K5GWV9),@RYR#2^TX/B(V\^FN9FV=P[IRU7=%_Q(;\S? ]E5S<0Y\6S
MAH9)[!.8=.3&2SD2$,R:V4<BD'124N3(S,]IJP;!_67691>[QRTY&U2/C74M
M7<FMO'!^]G3>E=?'$4--U>32[^Z*84W?RG#!X5(2/D4O1W9]5+J6?P;X<@T<
M?8>L);630:/41&C'Q#RU88%5QN[MF99VWCVRL(]-[50;_/7E[R=;HE_L?''2
M_4OFQ5WD+.J9'-"0Q/S$.P?[P!FF\/(QW.?L6#QM'XR9/>%;+V'6_1RMD]^B
MV6?YR8+6=R[[Z=[>?-ULFYLVM]N"WFU4_R@Y']'POO5K2\SEO-*:(]<8^=9R
MU:5G-SBN4_@0G@V.<X+>TLLZ%C:"%0>H0Y&_J;+@$2'@><.IY(MJ@'C=FY(S
M1I)21\H-LQ$25#,A<):<X;<=7CM1T#O8+J[D)"$ X!80*4(@V)?H]@FU(73/
MG;?3AJG=TQDXQ9&=YD'6'S^(73\3M93K=#D@_!61[8 ;6UR!I$9(]>][2 0A
MH&VUD'@<_T<(S#;/C[I4OZV>"C6 X,G[[IEXE>YHD>>]W&2LKGKFB]@"#300
M BQ;!FT2S54!L;P3^(5]0_55 ;THE:03PY:L34[<\"M:SXV0=]_Q\)"!X71K
MTE$X"T97-!?):_K5-I>\<2FX.>FKER,6M?CB^)$2A*2V$0?)(++$.&YT(E_S
M/4^!+P?ZM9DK$$(X9BG\S8P&,,["OMKO^Z#LO>IZ <I)+RN@Z:6"WG;G\LW%
M3IT:N&ZSA!$A(%L-(?DG89N<@!TD1PPA)F)5^+(,@44L3M'JSG55[P^9AO;#
MEE/'>BO^6KG@(L&L>]3V&WMO?\ ^)&6BK>$1&-_^VS?6O;&V(4<G\/WG>>7P
MO+5PF<M8[7C+G5JK %2X6-#P.FKC +;C!L^ZEZ-C$B?W9'6AR&\/[E8QY)KT
M9A7ZQ:)U9QM]0Z<11=O@)=>.0<\T(17;1*"QPFT<CT[,^#P]_EH4'9&JD?4N
MR;GUT^_H*T\^!2=[RJ;KIET!4"?DRS9NM%MA1O ,^9:"+.+,5YC4Z((F%V+"
M9WX0 _S+05S'4ICB9Q\P;"/!-5+O><.25Z%1U![,Q9K@,$V*C,KE<D!P\K][
MXPT.:]F5M8VW5V3P,+J62+=B1Y;!P!DFR.OG(2=-]"E++54_OIU;LCGWN;DF
MJW-W=4\&L$@<<^/"2SQENR"G31MZ@V3_3>R 1Y)"I)@L$UDPA^ZOB6M^L^Y*
MFV.1V9V_!5.L'#>_ -X58OMN.Q?>48(_6XT5P[.*_TA!2\=;\:TH334?6_R:
MY*Y699<]_KR$NE?N=9B3/A.0[[Z^2M-VAWCCG3^%&<"J)/<8[.LP@A>;R(J*
MX<5#GVD->D0UU+9.>BI[+BGO,+LPI- PV9*21^@+#3.X5W+%Q[8L9JKAW@X'
M>3C?/N]G[A0"<E@&,0N"Z^IDN.R2-N.;8K.\*5T(0YX2DS@F!"(.NS%W+WWE
M.?0;HB[K3C7_,MV]\F<K0,Z\9 8:&+)TV8[<%QP:2XR'C*>1V(D@FE&0'<$_
MR9&D-[YDUPZ=REX$C4,OC5"JHN0:2ZXZ[%\].^:S2?N^Q_BG8K-,.WV)EC;5
MHNX]%\,B+0JCL Z&_ID<G1B=W3_VZ>CR+*!.-/L#L=&0)<OS% (= ] X+"6G
M G]UA2<&BR<$QHCC5V.]F$O\%1ZFJ#F>\*(Q(%*SZ@1H".??U8]MJA"\)NHI
M+'-&CG8[PW<G-QNSWKX<1,WO4[!_W/[XQ_'0P0-+&__VK>IX[0G],DGZNKK4
MU);Q, $E!KK!(S3#QDV#>B#UO!DSYEKRL!FL-[O>N.)F<YUOSC&D6\9O&K;;
MMJ[6,F5BXC=NDXVYD:VRUS!+_51) S?XE9D(WQ$,9"<=8MMT+V2.DC;P7?PC
M9[TYQ=Q;XM<+2UFZ+_.8([-OKCG,9*1W/-O:-^^;K"RB_1D95I\_&D^SL/8=
M^V!A7KBZ!$E[\<2)G75H_WZI^!XTNX%*MQ8"U]UGCQ= BABF&9/6$%<-,9:0
MP4MSXW7]XU -)6*JYSPJ]6&"G1C71Y!"I!?"X2L$)F2Y)6M>%C3 (3[9M<<:
MSD>"="Z.B7[NJ8DQ^[!$8Z&"8GZ-JT[?C6RXQXZ!I!>$@$P1-T?P1 B$F($^
MU DD>Z#J$9*9PT0800H+ST./APJ!^?B/M/ EFU721>T7DTO!T7'Z]@"^C*_T
M:(VXI(@*,EI$>$AB1Q<L<QVT(6*[#QH\3*U%M7.G5BSZJ4SHTK2?W=2+)<U?
M<W8SA-6',& 8$\\AQM&]D%DK[(# ^&D-3.<"@*=U>>SYO=*QH,.W=B%B!J*-
M<C48$=9GFRCYTX;^S<S>2V$7]\^IK$0'S!,WM(C1R<HATY(<9+9E'-J;H_E7
MF\[ 0L.NATV?Y*3T[OITO=.)TMBP\%S[V<7S6\5>-<!I;83".Q3?Z6<BR$+/
M/("C1GNN9QLA<K&MCE&!E??^+A\4TZW_O)9"L=!#!N6K?\FZ^]JY&HO70QJS
M%YAP,A*_Q^Y/CFA#P 9A>[FHM%@%R$Q,X*N79JP>]V?(/ZP>=C+,7Y[LVW%J
MVXL0K[M93%E%HU\96T6--*]$&#]H*/PQAW]XXLJ7GA]2ZL87/O\F9\7;$=NM
MB6&RR,FH+AH%PT3P D.Q\E8+:6U:0_7$=#]M3DR"&G:H(>!TEG8QT_-EXF&#
M# -SEMS):WJS>LBZ[_<1.<09$I5]A*H4WXUMP':3)V9[J0W5-1S'+JIZ?;$.
M6NG4?(EFQAO_N"#])4.'E*"LTSCSXT9GTU6E'F;9]&7U?H1KK'MK(,&W)7-/
MU KNH>DA\"+TYZ(5YC7(7!K7D!LO!"A8EYBOJRC"V/@WYA3UV^3?IN?W0G54
MNAF;Q%WA;Z&Q;X?2)O#]W)C)@"5.YMS;#[_^7H9E0VG ?E:-5P[%LH_FJ!/;
M+2!+@DL3)RB9L;#AYY].? %F4*(HNNSSU$^7<I^W,AO+1)U#6VK5:Q!?^6]4
M,D;SX@=);'LLN-60]9YG.@V])C7:\%6J]^(Z1F[Z9"G.[0</RA>//(Y>5WZZ
M:40=&[1TQDA!+D*FOEO_<M0&=X')LZLQ:2WHBNFIT*:_FH.C+P08O!TS^75K
M>NKEJN^)W-2D]MXC@)UMJ1 XC8_O/<!S+.(:[;J_=#F"5B/ZJ^>OG9FS!BUJ
MO>CGP7P#$ML-#7,S>RH]3% $;:"F>.=<1]/70QTT;G_#J8UMG[A4NRNQ492W
MBSY[8[+O+%LIB[ Q?!4;2.KD3 ZX#<$R80]QR]DKO>F0%KZ@?:=W-^-@!)W,
MDN*[^8?'JK"JZE_Y[O]:?[RT^2PJ6'&1NF6TA> G@&L<>CA,-.(1\5-4=CVJ
M'5ZHI$[4YD$T707J6B(V$!NV9*-M6*B+JSH>!<5M)XJ6,JN-)G^3E<'@SIQU
M\9LYVLE)OJBW@:TMAS.KOC>G?8Y+QMY' ()\(>!/ H/($U1NHJ ,G@5V>02Q
M@\M9G_6,Z"\$SL05\1!,58FAMTLM,.;>*^8UVE.>:%:Y@KHP8"ZR5SIH$U'<
M?)#'6-#:SR@VY-XL.J11=MVT'FE@8C'=Z1R'.JR#VPN-U)5F]JY<B%A7K;G@
M\=%&9PM;4%V#2(ULF-SU6_;NV\FQODN)H2>"C<O_^J:ELX\91M\DEY>P)V\?
M4H2_%<8$.-.V.PB! *HT*0$)!ZBR$#@RT*;DC3'C;T'I@+?8N68;PN)5&G,=
MB+63TU5?D&'ILMJ)EVP=U&X:,1>NZ8B#J>PANFKJ#/$&6AV'VH3/P]0;5>'?
MP,,D]OBZ7[Y\^?;DY#5EL6\3-64RSR3WAM\?L,/0R4K&9#IUP]A/63'FWV-3
MI0^MH?D(0\FD]N6*89&E?E8J3X+8Z0D-H.N$0&\_Z$T=0[(?\B]$,\R8)*99
M S%B=:0#J?M^:99G;=X</QXU%#+OUQO,CJ&KDC@'%F;C4COZU^^?=1;L"*5,
MFZ4>I/@>9[RSV-&8^]VPD".FH;#QS$O[73,>CO8 X2G/E-ANQ!=CV]!M6-KL
M@XRR;+?>-@W!HW@3L*)GSZ^2/YN'H/;0JF[EXS\>7%^\=S1\8_>KQ3YCJ4/;
MC3H"80.:0],4:ETML1UE908:Z7\AU;T9-\V<N$@P;\2J.M';%[.4?U)#%OG4
MK5*$!=T+F>>V/;]-'M38*O8-F4-B'Z6*\5W1=0[I[+<]%T"C3E*=1[;E5-3^
MCV<&7!BT\7&OAE)KT8-V08B;Y(6TV_R6IX96'^,GB<]I?&MT=ILD?A123>7K
MDMA/4#L\\?-,VACI'#3&LW1SY.Z=OD0,GOHV][[K[F16JEWL;V61120++J36
M?8+9@1CW[0TN6Y!%C0B-7X]?7'IE#J*[MY43;!LXIL65H0.^5L-ZD^_MY.7Z
M= />>>P^Z7IM"?=SF3JFVP5KNK]%!49I,0ZI-^2W;T G4I1$YU8].DAW/5=8
M]:[@:8QI>:ULOBJ]V%/67_-:LP"GCEJJY!]@(U+MO!Z"LEVH70-,*YIB7!FD
M,*6ZXI9AU.K&Y*2;HM[+[KC"+]U,.VVKG#BF4K-/1XQ!'L-!BCAP&_8ZC*!P
M*F'7V^6 ]I R%C2#8/+*=*&%\EQ^3L616?'GQRF1_49OSLW9]A[AX-*HSXE\
M%5ZOGQI'K3V4.%,%J1>UHPP2?_7,'A]&B7HWM@:7G9)T:,P.6<B5UCK48V[;
M3073C'?S HYS,"F7(@Y,.HW8.?J'1N,G(TRJ<8J[#5%IE?L#EBN61>:HM3',
M3VP>=[>@R$Z%9\K?'MMGAYXA(MH?A];]M$A]41R +0SUVB?A>/'#Y+Y3-:_$
M ,)OV%[J<+ $$"X)GA-#%Y*(#:/,<5Z$(SNXAR3!C)Z/0!XKH#^FIJO.A-UT
MQ)F;?_8]J,%0N;6CSX#P.>OQ?G)U;UH+*IH,.O0T!PL>;EER29W(ZQ\7L.Y-
MY1#.5#D;NW,LE]Z4ISTNGGJNO+ZTI",!=410!/,Z-+A]KA.N0I%9<-U! HWW
MDKIH$F-]YB-\>37F_*/O6<^,]F]Q>,B=_O$EZ6R5ULN3MBVM92D&S3GCLMR-
M<,UQ ESE+,RF\DV0K 70%[*C< RY6*[A.+&&4&%/X:'OS?5Q_V9-4<_A/UB7
M-/SRADGX7D:L Y4]TAI8_JI6.;0R,O>LW)ZG6P^_7G[Z6]OYKT'CQ\._P\&(
MB >^0Z=.'5'0Q;H';1+Y?1]1U"8#0Y%UBS9[GA'#LF$LI,5;WNC^(\DRJ[2_
M4(WWCE.>>$(*LASRMRHZ8AAU42_K;H&L@F9-TD@;82V]9M(:N5F\W3^1; R<
M:Q++IY'CK.6B8J3S(*+3)XJ15N_A[KE\Q0I3GQP>Z+XX/J)RBRZA;VXD3WI8
M&/_ O\++\6EHS,?/D^^*'KR@W-YSN.U!ZKJX[6$ R)B#I&;9U&XBVYF<"@>@
M2W\Z4N5W> 4Y);\INO<ZR@"\^BZT*?M.E6=S:W5%A$*NJW*&[^T'E]_8)KRZ
M^19Q#?8!%C0^$^YMD,[!0#+C]!LTN1\:R2U-Q?VI;:+>7O-[!/47C2R57/2_
MW)RX=_)(_<WN%Y&VY\\[CM<?DWQ-:J#QE6(9*SG$\+V&7%  2Q FA5(BG$SJ
MH+$S\>4_(27?< >.>[;^TL.47Z,?DG-#2FUS+\6-B>R1R\2-\2!I- ?-)<(&
M20ZGL8^;92,;XQ:ZJ!KX3KHSWKF+NQ.TWFL]?(H8,OFYE'O -M7'QW.F(7$J
MXK*M*F+G7^]U3>*>V@/*KO_O&I[(5ZYS%SRH-ULC$STF 5Q,(H1)&Z$A&FS8
M-P<#S/"FU^53&EUS1V6:"W>(&.Q+$#UOM#@)27>S,9#\%<$S:I 0D""@P3OE
M>-WC8'O%]_R*V5ZP@,$3F'7;^.GB1UE4ZLN2C3JX^M4B^V:5F8C7Y+&<";%9
M7#(1[IFDHPO.SQ8;>K8.\,V>-'#+(N@"<[*9G(S#DI;TTN$3BMV.N]P2KGI\
MI?*5"R 9,7BNZ?@)="TU*QJY(4Q'%$R>%41UQER&-C0.$,0NMIGE>>*](G2O
M06\*CCG/K9Y>37;+1'EL2HCKYYV*'R'*HV?@S%^'OM9B<A\OV87:/1HMRS)[
M19)N$7E"D[;"*(8Y**C4RU\P[]B:O67I5-_-^ZJV]^[XO%W&@-LHK'2VT2RV
MLS^5Q#Z.'G-V H/I.3=T]),Z_10YHTEM^HX,61>T[PMWZZ:@1\CQ^R&%9RK3
M+7"9+WJ/UO*=>&[Q?>@&=WC9KZL37(?VQ'^ZZMC%NX>2"),UZPG'BH7!.FS_
MN*SYG5"^\ B/F% --\*S1DZZ?=MJJ@D<?CN!MUG;/A4A7 &+V?T=&I)\Y959
M;'=5[''.=,Z5&9*$']^?H]-2=M*Y?&(B]L9NUY'Q@*B77_YVT#VVJOL8B,-P
M>)#,$*>Y@\@^MK"!V+Z3&D0<NXI-*[%]SMZ;FF[9ZC?;Z_JC,,SGZ#O#0D')
MI_>5.Z ?!S??^Y9[UMZ^[T(KSVAM)RS>AG\*+.(<Y.X!.3Q='U")FP)>67O/
MY70))TK.RIT_S$DIVG2VL;ENN/O%XH-PDJFT%SU ]O"NR^O3EQ PRIU;2*+6
M./*U4CG!O=AZEW<3R,0&<H*?UI 9_R+7XFW@ ]^&OMPIG%Z6#_.C2^T))>L-
M1VJ,%%HT?J'/YF2L)97$S+6S+#!B3S[B^I?$!=,E._H3D&PRB2'G?M$^D"%_
M=<Z=%S4Y89=!#<F0JFL=W8S%G;RU,6'7 FBSPLU>([I@!=WT*5T0Q74>;*!)
M^/*C.79^6\!KS_@1M-B'0:LM\R&52$Q04_9G?MJA@73)S6Z/8S^0X11A)ZA&
MAR R47O!.-B)_8*4>FIZFP:(9>SFVS*H:2668!8R=7E^*O*S6%19Z&N3LMRO
M#XV?#36^[M22>^J.@VNW1/WX<5)=#+,,G4V<^9M8']R%!0^V[?2%!J:---")
M#>\-?FW\?9ALEME8-WGXS.+CC!-]'HA$B:L6>4MJ3"H;QS469,;K\SW6WDB4
M41L+>K$)D$4-2*H*UU%J&6PS#8_78=,R+35?\N?CCO15I36&9C-JJP^FR*SW
MW'-?\OM**G7F>8DV!\E7*F LL&#6+R-Y<K %R][=$&?+0'>81'EG:U;M]!FZ
MXQVN=$7KN&[/F^\#GRO/55>O_WAPZR)V;8\KDG@.+1+_P1N.OYU=5/91V2+D
M^ ?ND'/K2,M!FZZ[FEV7)R)F#Y$F;H6>&<,U(BSN?BIU"LPLK7Q>45P2/(L1
M@2NQ91*XN9]5S+&%I-?.X;39#=BY/@KK[(ZWX%17E-.<*\*>A[(7\HUN@(/.
MMQ7>:]PKN+A3%^CU[ZV$YW=T58+D;W#6A25LAS[L@140$VCT))@0SL'6[8>&
MD6(HY ]J8_\-..D4UTU";RE-Q8GO.:)$G:ZV+4F.K26[(AIZ!]H^'+V\N/%A
MX+4G2XU'DKL.W?'#0+*!G#I74 'V,TIP+=X8=*.75,P6'Y$/9J@T)M$C1#US
MX_S^+-G7U3<D!]Y,HV<]>7&#\.%RM\[J^@.W?-7XJC4*Z)E)G%9/FBBY@R2;
M?&R7&.MJX)4%OLKH;/P=WJ[X:2+[+TRVCBZ[^FGE#S\=HL:I\/,A?\X5%*B.
M2!X8&ORY?%"Q[G7C1[L"8P6OQGV3^W<IBRP;=M#68&?G#'IBJ1U;:\97]N%:
M#,6KGN*[9S )9IS49+OX)NA..6W2\=O;QY]?-EYC5=NU*)^1>7/XY,9O9'XD
M;)3;\1]UM@@J[-QX<(G3;DL\&X[.@ S!F,!@=->",KZHY^G][RBMDE\[31IR
M"C>5.#>79>+.9@&9R'OI<A5PL>_,\R' J)M8!]%(M06OR&.:O3<)ARB@#\?=
M+)VD2 BDSU_!NK"_%06NNR'?,BI^8)5R?'?6F>.>*IH)[_'$')1<_#M:+9:O
M8L9-'5P[Z" $ZOM[2(D0$FR8E2)@V20&(@FE%_9',I6P7^XC\;'G9Y>SA,<M
MC1>>2S\_LE[*38>-&# ;-X-D?"H(T>S1'H0X/U100D9I$4Z#2D!>KQ!8;]KP
M?>$!_G%][L\WOS[\V=71'QZE%=' ?_YZOUS95Y-OI.<(O@J..P1K<1/O0U_H
MQ2:2V'^I6R*3=3:U^!!5P,XN(:#TP.M^X)V'31'6P]ZE!0/[WAQ[QT!:V-]2
M0!2\?$$;P[RBL8]J+B"@031LQ].8B8,,R>Z<#3:=R8,M,;-H=;#BQ,C].^(-
M2][M\JQ%\1<A71<C%6S3/GW4BA1MC87DYS.V$F<RD76+]NK'"*K, YD7<:;2
MZ'2]CY)C35G);15E_4]\4\Q/=0P<47A37"FU2_?F^:L9_%-K#H3>H-D1P<Q;
M[++>M0-4*?R-I=_1R/JX#:1UH2CE3U85_6KDM&H3]SCC[JVY3GJY3H$4XK3Y
M492/*/4L/V[619-.O69%3BO1]<D?6I8WF'.E^M@&%0;(*5B2:ZU6BQN?=F0[
MO=(.7SK(G8:GH\)1(H(.Q8W']!2B&F:1TGRWT18/^F21O&[["$JDF=2E4?*0
MK<[RS]AMHAIBJ'C%7^],B=O6S==<]TGSB+!K7@J!8"JX6:V=FHQ4:(DM_X[5
M;C.FX=%T<IK=L8+8!GGK)5?&3_<["!N_0Q8]BQ7![V*BSR5\ZH;G=:/.%-/J
M)/D*9=PC;#CAIT+2'/8?HB@X.1.<L:PVVN""=G\1VN+_< J[/R VX.G"18I?
M["D')M-&=/W@(\!FELR,X5U8(\TO2*+W.92D:/(&?A"H4 %&,63Q1V;LFNYT
M[8GXW*]]S>_4YX-EI[;?96.C7^Z3/0TSIL3'Q/9#0B ("1KW,^_1B:#! E]I
MMI>"VLVA]")50[8QY"TZ'5\Z$;0?3M#VQ\7&/5W(-"'?'.$\VJR7^]?4V$9
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M*TJY,<JV3Z^YX&W(9Q2PCN2*=?PQ$5G\:-SQ2:@&0;7Q8_462F/:EDWS"<\
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M&M QO;%VZ%>+T[,L#/9%/47J3_),8^+PJ2..M+S7C90;%^;.;MVSM<H;X"^
M6+8;=UK01IPIQ\H2<9B)5*Y7T4Q, DH$'^5+89LE_UY0&@^[.IH6'>%-8U+4
M%*OR6BZ/#'1(J!1=P0]GO=T\SJ U8#J)H+%D3PZXK9O62\Q"LYV:29E4*93*
M_,6<A!+I>O K_;VF4WC:ET", FU_E'&NKV^3./[1'5W5=D[]<V.B7\A]Q#T[
M;1N6!X\(]5!54;+0&+)6?I3Y^QG8VUE(2;[$LP:3R_!WOM:W#96(Q=?^  ^_
ML?RP[ER,DDY4HM$7\O@<0Y*OBN7:"ZXOPRDWD,I7=(,4%]3PCATY=#-9OOT
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MA)LD;2H_'7GA<ZTMTQ@SE-K5U&EI=I\B7W.!I>-1.)5:?N/)>Z9IT:?>.F%
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MH"7_=6M_"6CA#ZQ*:@/S.24#$,398/) ).I/R8"EKI_^2)'^HL<QJ.14AD-
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M#8_$;*5OB#3)W69V9 "X^J1YGY3[.OV5M,#V%W$F@VM[Q@"-^Q'NV)&%QN1
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M\ZI-[<YIO-D\7=AX\AS]49OZCP_XM$P%-ZD%/-4:HEIK*Q('<UJ==1&;$%X
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MA@[2Y)0S]O:>,146(5P6>WBK,&KHK_ZD^)D,\RN"KMW)0R7^<A,X*U-,_88
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MK'J/N.%1TK'IT@(*3"ZLX9UK-G855,]CX0#V>"MU:>&VS?.J\M2J<:XUS6B
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MGRXJO5>'6$>+'&_JZ:LY3C#:IFZ$G^?=YW#*9'?H,>."E5P&B]V(\^J.0$K
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ME1[ZID@1PNI-WDQX&:0UU#T1QY6YF$K7GRY-.,*EHOGFR24N4'DS[8B"+8*
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M^*T>[&FO.9=TP?K.%WTO?=\JJZ+*>4#NG)W4O0)]5=.\4Q;*"OC>WH!U5.V
M?DYZKA93!EV*B_]#-D;"91L/ ):H\ F-/IB4(Q T1 DOD2[."\Q-+7\]+]+8
M&GYQ(H_OA<OY-Y#6VW6-9'P2C!NC"K;P.';"G#$!+-'<L5*>C7*TW>F2-'RX
M;T5=\+@9J^/VC:0Y2E&'N91 5Y;VW;3<_HRB^;.UVA?=OZ:7^BY>KENK0M0$
ME"3[J=UI.6E:M%_L^N]GCDY*>%S#DO=/L77"%M568E(2-I9Q;*DUFFG(-^9A
M=,:)4H"?4O?'C@0K_=VQ@="&(/JQ.G8SE,K>MSH!Q7T:Q -0SG.1?I5\\0D5
M&OO'O+=W?LOR\>8#Z18%:[]G-\C_<]L3Q@A_6SVC[]LZ=S0B0BF:ZHI@ZF+.
MTQA1E+K4&I1U?,/;SX%^C+P7]9W3US$Y"?S?+VQ"=@FR1$4X,5O54FG/0,40
M_4;0]Y^NLZFWX"C;0"0,Q7W#T90YPDDX^D5<,]?6!=F;D*P_JKDJ*H!"^#W7
MZ)]:\Z=E/3H4.($CO\E816X5<GW\-H-E!Z4]^,-??A*V2LWR6L"!?,@D@?QV
M$R(+)[_&";",,UE0\)V)F,.5_?4BU('J]*&+=!YB09R;27E-U?+'RS/AO*;/
MFR['F"V6[5<@AA[&@4&%' V3 2Z@F&Z<[I0,FE4'89\5)3B!%YV$&.D=$<FS
MH.PB??%[*Z;O]DGJ$:*,_]8YH9,?Y>[C'/_2/[LV3C>A-&.QC'D,(]V#W05
M&9$TS @BHLB17Q55?WA)7?W,LFS+7MZ.]/YM/\#9N5T%4C91Y85$2O=W!/E9
MR4DZ/R.#WII 7.3-2IBIZ,M-=+*M<SWRPF9TW4:NPS]]&.J%D0!40>T*;1;D
MQP@"_F^(WF_0<.)@D%Z<KYN-S<B(:/CA<\=]WFL'OTY?(T-%6:;,()8>/2.T
M7CF 3FA:@<=45/:1DTC-P)D79LA[J5&*:(Z,U.(FY"]SM0W%@+++&\$):SJ!
M%;H)E6K<X;E1: !+I1:9$-?Y\;.)HU]]%\9M;,1DF\Y^&!G^O"JVK-QL98@
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MQ'5<MK?W7+U[ IJ.+&E?,&;"L!\)M#MCA%UP#V,)AXH^7>3W-A_4I>HAC&E
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M_;7L47.Y[P<#/@O5=!U97GO#!Z79D !0P87AR#'0LL5NEF@5AQ=.A0JSCM<
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MN_IT8M\LB\:NN+2>@"JPMDY [\<U'<7",3?HJ$4)IB6+"P:GPZ.G5K36H!)
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MAE:M@/%+':A[U[ R*@[F#O80&=_3[NNU*MLKTW(_>[T]F7-3*G8DIO56"2(
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MBA/(&=N)* DB?/L5[R3'%^7O7[ZBN$Z+[6_K#7HR\1QD^$W\%<&HD1G&&KL
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MD*,/A.7.-FH D2.A@/*IFCO*@P*QVZD+IR!-RUGN]S_+R*W1JU@R&31D,\P
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M+UN!O$.2Z_7&% 3KQ^D"H0TDJ[A]<')%$'SK%.\+]HM"CBS+"/%@)"),1T/
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MV&7H#\9=A>T\>A5]Q0_F!X,.'NX,[#B,EV?[V'[EW3YV\&V_\N_8P;=#@%]
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M%C+V8ZM*CEBS$%:,OT/WSNHRW>HCLSLOW/J('T3NC!O'-N 2( =.TA!=Q<I
MWUM/H&21\@PG? V#-9U1YE@Y8*7ZK^Y=ORG2XIY=7YD@HC]29I3HI<U6\ 6%
MAEFB<7T(NKT!G'V&\Q!4(<2W.2S0#!R:B!,1<RX+2,K]_8U65K=ID<>^N&Q8
M?7R8\/O4D)B?648"#TN!'.L2&M5E>8MP0ZDL/T_RR\\BV1:!W0$$4_H06W8
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M;;Y2?9:D<HA#34RX$^-"H*%9\FPESG.HKHA<F!#"'ZG@YNW!MAA!7+4J&\/
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M$V$1*ZK(BV;)BCV=TVUH75Y?G;>>"<MAQWG2MRR705%WUN%Y;(<2DIJ$WMM
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MZ7]?C_[O+,'E-;;\VN(F6T8K3@&H9X9SVFU4/1SQ]O3%L]] %2"QAR015MU
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M@]\.L5Y%K(QWC#GBU,,H*HL98,8B]]I<6/GKJHNS'>=X9\'$$0C)HJ1X9NR
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M;0L.R842"[W[<G^XV6VSZ]H^7.]8G-O)?1WSZ<<MT\WFTT4L$B<%M&<9G^E
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M9V5CA^67ASHU38H^G^_?;8+4]\#"2/^R2WB5"#^M^L;(QOF6PEL-"$1O+*G
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MQ7Z3.CS5WDJC?,@0LSBSK_>]E CUH%:'1R9,E!^.=($]1!;[!VL;>%N%+EU
M&"5;>?N@ZRW\#3[_V!&?UF+Q2O&)JNK5L_OR=^Y=JV<MT(1&0@M_Z3?S+&N
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M GMWU/XFK=VS2@8AUQ&\?"J9\F^>!)._VQ)R_KM(VK\/4ODG'U@K_/=^"H.
M/TSHS^-T_IL&'UL'VMIVE6J)]1J\/3W\L4_[+LGPO/:-W..BVO4B":9+J0!O
MBAT+_<*JU= RB<'1"9O)$MB#?')9^WWD6H28E\.NB#R/##%6VZ]+Y+=^=W/-
M< L+AH9;2L_B%JYX$+1>S$F];/]&+Y[@K0_@O ;%V;3#8 E;5R QQ X>O1.1
MS2]@DL78IPDNFT-SQJDM$G<+9<54'-\G[H(-1]QJ]&X1 IY" %2/BQ(8"&@9
MJOQRQ/)526[5YJSDL_VE43K:'L[KB[NH:Z:9F4?MKEY]%%B$G3'RF^UM/75K
MR^',7Q?@Q<AI--<*NX/_U 0Y-A-.8#DB-V*=.J<1_9SVL-3<L*RZU87D+H_N
M6S2"_MW3W_;3>FI%1E(!KO._5,/_ ]7@+ U)S%;T@+$M/\57L'RUR?'Y4]OZ
M&:AH@R'C$SVQE.=#]G9O!]XX%EAG3 W^0LU+OQ8S;A+?]%BB;?82M\T=+*E%
M;&#/A!*K%<:(4I[4OKA\F@$Y)WNJ[^PGFE-MG?2FHN,2QQ]>MWZP^CY"EM7.
M4U[.?;R>_>J!YRAEM:#QWMK"''KM]J*>TO9PA\^<!9F,N$T1S^7\$)GQCBJ*
MT*PNIUV76K[^>UB_&^E39162L0ZT*,"<\OWX> RV#FO:$[]%SZ'%9^\V9^?J
M6\8U^L_7N^ZA_X@9>*%R &*0UZ&2:?<HX4234RQGVJAY3?.\XLG*$%(M+$*!
M:I;]\<;[<AVU/5)2/C$RIDPG]#1DY58NLW9/P<=A! FD:-1 @AWNK%]ZG9.Q
M"RP952;(.-&*T]]WYM#T92HS;(Z&[S<)S805D#=C35D$2)52%1J0(EX^ 4\Q
MR<?*>F\[]I4GK+_A>4.V32KT@+63H6H^=>JE7I#(2INVY< JU&OG(KP+ZY9-
M$,WT304*/&V0.'[TF!XG:2R50_\=H%']FX,%JY$\M4H*7T*!LM#5^0=P5&0&
M0 JKUK( $J"G4+% '?COR:OCAO_SRN)0RTG(639TZNR850,7OD;PCE!\JC&?
M@0<$G:\QZYW8213V9GT[$\M7M.5$2O+[5<N?M#U7\ZVX];I8O<<WB_G;A1#R
M0L +&8DJ^2S8!H9P]>$A=)E=.NC,X#I_@6JP8UE1Y9%MCB=]?1ZO9)%5DT7.
MEI=WR3T0':'02@3BC]$CE&B! O\I922=0M*(1"C1L>?YV86[YMLDNHQUUX'.
M](:]1^Z1E"KM3N\F.3+BU:T,5R;L3ML RZ6,Q,++DYO0-.61Y'H=8TZ"BC*%
M'5:+BE;JKV/:-I"E(A(MV'J>HRL,)&]?OH->[_)H<\7%^T_+-<4^$DI(3410
M"UX#![7#@BBN%)H&YUTW0@WCWX@2FT?)63&(:['ZW:7>CI+AOB=E7MX*"<@/
MFK[ZJ>NY\>L+8P9+3G\82)9A(V71GCY"XJ<.5PF!O />,^APN*Q@$U:=]0U3
M-YI7+[V^SNB$U2;=%YA@Z] /@U=NE:UKT=L9ZOI.L=E$ @!;!!(Q7'=!3R6L
MD1B$9UGI#E2="ZL1 K*X U-+T<F( SWZ*7[K&3%BIT@*"J3K-$MNOJ_BZ8&'
M3PZ?K0&*B]E(:;P';/F,/C0=J^1!-Z[R,F(I1>2S"QC]36\UK./>96BRX:'3
M^D.NA_I+O]J,.EJH-,L:1]U]=N-UY<S:D15RRE@ZJ:V75 L'=4G3*'958W=A
M7B@/&@<%<"?]0GIY';K TGO<\7 KQC8]QRYKLWVQV)$P?,W973[DG9"J@830
M!78_8VVZ;]D,#$RK'S9@KURW#W6JRV=:]4+JM<#ZU*,):AJAF _S#<"]9.8!
M[K++U0QGS'/OY;FPV@42[F.Z(1D2"<I^$%\VV<[J-TN?SCXNXY84\"WSQZ?%
M1+' %&OK2UDFJ9\I(W&$<CP3S?9N0*H@W:RH5:AB,&84=I^^[C*+!]]P6T=E
MLQ%R78V^CJ8]DZ&^\15CL-PZ2N1D9+9L#ITN!*ZU#]C^=FM>, 9ER0IK1,J"
MQ5HHZ2F]9E&,1F/_O9-1QHTR75?+_/9><OV,O7_Z1AO6&-)NC]CF]>A!K7I\
M.86WOHYSLGM."$20E?GI5-I9T/BVCS;SE=\I" M:OJE,-*-4EA_/JDS7W6)Y
MYTWB0@5L?+>('*"-K_&#U&J^$"B#^DY9@VEGA/'6ESA928%Q#%BH3K43.[G)
M4.E@1G:J7$YK/CIW4ERN]5P=IXKTZ*/_JZ],YD+T8C#\*5R$K 8V-:)$L8JC
MD(1\54B^%UO .&@T>Z9*4DD\+XEJZ$^]O_-+RJ\ T [8,IJ8EJ,$6M,(C"=C
M/.9>0XR#EOL)2#<;N8?CMLFS88VH6(>9V-OV"0OV%3TZV0F3S,SX['7J[PN?
MANR/-3B-8"-?+6-?--6RGCHSO9Y!B(*7Z=8L@!K>F1YW;*Z1]=AF474Z#^\D
MM:Q]UB_S)G)CKFZ([=8'%U6>W3= ^J!7"SZA%$T4GV$,.?M!ME@-MZG/$,QJ
M(#G#ROMW-=R/:$KT1%\_NLWFE]PK^,K,7\1'R8BW8#LDQ<K+-VH*AH3 "L1:
MWG7^JS)X'$&:?! 3.E.'SH6LI]*=M,*O1M'77T;X^QA$/D]=\;&JR]1ZW;H#
ME^J^QU&[.33^KY3+[8.U0H"3!]+'OF%,M'Q\E"?C\HP^616V[QVG]C5L$ +9
M;8;*<J?7M"0\?UDWCAK0XUCRGRZ?:J2>[A=(+-]FH<1J\7#>?6IG@.X#BIC*
M839V?Z?O:I6 7Q^,>_7O(=#WB<38/068L0!L.3KP=^ZPN']8H4((^L#_X0[S
M^(,/;6!YH]#D6$/U$5S#<77.N4/,V=2<?R*PYFM_'5[&JXAGW.%J)>'TQDF^
M1\SFHN%WVU3J'ZJ)^W.\]N^M0O_$ E-&/QF^J=K:I)RY'E&VQX/^@C<DC8O^
M9T+AEX_<SP^=Z.?@6&W5",7*=)OF=X\5K]/?XAZSW/[F:(&K.]'+UM!BY;!B
M98C]ZZZJ70J?^G)^TLM_[A3^A3*Z+,:_EA./ M.<B[LS,SC#'\6)WQ,V)(S>
MM=FX]=QG4;6$RF/A!]S]SHAOL:8"FB\45':R&G(K%$)]J\U=Y'.,T,%6"6SY
MNPJ]KAHW5$:LE_X1!O5" ;>#U19:)!9&K#9S6?OT9E7A2[=JL]2S4\]/C_-6
MH?[(I$*0UZS +1/3![BF6+,.Q';P".=FEWZ;Y7GP*?H5[W2@8?U2[F/YLLO-
M-WU;#KD;'5V0M52[AO*J6!3<2"04XM8)/B)7D 'LIC(^ 2>.U>GD:8VT:%GX
M%%8CGSI$><BHM:?@3N[QUV[MDG5Z$B6O-E[EI2DZT@CAMRN4D?"VVZ0VKM*P
M8N^^ETVCI$A2R)P8]_Q^#O$$OXPRDC(LR8<TT57"0T*1;<B\ILE!5LD[A#Z+
MV??VZ47+&W[[LAA\%3$[_>?C\=2353DO2KN,$>\_?4DO05WH-%5!<ZT%[PDE
MR<P*5N3$B#OS"*NRJ0&G]*8B=E+[>W:"HH^O:WOR#;2)=@*MM2I%7-7ODF+H
M]7H558X1M*I=<(W(UWD1912XH)TNY3O*M@IG)O0[L/$16+. EU.D?>\/6>++
M4*>TXVLEGO[H>)$0>7S[(14A8 9@$[F'($E8MWP+5"FQ42=@;"(.IP@FU37@
M=M[&;YARE@=C"CVU"HH;BW9D*#MF1X0?M7YO>GS3^-L\CA4_AG)5=P#-N(!?
MA72#!U>B@DWV)^O<TLD@C%ML[ZT#E.Y./,GPCCCQ@OA$J\3'6O$=<,]G@TB]
MH)-00JQII[:/Y%*XQK@.! Q:6,$UPYIEEC[^YH*.-Z7<DY8[3Q2,TRPVY8?%
MK#W;PXY]&)G#QG/.@:O8WSB^9'X\3ALCR;5EC.<\HTT:DE4@.Q_<6G*_\7)4
M>^B%7WU^9"T^?! [;-'<_A0:6E'N6:B+ND@7/.W(R$PP3@3715FI7(^3!7$N
MB'5=R0U*.?'=K3:C5+UQZL4&[93P5?PQ4OY$ZJQN,(6%IO-DK484&E PK ]H
MQ=V%\L2ILW*)J_,SIW39>O7)VZA3"K!-H3OF%2)/[A;S+MCQ]9 <Q^EW"2B"
M_WA"EHCYP]&;G[L,NF%_"N>SP_^1L]V7^#/-MU[2^O.9D?O[(W\64/$7UR&Q
M/?*O[D28V<^XYS\1)LF[QB_%>\Y0'3F#_ *!.NYC/M>#RMO2A9 1=*&D3?8P
MK$(==,-*!\O:W+YCCV1O8*L5T[,33&Y8[FQ?>3TS?/%L1' ^PGT274L(P9=-
MU+8/YM4+Q,!@[IDFMM4H+/XYY:&)VW/P</LQMZND%1^U4G20UYF;WB4]MCZ2
MKW@HDL>"E@B-=Q/ZJX/UZ5W/6&#ZL+Y9=9'50=3HPL.Y&%\AT$!>T7-[Z/1,
M7=2HEEQ/=FG/TY!3O6F>X\Q'=7J[#S=87XS\!G7W\; R_SF:XF)%)=6ABB&3
M3]Z&KWU;6=VO0W%]>V34)/GL5'P]]4*45!(3*\^X9C893GMBNM]60YI\'[$#
M1(T0P6V-CR'D,\AV#\&CTR3IH(_+ZB)X%)-GH9ZO6R]NXG4U;1KN2K6TJ&A[
M^K A9;/]R8?C1U 07"C&-R+#\460,")KD,K(D1RRSIMNK-D(.J1O@2XSO]D!
MO8^MHDFVRSG0VA]-OG#T2FEBD>)57_P^(7 ECJ8L6./(RA*L8=%+S)E.(W%K
M[7@7BEGIX\GL(PQ2I(FT%J;*FNVH':6%^R&J3]K[:;=''IV;S@YBW\6@?$!(
M!%?V0(-W'S= 9YE1!L^/T.O;J5(8T2;$BEX=GM7H9L,FLGR@B\%&GU>^5SI?
M$IG.'BW\#+&2JZ&76\AR:Q_F 2J'6#.,B:9T?X%D/U=>\ E?=L&0BHK#&=EC
MC_2,LJQ;ZYM&Z&L=,;YNG7/7\S:F;WV3%!!:FWC#7W.GQ.R2)80:MD -N(YK
M0Y(F@K5G*)YVV///)P72G?,6UZH/9F-J%TZ^)M_-BHER:O)4\[E^AI;;6JYP
M2PA@^L<)S# N EK_CG,$4)LX[<^ PZ'_CO D"WB'>DLI*H;W35R\67>T IQ$
MMG62G%]R+H]$E>@CJ\[98TMF;W513@H!-!W41$W'+2?%!0_FU7#=>7?*6&_I
MT;>COFV68,P9TT)Z7C%(A_;UEH:B-*]ZM+<_F&6=7@N8N ND(X3 (\7EO"9$
M)P@@G],Y39XG?H"!!@7+F824,02!^"(K&/KS%.L5-#8J",GZMI!*"CX6AR6B
MQ?O0OOYIH?<=2=_=(UC%ZV?'%%?"* A)W"?\*H&)H!>I@'>=6>GPS7.T/2C,
M7&5/PE*#:BF>:7RUHIQK$G3,<W>XO^^%FA'W0@!+X![&UXA11B)1:_!79^#8
M<R"?]<PC)"/F[DM,VFA_>+4+_L8KVHGPKL"R7<[7M#_03AR+E!G8>=>GRG,>
M!FXQC\%[PL()K..$H.&]_ *#S:<7&OJ'X6]N//?V;;M[-S>*]B#/2L^P=9IS
M>"BX2'O*>B#ILO>L_V@[3SY-(+Z<AO<0_Y5O*866QGD>_ Y5HE'+#U1C]==6
M$6!>) 7\^C([QQWY7O0K9?&JW<]<4EX^(1VON_T"\96?SD^D>*$&VSGOP:TY
M/#_^(YX_>A2YTKG%(#<YG^J9+'^CB/1+G9JW7/W9RH=7M#Z(-"EN$)G\#Q^4
M"^_TLO=T%,X5@4#OUV1BZQ)_-YB^[$"M1W)$(5K9J8MZ,O</=ZAUH5_,MB7!
M-\OB7IW<RJ(KCC2//)N$3Y7?STRM/;_SD&*C^;:7$&ZTZ9XO5+9)L"M]ZT#]
MDNE34E@]-:[W=< $7F@/J6XBOF#2R#:9GY]/H]UM+X:7GLX?-UPX9J4Q8/UO
M@.<M@["X$:(Z2X(HR"+(+06B4A"*RZ<(K" I^4J9VX/*Z_F7Z4CE(.5!4IU@
M%>M+?Q36^GE@LE6QZ8*MRGER@]JN.YG:=U4S]46RS.ZZ\_81I]L@* /5J=E/
M6<XT[H,:3!-$H@1GB7BP#?#AX<#U##I5H=;(/)AWJF!X\% 6.%8WK!'D*)LV
M/'&\M]!O_S:?*?.D']1MB ,#;4%KUWS7:D$RRO!7T4L[\(O'(/(QIH^O\Q*T
MTN?.08V."1 "C1ZBG>XL2NBKLA2>^2T&3=%@H^TUPQ\.6Y^(F8BI7M^4$591
MT/N%P*)22@SY&RB\+&<AL)R!_8\_*C)UVS;I+[\L!$)[^4\H7Z%9_J*T( 2B
M.\3R.YWMA8!T 5</WPDIPP\&,_^6T=R6<U4(/(.DXY$W7:!GJI+W7QB/>^ER
M?VG86P:1VL+!LW$43T;<6I#+5.CO?KGO-=[-*7=! _#UN \_9_IOTRD*&_6'
M:,\Z2$;60HTX^A;GWC\95C^SJ#Z\=7D+E"Z(N,=K__?@'W>!A"3W,*:;8\?_
MI=J5W<+X'H,.>/F5PVF^3(K7JQ&U\I.K>!-_/NEX?>YA,:<4DRO]);:;V=]&
MK1X@UO.T>WCN;&1=_U)>6)8,[9M\)2Y$/9ON_J1/PYT48Y\=<>0+J_"AU/4;
MIO"=@@\4*:0'09[GQR;%8J%VK%J+ES%#%V!P@7<X_35+)Y?0X2/>&[,Q'8<S
M:7&Z>U2;MN[<[7A7#!JBH"(>KF,.J<+3Y2?QT.Q]W%J$)#N]09##5K#INO(8
MO>MVR_Z>IKQ#GX-5#7K:OLA%*R U/\N+?9F)Z,2]KVRJ;]_TC<(ZQ<@?Q#K@
M93W@K!=,G/(@RJ&N*.L^7>>3B/R:PD.S41&/357AMZXCK?$UQTT4?5BSG,?@
M*NX-2 I+O%36@W=?.MN#4]Y:"F\$+9'CZW3*1)6"AB_H!4V_DUW;>M,,,.1H
M=%-&DN\02N5>)7*1O/6]Y,W8$]VW/=.LNDS.9GO=.\449$Q9?[;[3G#K&O%M
M'MHBX7A_8S_5@)573X]!2@H!7Q1M;&0K/V&^C'V"M[_';[-W8X9N5^$5^52G
MAWU345ZSQ??;C7>@M*]$_T!P$,]9=*8>:Z(!51H7@71+WRM]')-62Y4K+\QO
MUGD1=1Z-&'H OZM-W_U^YYXI#]$OL,$CG%O+(&&5(AO90*3>XA!9D6#=1S L
M'^-:<\\WQ]\P_IE'7X#,JDK5Y[&V5[6_'_A4]6!5&F(9"1'985&%)MO9NAP/
M=EP$T2\)/,0V/,/Z'I(_I?=DU_:NU2J=5VZU[,WWXYQYL?^LLR=W!ZZ3 EFR
M7S,TP#+N7ER?BC9$'DS,V+!S;&10V<%C'UW1A5_[TS9+K0VOM3C[J"!SXI8/
M\/C:/11/MJYF>%<5*ZZ>2$4U.F]\V^DX*@3JVX[4.Z@D/Z]U?1-FL=_RR#85
MZR='2)6/7>HD@"5(WC,EA_^DFWL7@_^LP/_// OV'P_B'C^(66VA6]-F7YI^
M8EB3PMC?=[.XUFZ"J?/1^R7_A0[6%C[-'W6G]/I<>6BO/G=\C=K=_(X^C3\'
M@5<* 6H_5&4#<GZ4L&1D!/# _VQD_)#JN>\UUL<L_@=[[QW6Y-;U#0:17J4+
M0D!Z$PM-0()Z:"(@*" U*B(=+"!!0T)14*JB@((0$1"1$NE*"[V*2&\"25#I
MD%#"+2G,S?G>F7F.SWG?YWEGOKF^F>N:/[S@#F;?>^^U]EJ_WUI[KZT(X9Q#
M"2)M2-7MZ)B)D%8L2]<)[YI7?A0BP>ZZ:]&E:$XS-A5$+R0HR"&6\15.LM$8
MZZ XDLU)IAV!B:EZ"A\^Y&+SWF)"0O5DXW...Y^5N6 J_41U+,@?;DUF?>J+
M]1:5"LY;*7-QZOE0 DR=5;T:+BL=%<GTFDO3!FY .P,:A'Q&*X8'Z5V $'4$
M"D+"@K._7!TM0<((A7234<LG @=O9$V()CB:R83+%>SG9S\<;AC]YKV7WL\4
MHC]O3VNZ,/YCZ9"Z[*?RCW;2%D*Q!\7V,1VTY9,U&*Z!J);3,T=^,$XB[/Q^
M7'J^=.%7P-(3WE7BQ^Z]._'Z?FF@!/;2:M =84@8E:(A 8HTH&<7PI0$]/_E
M::1-B*F=9E9.3J;ICW[>Z<V1[@^H?C_);[;N?&II(Q5WWE 1W:5-YJ.'K^Y"
M-BU&?X;]'TFY.VZ"P-5<A"F1+98A,^XC>GP*447\XCPF/_FCV7\EE84C(LON
M]$G%K)2!)V+"5]AEGWB]"9<>K"@^85JMG6Z5P5)D'">VDGW))2N?$])K#2(4
M-^JY@2UK#:JU9?7'=3C2$*E"E:"VR$:MJK3]1V6G&5Y60YD/[$8P_[C].VO"
M.]9_&<OHS[YH]'?WP5W(THX&G=MA80OB3H]K!_LM ;*K1G>&9M@_/FGMI5>N
M(.*/DGF VQQ4OT^RHZ'O[?[=9'H"4J><_ RI__6\>.^;['[_NZK. D;K#I)+
MOLMN.KN0UU-I#&8H^=T_94+_VB.MO9*IZMW(VV3;Z7-8I9&W&Y*BD,RIA__]
MR-X*TD%QF4Y(^S#L[_Y@W+ 5P2$=BAT:;4KYISRI9$)F?ISM@A35OA(1A2(+
M?(LT+?W+EI[_NA0AG.H$/M<@\AEU%\'V3%UB_OVER?Q= U 1C:XS+43T$ QQ
ML[CH!A4RIBE,U6XH%\@F8-B;-#<L99U??\@B3HL(6/L+-;CK)3U'\_N%A\(!
MN5"P+PA?<9.4(B3+,Y-2(-^#L+""M,QW[@KV#)'CT;UQW*G;3G&R2F/ZO?:W
MV9O?3N^$S/8E[D*\DYA\[IEDDW3P1])F5XY<SG>]VT2SDTI#!RI<[$*<G[^:
MPK[!K'K\T(KT%O89^II&!$;24 \!@DKTBN"L]8,=AXBZDZ1RHY'#I4.PJNS:
M80.K[4(Y58DB9C\1<L!=SM7+I;IBMXW8BM%-;C0M0D\@H%C=AA5TGA>Q6730
MDW_CXL/A$QEJ%^@?;O^$YS,$OP\!(J>3H(V.:\91U,=V(2# [T63+KGJ4]J
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M[FU9HD"F1K1SZX1A,9)R[VUF</XWYY: JK(5K^F#[!>:2)<:C)J345O8Y[B
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MM5J#W--<Z*F2F^\4TQ/B$AX2(MSN$$C51G?=)Z718Z3_S(JMS90B9AA1=^$
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M(BP@9_*4M-A#*0*@H*CW$X<,7*8/85K$J8S!5)+AZVE1D_5OWAZ6?:O&Y(P
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M/U:E'L#&5YP@6R)/@TJ0V"+#Z-+#4I(FT>4;25O.L.!:"61?QNIHF%.%74"
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MG.H2E!_=R4IEU/T UP@/D@Z7;!,KLI(JEC\7H&-]8S2@\=:?*^B_ROVEC-G
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M"D!FT&Q4P_,$)\NZZ92?&>^^-AMBI3<\H1+P]<^XF=UPA;H@O%HD?37)][Y
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MPU@P+G13.-K+D!<MAW)"J%/U\.J_20=7%QO^3*^C) E$>+A8QN86;>:8_KJ
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M<R+]P;[WOQW.'&I.;8"'*: #(YG^@M**CQH_)"S 7<I")])V"LZDMM9 4JW
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M^WHTJ%1K\L;NUUY5Z<,(E]N#N]*[O)G.S*3PG 0([BI>5T%(P=7&MJ$A;9Q
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M^O]\"KS:M[959D(5#_! V\RL*:]JV<MK,U7=TU/V+ RGQ*D0J2$CLE+SZ1_
M(RY%,  &2/'MFG5G94HDX?X#^8.[P^'^S__S^\,2?!-EE17YO_S@_^S] $3.
M"I[E=__RPV^W[V#ZP__\UW_ZIW_^OR#\MU=?WH,W!5L_B'P%7I>"K 0'?V:K
M>_!W+JH_@"R+!_#WHOPC^T8@_-?ZIM?%XU.9W=VO0. %_N%OR[\0[(4R0@)&
M08H@0EX"28(2*#SJJY_':1 $5W=_$0GW$A;%,."2090$*22^CZ&7>#1 $0D\
M+.J'+K/\C[_H/RBI!%#*Y57]SW_YX7ZU>OS++[_\^>>?/W^GY?+GHKS[)?"\
M\)?NZA_:R[\_N_[/L+[:QQC_4O]V<VF5';M0/=;_Y=\^O/_*[L4#@5E>K4C.
M] !5]I>J_N'[@I%5C?E9N<#)*_2_8'<9U#^"?@!#_^?O%?_A7_\)@ :.LEB*
M+T("_=_?OMR<'!+_HJ_X)1=W>F8_BS(K^-<5*5?O"15+)7W]M-73H_B7'ZKL
MX7$INI_=ET(>?^RR+/>>JJ7$6DH_UE+^MU.#_7*!^([D73V7U8%PM;H?7<G8
MA^E'9^+>*GX0XPN\,\S%(C<OU-N<3_7N;H:Z6/3Q)7;U6A0KLIS@M=@.LR/R
M4O_@O?I;.XQ^4 ^9UN.TU+TCJOB^$CD7#5ON/1ID_%]^4'];T"RCB[??'T5>
MB2QGZ[(4G#ZM[@4KENKW15GS^$)@'L8)"2!+$[5"Q9Z$V$]#R' 2\H G2>)Y
MB]7F#5^('/[VM1.F'M%FN!\LM%Z=^'I+417KDFW7O8?EL<5,K6-ZY4M_R<F#
MJ!Y)>X.269L(C1K_V@H,.HD!?0)*9K G]#__LE7V8KR7$Z.X_-\-0-Y:<NWK
M.QF0>^/.%=""[0FVU-9:41[B4S!+?!HNU/= ;0Y[./1JIC-\RB_/)OVZ[ 0E
M)3N#?GO%+ZQ0MNCC"NZ]T=IV'Z+1JACRGC2H*H%^ $7)1:D\CR/*;=YH+K)%
MYWC<JEL7-$ZCA" *8\I#B!BG,*5<N0.2^UX4!A$*I G9'CYX;K2Z\;:T<&9?
M_S.L^HGR$@1&ID0SY8V_U%.:;NV32@E9JUD)]O-=\>T7=8M2-_#T7_0'ZT'/
M;]VK__;L<9-\G*>4Z#[#D[^W^^#6%;PCY''Q=56P/VZJ:BWXFW69Y7>MGW9/
MU$3?EH)4Z_*IONB+R.K+%DQZQ.=I #W,8XC2E$'*4 JQB%#DR<B7:6KR:0X7
M86X?L19>N_^@D&KU>7@H<E!I><%:69YE^_?B4?,C(#EO?_"HAK_7WO^C>EAU
M!:I:83,.N&#Z^MEBFDD9F5=JN4 C/6C$!XW\5Z#1X IT.H#FXDZ+RUGH<@3W
M_*D:/4DJ6JO?/KSA++%<5=U/#LGK BDFH;G+4>H(T<&3AE'G)V7[E!^+O'@4
MVO;)[VYR]?&+UD1:"!G&/,4I9)QPB)(X@JEF39\*CXN(A8GD-C39/]S<*+&6
M]@KD8F5':&= -2,O=U"-3%2UH&!74M"("GYLA?W)'2&9H>*2?,Z,."G1F&E_
M2"J&=]D12.U)W2C_.+_+Z%)<5Y5856^_L^5:;\K\6A3\SVRYO"7J=[?B^^J5
M4N./11![21+B&!+?4U87\6-( RQ@D$KNR=CG(4D6WT1)"Z/XD^7P-M_,KA C
MVEP;!0"I-; (G=AB;Q")&A'/D3EH!\A&=+"1'73"@]]K\8&6']0*_+\CPFT1
MMQH1]HFB6,_>8R V\-^U2OSL*(HU$*W>F);M,Z>+< W4=B_>-?09 Q:$6\'N
M\V)9W&6,+*]S_D7<K9=Z-I^^KAD35?6Y+"BAV3);/2U8+&(2HP1&A"*(<$PA
M89A#$4@:ATS9GH&1#VX]\MSLS#W9:^=Z*SUHQ;\".PI8\);5C!BL$6/A//("
M,1N(+=:%L:">:%%P![G= C$$MM[5P>J!TRT-0_3<6Q<&/6!8F&$O=/%!/%!1
M+I!(12PY@0D+)$2(:?H7J$X0"E&<^$GJV\06CHPQ.Z+OXG5U\-0NJ' ,0K-(
MPH7 C,W,^S',WQL!3YOFUB&#'O5=Q@F.#3-I<*!'S\.(0-^EPS[PZV\D6VHS
M\EU1?B5+\56P=9FM,E&]$73U@:S:?UW3:E42MEIXOF2$!RD,$YI E*044HRD
M3DE)O8B@-(Q\LU# 4!'F%P[XNGYX(.I+*"1X7>2UD&NU=&Y%_PO8* EE44*M
M)MCJ:4<HUE-FQC9C3L/(5+0/;K4/[A70\N],!OB]4\$A60U%SR636<LP*<T-
M1>B0 P<_9QA!OB-9^3>R7+<^N#*WWF>-;:7&^%#3L>"?\B]:"KWQHR[X6.1E
M]\]7I,JV7R*F:8H94YYS%"CRC",.*4LB&"04XY@'09S&=N3I4KQ9$VL;G]+N
MR'*K(5":Z-GD@*R 5%B ;QH,.T)U.L5F9/M2TS8R$6NU0*W751?/U1.VHQOH
ME -%#C;JU5?M*@AJ#4=AZC&@=\GB3N6;E.''0/:0_4<98]C*H,6H0S'7RV7Q
MIT[!J6IGO!+E-[48%0\DRQ?$\XF?IAY4'K. "/LII"E2AHJ,<20D#<(PLG&6
M30:=F_?\]>UKH,\J\?52\8*O<[>NP$81L-6D#38UNH#?&VT,-WNL9L6,I%UC
M/3+YC@6S-</:X.:2.8W&G901;9 X9#JK>P=L^?S[S<=77_YQ>]V&I)*(A3*1
M"$9(&:0HP0FD$GDPC,(X8)Z4+!7&FSK[SYX;'W7266P5'(!EL-\R'(*1::(3
M['S$[BP,%GLBP^&8:-?#'!:[78WCBO?N6QS<,MW.Q'%9]_8>3EPR,/^[7:T^
MR6NF)EEO8BCC36<]O2X>'DMQ+_(J^R::M*?W154=Y&I(S+@7XA 2GH00!5X,
M28H)I-SW4A$GE$1&YS0<R3,WGNO4T>[SCD*@2?S;4VF3^:>U.IWV-\HLFAEC
M$\[-V';:T&FQ282RSQAW@Z_3]/$+19HVE]P-?L\2RQT]=AA!W^2?RT+O*&NS
M4]U]KRS0-^*;6!:/>DGN-H0CRAF.]!Z0XF*$4UT]@^@4T5A(@IA:WF(;&C8:
M=6YD>Y/#QT9J4+9BUWX6WPIN1ZMFV)N1IW-$1Z;(FQRT H,ONV#NR#S"AK,5
M2BZ)SFS@2>G,"HM#TK*[^<)]F9O\<;VJWNO'A^U'$4=2!]D\2./85ZS$,20)
MCJ%/<(!"Q!GRZ<!MEN>CS7#7)+O+,YDQHKZ2W_*"ZHA!;3@TPBMK0HL/0DL[
MKP]QRUV/RU"<<!.C$?0*M(B-0#H&F(RRNW!DN)?9+#BM]\G8?\\MP\BDIBO!
MJW=*3+VGK/BJW4A^^B0_D/(/L=(?T':K>2%2J3Q,/X(\E8ER/;&R>; G8>(K
M7S02$?$]2XJQEF%^Q-.IT)1JTWD83:SY89M[H7R>AXTNH!J8 F,_7V8$->H<
MC$Q;^^#7&48:^TY^C?Q6 Y/D(VLJ&XR>2X*S%V)2VAN,T2$9#G_0!0>.7^O"
M*_FJV7OMC"T_QCYG#*:Z;"*2Q%/>'U-_I'Y*)))"2&I]U/C(0'-S^)IP#6L$
MM3H&>!92,[)R =3(G-2&M%J,VHP0]S;4.22<'RL^-M;T!XI[-#YZE+CO^@$;
MB)_)D_;FE).G:">OKA\?EYG@UW=$%R15],37;/5%V6CY6G2[EE_$LC[(?%M\
M+K.B_(=R#A<)Q\I?BR5$/%'\D29"\0>.M,>6!@0E0H9LL5M9L'^CR8U41M_0
MV;J*3I?W5J]?6L5 )S6X+>K5O@*9CIHH!8#6P&)7S]%$&FR*3C@Y$QE=K4*@
MFY56)=#J!%JE0*O5-NUB=_I><M8L]G"GG[V)]GXWWQ8HVVDD[322=AH?VVDL
MVVDLNVDLNVE<%>HB/8U/2D=79Z;=(MZ[Z>QHJ.DVJ]UBL[?)[?C1 ];6-T(*
M7>/PEGS?R6^L@Q]?A!Y>?0]97O][X==5"0F'?JAWP7&8P)3KD"=)$\[C@(2A
M>6E8BX'G9I!WHH,5^;Z;(WX%N&#ZX)2NUFF3'VX]$P8KX$CXCKS,;:!58N]F
M<U]U<=*-[!KBOXT(L<5R-1+4$ZU)+B&W6W0&X-:[LM@\;[KE8X"6>VO$D/L'
M+ 2_Y8JYEME_"?YK6535KWH)^I2_*TJ1W>6-0\>>WH@R^Z;>1[4.?12K5T*J
M7RNY%C)*$,,Q@2P- [4R" 2I2&(H0TI"$E#"HL!X9;A$DKDM%5M=0*T,J+71
M1U):?4"G$-C1Z HHG:X K;72WZ4%QUTTCP;KRE2S,_)"\_^SB;%8C:::H(F6
MI[$GRF[)<@%N[QIVT0#3+6HN<-A;Y9P\<.3*!%*M&)]R<7M?%NN[^W=*#.U]
M59O=XD4:4\R#-(0\2-0RR&,$4T$#&*4^0^KU3KFT/'7K3+;Y[>&^60M M-CJ
M6Q9U, .L&NF!U!FI^B?J.Q;5*GNHTU:'GKIU-[]FVR4O,F>C^V5TM5?JX'F9
MB2NPF\_2;1%>U<?!6#V!>I?X:Y;?+<5VL_B-^LU5^QYH[8$"!+2(  W)"U1.
M,)V7%RFI<%:X>=9:,,5T<!$&XP'L%HFJ7"V^J"]!M#NF5!(L!0MAP)C>A$XQ
MQ#Y"$"<D\7GLI2(TJG=]\-RY^2U?M5FGF%<79FL/.S>YL%9'90_!Z^?/"R 9
MF?T&HV',42=T[V$8=<<.NZA_'3++X2,GX843>G1?]:E?#S/<=L(AUSFO2U7=
M%TMU?_7V/]=J<=F4RN!,HE"* *:1%T*$A(0X0!P&F!.1A*E'$DN[S'3H^9E=
M[V^N7]V\O[F]>?L57']\ ][^K]]N;O]A9U$9 V]F,(T!YLB,L%MH1)LUC:"C
ME!&Q1<>E56(\]J1&ARTBAS:%]?T#<WW;S;W;XIJIYY;B)E=+M_)G;O*O:UIE
M/"-E(\*UE$H>90E7"XECE'""81PG'D28AY!(%D".F/(N)68THHMG?4;/YYL.
MD&5 :LJI!JNC9$)4G>!/]2=(-H(/*9XY:++,Z&TT["?./%D5H%4 =!KH':%=
M'>J)V&KA,./W @R=)OT.D6/:O-\+D'J6^GO)LX:19K?;U9PSW=_S^BA6"\18
MG 9$0)^%'*(HIC"54D(>I7$@O$AZL6=GRIT9<7X6W-'T \-RY*8PFS&;0^BF
MRBMHS[D_V^O^V-/"R9JM#'%Q24SGAIR4@PSU/Z0;T]N&,DNW>7"3*_NNWKO2
MU/57P>]T_3:F?M4$EK**+0OMY&]+1\2$4IPF(<3"QQ Q@F!* P:YI+Z0Q"/"
MM_0@+Q%GCIS4:0-VU+'EI LFR)2PI@%]=#8[AG9M?+6:@*TJ8*L+^'V4BAXN
M4'7+A1?(,S%17H[<<Q9U\,RAIUM;!M]M0<"DQV(U4S#!B.K@FP^QGZ80<2\1
M.G$41=CFV-:Q0>86/M_(.,@5/8:BH:MY(39CNY(;6,9JY= '@-O#GT?&F?A\
MYVE-GQ_A[+EV4-)X3I;9[;THR:-8KS)6*9.M?5'](/$\]<G#((H2];G+!%*L
MOO[8)\1/A)<2S^B4YKF!YO;)-Z*"75FM,I-/(]K_Z;O$:72SY1E$VA\;4A^R
M#R^KS&TGN$V6J7T4/V?9V&>Q.)-]??K^*;.MSVIQD%U]_GH[AN0B6[19"D]O
MO[-[O=WY4<WJ0G!/"D$DC&+D010B#&E(=;]LS@*)8I*FQ(093PTP-T;L9 2=
MD$!+:?:1GP2QGPQ=0#,R"5JB8OP-GU-]:_U4G?E3"?;S7?'M%W5K8_FHOQP:
M/"<?.\DG?4ZI[E,^>]W0JH3[?5$_BM6SUJ@+1E**(LE@'$5<MZQ&$ =20,H9
M\V6"!"&I76C(9-CYA8">M?B] GE/4'4XX"*2J2>I#Y-0NY%^2"")(@F]).%Q
M$G#FLW"Q*E9D^3)P;X?^WP!L,[_3-80C<_"S9N!U_!_\^+PE^.G*=0.*/IIC
MY+;FH\&X$Y=\-$?B><5'BWL'N+8?E0JZLUZQ5%?<;?<[FW.];]KSO765DT6$
M$NJ%+(6"AABJ-<"'1$8QE)PF-*#,"V*C7%#;@>=FZ+W)JE69T75]1G15@'Q/
M%9"UNEBX=S:S8. >CX3MR"RU+_4FYT+7BFQ/F?_8B?Y34]-[)(0M'.J1D)[(
MP7:(N)WO/0"V7E_<YGG3^>8#M-SSU8?</[0;->%"EX_4&R?U/[0WT55-\Q%-
M8B(I3+'RYA&C <288"A3*@BG'B<BM>M+W3/:W,A^*VR]WUC_LW9A+7=[^R$V
M,SN= 3<RDY_&;)1NU@:@N.UKW3?@Q!VN#71_WNO:Y*8!MN37SS<?OUS_>]?$
M*!8^9DS7GTN%K_Y@!&)/.:^<)7$H8D2CP&@C],BSYT82G706!LD!6 96W7 (
MQ@[QM8(-V=@X@,'"]!H.QT36E3DL=L;3<<5[[:.#6Z8S@8[+NF?EG+CD\GKC
M-U6UUMW]/LGW17YW*\H'?81R(06/:,HIE!X2$'&?PY12"A/&HMC'-$&"V>5G
MG!MR;FRU7]":%F59_*D,S M*A9^ VLRJ<0O@R%RWCUTGKJX!K@6&:OH>@!9Y
MG.+?_?",5>W[Q*@O5MZ['X6^>MYG[AQ8P/M1E'6)PFVOJ 5.$LYI'$ O33!$
M4L:0$L0@YY'T"<,RC&*;F/V1,>87HJ\SS>OOHFC$+7+;PMU'H#0CD0L!&IDU
M-M(9M@.T+]1]6GVG-;J/##-M>>[3>CZKS-USZ= H27T6_JG.*OLB5EDI^.NB
M6GT0J_N"7S\4ZWRU0!Y3WDW(U)?O(X@"B6'J"ZS]'^%S05,2^@,.-)J,;?3"
M3W^ L9&V+B"@EDDU%P]%WN2)@L=UJ0EYI:/H7^])J<LXJY^Q>QU[5,1]1QZJ
M*T!6ZB[3>+K59)F&71QA/U7TI1&W23K5]2QKB:^ EADT0E^!1FR781ASD-Q&
M8PS&G3@H8X[$\]B,Q;T#0C2W3Q6A9=:66MYDK*-$>@&!/!54E_'R(?68#[T0
M$2%%&(08&0=JCHTP-P?H]A]?KU]]N;$(4QS%S2!F<RD:8U-% \2F"ON  ,Y1
M9"S".)<B-%$PQQHINYA.'PJ]D9VC-TX7W^F3>R_*TWOAQ>5PV@8L"X_X,F!"
MEX^((H@$"NMB[9 D4OV#8NR3Q,;M>C[$W+RN6SW&IEG23G'VP15N.BS-;*/+
M$!J9WO9./+?BC5*HYD#UD4K2=*.\5/&9 RU[RLP<7CGL _\BV))45=UQ5;/[
MI_7*J%MWNP@)$J<H$C$,&6(089; E BB;!O?2Q +2,2LMJTO$V=N-M"A-J!8
MU_[9CD*@[3*VJU(;P+!CEPLGTHR)IIN>D5GKLID988?=#;(N2?%"B28E4#?H
M'9*MHZ<.W&43I2S*!QU)KZ,VFT2AD"MF#3 444H@(IA XDD/1A&) A8E"?>-
M',DSX\R-2G?$!.L\LZT#<0I-P]VSRS$:>\ML!YY&Q#$.0O?#X'1K[,10T^Z'
M]>O[;!/LS.5#LGWT<S[)UX7RZ1X*S4'J+U*]_0O)U.<>AQ%DB:[I1U(.28IB
M&*5A'(2>YPOLFR?^G!IF;BSP*BON1/X_*E#5@6RU8"ONA;IFU6,CL"X>IU@9
M_/;SUY^!F@WPY>;VMW^[_ECGR/UZ_>__^)M5_M!)^ W"4DY '9DVFOV 3U)9
M.6 C)FCE= *43;*1"\"FRCOJWC^F.R=VP+4OH:L&BF<!Z<]'.GGWA*E)YS38
MSU(Z>_70(Y??1+6J:]:\>GI=Y%6QS+@VX*YSWN1_;W[R-E\U-5R_9XIC2> '
MOI20BA1#Q(D':41UX#X*DM!'GHPM"W0-E,3F YCJ8.9&$4"?P*XJ-=4>* ,Z
M;<#O6A_#V/>E\V=FW$TP)R.S^%B3,> XXD50NCVA.$R4B0\M7H37\W.,ESUN
M: U$NMIVT#CLK?&E[<!4IQG)!$5AB"(8<!9#%,81),0/8!B0E'J8<Y0:=DNW
M'WQ XL;HT<&V!]E2B6>[F6"!NAD-.D9R%BV$JKJ%T 9G+;S+"H6V@+FM1V@\
M^L35!VU1>5YKT/H)PXCK*[L7?+U4%N>K=97EHJKJBM155B=5OGK:^=>MEF 1
M2R:4Z1=!Y/D$(N9AB%G,8.!SZ6&1^L0/;4)OM@+,S1OOY-=^4*<!V%7A2ILC
M.S\ O]=Z6)I_UO-D1GACHC^VV^X<>&OV&XJ>2PZTEF%2)AR*T"$?#G[.,%9\
M73P\9*NNP*NR(G5ZK\B9XN*%\&4:<YXJ N2*!8DBP%10 =. )%@(&0?8LBQ1
MSVCS<WIWA*W]*K8KKAVG]:%L1E^.D!N9J0XA>VT$F34;&8#ADGCZAIN48PST
M/J03DUO&Z'F[_9=V1;M<LBB-L$<#B"(L()),0LJC ,J48QDI;I',J-K-<!'F
M9E-](.4?8J55 -5&7)>]:8_.@QGEC(ON'%S%K>13M8CM0VVZ7K!'I9A1T]<^
ME.RZN_8^Z;*>;&J\[<D:O8VA#^'4APP6E(:<!5X*8[U1BR)/\1R-,"08)R20
MG"(RY,#2^9$'1+TFZ;?6REII#V;5G:6YH,5:#_9!Z/D)Y@$4'"&UQ@@!*:.A
M;KA"41S[?H@]JX09-Z!/F3O3=5O3&^+E]O#7P4DQY\B;K2IN\1QY%=F#\LL>
ME(W S8$P]TWJSJ,S1DNZGE%?I '=>11.M9LSN'.@U5N7C-QTI\7,5\R>2A@+
M3YNU/($XCD/(DI0'(<-$$F+G(N\/,#^O^/KKU[>W7RU-U'W0#,W/P4",3 J-
M8*,TZCVNLU/#<'^$:8V^H]H],^B.7W5IT/]SJ2LHK)X^J[E<*5=8]^E]U%S1
M!)$I\Z078PHY"7R(:,QA*F0(4Y]'* P"GTHKU]1TX-D9#ZVT5Z"6=].9^K'I
M5G]90/_,'-@&\MTA.[89<1&H%P3KS1 :)TA_9NP7"LZ;(7(Z*&]XOQU;5>5J
M9XBF@WAS/'V;X_'\IZ(N,EBG/H7*#/&4;PF%X *B6/HPE3&!,J2!KW[&4F%4
M%_!20>;&9ENIK^IBF5;Y:!?/2C^?38GUR/QF"[,QH[G"J(?AU! [[*;^=<AL
M%\LP"=.Y0JIC/F?/&^AF,:;K<F3YW>=BF>G=BHWW$*1!A!)]%CWU]*ZD8#!E
M3'?SCA+*I9#*\;+:1#@YU-S8;"LIZ$0U\4)L 39TSYS -K:K-@PQ>[_M+!A.
M?;C3HTWKSYW5^IEO=_Z.RXN4ZET 99E](*NZF=,G61_<W,F67<B42R(P@C'S
M.4224X@]JL@$!4C@*"5A9'>HTF;TN;'*?OE-O3%6A^GUM*S$7<9 MI5]>#G3
M\Y-B&#X>"^KQ7< =E+7DM1?8R:X1;PZ@WQB@?5'!4V/4QJI]>EZ %RN#:HQ-
M7T54\X<,K)E(OHOJ,WG2#F=7689AGV."&:0A(\H!C 1,DS2$1$2Q'P4T(=(R
M5>O(*/,+1M="@L=&2LMBAD=0-*.@"Y$9F6@:2%KQ1BC1TZ.]TQJ$1X:9MN3@
M:3V?51CLN73 *? OHA)$[USEG(MO8EG4\:6Z1]^;XH%D^<(+I4B]6#D^N*ZW
M[J40IYX' TIC%/* $188GP8_.]S<#)9.X'H!W1&Y:6,(?F^DMBFX=Q[Q?F9P
MC^/()/$2$%H<#7<*Y41'Q#O,VE2!?GP=A<?LP.H]/G[^*=,=(S?6:.\XN?E=
M]LVXZ_.33]><JS>F^JI>)?&I5";?MTPILZ"(82_$'*8R3""*?+]NW MCSR<X
MB (L?*.,HW,#S8V'&UE!*^P5J,55D().8/,^W;WX]G.O2]1&9MWA@%FU\#9!
MXX)6WKV/GZREMXF2NZV]C:YW<2):=__*\KMV:W#UM/W-NV\?,UUX>A-H#9,D
M(E)Z4/HZ3=2K.UJ$H?K##Z*4H5A$TB8,-520N1'+3E*\J$4?G!L_>&K,/,$I
M !^9DY[ER;=:7&V2%!3\N[]_]S?X\:8M?#]&*/U23,<[=6TARPN>P;9'K/]$
M]H#G7;3E=QB306',./&4886(CFSQ6-E97$+BQQ3[BBXC:9MA>72@^06W.CF'
MQ;=.P&FUN3??*-<&F_$"7?T8C+"?]Z+AKGYM3^SCN0EZ/4^R>DVJ>WU:4?U'
MD\XWLM1A\R9)T ]]/_8] 3W)/=T"*(4XH A*1!(<28;"T,IH,AIU;A;2;D4
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MFTO!%Y3QQ*?*7>/UB9TDBIO*490&3'I!F%))!]0([!G2Z".9OCC@EY,5ZJX
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MK#9K>L::&Z.U<?/MYF<G[*#BUGT@FY&4(^A&YJ3!J%GSCP$>+NFF;[A)V<5
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M@MQ%=:$8^QZJFNO%[Z"Z&MO</QU]WK>=\;X\RUO)=O<K<3K1OIV7PDAAS'+
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M1/Q')O9QH _:K;4'P*D:N%X2X<5#,RWP<6GSVC>,'RMJ:_;/UG^B(L])DD#
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M?QH.[O 7JP%D>X$;UW"(7KZ*#3B^'ZV_I^7F;Z:*U8?5T_-N^[M^R2QA<X;
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M,1&"8.741/#6A'/CFV-YZR"9NCJ;5<=X/] M#Z4#0CGV$?4P%-V/K"VA"7J
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M^Z/2?D/'\C-Q_T8WI:F.]6&EN5S/^6ZUTU(<WH:'VG(\DQF760$X90(@D@A
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M#/VVON?_>"XW)I;I26YV/TU%U-W]2KS3/ZU*:2TR)5!.4&X"-25 N8:,TK@
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M/VKZ\& *"H$HD2DK"D7=+EW#+<3$IX=UP:PZ@=OLIJOKX-SGRVI;0)C$*8*
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MJD/K:[J5PM"/YIYJ^*;7_?UVN^:E(:C_6>Z^ORV5DA4=U3%\A]Q6*)1B@G
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M9+>FKJ5'_?%;(!,:IQ*S3/-K2@&"B@(M& -Q)G*,52883]WJ^X0#>9+HTBE
MMF7>8-"-3L(-:J9D>Z=2:$@2ML(B+!_W3SDQ-5OI?\[2=H]Y'%?<K^CRY[;<
M?E+WC^OGU4[_N1)OOIMB_!]6GS=K\<QW7^JDEB]R*S<_SM*E)&4<Q]J>T\RB
M "I4#C!G$L0XQU2;>(@EL?61Q6!QYL9$K4)5Z8A*C^C#*MHTLCLXO,,7RN)
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M0PQ1(#!,&5%_B"#VF6!<Q%:;<Z.D6)JUV"NA"7NSIP:HR4] .T5 IL,\>E7
M4Z>+;<VT,9-FQMF33\7D-+V;A7T-@%(!O-F;A9T6X.NE61A1>^T*%-W69!LC
MR,RUVJ[ ZKB&VS4/&Y'#_*G([^]$^:CY6CGE#^I=%%PQ]$9'P/F^QWT<*9J4
M"=2]Q2'V8P&Y2%(A*/=(:I1>=&F@I3&A%A5H68$65A?SZ<1M#*2-:4#;17R'
M&<TE:A.3UER 621&.P)NIA3I\0#:)4X;H#*80CUT_WS)U 9:'*15FUQ_;>O+
M-A7B=U$_%/QCKH\XVS@^;1RO2" H)LK*#)#T(.*804)# E&H>)0$'I%F:==V
MPRZ-5O<['G9)/ZW@8$_RKHNA;6J5V3R8F9#NT9V8?MT >T5/2!.<IFGU.#CR
M+^K@:(+&^<:,1G>/8ZO3(<1=G;FN]@CFV&>ID! E7@11+"DD<93"E,N48X1(
MS"USK Q&7=[&Y3<GJ0PF@!-E8@<1BV' 8@P1\4)($QHKP"D/.$E(8M8Y?2*X
MY^G9,!?89@N 8P@G9O]SZ1^@$WB"ZLL6 +FD?9-A9^5\"QQ>$[[-K2/<^L_9
M_4-=U:3LV\$@+&42$1A%*(6(,@&)Q 0F(?)($/@1DT8L<^KA2Z.3K7@67N=K
MO Q<\RM0F)@1MI*-*4?V&@D+G_L*1&;RLRV0L7.LSZ@^Z$R_OF<^!_J,M =.
M\[EK1L;G%#D757:?ZR/$[LT2*0DP%;IO!%><Y'L>I!%#RDEFL;*(I,3(JMS(
MB3$61TU%#78R E(!9?;?ZR"V;-N%W3(PYP2P9E;.E7!-S6$*J7<'2/U;A]2N
M7_T$ELT *$YC<DX,,V\PSGD]CZ)P!BX=W;2NW C^*2,T6S?GP]V+F_J"410'
MD#'N0R2#"%).$QC&L< B$2$2GF73NI,#+8T6.CG[!@]58\H7]8,P-&$N FO&
M""[@FI@6>J3V9)RF7=T@$([;U9T>:^YV=8,:GVA7-WS]V(*E'W-6E$]%F^[3
ME!UZJ_?IRY>W!1>K,/2$+Y2U0"+>[$XQF!)$%*R,I['ZOX08N3&&XRV-)[K"
MG0<RWX!&:AU:UTD.M.BV-4Z'<1_FCPG0G)A&7  YHBRJ$3Q75TD='F7FHJE&
M*A_74#6[S57/7-U9O*D)7Z_"-.9I)'5=9!% 1*ER2JBDT)<^Y1X.I!"I95SO
MP'#+V_B^/6Z9>P-R81NB.P2QL3'B!+;I#9+7_7-O )%J-6A"9G\T90&DYI12
M\*P&GPH=_MSI,66#W6.TIFVRNS?>+VZT>ZSYY6:[)^X9L>OZMT)]I+EV37>!
ML-UC^]TTCD@<!CY,F*Z?(0(,4X00Y"FAE,<!P9[A\9K9@,LCF)W(H-K*?/&#
M&(.UP1ZN4_PF9IH]X+X? 3=FI]?@;37?^W6*Y$R[P8.OXE\=[0P; S.X5WSY
M*?/M'AMK=+"?;'[7M:%8;TFEC]7T?W0PQ3-9;P,H[L3/^HU2Y)\K%$D:^R&#
M7"H.1E*&$'MA"B6)$L9]' H?V]EY=@(LCYB_;QX?B7)Z"@EDEBN[)2/K+G$=
M_,CJ!_"X3>?0U^@\+E _D!Q@#W#R4H$LUSF]@C=79SE@2O]F)ZOY0>R0&!O;
M932Q9M;E=),U\2JP'^OUM@>X^6%/^B[6"V@%0*/!)&%?-M!-$_YE),$O"@.S
M0>=\.)C54T:8K-_$L\@WHM*:$.5ZOWT7>'KCF3R)39VQI[*X+\GCZX^,X2#D
M"4T@\Q)=B3LD$$>8P% 2&49!@#U*C<,)1HFPM*VY7HFVQ(Y6 VH]P)XBH-?$
MPD8;-ST&EN_DH$_,@S9XV]"AJRFP,)TGGXJ9S&DGGX"=<7T5=(,&][@GSV>$
M7Z7Y@6%^W9/&5I-BQ:/0>V&Z<M69D.?/HOXBWV7/&1<YK[Z4[W17K8QNFD)P
M*Y_C-,080>E1'Z)4Z+8UZH](_3(.$&,H,EJ"W(FTM"5)ZZ*W<?7$<%#DX+N:
MQDU^#]YDA7C**O"?1:9<7S7[NAB?;56JJR?0S%"?=UHF7K1:9<!?M#J_M31Y
M-E_C!BBMM)6_U4N?3!UHYK+>E2N4W=;"NEJJF>MDN4+QN(:6LR>/\!'>%FOU
M<W<8=WM?BJ85D,ZH6WD^B9@7"YBF*()(1@RFDD60BM 7.*0Q8T:5%"Z,LS1J
M/9 4D%Y4H,9^M# M!X U,.'=P#4QY1TBM96R279U@Y2%I>T&L9G,Z5'(V9G/
ME_$8M)$';I_/$+ZLPX&U:W"YFYIB.MEXM]-]R]0[LUGK$,JF_J&N[D#6NK:#
M)O4W0A:EN",_5UXHXBAB#!+L48B\5 <X20YE@%(>$99PB?NF0V9VK1.YC#Z/
MPR9$4Q\C-E5 -UMQP5K]W;I7AY,Y,S-DYYN'1=03J]IZ8CNUNKJM.\6Z4 C:
MZ*;+VTQ7-NPJK*>L'#9.L%]:/.PJ+"_5#[ONX2-,V^[0JY"WK%:6LV[>W8Q7
M%[=\PTB^>23T8,EXM<U'J61-!"HC*($H19YB;NXKTN8!E\R+XMBH4Y(+899F
M).\=*/8*@4ZCII/95B=PH)2%57CM[!D8V3/.R=0GA^.FX[K-\VMGR,*XGW&F
M9O( CI%O(@FOFTA7&8^.X!YT,*X=8SXOQ!$:!ZZ*JV>.3<6XY5R]S=77HJK)
M^O_-GII, .;%F'B>A+&?QLI!"22D(4:0B3@,"?*\2""[#(Q3PRQM*>OR!3I1
M;T K+%#2CDJV.(GL\&+D#J^)EYFQ4(U(IQA"XNHLBI,/GSEY8DC!XYR)P:O'
MA(84[$$HPWOS]#>1J]5.L(<^+I2DF$B*H:2(ZWIF$J98>##$/"8B2G%,4_/P
MCW/#+(T$MN+9! ^<Q=# ]G2"S,2?>R,C:(0$6RE!*Z83G&P"*5S@-5>P1(/;
M_2%NKF*.+P(Q'/IP]NX9PQLN:7 8PG#QZC%; R+/BO)S48OJ0_8LONK#\KL?
MQ5>AWH"\?K<1=S_4?U\^%*7Z0UW0O:^AX#$BR(=2AJGB1JX,I"B)8,BE'T:"
M\20V:HYZA0Q+(\[HKVJ\_PE:94"C#> ; 0(/13:^Y+@),7'R)X=Y:M]^'UHM
M(6AT $H)T&D!="^.5@_0*-)>-R)O9.0\V+CRD\_'3"P_X;Q8>NM7(3KLI(][
M](R^^56Z'[KDUSUJQ"KT58VEK'NR_K#145J_9VM1U44NOI*7)NCC;?'XF#7Q
M'W?%W4-6\J]$C7W[]%06/[-'4HOURRH6D@6$)]"CB5J2U%\@\71#6HP#D> P
MII%Y\3<' BUM?=JJ!&2C$WCLE0)/G59-6^]6+;W'5FO%U#\JS2R(T\5<&JQF
M,\_0Q$O;;G):=<!6'] K!'8:@;L"-#J!1BEPH-7,4V6QX,T\93.M?E=]5X#L
M:^?*,W((]."BZ&*<^59(AZ@<+)<NGSNZUD=_A/Q%![6K$9]*\2#R2JW.NZC*
M=Z+,GM77\"S^?4/6F7S)\OO;2E><$VVG4MVLZO&IT,[EQ[QK7?I5M[$J\MNZ
MC;)L-M^+SPKN(J\5]$JJ^X_*%U5?5)]/'7F$>1[699Y]#E$2"+4&^WKSC 91
M$!.11%9]IQ:EW=)6];^1+*_ 7]JXH-]T_'LN:I!MXV6;THN68>^+ MR\D,IR
M9%Z08;$?F]0  PZ0 0?!^C=@AP_8 =37I11-RY8V^WF+T@W8X@0ZH, ^4GK!
M.\0*]&!-4]-N>:^!XY(T"U)P[AHX"U+]7*S7(H4<9U;T7<M77,91A 6%$8\9
M1($,(?4IAS(5// 98S@5*[7NF*WGKYNAFX7;UE,OI)U4=DOE#B(<1A)SI-!)
M)$0I#J&R>1 482H#AN.$1FCUI&:]X-]K9?]- %6WH+P>9'K(='CK?9;GFML+
M"5H!1N(8>G%,?!T5'@:),AYY"%,4(<@5'09I%*4IC3H<W^>&P>'C4>R'F -#
MH:OA7HF>F:TT!H^)S92+7Y^U)?!:29>+\/;9LZY_KS5ZO?0<_?NU)8;.]SW^
ME.7B8RT>JQ4+ N%'7,(8*;9#+/$@B9F (8U"++ D26!5WMYJ]*4Y8P;9 N!/
M+3UHQ!_=_LUD8LRH8#*X)^8+9TA?41C( K%IZ@*9"/"+R@)98'.^*I#-0]RD
MLQEU=O] LO+O9+T1*\JI'T6ALO(2%BN+)=9U+BF!$M,XDB)!@EF65[M.()L/
M=)YR:_K8-\N!W@Q_49+JY/YU$S"I?)1F[Y,#J:0'SUK\Z]+:+.?.<%MIMOGX
MM83YO4EDTX*#1O(;T.GV<M-4^&5M?Q)EHGY75KXBU_Z?P3OU+S= JPV4^M-E
MMXU#?LJT-DN)?FD^VSCT+B6RC7SJ.*X>VDYIBD+<D9\G=TB^DJ8@-_%2@B7W
MH1^P%"(O1A!+)* (TC3P>4PC&JSJHB9K,ZJ^4AXKVW4KU70$<:?':-NQZ./*
MO2WBK-LB7K=;Q'E;L*4>2&6=9/YB&?HBTL=*7L#T_'D08ZS[B(I I)[OQZE5
M*:0YYV\&W^/+<F?.;*F=<3XF7FL-SEFZJD=*I9NSIR:M7NY65$< NUQ2KQ5I
MUC75$7ZO%U57C[5/@'O7!<C<E42-JP?X)I[42"M&DS0,)(<D"37?"D6U**00
MQ1Z/?2^E*$U,T]_.#;(T_NSE!#M!02NI>=[;64"'&= 53%.[$/8(6:6[78+@
MBF2WLX^>+=7MDG+[B6X7KQUG0+_95%FNG&_%-33+FZBXMT5>*W].C:5^JC+U
MK.;7?<.SE[Z938)(3/Q8&5MQP"&2'H.4!Z$RI87'N9>@,/+L-CK&"[.\38Z^
M.\53MY"KA9UM==$_[I0!!5UG]V2XL*'KV3.SO^:9D8DYJE<"[&EQ W9Z@ -%
M;K8=%E\FZ%9T/: N3:TKI)G5RKH>M=<&EH,GCDFL*];*F=Z4^?<?6?W?HE2O
M:=^Y.(B#)/48A8G'?(@H9Y"P1,"$Q7$J2<+56VZ>/'=VG*596%M);\">K#8I
M6><A':8XAT!-S%^G,1J5OW8>+)L<-2>@S96'-A(\RR2SBY ,)Y*=OWW&9+&+
M.APFA%V^?.3Y6ZE,W/NF.&5UF_//14YVOVG,7\(:6ZEG3NXKU]./(&;J#Q3Q
M .(T#6&4"A3X,DV3-+ *+;<;?VF,NE<7YUF /66:DYK]O[=;4DTCH\.;_GQ7
M/)(LMPQ%L)TWP\.VZ69C8MJ>8R+L3]#&P>GTR,Q2A'G/R,;A<W0H-O(QXQCS
M_>/3NG@1XKLHGS,FOC^04KPA51LN+-18S3YA>V*K?OHBOPE6W.>ZG.37)K+P
M;5'5>V%")/82SR,>I P1B/R00IJD"90A#]7*A42*A VC.I9O:8S;Z .I5JA/
MS-S_O'6"A-:R.RM_2YZRNJWE>0-N'W4WUBOBOUQ/O1DI_\()G=K6GF<NK7E[
M(L1=\KIK$6?E_8GP?;TN3#7,N'7CLZAWQTJWM*I+M2JM:"I\+TT8]#F5$(6)
M#XDO$HAIS!,<AYQA:K>O>W*<Y6W9?E;^:*F_PW^UX^#3,)HQZ=703,R'^DSZ
ML'?/Z1-I\&<OO$/2&P3')76='FA6 AK4]36-#%\\8F/R V'-'N>=NO?V9U:M
MTI3BR)=2&7YQ %$:89@RR2'W&"5!R @-C4Y[3SY]:09<+Q_0 JHW68EHLZMV
M!)[!QN,UD$S\R;M&PV)G\1I49MI//$#'T>[A.;4']PR/;IIOI_"<O ?[@V<O
M&F>K[))CM[&C7^3NE[>Z6_=*^:4T0HD^D@X11'$40,+T?J GD,#$]Z59C(K-
MH$LCL[UL_::%^<WH8'HCR,W,'-= 3DR!>QC>MACN1\&W[5R:?W!GZ]@@Y-+T
M,1IW5DO(!HG7AI'5O:,;N)9"N6SO1/O?C_DM8^5&\-8BNR,_1?65O&CS>,7B
MF$CD$>B1D$&$8@$)#GWH(1+'D@1^)&++3JVF8R^-ECHGHB8_6UJJF@V4=7>X
MGMGVK[*9!3.*F@C;B9FJEQK\I9?[-YU;U:'=" TZJ9WV3+6%RG%S5./AY^Z"
M:HO+B7:GUH\8>6C0M%+=9>M\>/Z<?>N:3.D"4MJU7 5"4A1["61AI @L$<J@
MHFD*4S^(19J$(@A2N[T@DV&7MS7T2535OS8!^O>'M;6V+=VXTB>_UQW?NVH-
MNNR6:%L<5UMM+3?W3::($NI3(@24F"00^8)#K)QVF" 4($8\SJA16Y*I)FB.
MQ661$V-XE.(8[HG7FZYI]W[2Z(>_P\\?;T O--!2=YN%#L\_+&!R>JAA,NZ\
M)Q462!P=/]C<.]9/I_7'O*K+9C/F@WJ+VG.Q%<92U_'Q($,RABCU&,2A\& <
M,-]C$JN5QJ@[P*6!EL9-6C) &M%LW>\S2)JZW-?C,[F;3?7I0B^C]K(55K?#
M6(WPK(>!<.M-GQEK9@]Z6.-CK_G"]>.H8.N"?\R?-G7U23R+== '[262">Y'
MRIQ$&"**$TA"/X X\E(?!6'($;,S+ =&6YX]^3V[SS.9,;*-_OI"*U$^-X=J
MK0)J"=4J@.#\*FJ-NAES.$)R\F.*W8Y<*^@-Z!";H(:H 28N>61HN%FIQ$#O
MUVQB<LL5U1Z:/;RJ3V,*DS#2\6B01T19%=@7,$TYA2$+*(DC3_W",@GM>)#E
MT4>7U]^EF+7[:2/2]P^A-".'Z^"9F!-:7%KI)DC>.J^[\_SWPU'F3VD_J>7)
M+/735XY///_W#2F57;Y^Z=*D9<!#@1,?QI0@B&3*(<9^#$,N)$,T%2(QJAP_
M,,;27(9M4O56SM%9YZ_1'/[('6$TM=M@#<^HE/,S #C(.'_]Y-D3SL^H=BK?
M_-RE(X*,_E:HU3'7#]WM0'PN\HXZ^B:"(>-8IT"25!?\E8(HGR! ,$BP2"6/
M?9D8+NC&8RYO?=])O;=%J2OF0W9A31N)^C M3(+DQ"2Q!^'WDQ".R9\TPM(B
MWLDUIC/%0)W%MC>Y7/4LLL%G,%C*Z$'S!5#9Z'405&5UXVP507X7I-J438)$
MX_.M1$Q]/T#*9O-U:1#J>9!X$8,^DDF(4!01L[9[#F5:G(V75:S)%U%R6\9E
MN9@A,V=O9MPG7A*NJ .RIU6[V?1+*X*<P_@7EP8Y$FOI-4+.X>B@6,C91X\C
MY4^[.*GM]IIFD'6A1]GFG 1)C#C%'"8AEE#Q+(>4RA JODT2(6-E1$=VNV%F
M R_/@MZ3VS*;QQ!J,P)U#]_$'+DG\'[0*]@)/4FFCQU.+GG.<.19J<P.C==L
M97GW"$>^V?<KQ;/(-V*7\"8I87$8IS"6.(4HCA-(<, @EB%3U$/C-#2O8'1R
MB*79<.UV<R^ER8=ABJ6!/WXU0K/LQ4\!CH6#?35(,WG4]F#9.=*#. QZSJ?O
MG,]5'I3\P#<>OO+:OD=](Z4[\;-^HZ3[YRH(8B)]$<!($1Y$(B00,^9#/Y0!
M3T+F>S&Q,[8&1EN>A?5]\_A(RA==V%*-N@:R*'^0LFE7IF,MV8.NF5#I8/3[
M45WTAJ W,[X<P3DQ3_92:N!Z.<&?=TTDB)87- )/TJSH+"S3M"8Z'NX7-2(Z
MJ_?YMD/G;[DR-JH]/NW<1?XE_Z;W]73$\AM29=4?>;&-"VK\2%T/(M>)E<V"
M].:EN?WMFE156RIJ)3D.E24F8!PF5+F .K"*I@$DQ ]$3*@,4L]FZVTJ09=F
MR^WY.O2E#2$ C;@CHZ]<SVODQ;K2>@"5C^]#Q#P"*8\I9%'D$4E#@;D8&3#W
M"V=VGJ5J;S9'UK:;;%K-5K(E3-7$RZ#5'(T/WYL(P$EB_US+^FL"!R="_&S4
MX53C79-EMW5=4P\Q%!$?8I\QM3H+ 5,:I)"G5*W,),4\,MHC.?WXI:VI7;*0
MK>M_!CLSJAR/R,0$9P[&R.2H*7=)7XWP"Q*>+NUZGKEJ9 GBAD-.[)ZN$I\)
M%H4>#*6GN^"$,4SC-(9,>D09UW[( \L3EK-C+<^.:MK!618%/HNDV>?L!)TY
M3)=SQR4.2_=>@L)ID=ZS@\U;CO>2SD>%=R_>,.*\X^_9SZ(NL_LL%UV,ETC]
M)$F03K76?2,3'D&U>#.($\_S%1]$7FK4X?STXY>VCN\):+%Y?XR:P:G&55A,
M_)WOR38F>/ 8#XN#C*MPF>D0P^0UL3NV.*OUX)'%\5WS'5><E?C@J.+\5=<>
M4]SF=<:S]497.]J%"+[_R=8;+O@'):RN-+NIN_*R[TF9*]>H^BK*IA9ML^V\
M$I%DQ",<IA$A$/'4AY1$"NJ0!0F+ NQ3:>.EN!5O:>RXOX&_K]]^;&RO(="O
M"]C34=_4:PF4FJ#1L]O_M_27'+\%MH<L<\_MC.<R<TWK%6<Y+M&?YOC'B82_
MZ,3();KG#YF<CC)N)>FK@'S)/^;/HJJ;#A:[@U?.PC *2 JC*$80!4$(U7?D
MPS@1D><G+$#":F48'FYI3-]6MFD:9^LB0ME.9'W,?65-H0O(F[&Q.SPG9M>]
M(D$:RCU.G?+HVPP>E_1W8<19Z<Q,^]?T9'C7"+?Z35;<B[S2U%5(5CPI@0O-
M;.H'F=554;:UO%:<,"IP&$">$JQ3 C$D5-<ZBR/N42(3SHVJ:-H,NC3J:<4&
MC=QM+UFX%1UTLBOD02N]A5=J.@D&OOL$T$[,0K\<58L=@ G0G6E?P!'*=EL'
MEG -;BB8/FN^;09+[0XV'VSO'<'LNY4BTV5+'XN\JM5BT8Q9/:GWZD'WO%E%
M29!& H70CY1)B73 $HU2!%GL>5Z T@2E1M:DQ9A+X_6=U-J$;.4&C> W[0=3
M@:WL%OQC. $&I.X>UHDY_=<B:D'H[I&=B<^=(&S'YG98#9*YX:/FXW([W0ZH
MW/+6D8?AG&?ZA2+K#UE.<I:1]<=<%N5C\YKM3MAVOBKEB8>",(:2IAY$'@L@
MD1&"OA?(5$0I"Y%O>4AN*\/R#L_;% ^=+5JL,TYJP<%6%_!=?;-M=O$[49/,
M]I#=>H8,#]^G1'WJ0_FM['LP[TE_D-$XR6;#:/2<GN-;"S'O^?Y8C([._4<_
M:(1YN]>DN3>;M<VL:3?+[U<L]&F:>@&481HKLY8DD))4PE@()OT $2ZQL5D[
M/-;2S-D#:3O?#G2R6AA;%P V,%O=P38Q3YU$K-MC=@Z<A77J#L"9K-)K@+0S
M1LV@&31"+SQB/N/33)<#H]/PEFO;O.D*&SJ44_>/ZY(E?$$(]Z($IDP7>Q72
MUQF7 DHA!6$\21$;V=[M>+"E,>M>2[)>V)&Y+(,0FQF&KH";F%M'879%Y[;S
M8$S3L>W$>+^H4]MYS<]W:!NXY[HHJ$(J&S"KQ2<U"/^H%I[\/J/K+C'DPZ;6
M53 >B[+._KNAL*ZC>W/LN/.0A$1IHJPX2+ ?*JY))*1<(AWR+206W&-V)]TN
MA5L:-[VOZNRQ\6AEHX!N=['50">& \+^:Y.5ZH)LJ_&HLM5.I]B,ZW[5Q$W,
MC?OA3:UBL-$,[%3;%M)NM0/[ZH%.OUDRU5U"/T5LDQ/Y?DEDDTMDS\4U.1UC
MW,KP#Y'=/RA^NGT6);D7GS<ZYO:+?*=CK01O@J>J+YNZ4K)Q[2<EH8C30! H
MN:Y?&3$"*:48!CB4:<+24 16]2LMQU\:OW=R M%'-#Z)LCO.)75=9G13-R10
M%Z [Z_V8L_,U8!U-$8U$I);FD,8>1#A&D*81@T1@@N,XBOW87]4Z8>G73]%6
MB@GIO#UWV53-&@L86;/-FN@2A8"?G;UI9\AL>9T0]XE7T%YRT(D.6MGU@MK-
MQI[<-Z#3R-WJ.!(YEPN@K0BSKG$C\7F]C(U]S(A]Y=_5Y0^!Y^/FJ=]$?X+W
MM2SN2_+890WAB,0Q80%,B!]#E-! ,9^O.%#]4A#*$3?S3,R'7-IZI-_&+J)^
M)S'H1+;8+37#VV"WV3F*$U-7(R_0 I^%<4R&FQF>%IO0SG&=:2_:";YVF])6
M4 WN39L]:;XM:BO-#G:J[>X<6>#C51*&KC+"5K%(6.*+"")!U!_JA8$D)@$D
M$2)$(!D%46C9-_O4.,N+<FC$FM11. VXF;%Y-8@3\_)QRM@-:&1T6"MD" *G
M)4-.#C1OY9 A78\*B Q>;-_/['U>9_7+AVS=F8PKSV<T] 2&49 &$(4^@YCZ
M/J2,(!0D/J*8FS8R>_WPI5EHK7Q "]BY1>:MRXZ &_ZVKX5CZD_:' FK+F7G
M5+ZB/=G1(V?K2W9.F?V&9&>O&=^G_$19?Y0PGP6"*9<*2>52^0AB+T8P29DO
M_$1@]3_;+N77%?R?YW"9UI8E_FU -3U4OA:JR8^3K5$:U:Q\GL8'9T::O5&Y
M>6.#"U=?T5.XZY^UUSFA[T8H?$XC'$ 9T00BB3!,$>4PB/V8)E'(0]]HS38:
M;6FLH)/-BUP')1<2$,;*C=Y%;H]G*D!R#@JMSHC&PV?Q-F,*9RA.3!A=R'?7
M;W!/T@D:E!MAXKQ-\=D!Y^]8?$GWD\V++]XTCE245UL*4HEWHOWOQ[PM3[A+
M<__P_#E;)2GA$8]2*#W=VEAO$&!!4\A"+N,X#%./BU4N[G5HA1F_F UL](G@
M]A/9'WZZ+^4O.LO\MR8#%#3)1+HKWGW&]FLLV/&,X128$8Y#6.=*@FL%!7_I
M1?Y-'PMV-4AW8M^ #W^'GS^ZHR$[I%SRD>'(LQ*3'1JO&<KR[A$'3E]%V>1(
M*&6^Z\2Q/_*LKKZ+NEX+GN5O2?70K<LR0FF8A@1RCT:*J90)A/T8P]B71 8A
MIY*;]W8R'75I]M">W&VZ(]AHR4'5BMZ>NU</%@<FQO@;G$%-@>K$++4/:",S
M:(0&WW> :KG''$49(VMQ&C4%PC,=2#E#VNY0RA:QP7,IXX?-=S1EJ]_!Z93U
MS2,(_KMZ"<AC\;;)#6Y&Z5Y[/R2)%$+1.,<ZO#G D,8H@9[GI20@?L")D6,[
M.,K2"+R3TX)&SN)G0,@N4)F8@#L102MCQPPCV/8L3!;LZ@*NF=AT'&QVU'D)
MCD&J/'OS?-1X2?X#*KQX\3@W_+.H-8U^+8OGC O^YN6/2D<@=QG"^?TMJ[/G
MQI!><4Q#*2(*XR@5$,E(0DQB F-&. E\QA-?VH23F@]M19(S1)(JR1LS%LAU
M\6,;4"I[P0'92F[GD%M,AIE3/@W$$S.N1K>QM'JQ=;>QO_S1HOP;V H/;B_#
M;.V<VR/FTD&W&'U6)]T>E=>.^H@GC".T;^*)O#2;85_DIR*_OQ/EHSX565$6
MIB3F*0QQS"!*"%?FG!= $<1$K0UIC).PWTF\,S^N.#?>B W$NQGLNZVX^L""
M%F59_- 1'78\=19C,U:Z"K)Y.&@GHL9)"PF5]?T(M)CNR.82$"ZIY>Q8LQ+)
M)8U?T\;%ZT>%D.<;J9;HC<[%O\UY>\I15'6UHGZBK!S?@RQ-(V7BD!!2SF(H
M91 F(6>^SZE%W/BY<9;F]!U(NCNU!$P+:Q7<?!99 V?0#5X3$\,Q5'W1*F=0
M605_NX!LMHCO,=#9AGA? N1"7/?9V^<,YKZDPZL([HN7CRQJMV[ [A)XWN@R
M>3K<0>35?A+J*@QH$J:AA)(AIL\]$"38TYT;TS2@* B%3T?856:C+]3*VI<4
ME&+=)/[711OG#:E6!O0+FV4=.[-)\6.?ID$20BY]-15!G$ <H "F-(J(EV*?
MA<2RO*"[^9@UVO[['N1L?UJZ*)U)X#>S@]U#.O5>Z!Z67SLWXK8LU25-8<:;
MON*!PP*!5A YK0IH-O*\I0"MT#BJ_V=W]\A%@RE;8M,0GG+Y_\A+0=;9?VM7
MOP]2Z9LE=-O?!"6*J1""&"<8(A$QB"7F,!!^DDI%5!)9%:RR%6!IMOA.8G"O
M!*W:^FRB[0&R:YP"R#/)UDVFD"X>4Y&U+9/93I0AITT(_\3L=OOE[<<;L*<
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MA<:VC^FH2[.&^@;J6\%!*SG8B:[+\[3"6U@!QK-@8#E-@>W$C/++8;4PMZ:
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MQ/-]H5,FPT@HZX5', T)@1)YJ:"^SSS?,UFVA@99V@JC1 0[&2WK] ^B.;P
MN,)H8JZVA<>814WT'SB9Z&]O&:__VVNV&QQD%F(R4;/G$*-KQWG*G1M?W16W
M[+\V62FV/:@^%.5WLA:[_E1-/^XP\7&8I!A*]5KH=$(,"8DXY%B$,4$LI(DW
MPH^Q%&.AWLA7]: '4HDF"^.1E/\4=6.M[)JLV=FDMI-C9EE.@?5,^^Q]!_6Z
M )WL)DW4W%EV(Z%S:9_9BC"KE342G]>VTMC'C,Z;?AV[]EG47^0=^=E:5\JJ
M^JKW+HO\MJ[+C&Z:K_JN:)N&U H@]?3[C[FN#5O5JRA!%"$:PB@45!E+?@!Q
M$E$88A'1D"%"J)&Q-)%\2[.S#J-'LRYZ=-WX:61/'_W1YP<:J8M;E7;'J#7Y
M:9WG[73RS2CX%T[IQ!0]$ N\/7]26MZ K9Z@4Q3<OIKL0UU!KZS3)/4I9L%Q
M>KM3$>=.C)\"WQ,I]9,,,VXU:4ZW\JHNFZ/C.SW2*J(X#C".8:P6 HBB6$*<
M>@*&(?>BB(F QE8KPHDQEL;J?9"L_MX_%?D]5(,^=J?26\F5V]@(;UFR^Q3$
M9KQ[)7 3<Z<CS*QY<  5EUQV:IA9^6A S]><,G3I^+Z;N9J'%\5-NP90/**Q
MSS@,]"$0(LR'5!F($//0BV.21+%GV0GNU# VK_ALM7F>BGQ7KZ"5V=H_/HFI
M&1-<B]/$5+ 5KS6:INC!-(2 ZW:31^/,WDGRG*:GFD2>O7;<E_][EJMWNW[9
M^@@2!7'(H@#Z.,7*00P"F/HQ@4F0D(1QCR0XM?OJ7P^QO"_^\QG/S>Z#/X+2
M[&._!IZIUWQ=+/BA6*O7J?J_P?O_VNC0_]D]H7, N>2!HS%FY8!S&K[^_L]>
M=^6J?Z+!((U)&L8<03]4O@!"A$/""(%4I$$J(DJY- K5-QAK:=[!5E07;1V'
M,+8T!A;=LG$L:.,M@WEZ,0X-]VOL!/,^BR:WC-V57JN_ZHYCV;/8*W^S&^A.
M_*S?*/G_N5+> T))%,$PD BB*(TA%LB#,9-^()-8#8!L:WP:C[X\6^- ^"9@
MOJU3\$VLFY"*ZB%[LC0\;&;#= MX$H0GW][=AW9/[ -.TI*#1G2G)46M 7.[
M$VL^_,R[K-:X'.^@VC]B'*LIKTK7/OY:%L\9%_S-RQ^5CEW2-%K532JV$J$Y
MV-LNX2%+ R^B'#+")40TC& J2 !)*F(/^7'H"VQ';O9"+)#CMK6X@7XEFCV4
M1GA MM+_JQW'C9@;,ZJ;%N^)&4]OOS1@]^(#^@+^HC4 .E=AJP38:3&)438>
M1)<L.$**6<EP/$JO.?&*)XW($/^]*.M[<B]N\[:>3M,;XPUA_Q1\%^OPN<B[
MW/2N''GJ>;X?*"X,4ZH\2 \+F'+E2U+E4<H \Z8?HWE[ME%"+(\:>S4:RZ]H
M+#^B-0&T464O&DMOK, VN,XP6^"*R1KFRGDF8&*NW")_N[6Y&Q5 J\->F)9&
M?EOA8D37C7%38)&1//E4S)1</&Y*7/6+NPK%P?3><4^>+U/W*LT/DFZO>]*8
M:B5=]-TW46_*O+I]>EIG@M_JLA15K=9#OF'UM[9OR3>A4Q=$U7K6^?U=T4FA
M6SBM)(T12@6&!+, HI!$$ =>"+W0$UXD4<R%86ZL4[F,OM)9\UY[S?ZE4PWT
M<H.[ NAXQTHG*O5TJ76PJ?C@:CH-%K!9IVCFF.-^;CJE0*<5Z-0"G5Z@5^Q@
M$G_UW-G4XO@%<SA7I8W^.P-E-YFDFTS23>93-YE]>ZNRG\RRG\RZ )W%"%Z4
MEJY62M>H#]?&<#78C)4O'.-S6-?"]<-'K+K?U8M*'HL[M<*3)[&I,Z9S^_YZ
M>U^*9B^N,V%Q'!#*)8.(2AU<SD*8>M2',9<"H23@L8B,ZWN9C;FTP\-.:K O
M=A-/_%>PE=R"8PV!-UC]W,,Y=?"! 9)CO#-#2"T6)??0SK3DN('8;BVQ VMP
MI3!\U'SK@)UN!RQO>>O(8UM2/>C_UY$\S\IRUV5E<_[[-A=PY[+M#@QI(((P
MTHX19PE$08A@RF(*)6-4"B+"B%C&@XV08GG[>!^RG.1-E\*]Z&?+8]L1LV%X
M?#LMPE,?XRK);]ICC3T%;IH=TYT.^YM#$YWICD?1Z=GN"#'F/>,=C]/16>\5
MCQI'B<T&1F]:Y_QVO2Y^Z-IO56<&A#0B7I@2&(5>H*-70HCC6$ 6>U+@-$PD
MQC9Q<!?&6YHYVTEJ1VR7,#4C,8=(36ZIKL5N"T;3U$[8"=K7&@+CDH,N#3DK
MWQCJ_YI;3&\;X1[_D9>"K'7YR+[RC:B^Y!^*4F3WW=8W>]G5D-0U)=\(J?[Y
MCOQ<82Z8C],8>I%,=?D: K&B&!@%/DHXB7!*#0VLJV59GIFE=?B73\<E%PL)
M9*L2Z.N/Z%_\("5OJB_J(V]#UKI^!@V\[[EF96*FVZFQ5[%,5+_IV>F4Z>ON
MO.Q5\FVK^]X VJBD4ZSGFAH++WZN*9K)M[]]U&U#](>BJP]L=A-WWTQ<6\*@
MV3A6OZL+4#\(75 ^O]=E#BY]:N)G=VFI;M\K#U^IGRMU9?-04@'6!X*!!\'O
MV]R:K;?TUZ9"7ME5NB-[G;O:N AVJO9")ZFR_O3>1/U ZE;R@X'4U5H2G:&:
MY:UZ5'3-4M6S7&V+NWAC!C<XKAI@OFT/%S@<;(8X>>"8PV6A/C[U9=[K^M ;
M92D(+I[%NGC2[VO3$J'[8.KB?5:1;$6(D (E/HP$IQ!YA$&<Q Q2FB;2PXA%
ML7EO3-O1E^8K[.1O.*/1 .RIT#:5V.><1@V;$T?;^3$Y%9X0]:E/?Y<'N,U1
M[H3 SW5DZW@"+$]E1P(X?/IJ^] 93UE'ZGMXFCKV(6-3+-M,S:Z9<[<!0D7,
M>"(XE$FD7#[,"*0R3*$0'/DQ$2$+C9:-P5&6MCST0O8=TFWS*$\!:;:3=#4\
M$_/X:V0FV#,:A,!MON2I@6;.E!S0]3A'<NCBD7O*NM/[-_'4%=S\6A;W)7F\
M_9E5JR0AS ^X!U&,=4>.((8D0@(*7Z8"$:'LQMAJ._GL4$O[_!M)P4Y4T,D*
M_M326F95#R!LN+GL!+>I]Y5'0F:_HWP1#:>;R>='FW<?^:+61UO(E^\8:R8P
MY?%6XIUH__LQ[]N^?A-,9$W]]97O*:>22@\FD4 0A3JZ"K,$>E*$2< %Q3&W
MZ^9C,JS1]S!K0/*V<7&Y%=+6EC! V]2T<(3@7)9&*R;X2R_P;WKO;8OHM\N(
MCC ]S"%R:XD8C#NS86*.Q+&=8G&OB^*0G[)<?*S%8[6B7L@2['F0B(!!% 02
MDC@ED$L2XH )CZ=H?('([3A+,UA>E38$?VI)02/J524A=\":48P#N"9FE5%(
M75D(\@B'Z8I![H;ZA04AC_0=+@IY?/E(5V:O EA;_VO%B1>D!&/H<^E#Q)0M
M0H+(APR1-(@2R4A$5W51D[6A"W,TA!43; >:[OV^TV. -UEQ+_(V.K;2AF G
M\__Z'VG@)_\;B$9V2S_F&%Y#_^4JT*;V6TS*QGTE@XG-]C[,642<^B['H\SK
MLYS5\LA7.7_E6"I0MKWFEB^RK6-]F_,3U:UW%>18$"B_)($^TSSATP02&B/(
M1$H\3 +"N6^UU6$W_M+,B:WX^JC@9"'ZL27F;"?&E&$F@WMR^G& ] C^&867
M6W*R$V%FYAJ%SS&MC7O,B&B ?S1K_*82?]2ZJYTNII+S[YNGIZ*LO^MWKR]T
MPM(0,^Y!GO@$HB2*84KC" 9Q&,F8^X@P:AP$8#CHTMAM*_8-V K>1,)VHH-&
M=HN39U/PA\EL*D@G9C S-,<DOYG":G&./P&\,QW?7_G2VIW66\(T>$AO^JSY
MSN8MM3LXDK>]=P25ZYR2[Z*NUX)_%:4LRD<=^=ULY_=)"0GU(U\BY=9B1"$2
MH0=3D1"88"P\9;P2+S%J@V(XWM((O$FWJEJ1P=-.YM;5M0FE-L#:@+3=(C@Q
M7U\ ;PQ1&Z!HP=%NT9R)GJ]&U8Z@S3$:Y&:#Q\Q'R^8Z'3"RQ6TCR/@V#"+O
MN\BSHOQ<U*)ZMQ$?!"TWI'SQH\"+_/[]%C[1!YL0A4+9U2+&D'J*F[GOAQ&F
MJ<=B9LS(AH,NC9;#ORJQ_R=H!0>-Y#= R0YZX8$?W0 MOP6WF$Z  4U/ .O$
M7&V.Z!C:-GZWS;E[ HAG(G '+Z\=A5M"-<CCIL^:C\PMM3M@=-M[QVT1?\H(
MW3/ACP\W8H)DY"$?>D0PB#RNFPMQ KV0$$E80$.:V)P=71IPF2=)ZYW4C;LY
MYN3H(M1FN[PN 9R8N#^]0NW],&K6&[BF4+C<L;TXYJQ;M*8(O-Z3-;YO'*O<
M[C(#FQJC)[9[=8I8WU9U%6/-),I09#*2$&&*H"(7#@4-8S_A7BRXL*M88RF!
MS4<S3QKU[87D2IT-:L<_MI,B/#^*/$_"E.JV<BBFD*38@S$5.,!>(@+IKY23
MEQ7J!2)E_<LGYK4LOVYR#KJ.[S<3!U3<9WFNTVHI66L7;=HY3&C L?IXH$>C
M4,UA&$'*U6QB@KA/$C]-D%7P^H2S-X=O]J;%_ ;\/R1OK5EMS/KIM),0>A''
M.G<H%?JT*4T8I#@4,!2^QZ07"<*][D-ZGQO& 4_^&?62+/$C$CF?[0LR,\HF
MG(Z);;3]66CKN9\\?V_*1OS6=H]5LS!4#\+:C!L)GDNKSE:$68V\D?B\MOG&
M/F9T?H1ZH'K.R09S,@TE#7TH0J*6)9SZ$"=$!RES+PU\ZJ<XLNU3?7ZXY1EW
MW4>EQ+5O43T JQE7N8)J8F+:831]+S@32!PG.IP?;^X$AXN:GTALN'R/'6MP
MD:W>Y[7R/&\Y5V]1]5;]^*6\*W[D*Z:,)$E1# GR8X@"C&'J"Z1,6H:#F B/
M1$;'O -C+,U.;<4$G9PW0$NJ< 1:5C.^& )TF"8<P30Q.XQ"R)@7###8T4'5
M\T$EV%_OB^=_47>W5*!^>,T 0T^>Y<,W4*W_WDTN'=FV46]H?R4O3=H>8\HO
M59\UI&FJC8$H@D2''B=!A#$6.*4HL6S(N/?XY2W^C73@J17O!C!2EB_:G6EJ
M=UFV6-S'T6SU'XO-Q-]S"THGE\,NAR>T==J_</_Y\W8F/*'94<_!4]>,^V+?
M/SZMBQ<AOK6E5O;VC[M^%:L0>S+T)(,A1QY$OE VO6ZS&F$6>@FFGD^DS5;3
MQ1&7MFCO=;TM<B#&E$RYC++91^X4NZE7\DY6V-=<VI/VIF]TY(X1C*%Q21.7
M!YV5.XPQ>$THYC>.8YD/)"O_KI?!-R_;'_\M$Z5ZT,/+)UWUJ2D8XJ5Q0/PX
MAF$2"(B0QR"-0@2Q\(*$I8IJ*+&A&K-AE\8W6E30R JVPC;'K)]O_SZJ1(LA
M^F84Y![3B7GH&CBM6<@.'9=49#CRK'QDA\9K4K*\>QPS]2V][HI;]E^;K!0?
M\UJ]/9FRK)H&FM4*,1FE/)6*CR(&$6,<8N1AF$3$%Q3CT$/;6B]WYMQT<6"C
M3^BPVLO=#.S42%MEVA:J](E!MA6[[9YLN>]Y&7\S6G(#Y\RM(NL"=-*"G;AM
MW]WS,%ISDC$T+NGH\J"S,I$Q!J])R/S&$>'7?UL7E*P_94R?U>3W!X[&MMU4
M)\$M>\@4Y^D?"_DA*ZOZ;?'X*$K=^$CW4_@]6XNJ+G)1K6)"HH3Z"60,11!%
M0BHS"G/%6#'U%6?Y,3+/GYE&QJ797*V68*LF.'3ZMHK>@$[5&["GK.;!1EVP
MT[?IQPMV&EM$+D_T6@P3Z4(F>V+J_?_#/%L$M/_Z^9XI_OT7SKM=W/RT,S(8
M9C_1T/-%Y4^+W4$0_\1#C<RKU5TWJN))E$W+X6ZGLL]1#!"-=;5K*#!7S@QE
M*<0"(1B'U \9]2(>&Q6!,1IM:>O[V[XI274#MB+W>[FV*;6#,!NLLB[!FWB]
M',9M;#;M(("6N;2N@)PSD_8*0.T3:4T NIA&._B0>9-H3?0Y2J$UNFGL#I+>
M(.]+%R0TH50(&. DABB5".) 8JACWR(_"EF:!#8[V/L/7QJG7B@;=QDLAI(P
M2@A6WBD-((IC"=.01)!+A+V AL(/N5V P%BXY@D0:%/.FI1Y2$DE>!,8K=[$
M@Y/%_8CH*\ UW38;!]CD.V2E<-KO?$A?M]M>>\^?>8?K6+/CS:P3UXRM4-RW
M_-IKNMVW"'OS\F]MC[GF/%'O%#]D3\T9$_-IG/J"P#C&&.JM=4AI[$&*"(^2
M6 14<+L"QF/$6!J3=F*"?3E'G?2-G!4SKI@>ZXE990S,(VHC7X.2V]+)HR29
MN;+R-6@=%UZ^ZFDC8QNRG.3:E]^-V7Q4 9&)B'"J#!NBK)O00Y FB5[YE54H
M(H^$=BEZ9\99&I=MQ3PH0SXF:N$,KF9DY0"MB=EH#%#V\0C#,#@-0#@SU+P1
M!\/Z'H487+A\9'EF]B#X9BV^R#>;*LM%5>T?FK]YV?O;VR)O'-*\5C]5&1?M
M%N)=$_@K$HP2YBMGTF,Z02+EBCR8IX /6!Q['HU9:E6VV8U<2V.<7BWM,_6*
M@8,P!?JR__<;L-,.'*@'_FP4M"WZ[&BZS8CM%TSBQ$0XX_S9EY)VB[;3$M..
M1)NW]+1;/(]*4CM^_(ASF'="BK(4_([\W NC/>X9U(2SK:@@)&!^ @D1BN(3
MZD.<TA &21A@#TG?2X7QH8S5T$MC\5[XIA# >C]4/-MVRN+[G;(LTFI&3(S!
M,<YD<$_,MP=('P3EG^I)]C%O@V<G0]KBO&<RQ&<Z_'&,O-U9T"CP!@^&[)XX
MWRG1*$T/CHS&/6'4:L&:W=C \_'IEI;==K[T:>@CGD A9:S+]7&((^E!7\2Q
MH)P'06+4I]IJU.6M$:W<NK8/!N=ZLEHQE2'\1LN!>U G7PE,\!QSRF\,K!7[
MNP=X-N)W [0MX]L!=H'L#1\V)\_;Z?>*XBUO'K<7U%3D^:R4(=5#6U^C:V^^
M(BPA6"($/84U1 1A2.(PA,A/8TE0E$HF1N25G!W0Z+.8/Y^DD==NP^4\IF9;
M*-=!- \UMR6[.B&WQ;HZ.7]SM\%Q$0N76Q;G!YMU$^*BSJ^W%2[?,#)TJ"SX
MAO41&SCFD4>X!X7NX8E2(I2)EV"8D$1W/HDP]D*KV*']IR_-E.N$:X)=+*-<
M#D S^^)'0S'Q5][)-46@RRF-G4:Z' PP;ZC+*=V.8EU.7C2VYAT7,LNS6GS*
MG@5_G0+VYN5W\I]%^79-JJHYHI0>H2'B(8R\,-51+@E,8^%!0AB54>BG%!NU
MH1LY_M*^]9WX<*WE/TYV''5 ;#LK9E0Q(=83D\GU,(^HKS<*++<E]^Q$F+D*
MWRA\C@OSC7O,F(Y SR1;ZS.0#T6IDU.^"[8IF]TOW=7\=U)W?[N5BCD^*&G^
M0Y"RVN;GKP(:QQ[U RBD+BXNO032V%>SEF"1RL#'- G-8GI=B&/S=<X3 ZQ[
MKA M+)"Z"N^+%O<&B*K.'ILB.5)7J[ ]VKAVT@QVMV:<B(EI<JL)4*JT67P[
M98#6!NS4 8T^0"L$&HW KIS(C!-DTZ-HOHF::?/L[B&K@.*^1U"*)_7@MG3"
M@]C[5G3H -<S5VVUO0$_'C+V /16FXZL9_KKJ@OPJ!$X_@:!)N_FJ5WU<5 ]
M"%$#KK[*IEK,[FEJ413W19G]MWI@+K+&42<5>!!K#NL"/K80OX!<O5YU29J2
MYCNY_NJJP9*;>1YNO'3E&#,V9'*#QF&C)D?/'!U6>F:]_Z,2<K/^E$FQ\B+F
M44_&,$DH5XY&&D#B(P*#(,0^$\(+J+3+H#$9=GFKZOOM^KE6\MV OV1Y^UF?
MWRD;#[J9'^$:R(E7Q59<^.FDXW #6IF!%MII<*HQ1(XC52^/.W?8JC$2)V)8
MS>\=622TZ1VE^PH4N5I]WQ6/)-/UNV7L(1]#[/D"HB@1,$TXA;'D&#-*(Y98
MA:>>'&5I>QFMD& K)?BSE=-R[^(THF;,<C5.$U.)/43VQ3Z'('!:X//D0/,6
M]1S2]:B0Y^#%X[[^;\KDUC7W;G/^3E?=*YZTT?\Q_UH63%35"DLD"%8??DJT
M$8)"#JGT(R@D\2-&$4H%MN&!"^,MC1&ZNF <9#E\:D4$9:="XSGPG1)V)'$)
M>#.Z< CGQ,3Q;1^U/5EUM&<GK3L*,83%)9E<&G)66C'4_S7!F-YV1;3$F?Y%
MY]VQ6_Z?FZK6<FR[>[$P$ $+&<12YQDC7_W$XACZU/=]'J88D=3.,7(EVO*<
MIS_R4I!ULYUQKU:+JNW,)JK?0)'O;5P LMTXDT4)*K*^HE2!LXDVX\!?,7D3
MD^67MQ]OVMW*[WM[7EMEH)HC^+V9(YT N^WSUNY[[31KN-9IUS?76#L/0'$A
MV_SQ*@X1/1G>XO+Y8TM*;(.NVW,MO8W65E1;KXL?>E-VE4:21#Z-(8N1/EY"
M%-+8BV&<D# *>,A2G]G5C[@XYM+LS8,D@K;D\@W8* YGQ7W>L'C;CS87,K,T
M.$UFP(QP'>,Z,9=N(=5-Z6X[2+<2@ZW(+JM$&./CMB3$Y6%GKO]@C,-QL0?S
M6T<<A'\3.GQ(/2W+R^*%K.N7DM2BZ^Y4:'[L2CAJ0ZA:*;REAS""TN<^1 )%
MD"0\@'X8$L9E$*2Q4>N*$6,OC:"VTFN_K9,?: 7ZWEC:KMSIT%B2-B48+6=F
MF+ FQGMRCWE14%L<4T\'^4RGTFZAMSO['0?>X%&OY2/G.]D=I^O!0>[(1UQ;
M_..\Z=S6>Y#8"SB1"4Q(D.C^B FD(>,P\),PIB0. L]JW]1XY*4M&/L%( X=
MV.I5=,Z5]3DNS8B9;3L)SA,O%.X@OJ*$AB%<TQ3)N#3X+RJ#88C)^4(7I@\8
M%0LJ2G(ONDB7ER_R=U+^4]3ZL;M15BDF,4HXAHF7Z&!W/X4$)2&,?900@HGZ
MM6'/=_-!E[>)VHD-MM%?ZD-[W$I^$)?V6.3U@XT59C8/!G:N<VPG9JT>U%Y@
M\$6"G<A[K.4<3*N 2\>@SF3 ]N"60I\1ZR#%.GL4VQ#)XW?X*,"2'"\D4\0Y
M6L![(9K1Y$ESQBQ::/8J,M'FSM&YB4^BK%^^JI>FOLVYCBQXZG9[5[H!GA=$
M(12"$HB$6GAI2"2,/"$89X@''%M6[AX8;GELWTM[ YZTO,TABN@E'I?3>!YL
M,ZO4%8 34_H.N:];Y-[OD/L\@-R8',B+D#A.B3P_WMP9DA<U/Y$P>?D>U[',
MU>UC4=;9?S=K79=4K<.H[]2\B!5!B*?("Z"?L$C1C&"0"!;#0'?=9"3!(;4Z
M[1DIQ]+\Y?=].H/<M+D,>[+ON@BHES1P%?T\/$UF!#4#^!-SUX48Z>VT[*MS
MTZ0-@4:5.2*GC;"<)YAZ6)2%Q%<;X64><FWV.#L6Y2);O<]K9>C=D9\?N6+D
M3&:L&>'SIBF"@!+& QD22%B20!3% J8>)] +TU"9:6D<Q,B$)R^.M#@F;(1M
MCFT/Q06MO&;\=QG@889S"MO$'#8:,6..,D9CQT)53T/*??SK??'\+^H9+0.I
M'UX3S^7GST(MQFKVY&%^P[4'#Y\+_5"R5ERTR>OJB_RRJ2M%4SH3<=<BX6O1
ME<5M]@GOQ,_ZC=+KGRLF@Q G 8))A%*(:!)!XE,?2B9"Q2.4JO_8^7:.)%N>
M&_BA*$5VGP/E<I<B9R\Z,/('*75?I[PN"6OR5$D-?@B=A)HK1FS"Q.M"[[(H
M3.Z;4$K!2*7-AE(\B]PTK=CUK-L>?<PVDS,>C/0Z@4XI_;L]M<!.+[!5K#LO
M 5HWT"@WR=&)$[BG.5BY3K1?=.SB!,_SAS)N'C^F"VQ1/NDVM$)'!N_V M\V
M!%5O:\FFH2\DA8'4??=2E$#L!0Q*[,5IG$2AB P9WGC,Y7'W5NK7^]J@$]RF
MIZD)Z@;G,ZZ1G)@[=Q"^BD/O(1S5']8$2YL>L8XQG:M/[*77T]7YB@T^PVUB
M31XT8ZM8"[T.V\7:W#@RTCVKV+JH-J5:*M[NM0!M.I,)_K:HZJJI2?M&=PGM
MVHA7.V,MHDQR&E%(N1 0(1I#&F!=%CS%#&..TI38F>A72K0\>O^^UV6U%]<R
M&/[*23*SJ&<$?FI+^AAQ<%N6ZA+1MC:;Q$1VA)_3(/LK19HW -\-?D?!^8X>
M.XY?/XMZE\&TXD$:A<@3,,6^!U' /8A3/X4LXCX7S$M8D*QJW9O9C"L/GFZU
M([H=8[JO4 FG&^;H:M&DKLN,;MK@C;H ;[+B7N2ZEO1YV\$ 3I'02,&70"3#
M1*?6!I (',(T\0*AP$S4>F1S*#<>SADVF*>'TVR9& W2Q*2O\>F+DS<9IN#V
M%4P7NL1;$_Y))%S2]^$ LY+Q2=U>4^OIBT;L%;2U0LZY6 $AZA;$(0X\!%%"
M%'^&20213QD._"A S#-.:!H<:FG??%>_9C^MVGY+8!A<@[T 9Y!-?:!T%JTQ
MWO\P;!9NOS/X9O+W1[QT=GZ^$2"##O[P$^;S[(TT.7#IS>X86QO^=5.P+T]-
M+\G\_BUYRI3%=TNKYC!HY84I5I!BB%*9*D/4)Q#'A$ />Q)Y!-' HW9NN_G@
MR_/0WSYHU[#2Z7-%+W27S]Y$!1[T@,Q%_:^VU>&-Y\7,!)L&ZXG9^51?007X
M5G+0B0[^[(5W6AW>%C&WA>&-1Y^Y)KPM*L?EX*V?<$4YIKT&B!UOKF(LF(PD
MA7&*"418-R:/I0^E<@V]2) T$&)$=:7CD9;'6K>,E1O!^S#+AJF*D2VL3B";
MI%Z4".5<!U@'UOOJCU2$#$9)%,5>D*8IM\H)=8#K'";WG=X9 61:;,UHW@%B
M$W-ZVQKLH'VL,U/1$ 7G-9E.##5_B:7S^IZLF#1P^;417'\G9:8W4#XV,4-5
MW<2-;=.4L?0#*957'D>^A(@(Y:0G/H/JMP%E24 1-VH:;CGNTDAC/W2G%QST
MDH->]&MSQH>GPHQ3)@!XZL,<-]A>$?%DA-0T$4W#0_^BB"4C/,Y'))G=/C)5
ML#^^*7[/\D)G)#9'.P_%6CVC6L4<<\(##H/(5VXOB@2DH<^5 XR$1+'D3.(1
MC4Z'1S7ZEN;O=JKWRWE6M5OD.NJZ+D"N2Y#DM1)EK3VRK)LARPS""W/ >$CB
M((6B">KES(<IY8&:DHC$.$:1](S:ASL$?\YFDYVT&NW/AVCWWX-E<, %N,V6
M!7<@3KP:7(6??=JF$2Q.$S>'1YPW==-(^Z/D3;.[QFYQ/JMG%^7+[E1_%^82
M)AY2[GZDZ)QIC]77'BM%,(VX2&2(>,Q]VTW-\\,M;T-@*ZWM]N0 IJ8;DFYP
MFGP+LA,3[.2<*!C(!!&W6XP#X\V\J7A9\^-M1(-[1IPKO]E462ZJZHOZ )\S
M\>-KL<[8R^[M1A&/0Y$R& KEN2+<'(,@Y<U2@;'R8%/L&Q:/,!EN>8S1"VIQ
M+'H)4H/S9(<P34P8O:2@%Q7\V0IKE&1C#Y[%J;)#$&<Z5WXG*J:<#5V^/P=%
M#Z@NV?\@='G*)Y*_-!NMF<YW:H\1BMQ9]1Y#P ;/G2\]8[Z39T-M#LZ>3>]Q
MWS!CVR/!XXI?6>1!25D"4:Q<\91Z,61IX*$(1U[L2^M#A0N#+LT%;#?-V;[0
M?6!?T^[BMVEZ63CL4['$'A0-J ?R'D8#-@5]-*BS=9CX5=TCEM<9XIJN#U=V
M=*C*NHNY^5W4#P77EF95"_%9O4M=JSL_\*A($PQ3QD*(A"Y>(=, \I1&/L%1
MPI'1&<;EH9;&1*V$7;DK=9UE!T$#;(>YQBUB,SB/=F 9LXDY#@,<HAZRQQ_J
M;Z^YPV"461C#7-N>)RSN&.$D?M\\/I+RI9"WK,Z>U2!=9DA=O ]B#RN+],WM
MYP!Y_MMBK6XJ6KOT5=$"BB.)<,1A'*18D0C1I2H(@B1B0OHXC(+0B$2<2;0T
MKNET:JH^=UJ!3JTFA:%5J"W"MQ8Y%4Q-,:G!@8H6KI:3635P9N>>JZE/6X>G
MJ=&IF:1^P@[4LBE!,=&46;C0<T_=3'[V\1PT7?*<S*R#Q<XY](,>NY.!YG/K
M7>)RX/L[??#(F*)MDN5^&J;ND-26GKK-^=LUJ:IM+:J/^8<L)[ENA_%=?31-
M[FZU#94.$1&I+ST8,HH@2L,04C\.(&)Z,Y>S 'N6A7_="KB\W=[]M.A]#4%7
M'5#O0JPWO"D,I>M&5<4ZXPT_5%OM-'VTFQ6644QN)]]L#^/73>C4J_1P@OM-
M/Z.\(?0N$ELWY+OI"DI-$F0_#=Q. ZO<2CAO_-4DZ!Z%:4TSRK@5XWQ#$5T0
MI:LYK_M_ZDZR7W)Q]U 6F_N'#]ES4^FTKX#:)OFOXI"D22*5=Q9Z"=2MX"&5
M@81Q2"F3 @=)9-F(V:E\RULOWFU$UZ2WR 5XT<6#ZU8#(/7^JOZ-[KW0:Z'6
M#-M8,;<S;+8J_+)9FWA1,.K O!4>:.EOMOU,;D#WC7=KQO<LOU_OM3MYI_ZE
M;]G<E)%6P( .&:"A<;>,3#(_+E<1MP+.NHA,@NWK-62:0<8M(9^*_%Z-\JA'
MOE./N/V95:LH\!(F8@^B.%4.0R@9I!Z/H%H=TH @%-(@MCF%/#7(TO;?M(Q0
M"]E4R+L!6DYE!2I)+?,13B)JQKS7XC0Q@8Z!R)K=AC!P25(GQYF5:X8T?4T9
M@]>.-!Z;_.T^X\Z/*!$R\2$C.C8T"0)(,<<PEER&G%'!<6Q3>>G@Z5;?^@R5
ME]H<1M;5OF@3V2WML@/P#.VJL9!,_%GW7=2=9R:>5-BIH7$PP+R&PBG=CA;Z
MDQ?9MY3HGO AJQA9:Q/@?<ZUP;E*)4JPD!S*2"_4/$PA50LWC*-4"A8S&F&C
M5N9#@RQMH>Y+UK2"ML:V$K6QP,V;2)R%=/A;=@74Q)_T*(RLVD9< N&*CA%G
M'SU;LXA+RNWWB;AX[9ANKIQG;57RW[.UJ.HB%]TNYBJ1OH@CM3KS$.F]?.E#
MG')EJ3.!*(X3'GM&?;8NC+.TCWXG*7CL1=7=VQ_M2GT- #O\W3N$:^K5?(?4
M5LI^#]P-4C8-5YT@-E>7U8%WS%F+U(N #/=%/7_[C,U0+^IPV 'U\N4C*/(+
MJPLJ2KU\-%ORW\23>@\>2"6^EL5]21Z[.G0X#I-4;V6GJ0ZH9JFO_)I P@ K
M:%-&0AP;E4"U&71IY-F)K=L,>J 1'.PD!YWH%MQ@BKT!I4Z Z,3\:@3FF'J*
MIJA:T.\$Z,[$Q=>]LG:<;(G2($&;/FL^MK;4[H"Z;>\=MQ%U(K"]#VK?KU!\
M5QSFL_?I[*N4(3_ 'H6$$&4(>[%R@BF/E%<14DHX#0CA-KO55\JS-/9_>SZ1
MYJA0]IGZ%M7XC)MK)]=L:VW&*9O:<S?+T+DY*MY]IMB#N]T\1QB[W/^[5J19
M=PP=X?=ZC]'58\=Q]WM2YNIIU5=1-BO$-@#-QQ&61*908"P@BF0 :2(I3+V0
M2YI$BIPCNV"2<T,M+RYDKQ/!D[)A*BVM94G<L[B21%"NS Y(>8PA\CE5_HP(
M8!2F7A+2!$?"J'^P2U1GJ?3>R0F4H)U!:!"B9X>MV5KC K&)%Y%Q8%FO")>0
M<$GU9\>:E<,O:?R:G"]>/V9S^-T?__;^T^^=-X@X]Q(_22## NOZOB'$' EE
M"P<^2T7L)3;[P?N/7AH#=,+9[&$>(&6RP3M6_ZGW=%NYQNPJ'&)@LW4[%HNY
M=FLOO Z6^[*GM!W>BCVX8\;=UU.2'FZXGKQB9)!(7F<\6V]T#]Q=F-K[GVT>
MQ <EFK8_-^UD?Y&O^>Y3EHN/M7BL5APST53+IKZ0$ 7J#RQB 4-*6)Q$B8?"
MT,9N<278XEAN3Z_]-JV]9D"_#F!/-^T0GEKOM8:@4='2/'(VY6;FU*^8R*GI
M>LXYM(_*<0RXTX >5[+-&POD&-&C,"+7SQ_IZTLI=')DM\MP1WY^([7X)C1*
MV3IK1F]27&YS_DF]ANOM=:):43^,48HD]"32\852V:E")%"&C% _(2(*+6M/
M7B/.\O8,&DGU]JJPC$2\:E8,/=Z9D)[:*^[5Z+=5E8! :P(.5;D![63H-(]&
MG;WK==J(^JZ8TSA)%_@Z];6OD6=>?]P!<D<^NXMGCO'K;;)"SB1X>0$E6)((
M)D37#D<\A$32" 8((\9QF$2^8;=Q5R(MCVEW67O7)NDYFS:3K8EYIV)J"[G7
M!GS0E3>4/OMV<I.HMU,)-#HU271-)&OU*DEOYLFRV4.9=])FVGFY>\@JD"F#
M$I3B23VX*7O ]9Q5>\F5I&Z^I.W),>'_N6G+@U7@D7#1U%S1;:1$N^9V'V"W
M C>]I&#]0'*H!GHJ2EV9)7M\(EG9/.*F69T?!+]7ENX-R-3S\Y<;\.,A8P]
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M;A3E-/\\F8H#23<K+6,%'F57=9INMYN2[;9UT>KM&KPIUW=R9>ZHSM>*]K!
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M%_4>&[L59!_?C_T:L5=G]]87?Q]Y0CE;C>&OM%R9>@UOI-*?,856.)>(IH6
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M3__Q+]UO]'\8K>1__,O_!U!+ P04    " !U@E13#Q?G173;  !>QPD %0
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M]ZGYC4WJ0<P#;E^+^7+T:3Z+EV'Y<?XES;^-0SKY/EZ,4N!9:HSE)5IB(@4
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M6YWI.I/01N.7H4K^]QEY'#8X[AGFK6*C <M[S?)ZX;](TY3'RY'104@&N'=
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MK?8$SU"W@J]LH7)EF_/KVI7?>E;%"YC -*0O9RDM%_V7"SWP^)HB[L)1_Z5
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M9].2M%AMZ!1XX,$X(JS H")&1EP$@7^XDC])5ILJI0*/4M5(L\0>7.C>9-\
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M53O[V9?4;BC\61+\E5750+CP (<KYV(W@^5*O><BDDAEZ6QGT+\(UA(+6MB
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M[@-Q)B6+OA.U;(=-66S0L4CA3Z>S;[^MGW@%D/4WV_BX>>N 8.A'=;.CY-B
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MXQS-#I07D.J,#G^0I('G8O:B\@XX.D#^#2!I8XX_IY#&W\H"6Q\5.I=*:]5
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MW 9.=IS_>AFCUU03R%X1Z8PFG@N)G)AR<I.=R5UJY_^A*BGV4FRG2HI]I-S
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M)*^,GC6*4E_J=P*@#\2$0:/'$*="@M&&&MFI-J'31G#]UDXHT#^QXW"8?%L
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M'$'I$BG)8QD*6BYB3HG[-D.\)KC*V:T>>52S>3-&+GLCI<G 4WW<G$0![U!
M("_@E-:AL";#6@93V,O1UJBH.GRE,Z:^.@C7]IB!FU&\M!BC&):L?J;\F <$
MYQ/%&$)EQ9(V:)K [@ ]O5SPC*K]W?=8(ZBB T2]7X7%FE:NI>CO</7G/)&_
M?U/VUC_31Z[W?^ONH3W)+9CH0$LD>5K'P=7^;-HR+*Y0L%N:=( =DXF)VQF,
M@:IE)RJ>NOO>J^7J\W(5-OCUB="KZU55Q>W!D&+:"L,C),WK.&,,$ 33M6%X
MRHRB:)3\>Q'@X-6F!==T0%BVU,JD&>U3+/VZ7'S-53'21$LQ#0M59B76$>>2
M0=:<%UYDEF787)F!"TY[&-<UW,[2S?2(^^>2/FI1!71H!T6E?<',*4>7Y#&T
MIQWD% /GC&0\&LO4L $0WUUJV@NI/E VKC[ZQ-<W6T:[)$RM+S<^99*6UN"$
M%\#)=#LCBDW.G@RQDVQ9LRNK?E%VEE:F!]HOR]7F0_B )-<WFX^XVLX/?QG2
M'Y@/Q@867?#!0^&9&&0QTB:B "';8((2L8X/'P2[X]>>MI]R'R!LK+%G LEO
MMATGL:62)2 /C.R[)$N/,D Q@>N8B).DQD/E2=:QV?BE9P3,L_0V/39WCTN_
MYB5SJ:1Q%ASQ0:(+"$%%!4D4*74P6L<X"(-/+C,(:_9?&VOCZ6'J0Y)=3KY-
MC*)+Q &EXIS59V)"0B@J0?%<!IY*8;L]\P:"ZB0;YOYGX>HL;71PO#SD+/ZA
M5$)KKH,4 JRH<XD2<^#) H.0W'(*':0L3>[]CZ*REPJGEI<;[=36 28/LW1_
M^>@T;:;:P9='1;M,*03:LF3/,3N=B^8V-KG(^#YI_5^MG8B+95,E=0B[G;84
MGRAZK2^J7RW7FVVKQEG2-AI*F\#KVO&)N**L*7E@9.M1V<BE:5+A>2RATT)R
M;*!\!X>C:NUT5"XWX>H2J$SI^M/U59W ]<_5<KW^?;%Z]/#_)9;E"M^'OV>H
M<HI8KVMB%'4*KJ!X)R%P;8U/EAG?I@'?*-1/Z]"GQ6\#_?9O:@\R73M9/##-
M@M92._)<,:3ZBP>GK2,,^E*<<T+ZKD#]%?737LIT"NK3]7L\J/T-J!?XH1+2
M.'#]6@"SE)()J K8:#VH(@*XG"C^ETQ[4Q@)MTE%YE "I[W+N3 X1]%2%U7[
M7]/_?A7R?/%A3PWGZS]_G=> Z%Z<21.'/EB0M9^:<@2>&*($H;2R)HA$B6D+
M/)Y*</\I_CA)UD44VD$\<(B?6?9&:T9;4!@E:9]S#KZ*T:LB,7.G6)L^\(<(
MFGY6?7LX+!OH9L)$:N^Q[>[&'1IG*Y.CYH8"$9D8)8]U*&XFYX/14$0A33%I
MV-7V2 1-:P@OBL?)]-C;!=!PGK\.IR6J9))QX#@GGK/A]68B@S39BQ*2P6P:
M8[>C#.@Y8?=T/9Z;%KUOZN)GHO"LT7- 5V,C)*EZBPC&19L\8T*))LWU]A$S
M;<[3C6L_2B<=SVD__![SM#'M3WU>^S>D;8:T'_/:+TMCF:>$VVS;3RD-SDH)
M9(*B1.Z]W:U6?FYO2)\^%KCMY_Q8)!0O9(RTZ5BQ"(H3_5[Q;0>!4%()1NT6
ME%WB$.=;0I_/B](C,';<H<Z9VNOB<&<HAW7FW'SQ9H'_B6'UU?W7C LA@O$1
MF*JG9D[5,;C6@8_>U$,*M&UZ^IY/>J]7F&. ZT0DCZ3GYXOM^X&+LY)5B(8K
MX*QF<RD'<&@L&*N9+B)1V-*D+.D\LGN]UNP%TZ?I]UGA^46A0)C8??]QM;S^
M\/'U_,\MYU^7+<Q88%QQG<!7ETC)'X(7/@ +*2CG3&1Y4K,]B(M>[SLG1/OX
MVO^7 /_#OB>.'>:@0' ;0!E>'QDK8IV9$F-Q3*M)[?IW.>CU'K5#T)^F]>D?
M?!S%]X$M7F*P0F@-165>;[,9<6Q+O2>TWB165!KV['P$8J9]07<1R$ZBM^>*
MU(=]:;FWPFM;6XX74+1-P95H01HI0N$F<SWL_N!,0J9]2M<[0D_3US,('!X5
MYC"-3%DK +47H*1V$ TSD%Q0.0B47#?IU#QJ^52S!W@=N?T3==9_V?6^LG+D
MEC@"+C3Y D9,!F,\I)1Y,#SRI)M<935Y#-#L$=^DV!Q5AZ-A]))77SL[[.RK
M+WF!JZ\=FB]_]162"HEY!5%*2PFX3?5/'&R*,:=0M#:-YW*UOOIZNUHFQ+Q^
M3?MU6XE0I][?S"]]JL9QEF.NSVCKP(?B0&D5(<3(07AC(D:OO6Q2G7<BO<_F
M(NP8Q.T:O4OHLH.*T:=G1C^>?CKS1:!BS-51%10',T9RY:7.F- L1Z&C24U0
M.IS$7J8/-05F(XT]&RS6(JZ9TR&'G"T4GWP],8@0%?=@F)+)%JM39--AL9+8
MR_2B#K!XM,9&?(1TR:BP3H*^#E<CQX9WG]H^0MQ+_^7CQ(+*%,41>/3U-! 9
M..,I7_'96I3%^>=:(G5['(6K\ $?@HF;*6!UWSP*(XI4W&;:']E%26D^JV.<
M,(&1IDB='7-B6(>C0<L]FXCN&&SL' *.+?7G-OGC^QM_M(+.(4LU-&='<SJ^
MC7MQ=;5MS?;X2W<8MB8F[9@'U%C?F(=4Q\L(8$SKPE))7C<>*/P4>>,U0GIY
MO9XO<+U^D6@WK^=5N^N77Q[][:9]3W(I6*D52 H"0%&< +%D#B0,F2)%#:G-
M?.5C">W&1HZ%K<.]D!IH;L+T(N-\]C,%AE<_+C9D^K=C!FPP,9.S ",X&?HD
M/00?!9@@Z']!&F/V3&%>WZ%N32;HP_+/?Z./O@$<_6$79WN6[:6G40O]+L<1
M]L0XN:'ZMKD=RF1DU@A"*@9*U(JA;"AE2;YFSC$8W#->^6B0/%YS&H2<K;3E
M"!*<^GG@#[B@=/4]&=;P&:\W\[3^:9%NFQ%Z9F20=39#2K03/+>4(RL/41?K
M- _9[A90'8C&GUAD.M6?KK)E _E-C8-W8?$A?%K6Z?'+Q;O-,OUQUY$R68FN
ML'IXL>TW3NSH8D 4:YU55K(RK#_HH16F.;X<#P&C2*Z#<\B7X8KR!WSW$7'S
M<_WIJH%J$[VWUHJBP4=.V6>D$,NG)(!B+I-+1&*E2:AZB*!>VG<TC"=&U4FG
MV+K==]9@RI$GL*8V4RZI (G$ $]9J1*80-:D#>)ADJ:-5\=1^0 <G2#_#I"T
MS0%_72[23=OD;1/XNR'P07B#0F1(.M:.7VK;EAG!.>F16<?"[JRO<:#T!$W]
M8>D4M2_;Z* #.!T:R.=R,"QYDH=Q$530M,]T9&"\]?4QJ7(RM(#2.1,WFUVK
M7=3EC:&1#H U:K]Y6Y1+5EABV]3J"EG U>EY12L2,#/,YB;WOO_Z@S>/0E7+
MP9O'J'CR7'%3!^Y]F*='9[&WYA\]24^A)"EBO>_V$2)Z14F5K3T/I0^X4UM]
M*%L\N,:_T)#-HY2^'%\#/=A)^KDWY<6*Q/H![[>EU"'YX@-(4>?A4F0++@H'
MAF,.62I+DFMB\/91,^TSO(LZW_.UT0&D'I%?=RD%JN'A*]O]&])6>+<[QFFK
M)$\*> S5!R@&'C72+LP4KE+2%8QN ;8CZ9S8[IV/C-WZ^H9JFMQ#A@^X_TPX
M>"%2L1*2#93%YTRID2&)%:%+29B]V'WH<? X]< 2$S<[::G5Y>@BGAXHV\/C
M'4;^\>+#"K<2N[M)L,%I*17%"(D"A90">!(,Z%0\BB2CY<-&L0Y;;^+>(I>#
MT.C"GQI/3UU'60K^8B!7Q+&0L4:&%!D:8D89'Z0P?.@+W'.O\]KUZ;@4<L82
M<P?1TIZH\N?[[N,18T%G/&09*$OA,H*S-@+GB@6'M=="DSC\*:*F;3%PV>N?
ML70SM5G:DZ^^7:XV97DU7\Z<01EBC(""A*.06_!),\@<-3?6<.^_6X_YW54F
M/H@?39'?.04X3:K3=Y=XX&"^2-N;]'6]25]_)/&N/U^OTL>PQCP3PGKE"D(H
MJ;[:"&2P=0F0$R4;C!(1YO,@J Q;;]HXJ UH&DAZ:NORSZME#%<_SQ,N2&(?
M7BVOZ">6JQM%W05S+SXMKQ>;=ULVW]ZSZ4)4W#D-N19\*$:QG>,4"V@6HO<Y
M2F&'E3B=3L.T(5,;D%U((\\">-\PB(%CC@B<N40,%D,!@4<0T0FIK6!!#YLD
M?\KJTYYE3@BV<[3P+&!VQ]K;%?W<6UQM&9X9GXQ*18' 3 EL\K8F(QJL+(X)
M(5AB:3RP[:5AVGA]0LB=KY&I@??#_,]YQD7^SSE>9>(@5<U]P)F(*CC/):"C
MN$ %(<"E$L%$$XMQS' <>)*P?X%I>W2U@<P8LIP:#Z=8VGO@<ZE);HJ!#"&#
MDE&#\XYD:'UF6EED<5B;PG.HF+:W5C_^[R2M]#NOXP=<S?^DS_D3'UVR?TWV
ML'>=^S]HI%>; Z@<Z4WFWI5>+/*_8_Y0)\,D^M9-WZSY.ETMU]<K?.B958K+
M,D6PI;9_S^2@O,  WCOM6/1&FCWO?\9H,G$RS>>WX#AZZ?JD]B5]QA\SKV+4
MM@A(AH7:9$2"1V' Y:@\?4<(V:2 ^1RBIQY$>!ET?MNWXT)J[OF1_%XA;(^J
MQS.8MQ_7TFSNH[@#X^DYM]9$ 4S[0DXT>D*)<2!"9B*FE)1H4C<\H?%\N!'Y
M=5G5&ZYN#G;6;\J;Z\UZ$Q9U&-D#@6^7MY<E6Q4^;##,6G)EB#7&:A\QRR"F
MR" '3[FXRLFY)GYG)/J?KTD]!K.'7\]?3OE==!M^8'ROZ&LCLMH ZJ?%.P+!
M-@)_5 E*T7=9KC[5MQD/(G#6\Y!T!E,DJ4'1+R%J SHZ%;G-)JHF1=ZC<S+U
M5-FI=\(4@.AL3_R*FX=[IBIY),8?32C=OB!ZM?Q$M'ZL66L5%?E[K!+:L0S1
MT'^Q#C#QP=5R"@U1.5*,35['P&3<K2@?W2V,QLS4,VNGWAD3P:*#*IOO6(<#
M5N'66=XWY7]D&U +EH*L-Q?D+YDM$-%&4H_6V?'L[+Y.+LV=Q;%\3#TU=^H-
M<7DP/+O4]+:%V6BYZ=WGM4Q.]]+<079:CT="Y &,K$WP)7,0ZH D"KR51^%=
MXO]JV>G]=ED_$+'>]R[ZY9>''WBU7&P7KX\>7GZYI?('7,\_+,)#99]F+'(=
M-+B8<^W*J"":; $Q:!U\CJI-"[=V+#W?'/889'_SXK@/B$Q]N?? VUV[T)LG
M/E%BM#F #,90H)6)!1L+,!&,SHEBL-WY!0>KQO=]_L3/@CM1_7)</?0'I=L'
MK]$5&X/ 6F9?ATHQ#\XCTB],*8/6E]TSCL%@FO*5^6AZ>QH')PAQ:B2\^[A<
M;>BS/N4';FZ?200I./T?2M&,++9($*.(Q!2W] =9D(M!4#BX1%=8.$5WR]$%
M.2$<UJO-H\3GIM7U+[CYN,P/1P+??A7QU_ )MQM),&)$"U[+8VI/-6')H(8"
M0E'&H[E"M_M,8&^X170\"K7H;[MAUKF$3GO\V9E'NZC6)T;W(3[N&@R*9!ES
M%),*3/59J@(OA(#LN2M)([.#QLP/PN_3I$QC&"\+A643O4SN3L.G]?7BP\OY
M<CW_-+\*J]VWJK43-F9+,K*UFC!2,A2R]74.$Y<^)5;XP+=4WUEI.@R-J<YE
M*]EV<.1<ATKL=#M2F>(,&07MF_H6T68/L; (*6?I@XV2^V:SK'IJ:-:9DQQ)
M8]UA[M&N]$8G'U&"\35(=9[B7D9L88DY.:^S;#=%;1]!4Y]TG:?H)W%SHM0G
M=VVXF"]7ORXWN'[_U_+M<DZ<S!=X6RG_PS6^_XM^_W+SZUVO*TJ9D(4(3GC:
M;*F^LA=&0N$\B*2Y"6[8ZY83%N\)0:>J?'E!^4\<G+_:]BI--V<R7")'3RFS
M05[?X)!/C\D5RL)]9)XA*X,Z6@\*Q1\O/.UU9V=>[RRM3(BF=$OS[,75U2W]
M]4[B9OL%YUR(SD'!.@S59P/TUP0Y"4I2B#O<=TCQS?",NS5NX'7WMUUX/47)
M=/'YZ3I=CBS@'D#RX^^_S91U0NC(P6BL+VL*):[<*7"*.;*?/+"TYX7 N:"@
ME:<!P7CZVP7$L<*<M"KNGNI_OGP[X\RQ(&(&84VE6I*GY%*2E=1&LRPC8T.&
MZAP) 5IYFM/(=A X5I@]V(!7__YZ%@.G"-\K2*9V$LLI0Y2D,N^4-<:;HH0?
M'P"T\C29=CL '"O,'@#P_[S]SYFNW0:29:"EH1!)! N^5B@PHTK((B%3>^I8
MSP4 K3Q-T-D. ,<*LP< O'KQPPQ#+DQ2BF13;397'(,@D:CGGD='^5)P#:(
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M9RD-NZ\=NF*/N#E%P<O6TIX:0K_0TA^_RY$OOCCMR7 G,N&*D?6..GGBB(>
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ML%(FZT0V)C?IO'$DG<_B'/1$T)R&T),T>#) /U/HN\SO-F&UF02F]8TBRJ(
M,4H2*&,0D=A-45JIO3/9-6F]V0*F4QO1:6!ZC 8[L*-/\?02R[)6\W[].O>!
M5253#!PC2.>)58J2:O2,8(R-IDBAL$TK^#-HGC:CORAP+Z79#D"\R\AKDOP
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M$!.@4DS@C+90>/!H?7#X<*Y:^Y?/)A%[*[PTD/.(4Z'W\!'>WS3--#$RX52
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M5+9D?GE2((VUBDD1O6ER.]<+]4</A_U%DYQM1;\VE@DI,M#A5/M]&4E^#FI
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M:GFG^WDT'(5W'(16I8XD(1^?14WGLK2&Q<#)[>_XH-=AN6$S")HAIG]1C^
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M)U4H0O8JZR;UG[^@:^ Y#RT/N#XU,D: _7U!9_>$16>DEH:XR F4%>02*M1
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M@T@M>"VZ &Z@GV7/%#1H@L['  MFR3E3U)J-YX'/D07LZI[J',4^SI!0RL
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M?RS4"P\N&5M!<D]JZ\\=[)YO>%PE+Y0"W-.32\23JZ7D!H5X 'P'U:)[)+-
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MOP%02P$"% ,4    " !U@E13^]Y%SV5<! !L=C0 $0              @ $
M    8FEI8BTR,#(Q,#DS,"YH=&U02P$"% ,4    " !U@E13)F;,HU(;   ,
M.0$ $0              @ &47 0 8FEI8BTR,#(Q,#DS,"YX<V102P$"% ,4
M    " !U@E139+*9Y7$F   E@ $ %0              @ $5> 0 8FEI8BTR
M,#(Q,#DS,%]C86PN>&UL4$L! A0#%     @ =8)44\5C;$\?K   D6 ' !4
M             ( !N9X$ &)I:6(M,C R,3 Y,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( '6"5%.D,L/2H[X  *+T   4              "  0M+!0!B:6EB+3(P
M,C$P.3,P7V<Q+FIP9U!+ 0(4 Q0    ( '6"5%.Q/ A0Q]4  #;^   5
M          "  > )!@!B:6EB+3(P,C$P.3,P7V<Q,"YJ<&=02P$"% ,4
M" !U@E13Y@RZ!  7 0#[10$ %0              @ ':WP8 8FEI8BTR,#(Q
M,#DS,%]G,3$N:G!G4$L! A0#%     @ =8)44R8"=.[FRP$ PC " !4
M         ( !#?<' &)I:6(M,C R,3 Y,S!?9S$R+FIP9U!+ 0(4 Q0    (
M '6"5%,KPUL$$8\  #.]   5              "  2;#"0!B:6EB+3(P,C$P
M.3,P7V<Q,RYJ<&=02P$"% ,4    " !U@E13);;X36*$   GL0  %0
M        @ %J4@H 8FEI8BTR,#(Q,#DS,%]G,30N:G!G4$L! A0#%     @
M=8)44WVJ#KZ_A   ZK$  !4              ( !_]8* &)I:6(M,C R,3 Y
M,S!?9S$U+FIP9U!+ 0(4 Q0    ( '6"5%.<22O\6(L  +[    5
M      "  ?%;"P!B:6EB+3(P,C$P.3,P7V<Q-BYJ<&=02P$"% ,4    " !U
M@E13>UKR3A9V  #LHP  %0              @ %\YPL 8FEI8BTR,#(Q,#DS
M,%]G,3<N:G!G4$L! A0#%     @ =8)44S*='XH,C   .+T  !4
M     ( !Q5T, &)I:6(M,C R,3 Y,S!?9S$X+FIP9U!+ 0(4 Q0    ( '6"
M5%.O5_0Q7P8! 'Q# 0 5              "  03J# !B:6EB+3(P,C$P.3,P
M7V<Q.2YJ<&=02P$"% ,4    " !U@E13+^.5!BP_ 0"$CP$ %
M    @ &6\ T 8FEI8BTR,#(Q,#DS,%]G,BYJ<&=02P$"% ,4    " !U@E13
M('!V/\N&   KM@  %0              @ 'T+P\ 8FEI8BTR,#(Q,#DS,%]G
M,C N:G!G4$L! A0#%     @ =8)44^C:%23KCP  M;0  !4
M ( !\K8/ &)I:6(M,C R,3 Y,S!?9S(Q+FIP9U!+ 0(4 Q0    ( '6"5%.]
MKF[RU5T! &6P 0 4              "  1!'$ !B:6EB+3(P,C$P.3,P7V<S
M+FIP9U!+ 0(4 Q0    ( '6"5%,&^$*[.^<  !X: 0 4              "
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M+3(P,C$P.3,P7VQA8BYX;6Q02P$"% ,4    " !U@E13#Q?G173;  !>QPD
M%0              @ %7OA@ 8FEI8BTR,#(Q,#DS,%]P<F4N>&UL4$L! A0#
M%     @ =8)44T\'\M-$"   G2H  !8              ( !_ID9 &)I:6(M
M,C R,3DS,'AE>#,Q,2YH=&U02P$"% ,4    " !U@E13@]O\73T(   4*0
M%@              @ %VHAD 8FEI8BTR,#(Q.3,P>&5X,S$R+FAT;5!+ 0(4
M Q0    ( '6"5%.,<A;*E04  !LA   6              "  >>J&0!B:6EB
H+3(P,C$Y,S!X97@S,C$N:'1M4$L%!@     > !X S <  +"P&0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
